FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Ferreira, MVL
AF Ferreira, Marcus Vinicius Lucas
TI Response to:Can Transdermal Photobiomodulation Help Us at the Time of
   COVID-19?
SO PHOTOBIOMODULATION PHOTOMEDICINE AND LASER SURGERY
LA English
DT Letter
ID OXIDATIVE STRESS; LASER THERAPY; ERYTHROCYTES
C1 [Ferreira, Marcus Vinicius Lucas] Univ Fed Minas Gerais, Sch Dent, BR-31270901 Belo Horizonte, MG, Brazil.
RP Ferreira, MVL (corresponding author), Univ Fed Minas Gerais, Sch Dent, BR-31270901 Belo Horizonte, MG, Brazil.
EM mvlucas@uol.com.br
RI FERREIRA, MARCUS/ABA-5666-2020
OI FERREIRA, MARCUS/0000-0003-1137-9776
CR Dominguez A, 2020, PHOTOBIOMOD PHOTOMED, V38, P258, DOI 10.1089/photob.2020.4870
   Fisher-Wellman K, 2009, OXID MED CELL LONGEV, V2, P43, DOI 10.4161/oxim.2.1.7732
   Fujimaki Y, 2003, J CLIN LASER MED SUR, V21, P165, DOI 10.1089/104454703321895635
   INOUE K, 1989, LASER SURG MED, V9, P271, DOI 10.1002/lsm.1900090310
   Kutko II, 1996, ZH NEVROPATOL PSIKH, V96, P34
   Milic VD, 2009, TOXICOL MECH METHOD, V19, P24, DOI 10.1080/01612840802203098
   Pandey KB, 2010, OXID MED CELL LONGEV, V3, P2, DOI 10.4161/oxim.3.1.10476
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Szymczyszyn A, 2016, LASER MED SCI, V31, P1301, DOI 10.1007/s10103-016-1971-2
   Thais-Meneguzzo D., 2018, LOW LEVEL LIGHT THER, P319
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
NR 11
TC 1
Z9 1
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
EI 2578-5478
J9 PHOTOBIOMOD PHOTOMED
JI Photobiomodulation Photomed. Laser Surg.
PD JUN 1
PY 2020
VL 38
IS 6
BP 326
EP 327
DI 10.1089/photob.2020.4895
PG 2
WC Surgery
SC Surgery
GA MB4MX
UT WOS:000542578700002
PM 32579493
OA Bronze
DA 2021-01-01
ER

PT J
AU Camacho, AD
AF Camacho, Angela Dominguez
TI Author's Response to Ferreira:Can Transdermal Photobiomodulation Help Us
   at the Time of COVID-19? An Update
SO PHOTOBIOMODULATION PHOTOMEDICINE AND LASER SURGERY
LA English
DT Letter
ID INTRAVASCULAR LASER IRRADIATION; OXIDATIVE STRESS; BLOOD; THERAPY;
   ERYTHROCYTES; SECRETION; EFFICACY
C1 [Camacho, Angela Dominguez] Unicoc, Dept Orthodont, Cl 13N 3N-13, Cali 760036, Colombia.
RP Camacho, AD (corresponding author), Unicoc, Dept Orthodont, Cl 13N 3N-13, Cali 760036, Colombia.
EM angela.dominguezc@gmail.com
OI Dominguez, Angela/0000-0002-6434-1969
CR Agaiby AD, 2000, LASER SURG MED, V26, P357, DOI 10.1002/(SICI)1096-9101(2000)26:4<357::AID-LSM3>3.0.CO;2-O
   Camacho Angela Dominguez, 2014, World J Methodol, V4, P151, DOI 10.5662/wjm.v4.i3.151
   Carvalho JL, 2017, LASER MED SCI, V32, P305, DOI 10.1007/s10103-016-2115-4
   Contini C, 2020, J INFECT DEV COUNTR, V14, P254, DOI 10.3855/jidc.12671
   Carvalho JLC, 2016, J BIOPHOTONICS, V9, P1208, DOI 10.1002/jbio.201600061
   da Silva T, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010627
   DEDENKO IK, 1989, KLIN MED MOSCOW+, V67, P70
   Dominguez A., 2014, AUSTIN THER, V1, P2
   Dominguez A, 2014, PHOTOMED LASER SURG, V32, P476, DOI 10.1089/pho.2014.9857
   Ferreira MVL, 2020, PHOTOBIOMOD PHOTOMED, V38, P326, DOI 10.1089/photob.2020.4895
   Fisher-Wellman K, 2009, OXID MED CELL LONGEV, V2, P43, DOI 10.4161/oxim.2.1.7732
   Fujimaki Y, 2003, J CLIN LASER MED SUR, V21, P165, DOI 10.1089/104454703321895635
   GAMALEYA NF, 1989, VESTN KHIR IM GREKOV, V142, P143
   GOSTISHCHEV VK, 1991, KHIRURGIYA, P98
   GOSTISHCHEV VK, 1991, KHIRURGIYA, P121
   Grigorash G A, 1990, Klin Khir, P12
   Gromov V V, 1993, Voen Med Zh, P23
   Huang SF, 2012, PHOTOMED LASER SURG, V30, P579, DOI 10.1089/pho.2012.3228
   INOUE K, 1989, LASER SURG MED, V9, P271, DOI 10.1002/lsm.1900090310
   Isabella APJ, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015111
   KARNYUSHINA NL, 1989, VESTN KHIR IM GREKOV, V143, P48
   KazemiKhoo N, 2015, LASER MED SCI, V30, P363, DOI 10.1007/s10103-014-1672-7
   Khoo NK, 2013, LASER MED SCI, V28, P1527, DOI 10.1007/s10103-012-1247-4
   Konoplya A A, 2016, Vopr Kurortol Fizioter Lech Fiz Kult, V93, P19, DOI 10.17116/kurort2016519-22
   KONOVALOV EP, 1988, VRACHEBNOE DELO, P71
   Koviazin V A, 2004, Med Tekh, P13
   Kozhura V L, 1993, Anesteziol Reanimatol, P43
   Kutko II, 1996, ZH NEVROPATOL PSIKH, V96, P34
   Mi XQ, 2004, PHOTOMED LASER SURG, V22, P477, DOI 10.1089/pho.2004.22.477
   Mikhailov V A, 1998, Vopr Kurortol Fizioter Lech Fiz Kult, P23
   Milic VD, 2009, TOXICOL MECH METHOD, V19, P24, DOI 10.1080/01612840802203098
   Moraes GD, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/6798238
   Moskvin S V, 2017, Vopr Kurortol Fizioter Lech Fiz Kult, V94, P10, DOI 10.17116/kurort201794510-17
   Moskvin SV, 2017, J LASERS MED SCI, V8, P56, DOI 10.15171/jlms.2017.11
   Moskvin SV, 2008, B NEW MED TECHNOLOGI, V15, P167
   Moskvin SV, 2020, BIOMEDICINE, V10, p1e20
   OSANAI T, 1990, Laser Therapy, V2, P123
   Pandey KB, 2010, OXID MED CELL LONGEV, V3, P2, DOI 10.4161/oxim.3.1.10476
   Rigonato-Oliveira NC, 2019, INT J INFLAMM, V2019, DOI 10.1155/2019/3945496
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   SKOBELKIN O K, 1991, Laser Therapy, V3, P169
   Solov'eva N N, 1989, Feldsher Akush, V54, P17
   Stadin G I, 1991, Stomatologiia (Mosk), P44
   Szymczyszyn A, 2016, LASER MED SCI, V31, P1301, DOI 10.1007/s10103-016-1971-2
   Tadakuma Takushi, 1993, Keio Journal of Medicine, V42, P180
   Thais-Meneguzzo D., 2018, LOW LEVEL LIGHT THER, P319
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   ZHIVOTOVSKY LD, 1992, VESTN OFTALMOL, V108, P52
   Zvereva K. V., 1994, Terapevticheskii Arkhiv, V66, P29
NR 49
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
EI 2578-5478
J9 PHOTOBIOMOD PHOTOMED
JI Photobiomodulation Photomed. Laser Surg.
PD JUN 1
PY 2020
VL 38
IS 6
BP 328
EP 331
DI 10.1089/photob.2020.4899
PG 4
WC Surgery
SC Surgery
GA MB4MX
UT WOS:000542578700003
PM 32579491
DA 2021-01-01
ER

PT J
AU Lalla, U
   Allwood, BW
   Louw, EH
   Nortje, A
   Parker, A
   Taljaard, JJ
   Moodley, D
   Koegelenberg, CFN
AF Lalla, Usha
   Allwood, Brian W.
   Louw, Elizabeth H.
   Nortje, Andre
   Parker, Arifa
   Taljaard, Jantjie J.
   Moodley, Desiree
   Koegelenberg, Coenraad F. N.
TI The utility of high-flow nasal cannula oxygen therapy in the management
   of respiratory failure secondary to COVID-19 pneumonia
SO SAMJ SOUTH AFRICAN MEDICAL JOURNAL
LA English
DT Letter
C1 [Lalla, Usha; Allwood, Brian W.; Louw, Elizabeth H.; Nortje, Andre; Moodley, Desiree; Koegelenberg, Coenraad F. N.] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Med, Div Pulmonol, Cape Town, South Africa.
   [Lalla, Usha; Allwood, Brian W.; Louw, Elizabeth H.; Nortje, Andre; Parker, Arifa; Taljaard, Jantjie J.; Moodley, Desiree; Koegelenberg, Coenraad F. N.] Tygerberg Acad Hosp, Cape Town, South Africa.
   [Parker, Arifa; Taljaard, Jantjie J.] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Med, Div Infect Dis, Cape Town, South Africa.
RP Koegelenberg, CFN (corresponding author), Stellenbosch Univ, Fac Med & Hlth Sci, Dept Med, Div Pulmonol, Cape Town, South Africa.; Koegelenberg, CFN (corresponding author), Tygerberg Acad Hosp, Cape Town, South Africa.
EM coeniefn@sun.ac.za
CR Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00892-2020
   Namendys-Silva SA, 2020, LANCET RESP MED, V8, pE18, DOI 10.1016/S2213-2600(20)30110-7
   Nishimura M, 2015, J INTENSIVE CARE, V3, DOI 10.1186/s40560-015-0084-5
   Parker A, 2020, SAMJ S AFR MED J, V110, P463, DOI 10.7196/SAMJ.2020.v110i6.14809
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
NR 7
TC 1
Z9 1
U1 0
U2 0
PU SA MEDICAL ASSOC
PI PRETORIA
PA BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA
SN 0256-9574
EI 2078-5135
J9 SAMJ S AFR MED J
JI SAMJ S. Afr. Med. J.
PD JUN
PY 2020
VL 110
IS 6
BP 432
EP 432
DI 10.7196/SAMJ.2020.v110i6.14882
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA LZ4AW
UT WOS:000541170200002
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Jean, SS
   Hsueh, PR
AF Jean, Shio-Shin
   Hsueh, Po-Ren
TI Old and re-purposed drugs for the treatment of COVID-19
SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
LA English
DT Article
DE Remdesivir; COVID-19; SARS-COV-2; re-purposed; favipiravir
ID MERS-COV; IVERMECTIN; LOPINAVIR/RITONAVIR; INFECTION; VIRUS; SARS
AB Introduction The coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed since December 2019. It has caused a global pandemic with more than three hundred thousand case fatalities. However, apart from supportive care by respirators, no standard medical therapy is validated. Areas covered This paper presents old drugs with potentialin vitroefficacy against SARS-CoV-2. Thein vitrodatabase, adverse effects, and potential toxicities of these drugs are reviewed regarding their feasibility of clinical prescription for the treatment of patients with COVID-19. To obtain convincing recommendations, we referred to opinions from the US National Institute of Health regarding drugs repurposed for COVID-19 therapy. Expert opinion Although strong evidence of well-designed randomized controlled studies regarding COVID-19 therapy is presently lacking, remdesivir, teicoplanin, hydroxychloroquine (not in combination with azithromycin), and ivermectin might be effective antiviral drugs and are deemed promising candidates for controlling SARS-CoV-2. In addition, tocilizumab might be considered as the supplementary treatment for COVID-19 patients with cytokine release syndrome. In future, clinical trials regarding a combination of potentially effective drugs against SARS-CoV-2 need to be conducted to establish the optimal regimen for the treatment of patients with moderate-to-severe COVID-19.
C1 [Jean, Shio-Shin] Taipei Med Univ, Coll Med, Sch Med, Dept Emergency, Taipei, Taiwan.
   [Jean, Shio-Shin] Taipei Med Univ, Wan Fang Hosp, Dept Emergency Med, Dept Emergency & Crit Care Med, Taipei, Taiwan.
   [Hsueh, Po-Ren] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Lab Med, Coll Med, 7 Chung Shan South Rd, Taipei 100, Taiwan.
   [Hsueh, Po-Ren] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Internal Med, Coll Med, Taipeis, Taiwan.
RP Hsueh, PR (corresponding author), Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Lab Med, Coll Med, 7 Chung Shan South Rd, Taipei 100, Taiwan.; Hsueh, PR (corresponding author), Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Internal Med, Coll Med, 7 Chung Shan South Rd, Taipei 100, Taiwan.
EM hsporen@ntu.edu.tw
CR [Anonymous], MEDRXIV NEWS
   [Anonymous], 2020, COVID 19 UPD HYDR RE
   [Anonymous], NEWS
   Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Caly L, 2012, ANTIVIR RES, V95, P202, DOI 10.1016/j.antiviral.2012.06.008
   Camras LA, 2004, INT J PSYCHOL, V39, P10
   Canga AG, 2008, AAPS J, V10, P42, DOI 10.1208/s12248-007-9000-9
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chandler RE, 2018, AM J TROP MED HYG, V98, P382, DOI 10.4269/ajtmh.17-0042
   Chen Z, 2020, PREPRINT, DOI 10.1101/2020.03.22.20040758v2.full.pdf
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Cush J, 2020, NIH C GUID TREAT COV
   Fedson DS, 2020, MBIO, V11, DOI 10.1128/mBio.00398-20
   Fedson DS, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.11.03
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Harapan H, 2020, J INFECT PUBLIC HEAL, V13, P667, DOI 10.1016/j.jiph.2020.03.019
   Jean S, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01205-19
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P371, DOI 10.1016/j.jmii.2020.02.011
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Medscape, TREATM COR DIS 2019
   Navarro M, 2020, J ANTIMICROB CHEMOTH, V75, P827, DOI 10.1093/jac/dkz524
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Sajid MS, 2006, PARASITOLOGY, V132, P301, DOI 10.1017/S0031182005009108
   Society of Critical Care Medicine, COVID 19 GUID
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wagstaff KM, 2011, J BIOMOL SCREEN, V16, P192, DOI 10.1177/1087057110390360
   Wang YM, 2020, J INFECT DIS, V221, P1688, DOI 10.1093/infdis/jiz656
   Wang YZ, 2016, ANTIVIR RES, V125, P1, DOI 10.1016/j.antiviral.2015.11.003
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 37
TC 4
Z9 4
U1 9
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-7210
EI 1744-8336
J9 EXPERT REV ANTI-INFE
JI Expert Rev. Anti-Infect. Ther.
PD SEP 1
PY 2020
VL 18
IS 9
BP 843
EP 847
DI 10.1080/14787210.2020.1771181
EA JUN 2020
PG 5
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA NU2HJ
UT WOS:000542022000001
PM 32419524
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Egger, A
   Abrouk, M
   Brodsky, M
   Kirsner, RS
AF Egger, Andjela
   Abrouk, Michael
   Brodsky, Merrick
   Kirsner, Robert S.
TI COVID-19 Supply Chain Considerations for Prescription Drugs in
   Dermatology
SO JOURNAL OF DRUGS IN DERMATOLOGY
LA English
DT Article
C1 [Egger, Andjela; Abrouk, Michael; Kirsner, Robert S.] Univ Miami, Miller Sch Med, Dr Phillip Frost Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA.
   [Brodsky, Merrick] Univ Colorado, Dept Dermatol, Boulder, CO 80309 USA.
RP Egger, A (corresponding author), Univ Miami, Miller Sch Med, Dr Phillip Frost Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA.
EM axn404@med.miami.edu
CR Cascella M, 2020, EVALUATION TREATMENT
   Li DG, 2018, JAMA DERMATOL, V154, P1441, DOI 10.1001/jamadermatol.2018.3798
   Lupkin S., 2020, PHARM SUPPLY
   U.S. Food and Drug Administration, 2020, OR BOOK APPR DRUG PR
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 5
TC 0
Z9 0
U1 2
U2 2
PU JOURNAL OF DRUGS IN DERMATOLOGY
PI NEW YORK
PA 377 PARK AVE SOUTH, 6TH FLOOR, NEW YORK, NY 10016 USA
SN 1545-9616
J9 J DRUGS DERMATOL
JI J. Drugs Dermatol.
PD JUN
PY 2020
VL 19
IS 6
BP 666
EP 667
DI 10.36849/JDD.2020.5146
PG 2
WC Dermatology
SC Dermatology
GA MA1CC
UT WOS:000541651600015
PM 32574019
DA 2021-01-01
ER

PT J
AU Armitage, R
   Nellums, LB
AF Armitage, R.
   Nellums, L. B.
TI Substance misuse during COVID-19: protecting people who use drugs
SO PUBLIC HEALTH
LA English
DT Letter
C1 [Armitage, R.; Nellums, L. B.] Univ Nottingham, City Hosp Nottingham, Hucknall Rd, Nottingham, England.
RP Armitage, R (corresponding author), Univ Nottingham, City Hosp Nottingham, Hucknall Rd, Nottingham, England.
EM msxra37@nottingham.ac.uk; Laura.Nellums@nottingham.ac.uk
OI Armitage, Richard/0000-0003-1165-6753; Nellums,
   Laura/0000-0002-2534-6951
CR Chou KL, 2011, J CLIN PSYCHIAT, V72, P1468, DOI 10.4088/JCP.10m06019gry
   Degenhardt L, 2012, LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0
   Halpin DMG, 2020, LANCET RESP MED, V8, P436, DOI 10.1016/S2213-2600(20)30167-3
   Kinner SA, 2020, LANCET PUBLIC HEALTH, V5, pE188, DOI 10.1016/S2468-2667(20)30058-X
   Matsuzaki M, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5291-2
   Palmer F, 2012, PRIM CARE RESP J, V21, P377, DOI 10.4104/pcrj.2012.00069
   Tsai J, 2020, LANCET PUBLIC HEALTH, V5, pE186, DOI 10.1016/S2468-2667(20)30053-0
   WHO, 2020, MOD TRANSM VIR CAUS
NR 8
TC 2
Z9 2
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0033-3506
EI 1476-5616
J9 PUBLIC HEALTH
JI Public Health
PD JUN
PY 2020
VL 183
BP 63
EP 63
DI 10.1016/j.puhe.2020.05.010
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA LZ6ZX
UT WOS:000541371500020
PM 32405098
OA Green Published
DA 2021-01-01
ER

PT J
AU McIntosh, JJ
AF McIntosh, Jennifer Jury
TI Corticosteroid Guidance for Pregnancy during COVID-19 Pandemic
SO AMERICAN JOURNAL OF PERINATOLOGY
LA English
DT Article
DE COVID-19; corticosteroids; prematurity; betamethasone; dexamethasone
ID PATTERNS; WOMEN; RISK
AB The novel coronavirus disease 2019 (COVID-19) pandemic is causing a necessary, rapid adjustment within the field of obstetrics. Corticosteroid use is a mainstay of therapy for those women delivering prematurely. Unfortunately, corticosteroid use has been associated with worse outcomes in COVID-19 positive patients. Given this information, it is necessary that obstetricians adjust practice to carefully weigh the fetal benefits with maternal risks. Therefore, our institution has examined the risks and benefits and altered our corticosteroid recommendations.
C1 [McIntosh, Jennifer Jury] Med Coll Wisconsin, Dept Obstet & Gynecol, Div Maternal Fetal Med, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.
RP McIntosh, JJ (corresponding author), Med Coll Wisconsin, Dept Obstet & Gynecol, Div Maternal Fetal Med, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.
EM jmcintosh@mcw.edu
OI McIntosh, Jennifer/0000-0002-0299-9589
FU National Heart, Lung, and Blood Institute of the National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [K08HL150340]
FX Research reported in this publication was supported by the National
   Heart, Lung, and Blood Institute of the National Institutes of Health
   under Award Number K08HL150340 (J.J.M.). The content is solely the
   responsi-bility of the author and does not necessarily represent the
   official views of the National Institutes of Health.
CR Adams TM, 2015, J MATERN-FETAL NEO M, V28, P1598, DOI 10.3109/14767058.2014.962508
   [Anonymous], 2016, Obstet Gynecol, V127, pe157, DOI 10.1097/AOG.0000000000001483
   [Anonymous], 1994, NIH Consens Statement, V12, P1
   Boesveld M, 2014, J MATERN-FETAL NEO M, V27, P516, DOI 10.3109/14767058.2013.821975
   Brownfoot FC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006764.pub3
   El-Sayed YY, 2017, OBSTET GYNECOL, V130, pE102
   Food and Drug Administration, FDA ADV PAT US NONST
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gyamfi-Bannerman C, 2016, NEW ENGL J MED, V374, P1311, DOI 10.1056/NEJMoa1516783
   Haas DM, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6226
   PERRY KG, 1995, AM J OBSTET GYNECOL, V173, P1273, DOI 10.1016/0002-9378(95)91369-6
   Roberts D, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub2
   Roberts D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub3
   Shang J, 2020, TREATMENT OUTCOMES P, DOI 10.2139/ssrn.3546060
   Solaimanzadeh I, 2020, CUREUS, V12, DOI 10.7759/cureus.7343
   Travers CP, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j1039
NR 16
TC 8
Z9 8
U1 2
U2 4
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0735-1631
EI 1098-8785
J9 AM J PERINAT
JI Am. J. Perinatol.
PD JUN
PY 2020
VL 37
IS 08
BP 809
EP 812
DI 10.1055/s-0040-1709684
PG 4
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA MB4ZP
UT WOS:000542612800006
PM 32274772
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Plaze, M
   Attali, D
   Petit, AC
   Blatzer, M
   Simon-Loriere, E
   Vinckier, F
   Cachia, A
   Chretien, F
   Gaillard, R
AF Plaze, M.
   Attali, D.
   Petit, A-C
   Blatzer, M.
   Simon-Loriere, E.
   Vinckier, F.
   Cachia, A.
   Chretien, F.
   Gaillard, R.
TI Repurposing chlorpromazine to treat COVID-19: The reCoVery study
SO ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE
LA English
DT Article
DE Chlorpromazine; SARS-CoV-2; COVID-19; Repurposing of molecules; Clinical
   trial
ID ANTIPSYCHOTIC-DRUGS; IL-10 PRODUCTION; TNF PRODUCTION; VIRUS; BRAIN;
   REPLICATION; BLOOD; CELLS; INHIBITION; INFECTION
AB Objectives. - The ongoing COVID-19 pandemic has caused approximately 2,350,000 infections worldwide and killed more than 160,000 individuals. In Sainte-Anne Hospital (GHU PARIS Psychiatrie & Neuroscience, Paris, France) we have observed a lower incidence of symptomatic forms of COVID-19 among patients than among our clinical staff. This observation led us to hypothesize that psychotropic drugs could have a prophylactic action against SARS-CoV-2 and protect patients from the symptomatic and virulent forms of this infection, since several of these psychotropic drugs have documented antiviral properties. Chlorpromazine (CPZ), a phenothiazine derivative, is also known for its antiviral activity via the inhibition of clathrin-mediated endocytosis. Recentin vitro studies have reported that CPZ exhibits anti-MERS-CoV and anti-SARS-CoV-1 activity.
   Methods. - In this context, the ReCoVery study aims to repurpose CPZ, a molecule with an excellent tolerance profile and a very high biodistribution in the saliva, lungs and brain. We hypothesize that CPZ could reduce the unfavorable course of COVID-19 infection among patients requiring respiratory support without the need for ICU care, and that it could also reduce the contagiousness of SARS-CoV-2. For this purpose, we plan a pilot, multicenter, randomized, single blind, controlled, phase III therapeutic trial (standard treatment vs. CPZ + standard treatment).
   Conclusion. - This repurposing of CPZ for its anti-SARS-CoV-2 activity could offer an alternative, rapid strategy to alleviate infection severity. This repurposing strategy also avoids numerous developmental and experimental steps, and could save precious time to rapidly establish an anti-COVID-19 therapy with well-known, limited and easily managed side effects. (C) 2020 L'Encephale, Paris.
C1 [Plaze, M.; Attali, D.; Petit, A-C; Vinckier, F.; Gaillard, R.] Pole Hosp Univ Paris 15, GHU PARIS Psychiat & Neurosci, Site St Anne, Serv Hosp Univ, Paris, France.
   [Plaze, M.; Attali, D.; Vinckier, F.; Gaillard, R.] Univ Paris, Paris, France.
   [Attali, D.] Univ Paris Diderot, Phys Med Paris, INSERM, ESPCI Paris,CNRS,PSL Res Univ,Sorbonne Paris Cite, Paris, France.
   [Petit, A-C; Blatzer, M.; Chretien, F.; Gaillard, R.] Inst Pasteur, Expt Neuropathol Unit, Paris, France.
   [Simon-Loriere, E.] Inst Pasteur, G5 Evolutionary Genom RNA Viruses, Paris, France.
   [Cachia, A.] Univ Paris, Inst Psychiat & Neurosci Paris, INSERM, Paris, France.
   [Cachia, A.] Univ Paris, Lab Psychol Dev & Educ Enfant, CNRS, Paris, France.
   [Chretien, F.] GHU PARIS Psychiat & Neurosci, Serv Neuropathol, Site St Anne, Paris, France.
RP Plaze, M (corresponding author), Pole Hosp Univ Paris 15, GHU PARIS Psychiat & Neurosci, Site St Anne, Serv Hosp Univ, Paris, France.
EM m.plaze@ghu-paris.fr
RI Blatzer, Michael/AAZ-3824-2020
FU Fondation Pierre Deniker
FX The authors wish to thank the Fondation Pierre Deniker for its support,
   as well as Laetitia Canivet.
CR BERTINI R, 1993, IMMUNOLOGY, V79, P217
   BICKEL MH, 1983, LIFE SCI, V33, P2025, DOI 10.1016/0024-3205(83)90742-7
   Blanchard E, 2006, J VIROL, V80, P6964, DOI 10.1128/JVI.00024-06
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Chu H, 2020, LANCET MICROBE, V1, pE14
   COMAR D, 1979, PSYCHIAT RES, V1, P23, DOI 10.1016/0165-1781(79)90024-6
   Committee on Practice Bulletins-Obstetrics, 2018, Obstet Gynecol, V131, pe15, DOI 10.1097/AOG.0000000000002456
   Cong Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194868
   Daniel JA, 2015, TRAFFIC, V16, P635, DOI 10.1111/tra.12272
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   DELAY J, 1952, Ann Med Psychol (Paris), V110, P112
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   FORREST IS, 1968, BIOCHEM PHARMACOL, V17, P2061, DOI 10.1016/0006-2952(68)90180-9
   GADINA M, 1991, J EXP MED, V173, P1305, DOI 10.1084/jem.173.6.1305
   Giamarellos-Bourboulis E. J., 2020, CELL HOST MICROBE
   Gupta M, 2013, J PAIN SYMPTOM MANAG, V45, P338, DOI 10.1016/j.jpainsymman.2012.10.042
   HCSP, 2020, COR SARS COV 2 CRIT
   Hewlett I, 1997, J ACQ IMMUN DEF SYND, V15, P16, DOI 10.1097/00042560-199705010-00003
   Kanerva A, 2007, J GENE MED, V9, P3, DOI 10.1002/jgm.984
   KRIZANOVA O, 1982, ACTA VIROL, V26, P209
   Marmura MJ, 2015, HEADACHE, V55, P3, DOI 10.1111/head.12499
   MAY PRA, 1978, ARCH GEN PSYCHIAT, V35, P1091
   MENGOZZI M, 1994, IMMUNOLOGY, V82, P207
   Nawa M, 2003, J GEN VIROL, V84, P1737, DOI 10.1099/vir.0.18883-0
   Pho MT, 2000, J VIROL, V74, P2288, DOI 10.1128/JVI.74.5.2288-2292.2000
   Pohjala L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028923
   Pollmacher T, 2000, J PSYCHIATR RES, V34, P369, DOI 10.1016/S0022-3956(00)00032-7
   Rundle-Thiele D, 2016, BRIT J CLIN PHARMACO, V81, P199, DOI 10.1111/bcp.12785
   SGARAGLI GP, 1995, J PHARM PHARMACOL, V47, P782, DOI 10.1111/j.2042-7158.1995.tb06741.x
   SJOSTRAND SE, 1965, ARCH INT PHARMACOD T, V156, P34
   TARAZONA R, 1995, J IMMUNOL, V154, P861
   TSUNEIZUMI T, 1992, BIOL PSYCHIAT, V32, P817, DOI 10.1016/0006-3223(92)90085-E
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107
   Weinman D, 2014, HEADACHE, V54, P260, DOI 10.1111/head.12287
   WIESEL FA, 1976, EUR J PHARMACOL, V40, P263, DOI 10.1016/0014-2999(76)90061-3
   World Health Organization, 2020, COR DIS COVID 2019 R
   Wu Y, 2020, AIDS BEHAV 0508
   Yang ND, 2020, INT J BIOL SCI, V16, P1724, DOI 10.7150/ijbs.45498
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   ZUCKER S, 1990, MEDICINE, V69, P92, DOI 10.1097/00005792-199069020-00003
NR 41
TC 5
Z9 5
U1 3
U2 3
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0013-7006
J9 ENCEPHALE
JI Enceph.-Rev. Psychiatr. Clin. Biol. Ther.
PD JUN
PY 2020
VL 46
IS 3
BP 169
EP 172
DI 10.1016/j.encep.2020.05.006
PG 4
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA LZ3TS
UT WOS:000541151600002
PM 32425222
OA Green Published
DA 2021-01-01
ER

PT J
AU Trump, BD
   Bridges, TS
   Cegan, JC
   Cibulsky, SM
   Greer, SL
   Jarman, H
   Lafferty, BJ
   Surette, MA
   Linkov, I
AF Trump, Benjamin D.
   Bridges, Todd S.
   Cegan, Jeffrey C.
   Cibulsky, Susan M.
   Greer, Scott L.
   Jarman, Holly
   Lafferty, Brandon J.
   Surette, Melissa A.
   Linkov, Igor
TI An Analytical Perspective on Pandemic Recovery
SO HEALTH SECURITY
LA English
DT Article
DE Risk communication; National strategy; policy; COVID-19
AB After implementing restrictions to curb the spread of coronavirus, governments in the United States and around the world are trying to identify the path to social and economic recovery. The White House and the Centers for Disease Control and Prevention have published guidelines to assist US states, counties, and territories in planning these efforts. As the impact of the coronavirus pandemic has not been uniform, these central guidelines need to be translated into practice in ways that recognize variation among jurisdictions. We present a core methodology to assist governments in this task, presenting a case for appropriate actions at each stage of recovery based on scientific data and analysis. Specifically, 3 types of data are needed: data on the spread of disease should be analyzed alongside data on the overall health of the population and data on infrastructure-for example, the capacity of health systems. Local circumstances will produce different needs and present different setbacks, and governments may need to reinstate as well as relax restrictions. Transparent, defensible analysis can assist in making these decisions and communicating them to the public. In the absence of a widely administered vaccine, analysis remains one of our most important tools in addressing the coronavirus pandemic.
C1 [Trump, Benjamin D.; Bridges, Todd S.; Cegan, Jeffrey C.; Lafferty, Brandon J.; Linkov, Igor] US Army Corps Engineers, US Army Engineer Res & Dev Ctr, Vicksburg, MS 39180 USA.
   [Cibulsky, Susan M.] US Dept HHS, Off Assistant Secretary Preparedness & Response, Boston, MA USA.
   [Greer, Scott L.; Jarman, Holly] Univ Michigan, Global Publ Hlth & Polit Sci, Hlth Management & Policy, Ann Arbor, MI 48109 USA.
   [Surette, Melissa A.] Fed Emergency Management Assoc, Reg 1, COVID 19, Boston, MA USA.
RP Trump, BD (corresponding author), US Army Corps Engineers, US Army Engineer Res & Dev Ctr, Vicksburg, MS 39180 USA.
EM Benjamin.D.Trump@usace.army.mil
OI Greer, Scott Edward Lennarson/0000-0002-5288-0471
CR CDCc, BEH RISK FACT SURV S
   Greer SL, 2016, STRENGTHENING HLTH S, P27
   Hynes William, 2020, Environment Systems & Decisions, V40, DOI 10.1007/s10669-020-09776-x
   Linkov I., 2019, SCI PRACTICE RESILIE
   State of Michigan, 2020, MI SAFE START PLAN R
   Trump BD, 2020, ENVIRON SCI TECHNOL, V54, P4706, DOI 10.1021/acs.est.0c00607
   White House, 2020, GUID OP AM AG
   World Health Organization (WHO), CRIT DECL END EB OUT
NR 8
TC 1
Z9 1
U1 2
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2326-5094
EI 2326-5108
J9 HEALTH SECUR
JI Health Secur.
PD JUN 1
PY 2020
VL 18
IS 3
BP 250
EP 256
DI 10.1089/hs.2020.0057
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA LZ4WT
UT WOS:000541227100014
PM 32525747
DA 2021-01-01
ER

PT J
AU Caly, L
   Druce, JD
   Catton, MG
   Jans, DA
   Wagstaff, KM
AF Caly, Leon
   Druce, Julian D.
   Catton, Mike G.
   Jans, David A.
   Wagstaff, Kylie M.
TI The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2
   in vitro
SO ANTIVIRAL RESEARCH
LA English
DT Article
ID NUCLEAR IMPORT; NUCLEOCAPSID PROTEIN; LOCALIZATION; VIRUSES; TRANSPORT;
   SAFETY
AB Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect -5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
C1 [Caly, Leon; Druce, Julian D.; Catton, Mike G.] Royal Melbourne Hosp, Peter Doherty Inst Infect & Immun, Victorian Infect Dis Reference Lab, Melbourne, Vic 3000, Australia.
   [Jans, David A.; Wagstaff, Kylie M.] Monash Univ, Biomed Discovery Inst, Clayton, Vic 3800, Australia.
RP Wagstaff, KM (corresponding author), Monash Univ, Biomed Discovery Inst, Clayton, Vic 3800, Australia.
EM kylie.wagstaff@monash.edu
OI Catton, Michael/0000-0002-0297-1260
FU National Breast Cancer Foundation Fellowship, Australia [ECF-17-007];
   National Health and Medical Research Council (NHMRC), AustraliaNational
   Health and Medical Research Council of Australia [APP1103050]
FX This work was supported by a National Breast Cancer Foundation
   Fellowship, Australia (ECF-17-007) for KMW and an National Health and
   Medical Research Council (NHMRC), Australia Senior Prinicple Research
   Fellow (SPRF) (APP1103050) for DAJ.
CR Buonfrate D, 2019, LANCET INFECT DIS, V19, P1181, DOI 10.1016/S1473-3099(19)30289-0
   Caly L, 2012, ANTIVIR RES, V95, P202, DOI 10.1016/j.antiviral.2012.06.008
   Canga AG, 2008, AAPS J, V10, P42, DOI 10.1208/s12248-007-9000-9
   Corman V. M., 2020, EURO SURVEILL, V25
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   Gotz V, 2016, SCI REP-UK, V6, DOI 10.1038/srep23138
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Hiscox JA, 2001, J VIROL, V75, P506, DOI 10.1128/JVI.75.1.506-512.2001
   Jans DA, 2019, CURR OPIN CELL BIOL, V58, P50, DOI 10.1016/j.ceb.2019.01.001
   Ketkar H, 2019, DIAGN MICR INFEC DIS, V95, P38, DOI 10.1016/j.diagmicrobio.2019.03.012
   Kosyna FK, 2015, BIOL CHEM, V396, P1357, DOI 10.1515/hsz-2015-0171
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lundberg L, 2013, ANTIVIR RES, V100, P662, DOI 10.1016/j.antiviral.2013.10.004
   Lv CJ, 2018, ANTIVIR RES, V159, P55, DOI 10.1016/j.antiviral.2018.09.010
   Mastrangelo E, 2012, J ANTIMICROB CHEMOTH, V67, P1884, DOI 10.1093/jac/dks147
   Navarro M, 2020, J ANTIMICROB CHEMOTH, V75, P827, DOI 10.1093/jac/dkz524
   Nicolas P, 2020, LANCET GLOB HEALTH, V8, pE92, DOI 10.1016/S2214-109X(19)30453-X
   Ono N, 2001, J VIROL, V75, P4399, DOI 10.1128/JVI.75.9.4399-4401.2001
   Rowland RRR, 2005, J VIROL, V79, P11507, DOI 10.1128/JVI.79.17.11507-11512.2005
   Tay MYF, 2013, ANTIVIR RES, V99, P301, DOI 10.1016/j.antiviral.2013.06.002
   Timani KA, 2005, VIRUS RES, V114, P23, DOI 10.1016/j.virusres.2005.05.007
   van der Watt PJ, 2016, MOL CANCER THER, V15, P560, DOI 10.1158/1535-7163.MCT-15-0052
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   Wagstaff KM, 2011, J BIOMOL SCREEN, V16, P192, DOI 10.1177/1087057110390360
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wulan WN, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00553
   Wurm T, 2001, J VIROL, V75, P9345, DOI 10.1128/JVI.75.19.9345-9356.2001
   Yamasmith E., 2018, 34 ANN M ROYAL COLL, V1
   Yang SNY, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104760
NR 31
TC 314
Z9 324
U1 12
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD JUN
PY 2020
VL 178
AR 104787
DI 10.1016/j.antiviral.2020.104787
PG 4
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA LY2IN
UT WOS:000540343900009
PM 32251768
OA Other Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Choy, KT
   Wong, AYL
   Kaewpreedee, P
   Sia, SF
   Chen, DD
   Hui, KPY
   Chu, DKW
   Chan, MCW
   Cheung, PPH
   Huang, XH
   Peiris, M
   Yen, HL
AF Choy, Ka-Tim
   Wong, Alvina Yin-Lam
   Kaewpreedee, Prathanporn
   Sia, Sin Fun
   Chen, Dongdong
   Hui, Kenrie Pui Yan
   Chu, Daniel Ka Wing
   Chan, Michael Chi Wai
   Cheung, Peter Pak-Hang
   Huang, Xuhui
   Peiris, Malik
   Yen, Hui-Ling
TI Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2
   replication in vitro
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE COVID-19; Remdesivir; Lopinavir; Ritonavir; Emetine; Homoharringtonine
ID CORONAVIRUS
AB An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 mu M, 26.63 mu M, 2.55 mu M and 0.46 mu M, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 mu M. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 mu M in combination with emetine at 0.195 mu M may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits.
C1 [Choy, Ka-Tim; Wong, Alvina Yin-Lam; Kaewpreedee, Prathanporn; Sia, Sin Fun; Chen, Dongdong; Hui, Kenrie Pui Yan; Chu, Daniel Ka Wing; Chan, Michael Chi Wai; Peiris, Malik; Yen, Hui-Ling] Univ Hong Kong, LKS Fac Med, Sch Publ Hlth, Hong Kong, Peoples R China.
   [Cheung, Peter Pak-Hang; Huang, Xuhui] Hong Kong Univ Sci & Technol, Dept Chem, Hong Kong, Peoples R China.
RP Yen, HL (corresponding author), Univ Hong Kong, LKS Fac Med, Sch Publ Hlth, Hong Kong, Peoples R China.
EM hyen@hku.hk
RI Yen, Hui-Ling/C-4501-2009
OI Yen, Hui-Ling/0000-0003-2493-3609; Kaewpreedee,
   Prathanporn/0000-0002-0464-2401; Huang, Xuhui/0000-0002-7119-9358;
   Cheung, Pak Hang Peter/0000-0001-8474-2906
FU National Institute of Allergy and Infectious Diseases of the National
   Institutes of Health, USAUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [HHSN272201400006C];
   Theme-Based Research Scheme from the Research Grants Council, Hong Kong
   SAR, China [T11-705/14N]
FX This study was supported by Contract HHSN272201400006C from the National
   Institute of Allergy and Infectious Diseases of the National Institutes
   of Health, USA, and the Theme-Based Research Scheme (T11-705/14N) from
   the Research Grants Council, Hong Kong SAR, China.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Andersen PI, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100964
   [Anonymous], 2020, WHO CORONAVIRUS DIS
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao JZ, 2015, ANTIVIR RES, V114, P1, DOI 10.1016/j.antiviral.2014.11.010
   Valadao ALC, 2015, MOLECULES, V20, P11474, DOI 10.3390/molecules200611474
   China National Health Commission, 2020, NOV COR DIAGN TREATM
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Chu DKW, 2020, CLIN CHEM
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dong HJ, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110601
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007
   GROLLMAN AP, 1966, P NATL ACAD SCI USA, V56, P1867, DOI 10.1073/pnas.56.6.1867
   Ianevski A, 2017, BIOINFORMATICS, V33, P2413, DOI 10.1093/bioinformatics/btx162
   Kempf DJ, 1997, ANTIMICROB AGENTS CH, V41, P654, DOI 10.1128/AAC.41.3.654
   Khandelwal N, 2017, ANTIVIR RES, V144, P196, DOI 10.1016/j.antiviral.2017.06.006
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lopez-Cortes LF, 2013, ANTIMICROB AGENTS CH, V57, P3746, DOI 10.1128/AAC.00315-13
   Lu SQ, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-2
   MacGibeny MA, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007188
   Malyutina A, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006752
   Mukhopadhyay R, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005717
   Nemunaitis J, 2013, CANCER CHEMOTH PHARM, V71, P35, DOI 10.1007/s00280-012-1963-2
   Regenthal R, 1999, J CLIN MONITOR COMP, V15, P529, DOI 10.1023/A:1009935116877
   Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218, DOI 10.1128/AAC.42.12.3218
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shen L, 2019, J VIROL, V93, DOI 10.1128/JVI.00023-19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wong W, 2014, ELIFE, V3, DOI 10.7554/eLife.03080
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang S, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0034-1
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 36
TC 164
Z9 163
U1 12
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD JUN
PY 2020
VL 178
AR 104786
DI 10.1016/j.antiviral.2020.104786
PG 5
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA LY2IN
UT WOS:000540343900008
PM 32251767
OA Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Sallard, E
   Lescure, FX
   Yazdanpanah, Y
   Mentre, F
   Peiffer-Smadja, N
AF Sallard, Erwan
   Lescure, Francois-Xavier
   Yazdanpanah, Yazdan
   Mentre, France
   Peiffer-Smadja, Nathan
TI Type 1 interferons as a potential treatment against COVID-19
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE Interferon; COVID-19; SARS-CoV-2
ID RESPIRATORY SYNDROME CORONAVIRUS; SARS-CORONAVIRUS; SYNERGISTICALLY
   INHIBIT; BETA; RIBAVIRIN; REPLICATION; INFECTION; RESPONSES; MODEL
AB Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.
C1 [Sallard, Erwan] Ecole Normale Super Paris, 45 Rue Ulm, F-75005 Paris, France.
   [Lescure, Francois-Xavier; Yazdanpanah, Yazdan; Mentre, France; Peiffer-Smadja, Nathan] Univ Paris, INSERM, IAME, F-75018 Paris, France.
   [Lescure, Francois-Xavier; Yazdanpanah, Yazdan; Peiffer-Smadja, Nathan] Bichat Claude Bernard Univ Hosp, AP HP, Dept Infect & Trop Dis, 46 Rue Henri Huchard, F-75018 Paris, France.
RP Peiffer-Smadja, N (corresponding author), Bichat Claude Bernard Univ Hosp, AP HP, Dept Infect & Trop Dis, 46 Rue Henri Huchard, F-75018 Paris, France.
EM nathan.peiffer-smadja@inserm.fr
OI Lescure, Xavier/0000-0002-2828-125X; Sallard, Erwan/0000-0002-2324-3633
CR Al-Tawfiq JA, 2014, INT J INFECT DIS, V20, P42, DOI 10.1016/j.ijid.2013.12.003
   Arabi YM, 2017, AM J RESP CRIT CARE, V195
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Belhadi D, 2020, BRIEF REV ANTIVIRAL, DOI [10.1101/2020.03.18.20038190, DOI 10.1101/2020.03.18.20038190]
   Bellingan G, 2014, LANCET RESP MED, V2, P98, DOI 10.1016/S2213-2600(13)70259-5
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Channappanavar R, 2019, J CLIN INVEST, V129, P3625, DOI 10.1172/JCI126363
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Falzarano D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01686
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   Gao LL, 2010, VACCINE, V28, P4445, DOI 10.1016/j.vaccine.2010.03.062
   Hart BJ, 2014, J GEN VIROL, V95, P571, DOI 10.1099/vir.0.061911-0
   Hensley LE, 2004, EMERG INFECT DIS, V10, P317, DOI 10.3201/eid1002.030482
   Jakimovski D, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a032003
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   Kumari G, 2020, BIORXIV, DOI [10.1101/2020.03.07.982264, DOI 10.1101/2020.03.07.982264]
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633
   Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Mager DE, 2002, PHARMACEUT RES, V19, P1537, DOI 10.1023/A:1020468902694
   Martin C, 2020, ANN SCI, V77, P445, DOI 10.1080/00033790.2020.1814863
   Menachery VD, 2014, J VIROL, V88, P4251, DOI 10.1128/JVI.03571-13
   Morgenstern B, 2005, BIOCHEM BIOPH RES CO, V326, P905, DOI 10.1016/j.bbrc.2004.11.128
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Ranieri VM, 2020, JAMA-J AM MED ASSOC, V323, P725, DOI 10.1001/jama.2019.22525
   Sainz B, 2004, VIROLOGY, V329, P11, DOI 10.1016/j.virol.2004.08.011
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Scagnolari C, 2004, ANTIVIR THER, V9, P1003
   Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231
   Shalhoub S, 2015, J ANTIMICROB CHEMOTH, V70, P2129, DOI 10.1093/jac/dkv085
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shen KL, 2020, WORLD J PEDIATR, V16, P219, DOI 10.1007/s12519-020-00344-6
   Siddiqi HK, 2020, J HEART LUNG TRANSPL
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Thiel V, 2008, CYTOKINE GROWTH F R, V19, P121, DOI 10.1016/j.cytogfr.2008.01.001
   Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhao Z, 2003, J MED MICROBIOL, V52, P715, DOI 10.1099/jmm.0.05320-0
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 42
TC 123
Z9 122
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD JUN
PY 2020
VL 178
AR 104791
DI 10.1016/j.antiviral.2020.104791
PG 4
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA LY2IN
UT WOS:000540343900012
PM 32275914
OA Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Shannon, A
   Le, NTT
   Selisko, B
   Eydoux, C
   Alvarez, K
   Guillemot, JC
   Decroly, E
   Peersen, O
   Ferron, F
   Canard, B
AF Shannon, Ashleigh
   Nhung Thi-Tuyet Le
   Selisko, Barbara
   Eydoux, Cecilia
   Alvarez, Karine
   Guillemot, Jean-Claude
   Decroly, Etienne
   Peersen, Olve
   Ferron, Francois
   Canard, Bruno
TI Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp
   and nsp14 Exonuclease active-sites
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE RNA-Dependent RNA polymerase; Exonuclease; Nucleotide analogue;
   Remdesivir; Resistance; Mutation; Coronavirus; COVID-19
ID SARS-CORONAVIRUS; RNA-POLYMERASE; IN-VITRO; VIRUS; RIBAVIRIN; PROTEIN;
   SEQUENCE; EXORIBONUCLEASE; INHIBITION; MECHANISM
AB The rapid global emergence of SARS-CoV-2 has been the cause of significant health concern, highlighting the immediate need for antivirals. Viral RNA-dependent RNA polymerases (RdRp) play essential roles in viral RNA synthesis, and thus remains the target of choice for the prophylactic or curative treatment of several viral diseases, due to high sequence and structural conservation. To date, the most promising broad-spectrum class of viral RdRp inhibitors are nucleoside analogues (NAs), with over 25 approved for the treatment of several medically important viral diseases. However, Coronaviruses stand out as a particularly challenging case for NA drug design due to the presence of an exonuclease (ExoN) domain capable of excising incorporated NAs and thus providing resistance to many of these available antivirals. Here we use the available structures of the SARS-CoV RdRp and ExoN proteins, as well as Lassa virus N exonuclease to derive models of catalytically competent SARS-CoV-2 enzymes. We then map a promising NA candidate, GS-441524 (the active metabolite of Remdesivir) to the nucleoside active site of both proteins, identifying the residues important for nucleotide recognition, discrimination, and excision. Interestingly, GS-441524 addresses both enzyme active sites in a manner consistent with significant incorporation, delayed chain termination, and altered excision due to the ribose 1'-CN group, which may account for the increased antiviral effect compared to other available analogues. Additionally, we propose structural and function implications of two previously identified RdRp resistance mutations in relation to resistance against Remdesivir. This study highlights the importance of considering the balance between incorporation and excision properties of NAs between the RdRp and ExoN.
C1 [Shannon, Ashleigh; Nhung Thi-Tuyet Le; Selisko, Barbara; Eydoux, Cecilia; Alvarez, Karine; Guillemot, Jean-Claude; Decroly, Etienne; Peersen, Olve; Ferron, Francois; Canard, Bruno] Aix Marseille Univ, CNRS, UMR 7257, Architecture & Fonct Macromol Biol, 163 Ave Luminy, F-13288 Marseille, France.
   [Peersen, Olve] Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.
RP Ferron, F; Canard, B (corresponding author), Aix Marseille Univ, CNRS, UMR 7257, Architecture & Fonct Macromol Biol, 163 Ave Luminy, F-13288 Marseille, France.
EM francois.ferron@afmb.univ-mrs.fr; bruno.canard@afmb.univ-mrs.fr
OI Peersen, Olve/0000-0001-6208-2660; DECROLY, Etienne/0000-0002-6046-024X;
   Shannon, Ashleigh/0000-0003-4290-8247
FU REACTing, a multidisciplinary collaborative network of French research
   institutions working on emerging infectious diseases; Fondation pour la
   Recherche Medicale (Aide aux equipes)Fondation pour la Recherche
   Medicale
FX This work was performed with the support of REACTing, a
   multidisciplinary collaborative network of French research institutions
   working on emerging infectious diseases, which aims to prepare and
   respond to epidemics, and the Fondation pour la Recherche Medicale (Aide
   aux equipes).
CR Agostini M.L., 2019, J VIROL, V93
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Bouvet M, 2012, P NATL ACAD SCI USA, V109, P9372, DOI 10.1073/pnas.1201130109
   Campagnola G, 2015, J VIROL, V89, P275, DOI 10.1128/JVI.01574-14
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Crotty S, 2000, NAT MED, V6, P1375
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dehouck Y, 2009, BIOINFORMATICS, V25, P2537, DOI 10.1093/bioinformatics/btp445
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Fung A, 2014, ANTIMICROB AGENTS CH, V58, P3636, DOI 10.1128/AAC.02666-14
   Furuta Y, 2002, ANTIMICROB AGENTS CH, V46, P977, DOI 10.1128/AAC.46.4.977-981.2002
   Gong P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060272
   Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556
   Gouy M, 2010, MOL BIOL EVOL, V27, P221, DOI 10.1093/molbev/msp259
   Gross AE, 2015, ANN PHARMACOTHER, V49, P1125, DOI 10.1177/1060028015597449
   HALL CB, 1983, JAMA-J AM MED ASSOC, V249, P2666, DOI 10.1001/jama.249.19.2666
   Jiang X, 2013, J BIOL CHEM, V288, P16949, DOI 10.1074/jbc.M112.420521
   Jordan PC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006889
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Lehmann KC, 2015, NUCLEIC ACIDS RES, V43, P8416, DOI 10.1093/nar/gkv838
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104
   McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Mohni KN, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003652
   Ogando NS, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01813
   Peersen OB, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11080745
   Peersen OB, 2017, VIRUS RES, V234, P4, DOI 10.1016/j.virusres.2017.01.026
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pruijssers AJ, 2019, CURR OPIN VIROL, V35, P57, DOI 10.1016/j.coviro.2019.04.002
   Sexton NR, 2016, J VIROL, V90, P7415, DOI 10.1128/JVI.00080-16
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Yekwa E, 2017, ACTA CRYSTALLOGR D, V73, P641, DOI 10.1107/S205979831700866X
   Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 44
TC 53
Z9 54
U1 26
U2 31
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD JUN
PY 2020
VL 178
AR 104793
DI 10.1016/j.antiviral.2020.104793
PG 9
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA LY2IN
UT WOS:000540343900014
PM 32283108
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Weitz, JS
   Beckett, SJ
   Coenen, AR
   Demory, D
   Dominguez-Mirazo, M
   Dushoff, J
   Leung, CY
   Li, GL
   Magalie, A
   Park, SW
   Rodriguez-Gonzalez, R
   Shivam, S
   Zhao, CY
AF Weitz, Joshua S.
   Beckett, Stephen J.
   Coenen, Ashley R.
   Demory, David
   Dominguez-Mirazo, Marian
   Dushoff, Jonathan
   Leung, Chung-Yin
   Li, Guanlin
   Magalie, Andreea
   Park, Sang Woo
   Rodriguez-Gonzalez, Rogelio
   Shivam, Shashwat
   Zhao, Conan Y.
TI Modeling shield immunity to reduce COVID-19 epidemic spread
SO NATURE MEDICINE
LA English
DT Article
ID CORONAVIRUS; MULTISCALE; INFECTION; NETWORK
AB A new study models the potential effects of preferentially deploying recovered individuals, who are seropositive for anti-SARS-CoV-2 antibodies, into the community to reduce the number of interactions between susceptible and infected people, thereby limiting transmission of the virus.
   The COVID-19 pandemic has precipitated a global crisis, with more than 1,430,000 confirmed cases and more than 85,000 confirmed deaths globally as of 9 April 2020(1-4). Mitigation and suppression of new infections have emerged as the two predominant public health control strategies(5). Both strategies focus on reducing new infections by limiting human-to-human interactions, which could be both socially and economically unsustainable in the long term. We have developed and analyzed an epidemiological intervention model that leverages serological tests(6,7) to identify and deploy recovered individuals(8) as focal points for sustaining safer interactions via interaction substitution, developing what we term 'shield immunity' at the population scale. The objective of a shield immunity strategy is to help to sustain the interactions necessary for the functioning of essential goods and services(9) while reducing the probability of transmission. Our shield immunity approach could substantively reduce the length and reduce the overall burden of the current outbreak, and can work synergistically with social distancing. The present model highlights the value of serological testing as part of intervention strategies, in addition to its well-recognized roles in estimating prevalence(10,11) and in the potential development of plasma-based therapies(12-15).
C1 [Weitz, Joshua S.; Beckett, Stephen J.; Demory, David; Dominguez-Mirazo, Marian; Leung, Chung-Yin; Magalie, Andreea; Rodriguez-Gonzalez, Rogelio; Zhao, Conan Y.] Georgia Inst Technol, Sch Biol Sci, Atlanta, GA 30332 USA.
   [Weitz, Joshua S.; Coenen, Ashley R.; Leung, Chung-Yin; Li, Guanlin] Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA.
   [Weitz, Joshua S.] Georgia Inst Technol, Ctr Microbial Dynam & Infect, Atlanta, GA 30332 USA.
   [Dominguez-Mirazo, Marian; Li, Guanlin; Magalie, Andreea; Rodriguez-Gonzalez, Rogelio; Zhao, Conan Y.] Georgia Inst Technol, Interdisciplinary Grad Program Quantitat Biosci, Atlanta, GA 30332 USA.
   [Dushoff, Jonathan] McMaster Univ, Dept Biol, Hamilton, ON, Canada.
   [Dushoff, Jonathan] McMaster Univ, DeGroote Inst Infect Dis Res, Hamilton, ON, Canada.
   [Park, Sang Woo] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.
   [Shivam, Shashwat] Georgia Inst Technol, Sch Elect & Comp Engn, Atlanta, GA 30332 USA.
RP Weitz, JS (corresponding author), Georgia Inst Technol, Sch Biol Sci, Atlanta, GA 30332 USA.; Weitz, JS (corresponding author), Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA.; Weitz, JS (corresponding author), Georgia Inst Technol, Ctr Microbial Dynam & Infect, Atlanta, GA 30332 USA.
EM jsweitz@gatech.edu
OI Beckett, Stephen/0000-0002-4410-2960; Dushoff,
   Jonathan/0000-0003-0506-4794
FU Simons Foundation (SCOPE Award) [329108]; Army Research Office
   [W911NF1910384]; National Institutes of HealthUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [1R01AI46592-01]; National Science FoundationNational Science Foundation
   (NSF) [1806606, 1829636]; Canadian Institutes of Health ResearchCanadian
   Institutes of Health Research (CIHR); Natural Sciences and Engineering
   Research Council of CanadaNatural Sciences and Engineering Research
   Council of CanadaCGIAR
FX We thank P.S. Dodds, M. Lipsitch, K. Levy, D. Muratore, A. Sanz and J.
   Shaman for comments and feedback in the initial stages of development,
   and A. Kraay, B. Lopman and K. Nelson for discussions on serological
   testing characteristics as part of ongoing collaborative work. Tweet
   threads by T. Bedford and N. Christakis were influential in refining
   initial ideas into the current form. Research effort by J.S.W. and
   co-authors at the Georgia Institute of Technology was enabled by support
   from grants from the Simons Foundation (SCOPE Award ID 329108), the Army
   Research Office (W911NF1910384), the National Institutes of Health
   (1R01AI46592-01) and the National Science Foundation (1806606 and
   1829636). J.D. was supported in part by grants from the Canadian
   Institutes of Health Research and the Natural Sciences and Engineering
   Research Council of Canada.
CR Amanat F., SEROLOGICAL ASSAY DE
   [Anonymous], ANN EST RES POP SING
   [Anonymous], NAT COVID 19 CONV PL
   [Anonymous], 2020, GLOB OPT TOOLB
   Balcan D, 2009, P NATL ACAD SCI USA, V106, P21484, DOI 10.1073/pnas.0906910106
   Bansal S, 2007, J R SOC INTERFACE, V4, P879, DOI 10.1098/rsif.2007.1100
   Bellan SE, 2014, LANCET, V384, P1499, DOI 10.1016/S0140-6736(14)61839-0
   Bezanson J, 2017, SIAM REV, V59, P65, DOI 10.1137/141000671
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Chakravartula SSN, 2020, FOOD PACKAGING SHELF, V24, DOI 10.1016/j.fpsl.2020.100498
   Chan KH, 2013, J INFECTION, V67, P130, DOI 10.1016/j.jinf.2013.03.015
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Colizza V, 2006, P NATL ACAD SCI USA, V103, P2015, DOI 10.1073/pnas.0510525103
   Dormand J., 1980, J COMPUT APPL MATH, V6, P19, DOI [10.1016/0771-050X(80)90013-3, DOI 10.1016/0771-050X(80)90013-3]
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Emanuel EJ, 2020, NY TIMES
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Ferguson N., 2020, IMPACT NONPHARMACEUT
   Flaxman S., 2020, 13 IMP COLL
   Gottlieb S, 2020, NATL CORONAVIRUS RES
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Hennekens CH, 2020, AM J MED, V133, P648, DOI 10.1016/j.amjmed.2020.03.001
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Klompas M, 2020, ANN INTERN MED, V172, P619, DOI 10.7326/M20-0751
   Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Lou B, 2020, SEROLOGY CHARACTERIS
   Mckee M, 2020, NAT MED, V26, P640, DOI 10.1038/s41591-020-0863-y
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Park S. W., 2020, TIME SCALE ASYMPTOMA
   Park S. W, 2020, RECONCILING EARLY OU
   Rackauckas C., 2017, J OPEN RES STW, V5, P15, DOI [10.5334/jors.151, DOI 10.5334/JORS.151]
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Shampine LF, 1997, SIAM J SCI COMPUT, V18, P1, DOI 10.1137/S1064827594276424
   Soetaert K, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i09
   Tsitouras C, 2011, COMPUT MATH APPL, V62, P770, DOI 10.1016/j.camwa.2011.06.002
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Watts DJ, 2005, P NATL ACAD SCI USA, V102, P11157, DOI 10.1073/pnas.0501226102
   WHITLEY D, 1994, STAT COMPUT, V4, P65
   WHO, 2020, 70 WHO
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 49
TC 17
Z9 15
U1 4
U2 14
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD JUN
PY 2020
VL 26
IS 6
BP 849
EP +
DI 10.1038/s41591-020-0895-3
PG 19
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA LZ3ZG
UT WOS:000541166000025
PM 32382154
OA Bronze
DA 2021-01-01
ER

PT J
AU Dormont, F
   Brusini, R
   Cailleau, C
   Reynaud, F
   Peramo, A
   Gendron, A
   Mougin, J
   Gaudin, F
   Varna, M
   Couvreur, P
AF Dormont, Flavio
   Brusini, Romain
   Cailleau, Catherine
   Reynaud, Franceline
   Peramo, Arnaud
   Gendron, Amandine
   Mougin, Julie
   Gaudin, Francoise
   Varna, Mariana
   Couvreur, Patrick
TI Squalene-based multidrug nanoparticles for improved mitigation of
   uncontrolled inflammation in rodents
SO SCIENCE ADVANCES
LA English
DT Article
ID NITRIC-OXIDE PRODUCTION; OXIDATIVE STRESS; SEPTIC SHOCK; ADENOSINE;
   SEPSIS; LIPOPOLYSACCHARIDE; ALPHA; INHIBITION; ACTIVATION; PROTECTS
AB Uncontrolled inflammatory processes are at the root of numerous pathologies. Most recently, studies on confirmed COVID-19 cases have suggested that mortality might be due to virally induced hyperinflammation. Uncontrolled pro-inflammatory states are often driven by continuous positive feedback loops between pro-inflammatory signaling and oxidative stress, which cannot be resolved in a targeted manner. Here, we report on the development of multidrug nanoparticles for the mitigation of uncontrolled inflammation. The nanoparticles are made by conjugating squalene, a natural lipid, to adenosine, an endogenous immunomodulator, and then encapsulating a-tocopherol, as antioxidant. This resulted in high drug loading, biocompatible, multidrug nanoparticles. By exploiting the endothelial dysfunction at sites of acute inflammation, these multidrug nanoparticles delivered the therapeutic agents in a targeted manner, conferring survival advantage to treated animals in models of endotoxemia. Selectively delivering adenosine and antioxidants together could serve as a novel therapeutic approach for safe treatment of acute paradoxal inflammation.
C1 [Dormont, Flavio; Brusini, Romain; Cailleau, Catherine; Reynaud, Franceline; Peramo, Arnaud; Gendron, Amandine; Mougin, Julie; Varna, Mariana; Couvreur, Patrick] Univ Paris Saclay, Univ Paris Sud, Inst Galien Paris Sud, CNRS UMR 8612, F-92296 Chatenay Malabry, France.
   [Reynaud, Franceline] Univ Fed Rio de Janeiro, Sch Pharm, BR-2194459 Rio De Janeiro, Brazil.
   [Gaudin, Francoise] Univ Paris Saclay, Plateforme Histol Immunopathol Clamart PHIC, INSERM, CNRS,Inst Paris Saclay Innovat Therapeut, F-92296 Chatenay Malabry, France.
   [Gaudin, Francoise] Univ Paris Saclay, Inflammat Microbiome & Immunosurveillance, INSERM, F-92140 Clamart, France.
RP Couvreur, P (corresponding author), Univ Paris Saclay, Univ Paris Sud, Inst Galien Paris Sud, CNRS UMR 8612, F-92296 Chatenay Malabry, France.
EM patrick.couvreur@universite-paris-saclay.fr
RI COUVREUR, Patrick/AAY-7568-2020; Patrick, COUVREUR/G-4844-2011
OI Patrick, COUVREUR/0000-0001-7961-5443
FU la Fondation pour la Recherche Medicale (FRM)Fondation pour la Recherche
   Medicale [ANR-16-ENM2-0005-01];  [ECO20160736101]
FX The authors gratefully acknowledge the financial support from the 7th
   EuroNanoMed-II call for proposals, project NanoHeart no.
   ANR-16-ENM2-0005-01. This work was further supported by la Fondation
   pour la Recherche Medicale (FRM) grant no. ECO20160736101.
CR Andrades ME, 2011, CRIT CARE, V15, DOI 10.1186/cc10334
   Azzi A, 2016, ARCH BIOCHEM BIOPHYS, V595, P100, DOI 10.1016/j.abb.2015.11.010
   Azzopardi EA, 2013, J ANTIMICROB CHEMOTH, V68, P257, DOI 10.1093/jac/dks379
   BARTON BE, 1993, INFECT IMMUN, V61, P1496, DOI 10.1128/IAI.61.4.1496-1499.1993
   BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7
   Berger MM, 2007, CRIT CARE MED, V35, pS584, DOI 10.1097/01.CCM.0000279189.81529.C4
   Biswas SK, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5698931
   Borrelli E, 1996, CRIT CARE MED, V24, P392, DOI 10.1097/00003246-199603000-00006
   Brodie C, 1998, FEBS LETT, V429, P139, DOI 10.1016/S0014-5793(98)00556-0
   Chow CW, 2003, AM J RESP CELL MOL, V29, P427, DOI 10.1165/rcmb.F278
   Dandekar A, 2015, METHODS MOL BIOL, V1292, P205, DOI 10.1007/978-1-4939-2522-3_15
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Desmaele D, 2012, J CONTROL RELEASE, V161, P609, DOI 10.1016/j.jconrel.2011.07.038
   Dormont F, 2019, J CONTROL RELEASE, V307, P302, DOI 10.1016/j.jconrel.2019.06.040
   Dormont F, 2018, MATER TODAY, V21, P122, DOI 10.1016/j.mattod.2017.07.008
   ESTERBAUER H, 1991, AM J CLIN NUTR, V53, pS314, DOI 10.1093/ajcn/53.1.314S
   Flogel U, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003717
   Galley HF, 2010, CRIT CARE, V14, DOI 10.1186/cc9098
   Gaudin A, 2015, CHEM MATER, V27, P3636, DOI 10.1021/acs.chemmater.5b00267
   Gaudin A, 2014, NAT NANOTECHNOL, V9, P1054, DOI [10.1038/nnano.2014.274, 10.1038/NNANO.2014.274]
   Gibbison B, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1659-4
   Gomez H, 2014, SHOCK, V41, P3, DOI 10.1097/SHK.0000000000000052
   Goodman RB, 2003, CYTOKINE GROWTH F R, V14, P523, DOI 10.1016/S1359-6101(03)00059-5
   Gu YH, 2015, EXP THER MED, V10, P915, DOI 10.3892/etm.2015.2604
   Hakanpaa L, 2018, P NATL ACAD SCI USA, V115, pE6467, DOI 10.1073/pnas.1722317115
   Halliwell B., 2015, FREE RADICALS BIOL M
   Hasko G, 1996, J IMMUNOL, V157, P4634
   Hasko G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00085
   Hasko G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638
   Jacobs AT, 2001, J BIOL CHEM, V276, P47950, DOI 10.1074/jbc.M106639200
   Korhonen Riku, 2005, Current Drug Targets - Inflammation and Allergy, V4, P471, DOI 10.2174/1568010054526359
   Kotelevets L, 2017, CANCER RES, V77, P2964, DOI 10.1158/0008-5472.CAN-16-1741
   Kruzel ML, 2000, INFLAMMATION, V24, P33, DOI 10.1023/A:1006935908960
   Lane N, 2003, J THEOR BIOL, V225, P531, DOI 10.1016/S0022-5193(03)00304-7
   Lugrin J, 2014, BIOL CHEM, V395, P203, DOI 10.1515/hsz-2013-0241
   Majetschak M, 2004, SURGERY, V135, P536, DOI 10.1016/j.surg.2003.09.006
   Mangge H, 2014, WORLD J CARDIOL, V6, P462, DOI 10.4330/wjc.v6.i6.462
   Marik PE, 2017, CHEST, V151, P1229, DOI 10.1016/j.chest.2016.11.036
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Nakamura T, 1998, BIOFACTORS, V7, P21, DOI 10.1002/biof.5520070104
   PARMELY MJ, 1993, J IMMUNOL, V151, P389
   Prauchner CA, 2017, BURNS, V43, P471, DOI 10.1016/j.burns.2016.09.023
   Rosenblat M, 2002, ATHEROSCLEROSIS, V160, P69, DOI 10.1016/S0021-9150(01)00563-9
   Rouquette M, 2019, J PHARMACOL EXP THER, V369, P144, DOI 10.1124/jpet.118.254961
   Schwager S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00308
   Sewerynek E, 2011, J PHYSIOL PHARMACOL, V62, P677
   SEWERYNEK E, 1995, FREE RADICAL BIO MED, V19, P903, DOI 10.1016/0891-5849(95)00101-3
   Shrum Bradly, 2014, BMC Res Notes, V7, P233, DOI 10.1186/1756-0500-7-233
   Snoeck E, 1998, J PHARMACOL EXP THER, V286, P142
   Sobot D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15678
   SODERBACK U, 1987, ACTA PHYSIOL SCAND, V129, P189, DOI 10.1111/j.1748-1716.1987.tb08058.x
   Soh M, 2017, ANGEW CHEM, V129, P11557, DOI [10.1002/ange.201704904, DOI 10.1002/ANGE.201704904]
   SUZUKI YJ, 1993, BIOCHEM MOL BIOL INT, V31, P693
   Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999
   van der Poll T, 2017, NAT REV IMMUNOL, V17, P407, DOI 10.1038/nri.2017.36
   Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259
   Wu F, 2008, J CELL PHYSIOL, V217, P207, DOI 10.1002/jcp.21495
   Yang D, 2006, J CLIN INVEST, V116, P1913, DOI 10.1172/JCI27933
   Zisman DA, 1997, J CLIN INVEST, V99, P2832, DOI 10.1172/JCI119475
NR 59
TC 9
Z9 9
U1 7
U2 9
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD JUN
PY 2020
VL 6
IS 23
AR eaaz5466
DI 10.1126/sciadv.aaz5466
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LY8OH
UT WOS:000540787200018
PM 32548259
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sawalha, AH
   Zhao, M
   Coit, P
   Lu, QJ
AF Sawalha, Amr H.
   Zhao, Ming
   Coit, Patrick
   Lu, Qianjin
TI Epigenetic dysregulation of ACE2 and interferon-regulated genes might
   suggest increased COVID-19 susceptibility and severity in lupus patients
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE SARS-CoV-2; Lupus; COVID-19; Epigenetics; ACE2; Methylation; Interferon
ID NAIVE CD4+T CELLS; NEGATIVE T-CELLS; DNA METHYLATION; OXIDATIVE STRESS;
   DEMETHYLATION; PATHOGENESIS; ACTIVATION; PATHOLOGY; SIGNATURE; CORRELATE
AB Infection caused by SARS-CoV-2 can result in severe respiratory complications and death. Patients with a compromised immune system are expected to be more susceptible to a severe disease course. In this report we suggest that patients with systemic lupus erythematous might be especially prone to severe COVID-19 independent of their immunosuppressed state from lupus treatment. Specifically, we provide evidence in lupus to suggest hypomethylation and overexpression of ACE2, which is located on the X chromosome and encodes a functional receptor for the SARS-CoV-2 spike glycoprotein. Oxidative stress induced by viral infections exacerbates the DNA methylation defect in lupus, possibly resulting in further ACE2 hypomethylation and enhanced viremia. In addition, demethylation of interferon-regulated genes, NF.B, and key cytokine genes in lupus patients might exacerbate the immune response to SARS-CoV-2 and increase the likelihood of cytokine storm. These arguments suggest that inherent epigenetic dysregulation in lupus might facilitate viral entry, viremia, and an excessive immune response to SARS-CoV-2. Further, maintaining disease remission in lupus patients is critical to prevent a vicious cycle of demethylation and increased oxidative stress, which will exacerbate susceptibility to SARS-CoV-2 infection during the current pandemic. Epigenetic control of the ACE2 gene might be a target for prevention and therapy in COVID-19.
C1 [Sawalha, Amr H.; Coit, Patrick] Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Pediat, Div Rheumatol, Pittsburgh, PA 15213 USA.
   [Sawalha, Amr H.] Univ Pittsburgh, Dept Med, Div Rheumatol & Clin Immunol, Pittsburgh, PA USA.
   [Sawalha, Amr H.] Univ Pittsburgh, Sch Med, Lupus Ctr Excellence, Pittsburgh, PA USA.
   [Zhao, Ming; Lu, Qianjin] Cent South Univ, Xiangya Hosp 2, Dept Dermatol, Changsha, Hunan, Peoples R China.
   [Zhao, Ming; Lu, Qianjin] Cent South Univ, Xiangya Hosp 2, Hunan Key Lab Med Epigen, Changsha, Hunan, Peoples R China.
   [Coit, Patrick] Univ Michigan, Sch Med, Grad Immunol Program, Ann Arbor, MI USA.
RP Sawalha, AH (corresponding author), 7123 Rangos Res Ctr,4401 Penn Ave, Pittsburgh, PA 15224 USA.
EM asawalha@pitt.edu
FU Lupus Research Alliance [U19AI110502, R01AI097134]; National Institute
   of Allergy and Infectious Diseases of the National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19AI110502, R01AI097134]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81830097]; Innovation project of Chinese Academy of Medical
   Sciences [2019-I2M-5-033]; Hunan Province for fighting against
   coronavirus disease-2019 epidemic [2020SK3005]
FX This work was supported by the Lupus Research Alliance and the National
   Institute of Allergy and Infectious Diseases of the National Institutes
   of Health grants number U19AI110502 and R01AI097134 to Dr. Sawalha; and
   the National Natural Science Foundation of China (No. 81830097), the
   Innovation project of Chinese Academy of Medical Sciences (Research
   Unit, No. 2019-I2M-5-033) and an urgent grant of Hunan Province for
   fighting against coronavirus disease-2019 epidemic (2020SK3005) to Dr.
   Lu.
CR Coit P, 2016, ARTHRITIS RHEUMATOL, V68, P2200, DOI 10.1002/art.39720
   Coit P, 2015, J AUTOIMMUN, V58, P59, DOI 10.1016/j.jaut.2015.01.004
   Coit P, 2013, J AUTOIMMUN, V43, P78, DOI 10.1016/j.jaut.2013.04.003
   Crispin JC, 2008, J IMMUNOL, V181, P8761, DOI 10.4049/jimmunol.181.12.8761
   Gensterblum E, 2018, J AUTOIMMUN, V86, P19, DOI 10.1016/j.jaut.2017.09.011
   Gorelik G, 2007, J IMMUNOL, V179, P5553, DOI 10.4049/jimmunol.179.8.5553
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088
   Hoffmann M, 2020, CELL
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imgenberg-Kreuz J, 2018, ANN RHEUM DIS, V77, P736, DOI 10.1136/annrheumdis-2017-212379
   Katsuyama E, 2020, CELL REP, V30, P112, DOI 10.1016/j.celrep.2019.12.014
   Li YP, 2014, ARTHRITIS RHEUMATOL, V66, P1574, DOI 10.1002/art.38427
   Lu Q, 2007, J IMMUNOL, V179, P6352, DOI 10.4049/jimmunol.179.9.6352
   Perl A, 2013, NAT REV RHEUMATOL, V9, P674, DOI 10.1038/nrrheum.2013.147
   Renauer PA, 2015, CLIN IMMUNOL, V156, P19, DOI 10.1016/j.clim.2014.10.007
   Sawalha AH, 2009, J AUTOIMMUN, V33, P31, DOI 10.1016/j.jaut.2009.03.006
   Strickland FM, 2016, LUPUS SCI MED, V3, DOI 10.1136/lupus-2016-000147
   Teruel M, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926-017-0657-5
   Weeding E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00875
   Zhao M, 2014, J AUTOIMMUN, V54, P127, DOI 10.1016/j.jaut.2014.07.002
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 22
TC 54
Z9 54
U1 10
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD JUN
PY 2020
VL 215
AR 108410
DI 10.1016/j.clim.2020.108410
PG 4
WC Immunology
SC Immunology
GA LY0TV
UT WOS:000540237500004
PM 32276140
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Wills, TT
   Zuelzer, WA
   Tran, BW
AF Wills, Timothy T.
   Zuelzer, Wilhelm A.
   Tran, Bryant W.
TI Utilization of an Orthopedic Hood as Personal Protective Equipment for
   Intubation of Coronavirus Patients: a Brief Technical Report
SO GERIATRIC ORTHOPAEDIC SURGERY & REHABILITATION
LA English
DT Article
DE adult reconstructive surgery; anesthesia; geriatric medicine; systems of
   care; occupational therapy
AB Background:
   The novel coronavirus disease (COVID-19) has afflicted millions of people worldwide since its first case was reported in December 2019. Personal protective equipment (PPE) has been tailored accordingly, but as of April 2020, close to 10 000 health care workers in the United States have contracted COVID-19 despite wearing recommended PPE. As such, standard guidelines for PPE may be inadequate for the health care worker performing high-risk aerosolizing procedures such as endotracheal intubation. In this brief technical report, we describe the integration of an orthopedic hood cover as an item for full barrier protection against COVID-19 transmission.
   Technical Description:
   The Coronavirus Airway Task Force at Virginia Commonwealth University Medical Center approved this initiative and went live with the full barrier suit during the last week of March 2020. The PPE described in this report includes a Stryker T4 Hood, normally used in conjunction with the Stryker Steri-Shield T4 Helmet. Instead of the helmet, the hood is secured to the head via a baseball cap and binder clip. This head covering apparatus is to be used as an accessory to other PPE items that include an N95 mask, waterproof gown, and disposable gloves. The motor ventilation system is not used in order to prevent airborne viral entry into the hood.
   Discussion:
   An advantage of the full barrier suit is an additional layer of droplet protection during intubation. The most notable disadvantage is the absence of a ventilation system within the hood covering.
   Conclusion:
   Modification of existing PPE may provide protection for health care workers during high-risk aerosolizing procedures such as endotracheal intubation. Although the integration of this medical equipment meets the immediate needs of an escalating crisis, further innovation is on the horizon. More research is needed to confirm the safety of modified PPE.
C1 [Wills, Timothy T.; Tran, Bryant W.] Virginia Commonwealth Univ, Dept Anesthesiol, Med Ctr, POB 980695, Richmond, VA 23298 USA.
   [Zuelzer, Wilhelm A.] Virginia Commonwealth Univ, Dept Orthoped Surg, Med Ctr, Richmond, VA USA.
RP Tran, BW (corresponding author), Virginia Commonwealth Univ, Dept Anesthesiol, Med Ctr, POB 980695, Richmond, VA 23298 USA.
EM bryant.tran@vcuhealth.org
OI Tran, Bryant/0000-0002-1231-5611
CR CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   CDC (US Centers for Disease Control), 2020, CHARACTERISTICES HLT, V69, P477, DOI DOI 10.15585/MMWR.MM6915E6
   Centers for Disease Control and Prevention, 2020, INT INF PREV CONTR R
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Ortega R, 2020, NEW ENGL J MED, V382
   Santarpia JL, 2020, TRANSMISSION POTENTI
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 8
TC 2
Z9 2
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2151-4585
EI 2151-4593
J9 GERIATR ORTHOP SURG
JI Geriatr. Orthop. Surg. Rehabil.
PD JUN 1
PY 2020
VL 11
AR 2151459320930554
DI 10.1177/2151459320930554
PG 3
WC Geriatrics & Gerontology; Orthopedics; Rehabilitation; Surgery
SC Geriatrics & Gerontology; Orthopedics; Rehabilitation; Surgery
GA LY5QZ
UT WOS:000540585400001
PM 32537257
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pordany, B
   Herczeg, G
   Mate, M
AF Pordany Balint
   Herczeg Gyorgy
   Mate Miklos
TI Colon cancer during the coronavirus pandemic - recovery from COVID-19
   pneumonia of an elderly woman with multiple co-morbidities
SO ORVOSI HETILAP
LA Hungarian
DT Article
DE colon cancer; COVID-19; pneumonia; case report
AB COVID-19, caused by the new coronavirus, can lead to acute respiratory failure or even sepsis. Patients with multiple co-morbidities are more likely to develop these severe forms of the disease. The aim of this report is to highlight cases the analysis of which might help discover factors that influence the course and mortality of COVID-19 pneumonia. The past medical history of our elderly patient (75-year-old female) includes rectum resection with intraoperative cardiac arrest and successful resuscitation. In January 2020, the patient was diagnosed with adenocarcinoma of the ascending colon and concomittant pulmonary embolism. Following 6 weeks of therapeutic dose low-molecular-weight heparin (LMWH) treatment, the cancerous colonic section was resected. The patient arrested intraoperatively but was successfully resuscitated. On post-operative day 15, the patient developed arterial anastomosis bleed, which necessitated acute right-sided hemicolectomy. Post-operatively she became pyrexial and COVID-19 was confirmed, but later became apyrexial with symptomatic treatment. Subsequently, the patient developed partial anastomosis insufficiency, which resolved with conservative management. Following three negative SARS-CoV-2 tests, she was successfully discharged from hospital. It is worthy of note that due to the active anastomosis bleed the angiotensin -converting enzyme (ACE)-inhibitor treatment was stopped, and later the patient got infected with SARS-CoV-2. A long-lasting LMWH therapy was performed. The timely management of colorectal carcinoms remains important even during an epidemic. The appropriate treatment of these patients during the pandemic presents a great challenge for all doctors, but, as shown in our case report, surgical treatment of even those with multiple co-morbidities can be successful.
C1 [Pordany Balint; Herczeg Gyorgy; Mate Miklos] Szent Imre Egyet Oktatokorhaz, Altalanos Sebeszeti Profil, Budapest, Hungary.
RP Pordany, B (corresponding author), Szent Imre Egyet Oktatokorhaz, Altalanos Sebeszeti Profil, Budapest, Hungary.
EM pordanybalint@gmail.com
CR American Cancer Society, 2020, WHY PEOPL CANC AR MO
   Attard JAP, 2005, DIS COLON RECTUM, V48, P1460, DOI 10.1007/s10350-005-0047-3
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Fogarty H, 2020, BRIT J HAEMATOL, V189, P1044, DOI 10.1111/bjh.16749
   Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219
   Hungarian Surgical Society, INF PROT COVID 19 PA
   Li TH, 2020, EMERG MICROBES INFEC, V9, P687, DOI 10.1080/22221751.2020.1741327
   National Institutes of Health, COR DIS COVID 19
   National Public Health Center, FREQ QUEST COVID 19
   National Public Health Center, 2020, PROT DEAL COVID 19 I
   Pruitt SL, 2013, CANCER CAUSE CONTROL, V24, P961, DOI 10.1007/s10552-013-0172-6
   Stathopoulos GP, 2011, ONCOL LETT, V2, P731, DOI 10.3892/ol.2011.310
   Whimbey Estella, 1997, American Journal of Medicine, V102, P10, DOI 10.1016/S0002-9343(97)80004-6
   Yao Yanhong, 2020, Zhongguo Fei Ai Za Zhi, V23, P255, DOI 10.3779/j.issn.1009-3419.2020.102.13
NR 14
TC 0
Z9 0
U1 1
U2 2
PU AKADEMIAI KIADO ZRT
PI BUDAPEST
PA BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY
SN 0030-6002
EI 1788-6120
J9 ORVOSI HETILAP
JI Orvosi Hetilap
PD JUN
PY 2020
VL 161
IS 25
BP 1059
EP 1062
DI 10.1556/650.2020.31866
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA LY2SO
UT WOS:000540373600006
PM 32516124
DA 2021-01-01
ER

PT J
AU Fleming, AB
   Raabe, V
AF Fleming, Andrew B.
   Raabe, Vanessa
TI Current studies of convalescent plasma therapy for COVID-19 may
   underestimate risk of antibody-enhancement
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Letter
C1 [Fleming, Andrew B.] NYU, Grossman Sch Med, Langone Vaccine Ctr, New York, NY 10003 USA.
   NYU, Grossman Sch Med, Div Infect Dis & Immunol, Dept Med, New York, NY USA.
RP Fleming, AB (corresponding author), NYU, Grossman Sch Med, Langone Vaccine Ctr, New York, NY 10003 USA.
EM Andrew.fleming@nyulangone.org
OI Raabe, Vanessa/0000-0003-2579-1104
CR Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Ho MS, 2005, EMERG INFECT DIS, V11, P1730, DOI 10.3201/eid1111.040659
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Shen C, 2020, JAMA
   Yuan FF, 2005, TISSUE ANTIGENS, V66, P291, DOI 10.1111/j.1399-0039.2005.00476.x
NR 6
TC 13
Z9 13
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JUN
PY 2020
VL 127
AR 104388
DI 10.1016/j.jcv.2020.104388
PG 1
WC Virology
SC Virology
GA LX8ME
UT WOS:000540079600003
PM 32361326
OA Green Published
DA 2021-01-01
ER

PT J
AU Zhao, Q
   He, Y
AF Zhao, Qian
   He, Yong
TI Challenges of Convalescent Plasma Therapy on COVID-19
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Letter
ID PNEUMONIA
C1 [Zhao, Qian; He, Yong] Army Med Univ, Duping Hosp, Dept Pulm & Crit Care Med, Chongqing 400042, Peoples R China.
RP He, Y (corresponding author), Army Med Univ, Duping Hosp, Dept Pulm & Crit Care Med, Chongqing 400042, Peoples R China.
EM heyong8998@126.com
CR Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Department of General Administration of National Health Commission, 2020, PREV CONTR PLAN COVI
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Li G, 2003, NEW ENGL J MED, V349, P508, DOI 10.1056/NEJM200307313490520
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   MacLennan S, 2006, BEST PRACT RES CL HA, V19, P169, DOI 10.1016/j.beha.2005.01.033
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   The Joint Prevention and Control Mechanism of the State Council, 2020, INTR SIT PREV TREATM
   WHO, 2014, US CONV WHOL BLOOD P
NR 11
TC 21
Z9 21
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JUN
PY 2020
VL 127
AR 104358
DI 10.1016/j.jcv.2020.104358
PG 1
WC Virology
SC Virology
GA LX8ME
UT WOS:000540079600009
PM 32305026
OA Green Published
DA 2021-01-01
ER

PT J
AU Thangaraju, P
   Gurunthalingam, MP
   Venkatesan, S
   Thangaraju, E
AF Thangaraju, Pugazhenthan
   Gurunthalingam, Meenalotchini Prakash
   Venkatesan, Sajitha
   Thangaraju, Eswaran
TI COVID-19: Wait for a novel drug or act with the age old drug - Do we
   have a choice?
SO JOURNAL OF INFECTION AND PUBLIC HEALTH
LA English
DT Letter
ID VIRUS-INFECTION; CHLOROQUINE; CORONAVIRUS
C1 [Thangaraju, Pugazhenthan; Gurunthalingam, Meenalotchini Prakash] All India Inst Med Sci, Dept Pharmacol, Raipur, Madhya Pradesh, India.
   [Venkatesan, Sajitha] All India Inst Med Sci, Dept Microbiol, Raipur, Madhya Pradesh, India.
   [Thangaraju, Eswaran] AKT Mem Coll Engn & Technol, Kallakurichi, Tamil Nadu, India.
RP Thangaraju, P (corresponding author), All India Inst Med Sci, Dept Pharmacol, Raipur, Madhya Pradesh, India.
EM drpugal23@gmail.com
RI THANGARAJU, PUGAZHENTHAN/A-4707-2019
OI THANGARAJU, PUGAZHENTHAN/0000-0002-4090-2004
CR Bhatnagar T, 2020, INDIAN J MED RES, DOI [10.4103/ijmr.IJMR50220, DOI 10.4103/IJMR.IJMR50220]
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   CONNOLLY KM, 1988, AGENTS ACTIONS, V25, P94, DOI 10.1007/BF01969100
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Keyaerts E, 2009, ANTIMICROB AGENTS CH, V53, P3416, DOI 10.1128/AAC.01509-08
   Li CF, 2017, EBIOMEDICINE, V24, P189, DOI 10.1016/j.ebiom.2017.09.034
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Tan YW, 2018, ANTIVIR RES, V149, P143, DOI 10.1016/j.antiviral.2017.11.017
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1876-0341
EI 1876-035X
J9 J INFECT PUBLIC HEAL
JI J. Infect. Public Health
PD JUN
PY 2020
VL 13
IS 6
BP 899
EP 900
DI 10.1016/j.jiph.2020.05.006
PG 2
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA LX6HI
UT WOS:000539930200016
PM 32451256
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Di Pierro, F
   Bertuccioli, A
   Cavecchia, I
AF Di Pierro, Francesco
   Bertuccioli, Alexander
   Cavecchia, Ilaria
TI Possible therapeutic role of a highly standardized mixture of active
   compounds derived from cultured Lentinula edodes mycelia (AHCC) in
   patients infected with 2019 novel coronavirus
SO MINERVA GASTROENTEROLOGICA E DIETOLOGICA
LA English
DT Article
DE Coronavirus; Severe acute respiratory syndrome coronavirus 2; Middle
   east respiratory syndrome coronavirus; Shiitake mushrooms; Adjuvants;
   immunologic
ID IMMUNE-RESPONSE; SUPPLEMENTATION; MUSHROOMS; IMPROVES
AB The outbreak of SARS-CoV-2 disease (COVID-19) is currently, March 2020, affecting more than 100,000 people worldwide and, according to the WHO (World Health Organization), a pandemic is shortly expected. The virus infects the lower respiratory tract and causes severe pneumonia and mortality in approximately 10% and 3-5%, respectively, of cases, mainly among the elderly and/or people affected by other diseases. AHCC is an a-glucan-based standardized mushroom extract that has been extensively investigated as an immunostimulant both in animals and/or in humans affected by West Nile virus, influenza virus, avian influenza virus, hepatitis C virus, papillomavirus, herpes virus, hepatitis B virus and HIV by promoting a regulated and protective immune response. Although the efficacy of AHCC has not yet been specifically evaluated with respect to SARS-CoV-2 disease, its action in promoting a protective response to a wide range of viral infections, and the current absence of effective vaccines, could support its use in the prevention of diseases provoked by human pathogenic coronavirus, including COVID-19.
C1 [Di Pierro, Francesco; Cavecchia, Ilaria] Velleja Res, Dept Sci & Res, Milan, Italy.
   [Bertuccioli, Alexander] Carlo Bo Univ Urbino, Dept Biomol Sci, Urbino, Italy.
RP Di Pierro, F (corresponding author), Velleja Res, Dept Sci & Res, Milan, Italy.
EM f.dipierro@vellejaresearch.com
RI Bertuccioli, Alexander/ABC-7139-2020
CR Block Keith I, 2003, Integr Cancer Ther, V2, P247, DOI 10.1177/1534735403256419
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Ghazarian L, 2014, CURR OPIN IMMUNOL, V27, P83, DOI 10.1016/j.coi.2014.02.004
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jesenak M, 2017, NUTRIENTS, V9, DOI 10.3390/nu9070779
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Laksono BM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07515-0
   Lefkowitz EJ, 2018, NUCLEIC ACIDS RES, V46, pD708, DOI 10.1093/nar/gkx932
   Meng X, 2016, CARBOHYD RES, V424, P30, DOI 10.1016/j.carres.2016.02.008
   Munoz-Ruiz M, 2017, TRENDS IMMUNOL, V38, P336, DOI 10.1016/j.it.2017.01.007
   Nogusa S, 2009, NUTR RES, V29, P139, DOI 10.1016/j.nutres.2009.01.005
   Perussia, 1996, Methods, V9, P370
   Ritz BW, 2006, J NUTR, V136, P2868
   Roman BE, 2013, NUTR RES, V33, P12, DOI 10.1016/j.nutres.2012.11.001
   Shin MS, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/3758576
   Smith JA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00173
   Takanari J, 2018, J EVID-BASED INTEGR, V23, DOI 10.1177/2156587218756511
   Thaiudom S, 2010, MED NEWS THAILAND, V325, P13
   Wang SH, 2009, J NUTR, V139, P598, DOI 10.3945/jn.108.100297
   Wasser SP, 2017, INT J MED MUSHROOMS, V19, P279, DOI [10.1615/IntJMedMushrooms.v19.i4.10, 10.1615/intjmedmushrooms.v19.i4.10]
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 30
TC 9
Z9 9
U1 5
U2 6
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0026-4776
EI 1827-1642
J9 MINERVA GASTROENTERO
JI Minerva Gastroenterol. Dietol.
PD JUN
PY 2020
VL 66
IS 2
BP 172
EP 176
DI 10.23736/S1121-421X.20.02697-5
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA LY8SC
UT WOS:000540797500014
PM 32162896
DA 2021-01-01
ER

PT J
AU Wang, RR
   Pan, M
   Zhang, XM
   Han, MF
   Fan, XY
   Zhao, FD
   Miao, ML
   Xu, J
   Guan, ML
   Deng, X
   Chen, X
   Shen, LL
AF Wang, Ruirui
   Pan, Min
   Zhang, Xiumei
   Han, Mingfeng
   Fan, Xiaoyun
   Zhao, Fengde
   Miao, Manli
   Xu, Jing
   Guan, Minglong
   Deng, Xia
   Chen, Xu
   Shen, Leilei
TI Epidemiological and clinical features of 125 Hospitalized Patients with
   COVID-19 in Fuyang, Anhui, China
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; Epidemiological; Clinical features; Anhui province
AB Objective: To investigate the epidemiological and clinical features of patients with COVID-19 in Anhui province of China.
   Method: In this descriptive study, we obtained epidemiological, demographic, manifestations, laboratory data and radiological findings of patients confirmed by real-time RT-PCR in the NO.2 People's Hospital of Fuyang City from Jan 20 to Feb 9, 2020. Clinical outcomes were followed up to Feb 18, 2020.
   Results: Of 125 patients infected SARS-CoV-2, the mean age was 38.76 years (SD, 13.799) and 71(56.8%) were male. Common symptoms include fever [116 (92.8%)], cough [102(81.6%)], and shortness of breath [57(45.6%)]. Lymphocytopenia developed in 48(38.4%) patients. 100(80.0%) patients showed bilateral pneumonia, 26(20.8%) patients showed multiple mottling and ground-glass opacity. All patients were given antiviral therapy. 19(15.2%) patients were transferred to the intensive care unit. By February 18, 47 (37.6%) patients were discharged and none of patients died. Among the discharged patients, the median time of length of stay was 14.8 days (SD 4.16).
   Conclusion: In this single-center, retrospective, descriptive study, fever is the most common symptom. Old age, chronic underlying diseases and smoking history may be risk factors to worse condition. Certain laboratory inspection may contribute to the judgment of the severity of illness. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Wang, Ruirui; Pan, Min; Zhang, Xiumei; Fan, Xiaoyun; Miao, Manli; Guan, Minglong; Chen, Xu] Anhui Med Univ, Affiliated Hosp 1, Dept Geriatr Resp & Crit Care, Jixi Rd 218, Hefei 230022, Anhui, Peoples R China.
   [Wang, Ruirui; Han, Mingfeng; Zhao, Fengde; Xu, Jing; Deng, Xia; Shen, Leilei] Anhui Med Univ, Fuyang Infect Dis Clin Coll, Yingzhou West Rd 1088, Fuyang 236015, Anhui, Peoples R China.
   [Wang, Ruirui; Han, Mingfeng; Zhao, Fengde; Xu, Jing; Deng, Xia; Shen, Leilei] Second Peoples Hosp Fuyang City, Dept Resp & Crit Care, Yingzhou West Rd 1088, Fuyang 236015, Anhui, Peoples R China.
   [Pan, Min; Zhang, Xiumei; Fan, Xiaoyun; Miao, Manli; Guan, Minglong; Chen, Xu] Anhui Geriatr Inst, Jixi Rd 218, Hefei 230022, Anhui, Peoples R China.
   [Pan, Min; Zhang, Xiumei; Fan, Xiaoyun; Miao, Manli; Guan, Minglong; Chen, Xu] Anhui Med Univ, Inst Resp Dis, Jixi Rd 218, Hefei 230022, Anhui, Peoples R China.
RP Fan, XY (corresponding author), Anhui Med Univ, Affiliated Hosp 1, Dept Geriatr Resp & Crit Care, Jixi Rd 218, Hefei 230022, Anhui, Peoples R China.; Han, MF (corresponding author), Anhui Med Univ, Fuyang Infect Dis Clin Coll, Yingzhou West Rd 1088, Fuyang 236015, Anhui, Peoples R China.
EM fyhmf@163.com; 13956988552@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [U1803126]; Key Projects of Academic Support
   for Top Talents in Colleges and Universities, China [gxbjZD2016036]
FX This work was supported by the National Natural Science Foundation of
   China (grant numbers U1803126) and Key Projects of Academic Support for
   Top Talents in Colleges and Universities, China (grant numbers
   gxbjZD2016036).
CR [Anonymous], 2004, SUMM PROB SARS CAS O
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arabi YM, 2020, INTENSIVE CARE MED
   Cai G., 2020, BULK SINGLE CELL TRA, DOI [10.20944/preprints202002.0051.v2, DOI 10.20944/PREPRINTS202002.0051.V2]
   Chen L, 2020, ZHONGHUA JIE HE HE H
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dai W, 2020, CANADIAN ASS RADIOLO
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   General Office of National Health Commission, 2020, NOT TEMP NAM NOV COR
   General Office of National Health Commission General Office of National Administration of Traditional Chinese Medicine, 2020, DIAGN TREATM PROT NO
   Guan Weijie NZHY, 2020, CLIN CHARACTERISTICS
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kangpeng X, 2020, BIORXIV
   La Gruta NL, 2007, IMMUNOL CELL BIOL, V85, P85, DOI 10.1038/sj.icb.7100026
   Lee D.T.W.Y.L.H., 2004, CLIN INFECT DIS
   Li X, 2020, CLIN CHARACTERISTICS
   Li YM, 2004, ZHONGHUA YI XUE ZA Z, P33
   Lim J, 2020, J KOREAN MED SCI, V35
   Liu P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11110979
   Lu R, 2020, LANCET
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   National Health Commission of the People's Republic of China, 2020, WHT IS FEC OR TRANSM
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Tian H, 2020, IMPACT TRANSMISSION
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2019, 2019 WHO MIDDL E RES
   World Health Organization (WHO), 2020, 61 WHO
   Xiao JZ, 2004, ZHONGHUA NEI KE ZA Z
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Zhu N, 2020, NEW ENGLAND J MED
NR 32
TC 41
Z9 43
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD JUN
PY 2020
VL 95
BP 421
EP 428
DI 10.1016/j.ijid.2020.03.070
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA LY7VW
UT WOS:000540737100075
PM 32289565
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lu, LM
   Li, F
   Wen, H
   Ge, SQ
   Zeng, JC
   Luo, W
   Wang, L
   Tang, CZ
   Xu, NG
AF Lu, Liming
   Li, Fan
   Wen, Hao
   Ge, Shuqi
   Zeng, Jingchun
   Luo, Wen
   Wang, Lai
   Tang, Chunzhi
   Xu, Nenggui
TI An evidence mapping and analysis of registered COVID-19 clinical trials
   in China
SO BMC MEDICINE
LA English
DT Article
ID RECENT METHODOLOGICAL DEVELOPMENTS
AB Background This article aims to summarize the key characteristics of registered trials of 2019 novel coronavirus (COVID-19), in terms of their spatial and temporal distributions, types of design and interventions, and patient characteristics among others. Methods A comprehensive search of the registered COVID-19 trials has been performed on platforms including ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (WHO ICTRP), Chinese Clinical Trials Registry (CHiCTR), Australian Clinical Trials Registry, Britain's National Research Register (BNRR), Current Control Trials (CCT), and Glaxo Smith Kline Register. Trials registered at the first 8 weeks of the COVID-19 outbreak are included, without language restrictions. For each study, the registration information, study design, and administrator information are collected and summarized. Results A total of 220 registered trials were evaluated as of February 27, 2020. Hospital-initiated trials were the majority and account for 80% of the sample. Among the trials, pilot studies and phase 4 trials are more common and represent 35% and 19.1% of the sample, respectively. The median sample size of the registered trials is 100, with interquartile range 60-240. Further, 45.9% of the trials mentioned information on a data monitoring committee. 54.5% of the trials did not specify the disease severity among patients they intend to recruit. Four types of interventions are most common in the experimental groups across the registered studies: antiviral drugs, Traditional Chinese Medicine (TCM), biological agents, and hormone drugs. Among them, the TCM and biological agents are frequently used in pilot study and correspond to a variety of primary endpoints. In contrast, trials with antiviral drugs have more targeted primary outcomes such as "COVID-19 nucleic acid test" and "28-day mortality." Conclusions We provide an evidence mapping and analysis of registered COVID-19 clinical trials in China. In particular, it is critical for ongoing and future studies to refine their research hypothesis and better identify their intervention therapies and the corresponding primary outcomes. It is also imperative for multiple public health divisions and research institutions to work together for integrative clinical data capture and sharing, with a common objective of improving future studies that evaluate COVID-19 interventions.
C1 [Lu, Liming; Wen, Hao; Ge, Shuqi; Luo, Wen; Wang, Lai; Tang, Chunzhi; Xu, Nenggui] Guangzhou Univ Chinese Med, Clin Res & Data Ctr, South China Res Ctr Acupuncture & Moxibust, Guangzhou, Peoples R China.
   [Lu, Liming; Wen, Hao; Ge, Shuqi; Luo, Wen; Wang, Lai; Tang, Chunzhi; Xu, Nenggui] Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, Guangzhou, Peoples R China.
   [Li, Fan] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA.
   [Li, Fan] Yale Sch Publ Hlth, Ctr Methods Implementat & Prevent Sci, New Haven, CT USA.
   [Zeng, Jingchun] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Acupuncture, Guangzhou, Peoples R China.
   [Luo, Wen; Wang, Lai] Guangzhou Univ Chinese Med, Sch Med Informat Engn, Guangzhou, Peoples R China.
RP Tang, CZ; Xu, NG (corresponding author), Guangzhou Univ Chinese Med, Clin Res & Data Ctr, South China Res Ctr Acupuncture & Moxibust, Guangzhou, Peoples R China.; Tang, CZ; Xu, NG (corresponding author), Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, Guangzhou, Peoples R China.
EM jordan664@gzucm.edu.cn; ngxu8018@163.com
RI Li, Fan/AAX-8565-2020
OI Li, Fan/0000-0001-6183-1893
FU Youth Scientific Research Training Project of GZUCM [2019QNPY02]; Young
   Top Talent Project of Scientific and Technological Innovation in Special
   Support Plan for Training High-level Talents in Guangdong
   [2017TQ04R627]; special project of "Lingnan modernization of traditional
   Chinese medicine" in 2019 Guangdong Provincial RD Program
   [2020B1111100008]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81873375]
FX This study was supported by the Youth Scientific Research Training
   Project of GZUCM (2019QNPY02), the Young Top Talent Project of
   Scientific and Technological Innovation in Special Support Plan for
   Training High-level Talents in Guangdong (2017TQ04R627), the special
   project of "Lingnan modernization of traditional Chinese medicine" in
   2019 Guangdong Provincial R&D Program (2020B1111100008), and the
   National Natural Science Foundation of China (81873375).
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Hemming K, 2019, TRIALS, V20, DOI 10.1186/s13063-018-3116-3
   Hemming K, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k1614
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hussey MA, 2007, CONTEMP CLIN TRIALS, V28, P182, DOI 10.1016/j.cct.2006.05.007
   Kayem ND, 2019, EMERG INFECT DIS, V25, P2084, DOI 10.3201/eid2511.180628
   Maxmen A, 2020, NATURE, V578, P347, DOI 10.1038/d41586-020-00444-3
   Nason M, 2016, CLIN TRIALS, V13, P87, DOI 10.1177/1740774515620612
   News of the Communist Party of China, PEOPLES DAILY
   Rojek AM, 2018, CLIN INFECT DIS, V66, P1454, DOI 10.1093/cid/cix1061
   Rojek AM, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0760-x
   Turner EL, 2017, AM J PUBLIC HEALTH, V107, P1078, DOI 10.2105/AJPH.2017.303707
   Turner EL, 2017, AM J PUBLIC HEALTH, V107, P907, DOI 10.2105/AJPH.2017.303706
   WHO, 2020, WHO DIR GEN REM MED
   World Health Organization, WORLD EXP FUND SET P
   World Health Organization, COR DIS COVID 2019 S
   Wu JT, 2020, LANCET
   XINHUANET, VAR APPR AD VACC DEV
NR 18
TC 1
Z9 1
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD JUN 1
PY 2020
VL 18
IS 1
AR 167
DI 10.1186/s12916-020-01612-y
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA LX3CX
UT WOS:000539714200001
PM 32493331
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Calcaterra, D
   Heather, B
   Kohl, LP
   Erickson, HL
   Prekker, ME
AF Calcaterra, Domenico
   Heather, Beth
   Kohl, Louis P.
   Erickson, Heidi L.
   Prekker, Matthew E.
TI Bedside veno-venous ECMO cannulation: A pertinent strategy during the
   COVID-19 pandemic
SO JOURNAL OF CARDIAC SURGERY
LA English
DT Article
DE bedside cannulation; COVID-19; ECMO; perfusion
ID EXTRACORPOREAL MEMBRANE-OXYGENATION; DUAL-LUMEN CANNULA;
   ANTICOAGULATION; MALPOSITION; EXPERIENCE
AB Background Patient selection and cannulation arguably represent the key steps for the successful implementation of extracorporeal membrane oxygenation (ECMO) support. Cannulation is traditionally performed in the operating room or the catheterization laboratory for a number of reasons, including physician preference and access to real-time imaging, with the goal of minimizing complications and ensuring appropriate cannula positioning. Nonetheless, the patients' critical and unstable conditions often require emergent initiation of ECMO and preclude the safe transport of the patient to a procedural suite. Aims Therefore, with the objective of avoiding delay with the initiation of therapy and reducing the hazard of transport, we implemented a protocol for bedside ECMO cannulation. Matherial and Methods A total of 89 patients required ECMO support at Hennepin County Medical Center between March 2015 and December 2019. Twenty-eight (31%) required veno-venous support and were all cannulated at the bedside. Overall survival was 71% with no morbidity or mortality related to the cannulation procedure. Conclusion In the current pandemic, the strategy of veno-venous bedside cannulation may have additional benefits for the care of patients with refractory acute respiratory distress syndrome due to coronavirus-disease-2019, decreasing the risk of exposure of health care worker or other patients to the novel severe acute respiratory syndrome coronavirus-2 occurring during patient transport, preparation, or during disinfection of the procedural suite and the transportation pathway after ECMO cannulation.
C1 [Calcaterra, Domenico] Bethesda Heart Hosp Baptist South Florida, Dept Cardiothorac Surg, Boynton Beach, FL USA.
   [Heather, Beth] Hennepin Cty Med Ctr, Div Pulm & Crit Care, Crit Care Nursing, Minneapolis, MN 55415 USA.
   [Kohl, Louis P.] Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA.
   [Erickson, Heidi L.] Hennepin Cty Med Ctr, Dept Med, Div Pulm & Crit Care, Minneapolis, MN 55415 USA.
   [Prekker, Matthew E.] Hennepin Cty Med Ctr, Dept Med, Dept Emergency Med, Div Pulm & Crit Care, Minneapolis, MN 55415 USA.
RP Calcaterra, D (corresponding author), Bethesda Heart Hosp Baptist South Florida, 2815 S Seacrest Blvd, Boynton Beach, FL 33435 USA.
EM DomenicoC@BaptistHealth.net
CR Banfi C, 2016, J THORAC DIS, V8, P3762, DOI 10.21037/jtd.2016.12.88
   Bermudez CA, 2010, ANN THORAC SURG, V90, P991, DOI 10.1016/j.athoracsur.2010.06.017
   Brodie D, 2011, NEW ENGL J MED, V365, P1905, DOI 10.1056/NEJMct1103720
   Camboni D, 2012, ASAIO J, V58, P616, DOI 10.1097/MAT.0b013e31826a8a32
   Chimot L, 2013, ASAIO J, V59, P157, DOI 10.1097/MAT.0b013e31827db6f3
   Davies A, 2009, JAMA-J AM MED ASSOC, V302, P1888, DOI 10.1001/jama.2009.1535
   Dolch ME, 2011, ASAIO J, V57, P341, DOI 10.1097/MAT.0b013e3182179aae
   ELSO, 2014, ELSO ANTICOAGULATION
   Grasselli G, 2011, MINERVA ANESTESIOL, V77, P884
   Grecu L, 2020, CRIT CARE MED, V48, P264, DOI 10.1097/CCM.0000000000004157
   Griffee MJ, 2020, J CARDIOTHOR VASC AN, V34, P698, DOI 10.1053/j.jvca.2019.10.024
   Griffee MJ, 2018, J CARDIOTHOR VASC AN, V32, P370, DOI 10.1053/j.jvca.2017.07.028
   Hirose H, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-36
   Holzgraefe B, 2010, MINERVA ANESTESIOL, V76, P1043
   Jayaraman AL, 2017, ANN CARD ANAESTH, V20, pS11, DOI 10.4103/0971-9784.197791
   Kuhl T, 2015, THORAC CARDIOV SURG, V63, P653, DOI 10.1055/s-0035-1549359
   Lindholm JA, 2018, J THORAC DIS, V10, pS606, DOI 10.21037/jtd.2018.03.101
   Napp LC, 2016, CLIN RES CARDIOL, V105, P283, DOI 10.1007/s00392-015-0941-1
   Ngai CW, 2018, J THORAC DIS, V10, pS624, DOI 10.21037/jtd.2018.02.70
   Noah MA, 2011, JAMA-J AM MED ASSOC, V306, P1659, DOI 10.1001/jama.2011.1471
   Protti A, 2020, ANESTHESIOLOGY, V132, P562, DOI 10.1097/ALN.0000000000003044
   Shaheen A, 2016, J CARDIAC SURG, V31, P248, DOI 10.1111/jocs.12690
   Sklar MC, 2016, ANN AM THORAC SOC, V13, P2242, DOI 10.1513/AnnalsATS.201605-364SR
   Tabak B, 2012, J CLIN ULTRASOUND, V40, P183, DOI 10.1002/jcu.21873
   Teman NR, 2013, ASAIO J, V59, P442, DOI 10.1097/MAT.0b013e31829a0102
   Trimlett RH, 2011, INTENS CARE MED, V37, P1036, DOI 10.1007/s00134-011-2213-5
   Tulman DB, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-65
   Wang SG, 2019, ARTIF ORGANS, V43, P41, DOI 10.1111/aor.13318
   Yastrebov K, 2014, HEART LUNG CIRC, V23, pE4, DOI 10.1016/j.hlc.2013.05.643
NR 29
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0886-0440
EI 1540-8191
J9 J CARDIAC SURG
JI J. Card. Surg.
PD JUN
PY 2020
VL 35
IS 6
BP 1180
EP 1185
DI 10.1111/jocs.14641
PG 6
WC Cardiac & Cardiovascular Systems; Surgery
SC Cardiovascular System & Cardiology; Surgery
GA LX3VU
UT WOS:000539763300007
PM 32531129
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Abena, PM
   Decloedt, EH
   Bottieau, E
   Suleman, F
   Adejumo, P
   Sam-Agudu, NA
   TamFum, JJM
   Seydi, M
   Eholie, SP
   Mills, EJ
   Kallay, O
   Zumla, A
   Nachega, JB
AF Abena, Pascale M.
   Decloedt, Eric H.
   Bottieau, Emmanuel
   Suleman, Fatima
   Adejumo, Prisca
   Sam-Agudu, Nadia A.
   TamFum, Jean-Jacques Muyembe
   Seydi, Moussa
   Eholie, Serge P.
   Mills, Edward J.
   Kallay, Oscar
   Zumla, Alimuddin
   Nachega, Jean B.
TI Chloroquine and Hydroxychloroquine for the Prevention or Treatment of
   COVID-19 in Africa: Caution for Inappropriate Off-label Use in
   Healthcare Settings
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID METABOLISM; ISOFORMS; DRUG
AB The novel severe acute respiratory syndrome-coronavirus-2 pandemic has spread to Africa, where nearly all countries have reported laboratory-confirmed cases of novel coronavirus disease (COVID-19). Although there are ongoing clinical trials of repurposed and investigational antiviral and immune-based therapies, there are as yet no scientifically proven, clinically effective pharmacological treatments for COVID-19. Among the repurposed drugs, the commonly used antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) have become the focus of global scientific, media, and political attention despite a lack of randomized clinical trials supporting their efficacy. Chloroquine has been used worldwide for about 75 years and is listed by the WHO as an essential medicine to treat malaria. Hydroxychloroquine is mainly used as a therapy for autoimmune diseases. However, the efficacy and safety of CQ/HCQ for the treatment of COVID-19 remains to be defined. Indiscriminate promotion and widespread use of CQ/HCQ have led to extensive shortages, self-treatment, and fatal overdoses. Shortages and increased market prices leave all countries vulnerable to substandard and falsified medical products, and safety issues are especially concerning for Africa because of its healthcare system limitations. Much needed in Africa is a cross-continental collaborative network for coordinated production, distribution, and post-marketing surveillance aligned to low-cost distribution of any approved COVID-19 drug; this would ideally be piggybacked on existing global aid efforts. Meanwhile, African countries should strongly consider implementing prescription monitoring schemes to ensure that any off-label CQ/HCQ use is appropriate and beneficial during this pandemic.
C1 [Abena, Pascale M.] Cameroon & Infect Dis Soc Cameroon, Infect Dis Outpatient Clin, Yaounde, Cameroon.
   [Decloedt, Eric H.] Stellenbosch Univ, Dept Med, Div Clin Pharmacol, Cape Town, South Africa.
   [Bottieau, Emmanuel] Inst Trop Med, Dept Clin Sci, Antwerp, Belgium.
   [Suleman, Fatima] Univ Kwazulu Natal, Discipline Pharmaceut Sci, Durban, South Africa.
   [Adejumo, Prisca] Univ Ibadan, Dept Nursing, Ibadan, Nigeria.
   [Sam-Agudu, Nadia A.] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA.
   [Sam-Agudu, Nadia A.] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA.
   [Sam-Agudu, Nadia A.] Int Res Ctr Excellence, Inst Human Virol Nigeria, Abuja, Nigeria.
   [Sam-Agudu, Nadia A.] Univ Cape Coast, Sch Med Sci, Dept Paediat, Cape Coast, Ghana.
   [TamFum, Jean-Jacques Muyembe] Univ Kinshasa, Fac Med, Natl Inst Biomed Res INRB, Dept Med Microbiol & Virol, Kinshasa, DEM REP CONGO.
   [Seydi, Moussa] Univ Cheik Anta Diop, Ctr Hosp Univ Fann, Serv Malad Infect & Trop, Dakar, Senegal.
   [Eholie, Serge P.] Treichville Univ Teaching Hosp, Unit Infect Dis, Abidjan, Cote Ivoire.
   [Eholie, Serge P.] Univ Felix Houphouet Boigny, Unite Format & Rech, Unite Dermatol & Infectiol, Abidjan, Cote Ivoire.
   [Mills, Edward J.] Univ Kigali, Sch Publ Hlth, Kigali, Rwanda.
   [Kallay, Oscar] Free Univ Brussels, Erasme Hosp, Brussels, Belgium.
   [Zumla, Alimuddin] UCL, Ctr Clin Microbiol, Div Infect & Immun, Dept Infect, London, England.
   [Zumla, Alimuddin] Univ Coll London Hosp, Natl Inst Hlth Res Biomed Res Ctr, London, England.
   [Nachega, Jean B.] Stellenbosch Univ, Ctr Infect Dis, Cape Town, South Africa.
   [Nachega, Jean B.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth & Epidemiol, Baltimore, MD USA.
   [Nachega, Jean B.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
   [Nachega, Jean B.] Univ Pittsburgh, Ctr Global Hlth, Pittsburgh, PA 15261 USA.
RP Nachega, JB (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Infect Dis & Microbiol, Dept Epidemiol, 130 DeSoto St, Pittsburgh, PA 15261 USA.; Nachega, JB (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Ctr Global Hlth, 130 DeSoto St, Pittsburgh, PA 15261 USA.
EM abenamessomo@yahoo.fr; ericdecloedt@sun.ac.za; ebottieau@itg.be;
   sulemanf@ukzn.ac.za; nsamagudu@ihvnigeria.org; jjmuyembet@gmail.com;
   seydi.moussa@gmail.com; sergeholie@yahoo.fr; emills@mteksciences.com;
   oscar_kallay@yahoo.fr; a.zumla@ucl.ac.uk; jbn16@pitt.edu
RI ZUMLA, Alimuddin/ABA-8208-2020
OI Decloedt, Eric/0000-0003-1815-5150; Zumla, Professor Sir
   Alimuddin/0000-0002-5111-5735
FU U.S. National Institutes of Health (NIH)/National Institutes of Allergy
   and Infectious Diseases (NIAID) [5U01AI069521]; NIH/Fogarty
   International Center (FIC) (African Association for Health Professions
   Education and Research) [1R25TW011217-01]; University of Pittsburgh
   HIV-Comorbidities Research Training Program in South Africa
   [1D43TW01093701A1]; EDCTP; EUEuropean Union (EU); National Institutes of
   Health Research senior investigator awardUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA;
   NIH/National Institute of Child Health and Human Development
   (NICHD)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [R01HD089866];
   NIH/FIC award under the Adolescent HIV Prevention and Treatment
   Implementation Science Alliance (AHISA); Central and West Africa
   Implementation Science Alliance (CAWISA)
FX Nachega is an infectious disease internist and epidemiologist supported
   by U.S. National Institutes of Health (NIH)/National Institutes of
   Allergy and Infectious Diseases (NIAID) grant number 5U01AI069521
   (Stellenbosch University Clinical Trial Unit (CTU) of AIDS Clinical
   Trial Group [ACTG]) as well as NIH/Fogarty International Center (FIC)
   grant numbers 1R25TW011217-01 (African Association for Health
   Professions Education and Research) and 1D43TW01093701A1 (the University
   of Pittsburgh HIV-Comorbidities Research Training Program in South
   Africa). He serves on the scientific program committee of the American
   Society of Tropical Medicine and Hygiene (ASTMH) and is a senior fellow
   alumni of the European Developing Countries Clinical Trial Partnership
   (EDCTP). Muyembe-Tamfum has been on the front lines of Ebola research
   since 1970s, identifying nosocomial and burial transmission as two of
   the major causes of disease transmission, contributing to vaccine
   research, developing antisera therapy, and training a new generation of
   disease responders and Congolese laboratory. He is now leading the
   COVID-19 Task Force Response in the Democratic Republic of the Congo.
   Sir Zumla is a co-PI of the Pan-African Network on Emerging and
   Re-Emerging Infections (PANDORA-ID-NET-https://www.pandora-id.net/)
   funded by the EDCTP, the EU Horizon 2020 Framework Program for Research
   and Innovation. Sir Zumla is in receipt of a National Institutes of
   Health Research senior investigator award. Seydi is an infectious
   diseases and tropical medicine expert and member of the COVID-19 Task
   Force Response in Senegal. Suleman is a Public Health Pharmacist
   supported by a NIH/Fogarty International Center (FIC) grant number
   1R25TW011217-01 (African Association for Health Professions Education
   and Research). Dr. Sam-Agudu is a Pediatric Infectious Diseases
   clinician-scientist supported by the NIH/National Institute of Child
   Health and Human Development (NICHD) grant R01HD089866, and by an
   NIH/FIC award under the Adolescent HIV Prevention and Treatment
   Implementation Science Alliance (AHISA), for the Central and West Africa
   Implementation Science Alliance (CAWISA). Prisca Olabisi Adejumo is a
   professor of Medical Surgical Nursing, a nurse educator supported by
   NIH/Fogarty International Center (FIC) grant number 1R25TW011217-01
   (African Association for Health Professions Education and Research). All
   authors have an interest in emerging and reemerging pathogens and
   declare no conflicts of interest.
CR [Anonymous], 2019, IDF DIAB ATL 2019
   [Anonymous], 2019, POPULATION PYRAMIDS
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Ataklte F, 2015, HYPERTENSION, V65, P291, DOI 10.1161/HYPERTENSIONAHA.114.04394
   Borba MGS, 2020, CHLOROQUINE DIPHOSPH, DOI [10.1101/2020.04.07.20056424v2, DOI 10.1101/2020.04.07.20056424V2]
   Browne AJ, 2020, BMC MED, V18, DOI 10.1186/s12916-019-1443-1
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen Z, 2020, PREPRINT EFFICACY HY, DOI [10.1101/2020.03.22.20040758v2, DOI 10.1101/2020.03.22.20040758V2]
   Conrad MD, 2019, LANCET INFECT DIS, V19, pE338, DOI 10.1016/S1473-3099(19)30261-0
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Costedoat-Chalumeau N, 2015, CLIN REV ALLERG IMMU, V49, P317, DOI 10.1007/s12016-015-8469-8
   Decloedt E, 2020, S AFR MED J
   Desta Z, 2001, ANTIMICROB AGENTS CH, V45, P382, DOI 10.1128/AAC.45.2.382-392.2001
   Drug Interactions, 2020, MICROMEDEX SOLUTION
   Ducharme J, 1996, CLIN PHARMACOKINET, V31, P257, DOI 10.2165/00003088-199631040-00003
   Efavirenz CQ, 2020, DRUG INTERACTIONS 20
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gbinigie Kome, 2020, BJGP Open, V4, DOI 10.3399/bjgpopen20X101069
   Jensen M, 2009, PARASITOL RES, V105, P609, DOI 10.1007/s00436-009-1524-8
   Keshtkar-Jahromi M, 2020, AM J TROP MED HYG, V102, P932, DOI 10.4269/ajtmh.20-0230
   Kim KA, 2003, ARCH PHARM RES, V26, P631, DOI 10.1007/BF02976712
   Kolifarhood G, 2020, ARCH ACAD EMERG MED, V8
   LANDEWE RBM, 1995, CLIN EXP IMMUNOL, V102, P144
   Lunguya Octavie, 2012, PLoS Negl Trop Dis, V6, pe1921, DOI 10.1371/journal.pntd.0001921
   Maguire Brittany J, 2020, Wellcome Open Res, V5, P60, DOI 10.12688/wellcomeopenres.15821.1
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Newton PN, 2019, LANCET GLOB HEALTH, V7, pE1609, DOI 10.1016/S2214-109X(19)30426-7
   Politi D., 2020, NIGERIA REPORTS CHLO
   Projean D, 2003, DRUG METAB DISPOS, V31, P748, DOI 10.1124/dmd.31.6.748
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Roques P, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050268
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Shippey EA, 2018, CLEV CLIN J MED, V85, P459, DOI 10.3949/ccjm.85a.17034
   Taylor WRJ, 2004, DRUG SAFETY, V27, P25, DOI 10.2165/00002018-200427010-00003
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   University of Liverpool, 2020, COVID 19 DRUG DRUG I
   University of Oxford, 2020, CHLOR HYDR PREV COR
   Unubol M, 2011, JCR-J CLIN RHEUMATOL, V17, P46, DOI 10.1097/RHU.0b013e3182098e1f
   US Food and Drug Administration, 2020, AR CHLOR PHOSPH USP
   Williamson B, 2013, ANTIMICROB AGENTS CH, V57, P6366, DOI 10.1128/AAC.01124-13
   Winter EM, 2011, BMJ CASE REP, pbcr0620114393
   World Health Organization, 2020, MOD LIST ESS MED
   World Health Organization, 2020, COR DIS 2019 COVID 1
   World Health Organization, 2015, GUID TREATM MAL
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 51
TC 13
Z9 13
U1 4
U2 5
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUN
PY 2020
VL 102
IS 6
BP 1184
EP 1188
DI 10.4269/ajtmh.20-0290
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA LV9SO
UT WOS:000538787600018
PM 32323646
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Falcao, MB
   Cavalcanti, LPD
   Filgueiras, NM
   de Brito, CAA
AF Falcao, Melissa Barreto
   de Goes Cavalcanti, Luciano Pamplona
   Filgueiras Filho, Nivaldo Menezes
   Antunes de Brito, Carlos Alexandre
TI Case Report: Hepatotoxicity Associated with the Use of
   Hydroxychloroquine in a Patient with COVID-19
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID HEPATITIS; SECONDARY; DRUGS
AB Hydroxychloroquine (HCQ) has been used for the treatment of novel coronavirus disease (COVID-19) cases. However, evidence of efficacy remains limited, and adverse events can be associated with its use. Here, we report a case of a patient with severe COVID-19 who, after being administered HCQ, exhibited a 10-fold increase in serum levels of transaminases, followed by a rapid decrease after HCQ was withdrawn. Considering the significantly increased use of HCQduring the COVID-19 pandemic, this case alerts us to the potential for HCQ to be associated with hepatotoxicity and the need to monitor liver function during HCQ therapy.
C1 [Falcao, Melissa Barreto] Univ Estadual Feira de Santana, Res & Extens Ctr Hlth Surveillance, Feira De Santana, BA, Brazil.
   [de Goes Cavalcanti, Luciano Pamplona] Univ Fed Ceara, Sch Med, Dept Community Hlth, Fortaleza, Ceara, Brazil.
   [Filgueiras Filho, Nivaldo Menezes] Univ Salvador, Sch Med, Salvador, BA, Brazil.
   [Filgueiras Filho, Nivaldo Menezes] Univ Estado Bahia, Sch Med, Salvador, BA, Brazil.
   [Antunes de Brito, Carlos Alexandre] Clin Hosp Fed Univ, Dept Internal Med, Recife, PE, Brazil.
   [Antunes de Brito, Carlos Alexandre] Univ Fed Pernambuco, Trop Med Postgrad, Recife, PE, Brazil.
   [Antunes de Brito, Carlos Alexandre] Autoimmune Res Inst, Recife, PE, Brazil.
RP de Brito, CAA (corresponding author), Av Prof Moraes Rego S-N, BR-50670910 Recife, PE, Brazil.
EM melissa.falcao@hotmail.com; pamplona.luciano@gmail.com;
   nfilgueiras@gmail.com; cbritoc@gmail.com
CR Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Galil SMA, 2015, LUPUS, V24, P638, DOI 10.1177/0961203314561667
   Galvan VG, 2007, CLIN RHEUMATOL, V26, P971, DOI 10.1007/s10067-006-0218-1
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Guan WJ, 2019, CLIN CHARACTERISTICS, V2020, P2020, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jamshidzadeh A., 2016, Pharmaceutical Sciences, V22, P170, DOI 10.15171/PS.2016.27
   Keshtkar-Jahromi M, 2020, AM J TROP MED HYG, V102, P932, DOI 10.4269/ajtmh.20-0230
   Liang T., 2020, HDB COVID 19 PREVENT
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1166
   MAKIN AJ, 1994, GUT, V35, P569, DOI 10.1136/gut.35.4.569
   Megarbane B, 2020, CLIN TOXICOL, DOI 10.1080/15563650.2020.1748194
   Argumanez CM, 2017, MED INTENSIVA, V41, P257, DOI 10.1016/j.medin.2016.05.004
   Mizumoto K, 2020, EMERG INFECT DIS, V26, P1
   Mok MY, 2000, CLIN EXP RHEUMATOL, V18, P363
   Niknahad H, 2016, ADV PHARM BULL, V6, P617, DOI 10.15171/apb.2016.076
   RISMANBAF A, 2020, ARCH ACAD EMERG MED, V8
   Sunkara B, 2018, LUPUS, V27, P1383, DOI 10.1177/0961203318768884
   van Jaarsveld CHM, 2000, RHEUMATOLOGY, V39, P1374, DOI 10.1093/rheumatology/39.12.1374
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wei CH, 2015, EXP MOL PATHOL, V99, P341, DOI 10.1016/j.yexmp.2015.08.006
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yao X, 2020, CLIN INFECT DIS, V2, P1, DOI DOI 10.1093/CID/CIAA237
   Zhang B, 2020, CLIN CHARACTERISTICS, DOI [10.1017/CBO9781107415324.004, DOI 10.1017/CBO9781107415324.004]
   Zhou F, 2020, LANCET, V6736, P1, DOI DOI 10.1016/S0140-6736(20)30566-3
NR 33
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUN
PY 2020
VL 102
IS 6
BP 1214
EP 1216
DI 10.4269/ajtmh.20-0276
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA LV9SO
UT WOS:000538787600026
PM 32314698
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Di Fiore, F
   Bouche, O
   Lepage, C
   Sefrioui, D
   Gangloff, A
   Schwarz, L
   Tuech, JJ
   Aparicio, T
   Lecomte, T
   Boulagnon-Rombi, C
   Lievre, A
   Manfredi, S
   Phelip, JM
   Michel, P
AF Di Fiore, Frederic
   Bouche, Olivier
   Lepage, Come
   Sefrioui, David
   Gangloff, Alice
   Schwarz, Lilian
   Tuech, Jean Jacques
   Aparicio, Thomas
   Lecomte, Thierry
   Boulagnon-Rombi, Camille
   Lievre, Astrid
   Manfredi, Sylvain
   Phelip, Jean Marc
   Michel, Pierre
CA TNCD
   Soc Natl Francaise Gastroenterolog
   FFCD
   Grp Cooperateur Multidisciplinaire
   Federation Natl Ctr Lutte Canc UNI
   SFCD
   SFED
   SFRO
   SFR
   ACHBT
TI COVID-19 epidemic: Proposed alternatives in the management of digestive
   cancers: A French intergroup clinical point of view (SNFGE, FFCD,
   GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)
SO DIGESTIVE AND LIVER DISEASE
LA English
DT Article
DE COVID-19 infection; Digestive cancer; Chemotherapy; Surgery; French
   Clinical Practice Guidelines
ID COLON-CANCER; OPEN-LABEL; PHASE-III; CHEMOTHERAPY; OXALIPLATIN;
   MULTICENTER; CHEMORADIOTHERAPY; CAPECITABINE; GEMCITABINE; CARCINOMA
AB Introduction: Patients treated for malignancy are considered at risk of severe COVID-19. This exceptional pandemic has affected countries on every level, particularly health systems which are experiencing saturation. Like many countries, France is currently greatly exposed, and a complete reorganization of hospitals is ongoing. We propose here adaptations of diagnostic procedures, therapies and care strategies for patients treated for digestive cancer during the COVID-19 epidemic.
   Methods: French societies of gastroenterology and gastrointestinal (GI) oncology carried out this study to answer two main questions that have arisen (i) how can we limit high-risk situations for GI-cancer patients and (ii) how can we limit contact between patients and care centers to decrease patients' risk of contamination while continuing to treat their cancer. All recommendations are graded as experts' agreement according to the level of evidence found in the literature until March 2020.
   Results: A proposal to adapt treatment strategies was made for the main GI oncology situations. Considering the level of evidence and the heterogeneous progression of the COVID-19 epidemic, all proposals need to be considered by a multidisciplinary team and implemented with patient consent.
   Conclusion: COVID-19 epidemic may significantly affect patients treated for digestive malignancies. Healthcare teams need to consider adapting treatment sequences when feasible and according to the epidemic situation. (C) 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
C1 [Di Fiore, Frederic; Sefrioui, David; Gangloff, Alice; Michel, Pierre] Normandie Univ, Rouen Univ Hosp, Dept Hepatogastroenterol, UNIROUEN,INSERM,U1245,IRON Grp, F-76000 Rouen, France.
   [Bouche, Olivier] Univ Reims Champagne Ardennes, CHU Reims, Digest Oncol, Reims, France.
   [Lepage, Come; Manfredi, Sylvain] Univ Bourgogne & Franche Comte, Univ Hosp Le Bocage, Hepatogastroenterol Dept, EPICAD,INSERM,LNC,UMR 1231, Dijon, France.
   [Schwarz, Lilian; Tuech, Jean Jacques] Normandie Univ, Dept Digest Surg, UNIROUEN, Inserm,U1245,IRON Grp, F-76000 Rouen, France.
   [Aparicio, Thomas] Univ Paris, St Louis Hosp, AP HP, Gastroenterol & Digest Oncol, Paris, France.
   [Lecomte, Thierry] Univ F Rabelais Tours, Trousseau Hosp, Gastroenterol & Endoscopy Dept, Tours, France.
   [Boulagnon-Rombi, Camille] Univ Reims Champagne Ardennes, CHU Reims, Pathol, Reims, France.
   [Lievre, Astrid] Rennes 1 Univ, Rennes, France.
   [Lievre, Astrid] ADECI35, Assoc Depistage Canc Ille & Vilaine, Rennes, France.
   [Lievre, Astrid] CHU Pontchaillou, Dept Gastroenterol, Rennes, France.
   [Lievre, Astrid] INSERM, UMR 1242, COSS Chem Oncogenesis Stress Signaling, Rennes, France.
   [Phelip, Jean Marc] Univ Hosp St Etienne, Dept Gastroenterol & Digest Oncol, St Etienne, France.
RP Di Fiore, F; Michel, P (corresponding author), Normandie Univ, Rouen Univ Hosp, Dept Hepatogastroenterol, UNIROUEN,INSERM,U1245,IRON Grp, F-76000 Rouen, France.
EM frederic.di-fiore@chu-rouen.fr; pierre.michel@chu-rouen.fr
CR Al-Batran SE, 2019, LANCET, V393, P1948, DOI 10.1016/S0140-6736(18)32557-1
   Andre T, 2015, J CLIN ONCOL, V33, P4176, DOI 10.1200/JCO.2015.63.4238
   Bekaii-Saab TS, 2019, LANCET ONCOL, V20, P1070, DOI 10.1016/S1470-2045(19)30272-4
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y H, 2020, Zhonghua Wei Chang Wai Ke Za Zhi, V23, pI, DOI 10.3760/cma.j.issn.1671-0274.2020.02.001
   Conroy T, 2018, NEW ENGL J MED, V379, P2395, DOI 10.1056/NEJMoa1809775
   Erlandsson J, 2017, LANCET ONCOL, V18, P336, DOI 10.1016/S1470-2045(17)30086-4
   Henwood AF, 2020, J HISTOTECHNOL, P1, DOI [10.1080/01478885.2020.1734718, DOI 10.1080/01478885.2020.1734718.MAR]
   Iwanicki-Caron I, 2008, J CLIN ONCOL, V26, P3681, DOI 10.1200/JCO.2007.15.0904
   Karoui M, 2019, ANN SURG, DOI [10.1097/sla.00 0 0 000000003454, DOI 10.1097/SLA.00 0 0 000000003454]
   Kim ST, 2019, ANN ONCOL, V30, P788, DOI 10.1093/annonc/mdz058
   Kim YJ, 2019, INFECT DIS-NOR, V51, P502, DOI 10.1080/23744235.2019.1592217
   Laurent L, 2019, HPB, V21, P582, DOI 10.1016/j.hpb.2018.09.006
   Lefevre JH, 2016, J CLIN ONCOL, V34, P3773, DOI 10.1200/JCO.2016.67.6049
   Liang W, 2019, INT CONF MANIP MANU, P20, DOI 10.1109/3M-NANO46308.2019.8947411
   Luo Y, 2020, Zhonghua Wei Chang Wai Ke Za Zhi, V23, pE003, DOI 10.3760/cma.j.cn441530-20200217-00057
   Mariette C, 2014, J CLIN ONCOL, V32, P2416, DOI 10.1200/JCO.2013.53.6532
   Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   Meulendijks D, 2014, BRIT J CANCER, V111, P1726, DOI 10.1038/bjc.2014.467
   Morton UKD, 2012, LANCET ONCOL, V13, P1152, DOI 10.1016/S1470-2045(12)70348-0
   Renehan AG, 2016, LANCET ONCOL, V17, P174, DOI 10.1016/S1470-2045(15)00467-2
   Rullier E, 2017, LANCET, V390, P469, DOI 10.1016/S0140-6736(17)31056-5
   Simkens LHJ, 2015, LANCET, V385, P1843, DOI 10.1016/S0140-6736(14)62004-3
   Spinelli A, 2020, BRIT J SURG, V107, P785, DOI 10.1002/bjs.11627
   Tuech JJ, 2020, J VISC SURG, V157, pS7, DOI 10.1016/j.jviscsurg.2020.03.008
   Vezzosi D, 2011, INT J BIOL MARKER, V26, P94, DOI 10.5301/JBM.2011.8327
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhang Y, 2020, ZHONGHUA ZHONG LIU Z, V42, DOI DOI 10.3760/CMA.J.CN112152-20200227-00141
NR 29
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1590-8658
EI 1878-3562
J9 DIGEST LIVER DIS
JI Dig. Liver Dis.
PD JUN
PY 2020
VL 52
IS 6
BP 597
EP 603
DI 10.1016/j.dld.2020.03.031
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA LW5ZD
UT WOS:000539223600002
PM 32418773
OA Green Published
DA 2021-01-01
ER

PT J
AU Zingone, F
   Buda, A
   Savarino, EV
AF Zingone, Fabiana
   Buda, Andrea
   Savarino, Edoardo Vincenzo
TI Screening for active COVID-19 infection and immunization status prior to
   biologic therapy in IBD patients at the time of the pandemic outbreak
SO DIGESTIVE AND LIVER DISEASE
LA English
DT Article
DE COVID-19; Biologic; screening; IBD; Crohn's disease; Ulcerative Colitis
ID INFLAMMATORY-BOWEL-DISEASE; OPPORTUNISTIC INFECTIONS; RISK-FACTORS
AB Coronavirus disease 2019 has been recently classified as pandemic infection by the World Health Organization. Patients with inflammatory bowel disease (IBD) are invited to follow the national recommendations as any other person. It is unclear whether a more aggressive clinical course might develop in asymptomatic COVID-19 infected subjects during biological therapy and current evidence does not support treatment suspension. However, during pandemic, the start of treatment with immunosuppressive drugs and biologics should be postponed whenever possible and based on an individual risk assessment. When clinical conditions and the disease activity do not allow a treatment delay, before starting a biological therapy, screening of IBD patients for COVID-19 active infection by RT-PCR should be advisable, even in absence of clinical suspicion. Serum antibody testing, when available, could provide evidence of infection as well as identify patients already immune to the disease. (C) 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
C1 [Zingone, Fabiana; Savarino, Edoardo Vincenzo] Univ Padua, Dept Surg Oncol & Gastroenterol, Div Gastroenterol, Padua, Italy.
   [Buda, Andrea] S Maria del Prato Hosp, Dept Gastrointestinal Oncol Surg, Gastroenterol Unit, Feltre, Italy.
RP Savarino, EV (corresponding author), Univ Padua, Dept Surg Oncol & Gastroenterol, Div Gastroenterol, Padua, Italy.
EM edoardo.savarino@unipd.it
RI ; Zingone, Fabiana/O-5361-2018
OI Buda, Andrea/0000-0002-3099-8612; Zingone, Fabiana/0000-0003-1133-1502
CR Ford AC, 2013, AM J GASTROENTEROL, V108, P1268, DOI 10.1038/ajg.2013.138
   Gu J, 2020, GASTROENTEROLOGY, DOI [10.1053/j.gastro.2020.02.054., DOI 10.1053/J.GASTR0.2020.02.054, 10.1053/j.gastro.2020.02.054]
   Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P404, DOI 10.1016/j.jmii.2020.02.012
   Lamb CA, 2019, GUT, V68, pS1, DOI 10.1136/gutjnl-2019-318484
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Naganuma M, 2013, J GASTROENTEROL, V48, P595, DOI 10.1007/s00535-012-0686-9
   Osterman MT, 2016, AM J GASTROENTEROL, V111, P1806, DOI 10.1038/ajg.2016.433
   Ritchie AI, 2020, LANCET
   Singh S, 2020, CLIN GASTROENTEROL H, V18, P2179, DOI 10.1016/j.cgh.2020.01.008
   To KK, 2020, LANCET INFECT DIS
   Toruner M, 2008, GASTROENTEROLOGY, V134, P929, DOI 10.1053/j.gastro.2008.01.012
   Ungaro RC, 2020, CLIN GASTROENTEROL H, V18, P1409, DOI 10.1016/j.cgh.2020.03.020
   Xiao F, 2020, GASTROENTEROLOGY, V158, P6, DOI [10. 1053/j.gastro.2020.02.055., DOI 10.1053/J.GASTR0.2020.02.055, 10.1053/j.gastro.2020.02.055]
   Xiao YH, 2020, LANCET INFECT DIS, V20, P523, DOI 10.1016/S1473-3099(20)30152-3
   Zingone F, 2020, LANCET GASTROENTEROL, V5, P525, DOI 10.1016/S2468-1253(20)30085-6
NR 15
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1590-8658
EI 1878-3562
J9 DIGEST LIVER DIS
JI Dig. Liver Dis.
PD JUN
PY 2020
VL 52
IS 6
BP 604
EP 605
DI 10.1016/j.dld.2020.04.004
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA LW5ZD
UT WOS:000539223600003
PM 32360133
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Capra, R
   De Rossi, N
   Mattioli, F
   Romanelli, G
   Scarpazza, C
   Sormani, MP
   Cossi, S
AF Capra, Ruggero
   De Rossi, Nicola
   Mattioli, Flavia
   Romanelli, Giuseppe
   Scarpazza, Cristina
   Sormani, Maria Pia
   Cossi, Stefania
TI Impact of low dose tocilizumab on mortality rate in patients with
   COVID-19 related pneumonia
SO EUROPEAN JOURNAL OF INTERNAL MEDICINE
LA English
DT Article
DE COVID-19; SARS-cov-2; Tocilizumab; Retrospective study; Pneumonia;
   Respiratory failure
ID CYTOKINE STORM; SARS
AB Background: Pneumonia with respiratory failure represents the main cause of death in COVID-19, where hyper inflammation plays an important role in lung damage. This study aims to evaluate if tocilizumab, an anti-soluble IL-6 receptor monoclonal antibody, reduces patients' mortality.
   Methods: 85 consecutive patients admitted to the Montichiari Hospital (Italy) with COVID-19 related pneumonia and respiratory failure, not needing mechanical ventilation, were included if satisfying at least one among: respiratory rate 30 breaths/min, peripheral capillary oxygen saturation <= 93% or Pa02/FiO2 < = 300 mmHg. Patients admitted before March 13th (n= 23) were prescribed the standard therapy (hydroxychloroquine, lopinavir and ritonavir) and were considered controls. On March 13th tocilizumab was available and patients admitted thereafter (n = 62) received tocilizumab once within 4 days from admission, plus the standard care.
   Results: Patients receiving tocilizumab showed significantly greater survival rate as compared to control patients (hazard ratio for death, 0.035; 95% confidence interval [CI], 0.004 to 0.347; p = 0.004), adjusting for baseline clinical characteristics. Two out of 62 patients of the tocilizumab group and 11 out of 23 in the control group died. 92% and 42.1% of the discharged patients in the tocilizumab and control group respectively, recovered. The respiratory function resulted improved in 64.8% of the observations in tocilizumab patients who were still hospitalized, whereas 100% of controls worsened and needed mechanical ventilation. No infections were reported.
   Conclusions: Tocilizumab results to have a positive impact if used early during Covid-19 pneumonia with severe respiratory syndrome in terms of increased survival and favorable clinical course.
C1 [Capra, Ruggero; De Rossi, Nicola; Cossi, Stefania] Montichiari Hosp, Covid 19 Unit, Via Don Ciotti Montichiari, Brescia, Italy.
   [Mattioli, Flavia] ASST Spedali Civili, Via Nikolajewka 13, I-25123 Brescia, Italy.
   [Romanelli, Giuseppe] Univ Brescia, Dept Internal Med, Brescia, Italy.
   [Scarpazza, Cristina] Univ Padua, Dept Gen Psychol, Padua, Italy.
   [Sormani, Maria Pia] Univ Genoa, Dept Hlth Sci, Genoa, Italy.
   [Sormani, Maria Pia] IRCCS Osped Policlin San Martino, Genoa, Italy.
RP Capra, R (corresponding author), Montichiari Hosp, Covid 19 Unit, Via Don Ciotti Montichiari, Brescia, Italy.
EM ruggero.capra@gmail.com
RI Sormani, Maria Pia/ABH-8756-2020
OI Scarpazza, Cristina/0000-0002-4126-426X
CR Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Lippi G, 2020, CLIN CHEM LAB MED
   Liu T, POTENTIAL ROLE IL 6
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Ogata A, 2019, MOD RHEUMATOL, V29, P258, DOI [10.1080/14397595.2018.1533514, 10.1080/14397595.2018.1546357]
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Ortiz-Martinez Y., 2020, TRAVEL MED INFECT DI
   Ritchie AI, 2020, LANCET
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   Xu X, 2020, EFFECTIVE TREATMENT
   Xu Z, 2020, LANCET RESP MED
   Zhang XP, 2013, INT J CLIN PHARM TH, V51, P443, DOI 10.5414/CP201819
   Zhang X, 2007, VIROLOGY, V365, P324, DOI 10.1016/j.virol.2007.04.009
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 20
TC 48
Z9 51
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0953-6205
EI 1879-0828
J9 EUR J INTERN MED
JI Eur. J. Intern. Med.
PD JUN
PY 2020
VL 76
BP 31
EP 35
DI 10.1016/j.ejim.2020.05.009
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA LW6KV
UT WOS:000539254000009
PM 32405160
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Morena, V
   Milazzo, L
   Oreni, L
   Bestetti, G
   Fossali, T
   Bassoli, C
   Torre, A
   Cossu, MV
   Minari, C
   Ballone, E
   Perotti, A
   Mileto, D
   Niero, F
   Merli, S
   Foschi, A
   Vimercati, S
   Rizzardini, G
   Sollima, S
   Bradanini, L
   Galimberti, L
   Colombo, R
   Micheli, V
   Negri, C
   Ridolfo, AL
   Meroni, L
   Galli, M
   Antinori, S
   Corbellino, M
AF Morena, Valentina
   Milazzo, Laura
   Oreni, Letizia
   Bestetti, Giovanna
   Fossali, Tommaso
   Bassoli, Cinzia
   Torre, Alessandro
   Cossu, Maria Vittoria
   Minari, Caterina
   Ballone, Elisabetta
   Perotti, Andrea
   Mileto, Davide
   Niero, Fosca
   Merli, Stefania
   Foschi, Antonella
   Vimercati, Stefania
   Rizzardini, Giuliano
   Sollima, Salvatore
   Bradanini, Lucia
   Galimberti, Laura
   Colombo, Riccardo
   Micheli, Valeria
   Negri, Cristina
   Ridolfo, Anna Lisa
   Meroni, Luca
   Galli, Massimo
   Antinori, Spinello
   Corbellino, Mario
TI Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia
   in Milan, Italy
SO EUROPEAN JOURNAL OF INTERNAL MEDICINE
LA English
DT Article
DE COVID-19; tocilizumab; IL-6 inhibitors
ID CORONAVIRUS PNEUMONIA; RISK
AB Background: Tocilizumab, a humanized monoclonal antibody, targets IL-6 receptors blocking downstream proinflammatory effects of IL-6. In preliminary reports it was suggested to be beneficial in patients with severe COVID-19.
   Methods: In this open-label prospective study we describe clinical characteristics and outcome of 51 patients hospitalized with confirmed and severe COVID-19 pneumonia treated with tocilizumab intravenously. All patients had elevated IL-6 plasma level (>40 pg/mL) and oxygen saturation <93% in ambient air. Clinical outcomes, oxygen support, laboratory data and adverse events were collected over a follow-up of 30 days.
   Results: Forty-five patients (88%) were on high-flow oxygen supplementation, six of whom with invasive ventilation. From baseline to day 7 after tocilizumab we observed a dramatic drop of body temperature and CRP value with a significant increase in lymphocyte count (p < 0.001). Over a median follow-up time of 34 days from tocilizumab, 34 patients (67%) showed an improvement in their clinical severity class; 31 were discharged; 17 (33%) showed a worsening of their clinical status, of these 14 died (27%). The mortality rate was significantly associated with mechanical ventilation at baseline (83.3% vs 20% of patients on non-invasive oxygen support; p= 0.0001). The most frequent side effects were an increase of hepatic enzymes (29%), thrombocytopenia (14%), and serious bacterial and fungal infections (27%).
   Conclusion: Tocilizumab exerts a rapidly beneficial effect on fever and inflammatory markers, although no significant impact on the clinical outcome can be inferred by our results. Critically ill patients seem to have a high risk of serious infections with this drug.
C1 [Milazzo, Laura; Oreni, Letizia; Bestetti, Giovanna; Torre, Alessandro; Cossu, Maria Vittoria; Niero, Fosca; Merli, Stefania; Foschi, Antonella; Rizzardini, Giuliano; Sollima, Salvatore; Galimberti, Laura; Negri, Cristina; Ridolfo, Anna Lisa; Meroni, Luca; Galli, Massimo; Antinori, Spinello; Corbellino, Mario] ASST Fatebenefratelli Sacco, Dept Infect Dis, Via GB Grassi 74, I-20157 Milan, Italy.
   [Morena, Valentina; Bassoli, Cinzia; Bradanini, Lucia; Galli, Massimo] Univ Milan, Luigi Sacco Dept Biomed & Clin Sci, Milan, Italy.
   [Fossali, Tommaso; Minari, Caterina; Ballone, Elisabetta; Perotti, Andrea; Colombo, Riccardo] Luigi Sacco Hosp, Dept Anesthesiol & Intens Care, ASST Fatebenefratelli Sacco, Milan, Italy.
   [Mileto, Davide; Micheli, Valeria] ASST Fatebenefratelli Sacco, Microbiol Virol & Bioemergence Diagnost, Milan, Italy.
   [Vimercati, Stefania] ASST Fatebenefratelli Sacco, Clin Pathol Lab, Milan, Italy.
RP Milazzo, L (corresponding author), ASST Fatebenefratelli Sacco, Dept Infect Dis, Via GB Grassi 74, I-20157 Milan, Italy.
EM laura.milazzo@unimi.it
OI Colombo, Riccardo/0000-0002-9616-803X
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Di Giambenedetto S, 2020, J MED VIROL, V92, P1787, DOI 10.1002/jmv.25897
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kaly L, 2012, BEST PRACT RES CL RH, V26, P157, DOI 10.1016/j.berh.2012.01.001
   Lang VR, 2012, RHEUMATOLOGY, V51, P852, DOI 10.1093/rheumatology/ker223
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Nishimoto N, 2007, BLOOD, V110, p199A, DOI 10.1182/blood.V110.11.646.646
   Nishimoto N, 2006, NAT CLIN PRACT RHEUM, V2, P619, DOI 10.1038/ncprheum0338
   Pham T, 2011, JOINT BONE SPINE, V78, P15, DOI 10.1016/S1297-319X(11)70001-X
   Riegler LL, 2019, THER CLIN RISK MANAG, V15, P323, DOI 10.2147/TCRM.S150524
   Rodriguez-Acelas AL, 2017, AM J INFECT CONTROL, V45, pE149, DOI 10.1016/j.ajic.2017.08.016
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Seguin A, 2016, CHEST, V149, P1294, DOI 10.1016/j.chest.2015.11.004
   Spiteri G, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.9.2000178
   Sun PF, 2020, J MED VIROL, V92, P612, DOI 10.1002/jmv.25735
   Vincent JL, 2020, LANCET RESP MED, V8, P430, DOI 10.1016/S2213-2600(20)30165-X
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, COR DIS 2019 COVID 2
   Winthrop KL, 2018, CLIN MICROBIOL INFEC, V24, pS21, DOI 10.1016/j.cmi.2018.02.002
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Xu X, AXIV20200300026V1
   Xu YH, 2020, J INFECTION, V80, P394, DOI 10.1016/j.jinf.2020.02.017
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   YANG RQ, 2019, J CLIN INVEST, V20
   Yao X, 2020, CLIN INFECT DIS, DOI [10. 1093/cid/ciaa237.ciaa237, DOI 10.1093/CID/CIAA237.CIAA237]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 32
TC 40
Z9 42
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0953-6205
EI 1879-0828
J9 EUR J INTERN MED
JI Eur. J. Intern. Med.
PD JUN
PY 2020
VL 76
BP 36
EP 42
DI 10.1016/j.ejim.2020.05.011
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA LW6KV
UT WOS:000539254000010
PM 32448770
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Larrouquere, L
   Gabin, M
   Poingt, E
   Mouffak, A
   Hlavaty, A
   Lepelley, M
   Khouri, C
   Bellier, A
   Alexandre, J
   Bedouch, P
   Bertoletti, L
   Bordet, R
   Bouhanick, B
   Jonville-Bera, AP
   Laporte, S
   Le Jeunne, C
   Letinier, L
   Micallef, J
   Naudet, F
   Roustit, M
   Molimard, M
   Richard, V
   Cracowski, JL
AF Larrouquere, Louis
   Gabin, Manon
   Poingt, Emmanuelle
   Mouffak, Amelle
   Hlavaty, Alex
   Lepelley, Marion
   Khouri, Charles
   Bellier, Alexandre
   Alexandre, Joachim
   Bedouch, Pierrick
   Bertoletti, Laurent
   Bordet, Regis
   Bouhanick, Beatrice
   Jonville-Bera, Annie-Pierre
   Laporte, Silvy
   Le Jeunne, Claire
   Letinier, Louis
   Micallef, Joelle
   Naudet, Florian
   Roustit, Matthieu
   Molimard, Mathieu
   Richard, Vincent
   Cracowski, Jean-Luc
TI Genesis of an emergency public drug information website by the French
   Society of Pharmacology and Therapeutics during the COVID-19 pandemic
SO FUNDAMENTAL & CLINICAL PHARMACOLOGY
LA English
DT Article
DE COVID-19; pharmacology; public drug information; public health
ID HEALTH
AB On March 16, 2020, the French Society of Pharmacology and Therapeutics put online a national Question and Answer (Q&A) website, on the proper use of drugs during the COVID-19 pandemic. The working group 'Drugs and COVID-19' was composed of a scientific council, an editorial team, and experts in the field. The first questions were posted online during the first evening of home-confinement in France, March 17, 2020. Six weeks later, 140 Q&As have been posted. Questions on the controversial use of hydroxychloroquine and to a lesser extent concerning azithromycin have been the most consulted Q&As. Q&As have been consulted 226 014 times in 41 days. This large visibility was obtained through an early communication on Twitter, Facebook, traditional print, and web media. In addition, an early communication through the French Ministry of Health and the French National Agency for Medicines and Health Products Safety ANSM had a large impact in terms of daily number of views. There is a pressing need to sustain a public drug information service combining the expertise of scholarly pharmacology societies, pharmacovigilance network, and the Ministry of Health to quickly provide understandable, clear, expert answers to the general population's concerns regarding COVID-19 and drug use and to counter fake news.
C1 [Larrouquere, Louis; Gabin, Manon; Poingt, Emmanuelle; Mouffak, Amelle; Hlavaty, Alex; Lepelley, Marion; Khouri, Charles; Bellier, Alexandre; Bedouch, Pierrick; Roustit, Matthieu; Cracowski, Jean-Luc] Univ Grenoble Alpes, CHU Grenoble Alpes, Grenoble, France.
   [Alexandre, Joachim] Univ Caen Normandie, CHU Caen Normandie, Caen, France.
   [Bertoletti, Laurent; Laporte, Silvy] Univ St Etienne, CHU St Etienne, St Etienne, France.
   [Bordet, Regis] Univ Lille, CHU Lille, Lille, France.
   [Bouhanick, Beatrice] Univ Toulouse, CHU Toulouse, Toulouse, France.
   [Jonville-Bera, Annie-Pierre] Univ Tours, CHU Tours, Tours, France.
   [Le Jeunne, Claire] Univ Paris, APHP, Paris, France.
   [Letinier, Louis; Molimard, Mathieu] Univ Bordeaux, CHU Bordeaux, Bordeaux, France.
   [Micallef, Joelle] Aix Marseille Univ, Hop Univ Marseille APHM, Marseille, France.
   [Naudet, Florian] Univ Rennes, CHU Rennes, Rennes, France.
   [Richard, Vincent] Univ Rouen, CHU Rouen, Rouen, France.
RP Cracowski, JL (corresponding author), Univ Grenoble Alpes, CHU Grenoble Alpes, Grenoble, France.
EM Jean-Luc.Cracowski@univ-grenoble-alpes.fr
RI Alexandre, Joachim/ABE-2490-2020; Bedouch, Pierrick/AAI-5093-2020;
   Alexandre, Joachim/ABE-6176-2020
OI Bedouch, Pierrick/0000-0003-2245-0160; Alexandre,
   Joachim/0000-0002-9197-8404; Letinier, Louis/0000-0001-5082-4866
FU Agence Nationale de Securite du Medicament et des Produits de Sante
   Funding Source: Medline
CR Abd-Alrazaq A, 2020, J MED INTERNET RES, V22, DOI 10.2196/19016
   Agence Nationale de securite du medicament et des produits de sante, 2020, COVID 19 VOUS AV QUE
   [Anonymous], 2020, VEILLE SCI COVID 19
   Chou WYS, 2018, JAMA-J AM MED ASSOC, V320, P2417, DOI 10.1001/jama.2018.16865
   Formoso G, 2017, HEALTH POLICY, V121, P257, DOI 10.1016/j.healthpol.2016.12.007
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Kadam AB, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa057
   Liu M, 2020, MET MATER INT, DOI 10.1007/s12540-020-00726-5
   Ministere des solidarites et de la sante Francais, 2020, REP VOS UEST MED PEN
   Ministere des solidarites et de la sante Francais, 2020, QUEST REP COVID 19 B
   Molimard M, 2014, THERAPIE, V69, P361, DOI 10.2515/therapie/2014045
   O'Connor C, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1587
   Rovetta Alessandro, 2020, JMIR Public Health Surveill, V6, pe19374, DOI 10.2196/19374
   Shimizu K, 2020, LANCET, V395, P685, DOI 10.1016/S0140-6736(20)30357-3
   Societe Francaise de Pharmacologie et de Therapeutique, 2020, GROUP TRAV MED COVID
   The Food and Drug Administration (FDA), FREQ ASK QUEST COVID
   The Italian Ministry of Health, FREQ ASK QUEST COVID
   The World Health Organization (WHO), FREQ ASK QUEST COVID
NR 18
TC 8
Z9 8
U1 3
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0767-3981
EI 1472-8206
J9 FUND CLIN PHARMACOL
JI Fundam. Clin. Pharmacol.
PD JUN
PY 2020
VL 34
IS 3
BP 389
EP 396
DI 10.1111/fcp.12564
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LV8JL
UT WOS:000538683300009
PM 32394481
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Moore, Z
   Patton, D
   Avsar, P
   McEvoy, NL
   Curley, G
   Budri, A
   Nugent, L
   Walsh, S
   O'Connor, T
AF Moore, Zena
   Patton, Declan
   Avsar, Pinar
   McEvoy, Natalie L.
   Curley, Gerard
   Budri, Aglecia
   Nugent, Linda
   Walsh, Simone
   O'Connor, Tom
TI Prevention of pressure ulcers among individuals cared for in the prone
   position: lessons for the COVID-19 emergency
SO JOURNAL OF WOUND CARE
LA English
DT Article
DE pressure injury; pressure ulcer; prevention; prone possition;
   ventilation
ID RESPIRATORY-DISTRESS-SYNDROME; RANDOMIZED CONTROLLED-TRIAL;
   NURSING-HOMES; MECHANICAL VENTILATION; INTENSIVE-CARE; CLINICAL-TRIAL;
   PREVALENCE; IMPACT; SKIN; INCONTINENCE
AB Objective: Pressure ulcers (PUs) involve the destruction of skin and underlying tissue due to prolonged pressure and shear forces. These ulcers are painful and significantly reduce a person's quality of life. PUs are also expensive to manage and impact negatively on the achievement of cost-effective, efficient care delivery.
   Method: Prone positioning is a postural therapy that aims to enhance respiratory function through increasing oxygenation levels. In contemporary clinical practice, ventilation in the prone position is indicated for patients with severe acute respiratory distress syndrome. However, despite its advantages in terms of respiratory function, several studies have examined complications of prone position ventilation and have identified PUs (facial PUs as well as PUs on other weight-bearing areas of the body) as a frequent complication in patients who are already in a precarious medical situation. International data suggest that up to 57% of patients nursed in the prone position develop a PU. The aim of this clinical review is to identify and review evidence-based recommendations developed to facilitate the selection and application of preventive interventions aimed at reducing PU development in patients ventilated in the prone position. Given the current COVID-19 crisis, this review is timely as intensive care unit (ICU) patients with COVID-19 require ventilation in the prone position at a level that is disproportionate to the general intensive care population. Up to 28% of patients admitted to the ICU with confirmed infection due to severe COVID-19 are cared for in the prone position. The scope of this review is limited to adult individuals only.
   Results: The skin assessment should be undertaken before proning and following positioning the patient back into the supine position. Although it is essential to keep the skin clean and moisturised, using pH-balanced cleansers, there is inconsistency in terms of the evidence to support the type of moisturiser. Use of positioning devices in addition to repositioning is recommended to offload pressure points on the face and body. Further, using dressings such as hydrocolloids, transparent film and silicone may be of benefit in decreasing facial skin breakdown.
   Conclusion: Given the importance of PU prevention in this cohort of patients, adopting a focused prevention strategy, including skin assessment and care, offloading and pressure redistribution, and dressings for prevention may contribute to a reduction in the incidence and prevalence of these largely preventable wounds. Declaration of interest: The authors have no conflicts of interest to declare.
C1 [Moore, Zena; Patton, Declan; Avsar, Pinar; McEvoy, Natalie L.; Budri, Aglecia; Nugent, Linda; Walsh, Simone; O'Connor, Tom] Royal Coll Surgeons Ireland, Sch Nursing & Midwifery, Dublin, Ireland.
   [Curley, Gerard] Royal Coll Surgeons Ireland, Anaesthet & Crit Care, Dublin, Ireland.
RP Avsar, P (corresponding author), Royal Coll Surgeons Ireland, Sch Nursing & Midwifery, Dublin, Ireland.
EM pinaravsar@rcsi.com
OI Curley, Gerard/0000-0003-0271-195X
CR Aloweni F, 2017, WOUND PRACT RES, V25, P24
   Alsaghir AH, 2008, CRIT CARE MED, V36, P603, DOI 10.1097/01.CCM.0000299739.98236.05
   Avsar P, 2018, WORLDV EVID-BASED NU, V15, P54, DOI 10.1111/wvn.12264
   Barakat-Johnson M, 2019, J WOUND CARE, V28, P512, DOI 10.12968/jowc.2019.28.8.512
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Black J, 2015, INT WOUND J, V12, P322, DOI 10.1111/iwj.12111
   BRYAN AC, 1974, AM REV RESPIR DIS, V110, P143
   Capon A, 2007, J ADV NURS, V58, P263, DOI 10.1111/j.1365-2648.2007.04232.x
   Defloor T, 2005, INT J NURS STUD, V42, P37, DOI 10.1016/j.ijnurstu.2004.05.013
   Demarre L, 2015, INT J NURS STUD, V52, P1166, DOI 10.1016/j.ijnurstu.2015.03.005
   Gattinoni L, 2019, SEMIN RESP CRIT CARE, V40, P94, DOI 10.1055/s-0039-1685180
   Gefen Amit, 2020, J Wound Care, V29, pS1, DOI 10.12968/jowc.2020.29.Sup2a.S1
   Girard R, 2014, INTENS CARE MED, V40, P397, DOI 10.1007/s00134-013-3188-1
   Gorecki C, 2009, J AM GERIATR SOC, V57, P1175, DOI 10.1111/j.1532-5415.2009.02307.x
   Grisell M, 2008, SPINE, V33, P2938, DOI 10.1097/BRS.0b013e31818b9029
   Guerin C, 2018, INTENS CARE MED, V44, P22, DOI 10.1007/s00134-017-4996-5
   Haesler EE, 2019, PREV TREATM PRESS UL
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang TT, 2009, J ORAL MAXIL SURG, V67, P543, DOI 10.1016/j.joms.2008.06.100
   Igarashi A, 2013, ARCH GERONTOL GERIAT, V56, P220, DOI 10.1016/j.archger.2012.08.011
   Jolley DJ, 2004, MED J AUSTRALIA, V180, P324, DOI 10.5694/j.1326-5377.2004.tb05966.x
   Keelaghan E, 2008, WOUND REPAIR REGEN, V16, P331, DOI 10.1111/j.1524-475X.2008.00373.x
   Kim RS, 2016, J WOUND OSTOMY CONT, V43, P427, DOI 10.1097/WON.0000000000000247
   Kumagai A, 2019, J TISSUE VIABILITY, V28, P14, DOI 10.1016/j.jtv.2018.10.007
   Kwee MM, 2015, INT SURG, V100, P292, DOI 10.9738/INTSURG-D-13-00256.1
   Kwong EWY, 2011, J CLIN NURS, V20, P2777, DOI 10.1111/j.1365-2702.2011.03827.x
   Lahmann NA, 2006, OSTOMY WOUND MANAG, V52, P20
   Lucchini A, 2020, DIMENS CRIT CARE NUR, V39, P39, DOI 10.1097/DCC.0000000000000393
   Lupianez-Perez I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122238
   Moore Z, 2013, J CLIN NURS, V22, P2354, DOI 10.1111/j.1365-2702.2012.04310.x
   Moore Z, 2012, J CLIN NURS, V21, P362, DOI 10.1111/j.1365-2702.2011.03749.x
   Moore Z, 2011, J CLIN NURS, V20, P2633, DOI 10.1111/j.1365-2702.2011.03736.x
   Munshi L, 2017, ANN AM THORAC SOC, V14, pS280, DOI 10.1513/AnnalsATS.201704-343OT
   Nakos G, 2000, AM J RESP CRIT CARE, V161, P360, DOI 10.1164/ajrccm.161.2.9810037
   Pan C, 2020, AM J RESP CRIT CARE, V201, P1294, DOI 10.1164/rccm.202003-0527LE
   Park KH, 2014, J WOUND OSTOMY CONT, V41, P161, DOI 10.1097/WON.0000000000000005
   Otero DP, 2017, J WOUND CARE, V26, P128, DOI 10.12968/jowc.2017.26.3.128
   Porter-Armstrong AP, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011620.pub2
   Prebio M, 2005, WIEN KLIN WOCHENSCHR, V117, P98, DOI 10.1007/s00508-004-0299-2
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Roch A, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-16
   Romero CM, 2009, J CRIT CARE, V24, P81, DOI 10.1016/j.jcrc.2008.02.005
   Schreml S, 2010, J EUR ACAD DERMATOL, V24, P373, DOI 10.1111/j.1468-3083.2009.03413.x
   Scott JR, 2006, PLAST RECONSTR SURG, V117, P630, DOI 10.1097/01.prs.0000197210.94131.39
   Sivamani RK, 2003, SKIN RES TECHNOL, V9, P235, DOI 10.1034/j.1600-0846.2003.20361.x
   Stevenson R, 2013, INT J NURS STUD, V50, P1550, DOI 10.1016/j.ijnurstu.2013.04.001
   Sud S, 2014, CAN MED ASSOC J, V186, pE381, DOI 10.1503/cmaj.140081
   Tubaishat A, 2011, J TISSUE VIABILITY, V20, P14, DOI 10.1016/j.jtv.2010.08.001
   Vanderwee K, 2007, J EVAL CLIN PRACT, V13, P227, DOI 10.1111/j.1365-2753.2006.00684.x
   Verdu J, 2012, INT WOUND J, V9, P557, DOI 10.1111/j.1742-481X.2011.00918.x
   Weng Min-Hsueh, 2008, Intensive Crit Care Nurs, V24, P295, DOI 10.1016/j.iccn.2007.11.005
   Whitley AB, 2018, J BURN CARE RES, V39, P117, DOI 10.1097/BCR.0000000000000556
   Wu T, 2011, BIOL RES NURS, V13, P419, DOI 10.1177/1099800410392772
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yoshimura M, 2020, INT WOUND J, V17, P660, DOI 10.1111/iwj.13287
NR 55
TC 1
Z9 1
U1 7
U2 8
PU MA HEALTHCARE LTD
PI LONDON
PA ST JUDES CHURCH, DULWICH ROAD, LONDON SE24 0PB, ENGLAND
SN 0969-0700
EI 2062-2916
J9 J WOUND CARE
JI J. Wound Care
PD JUN
PY 2020
VL 29
IS 6
BP 312
EP 320
PG 8
WC Dermatology
SC Dermatology
GA LV6QY
UT WOS:000538560700003
PM 32530776
DA 2021-01-01
ER

PT J
AU Andreato, LV
   Coimbra, DR
   Andrade, A
AF Andreato, Leonardo V.
   Coimbra, Danilo R.
   Andrade, Alexandro
TI Challenges to Athletes During the Home Confinement Caused by the
   COVID-19 Pandemic
SO STRENGTH AND CONDITIONING JOURNAL
LA English
DT Article
DE exercise; health; physical fitness; sports science
ID DECISION-MAKING; PERFORMANCE; EXERCISE; PREVENTION; STRATEGIES;
   BEHAVIOR; HEALTH; SKILLS
AB The world is currently facing a serious coronavirus pandemic (COVID-19). This novel coronavirus is a new virus for which effective drugs and vaccines have not yet been developed. Amateur and professional athletic events around the world have been stopped, and teams and athletes have had to adopt social withdrawal measures, interrupting their training and preparation routines for competitions. Given this alarming scenario, this article aims to alert athletes to the importance of maintaining a conditioning routine during this confinement period.
C1 [Andreato, Leonardo V.; Andrade, Alexandro] State Univ Santa, Phys Educ Dept, Sci Ctr Hlth & Sport, Florianopolis, SC, Brazil.
   [Coimbra, Danilo R.] Univ Fed Juiz de Fora, Dept Phys Educ, Inst Life Sci, Governador Valadares, MG, Brazil.
RP Andreato, LV (corresponding author), State Univ Santa, Phys Educ Dept, Sci Ctr Hlth & Sport, Florianopolis, SC, Brazil.
EM vidal.leo@hotmail.com
RI Andrade, Alexandro/H-5226-2016
OI Andrade, Alexandro/0000-0002-6640-9314
FU Research Innovation Support Foundation of the State of Santa Catarina
   (FAPESC) [PAP 04/2018]; CAPES (Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior)CAPES
FX Conflicts of Interest and Source of Funding: This work was supported by
   the Research Innovation Support Foundation of the State of Santa
   Catarina (FAPESC) under public call no. PAP 04/2018. The researcher
   Leonardo Vidal Andreato thanks the CAPES (Coordenacao de Aperfeicoamento
   de Pessoal de Ni ' vel Superior) for scholarship.
CR Abe T, 2020, EUR J SPORT SCI, V20, P100, DOI 10.1080/17461391.2019.1612950
   Adegboye O, 2020, CHANGE OUTBREAK EPIC
   Andrade A, 2019, PHYSICIAN SPORTSMED, V47, P312, DOI 10.1080/00913847.2018.1553467
   Andrade A, 2016, J SPORT SCI MED, V15, P601
   Birrer D, 2010, SCAND J MED SCI SPOR, V20, P78, DOI 10.1111/j.1600-0838.2010.01188.x
   Brandt R, 2014, REV BRAS MED ESPORTE, V20, P276, DOI 10.1590/1517-86922014200401607
   Brocherie F, 2014, J SPORT SCI, V32, P1243, DOI 10.1080/02640414.2013.862840
   Campbell JP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00648
   Campos F, 2020, J STRENGTH COND RES
   Center for Diseases Control and Prevention (CDC), CLEAN DIS HOUS
   Chen PJ, 2020, J SPORT HEALTH SCI, V9, P103, DOI 10.1016/j.jshs.2020.02.001
   Close GL, 2019, INT J SPORT NUTR EXE, V29, P189, DOI 10.1123/ijsnem.2018-0290
   Cormier ML, 2015, J ATHL TRAINING, V50, P1267, DOI 10.4085/1062-6050-50.12.02
   Courel-Ibanez J, 2017, INT J PERF ANAL SPOR, V17, P44, DOI 10.1080/24748668.2017.1303982
   Garcia-Pallares J, 2010, MED SCI SPORT EXER, V42, P1209, DOI 10.1249/MSS.0b013e3181c9228c
   Gouttebarge V, 2016, J SPORT MED PHYS FIT, V56, P648
   Greenham G, 2018, SPORTS MED, V48, P2517, DOI 10.1007/s40279-018-0969-2
   Jamurtas AZ, 2018, J SPORT SCI MED, V17, P501
   Jensen MD, 2014, OBESITY, V22, pS5, DOI 10.1002/oby.20821
   Joo CH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196212
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Koundourakis NE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087803
   Kraemer M.U.G., 2020, SCIENCE
   Leppanen M, 2014, SPORTS MED, V44, P473, DOI 10.1007/s40279-013-0136-8
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Branco BHM, 2016, ARCH BUDO SCI MARTIA, V12, P145
   Meurer MC, 2017, PHYS THER SPORT, V28, P1, DOI 10.1016/j.ptsp.2017.07.004
   Moore EWG, 2019, STRENGTH COND J, V41, P1, DOI 10.1519/SSC.0000000000000468
   Dominguez AM, 2011, REV PSICOL DEPORTE, V20, P785
   Muir IL, 2020, J SPORT PSYCHOL ACTI, V11, P143, DOI 10.1080/21520704.2020.1738607
   Mujika I, 2000, SPORTS MED, V30, P79, DOI 10.2165/00007256-200030020-00002
   Ong SWX, 2020, JAMA
   Ormsbee MJ, 2012, J STRENGTH COND RES, V26, P2087, DOI 10.1519/JSC.0b013e31823b874c
   Pritchard H, 2015, STRENGTH COND J, V37, P72, DOI 10.1519/SSC.0000000000000125
   Rice SM, 2016, SPORTS MED, V46, P1333, DOI 10.1007/s40279-016-0492-2
   Rossi SJ, 2010, STRENGTH COND J, V32, P65, DOI 10.1519/SSC.0b013e3181fc5155
   Schinke RJ, 2018, INT J SPORT EXERC PS, V16, P622, DOI [10.1080/1612197x.2017.1295557, 10.1080/1612197X.2017.1295557]
   Schnabel L, 2018, AM J GASTROENTEROL, V113, P1217, DOI 10.1038/s41395-018-0137-1
   Silvers-Granelli H, 2015, AM J SPORT MED, V43, P2628, DOI 10.1177/0363546515602009
   Simpson RJ, 2015, PROG MOL BIOL TRANSL, V135, P355, DOI 10.1016/bs.pmbts.2015.08.001
   Souter G, 2018, SPORTS MED-OPEN, V4, DOI 10.1186/s40798-018-0175-7
   Vaeyens R, 2007, J SPORT EXERCISE PSY, V29, P147, DOI 10.1123/jsep.29.2.147
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   World Health Organization, 94 WHO
   World Health Organization (WHO), 66 WHO
NR 45
TC 3
Z9 3
U1 24
U2 28
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1524-1602
EI 1533-4295
J9 STRENGTH COND J
JI Strength Cond. J.
PD JUN
PY 2020
VL 42
IS 3
BP 1
EP 5
DI 10.1519/SSC.0000000000000563
PG 5
WC Sport Sciences
SC Sport Sciences
GA LW1AA
UT WOS:000538877200001
OA Green Published
DA 2021-01-01
ER

PT J
AU Ahmad, MN
   Dasgupta, A
   Chopra, S
AF Ahmad, M. Naiyaz
   Dasgupta, A.
   Chopra, S.
TI Remdesivir RNA-dependent RNA polymerase inhibitor Treatment of Ebola
   virus infection Treatment of SARS-CoV-2 infection (COVID-19)
SO DRUGS OF THE FUTURE
LA English
DT Article
DE Remdesivir; GS-5734; RNA-dependent RNA polymerase; Ebola; SARS-CoV-2;
   COVID-19
ID THERAPEUTIC-EFFICACY; GS-5734
AB Remdesivir (GS-5734) is a promising broad-spectrum experimental antiviral drug developed by Gilead Sciences. It is a nucleo-side analogue prodrug that undergoes rapid conversion into nucleoside triphosphate (NTP) by intracellular metabolic processes. These NTPs inhibit viral polymerase by acting as an alternate substrate. Initially, remdesivir was developed to treat Ebola virus disease as it exerts antiviral activity by inhibiting RNA-dependent RNA polymerase. As RNA-dependent RNA polymerase is a common enzyme found in all viruses belonging to the realm Riboviria, remdesivir has the potential to be used as a broad-spectrum antiviral against a wide range of viruses, which has been reflected in several in vitro and in vivo studies in which it has efficiently prevented the replication of viruses belonging to diverse families such as Ebola virus, coronavirus, Zika virus and Nipah virus. After qualifying preclinical efficacy and safety criteria, remdesivir is currently in randomized clinical trials in patients of Ebola virus and the recently emerged SARS-CoV-2.
   [GRAPHICS]
C1 [Ahmad, M. Naiyaz; Dasgupta, A.; Chopra, S.] CSIR Cent Drug Res Inst, Div Microbiol, Sect 10,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
   [Ahmad, M. Naiyaz] Acad Sci & Innovat Res AcSIR, Ghaziabad, India.
RP Chopra, S (corresponding author), CSIR Cent Drug Res Inst, Div Microbiol, Sect 10,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
EM skchopra007@gmail.com
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   [Anonymous], 2019, EB WHO R D BLUEPR AD
   [Anonymous], SOL CLIN TRIAL COVID
   [Anonymous], 2020, GIL SCI STAT REQ RES
   [Anonymous], 2015, REMD ORPH DRUG DES
   Beigel J. H., 2020, N ENGL J MED
   Bloom D. E., 2018, Finance & Development, V55, P46
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Chun B.K., Patent No. [US 2018311263, 2018311263]
   Chun B.K., Patent No. [WO 2016069826, 2016069826]
   Committee for Orphan Medicinal Products (COMP), 2016, COMM ORPH MED PROD C
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Development of remdesivir, DEV REMD
   European Medicines Agency, 2020, SUMM COMP US REMD GI
   Grein J, 2020, N ENGL J MED
   Lo MK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9242
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Mackman R.L., Patent No. [WO 2012012776, 2012012776]
   Madelain V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06215-z
   McMullan LK, 2019, LANCET INFECT DIS, V19, P1023, DOI 10.1016/S1473-3099(19)30291-9
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   OConnor S.J., Patent No. [WO 2007056170, 2007056170]
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Walker PJ, 2019, ARCH VIROL, V164, P2417, DOI 10.1007/s00705-019-04306-w
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   World Health Organization, GLOB HLTH OBS
NR 31
TC 0
Z9 0
U1 11
U2 14
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD JUN
PY 2020
VL 45
IS 6
BP 369
EP 382
DI 10.1358/dof.2020.45.6.3146067
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LV7KK
UT WOS:000538615500001
DA 2021-01-01
ER

PT J
AU Toldra, J
   Fernandez-Llamazares, AI
   Auderset, ME
   Komlos, D
   Odland, J
   Polychrones, J
   Spence, MF
   Castro, MM
AF Toldra, J.
   Fernandez-Llamazares, A., I
   Auderset, M. Egan
   Komlos, D.
   Odland, J.
   Polychrones, J.
   Spence, M. Fellin
   Moscoso Castro, M.
TI American Association for Cancer Research Virtual Annual Meeting I
SO DRUGS OF THE FUTURE
LA English
DT Article
DE GX-188E; ATOR-1015; BAY-2416964; AZD-9833; KA-2507; EOS-100850; SDX-7320
AB The American Association for Cancer Research (AACR) Annual Meeting is one of the most important events in the field of cancer research, covering all aspects and bringing together all players including physician-scientists and other health-care professionals, cancer survivors, patients and advocates. Due to the global COVID-19 infection pandemic, the 111th Meeting, due to be held in San Diego, California, was adapted into 2 virtual meetings, the first held April 27-28 and the second part to be held June 22-24. The first part included oral and poster sessions, mainly on clinical trial data, with mini-symposia focused on basic and translational science and New Drugs on the Horizon symposia focused on disclosures of innovative small molecules and biologics for which phase I clinical trials have begun. This report covers some of the highlights from the presentations given as part of the Virtual Meeting I.
C1 [Toldra, J.; Fernandez-Llamazares, A., I; Moscoso Castro, M.] Clarivate, Barcelona, Spain.
   [Auderset, M. Egan; Komlos, D.; Spence, M. Fellin] Clarivate, Philadelphia, PA USA.
   [Odland, J.; Polychrones, J.] Clarivate, Rockville, MD USA.
RP Toldra, J; Fernandez-Llamazares, AI (corresponding author), Clarivate, Barcelona, Spain.
EM Judit.toldra@clarivate.com; anairis.fernandez-llamazares@clarivate.com
NR 0
TC 0
Z9 0
U1 2
U2 2
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD JUN
PY 2020
VL 45
IS 6
BP 433
EP 443
DI 10.1358/dof.2020.45.6.3168440
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LV7KK
UT WOS:000538615500008
DA 2021-01-01
ER

PT J
AU Torres, T
   Puig, L
AF Torres, Tiago
   Puig, Luis
TI Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic
SO AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
LA English
DT Article
ID LESSONS
AB Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has spread rapidly worldwide and has been shown to have a wide spectrum of severity. COVID-19 has become a public health emergency of relevant international concern, and it was declared a pandemic by the World Health Organization on 11 March, 2020. SARS-CoV-2 infection in severe cases involves the host response as an important contributor to the disease process and tissue damage, mainly due to dysregulated and excessive innate immune responses. The primary immune response leads to viral clearance in the majority of cases. However, in a subgroup of patients, the secondary immune response may be exaggerated, leading to inflammatory-induced lung injury and other complications including pneumonitis, acute respiratory distress syndrome, respiratory failure, shock, organ failure, and potentially death. Several cutaneous immune-mediated diseases, including psoriasis, atopic dermatitis, and hidradenitis suppurativa, are therapeutically managed with biologic and non-biologic immunosuppressive and immunomodulatory drugs. The outbreak of COVID-19 affects the management of these chronic conditions, not only for those who are already receiving treatment but also for those who are about to start a new treatment to control their disease. In this article, the management of cutaneous immune-mediated diseases during the COVID-19 pandemic is discussed.
C1 [Torres, Tiago] Ctr Hosp Univ Porto, Dept Dermatol, Porto, Portugal.
   [Torres, Tiago] Univ Porto, Inst Ciencias Biomed Abel Salazar, Porto, Portugal.
   [Puig, Luis] Hosp Santa Creu I St Pau, Dept Dermatol, Barcelona, Spain.
RP Torres, T (corresponding author), Ctr Hosp Univ Porto, Dept Dermatol, Porto, Portugal.; Torres, T (corresponding author), Univ Porto, Inst Ciencias Biomed Abel Salazar, Porto, Portugal.
EM torres.tiago@outlook.com
RI ; Torres, Tiago/C-2604-2014
OI Puig, Luis/0000-0001-6083-0952; Torres, Tiago/0000-0003-0404-0870
CR AEDV, 2020, COM GRUP PSOR AEDV P
   American Academy of Dermatology Association, MAN YOUR PRACT COVID
   [Anonymous], 2020, RAP RISK ASS COR DIS
   Bashiri A, 2020, J MATERN-FETAL NEO M, DOI [10.1080/14767058.2020.1839877, 10.1080/09546634.2020.1742438]
   Cascella M, 2020, FEATURES EVALUATION
   Chen G, 2020, J CLIN INVEST, DOI [10.1172/JCI137244, DOI 10.1172/JCI137244]
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13298
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Deng X, 2020, REGULATION INTERFERO
   European League Against Rheumatism (EULAR), EULAR GUID PAT COVID
   Faure E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088716
   Favalli E.G., 2020, AUTOIMMUN REV, V20
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Fung SY, 2020, EMERG MICROBES INFEC, V9, P558, DOI 10.1080/22221751.2020.1736644
   Hawill B, 2020, REPURPOSING DUPILUMA, DOI DOI 10.31219/OSF.I0/HK7EP
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Hui DS, 2018, AM J RESP CRIT CARE, V197, P700, DOI 10.1164/rccm.201712-2371ED
   International Psoriasis Council, STAT COR COVID 19 OU
   IOIBD, IOIBD UPD COVID 19 P
   Josset L, 2013, MBIO, V4, DOI 10.1128/mBio.00165-13
   Kaltsas A, 2012, CURR OPIN INFECT DIS, V25, P423, DOI 10.1097/QCO.0b013e328355660b
   Kim AHJ, 2020, ANN INTERN MED, V172, P819, DOI 10.7326/M20-1223
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Li HO, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00483-20
   Ma WT, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.190109
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Price KN, 2020, J AM ACAD DERMATOL, V82, pE173, DOI 10.1016/j.jaad.2020.03.046
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Qin C., 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa248., DOI 10.1093/CID/CIAA248, 10.1093/cid/ciaa248]
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sanchez GAM, 2018, J CLIN INVEST, V128, P3041, DOI 10.1172/JCI98814
   Sarzi-Puttini P, 2019, AUTOIMMUN REV, V18, P583, DOI 10.1016/j.autrev.2018.12.009
   Shah P, 2020, J AM ACAD DERMATOL, V82, pE203, DOI 10.1016/j.jaad.2020.03.056
   WHO, COR DIS COVID 19 PAN
   World Health Organization, CLIN MAN SEV AC RESP
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 45
TC 17
Z9 17
U1 0
U2 0
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1175-0561
EI 1179-1888
J9 AM J CLIN DERMATOL
JI Am. J. Clin. Dermatol.
PD JUN
PY 2020
VL 21
IS 3
BP 307
EP 311
DI 10.1007/s40257-020-00514-2
PG 5
WC Dermatology
SC Dermatology
GA LV2CE
UT WOS:000538246800001
PM 32277351
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Pereira, L
   Critchley, AT
AF Pereira, Leonel
   Critchley, Alan T.
TI The COVID 19 novel coronavirus pandemic 2020: seaweeds to the rescue?
   Why does substantial, supporting research about the antiviral properties
   of seaweed polysaccharides seem to go unrecognized by the pharmaceutical
   community in these desperate times?
SO JOURNAL OF APPLIED PHYCOLOGY
LA English
DT Article
DE COVID-19; Novel coronavirus; Pandemic 2020; Seaweed compounds; Sulphated
   polysaccharides; Antiviral properties
ID RESPIRATORY ILLNESS; VIRUSES; INFECTIONS; EPIDEMIOLOGY; GRIFFITHSIN;
   AGENTS
AB Presently, there is lack of a vaccine that would lead to immunization against the virus COVID-19, but here are some of the characteristics that various seaweeds have and which may provide a glimpse into potential solutions of this global health problem in the near future and possibly forearm us for any future such pandemics. Many species of marine algae contain significant quantities of complex structural sulphated polysaccharides that have been shown to inhibit the replication of enveloped viruses. Other compounds, both of red algae (e.g., the lectin griffithsin and the phycocolloid carrageenan), and other sulphated polysaccharides extracted from green algae (i.e., ulvans) and brown algae (i.e., fucoidans) could be potential antiviral therapeutic agents against SARS-CoV-2.
C1 [Pereira, Leonel] Univ Coimbra, Marine & Environm Sci Ctr MARE, Dept Life Sci, P-3000456 Coimbra, Portugal.
   [Critchley, Alan T.] Cape Breton Univ, Verschuren Ctr Sustainabil Energy & Environm, Sydney, NSW, Australia.
RP Pereira, L (corresponding author), Univ Coimbra, Marine & Environm Sci Ctr MARE, Dept Life Sci, P-3000456 Coimbra, Portugal.
EM leonel.pereira@uc.pt; alan.critchley2016@gmail.com
RI Pereira, Leonel/M-3527-2013
OI Pereira, Leonel/0000-0002-6819-0619
FU FCT - Foundation for Science and Technology, I.P. - (MARE) Marine and
   Environmental Sciences Centre [UIDB/04292/2020]
FX This work was financed by national funds through the FCT - Foundation
   for Science and Technology, I.P., within the scope of the projects
   UIDB/04292/2020 - (MARE) Marine and Environmental Sciences Centre.
CR Barre A, 2019, MAR DRUGS, V17, DOI 10.3390/md17080440
   Barton C, 2014, ANTIMICROB AGENTS CH, V58, P120, DOI 10.1128/AAC.01407-13
   Booker B, 2020, JAPAN DECLARES NATIO
   Canducci F, 2008, J MED VIROL, V80, P716, DOI 10.1002/jmv.21108
   Eccles R, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0281-8
   Eccles R, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-108
   Gang HZ, 2020, J RENEW MATER, V8, P417, DOI 10.32604/jrm.2020.09201
   GELDERBLOM HR, 1991, AIDS, V5, P617, DOI 10.1097/00002030-199106000-00001
   GERBER P, 1958, P SOC EXP BIOL MED, V99, P590, DOI 10.3181/00379727-99-24429
   Goldmann DA, 2001, EMERG INFECT DIS, V7, P249, DOI 10.3201/eid0702.010220
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Kahn JS, 2007, CURR OPIN PHARMACOL, V7, P478, DOI 10.1016/j.coph.2007.07.004
   Koenighofer M, 2014, MULTIDISCIP RESP MED, V9, DOI 10.1186/2049-6958-9-57
   Lee C, 2019, MAR DRUGS, V17, DOI 10.3390/md17100567
   Leibbrandt A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014320
   Mackay IM, 2003, J CLIN MICROBIOL, V41, P100, DOI 10.1128/JCM.41.1.100-105.2003
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   MONTO AS, 1993, EPIDEMIOL INFECT, V110, P145, DOI 10.1017/S0950268800050779
   Monto AS, 2001, CLIN THER, V23, P1615, DOI 10.1016/S0149-2918(01)80133-8
   Monto AS, 2002, AM J MED, V112, p4S
   Morokutti-Kurz M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128794
   O'Keefe BR, 2010, J VIROL, V84, P2511, DOI 10.1128/JVI.02322-09
   Parvez MK, 2017, INTERVIROLOGY, V60, P1, DOI 10.1159/000478729
   Pereira L., 2018, INT BIOL REV, V2, P1, DOI DOI 10.18103/IBR.V2I2.1762
   Pereira L, 2018, THERAPEUTIC AND NUTRITIONAL USES OF ALGAE, P175
   Rosa GP, 2020, MAR DRUGS, V18, DOI 10.3390/md18010008
   Shi QM, 2017, CARBOHYD RES, V453-454, P1, DOI 10.1016/j.carres.2017.10.020
   Sloots TP, 2008, J CLIN VIROL, V42, P233, DOI 10.1016/j.jcv.2008.03.002
   Soares F, 2015, THESIS
   Styczynski Jan, 2019, Acta Haematologica Polonica, V50, P159, DOI 10.2478/ahp-2019-0026
   Weigl JAI, 2007, EUR J PEDIATR, V166, P957, DOI 10.1007/s00431-007-0496-x
NR 31
TC 6
Z9 7
U1 4
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0921-8971
EI 1573-5176
J9 J APPL PHYCOL
JI J. Appl. Phycol.
PD JUN
PY 2020
VL 32
IS 3
BP 1875
EP 1877
DI 10.1007/s10811-020-02143-y
EA JUN 2020
PG 3
WC Biotechnology & Applied Microbiology; Marine & Freshwater Biology
SC Biotechnology & Applied Microbiology; Marine & Freshwater Biology
GA ME0MX
UT WOS:000538463500001
PM 32836796
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Grimaud, M
   Starck, J
   Levy, M
   Marais, C
   Chareyre, J
   Khraiche, D
   Leruez-Ville, M
   Quartier, P
   Leger, PL
   Geslain, G
   Semaan, N
   Moulin, F
   Bendavid, M
   Jean, S
   Poncelet, G
   Renolleau, S
   Oualha, M
AF Grimaud, Marion
   Starck, Julie
   Levy, Michael
   Marais, Clemente
   Chareyre, Judith
   Khraiche, Diala
   Leruez-Ville, Marianne
   Quartier, Pierre
   Leger, Pierre Louis
   Geslain, Guillaume
   Semaan, Nada
   Moulin, Florence
   Bendavid, Matthieu
   Jean, Sandrine
   Poncelet, Geraldine
   Renolleau, Sylvain
   Oualha, Mehdi
TI Acute myocarditis and multisystem inflammatory emerging disease
   following SARS-CoV-2 infection in critically ill children
SO ANNALS OF INTENSIVE CARE
LA English
DT Article
DE Shock; Children; Acute myocarditis; Multisystem inflammatory syndrome;
   SARS-CoV-2
ID KAWASAKI-DISEASE; ORGAN DYSFUNCTION; SHOCK; MANAGEMENT
AB Background A recent increase in children admitted with hypotensive shock and fever in the context of the COVID-19 outbreak requires an urgent characterization and assessment of the involvement of SARS-CoV-2 infection. This is a case series performed at 4 academic tertiary care centers in Paris of all the children admitted to the pediatric intensive care unit (PICU) with shock, fever and suspected SARS-CoV-2 infection between April 15th and April 27th, 2020. Results 20 critically ill children admitted for shock had an acute myocarditis (left ventricular ejection fraction, 35% (25-55); troponin, 269 ng/mL (31-4607)), and arterial hypotension with mainly vasoplegic clinical presentation. The first symptoms before PICU admission were intense abdominal pain and fever for 6 days (1-10). All children had highly elevated C-reactive protein (> 94 mg/L) and procalcitonin (> 1.6 ng/mL) without microbial cause. At least one feature of Kawasaki disease was found in all children (fever, n = 20, skin rash, n = 10; conjunctivitis, n = 6; cheilitis, n = 5; adenitis, n = 2), but none had the typical form. SARS-CoV-2 PCR and serology were positive for 10 and 15 children, respectively. One child had both negative SARS-CoV-2 PCR and serology, but had a typical SARS-CoV-2 chest tomography scan. All children but one needed an inotropic/vasoactive drug support (epinephrine, n = 12; milrinone, n = 10; dobutamine, n = 6, norepinephrine, n = 4) and 8 were intubated. All children received intravenous immunoglobulin (2 g per kilogram) with adjuvant corticosteroids (n = 2), IL 1 receptor antagonist (n = 1) or a monoclonal antibody against IL-6 receptor (n = 1). All children survived and were afebrile with a full left ventricular function recovery at PICU discharge. Conclusions Acute myocarditis with intense systemic inflammation and atypical Kawasaki disease is an emerging severe pediatric disease following SARS-CoV-2 infection. Early recognition of this disease is needed and referral to an expert center is recommended. A delayed and inappropriate host immunological response is suspected. While underlying mechanisms remain unclear, further investigations are required to target an optimal treatment.
C1 [Grimaud, Marion; Chareyre, Judith; Moulin, Florence; Bendavid, Matthieu] Necker Enfants Malad Univ Hosp, AP HP, Pediat Intens Care Unit, Paris, France.
   [Starck, Julie; Jean, Sandrine] Armand Trousseau Univ Hosp, AP HP, Pediat & Neonatal Intens Care Unit, Paris, France.
   [Levy, Michael; Geslain, Guillaume; Poncelet, Geraldine] Univ Paris, Robert Debre Univ Hosp, AP HP, Pediat Intens Care Unit, Paris, France.
   [Marais, Clemente; Semaan, Nada] Kremlin Bicetre Univ Hosp, AP HP, Pediat & Neonatal Intens Care Unit, Paris, France.
   [Khraiche, Diala] Necker Enfants Malad Univ Hosp, AP HP, M3C Necker Congenital & Pediat Cardiol, Paris, France.
   [Leruez-Ville, Marianne] Paris Univ, Lab Virol, EA 7328, Paris, France.
   [Quartier, Pierre] Univ Paris, Necker Enfants Malad Univ Hosp, AP HP,Paediat Hematol Immunol & Rheumatol Unit, IMAGINE Inst,Reference Ctr Rheumat Autolmmune & S, Paris, France.
   [Leger, Pierre Louis] Sorbonne Univ, Armand Trousseau Univ Hosp, AP HP, Pediat & Neonatal Intens Care Unit, Paris, France.
   [Renolleau, Sylvain; Oualha, Mehdi] Paris Univ, Necker Enfants Malad Univ Hosp, AP HP, EA7323,Pediat Intens Care Unit, F-75006 Paris, France.
RP Oualha, M (corresponding author), Paris Univ, Necker Enfants Malad Univ Hosp, AP HP, EA7323,Pediat Intens Care Unit, F-75006 Paris, France.
EM mehdi.oualha@aphp.fr
OI Levy, Michael/0000-0003-2766-5777; Geslain,
   Guillaume/0000-0001-5869-9908
CR Castagnoli R, 2020, JAMA PEDIAT
   Gatterre P, 2012, INTENS CARE MED, V38, P872, DOI 10.1007/s00134-012-2473-8
   Inciardi RM, 2020, JAMA CARDIOL
   Kanegaye JT, 2009, PEDIATRICS, V123, pE783, DOI 10.1542/peds.2008-1871
   Leismann D.E., 2020, INTENS CARE MED, V28, P1
   Liu PP, 2020, CIRCULATION, V142, P68, DOI 10.1161/CIRCULATIONAHA.120.047549
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Madjid M, 2020, JAMA CARDIOL
   McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484
   Shi S, 2020, JAMA CARDIOL
   Tagarro A, 2020, JAMA PEDIAT
   Tomelleri A, 2020, ANN RHEUM DIS
   Weiss SL, 2020, INTENS CARE MED, V46, P10, DOI 10.1007/s00134-019-05878-6
   Zhu H, 2020, CURR CARDIOL REP, V22, DOI 10.1007/s11886-020-01292-3
NR 14
TC 32
Z9 35
U1 8
U2 12
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2110-5820
J9 ANN INTENSIVE CARE
JI Ann. Intensive Care
PD JUN 1
PY 2020
VL 10
IS 1
AR 69
DI 10.1186/s13613-020-00690-8
PG 5
WC Critical Care Medicine
SC General & Internal Medicine
GA LU9JI
UT WOS:000538062500002
PM 32488505
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rajagopal, K
   Keller, SP
   Akkanti, B
   Bime, C
   Loyalka, P
   Cheema, FH
   Zwischenberger, JB
   El Banayosy, A
   Pappalardo, F
   Slaughter, MS
   Slepian, MJ
AF Rajagopal, Keshava
   Keller, Steven P.
   Akkanti, Bindu
   Bime, Christian
   Loyalka, Pranav
   Cheema, Faisal H.
   Zwischenberger, Joseph B.
   El Banayosy, Aly
   Pappalardo, Federico
   Slaughter, Mark S.
   Slepian, Marvin J.
TI Advanced Pulmonary and Cardiac Support of COVID-19 Patients: Emerging
   Recommendations From ASAIO-A "Living Working Document"
SO ASAIO JOURNAL
LA English
DT Article
DE COVID-19; coronavirus; mechanical ventilation; extracorporeal membrane
   oxygenation; mechanical circulatory support; ARDS
ID EXTRACORPOREAL MEMBRANE-OXYGENATION; CORONAVIRUS DISEASE 2019;
   RESPIRATORY SYNDROME SARS; CARDIOGENIC-SHOCK; DEVICES; CHINA; HEART;
   ECMO; EPIDEMIOLOGY; PATHOGENESIS
AB The severe acute respiratory syndrome (SARS)-CoV-2 is an emerging viral pathogen responsible for the global coronavirus disease 2019 (COVID)-19 pandemic resulting in significant human morbidity and mortality. Based on preliminary clinical reports, hypoxic respiratory failure complicated by acute respiratory distress syndrome is the leading cause of death. Further, septic shock, late-onset cardiac dysfunction, and multiorgan system failure are also described as contributors to overall mortality. Although extracorporeal membrane oxygenation and other modalities of mechanical cardiopulmonary support are increasingly being utilized in the treatment of respiratory and circulatory failure refractory to conventional management, their role and efficacy as support modalities in the present pandemic are unclear. We review the rapidly changing epidemiology, pathophysiology, emerging therapy, and clinical outcomes of COVID-19; and based on these data and previous experience with artificial cardiopulmonary support strategies, particularly in the setting of infectious diseases, provide consensus recommendations from ASAIO. Of note, this is a "living document," which will be updated periodically, as additional information and understanding emerges.
C1 [Rajagopal, Keshava; Cheema, Faisal H.] Univ Houston, Coll Med, Dept Clin Sci, Houston, TX 77004 USA.
   [Rajagopal, Keshava; Cheema, Faisal H.] Univ Houston, Coll Med, Dept Biomed Sci, Houston, TX 77004 USA.
   [Rajagopal, Keshava; Loyalka, Pranav; Cheema, Faisal H.] HCA Houston Healthcare, Houston Heart, Houston, TX 77004 USA.
   [Keller, Steven P.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.
   [Keller, Steven P.] Harvard Med Sch, Boston, MA 02115 USA.
   [Akkanti, Bindu] Univ Texas Houston, Div Pulm & Crit Care Med, Dept Med, McGovern Med Sch, Houston, TX USA.
   [Bime, Christian] Univ Arizona, Coll Med Tucson, Dept Med, Div Pulm & Crit Care Med, Tucson, AZ USA.
   [Bime, Christian] Banner Hlth, Tucson, AZ USA.
   [Cheema, Faisal H.] HCA Res Inst, Nashville, TN USA.
   [Zwischenberger, Joseph B.] Univ Kentucky, Coll Med, Dept Surg, Lexington, KY USA.
   [Zwischenberger, Joseph B.] Med Ctr, Lexington, KY USA.
   [El Banayosy, Aly] Integris Baptist Med Ctr, Nazih Zuhdi Transplant Inst, Oklahoma City, OK USA.
   [Pappalardo, Federico] Univ Vita Salute San Raffaele, Milan, Italy.
   [Slaughter, Mark S.; Slepian, Marvin J.] Univ Louisville, Sch Med, Dept Cardiovasc & Thorac Surg, Louisville, KY 40292 USA.
   [Slaughter, Mark S.; Slepian, Marvin J.] Jewish Hosp, Louisville, KY USA.
   Univ Arizona, Sarver Heart Ctr, Dept Med, 1501 North Campbell Ave, Tucson, AZ 85724 USA.
   Univ Arizona, Sarver Heart Ctr, Dept Biomed Engn, 1501 North Campbell Ave, Tucson, AZ 85724 USA.
RP Slepian, MJ (corresponding author), Univ Arizona, Sarver Heart Ctr, Dept Med, 1501 North Campbell Ave, Tucson, AZ 85724 USA.; Slepian, MJ (corresponding author), Univ Arizona, Sarver Heart Ctr, Dept Biomed Engn, 1501 North Campbell Ave, Tucson, AZ 85724 USA.; Rajagopal, K (corresponding author), Univ Houston, Dept Clin Sci, Coll Med, Houston Heart,HCA Houston Healthcare, 1200 Binz St,Suite 900, Houston, TX 77004 USA.
EM krajago2@central.uh.edu; slepian@email.arizona.edu
RI Slepian, Marvin/ABG-8305-2020
OI Slepian, Marvin/0000-0002-7864-6691; Bime, Christian/0000-0003-4787-2685
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [K08 HL143342] Funding Source: Medline
CR Bartlett RH, 2020, ASAIO J, V66, P472, DOI 10.1097/MAT.0000000000001173
   Baseler L, 2017, ANNU REV PATHOL-MECH, V12, P387, DOI 10.1146/annurev-pathol-052016-100506
   Basir MB, 2019, CATHETER CARDIO INTE, V93, P1173, DOI 10.1002/ccd.28307
   BAVARIA JE, 1988, ANN THORAC SURG, V45, P526, DOI 10.1016/S0003-4975(10)64525-0
   Beitler JR, 2016, CLIN CHEST MED, V37, P633, DOI 10.1016/j.ccm.2016.07.004
   Bemtgen X, 2020, ASAIO J, V66, P607, DOI 10.1097/MAT.0000000000001178
   Bernheim A, 2020, COVID 19 RETROSPECTI
   Bonow RO, 2020, JAMA CARDIOL
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Calisher CH, 2006, CLIN MICROBIOL REV, V19, P531, DOI 10.1128/CMR.00017-06
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Carinci F, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m799
   Carroll D, 2018, SCIENCE, V359, P872, DOI 10.1126/science.aap7463
   Cherian SV, 2018, RESP MED, V141, P150, DOI 10.1016/j.rmed.2018.06.030
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Cohen J, 2020, SCIENCE, V368, P14, DOI 10.1126/science.368.6486.14
   de Pommereau Aurelien, 2021, ASAIO J, V67, pe49, DOI 10.1097/MAT.0000000000001179
   Delang L, 2018, ANTIVIR RES, V153, P85, DOI 10.1016/j.antiviral.2018.03.003
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Fineberg HV, 2014, NEW ENGL J MED, V370, P1335, DOI 10.1056/NEJMra1208802
   Garraud O, 2017, TRANSFUS APHER SCI, V56, P31, DOI 10.1016/j.transci.2016.12.014
   GLOWER DD, 1985, CIRCULATION, V71, P994, DOI 10.1161/01.CIR.71.5.994
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Hartman ME, 2020, ASAIO J, V66, P603, DOI 10.1097/MAT.0000000000001177
   Jonsson CB, 2010, CLIN MICROBIOL REV, V23, P412, DOI 10.1128/CMR.00062-09
   Kapur NK, 2017, CIRCULATION, V136, P314, DOI 10.1161/CIRCULATIONAHA.116.025290
   Kar S, 2018, CURR CARDIOL REP, V20, DOI 10.1007/s11886-018-0946-2
   Khan S, 2020, J CLIN MICROBIOL, V58, DOI [10.1128/JCM.01297-20, 10.1128/JCM.00187-20]
   Kim S, 2019, ACUTE CRIT CARE, V34, P263, DOI 10.4266/acc.2019.00577
   Kujawski SA, 2020, 1 12 PATIENTS CORONA, DOI 10.1101/2020.03.09.20032896
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li X, 2020, ASAIO J, V66, P475, DOI 10.1097/MAT.0000000000001172
   Lin QQ, 2020, J MICROBIOL IMMUNOL, V53, P821, DOI 10.1016/j.jmii.2020.03.015
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Lippi G, 2020, PROG CARDIOVASC DIS, V63, P390, DOI 10.1016/j.pcad.2020.03.001
   Liu SL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020130
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Lyons DM, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080407
   MacLaren G, 2020, JAMA-J AM MED ASSOC, V323, P1245, DOI 10.1001/jama.2020.2342
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Millar JE, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1570-4
   Miller PE, 2017, CRIT CARE MED, V45, P1922, DOI 10.1097/CCM.0000000000002676
   Morine Kevin J, 2016, Curr Treat Options Cardiovasc Med, V18, P6, DOI 10.1007/s11936-015-0426-6
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372
   Rajagopal K, 2019, ASAIO J, V65, P1, DOI 10.1097/MAT.0000000000000789
   Rajgor DD, 2020, LANCET INFECT DIS, V20, P776, DOI 10.1016/S1473-3099(20)30244-9
   Ramanathan K, 2020, LANCET RESP MED, V8, P518, DOI 10.1016/S2213-2600(20)30121-1
   Schmidt M, 2018, AM J RESP CRIT CARE, V197, P1297, DOI 10.1164/rccm.201708-1761OC
   Schmidt M, 2015, EUR HEART J, V36, P2246, DOI 10.1093/eurheartj/ehv194
   Scholten EL, 2017, CHEST, V151, P215, DOI 10.1016/j.chest.2016.06.032
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shen I, 2001, ANN THORAC SURG, V71, P862, DOI 10.1016/S0003-4975(00)02280-3
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Solholm A, 2020, PERFUSION-UK, V35, P763, DOI 10.1177/0267659120907557
   Tehrani BN, 2019, J AM COLL CARDIOL, V73, P1659, DOI 10.1016/j.jacc.2018.12.084
   Towner JS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000764
   Truby LK, 2017, ASAIO J, V63, P257, DOI 10.1097/MAT.0000000000000553
   Uriel N, 2018, J AM COLL CARDIOL, V72, P569, DOI 10.1016/j.jacc.2018.05.038
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang Q., 2020, QUANT SCI STUD, V1, P239, DOI 10.1162/qss_a_00011
   Wei WE, 2020, MMWR-MORBID MORTAL W, V69, P411, DOI 10.15585/mmwr.mm6914e1
   World Health Organization (WHO), 2020, LAB TEST COR DIS 201, P1
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu P, 2020, EUROSURVEILLANCE, V25, P4, DOI 10.2807/1560-7917.ES.2020.25.3.2000044
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiao SY, 2020, J MED VIROL, V92, P464, DOI 10.1002/jmv.25702
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zampieri FG, 2013, J CRIT CARE, V28, P998, DOI 10.1016/j.jcrc.2013.07.047
   Zhang JN, 2020, LANCET RESP MED, V8, pE11, DOI 10.1016/S2213-2600(20)30071-0
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 82
TC 8
Z9 8
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1058-2916
EI 1538-943X
J9 ASAIO J
JI Asaio J.
PD JUN
PY 2020
VL 66
IS 6
BP 588
EP 598
DI 10.1097/MAT.0000000000001180
PG 11
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA LV0VJ
UT WOS:000538161500004
PM 32358232
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kokorovic, A
   So, AI
   Hotte, SJ
   Black, PC
   Danielson, B
   Emmenegger, U
   Finelli, A
   Niazi, T
   Pouliot, F
   Shayegan, B
   Sridhar, S
   Vigneault, E
   Loblaw, A
   Rendon, RA
AF Kokorovic, Andrea
   So, Alan, I
   Hotte, Sebastien J.
   Black, Peter C.
   Danielson, Brita
   Emmenegger, Urban
   Finelli, Antonio
   Niazi, Tamim
   Pouliot, Frederic
   Shayegan, Bobby
   Sridhar, Srikala
   Vigneault, Eric
   Loblaw, Andrew
   Rendon, Ricardo A.
TI A Canadian framework for managing prostate cancer during the COVID-19
   pandemic: Recommendations from the Canadian Urologic Oncology Group and
   the Canadian Urological Association
SO CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL
LA English
DT Article
ID RADICAL PROSTATECTOMY; MEN; RADIOTHERAPY; THERAPY; DELAY
C1 [Kokorovic, Andrea] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [So, Alan, I; Black, Peter C.] Univ British Columbia, Dept Urol Sci, Vancouver, BC, Canada.
   [Hotte, Sebastien J.] McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada.
   [Danielson, Brita] Univ Alberta, Dept Oncol, Div Radiat Oncol, Edmonton, AB, Canada.
   [Emmenegger, Urban] Sunnybrook Odette Canc Ctr, Dept Med Oncol, Toronto, ON, Canada.
   [Finelli, Antonio] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada.
   [Niazi, Tamim] McGill Univ, Dept Oncol, Div Radiat Oncol, Montreal, PQ, Canada.
   [Pouliot, Frederic] Univ Laval, Dept Surg, Div Urol, Quebec City, PQ, Canada.
   [Shayegan, Bobby] McMaster Univ, Div Urol, Hamilton, ON, Canada.
   [Sridhar, Srikala] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Div Hematol & Med Oncol, Toronto, ON, Canada.
   [Vigneault, Eric] Univ Laval, Dept Radiat Oncol, CHUQ, Quebec City, PQ, Canada.
   [Loblaw, Andrew] Sunnybrook Odette Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada.
   [Rendon, Ricardo A.] Dalhousie Univ, Dept Urol, Halifax, NS, Canada.
RP Rendon, RA (corresponding author), Dalhousie Univ, Dept Urol, Halifax, NS, Canada.
EM Ricardo.Rendon@Dal.Ca
CR Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Boeve LMS, 2019, EUR UROL, V75, P410, DOI 10.1016/j.eururo.2018.09.008
   Boorjian SA, 2005, BJU INT, V96, P773, DOI 10.1111/j.1464-410X.2005.05763.x
   Burki TK, 2020, LANCET ONCOL, V21, P629, DOI 10.1016/S1470-2045(20)30217-5
   Curtis JR, 2020, JAMA-J AM MED ASSOC, V323, P1771, DOI 10.1001/jama.2020.4894
   Desai Aakash, 2020, JCO Glob Oncol, V6, P557, DOI 10.1200/GO.20.00097
   Ferreira R, 2020, CUAJ-CAN UROL ASSOC, V14, pE159, DOI 10.5489/cuaj.6551
   Fizazi K, 2019, NEW ENGL J MED, V380, P1235, DOI 10.1056/NEJMoa1815671
   Freedland SJ, 2006, J UROLOGY, V175, P1298, DOI 10.1016/S0022-5347(05)00646-4
   Gleave ME, 2001, J UROLOGY, V166, P500, DOI 10.1016/S0022-5347(05)65971-X
   Gupta N, 2019, BJU INT, V124, P268, DOI 10.1111/bju.14659
   Hamdy FC, 2016, NEW ENGL J MED, V375, P1415, DOI 10.1056/NEJMoa1606220
   Hindson J, 2020, NAT REV GASTRO HEPAT, V17, P259, DOI 10.1038/s41575-020-0295-7
   Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536
   James ND, 2017, NEW ENGL J MED, V377, P338, DOI 10.1056/NEJMoa1702900
   Khan MA, 2004, J UROLOGY, V172, P1835, DOI 10.1097/01.ju.0000140277.08623.13
   Kumar S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006019.pub2
   Lalani AKA, 2020, CUAJ-CAN UROL ASSOC, V14, pE154, DOI 10.5489/cuaj.6595
   Lei Shaoqing, 2020, EClinicalMedicine, V21, P100331, DOI 10.1016/j.eclinm.2020.100331
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   National Comprehensive Cancer Network, PROST CANC VERS 1 20
   NCCN, CAR PROST CANC PAT C
   Parker C, 2019, ANN ONCOL, V30
   Parker CC, 2018, LANCET, V392, P2353, DOI 10.1016/S0140-6736(18)32486-3
   Pisansky TM, 2015, J CLIN ONCOL, V33, P332, DOI 10.1200/JCO.2014.58.0662
   Ravi P, 2014, UROL ONCOL-SEMIN ORI, V32, P1333, DOI 10.1016/j.urolonc.2014.05.005
   Reichard CA, 2019, BJU INT, V124, P282, DOI 10.1111/bju.14671
   Rendon RA, 2017, CUAJ-CAN UROL ASSOC, V11, P298, DOI 10.5489/cuaj.4888
   Romero-Laorden N, 2018, BRIT J CANCER, V119, P1052, DOI 10.1038/s41416-018-0123-9
   Simcock R, 2020, CLIN TRANSL RAD ONCO, V22, P55, DOI 10.1016/j.ctro.2020.03.009
   Smith MR, 2018, NEW ENGL J MED, V378, P1408, DOI 10.1056/NEJMoa1715546
   Vale CL, 2019, ANN ONCOL, V30, P883
   Watts S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-003901
   Weiner AB, 2016, J UROLOGY, V195, P1383, DOI 10.1016/j.juro.2015.12.071
   Wilt TJ, 2017, NEW ENGL J MED, V377, P132, DOI 10.1056/NEJMoa1615869
   You B, 2020, LANCET ONCOL, V21, P619, DOI 10.1016/S1470-2045(20)30204-7
   Zheng MH, 2020, ANN SURG, V272, pE5, DOI 10.1097/SLA.0000000000003924
NR 37
TC 3
Z9 3
U1 2
U2 2
PU CANADIAN UROLOGICAL ASSOCIATION
PI DORVAL
PA 185 DORVAL AVENUE, STE 401, DORVAL, QC H9S 5J9, CANADA
SN 1911-6470
EI 1920-1214
J9 CUAJ-CAN UROL ASSOC
JI CUAJ-Can. Urol. Assoc. J.
PD JUN
PY 2020
VL 14
IS 6
BP 163
EP 168
DI 10.5489/cuaj.6667
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA LV0VM
UT WOS:000538161800012
PM 32374715
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kennedy, NA
   Jones, GR
   Lamb, CA
   Appleby, R
   Arnott, I
   Beattie, RM
   Bloom, S
   Brooks, AJ
   Cooney, R
   Dart, RJ
   Edwards, C
   Fraser, A
   Gaya, DR
   Ghosh, S
   Greveson, K
   Hansen, R
   Hart, A
   Hawthorne, AB
   Hayee, B
   Limdi, JK
   Murray, CD
   Parkes, GC
   Parkes, M
   Patel, K
   Pollok, RC
   Powell, N
   Probert, CS
   Raine, T
   Sebastian, S
   Selinger, C
   Smith, PJ
   Stansfield, C
   Younge, L
   Lindsay, JO
   Irving, PM
   Lees, CW
AF Kennedy, Nicholas A.
   Jones, Gareth-Rhys
   Lamb, Christopher A.
   Appleby, Richard
   Arnott, Ian
   Beattie, R. Mark
   Bloom, Stuart
   Brooks, Alenka J.
   Cooney, Rachel
   Dart, Robin J.
   Edwards, Cathryn
   Fraser, Aileen
   Gaya, Daniel R.
   Ghosh, Subrata
   Greveson, Kay
   Hansen, Richard
   Hart, Ailsa
   Hawthorne, A. Barney
   Hayee, Bu'Hussain
   Limdi, Jimmy K.
   Murray, Charles D.
   Parkes, Gareth C.
   Parkes, Miles
   Patel, Kamal
   Pollok, Richard C.
   Powell, Nick
   Probert, Chris S.
   Raine, Tim
   Sebastian, Shaji
   Selinger, Christian
   Smith, Philip J.
   Stansfield, Catherine
   Younge, Lisa
   Lindsay, James O.
   Irving, Peter M.
   Lees, Charlie W.
TI British Society of Gastroenterology guidance for management of
   inflammatory bowel disease during the COVID-19 pandemic
SO GUT
LA English
DT Article
AB The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government's advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.
C1 [Kennedy, Nicholas A.] Royal Devon & Exeter NHS Fdn Trust, Exeter, Devon, England.
   [Kennedy, Nicholas A.] Univ Exeter, Exeter, Devon, England.
   [Jones, Gareth-Rhys; Lees, Charlie W.] Univ Edinburgh, Edinburgh, Midlothian, Scotland.
   [Jones, Gareth-Rhys; Arnott, Ian; Lees, Charlie W.] Western Gen Hosp, Edinburgh, Midlothian, Scotland.
   [Lamb, Christopher A.] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England.
   [Lamb, Christopher A.] Newcastle Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England.
   [Appleby, Richard] Chelsea & Westminster Hosp NHS Fdn Trust, London, England.
   [Beattie, R. Mark] Univ Hosp Southampton NHS Fdn Trust, Southampton Childrens Hosp, Southampton, Hants, England.
   [Bloom, Stuart] Univ Coll London Hosp NHS Fdn Trust, London, England.
   [Brooks, Alenka J.] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England.
   [Cooney, Rachel; Ghosh, Subrata] Queen Elizabeth Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England.
   [Cooney, Rachel; Ghosh, Subrata] Univ Birmingham, Birmingham, W Midlands, England.
   [Dart, Robin J.; Hayee, Bu'Hussain; Irving, Peter M.] Kings Coll London, London, England.
   [Dart, Robin J.; Greveson, Kay; Murray, Charles D.] Royal Free Hosp, London, England.
   [Edwards, Cathryn] Torbay & South Devon NHS Fdn Trust, Torquay, England.
   [Fraser, Aileen] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England.
   [Gaya, Daniel R.] Glasgow Royal Infirm, Glasgow, Lanark, Scotland.
   [Gaya, Daniel R.; Hansen, Richard] Univ Glasgow, Glasgow, Lanark, Scotland.
   [Hansen, Richard] Royal Hosp Children, Glasgow, Lanark, Scotland.
   [Hart, Ailsa] St Marks Hosp, London, England.
   [Hart, Ailsa; Powell, Nick] Imperial Coll London, London, England.
   [Hawthorne, A. Barney] Univ Hosp Wales, Cardiff, Wales.
   [Hayee, Bu'Hussain] Kings Coll Hosp NHS Fdn Trust, London, England.
   [Limdi, Jimmy K.] Pennine Acute Hosp NHS Trust, Manchester, Lancs, England.
   [Limdi, Jimmy K.] Univ Manchester, Manchester, Lancs, England.
   [Parkes, Gareth C.; Lindsay, James O.] Barts & London Queen Marys Sch Med & Dent, London, England.
   [Parkes, Gareth C.; Lindsay, James O.] Barts Hlth NHS Trust, Royal London Hosp, London, England.
   [Parkes, Miles; Raine, Tim] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England.
   [Patel, Kamal; Pollok, Richard C.] St Georges Univ Hosp NHS Fdn Trust, London, England.
   [Pollok, Richard C.] St Georges Univ London, London, England.
   [Powell, Nick] Imperial Coll Healthcare NHS Trust, London, England.
   [Probert, Chris S.; Smith, Philip J.] Liverpool Univ Hosp NHS Fdn Trusts, Liverpool, Merseyside, England.
   [Probert, Chris S.] Univ Liverpool, Liverpool, Merseyside, England.
   [Sebastian, Shaji] Hull Univ Teaching Hosp NHS Trust, Kingston Upon Hull, N Humberside, England.
   [Selinger, Christian] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England.
   [Stansfield, Catherine] Salford Royal NHS Fdn Trust, Salford, Lancs, England.
   [Younge, Lisa] Crohns & Colitis UK, St Albans, Herts, England.
   [Irving, Peter M.] Guys & St Thomas NHS Fdn Trust, London, England.
RP Lees, CW (corresponding author), Univ Edinburgh, Inst Genet & Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland.
EM charlie.lees@ed.ac.uk
RI Limdi, Jimmy K/AAS-4941-2020; Murray, Charles/K-5327-2013
OI Limdi, Jimmy K/0000-0002-1039-6251; Appleby,
   Richard/0000-0001-5887-8922; Edwards, Cathryn/0000-0002-5550-9184;
   Beattie, Robert Mark/0000-0003-4721-0577; Dart,
   Robin/0000-0003-3470-8210; Irving, Peter/0000-0003-0972-8148; Murray,
   Charles/0000-0001-6736-1546; Raine, Tim/0000-0002-5855-9873; Bloom,
   Stuart/0000-0002-6361-4662; Brooks, Alenka/0000-0001-7162-7845; Kennedy,
   Nicholas/0000-0003-4368-1961; Hansen, Richard/0000-0002-3944-6646;
   Jones, Gareth-Rhys/0000-0001-7355-2357
FU Crohn's and Colitis UK
FX This guidance has been developed by the British Society of
   Gastroenterology COVID-19 IBD Working Group and we are grateful for the
   input from contributors within the group. The British Society of
   Gastroenterology COVID-19 IBD Working Group is thankful for the support
   of Crohn's and Colitis UK in developing a patient friendly version of
   this guidance and to the UK IBD Registry for supporting development of a
   patient self-identification tool implementing the guidance.
CR An P, PROTECTION 318 INFLA
   [Anonymous], 2020, INT SURV COVID 19 IT
   European Crohn's and Colitis Organisation, 2020, 1 INT COVID 19 ECCO
   Fardet L, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002024
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Heerasing N, 2017, ALIMENT PHARM THER, V45, P660, DOI 10.1111/apt.13934
   International Organization For the Study Of Inflammatory Bowel Disease, 2020, IOIBD UPD COVID19 PA
   Jones GR, 2019, GUT, V68, pA63, DOI 10.1136/gutjnl-2019-BSGAbstracts.125
   Jones GR, 2019, GUT, V68, P1953, DOI 10.1136/gutjnl-2019-318936
   Lamb CA, 2019, GUT, V68, pS1, DOI 10.1136/gutjnl-2019-318484
   Lichtenstein GR, 2012, AM J GASTROENTEROL, V107, P1409, DOI 10.1038/ajg.2012.218
   LITTLE P, 2013, BMJ-BRIT MED J, V347, DOI DOI 10.1136/BMJ.F6041
   Little P, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009769
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   Naganuma M, 2013, J GASTROENTEROL, V48, P595, DOI 10.1007/s00535-012-0686-9
   SECURE-IBD- Registry, 2020, SEC IBD REG SURV EP
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Wenham C, 2020, LANCET, V395, P846, DOI 10.1016/S0140-6736(20)30526-2
   Wisniewski A, 2020, UNITED EUR GASTROENT, V8, P303, DOI 10.1177/2050640619889763
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 21
TC 42
Z9 43
U1 1
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUN
PY 2020
VL 69
IS 6
BP 984
EP 990
DI 10.1136/gutjnl-2020-321244
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA LV0FW
UT WOS:000538121200008
PM 32303607
OA Green Accepted, Other Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Lin, L
   Jiang, XY
   Zhang, ZL
   Huang, SW
   Zhang, ZY
   Fang, ZX
   Gu, ZQ
   Gao, LQ
   Shi, HG
   Mai, L
   Liu, Y
   Lin, XQ
   Lai, RX
   Yan, ZX
   Li, XF
   Shan, H
AF Lin, Lu
   Jiang, Xiayang
   Zhang, Zhenling
   Huang, Siwen
   Zhang, Zhenyi
   Fang, Zhaoxiong
   Gu, Zhiqiang
   Gao, Liangqing
   Shi, Honggang
   Mai, Lei
   Liu, Yuan
   Lin, Xianqi
   Lai, Renxu
   Yan, Zhixiang
   Li, Xiaofeng
   Shan, Hong
TI Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection
SO GUT
LA English
DT Article
ID WUHAN; CHINA
AB Objective To study the GI symptoms in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients.
   Design We analysed epidemiological, demographic, clinical and laboratory data of 95 cases with SARS-CoV-2 caused coronavirus disease 2019. Real-time reverse transcriptase PCR was used to detect the presence of SARS-CoV-2 in faeces and GI tissues.
   Results Among the 95 patients, 58 cases exhibited GI symptoms of which 11 (11.6%) occurred on admission and 47 (49.5%) developed during hospitalisation. Diarrhoea (24.2%), anorexia (17.9%) and nausea (17.9%) were the main symptoms with five (5.3%), five (5.3%) and three (3.2%) cases occurred on the illness onset, respectively. A substantial proportion of patients developed diarrhoea during hospitalisation, potentially aggravated by various drugs including antibiotics. Faecal samples of 65 hospitalised patients were tested for the presence of SARS-CoV-2, including 42 with and 23 without GI symptoms, of which 22 (52.4%) and 9 (39.1%) were positive, respectively. Six patients with GI symptoms were subjected to endoscopy, revealing oesophageal bleeding with erosions and ulcers in one severe patient. SARS-CoV-2 RNA was detected in oesophagus, stomach, duodenum and rectum specimens for both two severe patients. In contrast, only duodenum was positive in one of the four non-severe patients.
   Conclusions GI tract may be a potential transmission route and target organ of SARS-CoV-2.
C1 [Lin, Lu; Jiang, Xiayang; Zhang, Zhenling; Huang, Siwen; Zhang, Zhenyi; Fang, Zhaoxiong; Gu, Zhiqiang; Gao, Liangqing; Shi, Honggang; Mai, Lei; Liu, Yuan; Lin, Xianqi; Lai, Renxu; Li, Xiaofeng] Sun Yat Sen Univ, Dept Gastroenterol, Affiliated Hosp 5, Zhuhai 519000, Guangdong, Peoples R China.
   [Yan, Zhixiang; Shan, Hong] Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Key Lab Biomed Imaging, Zhuhai 519000, Guangdong, Peoples R China.
   [Yan, Zhixiang; Shan, Hong] Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Engn Res Ctr Mol Imaging, Zhuhai, Guangdong, Peoples R China.
   [Shan, Hong] Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Intervent Med, Zhuhai, Peoples R China.
RP Li, XF (corresponding author), Sun Yat Sen Univ, Dept Gastroenterol, Affiliated Hosp 5, Zhuhai 519000, Guangdong, Peoples R China.; Yan, ZX; Shan, H (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Key Lab Biomed Imaging, Zhuhai 519000, Guangdong, Peoples R China.; Yan, ZX; Shan, H (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Engn Res Ctr Mol Imaging, Zhuhai, Guangdong, Peoples R China.
EM yanzhx3@mail.sysu.edu.cn; zdwylxf@163.com; shanhong@mail.sysu.edu.cn
FU National Key Research and Development Program of China [2020YFC082400];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31900070]; Task-Force Project on the
   Prevention and Control of Novel Coronavirus of Guangdong Province
   [20201113]; Three Major Constructions of Sun Yat-sen University (the
   Task-Force Project on the Prevention and Control of Novel Coronavirus of
   Sun Yat-sen University); Emergency Task-Force of SARS-C oV-2 research of
   Guangzhou Regenerative Medicine and Health Guangdong Laboratory;
   Emergency Task-Force Project on the Prevention and Control of Novel
   Coronavirus of Zhuhai 2020; Young and middle-aged talents in the Hundred
   Talents Program of Sun Yat-sen University
FX This work was supported by the National Key Research and Development
   Program of China (2020YFC082400), the National Natural Science
   Foundation of China (31900070), the Task-Force Project on the Prevention
   and Control of Novel Coronavirus of Guangdong Province (20201113), the
   Three Major Constructions of Sun Yat-sen University (the Task-Force
   Project on the Prevention and Control of Novel Coronavirus of Sun
   Yat-sen University), the Emergency Task-Force of SARS-C oV-2 research of
   Guangzhou Regenerative Medicine and Health Guangdong Laboratory, the
   Emergency Task-Force Project on the Prevention and Control of Novel
   Coronavirus of Zhuhai 2020, and Young and middle-aged talents in the
   Hundred Talents Program of Sun Yat-sen University.
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Song Y, 2020, GUT, V69, P1143, DOI 10.1136/gutjnl-2020-320891
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Young BE, 2020, JAMA
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 12
TC 153
Z9 158
U1 6
U2 13
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUN
PY 2020
VL 69
IS 6
BP 997
EP 1001
DI 10.1136/gutjnl-2020-321013
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA LV0FW
UT WOS:000538121200010
PM 32241899
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Aggour, M
   White, P
   Kulcsar, Z
   Fiehler, J
   Brouwer, P
AF Aggour, Mohamed
   White, Phil
   Kulcsar, Zsolt
   Fiehler, Jens
   Brouwer, Patrick
TI European Society of Minimally Invasive Neurological Therapy (ESMINT)
   recommendations for optimal interventional neurovascular management in
   the COVID-19 era
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
DE infection
C1 [White, Phil] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne, Tyne & Wear, England.
   [White, Phil] Newcastle Tyne Hosp, Neuroradiol, Newcastle Upon Tyne, Tyne & Wear, England.
   [Kulcsar, Zsolt] Zurich Univ Hosp, Neuroradiol, Zurich, Switzerland.
   [Fiehler, Jens] Univ Med Ctr Hamburg Eppendorf, Dept Neuroradiol, Hamburg, Germany.
   [Brouwer, Patrick] Karolinska Univ Sjukhuset, Neuroradiol, Stockholm, Sweden.
   [Brouwer, Patrick] LUMC Leiden, UNVC, Univ NeuroVasc Ctr, Leiden, Netherlands.
   [Brouwer, Patrick] HMC The Hague, The Hague, Netherlands.
EM aggour.mohamed@gmail.com
OI Kulcsar, Zsolt/0000-0002-6805-5150
CR Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   US Department of Veterans Affairs, MAN HEALTHC WORK STR
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
NR 3
TC 15
Z9 15
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD JUN
PY 2020
VL 12
IS 6
BP 542
EP 544
DI 10.1136/neurintsurg-2020-016137
PG 3
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA LV0GE
UT WOS:000538122000003
PM 32303584
OA Bronze
DA 2021-01-01
ER

PT J
AU Spagnolo, P
   Cozzi, A
   Foa, RA
   Spinazzola, A
   Monfardini, L
   Bna, C
   Ali, M
   Schiaffino, S
   Sardanelli, F
AF Spagnolo, Pietro
   Cozzi, Andrea
   Foa, Riccardo Alessandro
   Spinazzola, Angelo
   Monfardini, Lorenzo
   Bna, Claudio
   Ali, Marco
   Schiaffino, Simone
   Sardanelli, Francesco
TI CT-derived pulmonary vascular metrics and clinical outcome in COVID-19
   patients
SO QUANTITATIVE IMAGING IN MEDICINE AND SURGERY
LA English
DT Article
DE Tomography; X-ray Computed; COVID-19; hypertension; pulmonary;
   pneumonia; viral; SARS-CoV-2; patient outcome assessment
ID ARTERIAL ENLARGEMENT
AB To assess pulmonary vascular metrics on chest CT of COVID-19 patients, and their correlation with pneumonia extent (PnE) and outcome, we analyzed COVID-19 patients with an available previous chest CT, excluding those performed for cardiovascular disease. From February 21 to March 21, 2020, of 672 suspected COVID-19 patients from two centers who underwent CT, 45 RT-PCR-positives (28 males, median age 75, IQR 66-81 years) with previous CTs performed a median 36 months before (IQR 12-72 months) were included. We assessed PnE, pulmonary artery (PA) diameter, ascending aorta (Ao) diameter, and PA/Ao ratio. Most common presentations were fever and dyspnea (15/45) and fever alone (13/45). Outcome was available for 41/45 patients, 15/41 dead and 26/41 discharged. Ground-glass opacities (GGOs) alone were found in 29/45 patients, GGOs with consolidations in 15/45, consolidations alone in 1/45. All but one patient had bilateral pneumonia, 9/45 minimal, 22/45 mild, 9/45 moderate, and 5/45 severe PnE. PA diameter (median 31 mm, IQR 28-33 mm) was larger than before (26 mm, IQR 25-29 mm) (P<0.001), PA/Ao ratio (median 0.83, IQR 0.76-0.92) was higher than before (0.76, IQR 0.72-0.82) (P<0.001). Patients with adverse outcome (death) had higher PA diameter (P=0.001), compared to discharged ones. Only weak correlations were found between Delta PA or Delta PA/Ao and PnE (rho <= 0.453, P <= 0.032), with 4/45 cases with moderate-severe PnE and minimal increase in PA metrics. In conclusion, enlarged PA diameter was associated to death in COVID-19 patients, a finding deserving further investigation as a potential driver of therapy decision-making.
C1 [Spagnolo, Pietro; Ali, Marco; Schiaffino, Simone; Sardanelli, Francesco] IRCCS Policlin San Donato, Radiol Unit, Via Rodolfo Morandi 30, I-20097 San Donato Milanese, Italy.
   [Cozzi, Andrea; Sardanelli, Francesco] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy.
   [Foa, Riccardo Alessandro; Spinazzola, Angelo] ASST Crema Osped Maggiore, Dept Radiol, Unit Intervent Radiol, Crema, Italy.
   [Monfardini, Lorenzo; Bna, Claudio] Fdn Poliambulanza Ist Ospedaliero, Unit Intervent Radiol, Radiol Unit, Brescia, Italy.
   [Ali, Marco] CDI Ctr Diagnost Italiano SpA, Unit Diagnost Imaging & Stereotact Radiosurg, Milan, Italy.
RP Schiaffino, S (corresponding author), IRCCS Policlin San Donato, Radiol Unit, Via Rodolfo Morandi 30, I-20097 San Donato Milanese, Italy.
EM schiaffino.simone@gmail.com
RI Cozzi, Andrea/C-5453-2019; Sardanelli, Francesco/M-2917-2016
OI Cozzi, Andrea/0000-0003-4922-7065; Sardanelli,
   Francesco/0000-0001-6545-9427
FU Italian Ministry of HealthMinistry of Health, Italy
FX This study was partially supported by Ricerca Corrente funding from
   Italian Ministry of Health to IRCCS Policlinico San Donato.
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Beiderlinden M, 2006, INTENS CARE MED, V32, P852, DOI 10.1007/s00134-006-0122-9
   Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463
   Codari M, 2018, MAGN RESON IMAGING, V47, P77, DOI 10.1016/j.mri.2017.11.010
   Dolhnikoff M, 2020, J THROMB HAEMOST, V18, P1517, DOI 10.1111/jth.14844
   Grillet F, 2020, RADIOLOGY, V296, pE186, DOI 10.1148/radiol.2020201544
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Leonard-Lorant I, 2020, RADIOLOGY, V296, pE189, DOI 10.1148/radiol.2020201561
   Lewis G, 2015, QUANT IMAG MED SURG, V5, P423, DOI 10.3978/j.issn.2223-4292.2015.01.05
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Marongiu F, 2020, J THROMB HAEMOST, V18, P1511, DOI 10.1111/jth.14818
   Matsushita S, 2014, CLIN IMAG, V38, P454, DOI 10.1016/j.clinimag.2014.02.004
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   Raptis CA, 2020, AM J ROENTGENOL, V215, P839, DOI 10.2214/AJR.20.23202
   Salehi S, 2020, AM J ROENTGENOL, V215, P87, DOI [10.2214/AJR.20.23034, 10.2214/AJR.20.23034S.]
   Shen YC, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000256
   Tan CW, 2020, AM J HEMATOL, V95, pE156, DOI 10.1002/ajh.25822
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Thachil J, 2020, J THROMB HAEMOST, DOI [10.1148/radiol.2020201561., DOI 10.1148/RADIOL.2020201561]
   Truong QA, 2012, CIRC-CARDIOVASC IMAG, V5, P147, DOI 10.1161/CIRCIMAGING.111.968610
   Wang YXJ, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.71
   Wells JM, 2012, NEW ENGL J MED, V367, P913, DOI 10.1056/NEJMoa1203830
   Xiong M, 2020, BRIT J HAEMATOL, V189, P1050, DOI 10.1111/bjh.16725
   Xu R, 2020, QUANT IMAG MED SURG, V10, P800, DOI 10.21037/qims.2020.02.13
   Yang YH, 2005, J MED VIROL, V77, P1, DOI 10.1002/jmv.20407
   Zhang B, 2020, QUANT IMAG MED SURG, V10, P871, DOI 10.21037/qims.2020.03.12
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
NR 30
TC 4
Z9 4
U1 2
U2 2
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2223-4292
EI 2223-4306
J9 QUANT IMAG MED SURG
JI Quant. Imaging Med. Surg.
PD JUN
PY 2020
VL 10
IS 6
BP 1325
EP 1333
DI 10.21037/qims-20-546
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA LU8QF
UT WOS:000538012700013
PM 32550141
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Smith, MS
   Bonomo, J
   Knight, WA
   Prestigiacomo, CJ
   Richards, CT
   Ramser, E
   Adeoye, O
   Bertsch, S
   Shirani, P
   Vagal, A
   Fichtenbaum, CJ
   Housholder, A
   Khatri, P
   Kleindorfer, DO
   Broderick, JP
   Grossman, AW
AF Smith, Matthew S.
   Bonomo, Jordan
   Knight, William A.
   Prestigiacomo, Charles J.
   Richards, Christopher T.
   Ramser, Evan
   Adeoye, Opeolu
   Bertsch, Stuart
   Shirani, Peyman
   Vagal, Achala
   Fichtenbaum, Carl J.
   Housholder, Anne
   Khatri, Pooja
   Kleindorfer, Dawn O.
   Broderick, Joseph P.
   Grossman, Aaron W.
TI Endovascular Therapy for Patients With Acute Ischemic Stroke During the
   COVID-19 Pandemic: A Proposed Algorithm
SO STROKE
LA English
DT Article
DE brain ischemia; coronavirus; endovascular procedures; pandemics;
   thrombectomy
C1 [Smith, Matthew S.; Bonomo, Jordan; Knight, William A.; Shirani, Peyman; Khatri, Pooja; Kleindorfer, Dawn O.; Broderick, Joseph P.] Univ Cincinnati, Dept Neurol, Cincinnati, OH USA.
   [Bonomo, Jordan; Knight, William A.; Prestigiacomo, Charles J.; Adeoye, Opeolu; Shirani, Peyman; Grossman, Aaron W.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA.
   [Bonomo, Jordan; Knight, William A.; Richards, Christopher T.; Adeoye, Opeolu] Univ Cincinnati, Dept Emergency Med, Cincinnati, OH USA.
   [Ramser, Evan] Univ Cincinnati, Div Pulm Crit Care, Dept Internal Med, Cincinnati, OH USA.
   [Bertsch, Stuart] Univ Cincinnati, Dept Anesthesiol, Cincinnati, OH USA.
   [Vagal, Achala] Univ Cincinnati, Dept Radiol, Cincinnati, OH USA.
   [Fichtenbaum, Carl J.] Univ Cincinnati, Div Infect Dis, Dept Internal Med, Cincinnati, OH USA.
   [Housholder, Anne] Univ Cincinnati, Cincinnati Vet Affairs Med Ctr, Dept Dermatol, Healthcare Eth Consultant Certified HEC C, Cincinnati, OH USA.
RP Grossman, AW (corresponding author), Dept Neurol, 260 Stetson St,Suite 2300, Cincinnati, OH 45267 USA.
EM grossman@uc.edu
OI Richards, Christopher/0000-0003-3728-3860
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   [Anonymous], HUM INF 2019 NOV COR
   [Anonymous], ACR REC US CHEST RAD
   [Anonymous], 2020, STROKE, V51, P1910, DOI [DOI 10.1161/STROKEAHA.120.030023, 10.1161/STROKEAHA.120.030023]
   [Anonymous], STROK CAR COVID 19 P
   Berlinger N, ETHICAL FRAMEWORK HL
   Beume LA, 2018, STROKE, V49, P2323, DOI 10.1161/STROKEAHA.118.022253
   CDC, INT INF PREV CONTR R
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Fraser JF, 2020, J NEUROINTERV SURG, V12, P539, DOI 10.1136/neurintsurg-2020-016098
   Giacomelli A, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa330/5811989, DOI 10.1093/CID/CIAA330/5811989]
   Grandbastien B, 2015, NEW ENGL J MED, V372, P2464, DOI 10.1056/NEJMc1504851
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Jabre P, 2009, LANCET, V374, P293, DOI 10.1016/S0140-6736(09)60949-1
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li Y, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3550025, DOI 10.2139/SSRN.3550025]
   Maddali A, 2018, J EMERG TRAUMA SHOCK, V11, P111, DOI 10.4103/JETS.JETS_8_17
   Mao L., 2020, NEUROLOGICAL MANIFES, DOI [10.1101/2020.02.22.20026500., 10.1101/2020.02.22.20026500, DOI 10.1101/2020.02.22.20026500]
   Offeddu V, 2017, CLIN INFECT DIS, V65, P1934, DOI 10.1093/cid/cix681
   Powers CJ, 2019, AM J NEURORADIOL, V40, P1001, DOI 10.3174/ajnr.A6059
   Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sharma D, 2020, J NEUROSURG ANESTHES
   Vukasinovic I, 2019, J NEURORADIOLOGY, V46, P238, DOI 10.1016/j.neurad.2018.09.005
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 28
TC 10
Z9 11
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD JUN
PY 2020
VL 51
IS 6
BP 1902
EP 1909
DI 10.1161/STROKEAHA.120.029863
PG 8
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA LU5HE
UT WOS:000537785600050
PM 32352910
OA Green Published
DA 2021-01-01
ER

PT J
AU Du, YZ
   Tu, L
   Zhu, PJ
   Mu, M
   Wang, RS
   Yang, PC
   Wang, X
   Hu, C
   Ping, RY
   Hu, P
   Li, TZ
   Cao, F
   Chang, C
   Hu, QY
   Jin, Y
   Xu, GG
AF Du, Yingzhen
   Tu, Lei
   Zhu, Pingjun
   Mu, Mi
   Wang, Runsheng
   Yang, Pengcheng
   Wang, Xi
   Hu, Chao
   Ping, Rongyu
   Hu, Peng
   Li, Tianzhi
   Cao, Feng
   Chang, Christopher
   Hu, Qinyong
   Jin, Yang
   Xu, Guogang
TI Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan A
   Retrospective Observational Study
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE coronavirus disease 2019; severe acute respiratory syndrome coronavirus
   2; fatal cases; eosinophilopenia; copathogen
ID ACUTE RESPIRATORY SYNDROME; AIRWAY HYPERRESPONSIVENESS; PNEUMONIA;
   INFECTION; CHINA
AB Rationale: The global death toll from coronavirus disease (COVID-19) virus as of May 12, 2020, exceeds 286,000. The risk factors for death were attributed to advanced age and comorbidities but have not been accurately defined.
   Objectives: To report the clinical features of 85 fatal cases of COVID-19 in two hospitals in Wuhan.
   Methods: Medical records were collected of 85 fatal cases of COVID-19 between January 9, 2020, and February 15, 2020. Information recorded included medical history, exposure history, comorbidities, symptoms, signs, laboratory findings, computed tomographic scans, and clinical management.
   Measurements and Main Results: The median age of the patients was 65.8 years, and 72.9% were male. Common symptoms were fever (78[91.8%]), shortness of breath (50 [58.8%]), fatigue (50[58.8%]), and dyspnea (60 [70.6%]). Hypertension, diabetes, and coronary heart disease were the most common comorbidities. Notably, 81.2% of patients had very low eosinophil counts on admission. Complications included respiratory failure (80 [94.1%]), shock (69 [81.2%]), acute respiratory distress syndrome (63 [74.1%]), and arrhythmia (51 [60%]), among others. Most patients received antibiotic (77 [90.6%1), antiviral (78 [91.8%]), and glucocorticoid (65 [76.5%]) treatments. A total of 38 (447%) and 33 (38.8%) patients received intravenous immunoglobulin and IFN-u2b, respectively.
   Conclusions: In this depictive study of 85 fatal cases of COVID-19, most cases were males aged over 50 years with noncommunicable chronic diseases. The majority of the patients died of multiple organ failure. Early onset of shortness of breath may be used as an observational symptom for COVID-19 exacerbations. Eosinophilopenia may indicate a poor prognosis. A combination of antimicrobial drugs did not offer considerable benefit to the outcome of this group of patients.
C1 [Du, Yingzhen; Zhu, Pingjun; Mu, Mi; Wang, Runsheng] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 2, Dept Resp Med, Med Sch Chinese Peoples Liberat Army PLA, Beijing, Peoples R China.
   [Du, Yingzhen; Zhu, Pingjun; Mu, Mi; Wang, Runsheng] Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Med Sch Chinese Peoples Liberat Army PLA, Beijing, Peoples R China.
   [Wang, Xi] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 2, Dept Cardiol, Beijing, Peoples R China.
   [Wang, Xi; Hu, Chao; Ping, Rongyu; Hu, Peng; Li, Tianzhi; Cao, Feng; Xu, Guogang] Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing 100853, Peoples R China.
   [Hu, Chao; Ping, Rongyu; Hu, Peng; Li, Tianzhi; Cao, Feng; Xu, Guogang] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 2, Beijing 100853, Peoples R China.
   [Tu, Lei] Huazhong Univ Sci & Technol, Div Gastroenterol, Wuhan Union Hosp, Tongji Med Coll, Wuhan, Peoples R China.
   [Jin, Yang] Huazhong Univ Sci & Technol, Wuhan Union Hosp, Tongji Med Coll, Dept Resp & Crit Care Med,Natl Hlth Commiss,Key L, Wuhan, Peoples R China.
   [Yang, Pengcheng; Hu, Qinyong] Wuhan Univ, Canc Ctr, Renmin Hosp, Wuhan, Peoples R China.
   [Yang, Pengcheng; Hu, Qinyong] Wuhan Hannan Hosp, Wuhan, Peoples R China.
   [Chang, Christopher] Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA.
   [Chang, Christopher] Joe DiMaggio Childrens Hosp, Div Pediat Immunol & Allergy, Hollywood, FL USA.
RP Xu, GG (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing 100853, Peoples R China.; Xu, GG (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Med Ctr 2, Beijing 100853, Peoples R China.
EM guogang_xu@163.com
OI Wang, Runsheng/0000-0002-8016-5934; Xu, Guogang/0000-0002-6380-3500
FU Beijing Municipal Natural Science Foundation General Program [7192197]
FX Supported by Beijing Municipal Natural Science Foundation General
   Program grant 7192197.
CR Azhar EI, 2019, INFECT DIS CLIN N AM, V33, P891, DOI 10.1016/j.idc.2019.08.001
   BASS DA, 1980, J CLIN INVEST, V65, P1265, DOI 10.1172/JCI109789
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   Center for Systems Science and Engineering John Hopkins University, COVID 19 DASHB CTR S
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Echevarria C, 2014, EUR RESPIR J, V44
   Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   HAMANN KJ, 1990, GENOMICS, V7, P535, DOI 10.1016/0888-7543(90)90197-3
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Schwarze J, 1999, J IMMUNOL, V162, P4207
   Schwarze J, 1999, J IMMUNOL, V162, P2997
   Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 112 WHO
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yang Y, 2020, EPIDEMIOLOGICAL CLIN, DOI DOI 10.1101/2020.02.10
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 27
TC 170
Z9 174
U1 16
U2 28
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD JUN 1
PY 2020
VL 201
IS 11
BP 1372
EP 1379
DI 10.1164/rccm.202003-0543OC
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA LU5JJ
UT WOS:000537791300014
PM 32242738
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Carlsson, H
   Hjorton, K
   Abujrais, S
   Ronnblom, L
   Akerfeldt, T
   Kultima, K
AF Carlsson, Henrik
   Hjorton, Karin
   Abujrais, Sandy
   Ronnblom, Lars
   akerfeldt, Torbjorn
   Kultima, Kim
TI Measurement of hydroxychloroquine in blood from SLE patients using
   LC-HRMS-evaluation of whole blood, plasma, and serum as sample matrices
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; VALIDATION; PHARMACOKINETICS;
   RECOMMENDATIONS; QUANTIFICATION; CLASSIFICATION; RETINOPATHY; CRITERIA;
   TABLETS
AB Background Hydroxychloroquine (HCQ) is the standard of care in the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other inflammatory rheumatic diseases and potentially for the treatment in COVID-19 patients. Determination of HCQ for therapeutic drug monitoring (TDM) can be performed in whole blood (WB), serum, and plasma. Direct comparisons of WB, serum, and plasma levels of HCQ in patients with SLE have not previously been reported. We describe a method for the determination of HCQ in human blood using liquid chromatography-high-resolution mass spectrometry (LC-HRMS) and compare the suitability of the three sample matrices. Methods A method for the determination of HCQ in human blood using LC-HRMS was developed, validated, and applied for the determination of HCQ levels in WB, serum, and plasma from 26 SLE patients. The reproducibility of the method, in the three matrices, was evaluated using quality control samples and repeated preparations and measurements of patient samples. The performance of the developed method for HCQ measurement in serum was further evaluated by comparison with two previously reported extraction methods. Results The performance of the presented method demonstrated high accuracy and precision. A large range of HCQ concentrations was observed for the SLE patients in all three matrices (WB, serum, and plasma). The mean levels in WB were approximately two-fold the levels in serum and plasma (813 ng/mL compared to 436 ng/mL and 362 ng/mL, respectively). Spiked quality controls showed high reproducibility for all matrices (coefficient of variation, CV, approx. 5%), whereas in patient samples, equally high-precision was only found using WB as the matrix (CV 3%). The CV for serum and plasma was 14% and 39%, respectively. Two alternative methods applied to serum samples did not demonstrate improved precision. Conclusions A LC-HRMS method for the measurement of HCQ in human blood was developed and validated. Whole blood was found to be the superior sample matrix in terms of sample reproducibility. Thus, whole blood samples should be used for HCQ analysis when patients are monitored for HCQ treatment effects. The assay is in clinical use to monitor levels of HCQ in patients.
C1 [Carlsson, Henrik; Abujrais, Sandy; akerfeldt, Torbjorn; Kultima, Kim] Uppsala Univ, Uppsala Univ Hosp, Dept Med Sci, Clin Chem, Entrance 61,3rd Floor,Dag Hammarskjolds Vag 18, SE-75185 Uppsala, Sweden.
   [Hjorton, Karin; Ronnblom, Lars] Uppsala Univ, Rheumatol, Dept Med Sci, Uppsala, Sweden.
RP Kultima, K (corresponding author), Uppsala Univ, Uppsala Univ Hosp, Dept Med Sci, Clin Chem, Entrance 61,3rd Floor,Dag Hammarskjolds Vag 18, SE-75185 Uppsala, Sweden.
EM Kim.Kultima@medsci.uu.se
FU Region Uppsala (ALF-grant); King Gustaf V's 80-years Foundation; Swedish
   Society of Medicine; Uppsala University; Region Uppsala (RD funds);
   Swedish Rheumatism Association
FX This work was supported by Region Uppsala (ALF-grant and R&D funds), the
   Swedish Rheumatism Association, King Gustaf V's 80-years Foundation, and
   the Swedish Society of Medicine (the Ingegerd Johansson donation). Open
   access funding provided by Uppsala University.
CR Abdulaziz N, 2018, CURR OPIN RHEUMATOL, V30, P249, DOI 10.1097/BOR.0000000000000500
   Balevic SJ, 2019, J RHEUMATOL, V46, P57, DOI 10.3899/jrheum.180158
   Balevic SJ, 2019, CLIN PHARMACOKINET, V58, P525, DOI 10.1007/s40262-018-0712-z
   Bates D, 2013, J STAT SOFTW, V52, P1, DOI 10.18637/jss.v052.i05
   Bengtsson AA, 2017, J INTERN MED, V281, P52, DOI 10.1111/joim.12529
   Costedoat-Chalumeau N, 2007, ANN RHEUM DIS, V66, P821, DOI 10.1136/ard.2006.067835
   Costedoat-Chalumeau N, 2006, ARTHRITIS RHEUM, V54, P3284, DOI 10.1002/art.22156
   Costedoat-Chalumeau N, 2013, ANN RHEUM DIS, V72, P1786, DOI 10.1136/annrheumdis-2012-202322
   Durcan L, 2015, J RHEUMATOL, V42, P2092, DOI 10.3899/jrheum.150379
   Fan HW, 2015, RHEUMATOL THER, V2, P183, DOI 10.1007/s40744-015-0012-0
   Feldman CH, 2018, SEMIN ARTHRITIS RHEU, V48, P205, DOI 10.1016/j.semarthrit.2018.01.002
   Fuzery AK, 2013, CLIN CHIM ACTA, V421, P79, DOI 10.1016/j.cca.2013.02.018
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gladman DD, 2002, J RHEUMATOL, V29, P288
   Jallouli M, 2015, ARTHRITIS RHEUMATOL, V67, P2176, DOI 10.1002/art.39194
   Lee JY, 2016, ARTHRITIS RHEUMATOL, V68, P184, DOI 10.1002/art.39402
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   MCLACHLAN AJ, 1993, EUR J CLIN PHARMACOL, V44, P481, DOI 10.1007/BF00315548
   Melles RB, 2014, JAMA OPHTHALMOL, V132, P1453, DOI 10.1001/jamaophthalmol.2014.3459
   Mok CC, 2016, ARTHRIT CARE RES, V68, P1295, DOI 10.1002/acr.22837
   Munster T, 2002, ARTHRITIS RHEUM-US, V46, P1460, DOI 10.1002/art.10307
   Petri M, 2020, ARTHRITIS RHEUMATOL, V72, P448, DOI 10.1002/art.41121
   Petri M, 2012, ARTHRITIS RHEUM-US, V64, P4021, DOI 10.1002/art.34672
   Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473
   Pons-Estel GJ, 2010, SEMIN ARTHRITIS RHEU, V39, P257, DOI 10.1016/j.semarthrit.2008.10.007
   Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Shippey EA, 2018, CLEV CLIN J MED, V85, P459, DOI 10.3949/ccjm.85a.17034
   Smolen JS, 2014, ANN RHEUM DIS, V73, P492, DOI 10.1136/annrheumdis-2013-204573
   Soichot M, 2014, J PHARMACEUT BIOMED, V100, P131, DOI 10.1016/j.jpba.2014.07.009
   TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101
   TETT SE, 1988, BRIT J CLIN PHARMACO, V26, P303, DOI 10.1111/j.1365-2125.1988.tb05281.x
   TETT SE, 1989, BRIT J CLIN PHARMACO, V27, P771, DOI 10.1111/j.1365-2125.1989.tb03439.x
   WALLACE DJ, 1994, RHEUM DIS CLIN N AM, V20, P243
   Wang LZ, 2012, J PHARMACEUT BIOMED, V61, P86, DOI 10.1016/j.jpba.2011.11.034
NR 35
TC 1
Z9 1
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478-6354
EI 1478-6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD JUN 1
PY 2020
VL 22
IS 1
AR 125
DI 10.1186/s13075-020-02211-1
PG 9
WC Rheumatology
SC Rheumatology
GA LV6OG
UT WOS:000538553200001
PM 32475347
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Azria, D
   Hennequin, C
   Giraud, P
AF Azria, D.
   Hennequin, C.
   Giraud, P.
TI Practical update of total dose compensation in case of temporary
   interruption of external radiotherapy in the COVID-19 pandemic context
SO CANCER RADIOTHERAPIE
LA French
DT Article
DE Total dose; Treatment duration; Radiotherapy; Compensation
ID BREAST-CONSERVING SURGERY; TREATMENT TIME; RADIATION-THERAPY;
   PROSTATE-CANCER; EARLY-STAGE; LUNG; CARCINOMA; SURVIVAL; IMPACT;
   PROLONGATION
AB Overall treatment time is an important factor of local recurrence and indirectly of distant evolution, namely in case of protracted treatments. The current pandemic impacts on the duration of radiotherapy if patients under treatments and synchronously suffering from COVID-19. The models used to compensate the total dose in case of temporary treatment interruption are well known but it is of importance in that pandemic context to update and homogenize clinical practice in order to improve local control without increasing normal tissue complications. (C) 2020 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.
C1 [Azria, D.] IRCM, Inst Rech Cancerol Montpellier U1194, 208 Ave Apothicaires, F-34298 Montpellier 5, France.
   [Azria, D.] INSERM, U1194, 208 Ave Apothicaires, F-34298 Montpellier 5, France.
   [Azria, D.] Univ Montpellier, Ctr Rech, U1194, 208 Ave Apothicaires, F-34298 Montpellier 05, France.
   [Azria, D.] Federat Univ Oncol Radiotherapie, Inst Reg Canc Montpellier, ICM, Rue Croix Verte, F-34298 Montpellier 05, France.
   [Hennequin, C.] Hop St Louis, AP HP, Serv Cancerol Radiotherapie, 1 Ave Claude Vellefaux, F-75475 Paris, France.
   [Giraud, P.] Hop Europeen Georges Pompidou, AP HP, Serv Oncol Radiotherapie, 20 Rue Leblanc, F-75015 Paris, France.
   [Giraud, P.] Univ Paris, 20 Rue Leblanc, F-75015 Paris, France.
RP Azria, D (corresponding author), IRCM, Inst Rech Cancerol Montpellier U1194, 208 Ave Apothicaires, F-34298 Montpellier 5, France.; Azria, D (corresponding author), INSERM, U1194, 208 Ave Apothicaires, F-34298 Montpellier 5, France.; Azria, D (corresponding author), Univ Montpellier, Ctr Rech, U1194, 208 Ave Apothicaires, F-34298 Montpellier 05, France.; Azria, D (corresponding author), Federat Univ Oncol Radiotherapie, Inst Reg Canc Montpellier, ICM, Rue Croix Verte, F-34298 Montpellier 05, France.
EM david.azria@icm.unicancer.fr
CR Azria D, 2010, LANCET ONCOL, V11, P258, DOI 10.1016/S1470-2045(10)70013-9
   Benchalal M, 2005, CANCER, V104, P240, DOI 10.1002/cncr.21161
   Bese NS, 2007, INT J RADIAT ONCOL, V68, P654, DOI 10.1016/j.ijrobp.2007.03.010
   Bourgier C, 2015, CRIT REV ONCOL HEMAT, V93, P312, DOI 10.1016/j.critrevonc.2014.11.004
   COX JD, 1993, INT J RADIAT ONCOL, V27, P493, DOI 10.1016/0360-3016(93)90371-2
   Dale RG, 2000, BRIT J RADIOL, V73, P892, DOI 10.1259/bjr.73.872.11026867
   Dale RG, 2002, CLIN ONCOL-UK, V14, P382, DOI 10.1053/clon.2002.0111
   De Ruysscher D, 2006, J CLIN ONCOL, V24, P1057, DOI 10.1200/JCO.2005.02.9793
   Dong YQ, 2018, J MED IMAG RADIAT ON, V62, P116, DOI 10.1111/1754-9485.12675
   Fowler JF, 2000, INT J RADIAT ONCOL, V46, P516
   Giraud P, 2020, CANCER RADIOTHER, V24, P87, DOI 10.1016/j.canrad.2020.03.007
   Ferreira JAG, 2015, REP PRACT ONCOL RADI, V20, P328, DOI 10.1016/j.rpor.2015.05.010
   Harris EER, 2005, J CLIN ONCOL, V23, P11, DOI 10.1200/JCO.2005.09.056
   Hendry J H, 1996, Clin Oncol (R Coll Radiol), V8, P297, DOI 10.1016/S0936-6555(05)80715-0
   Hershman DL, 2006, INT J RADIAT ONCOL, V65, P1353, DOI 10.1016/j.ijrobp.2006.03.048
   Hong JC, 2017, JCO CLIN CANCER INFO, V1, DOI 10.1200/CCI.16.00072
   King CR, 2000, INT J RADIAT ONCOL, V47, P1165, DOI 10.1016/S0360-3016(00)00543-5
   Klement RJ, 2020, RADIOTHER ONCOL, V142, P210, DOI 10.1016/j.radonc.2019.07.008
   Machtay M, 2005, INT J RADIAT ONCOL, V63, P667, DOI 10.1016/j.ijrobp.2005.03.037
   Mahe M-A, 2016, Cancer Radiother, V20 Suppl, pS4, DOI 10.1016/j.canrad.2016.07.014
   Nix MG, 2020, RADIOTHER ONCOL, V143, P58, DOI 10.1016/j.radonc.2019.07.026
   Partridge M, 2011, RADIOTHER ONCOL, V99, P6, DOI 10.1016/j.radonc.2011.02.014
   PEREZ CA, 1995, INT J RADIAT ONCOL, V32, P1275, DOI 10.1016/0360-3016(95)00220-S
   Pierce LJ, 2005, J CLIN ONCOL, V23, P24, DOI 10.1200/JCO.2005.01.198
   Qi XS, 2011, RADIOTHER ONCOL, V100, P282, DOI 10.1016/j.radonc.2011.01.010
   Sandler HM, 2018, INT J RADIAT ONCOL, V100, P841, DOI 10.1016/j.ijrobp.2017.12.278
   SLEVIN NJ, 1992, RADIOTHER ONCOL, V24, P215, DOI 10.1016/0167-8140(92)90226-K
   Thames HD, 2010, RADIOTHER ONCOL, V96, P6, DOI 10.1016/j.radonc.2010.03.020
   Topkan E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218627
   TROTT KR, 1985, RADIOTHER ONCOL, V3, P1, DOI 10.1016/S0167-8140(85)80002-5
   van Leeuwen CM, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-018-1040-z
   Yom SS, 2018, INT J RADIAT ONCOL, V100, P832, DOI 10.1016/j.ijrobp.2017.12.001
   Zheleva V, 2020, ANN SURG ONCOL, V27, P2614, DOI 10.1245/s10434-020-08326-8
NR 33
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 1278-3218
EI 1769-6658
J9 CANCER RADIOTHER
JI Cancer Radiother.
PD JUN
PY 2020
VL 24
IS 3
BP 182
EP 187
DI 10.1016/j.canrad.2020.04.001
PG 6
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA LU4DB
UT WOS:000537706600002
PM 32307313
OA Green Published
DA 2021-01-01
ER

PT J
AU Loap, P
   Kirova, Y
   Takanen, S
   Crehange, G
   Fourquet, A
AF Loap, P.
   Kirova, Y.
   Takanen, S.
   Crehange, G.
   Fourquet, A.
TI Breast radiation therapy during COVID-19 outbreak: Practical advice
SO CANCER RADIOTHERAPIE
LA French
DT Article
ID RADIOTHERAPY HYPOFRACTIONATION; CONSERVING SURGERY; FOLLOW-UP; UK
   STANDARDIZATION; CANCER; IRRADIATION; TRIAL; OLDER
C1 [Loap, P.; Kirova, Y.; Takanen, S.; Crehange, G.; Fourquet, A.] Inst Curie, Dept Radiotherapie Oncol, 25 Rue Ulm, F-75005 Paris, France.
RP Loap, P (corresponding author), Inst Curie, Dept Radiotherapie Oncol, 25 Rue Ulm, F-75005 Paris, France.
EM pierre.loap@gmail.com
OI Loap, Pierre/0000-0001-8863-8110
CR Bartelink H, 2015, LANCET ONCOL, V16, P47, DOI 10.1016/S1470-2045(14)71156-8
   Bentzen SM, 2008, LANCET ONCOL, V9, P331, DOI [10.1016/S1470-2045(08)60348-7, 10.1016/S1470-2045(08)70077-9]
   Froud PJ, 2000, INT J RADIAT ONCOL, V46, P363, DOI 10.1016/S0360-3016(99)00412-5
   Giraud P, 2020, CANCER RADIOTHER, V24, P87, DOI 10.1016/j.canrad.2020.03.007
   Haviland JS, 2013, LANCET ONCOL, V14, P1086, DOI 10.1016/S1470-2045(13)70386-3
   Huang J, 2003, J CLIN ONCOL, V21, P555, DOI 10.1200/JCO.2003.04.171
   Hughes KS, 2013, J CLIN ONCOL, V31, P2382, DOI 10.1200/JCO.2012.45.2615
   Kirova YM, 2009, INT J RADIAT ONCOL, V75, P76, DOI 10.1016/j.ijrobp.2008.11.005
   Kunkler IH, 2015, LANCET ONCOL, V16, P266, DOI 10.1016/S1470-2045(14)71221-5
   Whelan TJ, 2010, NEW ENGL J MED, V362, P513, DOI 10.1056/NEJMoa0906260
   Yarnold JR, 2011, RADIOTHER ONCOL, V100, P93, DOI 10.1016/j.radonc.2011.06.026
NR 11
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 1278-3218
EI 1769-6658
J9 CANCER RADIOTHER
JI Cancer Radiother.
PD JUN
PY 2020
VL 24
IS 3
BP 196
EP 198
DI 10.1016/j.canrad.2020.04.004
PG 3
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA LU4DB
UT WOS:000537706600005
PM 32389580
OA Green Published
DA 2021-01-01
ER

PT J
AU Kramer, JB
   Brown, DE
   Kopar, PK
AF Kramer, Jessica B.
   Brown, Douglas E.
   Kopar, Piroska K.
TI Ethics in the Time of Coronavirus: Recommendations in the COVID-19
   Pandemic
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID CARE; PHYSICIANS; THERAPIES; DUTY; AIDS
C1 [Kramer, Jessica B.; Brown, Douglas E.; Kopar, Piroska K.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.
RP Kopar, PK (corresponding author), Washington Univ, Sch Med, CHESS Ctr Humanism & Eth Surg Specialties Acute &, 660 Euclid Ave,Campus Box 8109, St Louis, MO 63110 USA.
EM pkopar@wustl.edu
CR American College of Physicians and Infectious Diseases Society of America, 1994, ANN INTERN MED, V120, P316
   American College of Surgeons, 2020, ETH CONS
   Angell M, 1993, Kennedy Inst Ethics J, V3, P279
   ANGOFF NR, 1991, YALE J BIOL MED, V64, P207
   [Anonymous], 2006, ETHICS ORGAN ALLOCAT
   [Anonymous], PEOPL WHO AR HIGH RI
   [Anonymous], 2020, AM HEART ASS GUIDLIN
   Berlinger N, 2020, ETHICAL FRAMEWORK HL
   Bernat J, 2008, ETHICAL ISSUES NEURO, P438
   BLENDON RJ, 1988, NEW ENGL J MED, V319, P1022, DOI 10.1056/NEJM198810133191522
   Centers for Disease Control, PERSONAL PROTECTIVE
   Elwyn G, 2012, J GEN INTERN MED, V27, P1361, DOI 10.1007/s11606-012-2077-6
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   FREEDMAN B, 1989, HASTINGS CENT REP, V19, P14, DOI 10.2307/3562738
   Gostin LO, 2006, JAMA-J AM MED ASSOC, V296, P2023, DOI 10.1001/jama.296.16.2023
   Guan WJ, 2019, CLIN CHARACTERISTICS, V2020, P2020, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974]
   Lilly CM, 2003, CRIT CARE MED, V31, pS394, DOI 10.1097/01.CCM.0000065279.77449.B4
   Nash W, 1989, HLTH HUMANITIES CAMU
   Papadimos TJ, 2018, CRIT CARE MED, V46, P1842, DOI 10.1097/CCM.0000000000003416
   Persad G, 2009, LANCET, V373, P423, DOI 10.1016/S0140-6736(09)60137-9
   Rosenbaum L., 2020, N ENGL J MED
   Scheunemann LP, 2011, CHEST, V140, P1625, DOI 10.1378/chest.11-0622
   Schultz CH, 2012, ANN EMERG MED, V59, P191, DOI 10.1016/j.annemergmed.2011.07.037
   SELLS RA, 1989, TRANSPLANT P, V21, P1391
   Simon V, 2006, LANCET, V368, P489, DOI 10.1016/S0140-6736(06)69157-5
   STOLLEY PD, 1993, ANN INTERN MED, V118, P822, DOI 10.7326/0003-4819-118-10-199305150-00011
   TEGTMEIER JW, 1990, AM J LAW MED, V16, P249
   Wenger NS, 2001, JAMA-J AM MED ASSOC, V285, P2880, DOI 10.1001/jama.285.22.2880
   YOUNG FE, 1988, JAMA-J AM MED ASSOC, V259, P2267, DOI 10.1001/jama.259.15.2267
NR 29
TC 9
Z9 9
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1072-7515
EI 1879-1190
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2020
VL 230
IS 6
BP 1114
EP 1118
DI 10.1016/j.jamcollsurg.2020.04.004
PG 5
WC Surgery
SC Surgery
GA LW0FF
UT WOS:000538821900055
PM 32278728
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Cagliani, R
   Forni, D
   Clerici, M
   Sironi, M
AF Cagliani, Rachele
   Forni, Diego
   Clerici, Mario
   Sironi, Manuela
TI Computational Inference of Selection Underlying the Evolution of the
   Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE N protein; Nsp1; ORF8; SARS-CoV-2; spike protein; positive selection;
   viral evolution
ID NUCLEOCAPSID PROTEIN; DIMERIZATION DOMAIN; SPIKE GLYCOPROTEIN;
   MEMBRANE-PROTEIN; RNA-SYNTHESIS; SARS-COV; RECEPTOR; HOST;
   RECOMBINATION; REGION
AB The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that recently emerged in China is thought to have a bat origin, as its closest known relative (BatCoV RaTG13) was described previously in horseshoe bats. We analyzed the selective events that accompanied the divergence of SARS-CoV-2 from BatCoV RaTG13. To this end, we applied a population genetics-phylogenetics approach, which leverages within-population variation and divergence from an outgroup. Results indicated that most sites in the viral open reading frames (ORFs) evolved under conditions of strong to moderate purifying selection. The most highly constrained sequences corresponded to some nonstructural proteins (nsps) and to the M protein. Conversely, nsp1 and accessory ORFs, particularly ORF8, had a non-negligible proportion of codons evolving under conditions of very weak purifying selection or close to selective neutrality. Overall, limited evidence of positive selection was detected. The 6 bona fide positively selected sites were located in the N protein, in ORF8, and in nsp1. A signal of positive selection was also detected in the receptor-binding motif (RBM) of the spike protein but most likely resulted from a recombination event that involved the BatCoV RaTG13 sequence. In line with previous data, we suggest that the common ancestor of SARS-CoV-2 and BatCoV RaTG13 encoded/encodes an RBM similar to that observed in SARS-CoV-2 itself and in some pangolin viruses. It is presently unknown whether the common ancestor still exists and, if so, which animals it infects. Our data, however, indicate that divergence of SARS-CoV-2 from BatCoV RaTG13 was accompanied by limited episodes of positive selection, suggesting that the common ancestor of the two viruses was poised for human infection.
   IMPORTANCE Coronaviruses are dangerous zoonotic pathogens; in the last 2 decades, three coronaviruses have crossed the species barrier and caused human epidemics. One of these is the recently emerged SARS-CoV-2. We investigated how, since its divergence from a closely related bat virus, natural selection shaped the genome of SARS-CoV-2. We found that distinct coding regions in the SARS-CoV-2 genome evolved under conditions of different degrees of constraint and are consequently more or less prone to tolerate amino acid substitutions. In practical terms, the level of constraint provides indications about which proteins/protein regions are better suited as possible targets for the development of antivirals or vaccines. We also detected limited signals of positive selection in three viral ORFs. However, we warn that, in the absence of knowledge about the chain of events that determined the human spillover, these signals should not be necessarily interpreted as evidence of an adaptation to our species.
C1 [Cagliani, Rachele; Forni, Diego; Sironi, Manuela] Sci Inst IRCCS E MEDEA, Bioinformat, Bosisio Parini, Italy.
   [Clerici, Mario] Univ Milan, Dept Physiopathol & Transplantat, Milan, Italy.
   [Clerici, Mario] IRCCS, Don C Gnocchi Fdn ONLUS, Milan, Italy.
RP Cagliani, R (corresponding author), Sci Inst IRCCS E MEDEA, Bioinformat, Bosisio Parini, Italy.
EM rachele.cagliani@lanostrafamiglia.it
RI Forni, Diego/K-5643-2016; sironi, manuela/AAH-5456-2019; Cagliani,
   Rachele/K-4545-2016
OI Forni, Diego/0000-0001-9291-5352; sironi, manuela/0000-0002-2267-5266;
   Cagliani, Rachele/0000-0003-2670-3532
FU Italian Ministry of HealthMinistry of Health, Italy
FX This work was supported by the Italian Ministry of Health (Ricerca
   Corrente 20192020 to M.S. and Ricerca Corrente 2018-2020 to D.F.).
CR ARMSTRONG J, 1984, NATURE, V308, P751, DOI 10.1038/308751a0
   Benkert P, 2011, BIOINFORMATICS, V27, P343, DOI 10.1093/bioinformatics/btq662
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Brand CL, 2018, CURR BIOL, V28, P1289, DOI 10.1016/j.cub.2018.02.056
   Brockway SM, 2005, VIROLOGY, V340, P209, DOI 10.1016/j.virol.2005.06.035
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Chen CY, 2007, J MOL BIOL, V368, P1075, DOI 10.1016/j.jmb.2007.02.069
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   CHINESE SME, 2004, SCIENCE, V303, P1666, DOI DOI 10.1126/SCIENCE.1092002
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   Gorbalenya AE, 2004, J VIROL, V78, P7863, DOI 10.1128/JVI.78.15.7863-7866.2004
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Hai P, 2004, J GEN VIROL, V85, P3109, DOI 10.1099/vir.0.80111-0
   Haijema BJ, 2003, J VIROL, V77, P4528, DOI 10.1128/JVI.77.8.4528-4538.2003
   Hemmer LW, 2016, BMC EVOL BIOL, V16, DOI 10.1186/s12862-016-0670-8
   Ho SYW, 2011, MOL ECOL, V20, P3087, DOI 10.1111/j.1365-294X.2011.05178.x
   Hu B, 2017, BLOOD, V130
   Jauregui AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062416
   Jimenez-Guardeno JM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005215
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000
   Lam TT-Y, 2020, IDENTIFICATION 2019, DOI [10.1101/2020.02.13.945485, 10.1101/2020.02.13.945485., DOI 10.1101/2020.02.13.945485]
   Lau SKP, 2015, J VIROL, V89, P10532, DOI 10.1128/JVI.01048-15
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Liu J, 2010, J INFECT DIS, V202, P1171, DOI 10.1086/656315
   Liu P, 2020, ARE PANGOLINS INTERM, DOI [10.1101/2020.02.18.954628, DOI 10.1101/2020.02.18.954628]
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luk HKH, 2019, INFECT GENET EVOL, V71, P21, DOI 10.1016/j.meegid.2019.03.001
   Martin DP, 2017, METHODS MOL BIOL, V1525, P433, DOI 10.1007/978-1-4939-6622-6_17
   Martin DP, 2011, MOL ECOL RESOUR, V11, P943, DOI 10.1111/j.1755-0998.2011.03026.x
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Moore MJ, 2004, J VIROL, V78, P10628, DOI 10.1128/JVI.78.19.10628-10635.2004
   Muth D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33487-8
   Narayanan K, 2015, VIRUS RES, V202, P89, DOI 10.1016/j.virusres.2014.11.019
   Neuman BW, 2016, ANTIVIR RES, V135, P97, DOI 10.1016/j.antiviral.2016.10.005
   Oostra M, 2007, J VIROL, V81, P13876, DOI 10.1128/JVI.01631-07
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Qu XX, 2005, J BIOL CHEM, V280, P29588, DOI 10.1074/jbc.M500662200
   Schickli JH, 2004, J VIROL, V78, P9073, DOI 10.1128/JVI.78.17.9073-9083.2004
   Siu YL, 2008, J VIROL, V82, P11318, DOI 10.1128/JVI.01052-08
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Sung SC, 2009, VIROLOGY, V387, P402, DOI 10.1016/j.virol.2009.02.021
   Surjit M, 2008, INFECT GENET EVOL, V8, P397, DOI 10.1016/j.meegid.2007.07.004
   Takeda M, 2008, J MOL BIOL, V380, P608, DOI 10.1016/j.jmb.2007.11.093
   Wang LH, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2016.140
   Wathelet MG, 2007, J VIROL, V81, P11620, DOI 10.1128/JVI.00702-07
   Wertheim JO, 2013, J VIROL, V87, P7039, DOI 10.1128/JVI.03273-12
   Wertheim JO, 2011, MOL BIOL EVOL, V28, P3355, DOI 10.1093/molbev/msr170
   Wilson DJ, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002395
   Wong Matthew C, 2020, bioRxiv, DOI 10.1101/2020.02.07.939207
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu KL, 2012, J BIOL CHEM, V287, P8904, DOI 10.1074/jbc.M111.325803
   Xiao K., 2020, ISOLATION CHARACTERI, DOI [10.1101/2020.02.17.951335, DOI 10.1101/2020.02.17.951335]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zust R, 2007, PLOS PATHOG, V3, P1062, DOI 10.1371/journal.ppat.0030109
NR 70
TC 33
Z9 33
U1 4
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUN
PY 2020
VL 94
IS 12
AR e00411-20
DI 10.1128/JVI.00411-20
PG 11
WC Virology
SC Virology
GA LU6GV
UT WOS:000537852600015
PM 32238584
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Dashraath, P
   Wong, JLJ
   Lim, MXK
   Lim, LM
   Li, S
   Biswas, A
   Choolani, M
   Mattar, C
   Su, LL
AF Dashraath, Pradip
   Wong, Jing Lin Jeslyn
   Lim, Mei Xian Karen
   Lim, Li Mm
   Li, Sarah
   Biswas, Arijit
   Choolani, Mahesh
   Mattar, Citra
   Su, Lin Lin
TI Coronavirus disease 2019 (COVID-19) pandemic and pregnancy
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE antiviral; baricitinib; chloroquine; coronavirus; virus; COVID-19;
   pandemic; fever; mask; MERS-CoV,morbidity; mortality; obstetric
   management; pregnancy; remdesivir; respiratory distress syndrome;
   respiratory failure; SARS-CoV; SARS-CoV-2; sepsis; susceptibility
ID RESPIRATORY SYNDROME CORONAVIRUS; MERS-COV; NEONATES BORN; INFECTION;
   SARS; PNEUMONIA; CHLOROQUINE; LOPINAVIR/RITONAVIR; REMDESIVIR; OUTCOMES
AB The current coronavirus disease 2019 (COVID-19) pneumonia pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading globally at an accelerated rate, with a basic reproduction number (R0) of 2-2.5, indicating that 2-3 persons will be infected from an index patient. A serious public health emergency, it is particularly deadly in vulnerable populations and communities in which healthcare providers are insufficiently prepared to manage the infection. As of March 16, 2020, there are more than 180,000 confirmed cases of COVID-19 worldwide, with more than 7000 related deaths. The SARS-CoV-2 virus has been isolated from asymptomatic individuals, and affected patients continue to be infectious 2 weeks after cessation of symptoms. The substantial morbidity and socioeconomic impact have necessitated drastic measures across all continents, including nationwide lockdowns and border closures.
   Pregnant women and their fetuses represent a high-risk population during infectious disease outbreaks. To date, the outcomes of 55 pregnant women infected with COVID-19 and 46 neonates have been reported in the literature, with no definite evidence of vertical transmission. Physiological and mechanical changes in pregnancy increase susceptibility to infections in general, particularly when the cardiorespiratory system is affected, and encourage rapid progression to respiratory failure in the gravida. Furthermore, the pregnancy bias toward T-helper 2 (Th2) system dominance, which protects the fetus, leaves the mother vulnerable to viral infections, which are more effectively contained by the Th1 system. These unique challenges mandate an integrated approach to pregnancies affected by SARS-CoV-2.
   Here we present a review of COVID-19 in pregnancy, bringing together the various factors integral to the understanding of pathophysiology and susceptibility, diagnostic challenges with real-time reverse transcription polymerase chain reaction (RT-PCR) assays, therapeutic controversies, intrauterine transmission, and maternal-fetal complications. We discuss the latest options in antiviral therapy and vaccine development, including the novel use of chloroquine in the management of COVID-19. Fetal surveillance, in view of the predisposition to growth restriction and special considerations during labor and delivery, is addressed. In addition, we focus on keeping frontline obstetric care providers safe while continuing to provide essential services. Our clinical service model is built around the principles of workplace segregation, responsible social distancing, containment of cross-infection to healthcare providers, judicious use of personal protective equipment, and telemedicine. Our aim is to share a framework that can be adopted by tertiary maternity units managing pregnant women in the flux of a pandemic while maintaining the safety of the patient and healthcare provider at its core.
C1 [Dashraath, Pradip; Wong, Jing Lin Jeslyn; Lim, Mei Xian Karen; Lim, Li Mm; Li, Sarah; Biswas, Arijit; Choolani, Mahesh; Mattar, Citra; Su, Lin Lin] Natl Univ Singapore Hosp, Dept Obstet & Gynaecol, Singapore, Singapore.
   [Biswas, Arijit; Choolani, Mahesh; Mattar, Citra; Su, Lin Lin] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
RP Dashraath, P (corresponding author), Natl Univ Singapore Hosp, Dept Obstet & Gynaecol, Singapore, Singapore.
EM pradip_dashraath_vijayakumar@nuhs.edu.sg
OI Lim, Karen/0000-0002-8524-2177
CR Ai T., 2020, RADIOLOGY
   Alfaraj SH, 2019, J MICROBIOL IMMUNOL, V52, P501, DOI 10.1016/j.jmii.2018.04.005
   Alserehi H, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1437-y
   Assiri A, 2016, CLIN INFECT DIS, V63, P951, DOI 10.1093/cid/ciw412
   BASSEAL JM, 2017, AUSTRALAS J ULTRASOU, V20, P30, DOI DOI 10.1002/ajum.12042
   Berger A, 2000, BRIT MED J, V321, P424, DOI 10.1136/bmj.321.7258.424
   Cai J, 2020, CLIN INFECT DIS
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen S, 2020, Zhonghua Bing Li Xue Za Zhi, V49, P418, DOI 10.3760/cma.j.cn112151-20200225-00138
   Chen Y, 2020, FRONT PEDIAT
   Chilvers RJ, 2000, ANAESTHESIA, V55, P176, DOI 10.1046/j.1365-2044.2000.055002176.x
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Corman VM, 2020, EURO SURVEILL
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dharani K, 2019, CRITICAL CARE OBSTET, P403
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gardner MO, 2004, OBSTET GYN CLIN N AM, V31, P385, DOI 10.1016/j.ogc.2004.03.010
   Guan WJ, 2020, N ENGL J MED
   Gustavson K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45920-7
   Hanada S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02640
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui D S C, 2014, Hong Kong Med J, V20 Suppl 4, P9
   Hulme KD, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00861
   James JL, 2006, HUM REPROD UPDATE, V12, P137, DOI 10.1093/humupd/dmi043
   Jeong SY, 2017, J KOREAN MED SCI, V32, P1717, DOI 10.3346/jkms.2017.32.10.1717
   Jiang CD, 2020, NEURORADIOLOGY, V62, P803, DOI 10.1007/s00234-020-02392-1
   Jiang XG, 2004, CLIN DIAGN LAB IMMUN, V11, P1182, DOI 10.1128/CDLI.11.6.1182-1184.2004
   Karunajeewa HA, 2010, ANTIMICROB AGENTS CH, V54, P1186, DOI 10.1128/AAC.01269-09
   Kilianski A, 2013, J VIROL, V87, P11955, DOI 10.1128/JVI.02105-13
   KOCHHAR DM, 1980, TOXICOL APPL PHARM, V52, P99, DOI 10.1016/0041-008X(80)90252-5
   Kovac M, 2010, EUR J OBSTET GYN R B, V148, P27, DOI 10.1016/j.ejogrb.2009.09.005
   Lau KK, 2004, EMERG INFECT DIS, V10, P342, DOI 10.3201/eid1002.030638
   Levy A, 2008, AM J PHYSIOL-REG I, V295, pR1953, DOI 10.1152/ajpregu.90592.2008
   Littauer EQ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006757
   Liu F, 2020, INT J INFECT DIS, V95, P183, DOI 10.1016/j.ijid.2020.03.013
   Liu Y, 2020, J INFECT
   Malik A, 2016, EMERG INFECT DIS, V22, P515, DOI 10.3201/eid2203.151049
   Maxwell C, 2017, J OBSTET GYNAECOL CA, V39, pE130, DOI 10.1016/j.jogc.2017.04.024
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Murphy S, NEWBORN BABY TESTS P
   Nelson-Piercy C., 2015, HDB OBSTET MED, P63
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Park MH, 2016, KOREAN J ANESTHESIOL, V69, P287, DOI 10.4097/kjae.2016.69.3.287
   Payne DC, 2014, J INFECT DIS, V209, P1870, DOI 10.1093/infdis/jiu068
   Pilu G., AJOG PRESENTS PRACTI
   Plante LA, 2019, AM J OBSTET GYNECOL, V220, pB2, DOI 10.1016/j.ajog.2019.01.216
   Qiao J, 2020, LANCET, V395, P760, DOI 10.1016/S0140-6736(20)30365-2
   Racelis S, 2015, WEST PAC SURVEILL RE, V6, P3, DOI [10.5365/WPSAR.2015.6.2.012, 10.5365/wpsar.2015.6.2.012]
   Radonovich LJ, 2019, JAMA-J AM MED ASSOC, V322, P824, DOI 10.1001/jama.2019.11645
   Rasmussen SA, 2020, AM J OBSTET GYNECOL, V222, P415, DOI 10.1016/j.ajog.2020.02.017
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Roberge RJ, 2014, AM J INFECT CONTROL, V42, P1097, DOI 10.1016/j.ajic.2014.06.025
   Robertson CA, 2004, EMERG INFECT DIS, V10, P345, DOI 10.3201/eid1002.030736
   Royal College of Obstetricians and Gynaecologists United Kingdom, 2020, INF HEALTHC PROF
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sass L, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1585-0
   Schwartz DA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020194
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427
   Stockman LJ, 2004, EMERG INFECT DIS, V10, P1689, DOI 10.3201/eid1009.040244
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Tong PSY, 2015, ANTIMICROB RESIST IN, V4, DOI 10.1186/s13756-015-0086-z
   Tookey PA, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1400-y
   United States Centers for Disease Control and Prevention (CDC), 2020, PLAN PREP RESP COR D
   United States Centers for Disease Control and Prevention (CDC), 2020, INT INF PREV CONTR R
   United States Centers for Disease Control and Prevention (CDC), 2020, INT GUID BREASTF MOT
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YX, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4938-7
   WHO, 2020, DIR GEN OP REM MED B
   Winthrop KL, 2017, NAT REV RHEUMATOL, V13, P234, DOI 10.1038/nrrheum.2017.23
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wong SF, 2004, AM J OBSTET GYNECOL, V191, P292, DOI 10.1016/j.ajog.2003.11.019
   Wong SF, 2003, BJOG-INT J OBSTET GY, V110, P641, DOI 10.1046/j.1471-0528.2003.03008.x
   Woo PCY, 2004, CLIN DIAGN LAB IMMUN, V11, P665, DOI 10.1128/CDLI.11.4.665-668.2004
   Woodward A., PREGNANT MOTHER INFE
   World Health Organization, 46 WHO
   World Health Organization (WHO), NOV COR TECHN GUID P
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Yudin MH, 2005, OBSTET GYNECOL, V105, P124, DOI 10.1097/01.AOG.0000151598.49129.de
   Zhang L, 2020, Zhonghua Fu Chan Ke Za Zhi, V55, P166, DOI 10.3760/cma.j.cn112141-20200218-00111
   Zhao Y., 2020, BIORXIV
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu HP, 2020, TRANSL PEDIATR, V9, P51, DOI 10.21037/tp.2020.02.06
NR 86
TC 130
Z9 133
U1 42
U2 55
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD JUN
PY 2020
VL 222
IS 6
BP 521
EP 531
DI 10.1016/j.ajog.2020.03.021
PG 11
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA LT8LD
UT WOS:000537318500003
PM 32217113
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Arslan, H
   Musabak, U
   Soy, EHA
   Azap, OK
   Sayin, B
   Akcay, S
   Haberal, KM
   Akdur, A
   Yildirim, S
   Haberal, M
AF Arslan, Hande
   Musabak, Ugur
   Soy, Ebru H. Ayvazoglu
   Azap, Ozlem Kurt
   Sayin, Burak
   Akcay, Sule
   Haberal, K. Murat
   Akdur, Aydincan
   Yildirim, Sedat
   Haberal, Mehmet
TI Incidence and Immunologic Analysis of Coronavirus Disease (COVID-19) in
   Hemodialysis Patients: A Single-Center Experience
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Article
DE Chronic renal failure; Pandemic; SARS-CoV-2
ID KILLER; GENES
AB Objectives: COVID-19 is a great threat to the modern world and significant threat to immunocompromised patients, including patients with chronic renal failure. We evaluated COVID-19 incidence among our hemodialysis patients and investigated the most probable immune mechanisms against COVID-19.
   Materials and Methods: Baskent University has 21 dialysis centers across Turkey, with 2420 patients on hemodialysis and 30 on peritoneal dialysis. Among these, we retrospectively evaluated 602 patients (257 female/345 male) with chronic renal failure receiving hemodialysis as renal replacement therapy; 7 patients (1.1%) were infected with SARS-CoV-2. We retrospectively collected patient demographic characteristics, clinical data, and immunological factors affecting the clinical course of the disease. We divided patients into groups and included 2 control groups ( individuals with normal renal functions): group I included COVID-19-positive patients with normal renal function, group II included COVID-19-positive hemodialysis patients, group III included COVID-19-negative hemodialysis patients, and group IV included COVID-19-negative patients with normal renal function. Lymphocyte subsets in peripheral blood and typing of human leukocyte antigens were analyzed in all groups, with killer cell immunoglobulin-like receptor genes analyzed only in COVID-19-positive patients and healthy controls.
   Results: No deaths occurred among the 7 COVID-19-positive hemodialysis patients. Group I patients were significantly older than patients in groups II and III ( P = .039, P = .030, respectively) but not significantly different from group IV (P = .060). Absolute counts of natural killer cells in healthy controls were higher than in other groups (but not significantly). Activated T cells were significantly increased in both COVID-19-positive groups versus COVID-19-negative groups. Groups showed significant differences in C and DQ loci with respect to distribution of alleles in both HLA classes.
   Conclusions: Although immunocompromised patients are at greater risk for COVID-19, we found lower COVID-19 incidence in our hemodialysis patients, which should be further investigated in in vitro and molecular studies.
C1 [Arslan, Hande; Azap, Ozlem Kurt] Baskent Univ, Dept Infect Dis, Ankara, Turkey.
   [Musabak, Ugur] Baskent Univ, Dept Immunol, Ankara, Turkey.
   [Soy, Ebru H. Ayvazoglu; Akdur, Aydincan; Yildirim, Sedat; Haberal, Mehmet] Baskent Univ, Dept Gen Surg, Div Transplantat, Ankara, Turkey.
   [Sayin, Burak] Baskent Univ, Dept Nephrol, Ankara, Turkey.
   [Akcay, Sule] Baskent Univ, Dept Pulm Dis, Ankara, Turkey.
   [Haberal, K. Murat] Baskent Univ, Dept Radiol, Ankara, Turkey.
RP Soy, EHA (corresponding author), Baskent Univ, Dept Gen Surg, Div Transplantat, Ankara, Turkey.
EM ebruayvazoglu@gmail.com
RI Musabak, Ugur/AAU-1810-2020; SOY, EBRU H. AYVAZOGLU/AAC-5566-2019
OI Musabak, Ugur/0000-0003-1511-7634; SOY, EBRU H.
   AYVAZOGLU/0000-0002-0993-9917
CR Choi YH, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002845
   Esposito P, 2020, HEMODIAL INT, V24, P423, DOI 10.1111/hdi.12837
   Haberal M, 2020, EXP CLIN TRANSPLANT, V18, P139, DOI 10.6002/ect.2020.000e
   Hajeer AH, 2016, ANN THORAC MED, V11, P211, DOI 10.4103/1817-1737.185756
   Jiao XY, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1475-y
   Jost S, 2013, ANNU REV IMMUNOL, V31, P163, DOI 10.1146/annurev-immunol-032712-100001
   Kartal O, 2016, WIEN KLIN WOCHENSCHR, V128, P822, DOI 10.1007/s00508-015-0769-8
   Lin Marie, 2003, BMC Med Genet, V4, P9, DOI 10.1186/1471-2350-4-9
   Moretta L, 2004, CURR OPIN IMMUNOL, V16, P626, DOI 10.1016/j.coi.2004.07.010
   Rajagopalan S, 2005, J EXP MED, V201, P1025, DOI 10.1084/jem.20050499
   Rombola G, 2020, J NEPHROL, V33, P193, DOI 10.1007/s40620-020-00727-y
   Sarialioglu F, 2020, EXP CLIN TRANSPLANT, V18, P141, DOI 10.6002/ect.2020.0109
   Turner JE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00587
   Vacher-Coponat H, 2008, NEPHROL DIAL TRANSPL, V23, P1406, DOI 10.1093/ndt/gfm596
   Wang JH, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-46
   WHO, BAC CALM GUER BCG VA
NR 16
TC 3
Z9 3
U1 2
U2 2
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304-0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD JUN
PY 2020
VL 18
IS 3
BP 275
EP 283
DI 10.6002/ect.2020.0194
PG 9
WC Transplantation
SC Transplantation
GA LU0IL
UT WOS:000537447100003
PM 32519618
DA 2021-01-01
ER

PT J
AU Burgueno, JF
   Reich, A
   Hazime, H
   Quintero, MA
   Fernandez, I
   Fritsch, J
   Santander, AM
   Brito, N
   Damas, OM
   Deshpande, A
   Kerman, DH
   Zhang, LY
   Gao, Z
   Ban, YG
   Wang, L
   Pignac-Kobinger, J
   Abreu, MT
AF Burgueno, Juan F.
   Reich, Adrian
   Hazime, Hajar
   Quintero, Maria A.
   Fernandez, Irina
   Fritsch, Julia
   Santander, Ana M.
   Brito, Nivis
   Damas, Oriana M.
   Deshpande, Amar
   Kerman, David H.
   Zhang, Lanyu
   Gao, Zhen
   Ban, Yuguang
   Wang, Lily
   Pignac-Kobinger, Judith
   Abreu, Maria T.
TI Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of
   Patients With IBD
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE coronavirus; Crohn disease; ulcerative colitis
ID FUNCTIONAL RECEPTOR; SARS CORONAVIRUS
AB Background: Patients with inflammatory bowel disease (IBD) have intestinal inflammation and are treated with immune-modulating medications. In the face of the coronavirus disease-19 pandemic, we do not know whether patients with IBD will be more susceptible to infection or disease. We hypothesized that the viral entry molecules angiotensin I converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) are expressed in the intestine. We further hypothesized that their expression could be affected by inflammation or medication usage.
   Methods: We examined the expression of Ace2 and Tmprss2 by quantitative polymerase chain reacion in animal models of IBD. Publicly available data from organoids and mucosal biopsies from patients with IBD were examined for expression of ACE2 and TMPRSS2. We conducted RNA sequencing for CD11b-enriched cells and peripheral and lamina propria T-cells from well-annotated patient samples.
   Results: ACE2 and TMPRSS2 were abundantly expressed in the ileum and colon and had high expression in intestinal epithelial cells. In animal models, inflammation led to downregulation of epithelial Ace2. Expression of ACE2 and TMPRSS2 was not increased in samples from patients with compared with those of control patients. In CD11b-enriched cells but not T-cells, the level of expression of ACE2 and TMPRSS2 in the mucosa was comparable to other functional mucosal genes and was not affected by inflammation. Anti-tumor necrosis factor drugs, vedolizumab, ustekinumab, and steroids were linked to significantly lower expression of ACE2 in CD11b-enriched cells.
   Conclusions: The viral entry molecules ACE2 and TMPRSS2 are expressed in the ileum and colon. Patients with IBD do not have higher expression during inflammation; medical therapy is associated with lower levels of ACE2. These data provide reassurance for patients with IBD.
C1 [Burgueno, Juan F.; Hazime, Hajar; Quintero, Maria A.; Fernandez, Irina; Fritsch, Julia; Santander, Ana M.; Brito, Nivis; Damas, Oriana M.; Deshpande, Amar; Kerman, David H.; Pignac-Kobinger, Judith; Abreu, Maria T.] Univ Miami, Miller Sch Med, Dept Med, Div Gastroenterol, Miami, FL 33136 USA.
   [Reich, Adrian] Scripps Res Inst, Ctr Computat Biol & Bioinformat, Jupiter, FL USA.
   [Zhang, Lanyu; Gao, Zhen; Ban, Yuguang; Wang, Lily] Univ Miami, Miller Sch Med, Biostat & Bioinformat Shared Resource, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
RP Abreu, MT (corresponding author), 1011 NW 15th St D-149,Gautier Bldg,Suite 510, Miami, FL 33136 USA.
EM mabreu1@miami.edu
RI , G/J-8438-2019
OI , G/0000-0003-3461-1910; Burgueno, Juan F/0000-0002-7641-5136; Quintero
   Cusguen, Maria Alejandra/0000-0003-2249-6564
FU National Institute of Diabetes and Digestive and Kidney DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [R01DK09907]; Takeda Pharmaceutical, U.S.A.,
   Inc. [IISR-2014-1000892]; PfizerPfizer [WI227247]; Micky & Madeleine
   Arison Family Foundation Crohn's & Colitis Discovery Laboratory; Martin
   Kalser Chair
FX This work was supported by grants from the National Institute of
   Diabetes and Digestive and Kidney Diseases (grant number R01DK09907),
   Takeda Pharmaceutical, U.S.A. (grant number IISR-2014-1000892), Inc.,
   Pfizer (ASPIRE award number WI227247), The Micky & Madeleine Arison
   Family Foundation Crohn's & Colitis Discovery Laboratory, and the Martin
   Kalser Chair (to coauthor MTA).
CR Ahn J, 2017, CELL REP, V21, P3873, DOI 10.1016/j.celrep.2017.11.101
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Burgueno JF, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0653-0
   Burgueno JF, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01484
   de Lang A, 2006, VIROLOGY, V353, P474, DOI 10.1016/j.virol.2006.06.011
   Dheer R, 2020, CELL MOL GASTROENTER, V9, P387, DOI 10.1016/j.jcmgh.2019.10.013
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dotti I, 2017, GUT, V66, P2069, DOI 10.1136/gutjnl-2016-312609
   Fernandez-Ruiz M, 2019, REV ESP QUIM, V32, P63
   Fujii M, 2016, CELL STEM CELL, V18, P827, DOI 10.1016/j.stem.2016.04.003
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hindson J, 2020, NAT REV GASTRO HEPAT, V17, P259, DOI 10.1038/s41575-020-0295-7
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kraiczy J, 2019, GUT, V68, P49, DOI 10.1136/gutjnl-2017-314817
   Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI 10.1053/S0016-5085(03)01215-0
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Lyons J, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2002417
   Middendorp S, 2014, STEM CELLS, V32, P1083, DOI 10.1002/stem.1655
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   SMITH DM, 1992, J LEUKOCYTE BIOL, V52, P670
   Suzuki K, 2018, J GASTROENTEROL, V53, P1035, DOI 10.1007/s00535-018-1437-3
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Vanhove W, 2015, INFLAMM BOWEL DIS, V21, P2673, DOI 10.1097/MIB.0000000000000535
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang W, 2020, DEFINITION RISKS CYT, DOI [10.1101/2020.02.26.20026989, DOI 10.1101/2020.02.26.20026989]
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wong SH, 2020, J GASTROEN HEPATOL, V35, P744, DOI 10.1111/jgh.15047
   World Health Organization, 2020, 74 WHO
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 40
TC 32
Z9 33
U1 1
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD JUN
PY 2020
VL 26
IS 6
BP 797
EP 808
DI 10.1093/ibd/izaa085
PG 12
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA LU0KX
UT WOS:000537453600012
PM 32333601
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Zhang, LT
   Yan, XS
   Fan, QK
   Liu, HY
   Liu, XT
   Liu, ZJ
   Zhang, ZL
AF Zhang, Litao
   Yan, Xinsheng
   Fan, Qingkun
   Liu, Haiyan
   Liu, Xintian
   Liu, Zejin
   Zhang, Zhenlu
TI D-dimer levels on admission to predict in-hospital mortality in patients
   with Covid-19
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE coronavirus disease; D-dimer; mortality; prognosis; SARS-CoV-2
AB Background The outbreak of the coronavirus disease 2019 (Covid-19) has shown a global spreading trend. Early and effective predictors of clinical outcomes are urgently needed to improve management of Covid-19 patients.
   Objective The aim of the present study was to evaluate whether elevated D-dimer levels could predict mortality in patients with Covid-19.
   Methods Patients with laboratory confirmed Covid-19 were retrospective enrolled in Wuhan Asia General Hospital from January 12, 2020, to March 15, 2020. D-dimer levels on admission and death events were collected to calculate the optimum cutoff using receiver operating characteristic curves. According to the cutoff, the subjects were divided into two groups. Then the in-hospital mortality between two groups were compared to assess the predictive value of D-dimer level.
   Results A total of 343 eligible patients were enrolled in the study. The optimum cutoff value of D-dimer to predict in-hospital mortality was 2.0 mu g/mL with a sensitivity of 92.3% and a specificity of 83.3%. There were 67 patients with D-dimer >= 2.0 mu g/mL, and 267 patients with D-dimer <2.0 mu g/mL on admission. 13 deaths occurred during hospitalization. Patients with D-dimer levels >= 2.0 mu g/mL had a higher incidence of mortality when comparing with those who with D-dimer levels <2.0 mu g/mL (12/67 vs 1/267, P < .001; hazard ratio, 51.5; 95% confidence interval, 12.9-206.7).
   Conclusions D-dimer on admission greater than 2.0 mu g/mL (fourfold increase) could effectively predict in-hospital mortality in patients with Covid-19, which indicated D-dimer could be an early and helpful marker to improve management of Covid-19 patients. (Chinese Clinical Trial Registry: ChiCTR2000031428).
C1 [Zhang, Litao; Fan, Qingkun; Zhang, Zhenlu] Wuhan Asia Heart Hosp, Lab Med, 753 Jinghan Ave, Wuhan 430022, Hubei, Peoples R China.
   [Zhang, Litao; Zhang, Zhenlu] Wuhan Inst Design & Sci, Sch Nursing, Physiol Grp, Wuhan, Hubei, Peoples R China.
   [Zhang, Litao; Yan, Xinsheng; Liu, Haiyan; Liu, Zejin; Zhang, Zhenlu] Wuhan Asia Gen Hosp, Lab Med, Wuhan, Hubei, Peoples R China.
   [Liu, Xintian] Wuhan Asia Heart Hosp, Dept Cardiol, Wuhan, Peoples R China.
RP Zhang, ZL (corresponding author), Wuhan Asia Heart Hosp, Lab Med, 753 Jinghan Ave, Wuhan 430022, Hubei, Peoples R China.
EM zhenluzhangwh@163.com
OI Zhang, Litao/0000-0003-4918-611X
CR [Anonymous], 2020, CORONAVIRUS DIS COVI
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Barbar S, 2010, J THROMB HAEMOST, V8, P2450, DOI 10.1111/j.1538-7836.2010.04044.x
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gupta N, 2019, THROMB RES, V181, P77, DOI 10.1016/j.thromres.2019.07.013
   Harper PL, 2007, INTERN MED J, V37, P607, DOI 10.1111/j.1445-5994.2007.01388.x
   Hess K, 2011, THROMB HAEMOSTASIS, V105, pS43, DOI 10.1160/THS10-11-0739
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iba T, 2019, J THROMB HAEMOST, V17, P1989, DOI 10.1111/jth.14578
   Levi M, 2017, THROMB RES, V149, P38, DOI 10.1016/j.thromres.2016.11.007
   Mager JJ, 2001, THROMB HAEMOSTASIS, V86, P1578
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Tripodi A, 2011, CLIN CHEM, V57, P1256, DOI 10.1373/clinchem.2011.166249
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   Wong JP, 2017, FUTURE MED CHEM, V9, P169, DOI 10.4155/fmc-2016-0181
   Zhang L, 2018, INT J LAB HEMATOL, V40, P503, DOI 10.1111/ijlh.12864
   Zhang L, 2017, J THROMB HAEMOST, V15, P1934, DOI 10.1111/jth.13782
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 19
TC 160
Z9 162
U1 4
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD JUN
PY 2020
VL 18
IS 6
BP 1324
EP 1329
DI 10.1111/jth.14859
PG 6
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA LU2DH
UT WOS:000537569900015
PM 32306492
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Koo, JR
   Cook, AR
   Park, M
   Sun, YXH
   Sun, HY
   Lim, JT
   Tam, C
   Dickens, BL
AF Koo, Joel R.
   Cook, Alex R.
   Park, Minah
   Sun, Yinxiaohe
   Sun, Haoyang
   Lim, Jue Tao
   Tam, Clarence
   Dickens, Borame L.
TI Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a
   modelling study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
AB Background Since the coronavirus disease 2019 outbreak began in the Chinese city of Wuhan on Dec 31, 2019, 68 imported cases and 175 locally acquired infections have been reported in Singapore. We aimed to investigate options for early intervention in Singapore should local containment (eg, preventing disease spread through contact tracing efforts) be unsuccessful.
   Methods We adapted an influenza epidemic simulation model to estimate the likelihood of human-to-human transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a simulated Singaporean population. Using this model, we estimated the cumulative number of SARS-CoV-2 infections at 80 days, after detection of 100 cases of community transmission, under three infectivity scenarios (basic reproduction number [R-0] of 1.5, 2.0, or 2.5) and assuming 7.5% of infections are asymptomatic. We first ran the model assuming no intervention was in place (baseline scenario), and then assessed the effect of four intervention scenarios compared with a baseline scenario on the size and progression of the outbreak for each R-0 value. These scenarios included isolation measures for infected individuals and quarantining of family members (hereafter referred to as quarantine); quarantine plus school closure; quarantine plus workplace distancing; and quarantine, school closure, and workplace distancing (hereafter referred to as the combined intervention). We also did sensitivity analyses by altering the asymptomatic fraction of infections (22.7%, 30.0%, 40.0%, and 50.0%) to compare outbreak sizes under the same control measures.
   Findings For the baseline scenario, when R 0 was 1.5, the median cumulative number of infections at day 80 was 279 000 (IQR 245 000-320 000), corresponding to 7.4% (IQR 6.5-8.5) of the resident population of Singapore. The median number of infections increased with higher infectivity: 727 000 cases (670 000-776 000) when R-0 was 2.0, corresponding to 19.3% (17.8-20.6) of the Singaporean population, and 1 207 000 cases (1 164 000-1 249 000) when R-0 was 2.5, corresponding to 32% (30.9-33.1) of the Singaporean population. Compared with the baseline scenario, the combined intervention was the most effective, reducing the estimated median number of infections by 99.3% (IQR 92.6-99.9) when R-0 was 1.5, by 93.0% (81.5-99.7) when R-0 was 2.0, and by 78.2% (59.0 -94.4) when R-0 was 2.5. Assuming increasing asymptomatic fractions up to 50.0%, up to 277 000 infections were estimated to occur at day 80 with the combined intervention relative to 1800 for the baseline at R-0 of 1.5.
   Interpretation Implementing the combined intervention of quarantining infected individuals and their family members, workplace distancing, and school closure once community transmission has been detected could substantially reduce the number of SARS-CoV-2 infections. We therefore recommend immediate deployment of this strategy if local secondary transmission is confirmed within Singapore. However, quarantine and workplace distancing should be prioritised over school closure because at this early stage, symptomatic children have higher withdrawal rates from school than do symptomatic adults from work. At higher asymptomatic proportions, intervention effectiveness might be substantially reduced requiring the need for effective case management and treatments, and preventive measures such as vaccines.
C1 [Koo, Joel R.; Cook, Alex R.; Park, Minah; Sun, Yinxiaohe; Sun, Haoyang; Lim, Jue Tao; Tam, Clarence; Dickens, Borame L.] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117549, Singapore.
   [Tam, Clarence] London Sch Hyg & Trop Med, London, England.
RP Cook, AR (corresponding author), Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117549, Singapore.
EM alex.richard.cook@gmail.com
RI Cook, Alex/B-5941-2011
OI Cook, Alex/0000-0002-6271-5832; Tam, Clarence/0000-0003-1697-286X
FU Singapore Ministry of Health, Singapore Population Health Improvement
   Centre
FX Singapore Ministry of Health, Singapore Population Health Improvement
   Centre.
CR Ahmed F, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5446-1
   [Anonymous], 2020, JAPAN TIMES
   [Anonymous], 2020, THE STRAIT TIMES
   [Anonymous], 2020, PNEUM UNKN CAUS
   BBC, 2020, BBC
   Chao DL, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000656
   Chen YR, 2018, AM J TROP MED HYG, V99, P1625, DOI 10.4269/ajtmh.18-0099
   Chu CY, 2010, EMERG INFECT DIS, V16, P1300, DOI 10.3201/eid1608.091787
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Department of Statistics Singapore, 2011, SING CENS POP 2010 S
   Donnelly CA, 2019, EMERG INFECT DIS, V25, P1758, DOI 10.3201/eid2509.190143
   Furuya-Kanamori L, 2016, EMERG INFECT DIS, V22, P1052, DOI 10.3201/eid2206.151080
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   McBryde ES, 2006, B MATH BIOL, V68, P889, DOI 10.1007/s11538-005-9005-4
   Meltzer MI, 2004, EMERG INFECT DIS, V10, P207, DOI 10.3201/eid1002.030426
   Ministry of Health Singapore, UPD COVID 19 COR DIS
   Ministry of Health Singapore, SPEC FEAT SEV AC RES
   Ministry of Health Singapore, 2020, 2 MOR CAS CONF IMP C
   Ministry of Health Singapore, 2020, CONF IMP CAS NOV COR
   Ministry of Manpower Singapore, SUMM TABL UN
   Ministry of the Environment and Water Resources Singapore, HAWK CTR 3 0 COMM RE
   National Environment Agency, ZIK CAS CLUST
   Nishiura H, 2020, ESTIMATION ASYMPTOMA, DOI DOI 10.1101/2020.02.03.20020248
   Ooi EE, 2006, EMERG INFECT DIS, V12, P887, DOI 10.3201/10.3201/eid1206.051210
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Phan TP, 2014, BMJ OPEN DIAB RES CA, V2, DOI 10.1136/bmjdrc-2013-000012
   Read J. M., 2020, NOVEL CORONAVIRUS 20, DOI [10.1101/2020.01.23.20018549, DOI 10.1101/2020.01.23.20018549]
   Rogerson A, 2018, GERIATRICS-BASEL, V3, DOI 10.3390/geriatrics3040081
   Singapore Tourism Board, 2019, CAPT QUAL GROWTH AM
   WHO Novel Coronavirus disease, 2020, 3 WHO
   Wilder-Smith A, 2005, EMERG INFECT DIS, V11, P1142, DOI 10.3201/eid1107.041165
   World Health Organization, 2020, 55 WHO
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
NR 35
TC 107
Z9 108
U1 11
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JUN
PY 2020
VL 20
IS 6
BP 678
EP 688
DI 10.1016/S1473-3099(20)30162-6
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA LT9MY
UT WOS:000537391000044
PM 32213332
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Pult, H
AF Pult, Heiko
TI COVID-19 Pandemic: Survey of future use of personal protective equipment
   in optometric practice
SO CONTACT LENS & ANTERIOR EYE
LA English
DT Article
DE COVID-19; Personal protective equipment; Eye care practitioners; Survey
AB Purpose: The aim of this project was to evaluate which personal protective equipment (PPE) eye care practitioners (ECP) will use during the next months and also what they will ask the patient to use in clinical practice.
   Methods: A social-media survey was carried out, asking 257 optometrists and opticians in Germany, Austria and Switzerland (i) which PPE they intended to use in the future (after lockdown and before herd immunity and / or vaccine availability) and (ii) what they would ask the patient to do in terms of this.
   Results: 75 % of the ECPs planned on wearing masks during refractions and 69 % when fitting contact lens. 62 % of the ECPs also expected their patients to wear masks in these tasks. This number is higher than for distance tasks such as fitting frames. Around 90 % of the ECPs would, in addition to hand washing, disinfect their hands and around 80 % expected their patients to do so too. Less than one third of ECPs favoured wearing safety spectacles, gloves and / or protective facial shields. 73 % planed on disinfecting frames after they would have been tried on by customers.
   Conclusions: In summary, most ECPs planed on continuing to use higher standards of PPE. Those, who intended to wear masks themselves, would ask their patients to also do so, combined with hand disinfection.
C1 [Pult, Heiko] Dr Heiko Pult Optometry & Vis Res, Weinheim, Germany.
   [Pult, Heiko] Aston Univ, Life & Hlth Sci, Ophthalm Res Grp, Birmingham, W Midlands, England.
   [Pult, Heiko] Cardiff Univ, Sch Biomed & Life Sci, Cardiff, Wales.
RP Pult, H (corresponding author), Steingasse 15, D-69469 Weinheim, Germany.
EM ovr@heiko-pult.de
CR [Anonymous], 2020, CONFLICTS CORONA CRI
   [Anonymous], 2020, DEALING PEOPLE MED T
   Jones L., 2020, CONT LENS ANTERIOR E
   Zeri F, 2020, CONT LENS ANTERIOR E, P30050
   Zhou M, 2020, J HOSP INFECT, V40
NR 5
TC 2
Z9 3
U1 1
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1367-0484
EI 1476-5411
J9 CONTACT LENS ANTERIO
JI Contact Lens Anterior Eye
PD JUN
PY 2020
VL 43
IS 3
BP 208
EP 210
DI 10.1016/j.clae.2020.04.006
PG 3
WC Ophthalmology
SC Ophthalmology
GA LS7RB
UT WOS:000536577600004
PM 32354653
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Alhazzani, W
   Moller, MH
   Arabi, YM
   Loeb, M
   Gong, MN
   Fan, E
   Oczkowski, S
   Levy, MM
   Derde, L
   Dzierba, A
   Du, B
   Aboodi, M
   Wunsch, H
   Cecconi, M
   Koh, Y
   Chertow, DS
   Maitland, K
   Alshamsi, F
   Belley-Cote, E
   Greco, M
   Laundy, M
   Morgan, JS
   Kesecioglu, J
   McGeer, A
   Mermel, L
   Mammen, MJ
   Alexander, PE
   Arrington, A
   Centofanti, JE
   Citerio, G
   Baw, B
   Memish, ZA
   Hammond, N
   Hayden, FG
   Evans, L
   Rhodes, A
AF Alhazzani, Waleed
   Moller, Morten Hylander
   Arabi, Yaseen M.
   Loeb, Mark
   Gong, Michelle Ng
   Fan, Eddy
   Oczkowski, Simon
   Levy, Mitchell M.
   Derde, Lennie
   Dzierba, Amy
   Du, Bin
   Aboodi, Michael
   Wunsch, Hannah
   Cecconi, Maurizio
   Koh, Younsuck
   Chertow, Daniel S.
   Maitland, Kathryn
   Alshamsi, Fayez
   Belley-Cote, Emilie
   Greco, Massimiliano
   Laundy, Matthew
   Morgan, Jill S.
   Kesecioglu, Jozef
   McGeer, Allison
   Mermel, Leonard
   Mammen, Manoj J.
   Alexander, Paul E.
   Arrington, Amy
   Centofanti, John E.
   Citerio, Giuseppe
   Baw, Bandar
   Memish, Ziad A.
   Hammond, Naomi
   Hayden, Frederick G.
   Evans, Laura
   Rhodes, Andrew
TI Surviving Sepsis Campaign: Guidelines on the Management of Critically
   Ill Adults with Coronavirus Disease 2019 (COVID-19)
SO CRITICAL CARE MEDICINE
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; CLINICAL-PRACTICE GUIDELINE;
   END-EXPIRATORY PRESSURE; ACUTE LUNG INJURY; LOW TIDAL VOLUME;
   CONSERVATIVE OXYGEN-THERAPY; HEALTH-CARE WORKERS; MERS-COV INFECTION;
   FLOW NASAL CANNULA; NONINVASIVE VENTILATION
AB Background:
   The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent guidance for clinicians caring for the sickest of these patients is needed.
   Methods:
   We formed a panel of 36 experts from 12 countries. All panel members completed the World Health Organization conflict of interest disclosure form. The panel proposed 53 questions that are relevant to the management of COVID-19 in the ICU. We searched the literature for direct and indirect evidence on the management of COVID-19 in critically ill patients in the ICU. We identified relevant and recent systematic reviews on most questions relating to supportive care. We assessed the certainty in the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, then generated recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility. Recommendations were either strong or weak, or in the form of best practice recommendations.
   Results:
   The Surviving Sepsis Campaign COVID-19 panel issued 54 statements, of which four are best practice statements, nine are strong recommendations, and 35 are weak recommendations. No recommendation was provided for six questions. The topics were: 1) infection control, 2) laboratory diagnosis and specimens, 3) hemodynamic support, 4) ventilatory support, and 5) COVID-19 therapy.
   Conclusion:
   The Surviving Sepsis Campaign COVID-19 panel issued several recommendations to help support healthcare workers caring for critically ill ICU patients with COVID-19. When available, we will provide new evidence in further releases of these guidelines.
C1 [Alhazzani, Waleed; Loeb, Mark; Oczkowski, Simon; Belley-Cote, Emilie; Baw, Bandar] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Alhazzani, Waleed; Loeb, Mark; Oczkowski, Simon; Alexander, Paul E.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
   [Moller, Morten Hylander] Copenhagen Univ Hosp, Dept Intens Care, Rigshosp, Copenhagen, Denmark.
   [Moller, Morten Hylander] Scandinavian Soc Anaesthesiol & Intens Care Med S, Copenhagen, Denmark.
   [Arabi, Yaseen M.] King Saud Bin Abdulaziz Univ Hlth Sci, King Abdullah Int Med Res Ctr, Intens Care Dept, Minist Natl Guard Hlth Affairs, Riyadh, Saudi Arabia.
   [Gong, Michelle Ng; Aboodi, Michael] Albert Einstein Coll Med, Div Crit Care Med, Div Pulm Med, Dept Med,Montefiore Healthcare Syst, Bronx, NY 10467 USA.
   [Fan, Eddy; Wunsch, Hannah] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada.
   [Fan, Eddy] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.
   [Levy, Mitchell M.; Mermel, Leonard] Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA.
   [Levy, Mitchell M.] Rhode Isl Hosp, Providence, RI USA.
   [Derde, Lennie; Kesecioglu, Jozef] Univ Utrecht, Univ Med Ctr Utrecht, Dept Intens Care Med, Utrecht, Netherlands.
   [Derde, Lennie] Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Dzierba, Amy] Columbia Univ, Dept Pharm, New York Presbyterian Hosp, Irving Med Ctr, New York, NY USA.
   [Du, Bin] Peking Union Med Coll Hosp, Med ICU, Beijing, Peoples R China.
   [Wunsch, Hannah] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON, Canada.
   [Wunsch, Hannah] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada.
   [Cecconi, Maurizio; Greco, Massimiliano] Humanitas Clin & Res Ctr, Dept Anesthesia & Intens Care, Milan, Italy.
   [Cecconi, Maurizio; Greco, Massimiliano] Humanitas Univ, Dept Biomed Sci, Milan, Italy.
   [Koh, Younsuck] Univ Ulsan, Asan Med Ctr, Dept Pulm & Crit Care Med, Coll Med, Seoul, South Korea.
   [Chertow, Daniel S.] NIAID, Dept Crit Care Med, NIH, Clin Ctr & Lab Immunoregulat, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Maitland, Kathryn] Imperial Coll, Fac Med, London, England.
   [Alshamsi, Fayez] United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Internal Med, Al Ain, U Arab Emirates.
   [Belley-Cote, Emilie] Populat Hlth Res Inst, Hamilton, ON, Canada.
   [Laundy, Matthew] St Georges Univ Hosp NHS Fdn Trust & St Georges U, Microbiol & Infect Control, London, England.
   [Morgan, Jill S.] Emory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA.
   [McGeer, Allison] Univ Toronto, Div Infect Dis, Toronto, ON, Canada.
   [Mammen, Manoj J.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Med, Buffalo, NY USA.
   [Alexander, Paul E.] GUIDE Res Methods Grp, Hamilton, ON, Canada.
   [Arrington, Amy] Baylor Coll Med, Houston Childrens Hosp, Houston, TX 77030 USA.
   [Centofanti, John E.] McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada.
   [Citerio, Giuseppe] Milano Bicocca Univ, Dept Med & Surg, Milan, Italy.
   [Citerio, Giuseppe] Desio & San Gerardo Hosp, ASST Monza, Monza, Italy.
   [Baw, Bandar] King Abdul Aziz Med City, Dept Emergency Med, Riyadh, Saudi Arabia.
   [Memish, Ziad A.] Minist Hlth, Res & Innovat Ctr, King Saud Med City, Riyadh, Saudi Arabia.
   [Hammond, Naomi] George Inst Global Hlth, Crit Care Div, Sydney, NSW, Australia.
   [Hammond, Naomi] UNSW Sydney, Sydney, NSW, Australia.
   [Hammond, Naomi] Royal North Shore Hosp, Malcolm Fisher Dept Intens Care, Sydney, NSW, Australia.
   [Hayden, Frederick G.] Univ Virginia, Sch Med, Dept Med, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA.
   [Evans, Laura] Univ Washington, Div Pulm Crit Care & Sleep Med, Seattle, WA 98195 USA.
   [Rhodes, Andrew] St Georges Univ Hosp NHS Fdn Trust & St Georges U, Adult Crit Care, London, England.
RP Rhodes, A (corresponding author), St Georges Univ Hosp NHS Fdn Trust & St Georges U, Adult Crit Care, London, England.
EM andrewrhodes@nhs.net
RI Rhodes, Andrew/G-4265-2011; Arabi, Yaseen/ABF-3316-2020; Moller, Morten
   Hylander/AAQ-6891-2020; Cecconi, Maurizio/A-6241-2012
OI Rhodes, Andrew/0000-0002-8737-574X; Arabi, Yaseen/0000-0001-5735-6241;
   Moller, Morten Hylander/0000-0002-6378-9673; Cecconi,
   Maurizio/0000-0002-4376-6538; Derde, Lennie/0000-0002-3577-5629; Mammen,
   Manoj/0000-0003-0343-3234
CR Ai T., 2020, RADIOLOGY
   Akl EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057132
   Albert RK, 2000, AM J RESP CRIT CARE, V161, P1660, DOI 10.1164/ajrccm.161.5.9901037
   Alhazzani W, 2018, INTENS CARE MED, V44, P1691, DOI 10.1007/s00134-018-5367-6
   Alhazzani W, 2013, CRIT CARE, V17, DOI 10.1186/cc12557
   Alraddadi BM, 2019, INFLUENZA OTHER RESP, V13, P382, DOI 10.1111/irv.12635
   Alshahrani MS, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-017-0350-x
   Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602
   Andrews J, 2013, J CLIN EPIDEMIOL, V66, P719, DOI 10.1016/j.jclinepi.2012.03.013
   Antequera Martin AM, 2019, COCHRANE DB SYST REV, V7, pCd012247
   Arabi YM, 2020, INTENS CARE MED, V46, P315, DOI 10.1007/s00134-020-05943-5
   Arabi YM, 2020, TRIALS, V21, DOI 10.1186/s13063-019-3846-x
   Arabi YM, 2020, CLIN INFECT DIS, V70, P1837, DOI 10.1093/cid/ciz544
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Arabi YM, 2017, CRIT CARE MED, V45, P1683, DOI 10.1097/CCM.0000000000002621
   Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Barrot L, 2020, NEW ENGL J MED, V382, P999, DOI 10.1056/NEJMoa1916431
   Bednarczyk JM, 2017, CRIT CARE MED, V45, P1538, DOI 10.1097/CCM.0000000000002554
   Beigel JH, 2019, LANCET RESP MED, V7, P941, DOI 10.1016/S2213-2600(19)30199-7
   Beigel JH, 2019, ANTIVIR RES, V167, P45, DOI 10.1016/j.antiviral.2019.04.006
   Bentzer P, 2016, JAMA-J AM MED ASSOC, V316, P1298, DOI 10.1001/jama.2016.12310
   Bernard GR, 1997, NEW ENGL J MED, V336, P912, DOI 10.1056/NEJM199703273361303
   Biggerstaff M, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-480
   Blaser AR, 2017, INTENS CARE MED, V43, P380, DOI 10.1007/s00134-016-4665-0
   Bloomfield R, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008095.pub2
   Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218
   BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301
   Brochard L, 2014, SEMIN RESP CRIT CARE, V35, P492, DOI 10.1055/s-0034-1383863
   Brower RG, 1999, CRIT CARE MED, V27, P1492, DOI 10.1097/00003246-199908000-00015
   Brower RG, 2004, NEW ENGL J MED, V351, P327
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Brunner HI, 2015, ANN RHEUM DIS, V74, P1110, DOI 10.1136/annrheumdis-2014-205351
   Cabrini L, 2020, LANCET, V395, P685, DOI 10.1016/S0140-6736(20)30359-7
   Campbell L, 2011, RHEUMATOLOGY, V50, P552, DOI 10.1093/rheumatology/keq343
   Cao B, 2020, NEW ENGL J MED, V382
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Cavalcanti AB, 2017, JAMA-J AM MED ASSOC, V318, P1335, DOI 10.1001/jama.2017.14171
   Centers for Disease Control and Prevention, INT GUID COLL HANDL
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chan PKS, 2004, EMERG INFECT DIS, V10, P825, DOI 10.3201/eid1005.030682
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen X, 2020, DETECTABLE SERUM SAR
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Chu DK, 2018, LANCET, V391, P1693, DOI 10.1016/S0140-6736(18)30479-3
   Claesson J, 2016, ACTA ANAESTH SCAND, V60, P697, DOI 10.1111/aas.12713
   Combes A, 2018, NEW ENGL J MED, V378, P1965, DOI 10.1056/NEJMoa1800385
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cornejo RA, 2013, AM J RESP CRIT CARE, V188, P440, DOI 10.1164/rccm.201207-1279OC
   Cortegiani A, 2020, J CRIT CARE
   Davey RT, 2019, LANCET RESP MED, V7, P951, DOI 10.1016/S2213-2600(19)30253-X
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Esquinas AM, 2014, EUR RESPIR REV, V23, P427, DOI 10.1183/09059180.00009413
   European Centre for Disease Prevention and Control, 2020, SIT UPD WORLDW
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Falzarano D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01686
   Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST
   Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690
   Fowler RA, 2004, AM J RESP CRIT CARE, V169, P1198, DOI 10.1164/rccm.200305-715OC
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Gamino-Arroyo AE, 2019, CLIN INFECT DIS, V69, P1903, DOI 10.1093/cid/ciz100
   Gamper G, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003709.pub4
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052
   Gebistorf F, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002787.pub3
   Geng Z, 2019, CLIN EXP RHEUMATOL, V37, P318
   Genovese MC, 2018, RHEUMATOLOGY, V57, P1423, DOI 10.1093/rheumatology/key121
   Goligher EC, 2018, JAMA-J AM MED ASSOC, V320, P2251, DOI 10.1001/jama.2018.14276
   Goligher EC, 2017, ANN AM THORAC SOC, V14, pS304, DOI 10.1513/AnnalsATS.201704-340OT
   Gozzoli V, 2001, ARCH INTERN MED, V161, P121, DOI 10.1001/archinte.161.1.121
   Griffiths M, 2019, THORAX, V74, P931, DOI 10.1136/thoraxjnl-2018-212885
   Guan WJ, 2020, N ENGL J MED
   Guo LQ, 2018, BMC ANESTHESIOL, V18, DOI 10.1186/s12871-018-0631-4
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P158, DOI 10.1016/j.jclinepi.2012.01.012
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012
   Haffizulla J, 2014, LANCET INFECT DIS, V14, P609, DOI 10.1016/S1473-3099(14)70717-0
   Han SW, 2020, CANCER MED-US, V9, P6667, DOI 10.1002/cam4.3289
   Hart BJ, 2014, J GEN VIROL, V95, P571, DOI 10.1099/vir.0.061911-0
   HAUPT MT, 1991, CRIT CARE MED, V19, P1339, DOI 10.1097/00003246-199111000-00006
   Hernandez G, 2019, JAMA-J AM MED ASSOC, V321, P654, DOI 10.1001/jama.2019.0071
   Hodgson CL, 2019, AM J RESP CRIT CARE, V200, P1363, DOI 10.1164/rccm.201901-0109OC
   Hodgson CL, 2011, CRIT CARE, V15, DOI 10.1186/cc10249
   Honarmand Hooshyar, 2012, Daru, V20, P12, DOI 10.1186/2008-2231-20-12
   Honarmand K, 2020, CAN J ANESTH, V67, P369, DOI 10.1007/s12630-019-01546-x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang XJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep08528
   Huh JW, 2009, CRIT CARE, V13, DOI 10.1186/cc7725
   Hui DS, 2018, AM J RESP CRIT CARE, V197, P700, DOI 10.1164/rccm.201712-2371ED
   Hui DS, 2015, CHEST, V147, P1336, DOI 10.1378/chest.14-1934
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Hung IFN, 2013, CHEST, V144, P712, DOI 10.1378/chest.13-0571
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Janz DR, 2015, CRIT CARE MED, V43, P534, DOI 10.1097/CCM.0000000000000718
   Kacmarek RM, 2016, CRIT CARE MED, V44, P32, DOI 10.1097/CCM.0000000000001383
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Kong L K, 2006, Hong Kong Med J, V12, P489
   Lamontagne F, 2020, JAMA-J AM MED ASSOC, V323, P938, DOI 10.1001/jama.2020.0930
   Lamontagne F, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3284
   Lamontagne F, 2018, INTENS CARE MED, V44, P12, DOI 10.1007/s00134-017-5016-5
   Lansbury L, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010406.pub3
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Lee JM, 2014, CRIT CARE MED, V42, P1252, DOI 10.1097/CCM.0000000000000122
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007
   Lewis SR, 2017, BRIT J ANAESTH, V119, P369, DOI 10.1093/bja/aex228
   Lewis SR, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004477.pub3
   Lewis SR, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub7
   Lewis SR, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011136.pub2
   Lian XJ, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3175047
   Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538
   Livingston E., 2020, JAMA
   Loeb M, 2009, JAMA-J AM MED ASSOC, V302, P1865, DOI 10.1001/jama.2009.1466
   Long Y, 2020, J EVID BASED MED
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   MacIntyre CR, 2014, PREV MED, V62, P1, DOI 10.1016/j.ypmed.2014.01.015
   MacIntyre CR, 2013, AM J RESP CRIT CARE, V187, P960, DOI 10.1164/rccm.201207-1164OC
   MacIntyre CR, 2011, INFLUENZA OTHER RESP, V5, P170, DOI 10.1111/j.1750-2659.2011.00198.x
   Mackle D, 2020, NEW ENGL J MED, V382, P989, DOI 10.1056/NEJMoa1903297
   MacLaren G, 2020, JAMA
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549
   McCullers JA, 2013, CLIN MICROBIOL INFEC, V19, P113, DOI 10.1111/1469-0691.12093
   McIntyre WF, 2018, JAMA-J AM MED ASSOC, V319, P1889, DOI 10.1001/jama.2018.4528
   Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Memis D, 2004, CRIT CARE, V8, pR474, DOI 10.1186/cc2969
   Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646
   Meyhoff TS, 2020, CHEST
   Milton DK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003205
   Moller MH, 2018, ACTA ANAESTH SCAND, V62, P420, DOI 10.1111/aas.13089
   Moller MH, 2016, ACTA ANAESTH SCAND, V60, P1347, DOI 10.1111/aas.12780
   Momattin H, 2013, INT J INFECT DIS, V17, pE792, DOI 10.1016/j.ijid.2013.07.002
   Mora-Arteaga JA, 2015, MED INTENSIVA, V39, P352, DOI [10.1016/j.medine.2014.11.004, 10.1016/j.medin.2014.11.003]
   Moss M, 2019, NEW ENGL J MED, V380, P1997, DOI 10.1056/NEJMoa1901686
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Munshi L, 2019, LANCET RESP MED, V7, P163, DOI 10.1016/S2213-2600(18)30452-1
   Munshi L, 2017, ANN AM THORAC SOC, V14, pS280, DOI 10.1513/AnnalsATS.201704-343OT
   Murray MJ, 2016, CRIT CARE MED, V44, P2079, DOI 10.1097/CCM.0000000000002027
   Ni YN, 2018, AM J EMERG MED, V36, P226, DOI 10.1016/j.ajem.2017.07.083
   Niven DJ, 2013, J CRIT CARE, V28, P296, DOI 10.1016/j.jcrc.2012.08.015
   Nyren S, 2010, ANESTHESIOLOGY, V112, P682, DOI 10.1097/ALN.0b013e3181cf40c8
   Orme J, 2003, AM J RESP CRIT CARE, V167, P690, DOI 10.1164/rccm.200206-542OC
   Ou XF, 2017, CAN MED ASSOC J, V189, pE260, DOI 10.1503/cmaj.160570
   Pan JZ, 2019, MEDICINE, V98, DOI [10.1097/MD.0000000000014453, 10.1097/md.0000000000014453]
   Papazian L, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0540-9
   Patel BK, 2016, JAMA-J AM MED ASSOC, V315, P2435, DOI 10.1001/jama.2016.6338
   Qian H, 2010, BUILD SIMUL-CHINA, V3, P215, DOI 10.1007/s12273-010-0005-4
   Raboud J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010717
   Radonovich LJ, 2019, JAMA-J AM MED ASSOC, V322, P824, DOI 10.1001/jama.2019.11645
   Ranieri VM, 2020, JAMA
   Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255
   Rice TW, 2012, CRIT CARE MED, V40, P1487, DOI 10.1097/CCM.0b013e3182416f23
   Rochwerg B, 2019, INTENS CARE MED, V45, P563, DOI 10.1007/s00134-019-05590-5
   Rochwerg B, 2018, CRIT CARE MED, V46, P1411, DOI 10.1097/CCM.0000000000003262
   Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Roques P, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050268
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Russell Terrie-Marie, 2018, J Perioper Pract, V28, P322, DOI 10.1177/1750458918788985
   Rygard SL, 2018, INTENS CARE MED, V44, P1003, DOI 10.1007/s00134-018-5197-6
   Schortgen F, 2015, INTENS CARE MED, V41, P1800, DOI 10.1007/s00134-015-3987-7
   Schortgen F, 2012, AM J RESP CRIT CARE, V185, P1088, DOI 10.1164/rccm.201110-1820OC
   Schulman Carl I, 2005, Surg Infect (Larchmt), V6, P369
   Schunemann HJ, 2017, J CLIN EPIDEMIOL, V81, P101, DOI 10.1016/j.jclinepi.2016.09.009
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Shieh WJ, 2010, AM J PATHOL, V177, P166, DOI 10.2353/ajpath.2010.100115
   Siemieniuk RAC, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4169
   Siemieniuk RAC, 2015, ANN INTERN MED, V163, P519, DOI 10.7326/M15-0715
   Silversides JA, 2017, INTENS CARE MED, V43, P155, DOI 10.1007/s00134-016-4573-3
   Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707
   Smith JD, 2016, CAN MED ASSOC J, V188, P567, DOI 10.1503/cmaj.150835
   Stiehm ER, 2013, TRANSFUS MED REV, V27, P171, DOI 10.1016/j.tmrv.2013.05.004
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Thille AW, 2006, INTENS CARE MED, V32, P1515, DOI 10.1007/s00134-006-0301-8
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Tuite A. R., 2020, ANN INTERN MED
   Twu SJ, 2003, EMERG INFECT DIS, V9, P718
   Uyeki TM, 2019, CLIN INFECT DIS, V68, P895, DOI 10.1093/cid/ciy874
   van den Boom W, 2020, CHEST, V157, P566, DOI 10.1016/j.chest.2019.09.015
   van der Voort PHJ, 2001, CRIT CARE, V5, P216, DOI 10.1186/cc1026
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Vandvik PO, 2018, INTENS CARE MED, V44, P1738, DOI 10.1007/s00134-018-5338-y
   Villar J, 2006, CRIT CARE MED, V34, P1311, DOI 10.1097/01.CCM.0000215598.84885.01
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Walkey AJ, 2017, ANN AM THORAC SOC, V14, pS271, DOI 10.1513/AnnalsATS.201704-337OT
   Walkey AJ, 2017, ANN AM THORAC SOC, V14, pS297, DOI 10.1513/AnnalsATS.201704-338OT
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang T, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0289-y
   Wang YJW, 2020, EARLY LOW DOSE SHORT
   WHO, 2020, CLIN MAN SEV AC RESP
   Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564
   World Health O, 2020, INF CONS PRIOR CAND, P2020
   Wu Guobao, 1998, Hunan Yike Daxue Xuebao, V23, P57
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Wu JY, 2020, INFECT DIS THER, V9, P17, DOI 10.1007/s40121-020-00286-6
   Wu X, 2020, EMERG INFECT DIS
   Wu Z, 2020, JAMA
   Xi XM, 2010, CHINESE MED J-PEKING, V123, P3100, DOI 10.3760/cma.j.issn.0366-6999.2010.21.027
   Xie CB, 2020, INT J INFECT DIS, V93, P264, DOI 10.1016/j.ijid.2020.02.050
   Xu XP, 2017, CRIT CARE MED, V45, pE727, DOI 10.1097/CCM.0000000000002361
   Yam LYC, 2003, RESPIROLOGY, V8, pS31, DOI 10.1046/j.1440-1843.2003.00521.x
   Yam WC, 2003, J CLIN MICROBIOL, V41, P4521, DOI 10.1128/JCM.41.10.4521-4524.2003
   Yang YL, 2013, CHINESE MED J-PEKING, V126, P1809, DOI 10.3760/cma.j.issn.0366-6999.20121880
   Yao X, 2020, CLIN INFECT DIS
   Yasuda H, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015091
   Yokota S, 2008, LANCET, V371, P998, DOI 10.1016/S0140-6736(08)60454-7
   Young P, 2015, NEW ENGL J MED, V373, P2215, DOI 10.1056/NEJMoa1508375
   Zayed Y, 2019, RESPIR MED CASE REP, V27, DOI 10.1016/j.rmcr.2019.100855
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 220
TC 537
Z9 555
U1 61
U2 89
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD JUN
PY 2020
VL 48
IS 6
BP E440
EP E469
DI 10.1097/CCM.0000000000004363
PG 30
WC Critical Care Medicine
SC General & Internal Medicine
GA LT5KJ
UT WOS:000537109200001
PM 32224769
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Eyal, N
   Lipsitch, M
   Smith, PG
AF Eyal, Nir
   Lipsitch, Marc
   Smith, Peter G.
TI Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE coronavirus; vaccines; human challenge studies; randomized controlled
   trials; risk-taking; ethics
AB Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines. By replacing conventional phase 3 testing of vaccine candidates, such trials may subtract many months from the licensure process, making efficacious vaccines available more quickly. Obviously, challenging volunteers with this live virus risks inducing severe disease and possibly even death. However, we argue that such studies, by accelerating vaccine evaluation, could reduce the global burden of coronavirus-related mortality and morbidity. Volunteers in such studies could autonomously authorize the risks to themselves, and their net risk could be acceptable if participants comprise healthy young adults, who are at relatively low risk of serious disease following natural infection, if they have a high baseline risk of natural infection, and if during the trial they receive frequent monitoring and, following any infection, the best available care.
C1 [Eyal, Nir] Rutgers State Univ, Ctr Populat Level Bioeth, 112 Paterson St, New Brunswick, NJ 08901 USA.
   [Eyal, Nir] Rutgers State Univ, Dept Philosophy, New Brunswick, NJ USA.
   [Eyal, Nir] Rutgers Sch Publ Hlth, Dept Hlth Behav Soc & Policy, Piscataway, NJ USA.
   [Lipsitch, Marc] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Ctr Communicable Dis Dynam, Boston, MA USA.
   [Lipsitch, Marc] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA.
   [Smith, Peter G.] London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London, England.
RP Eyal, N (corresponding author), Rutgers State Univ, Ctr Populat Level Bioeth, 112 Paterson St, New Brunswick, NJ 08901 USA.
EM nir.eyal@rutgers.edu
RI smith, peter/ABH-9627-2020
OI smith, peter/0000-0003-0080-7560; Lipsitch, Marc/0000-0003-1504-9213;
   Eyal, Nir/0000-0003-1056-6609
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI114617-01A1]; National Institute of General Medical SciencesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of General Medical Sciences
   (NIGMS) [U54GM088558]; Morris-Singer Foundation; Department of Health
   and Social Care; UK Department for International Development (DFID)
   under the MRC/DFID Concordat agreement; European Union (EDCTP2
   program)European Union (EU); UK Medical Research Council (MRC) under the
   MRC/DFID Concordat agreement; UK AidCGIAR
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases (grant number AI114617-01A1 to N. E.); National
   Institute of General Medical Sciences (grant number U54GM088558 to M.
   L.); M. L.'s work is supported by the Morris-Singer Foundation, and the
   Department of Health and Social Care with UK Aid funding managed by the
   National Institute for Health Research; P. G. S.'s work is partly funded
   by the UK Medical Research Council (MRC) and the UK Department for
   International Development (DFID) under the MRC/DFID Concordat agreement;
   and the European Union (EDCTP2 program).
CR [Anonymous], 2020, DRAFT LANDSC COVID 1
   Begley S., 2020, STATNEWS
   Bi Q, 2020, EPIDEMIOLOGY TRANSMI, DOI [10.1101/2020.03.03.20028423, DOI 10.1101/2020.03.03.20028423]
   Boodman E., 2020, STATNEWS
   Centers for Disease Control And Prevention, PEOPL WHO AR HIGH RI
   Cohen J., 2016, SCIENCE
   Eyal N, 2019, J INFECT DIS, V220, pS1, DOI 10.1093/infdis/jiz173
   Eyal N, 2018, CURR OPIN HIV AIDS, V13, P422, DOI 10.1097/COH.0000000000000489
   Ferguson NM, 2020, IMPACT NON PHARM INT, DOI [10.25561/77482/, DOI 10.25561/77482/]
   Miller FG, 2012, ETHICAL CHALLENGES H
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Sherman AC, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00107
   Spinney L, GUARDIAN
   Thombre AC, 2017, INT CONF COMPUT
   Walker P, 2020, GLOBAL IMPACT COVID, DOI [10.25561/77735, DOI 10.25561/77735]
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
NR 17
TC 57
Z9 58
U1 3
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 1
PY 2020
VL 221
IS 11
BP 1752
EP 1756
DI 10.1093/infdis/jiaa152
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA LU0MN
UT WOS:000537458000004
PM 32232474
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Muhovic, D
   Bojovic, J
   Bulatovic, A
   Vukcevic, B
   Ratkovic, M
   Lazovic, R
   Smolovic, B
AF Muhovic, Damir
   Bojovic, Jelena
   Bulatovic, Ana
   Vukcevic, Batric
   Ratkovic, Marina
   Lazovic, Ranko
   Smolovic, Brigita
TI First case of drug-induced liver injury associated with the use of
   tocilizumab in a patient with COVID-19
SO LIVER INTERNATIONAL
LA English
DT Article
DE COVID-19; drug-induced liver injury; hepatotoxicity; SARS-CoV-2;
   tocilizumab
AB Background and Aims Tocilizumab (TCZ; interleukine-6 receptor antagonist) has been proposed to treat severe forms of Coronavirus disease-19 (COVID-19) because interleukine-6 plays an important role in COVID-19-induced cytokine storm. Several clinical studies have shown very good effects of TCZ in patients with COVID-19, with a few minor side effects reported. Only eight serious liver injuries caused by TCZ were reported before being used in the treatment of patients with COVID-19. Considering the significantly increased use of TCZ for the treatment of COVID-19, we would like to warn of its rare but possible serious hepatotoxicity, especially when used together with other hepatotoxic drugs.
   Methods We describe a patient with COVID-19-induced cytokine storm who developed drug-induced liver injury associated with the use of TCZ.
   Results One day after TCZ administration, serum transaminase levels increased 40-fold. Nevertheless, TCZ had a positive effect on clinical and laboratory parameters in cytokine storm, with transaminases values normalizing in 10 days.
   Conclusions This is the first reported case of DILI caused by TCZ in a COVID-19 patient. Intensive liver function monitoring is imperative in COVID-19 patients, because of frequent polypharmacy with potentially hepatotoxic drugs.
C1 [Muhovic, Damir; Vukcevic, Batric; Ratkovic, Marina; Lazovic, Ranko; Smolovic, Brigita] Univ Montenegro, Fac Med, Podgorica, Montenegro.
   [Muhovic, Damir; Smolovic, Brigita] Clin Ctr Montenegro, Dept Gastroenterohepatol, Podgorica 20000, Montenegro.
   [Bojovic, Jelena] Clin Ctr Montenegro, Dept Pulmonol, Podgorica, Montenegro.
   [Bulatovic, Ana] Clin Ctr Montenegro, Dept Rheumatol, Podgorica, Montenegro.
RP Muhovic, D (corresponding author), Clin Ctr Montenegro, Dept Gastroenterohepatol, Podgorica 20000, Montenegro.
EM damir_muhovic@yahoo.com
RI Muhovic, Damir/AAU-3094-2020
OI Muhovic, Damir/0000-0002-0099-678X
CR Andrade RJ, 2019, J HEPATOL, V70, P1222, DOI 10.1016/j.jhep.2019.02.014
   [Anonymous], 2012, LIVERTOX CLIN RES IN
   Australian Government Department of Health, 2019, MED SAF UPS UPD TOC
   Cai QX, 2020, J HEPATOL, V73, P566, DOI 10.1016/j.jhep.2020.04.006
   DANAN G, 1993, J CLIN EPIDEMIOL, V46, P1323, DOI 10.1016/0895-4356(93)90101-6
   Di Giambenedetto S, 2020, J MED VIROL, V92, P1787, DOI 10.1002/jmv.25897
   Fontana F, 2020, AM J TRANSPLANT, V20, P1902, DOI 10.1111/ajt.15935
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Lombardy Section Italian Society Infectious And Tropical Diseases -, 2020, Infez Med, V28, P143
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Morrison AR, 2020, J MED VIROL, V92, P1791, DOI 10.1002/jmv.25907
   National Health Commission & State Administration of Traditional Chinese Medicine, 2020, DIAGN TREAT PROT NOV
   Sheppard M, 2017, HUM VACC IMMUNOTHER, V13, P1972, DOI 10.1080/21645515.2017.1316909
   Sun J, 2020, LIVER INT, V40, P1278, DOI 10.1111/liv.14470
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhao M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105982
NR 18
TC 8
Z9 8
U1 2
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1478-3223
EI 1478-3231
J9 LIVER INT
JI Liver Int.
PD AUG
PY 2020
VL 40
IS 8
BP 1901
EP 1905
DI 10.1111/liv.14516
EA JUN 2020
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA MN1CI
UT WOS:000536613000001
PM 32478465
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Mahmoudjafari, Z
   Alexander, M
   Roddy, J
   Shaw, R
   Shigle, TL
   Timlin, C
   Culos, K
AF Mahmoudjafari, Zahra
   Alexander, Maurice
   Roddy, Julianna
   Shaw, Ryan
   Shigle, Terri Lynn
   Timlin, Colleen
   Culos, Katie
TI American Society for Transplantation and Cellular Therapy Pharmacy
   Special Interest Group Position Statement on Pharmacy Practice
   Management and Clinical Management for COVID-19 in Hematopoietic Cell
   Transplantation and Cellular Therapy Patients in the United States
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE COVID-19; Coronavirus; Pharmacy; Pharmacist; HCT; Cellular therapy
ID HYDROXYCHLOROQUINE; CHLOROQUINE; GS-5734; EBOLA; SARS
AB The coronavirus-19 (COVID-19) pandemic poses a significant risk to patients undergoing hematopoietic stem cell transplantation (HCT) or cellular therapy. The American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Steering Committee aims to provide pharmacy practice management recommendations for how to transition clinical HCT or cellular therapy pharmacy services using telemedicine capabilities in the inpatient and outpatient settings to maintain an equivalent level of clinical practice while minimizing viral spread in a high-risk, immunocompromised population. In addition, the Steering Committee offers clinical management recommendations for COVID-19 in HCT and cellular therapy recipients based on the rapidly developing literature. As the therapeutic and supportive care interventions for COVID-19 expand, collaboration with clinical pharmacy providers is critical to ensure safe administration in HCT recipients. Attention to drug-drug interactions (DDIs) and toxicity, particularly QTc prolongation, warrants close cardiac monitoring and potential cessation of concomitant QTc-prolonging agents. Expanded indications for hydroxychloroquine and tocilizumab have already caused stress on the usual supply chain. Detailed prescribing algorithms, decision pathways, and specific patient population stock may be necessary. The COVID-19 pandemic has challenged all members of the healthcare team, and we must continue to remain vigilant in providing pharmacy clinical services to one of the most high-risk patient populations while also remaining committed to providing compassionate and safe care for patients undergoing HCT and cellular therapies. (C) 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
C1 [Mahmoudjafari, Zahra] Univ Kansas, Univ Kansas Hlth Syst, Canc Ctr, Div Pharm, Lawrence, KS 66045 USA.
   [Alexander, Maurice; Shaw, Ryan] Univ N Carolina, Div Pharm, Chapel Hill, NC 27515 USA.
   [Roddy, Julianna] Ohio State Univ, Arthur G James Canc Hosp, Div Pharm, Columbus, OH 43210 USA.
   [Shigle, Terri Lynn] Univ Texas MD Anderson Canc Ctr, Div Pharm, Houston, TX 77030 USA.
   [Timlin, Colleen] Hosp Univ Penn, Div Pharm, 3400 Spruce St, Philadelphia, PA 19104 USA.
   [Culos, Katie] Vanderbilt Univ, Med Ctr, Div Pharm, Nashville, TN USA.
RP Mahmoudjafari, Z (corresponding author), Univ Kansas, Canc Ctr, Univ Kansas Hlth Syst, Div Pharm, 2330 Shawnee Mission Pkwy,Mail Stop 5028, West Wood, KS 66205 USA.
EM zmahmoudjafari@kumc.edu
CR American Society of Transplantation and Cellular Therapy, INT GUID COVID 19 MA
   Anderson LA, 2020, GILEAD HALTS REMDESI
   [Anonymous], 2019, PRESCR INF
   Arabi YM, 2020, CLIN INFECT DIS, V70, P1837, DOI 10.1093/cid/ciz544
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Collins KP, 2018, J PHARMACOL EXP THER, V365, P447, DOI 10.1124/jpet.117.245639
   European Society for Blood and Marrow Transplantation (EBMT), 2020, COR DIS COVID 19 EBM
   FINIELZ P, 1993, NEPHRON, V65, P333, DOI 10.1159/000187506
   Foundation for the Accreditation of Cellular Therapy (FACT), 7 ED FACT JACIE INT
   GUSTAFSSON LL, 1983, BRIT J CLIN PHARMACO, V15, P471, DOI 10.1111/j.1365-2125.1983.tb01532.x
   Haagmans BL, 2006, ANTIVIR RES, V71, P397, DOI 10.1016/j.antiviral.2006.05.019
   Kim S, 2012, RHEUMATOL INT, V32, P2601, DOI 10.1007/s00296-012-2423-3
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liverpul drug interactions group, 2020, INT EXP COVID 19 THE
   McCreary EK, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofz538
   Mohammad S, 2018, ARTHRIT CARE RES, V70, P481, DOI 10.1002/acr.23296
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   NAMPOORY MRN, 1992, NEPHRON, V62, P108
   Pesko L, 1993, AM DRUGGIST, P207
   Projean D, 2003, DRUG METAB DISPOS, V31, P748, DOI 10.1124/dmd.31.6.748
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   TETT SE, 1988, BRIT J CLIN PHARMACO, V26, P303, DOI 10.1111/j.1365-2125.1988.tb05281.x
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wasko MCM, 2007, JAMA-J AM MED ASSOC, V298, P187, DOI 10.1001/jama.298.2.187
   World Health Organisation, 2019, 51 WHO
   Xu X, AXIV20200300026
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 38
TC 8
Z9 8
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD JUN
PY 2020
VL 26
IS 6
BP 1043
EP 1049
DI 10.1016/j.bbmt.2020.04.005
PG 7
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA LS1RJ
UT WOS:000536168600004
PM 32305359
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Baumann, BC
   Macarthur, KM
   Brewer, JD
   Mendenhall, WM
   Barker, CA
   Etzkorn, JR
   Jellinek, NJ
   Scott, JF
   Gay, HA
   Baumann, JC
   Manian, FA
   Devlin, PM
   Michalski, JM
   Lee, NY
   Thorstad, WL
   Wilson, LD
   Perez, CA
   Miller, CJ
AF Baumann, Brian C.
   Macarthur, Kelly M.
   Brewer, Jerry D.
   Mendenhall, William M.
   Barker, Christopher A.
   Etzkorn, Jeremy R.
   Jellinek, Nathaniel J.
   Scott, Jeffrey F.
   Gay, Hiram A.
   Baumann, John C.
   Manian, Farrin A.
   Devlin, Phillip M.
   Michalski, Jeff M.
   Lee, Nancy Y.
   Thorstad, Wade L.
   Wilson, Lynn D.
   Perez, Carlos A.
   Miller, Christopher J.
TI Management of primary skin cancer during a pandemic: Multidisciplinary
   recommendations
SO CANCER
LA English
DT Article
DE basal cell carcinoma; coronavirus disease 2019 (COVID-19); cutaneous
   squamous cell carcinoma; melanoma; Merkel cell carcinoma; Mohs surgery;
   radiotherapy; skin cancer; treatment delays
ID SQUAMOUS-CELL CARCINOMA; CUTANEOUS MALIGNANT-MELANOMA; AMERICAN JOINT
   COMMITTEE; PROGNOSTIC-FACTORS; RADIATION-THERAPY; RISK-FACTORS; DELAY;
   SURVIVAL; METASTASIS; RECURRENCE
AB During the coronavirus disease 2019 (COVID-19) pandemic, providers and patients must engage in shared decision making regarding the pros and cons of early versus delayed interventions for localized skin cancer. Patients at highest risk of COVID-19 complications are older; are immunosuppressed; and have diabetes, cancer, or cardiopulmonary disease, with multiple comorbidities associated with worse outcomes. Physicians must weigh the patient's risk of COVID-19 complications in the event of exposure against the risk of worse oncologic outcomes from delaying cancer therapy. Herein, the authors have summarized current data regarding the risk of COVID-19 complications and mortality based on age and comorbidities and have reviewed the literature assessing how treatment delays affect oncologic outcomes. They also have provided multidisciplinary recommendations regarding the timing of local therapy for early-stage skin cancers during this pandemic with input from experts at 11 different institutions. For patients with Merkel cell carcinoma, the authors recommend prioritizing treatment, but a short delay can be considered for patients with favorable T1 disease who are at higher risk of COVID-19 complications. For patients with melanoma, the authors recommend delaying the treatment of patients with T0 to T1 disease for 3 months if there is no macroscopic residual disease at the time of biopsy. Treatment of tumors >= T2 can be delayed for 3 months if the biopsy margins are negative. For patients with cutaneous squamous cell carcinoma, those with Brigham and Women's Hospital T1 to T2a disease can have their treatment delayed for 2 to 3 months unless there is rapid growth, symptomatic lesions, or the patient is immunocompromised. The treatment of tumors >= T2b should be prioritized, but a 1-month to 2-month delay is unlikely to worsen disease-specific mortality. For patients with squamous cell carcinoma in situ and basal cell carcinoma, treatment can be deferred for 3 months unless the individual is highly symptomatic.
C1 [Baumann, Brian C.; Gay, Hiram A.; Michalski, Jeff M.; Thorstad, Wade L.; Perez, Carlos A.] Washington Univ, Dept Radiat Oncol, St Louis, MO 63110 USA.
   [Baumann, Brian C.] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
   [Macarthur, Kelly M.] Washington Univ, Div Dermatol Surg, St Louis, MO 63110 USA.
   [Brewer, Jerry D.] Mayo Clin, Div Dermatol Surg, Rochester, MN USA.
   [Mendenhall, William M.] Univ Florida, Dept Radiat Oncol, Gainesville, FL USA.
   [Barker, Christopher A.; Lee, Nancy Y.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA.
   [Etzkorn, Jeremy R.; Miller, Christopher J.] Univ Penn, Dept Dermatol, Div Dermatol Surg, Philadelphia, PA 19104 USA.
   [Jellinek, Nathaniel J.] Dermatol Professionals Inc, East Greenwich, RI USA.
   [Jellinek, Nathaniel J.] Brown Univ, Dept Dermatol, Div Dermatol Surg, Providence, RI 02912 USA.
   [Jellinek, Nathaniel J.] Univ Massachusetts, Div Dermatol Surg, Dept Dermatol, Worcester, MA 01605 USA.
   [Scott, Jeffrey F.] Johns Hopkins Univ, Dept Dermatol, Div Dermatol Surg, Baltimore, MD USA.
   [Baumann, John C.] Princeton Radiat Oncol, Princeton, NJ USA.
   [Manian, Farrin A.] Harvard Univ, Dept Internal Med, Massachusetts Gen Hosp, Boston, MA 02115 USA.
   [Devlin, Phillip M.] Harvard Univ, Dept Radiat Oncol, Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Wilson, Lynn D.] Yale Univ, Dept Therapeut Radiol, New Haven, CT USA.
RP Macarthur, KM (corresponding author), Washington Univ, Barnes Jewish Hosp, Div Dermatol Surg, Sch Med, St Louis, MO 63110 USA.
EM MacarthurKellyM@wustl.edu
OI Baumann, Brian/0000-0002-7482-1413
CR Alam M, 2011, J AM ACAD DERMATOL, V64, P839, DOI 10.1016/j.jaad.2010.06.028
   American College of Mohs Surgery, 2020, AM COLL MOHS SURG CO
   Asgari MM, 2015, JAMA DERMATOL, V151, P976, DOI 10.1001/jamadermatol.2015.1188
   Baccard M, 1997, ANN DERMATOL VENER, V124, P601
   Basnet A, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.e21586
   Brantsch KD, 2008, LANCET ONCOL, V9, P713, DOI 10.1016/S1470-2045(08)70178-5
   British Association of Dermatologists, 2020, COVID 19 SKIN CANC S
   Buck DW, 2012, J AM ACAD DERMATOL, V67, P861, DOI 10.1016/j.jaad.2012.01.039
   CASSILETH BR, 1982, CANCER-AM CANCER SOC, V49, P198, DOI 10.1002/1097-0142(19820101)49:1<198::AID-CNCR2820490138>3.0.CO;2-9
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Cimbak N, 2016, INT J RADIAT ONCOL, V96, pS160, DOI 10.1016/j.ijrobp.2016.06.387
   Clayman GL, 2005, J CLIN ONCOL, V23, P759, DOI 10.1200/JCO.2005.02.155
   Conic RZ, 2018, J AM ACAD DERMATOL, V78, P40, DOI 10.1016/j.jaad.2017.08.039
   Connolly KL, 2017, J AM ACAD DERMATOL, V76, P344, DOI 10.1016/j.jaad.2016.10.007
   Cornejo C, 2019, DERMATOL CLIN, V37, P269, DOI 10.1016/j.det.2019.03.001
   Eide MJ, 2005, J INVEST DERMATOL, V124, P308, DOI 10.1111/j.0022-202X.2004.23546.x
   Eigentler TK, 2017, J INVEST DERMATOL, V137, P2309, DOI 10.1016/j.jid.2017.06.025
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Fields RC, 2012, CANCER-AM CANCER SOC, V118, P3311, DOI 10.1002/cncr.26626
   Fields RC, 2011, ANN SURG, V254, P465, DOI 10.1097/SLA.0b013e31822c5fc1
   Fischer-Valuck BW, 2019, CLIN TRANSL RAD ONCO, V15, P38, DOI 10.1016/j.ctro.2018.12.001
   Gershenwald JE, 2017, CA-CANCER J CLIN, V67, P472, DOI 10.3322/caac.21409
   Halperin EC, 2019, PEREZ BRADYS PRINCIP
   Harms KL, 2016, ANN SURG ONCOL, V23, P3564, DOI 10.1245/s10434-016-5266-4
   HEENAN PJ, 1982, AM J DERMATOPATH, V4, P477
   Italian Department of Health, REP CHAR DEC COVID 1
   Iyer JG, 2015, CANCER MED-US, V4, P1161, DOI 10.1002/cam4.458
   Karia PS, 2014, J CLIN ONCOL, V32, P327, DOI 10.1200/JCO.2012.48.5326
   Karia PS, 2013, J AM ACAD DERMATOL, V68, P957, DOI 10.1016/j.jaad.2012.11.037
   Kirkup ME, 1999, BRIT J DERMATOL, V141, P876, DOI 10.1046/j.1365-2133.1999.03111.x
   KRIGE JEJ, 1991, CANCER, V68, P2064, DOI 10.1002/1097-0142(19911101)68:9<2064::AID-CNCR2820680937>3.0.CO;2-3
   Lattanzi M, 2019, JNCI-J NATL CANCER I, V111, P180, DOI 10.1093/jnci/djy086
   Lee EH, 2015, J SKIN CANCER, V2015, DOI 10.1155/2015/953479
   Likhacheva A, 2020, PRACT RADIAT ONCOL, V10, P8, DOI 10.1016/j.prro.2019.10.014
   Locke J, 2001, INT J RADIAT ONCOL, V51, P748, DOI 10.1016/S0360-3016(01)01656-X
   McKenna DB, 2002, BRIT J DERMATOL, V147, P48, DOI 10.1046/j.1365-2133.2002.04815.x
   Mendenhall WM, 2018, ACTA ONCOL, V57, P320, DOI 10.1080/0284186X.2017.1349926
   Murphy CT, 2016, J CLIN ONCOL, V34, P169, DOI 10.1200/JCO.2015.61.5906
   National Comprehensive Cancer Network, 2020, NCCN SHORT TERM REC
   National Comprehensive Cancer Network, 2020, ADV STAT NONM SKIN C
   National Comprehensive Cancer Network, 2020, NAT COMPR CANC NETW
   Nghiem PT, 2016, NEW ENGL J MED, V374, P2542, DOI 10.1056/NEJMoa1603702
   Paulson KG, 2018, J AM ACAD DERMATOL, V78, P457, DOI 10.1016/j.jaad.2017.10.028
   Renzi C, 2010, J AM ACAD DERMATOL, V63, P404, DOI 10.1016/j.jaad.2009.09.044
   Ruiz ES, 2019, JAMA DERMATOL, V155, P819, DOI 10.1001/jamadermatol.2019.0032
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Tarantola TI, 2013, J AM ACAD DERMATOL, V68, P425, DOI 10.1016/j.jaad.2012.09.036
   TEMOSHOK L, 1984, CANCER, V54, P3048, DOI 10.1002/1097-0142(19841215)54:12<3048::AID-CNCR2820541239>3.0.CO;2-M
   TEMOSHOK L, 1985, J PSYCHOSOM RES, V29, P139, DOI 10.1016/0022-3999(85)90035-2
   Thompson AK, 2016, JAMA DERMATOL, V152, P419, DOI 10.1001/jamadermatol.2015.4994
   Tsang G, 2004, Australas Radiol, V48, P371, DOI 10.1111/j.0004-8461.2004.01321.x
   Venables ZC, 2019, JAMA DERMATOL, V155, P298, DOI 10.1001/jamadermatol.2018.4219
   Wehner MR, 2018, BRIT J DERMATOL, V179, P767, DOI 10.1111/bjd.16730
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 54
TC 4
Z9 4
U1 3
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD SEP 1
PY 2020
VL 126
IS 17
BP 3900
EP 3906
DI 10.1002/cncr.32969
EA JUN 2020
PG 7
WC Oncology
SC Oncology
GA MX1VA
UT WOS:000536669500001
PM 32478867
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Al-Kofahi, M
   Jacobson, P
   Boulware, DR
   Matas, A
   Kandaswamy, R
   Jaber, MM
   Rajasingham, R
   Young, JAH
   Nicol, MR
AF Al-Kofahi, Mahmoud
   Jacobson, Pamala
   Boulware, David R.
   Matas, Arthur
   Kandaswamy, Raja
   Jaber, Mutaz M.
   Rajasingham, Radha
   Young, Jo-Anne H.
   Nicol, Melanie R.
TI Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The
   Desperate Search for Effectiveness
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID PROTEIN-BINDING
AB Hydroxychloroquine is an antimalarial drug being tested as a potential treatment for the novel coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2. Although the efficacy of hydroxychloroquine for COVID-19 remains uncertain, it may serve as a potential prophylactic agent especially in those at high risk, such as healthcare workers, household contacts of infected patients, and the immunocompromised. Our aim was to identify possible hydroxychloroquine dosing regimens through simulation in those at high risk of infections by optimizing exposures above the in vitro generated half maximal effective concentration (EC50) and to help guide researchers in dose-selection for COVID-19 prophylactic studies. To maintain weekly troughs above EC50 in > 50% of subjects at steady-state in a pre-exposure prophylaxis setting, an 800 mg loading dose followed by 400 mg twice or 3 times weekly is required. In an exposure driven, post-exposure prophylaxis setting, 800 mg loading dose followed in 6 hours by 600 mg, then 600 mg daily for 4 more days achieved daily troughs above EC50 in > 50% subjects. These doses are higher than recommended for malaria chemoprophylaxis, and clinical trials are needed to establish safety and efficacy.
C1 [Al-Kofahi, Mahmoud; Jacobson, Pamala; Jaber, Mutaz M.; Nicol, Melanie R.] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA.
   [Boulware, David R.; Rajasingham, Radha; Young, Jo-Anne H.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA.
   [Matas, Arthur; Kandaswamy, Raja] Univ Minnesota, Sch Med, Dept Surg, Minneapolis, MN 55455 USA.
RP Nicol, MR (corresponding author), Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA.
EM mrnicol@umn.edu
RI ; Young, Jo-Anne/G-2617-2013
OI Boulware, David/0000-0002-4715-0060; Al-Kofahi,
   Mahmoud/0000-0002-5458-0712; Young, Jo-Anne/0000-0003-4182-341X; Jaber,
   Mutaz/0000-0002-7536-8753; Nicol, Melanie R/0000-0001-5513-5509
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI140303, U01AI125003] Funding Source: Medline; NIAID NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [K23 AI138851, K08 AI134262, K08 AI134262] Funding
   Source: Medline
CR Al-Rawi H, 2018, LUPUS, V27, P847, DOI 10.1177/0961203317727601
   [Anonymous], 2020, REPORT WHO CHINA JOI
   Chen J., J ZHEJIANG U MED SCI
   Chhonker YS, 2018, J CHROMATOGR B, V1072, P320, DOI 10.1016/j.jchromb.2017.11.026
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Garcia-Cremades M, 2020, CLIN PHARMACOL THER, V108, P253, DOI 10.1002/cpt.1856
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   MCLACHLAN AJ, 1993, EUR J CLIN PHARMACOL, V44, P481, DOI 10.1007/BF00315548
   Perinel Sophie, 2020, Clin Infect Dis, V71, P2227, DOI 10.1093/cid/ciaa394
   Warhurst DC, 2003, J ANTIMICROB CHEMOTH, V52, P188, DOI 10.1093/jac/dkg319
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zeitlinger MA, 2011, ANTIMICROB AGENTS CH, V55, P3067, DOI 10.1128/AAC.01433-10
NR 14
TC 18
Z9 18
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD OCT
PY 2020
VL 108
IS 4
BP 766
EP 769
DI 10.1002/cpt.1874
EA JUN 2020
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NQ3JW
UT WOS:000536680800001
PM 32344449
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Paneesha, S
   Pratt, G
   Parry, H
   Moss, P
AF Paneesha, S.
   Pratt, G.
   Parry, H.
   Moss, P.
TI Covid-19 infection in therapy-naive patients with B-cell chronic
   lymphocytic leukemia
SO LEUKEMIA RESEARCH
LA English
DT Letter
C1 [Paneesha, S.; Pratt, G.; Parry, H.; Moss, P.] Univ Hosp Birmingham NHS Fdn Trust, Birmingham Hlth Partners, Birmingham, W Midlands, England.
   [Paneesha, S.; Pratt, G.; Parry, H.; Moss, P.] Univ Birmingham, Birmingham, W Midlands, England.
RP Moss, P (corresponding author), Univ Hosp Birmingham NHS Fdn Trust, Birmingham Hlth Partners, Birmingham, W Midlands, England.; Moss, P (corresponding author), Univ Birmingham, Birmingham, W Midlands, England.
EM p.moss@bham.ac.uk
RI Moss, Paul/D-1728-2009
OI Moss, Paul/0000-0002-6895-1967
CR ELLARD R, 2019, LANCET INFECT DIS, V30
   Forconi F, 2015, BLOOD, V126, P573, DOI 10.1182/blood-2015-03-567388
   Henry B.M., 2020, CLIN CHEM LAB MED
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin XH, 2020, LANCET HAEMATOL, V7, pE351, DOI 10.1016/S2352-3026(20)30074-0
   Strati P, 2015, BLOOD, V126, P454, DOI 10.1182/blood-2015-02-585059
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Treon S.P., 2020, BLOOD
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 9
TC 9
Z9 9
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0145-2126
EI 1873-5835
J9 LEUKEMIA RES
JI Leuk. Res.
PD JUN
PY 2020
VL 93
AR 106366
DI 10.1016/j.leukres.2020.106366
PG 3
WC Oncology; Hematology
SC Oncology; Hematology
GA LS5NI
UT WOS:000536430300004
PM 32388230
OA Green Published
DA 2021-01-01
ER

PT J
AU Zhang, HP
   Saravanan, KM
   Yang, Y
   Hossain, MT
   Li, JX
   Ren, XH
   Pan, Y
   Wei, YJ
AF Zhang, Haiping
   Saravanan, Konda Mani
   Yang, Yang
   Hossain, Md Tofazzal
   Li, Junxin
   Ren, Xiaohu
   Pan, Yi
   Wei, Yanjie
TI Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov
SO INTERDISCIPLINARY SCIENCES-COMPUTATIONAL LIFE SCIENCES
LA English
DT Article
DE Coronavirus; Deep learning; Drug screening; Homology modeling; 3C-like
   protease
ID PROTEIN; OUTBREAK
AB A novel coronavirus, called 2019-nCoV, was recently found in Wuhan, Hubei Province of China, and now is spreading across China and other parts of the world. Although there are some drugs to treat 2019-nCoV, there is no proper scientific evidence about its activity on the virus. It is of high significance to develop a drug that can combat the virus effectively to save valuable human lives. It usually takes a much longer time to develop a drug using traditional methods. For 2019-nCoV, it is now better to rely on some alternative methods such as deep learning to develop drugs that can combat such a disease effectively since 2019-nCoV is highly homologous to SARS-CoV. In the present work, we first collected virus RNA sequences of 18 patients reported to have 2019-nCoV from the public domain database, translated the RNA into protein sequences, and performed multiple sequence alignment. After a careful literature survey and sequence analysis, 3C-like protease is considered to be a major therapeutic target and we built a protein 3D model of 3C-like protease using homology modeling. Relying on the structural model, we used a pipeline to perform large scale virtual screening by using a deep learning based method to accurately rank/identify protein-ligand interacting pairs developed recently in our group. Our model identified potential drugs for 2019-nCoV 3C-like protease by performing drug screening against four chemical compound databases (Chimdiv, Targetmol-Approved_Drug_Library, Targetmol-Natural_Compound_Library, and Targetmol-Bioactive_Compound_Library) and a database of tripeptides. Through this paper, we provided the list of possible chemical ligands (Meglumine, Vidarabine, Adenosine, d-Sorbitol, d-Mannitol, Sodium_gluconate, Ganciclovir and Chlorobutanol) and peptide drugs (combination of isoleucine, lysine and proline) from the databases to guide the experimental scientists and validate the molecules which can combat the virus in a shorter time.
C1 [Zhang, Haiping; Saravanan, Konda Mani; Hossain, Md Tofazzal; Wei, Yanjie] Chinese Acad Sci, Ctr High Performance Comp, Joint Engn Res Ctr Hlth Big Data Intelligent Anal, Shenzhen Inst Adv Technol, Shenzhen 518055, Guangdong, Peoples R China.
   [Yang, Yang] Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Hosp 2,State Key Discipline Infect Dis, Shenzhen Key Lab Pathogen & Immun,Guangdong Key L, Shenzhen 518112, Peoples R China.
   [Li, Junxin] Univ City Shenzhen, Chinese Acad Sci, Inst Biomed & Biotechnol, Shenzhen Lab Human Antibody Engn,Shenzhen Inst Ad, 1068 Xueyuan Blvd, Shenzhen 518055, Peoples R China.
   [Ren, Xiaohu] Shenzhen Ctr Dis Control & Prevent, Inst Toxicol, 8 Longyuan Rd, Shenzhen 518055, Peoples R China.
   [Pan, Yi] Georgia State Univ, Dept Comp Sci, Atlanta, GA 30302 USA.
   [Hossain, Md Tofazzal] Univ Chinese Acad Sci, 19 A Yuquan Rd, Beijing 100049, Peoples R China.
RP Wei, YJ (corresponding author), Chinese Acad Sci, Ctr High Performance Comp, Joint Engn Res Ctr Hlth Big Data Intelligent Anal, Shenzhen Inst Adv Technol, Shenzhen 518055, Guangdong, Peoples R China.
EM yj.wei@siat.ac.cn
RI KM, Saravanan K/G-3121-2014; Saravanan, Konda Mani/AAH-3960-2019
OI KM, Saravanan K/0000-0002-5541-234X; Saravanan, Konda
   Mani/0000-0002-5541-234X
FU National Key Research and Development Program of China [2018YFB0204403,
   2016YFB0201305]; National Science Foundation of ChinaNational Natural
   Science Foundation of China (NSFC) [U1813203, 61433012]; National
   Natural Youth Science Foundation of China [31601028]; Shenzhen Basic
   Research Fund [JCYJ20180507182818013, GGFW2017073114031767,
   JCYJ20170413093358429]; China Postdoctoral Science FoundationChina
   Postdoctoral Science Foundation [2019M653132]; CAS Key Lab
   [2011DP173015]; Shenzhen Discipline Construction Project for Urban
   Computing and Data Intelligence, Youth Innovation Promotion Association,
   CAS
FX This work was partly supported by the National Key Research and
   Development Program of China under Grant Nos. 2018YFB0204403 and
   2016YFB0201305, National Science Foundation of China under Grant no.
   U1813203 and 61433012; the National Natural Youth Science Foundation of
   China (Grant No. 31601028), the Shenzhen Basic Research Fund under Grant
   Nos. JCYJ20180507182818013, GGFW2017073114031767 and
   JCYJ20170413093358429, the China Postdoctoral Science Foundation under
   Grant No. 2019M653132, CAS Key Lab under Grant No. 2011DP173015. We
   would also like to thank the funding support by the Shenzhen Discipline
   Construction Project for Urban Computing and Data Intelligence, Youth
   Innovation Promotion Association, CAS to Yanjie Wei.
CR Accelrys: Materials Studio is a Software Environment for Molecular Modeling, 2009, ACC MAT STUD SOFTW E, DOI [10.1007/s10822-010-9395-8, DOI 10.1007/S10822-010-9395-8]
   Benkert P, 2008, PROTEINS, V71, P261, DOI 10.1002/prot.21715
   Chen HM, 2018, DRUG DISCOV TODAY, V23, P1241, DOI 10.1016/j.drudis.2018.01.039
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Ekins S, 2019, NAT MATER, V18, P435, DOI 10.1038/s41563-019-0338-z
   Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8
   Fleming N, 2018, NATURE, V557, pS55, DOI 10.1038/d41586-018-05267-x
   Goetz DH, 2007, BIOCHEMISTRY-US, V46, P8744, DOI 10.1021/bi0621415
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jaeger S, 2018, J CHEM INF MODEL, V58, P27, DOI 10.1021/acs.jcim.7b00616
   Kim Y, 2012, J VIROL, V86, P11754, DOI 10.1128/JVI.01348-12
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Liu ZH, 2015, BIOINFORMATICS, V31, P405, DOI 10.1093/bioinformatics/btu626
   Liu ZH, 2019, DATABASE-OXFORD, DOI 10.1093/database/baz104
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Santos S, 2012, BIOPOLYMERS, V98, P288, DOI 10.1002/bip.22067
   Saravanan KM, 2012, BIOPOLYMERS, V98, P11, DOI 10.1002/bip.21676
   Saravanan KM, 2018, J BIOMOL STRUCT DYN, V36, P4338, DOI 10.1080/07391102.2017.1415822
   Shen MY, 2006, PROTEIN SCI, V15, P2507, DOI 10.1110/ps.062416606
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Sievers F, 2018, PROTEIN SCI, V27, P135, DOI 10.1002/pro.3290
   Thompson R, 2020, LANCET INFECT DIS, V20, P280, DOI 10.1016/S1473-3099(20)30068-2
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wendler J, 2018, GASTROENTEROLOGY, V154, pS1040
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Zhang HP, 2019, PEERJ, V7, DOI 10.7717/peerj.7362
   Zhang HP, 2019, METHODS, V166, P57, DOI 10.1016/j.ymeth.2019.03.012
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 31
TC 7
Z9 7
U1 8
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1913-2751
EI 1867-1462
J9 INTERDISCIP SCI
JI Interdiscip. Sci.
PD SEP
PY 2020
VL 12
IS 3
BP 368
EP 376
DI 10.1007/s12539-020-00376-6
EA JUN 2020
PG 9
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA MW5OI
UT WOS:000537395500001
PM 32488835
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Yu, JJ
   Zhang, T
   Zhao, D
   Haapasalo, M
   Shen, Y
AF Yu, Jingjing
   Zhang, Tian
   Zhao, Dan
   Haapasalo, Markus
   Shen, Ya
TI Characteristics of Endodontic Emergencies during Coronavirus Disease
   2019 Outbreak in Wuhan
SO JOURNAL OF ENDODONTICS
LA English
DT Article
DE Coronavirus disease 19 outbreak; endodontic emergency; epidemiologic
   investigation; verbal numerical rating scale; vital pulp therapy
ID MINERAL TRIOXIDE AGGREGATE; ACUTE RESPIRATORY SYNDROME; MATURE PERMANENT
   TEETH; DENTAL-CARE; PULPOTOMY; VISITS; PAIN
AB Introduction: In late 2019, an outbreak of a new coronavirus named severe acute respiratory syndrome coronavirus 2 was detected in Wuhan, China. A great percentage of patients with this disease developed symptoms of dry cough, malaise, and a high fever. During this time, several patients requiring assessment and treatment of endodontic emergencies were directed to the School and Hospital of Stomatology at Wuhan University, Wuhan, China. We examined the characteristics of these patients. Methods: A total of 96 patients with a mean age of 42.24 6 18.32 years visited the general and emergency department of the School and Hospital of Stomatology at Wuhan University because of endodontic emergencies during the peak period of February 22 to March 2, 2020. Patient information was collected and organized by date of visit, sex, age, and systemic disease history. Body temperature was measured and acquired for each patient, a coronavirus disease 2019 (COVID-19) epidemiologic investigation questionnaire was given to each patient, an endodontic diagnosis was determined for the offending tooth, and a verbal numerical rating scale (VNRS) was used to record pain levels. Results: Of the total patient visits during this period, 50.26% of visits were for endodontic treatment. No patients had a fever (>37.2 degrees C). One patient with a confirmed COVID-19 history was admitted after recovery. Three admitted patients had been exposed to confirmed or suspected COVID-19 patients. Twelve admitted patients (12.5%) with a mean age of 62.426 13.77 years had a history of systemic diseases. The most common age group for endodontic emergencies was 45-64 years (30.21%), and patients of this group showed a significantly higher mean VNRS score compared with that of the 6- to 19-year age group and the 20- to 34-year age group (P<.05). The majority of endodontic emergency diagnoses were diseases of symptomatic irreversible pulpitis (53.10%). Patients who were diagnosed with symptomatic irreversible pulpitis, symptomatic apical periodontitis, and acute apical abscess showed a significantly higher mean VNRS score than that of other groups (P<.05). Conclusions: Endodontic emergencies, with symptomatic irreversible pulpitis being the most common, consist of a much higher proportion of dental emergencies in a COVID-19 high-risk area than normally. Vital pulp therapy can advantageously reduce treatment time, resulting in a reduced risk of infection for vital pulp cases. Rubber dams, personal protective equipment, and patient screening are of great importance during the COVID-19 outbreak in protecting clinicians.
C1 [Yu, Jingjing; Zhao, Dan] Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Minist Educ, Sch & Hosp Stomatol, Luoyu Rd 237, Wuhan 430079, Hubei, Peoples R China.
   [Yu, Jingjing; Zhao, Dan] Wuhan Univ, Key Lab Oral Biomed, Minist Educ, Sch & Hosp Stomatol, Luoyu Rd 237, Wuhan 430079, Hubei, Peoples R China.
   [Zhang, Tian; Haapasalo, Markus; Shen, Ya] Univ British Columbia, Fac Dent, Dept Oral Biol & Med Sci, Div Endodont, Vancouver, BC, Canada.
   [Zhao, Dan] Wuhan Univ, Sch & Hosp Stomatol, Gen & Emergency Dept, Wuhan, Peoples R China.
RP Zhao, D (corresponding author), Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Minist Educ, Sch & Hosp Stomatol, Luoyu Rd 237, Wuhan 430079, Hubei, Peoples R China.; Zhao, D (corresponding author), Wuhan Univ, Key Lab Oral Biomed, Minist Educ, Sch & Hosp Stomatol, Luoyu Rd 237, Wuhan 430079, Hubei, Peoples R China.
EM wb00321@whu.edu.cn
RI Shen, Ya/X-5855-2019
OI , Ya/0000-0002-0792-4279
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81901000]
FX Supported by grants from the National Natural Science Foundation of
   China (grant no. 81901000).
CR Ather A, 2020, J ENDOD, V46
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Currie CC, 2017, J ORAL REHABIL, V44, P105, DOI 10.1111/joor.12462
   Davidson JRT, 2006, J CLIN PSYCHIAT, V67, P9
   Fan B, 2012, INT ENDOD J, V45, P1035, DOI 10.1111/j.1365-2591.2012.02070.x
   Glickman GN, 2009, J ENDODONT, V35, P1619, DOI 10.1016/j.joen.2009.09.029
   HASSELGREN G, 1989, J ENDODONT, V15, P254, DOI 10.1016/S0099-2399(89)80219-5
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang JY, 2019, J DENT SCI, V14, P395, DOI 10.1016/j.jds.2019.08.003
   Huang SM, 2019, J FORMOS MED ASSOC, V118, P582, DOI 10.1016/j.jfma.2018.11.012
   Kim Chihun, 2019, J Dent Anesth Pain Med, V19, P21, DOI 10.17245/jdapm.2019.19.1.21
   Kundzina R, 2017, INT ENDOD J, V50, P924, DOI 10.1111/iej.12719
   Kuzekanani M, 2018, J INT SOC PREV COMMU, V8, P386, DOI 10.4103/jispcd.JISPCD_225_18
   Lan L, 2020, JAMA-J AM MED ASSOC
   Liu L, 2011, J VIROL, V85, P4025, DOI 10.1128/JVI.02292-10
   Lu BJ, 2010, IMMUNOLOGY, V130, P254, DOI 10.1111/j.1365-2567.2010.03231.x
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M408
   McCarthy PJ, 2010, J ENDODONT, V36, P801, DOI 10.1016/j.joen.2009.12.035
   Meng L, 2020, J DENT RES, V99, P481, DOI 10.1177/0022034520914246
   National Health Commission of China, UPD EP SIT NEW COR P
   Qu X, 2020, CHIN J STOMATOL, V55
   Quinonez C, 2011, INT J DENT HYG, V9, P17, DOI 10.1111/j.1601-5037.2009.00416.x
   Quinonez C, 2009, COMMUNITY DENT ORAL, V37, P366, DOI 10.1111/j.1600-0528.2009.00476.x
   Sabino-Silva R, 2020, CLIN ORAL INVEST, V24, P1619, DOI 10.1007/s00784-020-03248-x
   Samaranayake LP, 2004, J AM DENT ASSOC, V135, P1292, DOI 10.14219/jada.archive.2004.0405
   SAMARANAYAKE LP, 1989, J DENT CHILD, V56, P442
   Smales FC, 2003, BRIT DENT J, V195, P557, DOI 10.1038/sj.bdj.4810723
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Taha NA, 2017, INT ENDOD J, V50, P117, DOI 10.1111/iej.12605
   Taha NA, 2017, J ENDODONT, V43, P1417, DOI 10.1016/j.joen.2017.03.033
   Verma S, 2014, AUST DENT J, V59, P329, DOI 10.1111/adj.12202
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 33
TC 12
Z9 14
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0099-2399
EI 1878-3554
J9 J ENDODONT
JI J. Endod.
PD JUN
PY 2020
VL 46
IS 6
BP 730
EP 735
DI 10.1016/j.joen.2020.04.001
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA LR7QT
UT WOS:000535891600003
PM 32360053
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Chen, XD
   Liu, YH
   Gong, YH
   Guo, XY
   Zuo, MZ
   Li, J
   Shi, WZ
   Li, H
   Xu, XH
   Mi, WD
   Huang, YG
AF Chen, Xiangdong
   Liu, Yanhong
   Gong, Yahong
   Guo, Xiangyang
   Zuo, Mingzhang
   Li, Jun
   Shi, Wenzhu
   Li, Hao
   Xu, Xiaohan
   Mi, Weidong
   Huang, Yuguang
TI Perioperative Management of Patients Infected with the Novel
   Coronavirus: Recommendation from the Joint Task Force of the Chinese
   Society of Anesthesiology and the Chinese Association of
   Anesthesiologists
SO ANESTHESIOLOGY
LA English
DT Article
AB The outbreak of the new Coronavirus disease, COVID-19, has been involved in 77,262 cases in China as well as in 27 other countries as of February 24, 2020. Because the virus is novel to human beings, and there is no vaccine yet available, every individual is susceptible and can become infected. Healthcare workers are at high risk, and unfortunately, more than 3,000 healthcare workers in China have been infected. Anesthesiologists are among healthcare workers who are at an even higher risk of becoming infected because of their close contact with infected patients and high potential of exposure to respiratory droplets or aerosol from their patients' airways. In order to provide healthcare workers with updated recommendations on the management of patients in the perioperative setting as well as for emergency airway management outside of the operating room, the two largest anesthesia societies, the Chinese Society of Anesthesiology (CSA) and the Chinese Association of Anesthesiologists (CAA) have formed a task force to produce the recommendations. The task force hopes to help healthcare workers, particularly anesthesiologists, optimize the care of their patients and protect patients, healthcare workers, and the public from becoming infected. The recommendations were created mainly based on the practice and experience of anesthesiologists who provide care to patients in China. Therefore, adoption of these recommendations outside of China must be done with caution, and the local environment, culture, uniqueness of the healthcare system, and patients' needs should be considered. The task force will continuously update the recommendations and incorporate new information in future versions.
C1 [Chen, Xiangdong] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Anesthesiol, Union Hosp, Wuhan, Peoples R China.
   [Liu, Yanhong; Shi, Wenzhu; Li, Hao; Mi, Weidong] Chinese Peoples Liberat Army Gen Hosp, Anesthesia & Operat Ctr, 28 Tuxing Rd, Beijing 100853, Peoples R China.
   [Gong, Yahong; Xu, Xiaohan; Huang, Yuguang] Chinese Acad Med Sci & Peking Union Med Coll Hosp, Dept Anesthesiol, Beijing, Peoples R China.
   [Guo, Xiangyang] Peking Univ, Dept Anesthesiol, Hosp 3, Beijing, Peoples R China.
   [Zuo, Mingzhang] Chinese Acad Med Sci, Inst Geriatr Med, Natl Ctr Gerontol, Dept Anesthesiol,Beijing Hosp, Beijing, Peoples R China.
   [Li, Jun] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 6, Dept Anesthesiol, Beijing, Peoples R China.
RP Mi, WD (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Anesthesia & Operat Ctr, 28 Tuxing Rd, Beijing 100853, Peoples R China.
EM wwdd1962@aliyun.com
CR [Anonymous], NAT REC DIAGN TREATM
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chen ZM, 2020, WORLD J PEDIATR, V16, P240, DOI 10.1007/s12519-020-00345-5
   Chinese Society of Anesthesiology Task Force on Airway Management, 2020, CHIN J ANESTHESIOL, P40
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Missair A, 2015, ANESTH ANALG, V121, P810, DOI 10.1213/ANE.0000000000000573
   Park J, 2020, SCI REP, V10, P1, DOI DOI 10.1038/S41598-019-56847-4
   Perioperative Infection Control Society of Chinese Society of Cardiothoracic and Vascular Anesthesia PLA Society of Anesthesiology and Resuscitation, 2020, PERIOPER SAF QUAL AS, V4, P63, DOI 10.3969/j.issn.2096-2681.2020.02.001
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Wax RS, 2020, CAN J ANAESTH, DOI [10.1007/s12630-020-01591-x., DOI 10.1007/S12630-020-01591-X.]
   World Health Organization, RAT US PERS PROT EQ
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 13
TC 63
Z9 65
U1 3
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD JUN
PY 2020
VL 132
IS 6
BP 1307
EP 1316
DI 10.1097/ALN.0000000000003301
PG 10
WC Anesthesiology
SC Anesthesiology
GA LP9LA
UT WOS:000534635800007
PM 32195699
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Meng, LZ
   Qiu, HB
   Wan, L
   Ai, YH
   Xue, ZG
   Guo, QL
   Deshpande, R
   Zhang, LN
   Meng, J
   Tong, CY
   Liu, H
   Xiong, LZ
AF Meng, Lingzhong
   Qiu, Haibo
   Wan, Li
   Ai, Yuhang
   Xue, Zhanggang
   Guo, Qulian
   Deshpande, Ranjit
   Zhang, Lina
   Meng, Jie
   Tong, Chuanyao
   Liu, Hong
   Xiong, Lize
TI Intubation and Ventilation amid the COVID-19 Outbreak: Wuhan's
   Experience
SO ANESTHESIOLOGY
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; EXTRACORPOREAL MEMBRANE-OXYGENATION;
   NONINVASIVE VENTILATION; MANAGEMENT; CORONAVIRUS; EMERGENCE; INFECTION;
   PREOXYGENATION; REMIFENTANIL; EXTUBATION
AB The COVID-19 outbreak has led to 80,409 diagnosed cases and 3,012 deaths in mainland China based on the data released on March 4, 2020. Approximately 3.2% of patients with COVID-19 required intubation and invasive ventilation at some point in the disease course. Providing best practices regarding intubation and ventilation for an overwhelming number of patients with COVID-19 amid an enhanced risk of cross-infection is a daunting undertaking. The authors presented the experience of caring for the critically ill patients with COVID-19 in Wuhan. It is extremely important to follow strict self-protection precautions. Timely, but not premature, intubation is crucial to counter a progressively enlarging oxygen debt despite high-flow oxygen therapy and bilevel positive airway pressure ventilation. Thorough preparation, satisfactory preoxygenation, modified rapid sequence induction, and rapid intubation using a video laryngoscope are widely used intubation strategies in Wuhan. Lung-protective ventilation, prone position ventilation, and adequate sedation and analgesia are essential components of ventilation management.
C1 [Meng, Lingzhong; Deshpande, Ranjit] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA.
   [Qiu, Haibo] Southeast Univ, Sch Med, Zhongda Hosp, Dept Crit Care Med, Nanjing, Jiangsu, Peoples R China.
   [Wan, Li] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Anesthesiol, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Ai, Yuhang; Zhang, Lina] Cent South Univ, Xiangya Hosp, Dept Crit Care Med, Changsha, Hunan, Peoples R China.
   [Guo, Qulian] Cent South Univ, Xiangya Hosp, Dept Anesthesiol, Changsha, Hunan, Peoples R China.
   [Meng, Jie] Cent South Univ, Xiangya Hosp, Dept Resp Med, Changsha, Hunan, Peoples R China.
   [Xue, Zhanggang] Fudan Univ, Zhongshan Hosp, Dept Anesthesiol, Shanghai, Peoples R China.
   [Tong, Chuanyao] Wake Forest Univ, Dept Anesthesiol, Winston Salem, NC 27101 USA.
   [Liu, Hong] Univ Calif Davis, Dept Anesthesiol & Pain Med, Sacramento, CA 95817 USA.
   [Xiong, Lize] Tongji Univ, Sch Med, Dept Anesthesiol & Perioperat Med, Shanghai Peoples Hosp 4, Shanghai 200081, Peoples R China.
RP Xiong, LZ (corresponding author), Tongji Univ, Sch Med, Dept Anesthesiol & Perioperat Med, Shanghai Peoples Hosp 4, Shanghai 200081, Peoples R China.
EM mzkxlz@126.com
RI Meng, Lingzhong/ABG-8186-2020
OI Meng, Lingzhong/0000-0002-5168-5084
FU Ministry of Science and Technology of the People's Republic of China
   (Beijing, China)Ministry of Science and Technology, China
   [2020YLC0843700]
FX This work was supported. in part, by research grant Ni. 2020YLC0843700
   from the Ministry of Science and Technology of the People's Republic of
   China (Beijing, China: to Dr. I laitio Qua). It was also supported by
   institutional and departmental sources with which the authors are
   affiliated.
CR Al-Dorzi HM, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1234-4
   Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639
   Aretha D, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/1035730
   Baillard C, 2018, BRIT J ANAESTH, V120, P361, DOI 10.1016/j.bja.2017.11.067
   Baillard C, 2006, AM J RESP CRIT CARE, V174, P171, DOI 10.1164/rccm.200509-1507OC
   BIDWAI AV, 1979, ANESTHESIOLOGY, V51, P171, DOI 10.1097/00000542-197908000-00020
   Bloomfield R, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008095.pub2
   BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Caputo KM, 2006, CAN J ANAESTH, V53, P122, DOI 10.1007/BF03021815
   Chacko B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008807.pub2
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Combes A, 2018, NEW ENGL J MED, V378, P1965, DOI 10.1056/NEJMoa1800385
   Cui Y, 2020, RESPIRATION, V99, P264, DOI 10.1159/000501045
   Davies A, 2009, JAMA-J AM MED ASSOC, V302, P1888, DOI 10.1001/jama.2009.1535
   Demirkaya M, 2012, J CLIN ANESTH, V24, P392, DOI 10.1016/j.jclinane.2011.11.006
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Goligher EC, 2018, JAMA-J AM MED ASSOC, V320, P2251, DOI 10.1001/jama.2018.14276
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Guery B, 2013, LANCET, V381, P2265, DOI 10.1016/S0140-6736(13)60982-4
   Heuer JF, 2013, GMS HYG INFECT CONTR, V8, DOI 10.3205/dgkh000209
   Ho ATN, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-0431-z
   Hodgson C, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006667.pub3
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kallet Richard H, 2005, Respir Care, V50, P1623
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Kilinc FS, 2015, J ENG FIBER FABR, V10, P180
   Kim SY, 2013, BRIT J ANAESTH, V111, P222, DOI 10.1093/bja/aet056
   Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093
   Mao L., 2020, NEUROLOGICAL MANIFES, DOI [10.1101/2020.02.22.20026500., 10.1101/2020.02.22.20026500, DOI 10.1101/2020.02.22.20026500]
   Marini JJ, 2004, CRIT CARE MED, V32, P250, DOI 10.1097/01.CCM.0000104946.66723.A8
   Martin-Loeches I, 2011, INTENS CARE MED, V37, P272, DOI 10.1007/s00134-010-2078-z
   McCracken J, 2009, CAN MED ASSOC J, V181, P663, DOI 10.1503/cmaj.081987
   MENDEL P, 1995, J CLIN ANESTH, V7, P114, DOI 10.1016/0952-8180(94)00024-X
   Moss M, 2019, NEW ENGL J MED, V380, P1997, DOI 10.1056/NEJMoa1901686
   Munshi L, 2017, ANN AM THORAC SOC, V14, pS280, DOI 10.1513/AnnalsATS.201704-343OT
   Nho JS, 2009, BRIT J ANAESTH, V103, P817, DOI 10.1093/bja/aep307
   Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372
   PARKER JC, 1993, CRIT CARE MED, V21, P131, DOI 10.1097/00003246-199301000-00024
   Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2
   Petrucci N, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003844.pub4
   Ramsey CD, 2010, CRIT CARE MED, V38, pE58, DOI 10.1097/CCM.0b013e3181cde600
   Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6
   Rodrigo C, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010406.pub2
   SHOEMAKER WC, 1992, CHEST, V102, P208, DOI 10.1378/chest.102.1.208
   Sud S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004085.pub4
   Sweeney AM, 2005, CRIT CARE MED, V33, P204
   Taccone P, 2009, JAMA-J AM MED ASSOC, V302, P1977, DOI 10.1001/jama.2009.1614
   Venkatesan T, 2006, J NEUROSURG ANESTH, V18, P230, DOI 10.1097/00008506-200610000-00002
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009946.pub2
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xie H, 2018, WORLD J EMERG MED, V9, P118, DOI 10.5847/wjem.j.1920-8642.2018.02.006
   Xie JF, 2020, INTENS CARE MED, V46, P837, DOI 10.1007/s00134-020-05979-7
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   YUKIOK H, 1993, ANESTH ANALG, V77, P309, DOI 10.1213/00000539-199377020-00016
   Zuo Mingzhang, 2020, Chinese Medical Sciences Journal, V35, P105, DOI 10.24920/003724
NR 62
TC 128
Z9 130
U1 12
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD JUN
PY 2020
VL 132
IS 6
BP 1317
EP 1332
DI 10.1097/ALN.0000000000003296
PG 16
WC Anesthesiology
SC Anesthesiology
GA LP9LA
UT WOS:000534635800008
PM 32195705
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zhang, HF
   Bo, LL
   Lin, Y
   Li, FX
   Sun, SJ
   Lin, HB
   Xu, SY
   Bian, JJ
   Yao, SL
   Chen, XD
   Meng, LZ
   Deng, XM
AF Zhang, Hong-Fei
   Bo, Lulong
   Lin, Yun
   Li, Feng-Xian
   Sun, Shujun
   Lin, Hong-Bin
   Xu, Shi-Yuan
   Bian, Jinjun
   Yao, Shanglong
   Chen, Xiangdong
   Meng, Lingzhong
   Deng, Xiaoming
TI Response of Chinese Anesthesiologists to the COVID-19 Outbreak
SO ANESTHESIOLOGY
LA English
DT Article
ID CORONAVIRUS
AB The coronavirus disease 2019, named COVID-19 officially by the World Health Organization (Geneva, Switzerland) on February 12, 2020, has spread at unprecedented speed. After the first outbreak in Wuhan, China, Chinese anesthesiologists encountered increasing numbers of infected patients since December 2019. Because the main route of transmission is via respiratory droplets and close contact, anesthesia providers are at a high risk when responding to the devastating mass emergency. So far, actions have been taken including but not limited to nationwide actions and online education regarding special procedures of airway management, oxygen therapy, ventilation support, hemodynamic management, sedation, and analgesia. As the epidemic situation has lasted for months (thus far), special platforms have also been set up to provide free mental health care to all anesthesia providers participating in acute and critical caring for COVID-19 patients. The current article documents the actions taken, lesson learned, and future work needed.
C1 [Zhang, Hong-Fei; Li, Feng-Xian; Lin, Hong-Bin; Xu, Shi-Yuan] Southern Med Univ, Dept Anesthesiol, Zhujiang Hosp, Guangzhou, Peoples R China.
   [Bo, Lulong; Bian, Jinjun; Deng, Xiaoming] Naval Med Univ, Changhai Hosp, Fac Anesthesiol, Shanghai, Peoples R China.
   [Lin, Yun; Sun, Shujun; Yao, Shanglong; Chen, Xiangdong] Huazhong Univ Sci & Technol, Inst Anesthesiol & Crit Care Med, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China.
   [Meng, Lingzhong] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA.
RP Deng, XM (corresponding author), Naval Med Univ, Changhai Hosp, Shanghai 200433, Peoples R China.
EM deng_x@yahoo.com
RI Meng, Lingzhong/ABG-8186-2020
OI Meng, Lingzhong/0000-0002-5168-5084; zhang, hongfei/0000-0001-7558-4934
CR Chen X., 2020, TRANSL PERIOPER PAIN, V15, P216
   Chen ZL, 2020, CHINESE MED J-PEKING, V133, P1112, DOI 10.1097/CM9.0000000000000776
   Chinese Society of Anesthesiology, LETT HEADS AN DEP CH
   CSA Pediatric Anesthesiology Task Force and CSA Youth Committee, 2020, CHIN J ANESTHESIOL, DOI [10.3760/cma.j.issn.0254-1416.2020.0005, DOI 10.3760/CMA.J.ISSN.0254-1416.2020.0005]
   CSA Task Force on Airway Management, 2020, CHIN J ANESTHESIOL, DOI [10.3760/cma.j.issn.0254-1416.2020.02.003, DOI 10.3760/CMA.J.ISSN.0254-1416.2020.02.003]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, DOI 10.46234/ccdcw2020.032
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   WHO, SUMM PROB SARS CAS O
   World Health Organization, COR DIS COVID 19 OUT
   World Health Organization, MENT HLTH CAR PLATF
   World Health Organization, NOV COR COVID 19 SIT
   World Health Organization, AN EXP ONL Q A FOR
   World Health Organization, COR FIGHT RAC DEATH
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xinhua News Agency, XINHUA NEWS AGENCY
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 20
TC 18
Z9 19
U1 3
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD JUN
PY 2020
VL 132
IS 6
BP 1333
EP 1338
DI 10.1097/ALN.0000000000003300
PG 6
WC Anesthesiology
SC Anesthesiology
GA LP9LA
UT WOS:000534635800009
PM 32195704
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Greenland, JR
   Michelow, MD
   Wang, LL
   London, MJ
AF Greenland, John R.
   Michelow, Marilyn D.
   Wang, Linlin
   London, Martin J.
TI COVID-19 Infection: Implications for Perioperative and Critical Care
   Physicians
SO ANESTHESIOLOGY
LA English
DT Article
ID FLOW NASAL CANNULA; CORONAVIRUS PNEUMONIA; RESPIRATORY-FAILURE;
   IMMUNE-RESPONSE; OXYGEN-THERAPY; ILL PATIENTS; SARS; RECEPTOR; ACE2;
   VENTILATION
AB Healthcare systems worldwide are responding to Coronavirus Disease 2019 (COVID-19), an emerging infectious syndrome caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. Patients with COVID-19 can progress from asymptomatic or mild illness to hypoxemic respiratory failure or multisystem organ failure, necessitating intubation and intensive care management. Healthcare providers, and particularly anesthesiologists, are at the frontline of this epidemic, and they need to be aware of the best available evidence to guide therapeutic management of patients with COVID-19 and to keep themselves safe while doing so. Here, the authors review COVID-19 pathogenesis, presentation, diagnosis, and potential therapeutics, with a focus on management of COVID-19-associated respiratory failure. The authors draw on literature from other viral epidemics, treatment of acute respiratory distress syndrome, and recent publications on COVID-19, as well as guidelines from major health organizations. This review provides a comprehensive summary of the evidence currently available to guide management of critically ill patients with COVID-19.
C1 [Greenland, John R.] San Francisco Vet Adm Hlth Care Syst, Pulm & Crit Care Med, San Francisco, CA USA.
   [Michelow, Marilyn D.; London, Martin J.] San Francisco Vet Adm Hlth Care Syst, Anesthesia & Perioperat Care, San Francisco, CA USA.
   [Wang, Linlin] Univ Calif San Francisco, Lab Med, San Francisco, CA 94143 USA.
   [Greenland, John R.; Michelow, Marilyn D.; London, Martin J.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Greenland, JR (corresponding author), 4150 Clement St,Box 111D, San Francisco, CA 94121 USA.
EM john.greenland@ucsf.edu
OI Greenland, John/0000-0003-1422-8367
FU CSRD VA [IK2 CX001034] Funding Source: Medline
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Alshahrani MS, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-017-0350-x
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Basarakodu Krishnamohan R, 2007, Am J Ther, V14, P422, DOI 10.1097/01.pap.0000249905.63211.a1
   Bedford T, CRYPTIC TRANSMISSION
   Bellani G, 2017, AM J RESP CRIT CARE, V195, P67, DOI 10.1164/rccm.201606-1306OC
   Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463
   Burton DR, 2012, CELL HOST MICROBE, V12, P396, DOI 10.1016/j.chom.2012.09.008
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Cavalcanti AB, 2017, JAMA-J AM MED ASSOC, V318, P1335, DOI 10.1001/jama.2017.14171
   Chan KH, 2005, CLIN DIAGN LAB IMMUN, V12, P1317, DOI 10.1128/CDLI.12.11.1317-1321.2005
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chaudhuri D, 2020, CRIT CARE MED, V48, P571, DOI 10.1097/CCM.0000000000004217
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RF, 2006, MICROBES INFECT, V8, P122, DOI 10.1016/j.micinf.2005.06.007
   Chen X., 2020, TRANSL PERIOPER PAIN, V15, P216
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Combes A, 2018, NEW ENGL J MED, V378, P1965, DOI 10.1056/NEJMoa1800385
   Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST
   Fan Z., 2020, CLIN FEATURES COVID, DOI [10.1101/2020.02.26.20026971, DOI 10.1101/2020.02.26.20026971]
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Fowler RA, 2004, NEW ENGL J MED, V351, P610
   Frat JP, 2018, CRIT CARE MED, V46, P208, DOI 10.1097/CCM.0000000000002818
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Geiben-Lynn R, 2008, CLIN VACCINE IMMUNOL, V15, P691, DOI 10.1128/CVI.00418-07
   Goligher EC, 2018, JAMA-J AM MED ASSOC, V320, P2251, DOI 10.1001/jama.2018.14276
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Griffiths M, 2019, THORAX, V74, P931, DOI 10.1136/thoraxjnl-2018-212885
   Griffiths MJD, 2019, BMJ OPEN RESPIR RES, V6, DOI 10.1136/bmjresp-2019-000420
   Gu L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160777
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hijano DR, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220908
   Hoffman TW, 2018, CURR OPIN PULM MED, V24, P269, DOI 10.1097/MCP.0000000000000475
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Hui DS, 2011, RESPIROLOGY, V16, P1005, DOI 10.1111/j.1440-1843.2011.01995.x
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Johns Hopkins CSSE: Coronavirus COVID-19 Global Cases, COR COVID 19 GLOB CA
   Kamming D, 2003, BRIT J ANAESTH, V90, P715, DOI 10.1093/bja/aeg173
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Khanolkar A, 2009, J VIROL, V83, P9258, DOI 10.1128/JVI.00355-09
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Lewis SR, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004477.pub3
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Liu S, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01044-2019
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0
   Mauri T, 2017, AM J RESP CRIT CARE, V195, P1207, DOI 10.1164/rccm.201605-0916OC
   Michaels MG, 2020, AM J TRANSPLANT, V20, P1768, DOI 10.1111/ajt.15832
   Monro-Somerville T, 2017, CRIT CARE MED, V45, pE449, DOI 10.1097/CCM.0000000000002091
   Moss M, 2019, NEW ENGL J MED, V380, P1997, DOI 10.1056/NEJMoa1901686
   NIAID, NOV COR SARS COV 2
   Nicolle L, 2003, CAN J ANAESTH, V50, P983, DOI 10.1007/BF03018360
   Parke RL, 2011, RESP CARE, V56, P1151, DOI 10.4187/respcare.01106
   Patel BK, 2016, JAMA-J AM MED ASSOC, V315, P2435, DOI 10.1001/jama.2016.6338
   Peng PWH, 2020, BRIT J ANAESTH, V124, P497, DOI 10.1016/j.bja.2020.02.008
   Peng PWH, 2003, CAN J ANAESTH, V50, P989, DOI 10.1007/BF03018361
   Raboud J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010717
   Radzikowska E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184739
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Roca O, 2019, AM J RESP CRIT CARE, V199, P1368, DOI 10.1164/rccm.201803-0589OC
   Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016
   Rodriguez A, 2017, RESP CARE, V62, P1307, DOI 10.4187/respcare.05481
   Rynda-Apple A, 2015, INFECT IMMUN, V83, P3764, DOI 10.1128/IAI.00298-15
   Song FX, 2020, RADIOLOGY, V295, P210, DOI 10.1148/radiol.2020200274
   STEVENS RH, 1988, J PERIODONTOL, V59, P741, DOI 10.1902/jop.1988.59.11.741
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Tien MHC, 2005, CAN J SURG, V48, P71
   U.S. Centers for Disease Control and Prevention (CDC), INT CLIN GUID MAN PA
   van Riel D, 2007, AM J PATHOL, V171, P1215, DOI 10.2353/ajpath.2007.070248
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Walls AC, 2020, STRUCTURE FUNCTION A, DOI [10.1101/2020.02.19.956581, DOI 10.1101/2020.02.19.956581]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wax RS, 2020, CAN J ANESTH, V67, P568, DOI 10.1007/s12630-020-01591-x
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   World Health Organization, CLIN MAN SEV AC RESP
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xia JG, 2020, CHINESE MED J-PEKING, V133, P1109, DOI 10.1097/CM9.0000000000000761
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
   Xie XD, 2006, LIFE SCI, V78, P2166, DOI 10.1016/j.lfs.2005.09.038
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yeo C, 2020, LANCET GASTROENTEROL, V5, P335, DOI 10.1016/S2468-1253(20)30048-0
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhao S, 2020, J CARDIOTHOR VASC AN, V34, P1125, DOI 10.1053/j.jvca.2020.02.039
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhu MS, 2004, CELL MOL IMMUNOL, V1, P193
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 106
TC 60
Z9 60
U1 2
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD JUN
PY 2020
VL 132
IS 6
BP 1346
EP 1361
DI 10.1097/ALN.0000000000003303
PG 16
WC Anesthesiology
SC Anesthesiology
GA LP9LA
UT WOS:000534635800011
PM 32195698
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Iwabuchi, K
   Yoshie, K
   Kurakami, Y
   Takahashi, K
   Kato, Y
   Morishima, T
AF Iwabuchi, Keisuke
   Yoshie, Koichiro
   Kurakami, Yuichi
   Takahashi, Kota
   Kato, Yoshio
   Morishima, Tsuneo
TI Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia:
   Report of three cases
SO JOURNAL OF INFECTION AND CHEMOTHERAPY
LA English
DT Article
DE Ciclesonide; Inhalation; Coronavirus disease 2019
AB No specific and effective anti-viral treatment has been approved for COVID-19 so far. Systemic corticosteroid has been sometimes administered to severe infectious diseases combined with the specific treatment. However, as lack of the specific anti-SARS-CoV-2 drug, systemic steroid treatment has not been recommended for COVID-19. We report here three cases of the COVID-19 pneumonia successfully treated with ciclesonide inhalation. Rationale of the treatment is to mitigate the local inflammation with inhaled steroid that stays in the lung and to inhibit proliferation of the virus by antiviral activity. Larger and further studies are warranted to confirm the result of these cases. (C) 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
C1 [Iwabuchi, Keisuke; Yoshie, Koichiro; Kurakami, Yuichi; Takahashi, Kota; Kato, Yoshio] Kanagawa Prefectural Ashigarakami Hosp, Dept Gen Med, 866-1 Matsuda Soryo,Matsuda Machi, Ashigarakami, Kanagawa 2580003, Japan.
   [Morishima, Tsuneo] Aichi Med Univ, Nagakute, Aichi, Japan.
   [Morishima, Tsuneo] AMED Study Diag & Treatment Methods Serious Viral, Tokyo, Japan.
RP Iwabuchi, K (corresponding author), Kanagawa Prefectural Ashigarakami Hosp, Dept Gen Med, 866-1 Matsuda Soryo,Matsuda Machi, Ashigarakami, Kanagawa 2580003, Japan.; Morishima, T (corresponding author), Aichi Med Univ, Pediat Dept, Nagakute, Aichi, Japan.
EM iwabuchi@ashigarakami-hospital.jp; tmorishima@aichi-med-u.ac.jp
CR Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
NR 1
TC 17
Z9 17
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1341-321X
EI 1437-7780
J9 J INFECT CHEMOTHER
JI J. Infect. Chemother.
PD JUN
PY 2020
VL 26
IS 6
BP 625
EP 632
DI 10.1016/j.jiac.2020.04.007
PG 8
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA LP7WU
UT WOS:000534530100017
PM 32362440
OA Green Published
DA 2021-01-01
ER

PT J
AU Yu, MH
   Liu, Y
   Xu, D
   Zhang, RG
   Lan, L
   Xu, HB
AF Yu, Minhua
   Liu, Ying
   Xu, Dan
   Zhang, Rongguo
   Lan, Lan
   Xu, Haibo
TI Prediction of the Development of Pulmonary Fibrosis Using Serial
   Thin-Section CT and Clinical Features in Patients Discharged after
   Treatment for COVID-19 Pneumonia
SO KOREAN JOURNAL OF RADIOLOGY
LA English
DT Article
DE COVID-19; Computed tomography; Prediction; Clinical characteristic;
   Fibrosis; Follow-up
ID ACUTE RESPIRATORY SYNDROME; SEQUELAE
AB Objective: To identify predictors of pulmonary fibrosis development by combining follow-up thin-section CT findings and clinical features in patients discharged after treatment for COVID-19.
   Materials and Methods: This retrospective study involved 32 confirmed COVID-19 patients who were divided into two groups according to the evidence of fibrosis on their latest follow-up CT imaging. Clinical data and CT imaging features of all the patients in different stages were collected and analyzed for comparison.
   Results: The latest follow-up CT imaging showed fibrosis in 14 patients (male, 12; female, 2) and no fibrosis in 18 patients (male, 10; female, 8). Compared with the non-fibrosis group, the fibrosis group was older (median age: 54.0 years vs. 37.0 years, p = 0.008), and the median levels of C-reactive protein (53.4 mg/L vs. 10.0 mg/L, p = 0.002) and interleukin-6 (79.7 pg/L vs. 11.2 pg/L, p = 0.04) were also higher. The fibrosis group had a longer-term of hospitalization (19.5 days vs. 10.0 days, p = 0.001), pulsed steroid therapy (11.0 days vs. 5.0 days, p < 0.001), and antiviral therapy (12.0 days vs. 6.5 days, p = 0.012). More patients on the worst-state CT scan had an irregular interface (59.4% vs. 34.4%, p = 0.045) and a parenchymal band (71.9% vs. 28.1%, p < 0.001). On initial CT imaging, the irregular interface (57.1%) and parenchymal band (50.0%) were more common in the fibrosis group. On the worst-state CT imaging, interstitial thickening (78.6%), air bronchogram (57.1%), irregular interface (85.7%), coarse reticular pattern (28.6%), parenchymal band (92.9%), and pleural effusion (42.9%) were more common in the fibrosis group.
   Conclusion: Fibrosis was more likely to develop in patients with severe clinical conditions, especially in patients with high inflammatory indicators. Interstitial thickening, irregular interface, coarse reticular pattern, and parenchymal band manifested in the process of the disease may be predictors of pulmonary fibrosis. Irregular interface and parenchymal band could predict the formation of pulmonary fibrosis early.
C1 [Yu, Minhua; Liu, Ying; Xu, Dan; Lan, Lan; Xu, Haibo] Wuhan Univ, Zhongnan Hosp, Dept Radiol, Wuhan 430071, Hubei, Peoples R China.
   [Zhang, Rongguo] Infervision, Inst Adv Res, Beijing, Peoples R China.
RP Xu, HB (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Radiol, Wuhan 430071, Hubei, Peoples R China.
EM xuhaibo1120@hotmail.com
OI Xu, Dan/0000-0001-9128-5328
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81771819]
FX This study was supported by the National Natural Science Foundation of
   China (Grants No. 81771819).
CR Antonio GE, 2003, RADIOLOGY, V228, P810, DOI 10.1148/radiol.2283030726
   BECROFT DMO, 1971, J CLIN PATHOL, V24, P72, DOI 10.1136/jcp.24.1.72
   Cameron MJ, 2008, VIRUS RES, V133, P13, DOI 10.1016/j.virusres.2007.02.014
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Duan YN, 2020, RADIOLOGY, V295, P21, DOI 10.1148/radiol.2020200323
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lew TWK, 2003, JAMA-J AM MED ASSOC, V290, P374, DOI 10.1001/jama.290.3.374
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST
   Shi HS, 2020, RADIOLOGY, V295, P20, DOI 10.1148/radiol.2020200269
   Song FX, 2020, RADIOLOGY, V295, P210, DOI 10.1148/radiol.2020200274
   Wang FS, 2020, LANCET, V395, P391, DOI 10.1016/S0140-6736(20)30300-7
   Ward PA, 1998, AM J RESP CRIT CARE, V157, pS123, DOI 10.1164/ajrccm.157.4.nhlbi-10
   Wei JP, 2020, KOREAN J RADIOL, V21, P501, DOI 10.3348/kjr.2020.0112
   WINTERBAUER RH, 1977, JOHNS HOPKINS MED J, V141, P148
   Wong KT, 2003, RADIOLOGY, V228, P395, DOI 10.1148/radiol.2283030541
   Zerhouni E A, 1985, J Thorac Imaging, V1, P54, DOI 10.1097/00005382-198512000-00008
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 7
Z9 7
U1 8
U2 13
PU KOREAN RADIOLOGICAL SOC
PI SEOUL
PA 121-8 YANGJAE-DONG, SEOCHO-GU, SEOUL 137-130, SOUTH KOREA
SN 1229-6929
EI 2005-8330
J9 KOREAN J RADIOL
JI Korean J. Radiol.
PD JUN
PY 2020
VL 21
IS 6
BP 746
EP 755
DI 10.3348/kjr.2020.0215
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA LP5KG
UT WOS:000534356000011
PM 32410413
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Saavedra, JM
AF Saavedra, Juan M.
TI Angiotensin receptor blockers and COVID-19
SO PHARMACOLOGICAL RESEARCH
LA English
DT Letter
DE COVID-19; SARS-CoV-2; ACE2; Angiotensin receptor blockers; Coronavirus
AB Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current COVID-19 pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for COVID-19 patients.
C1 [Saavedra, Juan M.] Georgetown Univ, Dept Physiol & Pharmacol, Med Ctr, 3900 Reservoir Rd NW, Washington, DC 20057 USA.
RP Saavedra, JM (corresponding author), Georgetown Univ, Dept Physiol & Pharmacol, Med Ctr, 3900 Reservoir Rd NW, Washington, DC 20057 USA.
EM juan.saavedra@georgetown.edu
OI Saavedra, Juan/0000-0002-7238-9647
CR AlGhatrif M, 2020, JAMA CARDIOL, V5, P747, DOI 10.1001/jamacardio.2020.1329
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fedson DS, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.11.03
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Jia HP, 2016, SHOCK, V46, P239, DOI 10.1097/SHK.0000000000000633
NR 6
TC 23
Z9 23
U1 1
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD JUN
PY 2020
VL 156
AR 104832
DI 10.1016/j.phrs.2020.104832
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LP3UP
UT WOS:000534244400003
PM 32304747
OA Green Published
DA 2021-01-01
ER

PT J
AU Kansal, NK
AF Kansal, Naveen Kumar
TI COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic
   arthritis: A word of caution
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Letter
ID THALIDOMIDE
C1 [Kansal, Naveen Kumar] All India Inst Med Sci, Dept Dermatol Venereol & Leprosy, Rishikesh 249203, India.
RP Kansal, NK (corresponding author), All India Inst Med Sci, Dept Dermatol Venereol & Leprosy, Rishikesh 249203, India.
EM kansalnaveen29@gmail.com
RI Kansal, Naveen Kumar/B-7087-2015
OI Kansal, Naveen Kumar/0000-0001-9214-3137
CR FLORENCE AL, 1960, BRIT MED J, V2, P1954, DOI 10.1136/bmj.2.5217.1954
   Kansal NK, 2018, CLIN EXP DERMATOL, V43, P831, DOI 10.1111/ced.13625
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Uslu U, 2017, CLIN EXP DERMATOL, V42, P836, DOI 10.1111/ced.13189
   WARD SP, 1962, BMJ-BRIT MED J, P646
NR 5
TC 4
Z9 4
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
EI 1097-6787
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD JUN
PY 2020
VL 82
IS 6
BP E213
EP E213
DI 10.1016/j.jaad.2020.03.079
PG 1
WC Dermatology
SC Dermatology
GA LN2RF
UT WOS:000532790300013
PM 32246966
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lebwohl, M
   Rivera-Oyola, R
   Murrell, DF
AF Lebwohl, Mark
   Rivera-Oyola, Ryan
   Murrell, Dedee F.
TI Reply to: "COVID-19, syphilis, and biologic therapies for psoriasis and
   psoriatic arthritis: A word of caution''
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Letter
C1 [Lebwohl, Mark; Rivera-Oyola, Ryan] Icahn Sch Med Mt Sinai Hosp, Kimberly & Eric J Waldman Dept Dermatol, New York, NY USA.
   [Murrell, Dedee F.] Univ New South Wales, St George Hosp, Dept Dermatol, Sydney, NSW, Australia.
RP Rivera-Oyola, R (corresponding author), Kimberly & Eric J Waldman Dept Dermatol, 5 E 98th St,5th Floor, New York, NY 10029 USA.
EM ryan.riveraoyola@mountsinai.org
CR Altare F, 1998, CURR OPIN IMMUNOL, V10, P413, DOI 10.1016/S0952-7915(98)80114-3
   Conti P, 2020, J BIOL REGUL HOMEOST, V34, DOI [10.1016/j.jaad.2020.03.103, DOI 10.1016/J.JAAD.2020.03.103]
   Kansal NK, 2020, J AM ACAD DERMATOL, V82, pE213, DOI 10.1016/j.jaad.2020.03.079
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Puel A, 2012, CURR OPIN ALLERGY CL, V12, P616, DOI 10.1097/ACI.0b013e328358cc0b
NR 5
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
EI 1097-6787
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD JUN
PY 2020
VL 82
IS 6
BP E215
EP E215
DI 10.1016/j.jaad.2020.03.103
PG 1
WC Dermatology
SC Dermatology
GA LN2RF
UT WOS:000532790300014
PM 32283232
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Shah, P
   Zampella, JG
AF Shah, Payal
   Zampella, John G.
TI Use of systemic immunomodulatory therapies during the coronavirus
   disease 2019 (COVID-19) pandemic
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Letter
C1 [Shah, Payal; Zampella, John G.] NYU, Sch Med, Ronald O Perelman Dept Dermatol, New York, NY USA.
RP Zampella, JG (corresponding author), NYU, Sch Med, Ronald O Perelman Dept Dermatol, Preston Robert Tisch Ctr Mens Hlth, 555 Madison Ave, New York, NY 10022 USA.
EM john.zampella@nyulangone.org
CR American Academy of Dermatology, 2020, GUID US BIOL AG COVI
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li CG, 2012, CELL RES, V22, P528, DOI 10.1038/cr.2011.165
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Ma WT, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.190109
   Swain SL, 2012, NAT REV IMMUNOL, V12, P136, DOI 10.1038/nri3152
NR 6
TC 6
Z9 7
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
EI 1097-6787
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD JUN
PY 2020
VL 82
IS 6
BP E203
EP E204
DI 10.1016/j.jaad.2020.03.056
PG 2
WC Dermatology
SC Dermatology
GA LN2RF
UT WOS:000532790300009
PM 32244021
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lara, PC
   Nguyen, NP
   Macias-Verde, D
   Burgos-Burgos, J
   Arenas, M
   Zamagni, A
   Vinh-Hung, V
   Baumert, BG
   Motta, M
   Myint, AS
   Bonet, M
   Popescu, T
   Vuong, T
   Appalanaido, GK
   Trigo, L
   Karlsson, U
   Thariat, J
AF Lara, Pedro C.
   Nguyen, Nam P.
   Macias-Verde, David
   Burgos-Burgos, Javier
   Arenas, Meritxell
   Zamagni, Alice
   Vinh-Hung, Vincent
   Baumert, Brigitta G.
   Motta, Micaela
   Myint, Arthur Sun
   Bonet, Marta
   Popescu, Tiberiu
   Te Vuong
   Appalanaido, Gokula Kumar
   Trigo, Lurdes
   Karlsson, Ulf
   Thariat, Juliette
TI Whole-lung Low Dose Irradiation for SARS-Cov2 Induced Pneumonia in the
   Geriatric Population: An Old Effective Treatment for a New Disease?
   Recommendation of the International Geriatric Radiotherapy Group
SO AGING AND DISEASE
LA English
DT Article
DE elderly; SARS-Cov 2; LDRT; treatment; inflammation
ID X-RAYS; ROENTGEN THERAPY; HISTORICAL USE; INFLAMMATION; INFECTIONS
AB A cytokine storm induced by SARS-Cov2 may produce pneumonitis which may be fatal for older patients with underlying lung disease. Hyper-elevation of Interleukin1 (IL-1), Tumor necrosis factor-1alfa (TNF1 alfa), and Interleukin 6 (IL-6) produced by inflammatory macrophage M1 may damage the lung alveoli leading to severe pneumonitis, decreased oxygenation, and potential death despite artificial ventilation. Older patients may not be suitable candidates for pharmaceutical intervention targeting IL-1/6 blockade or artificial ventilation. Low dose total lung (LDTL) irradiation at a single dose of 50 cGy may stop this cytokine cascade, thus preventing, and/or reversing normal organs damage. This therapy has been proven in the past to be effective against pneumonitis of diverse etiology and could be used to prevent death of older infected patients. Thus, LDRT radiotherapy may be a cost-effective treatment for this frail patient population whom radiation - induced malignancy is not a concern because of their advanced age. This hypothesis should be tested in future prospective trials.
C1 [Lara, Pedro C.; Macias-Verde, David; Burgos-Burgos, Javier] Fernando Pessoa Canarias Las Palmas Univ, Hosp Univ San Roque, Dept Radiat Oncol, Las Palmas Gran Canaria, Spain.
   [Nguyen, Nam P.] Howard Univ, Dept Radiat Oncol, Washington, DC 20059 USA.
   [Arenas, Meritxell] Univ Rovira & Virgili, St Joan de Reus Univ, Dept Radiat Oncol, Tarragona, Spain.
   [Zamagni, Alice] Univ Bologna, St Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Radiat Oncol Ctr, Bologna, Italy.
   [Vinh-Hung, Vincent] Univ Hosp Martinique, Dept Radiat Oncol, Fort De France, Martinique, France.
   [Baumert, Brigitta G.] Cantonal Hosp Graubuenden, Inst Radiat Oncol, Chur, Switzerland.
   [Motta, Micaela] ASST Papa Giovanni XXIII, Dept Radiat Oncol, Bergamo, Italy.
   [Myint, Arthur Sun] Clatterbridge Canc Ctr, Dept Radiat Oncol, Liverpool, Merseyside, England.
   [Bonet, Marta] Arnau de Vilanova Univ Hosp, Dept Radiat Oncol, Lleida, Spain.
   [Popescu, Tiberiu] Prof Dr Ion Chricuta Oncol Inst, Dept Radiat Oncol, Cluj Napoca, Romania.
   [Te Vuong] McGill Univ, Dept Radiat Oncol, Montreal, PQ, Canada.
   [Appalanaido, Gokula Kumar] Penang Adventist Hosp, Dept Radiat Oncol, George Town, Malaysia.
   [Trigo, Lurdes] Inst Portuges Oncol Porto Francisco Gentil EPE, Dept Radiat Oncol, Porto, Portugal.
   [Karlsson, Ulf] Int Geriatr Grp, Dept Radiat Oncol, Washington, DC USA.
   [Thariat, Juliette] Baclesse Canc Ctr, Dept Radiat Oncol, Caen, France.
RP Lara, PC (corresponding author), Fernando Pessoa Canarias Las Palmas Univ, Hosp Univ San Roque, Dept Radiat Oncol, Las Palmas Gran Canaria, Spain.
EM pedrocarlos.lara@ulugc.es
OI Zamagni, Alice/0000-0001-8942-793X
CR Adam Monteagudo L, 2020, CONTINUOUS INTRAVENO
   Aggarwal NR, 2014, AM J PHYSIOL-LUNG C, V306, pL709, DOI 10.1152/ajplung.00341.2013
   Aguirre-Valencia D, 2019, AUTOIMMUN DIS, V2019, DOI 10.1155/2019/5350960
   Arenas M, 2012, STRAHLENTHER ONKOL, V188, P975, DOI 10.1007/s00066-012-0170-8
   Arenas M, 2006, INT J RADIAT ONCOL, V66, P560, DOI 10.1016/j.ijrobp.2006.06.004
   Bhimraj A, 2020, INFECT DIS SOC AM GU
   Calabrese EJ, 2019, HUM EXP TOXICOL, V38, P888, DOI 10.1177/0960327119846925
   Calabrese EJ, 2014, HUM EXP TOXICOL, V33, P542, DOI 10.1177/0960327113493303
   Calabrese EJ, 2015, RADIAT RES, V184, P180, DOI 10.1667/RR14080.1
   Calabrese EJ, 2014, ARCH TOXICOL, V88, P1503, DOI 10.1007/s00204-014-1295-6
   Calabrese Edward J., 2013, Yale Journal of Biology and Medicine, V86, P555
   Calabrese EJ, 2013, DOSE-RESPONSE, V11, P469, DOI 10.2203/dose-response.13-004.Calabrese
   Calabrese EJ, 2013, HUM EXP TOXICOL, V32, P817, DOI 10.1177/0960327112467046
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen G, 2020, J CLIN INV
   Crayne CB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00119
   Deloch L, 2018, FRONTIERS IMMUN, V9, P1
   Deloch L, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/3161750
   Dhawan G, 2019, DISE RESPONSE, V1, P6
   DUBIN IN, 1946, AM J ROENTGENOL, V55, P478
   Erickson RW, 1944, SEM ARTHRITIS RHEUM, V24, P114
   Favalli EG, 2020, LANCET INFECT DIS
   Fukui S, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01958
   Gonzales J., 2015, AUSTIN J VASC MED, V2, P1, DOI [10.1080/10590501.2015.1002999.A, DOI 10.1080/10590501.2015.1002999.A]
   Hildebrandt G, 2003, STRAHLENTHER ONKOL, V179, P158, DOI 10.1007/s00066-003-1044-x
   ISBISTER JP, 1981, ARCH INTERN MED, V141, P1081, DOI 10.1001/archinte.141.8.1081
   Johnston LK, 2012, AM J RESP CELL MOL, V47, P417, DOI 10.1165/rcmb.2012-0090OC
   Jones SA, 2018, NAT REV IMMUNOL, V18, P773, DOI 10.1038/s41577-018-0066-7
   Knaup H, 2018, BMC, V1, P11
   Leblond MM, 2017, ONCOTARGET, V8, P72597, DOI 10.18632/oncotarget.19994
   Li J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185854
   Li X, 2020, INT J RAD ONCOL BIOL
   Liu BC, 2020, RESP MED, V161, DOI 10.1016/j.rmed.2019.09.009
   Lu HL, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171555
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2019.102456
   Nakatsukasa H, 2010, RADIAT RES, V174, P313, DOI 10.1667/RR2121.1
   Oppenheimer A, 1943, AM J ROENTGENOL RADI, V49, P635
   Oppenheimer A, 1943, J PEDIATR-US, V23, P534, DOI 10.1016/S0022-3476(43)80256-0
   Popescu T, 2019, CANCERS, V11, DOI 10.3390/cancers11030371
   Powell EV, 1938, J AMER MED ASSOC, V110, P19, DOI 10.1001/jama.1938.02790010021004
   Scott WR, 1939, AM J ROENTGENOL RAD, V33, P331
   Short KR, 2014, LANCET INFECT DIS, V14, P57, DOI 10.1016/S1473-3099(13)70286-X
   Swiss Society of Intensive Care Medicine, 2020, REC ADM PAT COVID 19, V150
   Tian S, 2020, J THORACIC ONCOL
   Trott KR, 2006, STRAHLENTHER ONKOL, V182, P431, DOI 10.1007/s00066-006-1542-8
   Wolfe KR, 2020, PEDIATR TRANSPLANT, V24, DOI 10.1111/petr.13615
   Wunderlich R, 2015, CLIN EXP IMMUNOL, V179, P50, DOI 10.1111/cei.12344
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 48
TC 3
Z9 3
U1 2
U2 3
PU INT SOC AGING & DISEASE
PI FORT WORTH
PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA
SN 2152-5250
J9 AGING DIS
JI Aging Dis.
PD JUN
PY 2020
VL 11
IS 3
BP 489
EP 493
DI 10.14336/AD.2020.0506
PG 5
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA LO3TC
UT WOS:000533551200005
PM 32489696
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Caccialanza, R
   Laviano, A
   Lobascio, F
   Montagna, E
   Bruno, R
   Ludovisi, S
   Corsico, AG
   Di Sabatino, A
   Belliato, M
   Calvi, M
   Iacona, I
   Grugnetti, G
   Bonadeo, E
   Muzzi, A
   Cereda, E
AF Caccialanza, Riccardo
   Laviano, Alessandro
   Lobascio, Federica
   Montagna, Elisabetta
   Bruno, Raffaele
   Ludovisi, Serena
   Corsico, Angelo Guido
   Di Sabatino, Antonio
   Belliato, Mirko
   Calvi, Monica
   Iacona, Isabella
   Grugnetti, Giuseppina
   Bonadeo, Elisa
   Muzzi, Alba
   Cereda, Emanuele
TI Early nutritional supplementation in non-critically ill patients
   hospitalized for the 2019 novel coronavirus disease (COVID-19):
   Rationale and feasibility of a shared pragmatic protocol
SO NUTRITION
LA English
DT Article
DE Coronavirus disease (COVID-19); Malnutrition; Nutritional support; Oral
   nutritional supplements; Whey proteins; Vitamin D; Pragmatic protocol
ID MICRONUTRIENT SUPPLEMENTATION; NONINVASIVE VENTILATION; ENTERAL
   NUTRITION; OXIDATIVE STRESS; PROGRESSION; INFECTION; INITIATION;
   THERAPY; PROTEIN; ADULTS
AB Objectives: Beginning in December 2019, the 2019 novel coronavirus disease (COVID-19) has caused a pneumonia epidemic that began in Wuhan, China, and is rapidly spreading throughout the whole world. Italy is the hardest hit country after China. Considering the deleterious consequences of malnutrition, which certainly can affect patients with COVID-19, the aim of this article is to present a pragmatic protocol for early nutritional supplementation of non-critically ill patients hospitalized for COVID-19 disease. It is based on the observation that most patients present at admission with severe inflammation and anorexia leading to a drastic reduction of food intake, and that a substantial percentage develops respiratory failure requiring non-invasive ventilation or even continuous positive airway pressure.
   Methods: High-calorie dense diets in a variety of different consistencies with highly digestible foods and snacks are available for all patients. Oral supplementation of whey proteins as well as intravenous infusion of multivitamin, multimineral trace elements solutions are implemented at admission. In the presence of 25-hydroxyvitamin D deficit, cholecalciferol is promptly supplied. If nutritional risk is detected, two to three bottles of protein-calorie oral nutritional supplements (ONS) are provided. If <2 bottles/d of ONS are consumed for 2 consecutive days and/or respiratory conditions are worsening, supplemental/total parenteral nutrition is prescribed.
   Conclusion: We are aware that our straight approach may be debatable. However, to cope with the current emergency crisis, its aim is to promptly and pragmatically implement nutritional care in patients with COVID-19, which might be overlooked despite being potentially beneficial to clinical outcomes and effective in preventing the consequences of malnutrition in this patient population. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Caccialanza, Riccardo; Lobascio, Federica; Montagna, Elisabetta; Cereda, Emanuele] Fdn IRCCS Policlin San Matteo, Clin Nutr & Dietet Unit, Pavia, Italy.
   [Laviano, Alessandro] Univ Roma La Sapienza, Dept Translat & Precis Med, Rome, Italy.
   [Bruno, Raffaele; Ludovisi, Serena] Fdn IRCCS Policlin San Matteo, Div Infect Dis Unit, Pavia, Italy.
   [Bruno, Raffaele; Ludovisi, Serena] Univ Pavia, Dept Med Surg Diagnost & Paediat Sci, Pavia, Italy.
   [Corsico, Angelo Guido] Fdn IRCCS Policlin San Matteo, Pneumol Unit, Pavia, Italy.
   [Corsico, Angelo Guido] Univ Pavia, Dept Internal Med & Therapeut, Pavia, Italy.
   [Di Sabatino, Antonio] Fdn IRCCS Policlin San Matteo, Dept Internal Med 1, Pavia, Italy.
   [Di Sabatino, Antonio] Univ Pavia, Pavia, Italy.
   [Belliato, Mirko] Fdn IRCCS Policlin San Matteo, UOC Anestesia & Rianimaz 1, UOS Adv Resp Intens Care Unit, Pavia, Italy.
   [Calvi, Monica; Iacona, Isabella] Fdn IRCCS Policlin San Matteo, Pharm Unit, Pavia, Italy.
   [Grugnetti, Giuseppina] Fdn IRCCS Policlin San Matteo, Nursing Tech & Rehabil Serv, Pavia, Italy.
   [Bonadeo, Elisa; Muzzi, Alba] Fdn IRCCS Policlin San Matteo, UOC Direz Med Presidio, Pavia, Italy.
RP Caccialanza, R (corresponding author), Fdn IRCCS Policlin San Matteo, Clin Nutr & Dietet Unit, Pavia, Italy.
EM r.caccialanza@smatteo.pv.it
RI ; Caccialanza, Riccardo/J-1904-2015
OI belliato, mirko/0000-0002-3411-6293; Corsico, Angelo
   Guido/0000-0002-8716-4694; Caccialanza, Riccardo/0000-0002-9379-3569
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Jimenez-Sousa MA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00458
   Baum MK, 2013, JAMA-J AM MED ASSOC, V310, P2154, DOI 10.1001/jama.2013.280923
   Beard JA, 2011, J CLIN VIROL, V50, P194, DOI 10.1016/j.jcv.2010.12.006
   Beck MA, 2001, J AM COLL NUTR, V20, p384S, DOI 10.1080/07315724.2001.10719172
   Beck MA, 1998, NUTR REV, V56, pS140
   Bezabih YM, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4170-5
   Calder PC, 2010, P NUTR SOC, V69, P565, DOI 10.1017/S0029665110000157
   Camini FC, 2017, ARCH VIROL, V162, P907, DOI 10.1007/s00705-016-3187-y
   Cereda E, 2019, CANCER MED-US, V8, P6923, DOI 10.1002/cam4.2517
   Cross ML, 2000, BRIT J NUTR, V84, pS81
   Dikman AE, 2015, DIGEST DIS SCI, V60, P2236, DOI 10.1007/s10620-015-3615-y
   Doig GS, 2013, JAMA-J AM MED ASSOC, V309, P2130, DOI 10.1001/jama.2013.5124
   Evans P, 2001, BRIT J NUTR, V85, pS67, DOI 10.1079/BJN2000296
   Gomes F, 2018, CLIN NUTR, V37, P336, DOI 10.1016/j.clnu.2017.06.025
   Gruber-Bzura BM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082419
   Guan WJ, 2020, N ENGL J MED
   Gupta S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060603
   Gutierrez S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205028
   Havers F, 2014, J INFECT DIS, V210, P244, DOI 10.1093/infdis/jiu259
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Isanaka S, 2012, JAMA-J AM MED ASSOC, V308, P1535, DOI 10.1001/jama.2012.13083
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Keller U, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060775
   Kogo M, 2017, RESP CARE, V62, P1119, DOI 10.4187/respcare.05684
   Kogo M, 2017, RESP CARE, V62, P459, DOI 10.4187/respcare.05003
   Lee H, 2016, SCI REP-UK, V6, DOI 10.1038/srep25835
   Levett-Jones T, 2017, J ASSOC NURSE AIDS C, V28, P984, DOI 10.1016/j.jana.2017.08.007
   Li ZG, 2017, ARCH VIROL, V162, P603, DOI 10.1007/s00705-016-3130-2
   Liu MM, 2017, MICROBES INFECT, V19, P580, DOI 10.1016/j.micinf.2017.08.008
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   Lomax AR, 2009, BRIT J NUTR, V101, P633, DOI 10.1017/S0007114508055608
   McGill JL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51684-x
   McPherson RA, 2011, CURR OPIN CLIN NUTR, V14, P562, DOI 10.1097/MCO.0b013e32834c1780
   Meyer M, 2015, AM J PHYSIOL-LUNG C, V308, pL1189, DOI 10.1152/ajplung.00028.2015
   Ng T, 2015, APPL MICROBIOL BIOT, V99, P6997, DOI 10.1007/s00253-015-6818-4
   Norman K, 2008, CLIN NUTR, V27, P5, DOI 10.1016/j.clnu.2007.10.007
   Olsen MF, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3187
   Pan T, 2020, SCAND J GASTROENTERO, V55, P123, DOI 10.1080/00365521.2019.1707275
   Rondanelli M, 2020, NUTRITION, V72, DOI 10.1016/j.nut.2019.110667
   Schuetz P, 2019, LANCET, V393, P2312, DOI 10.1016/S0140-6736(18)32776-4
   Singer P, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-1947-7
   Tasca KI, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9834803
   Teixeira FJ, 2019, PHARMACOL RES, V144, P245, DOI 10.1016/j.phrs.2019.04.019
   Teymoori-Rad M, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2032
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
   Weger-Lucarelli J, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008089
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yaqoob P, 2017, P NUTR SOC, V76, P347, DOI 10.1017/S0029665116000781
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
NR 51
TC 37
Z9 38
U1 25
U2 41
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0899-9007
EI 1873-1244
J9 NUTRITION
JI Nutrition
PD JUN
PY 2020
VL 74
AR 110835
DI 10.1016/j.nut.2020.110835
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA LN2VG
UT WOS:000532800900023
PM 32280058
OA Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Angeletti, S
   Benvenuto, D
   Bianchi, M
   Giovanetti, M
   Pascarella, S
   Ciccozzi, M
AF Angeletti, Silvia
   Benvenuto, Domenico
   Bianchi, Martina
   Giovanetti, Marta
   Pascarella, Stefano
   Ciccozzi, Massimo
TI COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE epidemiology; infection; pandemics; pathogenesis; protein-protein
   interaction analysis; research and analysis methods
ID PREDICTION
AB Last December 2019, a new virus, named novel Coronavirus (COVID-2019) causing many cases of severe pneumonia was reported in Wuhan, China. The virus knowledge is limited and especially about COVID-2019 pathogenesis. The Open Reading Frame 1ab (ORF1ab) of COVID-2019 has been analyzed to evidence the presence of mutation caused by selective pressure on the virus. For selective pressure analysis fast-unconstrained Bayesian approximation (FUBAR) was used. Homology modelling has been performed by SwissModel and HHPred servers. The presence of transmembrane helical segments in Coronavirus ORF1ab non structural protein 2 (nsp2) and nsp3 was tested by TMHMM, MEMSAT, and MEMPACK tools. Three-dimensional structures have been analyzed and displayed using PyMOL. FUBAR analysis revealed the presence of potential sites under positive selective pressure (P < .05). Position 723 in the COVID-2019 has a serine instead a glycine residue, while at aminoacidic position 1010 a proline instead an isoleucine. Significant (P < .05) pervasive negative selection in 2416 sites (55%) was found. The positive selective pressure could account for some clinical features of this virus compared with severe acute respiratory syndrome (SARS) and Bat SARS-like CoV. The stabilizing mutation falling in the endosome-associated-protein-like domain of the nsp2 protein could account for COVID-2019 high ability of contagious, while the destabilizing mutation in nsp3 proteins could suggest a potential mechanism differentiating COVID-2019 from SARS. These data could be helpful for further investigation aimed to identify potential therapeutic targets or vaccine strategy, especially in the actual moment when the epidemic is ongoing and the scientific community is trying to enrich knowledge about this new viral pathogen.
C1 [Angeletti, Silvia] Univ Campus Biomed Rome, Unit Clin Lab Sci, I-00128 Rome, Italy.
   [Benvenuto, Domenico; Ciccozzi, Massimo] Univ Campus Biomed Rome, Unit Med Stat & Mol Epidemiol, Rome, Italy.
   [Bianchi, Martina; Pascarella, Stefano] Univ Roma La Sapienza, Dept Biochem Sci A Rossi Fanelli, Rome, Italy.
   [Giovanetti, Marta] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Flavivirus Lab, Rio De Janeiro, Brazil.
RP Angeletti, S (corresponding author), Univ Campus Biomed Rome, Unit Clin Lab Sci, I-00128 Rome, Italy.
EM s.angeletti@unicampus.it
RI Benvenuto, Domenico/AAO-5576-2020; ciccozzi, massimo/C-6484-2016
OI Benvenuto, Domenico/0000-0003-3833-2927; ciccozzi,
   massimo/0000-0003-3866-9239
CR [Anonymous], 2020, LANCET, V395, P311, DOI 10.1016/S0140-6736(20)30186-0
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Giovanetti M, 2020, J MED VIROL, V92, P518, DOI 10.1002/jmv.25699
   Guarner J, 2020, AM J CLIN PATHOL, V153, P420, DOI 10.1093/ajcp/aqaa029
   Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646
   Murrell B, 2013, MOL BIOL EVOL, V30, P1196, DOI 10.1093/molbev/mst030
   Murrell B, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002764
   Nugent T, 2011, BIOINFORMATICS, V27, P1438, DOI 10.1093/bioinformatics/btr096
   Nugent T, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-159
   Saikatendu KS, 2005, STRUCTURE, V13, P1665, DOI 10.1016/j.str.2005.07.022
   Schrodinger L., 2015, PYMOL MOL GRAPHICS S
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213
   Zhang Y, 2004, PROTEINS, V57, P702, DOI 10.1002/prot.20264
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zimmermann L, 2018, J MOL BIOL, V430, P2237, DOI 10.1016/j.jmb.2017.12.007
NR 22
TC 73
Z9 73
U1 17
U2 54
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD JUN
PY 2020
VL 92
IS 6
BP 584
EP 588
DI 10.1002/jmv.25719
PG 5
WC Virology
SC Virology
GA LE1CY
UT WOS:000526462000014
PM 32083328
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Bhattacharya, M
   Sharma, AR
   Patra, P
   Ghosh, P
   Sharma, G
   Patra, BC
   Lee, SS
   Chakraborty, C
AF Bhattacharya, Manojit
   Sharma, Ashish R.
   Patra, Prasanta
   Ghosh, Pratik
   Sharma, Garima
   Patra, Bidhan C.
   Lee, Sang-Soo
   Chakraborty, Chiranjib
TI Development of epitope-based peptide vaccine against novel coronavirus
   2019 (SARS-COV-2): Immunoinformatics approach
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE epitopes; immunoinformatics; SARS-COV-2; vaccine
ID GLOBAL HEALTH; PROTEIN; PREDICTION; RECOGNITION; OUTBREAK; WUHAN
AB Recently, a novel coronavirus (SARS-COV-2) emerged which is responsible for the recent outbreak in Wuhan, China. Genetically, it is closely related to SARS-CoV and MERS-CoV. The situation is getting worse and worse, therefore, there is an urgent need for designing a suitable peptide vaccine component against the SARS-COV-2. Here, we characterized spike glycoprotein to obtain immunogenic epitopes. Next, we chose 13 Major Histocompatibility Complex-(MHC) I and 3 MHC-II epitopes, having antigenic properties. These epitopes are usually linked to specific linkers to build vaccine components and molecularly dock on toll-like receptor-5 to get binding affinity. Therefore, to provide a fast immunogenic profile of these epitopes, we performed immunoinformatics analysis so that the rapid development of the vaccine might bring this disastrous situation to the end earlier.
C1 [Bhattacharya, Manojit; Sharma, Ashish R.; Lee, Sang-Soo; Chakraborty, Chiranjib] Hallym Univ, Chuncheon Sacred Heart Hosp, Inst Skeletal Aging & Orthoped Surg, Chuncheon Si 24252, Gangwon Do, South Korea.
   [Bhattacharya, Manojit; Patra, Prasanta; Ghosh, Pratik; Patra, Bidhan C.] Vidyasagar Univ, Dept Zool, Midnapore, W Bengal, India.
   [Sharma, Garima] Kangwon Natl Univ, Coll Pharm, Neuropsychopharmacol & Toxicol Program, Chunchon, South Korea.
   [Chakraborty, Chiranjib] Adamas Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Barasat Barrackpore Rd, Kolkata 700126, W Bengal, India.
RP Lee, SS (corresponding author), Hallym Univ, Chuncheon Sacred Heart Hosp, Inst Skeletal Aging & Orthoped Surg, Chuncheon Si 24252, Gangwon Do, South Korea.; Chakraborty, C (corresponding author), Adamas Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Barasat Barrackpore Rd, Kolkata 700126, W Bengal, India.
EM 123sslee@gmail.com; drchiranjib@yahoo.com
RI Sharma, Ashish Ranjan/W-4816-2019; Bhattacharya, Manojit/A-2027-2012
OI Sharma, Ashish Ranjan/0000-0003-3973-6755; GHOSH,
   PRATIK/0000-0001-8117-7681; PATRA, PRASANTA/0000-0003-3901-8569;
   Chkraborty, Chiranjib/0000-0002-3958-239X; Bhattacharya,
   Manojit/0000-0001-9669-1835
FU National Research Foundation of Korea (NRF)National Research Foundation
   of Korea [NRF-2017R1A2B4012944] Funding Source: Medline; Hallym
   University Research Fund Funding Source: Medline
CR Agarwala R, 2016, NUCLEIC ACIDS RES, V44, pD7, DOI [10.1093/nar/gkv1290, 10.1093/nar/gkx1095, 10.1093/nar/gks1189]
   Al-Moubarak E, 2011, J MOL MODEL, V17, P1679, DOI 10.1007/s00894-010-0871-9
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039
   Chung MS, 2020, EUR RADIOL, V30, P2182, DOI [10.1148/radiol.2020200230, 10.1007/s00330-019-06574-1]
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438
   Laskowski R., 2006, PROCHECK VALIDATION
   Lavi A, 2013, PROTEINS, V81, P2096, DOI 10.1002/prot.24422
   Patra P, 2020, INT J PEPT RES THER, V26, P1687, DOI 10.1007/s10989-019-09978-1
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Ramanathan K, 2009, INTERDISCIP SCI, V1, P290, DOI 10.1007/s12539-009-0035-8
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Singh H, 2003, BIOINFORMATICS, V19, P1009, DOI 10.1093/bioinformatics/btg108
   Singh H, 2001, BIOINFORMATICS, V17, P1236, DOI 10.1093/bioinformatics/17.12.1236
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Yang YD, 2011, BIOINFORMATICS, V27, P2076, DOI 10.1093/bioinformatics/btr350
   Yin DH, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1552-9
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 26
TC 68
Z9 68
U1 13
U2 68
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD JUN
PY 2020
VL 92
IS 6
BP 618
EP 631
DI 10.1002/jmv.25736
PG 14
WC Virology
SC Virology
GA LE1CY
UT WOS:000526462000019
PM 32108359
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Fang, YQ
   Nie, YT
   Penny, M
AF Fang, Yaqing
   Nie, Yiting
   Penny, Marshare
TI Transmission dynamics of the COVID-19 outbreak and effectiveness of
   government interventions: A data-driven analysis
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE basic reproductive number; COVID-19; data fitting; data simulation;
   effective reproductive number; effectiveness; intervention; SARS-CoV-2;
   SEIR; sensitivity analysis; transmission
ID CORONAVIRUS
AB Using the parameterized susceptible-exposed-infectious-recovered model, we simulated the spread dynamics of coronavirus disease 2019 (COVID-19) outbreak and impact of different control measures, conducted the sensitivity analysis to identify the key factor, plotted the trend curve of effective reproductive number (R), and performed data fitting after the simulation. By simulation and data fitting, the model showed the peak existing confirmed cases of 59 769 arriving on 15 February 2020, with the coefficient of determination close to 1 and the fitting bias 3.02%, suggesting high precision of the data-fitting results. More rigorous government control policies were associated with a slower increase in the infected population. Isolation and protective procedures would be less effective as more cases accrue, so the optimization of the treatment plan and the development of specific drugs would be of more importance. There was an upward trend of R in the beginning, followed by a downward trend, a temporary rebound, and another continuous decline. The feature of high infectiousness for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) led to an upward trend, and government measures contributed to the temporary rebound and declines. The declines of R could be exploited as strong evidence for the effectiveness of the interventions. Evidence from the four-phase stringent measures showed that it was significant to ensure early detection, early isolation, early treatment, adequate medical supplies, patients' being admitted to designated hospitals, and comprehensive therapeutic strategy. Collaborative efforts are required to combat the novel coronavirus, focusing on both persistent strict domestic interventions and vigilance against exogenous imported cases.
C1 [Fang, Yaqing] Hangzhou Med Coll, Sch Publ Hlth, Hangzhou 310053, Zhejiang, Peoples R China.
   [Nie, Yiting] Harbin Med Univ, Grad Sch, Harbin, Peoples R China.
   [Penny, Marshare] Calif Baptist Univ, Dept Publ Hlth Sci, Riverside, CA USA.
RP Fang, YQ (corresponding author), Hangzhou Med Coll, Sch Publ Hlth, Hangzhou 310053, Zhejiang, Peoples R China.
EM colourwind1035@126.com
RI Ribeiro, Nuno/AAH-2299-2020
CR [Anonymous], HINDUSTANTIMES
   [Anonymous], CHINANEWS
   [Anonymous], CHINADAILY
   Centers for Disease Control and Prevention, 2020, CDC CONF POSS INST C
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Delamater PL, 2019, EMERG INFECT DIS, V25, P1, DOI 10.3201/eid2501.171901
   Getz WM, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2018.0282
   Government of People's Republic of China, DIAGN TREATM PLAN NC
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Li Q, 2020, CHINA CDC WEEKLY, V2, P79, DOI DOI 10.46234/ccdcw2020.022
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616
   Ma ZE, 2004, MATH MODELING EPIDEM
   National Health Commission of the People's Republic of China, 2020, UPD COVID 19 17 FEBR
   National Health Commission of the People's Republic of China, 2020, UPD COVID 19 29 FEBR
   Nature, COR LAT SCI SCRAMBL
   Qian G, 2020, MATH BIOSCI, V323, DOI 10.1016/j.mbs.2020.108306
   Read J. M., 2020, NOVEL CORONAVIRUS 20, DOI [10.1101/2020.01.23.20018549, DOI 10.1101/2020.01.23.20018549]
   Roberts MG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017835
   Sina, BEIJ HAS DISCH 9 PAT
   Tan W, 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/ccdcw2020.017
   Wallinga J, 2007, P ROY SOC B-BIOL SCI, V274, P599, DOI 10.1098/rspb.2006.3754
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, COR DIS 2019 COVID 1
   World Health Organization, STAT 2 M INT HLTH RE
   World Health Organization, WHO DIR GEN REM MED
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xie Zhifu, 2019, Osong Public Health Res Perspect, V10, P187, DOI 10.24171/j.phrp.2019.10.3.10
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 31
TC 64
Z9 66
U1 18
U2 96
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD JUN
PY 2020
VL 92
IS 6
BP 645
EP 659
DI 10.1002/jmv.25750
PG 15
WC Virology
SC Virology
GA LE1CY
UT WOS:000526462000022
PM 32141624
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Amad, A
   Magnat, M
   Quiles, C
   Yrondi, A
   Sauvaget, A
   Bulteau, S
   Plaze, M
   Rotharmel, M
   Polosan, M
   Levy-Chavagnat, D
   Jaafari, N
   Vaiva, G
   Thomas, P
AF Amad, A.
   Magnat, M.
   Quiles, C.
   Yrondi, A.
   Sauvaget, A.
   Bulteau, S.
   Plaze, M.
   Rotharmel, M.
   Polosan, M.
   Levy-Chavagnat, D.
   Jaafari, N.
   Vaiva, G.
   Thomas, P.
TI Evolution of electro-convulsive therapy activity in France since the
   beginning of the COVID-19 pandemic
SO ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE
LA French
DT Article
DE Electroconvulsive therapy; Epidemiology; Complications; Health care
   access; COVID-19
AB The recent COVID-19 pandemic has led to major organisational changes in health care settings, especially in psychiatric hospitals. We conducted a national online survey to assess the evolution of electroconvulsive therapy (ECT) in the different centres practicing this treatment. 65 responses from all over France were analysed. More than 90 % of the centres practising ECT experienced a decrease in their activity. Half of the centres experienced a total cessation of activity and 25 % of the centres experienced a decrease of more than half of their usual activity. Post-pandemic COVID-19 psychiatric care is expected to be difficult. It is essential not to add to this difficulty the complications, often serious, that will be associated with delaying or stopping the practice of ECT. It will also be necessary to remain vigilant with regard to the specific neuropsychiatric consequences that will follow the pandemic. (C) 2020 L'Encephale, Paris.
C1 [Amad, A.; Magnat, M.; Vaiva, G.; Thomas, P.] aUniv Lille, U1172 LilNCog Lille Neurosci & Cognit, CHU Lille, INSERM, F-59000 Lille, France.
   [Quiles, C.] Ctr Hosp Charles Perrens, F-33000 Bordeaux, France.
   [Yrondi, A.] Univ Toulouse, Ctr Expert Depress Resistante FondaMental, NeuroImaging Ctr,INSERM,UPS,ToNIC Toulouse NeuroI, CHU Toulouse,Hop Purpan,Serv Psychiat & Psychol M, Toulouse, France.
   [Sauvaget, A.; Bulteau, S.] Univ Nantes, Nantes Univ, Performance MIP, CHU Nantes Movement Interact,EA 4334, Nantes, France.
   [Plaze, M.] Univ Paris, F-75005 Paris, France.
   [Plaze, M.] GHU Paris Psychiat & Neurosci, Serv Hosp Univ, F-75014 Paris, France.
   [Rotharmel, M.] Ctr Hosp Rouvray, Serv Hosp Univ Unite START, Sotteville Les Rouen, France.
   [Polosan, M.] Univ Grenoble Alpes, INSERM, CHU Grenoble Alpes, U1216,GIN, F-38000 Grenoble, France.
   [Levy-Chavagnat, D.; Jaafari, N.] Univ Poitiers, Ctr Hosp Henri Laborit, Unite Rech Clin, F-86021 Poitiers, France.
RP Amad, A (corresponding author), CHU Lille, Hop Fontan, F-59037 Lille, France.
EM ali.amad@chru-lille.fr
CR ANAES, 1998, INT MOD EL FED AIS P
   Dale RC, 2004, BRAIN, V127, P21, DOI 10.1093/brain/awh008
   Heijnen WT, 2010, J CLIN PSYCHOPHARM, V30, P616, DOI 10.1097/JCP.0b013e3181ee0f5f
   Jang HM, 2009, P NATL ACAD SCI USA, V106, P14063, DOI 10.1073/pnas.0900096106
   Leroy A, 2018, EUR ARCH PSY CLIN N, V268, P675, DOI 10.1007/s00406-017-0819-5
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Weiss A, 2019, AUST NZ J PSYCHIAT, V53, P609
NR 7
TC 2
Z9 2
U1 1
U2 1
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0013-7006
J9 ENCEPHALE
JI Enceph.-Rev. Psychiatr. Clin. Biol. Ther.
PD JUN
PY 2020
VL 46
IS 3
SU S
BP S40
EP S42
DI 10.1016/j.encep.2020.04.004
PG 3
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA MF8UE
UT WOS:000545613500005
PM 32370981
OA Green Published
DA 2021-01-01
ER

PT J
AU Bottemanne, H
   Morlaas, O
   Schmidt, L
   Fossati, P
AF Bottemanne, H.
   Morlaas, O.
   Schmidt, L.
   Fossati, P.
TI Coronavirus: Predictive brain and terror management
SO ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE
LA French
DT Article
DE Coronavirus; Covid-19; Belief; Perceived risk; Predictive coding;
   Cognitive biases; Bayesian brain; Terror management theory
ID UNREALISTIC OPTIMISM; MORTALITY SALIENCE; RISK; EVOLUTION
AB Emerging infectious diseases like Covid-19 cause a major threat to global health. When confronted with new pathogens, individuals generate several beliefs about the epidemic phenomenon. Many studies have shown that individual protective behaviors largely depend on these beliefs. Due to the absence of treatment and vaccine against these emerging pathogens, the relation between these beliefs and these behaviors represents a crucial issue for public health policies. In the premises of the Covid-19 pandemic, several preliminary studies have highlighted a delay in the perception of risk by individuals, which potentially holds back the implementing of the necessary precautionary measures: people underestimated the risks associated with the virus, and therefore also the importance of complying with sanitary guidelines. During the peak of the pandemic, the salience of the threat and of the risk of mortality could then have transformed the way people generate their beliefs. This potentially leads to upheavals in the way they understand the world. Here, we propose to explore the evolution of beliefs and behaviors during the Covid-19 crisis, using the theory of predictive coding and the theory of terror management, two influential frameworks in cognitive science and in social psychology. (C) 2020 L'Encephale, Paris.
C1 [Bottemanne, H.; Morlaas, O.; Schmidt, L.; Fossati, P.] Sorbonne Univ, Inst Cerveau & Moelle Epiniere ICM, Control Interocept Attent Team, UMR 7225,UMR S 1127,CNRS INSERM, Paris, France.
   [Bottemanne, H.; Fossati, P.] Hop La Pitie Salpetriere, AP HP, Dept Adult Psychiat, Paris, France.
RP Bottemanne, H (corresponding author), Sorbonne Univ, Inst Cerveau & Moelle Epiniere ICM, Control Interocept Attent Team, UMR 7225,UMR S 1127,CNRS INSERM, Paris, France.
EM hugo.bottemanne@gmail.com
OI Bottemanne, Hugo/0000-0003-2958-0849
CR Arrowood RB, 2017, DEATH STUD, V41, P585, DOI 10.1080/07481187.2017.1322644
   Beall AT, 2016, PSYCHOL SCI, V27, P595, DOI 10.1177/0956797616628861
   Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107
   Bortolotti L, 2015, CURR OPIN PSYCHIATR, V28, P194, DOI 10.1097/YCO.0000000000000143
   Brewer NT, 2004, ANN BEHAV MED, V27, P125, DOI 10.1207/s15324796abm2702_7
   Brug J, 2004, EMERG INFECT DIS, V10, P1486, DOI 10.3201/eid1008.040283
   Burke BL, 2010, PERS SOC PSYCHOL REV, V14, P155, DOI 10.1177/1088868309352321
   Cowling BJ, 2010, J INFECT DIS, V202, P867, DOI 10.1086/655811
   Fast SM, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2014.1105
   Friston K, 2017, NEURAL COMPUT, V29, P1, DOI 10.1162/NECO_a_00912
   Friston KJ, 2005, PHILOS T R SOC B, V360, P815, DOI 10.1098/rstb.2005.1622
   Funk S, 2010, J R SOC INTERFACE, V7, P1247, DOI 10.1098/rsif.2010.0142
   Garrett N, 2018, J NEUROSCI, V38, P7901, DOI 10.1523/JNEUROSCI.0716-18.2018
   Gilovich T., 2002, HEURISTICS BIASES PS, DOI [DOI 10.1017/CBO9780511808098, 10.1017/CBO9780511808098]
   Gomez EJ, 2015, CONTESTED EPIDEMICS
   Goncalves-Sa J, 2020, NAT MED, V26, P305, DOI 10.1038/s41591-020-0802-y
   Herwig U, 2010, PSYCHOL MED, V40, P789, DOI 10.1017/S0033291709991073
   Hohwy J., 2010, ASCS09, P135, DOI DOI 10.5096/ASCS200922
   Hohwy J., 2013, PREDICTIVE MIND
   Hohwy J, 2017, CONSCIOUS COGN, V47, P75, DOI 10.1016/j.concog.2016.09.004
   Ji LJ, 2004, ASIAN J SOC PSYCHOL, V7, P25, DOI 10.1111/j.1467-839X.2004.00132.x
   Johnson D, 2009, CURR SCI INDIA, V97, P1593
   Johnson DDP, 2011, NATURE, V477, P317, DOI 10.1038/nature10384
   Jost JT, 2003, PSYCHOL BULL, V129, P339, DOI 10.1037/0033-2909.129.3.339
   Kahneman D, 1994, J INSTITTHEORETECONO, V150, P1836
   KASPERSON RE, 1988, RISK ANAL, V8, P177, DOI 10.1111/j.1539-6924.1988.tb01168.x
   Knill DC, 2004, TRENDS NEUROSCI, V27, P712, DOI 10.1016/j.tins.2004.10.007
   Kuper-Smith B., 2020, OPTIMISTIC BELIEFS P, DOI [10.31234/osf.io/epcyb, DOI 10.31234/OSF.IO/EPCYB]
   Lau JTF, 2009, J INFECTION, V59, P122, DOI 10.1016/j.jinf.2009.06.004
   Lieberman EJ, 2004, AM J PSYCHIAT, V161, P1508, DOI 10.1176/appi.ajp.161.8.1508
   McCann SJH, 1997, J PERS SOC PSYCHOL, V73, P160, DOI 10.1037/0022-3514.73.1.160
   McKay RT, 2009, BEHAV BRAIN SCI, V32, P541, DOI 10.1017/S0140525X09991555
   McKay RT, 2009, BEHAV BRAIN SCI, V32, P493, DOI 10.1017/S0140525X09990975
   Nail PR, 2009, SOC JUSTICE RES, V22, P231, DOI 10.1007/s11211-009-0098-z
   Oaksford M, 2009, BEHAV BRAIN SCI, V32, P69, DOI 10.1017/S0140525X09000284
   Raude J., 2020, ARE PEOPLE EXCESSIVE, DOI [10.31234/osf.io/364qj., DOI 10.31234/OSF.IO/364QJ]
   Riley S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000442
   ROGERS RW, 1975, J PSYCHOL, V91, P93, DOI 10.1080/00223980.1975.9915803
   Rogers RW, 1983, COGNITIVE PHYSIOL PR
   Rosenfeld D. L., 2020, PANDEMIC MAKE PEOPLE, DOI [10.31234/osf.io/zg7s4, DOI 10.31234/OSF.IO/ZG7S4]
   See YHM, 2006, PERS SOC PSYCHOL B, V32, P405, DOI 10.1177/0146167205282737
   Sharot T, 2011, NAT NEUROSCI, V14, P1475, DOI 10.1038/nn.2949
   Tabri N, 2020, FRAMING COVID 19 EXI, DOI [10.31234/osf.io/mpbtr, DOI 10.31234/OSF.IO/MPBTR]
   Vail KE, 2010, PERS SOC PSYCHOL REV, V14, P84, DOI 10.1177/1088868309351165
   WEINSTEIN ND, 1980, J PERS SOC PSYCHOL, V39, P806, DOI 10.1037/0022-3514.39.5.806
   White AIR, 2020, LANCET, V395, P1250, DOI 10.1016/S0140-6736(20)30737-6
   Wise Toby, 2020, CHANGES RISK PERCEPT, DOI [10.31234/osf.io/dz428, DOI 10.31234/OSF.IO/DZ428]
   World Health Organization (WHO), COMM RISK PUBL HLTH
   Xu J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117012
NR 49
TC 0
Z9 0
U1 3
U2 3
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0013-7006
J9 ENCEPHALE
JI Enceph.-Rev. Psychiatr. Clin. Biol. Ther.
PD JUN
PY 2020
VL 46
IS 3
SU S
BP S107
EP S113
DI 10.1016/j.encep.2020.05.012
PG 7
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA MF8UE
UT WOS:000545613500015
PM 32517998
OA Green Published
DA 2021-01-01
ER

PT J
AU Boyer, L
   Auquier, P
   Fond, G
AF Boyer, L.
   Auquier, P.
   Fond, G.
TI Real-life data and Covid-19: The third avenue of reseach
SO ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE
LA French
DT Article
DE Psychiatry; Covid; Infection; Treatment; Public health; Method; Evidence
ID MEDICINE
AB The analysis of real-life data from hospital information systems could make possible to decide on the efficacy and safety of Covid-19 treatments by avoiding the pitfalls of preliminary studies and randomized clinical trials. The different drugs tested in current clinical trials are already widely prescribed to patients by doctors in hospitals, and can therefore be immediately analysed according to validated methodological standards. (C) 2020 L'Encephale, Paris.
C1 [Boyer, L.; Auquier, P.; Fond, G.] Aix Marseille Univ Marseille, Fac Med, Ctr Etud & Rech Serv Sante & Qualite Vie CEReSS, Sect Timone,EA 3279, 27 Blvd Jean Moulin, F-13005 Marseille, France.
RP Fond, G (corresponding author), Aix Marseille Univ Marseille, Fac Med, Ctr Etud & Rech Serv Sante & Qualite Vie CEReSS, Sect Timone,EA 3279, 27 Blvd Jean Moulin, F-13005 Marseille, France.
EM guillaume.fond@ap-hm.fr
CR Duba A, 2020, ENCEPHALE
   Fond G, 2020, J AFFECT DISORDERS, V263, P326, DOI 10.1016/j.jad.2019.12.003
   Fond G, 2019, LANCET PUBLIC HEALTH, V4, pE583, DOI 10.1016/S2468-2667(19)30187-2
   Gautret P, 2020, INT J ANTIMICROB AG, DOI 10.1016/ j.tmaid.2020.101663
   Howick J., 2011, BMJ BOOKS
   Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71
   Schmoll S, 2015, ENCEPHALE, V41, P123, DOI 10.1016/j.encep.2013.01.002
   Yao X, 2020, CLIN INFECT DIS, V2
   Zarin DA, 2005, SOC PSYCH PSYCH EPID, V40, P27, DOI 10.1007/s00127-005-0838-9
NR 9
TC 0
Z9 0
U1 0
U2 0
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0013-7006
J9 ENCEPHALE
JI Enceph.-Rev. Psychiatr. Clin. Biol. Ther.
PD JUN
PY 2020
VL 46
IS 3
SU S
BP S114
EP S115
DI 10.1016/j.encep.2020.04.003
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA MF8UE
UT WOS:000545613500016
PM 32362504
OA Green Published
DA 2021-01-01
ER

PT J
AU Fovet, T
   Lancelevee, C
   Eck, M
   Scouflaire, T
   Becache, E
   Dandelot, D
   Giravalli, P
   Guillard, A
   Horrach, P
   Lacambre, M
   Lefebvre, T
   Moncany, AH
   Touitou, D
   David, M
   Thomas, P
AF Fovet, T.
   Lancelevee, C.
   Eck, M.
   Scouflaire, T.
   Becache, E.
   Dandelot, D.
   Giravalli, P.
   Guillard, A.
   Horrach, P.
   Lacambre, M.
   Lefebvre, T.
   Moncany, A-H
   Touitou, D.
   David, M.
   Thomas, P.
TI Mental health care in French correctional facilities during the Covid-19
   pandemic
SO ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE
LA French
DT Article
DE Coronavirus; SARS-Cov-2; Covid-19; Epidemic; Pandemic; Psychiatry;
   Prison; Lockdown
ID PRISON
AB Objective. - The impact of the Covid-19 pandemic on the 11 million people currently incarcerated worldwide is the subject of many concerns. Prisons and jails are filled with people suffering from many preexisting medical conditions increasing the risk of complications. Detainees' access to medical services is already limited and overcrowding poses a threat of massive contagion. Beyond the health impact of the crisis, the tightening of prison conditions worries. On March 16, 2020, in France, the lockdown measures have been accompanied by specific provisions for prisons: all facilities have suspended visitations, group activities and external interventions. Over 10,000 prisoners have been released to reduce the prison population and the risk of virus propagation. These adjustments had major consequences on the healthcare system in French prisons. The objectives of this article are to describe the reorganization of the three levels of psychiatric care for inmates in France in the context of Covid-19 pandemic and to have a look at the impact of lockdown measures and early releases on mental health of prisoners.
   Methods. - This work is based on a survey conducted in April 2020 in France among psychiatric healthcare providers working in 42 ambulatory units for inmates and in the 9 full-time inpatient psychiatric wards exclusively for inmates called "UHSAs" (which stands for "unites hospitalieres specialement arnenagees", and can be translated as "specially equipped hospital units"). A review of the international literature on mental healthcare system for inmates during the Covid-19 epidemic has also been performed.
   Results. - The Covid-19 epidemic has been rather contained during the period of confinement in French prisons but the impact of confinement measures on the prison population is significant. The three levels of psychiatric care for inmates have implemented specific measures to ensure continuity of care, to support detainees during Coronavirus lockdown and to prevent an infection's spread. Among the most important are: limitation of medical consultations to serious and urgent cases, creation of "Covid units", cancellation of voluntary psychiatric hospitalizations, reinforcement of preventive hygiene measures and reshuffling of medical staff. Prolonged confinement has consequences on mental health of detainees. Currently, mental health workers are facing multiple clinical situations such as forced drug and substance withdrawal (linked to difficulties in supplying psychoactive substances), symptoms of anxiety (due to concerns for their own and their relatives' well-being) and decompensation among patients with severe psychiatric conditions. Early releases from prison may also raise some issues. People recently released from prison are identified as at high risk of death by suicide and drug overdose. The lack of time to provide the necessary link between health services within prisons and health structures outside could have serious consequences, emphasizing the well-known "revolving prison doors" effect.
   Discussion. - The current lockdown measures applied in French jails and prisons point out the disparities between psychiatric care for inmates and psychiatric care for general population. Giving the high vulnerability of prison population, public health authorities should pay more attention to health care in prisons. (C) 2020 L'Encephale, Paris.
C1 [Fovet, T.; Eck, M.; Scouflaire, T.; Thomas, P.] CHU Lille, Pole Psychiat, F-59000 Lille, France.
   [Fovet, T.; Thomas, P.] Univ Lille, U1172 Lille Neurosci & Cognit Equipe Plastic & Su, INSERM, F-59000 Lille, France.
   [Lancelevee, C.] Federat Rech Psychiat & Sante Mentale Hauts Franc, St Andre Lez Lille, France.
   [Becache, E.] Ctr Hosp Vinatier, Pole Sante Mentale Detenus & Psychiat Legale, UHSA Simone Veil, Bron, France.
   [Dandelot, D.] Ctr Hosp Cadillac, Pole Psychiat Medicolegale, UHSA, Cadillac, France.
   [Giravalli, P.] AP HM, UMR ADES AMU, Med Legale, Pole Psychiat Med Addictol Detent 11, Marseille, France.
   [Guillard, A.] EPSM Georges Daumezon, Pole Psychiat Milieu Penitentiaire, Loiret, France.
   [Horrach, P.] Ctr Hosp Lorquin, Dept Sante Mentale Justice, Pole SMPR, CPN Nancy Laxou, Lorquin, France.
   [Lacambre, M.] CHU Montpellier, Montpellier, France.
   [Lefebvre, T.] Ctr Hosp Guillaume Regnier, Pole Psychiat Milieu Penitentiaire, UHSA Rennes, Rennes, France.
   [Moncany, A-H] Ctr Hosp Marchant, Pole Psychiat & Conduites Addict Milieu Penitiair, Toulouse, France.
   [Touitou, D.] UHSA Paul Verlaine, Grp Hosp Paul Guiraud, F-94800 Villejuif, France.
   [David, M.] Assoc Secteurs Psychiat Milieu Penitentiaire & Fe, Paris, France.
RP Fovet, T (corresponding author), Unite Hospitalisat Specialement Amenagee UHSA Lil, Chemin Bois Hop, F-59113 Seclin, France.
EM thomas.fovet@chru-lille.fr
RI Fovet, Thomas/I-6845-2019
OI Fovet, Thomas/0000-0003-0077-624X
CR Akiyama MJ, 2020, NEW ENGL J MED, V382, P2075, DOI 10.1056/NEJMp2005687
   [Anonymous], 2020, COVID 19 PRIS MES GO
   [Anonymous], 2020, GLOB PRIS TRENDS 202
   Awofeso N, 2001, AUST NZ J PUBL HEAL, V25, P443, DOI 10.1111/j.1467-842X.2001.tb00290.x
   Baillargeon J, 2009, AM J PSYCHIAT, V166, P103, DOI 10.1176/appi.ajp.2008.08030416
   Besney J, 2017, J INFECT PREV, V18, P193
   Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115
   Burki T, 2020, LANCET, V395, P1411, DOI 10.1016/S0140-6736(20)30984-3
   Chen QN, 2020, LANCET PSYCHIAT, V7, pE15, DOI 10.1016/S2215-0366(20)30078-X
   Chevance A, 2020, ENCEPHALE, DOI [10.1016/j.encep.2020.03.001, DOI 10.1016/J.ENCEP.2020.03.001]
   Cloud DH, 2015, AM J PUBLIC HEALTH, V105, P18, DOI 10.2105/AJPH.2014.302205
   de Labrouhe D, 2017, REV EPIDEMIOL SANTE, V65, P285, DOI 10.1016/j.respe.2017.03.129
   Direction de l'administration penitentiaire, 2020, STAT POP DET ECR ANN
   Dolan K, 2016, LANCET, V388, P1089, DOI 10.1016/S0140-6736(16)30466-4
   Eck M, 2019, PRESSE MED, V48, P46, DOI 10.1016/j.lpm.2018.11.009
   Falissard B, 2006, BMC PSYCHIATRY, V6, DOI 10.1186/1471-244X-6-33
   Fazel S, 2006, ADDICTION, V101, P181, DOI 10.1111/j.1360-0443.2006.01316.x
   Fazel S, 2011, LANCET, V377, P956, DOI 10.1016/S0140-6736(10)61053-7
   Fazel S, 2011, SCHIZOPHRENIA BULL, V37, P800, DOI 10.1093/schbul/sbp135
   Finnie TJR, 2014, EPIDEMIOL INFECT, V142, P107, DOI 10.1017/S0950268813000733
   Fovet T, 2016, ENCEPHALE, V42, P177, DOI 10.1016/j.encep.2015.11.002
   Fovet T, 2020, EUR PSYCHIAT, V63, DOI 10.1192/j.eurpsy.2020.38
   Fovet T, 2020, PSYCHIAT SERV, V71, P824, DOI 10.1176/appi.ps.201900497
   Fovet T, 2015, ANN MED-PSYCHOL, V173, P726, DOI 10.1016/j.amp.2015.07.033
   Fovet T, 2015, LANCET PSYCHIAT, V2, pE20, DOI 10.1016/S2215-0366(15)00272-2
   Fovet T, 2014, PRESSE MED, V43, P520, DOI 10.1016/j.lpm.2013.08.005
   GAFFNEY AW, JAMA INTERN MED, DOI DOI 10.1001/JAMAINTERNMED.2020.1856
   Gharib A, 2019, ENCEPHALE, V45, P139, DOI 10.1016/j.encep.2018.06.004
   Grassian S, 1986, Int J Law Psychiatry, V8, P49, DOI 10.1016/0160-2527(86)90083-X
   GRASSIAN S, 1983, AM J PSYCHIAT, V140, P1450
   Grassian S., 2006, J LAW POLICY, V22, P325
   Haney C., 2020, REFORMING PUNISHMENT
   JIANG XX, PSYCHIAT RES, V286
   Kinner SA, 2020, LANCET PUBLIC HEALTH, V5, pE188, DOI 10.1016/S2468-2667(20)30058-X
   Kinner SA, 2018, EPIDEMIOL REV, V40, P4, DOI 10.1093/epirev/mxx018
   Lee AS, 2014, J CORRECT HEALTH CAR, V20, P228, DOI 10.1177/1078345814532223
   Liebrenz M, 2020, FORENSIC SCI INT MIN, V1
   Mengin A, 2020, ENCEPHALE, V46, pS43, DOI 10.1016/j.encep.2020.04.007
   Metzner JL, 2010, J AM ACAD PSYCHIATRY, V38, P104
   Ministere des Solidarites et de la Sante CAB Solidarites, 2020, FEUILL ROUT SURTR AN
   Moncany AH, 2019, ANN MED-PSYCHOL, V177, P295, DOI 10.1016/j.amp.2019.01.004
   Okano JT, 2020, LANCET, V395, P1542, DOI 10.1016/S0140-6736(20)31015-1
   Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   Reiter K, 2020, AM J PUBLIC HEALTH, V110, pS56, DOI 10.2105/AJPH.2019.305375
   Rupp DE, 1997, J SOC BEHAV PERS, V12, P925
   Simpson PL, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1551
   Simpson PL, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026806
   Subcommittee on Prevention of Torture and Other Cruel Inhuman or Degra- ding Treatment or Punishment, 2020, ADV SUBC PREV TORT S
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wildeman C, 2020, LANCET PUBLIC HEALTH, V5, pE107, DOI 10.1016/S2468-2667(19)30271-3
   World Health Organization, PREP PREV CONTR COVI
   Yang H, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1362
   Yao H, 2020, LANCET PSYCHIAT, V7, pE21, DOI 10.1016/S2215-0366(20)30090-0
   Zhu YH, 2020, NEUROSCI BULL, V36, P299, DOI 10.1007/s12264-020-00476-9
NR 55
TC 3
Z9 3
U1 4
U2 4
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0013-7006
J9 ENCEPHALE
JI Enceph.-Rev. Psychiatr. Clin. Biol. Ther.
PD JUN
PY 2020
VL 46
IS 3
SU S
BP S60
EP S65
DI 10.1016/j.encep.2020.05.002
PG 6
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA MF8UE
UT WOS:000545613500008
PM 32475693
OA Green Published
DA 2021-01-01
ER

PT J
AU Javelot, H
   Llorca, PM
   Drapier, D
   Fakra, E
   Hingray, C
   Meyer, G
   Dizet, S
   Egron, A
   Straczek, C
   Roser, M
   Masson, M
   Gaillard, R
   Fossati, P
   Haffen, E
AF Javelot, H.
   Llorca, P-M
   Drapier, D.
   Fakra, E.
   Hingray, C.
   Meyer, G.
   Dizet, S.
   Egron, A.
   Straczek, C.
   Roser, M.
   Masson, M.
   Gaillard, R.
   Fossati, P.
   Haffen, E.
TI Informations on psychotropics and their adaptations for patients
   suffering from mental disorders in France during the SARS-CoV-2 epidemic
SO ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE
LA French
DT Article
DE COVID-19; Psychotropics; Drug interactions
ID CLOZAPINE; SMOKING
AB The 2019-20 coronavirus pandemic (SARS-CoV-2; severe acute respiratory syndrome coronavirus 2) has dramatic consequences on populations in terms of morbidity and mortality and in social terms, the general confinement of almost half of the world's population being a situation unprecedented in history, which is difficult today to measure the impact at the individual and collective levels. More specifically, it affects people with various risk factors, which are more frequent in patients suffering from psychiatric disorders. Psychiatrists need to know: (i) how to identify, the risks associated with the prescription of psychotropic drugs and which can prove to be counterproductive in their association with COVID-19 (coronavirus disease 2019), (ii) how to assess in terms of benefit/risk ratio, the implication of any hasty and brutal modification on psychotropic drugs that can induce confusion for a differential diagnosis with the evolution of COVID-19. We carried out a review of the literature aimed at assessing the specific benefit/risk ratio of psychotropic treatments in patients suffering from COVID-19. Clinically, symptoms suggestive of COVID-19 (fever, cough, dyspnea, digestive signs) can be caused by various psychotropic drugs and require vigilance to avoid false negatives and false positives. In infected patients, psychotropic drugs should be used with caution, especially in the elderly, considering the pulmonary risk. Lithium and Clozapine, which are the reference drugs in bipolar disorder and resistant schizophrenia, warrant specific attention. For these two treatments the possibility of a reduction in the dosage - in case of minimal infectious signs and in a situation, which does not allow rapid control - should ideally be considered taking into account the clinical response (even biological; plasma concentrations) observed in the face of previous dose reductions. Tobacco is well identified for its effects as an inducer of CYP1A2 enzyme. In a COVID+ patient, the consequences of an abrupt cessation of smoking, particularly related with the appearance of respiratory symptoms (cough, dyspnea), must therefore be anticipated for patients receiving psycho tropics metabolized by CYP1A2. Plasma concentrations of these drugs are expected to decrease and can be related to an increase risk of relapse. The symptomatic treatments used in COVID-19 have frequent interactions with the most used psychotropics. If there is no curative treatment for infection to SARS-CoV-2, the interactions of the various molecules currently tested with several classes of psychotropic drugs (antidepressants, antipsychotics) are important to consider because of the risk of changes in cardiac conduction. Specific knowledge on COVID-19 remains poor today, but we must recommend rigor in this context in the use of psychotropic drugs, to avoid adding, in patients suffering from psychiatric disorders, potentially vulnerable in the epidemic context, an iatrogenic risk or loss of efficiency. (C) 2020 L'Encephale, Paris.
C1 [Javelot, H.] Etab Publ Sante Alsace Nord, Brumath, France.
   [Javelot, H.] Univ Strasbourg, Lab Toxicol & Pharmacol Neurocardiovasc, Strasbourg, France.
   [Llorca, P-M] CHU Clermont Ferrand, Clermont Ferrand, France.
   [Llorca, P-M] Univ Clermont Auvergne, Clermont Ferrand, France.
   [Drapier, D.] Ctr Hosp Guillaume Regnier, Pole Hosp Univ Psychiat Adulte, Rennes, France.
   [Drapier, D.] Univ Rennes 1, EA 4712, Comportements & Noyaux Gris Centraux, Rennes, France.
   [Fakra, E.] CHU St Etienne, Pole Univ Psychiat, St Etienne, France.
   [Hingray, C.] Ctr Psychotherap Nancy, Pole Hosp Univ Psychiat Dadultes Grand Nanc, Laxou, France.
   [Hingray, C.] CHU Nancy, Dept Neurol, Nancy, France.
   [Meyer, G.] Etab Publ Sante Alsace Nord, Serv Pharm, Brumath, France.
   [Meyer, G.] CHU Strasbourg, Serv Pharm, Strasbourg, France.
   [Dizet, S.] CHS Sevrey, Serv Pharm, Chalon Sur Saone, Saone & Loire, France.
   [Egron, A.] Ctr Hosp Cadillac, Serv Pharm, Cadillac, France.
   [Straczek, C.] CHU Henri Mondor, Dept Pharm, Creteil, France.
   [Straczek, C.; Roser, M.] Inst Mondor Rech Biomed, INSERM, U955, Equipe Neuropsychiat Translat 15, Creteil, France.
   [Roser, M.] Serv Psychiat Sectorisee, Hop Albert Chenevier, Creteil, France.
   [Masson, M.] Nightingale Hosp Paris, Clin Chateau Garches, Garches, France.
   [Masson, M.] GHU Psychiat & Neurosci, SHU, Paris, France.
   [Gaillard, R.] Univ Paris, GHU Psychiat & Neurosci, Paris, France.
   [Gaillard, R.] Conseil Natl Univ CNU, Paris, France.
   [Fossati, P.] Sorbonne Univ, Grp Hosp Pitie Salpetriere, AP HP, INSERM,U1127,Serv Psychiat Adultes,ICM, Paris, France.
   [Haffen, E.] CHU Besancon, Serv Psychiat, CIC 1431, INSERM, Besancon, France.
   [Haffen, E.] Univ Franche Comte, Lab Neurosci, Besancon, France.
RP Javelot, H (corresponding author), Univ Strasbourg, Etab Publ Sante Alsace Nord, Lab Toxicol & Pharmacol Neurocardiovasc, Brumath Strasbourg, France.
EM herve.javelot@ch-epsan.fr
CR Anderson GD, 2016, CLIN PHARMACOKINET, V55, P1353, DOI 10.1007/s40262-016-0400-9
   ANSM, 2019, THES INT MED
   Baldessarini RJ, 1996, AM J THER, V3, P492
   Bansal M, 2020, DIABETES METAB SYND, V14, P247, DOI 10.1016/j.dsx.2020.03.013
   Berliner D, 2016, DTSCH ARZTEBL INT, V113, P834, DOI 10.3238/arztebl.2016.0834
   Boivin Z, 2019, ERJ OPEN RES, V5, DOI 10.1183/23120541.00223-2018
   Briet J, 2017, THERAPIE, V72, P427, DOI 10.1016/j.therap.2016.12.010
   Chatterjee S, 2016, J AM GERIATR SOC, V64, P394, DOI 10.1111/jgs.13932
   Chevance A, 2020, ASSURER SOINS PATIEN
   Chiappini S, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10020105
   Ciriaco M, 2013, J PHARMACOL PHARMACO, V4, pS94, DOI 10.4103/0976-500X.120975
   Correll CU, 2015, WORLD PSYCHIATRY, V14, P119, DOI 10.1002/wps.20204
   Couchman L, 2010, THER DRUG MONIT, V32, P438, DOI 10.1097/FTD.0b013e3181dad1fb
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1086
   de Leon J, 2004, PSYCHIAT SERV, V55, P491, DOI 10.1176/appi.ps.55.5.491
   de Leon J, 2020, WORLD PSYCHIATRY, V19, P120, DOI 10.1002/wps.20707
   Carvalho PMD, 2020, PSYCHIAT RES, V286, DOI 10.1016/j.psychres.2020.112902
   Dubovsky AN, 2012, PSYCHOSOMATICS, V53, P103, DOI 10.1016/j.psym.2011.12.007
   Dzahini O, 2018, J PSYCHOPHARMACOL, V32, P1167, DOI 10.1177/0269881118795333
   Fankhauser MP, 2013, CURR PSYCHIAT, V12, P12
   Fava GA, 2018, PSYCHOTHER PSYCHOSOM, V87, P195, DOI 10.1159/000491524
   Fava GA, 2015, PSYCHOTHER PSYCHOSOM, V84, P72, DOI 10.1159/000370338
   FFP-CNPP, 2015, REC BONN PRAT PSYCH
   FitzGerald GA, 2020, SCIENCE, V367, P1434, DOI 10.1126/science.abb8034
   Franke AG, 2014, EUR ARCH PSY CLIN N, V264, pS83, DOI 10.1007/s00406-014-0537-1
   Gauthier C, 2018, ENCEPHALE, V44, P379, DOI 10.1016/j.encep.2018.08.001
   Gautret P, 2020, INT J ANTIMICROB, DOI DOI 10.1016/J.IJANTIMICAG.2020.105949[105949]
   Gitlin MJ, 2016, INT J BIPOLAR DISORD, V4, P27
   Guina J, 2018, J CLIN MED, V7, DOI 10.3390/jcm7020020
   Hancox JC, 2013, THER ADV INFECT DIS, V1, P155, DOI 10.1177/2049936113501816
   Jamshidi N, 2019, AUST PRESCR, V42, P24, DOI 10.18773/austprescr.2019.006
   Johnson BA, 2014, HDB CLIN NEUROL, V125, P543
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Keks N, 2019, AUST PRESCR, V42, P152, DOI 10.18773/austprescr.2019.052
   Koonrungsesomboon N, 2018, PHARMACOGENOMICS J, V18, P760, DOI 10.1038/s41397-017-0011-3
   Li W, 2020, INT J BIOL SCI, V16, P1732, DOI 10.7150/ijbs.45120
   Little P, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1185
   Lowe EJ, 2010, ANN PHARMACOTHER, V44, P727, DOI 10.1345/aph.1M398
   LOWRY R, 1994, BRIT J CLIN PHARMACO, V37, P187, DOI 10.1111/j.1365-2125.1994.tb04259.x
   Montastruc JL, 2000, LETT PHARM, V14
   Moret C, 2009, J PSYCHOPHARMACOL, V23, P967, DOI 10.1177/0269881108093582
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   MULLEROERLINGHAUSE, ADV BIOL PSYCHIAT, V30, P145, DOI DOI 10.1159/000434747
   Oka T, 2018, HAND CLINIC, V157, P599, DOI 10.1016/B978-0-444-64074-1.00035-5
   Olivier B., 2015, TEMPERATURE, V2, P324, DOI 10.1080/23328940.2015.1071701
   Paul KJ, 2015, J AM GERIATR SOC, V63, P476, DOI 10.1111/jgs.13327
   Philpott HL, 2014, FRONTLINE GASTROENTE, V5, P49, DOI 10.1136/flgastro-2013-100316
   Rajamaki B, 2020, DRUG AGING, V37, P241, DOI 10.1007/s40266-020-00754-1
   Ricoux A, 2013, REV MED INTERNE, V34, P293, DOI 10.1016/j.revmed.2012.12.011
   Rochoy M, 2017, REV EPIDEMIOL SANTE, V65, P1, DOI 10.1016/j.respe.2016.06.335
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   Simou E, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022344
   Siskind D, 2020, J PSYCHIAT NEUROSCI, V45, P2
   Sisson JH, 2007, ALCOHOL, V41, P293, DOI 10.1016/j.alcohol.2007.06.003
   Spreux-Varoquaux O, 2013, INFO PSYCHIAT, V10, P819
   Sultana J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187034
   Trifiro Gianluca, 2011, Curr Infect Dis Rep, V13, P262, DOI 10.1007/s11908-011-0175-y
   Tsuda Y, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004216
   Vandael E, 2017, INT J CLIN PHARM-NET, V39, P16, DOI 10.1007/s11096-016-0414-2
   Verdoux H, 2019, SCHIZOPHR RES, V211, P1, DOI 10.1016/j.schres.2019.07.040
   Wagner S, 2011, EUR J CLIN PHARMACOL, V67, P533, DOI 10.1007/s00228-010-0925-z
   Wijeratne C, 2011, AUST NZ J PSYCHIAT, V45, P1026, DOI 10.3109/00048674.2011.610296
   Willsher K., 2020, ANTIINFLAMMATORIES M
   Wilson E, 2015, THER ADV PSYCHOPHARM, V5, P357, DOI 10.1177/2045125315612334
   Woosley RL, 2018, TRENDS CARDIOVAS MED, V28, P94, DOI 10.1016/j.tcm.2017.07.010
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yadav DS, 2013, PROG NEUROL PSYCHIAT, V17, P14, DOI 10.1002/pnp.272
   Yang SY, 2013, J CLIN PSYCHIAT, V74, pE79, DOI 10.4088/JCP.12m07938
   Zalsman G, 2016, LANCET PSYCHIAT, V3, P646, DOI 10.1016/S2215-0366(16)30030-X
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 71
TC 1
Z9 1
U1 1
U2 1
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0013-7006
J9 ENCEPHALE
JI Enceph.-Rev. Psychiatr. Clin. Biol. Ther.
PD JUN
PY 2020
VL 46
IS 3
SU S
BP S14
EP S34
DI 10.1016/j.encep.2020.04.006
PG 21
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA MF8UE
UT WOS:000545613500003
PM 32376004
OA Green Published
DA 2021-01-01
ER

PT J
AU Plaze, M
   Attali, D
   Petit, AC
   Blatzer, M
   Simon-Loriere, E
   Vinckier, F
   Cachia, A
   Chretien, F
   Gaillard, R
AF Plaze, M.
   Attali, D.
   Petit, A-C
   Blatzer, M.
   Simon-Loriere, E.
   Vinckier, F.
   Cachia, A.
   Chretien, F.
   Gaillard, R.
TI Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study
SO ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE
LA French
DT Article
DE Chlorpromazine; SARS-CoV-2; COVID-19; Repurposing of drugs; Clinical
   trial
ID IL-10 PRODUCTION; TNF PRODUCTION; VIRUS; BRAIN; CELLS; REPLICATION;
   METABOLITES; INHIBITION; INFECTION; DRUG
AB Objectives. - The ongoing COVID-19 pandemic comprises a total of more than 2,350,000 cases and 160,000 deaths. The interest in anti-coronavirus drug development has been limited so far and effective methods to prevent or treat coronavirus infections in humans are still lacking. Urgent action is needed to fight this fatal coronavirus infection by reducing the number of infected people along with the infection contagiousness and severity. Since the beginning of the COVID-19 outbreak several weeks ago, we observe in GHU PARIS Psychiatrie & Neurosciences (Sainte-Anne hospital, Paris, France) a lower prevalence of symptomatic and severe forms of COVID-19 infections in psychiatric patients (similar to 4%) compared to health care professionals (similar to 14%). Similar observations have been noted in other psychiatric units in France and abroad. Our hypothesis is that psychiatric patients could be protected from severe forms of COVID-19 by their psychotropic treatments. Chlorpromazine (CPZ) is a phenothiazine derivative widely used in clinical routine in the treatment of acute and chronic psychoses. This first antipsychotic medication has been discovered in 1952 by Jean Delay and Pierre Deniker at Sainte-Anne hospital. In addition, to its antipsychotic effects, several in vitro studies have also demonstrated a CPZ antiviral activity via the inhibition of clathrin-mediated endocytosis. Recently, independent studies revealed that CPZ is an anti-MERS-CoV and an anti-SARS-CoV-1 drug. In comparison to other antiviral drugs, the main advantages of CPZ lie in its biodistribution: (i) preclinical and clinical studies have reported a high CPZ concentration in the lungs (20-200 times higher than in plasma), which is critical because of the respiratory tropism of SARS-CoV-2; (ii) CPZ is highly concentrated in saliva (30-100 times higher than in plasma) and could therefore reduce the contagiousness of COVID-19; (iii) CPZ can cross the blood -brain barrier and could therefore prevent the neurological forms of COVID-19.
   Methods. - Our hypothesis is that CPZ could decrease the unfavorable evolution of COVID-19 infection in oxygen-requiring patients without the need for intensive care, but also reduce the contagiousness of SARS-CoV-2. At this end, we designed a pilot, phase III, multicenter, single blind, randomized controlled clinical trial. Efficacy of CPZ will be assessed according to clinical, biological and radiological criteria. The main objective is to demonstrate a shorter time to response (TTR) to treatment in the CPZ + standard of-care (CPZ + SOC) group, compared to the SOC group. Response to treatment is defined by a reduction of at least one level of severity on the WHO-Ordinal Scale for Clinical Improvement (WHO-OSCI). The secondary objectives are to demonstrate in the CPZ + SOC group, compared to the SOC group: (A) superior clinical improvement; (B) a greater decrease in the biological markers of viral attack by SARS-CoV-2 (PCR, viral load); (C) a greater decrease in inflammatory markers (e.g. CRP and lymphopenia); (D) a greater decrease in parenchymal involvement (chest CT) on the seventh day post-randomization; (E) to define the optimal dosage of CPZ and its tolerance; (F) to evaluate the biological parameters of response to treatment, in particular the involvement of inflammatory cytokines. Patient recruitment along with the main and secondary objectives are in line with WHO 2020 COVID-19 guidelines.
   Conclusion. - This repositioning of CPZ as an anti-SARS-CoV-2 drug offers an alternative and rapid strategy to alleviate the virus propagation and the infection severity and lethality. This CPZ repositioning strategy also avoids numerous developmental and experimental steps and can save precious time to rapidly establish an anti-COVID-19 therapy with well-known, limited and easy to manage side effects. Indeed, CPZ is an FDA-approved drug with an excellent tolerance profile, prescribed for around 70 years in psychiatry but also in clinical routine in nausea and vomiting of pregnancy, in advanced cancer and also to treat headaches in various neurological conditions. The broad spectrum of CPZ treatment including antipsychotic, anxiolytic, antiemetic, antiviral, immunomodulatory effects along with inhibition of clathrin-mediated endocytosis and modulation of blood-brain barrier is in line with the historical French commercial name for CPZ, i.e. LARGACTIL, chosen as a reference to its "LARGe ACTion" properties. The discovery of those CPZ properties, as for many other molecules in psychiatry, is both the result of serendipity and careful clinical observations. Using this approach, the field of mental illness could provide innovative therapeutic approaches to fight SARS-CoV-2. (C) 2020 L'Encephale, Paris.
C1 [Plaze, M.; Attali, D.; Petit, A-C; Vinckier, F.; Gaillard, R.] Pole Hosp Univ Paris 15, GHU Paris Psychiat & Neurosci, Serv Hosp Univ, Paris, France.
   [Plaze, M.; Attali, D.; Vinckier, F.; Gaillard, R.] Univ Paris, Paris, France.
   [Attali, D.] PSL Res Univ, Univ Paris Diderot, Sorbonne Paris Cite, Phys Med Paris,INSERM,ESPCI Paris,CNRS, Paris, France.
   [Petit, A-C; Blatzer, M.; Chretien, F.; Gaillard, R.] Inst Pasteur, Expt Neuropathol Unit, Paris, France.
   [Simon-Loriere, E.] Inst Pasteur, G5 Evolutionary Genom RNA Viruses, Paris, France.
   [Cachia, A.] Univ Paris, Inst Psychiat & Neurosci Paris, INSERM, Paris, France.
   [Cachia, A.] Univ Paris, Lab Psychol Dev & Educ Enfant, CNRS, Paris, France.
   [Chretien, F.] GHU PARIS Psychiat & Neurosci, Serv Neuropathol, Paris, France.
RP Plaze, M (corresponding author), GHU PARIS Psychiat & Neurosci, Serv Hosp Univ, Site St Anne,1,Rue Cabanis, F-75014 Paris, France.
EM m.plaze@ghu-paris.fr
RI Blatzer, Michael/AAZ-3824-2020
OI PETIT, Anne-Cecile/0000-0003-4143-9848; Cachia,
   Arnaud/0000-0003-2125-4985
CR [Anonymous], SIT UPD WORLDW AS 20
   BERTINI R, 1993, IMMUNOLOGY, V79, P217
   BICKEL MH, 1983, LIFE SCI, V33, P2025, DOI 10.1016/0024-3205(83)90742-7
   Blanchard E, 2006, J VIROL, V80, P6964, DOI 10.1128/JVI.00024-06
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Chu Hin, 2020, Lancet Microbe, V1, pe14, DOI 10.1016/S2666-5247(20)30004-5
   COMAR D, 1979, PSYCHIAT RES, V1, P23, DOI 10.1016/0165-1781(79)90024-6
   Committee on Practice B-O, 2018, OBSTET GYNECOL, V131, pe15
   Cong Y, 2018, PLOS ONE, V13
   Daniel JA, 2015, TRAFFIC, V16, P635, DOI 10.1111/tra.12272
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   DELAY J, 1952, Ann Med Psychol (Paris), V110, P112
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   FORREST IS, 1968, BIOCHEM PHARMACOL, V17, P2061, DOI 10.1016/0006-2952(68)90180-9
   GADINA M, 1991, J EXP MED, V173, P1305, DOI 10.1084/jem.173.6.1305
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE
   Gupta M, 2013, J PAIN SYMPTOM MANAG, V45, P338, DOI 10.1016/j.jpainsymman.2012.10.042
   Hcsp, 2020, COR SARS COV 2 CRIT
   Hewlett I, 1997, J ACQ IMMUN DEF SYND, V15, P16, DOI 10.1097/00042560-199705010-00003
   Kanerva A, 2007, J GENE MED, V9, P3, DOI 10.1002/jgm.984
   KRIZANOVA O, 1982, ACTA VIROL, V26, P209
   Marmura MJ, 2015, HEADACHE, V55, P3, DOI 10.1111/head.12499
   MAY PRA, 1981, ARCH GEN PSYCHIAT, V38, P202
   MENGOZZI M, 1994, IMMUNOLOGY, V82, P207
   Nawa M, 2003, J GEN VIROL, V84, P1737, DOI 10.1099/vir.0.18883-0
   Pho MT, 2000, J VIROL, V74, P2288, DOI 10.1128/JVI.74.5.2288-2292.2000
   Pohjala L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028923
   Pollmacher T, 2000, J PSYCHIATR RES, V34, P369, DOI 10.1016/S0022-3956(00)00032-7
   Rundle-Thiele D, 2016, BRIT J CLIN PHARMACO, V81, P199, DOI 10.1111/bcp.12785
   SGARAGLI GP, 1995, J PHARM PHARMACOL, V47, P782, DOI 10.1111/j.2042-7158.1995.tb06741.x
   SJOSTRAND SE, 1965, ARCH INT PHARMACOD T, V156, P34
   TARAZONA R, 1995, J IMMUNOL, V154, P861
   TSUNEIZUMI T, 1992, BIOL PSYCHIAT, V32, P817, DOI 10.1016/0006-3223(92)90085-E
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107
   Weinman D, 2014, HEADACHE, V54, P260, DOI 10.1111/head.12287
   WHO, COR DIS COVID 2019 R
   WIESEL FA, 1976, EUR J PHARMACOL, V40, P263, DOI 10.1016/0014-2999(76)90061-3
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Yang ND, 2020, INT J BIOL SCI, V16, P1724, DOI 10.7150/ijbs.45498
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   ZUCKER S, 1990, MEDICINE, V69, P92, DOI 10.1097/00005792-199069020-00003
NR 42
TC 8
Z9 8
U1 3
U2 3
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0013-7006
J9 ENCEPHALE
JI Enceph.-Rev. Psychiatr. Clin. Biol. Ther.
PD JUN
PY 2020
VL 46
IS 3
SU S
BP S35
EP S39
DI 10.1016/j.encep.2020.04.010
PG 5
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA MF8UE
UT WOS:000545613500004
PM 32387014
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Sauvaget, A
   Dumont, R
   Bukowski, N
   Bonnot, O
   Auffret, R
   Poulet, E
   Szekely, D
   Quiles, C
   Yrondi, A
   Plaze, M
   de Carvalho, W
   Amad, A
   Bulteau, S
AF Sauvaget, A.
   Dumont, R.
   Bukowski, N.
   Bonnot, O.
   Auffret, R.
   Poulet, E.
   Szekely, D.
   Quiles, C.
   Yrondi, A.
   Plaze, M.
   de Carvalho, W.
   Amad, A.
   Bulteau, S.
TI Recommendations for a gradual and controlled resumption of
   electroconvulsive therapy in France during the period of lifting of the
   containment and of the COVID-19 pandemic linked to SARS-CoV-2
SO ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE
LA French
DT Article
DE Electroconvulsive therapy; Guidelines; Accessibility; COVID-19
AB The COVID-19 pandemic has had major consequences for the organization of care. In France and around the world, centers practicing electroconvulsive therapy (ECT) have seen their activity decrease, or even stop for many reasons. In this context, maintaining or resuming this essential therapeutic activity for many patients suffering from psychiatric disorders requires material, human and logistical adaptations that should be supervised. The objective of this collective and national work is to offer simple recommendations that can be applied immediately by any healthcare establishment, public or private, practicing ECT. They are the result of feedback from multiprofessional and inter-establishment experiences. Declined in three stages, these recommendations are accompanied by a practical sheet which describes in detail the necessary conditions and prerequisites for any resumption of ECT activity. (C) 2020 L'Encephale,
C1 [Sauvaget, A.; Poulet, E.; Szekely, D.; Yrondi, A.; Plaze, M.; Bulteau, S.] French Soc Biol Psychiat & Neuropsychopharmacol, STEP Sect Stimulat Transcranienne Psychiat, St Germain En Laye, France.
   [Sauvaget, A.] Univ Nantes, EA 4334, Nantes Univ, CHU Nantes,Movement,Interact,Performance MIP, Nantes, France.
   [Dumont, R.] CHU Nantes, Dept Anesthesiol & Crit Care Med, Hotel Dieu PTMC, Nantes, France.
   [Bukowski, N.; Auffret, R.; Bulteau, S.] CHU Nantes, Dept Addictol & Psychiat, Nantes, France.
   [Bonnot, O.] CHU, Child & Adolescent Psychiat Dept, Nantes, France.
   [Bonnot, O.] Univ Nantes, Nantes, France.
   [Poulet, E.] Ctr Hosp Le Vinatier, Bron, France.
   [Poulet, E.] Univ Lille, INSERM, CHU Lille, U1172,LiINCog Lille Neurosci & Cognit, F-69000 Lyon, France.
   [Poulet, E.] Univ Lyon 1, F-69000 Villeurbanne, France.
   [Poulet, E.] Univ Hosp Edouard Herriot, Dept Emergency Psychiat, Hosp Civils Lyon, Lyon, France.
   [Szekely, D.] Ctr Hosp Princesse Grace, Dept Psychiat, F-98000 Monaco, Monaco.
   [Quiles, C.] Ctr Hosp Charles Perrens, F-33000 Bordeaux, France.
   [Yrondi, A.] CHU Toulouse, Ctr Expert Depress Resistante Fondamental, Serv Psychiat & Psychol Med, Toulouse, France.
   [Yrondi, A.] Univ Toulouse, Hop Purpan, ToNIC Toulouse NeuroImaging Ctr, INSERM,UPS, Toulouse, France.
   [Plaze, M.] Univ Paris, F-75005 Paris, France.
   [Plaze, M.] GHU Paris Psychiat & Neurosci, Serv Hosp Univ, F-75014 Paris, France.
   [de Carvalho, W.] Clin BELLEVUE, Grp SINOUE, Pole ECT, F-92190 Meudon, France.
   [Amad, A.] Univ Lille, CHU Lille, INSERM, U1172,LiINCog Lille Neurosci & Cognit, F-59000 Lille, France.
   [Bulteau, S.] SPHERE Univ Nantes, INSERM, U1246, Nantes, France.
   [Bulteau, S.] Univ Tours, Nantes, France.
RP Sauvaget, A (corresponding author), French Soc Biol Psychiat & Neuropsychopharmacol, STEP Sect Stimulat Transcranienne Psychiat, St Germain En Laye, France.
EM anne.sauvaget@chu-nantes.fr
CR Amad A, 2020, ENCEPHALE, V46, pS40, DOI 10.1016/j.encep.2020.04.004
   ANAES, 1998, IND MOD EL
   Bulteau S, 2018, J ECT, V34, P55, DOI 10.1097/YCT.0000000000000451
   Chevance A, 2020, ENCEPHALE, DOI [10.1016/j.encep.2020.03.001, DOI 10.1016/J.ENCEP.2020.03.001]
   Consoli A, 2010, J ECT, V26, P259, DOI 10.1097/YCT.0b013e3181fb3924
   Espinoza Randall T, 2020, J ECT, DOI 10.1097/YCT.0000000000000689
   Jelovac A, 2013, NEUROPSYCHOPHARMACOL, V38, P2467, DOI 10.1038/npp.2013.149
   Longpre-Poirier C, 2020, AM J GERIAT PSYCHIAT, V28, P892, DOI 10.1016/j.jagp.2020.04.024
   Poulet Emmanuel, 2012, ELECTROCONVULSIVOTHE, P403
   Samalin L, 2020, J AFFECT DISORDERS, V264, P318, DOI 10.1016/j.jad.2020.01.004
   Sauvaget A, 2018, J ECT, V34, P211, DOI 10.1097/YCT.0000000000000513
   Sienaert P, 2020, AM J GERIAT PSYCHIAT, V28, P772, DOI 10.1016/j.jagp.2020.04.013
   Tor Phern Chern, 2020, J ECT, DOI 10.1097/YCT.0000000000000690
NR 13
TC 0
Z9 0
U1 0
U2 0
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0013-7006
J9 ENCEPHALE
JI Enceph.-Rev. Psychiatr. Clin. Biol. Ther.
PD JUN
PY 2020
VL 46
IS 3
SU S
BP S119
EP S122
DI 10.1016/j.encep.2020.05.008
PG 4
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA MF8UE
UT WOS:000545613500018
PM 32507557
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Ayerbe, L
   Risco, C
   Ayis, S
AF Ayerbe, Luis
   Risco, Carlos
   Ayis, Salma
TI The association between treatment with heparin and survival in patients
   with Covid-19
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Article
DE Coronavirus infections; Covid-19; Thrombosis; Pulmonary embolism;
   Heparin; Mortality
AB This study investigates the association between the treatment with heparin and mortality in patients admitted with Covid-19. Routinely recorded, clinical data, up to the 24th of April 2020, from the 2075 patients with Covid-19, admitted in 17 hospitals in Spain between the 1st of March and the 20th of April 2020 were used. The following variables were extracted for this study: age, gender, temperature, and saturation of oxygen on admission, treatment with heparin, hydroxychloroquine, azithromycin, steroids, tocilizumab, a combination of lopinavir with ritonavir, and oseltamivir, together with data on mortality. Multivariable logistic regression models were used to investigate the associations. At the time of collecting the data, 301 patients had died, 1447 had been discharged home from the hospitals, 201 were still admitted, and 126 had been transferred to hospitals not included in the study. Median follow up time was 8 (IQR 5-12) days. Heparin had been used in 1734 patients. Heparin was associated with lower mortality when the model was adjusted for age and gender, with OR (95% CI) 0.55 (0.37-0.82) p = 0.003. This association remained significant when saturation of oxygen < 90%, and temperature > 37 degrees C were added to de model with OR 0.54 (0.36-0.82) p = 0.003, and also when all the other drugs were included as covariates OR 0.42 (0.26-0.66) p < 0.001. The association between heparin and lower mortality observed in this study can be acknowledged by clinicians in hospitals and in the community. Randomized controlled trials to assess the causal effects of heparin in different therapeutic regimes are required.
C1 [Ayerbe, Luis] Queen Mary Univ London, Ctr Primary Care & Publ Hlth, 58 Turner St, London E1 2AB, England.
   [Ayerbe, Luis] Carnarvon Med Ctr, Southend On Sea, England.
   [Risco, Carlos] Hosp Univ HM Sanchinarro, Serv Internal Med, Madrid, Spain.
   [Ayis, Salma] Kings Coll London, Sch Populat Hlth & Environm Sci, London, England.
   [Ayis, Salma] Guys & St Thomas NHS Fdn Trust, Natl Inst Hlth Res, Biomed Res Ctr, London, England.
RP Ayerbe, L (corresponding author), Queen Mary Univ London, Ctr Primary Care & Publ Hlth, 58 Turner St, London E1 2AB, England.; Ayerbe, L (corresponding author), Carnarvon Med Ctr, Southend On Sea, England.
EM l.garcia-morzon@qmul.ac.uk
OI Ayerbe Garcia-Monzon, Luis/0000-0001-7177-0262; Ayis,
   Salma/0000-0002-0449-869X
FU National Institute for Health Research (NIHR) Biomedical Research Centre
   based at Guy's and St Thomas' NHS Foundation Trust and King's College
   London
FX Salma Ayis was funded by the National Institute for Health Research
   (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS
   Foundation Trust and King's College London. The views expressed are
   those of the authors and not necessarily those of the NHS, the NIHR or
   the Department of Health.
CR [Anonymous], 2020, LANCET, V395, P1011, DOI DOI 10.1016/S0140-6736(20)30686-3
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Carsana L, 2020, PULMONARY POSTMORTEM, DOI [10.1101/2020.04.19.20054262, DOI 10.1101/2020.04.19.20054262]
   Cattaneo M, 2020, THROMB HAEMOSTASIS, V120, P1230, DOI 10.1055/s-0040-1712097
   Lang Min, 2020, Lancet Infect Dis, V20, P1365, DOI 10.1016/S1473-3099(20)30367-4
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   WHO, 2020, COR DIS COVID 19 PAN
   World Health Organization, 2020, NAM COR DIS COVID 19
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
NR 11
TC 20
Z9 21
U1 1
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
PD AUG
PY 2020
VL 50
IS 2
BP 298
EP 301
DI 10.1007/s11239-020-02162-z
EA MAY 2020
PG 4
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA ML6VE
UT WOS:000536747700001
PM 32476080
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wilson, A
   Warrier, A
   Rathish, B
AF Wilson, Arun
   Warrier, Anup
   Rathish, Balram
TI Contact tracing: a lesson from the Nipah virus in the time of COVID-19
SO TROPICAL DOCTOR
LA English
DT Article
DE COVID-19; Nipah; contact tracing; contact list
AB Without a vaccine or proven therapeutic options in COVID-19, the World Health Organization (WHO) recommends a combination of measures: rapid diagnosis and immediate isolation of cases; rigorous contact tracing; and precautionary self-isolation of close contacts to curb the spread of COVID-19. During a Nipah outbreak in Kerala, India in 2019, it was confined to a single case. The authors were involved in the in-hospital contact tracing. With a single patient producing a contact list of 98 in a healthcare setting, the implications in a community setting during a pandemic of the scale of COVID-19 are huge but it proves that early and rigorous tracing with quarantining is an effective strategy to limit clusters. We believe that if the public is encouraged to maintain their own contact list on a daily basis, it would help in significantly reducing the time and effort invested into contact tracing in the event of a person contracting COVID-19.
C1 [Wilson, Arun; Warrier, Anup] Aster Medc, Dept Infect Dis, Kochi, Kerala, India.
   [Rathish, Balram] Dept Internal Med, Aster Medc, Kochi, Kerala, India.
RP Rathish, B (corresponding author), Dept Internal Med, Aster Medc, Kochi, Kerala, India.
EM balramrnair@gmail.com
OI Wilson, Arun/0000-0002-2200-3611; Rathish, Balram/0000-0002-5630-704X
CR Aditi, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268819000086
   Arunkumar G, 2019, J INFECT DIS, V219, P1867, DOI 10.1093/infdis/jiy612
   Bhalla A, 2020, INDIA TODAY
   Centers for Disease Control and Prevention (CDC), 2020, CONT TRAC PART MULT
   De La Garza A, 2020, WHAT IS CONTACT TRAC
   Marcel S, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20225
   Morrison S, 2020, GUARDIAN
   World Health Organization, 2020, 99 WHO
NR 8
TC 1
Z9 1
U1 2
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0049-4755
EI 1758-1133
J9 TROP DOCT
JI Trop. Dr.
PD JUL
PY 2020
VL 50
IS 3
BP 174
EP 175
AR 0049475520928217
DI 10.1177/0049475520928217
EA MAY 2020
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA MS8TT
UT WOS:000537160900001
PM 32476600
OA Bronze
DA 2021-01-01
ER

PT J
AU Kelly, ME
   Murphy, E
   Bolger, JC
   Cahill, RA
AF Kelly, M. E.
   Murphy, E.
   Bolger, J. C.
   Cahill, R. A.
TI COVID-19 and the treatment of acute appendicitis in Ireland: a new era
   or short-term pivot?
SO COLORECTAL DISEASE
LA English
DT Letter
ID UNCOMPLICATED APPENDICITIS; ANTIBIOTIC-THERAPY; APPENDECTOMY
C1 [Kelly, M. E.; Murphy, E.; Bolger, J. C.; Cahill, R. A.] Mater Misericordiae Univ Hosp, Dept Surg, Dublin, Ireland.
RP Kelly, ME (corresponding author), Mater Misericordiae Univ Hosp, Dept Surg, Dublin, Ireland.
EM Kellym11@tcd.ie
CR American College of Surgeons, COVID 19 GUID TRAIG
   Brat Gabriel A, 2020, Ann Surg, DOI 10.1097/SLA.0000000000003926
   Hansson J, 2009, BRIT J SURG, V96, P473, DOI 10.1002/bjs.6482
   Lei S, 2020, ECLINICALMEDICINE, V21, DOI [10.1016/j.eclinm.2020.100331.9., DOI 10.1016/JECLINM.2020.200331]
   O'Connell EP, 2018, IRISH J MED SCI, V187, P1029, DOI 10.1007/s11845-018-1758-5
   Park HC, 2014, INT J SURG, V12, P897, DOI 10.1016/j.ijsu.2014.07.011
   Royal College of Surgeons, UPD GEN SURG GUID CO
   Vons C, 2011, LANCET, V377, P1573, DOI 10.1016/S0140-6736(11)60410-8
NR 8
TC 4
Z9 5
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8910
EI 1463-1318
J9 COLORECTAL DIS
JI Colorectal Dis.
PD JUN
PY 2020
VL 22
IS 6
BP 648
EP 649
DI 10.1111/codi.15141
EA MAY 2020
PG 2
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA LY1SX
UT WOS:000536337900001
PM 32403188
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Yang, YC
AF Yang, Yichang
TI Use of herbal drugs to treat COVID-19 should be with caution
SO LANCET
LA English
DT Letter
C1 [Yang, Yichang] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Tradit Chinese Med, Hangzhou 310009, Peoples R China.
RP Yang, YC (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Tradit Chinese Med, Hangzhou 310009, Peoples R China.
EM yangyichang.ll@163.com
CR [Anonymous], 2017, NATURE, V551, P541, DOI DOI 10.1038/D41586-017-07650-6
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Ding YW, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1585-7
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   Lord GM, 2001, LANCET, V358, P1515, DOI 10.1016/S0140-6736(01)06576-X
   National Health Commission, 2020, PRESS C JOINT PREV C
   National Health Commission, 2020, DIAGN TREATM PROT CO
   VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2
   Yang Y, 2020, TRADITIONAL CHINESE
NR 10
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD MAY 30
PY 2020
VL 395
IS 10238
BP 1689
EP 1690
DI 10.1016/S0140-6736(20)31143-0
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA ND0PJ
UT WOS:000561610000016
PM 32422123
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hung, IFN
   Lung, KC
   Tso, EYK
   Liu, R
   Chung, TWH
   Chu, MY
   Ng, YY
   Lo, J
   Chan, J
   Tam, AR
   Shum, HP
   Chan, V
   Wu, AKL
   Sin, KM
   Leung, WS
   Law, WL
   Lung, DC
   Sin, S
   Yeung, P
   Yip, CCY
   Zhang, RR
   Fung, AYF
   Yan, EYW
   Leung, KH
   Ip, JD
   Chu, AWH
   Chan, WM
   Ng, ACK
   Lee, R
   Fung, K
   Yeung, A
   Wu, TC
   Chan, JWM
   Yan, WW
   Chan, WM
   Chan, JFW
   Lie, AKW
   Tsang, OTY
   Cheng, VCC
   Que, TL
   Lau, CS
   Chan, KH
   To, KKW
   Yuen, KY
AF Hung, Ivan Fan-Ngai
   Lung, Kwok-Cheung
   Tso, Eugene Yuk-Keung
   Liu, Raymond
   Chung, Tom Wai-Hin
   Chu, Man-Yee
   Ng, Yuk-Yung
   Lo, Jenny
   Chan, Jacky
   Tam, Anthony Raymond
   Shum, Hoi-Ping
   Chan, Veronica
   Wu, Alan Ka-Lun
   Sin, Kit-Man
   Leung, Wai-Shing
   Law, Wai-Lam
   Lung, David Christopher
   Sin, Simon
   Yeung, Pauline
   Yip, Cyril Chik-Yan
   Zhang, Ricky Ruiqi
   Fung, Agnes Yim-Fong
   Yan, Erica Yuen-Wing
   Leung, Kit-Hang
   Ip, Jonathan Daniel
   Chu, Allen Wing-Ho
   Chan, Wan-Mui
   Ng, Anthony Chin-Ki
   Lee, Rodney
   Fung, Kitty
   Yeung, Alwin
   Wu, Tak-Chiu
   Chan, Johnny Wai-Man
   Yan, Wing-Wah
   Chan, Wai-Ming
   Chan, Jasper Fuk-Woo
   Lie, Albert Kwok-Wai
   Tsang, Owen Tak-Yin
   Cheng, Vincent Chi-Chung
   Que, Tak-Lun
   Lau, Chak-Sing
   Chan, Kwok-Hung
   To, Kelvin Kai-Wang
   Yuen, Kwok-Yung
TI Triple combination of interferon beta-1b, lopinavir-ritonavir, and
   ribavirin in the treatment of patients admitted to hospital with
   COVID-19: an open-label, randomised, phase 2 trial
SO LANCET
LA English
DT Article
ID SARS CORONAVIRUS; IN-VITRO; INFECTION; LOPINAVIR/RITONAVIR; INFLUENZA
AB Background Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir-ritonavir, and ribavirin for treating patients with COVID-19.
   Methods This was a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19 who were admitted to six hospitals in Hong Kong. Patients were randomly assigned (2:1) to a 14-day combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days (combination group) or to 14 days of lopinavir 400 mg and ritonavir 100 mg every 12 h (control group). The primary endpoint was the time to providing a nasopharyngeal swab negative for severe acute respiratory syndrome coronavirus 2 RT-PCR, and was done in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT04276688.
   Findings Between Feb 10 and March 20, 2020, 127 patients were recruited; 86 were randomly assigned to the combination group and 41 were assigned to the control group. The median number of days from symptom onset to start of study treatment was 5 days (IQR 3-7). The combination group had a significantly shorter median time from start of study treatment to negative nasopharyngeal swab (7 days [IQR 5-11]) than the control group (12 days [8-15]; hazard ratio 4.37 [95% CI 1.86-10.24], p=0.0010). Adverse events included self-limited nausea and diarrhoea with no difference between the two groups. One patient in the control group discontinued lopinavir-ritonavir because of biochemical hepatitis. No patients died during the study.
   Interpretation Early triple antiviral therapy was safe and superior to lopinavir-ritonavir alone in alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19. Future clinical study of a double antiviral therapy with interferon beta-1b as a backbone is warranted.
C1 [Hung, Ivan Fan-Ngai; Tam, Anthony Raymond; Zhang, Ricky Ruiqi; Lie, Albert Kwok-Wai; Lau, Chak-Sing] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China.
   [Hung, Ivan Fan-Ngai; Zhang, Ricky Ruiqi; Fung, Agnes Yim-Fong; Yan, Erica Yuen-Wing; Leung, Kit-Hang; Chu, Allen Wing-Ho; Chan, Wan-Mui; Ng, Anthony Chin-Ki; Chan, Jasper Fuk-Woo; Chan, Kwok-Hung; To, Kelvin Kai-Wang; Yuen, Kwok-Yung] Univ Hong Kong, Carol Yu Ctr Infect, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China.
   [Chung, Tom Wai-Hin; Yip, Cyril Chik-Yan; Cheng, Vincent Chi-Chung] Univ Hong Kong, Dept Microbiol, Hong Kong, Peoples R China.
   [Sin, Simon; Yeung, Pauline; Chan, Wai-Ming] Univ Hong Kong, Queen Mary Hosp, Dept Intens Care, Hong Kong, Peoples R China.
   [Lung, Kwok-Cheung] Pamela Youde Nethersole Eastern Hosp, Dept Med, Hong Kong, Peoples R China.
   [Wu, Alan Ka-Lun; Lee, Rodney] Pamela Youde Nethersole Eastern Hosp, Dept Microbiol, Hong Kong, Peoples R China.
   [Shum, Hoi-Ping; Yan, Wing-Wah] Pamela Youde Nethersole Eastern Hosp, Dept Intens Care, Hong Kong, Peoples R China.
   [Tso, Eugene Yuk-Keung; Chan, Veronica] United Christian Hosp, Dept Med, Hong Kong, Peoples R China.
   [Fung, Kitty] United Christian Hosp, Dept Microbiol, Hong Kong, Peoples R China.
   [Liu, Raymond; Lo, Jenny; Yeung, Alwin] Ruttonjee Hosp, Dept Med & Geriatr, Hong Kong, Peoples R China.
   [Chu, Man-Yee; Law, Wai-Lam; Wu, Tak-Chiu; Chan, Johnny Wai-Man] Queen Elizabeth Hosp, Dept Med, Hong Kong, Peoples R China.
   [Lung, David Christopher] Queen Elizabeth Hosp, Dept Microbiol, Hong Kong, Peoples R China.
   [Ng, Yuk-Yung; Sin, Kit-Man] Tuen Mun Hosp, Dept Med, Hong Kong, Peoples R China.
   [Que, Tak-Lun] Tuen Mun Hosp, Dept Microbiol, Hong Kong, Peoples R China.
   [Chan, Jacky; Leung, Wai-Shing; Tsang, Owen Tak-Yin] Princess Margaret Hosp, Dept Med, Hong Kong, Peoples R China.
RP Yuen, KY (corresponding author), Univ Hong Kong, Carol Yu Ctr Infect, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China.
EM kyyuen@hku.hk
OI Shum, Hoi Ping/0000-0001-7002-3548; Chung, Tom
   Wai-Hin/0000-0003-1780-821X
FU Shaw-Foundation; Sanming Project of Medicine
FX The Shaw-Foundation, Richard and Carol Yu, May Tam Mak Mei Yin, and
   Sanming Project of Medicine.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Arabi YM, 2020, CLIN INFECT DIS, V70, P1837, DOI 10.1093/cid/ciz544
   Beigel JH, 2019, ANTIVIR RES, V167, P45, DOI 10.1016/j.antiviral.2019.04.006
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Cheng VCC, 2004, J INFECTION, V49, P262, DOI 10.1016/j.jinf.2004.07.010
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   Cunningham AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2818-6
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Dunning J, 2014, LANCET INFECT DIS, V14, P1259, DOI 10.1016/S1473-3099(14)70821-7
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hayden FG, 2018, NEW ENGL J MED, V379, P913, DOI 10.1056/NEJMoa1716197
   Hung IFN, 2017, CHEST, V151, P1069, DOI 10.1016/j.chest.2016.11.012
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Luckhardt TR, 2011, FIBROGENESIS TISSUE, V4, DOI 10.1186/1755-1536-4-18
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Rossingol JF, 2016, J INFECT PUBLIC HEAL, V9, P227, DOI 10.1016/j.jiph.2016.04.001
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
NR 30
TC 244
Z9 250
U1 11
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD MAY 30
PY 2020
VL 395
IS 10238
BP 1695
EP 1704
DI 10.1016/S0140-6736(20)31042-4
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA ND0PJ
UT WOS:000561610000023
PM 32401715
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU de Abajo, FJ
   Rodriguez-Martin, S
   Lerma, V
   Mejia-Abril, G
   Aguilar, M
   Garcia-Luque, A
   Laredo, L
   Laosa, O
   Centeno-Soto, GA
   Galvez, MA
   Puerro, M
   Gonzalez-Rojano, E
   Pedraza, L
   de Pablo, I
   Abad-Santos, F
   Rodriguez-Manas, L
   Gil, M
   Tobias, A
   Rodriguez-Miguel, A
   Rodriguez-Puyol, D
AF de Abajo, Francisco J.
   Rodriguez-Martin, Sara
   Lerma, Victoria
   Mejia-Abril, Gina
   Aguilar, Monica
   Garcia-Luque, Amelia
   Laredo, Leonor
   Laosa, Olga
   Centeno-Soto, Gustavo A.
   Galvez, Maria Angeles
   Puerro, Miguel
   Gonzalez-Rojano, Esperanza
   Pedraza, Laura
   de Pablo, Itziar
   Abad-Santos, Francisco
   Rodriguez-Manas, Leocadio
   Gil, Miguel
   Tobias, Aurelio
   Rodriguez-Miguel, Antonio
   Rodriguez-Puyol, Diego
CA MED-ACE2-COVID19 Study Grp
TI Use of renin-angiotensin-aldosterone system inhibitors and risk of
   COVID-19 requiring admission to hospital: a case-population study
SO LANCET
LA English
DT Article
ID CONVERTING ENZYME-2; ACE2
AB Background Concerns have been raised about the possibility that inhibitors of the renin-angiotensin-aldosterone system (RAAS) could predispose individuals to severe COVID-19; however, epidemiological evidence is lacking. We report the results of a case-population study done in Madrid, Spain, since the outbreak of COVID-19.
   Methods In this case-population study, we consecutively selected patients aged 18 years or older with a PCR-confirmed diagnosis of COVID-19 requiring admission to hospital from seven hospitals in Madrid, who had been admitted between March 1 and March 24, 2020. As a reference group, we randomly sampled ten patients per case, individually matched for age, sex, region (ie, Madrid), and date of admission to hospital (month and day; index date), from Base de datos para la Investigacion Farmacoepidemiologica en Atencion Primaria (BIFAP), a Spanish primary health-care database, in its last available year (2018). We extracted information on comorbidities and prescriptions up to the month before index date (ie, current use) from electronic clinical records of both cases and controls. The outcome of interest was admission to hospital of patients with COVID-19. To minimise confounding by indication, the main analysis focused on assessing the association between COVID-19 requiring admission to hospital and use of RAAS inhibitors compared with use of other antihypertensive drugs. We calculated odds ratios (ORs) and 95% CIs, adjusted for age, sex, and cardiovascular comorbidities and risk factors, using conditional logistic regression. The protocol of the study was registered in the EU electronic Register of Post-Authorisation Studies, EUPAS34437.
   Findings We collected data for 1139 cases and 11 390 population controls. Among cases, 444 (39.0%) were female and the mean age was 69.1 years (SD 15.4), and despite being matched on sex and age, a significantly higher proportion of cases had pre-existing cardiovascular disease (OR 1.98, 95% CI 1.62-2.41) and risk factors (1.46, 1.23-1.73) than did controls. Compared with users of other antihypertensive drugs, users of RAAS inhibitors had an adjusted OR for COVID-19 requiring admission to hospital of 0.94 (95% CI 0.77-1.15). No increased risk was observed with either angiotensin-converting enzyme inhibitors (adjusted OR 0.80, 0.64-1.00) or angiotensin-receptor blockers (1.10, 0.88-1.37). Sex, age, and background cardiovascular risk did not modify the adjusted OR between use of RAAS inhibitors and COVID-19 requiring admission to hospital, whereas a decreased risk of COVID-19 requiring admission to hospital was found among patients with diabetes who were users of RAAS inhibitors (adjusted OR 0.53, 95% CI 0.34-0.80). The adjusted ORs were similar across severity degrees of COVID-19.
   Interpretation RAAS inhibitors do not increase the risk of COVID-19 requiring admission to hospital, including fatal cases and those admitted to intensive care units, and should not be discontinued to prevent a severe case of COVID-19.
C1 [de Abajo, Francisco J.; Rodriguez-Martin, Sara; Lerma, Victoria; Rodriguez-Miguel, Antonio] Univ Hosp Principe Asturias, Clin Pharmacol Unit, Madrid, Spain.
   [Rodriguez-Puyol, Diego] Univ Hosp Principe Asturias, Dept Nephrol, Madrid, Spain.
   [de Abajo, Francisco J.; Rodriguez-Martin, Sara; Garcia-Luque, Amelia; Puerro, Miguel; Rodriguez-Miguel, Antonio] Univ Alcala IRYCIS, Dept Biomed Sci, Pharmacol Sect, Madrid, Spain.
   [Rodriguez-Puyol, Diego] Univ Alcala IRYCIS, Dept Med, Madrid, Spain.
   [Mejia-Abril, Gina; Abad-Santos, Francisco] Autonomous Univ Madrid, Inst Hlth La Princesa, Univ Hosp La Princesa, Dept Clin Pharmacol,Teofilo Hernando Inst, Madrid, Spain.
   [Aguilar, Monica; Galvez, Maria Angeles; de Pablo, Itziar] Univ Hosp Ramon y Cajal IRYCIS, Clin Pharmacol Unit, Madrid, Spain.
   [Garcia-Luque, Amelia; Puerro, Miguel] Def Cent Hosp, Dept Clin Pharmacol, Madrid, Spain.
   [Laredo, Leonor; Gonzalez-Rojano, Esperanza] Complutense Univ Madrid IdISSC, Clin Hosp San Carlos, Dept Clin Pharmacol, Dept Pharmacol andToxicol, Madrid, Spain.
   [Rodriguez-Manas, Leocadio] Univ Hosp Getafe, Dept Geriatr, Madrid, Spain.
   [Pedraza, Laura] Univ Hosp Getafe, Inst Biomed Res, Madrid, Spain.
   [Laosa, Olga; Rodriguez-Manas, Leocadio] Inst Hlth Carlos III, Ctr Network Biomed Res Frailty & Healthy Ageing C, Madrid, Spain.
   [Centeno-Soto, Gustavo A.] Univ Hosp Puerta Hierro, Dept Clin Pharmacol, Madrid, Spain.
   [Gil, Miguel] Spanish Agcy Med & Med Devices, Div Pharmacoepidemiol & Pharmacovigilance, Madrid, Spain.
   [Tobias, Aurelio] CSIC, Spanish Council Sci Res, Inst Environm Assessment & Water Res IDAEA, Barcelona, Spain.
RP de Abajo, FJ (corresponding author), Univ Alcala De Henares, Dept Biomed Sci, Madrid 28805, Spain.
EM francisco.abajo@uah.es
RI de Abajo, Fancisco/Z-1711-2019; Tobias, Aurelio/ABE-5682-2020
OI de Abajo, Fancisco/0000-0001-9119-8646; Navares Gomez,
   Marcos/0000-0003-2501-6845; Rodriguez Puyol, Diego/0000-0002-9125-9311;
   Rodriguez-Martin, Sara/0000-0003-3539-1470; Zubiaur,
   Pablo/0000-0002-6150-4320
FU Institute of Health Carlos IIIInstituto de Salud Carlos III
   [COV20/00027]
FX This study was funded by a research grant from the Institute of Health
   Carlos III (COV20/00027). We thank the health professionals, patients,
   and administrative staff from the hospitals that participated in this
   study, and the primary care practitioners and staff of BIFAP. We also
   thank Arturo Alvarez, for his diligence and skill in extracting the
   information from population controls, and Dolores Montero and Miguel A
   Macia. We also thank Maria Jose Bleda, Luis A Garcia Rodriguez, and
   Alberto Garcia-Lledo who provided helpful suggestions and comments
   during preparation of the protocol, statistical analysis plan, and
   manuscript. This Article is dedicated to all researchers' relatives and
   friends who have died due to COVID-19; they gave us moral strength to
   complete this research. The results, discussion, and conclusions in this
   Article are those of the authors and do not necessarily represent the
   position of their Institutions or the Spanish Agency for Medicines and
   Medical Devices.
CR Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219
   [Anonymous], 2015, PHILADELPHIA
   [Anonymous], 2020, MEDICAMENTOS ANTIHIP
   Bean D., 2020, TREATMENT ACE INHIBI, DOI [10.1101/2020.04.07.20056788, DOI 10.1101/2020.04.07.20056788]
   Cheng H, 2020, J MED VIROL, V92, P726, DOI [10.1002/jmv.25785, 10.2112/JCR-SI112-001.1]
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   HAN SW, 2020, LANCET RESP MED, DOI DOI 10.1016/S2213-2600(20)30079-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Keidar S, 2005, CIRC RES, V97, P946, DOI 10.1161/01.RES.0000187500.24964.7A
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624
   Li XC, 2017, PHARMACOL RES, V125, P21, DOI 10.1016/j.phrs.2017.06.005
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Ocaranza MP, 2006, HYPERTENSION, V48, P572, DOI 10.1161/01.HYP.0000237862.94083.45
   OMara G, 2020, BMJ-BRIT MED J, V368, pm406, DOI DOI 10.1136/BMJ.M406
   Psaty BM, 1999, J AM GERIATR SOC, V47, P749, DOI 10.1111/j.1532-5415.1999.tb01603.x
   Reddy R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213096
   Roca-Ho H, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030563
   Rodriguez-Martin S, 2018, PHARMACOEPIDEM DR S, V27, P1042, DOI 10.1002/pds.4622
   Soler MJ, 2009, AM J PHYSIOL-RENAL, V296, pF398, DOI 10.1152/ajprenal.90488.2008
   Sommerstein R, 2020, BMJ-BRIT MED J, V368, pm810, DOI [10.1136/bmj.m810, DOI 10.1136/BMJ.M810]
   Sommerstein R, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016509
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Xie XD, 2006, LIFE SCI, V78, P2166, DOI 10.1016/j.lfs.2005.09.038
   Yang PH, 2014, SCI REP-UK, V4, DOI 10.1038/srep07027
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
NR 34
TC 85
Z9 85
U1 5
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD MAY 30
PY 2020
VL 395
IS 10238
BP 1705
EP 1714
DI 10.1016/S0140-6736(20)31030-8
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA ND0PJ
UT WOS:000561610000024
PM 32416785
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Kumar, V
   Dhanjal, JK
   Kaul, SC
   Wadhwa, R
   Sundar, D
AF Kumar, Vipul
   Dhanjal, Jaspreet Kaur
   Kaul, Sunil C.
   Wadhwa, Renu
   Sundar, Durai
TI Withanone and caffeic acid phenethyl ester are predicted to interact
   with main protease (M-pro) of SARS-CoV-2 and inhibit its activity
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2 coronavirus; Ashwagandha; Withanone; Withaferin-A; honeybee
   propolis; caffeic acid phenethyl ester; molecular docking; binding; main
   protease (M-pro)
ID IN-VITRO; CORONAVIRUS; PROPOLIS; STRATEGIES; MOLECULES; DOCKING; GLIDE
AB The recent novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/2019-nCoV) has caused a large number of deaths around the globe. There is an urgent need to understand this new virus and develop prophylactic and therapeutic drugs. Since drug development is an expensive, intense and time-consuming path, timely repurposing of the existing drugs is often explored wherein the research avenues including genomics, bioinformatics, molecular modeling approaches offer valuable strengths. Here, we have examined the binding potential of Withaferin-A (Wi-A), Withanone (Wi-N) (active withanolides of Ashwagandha) and Caffeic Acid Phenethyl Ester (CAPE, bioactive ingredient of propolis) to a highly conserved protein, M(pro)of SARS-CoV-2. We found that Wi-N and CAPE, but not Wi-A, bind to the substrate-binding pocket of SARS-CoV-2 M(pro)with efficacy and binding energies equivalent to an already claimed N3 protease inhibitor. Similar to N3 inhibitor, Wi-N and CAPE were interacting with the highly conserved residues of the proteases of coronaviruses. The binding stability of these molecules was further analyzed using molecular dynamics simulations. The binding free energies calculated using MM/GBSA for N3 inhibitor, CAPE and Wi-N were also comparable. Data presented here predicted that these natural compounds may possess the potential to inhibit the functional activity of SARS-CoV-2 protease (an essential protein for virus survival), and hence (i) may connect to save time and cost required for designing/development, and initial screening for anti-COVID drugs, (ii) may offer some therapeutic value for the management of novel fatal coronavirus disease, (iii) warrants prioritized further validation in the laboratory and clinical tests. Communicated by Ramaswamy H. Sarma
C1 [Kumar, Vipul; Sundar, Durai] Indian Inst Technol IIT Delhi, Dept Biochem Engn & Biotechnol, DAILAB, New Delhi, India.
   [Dhanjal, Jaspreet Kaur; Kaul, Sunil C.; Wadhwa, Renu] Natl Inst Adv Ind Sci & Technol, DBT AIST Int Ctr Translat & Environm Res DAICTR, AIST INDIA DAILAB, Tsukuba, Ibaraki 3058565, Japan.
RP Sundar, D (corresponding author), Indian Inst Technol IIT Delhi, Dept Biochem Engn & Biotechnol, DAILAB, New Delhi, India.; Wadhwa, R (corresponding author), Natl Inst Adv Ind Sci & Technol, DBT AIST Int Ctr Translat & Environm Res DAICTR, AIST INDIA DAILAB, Tsukuba, Ibaraki 3058565, Japan.
EM renu-wadhwa@aist.go.jp; sundar@dbeb.iitd.ac.in
FU AIST (Japan); Department of Biotechnology
FX This study was supported by the funds granted by AIST (Japan) and
   Department of Biotechnology (Govt. of India). The computations were
   performed at the Bioinformatics Centre at IIT Delhi.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abdelli I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763199
   Akyol S, 2013, NUTR CANCER, V65, P515, DOI 10.1080/01635581.2013.776693
   Al-Khafaji K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764392
   AMOROS M, 1994, J NAT PROD, V57, P644, DOI 10.1021/np50107a013
   Anjaly K, 2018, ANTI-CANCER AGENT ME, V18, P468, DOI 10.2174/1871520617666171113143945
   [Anonymous], 2020, COR DIS COVID 19 DAS
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Thuy BTP, 2020, ACS OMEGA, V5, P8312, DOI 10.1021/acsomega.0c00772
   Cai Z, 2015, CELL BIOCHEM BIOPHYS, V72, P727, DOI 10.1007/s12013-015-0524-9
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chang Y. C., 2020, P MILITARY COMMUNICA, P1, DOI [10.20944/preprints202002.0242.v1, DOI 10.20944/PREPRINTS202002.0242.V1]
   Coleman JJ, 2016, FUTURE MED CHEM, V8, P2033, DOI 10.4155/fmc-2016-0085
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Costi R, 2004, BIOORGAN MED CHEM, V12, P199, DOI 10.1016/j.bmc.2003.10.005
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   De Clercq E, 2002, NAT REV DRUG DISCOV, V1, P13, DOI 10.1038/nrd703
   Demestre M, 2009, PHYTOTHER RES, V23, P226, DOI 10.1002/ptr.2594
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Erdemli HK, 2015, J INTERCULT ETHNOPHA, V4, P344, DOI 10.5455/jice.20151012013034
   FESEN MR, 1993, P NATL ACAD SCI USA, V90, P2399, DOI 10.1073/pnas.90.6.2399
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Greenwood JR, 2010, J COMPUT AID MOL DES, V24, P591, DOI 10.1007/s10822-010-9349-1
   Gupta MK, 2020, J BIOMOL STRUCT DYN, V38, P137, DOI 10.1080/07391102.2019.1567391
   Gupta M, 2020, J THERM ANAL CALORIM, V142, P1545, DOI [10.1007/s10973-020-09453-w, 10.1080/01694243.2020.1749448]
   Gyebi GA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764868
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Ho CC, 2005, J ANTIMICROB CHEMOTH, V56, P372, DOI 10.1093/jac/dki244
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kaul S. C., 2017, SCI ASHWAGANDHA PREV
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan S, 2020, MITOCHONDRIAL DNA A, DOI [10.1080/24701394.2020.1845323, 10.1016/B978-0-12-816960-5.00001-X]
   Kishimoto Noriaki, 2005, Biocontrol Science, V10, P155
   Kumar D, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779131
   Kwon MJ, 2020, J APICULT RES, V59, P413, DOI 10.1080/00218839.2019.1695715
   Latheef Shyma K., 2017, VirusDisease, V28, P115, DOI 10.1007/s13337-016-0355-3
   Lefkovits I, 1997, INT J ONCOL, V11, P59
   Li XG, 2020, J MED VIROL, V92, P448, DOI 10.1002/jmv.25693
   Li XG, 2020, J MED VIROL, V92, P501, DOI 10.1002/jmv.25701
   Lobo-Galo N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764393
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lyu SY, 2005, ARCH PHARM RES, V28, P1293, DOI 10.1007/BF02978215
   Maruta H., 2020, J INFECT DIS THERAPY, V8, P418
   Munagala R, 2011, CARCINOGENESIS, V32, P1697, DOI 10.1093/carcin/bgr192
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Murtaza G, 2015, J FOOD DRUG ANAL, V23, P11, DOI 10.1016/j.jfda.2014.06.001
   Norris PJ, 2010, VIRULENCE, V1, P19, DOI 10.4161/viru.1.1.9868
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Schrodinger, 2020, MAESTR 019 3SR GLID
   SERKEDJIEVA J, 1992, J NAT PROD, V55, P294, DOI 10.1021/np50081a003
   Shen H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082299
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   SUDINA GF, 1993, FEBS LETT, V329, P21, DOI 10.1016/0014-5793(93)80184-V
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Varshney A., 2020, VIROL J, DOI [10.21203/rs.3.rs-17806/v1, DOI 10.21203/RS.3.RS-17806/V1]
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wang FH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22677
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zandi K, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-560
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 78
TC 22
Z9 23
U1 6
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1772108
EA MAY 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MA6GH
UT WOS:000542008800001
PM 32469279
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Maurya, SK
   Maurya, AK
   Mishra, N
   Siddique, HR
AF Maurya, Santosh K.
   Maurya, Akhilesh Kumar
   Mishra, Nidhi
   Siddique, Hifzur R.
TI Virtual screening, ADME/T, and binding free energy analysis of
   anti-viral, anti-protease, and anti-infectious compounds against
   NSP10/NSP16 methyltransferase and main protease of SARS CoV-2
SO JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
LA English
DT Article
DE SARS CoV-2; COVID-19; NSP10; NSP16 methyltransferase; protease complex;
   anti-viral; anti-infectious; anti-protease drugs
ID DRUG DISCOVERY; CORONAVIRUS; SOLUBILITY
AB Recently, a pathogen has been identified as a novel coronavirus (SARS-CoV-2) and found to trigger novel pneumonia (COVID-19) in human beings and some other mammals. The uncontrolled release of cytokines is seen from the primary stages of symptoms to last acute respiratory distress syndrome (ARDS). Thus, it is necessary to find out safe and effective drugs against this deadly coronavirus as soon as possible. Here, we downloaded the three-dimensional model of NSP10/NSP16 methyltransferase (PDB-ID: 6w6l) and main protease (PDB-ID: 6lu7) of COVID-19. Using these molecular models, we performed virtual screening with our anti-viral, inti-infectious, and anti-protease compounds, which are attractive therapeutics to prevent infection of the COVID-19. We found that top screened compound binds with protein molecules with good dock score with the help of hydrophobic interactions and hydrogen bonding. We observed that protease complexed with Cyclocytidine hydrochloride (anti-viral and anti-cancer), Trifluridine (anti-viral), Adonitol, and Meropenem (anti-bacterial), and Penciclovir (anti-viral) bound with a good docking score ranging from -6.8 to -5.1 (Kcal/mol). Further, NSP10/NSP16 methyltransferase complexed with Telbivudine, Oxytetracycline dihydrate (anti-viral), Methylgallate (anti-malarial), 2-deoxyglucose and Daphnetin (anti-cancer) from the docking score of -7.0 to -5.7 (Kcal/mol). In conclusion, the selected compounds may be used as a novel therapeutic agent to combat this deadly pandemic disease, SARS-CoV-2 infection, but needs further experimental research.
C1 [Maurya, Santosh K.; Siddique, Hifzur R.] Aligarh Muslim Univ, Genet Sect, Dept Zool, Mol Canc Genet & Translat Res Lab, Aligarh 202002, Uttar Pradesh, India.
   [Maurya, Akhilesh Kumar; Mishra, Nidhi] Indian Inst Informat Technol Allahabad, Prayagraj, India.
RP Siddique, HR (corresponding author), Aligarh Muslim Univ, Genet Sect, Dept Zool, Mol Canc Genet & Translat Res Lab, Aligarh 202002, Uttar Pradesh, India.
EM hifzur.zo@amu.ac.in
RI Maurya, Akhilesh Kumar/AAY-3479-2020; Siddique, Hifzur R/H-4049-2019;
   Maurya, Santosh K/AAP-5685-2020
OI Maurya, Akhilesh Kumar/0000-0003-3281-532X; Siddique, Hifzur
   R/0000-0001-8736-0487; Maurya, Santosh/0000-0002-0091-6102
FU DST-SERB, India; UGC, New DelhiUniversity Grants Commission, India
   [F.30377/2017(BSR)]; DST-SERB, New Delhi [EMR/20l7/001758]
FX SK acknowledges DST-SERB, India, for providing financial assistance as a
   Junior Research Fellowship. HRS is thankful to the UGC [Grant no.
   F.30377/2017(BSR)] and DST-SERB [Grant no. EMR/20l7/001758], New Delhi,
   for providing financial help.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Jorgensen WL, 2002, ADV DRUG DELIVER REV, V54, P355, DOI 10.1016/S0169-409X(02)00008-X
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Ke M, 2012, VIRUS RES, V167, P322, DOI 10.1016/j.virusres.2012.05.017
   Li JN, 2011, PROTEINS, V79, P2794, DOI 10.1002/prot.23106
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Liu K, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-019-0132-8
   Mackenzie JS, 2020, MICROBIOL AUST, V41, P45, DOI 10.1071/MA20013
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998
   Pushpendra S, 2018, INDIAN J PHARM EDUC, V52, P122, DOI 10.5530/ijper.52.1.14
   Wang Y, 2015, J VIROL, V89, P8416, DOI 10.1128/JVI.00948-15
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 20
TC 3
Z9 4
U1 4
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1079-9893
EI 1532-4281
J9 J RECEPT SIG TRANSD
JI J. Recept. Signal Transduct.
PD NOV 1
PY 2020
VL 40
IS 6
BP 605
EP 612
DI 10.1080/10799893.2020.1772298
EA MAY 2020
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NW3VV
UT WOS:000542465500001
PM 32476594
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Vakil-Gilani, K
   O'Rourke, K
AF Vakil-Gilani, Kiana
   O'Rourke, Kenneth
TI Are patients with rheumatologic diseases on chronic immunosuppressive
   therapy at lower risk of developing severe symptoms when infected with
   COVID-19?
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Chronic immunosuppressive therapy; COVID-19 disease severity;
   Rheumatologic disease
C1 [Vakil-Gilani, Kiana; O'Rourke, Kenneth] Maine Med Ctr, Dept Rheumatol, Portland, ME 04102 USA.
RP Vakil-Gilani, K (corresponding author), Maine Med Ctr, Dept Rheumatol, Portland, ME 04102 USA.
EM KVakilGila@mmc.org; korheum@gmail.com
CR Ceribelli A, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102442
   Chen N, 2020, LANCET, V395, P497, DOI [10.1016/S0140-6736(20)30183-5, DOI 10.1016/S0140-6736(20)30183-5]
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Favalli EG, 2020, LANCET INFECT DIS, V20, P1012, DOI 10.1016/S1473-3099(20)30262-0
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Misra DP, 2020, CLIN RHEUMATOL, V39, P2055, DOI 10.1007/s10067-020-05073-9
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Robinson PC, 2020, NAT REV RHEUMATOL, V16, P293, DOI 10.1038/s41584-020-0418-0
   Sawalha AH, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108410
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
NR 10
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770-3198
EI 1434-9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD JUL
PY 2020
VL 39
IS 7
BP 2067
EP 2068
DI 10.1007/s10067-020-05184-3
EA MAY 2020
PG 2
WC Rheumatology
SC Rheumatology
GA LY1IL
UT WOS:000536442100004
PM 32474884
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Shenoy, P
   Ahmed, S
   Paul, A
   Skaria, TG
   Joby, J
   Alias, B
AF Shenoy, Padmanabha
   Ahmed, Sakir
   Paul, Aby
   Skaria, Teny Grace
   Joby, Joel
   Alias, Bazil
TI Switching to teleconsultation for rheumatology in the wake of the
   COVID-19 pandemic: feasibility and patient response in India
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE COVID-19; Telemedicine; Telerheumatology; Social distancing; Video
   consultation
ID TELEMEDICINE; OUTBREAK
AB The emergent COVID-19 pandemic dictates an urgent switch to teleconsultation. India has high patient to rheumatologist ratio, and patients have limited concepts about telemedicine. Thus, we attempted to find the feasibility and acceptance of patients in switching to teleconsultation. The CARE rheumatology clinic at Kerala, India, caters to average 170 (range: 140-240) patients per day. Patients with prefixed appointments had two-level screening for eligibility for teleconsultation. Those eligible were given the option for teleconsultation on the widely available WhatsApp app. Of those who completed teleconsultations, 100 were chosen at random to provide feedback. In the first 7 days, out of 1469 appointments, 975 were found eligible for teleconsultation. Of these, 723 (74%) opted for it. The average footfall in the clinic was reduced to 67 (range 29-117). The proportion of patients accepting teleconsultations increased with time. Amongst the 100 respondents, median satisfaction was 9 (IQR 8-10) and recommendation for continuing was 9.5 (IQR 8-10) on a 0-10 scale. Multivariate analysis showed the recommendation score was dependent on beliefs about social distancing, perceptions about clinical examination, and the satisfaction score of the first teleconsultation. Age, sex, availability of personal video conferencing app or of vehicles did not independently influence this score. Without teleconsultation facilities, three-fourths of the respondents would have stopped drugs or self-medicated. The switch was feasible and accepted by patients. It enabled quick reduction in the number of persons travelling to the centre. Not making the switch could have deprived approximately three-quarters of these patients of proper medical care.
C1 [Shenoy, Padmanabha; Paul, Aby; Skaria, Teny Grace; Joby, Joel; Alias, Bazil] Ctr Arthrit & Rheumatism Excellence CARE, Cochin, Kerala, India.
   [Ahmed, Sakir] KIIT Univ, Kalinga Inst Med Sci KIMS, Dept Clin Immunol & Rheumatol, Bhubaneswar 751024, India.
RP Shenoy, P (corresponding author), Ctr Arthrit & Rheumatism Excellence CARE, Cochin, Kerala, India.
EM drdpshenoy@gmail.com; sakir005@gmail.com; 26abypaul@gmail.com;
   teny18gs@gmail.com; joeljoby777@gmail.com;
   bazilaliaskuttuvelil@gmail.com
RI Ahmed, Sakir/J-1876-2019
OI Ahmed, Sakir/0000-0003-4631-311X; SHENOY, PADMANABHA/0000-0002-7666-1361
CR Ateriya N, 2018, NATL MED J INDIA, V31, P215, DOI 10.4103/0970-258X.258220
   Joshi VR, 2019, INDIAN J RHEUMATOL, V14, P250, DOI 10.4103/injr.injr_111_19
   Kandel N, 2020, LANCET, V395, P1047, DOI 10.1016/S0140-6736(20)30553-5
   Kataria S, 2018, RHEUMATOL INT, V38, P1949, DOI 10.1007/s00296-018-4037-x
   Lurie N, 2018, JAMA INTERN MED, V178, P745, DOI 10.1001/jamainternmed.2018.1314
   Organization WH, 2020, WHO DIR GEN OP REM M
   Piga M, 2017, SEMIN ARTHRITIS RHEU, V47, P121, DOI 10.1016/j.semarthrit.2017.03.014
   Porter G, 2016, J PUBLIC HEALTH-UK, V38, pE150, DOI 10.1093/pubmed/fdv072
   Rahim AA, 2019, INDIAN J PUBLIC HLTH, V63, P261, DOI 10.4103/ijph.IJPH_117_19
   Wang JG, 2020, LANCET, V395, P1094, DOI 10.1016/S0140-6736(20)30561-4
   Williams L, 2015, PSYCHOL HEALTH MED, V20, P832, DOI 10.1080/13548506.2015.1028946
NR 11
TC 4
Z9 4
U1 0
U2 2
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770-3198
EI 1434-9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD SEP
PY 2020
VL 39
IS 9
BP 2757
EP 2762
DI 10.1007/s10067-020-05200-6
EA MAY 2020
PG 6
WC Rheumatology
SC Rheumatology
GA NB8UO
UT WOS:000536442100003
PM 32474883
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhang, JN
   Wang, WJ
   Peng, B
   Peng, W
   Zhang, YS
   Wang, YL
   Wan, Y
   Chang, J
   Mao, L
   Miao, XP
   Li, YN
   Zhou, YF
   Hu, B
AF Zhang, Jin-nong
   Wang, Wen-jing
   Peng, Bo
   Peng, Wei
   Zhang, Yi-sheng
   Wang, Ya-ling
   Wan, Yan
   Chang, Jiang
   Mao, Ling
   Miao, Xiao-ping
   Li, Ya-nan
   Zhou, Yi-fan
   Hu, Bo
TI Potential of Arbidol for Post-exposure Prophylaxis of COVID-19
   Transmission-A Preliminary Report of a Retrospective Cohort Study
SO CURRENT MEDICAL SCIENCE
LA English
DT Article
DE Arbidol; COVID-19; SARS-CoV-2; post-exposure prophylaxis
ID ANTIVIRAL ACTIVITY; DRUG
AB The efficient transmission of severe acute respiratory syndrome-2 coronavirus (SARS-CoV-2) from patients to health care workers or family members has been a worrisome and prominent feature of the ongoing outbreak. On the basis of clinical practice and in-vitro studies, we postulated that post-exposure prophylaxis (PEP) using Arbidol is associated with decreased infection among individuals exposed to confirmed cases of COVID-19 infection. We conducted a retrospective cohort study on family members and health care workers who were exposed to patients confirmed to have SARS-CoV-2 infection by real-time RT-PCR and chest computed tomography (CT) from January 1 to January 16, 2020. The last follow-up date was Feb. 26, 2020. The emergence of fever and/or respiratory symptoms after exposure to the primary case was collected. The correlations between post-exposure prophylaxis and infection in household contacts and health care workers were respectively analyzed. A total of 66 members in 27 families and 124 health care workers had evidence of close exposure to patients with confirmed COVID-19. The Cox regression based on the data of the family members and health care workers with Arbidol or not showed that Arbidol PEP was a protective factor against the development of COVID-19 (HR 0.025, 95% CI 0.003-0.209, P=0.0006 for family members and HR 0.056, 95% CI 0.005-0.662, P=0.0221 for health care workers). Our findings suggest Arbidol could reduce the infection risk of the novel coronavirus in hospital and family settings. This treatment should be promoted for PEP use and should be the subject of further investigation.
C1 [Zhang, Jin-nong; Wang, Wen-jing] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Emergency Med, Wuhan 430022, Peoples R China.
   [Peng, Bo] Peng Consulting Grp, Salt Lake City, UT 84108 USA.
   [Peng, Wei] Heart & Lung Inst Utah, Salt Lake Reg Med Ctr, Salt Lake City, UT 84108 USA.
   [Zhang, Yi-sheng] Huazhong Univ Sci & Technol, Sch Mat Sci & Engn, Wuhan 430074, Peoples R China.
   [Wang, Ya-ling; Wan, Yan; Mao, Ling; Li, Ya-nan; Zhou, Yi-fan; Hu, Bo] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurol, Wuhan 430022, Peoples R China.
   [Chang, Jiang; Miao, Xiao-ping] Huazhong Univ Sci & Technol, Sch Publ Hlth, Dept Epidemiol & Biostat, Key Lab Environm & Hlth, Wuhan 430030, Peoples R China.
RP Li, YN; Zhou, YF; Hu, B (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurol, Wuhan 430022, Peoples R China.
EM zhangjnwhhb@163.com; wwj2010yx@163.com; liyn@mail.hust.edu.cn;
   yifan0180@hust.edu.cn; hubo@mail.hust.edu.cn
OI Wang, Wenjing/0000-0003-0131-8283; Zhang, Jin-Nong/0000-0002-8331-3584
CR Brooks MJ, 2012, J MED VIROL, V84, P170, DOI 10.1002/jmv.22234
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Guan W, 2020, CLIN CHARACTERISTICS
   Ji XG, 2004, PHARM J CHIN PLA, V20, P274
   Khamitov R. A., 2008, Voprosy Virusologii, V53, P9
   Pecheur EI, 2016, J VIROL, V90, P3086, DOI 10.1128/JVI.02077-15
   Uyeki TM, 2019, CLIN INFECT DIS, V68, pE1, DOI 10.1093/cid/ciy866
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhang JN, 2020, LANCET RESP MED, V8, pE11, DOI 10.1016/S2213-2600(20)30071-0
NR 10
TC 7
Z9 7
U1 2
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2096-5230
EI 2523-899X
J9 CURR MED SCI
JI Curr. Med. Sci.
PD JUN
PY 2020
VL 40
IS 3
BP 480
EP 485
DI 10.1007/s11596-020-2203-3
EA MAY 2020
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA ML7CP
UT WOS:000536429600001
PM 32474860
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Fang, X
   Li, X
   Bian, Y
   Ji, X
   Lu, JP
AF Fang, Xu
   Li, Xiao
   Bian, Yun
   Ji, Xiang
   Lu, Jianping
TI Relationship between clinical types and radiological subgroups defined
   by latent class analysis in 2019 novel coronavirus pneumonia caused by
   SARS-CoV-2
SO EUROPEAN RADIOLOGY
LA English
DT Article
DE Coronavirus infections; Tomography; X-ray computed; Pneumonia; Latent
   class analysis
ID CT FEATURES
AB Objectives To investigate whether meaningful subgroups sharing the CT features of patients with COVID-19 pneumonia could be identified using latent class analysis (LCA) and explore the relationship between the LCA-derived subgroups and clinical types. Methods This retrospective review included 499 patients with confirmed COVID-19 pneumonia between February 11 and March 8, 2020. Subgroups sharing the CT features were identified using LCA. Univariate and multivariate logistic regression models were utilized to analyze the association between clinical types and the LCA-derived subgroups. Results Two radiological subgroups were identified using LCA. There were 228 subjects (45.69%) in class 1 and 271 subjects (54.31%) in class 2. The CT findings of class 1 were smaller pulmonary infection volume, more peripheral distribution, more GGO, more maximum lesion range <= 5 cm, a smaller number of lesions, less involvement of lobes, less air bronchogram, less dilatation of vessels, less hilar and mediastinal lymph node enlargement, and less pleural effusion than the CT findings of class 2. Univariate analysis demonstrated that older age, therapy, presence of fever, presence of hypertension, decreased lymphocyte count, and increased CRP levels were significant parameters associated with an increased risk for class 2. Multivariate analyses revealed that the patients with clinically severe type disease had a 1.97-fold risk of class 2 than the patients with clinically moderate-type disease. Conclusions The demographic and clinical differences between the two radiological subgroups based on the LCA were significantly different. Two radiological subgroups were significantly associated with clinical moderate and severe types.
C1 [Fang, Xu; Bian, Yun; Lu, Jianping] Navy Mil Med Univ, Dept Radiol, Changhai Hosp, Changhai Rd 168, Shanghai 200434, Peoples R China.
   [Li, Xiao] Nanjing Univ, Jinling Hosp, Dept Med Imaging, Med Sch, Nanjing 210002, Jiangsu, Peoples R China.
   [Li, Xiao] Wuhan Huoshenshan Hosp, Dept Radiol, Wuhan 430000, Hubei, Peoples R China.
   [Ji, Xiang] Shanghai United Imaging Intelligence Healthcare S, Shanghai, Peoples R China.
RP Bian, Y (corresponding author), Navy Mil Med Univ, Dept Radiol, Changhai Hosp, Changhai Rd 168, Shanghai 200434, Peoples R China.
EM bianyun2012@foxmail.com
OI Yun, Bian/0000-0002-4863-4956
FU National Science Foundation for Scientists of China [81871352]; National
   Science Foundation for Young Scientists of China [81701689]
FX This work was supported in part by National Science Foundation for
   Scientists of China (81871352) and National Science Foundation for Young
   Scientists of China (81701689).
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Albarello F, 2020, INT J INFECT DIS, V93, P192, DOI 10.1016/j.ijid.2020.02.043
   [Anonymous], 2019, ORG WH CLIN MANAGEME
   [Anonymous], 2004, ORG WH WHO GUIDELINE
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Buijze GA, 2011, CLIN ORTHOP RELAT R, V469, P3400, DOI 10.1007/s11999-011-2074-9
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cowman SA, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0675-8
   Duan YN, 2020, RADIOLOGY, DOI [10.1148/radiol.2020200323:200323, DOI 10.1148/RADIOL.2020200323:200323]
   Fang Y, 2020, RADIOLOGY, DOI [10.1148/radiol.2020200280:200280, DOI 10.1148/RADIOL.2020200280:200280]
   Franquet T, 2011, RADIOLOGY, V260, P18, DOI 10.1148/radiol.11092149
   General Office of National Health Committee. Office of State Administration of Traditional Chinese Medicine, 2020, OFF STAT ADM TRAD CH
   Giovanetti M, 2020, J MED VIROL, V92, P518, DOI 10.1002/jmv.25699
   Harisinghani M.G., 2013, ATLAS LYMPH NODE ANA
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Iwasawa T, 2020, JPN J RADIOL, V38, P394, DOI 10.1007/s11604-020-00956-y
   Koo HJ, 2018, RADIOGRAPHICS, V38, P719, DOI 10.1148/rg.2018170048
   Lei J, 2020, RADIOLOGY, DOI [10.1148/radiol.2020200236:200236, DOI 10.1148/RADIOL.2020200236:200236]
   Li KH, 2020, INVEST RADIOL, V55, P327, DOI 10.1097/RLI.0000000000000672
   Organization, 2017, ORG WH MIDDLE E RESP
   Pan F, 2020, RADIOLOGY, DOI [10.1148/radiol.2020200370:200370, DOI 10.1148/RADIOL.2020200370:200370]
   Pan YY, 2020, EUR RADIOL, V30, P3306, DOI 10.1007/s00330-020-06731-x
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Scheltens NME, 2016, J NEUROL NEUROSUR PS, V87, P235, DOI 10.1136/jnnp-2014-309582
   Shi H, 2020, RADIOLOGY, DOI [10.1148/radiol.2020200269:200269, DOI 10.1148/RADIOL.2020200269:200269]
   Wu J, 2020, INVEST RADIOL, V55, P257, DOI 10.1097/RLI.0000000000000670
   Xie XZ, 2020, RADIOLOGY, V296, pE41, DOI 10.1148/radiol.2020200343
   Xiong Y, 2020, INVEST RADIOL, V55, P332, DOI 10.1097/RLI.0000000000000674
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zwemmer JNP, 2006, MULT SCLER J, V12, P565, DOI 10.1177/1352458506070759
NR 31
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0938-7994
EI 1432-1084
J9 EUR RADIOL
JI Eur. Radiol.
PD NOV
PY 2020
VL 30
IS 11
BP 6139
EP 6150
DI 10.1007/s00330-020-06973-9
EA MAY 2020
PG 12
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA OA4DM
UT WOS:000536424900001
PM 32474631
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rubio-San-Simon, A
   Verdu-Amoros, J
   Hladun, R
   Juan-Ribelles, A
   Molero, M
   Guerra-Garcia, P
   Perez-Martinez, A
   Castaneda, A
   Canete, A
   de Rojas, T
   Moreno, L
   Bautista, F
AF Rubio-San-Simon, A.
   Verdu-Amoros, J.
   Hladun, R.
   Juan-Ribelles, A.
   Molero, M.
   Guerra-Garcia, P.
   Perez-Martinez, A.
   Castaneda, A.
   Canete, A.
   de Rojas, T.
   Moreno, L.
   Bautista, F.
TI Challenges in early phase clinical trials for childhood cancer during
   the COVID-19 pandemic: a report from the new agents group of the Spanish
   Society of Paediatric Haematology and Oncology (SEHOP)
SO CLINICAL & TRANSLATIONAL ONCOLOGY
LA English
DT Article; Early Access
DE COVID-19; Clinical trials; Clinical research; Paediatric haematology and
   oncology; Development policy
AB Purpose The COVID-19 pandemic has forced healthcare stakeholders towards challenging decisions. We analyse the impact of the pandemic on the conduct of phase I-II trials for paediatric cancer during the first month of state of alarm in Spain. Methods A questionnaire was sent to all five ITCC-accredited Spanish Paediatric Oncology Early Phase Clinical Trial Units, including questions about impact on staff activities, recruitment, patient care, supply of investigational products, and legal aspects. Results All units suffered personnel shortages and difficulties in enrolling patients, treatment continuity, or performing trial assessments. Monitoring activity was frequently postponed (73%), and 49% of on-going trials interrupted recruitment. Only two patients could be recruited during this period (75% reduction in the expected rate). Conclusions The COVID-19 crisis has significantly impacted clinical research practice and access to innovation for children with cancer. Structural and functional changes are under way to better cope with the expected future restrictions.
C1 [Rubio-San-Simon, A.; Verdu-Amoros, J.; de Rojas, T.; Bautista, F.] Hosp Univ Nino Jesus, Div Paediat Haematol & Oncol, Madrid, Spain.
   [Hladun, R.; Moreno, L.] Hosp Univ Vall DHebron, Div Paediat Haematol & Oncol, Barcelona, Spain.
   [Juan-Ribelles, A.; Canete, A.] Hosp Univ & Politecn La Fe, Div Paediat Haematol & Oncol, Valencia, Spain.
   [Molero, M.; Castaneda, A.] Hosp St Joan de Deu, Div Paediat Haematol & Oncol, Barcelona, Spain.
   [Guerra-Garcia, P.; Perez-Martinez, A.] Hosp Univ La Paz, Div Paediat Haematol & Oncol, Madrid, Spain.
RP Bautista, F (corresponding author), Hosp Univ Nino Jesus, Div Paediat Haematol & Oncol, Madrid, Spain.
EM franciscojose.bautista@salud.madrid.org;
   franciscojose.bautista@salud.madrid.org
RI Canete, Adela/ABG-7558-2020
OI Guerra-Garcia, Pilar/0000-0002-7740-0614
CR Agencia Espanola de Medicamentos y Productos Sanitarios, 2020, MED EXC APL ENS CLIN
   [Anonymous], 2018, LANCET ONCOL, V19, P705, DOI [10.1016/S1470-2045(18)30119-0, DOI 10.1016/S1470-2045(18)30119-0]
   [Anonymous], COR DIS COVID 19 SIT
   BOE.es, BOEA20203692
   Bouffet E, 2020, PEDIAT BLOOD CANC
   Chen Z, 2020, ZHONGHUA XUE YE XUE
   Cortiula F, 2020, ANN ONCOL
   Cristina Calvo, 2020, ANALES PEDIAT, V92, DOI 10.1016/j.anpedi.2020.03.001
   Liang W, 2020, LANCET ONCOLOGY
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Lunt H, 2019, CONT CLIN TRIAL COMM, V16, DOI 10.1016/j.conctc.2019.100487
   McDuffie R, 2008, CONT CLIN TRIALS
   Paul SM, 2010, NATURE REV DRUG DISC
   Shen KL, 2020, WORLD J PEDIAT
   Zwaan CM, 2010, CANC TREATMENT REV
NR 15
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1699-048X
EI 1699-3055
J9 CLIN TRANSL ONCOL
JI Clin. Transl. Oncol.
DI 10.1007/s12094-020-02399-3
EA MAY 2020
PG 7
WC Oncology
SC Oncology
GA NB6YZ
UT WOS:000560661900001
PM 32472454
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tsilingiris, D
   Papatheodoridi, M
   Kapelios, CJ
AF Tsilingiris, Dimitrios
   Papatheodoridi, Margarita
   Kapelios, Chris J.
TI Providing evidence on the ongoing health care workers' mask debate
SO INTERNAL AND EMERGENCY MEDICINE
LA English
DT Article
DE Covid-19; Medical personnel; Medical mask; N95; Respirator; SARS-CoV-2;
   Pandemic
ID RANDOMIZED CLINICAL-TRIAL; N95 RESPIRATORS; MEDICAL MASKS; PREVENTING
   INFLUENZA; PERSONNEL
AB The scarcity of facemasks, particularly N95 respirators, combined with the lack of solid data to address the suitability of each mask type for adequate health care worker (HCW) protection have caused turmoil among HCWs. Current recommendations suggest mask usage solely during HCW contact with Covid-19 patients, namely plain medical mask for low-risk contacts and N95 for aerosol generating procedures. The distinction regarding the escalation of mask complexity depending on contact type is nevertheless based on plausible theoretical assumptions rather than hard evidence of a clear benefit. Conversely, we suggest that at least a plain mask should be used during all HCWs' contacts in healthcare facilities which constitute a highly probable but often overlooked means of SARS-CoV-2 transmission among HCWs.
C1 [Tsilingiris, Dimitrios] Natl & Kapodistrian Univ Athens, Dept Propaedeut Internal Med 1, Laiko Gen Hosp, Athens, Greece.
   [Papatheodoridi, Margarita] UCL, Inst Liver & Digest Hlth, Sch Life & Med Sci, Royal Free Hosp, London, England.
   [Kapelios, Chris J.] Laikon Gen Hosp, Dept Cardiol, 17 Agiou Thoma St, Athens 11527, Greece.
   [Kapelios, Chris J.] London Sch Econ & Polit Sci, Dept Hlth Policy, London, England.
RP Kapelios, CJ (corresponding author), Laikon Gen Hosp, Dept Cardiol, 17 Agiou Thoma St, Athens 11527, Greece.; Kapelios, CJ (corresponding author), London Sch Econ & Polit Sci, Dept Hlth Policy, London, England.
EM chriskapel@hotmail.com
RI PAPATHEODORIDI, MARGARITA/ABF-2065-2020
CR Ang B, 2010, CLIN INFECT DIS, V50, P1011, DOI 10.1086/651159
   [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   [Anonymous], 2020, COVID 19 WHAT WE KNO
   Asadi S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38808-z
   Bourouiba L, 2020, JAMA-J AM MED ASSOC, V323, P1837, DOI 10.1001/jama.2020.4756
   Campbell D, 2020, NOT FIT PURPOSE UK M
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Cheng VCC, 2020, INFECT CONT HOSP EP, V41, P493, DOI [10.1017/ice.2020.58, 10.1017/ice.2020.282]
   Department of Health, 2020, AN 1383 CAS COVID 19
   Guo ZD, 2020, EMERG INFECT DIS, V26, P1586, DOI 10.3201/eid2607.200885
   Jefferson T, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006207.pub4
   Lesho E, 2020, NEW ENGL J MED, V382, P1963, DOI 10.1056/NEJMc2007942
   Leung NHL, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0843-2
   Li Y, 2005, INT ARCH OCC ENV HEA, V78, P501, DOI 10.1007/s00420-004-0584-4
   Livingston E, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.4344, DOI 10.1001/JAMA.2020.434]
   Loeb M, 2009, JAMA-J AM MED ASSOC, V302, P1865, DOI 10.1001/jama.2009.1466
   MacIntyre CR, 2013, AM J RESP CRIT CARE, V187, P960, DOI 10.1164/rccm.201207-1164OC
   MacIntyre CR, 2011, INFLUENZA OTHER RESP, V5, P170, DOI 10.1111/j.1750-2659.2011.00198.x
   Maclntyre CR, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h694
   Maclntyre CR, 2009, EMERG INFECT DIS, V15, P233, DOI 10.3201/eid1502.081167
   Ng K, 2020, ANN INTERN MED, V172, P766, DOI 10.7326/L20-0175
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Radonovich LJ, 2019, JAMA-J AM MED ASSOC, V322, P824, DOI 10.1001/jama.2019.11645
   Ran Li, 2020, Clin Infect Dis, V71, P2218, DOI 10.1093/cid/ciaa287
   Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
   Rebmann T, 2013, AM J INFECT CONTROL, V41, P1218, DOI 10.1016/j.ajic.2013.02.017
   Schwartz KL, 2020, NEW ENGL J MED, V382, P1963, DOI 10.1056/NEJMc2007942
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, MOD TRANSM VIR CAUS
   Wong SCY, 2020, J HOSP INFECT, V105, P119, DOI 10.1016/j.jhin.2020.03.036
   World Health Organization, 2020, RAT US PERS PROT EQ
   Xie X, 2007, INDOOR AIR, V17, P211, DOI 10.1111/j.1600-0668.2007.00469.x
NR 33
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1828-0447
EI 1970-9366
J9 INTERN EMERG MED
JI Intern. Emerg. Med.
PD AUG
PY 2020
VL 15
IS 5
SI SI
BP 773
EP 777
DI 10.1007/s11739-020-02382-4
EA MAY 2020
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA MZ0DG
UT WOS:000556447100001
PM 32468509
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Cariou, B
   Hadjadj, S
   Wargny, M
   Pichelin, M
   Al-Salameh, A
   Allix, I
   Amadou, C
   Arnault, G
   Baudoux, F
   Bauduceau, B
   Borot, S
   Bourgeon-Ghittori, M
   Bourron, O
   Boutoille, D
   Cazenave-Roblot, F
   Chaumeil, C
   Cosson, E
   Coudol, S
   Darmon, P
   Disse, E
   Ducet-Boiffard, A
   Gaborit, B
   Joubert, M
   Kerlan, V
   Laviolle, B
   Marchand, L
   Meyer, L
   Potier, L
   Prevost, G
   Riveline, JP
   Robert, R
   Saulnier, PJ
   Sultan, A
   Thebaut, JF
   Thivolet, C
   Tramunt, B
   Vatier, C
   Roussel, R
   Gautier, JF
   Gourdy, P
AF Cariou, Bertrand
   Hadjadj, Samy
   Wargny, Matthieu
   Pichelin, Matthieu
   Al-Salameh, Abdallah
   Allix, Ingrid
   Amadou, Coralie
   Arnault, Gwenaelle
   Baudoux, Florence
   Bauduceau, Bernard
   Borot, Sophie
   Bourgeon-Ghittori, Muriel
   Bourron, Olivier
   Boutoille, David
   Cazenave-Roblot, France
   Chaumeil, Claude
   Cosson, Emmanuel
   Coudol, Sandrine
   Darmon, Patrice
   Disse, Emmanuel
   Ducet-Boiffard, Amelie
   Gaborit, Benedicte
   Joubert, Michael
   Kerlan, Veronique
   Laviolle, Bruno
   Marchand, Lucien
   Meyer, Laurent
   Potier, Louis
   Prevost, Gaetan
   Riveline, Jean-Pierre
   Robert, Rene
   Saulnier, Pierre-Jean
   Sultan, Ariane
   Thebaut, Jean-Francois
   Thivolet, Charles
   Tramunt, Blandine
   Vatier, Camille
   Roussel, Ronan
   Gautier, Jean-Francois
   Gourdy, Pierre
CA CORONADO Investigators
TI Phenotypic characteristics and prognosis of inpatients with COVID-19 and
   diabetes: the CORONADO study
SO DIABETOLOGIA
LA English
DT Article
DE BMI; COVID-19; Death; Diabetes; HbA(1c); Hypertension; Mechanical
   ventilation
ID PEOPLE; RISK
AB Aims/hypothesis Coronavirus disease-2019 (COVID-19) is a life-threatening infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Diabetes has rapidly emerged as a major comorbidity for COVID-19 severity. However, the phenotypic characteristics of diabetes in COVID-19 patients are unknown.
   Methods We conducted a nationwide multicentre observational study in people with diabetes hospitalised for COVID-19 in 53 ench centres in the period 10-31 March 2020. The primary outcome combined tracheal intubation for mechanical ventilation and/or death within 7 days of admission. Age- and sex-adjusted multivariable logistic regressions were performed to assess the prognostic value of clinical and biological features with the endpoint. ORs are reported for a 1 SD increase after standardisation.
   Results The current analysis focused on 1317 participants: 64.9% men, mean age 69.8 +/- 13.0 years, median BMI 28.4 (25th-75th percentile: 25.0-32.7) kg/m(2); with a predominance of type 2 diabetes (88.5%). Microvascular and macrovascular diabetic complications were found in 46.8% and 40.8% of cases, respectively. The primary outcome was encountered in 29.0% (95% CI 26.6, 31.5) of participants, while 10.6% (9.0, 12.4) died and 18.0% (16.0, 20.2) were discharged on day 7. In univariate analysis, characteristics prior to admission significantly associated with the primary outcome were sex, BMI and previous treatment with renin-angiotensin-aldosterone system (RAAS) blockers, but not age, type of diabetes, HbA(1c), diabetic complications or glucose-lowering therapies. In multivariable analyses with covariates prior to admission, only BMI remained positively associated with the primary outcome (OR 1.28 [1.10, 1.47]). On admission, dyspnoea (OR 2.10 [1.31, 3.35]), as well as lymphocyte count (OR 0.67 [0.50, 0.88]), C-reactive protein (OR 1.93 [1.43, 2.59]) and AST (OR 2.23 [1.70, 2.93]) levels were independent predictors of the primary outcome. Finally, age (OR 2.48 [1.74, 3.53]), treated obstructive sleep apnoea (OR 2.80 [1.46, 5.38]), and microvascular (OR 2.14 [1.16, 3.94]) and macrovascular complications (OR 2.54 [1.44, 4.50]) were independently associated with the risk of death on day 7.
   Conclusions/interpretations In people with diabetes hospitalised for COVID-19. BMI, but not long-term glucose control, was positively and independently associated with tracheal intubation and/or death within 7 days.
C1 [Cariou, Bertrand; Hadjadj, Samy; Wargny, Matthieu; Pichelin, Matthieu] Univ Nantes, Dept Endocrinol Diabetol & Nutr, Hop Guillaume & Rene Laennec, Inst Thorax,Inserm,CNRS,CHU Nantes, F-44093 Nantes 01, France.
   [Wargny, Matthieu; Coudol, Sandrine] CHU Nantes, Clin Donnees, CIC EC 1413, Nantes, France.
   [Al-Salameh, Abdallah] Univ Picardie, PeriToxUMR I 01, Dept Endocrinol Diabetol & Nutr, CHU Amiens, Amiens, France.
   [Allix, Ingrid] CHU Angers, Dept Endocrinol Diabetol Nutr, Angers, France.
   [Amadou, Coralie] Ctr Hosp Sud Francilien, Dept Diabetol, Corbeil Essonnes, France.
   [Arnault, Gwenaelle] Ctr Hosp Bretagne Atlantique, Dept Endocrinol Diabetol & Malad Metabol, Vannes, France.
   [Baudoux, Florence] CHRU Lille, Hop Claude Huriez, Clin Endocrinol Marc Linquette, Lille, France.
   [Bauduceau, Bernard] HIA Begin, Dept Diabetol, St Mande, France.
   [Bauduceau, Bernard] Fdn Francophone Rech Diabet FFRD, Paris, France.
   [Borot, Sophie] CHU Besancon, Dept Endocrinol Diabetol & Nutr, Besancon, France.
   [Bourgeon-Ghittori, Muriel] Univ Paris Saclay, Hop Antoine Beclere, Hop Bicetre, AP HP,Dept Endocrinol Diabetol & Nutr, Le Kremlin Bicetre, France.
   [Bourron, Olivier] Sorbonne Univ, CHU La Pitie Salpetriere Charles Foix, Ctr Rech Cordeliers,Inst Cardiometab & Nutr, Dept Diabetol,Inserm,UMR S 1138,Paris 06, Paris, France.
   [Boutoille, David] CHU Nantes, Dept Malad Infect & Trop, Nantes, France.
   [Cazenave-Roblot, France] CHU Poitiers, INSERM U1070, Dept Malad Infect & Trop, Poitiers, France.
   [Cazenave-Roblot, France] Soc Pathol Infect Langue Francaise SPILF, Paris, France.
   [Chaumeil, Claude; Thebaut, Jean-Francois] Federat Francaise Diabet FFD, Paris, France.
   [Cosson, Emmanuel] Univ Paris 13, Dept Endocrinol Diabetol & Nutr, Hop Avicenne, AP HP,Sorbonne Paris Cite,CRNH IdF,CINFO, Bobigny, France.
   [Cosson, Emmanuel] Univ Paris 13, Unite Rech Epidemiol Nutr, Sorbonne Paris Cite, UMR U557,Inserm,U11125 INRAE,CNAM, Bobigny, France.
   [Darmon, Patrice] Hop Conception, AP HM, Dept Endocrinol & Diabetol, Marseille, France.
   [Disse, Emmanuel] Univ Claude Bernard Lyon 1, Dept Endocrinol Diabetol & Nutr, Hosp Civils Lyon, CarMeN Lab,Inserm 1060, Lyon, France.
   [Ducet-Boiffard, Amelie] Ctr Hosp Dept Vendee, Dept Endocrinol & Diabetol, La Roche Sur Yon, France.
   [Gaborit, Benedicte] Hop Nord Marseille, AP HM, Dept Endocrinol & Diabetol, Marseille, France.
   [Joubert, Michael] CHU Caen, Dept Diabetol, Caen, France.
   [Kerlan, Veronique] CHU Brest, GETBO EA 3878, Dept Endocrinol, Brest, France.
   [Laviolle, Bruno] Univ Rennes, CHU Rennes, INSERM, Ctr Invest Clin Rennes CIC 1414, Rennes, France.
   [Marchand, Lucien] Ctr Hosp St Joseph St Luc, Dept Endocrinol & Diabetol, Lyon, France.
   [Meyer, Laurent] Hop Univ Strasbourg, Dept Endocrinol Diabetol & Nutr, Strasbourg, France.
   [Potier, Louis] Univ Paris, Dept Endocrinol Diabetol & Nutr, Hop Bichat, AP HP,Ctr Rech Cordeliers,Inserm,U 1138, Paris, France.
   [Prevost, Gaetan] Univ Rouen, CHU Rouen, Dept Endocrinol Diabetol & Malad Metabol, Rouen, France.
   [Riveline, Jean-Pierre; Gautier, Jean-Francois] Hop Lariboisiere, AP HP, Dept Diabete & Endocrinol, Paris, France.
   [Riveline, Jean-Pierre] Paris Diderot Paris VII Univ, Paris, France.
   [Riveline, Jean-Pierre; Gautier, Jean-Francois] Univ Paris Diderot Paris VII, Sorbonne Paris Cite, Inserm UMRS 1138, Paris, France.
   [Robert, Rene] Univ Poitiers, CIC Inserm 1402, Med Intens Reanimat, Poitiers, France.
   [Riveline, Jean-Pierre] Univ Poitiers, CHU Poitiers, Ctr Invest Clin CIC 1402, INSERM, Poitiers, France.
   [Sultan, Ariane] CHU Montpellier, Dept Endocrinol Diabet Nutr, Montpellier, France.
   [Sultan, Ariane] CHU Montpellier, CIC Inserm 1411, Montpellier, France.
   [Thivolet, Charles] Univ Claude Bernard Lyon 1, Hosp Civils Lyon, Ctr Diabete DIABeCARE, Lyon, France.
   [Thivolet, Charles] Univ Claude Bernard Lyon 1, Lab CarMeN, INSERM, INRA,INSA, Lyon, France.
   [Thivolet, Charles] Soc Francophone Diabete SFD, Paris, France.
   [Tramunt, Blandine; Gourdy, Pierre] Univ Toulouse, Dept Endocrinol Diabetol & Nutr, Inst Malad Metabol & Cardiovasc, CHU Toulouse,UMR1048 Inserm UPS, Toulouse, France.
   [Vatier, Camille] St Antoine Hosp, AP HP, Reference Ctr Rare Dis Insulin Secret & Insulin S, Dept Endocrinol, Paris, France.
   [Vatier, Camille] Sorbonne Univ, St Antoine Res Ctr, Inserm UMRS 938, Paris, France.
RP Cariou, B; Hadjadj, S (corresponding author), Univ Nantes, Dept Endocrinol Diabetol & Nutr, Hop Guillaume & Rene Laennec, Inst Thorax,Inserm,CNRS,CHU Nantes, F-44093 Nantes 01, France.
EM bertrand.cariou@univ-nantes.fr; samy.hadjadj@univ-nantes.fr
RI Wargny, Matthieu/Y-1071-2018; PICHELIN, Matthieu/D-3562-2015;
   Al-Salameh, Abdallah/S-7043-2016; GABORIT, Benedicte/AAK-3842-2020;
   Marchand, Lucien/P-8512-2016
OI Wargny, Matthieu/0000-0001-6027-9486; PICHELIN,
   Matthieu/0000-0002-6822-6132; Al-Salameh, Abdallah/0000-0002-7951-9926;
   GABORIT, Benedicte/0000-0002-4180-158X; Amadou,
   Coralie/0000-0002-0581-7592; Cariou, Bertrand/0000-0002-1580-8040;
   Saulnier, Patrick/0000-0002-6408-3533; Marchand,
   Lucien/0000-0001-9101-5002
FU Fondation Francophone de Recherche sur le Diabete (FFRD) - Novo Nordisk;
   MSD; AbbottAbbott Laboratories; AstraZenecaAstraZeneca; LillyEli Lilly;
   FFD (Federation Francaise des Diabetiques) - CORONADO initiative
   emergency grant; Societe Francophone du Diabete (SFD) - CORONADO
   initiative emergency grant; Air Liquide Health Care international
FX This study received the following funding: the Fondation Francophone de
   Recherche sur le Diabete (FFRD), supported by Novo Nordisk, MSD, Abbott,
   AstraZeneca, Lilly and FFD (Federation Francaise des Diabetiques) -
   CORONADO initiative emergency grant; Societe Francophone du Diabete
   (SFD) - CORONADO initiative emergency grant; Air Liquide Health Care
   international. All research facilities are acknowledged for providing
   research associates and research technicians for clinical investigations
   pro bono. The funders of the study had no role in study design, data
   collection, data analysis, data interpretation or writing of the report.
   The corresponding authors (BC and SH) had full access to all the data in
   the study and had final responsibility for the decision to submit for
   publication.
CR Alqahtani FY, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268818002923
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Chen Q, 2019, PROCEEDINGS OF THE 2019 INTERNATIONAL CONFERENCE ON INDUSTRIAL ENGINEERING AND SYSTEMS MANAGEMENT (IESM 2019), P207
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Drucker DJ, 2020, ENDOCR REV, V41, P457, DOI 10.1210/endrev/bnaa011
   Fosse-Edorh S, 2018, POIDS DIABETE FRANCE
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang I, 2020, DIABETES METAB SYND, V14, P395, DOI 10.1016/j.dsx.2020.04.018
   Kulcsar KA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131774
   Muller LMAJ, 2005, CLIN INFECT DIS, V41, P281, DOI 10.1086/431587
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Pornet C, 2011, DIABETES METAB, V37, P152, DOI 10.1016/j.diabet.2011.02.001
   Roncon L, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104354
   Sauerbrei W, 2006, COMPUT STAT DATA AN, V50, P3464, DOI 10.1016/j.csda.2005.07.015
   Schetz M, 2019, INTENS CARE MED, V45, P757, DOI 10.1007/s00134-019-05594-1
   Shah BR, 2003, DIABETES CARE, V26, P510, DOI 10.2337/diacare.26.2.510
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 27
TC 75
Z9 76
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD AUG
PY 2020
VL 63
IS 8
BP 1500
EP 1515
DI 10.1007/s00125-020-05180-x
EA MAY 2020
PG 16
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA MH8GC
UT WOS:000545060300001
PM 32472191
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Tsallis, C
   Tirnakli, U
AF Tsallis, Constantino
   Tirnakli, Ugur
TI Predicting COVID-19 Peaks Around the World
SO FRONTIERS IN PHYSICS
LA English
DT Article
DE COVID-19; pandemics; complex systems; non-extensive statistical
   mechanics; epidemiology
ID DISTRIBUTIONS; WEIBULL
AB The official data for the time evolution of active cases of COVID-19 pandemics around the world are available online. For all countries, a peak has been either observed (China and South Korea) or is expected in the near future. The approximate dates and heights of those peaks have important epidemiological implications. Inspired by similar complex behavior of volumes of transactions of stocks at the NYSE and NASDAQ, we propose aq-statistical functional form that appears to describe satisfactorily the available data for all countries. Consistently, predictions of the dates and heights of those peaks in severely affected countries become possible unless efficient treatments or vaccines, or sensible modifications of the adopted epidemiological strategies, emerge.
C1 [Tsallis, Constantino] Natl Inst Sci & Technol Complex Syst, Ctr Brasileiro Pesquisas Fis, Rio De Janeiro, Brazil.
   [Tsallis, Constantino] Santa Fe Inst, Santa Fe, NM 87501 USA.
   [Tsallis, Constantino] Complex Sci Hub Vienna, Vienna, Austria.
   [Tirnakli, Ugur] Ege Univ, Fac Sci, Dept Phys, Izmir, Turkey.
RP Tirnakli, U (corresponding author), Ege Univ, Fac Sci, Dept Phys, Izmir, Turkey.
EM ugur.tirnakli@ege.edu.tr
RI TIRNAKLI, Ugur/K-6866-2012
OI TIRNAKLI, Ugur/0000-0002-1104-0847
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FaperjCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ)
FX We have benefitted from useful remarks by E. P. Borges, R. Dickman and
   P. M. C. Oliveira as well as from partial support by CNPq and Faperj
   (Brazilian Agencies).
CR Assis EM, 2013, INT J QUAL RELIAB MA, V30, P720, DOI 10.1108/IJQRM-Oct-2011-0143
   Bastos SB, 2020, ARXIV200314288V2
   Gell-Mann M., 2004, NONEXTENSIVE ENTROPY
   Loli Piccolomini E., 2020, ARXIV200309909
   Osorio R, 2003, SFI S SCI C, P321
   Perc M, 2020, FRONT PHYS-LAUSANNE, V8, DOI 10.3389/fphy.2020.00127
   Pickup RM, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.097202
   Picoli S, 2003, PHYSICA A, V324, P678, DOI 10.1016/S0378-4371(03)00071-2
   Pluchino A, 2020, ARXIV200402739
   Ruiz G, 2018, EUR PHYS J B, V91, DOI 10.1140/epjb/e2017-80535-3
   TSALLIS C, 1988, J STAT PHYS, V52, P479, DOI 10.1007/BF01016429
   Tsallis C, 2003, PHYSICA A, V324, P89, DOI 10.1016/S0378-4371(03)00042-6
   Tsallis C., 2009, INTRO NONEXTENSIVE S
   Vasconcelos GL, 2020, MODELLING FATALITY C, DOI [10.1101/2020.04.02.20051557, DOI 10.1101/2020.04.02.20051557]
   Podesta TSV, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180777
   White DR, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.016119
   Xu M, 2019, USING Q WEIBULL DIST
   Zlatic V, 2020, ARXIV200308479
NR 18
TC 7
Z9 7
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-424X
J9 FRONT PHYS-LAUSANNE
JI Front. Physics
PD MAY 29
PY 2020
VL 8
AR 217
DI 10.3389/fphy.2020.00217
PG 6
WC Physics, Multidisciplinary
SC Physics
GA MA9HD
UT WOS:000542220300001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Yang, CG
   Ke, CJ
   Yue, DY
   Li, WG
   Hu, ZQ
   Liu, W
   Hu, SH
   Wang, SG
   Liu, JH
AF Yang, Chunguang
   Ke, Chunjin
   Yue, Daoyuan
   Li, Wengang
   Hu, Zhiquan
   Liu, Wei
   Hu, Shuhua
   Wang, Shaogang
   Liu, Jihong
TI Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE SARS-CoV-2; COVID-19; arbidol; health professional; primary prevention
AB Background:Frontline health professionals are a COVID-19-susceptible population during the outbreak of COVID-19, but prophylactic drugs against SARS-CoV-2 infection are to be explored. Method:Frontline health professionals diagnosed with COVID-19 before February 9, 2020 in Tongji Hospital, Wuhan, China and the same amount of controls in the uninfected group were included in this study. Clinical and laboratory data were collected with standardized forms. Results:A total of 164 subjects were included in this study, 82 cases in the infected group and 82 controls in the uninfected group, with a median age of 37 years, including 63 males and 101 females. Nineteen (23.2%) patients in the infected group were administered oral arbidol, and 48 (58.5%) in the uninfected group (OR = 0.214, 95% CI 0.109-0.420). The cumulative uninfected rate of health professionals in the arbidol group was significantly higher than that of individuals in the non-arbidol group (log-rank test, chi(2)= 98.74;P< 0.001). Forty-eight patients (58.5%) in the infection group were hospitalized, with a median age of 39 (31-49) years, of whom 7 (14.6%) were prophylactically administered arbidol. Thirty-four patients (41.5%) with mild symptoms were treated outside the hospital, among which the median age was 34 (30-39) years, and twelve patients (35.3%) took prophylactic oral arbidol. The hospitalization rate was significantly associated with age (P= 0.024) and oral arbidol administration (OR = 0.313, 95% CI 0.108-0.909). In the age-matched case-control study, the hospitalization rate was not significantly associated with arbidol administration (P= 0.091). Conclusion:Prophylactic oral arbidol was associated with a lower incidence of SARS-CoV-2 infection but not hospitalization rate in health professionals, providing a basis for the selection of prophylactic drugs for high-risk populations.
C1 [Yang, Chunguang; Ke, Chunjin; Hu, Zhiquan; Wang, Shaogang; Liu, Jihong] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Urol, Wuhan, Peoples R China.
   [Yue, Daoyuan] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Clin Lab, Wuhan, Peoples R China.
   [Li, Wengang; Liu, Wei; Hu, Shuhua] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Prevent & Hlth, Wuhan, Peoples R China.
RP Hu, ZQ (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Urol, Wuhan, Peoples R China.; Li, WG (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Prevent & Hlth, Wuhan, Peoples R China.
EM lwg027@126.com; huzhiquan2000@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81702989]
FX This work was supported by National Natural Science Foundation of China
   (Grand No. 81702989).
CR Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Boriskin YS, 2008, CURR MED CHEM, V15, P997, DOI 10.2174/092986708784049658
   Cho SY, 2016, LANCET, V388, P994, DOI 10.1016/S0140-6736(16)30623-7
   Deng L, 2020, J INFECTION
   GAGARINOVA VM, 1993, ZH MIKROB EPID IMMUN, P40
   Khamitov R. A., 2008, Voprosy Virusologii, V53, P9
   Kramarev S A, 2013, Lik Sprava, P99
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Titova O N, 2018, Ter Arkh, V90, P48, DOI [10.26442/terarkh201890848-52, https//doi.org/10.26442/terarkh201890848-52]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, WHO COR DIS COVID 19
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 14
TC 4
Z9 4
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD MAY 29
PY 2020
VL 8
AR 249
DI 10.3389/fpubh.2020.00249
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MA7VG
UT WOS:000542119500001
PM 32574310
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ridgway, JP
   Farley, B
   Benoit, JL
   Frohne, C
   Hazra, A
   Pettit, N
   Pho, M
   Pursell, K
   Saltzman, J
   Schmitt, J
   Uvin, AZ
   Pitrak, D
   McNulty, M
AF Ridgway, Jessica P.
   Farley, Brianna
   Benoit, Jean-Luc
   Frohne, Christopher
   Hazra, Aniruddha
   Pettit, Natasha
   Pho, Mai
   Pursell, Kenneth
   Saltzman, Jina
   Schmitt, Jessica
   Uvin, Arno Ziggy
   Pitrak, David
   McNulty, Moira
TI A Case Series of Five People Living with HIV Hospitalized with COVID-19
   in Chicago, Illinois
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
DE HIV; COVID-19; coinfection
AB The risk of COVID-19 among people living with HIV (PLWH) is largely unknown and there have been very few reported cases in the literature. We report a case series of five PLWH with COVID-19. We identified all patients with a diagnosis of HIV who tested positive for SARS-CoV-2 at University of Chicago Medicine between March 1, 2020, and April 7, 2020. We retrospectively collected data regarding demographics, comorbidities, medications, laboratory test results, radiology results, and outcomes associated with COVID-19. All five PLWH with COVID-19 were African American; 80% (4/5) were cisgender females. The mean age of patients was 48 years old (range 38-53). The majority of patients presented with cough, fever, and shortness of breath. Three patients had diarrhea. One patient presented with predominantly cardiac symptoms. All were taking antiretroviral therapy (ART) with CD4 count >200 cells/mm(3) and suppressed HIV viral loads at the time of COVID-19 diagnosis. All five patients were hospitalized, two required supplemental oxygen, and none required mechanical ventilation. Four patients were treated with azithromycin and a cephalosporin and two were also treated with hydroxychloroquine. The median length of stay was 3 days (range 2-7). All patients recovered. More research is needed to understand the risks of COVID-19 among PLWH and the impact of ART on outcomes for patients with COVID-19.
C1 [Ridgway, Jessica P.; Benoit, Jean-Luc; Frohne, Christopher; Hazra, Aniruddha; Pho, Mai; Pursell, Kenneth; Saltzman, Jina; Schmitt, Jessica; Uvin, Arno Ziggy; Pitrak, David; McNulty, Moira] Univ Chicago, Dept Med, 5841 S Maryland Ave,MC 5065, Chicago, IL 60637 USA.
   [Farley, Brianna] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
   [Pettit, Natasha] Univ Chicago, Dept Pharm, Chicago, IL 60637 USA.
RP Ridgway, JP (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC 5065, Chicago, IL 60637 USA.
EM jessica.ridgway@uchospitals.edu
CR Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Centers for Disease Control and Prevention, 2019, PREL EST PREV SEL UN
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen ZH, 2020, KOREAN J RADIOL, V21, P623, DOI 10.3348/kjr.2020.0195
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Docherty AB, FEATURES 16749 HOSP, DOI 10.11 01/2020.04.23.20076042v1
   Fang Y., 2020, RADIOLOGY, DOI DOI 10.1148/RADI0L.2020200432
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Joob B, 2020, J MED VIROL, V92, P1415, DOI 10.1002/jmv.25782
   Mascolo S, 2020, J MED VIROL, V92, P1777, DOI 10.1002/jmv.25881
   Pan L, 2020, AM J GASTROENTEROL, V115, P766, DOI 10.14309/ajg.0000000000000620
   Plan Nacional sobre el Sida (PNS), RAND CLIN TRIAL PREV
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Shanghai Public Health Clinical Center, EFF SAF DAR COB TREA
   Thebault R, 2020, WASH POST, P2020
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, Q A COVID 19 HIV ANT
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Zhao Juanjuan, 2020, Clin Infect Dis, V71, P2233, DOI 10.1093/cid/ciaa408
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu F, 2020, J MED VIROL, V92, P529, DOI 10.1002/jmv.25732
NR 23
TC 13
Z9 13
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
EI 1557-7449
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD AUG 1
PY 2020
VL 34
IS 8
BP 331
EP 335
DI 10.1089/apc.2020.0103
EA MAY 2020
PG 5
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA MV2IY
UT WOS:000538092500001
PM 32469614
OA Bronze
DA 2021-01-01
ER

PT J
AU Adeli, SH
   Asghari, A
   Tabarraii, R
   Shajari, R
   Afshari, S
   Kalhor, N
   Vafaeimanesh, J
AF Adeli, Seyed Hasan
   Asghari, Akram
   Tabarraii, Reihane
   Shajari, Rasoul
   Afshari, Sara
   Kalhor, Narges
   Vafaeimanesh, Jamshid
TI Therapeutic plasma exchange as a rescue therapy in patients with
   coronavirus disease 2019: a case series
SO POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY
   WEWNETRZNEJ
LA English
DT Letter
ID COVID-19
C1 [Adeli, Seyed Hasan; Asghari, Akram; Tabarraii, Reihane; Shajari, Rasoul] Qom Univ Med Sci, Sch Med, Dept Internal Med, Qom, Iran.
   [Afshari, Sara; Kalhor, Narges] Qom Univ Med Sci, Student Res Comm, Qom, Iran.
   [Vafaeimanesh, Jamshid] Qom Univ Med Sci, Gastroenterol & Hepatol Dis Res Ctr, Qom 3716615504, Iran.
   [Vafaeimanesh, Jamshid] Qom Univ Med Sci, Shahid Beheshti Hosp, Clin Res Dev Ctr, Qom, Iran.
RP Vafaeimanesh, J (corresponding author), Qom Univ Med Sci, Gastroenterol & Hepatol Dis Res Ctr, Qom 3716615504, Iran.
EM jvafaeemanesh@yahoo.com
CR Arab-Mazar Z, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101630
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Kawashima Hisashi, 2005, J Infect, V51, pE53, DOI 10.1016/j.jinf.2004.08.017
   Liu XL, 2015, THER APHER DIAL, V19, P178, DOI 10.1111/1744-9987.12240
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Patel P, 2011, PEDIATR CRIT CARE ME, V12, pE87, DOI 10.1097/PCC.0b013e3181e2a569
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   World Health Organization, COR DIS COVID 2019 S
   Wu Z, 2020, JAMA
NR 12
TC 3
Z9 3
U1 1
U2 1
PU MEDYCYNA PRAKTYCZNA SP K SP ZOO
PI KRAKOW
PA REJTANA 2, KRAKOW, 30-510    AP, POLAND
SN 0032-3772
EI 1897-9483
J9 POL ARCH INTERN MED
JI Pol. Intern. Med.
PD MAY 29
PY 2020
VL 130
IS 5
BP 455
EP 458
DI 10.20452/pamw.15340
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA LU8ZU
UT WOS:000538037700018
PM 32380821
OA Bronze
DA 2021-01-01
ER

PT J
AU Satoru, M
   Masaki, Y
   Hiroki, H
   Hirokazu, I
   Kenichi, K
AF Satoru, Mitsuboshi
   Masaki, Yoshino
   Hiroki, Hosokawa
   Hirokazu, Isobe
   Kenichi, Kobayashi
TI Use of personal protective equipment while admixing antineoplastic drugs
   during the COVID-19 pandemic era: Questionnaire survey in Niigata, Japan
SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE
LA English
DT Letter
C1 [Satoru, Mitsuboshi] Kaetsu Hosp, Dept Pharm, Niigata, Japan.
   [Masaki, Yoshino] Niigata Prefectural Canc Ctr Hosp, Dept Pharm, Niigata, Japan.
   [Hiroki, Hosokawa] Agano City Hosp, Dept Pharm, Niigata, Japan.
   [Hirokazu, Isobe] Niigata Univ, Med & Dent Hosp, Div Pharm, Niigata, Japan.
   [Kenichi, Kobayashi] Nagaoka Red Cross Hosp, Dept Pharm, Niigata, Japan.
RP Satoru, M (corresponding author), 1459-1 Higashikanazawa,Akiha Ku, Niigata, Niigata 9560814, Japan.
EM mitsuboshi_s@niigata-min.or.jp
RI Mitsuboshi, Satoru/A-1658-2019
OI Mitsuboshi, Satoru/0000-0002-6244-1253
CR Andrews SR, 2018, HOSP PHARM, V53, P132, DOI 10.1177/0018578718763850
   Connor TH, 2004, NATL I OCCUPATIONAL, P1
   Iacobucci G, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1316
   Kissler SM, 2020, SCIENCE, DOI DOI 10.1101/2020.03.04.20031112
NR 4
TC 0
Z9 0
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1078-1552
EI 1477-092X
J9 J ONCOL PHARM PRACT
JI J. Oncol. Pharm. Pract.
PD SEP
PY 2020
VL 26
IS 6
BP 1553
EP 1554
AR 1078155220932342
DI 10.1177/1078155220932342
EA MAY 2020
PG 2
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA ND8AA
UT WOS:000536634200001
PM 32469683
OA Bronze
DA 2021-01-01
ER

PT J
AU Elgarhy, LH
AF Hamouda Elgarhy, Lamia
TI Could patients taking isotretinoin therapy be immune against SARS-CoV-2?
SO DERMATOLOGIC THERAPY
LA English
DT Article
C1 [Hamouda Elgarhy, Lamia] Tanta Univ, Dermatol & Venereol Dept, Tanta, Egypt.
RP Elgarhy, LH (corresponding author), Tanta Univ, Dermatol & Venereol, Fac Med, El Giesh St, Tanta 31111, Egypt.
EM lamia_elgarhy@yahoo.com
OI Elgarhy, Lamia/0000-0001-5277-4751
CR Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Harms M, 1998, DERMATOLOGY, V196, P163, DOI 10.1159/000017853
   Layton A, 2009, DERM-ENDOCRINOL, V1, P162, DOI 10.4161/derm.1.3.9364
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Sinha S., 2020, SYSTEMATIC CELL LINE, V97, P84, DOI [10.20944/preprints202003.0446.v1, DOI 10.20944/PREPRINTS202003.0446.V1]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
NR 6
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13573
DI 10.1111/dth.13573
EA MAY 2020
PG 1
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000536051700001
PM 32406143
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tsuji, M
AF Tsuji, Motonori
TI Potential anti-SARS-CoV-2 drug candidates identified through virtual
   screening of the ChEMBL database for compounds that target the main
   coronavirus protease
SO FEBS OPEN BIO
LA English
DT Article
DE 2019 novel coronavirus; COVID-19; drug repositioning; M-pro; SARS-CoV-2;
   virtual screening
ID DOCKING
AB A novel coronavirus [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or 2019 novel coronavirus] has been identified as the pathogen of coronavirus disease 2019. The main protease (M-pro, also called 3-chymotrypsin-like protease) of SARS-CoV-2 is a potential target for treatment of COVID-19. A M-pro homodimer structure suitable for docking simulations was prepared using a crystal structure (PDB ID: 6Y2G; resolution 2.20 angstrom). Structural refinement was performed in the presence of peptidomimetic alpha-ketoamide inhibitors, which were previously disconnected from each Cys145 of the M-pro homodimer, and energy calculations were performed. Structure-based virtual screenings were performed using the ChEMBL database. Through a total of 1 485 144 screenings, 64 potential drugs (11 approved, 14 clinical, and 39 preclinical drugs) were predicted to show high binding affinity with M-pro. Additional docking simulations for predicted compounds with high binding affinity with M-pro suggested that 28 bioactive compounds may have potential as effective anti-SARS-CoV-2 drug candidates. The procedure used in this study is a possible strategy for discovering anti-SARS-CoV-2 drugs from drug libraries that may significantly shorten the clinical development period with regard to drug repositioning.
C1 [Tsuji, Motonori] Inst Mol Funct, 2-105-14 Takasu, Saitama 3410037, Japan.
RP Tsuji, M (corresponding author), Inst Mol Funct, 2-105-14 Takasu, Saitama 3410037, Japan.
EM motonori@molfunction.com
RI Tsuji, Motonori/O-1205-2016
OI Tsuji, Motonori/0000-0003-0734-0334
CR Berthold MR, 2008, STUD CLASS DATA ANAL, P319, DOI 10.1145/1656274.1656280
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Davies M, 2015, NUCLEIC ACIDS RES, V43, pW612, DOI 10.1093/nar/gkv352
   Gentile D, 2020, PREPRINTS, DOI [10.20944/preprints202003.0372.v1, DOI 10.20944/PREPRINTS202003.0372.V1]
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jin Z, 2020, PREPRINT
   Kanehisa M, 2020, PROTEIN SCI, V29, P28, DOI 10.1002/pro.3711
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Ruiz-Carmona S, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003571
   Sekhar T., 2020, PREPRINTS, DOI [10.20944/ preprints202002.0418.v2, DOI 10.20944/PREPRINTS202002.0418.V2, 10.20944/preprints202002.0418.v2]
   Sud M, 2016, J CHEM INF MODEL, V56, P2292, DOI 10.1021/acs.jcim.6b00505
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsuji M, 2007, MOL SCI, V1, pNP004
   Tsuji M, 2018, HOMOLOGY MODELING PR
   Tsuji M, 2018, DOCKING STUDY HYPERC
   Tsuji M, 2015, J COMPUT AID MOL DES, V29, P975, DOI 10.1007/s10822-015-9869-9
   Vainio MJ, 2007, J CHEM INF MODEL, V47, P2462, DOI 10.1021/ci6005646
   Wang Q., 2020, QUANT SCI STUD, V1, P239, DOI 10.1162/qss_a_00011
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang L., 2020, PREPRINT
NR 22
TC 8
Z9 9
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2211-5463
J9 FEBS OPEN BIO
JI FEBS Open Bio
PD JUN
PY 2020
VL 10
IS 6
BP 995
EP 1004
DI 10.1002/2211-5463.12875
EA MAY 2020
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA LS8RK
UT WOS:000536011300001
PM 32374074
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Xu, Y
   Liu, HS
   Hu, K
   Wang, MZ
AF Xu, Yan
   Liu, Hongsheng
   Hu, Ke
   Wang, Mengzhao
TI Clinical recommendations on lung cancer management during the COVID-19
   pandemic
SO THORACIC CANCER
LA English
DT Article
DE COVID-19; lung neoplasms; patient management
ID SARS-COV-2
AB Coronavirus disease 2019 (COVID-19) is spreading worldwide, and has been declared as an international public health concern. Patients with lung cancer are highly susceptible to infection compared to healthy individuals because of systemic immunosuppression induced by malignancy and anticancer therapy. Furthermore, patients with cancer demonstrate poorer outcomes following infection. Hence, patients with lung cancer should be considered a priority group for COVID-19 prevention. Furthermore, the routine treatment of patients with cancer has been affected during the COVID-19 pandemic, and patients may not have been able to undergo timely and effective antitumor treatment, thereby indicating a poor prognosis. Here, we provide some suggestions for early identification of COVID-19 and differential diagnosis in patients with lung cancer who have fever and respiratory symptoms. Our medical team also provide clinical recommendations on lung cancer management during the COVID-19 pandemic, for carrying out meticulous and individualized clinical management of lung cancer patients and maximum protection to effectively prevent COVID-19.
   Key points Significant findings of the study
   This article provides suggestions for early identification of COVID-19 and differential diagnosis in patients with lung cancer with fever and respiratory symptoms.
   What this study adds
   This article makes clinical recommendations on lung cancer management during the COVID-19 pandemic.
C1 [Xu, Yan; Wang, Mengzhao] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Resp & Crit Care Med, Beijing 100730, Peoples R China.
   [Liu, Hongsheng] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Thorac Surg, Beijing, Peoples R China.
   [Hu, Ke] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Radiat Oncol, Beijing, Peoples R China.
RP Wang, MZ (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Resp & Crit Care Med, Beijing 100730, Peoples R China.
EM mengzhaowang@sina.com
FU "13th Five-Year" National Science and Technology Major Project for New
   Drugs [2019ZX09734001-002]; CAMS Innovation Fund for Medical Sciences
   (CIFMS) [2018-I2M-1-003]; National Natural Science Foundation of
   BeijingBeijing Natural Science Foundation [7194311]
FX This study was supported by a grant from the "13th Five-Year" National
   Science and Technology Major Project for New Drugs (No:
   2019ZX09734001-002), CAMS Innovation Fund for Medical Sciences (CIFMS)
   (to Mengzhao WANG) (Grant No. 2018-I2M-1-003),and a grant from the
   National Natural Science Foundation of Beijing (to Yan XU)(No.7194311).
CR [Anonymous], 2020, GUID DIAGN TREATM NO
   Banna G, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2020-000765
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chinese Thoracic Society Chinese Association of Chest Physicians, 2020, CHIN J TUBERC RESP D, V43
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hanania AN, 2019, CHEST, V156, P150, DOI 10.1016/j.chest.2019.03.033
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kamboj M, 2009, LANCET ONCOL, V10, P589, DOI 10.1016/S1470-2045(09)70069-5
   Bonilla-Aldana DK, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2020.101566
   Li Xin, 2020, Zhongguo Fei Ai Za Zhi, V23, P133, DOI 10.3779/j.issn.1009-3419.2020.03.01
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lung Cancer Study Group Chinese Thoracic Society Chinese Medical Association, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P297, DOI 10.3760/cma.j.cn112147-20200221-00138
   NELSON B, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1544
   Ouyang W, 2020, J THORAC ONCOL
   Passaro A, 2020, ANN ONCOL
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Sears CR, 2019, AM J RESP CRIT CARE, V200, pE31, DOI 10.1164/rccm.201906-1202ST
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Wang Z., 2020, JAMA ONCOL
   World Health Organization, COR DIS COVID 19 OUT
   You B, 2020, LANCET ONCOL, V21, P619, DOI 10.1016/S1470-2045(20)30204-7
   Zhong WZ, 2018, LANCET ONCOL, V19, P139, DOI 10.1016/S1470-2045(17)30729-5
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 29
TC 2
Z9 2
U1 2
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1759-7706
EI 1759-7714
J9 THORAC CANCER
JI Thorac. Cancer
PD JUL
PY 2020
VL 11
IS 7
BP 2067
EP 2074
DI 10.1111/1759-7714.13498
EA MAY 2020
PG 8
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA ME1CN
UT WOS:000535995600001
PM 32469164
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hepburn, M
   Mullaguri, N
   George, P
   Hantus, S
   Punia, V
   Bhimraj, A
   Newey, CR
AF Hepburn, Madihah
   Mullaguri, Naresh
   George, Pravin
   Hantus, Stephen
   Punia, Vineet
   Bhimraj, Adarsh
   Newey, Christopher R.
TI Acute Symptomatic Seizures in Critically Ill Patients with COVID-19: Is
   There an Association?
SO NEUROCRITICAL CARE
LA English
DT Article; Early Access
DE Seizures; Status epilepticus; Coronavirus
ID CORONAVIRUS
AB Background The coronavirus disease of 2019 (COVID-19) emerged as a global pandemic. Historically, the group of human coronaviruses can also affect the central nervous system leading to neurological symptoms; however, the causative mechanisms of the neurological manifestations of COVID-19 disease are not well known. Seizures have not been directly reported as a part of COVID-19 outside of patients with previously known brain injury or epilepsy. We report two cases of acute symptomatic seizures, in non-epileptic patients, associated with severe COVID-19 disease. Case Presentations Two advanced-age, non-epileptic, male patients presented to our northeast Ohio-based health system with concern for infection in Mid-March 2020. Both had a history of lung disease and during their hospitalization tested positive for SARS-CoV-2. They developed acute encephalopathy days into their hospitalization with clinical and electrographic seizures. Resolution of seizures was achieved with levetiracetam. Discussion Patients with COVID-19 disease are at an elevated risk for seizures, and the mechanism of these seizures is likely multifactorial. Clinical (motor) seizures may not be readily detected in this population due to the expansive utilization of sedatives and paralytics for respiratory optimization strategies. Many of these patients are also not electrographically monitored for seizures due to limited resources, multifactorial risk for acute encephalopathy, and the risk of cross-contamination. Previously, several neurological symptoms were seen in patients with more advanced COVID-19 disease, and these were thought to be secondary to multi-system organ failure and/or disseminated intravascular coagulopathy-related brain injury. However, these patients may also have an advanced breakdown of the blood-brain barrier precipitated by pro-inflammatory cytokine reactions. The neurotropic effect and neuroinvasiveness of SARS-Coronavirus-2 have not been directly established. Conclusions Acute symptomatic seizures are possible in patients with COVID-19 disease. These seizures are likely multifactorial in origin, including cortical irritation due to blood-brain barrier breakdown, precipitated by the cytokine reaction as a part of the viral infection. Patients with clinical signs of seizures or otherwise unexplained encephalopathy may benefit from electroencephalography monitoring and/or empiric anti-epileptic therapy. Further studies are needed to elucidate the risk of seizures and benefit of monitoring in this population.
C1 [Hepburn, Madihah; Mullaguri, Naresh; George, Pravin; Newey, Christopher R.] Cleveland Clin Fdn, Cerebrovasc Ctr, Neurol Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Hantus, Stephen; Punia, Vineet; Newey, Christopher R.] Cleveland Clin Fdn, Epilepsy Ctr, Neurol Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Bhimraj, Adarsh] Cleveland Clin Fdn, Resp Inst, Dept Infect Dis, Sect Neurol Infect Dis, 9500 Euclid Ave, Cleveland, OH 44195 USA.
RP Hepburn, M (corresponding author), Cleveland Clin Fdn, Cerebrovasc Ctr, Neurol Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM madihah.hepburn@gmail.com
RI Mullaguri, Naresh/M-2061-2017
OI Mullaguri, Naresh/0000-0001-6850-3294; Hepburn,
   Madihah/0000-0002-7070-4033
CR Arbour N, 2000, J VIROL, V74, P8913, DOI 10.1128/JVI.74.19.8913-8921.2000
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Koch M, 2008, EPILEPSIA, V49, P948, DOI 10.1111/j.1528-1167.2008.01565.x
   Li YY, 2016, INTERVIROLOGY, V59, P163, DOI 10.1159/000453066
   Mao L, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3544840, DOI 10.2139/SSRN.3544840]
   Newey CR, 2018, J CLIN NEUROPHYSIOL, V35, P325, DOI 10.1097/WNP.0000000000000475
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Steardo L, 2020, ACTA PHYSIOL, V229, DOI 10.1111/apha.13473
   Xu J, 2005, CLIN INFECT DIS, V41, P1089, DOI 10.1086/444461
   Yao Y, 2014, CELL MOL LIFE SCI, V71, P683, DOI 10.1007/s00018-013-1459-1
NR 11
TC 18
Z9 18
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1541-6933
EI 1556-0961
J9 NEUROCRIT CARE
JI Neurocrit. Care
DI 10.1007/s12028-020-01006-1
EA MAY 2020
PG 5
WC Critical Care Medicine; Clinical Neurology
SC General & Internal Medicine; Neurosciences & Neurology
GA MZ1ZU
UT WOS:000558921100001
PM 32462412
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Perotti, C
   Del Fante, C
   Baldanti, F
   Franchini, M
   Percivalle, E
   Nepita, EV
   Seminari, E
   De Silvestri, A
   Bruno, R
   Klersy, C
AF Perotti, Cesare
   Del Fante, Claudia
   Baldanti, Fausto
   Franchini, Massimo
   Percivalle, Elena
   Nepita, Edoardo Vecchio
   Seminari, Elena
   De Silvestri, Annalisa
   Bruno, Raffele
   Klersy, Catherine
TI Plasma from donors recovered from the new Coronavirus 2019 as therapy
   for critical patients with COVID-19 (COVID-19 plasma study): a
   multicentre study protocol
SO INTERNAL AND EMERGENCY MEDICINE
LA English
DT Article
DE COVID-19; Hyperimmune plasma; Plasmapheresis
ID CONVALESCENT PLASMA; HIV-1
AB Since the end of 2019, a new coronavirus strain has been reported in the Chinese province of Wuhan, indicated as 2019-nCoV or SARS-CoV-2. In February 2020, the first case of transmission on Italian soil was reported. On March 09, 2020, at the time of protocol design, the Italian Ministry of Health reported 10,149 people who had contracted the virus; of these, 8514 were positive, of which 5038 were hospitalized with symptoms (59.2%) and 877 in intensive care (10.3%), while the remaining 2599 were in home isolation; 631 were deceased (6.2%) and 1004 healed (9.9%). To date there are no studies in the literature that demonstrate its feasibility and efficacy in the context of the worldwide SARS-CoV-2 epidemic. Based upon the little existing evidence, we planned to assess the efficacy of the infusion of hyperimmune plasma in COVID-19 patients in a one-armproof-of-conceptclinical trial. The primary objective of our study is to evaluate the efficacy of the administration of plasma taken from convalescent donors of COVID-19 to critically ill patients with COVID-19 in terms of their survival. Death from any cause will be considered. The main limit of this study is its one-arm proof-of-concept design with only 43 patients enrolled. However, in the absence of previous evidence, larger and/or randomized trials did not appear to be ethically acceptable. Moreover, the results from this study, if encouraging, will allow us to plan further informed large clinical trials. Trial registration: NCT 04321421 March 23, 2020.
C1 [Perotti, Cesare; Del Fante, Claudia] Fdn IRCCS Policlin San Matteo, Immunohematol & Transfus Serv, Pavia, Italy.
   [Baldanti, Fausto; Percivalle, Elena; Nepita, Edoardo Vecchio] Fdn IRCCS Policlin San Matteo, Mol Virol Unit, Pavia, Italy.
   [Baldanti, Fausto; Seminari, Elena; Bruno, Raffele] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy.
   [Franchini, Massimo] Carlo Poma Hosp, Immunohematol & Transfus Serv, Mantua, Italy.
   [Bruno, Raffele] Fdn IRCCS Policlin San Matteo, Infect Dis 1, Pavia, Italy.
   [De Silvestri, Annalisa; Klersy, Catherine] Fdn IRCCS Policlin San Matteo, Clin Epidemiol & Biometry Unit, Pavia, Italy.
RP Del Fante, C (corresponding author), Fdn IRCCS Policlin San Matteo, Immunohematol & Transfus Serv, Pavia, Italy.
EM c.delfante@smatteo.pv.it
RI Bruno, Raffaele/L-3530-2018; De Silvestri, Annalisa/I-6024-2014; Klersy,
   Catherine/AAA-3003-2019; Percivalle, Elena/K-7994-2016; Del Fante,
   Claudia/F-8911-2016
OI Bruno, Raffaele/0000-0002-0235-9207; De Silvestri,
   Annalisa/0000-0003-3128-8441; Klersy, Catherine/0000-0003-0314-8548;
   Percivalle, Elena/0000-0002-3355-1410; Del Fante,
   Claudia/0000-0003-0822-0342; Seminari, Elena/0000-0001-5246-928X
CR Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hung IFN, 2013, CHEST, V144, P712, DOI 10.1378/chest.13-0571
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Keller MA, 2000, CLIN MICROBIOL REV, V13, P602, DOI 10.1128/CMR.13.4.602-614.2000
   Lai ST, 2005, EUR J CLIN MICROBIOL, V24, P583, DOI 10.1007/s10096-005-0004-z
   Lu CL, 2016, SCIENCE, V352, P1001, DOI 10.1126/science.aaf1279
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Rajam Gowrisankar, 2010, Recent Pat Antiinfect Drug Discov, V5, P157
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Schoofs T, 2016, SCIENCE, V352, P997, DOI 10.1126/science.aaf0972
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   World Health Organization, 2020, CLIN MAN SEV AC RESP
NR 17
TC 10
Z9 10
U1 2
U2 2
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1828-0447
EI 1970-9366
J9 INTERN EMERG MED
JI Intern. Emerg. Med.
PD AUG
PY 2020
VL 15
IS 5
SI SI
BP 819
EP 824
DI 10.1007/s11739-020-02384-2
EA MAY 2020
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA MZ0DG
UT WOS:000556447200001
PM 32468508
OA Bronze
DA 2021-01-01
ER

PT J
AU Deana, C
AF Deana, Cristian
TI The COVID-19 pandemic: is our medicine still evidence-based?
SO IRISH JOURNAL OF MEDICAL SCIENCE
LA English
DT Article; Early Access
DE COVID-19; Evidence-based medicine; Randomized controlled trial;
   Remdesivir
AB There is no randomized controlled trial that demonstrated the efficacy of antiviral therapy against COVID-19 yet. However, physicians are prescribing different drugs to a large part of COVID-19 population in the hope they will cure them. This does not reflect the evidence-based medicine approach. What we need is more evidence-based knowledge about what routine care practices we should to apply to ameliorate symptoms of patients and fight COVID-19 pathology.
C1 [Deana, Cristian] Acad Hosp Udine, Dept Anesthesia & Intens Care 1, Anesthesia & Intens Care 1, Udine, Italy.
RP Deana, C (corresponding author), Acad Hosp Udine, Dept Anesthesia & Intens Care 1, Anesthesia & Intens Care 1, Udine, Italy.
EM deana.cristian@gmail.com
OI DEANA, CRISTIAN/0000-0002-1626-3177
CR Masic Izet, 2008, Acta Inform Med, V16, P219, DOI 10.5455/aim.2008.16.219-225
   Thorlund K, 2020, LANCET DIGIT HEALTH, V2, pE286, DOI 10.1016/S2589-7500(20)30086-8
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
NR 3
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0021-1265
EI 1863-4362
J9 IRISH J MED SCI
JI Irish J. Med. Sci.
DI 10.1007/s11845-020-02258-8
EA MAY 2020
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA MV6DE
UT WOS:000556445300001
PM 32468413
OA Bronze
DA 2021-01-01
ER

PT J
AU Tian, H
   Sui, YD
   Tian, SC
   Zou, XL
   Xu, ZP
   He, H
   Wu, TJ
AF Tian, Hui
   Sui, Yuanda
   Tian, Suochen
   Zou, Xiuli
   Xu, Zhiping
   He, Huang
   Wu, Tiejun
TI Case Report: Clinical Treatment of the First Critical Patient With
   Coronavirus Disease (COVID-19) in Liaocheng, Shandong Province
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID-19; critical COVID-19 patient; clinical characteristics; clinical
   diagnosis and treatment; plasma exchange; high-flow nasal cannula; case
   report
AB This paper reports the clinical characteristics, diagnosis, and treatment of the first critical COVID-19 patient in Liaocheng City, who was admitted to the intensive care unit isolation ward of Liaocheng People's Hospital on February 11, 2020. On admission, the patient had difficulty breathing, the oxygenation index was 135 mmHg, and the blood lactate was 5.6 mmol/L. After comprehensive treatment including high-flow nasal cannula oxygen therapy, plasma exchange, antiviral and anti-infection therapies, immune regulation, liquid volume management, glucocorticoid, enteral nutrition support, analgesia and sedation, blood glucose control, anticoagulation and thrombus prevention, and electrolyte balance maintenance, the patient was finally cured, and discharged. The purpose of this case report is to provide a reference for the clinical diagnosis and treatment of critical COVID-19 patients.
C1 [Tian, Hui; Sui, Yuanda; Tian, Suochen; Zou, Xiuli; Xu, Zhiping; He, Huang; Wu, Tiejun] Liaocheng Peoples Hosp, Dept Crit Care Med, Liaocheng, Shandong, Peoples R China.
RP Wu, TJ (corresponding author), Liaocheng Peoples Hosp, Dept Crit Care Med, Liaocheng, Shandong, Peoples R China.
EM tiejunwu@hotmail.com
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jingsong Z, 2018, CHIN CRITI CARE MED, V30, P456, DOI [10.3760/cma.j.issn.2095-4352.2018.05.012, DOI 10.3760/CMA.J.ISSN.2095-4352.2018.05.012]
   Khwannimit Bodin, 2008, Journal of the Medical Association of Thailand, V91, P1336
   Lee CC, 2016, RESP MED, V121, P100, DOI 10.1016/j.rmed.2016.11.004
   National Heath Commission of People's Republic of China, GUID NOV COR INF PNE
   WHO, 2020, CLIN MAN SEV AC RESP
   Xinghua P, 2017, CHIN CRIT CARE MED, V29, P821, DOI [10.3760/cma.j.issn.2095-4352.2017.09.011, DOI 10.3760/CMA.J.ISSN.2095-4352.2017.09.011]
   Yang P, 2020, EPIDEMIOLOGICAL CLIN, DOI [10.1101/2020.02.28.20028068, DOI 10.1101/2020.02.28.20028068]
   Yu K Y, 2020, Zhonghua Yi Xue Za Zhi, V100, P724, DOI 10.3760/cma.j.cn112137-20200205-00196
NR 11
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD MAY 28
PY 2020
VL 7
AR 249
DI 10.3389/fmed.2020.00249
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA MC1SU
UT WOS:000543076600001
PM 32574337
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kell, DB
   Heyden, EL
   Pretorius, E
AF Kell, Douglas B.
   Heyden, Eugene L.
   Pretorius, Etheresia
TI The Biology of Lactoferrin, an Iron-Binding Protein That Can Help Defend
   Against Viruses and Bacteria
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE lactoferrin; coronaviruses; iron; membrane receptors; HSPGs
ID NEUTROPHIL EXTRACELLULAR TRAPS; HEPARAN-SULFATE PROTEOGLYCANS;
   RECEPTOR-RELATED PROTEIN-1; BOVINE LACTOFERRIN; CELLULAR UPTAKE;
   ANTIMICROBIAL PEPTIDES; GASTROINTESTINAL-TRACT; PHARMACEUTICAL DRUGS;
   BLOOD-CIRCULATION; PLASMA-MEMBRANE
AB Lactoferrin is a nutrient classically found in mammalian milk. It binds iron and is transferred via a variety of receptors into and between cells, serum, bile, and cerebrospinal fluid. It has important immunological properties, and is both antibacterial and antiviral. In particular, there is evidence that it can bind to at least some of the receptors used by coronaviruses and thereby block their entry. Of importance are Heparan Sulfate Proteoglycans (HSPGs) and the host receptor angiotensin-converting enzyme 2 (ACE2), as based on other activities lactoferrin might prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from attaching to the host cells. Lactoferrin (and more specifically enteric-coated LF because of increased bioavailability) may consequently be of preventive and therapeutic value during the present COVID-19 pandemic.
C1 [Kell, Douglas B.] Univ Liverpool, Fac Hlth & Life Sci, Inst Integrat Biol, Dept Biochem, Liverpool, Merseyside, England.
   [Kell, Douglas B.] Tech Univ Denmark, Novo Nordisk Fdn Ctr Biosustainabil, Lyngby, Denmark.
   [Kell, Douglas B.; Pretorius, Etheresia] Stellenbosch Univ, Fac Sci, Dept Physiol Sci, Stellenbosch, South Africa.
RP Kell, DB (corresponding author), Univ Liverpool, Fac Hlth & Life Sci, Inst Integrat Biol, Dept Biochem, Liverpool, Merseyside, England.; Kell, DB (corresponding author), Tech Univ Denmark, Novo Nordisk Fdn Ctr Biosustainabil, Lyngby, Denmark.; Kell, DB; Pretorius, E (corresponding author), Stellenbosch Univ, Fac Sci, Dept Physiol Sci, Stellenbosch, South Africa.
EM dbk@liv.ac.uk; resiap@sun.ac.za
FU Medical Research Council of South Africa (MRC) [A0X331]; UK
   BBSRCBiotechnology and Biological Sciences Research Council (BBSRC)
   [BB/L025752/1]
FX We thank the Medical Research Council of South Africa (MRC)
   (Self-Initiated Research Program: A0X331) and the UK BBSRC (grant
   BB/L025752/1) for supporting this collaboration.
CR Ames BN, 2018, P NATL ACAD SCI USA, V115, P10836, DOI 10.1073/pnas.1809045115
   Anderberg RJ, 2015, LAB INVEST, V95, P250, DOI 10.1038/labinvest.2014.163
   ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0
   Andres MT, 2016, ANTIMICROB AGENTS CH, V60, P4206, DOI 10.1128/AAC.03130-15
   Ashall L, 2009, SCIENCE, V324, P242, DOI 10.1126/science.1164860
   Assinger A, 2012, THROMB RES, V130, pE73, DOI 10.1016/j.thromres.2012.04.017
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Ballard O, 2013, PEDIATR CLIN N AM, V60, P49, DOI 10.1016/j.pcl.2012.10.002
   Bard E, 2003, CLIN CHEM LAB MED, V41, P127, DOI 10.1515/CCLM.2003.021
   Baveye S, 1999, CLIN CHEM LAB MED, V37, P281, DOI 10.1515/CCLM.1999.049
   Beddek AJ, 2010, BIOMETALS, V23, P377, DOI 10.1007/s10534-010-9299-z
   BELLAMY W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P130, DOI 10.1016/0167-4838(92)90346-F
   Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8
   BLUARDDE.JM, 1974, BIOCHIM BIOPHYS ACTA, V365, P311, DOI 10.1016/0005-2795(74)90002-6
   Boesch AW, 2013, J IMMUNOL METHODS, V397, P71, DOI 10.1016/j.jim.2013.09.001
   Borodina I, 2020, NUTR RES REV, V33, P190, DOI 10.1017/S0954422419000301
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Brock JH, 2012, BIOCHEM CELL BIOL, V90, P245, DOI [10.1139/O2012-018, 10.1139/o2012-018]
   Brock JH, 2002, BIOCHEM CELL BIOL, V80, P1, DOI 10.1139/o01-212
   Brooks CL, 2014, ACTA CRYSTALLOGR F, V70, P1312, DOI 10.1107/S2053230X14019372
   Buonfiglio LGV, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0743-x
   Cagno V, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11070596
   Cai XK, 2018, FOOD FUNCT, V9, P4216, DOI 10.1039/c7fo01559c
   Carro Eva, 2017, Alzheimers Dement (Amst), V8, P131, DOI 10.1016/j.dadm.2017.04.002
   Carvalho CAM, 2017, J GEN VIROL, V98, P1749, DOI 10.1099/jgv.0.000849
   Castanheira FVS, 2019, BLOOD, V133, P2178, DOI 10.1182/blood-2018-11-844530
   Chanda W, 2017, MED HYPOTHESES, V106, P15, DOI 10.1016/j.mehy.2017.06.029
   Chen B, 2019, TRENDS MICROBIOL, V27, P878, DOI 10.1016/j.tim.2019.06.002
   Chen JM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091957
   Chow BDW, 2016, J HUM LACT, V32, P168, DOI 10.1177/0890334415592402
   Christianson HC, 2014, MATRIX BIOL, V35, P51, DOI 10.1016/j.matbio.2013.10.004
   Cole AM, 2006, CURR TOP MICROBIOL, V306, P199
   Cooper CA, 2013, TRANSGENIC RES, V22, P571, DOI 10.1007/s11248-012-9662-7
   CornishBowden A, 1995, BIOORG CHEM, V23, P439, DOI 10.1006/bioo.1995.1030
   Cutone A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092128
   Czosnykowska-Lukacka M, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102350
   D'Elia RV, 2013, CLIN VACCINE IMMUNOL, V20, P319, DOI 10.1128/CVI.00636-12
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   De Filippo K, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12949
   Delgado-Rizo V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00081
   Dobson PD, 2008, NAT REV DRUG DISCOV, V7, P205, DOI 10.1038/nrd2438
   Dreyfuss JL, 2009, AN ACAD BRAS CIENC, V81, P409, DOI 10.1590/S0001-37652009000300007
   Drobni P, 2004, ANTIVIR RES, V64, P63, DOI 10.1016/j.antiviral.2004.05.005
   Elass-Rochard E, 1998, INFECT IMMUN, V66, P486, DOI 10.1128/IAI.66.2.486-491.1998
   Farah R, 2018, BIOMED J, V41, P63, DOI 10.1016/j.bj.2018.03.004
   Fernandes KE, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00002
   Fillebeen C, 1999, J BIOL CHEM, V274, P7011, DOI 10.1074/jbc.274.11.7011
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   FRANSSON GB, 1980, J PEDIATR-US, V96, P380, DOI 10.1016/S0022-3476(80)80676-7
   FURMANSKI P, 1989, J EXP MED, V170, P415, DOI 10.1084/jem.170.2.415
   Futosi K, 2013, INT IMMUNOPHARMACOL, V17, P638, DOI 10.1016/j.intimp.2013.06.034
   Ganz T, 2018, INT J HEMATOL, V107, P7, DOI 10.1007/s12185-017-2366-2
   Gao CH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00037
   Garcia-Culebras A, 2019, STROKE, V50, P2922, DOI 10.1161/STROKEAHA.119.025085
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Girardi E, 2020, NAT CHEM BIOL, V16, P469, DOI 10.1038/s41589-020-0483-3
   Gleerup HS, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/4761054
   Glimvall P, 2012, J PERIODONTAL RES, V47, P655, DOI 10.1111/j.1600-0765.2012.01479.x
   Grey A, 2004, MOL ENDOCRINOL, V18, P2268, DOI 10.1210/me.2003-0456
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Hahn J, 2016, CLIN EXP RHEUMATOL, V34, pS6
   Harada E, 1999, COMP BIOCHEM PHYS A, V124, P321, DOI 10.1016/S1095-6433(99)00122-1
   He YY, 2016, ADV NUTR, V7, P102, DOI 10.3945/an.115.010090
   Hediger MA, 2013, MOL ASPECTS MED, V34, P95, DOI 10.1016/j.mam.2012.12.009
   Heidt T, 2016, SCI REP-UK, V6, DOI 10.1038/srep25044
   Hettinga K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019433
   Hondermarck Hubert, 2020, FASEB Bioadv, V2, P296, DOI 10.1096/fba.2020-00015
   Huang WL, 2017, ANNU REV BIOCHEM, V86, P799, DOI 10.1146/annurev-biochem-060815-014214
   Ikoma-Seki K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141378
   Ishikado A, 2005, BIOL PHARM BULL, V28, P1717, DOI 10.1248/bpb.28.1717
   JALIL RA, 1993, J PERIODONTAL RES, V28, P130, DOI 10.1111/j.1600-0765.1993.tb01060.x
   Jameson GB, 1998, ACTA CRYSTALLOGR D, V54, P1319, DOI 10.1107/S0907444998004417
   Jiang RL, 2011, J CELL PHYSIOL, V226, P3022, DOI 10.1002/jcp.22650
   Jorch SK, 2017, NAT MED, V23, P279, DOI 10.1038/nm.4294
   Kai H, 2020, HYPERTENS RES, V43, P648, DOI 10.1038/s41440-020-0455-8
   Kamemori N, 2008, J VET MED SCI, V70, P313, DOI 10.1292/jvms.70.313
   Kanekiyo T, 2013, J NEUROSCI, V33, P19276, DOI 10.1523/JNEUROSCI.3487-13.2013
   Karav S, 2018, CELL MOL BIOL, V64, P52, DOI 10.14715/cmb/2018.64.9.8
   Karav S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040870
   Kawakami H, 2015, INT DAIRY J, V47, P79, DOI 10.1016/j.idairyj.2015.02.001
   KELL DB, 2015, PERSPECT SCI, V6, P66, DOI DOI 10.1016/J.PISC.2015.06.004
   Kell DB, 2006, SYSTEM MODELING CELL, P3, DOI DOI 10.7551/MITPRESS/9780262195485.003.0001
   Kell DB, 2018, BIOL REV, V93, P1518, DOI 10.1111/brv.12407
   Kell DB, 2018, SEMIN THROMB HEMOST, V44, P224, DOI 10.1055/s-0037-1604108
   Kell DB, 2015, INTEGR BIOL-UK, V7, P1339, DOI 10.1039/c5ib00158g
   Kell DB, 2015, TRENDS PHARMACOL SCI, V36, P15, DOI 10.1016/j.tips.2014.10.005
   Kell DB, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00231
   Kell DB, 2014, METALLOMICS, V6, P748, DOI 10.1039/c3mt00347g
   Kell DB, 2013, DRUG DISCOV TODAY, V18, P218, DOI 10.1016/j.drudis.2012.11.008
   Kell DB, 2011, DRUG DISCOV TODAY, V16, P704, DOI 10.1016/j.drudis.2011.05.010
   Kell DB, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-2
   Kimoto Y, 2013, J VET MED SCI, V75, P159, DOI 10.1292/jvms.12-0154
   Koshi R, 2018, DIS MARKERS, V2018, DOI 10.1155/2018/4308291
   Lang JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023710
   Laubel DM, 2006, CURR TOP MICROBIOL, V306, P153
   Law SM, 2017, J INFLAMM-LOND, V14, DOI 10.1186/s12950-017-0176-1
   Lee ACY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1684-0
   Lee KH, 2017, AUTOIMMUN REV, V16, P1160, DOI 10.1016/j.autrev.2017.09.012
   Legrand D, 2016, J PEDIATR-US, V173, pS10, DOI 10.1016/j.jpeds.2016.02.071
   Lepanto MS, 2019, MOLECULES, V24, DOI 10.3390/molecules24071323
   Liao H, 2019, BMC MICROBIOL, V19, DOI 10.1186/s12866-018-1370-x
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Liu C, 2019, INFLAMMATION, V42, P2192, DOI 10.1007/s10753-019-01083-1
   Liu Q, 2007, NEURON, V56, P66, DOI 10.1016/j.neuron.2007.08.008
   Lonnerdal B, 2016, J PEDIATR-US, V173, pS4, DOI 10.1016/j.jpeds.2016.02.070
   Lv XW, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1087-3
   Marshall LJ, 2016, INT J PHARMACEUT, V514, P399, DOI 10.1016/j.ijpharm.2016.09.034
   Matsuzaki T, 2019, BIOL PHARM BULL, V42, P989, DOI 10.1248/bpb.b19-00011
   McMahon CM, 2020, J AM CHEM SOC, V142, P2386, DOI 10.1021/jacs.9b11699
   Mehrbod P, 2019, VIRULENCE, V10, P376, DOI 10.1080/21505594.2019.1605803
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Milewska A, 2018, J VIROL, V92, DOI 10.1128/JVI.01933-17
   Milewska A, 2014, J VIROL, V88, P13221, DOI 10.1128/JVI.02078-14
   Mizuhashi F, 2015, J PROSTHET DENT, V113, P35, DOI 10.1016/j.prosdent.2013.12.028
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Moore SA, 1997, J MOL BIOL, V274, P222, DOI 10.1006/jmbi.1997.1386
   Morita Y, 2017, GERIATR GERONTOL INT, V17, P714, DOI 10.1111/ggi.12776
   Nairz M, 2010, CELL MICROBIOL, V12, P1691, DOI 10.1111/j.1462-5822.2010.01529.x
   Naskalska A, 2019, J VIROL, V93, DOI 10.1128/JVI.00355-19
   Oda H, 2019, CLIN COSMET INV DERM, V12, P875, DOI 10.2147/CCID.S228153
   Okubo K, 2016, EBIOMEDICINE, V10, P204, DOI 10.1016/j.ebiom.2016.07.012
   Olumuyiwa-Akeredolu OO, 2019, NAT REV RHEUMATOL, V15, P237, DOI 10.1038/s41584-019-0187-9
   Page MJ, 2020, SEMIN THROMB HEMOST, V46, P302, DOI 10.1055/s-0040-1708827
   Palipane M, 2019, MICROB PATHOGENESIS, V127, P212, DOI 10.1016/j.micpath.2018.12.008
   Pammi M, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007137.pub5
   Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105
   Patel P, 2017, J CHEM NEUROANAT, V85, P36, DOI 10.1016/j.jchemneu.2017.06.007
   Patras KA, 2019, J INNATE IMMUN, V11, P481, DOI 10.1159/000499342
   Pedersen AML, 2019, J DENT, V80, pS3, DOI 10.1016/j.jdent.2018.08.010
   Peroni DG, 2020, J PEDIATR NEONATAL I, V9, DOI 10.7363/090142
   Petrik M, 2017, CLIN TRANSL IMAGING, V5, P15, DOI 10.1007/s40336-016-0211-x
   Pogoutse AK, 2017, CRIT REV BIOCHEM MOL, V52, P314, DOI 10.1080/10409238.2017.1293606
   Posey JE, 2000, SCIENCE, V288, P1651, DOI 10.1126/science.288.5471.1651
   Pretorius E, 2019, TRENDS ENDOCRIN MET, V30, P532, DOI 10.1016/j.tem.2019.05.003
   Puddu P, 1998, INT J BIOCHEM CELL B, V30, P1055, DOI 10.1016/S1357-2725(98)00066-1
   QUERINJE.P, 1971, EUR J BIOCHEM, V20, P420, DOI 10.1111/j.1432-1033.1971.tb01408.x
   Rawat P, 2012, BIOCHEM CELL BIOL, V90, P329, DOI [10.1139/O11-058, 10.1139/o11-058]
   Redwan EM, 2014, CR BIOL, V337, P581, DOI 10.1016/j.crvi.2014.08.003
   Reghunathan R, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-2
   Rosa L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091985
   Roseanu A, 2010, BIOMETALS, V23, P485, DOI 10.1007/s10534-010-9312-6
   Russo R, 2018, ARCH GYNECOL OBSTET, V298, P139, DOI 10.1007/s00404-018-4771-z
   Sangermano R, 2019, CLIN TER, V170, pE373, DOI 10.7417/CT.2019.2163
   Sanui T, 2017, IMMUNOL INVEST, V46, P190, DOI 10.1080/08820139.2016.1238925
   Sarrazin S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004952
   Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x
   Seo YD, 2019, CLIN CANCER RES, V25, P3934, DOI 10.1158/1078-0432.CCR-19-0081
   Seong KJ, 2016, KOREAN J PHYSIOL PHA, V20, P41, DOI 10.4196/kjpp.2016.20.1.41
   Sessa R, 2017, PATHOG DIS, V75, DOI 10.1093/femspd/ftx054
   Shin K, 2008, BIOL PHARM BULL, V31, P1605, DOI 10.1248/bpb.31.1605
   Singer-Englar T, 2019, EXPERT REV GASTROENT, V13, P3, DOI 10.1080/17474124.2019.1543023
   Skaar EP, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000949
   Sorensen M, 1939, COMPTE RENDU TRAVAUX
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Srivastava M, 2019, INT IMMUNOPHARMACOL, V71, P188, DOI 10.1016/j.intimp.2019.03.031
   Superti F, 2001, BBA-GEN SUBJECTS, V1528, P107, DOI 10.1016/S0304-4165(01)00178-7
   Superti-Furga G, 2020, NAT REV DRUG DISCOV, V19, P429, DOI 10.1038/d41573-020-00056-6
   Suzuki YA, 2005, CELL MOL LIFE SCI, V62, P2560, DOI 10.1007/s00018-005-5371-1
   Szczepanski A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040328
   Takayama Y, 2017, BIOCHEM CELL BIOL, V95, P57, DOI 10.1139/bcb-2016-0039
   Takeuchi T, 2004, EXP PHYSIOL, V89, P263, DOI 10.1113/expphysiol.2003.026633
   Takeuchi T, 2006, EXP PHYSIOL, V91, P1033, DOI 10.1113/expphysiol.2006.034876
   Talukder MJR, 2003, J VET MED A, V50, P123, DOI 10.1046/j.1439-0442.2003.00512.x
   Talukder MJR, 2003, J VET MED SCI, V65, P957, DOI 10.1292/jvms.65.957
   Tamaki C, 2007, MOL PHARMACOL, V72, P850, DOI 10.1124/mol.107.036913
   Tang AT, 2017, NATURE, V545, P305, DOI 10.1038/nature22075
   Tang N, 2020, J THROMB HAEMOST, V18, P1520, DOI 10.1111/jth.14851
   Telang S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091228
   Teraguchi S, 2004, BIOMETALS, V17, P231, DOI 10.1023/B:BIOM.0000027697.83706.32
   Togawa J, 2002, AM J PHYSIOL-GASTR L, V283, pG187, DOI 10.1152/ajpgi.00331.2001
   Tse GMK, 2004, J CLIN PATHOL, V57, P260, DOI 10.1136/jcp.2003.013276
   Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639
   Valenti P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00376
   van Leeuwen SJM, 2019, BIOL BLOOD MARROW TR, V25, P1055, DOI 10.1016/j.bbmt.2019.01.026
   Vogel HJ, 2012, BIOCHEM CELL BIOL, V90, P233, DOI [10.1139/o2012-016, 10.1139/O2012-016]
   Vogel S, 2018, BRIT J HAEMATOL, V180, P761, DOI 10.1111/bjh.15117
   Wakabayashi H, 2004, BIOSCI BIOTECH BIOCH, V68, P853, DOI 10.1271/bbb.68.853
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3
   Wang AL, 2018, FOOD FUNCT, V9, P4948, DOI [10.1039/c8fo00813b, 10.1039/C8FO00813B]
   Wang B, 2019, CRIT REV FOOD SCI, V59, P580, DOI 10.1080/10408398.2017.1381583
   Wang M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11462-z
   Ward PP, 2002, BIOCHEM CELL BIOL, V80, P95, DOI 10.1139/o01-214
   Watanabe T, 2017, COMPR PHYSIOL, V7, P765, DOI 10.1002/cphy.c160043
   Weinberg ED, 2009, BBA-GEN SUBJECTS, V1790, P600, DOI 10.1016/j.bbagen.2008.07.002
   White KN, 2012, BBA-GEN SUBJECTS, V1820, P411, DOI 10.1016/j.bbagen.2011.10.006
   Woodman T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201819
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Xu D, 2015, INFECT IMMUN, V83, P3648, DOI 10.1128/IAI.00545-15
   Yan FL, 2008, ACTA NEUROPATHOL, V116, P529, DOI 10.1007/s00401-008-0435-6
   Yang J, 2020, AGING-US, V12, P6518, DOI 10.18632/aging.103100
   Zenewicz Lauren A, 2018, Immunohorizons, V2, P198, DOI 10.4049/immunohorizons.1800006
   Zhang GM, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01338-8
   Zhang GY, 2009, J IMMUNOL, V182, P7997, DOI 10.4049/jimmunol.0802884
   Zhang JC, 2020, BRAIN BEHAV IMMUN, V87, P59, DOI 10.1016/j.bbi.2020.04.046
   Zhou P, 2018, NATURE, V561, P122, DOI 10.1038/s41586-018-0433-3
NR 196
TC 9
Z9 9
U1 9
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAY 28
PY 2020
VL 11
AR 1221
DI 10.3389/fimmu.2020.01221
PG 15
WC Immunology
SC Immunology
GA MA8VI
UT WOS:000542188300001
PM 32574271
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Khalil, A
   Kamar, A
   Nemer, G
AF Khalil, Athar
   Kamar, Amina
   Nemer, Georges
TI Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest
   Victims of Yet Another Theoretical Drug-Repurposing?
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE COVID-19; cytokine storm; lung injury; thalidomide; anti-inflammatory
   drug
ID INDUCED PULMONARY INJURY; CYTOKINE STORM; CORONAVIRUS; MECHANISM;
   FIBROSIS; COUGH
AB The coronavirus disease 2019 (COVID-19) pandemic is a worldwide threatening health issue. The progression of this viral infection occurs in the airways of the lungs with an exaggerated inflammatory response referred to as the "cytokine storm" that can lead to lethal lung injuries. In the absence of an effective anti-viral molecule and until the formulation of a successful vaccine, anti-inflammatory drugs might offer a complementary tool for controlling the associated complications of COVID-19 and thus decreasing the subsequent fatalities. Drug repurposing for several molecules has emerged as a rapid temporary solution for COVID-19. Among these drugs is Thalidomide; a historically emblematic controversial molecule that harbors an FDA approval for treating erythema nodosum leprosum (ENL) and multiple myeloma (MM). Based on just one-case report that presented positive outcomes in a patient treated amongst others with Thalidomide, two clinical trials on the efficacy and safety of Thalidomide in treating severe respiratory complications in COVID-19 patients were registered. Yet, the absence of substantial evidence on Thalidomide usage in that context along with the discontinued studies on the efficiency of this drug in similar pulmonary diseases, might cause a significant obstacle for carrying out further clinical evaluations. Herein, we will discuss the theoretical effectiveness of Thalidomide in attenuating inflammatory complications that are encountered in COVID-19 patients while pinpointing the lack of the needed evidences to move forward with this drug.
C1 [Khalil, Athar; Nemer, Georges] Amer Univ Beirut, Dept Biochem & Mol Genet, Beirut, Lebanon.
   [Kamar, Amina] Amer Univ Beirut, Dept Internal Med, Vasc Med Program, Beirut, Lebanon.
   [Nemer, Georges] Hamad Bin Khalifa Univ, Coll Hlth & Life Sci, Genom & Translat Biomed, Doha, Qatar.
RP Khalil, A; Nemer, G (corresponding author), Amer Univ Beirut, Dept Biochem & Mol Genet, Beirut, Lebanon.; Nemer, G (corresponding author), Hamad Bin Khalifa Univ, Coll Hlth & Life Sci, Genom & Translat Biomed, Doha, Qatar.
EM aak67@mail.aub.edu; gnemer@hbku.edu.qa
RI Nemer, Georges/ABB-5117-2020
OI KAMAR, AMINA/0000-0002-9045-6452
CR Amirshahrokhi K, 2013, INT IMMUNOPHARMACOL, V17, P210, DOI 10.1016/j.intimp.2013.06.005
   Behrens EM, 2017, ARTHRITIS RHEUMATOL, V69, P1135, DOI 10.1002/art.40071
   Birring SS, 2018, CHEST, V154, P904, DOI 10.1016/j.chest.2018.06.038
   Bonam Srinivasa Reddy, 2020, Cell Rep Med, V1, P100016, DOI 10.1016/j.xcrm.2020.100016
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen CS, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.35
   Chen M, 2010, DERMATOL CLIN, V28, P577, DOI 10.1016/j.det.2010.03.003
   Clinicaltrials.gov, 2020, THAL RECR STUD LIST
   Dong XY, 2017, INFLAMMATION, V40, P1836, DOI 10.1007/s10753-017-0625-2
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Ghobrial Irene M, 2003, J Support Oncol, V1, P194
   Hawkins RB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01511
   Horton MR, 2012, ANN INTERN MED, V157, P398, DOI 10.7326/0003-4819-157-6-201209180-00003
   Ito T, 2011, CELL MOL LIFE SCI, V68, P1569, DOI 10.1007/s00018-010-0619-9
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Khalil A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00482
   Khalil A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01641-3
   Khalil AA, 2017, ONCOTARGET, V8, P68230, DOI 10.18632/oncotarget.19938
   Khalsa Satkirin K, 2007, Radiol Case Rep, V2, P41, DOI 10.2484/rcr.v2i2.71
   Kumar V, 2008, EUR J PHARMACOL, V592, P146, DOI 10.1016/j.ejphar.2008.07.019
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74
   Majumder S, 2012, CURR TOP MED CHEM, V12, P1456, DOI 10.2174/156802612801784443
   Matthews SJ, 2003, CLIN THER, V25, P342, DOI 10.1016/S0149-2918(03)80085-1
   MCHUGH SM, 1995, CLIN EXP IMMUNOL, V99, P160
   MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062
   Millrine D, 2017, TRENDS MOL MED, V23, P348, DOI 10.1016/j.molmed.2017.02.006
   Nemer G, 2019, DRUG RES, V69, P512, DOI 10.1055/a-0873-3529
   Palumbo A, 2012, THER ADV DRUG SAF, V3, P255, DOI 10.1177/2042098612452291
   Paravar T, 2008, INT REV IMMUNOL, V27, P111, DOI 10.1080/08830180801911339
   Phadke M, 2020, DRUG DEVELOP RES, V81, P541, DOI 10.1002/ddr.21666
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Semeraro M, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26494
   SHANNON EJ, 1981, SCAND J IMMUNOL, V13, P553, DOI 10.1111/j.1365-3083.1981.tb00169.x
   Shim JS, 2014, INT J BIOL SCI, V10, P654, DOI 10.7150/ijbs.9224
   Stephens TD, 2000, BIOCHEM PHARMACOL, V59, P1489, DOI 10.1016/S0006-2952(99)00388-3
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Vargesson N, 2015, BIRTH DEFECTS RES C, V105, P140, DOI 10.1002/bdrc.21096
   Verbon A, 2000, ANTIMICROB AGENTS CH, V44, P2286, DOI 10.1128/AAC.44.9.2286-2290.2000
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang HL, 2008, AM J EMERG MED, V26, P711, DOI 10.1016/j.ajem.2007.10.031
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
   World Health Organization, 2020, COR DIS 2019
   Xia J, 2020, EFFICACY SAFETY THAL
   Yang YS, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102434
   Yi Y, 2020, INT J BIOL SCI, V16, P1753, DOI 10.7150/ijbs.45134
   Zhang R, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117583
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
   Zhu HY, 2014, INFLAMMATION, V37, P2091, DOI 10.1007/s10753-014-9943-9
NR 52
TC 3
Z9 3
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAY 28
PY 2020
VL 11
AR 1248
DI 10.3389/fimmu.2020.01248
PG 7
WC Immunology
SC Immunology
GA LZ8DQ
UT WOS:000541451600001
PM 32574274
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vuagnat, P
   Frelaut, M
   Ramtohul, T
   Basse, C
   Diakite, S
   Noret, A
   Bellesoeur, A
   Servois, V
   Hequet, D
   Laas, E
   Kirova, Y
   Cabel, L
   Pierga, JY
   Bozec, L
   Paoletti, X
   Cottu, P
   Bidard, FC
AF Vuagnat, Perrine
   Frelaut, Maxime
   Ramtohul, Toulsie
   Basse, Clemente
   Diakite, Sarah
   Noret, Aurelien
   Bellesoeur, Audrey
   Servois, Vincent
   Hequet, Delphine
   Laas, Enora
   Kirova, Youlia
   Cabel, Luc
   Pierga, Jean-Yves
   Bozec, Laurence
   Paoletti, Xavier
   Cottu, Paul
   Bidard, Francois-Clement
CA Inst Curie Breast Canc
   COVID Grp
TI COVID-19 in breast cancer patients: a cohort at the Institut Curie
   hospitals in the Paris area
SO BREAST CANCER RESEARCH
LA English
DT Article
DE SARS-CoV-2; COVID-19; Breast cancer; Outcome; Survival
AB Background Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France). Methods An IRB-approved prospective registry was set up at ICH on March 13, 2020, for all breast cancer patients with COVID-19 symptoms or radiologic signs. Registered data included patient history, tumor characteristics and treatments, COVID-19 symptoms, radiological features, and outcome. Data extraction was done on April 25, 2020. COVID-19 patients were defined as those with either a positive RNA test or typical, newly appeared lung CT scan abnormalities. Results Among 15,600 patients actively treated for early or metastatic breast cancer during the last 4 months at ICH, 76 patients with suspected COVID-19 infection were included in the registry and followed. Fifty-nine of these patients were diagnosed with COVID-19 based on viral RNA testing (N = 41) or typical radiologic signs: 37/59 (63%) COVID-19 patients were treated for metastatic breast cancer, and 13/59 (22%) of them were taking corticosteroids daily. Common clinical features mostly consisted of fever and/or cough, while ground-glass opacities were the most common radiologic sign at diagnosis. We found no association between prior radiation therapy fields or extent of radiation therapy sequelae and extent of COVID-19 lung lesions. Twenty-eight of these 59 patients (47%) were hospitalized, and 6 (10%) were transferred to an intensive care unit. At the time of analysis, 45/59 (76%) patients were recovering or had been cured, 10/59 (17%) were still followed, and 4/59 (7%) had died from COVID-19. All 4 patients who died had significant non-cancer comorbidities. In univariate analysis, hypertension and age (> 70) were the two factors associated with a higher risk of intensive care unit admission and/or death. Conclusions This prospective registry analysis suggests that the COVID-19 mortality rate in breast cancer patients depends more on comorbidities than prior radiation therapy or current anti-cancer treatment. Special attention must be paid to comorbidities when estimating the risk of severe COVID-19 in breast cancer patients.
C1 [Vuagnat, Perrine; Paoletti, Xavier; Bidard, Francois-Clement] Univ Paris Saclay, UVSQ, St Cloud, France.
   [Vuagnat, Perrine; Basse, Clemente; Diakite, Sarah; Noret, Aurelien; Bellesoeur, Audrey; Cabel, Luc; Pierga, Jean-Yves; Bozec, Laurence; Cottu, Paul; Bidard, Francois-Clement] Inst Curie, Dept Med Oncol, Paris, France.
   [Vuagnat, Perrine; Basse, Clemente; Diakite, Sarah; Noret, Aurelien; Bellesoeur, Audrey; Cabel, Luc; Pierga, Jean-Yves; Bozec, Laurence; Cottu, Paul; Bidard, Francois-Clement] Inst Curie, Dept Med Oncol, St Cloud, France.
   [Frelaut, Maxime] Inst Curie, Dept Drug Dev & Innovat, Paris, France.
   [Ramtohul, Toulsie; Servois, Vincent] Inst Curie, Dept Radiol, Paris, France.
   [Hequet, Delphine; Laas, Enora] Inst Curie, Dept Surg Oncol, Paris, France.
   [Kirova, Youlia] Inst Curie, Dept Radiat Oncol, Paris, France.
   [Pierga, Jean-Yves] Univ Paris, Paris, France.
   [Paoletti, Xavier] INSERM, U900 STAMPM Team, St Cloud, France.
RP Bidard, FC (corresponding author), Univ Paris Saclay, UVSQ, St Cloud, France.; Bidard, FC (corresponding author), Inst Curie, Dept Med Oncol, Paris, France.; Bidard, FC (corresponding author), Inst Curie, Dept Med Oncol, St Cloud, France.
EM fcbidard@curie.fr
RI Cottu, Paul/ABC-8595-2020; Alimi, Adel M./A-5697-2012
OI Alimi, Adel M./0000-0002-0642-3384; Servois,
   Vincent/0000-0002-8378-8432; Lantz, olivier/0000-0003-3161-7719
FU Institut Curie, Universite de Versailles Saint Quentin; Universite
   Paris-Saclay
FX Institut Curie, Universite de Versailles Saint Quentin, and Universite
   Paris-Saclay (no grant number applicable).
CR Claude L, 2004, RADIOTHER ONCOL, V71, P175, DOI 10.1016/j.radonc.2004.02.005
   Hansell DM, 2008, RADIOLOGY, V246, P697, DOI 10.1148/radiol.2462070712
   Huang GQ, 2020, AM J ROENTGENOL, V215, P367, DOI 10.2214/AJR.20.23078
   Kabore EG, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002989
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Salehi S, 2020, AM J ROENTGENOL, V215, P87, DOI [10.2214/AJR.20.23034, 10.2214/AJR.20.23034S.]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 11
TC 10
Z9 10
U1 3
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD MAY 28
PY 2020
VL 22
IS 1
AR 55
DI 10.1186/s13058-020-01293-8
PG 10
WC Oncology
SC Oncology
GA LV4CF
UT WOS:000538384700001
PM 32460829
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU DeBaun, MR
AF DeBaun, Michael R.
TI Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in
   children with SCA during the COVID-19 pandemic
SO BLOOD
LA English
DT Letter
ID CELL ANEMIA; SICKLE; TRANSFUSIONS
C1 [DeBaun, Michael R.] Vanderbilt Univ, Med Ctr, Vanderbilt Meharry Ctr Excellence Sickle Cell Dis, Nashville, TN USA.
RP DeBaun, MR (corresponding author), Vanderbilt Meharry Ctr Excellence Sickle Cell Dis, 2525 West End Ave,Suite 750, Nashville, TN 37203 USA.
EM m.debaun@vumc.org
OI DeBaun, Michael/0000-0002-0574-1604
CR Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102
   Akingbola TS, 2019, AM J HEMATOL, V94, pE112, DOI 10.1002/ajh.25412
   Ali SB, 2011, AM J HEMATOL, V86, P846, DOI 10.1002/ajh.22142
   DeBaun MR, 2016, BLOOD, V127, P829, DOI 10.1182/blood-2015-09-618579
   Galadanci NA, 2018, AM J HEMATOL, V93, pE83, DOI 10.1002/ajh.25012
   Ghafuri DL, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26401
   Kassim AA, 2015, BLOOD, V125, P3401, DOI 10.1182/blood-2014-09-551564
   Lagunju I A, 2013, Niger Postgrad Med J, V20, P181
   Sethy S, 2018, INDIAN J HEMATOL BLO, V34, P294, DOI 10.1007/s12288-017-0869-x
   Ware RE, 2016, LANCET, V387, P661, DOI 10.1016/S0140-6736(15)01041-7
NR 10
TC 8
Z9 8
U1 2
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAY 28
PY 2020
VL 135
IS 22
BP 1997
EP 1999
DI 10.1182/blood.2020005992
PG 4
WC Hematology
SC Hematology
GA LT9LX
UT WOS:000537388300013
PM 32282033
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Uzun, T
   Toptas, O
AF Uzun, Tugcenur
   Toptas, Orcun
TI Artesunate: could be an alternative drug to chloroquine in COVID-19
   treatment?
SO CHINESE MEDICINE
LA English
DT Article
DE SARS-CoV-2; Choroquine; Artesunate
ID NF-KAPPA-B; IN-VITRO; ARTEMISININ; INHIBITION; MALARIA; CARDIOMYOPATHY;
   REPLICATION; CYTOKINES; PROTEINS
AB SARS (Severe Acute Respiratory Syndrome Coronavirus)-CV-2 (2019-nCov), which showed up in China in December 2019 and spread all over the world, has becomed a serious health problem. An effective, safe and proven treatment has not yet been found. Chloroquine has been recommended by some authors to be used for the treatment of patients infected with this virus however chloroquine may have side effects and drug resistance problems. Artesunate is a semisynthetic derivative of artemisinin, an antimalarial drug. Artesunate was thought to be an effective treatment for covid-19 because of its anti-inflammatory activity, NF-kappa B (nuclear Factor kappa B)-coronavirus effect and chloroquine-like endocytosis inhibition mechanism.
C1 [Uzun, Tugcenur] Trabzon Oral & Dent Hlth Hosp, DDS, Dept Oral & Maxillofacial Surg, Trabzon, Turkey.
   [Toptas, Orcun] Abant Izzet Baysal Univ, Dept Oral & Maxillofacial Surg, Fac Dent, Bolu, Turkey.
RP Uzun, T (corresponding author), Trabzon Oral & Dent Hlth Hosp, DDS, Dept Oral & Maxillofacial Surg, Trabzon, Turkey.
EM tugce--nur@hotmail.com
CR Adjuik M, 2004, LANCET, V363, P9
   Aldieri E, 2003, FEBS LETT, V552, P141, DOI 10.1016/S0014-5793(03)00905-0
   Anthony SJ, 2017, MBIO, V8, DOI [10.1128/mBio.00373-17, 10.1128/mbio.00373-17]
   BERNSTEIN HN, 1991, ANN OPHTHALMOL, V23, P292
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Canton J, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006838
   CHEN H, 1994, CONTACT DERMATITIS, V30, P280, DOI 10.1111/j.1600-0536.1994.tb00598.x
   Christman JW, 2000, CHEST, V117, P1482, DOI 10.1378/chest.117.5.1482
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   CUBERO GI, 1993, BRIT HEART J, V69, P451
   D'Alessandro S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8010085
   Dai RJ, 2016, VIRUS GENES, V52, P22, DOI 10.1007/s11262-015-1285-7
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Drouot E, 2016, ANTIVIR THER, V21, P535, DOI 10.3851/IMP3028
   Efferth T, 2006, CURR DRUG TARGETS, V7, P407, DOI 10.2174/138945006776359412
   Efferth T, 2008, CLIN INFECT DIS, V47, P804, DOI 10.1086/591195
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   He Y, 2011, RHEUMATOL INT, V31, P53, DOI 10.1007/s00296-009-1218-7
   Herold T, 2020, LEVEL IL 6 PREDICTS, DOI [10.1101/2020.04.01.200473814, DOI 10.1101/2020.04.01.200473814]
   Hoppe HC, 2004, ANTIMICROB AGENTS CH, V48, P2370, DOI 10.1128/AAC.48.7.2370-2378.2004
   Hu B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006698
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang WW, 2016, PHYTOMEDICINE, V23, P1259, DOI 10.1016/j.phymed.2016.06.004
   Kanzawa N, 2006, FEBS LETT, V580, P6807, DOI 10.1016/j.febslet.2006.11.046
   Kaptein SJF, 2006, ANTIVIR RES, V69, P60, DOI 10.1016/j.antiviral.2005.10.003
   Lee JY, 2019, J MICROBIOL BIOTECHN, V29, P1316, DOI 10.4014/jmb.1908.08004
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910
   Li T, 2013, INT IMMUNOPHARMACOL, V16, P306, DOI 10.1016/j.intimp.2013.03.011
   Mo Han-You, 2012, Zhongguo Zhong Xi Yi Jie He Za Zhi, V32, P253
   Obeid S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081783
   RATLIFF NB, 1987, NEW ENGL J MED, V316, P191, DOI 10.1056/NEJM198701223160405
   Romero MR, 2005, ANTIVIR RES, V68, P75, DOI 10.1016/j.antiviral.2005.07.005
   Sharma BN, 2014, ANTIMICROB AGENTS CH, V58, P6724, DOI 10.1128/AAC.03714-14
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Xu H, 2007, RHEUMATOLOGY, V46, P920, DOI 10.1093/rheumatology/kem014
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 39
TC 4
Z9 4
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749-8546
J9 CHIN MED-UK
JI Chin. Med.
PD MAY 28
PY 2020
VL 15
IS 1
AR 54
DI 10.1186/s13020-020-00336-8
PG 4
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA LW0HM
UT WOS:000538827800001
PM 32514287
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Giurgea, LT
   Han, A
   Memoli, MJ
AF Giurgea, Luca T.
   Han, Alison
   Memoli, Matthew J.
TI Universal coronavirus vaccines: the time to start is now
SO NPJ VACCINES
LA English
DT Article
ID NEURAMINIDASE; ANTIBODY; SPIKE
AB The continued explosive spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) despite aggressive public health measures has triggered an unprecedented international vaccine effort. However, correlates of protection, which can help guide intelligent vaccine design, are not known for SARS-CoV-2. Research on influenza immunity and vaccine development may provide valuable lessons for coronavirus efforts, especially considering similarities in rapid evolutionary potential. The apparent inevitability of future novel coronavirus outbreaks must prompt work on a universal coronavirus vaccine.
C1 [Giurgea, Luca T.; Han, Alison; Memoli, Matthew J.] NIAID, LID Clin Studies Unit, Infect Dis Lab, Div Intramural Res,NIH, Bethesda, MD 20892 USA.
RP Giurgea, LT (corresponding author), NIAID, LID Clin Studies Unit, Infect Dis Lab, Div Intramural Res,NIH, Bethesda, MD 20892 USA.
EM luca.giurgea@nih.gov
OI Giurgea, Luca/0000-0002-8696-6927
FU Intramural Research Program of the NIH, NIAIDUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
FX This research was supported [in part] by the Intramural Research Program
   of the NIH, NIAID.
CR Anderson RM, 2004, PHILOS T R SOC B, V359, P1091, DOI 10.1098/rstb.2004.1490
   Centers for Disease Control and Prevention, 2019, SEAS VACC EFF EST
   Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li N, 2020, J MED VIROL, V92, P2286, DOI 10.1002/jmv.25952
   Liu W, 2006, J INFECT DIS, V193, P792, DOI 10.1086/500469
   Memoli M., 2016, MBIO, V7, P1, DOI DOI 10.1128/MBI0.00417-16
   Memoli MJ, 2020, CLIN INFECT DIS, V70, P748, DOI 10.1093/cid/ciz281
   MONTO AS, 1973, LANCET, V1, P623, DOI 10.1016/S0140-6736(73)92196-X
   Morens DM, 2019, J INFECT DIS, V219, pS5, DOI 10.1093/infdis/jiy728
   Paules CI, 2017, IMMUNITY, V47, P599, DOI 10.1016/j.immuni.2017.09.007
   Ren LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep11451
   Sandbulte MR, 2011, P NATL ACAD SCI USA, V108, P20748, DOI 10.1073/pnas.1113801108
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Sui JH, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000197
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365v2, DOI 10.1101/2020.03.30.200473]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhong XF, 2005, J VIROL, V79, P3401, DOI 10.1128/JVI.79.6.3401-3408.2005
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 29
TC 2
Z9 2
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2059-0105
J9 NPJ VACCINES
JI npj Vaccines
PD MAY 28
PY 2020
VL 5
IS 1
AR 43
DI 10.1038/s41541-020-0198-1
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LS0JG
UT WOS:000536079800001
PM 32528732
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bragazzi, NL
   Ricco, M
   Pacifico, A
   Malagoli, P
   Kridin, K
   Pigatto, P
   Damiani, G
AF Bragazzi, Nicola Luigi
   Ricco, Matteo
   Pacifico, Alessia
   Malagoli, Piergiorgio
   Kridin, Khalaf
   Pigatto, Paolo
   Damiani, Giovanni
TI COVID-19 knowledge prevents biologics discontinuation: Data from an
   Italian multicenter survey during RED-ZONE declaration
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE atopic dermatitis; biologics; COVID-19; COVID-19 questionnaire;
   hidradenitis suppurativa; psoriasis; SARS-CoV-2
ID PSORIASIS; GUIDELINES; SEVERITY; DERMATOLOGY; ADHERENCE; THERAPY;
   SOCIETY
AB SARS-CoV-2 become pandemics and there is still a dearth of data about its the potentially among dermatological patients under biologics. We aimed to assess health literacy, disease knowledge, treatment dissatisfaction and biologics attitudes toward COVID-19. We performed a cross-sectional, questionnaire-based survey on 98/105 consecutive dermatological patients treated with biologics-51 suffering from plaque psoriasis, 22 from atopic dermatitis, and 25 from hidradenitis suppurativa. An ad hoc, validated questionnaire has 44 items investigating the following domains: knowledge of COVID-19 related to (a) epidemiology, (b) pathogenesis, (c) clinical symptoms, (d) preventive measures, and (e) attitudes. Patients data and questionnaires were collected. Despite only 8.1% thought that biologics may increase the risk of COVID-19, 18.4% and 21.4% of the patients were evaluating the possibility to discontinue or modify the dosage of the current biologic therapy, respectively. Globally, male patients (P = .001) with higher scholarity level (P = .005) displayed higher knowledge of COVID-19. Patients with lower DLQI (P = .006), longer disease duration (P = .051) and lower scholarity (P = .007) have thought to discontinue/modify autonomously their biologic therapy. At the multivariate logistic regression, only the knowledge of epidemiology and preventive measures resulted independent predictors of continuation vs discontinuation and modification vs no modification, respectively. Dermatologists should promote COVID-19 knowledge to prevent biologics disruption.
C1 [Bragazzi, Nicola Luigi] York Univ, Dept Math & Stat, Lab Ind & Appl Math LIAM, Toronto, ON, Canada.
   [Ricco, Matteo] Univ Genoa, Postgrad Sch Publ Hlth, Dept Hlth Sci DISSAL, Genoa, Italy.
   [Pacifico, Alessia] IRCCS, San Gallicano Dermatol Inst, Rome, Italy.
   [Malagoli, Piergiorgio] Azienda Osped San Donato Milanese, Dermatol Unit, Milan, Italy.
   [Kridin, Khalaf] Univ Lubeck, Lubeck Inst Expt Dermatol, Lubeck, Germany.
   [Pigatto, Paolo; Damiani, Giovanni] IRCCS Ist Ortoped Galeazzi, Clin Dermatol, Via Riccardo Galeazzi 4, I-20161 Milan, Italy.
   [Pigatto, Paolo; Damiani, Giovanni] Univ Milan, Dept Biomed Surg & Dent Sci, Milan, Italy.
RP Damiani, G (corresponding author), IRCCS Ist Ortoped Galeazzi, Clin Dermatol, Via Riccardo Galeazzi 4, I-20161 Milan, Italy.
EM dr.giovanni.damiani@gmail.com
RI Pacifico, Alessia/AAE-9908-2019; Kridin, Khalaf/ABD-8694-2020; Bragazzi,
   Nicola/G-1672-2011
OI Pacifico, Alessia/0000-0003-0348-0620; Kridin,
   Khalaf/0000-0001-9971-9151; Malagoli, Piergiorgio/0000-0002-6181-6922;
   Damiani, Giovanni/0000-0002-2390-6505; Bragazzi,
   Nicola/0000-0001-8409-868X; Ricco, Matteo/0000-0002-6525-2159
CR Acharya P, 2020, J AM ACAD DERMATOL, V82, P1006, DOI 10.1016/j.jaad.2019.10.044
   Aw M, 2020, INT ARCH ALLERGY IMM, V181, P1, DOI 10.1159/000502958
   Brown MT, 2011, MAYO CLIN PROC, V86, P304, DOI 10.4065/mcp.2010.0575
   Cazzaniga S, 2018, J EUR ACAD DERMATOL, V32, P1993, DOI 10.1111/jdv.15050
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13298
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Damiani G, 2016, BRIT J DERMATOL, V175, P797, DOI 10.1111/bjd.14546
   Damiani G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13475
   Damiani G, 2019, DERMATOL THER, V32, DOI 10.1111/dth.13121
   Damiani G, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-210901
   Doshi JA, 2016, J AM ACAD DERMATOL, V74, P1057, DOI 10.1016/j.jaad.2016.01.048
   Eisbruch A, 2017, CLIN CANCER RES, V23
   Ellis A, 2020, J AM ACAD DERMATOL, V83, P246, DOI 10.1016/j.jaad.2020.01.012
   Elston DM, 2020, J AM ACAD DERMATOL, V82, P1085, DOI 10.1016/j.jaad.2020.03.012
   FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x
   FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839
   Gisondi P, 2017, J EUR ACAD DERMATOL, V31, P774, DOI 10.1111/jdv.14114
   Gori A, 2020, AM J TRANSPLANT, V20, P1939, DOI 10.1111/ajt.15853
   Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x
   Hurley H, 1989, DERMATOLOGIC SURG PR
   Kimball AB, 2016, NEW ENGL J MED, V375, P422, DOI 10.1056/NEJMoa1504370
   Lan JJ, 2020, J AM ACAD DERMATOL, V82, P1215, DOI 10.1016/j.jaad.2020.03.014
   Lazzerini M, 2020, LANCET GLOB HEALTH, V8, pE641, DOI 10.1016/S2214-109X(20)30110-8
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Li XT, 2020, ANN RHEUM DIS, V79, P285, DOI 10.1136/annrheumdis-2019-216102
   Lippi G, 2020, EUR J INTERN MED, V75, P107, DOI 10.1016/j.ejim.2020.03.014
   Malerba M, 2015, BRIT J DERMATOL, V173, P1544, DOI 10.1111/bjd.13988
   Megna M, 2015, GIORN ITAL DERMAT V, V150, P731
   Naldi L, 2016, PSORIASIS-TARGETS TH, V6, P65, DOI 10.2147/PTT.S85189
   Nell-Duxneuner VP, 2010, ANN RHEUM DIS, V69, P546, DOI 10.1136/ard.2009.117945
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Pacifico A, 2020, BRIT J DERMATOL, V183, P375, DOI 10.1111/bjd.19145
   Radi G, 2020, J EUR ACAD DERMATOL, V34, pE213, DOI 10.1111/jdv.16386
   Ricco Matteo, 2020, Acta Biomed, V91, P57, DOI 10.23750/abm.v91i2.9573
   Rosenbaum L, 2020, NEW ENGL J MED, V382, P1873, DOI 10.1056/NEJMp2005492
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Santus P, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3140682
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Stingeni L, 2019, GIORN ITAL DERMAT V, V154, P227, DOI 10.23736/S0392-0488.19.06301-6
   Thaci D, 2019, J DERMATOL SCI, V94, P266, DOI 10.1016/j.jdermsci.2019.02.002
   van Der Schoot LS, 2019, J EUR ACAD DERMATOL, V33, P1913, DOI 10.1111/jdv.15733
   Wang W, 2019, J DERMATOL TREAT, V30, P525, DOI 10.1080/09546634.2018.1476652
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wu D, 2020, INT J INFECT DIS, V94, P44, DOI 10.1016/j.ijid.2020.03.004
   Zayed Yazan, 2019, J Asthma, V56, P1110, DOI 10.1080/02770903.2018.1520865
   Zouboulis CC, 2017, BRIT J DERMATOL, V177, P1401, DOI 10.1111/bjd.15748
NR 46
TC 7
Z9 7
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13508
DI 10.1111/dth.13508
EA MAY 2020
PG 8
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000535840100001
PM 32415727
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Stefano, ML
   Kream, RM
   Stefano, GB
AF Stefano, Michelle L.
   Kream, Richard M.
   Stefano, George B.
TI A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing
   Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of
   Viral/Nicotinic Acetylcholine Receptor Complexes
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Coronavirus; COVID-19; Rabies virus; Receptors, Nicotinic; Vaccines
ID SNAKE-VENOM NEUROTOXINS; CENTRAL-NERVOUS-SYSTEM; GLYCOPROTEIN; GP120;
   PEPTIDES; BINDING; MOUSE; LIVE
AB The emergence of the novel beta-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic of coronavirus disease 2019 (COVID-19). Clinical studies have documented that potentially severe neurological symptoms are associated with SARS-CoV-2 infection, thereby suggesting direct CNS penetration by the virus. Prior studies have demonstrated that the destructive neurological effects of rabies virus (RABV) infections are mediated by CNS transport of the virus tightly bound to the nicotinic acetylcholine receptor (nAChR). By comparison, it has been hypothesized that a similar mechanism exists to explain the multiple neurological effects of SARS-CoV-2 via binding to peripheral nAChRs followed by orthograde or retrograde transport into the CNS. Genetic engineering of the RABV has been employed to generate novel vaccines consisting of non-replicating RABV particles expressing chimeric capsid proteins containing human immunodeficiency virus 1 (HIV-1), Middle East respiratory syndrome (MERS-CoV), Ebolavirus, and hepatitis C virus (HCV) sequences. Accordingly, we present a critical discussion that integrates lessons learned from prior RABV research and vaccine development into a working model of a SARS-CoV-2 vaccine that selectively targets and neutralizes CNS penetration of a tightly bound viral nAChR complex.
C1 [Stefano, Michelle L.] Lib Congress, Washington, DC 20540 USA.
   [Kream, Richard M.; Stefano, George B.] Charles Univ Prague, Dept Psychiat, Fac Med 1, Prague, Czech Republic.
   [Kream, Richard M.; Stefano, George B.] Gen Univ Hosp Prague, Ctr Cognit & Mol Neurosci, Prague, Czech Republic.
   [Kream, Richard M.; Stefano, George B.] Int Sci Informat Inc, Melville, NY 11747 USA.
RP Stefano, GB (corresponding author), Charles Univ Prague, Dept Psychiat, Fac Med 1, Prague, Czech Republic.; Stefano, GB (corresponding author), Gen Univ Hosp Prague, Ctr Cognit & Mol Neurosci, Prague, Czech Republic.; Stefano, GB (corresponding author), Int Sci Informat Inc, Melville, NY 11747 USA.
EM gbstefano@yahoo.com
CR Alimohammadi H, 2000, CHEM SENSES, V25, P61, DOI 10.1093/chemse/25.1.61
   BABIC N, 1994, VIROLOGY, V204, P616, DOI 10.1006/viro.1994.1576
   Bracci L, 1997, BLOOD, V90, P3623, DOI 10.1182/blood.V90.9.3623
   BRACCI L, 1992, FEBS LETT, V311, P115, DOI 10.1016/0014-5793(92)81380-5
   Butowt R, 2020, ACS CHEM NEUROSCI, V11, P1200, DOI 10.1021/acschemneuro.0c00172
   Capo-Velez CM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20271-x
   CHANGEUX jean-pierre, 2020, QEIOS
   Chen Y, 2020, BIOCH BIOPHYS RES CO
   De Felice FG, 2020, TRENDS NEUROSCI
   Farsalinos K, 2020, TOXICOL REP
   Frasnelli J, 2007, CEREB CORTEX, V17, P2268, DOI 10.1093/cercor/bhl135
   Gastka M, 1996, J GEN VIROL, V77, P2437, DOI 10.1099/0022-1317-77-10-2437
   Guo YD, 2019, VIRUS RES, V263, P217, DOI 10.1016/j.virusres.2019.02.006
   Helms J, 2020, N ENGL J MED
   Hemachudha T, 2013, LANCET NEUROL, V12, P498, DOI 10.1016/S1474-4422(13)70038-3
   Huey R, 2017, J DRUG TARGET, V25, P379, DOI 10.1080/1061186X.2016.1223676
   Husner A, 2006, LARYNGOSCOPE, V116, P1520, DOI 10.1097/01.mlg.0000225946.37489.4c
   Joob B, 2020, J MED VIROL, V92, P1415, DOI 10.1002/jmv.25782
   LAFAY F, 1991, VIROLOGY, V183, P320, DOI 10.1016/0042-6822(91)90145-2
   LENTZ TL, 1987, PROTEINS, V2, P298, DOI 10.1002/prot.340020406
   Li YC, 2020, J MED VIROL, V92, P707, DOI 10.1002/jmv.25824
   Liu L, 1998, BRAIN RES, V809, P238, DOI 10.1016/S0006-8993(98)00862-2
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   McKenna PA, 2003, J VIROL, V77, P12782, DOI 10.1128/JVI.77.23.12782-12794.2003
   Mechawar N, 2004, P NATL ACAD SCI USA, V101, P9822, DOI 10.1073/pnas.0403361101
   NERI P, 1990, ARCH VIROL, V114, P265, DOI 10.1007/BF01310756
   Priestnall SL, 2020, VET PATHOL, V57, P467, DOI 10.1177/0300985820926485
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Schnell MJ, 2010, NAT REV MICROBIOL, V8, P51, DOI 10.1038/nrmicro2260
   Schnell MJ, 2000, P NATL ACAD SCI USA, V97, P3544, DOI 10.1073/pnas.050589197
   SHANKAR V, 1991, J VIROL, V65, P2736, DOI 10.1128/JVI.65.5.2736-2738.1991
   Siler CA, 2002, VIROLOGY, V292, P24, DOI 10.1006/viro.2001.1212
   Stefano G.B., 1986, P271
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Willet M, 2015, J INFECT DIS, V212, pS414, DOI 10.1093/infdis/jiv251
   Wirblich C, 2017, J VIROL, V91, DOI 10.1128/JVI.02040-16
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
NR 37
TC 3
Z9 3
U1 7
U2 13
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD MAY 28
PY 2020
VL 26
AR e926016
DI 10.12659/MSM.926016
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LR7HQ
UT WOS:000535865600001
PM 32463026
DA 2021-01-01
ER

PT J
AU Sk, MF
   Roy, R
   Jonniya, NA
   Poddar, S
   Kar, P
AF Sk, Md Fulbabu
   Roy, Rajarshi
   Jonniya, Nisha Amarnath
   Poddar, Sayan
   Kar, Parimal
TI Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2
   main protease by using molecular dynamics simulations and free energy
   calculations
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2 3CLpro; Molecular Dynamics; MM-PBSA; binding free
   energy
ID CONFORMATIONAL-CHANGES; POLAR SOLVATION; MOTIONS; GENERATION;
   DEPENDENCE; ENERGETICS; EFFICIENT; POTENCY; EWALD
AB The recent outbreak of novel "coronavirus disease 2019" (COVID-19) has spread rapidly worldwide, causing a global pandemic. In the present work, we have elucidated the mechanism of binding of two inhibitors, namely alpha-ketoamide and Z31792168, to SARS-CoV-2 main protease (M(pro)or 3CL(pro)) by using all-atom molecular dynamics simulations and free energy calculations. We calculated the total binding free energy (Delta G(bind)) of both inhibitors and further decomposed Delta G(bind)into various forces governing the complex formation using the Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) method. Our calculations reveal that alpha-ketoamide is more potent (Delta G(bind)= - 9.05 kcal/mol) compared to Z31792168 (Delta G(bind)= - 3.25 kcal/mol) against COVID-19 3CL(pro). The increase in Delta G(bind)for alpha-ketoamide relative to Z31792168 arises due to an increase in the favorable electrostatic and van der Waals interactions between the inhibitor and 3CL(pro). Further, we have identified important residues controlling the 3CL(pro)-ligand binding from per-residue based decomposition of the binding free energy. Finally, we have compared Delta G(bind)of these two inhibitors with the anti-HIV retroviral drugs, such as lopinavir and darunavir. It is observed that alpha-ketoamide is more potent compared to lopinavir and darunavir. In the case of lopinavir, a decrease in van der Waals interactions is responsible for the lower binding affinity compared to alpha-ketoamide. On the other hand, in the case of darunavir, a decrease in the favorable intermolecular electrostatic and van der Waals interactions contributes to lower affinity compared to alpha-ketoamide. Our study might help in designing rational anti-coronaviral drugs targeting the SARS-CoV-2 main protease. Communicated by Ramaswamy H. Sarma
C1 [Sk, Md Fulbabu; Roy, Rajarshi; Jonniya, Nisha Amarnath; Poddar, Sayan; Kar, Parimal] Indian Inst Technol Indore, Discipline Biosci & Biomed Engn, Indore 453552, India.
RP Kar, P (corresponding author), Indian Inst Technol Indore, Discipline Biosci & Biomed Engn, Indore 453552, India.
EM parimal@iiti.ac.in
RI Roy, Rajarshi/AAF-3391-2019; Sk, Fulbabu/AAF-3969-2019
OI Roy, Rajarshi/0000-0002-5788-9424; Sk, Fulbabu/0000-0003-4341-8370;
   Amarnath Jonniya, Nisha/0000-0001-8022-3113; Kar,
   Parimal/0000-0001-8451-9739; Poddar, Sayan/0000-0002-7192-293X
FU Department of Biotechnology, Govt. of IndiaDepartment of Biotechnology
   (DBT) India [BT/RLF/Re-entry/40/2014]; Department of Science and
   Technology (DST), Govt. of IndiaDepartment of Science & Technology
   (India) [ECR/2017/000010]; DST, Govt. of IndiaDepartment of Science &
   Technology (India) [DST/INSPIRE Fellowship/2017/IF170145]
FX This work was partially supported by the Department of Biotechnology,
   Govt. of India (grant number BT/RLF/Re-entry/40/2014, DBTRamalingaswami
   Re-entry Fellowship), and Department of Science and Technology (DST),
   Govt. of India (grant number ECR/2017/000010). MFS would like to thank
   DST, Govt. of India, for providing with the INSPIRE Fellowship
   (DST/INSPIRE Fellowship/2017/IF170145).
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abdelli I., 2020, J BIOMOLECULAR STRUC, DOI [10.1080/07391102.07392020.01763199, DOI 10.1080/07391102.07392020.01763199]
   Alamri M. A., 2020, PHARMACOINFORMATICS, DOI [10.20944/preprints202002.200308.v202001, DOI 10.20944/PREPRINTS202002.200308.V202001]
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Case D., 2018, AMBER 2018
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   Elfiky A. A., 2020, J BIOMOLECULAR STRUC, DOI [10.1080/07391102.07392020.01761882, DOI 10.1080/07391102.07392020.01761882]
   Elfiky A. A., 2020, J BIOMOLECULAR STRUC, DOI [10.1080/07391102.07392020.01761881, DOI 10.1080/07391102.07392020.01761881]
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Fearon D., 2020, PANDDA ANAL COVID 19
   Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8
   FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933
   Gupta M. K., 2020, J BIOMOLECULAR STRUC, DOI [10.1080/07391102.07392020.01751300, DOI 10.1080/07391102.07392020.01751300]
   Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   HUNENBERGER PH, 1995, J MOL BIOL, V252, P492, DOI 10.1006/jmbi.1995.0514
   ICHIYE T, 1991, PROTEINS, V11, P205, DOI 10.1002/prot.340110305
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jonniya NA, 2020, J BIOMOL STRUCT DYN, V38, P1306, DOI 10.1080/07391102.2019.1602079
   Jonniya NA, 2019, ACS OMEGA, V4, P17404, DOI 10.1021/acsomega.9b02187
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kar P, 2007, J COMPUT CHEM, V28, P2538, DOI 10.1002/jcc.20698
   Kar P, 2007, J PHYS CHEM B, V111, P8910, DOI 10.1021/jp072302u
   Kar P, 2013, J PHYS CHEM B, V117, P5793, DOI 10.1021/jp3085292
   Kar P, 2012, J PHYS CHEM B, V116, P6269, DOI 10.1021/jp300818c
   Kar P, 2012, J PHYS CHEM B, V116, P6137, DOI 10.1021/jp3022612
   Kar P, 2012, J COMPUT AID MOL DES, V26, P215, DOI 10.1007/s10822-012-9550-5
   Kar P, 2012, J PHYS CHEM B, V116, P2605, DOI 10.1021/jp211768n
   Kar P, 2011, J PHYS CHEM B, V115, P7661, DOI 10.1021/jp201538t
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Khan S. A., 2020, J BIOMOLECULAR STRUC, DOI 10.1080/07391102.07392020.01751298
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Krautler V, 2001, J COMPUT CHEM, V22, P501, DOI 10.1002/1096-987X(20010415)22:5<501::AID-JCC1021>3.0.CO;2-V
   Lin S., 2020, MOL MODELING EVALUAT, DOI [10.1101/2020.1101.1131.929695, DOI 10.1101/2020.1101.1131.929695]
   LONCHARICH RJ, 1992, BIOPOLYMERS, V32, P523, DOI 10.1002/bip.360320508
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   MCCAMMON JA, 1984, REP PROG PHYS, V47, P1, DOI 10.1088/0034-4885/47/1/001
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Olsson MHM, 2011, J CHEM THEORY COMPUT, V7, P525, DOI 10.1021/ct100578z
   Onufriev A, 2004, PROTEINS, V55, P383, DOI 10.1002/prot.20033
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Price DJ, 2004, J CHEM PHYS, V121, P10096, DOI 10.1063/1.1808117
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Roy R, 2020, ACS OMEGA, V5, P3932, DOI 10.1021/acsomega.9b03398
   Salomon-Ferrer R, 2013, WIRES COMPUT MOL SCI, V3, P198, DOI 10.1002/wcms.1121
   Sang P., 2020, INSIGHT DERIVED MOLE, DOI [10.26434/chemrxiv.11932995.v11932991, DOI 10.26434/CHEMRXIV.11932995.V11932991]
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   Sk MF, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1724196
   Umesh D. K., 2020, J BIOMOLECULAR STRUC, DOI 10.1080/07391102.07392020.01763202
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang J., 2020, J CHEM INF MODEL, DOI [10.1021/acs.jcim.1020c00179, DOI 10.1021/ACS.JCIM.1020C00179]
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   WANG JM, 2001, ABSTR PAP AM CHEM 1, V222
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Webb B., 2014, CURR PROTOC BIOINF, V47, DOI [10.1002/0471250953.bi0506s47, DOI 10.1088/1751-8113/47/31/315202]
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xu BS, 2011, J COMPUT CHEM, V32, P3188, DOI 10.1002/jcc.21900
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 75
TC 11
Z9 11
U1 5
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1768149
EA MAY 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MA6GD
UT WOS:000542008400001
PM 32396767
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Peele, KA
   Srihansa, T
   Krupanidhi, S
   Ayyagari, VS
   Venkateswarulu, TC
AF Abraham Peele, K.
   Srihansa, T.
   Krupanidhi, S.
   Ayyagari, Vijaya Sai
   Venkateswarulu, T. C.
TI Design of multi-epitope vaccine candidate against SARS-CoV-2:
   ain-silicostudy
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; vaccine design; immuno-informatics; Vaxigen; IEDB; spike
   glycoprotein
ID CORONAVIRUS
AB The best therapeutic strategy to find an effective vaccine against SARS-CoV-2 is to explore the target structural protein. In the present study, a novel multi-epitope vaccine is designed usingin silicotools that potentially trigger both CD4 and CD8 T-cell immune responses against the novel Coronavirus. The vaccine candidate was designed using B and T-cell epitopes that can act as an immunogen and elicits immune response in the host system. NCBI was used for the retrieval of surface spike glycoprotein, of novel corona virus (SARS-CoV-2) strains. VaxiJen server screens the most important immunogen of all the proteins and IEDB server gives the prediction and analysis of B and T cell epitopes. Final vaccine construct was designedin silicocomposed of 425 amino acids including the 50S ribosomal protein adjuvant and the construct was computationally validated in terms of antigenicity, allergenicity and stability on considering all critical parameters into consideration. The results subjected to the modeling and docking studies of vaccine were validated. Molecular docking study revealed the protein-protein binding interactions between the vaccine construct and TLR-3 immune receptor. The MD simulations confirmed stability of the binding pose. The immune simulation results showed significant response for immune cells. The findings of the study confirmed that the final vaccine construct of chimeric peptide could able to enhance the immune response against nCoV-19.
C1 [Abraham Peele, K.; Srihansa, T.; Krupanidhi, S.; Ayyagari, Vijaya Sai; Venkateswarulu, T. C.] Vignans Fdn Sci Technol & Res, Dept Biotechnol, Guntur 522213, Andhra Pradesh, India.
RP Venkateswarulu, TC (corresponding author), Vignans Fdn Sci Technol & Res, Dept Biotechnol, Guntur 522213, Andhra Pradesh, India.
EM venki_biotech327@yahoo.com
OI Ayyagari, Vijaya Sai/0000-0001-5438-2268
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa011
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Galante O, 2016, AM J RESP CRIT CARE, V193, P100, DOI 10.1164/rccm.201506-1239LE
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   Tse GMK, 2004, J CLIN PATHOL, V57, P260, DOI 10.1136/jcp.2003.013276
   Van De Veerdonk FL, 2020, KININS CYTOKINES COV, DOI [10.20944/preprints202004.0023.v1, DOI 10.20944/PREPRINTS202004.0023.V1]
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Yi Y, 2020, INT J BIOL SCI, V16, P1753, DOI 10.7150/ijbs.45134
NR 29
TC 17
Z9 17
U1 3
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1770127
EA MAY 2020
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MA5XP
UT WOS:000541986200001
PM 32419646
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Choudhury, C
AF Choudhury, Chinmayee
TI Fragment tailoring strategy to design novel chemical entities as
   potential binders of novel corona virus main protease
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Covid-19; main protease; fragment-based drug discovery; docking;
   molecular dynamics
ID DYNAMICS; DISCOVERY; LIGANDS; DOCKING; MODELS
AB The recent pandemic of severe acute respiratory syndrome-coronavirus2 (SARS-CoV-2) infection (COVID-19) has put the world on serious alert. The main protease of SARS-CoV-2 (SARS-CoV-2-M-Pro) cleaves the long polyprotein chains to release functional proteins required for replication of the virus and thus is a potential drug target to design new chemical entities in order to inhibit the viral replication in human cells. The current study employs state of art computational methods to design novel molecules by linking molecular fragments which specifically bind to different constituent sub-pockets of the SARS-CoV-2-M(Pro)binding site. A huge library of 191678 fragments was screened against the binding cavity of SARS-CoV-2-M(Pro)and high affinity fragments binding to adjacent sub-pockets were tailored to generate new molecules. These newly formed molecules were further subjected to molecular docking, ADMET filters and MM-GBSA binding energy calculations to select 17 best molecules (named as MP-In1 to MP-In17), which showed comparable binding affinities and interactions with the key binding site residues as the reference ligand. The complexes of these 17 molecules and the reference molecule with SARS-CoV-2-M-Pro, were subjected to molecular dynamics simulations, which assessed the stabilities of their binding with SARS-CoV-2-M-Pro. Fifteen molecules were found to form stable complexes with SARS-CoV-2-M-Pro. These novel chemical entities designed specifically according to the pharmacophoric requirements of SARS-CoV-2-M(Pro)binding pockets showed good synthetic feasibility and returned no exact match when searched against chemical databases. Considering their interactions, binding efficiencies and novel chemotypes, they can be further evaluated as potential starting points for SARS-CoV-2 drug discovery.
   [GRAPHICS]
   .
C1 [Choudhury, Chinmayee] PGIMER, Dept Expt Med & Biotechnol, Sect 12, Chandigarh 160012, India.
RP Choudhury, C (corresponding author), PGIMER, Dept Expt Med & Biotechnol, Sect 12, Chandigarh 160012, India.
EM chinmayee.choudhury@gmail.com
FU Department of Science and TechnologyDepartment of Science & Technology
   (India)
FX CC thanks Department of Science and Technology for financial assistance
   in the form of DST-INSPIRE Faculty award, Dr. Anuradha Chakravarti,
   Head, Department of Experimental Medicine and Biotechnology, PGIMER,
   Chandigarh for providing required infrastructure and fruitful
   discussions and Schrodinger for providing short term licences for some
   of the modules.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abad-Zapatero C, 2005, DRUG DISCOV TODAY, V10, P464, DOI 10.1016/S1359-6446(05)03386-6
   Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101615
   AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408
   [Anonymous], 2019, PROT PREP WIZ EP
   [Anonymous], 2019, QIKPROP
   [Anonymous], 2019, LIGPREP
   [Anonymous], 2018, MAESTR DESM INT TOOL
   [Anonymous], 2019, PRIME
   [Anonymous], 2019, GLID
   Bhatnagar T, 2020, INDIAN J MED RES, DOI [10.4103/ijmr.IJMR_502_20, DOI 10.4103/IJMR.IJMR_502_20]
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Bung N, 2020, DE NOVO DESIGN NEW C, DOI [10.26434/chemrxiv.11998347.v2, DOI 10.26434/CHEMRXIV.11998347.V2]
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Choudhury C, 2016, J CHEM SCI, V128, P719, DOI 10.1007/s12039-016-1069-1
   Choudhury C, 2015, J CHEM INF MODEL, V55, P848, DOI 10.1021/ci500737b
   Choudhury C, 2014, J STRUCT BIOL, V187, P38, DOI 10.1016/j.jsb.2014.04.007
   Coutard B, 2014, ANTIVIR RES, V106, P61, DOI 10.1016/j.antiviral.2014.03.013
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gahtori J, 2019, MOL DIVERS, DOI 10.1007/s11030-019-10015-y
   Gu XY, 2020, LANCET, V395, P948, DOI 10.1016/S0140-6736(20)30371-8
   Gupta MK, 2020, J BIOMOL STRUCT DYN, V38, P137, DOI 10.1080/07391102.2019.1567391
   Guterres H, 2020, J CHEM INF MODEL, V60, P2189, DOI 10.1021/acs.jcim.0c00057
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hasan M, 2019, MICROB PATHOGENESIS, V130, P19, DOI 10.1016/j.micpath.2019.02.023
   Heydari M, 2020, ROUT ADV RISK MANAGE, P1
   Hoffer L, 2011, COMB CHEM HIGH T SCR, V14, P500, DOI 10.2174/138620711795767884
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kanakaveti Vishnupriya, 2020, Adv Protein Chem Struct Biol, V121, P25, DOI 10.1016/bs.apcsb.2019.11.013
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Khot Wasim Yunus, 2020, J Assoc Physicians India, V68, P67
   Ko WC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105933
   Li H, 2020, DIABETES CARE, V43, pE8, DOI 10.2337/dc19-1802
   Loving K, 2010, CURR TOP MED CHEM, V10, P14, DOI 10.2174/156802610790232305
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Murgueitio Manuela S, 2012, Drug Discov Today Technol, V9, pe219, DOI 10.1016/j.ddtec.2012.07.009
   Mysinger MM, 2012, J MED CHEM, V55, P6582, DOI 10.1021/jm300687e
   Najjar A, 2019, PHYS SCI REV, V4, DOI 10.1515/psr-2018-0110
   Njogu PM, 2016, ACS INFECT DIS, V2, P8, DOI 10.1021/acsinfecdis.5b00093
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Rathi E., 2019, C DRUG DES DISC TECH, V355, P25
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Schuler J, 2017, MOLECULES, V22, DOI 10.3390/molecules22101777
   Shivakumar D, 2010, J CHEM THEORY COMPUT, V6, P1509, DOI 10.1021/ct900587b
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   Srivastava HK, 2012, MED CHEM, V8, P811
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Xu Z, 2020, LANCET, V395, P947, DOI 10.1016/S0140-6736(20)30308-1
   Zhou PL, 2020, PLANT MOL BIOL REP, V38, P1, DOI 10.1007/s11105-019-01167-0
   Zoete V, 2016, J CHEM INF MODEL, V56, P1399, DOI 10.1021/acs.jcim.6b00174
NR 59
TC 5
Z9 5
U1 1
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1771424
EA MAY 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MA5YA
UT WOS:000541987300001
PM 32452282
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Khan, MT
   Ali, A
   Wang, QK
   Irfan, M
   Khan, A
   Zeb, MT
   Zhang, YJ
   Chinnasamy, S
   Wei, DQ
AF Khan, Muhammad Tahir
   Ali, Arif
   Wang, Qiankun
   Irfan, Muhammad
   Khan, Abbas
   Zeb, Muhammad Tariq
   Zhang, Yu-Juan
   Chinnasamy, Sathishkumar
   Wei, Dong-Qing
TI Marine natural compounds as potents inhibitors against the main protease
   of SARS-CoV-2-a molecular dynamic study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Marine drugs; COVID-19; dock; interactions; molecular dynamics
ID SARS CORONAVIRUS; PRODUCTS; SIMULATIONS; GYRATION; DESIGN; RADIUS;
   AGENTS
AB Sever acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a single-stranded RNA (ssRNA) virus, responsible for severe acute respiratory disease (COVID-19). A large number of natural compounds are under trial for screening compounds, possessing potential inhibitory effect against the viral infection. Keeping in view the importance of marine compounds in antiviral activity, we investigated the potency of some marine natural products to target SARS-CoV-2 main protease (M-pro) (PDB ID 6MO3). The crystallographic structure of M-pro in an apo form was retrieved from Protein Data Bank and marine compounds from PubChem. These structures were prepared for docking and the complex with good docking score was subjected to molecular dynamic (MD) simulations for a period of 100 ns. To measure the stability, flexibility, and average distance between the target and compounds, root mean square deviations (RMSD), root mean square fluctuation (RMSF), and the distance matrix were calculated. Among five marine compounds, C-1 (PubChem CID 11170714) exhibited good activity, interacting with the active site and surrounding residues, forming many hydrogen and hydrophobic interactions. The C-1 also attained a stable dynamic behavior, and the average distance between compound and target remains constant. In conclusion, marine natural compounds may be used as a potential inhibitor against SARS-CoV-2 for better management of COVID-19.
   [GRAPHICS]
   .
C1 [Khan, Muhammad Tahir] Capital Univ Sci & Technol, Dept Bioinformat & Biosci, Islamabad, Pakistan.
   [Ali, Arif; Wang, Qiankun; Khan, Abbas; Chinnasamy, Sathishkumar; Wei, Dong-Qing] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, State Key Lab Microbial Metab, Minist Educ, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.
   [Ali, Arif; Wang, Qiankun; Khan, Abbas; Chinnasamy, Sathishkumar; Wei, Dong-Qing] Shanghai Jiao Tong Univ, Joint Lab Int Cooperat Metab & Dev Sci, Minist Educ, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.
   [Irfan, Muhammad] Univ Florida, Coll Dent, Dept Oral Biol, Gainesville, FL 32610 USA.
   [Zeb, Muhammad Tariq] Vet Res Inst, In Charge Genom Lab, Peshawar, Peshawar, Pakistan.
   [Zhang, Yu-Juan] Chongqing Normal Univ, Coll Life Sci, Chongqing, Peoples R China.
   [Wei, Dong-Qing] Peng Cheng Lab, Shenzhen, Guangdong, Peoples R China.
RP Wei, DQ (corresponding author), Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, State Key Lab Microbial Metab, Minist Educ, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.; Wei, DQ (corresponding author), Shanghai Jiao Tong Univ, Joint Lab Int Cooperat Metab & Dev Sci, Minist Educ, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.
EM dqwei@sjtu.edu.cn
RI khan, Muhammad Tahir/ABC-6368-2020
OI khan, Muhammad Tahir/0000-0003-1158-2133
FU Key Research Area Grant of the Ministry of Science and Technology of
   China [2016YFA0501703]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [61832019,
   61503244]; Science and Technology Commission of Shanghai
   MunicipalityScience & Technology Commission of Shanghai Municipality
   (STCSM) [19430750600]; Natural Science Foundation of Henan Province
   [162300410060]; Joint Research Funds for Medical and Engineering and
   Scientific Research at Shanghai Jiao Tong University [YG2017ZD14]
FX Dong-Qing Wei is supported by the grants from the Key Research Area
   Grant 2016YFA0501703 of the Ministry of Science and Technology of China,
   the National Natural Science Foundation of China (Contract no. 61832019,
   61503244), the Science and Technology Commission of Shanghai
   Municipality (Grant: 19430750600), the Natural Science Foundation of
   Henan Province (162300410060), and Joint Research Funds for Medical and
   Engineering and Scientific Research at Shanghai Jiao Tong University
   (YG2017ZD14). The computations were partially performed at the Peng
   Cheng Lab and the Center for High-Performance Computing, Shanghai Jiao
   Tong University.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abdelli I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763199
   Ahmadi A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/825203
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Anand K, 2005, BIRK ADV INFECT DIS, P173
   Aneiros A, 2004, J CHROMATOGR B, V803, P41, DOI 10.1016/j.jchromb.2003.11.005
   [Anonymous], CORONAVIRUS DIS 2019
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bernardi A, 2019, SOFTWAREX, V10, DOI 10.1016/j.softx.2019.100241
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   CHE CT, 1991, DRUG DEVELOP RES, V23, P201, DOI 10.1002/ddr.430230302
   Chen J., 2009, COMPUTATIONAL ANAL A
   Chou KC, 2009, PROTEASES BIOL DIS, V8, P1, DOI 10.1007/978-90-481-2348-3_1
   Chu LHM, 2006, PROTEIN SCI, V15, P699, DOI 10.1110/ps.052007306
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   DeGoey DA, 2018, J MED CHEM, V61, P2636, DOI 10.1021/acs.jmedchem.7b00717
   Dias DA, 2012, METABOLITES, V2, DOI 10.3390/metabo2020303
   Doniach S, 1999, CURR OPIN STRUC BIOL, V9, P157, DOI 10.1016/S0959-440X(99)80022-0
   Dubey KD, 2013, CURR COMPUT-AID DRUG, V9, P518, DOI 10.2174/15734099113096660036
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761881
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Ernst M, 2015, J CHEM PHYS, V143, DOI 10.1063/1.4938249
   Felix CR, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00743-17
   Gajula MNVP, 2016, BIO-PROTOCOL, V6, P1, DOI DOI 10.21769/BIOPROTOC.2051
   Gan YR, 2006, PEPTIDES, V27, P622, DOI 10.1016/j.peptides.2005.09.006
   Gogineni V, 2015, CHEM REV, V115, P9655, DOI 10.1021/cr4006318
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Guarner J, 2020, AM J CLIN PATHOL, V153, P420, DOI 10.1093/ajcp/aqaa029
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Heymann DL, 2020, LANCET, V395, P542, DOI 10.1016/S0140-6736(20)30374-3
   Hu YW, 2015, MAR DRUGS, V13, P202, DOI 10.3390/md13010202
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Keener A. B., 2020, NAT MED, DOI [10.1038/d41591-020-00002-4, DOI 10.1038/D41591-020-00002-4]
   Khan A, 2020, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00159
   Khan MT, 2019, MAR DRUGS, V17, DOI 10.3390/md17100549
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kumar D, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752310
   Letko Michael, 2020, bioRxiv, DOI 10.1101/2020.01.22.915660
   Lobanov MY, 2008, MOL BIOL+, V42, P623, DOI 10.1134/S0026893308040195
   Mani D, 2019, J YOUNG PHARM, V11, P117, DOI 10.5530/jyp.2019.11.26
   Mayer AMS, 2020, MAR DRUGS, V18, DOI 10.3390/md18010005
   Moghadamtousi SZ, 2015, MAR DRUGS, V13, P4520, DOI 10.3390/md13074520
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Raveh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082318
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Sagar S, 2010, MAR DRUGS, V8, P2619, DOI 10.3390/md8102619
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   Sirois S., 2007, DISCOVERY POTENT ANT
   Smilgies DM, 2015, J APPL CRYSTALLOGR, V48, P1604, DOI 10.1107/S1600576715015551
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Uzair B, 2011, BIOIMPACTS, V1, P203, DOI 10.5681/bi.2011.029
   Vijayakumar S, 2015, J ACUTE MED, V5, P15, DOI 10.1016/j.jacme.2015.02.004
   Vilar S, 2008, CURR TOP MED CHEM, V8, P1555, DOI 10.2174/156802608786786624
   Vo TS, 2010, MAR DRUGS, V8, P2871, DOI 10.3390/md8122871
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wei DQ, 2006, AMINO ACIDS, V31, P73, DOI 10.1007/s00726-006-0361-7
   Wittine K, 2019, MOLECULES, V24, DOI 10.3390/molecules24193486
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zheng XL, 2013, AAPS J, V15, P228, DOI 10.1208/s12248-012-9426-6
NR 75
TC 18
Z9 19
U1 6
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1769733
EA MAY 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MA6GL
UT WOS:000542009200001
PM 32410504
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Paniri, A
   Hosseini, MM
   Akhavan-Niaki, H
AF Paniri, Alireza
   Hosseini, Mohammad Mahdi
   Akhavan-Niaki, Haleh
TI First comprehensive computational analysis of functional consequences
   ofTMPRSS2SNPs in susceptibility to SARS-CoV-2 among different
   populations
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE In silico; TMPRSS2; SARS-CoV-2; single nucleotide polymorphisms; SNPs
ID SARS CORONAVIRUS; PROSTATE-CANCER; PROTEASE INHIBITOR; EXPRESSION;
   TMPRSS2; SERINE; RECEPTOR; GENE; FUSION; ACE2
AB Current SARS-CoV-2 pandemy mortality created the hypothesis that some populations may be more susceptible to SARS-CoV-2.TMPRSS2encodes a transmembrane serine protease which plays a crucial role in SARS-CoV-2 cell entry. Single nucleotide polymorphisms (SNPs) inTMPRSS2might influence SARS-CoV2 entry into the cell. This study aimed to investigate the impact of SNPs on TMPRSS2 function and structure.In silicotools such as Ensembl, Gtex, ExPASY 2, GEPIA, CCLE, KEGG and GO were engaged to characterizeTMPRSS2and its expression profile. The functional effects of SNPs were analyzed by PolyPhen-2, PROVEN, SNAP2, SIFT and HSF. Also, Phyre2, GOR IV and PSIPRED were used to predict the secondary structure of TMPRSS2. Moreover, post-translational modification (PTM) and secretory properties were analyzed through Modpredand Phobius, respectively. Finally, miRNA profiles were investigated by PolymiRTS and miRSNPs. Out of 11,184 retrieved SNPs from dbSNP, 92 showed a different frequency between Asians and other populations. Only 21 SNPs affected the function and structure of TMPRSS2 by influencing the protein folding, PTM, splicing and miRNA function. Particularly, rs12329760 may create ade novopocket protein. rs875393 can create a donor site, silencer and broken enhancer motifs. rs12627374 affects a wide spectrum of miRNAs profile. This study highlighted the role ofTMPRSS2 SNPsand epigenetic mechanisms especially non-coding RNAs in appearance of different susceptibility to SARS-CoV-2 among different populations. Also, this study could pave the way to potential therapeutic implication of TMPRSS2 in designing antiviral drugs. Communicated by Ramaswamy H. Sarma
C1 [Paniri, Alireza; Hosseini, Mohammad Mahdi] Babol Univ Med Sci, Student Res Comm, Babol Sar, Iran.
   [Paniri, Alireza; Akhavan-Niaki, Haleh] Babol Univ Med Sci, Dept Genet, Fac Med, Babol Sar, Iran.
   [Akhavan-Niaki, Haleh] Pasteur Inst Iran, Zoonoses Res Ctr, Amol, Iran.
RP Akhavan-Niaki, H (corresponding author), Babol Univ Med Sci, Dept Genet, Fac Med, Babol Sar, Iran.; Akhavan-Niaki, H (corresponding author), Pasteur Inst Iran, Zoonoses Res Ctr, Amol, Iran.
EM halehakhavan@yahoo.com
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Bhanushali A, 2018, PROSTATE INT, V6, P145, DOI 10.1016/j.prnil.2018.03.004
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, PHYTOTHER RES, V34, P2159, DOI 10.1002/ptr.6667
   Chen ZK, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080864
   Clinckemalie L., 2013, TMPRSS2 GENE STUDY A
   Clinckemalie L, 2013, MOL ENDOCRINOL, V27, P2028, DOI 10.1210/me.2013-1098
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Emami NC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10808-7
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   FitzGerald LM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-230
   Frick Elisabet, 2019, Oncotarget, V10, P4664, DOI 10.18632/oncotarget.27083
   Garcia-Perdomo H. A., 2018, REV MEXICANA UROLOGI, V78, P354
   Graff RE, 2015, PROSTATE, V75, P897, DOI 10.1002/pros.22973
   Gupta M, 2020, J THERM ANAL CALORIM, V142, P1545, DOI [10.1007/s10973-020-09453-w, 10.1080/01694243.2020.1749448]
   Hagglof C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086824
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hofmann H, 2004, BIOCHEM BIOPH RES CO, V319, P1216, DOI 10.1016/j.bbrc.2004.05.114
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan S, 2020, MITOCHONDRIAL DNA A, DOI [10.1080/24701394.2020.1845323, 10.1016/B978-0-12-816960-5.00001-X]
   Ko CJ, 2015, CANCER RES, V75, P2949, DOI 10.1158/0008-5472.CAN-14-3297
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lim J, 1997, MOL CELL ENDOCRINOL, V131, P205, DOI 10.1016/S0303-7207(97)00109-3
   Lin BY, 1999, CANCER RES, V59, P4180
   Luostari K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102519
   Maekawa S, 2014, INT J UROL, V21, P1234, DOI 10.1111/iju.12578
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Nickols NG, 2007, P NATL ACAD SCI USA, V104, P10418, DOI 10.1073/pnas.0704217104
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   PIERUZZI F, 1995, CIRCULATION, V92, P3105, DOI 10.1161/01.CIR.92.10.3105
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Vaarala MH, 2001, J PATHOL, V193, P134, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH743>3.0.CO;2-T
   Villela D, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/2584940
   Wu WY, 2019, EXP THER MED, V17, P3209, DOI 10.3892/etm.2019.7328
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yamauchi J, 2001, PANCREATOLOGY, V1, P662, DOI 10.1159/000055878
   Yamaya M, 2015, PULM PHARMACOL THER, V33, P66, DOI 10.1016/j.pupt.2015.07.001
   Yates C, 2017, FRONT BIOSCI-LANDMRK, V22, P212, DOI 10.2741/4482
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
NR 50
TC 13
Z9 13
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1767690
EA MAY 2020
PG 18
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MA6CB
UT WOS:000541997800001
PM 32410502
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Allen, MB
   Mirsaeidi, M
AF Allen, Mary Beth
   Mirsaeidi, Mehdi
TI Health and Economy in COVID-19 Era: A Plan for Reconstituting Long-Term
   Economic Security
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE health; economy; immunity; COVID-19; pandemic
AB COVID-19 is a rapidly evolving pandemic, which represents a multifaceted global threat. Given the economic consequences, most researchers agree that social distancing measures are an effective strategy relative to the cost. Previous studies indicate that community size as well as viral population risk groups should be considered in forming an effective targeted social distancing strategy. The resultant delay in the occurrence of infections in order to support vaccine development has been shown to be an effective policy. However, a return to normalcy from the current situation would require policy intervention that transforms the American economy along with continued targeted social distancing and the use of medical science as a tool to facilitate gradual personal interactions of low-risk individuals. We believe that the adoption of rapid IgG testing would be best suitable for widespread population-level screening as part of a comprehensive plan for incrementally rebuilding the in-person workforce. As such, this crisis represents an opportunity for the United States to increase automation of the manufacturing sector, shrink supply chains, and create higher-level jobs in order to reduce the dependency on other countries for critical supplies. This economic transition to better utilize technology along with reconstruction of the workforce could improve the standard of living for many Americans as well as better prepare the US for future pandemics.
C1 [Allen, Mary Beth; Mirsaeidi, Mehdi] Univ Miami, Div Pulm & Crit Care, Miami, FL 33136 USA.
   [Mirsaeidi, Mehdi] Univ Miami, Dept Publ Hlth Sci, Miami, FL 33136 USA.
RP Mirsaeidi, M (corresponding author), Univ Miami, Div Pulm & Crit Care, Miami, FL 33136 USA.; Mirsaeidi, M (corresponding author), Univ Miami, Dept Publ Hlth Sci, Miami, FL 33136 USA.
EM msm249@miami.edu
CR Borba MGS, 2020, CHLOROQUINE DIPHOSPH, DOI [10.1101/2020.04.07.20056424, DOI 10.1101/2020.04.07.20056424]
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Glass RJ, 2006, EMERG INFECT DIS, V12, P1671, DOI 10.3201/eid1211.060255
   Greer AL, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-669
   NIAID, 2020, NIH CLIN TRIAL SHOWS
   Rashid H, 2015, PAEDIATR RESPIR REV, V16, P119, DOI 10.1016/j.prrv.2014.01.003
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Spiteri J, 2019, SOC SCI MED, V224, P37, DOI 10.1016/j.socscimed.2019.01.050
NR 8
TC 2
Z9 2
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD MAY 27
PY 2020
VL 8
AR 235
DI 10.3389/fpubh.2020.00235
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA LZ1MT
UT WOS:000540994500001
PM 32574304
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Minniti, A
   Maglione, W
   Pignataro, F
   Cappadona, C
   Caporali, R
   Del Papa, N
AF Minniti, Antonina
   Maglione, Wanda
   Pignataro, Francesca
   Cappadona, Carmela
   Caporali, Roberto
   Del Papa, Nicoletta
TI Taking care of systemic sclerosis patients during COVID-19 pandemic:
   rethink the clinical activity
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE COVID-19; Patient care; Public health; Systemic sclerosis
AB COVID-19 outbreak has quickly spread worldwide, causing a high pressure on the health-care system. In Italy, from March 8, 2020, all the deferrable clinical activities have been suspended to increase the health care offer for COVID-19 patients. The hospital organization has been modified also in order to assure non-COVID-19 patients assistance. The Scleroderma Unit of ASST Pini-CTO Hospital, in Milan, in the region mostly hit by SARS-CoV-2 in Italy, follows more than 600 patients affected by systemic sclerosis (SSc). Patients with SSc need a close follow-up with a regular screening of organ involvement and frequent intravenous treatments. All SSc patients have been educated about ministerial directives to limit COVID-19 spread. The organization of our Scleroderma Unit has been quickly rethought to assure SSc patients assistance in safety for them and for health-care workers during urgent visits or infusion therapies. Using electronic way of communication with frequent virtual contact and guarantying home deliveries of some therapies, we allowed a continuity of care also outside the Hospital.
C1 [Minniti, Antonina; Maglione, Wanda; Pignataro, Francesca; Cappadona, Carmela; Caporali, Roberto; Del Papa, Nicoletta] ASST Pini CTO, Dept Rheumatol, Milan, Italy.
   [Caporali, Roberto] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Caporali, Roberto] Univ Milan, Res Ctr Pediat & Adult Rheumat Dis RECAP RD, Milan, Italy.
   [Del Papa, Nicoletta] ASST Pini CTO, Dept Rheumatol, Scleroderma Unit, Milan, Italy.
RP Del Papa, N (corresponding author), ASST Pini CTO, Dept Rheumatol, Milan, Italy.; Del Papa, N (corresponding author), ASST Pini CTO, Dept Rheumatol, Scleroderma Unit, Milan, Italy.
EM nicoletta.delpapa@asst-pini-cto.it
OI Pignataro, Francesca/0000-0003-2772-3308
CR Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Denton CP, 2017, LANCET, V390, P1685, DOI 10.1016/S0140-6736(17)30933-9
   Gabrielli A, 2009, NEW ENGL J MED, V360, P1989, DOI 10.1056/NEJMra0806188
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
NR 4
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770-3198
EI 1434-9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD JUL
PY 2020
VL 39
IS 7
BP 2063
EP 2065
DI 10.1007/s10067-020-05191-4
EA MAY 2020
PG 3
WC Rheumatology
SC Rheumatology
GA LY1IL
UT WOS:000538958400002
PM 32462423
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, YX
   Ding, J
   Ren, SD
   Wang, WH
   Yang, YP
   Li, SJ
   Meng, M
   Wu, TJ
   Liu, DL
   Tian, SC
   Tian, H
   Chen, SF
   Zhou, CH
AF Zhang, Yingxin
   Ding, Jie
   Ren, Shaoda
   Wang, Weihua
   Yang, Yapei
   Li, Shuangjing
   Meng, Min
   Wu, Tiejun
   Liu, Daliang
   Tian, Suochen
   Tian, Hui
   Chen, Shuangfeng
   Zhou, Changhui
TI Intravenous infusion of human umbilical cord Wharton's jelly-derived
   mesenchymal stem cells as a potential treatment for patients with
   COVID-19 pneumonia
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE COVID-19; Human umbilical cord Wharton's jelly-derived MSCs;
   Immunomodulatory; Treatment
AB The novel coronavirus disease 2019 (COVID-19) has grown to be a global public health emergency since patients were first detected in Wuhan, China. Thus far, no specific drugs or vaccines are available to cure the patients with COVID-19 infection. The immune system and inflammation are proposed to play a central role in COVID-19 pathogenesis. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. Intravenous infusion of MSCs has shown promising results in COVID-19 treatment. Here, we report a case of a severe COVID-19 patient treated with human umbilical cord Wharton's jelly-derived MSCs (hWJCs) from a healthy donor in Liaocheng People's Hospital, China, from February 24, 2020. The pulmonary function and symptoms of the patient with COVID-19 pneumonia was significantly improved in 2days after hWJC transplantation, and recovered and discharged in 7days after treatment. After treatment, the percentage and counts of lymphocyte subsets (CD3(+), CD4(+), and CD8(+) T cell) were increased, and the level of IL-6, TNF-alpha, and C-reactive protein is significantly decreased after hWJC treatment. Thus, the intravenous transplantation of hWJCs was safe and effective for the treatment of patients with COVID-19 pneumonia, especially for the patients in a critically severe condition. This report highlights the potential of hWJC infusions as an effective treatment for COVID-19 pneumonia.
C1 [Zhang, Yingxin; Ding, Jie; Ren, Shaoda; Wang, Weihua; Yang, Yapei; Li, Shuangjing; Meng, Min; Chen, Shuangfeng; Zhou, Changhui] Liaocheng Peoples Hosp, Dept Cent Lab, Dongchang West Rd 67, Liaocheng 252000, Shandong, Peoples R China.
   [Wu, Tiejun; Tian, Suochen; Tian, Hui] Liaocheng Peoples Hosp, Dept ICU, Liaocheng 252000, Shandong, Peoples R China.
   [Liu, Daliang] Liaocheng Peoples Hosp, Dept CT Room, Liaocheng 252000, Shandong, Peoples R China.
RP Chen, SF; Zhou, CH (corresponding author), Liaocheng Peoples Hosp, Dept Cent Lab, Dongchang West Rd 67, Liaocheng 252000, Shandong, Peoples R China.
EM csfcscn@163.com; zhouchanghui008@163.com
CR [Anonymous], 2020, NEW CORONAVIRUS PNEU
   Chen C, 2020, Zhonghua Shao Shang Za Zhi, V36, P471, DOI 10.3760/cma.j.cn501120-20200224-00088
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Harrell CR, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4236973
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Liang B., 2020, CLIN REMISSION CRITI
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Matthay MA, 2010, CHEST, V138, P965, DOI 10.1378/chest.10-0518
   Naji A, 2017, STEM CELL TRANSL MED, V6, P713, DOI 10.5966/sctm.2016-0289
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Sauler M, 2019, ANNU REV PHYSIOL, V81, P375, DOI 10.1146/annurev-physiol-020518-114320
   Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhou CH, 2011, CELL IMMUNOL, V272, P33, DOI 10.1016/j.cellimm.2011.09.010
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 19
TC 15
Z9 15
U1 1
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD MAY 27
PY 2020
VL 11
IS 1
DI 10.1186/s13287-020-01725-4
PG 6
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA LU7QJ
UT WOS:000537945100006
PM 32460839
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fox, ER
   Stolbach, AI
   Mazer-Amirshahi, M
AF Fox, Erin R.
   Stolbach, Andrew, I
   Mazer-Amirshahi, Maryann
TI The Landscape of Prescription Drug Shortages During the COVID-19
   Pandemic
SO JOURNAL OF MEDICAL TOXICOLOGY
LA English
DT Article
DE Prescription drug shortages; COVID-19 pandemic
C1 [Fox, Erin R.] Univ Utah Hlth, Dept Pharm, Salt Lake City, UT USA.
   [Stolbach, Andrew, I] Johns Hopkins Sch Med, Baltimore, MD USA.
   [Mazer-Amirshahi, Maryann] MedStar Washington Hosp Ctr, Dept Emergency Med, 110 Irving St NW, Washington, DC 20010 USA.
   [Mazer-Amirshahi, Maryann] Georgetown Univ, Sch Med, Washington, DC 20057 USA.
RP Mazer-Amirshahi, M (corresponding author), MedStar Washington Hosp Ctr, Dept Emergency Med, 110 Irving St NW, Washington, DC 20010 USA.; Mazer-Amirshahi, M (corresponding author), Georgetown Univ, Sch Med, Washington, DC 20057 USA.
EM maryannmazer@gmail.com
CR American Society of Health Systems Pharmacists, CURR DRUG SHORT
   Centers for Disease Control and Prevention, HEALTHC INF PREV CON
   Dill S, 2014, EUR J CLIN PHARMACOL, V70, P1405, DOI 10.1007/s00228-014-1747-1
   Food and Drug Administration, 2019, DRUG SHORT ROOT CAUS
   Food and Drug Administration, FDA DRUG SHORT
   Fox Erin R, 2018, Am J Health Syst Pharm, V75, P1742, DOI 10.2146/ajhp180441
   Hick JL, 2014, NEW ENGL J MED, V370, P1573, DOI 10.1056/NEJMp1401833
   Mazer-Amirshahi M, 2018, NEW ENGL J MED, V378, P1472, DOI 10.1056/NEJMp1800347
   Mazer-Amirshahi M, 2017, J CRIT CARE, V41, P283, DOI 10.1016/j.jcrc.2017.06.005
   Woodcock J, 2013, CLIN PHARMACOL THER, V93, P170, DOI 10.1038/clpt.2012.220
NR 13
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1556-9039
EI 1937-6995
J9 J MED TOXICOL
JI J. Med. Toxicol.
PD JUL
PY 2020
VL 16
IS 3
SI SI
BP 311
EP 313
DI 10.1007/s13181-020-00786-4
EA MAY 2020
PG 3
WC Toxicology
SC Toxicology
GA MC7JB
UT WOS:000535768700001
PM 32458230
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Haq, FU
   Roman, M
   Ahnnad, K
   Rahman, SU
   Shah, SMA
   Suleman, N
   Ullah, S
   Ahnnad, I
   Ullah, W
AF Haq, Faiz Ul
   Roman, Muhammad
   Ahnnad, Kashif
   Rahman, Saeed Ur
   Shah, Syed Murtaza Ali
   Suleman, Naveed
   Ullah, Sami
   Ahnnad, Iftekhar
   Ullah, Wajahat
TI Artemisia annua: Trials are needed for COVID-19
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE Artemisia annua; bioactive compound; coronavirus; antiviral agents;
   COVID-19; SARS-CoV-2
ID ANTIVIRAL ACTIVITIES; ANTIOXIDANTS
AB In December 2019, a number of pneumonia cases associated with 2019 novel coronavirus occurred in Wuhan, China. Later taxonomist name the virus SARS-CoV-2 and disease called COVID-19. No approved vaccine or treatment are available for this virus. Current technical guide is related to address therapeutic option for SARS-CoV-2. COVID-19 is great challenge for scientist across the globe. Bioactive compound present in Artemisia annua against, hepatitis B virus, bovine viral diarrhea virus, and Epstein-Barr virus. A. annua have shown significant activity against SARS coronavirus that occur in 2002. This agent is cheap and easily available and will be of great value if they have efficacy against SARS-CoV-2. Scientific attention is needed toward this agent to address for the treatment of COVID-19.
C1 [Haq, Faiz Ul; Ahnnad, Kashif; Ahnnad, Iftekhar; Ullah, Wajahat] Univ Swat, Ctr Biotechnol & Microbiol, Swat, Pakistan.
   [Haq, Faiz Ul; Roman, Muhammad; Shah, Syed Murtaza Ali] Univ Hlth Sci Lahore, Dept Microbiol, Lahore, Pakistan.
   [Ahnnad, Kashif] Hazara Univ, Dept Microbiol, Mansehra, Pakistan.
   [Rahman, Saeed Ur] Univ Hlth Sci Lahore, Dept Nursing, Lahore, Pakistan.
   [Suleman, Naveed] Univ Hlth Sci Lahore, Dept Pharmacol, Lahore, Pakistan.
   [Ullah, Sami] Univ Hlth Sci Lahore, Dept Forens Sci, Lahore, Pakistan.
RP Haq, FU (corresponding author), Univ Swat, Ctr Biotechnol & Microbiol, Swat, Pakistan.
EM faizulhaq553@gmail.com
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P333, DOI 10.23812/Editorial-Conti-2
   Day BJ, 2008, ANTIOXID REDOX SIGN, V10, P355, DOI 10.1089/ars.2007.1916
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Efferth T, 2008, CLIN INFECT DIS, V47, P804, DOI 10.1086/591195
   Ferreira JFS, 2010, MOLECULES, V15, P3135, DOI 10.3390/molecules15053135
   Heinrich M, 2020, J ETHNOPHARMACOL, V246, DOI 10.1016/j.jep.2019.112230
   Karamoddini MK, 2011, ASIAN BIOMED, V5, P63, DOI 10.5372/1905-7415.0501.007
   KHAN MMAA, 1991, PLANT SCI, V75, P161, DOI 10.1016/0168-9452(91)90230-6
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Lin Lin, 2003, Zhongguo Zhong Xi Yi Jie He Za Zhi, V23, P409
   Mitja O, 2020, LANCET GLOB HEALTH, V8, pE639, DOI 10.1016/S2214-109X(20)30114-5
   Wang CM, 2015, MOL MED REP, V12, P1291, DOI 10.3892/mmr.2015.3500
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
NR 15
TC 5
Z9 5
U1 4
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD OCT
PY 2020
VL 34
IS 10
BP 2423
EP 2424
DI 10.1002/ptr.6733
EA MAY 2020
PG 2
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OC4MU
UT WOS:000535689800001
PM 32424845
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ramirez, AV
   Efe, D
   Fischer, M
AF Vanegas Ramirez, A.
   Efe, D.
   Fischer, M.
TI Drug-induced vasculitis in a patient with COVID-19
SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
LA English
DT Letter
C1 [Vanegas Ramirez, A.; Efe, D.; Fischer, M.] Bundeswehrkrankenhaus, Dept Dermatol Venereol & Allergol, Hamburg, Germany.
RP Ramirez, AV (corresponding author), Bundeswehrkrankenhaus, Dept Dermatol Venereol & Allergol, Hamburg, Germany.
EM andreavane-gas@web.de
OI Vanegas, Andrea/0000-0003-1303-2960
CR Bouaziz JD, 2020, J EUR ACAD DERMATOL, V34, pE451, DOI 10.1111/jdv.16544
   Fernandez-Nieto D, 2020, J AM ACAD DERMATOL, V20, P1, DOI [10.1016/j.jaad.2020.04.093, DOI 10.1016/J.JAAD.2020.04.09]
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Tammaro A, 2020, J EUR ACAD DERMATOL, V34, pE306, DOI 10.1111/jdv.16530
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 6
TC 5
Z9 5
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0926-9959
EI 1468-3083
J9 J EUR ACAD DERMATOL
JI J. Eur. Acad. Dermatol. Venereol.
PD AUG
PY 2020
VL 34
IS 8
BP E361
EP E362
DI 10.1111/jdv.16588
EA MAY 2020
PG 2
WC Dermatology
SC Dermatology
GA MZ2BW
UT WOS:000535589600001
PM 32378770
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Schwartz, RA
   Kapila, R
AF Schwartz, Robert A.
   Kapila, Rajendra
TI Cutaneous manifestations of a 21st century worldwide fungal epidemic
   possibly complicating the COVID-19 pandemic to jointly menace mankind
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE Candida auris; Candida; Candida parasilopsis; coronavirus disease 2019
   (COVID-19); eschar; nosocomial infection; SARS-CoV-2; sepsis
ID DESORPTION-IONIZATION-TIME; FLIGHT MASS-SPECTROMETRY; CANDIDA-AURIS;
   ALBICANS
AB In view of the new viral COVID-19 pandemic, the fungal Candida auris epidemic still in progress worldwide highlights non-Candida albicans candidal infections. We describe an immunocompetent woman with a cutaneous manifestation of Candida parasilopsis fungemia, a prominent eschar, which proved to be the nidus for the candidemia. We stress the value of selectively removing eschars. C. parasilopsis and C. auris are increasingly important causes of sepsis and wound infections. We emphasize that commercially available biochemical-based tests may misidentify C. auris as C. parapsilosis, and stress the added danger of C. auris to critically ill-hospitalized COVID-19 patients. Any health care facility with evidence of infection or colonization with C. auris requires very close monitoring, since this fungus is a nosocomial threat comparable to SARS-CoV-2 in its mortality and fomite adhesiveness! Both organisms have the potential to be transmitted as nosocomial pathogens; health care workers need to follow strict CDC guidelines. During this COVID-19 pandemic, every health care facility should closely monitor for the possible deadly combination of the SARS-CoV-2 and C. auris. The identification of C. auris necessitates use of sophisticated technology not readily available to make this essential diagnosis since C. auris is multi-drug resistant and isolation precautions would become paramount.
C1 [Schwartz, Robert A.; Kapila, Rajendra] Rutgers New Jersey Med Sch, Dermatol Med & Pathol, Newark, NJ USA.
RP Schwartz, RA (corresponding author), 185 South Orange Ave, Newark, NJ 07103 USA.
EM roschwar@cal.berkeley.edu
OI Schwartz, Robert/0000-0003-3036-3825
CR Abdolrasouli A, 2017, MYCOSES, V60, P758, DOI 10.1111/myc.12699
   Adams E, 2018, EMERG INFECT DIS, V24, P1816, DOI 10.3201/eid2410.180649
   Almutairi N, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13544
   Chakrabarti A, 2020, EXPERT REV ANTI-INFE, V13, P1
   Cortegiani A, 2018, J INTENSIVE CARE, V6, DOI 10.1186/s40560-018-0342-4
   Crum-Cianflone NF, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw171
   Escandon P, 2019, CLIN INFECT DIS, V68, P15, DOI 10.1093/cid/ciy411
   Estebanez A, 2020, J EUR ACAD DERMATOL, V34, pE250, DOI 10.1111/jdv.16474
   Iguchi S, 2019, J INFECT CHEMOTHER, V25, P743, DOI 10.1016/j.jiac.2019.05.034
   Jewell NP, 2020, ANN INTERN MED, V173, P226, DOI 10.7326/M20-1565
   Kathuria S, 2015, J CLIN MICROBIOL, V53, P1823, DOI 10.1128/JCM.00367-15
   Khan Z, 2018, INFECTION, V46, P641, DOI 10.1007/s15010-018-1164-y
   Kroumpouzos G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13399
   Kurli R, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01229
   Lone SA, 2019, MYCOSES, V62, P620, DOI 10.1111/myc.12904
   Misseri G, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2702-4
   Neji S, 2018, MYCOPATHOLOGIA, V183, P765, DOI 10.1007/s11046-018-0278-1
   Quindos G, 2018, INT MICROBIOL, V21, P107, DOI 10.1007/s10123-018-0014-1
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Rijnders Bart J A, 2020, Clin Infect Dis, V71, P1764, DOI 10.1093/cid/ciaa010
   Sadeghi G, 2018, J MYCOL MED, V28, P51, DOI 10.1016/j.mycmed.2017.12.008
   Satoh K, 2009, MICROBIOL IMMUNOL, V53, P41, DOI 10.1111/j.1348-0421.2008.00083.x
   Schwartz RA, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13380
   Sekercioglu AO, 2017, CLIN LAB, V63, P839, DOI 10.7754/Clin.Lab.2016.160907
   Shastri PS, 2020, J CRIT CARE, V57, P42, DOI 10.1016/j.jcrc.2020.01.004
   Sherry L, 2017, EMERG INFECT DIS, V23, P328, DOI 10.3201/eid2302.161320
   Short B, 2019, J HOSP INFECT, V103, P92, DOI [10.1016/j.jhin.2019.06.006, 10.1016/j.jhin.2019.0]
   Singh S, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007460
   SPEBAR MJ, 1981, J TRAUMA, V21, P237, DOI 10.1097/00005373-198103000-00007
   Toth R, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00111-18
   Welsh RM, 2017, J CLIN MICROBIOL, V55, P2996, DOI [10.1128/JCM.00921-17, 10.1128/jcm.00921-17]
   Yamamoto M, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.00591-18
   Yen MY, 2020, J MICROBIOL IMMUNOL, V53, P377, DOI 10.1016/j.jmii.2020.03.011
   Zou PF, 2020, J INFECT DIS, V221, pS193, DOI 10.1093/infdis/jiz682
NR 34
TC 3
Z9 3
U1 4
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13481
DI 10.1111/dth.13481
EA MAY 2020
PG 4
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000535647200001
PM 32369240
DA 2021-01-01
ER

PT J
AU Hosangadi, D
   Warmbrod, KL
   Martin, EK
   Adalja, A
   Cicero, A
   Inglesby, T
   Watson, C
   Watson, M
   Connell, N
AF Hosangadi, Divya
   Warmbrod, Kelsey Lane
   Martin, Elena K.
   Adalja, Amesh
   Cicero, Anita
   Inglesby, Thomas
   Watson, Crystal
   Watson, Matthew
   Connell, Nancy
TI Enabling emergency mass vaccination: Innovations in manufacturing and
   administration during a pandemic
SO VACCINE
LA English
DT Article
DE Vaccines; Mass vaccination; Pandemic; COVID-19
C1 [Hosangadi, Divya; Warmbrod, Kelsey Lane; Martin, Elena K.; Adalja, Amesh; Cicero, Anita; Inglesby, Thomas; Watson, Crystal; Watson, Matthew; Connell, Nancy] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Ctr Hlth Secur, 621 East Pratt St,Suite 210, Baltimore, MD 21202 USA.
   [Inglesby, Thomas; Watson, Crystal; Connell, Nancy] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth & Engn, 621 East Pratt St,Suite 210, Baltimore, MD 21202 USA.
RP Connell, N (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Ctr Hlth Secur, 621 East Pratt St,Suite 210, Baltimore, MD 21202 USA.
EM NancyConnell@jhu.edu
OI Warmbrod, Lane/0000-0003-4326-7541
FU Open Philanthropy Project [133072]
FX This work is supported by Open Philanthropy Project #133072.
CR Adalja AA, 2019, VACCINE PLATFORMS ST
   Branswell H., 2019, STAT NEWS
   Hamilton IA, 2020, BUSINESS INSIDER
   Khan AI, 2019, VACCINE, V37, P827, DOI 10.1016/j.vaccine.2018.12.048
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Meyer D, 2018, AM J PUBLIC HEALTH, V108, pS188, DOI 10.2105/AJPH.2018.304527
   Office of the Assistant Secretary of Preparedness and Response, 2016, ADV DOM INT VACC MAN
   Plotkin S, 2017, VACCINE, V35, P4064, DOI 10.1016/j.vaccine.2017.06.003
   World Health Organization, 2020, CORD GLOB RES ROADM
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Yen C, 2015, LANCET INFECT DIS, V15, P340, DOI 10.1016/S1473-3099(14)70999-5
   Zehrung D, 2017, VACCINE, V35, P2265, DOI 10.1016/j.vaccine.2016.11.095
NR 12
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2020
VL 38
IS 26
BP 4167
EP 4169
DI 10.1016/j.vaccine.2020.04.037
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LP8NH
UT WOS:000534573700006
PM 32381478
OA Green Published
DA 2021-01-01
ER

PT J
AU Privor-Dumm, L
   Vasudevan, P
   Kobayashi, K
   Gupta, J
AF Privor-Dumm, Lois
   Vasudevan, Prarthana
   Kobayashi, Kana
   Gupta, Jaya
TI Archetype analysis of older adult immunization decision-making and
   implementation in 34 countries
SO VACCINE
LA English
DT Article
DE Adult immunization; Decision-making; Implementation; Vaccine; Policy;
   Archetype; Healthy aging; Older adults; Life-course; COVID-19
ID VACCINATION; HEALTH; DISEASES; POLICIES; RECOMMENDATIONS; FRAMEWORK;
   BURDEN
AB The global population of adults over 65 years of age is growing rapidly and is expected to double by 2050. Countries will face substantial health, economic and social burden deriving from vaccine-preventable diseases (VPDs) such as influenza, pneumonia and herpes zoster in older adults. It will be essential that countries utilize several public health strategies, including immunization. Understanding the different approaches countries have taken on adult immunization could help provide future learnings and technical support for adult vaccines within life-course immunization strategies. In this study, we describe the priorities and approaches that underlie adult immunization decision-making and implementation processes in 32 high-and-middle-income countries and two territories ("34 countries") who recommend adult vaccines in their national schedule. We conducted an archetype analysis based on a subset of two dozen indicators abstracted from a larger database. The analysis was based on a mixed-methods study, including results from 120 key informant interviews in six countries and a landscape review of secondary data from 34 countries. We found four distinct archetypes: disease prevention-focused; health security-focused; evolving adult focus; and, child-focused and cost-sensitive. The highest performing countries belonged to the disease prevention-focused and health security archetypes, although there was a range of performance within each archetype. Considering common barriers and facilitators of decision-making and implementation of adult vaccines within a primary archetype could help provide a framework for strategies to support countries with similar needs and approaches. It can also help in developing context-specific policies and guidance, including for countries prioritizing adult immunization programs in light of COVID-19. Further research may be beneficial to further refine archetypes and expand the understanding of what influences success within them. This can help advance policies and action that will improve vaccine access for older adults and build a stronger appreciation of the value of immunization amongst a variety of stakeholders. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Privor-Dumm, Lois; Vasudevan, Prarthana; Kobayashi, Kana; Gupta, Jaya] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, 415 N Washington St,5th Floor, Baltimore, MD 21231 USA.
RP Privor-Dumm, L (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, 415 N Washington St,5th Floor, Baltimore, MD 21231 USA.
EM lprivor1@jhu.edu; pvasude2@jhu.edu; kkobaya7@jhu.edu; jayagups@gmail.com
RI Gupta, Jaya/ABC-3560-2020
OI Gupta, Jaya/0000-0002-4913-0872; Privor-Dumm, Lois/0000-0001-9807-2544
FU GlaxoSmithKline (GSK) Biologicals, Belgium; MerckMerck & Company;
   GSKGlaxoSmithKline
FX GlaxoSmithKline (GSK) Biologicals, Belgium provided funding for the
   archetype analysis. Merck and GSK provided funding for the landscape
   analysis and case studies. The authors thank Nina Martin, Geervani
   Daggupati, Nobutoshi Nawa, So Yoon Sim, Dexter Waters, and Gatien de
   Broucker, for their valuable contributions; members of the International
   Council on Adult Immunization (ICAI) for their review and input; the
   in-country experts who participated in case study interviews and
   provided input in the validation process; and Haley Budigan for her
   careful proofreading.
CR Aguado MT, 2018, VACCINE, V36, P921, DOI 10.1016/j.vaccine.2017.12.029
   Allen N, 2013, HEALTH POLICY, V113, P305, DOI 10.1016/j.healthpol.2013.09.007
   Andrew MK, 2019, DRUG AGING, V36, P29, DOI 10.1007/s40266-018-0597-4
   [Anonymous], 2020, LANCET, V395, P755, DOI 10.1016/S0140-6736(20)30522-5
   [Anonymous], 2012, PUBLIC HEALTH REP, V127, P1
   Beard JR, 2016, LANCET, V387, P2145, DOI 10.1016/S0140-6736(15)00516-4
   Bloom DE, 2017, VACCINE, V35, pA29, DOI 10.1016/j.vaccine.2016.12.001
   Bonanni P, 2018, VACCINE, V36, P5358, DOI 10.1016/j.vaccine.2017.07.100
   Cafiero-Fonseca ET, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186903
   CDC, 2009, DEATHS REL 2009 PAND
   CDC, 2010, PREV CONTR INFL VACC
   Cull A., 2019, CHARACTERIZING GLOBA
   Dabestani NM, 2019, PREV MED, V126, DOI 10.1016/j.ypmed.2019.05.022
   de Gomensoro E, 2018, ANN MED, V50, P181, DOI 10.1080/07853890.2017.1417632
   Doherty TM, 2019, ANN MED, V51, P128, DOI 10.1080/07853890.2019.1588470
   Ecarnot F, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-8044-y
   Esposito S, 2018, VACCINE, V36, P2523, DOI 10.1016/j.vaccine.2018.03.053
   Esposito S, 2016, HUM VACC IMMUNOTHER, V12, P1777, DOI 10.1080/21645515.2016.1150396
   Feifer C, 2007, ANN FAM MED, V5, P233, DOI 10.1370/afm.697
   Fitzgerald TJ, 2016, VACCINE, V34, P5643, DOI 10.1016/j.vaccine.2016.09.020
   Friesen KJ, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2185-3
   Harris Katherine M, 2012, Rand Health Q, V2, P15
   Johnson Robert W, 2015, Ther Adv Vaccines, V3, P109, DOI 10.1177/2051013615599151
   Kanitz EE, 2012, VACCINE, V30, P5222, DOI 10.1016/j.vaccine.2012.06.012
   Kyu HH, 2018, LANCET, V392, P1859, DOI 10.1016/s0140-6736(18)32335-3
   Leidner AJ, 2019, VACCINE, V37, P226, DOI 10.1016/j.vaccine.2018.11.056
   MAZUMDER D, 2016, VALUE HEALTH, V19, pA832
   McElhaney JE, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00041
   McLaughlin JM, 2015, J PRIM PREV, V36, P259, DOI 10.1007/s10935-015-0394-3
   Menzies RI, 2017, MED J AUSTRALIA, V206, P1, DOI 10.5694/mja16.00811
   Gutierrez-Robledo LM, 2017, GAC MED MEX, V153, P5
   Ministy of Health Labour and Welfare, 2018, PNEUM VACC PPSV23
   Mulpuru S, 2019, CHEST, V155, P69, DOI 10.1016/j.chest.2018.10.044
   Naito T., 2015, J GEN FAMILY MED, V38, P123
   Naito T, 2014, J INFECT CHEMOTHER, V20, P450, DOI 10.1016/j.jiac.2014.03.004
   Ng YX, 2020, MMWR-MORBID MORTAL W, V69, P307, DOI 10.15585/mmwr.mm6911e1
   Ortiz JR, 2016, VACCINE, V34, P5400, DOI 10.1016/j.vaccine.2016.07.045
   Ozawa S, 2016, HEALTH AFFAIR, V35, P2124, DOI 10.1377/hlthaff.2016.0462
   Ozawa S, 2014, VACCINE, V32, P4089, DOI 10.1016/j.vaccine.2014.05.026
   Privor-Dumm L., 2019, LIFE COURSE IMMUNIZA
   Rehm SJ, 2012, POSTGRAD MED, V124, P71, DOI 10.3810/pgm.2012.05.2550
   SAATI Partnership, 2013, AD VACC KEY COMP HLT
   Sauer M, SITUATIONAL ASSESSME
   Shiffman J, 2007, LANCET, V370, P1370, DOI 10.1016/S0140-6736(07)61579-7
   Sobczak D, POP AG EUR IMPL POL
   Sun M, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5284-1
   Superior Health Council Belgium, 2019, ADV 9141 BAS
   Tan LJ, 2015, HUM VACC IMMUNOTHER, V11, P2158, DOI 10.4161/21645515.2014.982998
   The World Health Organization, 2019, IMM AG 2030 GLOB STR
   United Nations Department of Economic and Social Affairs Population Division, 2019, WORLD POP PROSP 2019
   Vong S, 2014, B WORLD HEALTH ORGAN, V92, P303, DOI 10.2471/BLT.13.125989
   Wateska AR, 2019, VACCINE, V37, P2026, DOI 10.1016/j.vaccine.2019.01.002
   Webster F, 2019, AUST NZ J PUBL HEAL, DOI 10.1111/1753-6405.12944
   Weinberger B, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-017-0107-2
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   Wu LA, 2013, INT J PUBLIC HEALTH, V58, P865, DOI 10.1007/s00038-012-0438-x
NR 56
TC 1
Z9 1
U1 2
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2020
VL 38
IS 26
BP 4170
EP 4182
DI 10.1016/j.vaccine.2020.04.027
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LP8NH
UT WOS:000534573700007
PM 32376108
OA Green Published
DA 2021-01-01
ER

PT J
AU Richardson, S
   Hirsch, JS
   Narasimhan, M
   Crawford, JM
   McGinn, T
   Davidson, KW
AF Richardson, Safiya
   Hirsch, Jamie S.
   Narasimhan, Mangala
   Crawford, James M.
   McGinn, Thomas
   Davidson, Karina W.
CA Northwell COVID-19 Res Consortium
TI Presenting Characteristics, Comorbidities, and Outcomes Among 5700
   Patients Hospitalized With COVID-19 in the New York City Area
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID TRENDS
AB Question What are the characteristics, clinical presentation, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19) in the US? Findings In this case series that included 5700 patients hospitalized with COVID-19 in the New York City area, the most common comorbidities were hypertension, obesity, and diabetes. Among patients who were discharged or died (n = 2634), 14.2% were treated in the intensive care unit, 12.2% received invasive mechanical ventilation, 3.2% were treated with kidney replacement therapy, and 21% died. Meaning This study provides characteristics and early outcomes of patients hospitalized with COVID-19 in the New York City area.
   Importance There is limited information describing the presenting characteristics and outcomes of US patients requiring hospitalization for coronavirus disease 2019 (COVID-19). Objective To describe the clinical characteristics and outcomes of patients with COVID-19 hospitalized in a US health care system. Design, Setting, and Participants Case series of patients with COVID-19 admitted to 12 hospitals in New York City, Long Island, and Westchester County, New York, within the Northwell Health system. The study included all sequentially hospitalized patients between March 1, 2020, and April 4, 2020, inclusive of these dates. Exposures Confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by positive result on polymerase chain reaction testing of a nasopharyngeal sample among patients requiring admission. Main Outcomes and Measures Clinical outcomes during hospitalization, such as invasive mechanical ventilation, kidney replacement therapy, and death. Demographics, baseline comorbidities, presenting vital signs, and test results were also collected. Results A total of 5700 patients were included (median age, 63 years [interquartile range {IQR}, 52-75; range, 0-107 years]; 39.7% female). The most common comorbidities were hypertension (3026; 56.6%), obesity (1737; 41.7%), and diabetes (1808; 33.8%). At triage, 30.7% of patients were febrile, 17.3% had a respiratory rate greater than 24 breaths/min, and 27.8% received supplemental oxygen. The rate of respiratory virus co-infection was 2.1%. Outcomes were assessed for 2634 patients who were discharged or had died at the study end point. During hospitalization, 373 patients (14.2%) (median age, 68 years [IQR, 56-78]; 33.5% female) were treated in the intensive care unit care, 320 (12.2%) received invasive mechanical ventilation, 81 (3.2%) were treated with kidney replacement therapy, and 553 (21%) died. As of April 4, 2020, for patients requiring mechanical ventilation (n = 1151, 20.2%), 38 (3.3%) were discharged alive, 282 (24.5%) died, and 831 (72.2%) remained in hospital. The median postdischarge follow-up time was 4.4 days (IQR, 2.2-9.3). A total of 45 patients (2.2%) were readmitted during the study period. The median time to readmission was 3 days (IQR, 1.0-4.5) for readmitted patients. Among the 3066 patients who remained hospitalized at the final study follow-up date (median age, 65 years [IQR, 54-75]), the median follow-up at time of censoring was 4.5 days (IQR, 2.4-8.1). Conclusions and Relevance This case series provides characteristics and early outcomes of sequentially hospitalized patients with confirmed COVID-19 in the New York City area.
   This case series describes clinical characteristics, health services use, and outcomes of patients with confirmed coronavirus disease 2019 (COVID-19) cared for at 12 hospitals of a single health system in the New York City (NYC) area.
C1 [Richardson, Safiya; Hirsch, Jamie S.; McGinn, Thomas; Davidson, Karina W.] Northwell Hlth, Inst Hlth Innovat & Outcomes Res, Feinstein Inst Med Res, Manhasset, NY USA.
   [Richardson, Safiya; Hirsch, Jamie S.; Narasimhan, Mangala; Crawford, James M.; McGinn, Thomas; Davidson, Karina W.] Northwell Hlth, Donald & Barbara Zucker Sch Med Hofstra Northwell, Hempstead, NY USA.
   [Hirsch, Jamie S.] Northwell Hlth, Dept Informat Serv, New Hyde Pk, NY USA.
RP Davidson, KW (corresponding author), Northwell Hlth, 130 59th St,Ste 14C, New York, NY 10022 USA.
EM KDavidson2@northwell.edu
OI Zanos, Theodoros/0000-0002-9204-9551
FU National Institute on Aging of the National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Aging (NIA) [R24AG064191];
   National Library of Medicine of the National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Library of Medicine (NLM) [R01LM012836];
   National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [K23HL145114]; NHLBI NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [K23 HL145114] Funding Source: Medline; NIA NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [R24 AG064191] Funding Source: Medline; NLM NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Library of Medicine (NLM) [R01 LM012836] Funding
   Source: Medline
FX This work was supported by grants R24AG064191 from the National
   Institute on Aging of the National Institutes of Health; R01LM012836
   from the National Library of Medicine of the National Institutes of
   Health; and K23HL145114 from the National Heart, Lung, and Blood
   Institute.
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chen ZM, 2015, LANCET, V386, P1447, DOI 10.1016/S0140-6736(15)00340-2
   Derington CG, 2020, HYPERTENSION, V75, P973, DOI 10.1161/HYPERTENSIONAHA.119.14360
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Institute for Health Metrics and Evaluation, GBD COMP VIZ HUB
   Sommerstein R, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016509
   The Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, COR CIVID 19 GLOB CA
   United Nations Department of Economic and Social Affairs, WORLD POP PROSP 2019
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 13
TC 1240
Z9 1248
U1 12
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 26
PY 2020
VL 323
IS 20
BP 2052
EP 2059
DI 10.1001/jama.2020.6775
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA LU8UM
UT WOS:000538023900036
PM 32320003
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Ju, B
   Zhang, Q
   Ge, JW
   Wang, RK
   Sun, J
   Ge, XY
   Yu, JZ
   Shan, SS
   Zhou, B
   Song, S
   Tang, X
   Yu, JF
   Lan, J
   Yuan, J
   Wang, HY
   Zhao, JN
   Zhang, SY
   Wang, YC
   Shi, XL
   Liu, L
   Zhao, JC
   Wang, XQ
   Zhang, Z
   Zhang, LQ
AF Ju, Bin
   Zhang, Qi
   Ge, Jiwan
   Wang, Ruoke
   Sun, Jing
   Ge, Xiangyang
   Yu, Jiazhen
   Shan, Sisi
   Zhou, Bing
   Song, Shuo
   Tang, Xian
   Yu, Jinfang
   Lan, Jun
   Yuan, Jing
   Wang, Haiyan
   Zhao, Juanjuan
   Zhang, Shuye
   Wang, Youchun
   Shi, Xuanling
   Liu, Lei
   Zhao, Jincun
   Wang, Xinquan
   Zhang, Zheng
   Zhang, Linqi
TI Human neutralizing antibodies elicited by SARS-CoV-2 infection
SO NATURE
LA English
DT Article
ID SARS CORONAVIRUS; SPIKE; COV; VACCINE; PROTEIN
AB The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents a global health emergency that is in urgent need of intervention(1-3). The entry of SARS-CoV-2 into its target cells depends on binding between the receptor-binding domain (RBD) of the viral spike protein and its cellular receptor, angiotensin-converting enzyme 2 (ACE2)(2,4-6). Here we report the isolation and characterization of 206 RBD-specific monoclonal antibodies derived from single B cells from 8 individuals infected with SARS-CoV-2. We identified antibodies that potently neutralize SARS-CoV-2; this activity correlates with competition with ACE2 for binding to RBD. Unexpectedly, the anti-SARS-CoV-2 antibodies and the infected plasma did not cross-react with the RBDs of SARS-CoV or Middle East respiratory syndrome-related coronavirus (MERS-CoV), although there was substantial plasma cross-reactivity to their trimeric spike proteins. Analysis of the crystal structure of RBD-bound antibody revealed that steric hindrance inhibits viral engagement with ACE2, thereby blocking viral entry. These findings suggest that anti-RBD antibodies are largely viral-species-specific inhibitors. The antibodies identified here may be candidates for development of clinical interventions against SARS-CoV-2.
   In a study of antibodies isolated from patients infected with SARS-CoV-2, antibodies that potently neutralized the virus competed with angiotensin-converting enzyme 2 for binding to the receptor-binding domain of the viral spike protein, suggesting that antibodies that disrupt this interaction could be developed to treat SARS-CoV-2 infection.
C1 [Ju, Bin; Ge, Xiangyang; Yu, Jiazhen; Zhou, Bing; Song, Shuo; Tang, Xian; Wang, Haiyan; Zhao, Juanjuan; Liu, Lei; Zhang, Zheng] Shenzhen Third Peoples Hosp, Inst Hepatol, Natl Clin Res Ctr Infect Dis, Shenzhen, Peoples R China.
   [Ju, Bin; Zhao, Juanjuan; Liu, Lei; Zhang, Zheng] Southern Univ Sci & Technol, Sch Med, Affiliated Hosp 2, Shenzhen, Peoples R China.
   [Zhang, Qi; Wang, Ruoke; Shan, Sisi; Shi, Xuanling; Zhang, Linqi] Tsinghua Univ, Comprehens AIDS Res Ctr, Ctr Global Hlth & Infect Dis, Beijing, Peoples R China.
   [Zhang, Qi; Wang, Ruoke; Shan, Sisi; Shi, Xuanling; Zhang, Linqi] Tsinghua Univ, Beijing Adv Innovat Ctr Struct Biol, Sch Med, Beijing, Peoples R China.
   [Zhang, Qi; Wang, Ruoke; Shan, Sisi; Shi, Xuanling; Zhang, Linqi] Tsinghua Univ, Vanke Sch Publ Hlth, Beijing, Peoples R China.
   [Ge, Jiwan; Yu, Jinfang; Lan, Jun; Wang, Xinquan] Tsinghua Univ, Collaborat Innovat Ctr Biotherapy,Sch Life Sci, Beijing Frontier Res Ctr Biol Struct,Minist Educ, Beijing Adv Innovat Ctr Struct Biol,Key Lab Prot, Beijing, Peoples R China.
   [Sun, Jing; Zhao, Jincun] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, Natl Clin Res Ctr Resp Dis,State Key Lab Resp Dis, Guangzhou, Peoples R China.
   [Yuan, Jing] Shenzhen Third Peoples Hosp, Dept Infect Dis, Shenzhen, Peoples R China.
   [Zhang, Shuye] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China.
   [Zhang, Shuye] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China.
   [Wang, Youchun] Natl Inst Food & Drug Control, Div HIV AIDS & Sex Transmitted Virus Vaccines, Beijing, Peoples R China.
RP Zhang, Z (corresponding author), Shenzhen Third Peoples Hosp, Inst Hepatol, Natl Clin Res Ctr Infect Dis, Shenzhen, Peoples R China.; Zhang, Z (corresponding author), Southern Univ Sci & Technol, Sch Med, Affiliated Hosp 2, Shenzhen, Peoples R China.; Zhang, LQ (corresponding author), Tsinghua Univ, Comprehens AIDS Res Ctr, Ctr Global Hlth & Infect Dis, Beijing, Peoples R China.; Zhang, LQ (corresponding author), Tsinghua Univ, Beijing Adv Innovat Ctr Struct Biol, Sch Med, Beijing, Peoples R China.; Zhang, LQ (corresponding author), Tsinghua Univ, Vanke Sch Publ Hlth, Beijing, Peoples R China.; Wang, XQ (corresponding author), Tsinghua Univ, Collaborat Innovat Ctr Biotherapy,Sch Life Sci, Beijing Frontier Res Ctr Biol Struct,Minist Educ, Beijing Adv Innovat Ctr Struct Biol,Key Lab Prot, Beijing, Peoples R China.
EM xinquanwang@mail.tsinghua.edu.cn; zhangzheng1975@aliyun.com;
   zhanglinqi@tsinghua.edu.cn
FU Bill & Melinda Gates FoundationBill & Melinda Gates Foundation; Science
   and Technology Innovation Committee of Shenzhen Municipality
   [202002073000002]; Tsinghua University Initiative Scientific Research
   Program [20201080053]; National Beijing Municipal Science and Technology
   Commission [171100000517-001, 171100000517-003]; Beijing Advanced
   Innovation Center for Structural Biology at Tsinghua University;
   National Key Plan for Scientific Research and Development of China
   [2016YFD0500307]; Tencent Foundation; Shuidi Foundation; TH Capital
FX We acknowledge the work and contribution of all the health providers
   from Shenzhen Third People's Hospital. We also thank patients for their
   active participation. This study was supported by Bill & Melinda Gates
   Foundation, the Science and Technology Innovation Committee of Shenzhen
   Municipality (202002073000002), and by Tsinghua University Initiative
   Scientific Research Program (20201080053). This work is also partially
   supported by the National Beijing Municipal Science and Technology
   Commission (171100000517-001 and 171100000517-003), Beijing Advanced
   Innovation Center for Structural Biology at Tsinghua University, the
   National Key Plan for Scientific Research and Development of China
   (grant number 2016YFD0500307), Tencent Foundation, Shuidi Foundation and
   TH Capital. The funders had no role in study design, data collection,
   data analysis, data interpretation or writing of the report.
CR Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Cohen SX, 2008, ACTA CRYSTALLOGR D, V64, P49, DOI 10.1107/S0907444907047580
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Janson G, 2017, BIOINFORMATICS, V33, P444, DOI 10.1093/bioinformatics/btw638
   Jia WX, 2019, EMERG MICROBES INFEC, V8, P760, DOI 10.1080/22221751.2019.1620083
   Jiang LW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008140
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kong L, 2016, IMMUNITY, V44, P939, DOI 10.1016/j.immuni.2016.03.006
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liao HX, 2013, NATURE, V496, P469, DOI 10.1038/nature12053
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Niu PH, 2018, J INFECT DIS, V218, P1249, DOI 10.1093/infdis/jiy311
   Sanders RW, 2002, J VIROL, V76, P8875, DOI 10.1128/JVI.76.17.8875-8889.2002
   Scheid JF, 2009, NATURE, V458, P636, DOI 10.1038/nature07930
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Xu JY, 2019, EMERG MICROBES INFEC, V8, P841, DOI 10.1080/22221751.2019.1624482
   Yu L, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93042
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhang LQ, 2006, J MED VIROL, V78, P1, DOI 10.1002/jmv.20499
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 35
TC 123
Z9 120
U1 22
U2 33
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD AUG 6
PY 2020
VL 584
IS 7819
BP 115
EP +
DI 10.1038/s41586-020-2380-z
EA MAY 2020
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NB1QU
UT WOS:000554511300002
PM 32454513
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Grandi, G
   Facchinetti, F
   Bitzer, J
AF Grandi, Giovanni
   Facchinetti, Fabio
   Bitzer, Johannes
TI The gendered impact of coronavirus disease (COVID-19): do estrogens play
   a role?
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
DE Androgen; combined hormonal contraception; COVID-19; estradiol;
   estrogen; postmenopausal hormone therapy; progesterone; testosterone
ID WOMEN; PREVALENCE; PREGNANCY
AB Objective:Although sex-disaggregated data for COVID-19 show equal numbers of cases between men and women, there seem to be sex differences in mortality rate and vulnerability to the disease: more men than women are dying. Methods:We have explored the potential role of estrogens in this COVID-19 gendered impact. Results:Estrogens stimulate the humoral response to viral infections, while testosterone and progesterone give an immune suppression of both innate and cell-mediated immune responses. We hypothesise that estrogens, in particular estradiol but also synthetic estrogen such as ethinylestradiol, could protect women from the most serious complications of COVID-19. The use of medications that keep hormonal levels high and stable, such as combined hormonal contraceptive, could therefore play a protective role. These potential benefits overtake the thrombotic risk in healthy women. As stated by the World Health Organization, all modern methods of contraception were safe to use during the COVID-19 pandemic.
C1 [Grandi, Giovanni; Facchinetti, Fabio] Univ Modena & Reggio Emilia, Dept Med & Surg Sci Mother Child & Adult, Modena, Italy.
   [Grandi, Giovanni; Facchinetti, Fabio] Azienda Osped Univ Policlin, Modena, Italy.
   [Bitzer, Johannes] Basel Univ Hosp, Dept Obstet & Gynaecol, Basel, Switzerland.
RP Grandi, G (corresponding author), Univ Modena & Reggio Emilia, Azienda Osped Univ Policlin, Via Pozzo 71, I-41124 Modena, Italy.
EM giovanni.grandi@unimore.it
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Ghosh S, 2017, J IMMUNOL, V198, P1782, DOI 10.4049/jimmunol.1601166
   Kaushic C, 2011, J REPROD IMMUNOL, V88, P204, DOI 10.1016/j.jri.2010.12.004
   Khan D, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00635
   Liang H, 2020, ACTA OBSTET GYN SCAN, V99, P439, DOI 10.1111/aogs.13836
   Liu SW, 2017, J EPIDEMIOL COMMUN H, V71, P154, DOI 10.1136/jech-2016-207805
   Lu FX, 2002, CLIN EXP IMMUNOL, V128, P10, DOI 10.1046/j.1365-2249.2002.01780.x
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Polis CB, 2016, AIDS, V30, P2665, DOI 10.1097/QAD.0000000000001228
   Ruggieri A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02302
   van Vlijmen EFW, 2011, BLOOD, V118, P2055, DOI 10.1182/blood-2011-03-345678
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
   Wenham C, 2020, LANCET, V395, P846, DOI 10.1016/S0140-6736(20)30526-2
   World Health Organization, 2020, CONTR FAM PLANN COVI
NR 15
TC 7
Z9 7
U1 3
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PD MAY 3
PY 2020
VL 25
IS 3
BP 233
EP 234
DI 10.1080/13625187.2020.1766017
EA MAY 2020
PG 2
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA ME1XK
UT WOS:000541439000001
PM 32469251
OA Bronze
DA 2021-01-01
ER

PT J
AU Chrzanowski, W
   Kim, SY
   McClements, L
AF Chrzanowski, Wojciech
   Kim, Sally Yunsun
   McClements, Lana
TI Can Stem Cells Beat COVID-19: Advancing Stem Cells and Extracellular
   Vesicles Toward Mainstream Medicine for Lung Injuries Associated With
   SARS-CoV-2 Infections
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE stem cell; lung injuries; Coronavirus (2019-nCoV); SARS-CoV-2; stem cell
   therapy; extracellular vesicles
ID MESENCHYMAL STROMAL CELLS; ACUTE RESPIRATORY SYNDROME; CORONAVIRUS;
   THERAPY; TYPE-1; SARS
AB A number of medicines are currently under investigation for the treatment of COVID-19 disease including anti-viral, anti-malarial, and anti-inflammatory agents. While these treatments can improve patient's recovery and survival, these therapeutic strategies do not lead to unequivocal restoration of the lung damage inflicted by this disease. Stem cell therapies and, more recently, their secreted extracellular vesicles (EVs), are emerging as new promising treatments, which could attenuate inflammation but also regenerate the lung damage caused by COVID-19. Stem cells exert their immunomodulatory, anti-oxidant, and reparative therapeutic effects likely through their EVs, and therefore, could be beneficial, alone or in combination with other therapeutic agents, in people with COVID-19. In this review article, we outline the mechanisms of cytokine storm and lung damage caused by SARS-CoV-2 virus leading to COVID-19 disease and how mesenchymal stem cells (MSCs) and their secreted EVs can be utilized to tackle this damage by harnessing their regenerative properties, which gives them potential enhanced clinical utility compared to other investigated pharmacological treatments. There are currently 17 clinical trials evaluating the therapeutic potential of MSCs for the treatment of COVID-19, the majority of which are administered intravenously with only one clinical trial testing MSC-derived exosomes via inhalation route. While we wait for the outcomes from these trials to be reported, here we emphasize opportunities and risks associated with these therapies, as well as delineate the major roadblocks to progressing these promising curative therapies toward mainstream treatment for COVID-19.
C1 [Chrzanowski, Wojciech] Univ Sydney, Fac Med & Hlth, Sydney Sch Pharm, Sydney Nano Inst, Camperdown, NSW, Australia.
   [Kim, Sally Yunsun] Imperial Coll London, Natl Heart & Lung Inst, London, England.
   [McClements, Lana] Univ Technol Sydney, Fac Sci, Sch Life Sci, Sydney, NSW, Australia.
RP Chrzanowski, W (corresponding author), Univ Sydney, Fac Med & Hlth, Sydney Sch Pharm, Sydney Nano Inst, Camperdown, NSW, Australia.
EM wchrzanowski@sydney.edu.au
RI Kim, Sally Yunsun/P-8365-2018
OI Kim, Sally Yunsun/0000-0002-2134-8810; McClements,
   Lana/0000-0002-4911-1014
CR Abdi R, 2008, DIABETES, V57, P1759, DOI 10.2337/db08-0180
   Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015
   Baker S, 2020, 80 NYCS CORONAVIRUS
   Bartosh TJ, 2010, P NATL ACAD SCI USA, V107, P13724, DOI 10.1073/pnas.1008117107
   Bhattacharya J, 2013, ANNU REV PHYSIOL, V75, P593, DOI 10.1146/annurev-physiol-030212-183756
   Bjorge IM, 2017, BIOMATER SCI-UK, V6, P60, DOI 10.1039/c7bm00479f
   Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chaudhuri O, 2016, NAT MATER, V15, P326, DOI [10.1038/NMAT4489, 10.1038/nmat4489]
   Chen Jiajia, 2020, Engineering (Beijing), V6, P1153, DOI 10.1016/j.eng.2020.02.006
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cho J, 2018, AM J STEM CELLS, V7, P82
   Curley GF, 2013, ANESTHESIOLOGY, V118, P924, DOI 10.1097/ALN.0b013e318287ba08
   Dinh PUC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14344-7
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Fatima F, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00161
   Fergie N, 2019, FASEB J, V33, P5585, DOI 10.1096/fj.201802056R
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hu CX, 2018, J CELL MOL MED, V22, P1428, DOI 10.1111/jcmm.13492
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kardia E., 2016, STEM CELL HETEROGENE, P243, DOI [10.1007/7651_2016_327, DOI 10.1007/7651_2016_327]
   Karlberg J, 2004, AM J EPIDEMIOL, V159, P229, DOI 10.1093/aje/kwh056
   Kim J, 2015, PHARMACOL THERAPEUT, V151, P8, DOI 10.1016/j.pharmthera.2015.02.003
   Kim SY, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800166
   Kim SY, 2016, J AEROSOL MED PULM D, V29, P514, DOI 10.1089/jamp.2016.1289
   Kim YS, 2019, I C INF COMM TECH CO, P245
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Madl CM, 2018, NATURE, V557, P335, DOI 10.1038/s41586-018-0089-z
   Madl CM, 2017, NAT MATER, V16, P1233, DOI [10.1038/NMAT5020, 10.1038/nmat5020]
   Mahla Ranjeet Singh, 2016, Int J Cell Biol, V2016, P6940283, DOI 10.1155/2016/6940283
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   Morra ME, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1977
   Mortman K., 2020, PODCAST GW HOSP USES
   Namba F, 2019, PEDIATR INT, V61, P945, DOI 10.1111/ped.14001
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Saparov A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3924858
   Sart S, 2014, BIORESEARCH OPEN ACC, V3, P137, DOI 10.1089/biores.2014.0012
   Skolasinski S., 2020, AM J RESP CRIT CARE, V201, pA7634
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Suvakov S, 2020, CURR HYPERTENS REP, V22, DOI 10.1007/s11906-020-1034-8
   Thakkar UG, 2015, CYTOTHERAPY, V17, P940, DOI 10.1016/j.jcyt.2015.03.608
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Wada N, 2013, PERIODONTOL 2000, V63, P198, DOI 10.1111/prd.12024
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/S2213-2600(14)70291-7, 10.1016/s2213-2600(14)70291-7]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu PF, 2019, CELL TRANSPLANT, V28, P36, DOI 10.1177/0963689718808471
   Yang C, 2014, NAT MATER, V13, P645, DOI [10.1038/NMAT3889, 10.1038/nmat3889]
   Zebin L., 2020, NUCLEOCAPSID PROTEIN, DOI [10.1101/2020.03.26.010694, DOI 10.1101/2020.03.26.010694]
NR 56
TC 8
Z9 8
U1 5
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD MAY 26
PY 2020
VL 8
AR 554
DI 10.3389/fbioe.2020.00554
PG 8
WC Biotechnology & Applied Microbiology; Multidisciplinary Sciences
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA LY5WA
UT WOS:000540598500001
PM 32574317
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mondal, S
   De, NLJ
   Pal, A
AF Mondal, Sourav
   De, Nilanjan
   Pal, Anita
TI Topological Indices of Some Chemical Structures Applied for the
   Treatment of COVID-19 Patients
SO POLYCYCLIC AROMATIC COMPOUNDS
LA English
DT Article; Early Access
DE Primary; Secondary; Chloroquine; COVID-19; hydroxychloroquine;
   M-polynomial; molecular graph; remdesivir (GS-5734); theaflavin;
   topological index
ID MOLECULAR-STRUCTURE; GRAPH-THEORY; INFLUENZA-A; POLYNOMIALS; VIRUS;
   CHLOROQUINE; ORBITALS
AB The novel coronavirus disease 2019 (COVID-19) emerged in Wuhan, China, and has spread rapidly to nearly every part of the world. Unfortunately, no drug or vaccine has been accepted for the treatment of this pandemic. Researchers have established the efficacy of some existing antiviral drugs to control COVID-19 in vitro. Some of them are remdesivir (GS-5734), chloroquine, hydroxychloroquine, theaflavin. Topological indices are mathematical interpretations of a molecule generated by an algorithm implemented to a given molecular representation. Topological indices are used to model different physicochemical properties and biological activities of chemical compounds. In this work, some degree-based and neighborhood degree sum-based topological indices are investigated for the aforesaid antiviral drugs using polynomial approach. The results obtained can aid in the design of new medicine for the treatment of COVID-19.
C1 [Mondal, Sourav; Pal, Anita] NIT Durgapur, Dept Math, Durgapur, W Bengal, India.
   [De, Nilanjan] Calcutta Inst Engn & Management, Dept Basic Sci & Humanities Math, Kolkata, India.
RP De, NLJ (corresponding author), Calcutta Inst Engn & Management, Dept Basic Sci & Humanities Math, Kolkata, India.
EM de.nilanjan@rediffmail.com
RI De, Nilanjan/AAG-2921-2019
OI De, Nilanjan/0000-0001-9143-7045; MONDAL, SOURAV/0000-0003-1928-7075
FU Department of Science and Technology (DST), Government of India (INSPIRE
   Fellowship)
FX This work was supported by Department of Science and Technology (DST),
   Government of India (INSPIRE Fellowship).
CR Alamian V, 2008, INT J MOL SCI, V9, P229, DOI 10.3390/ijms9030229
   Ali A, 2018, OPEN CHEM, V16, P73, DOI 10.1515/chem-2018-0010
   Amic D, 1998, J CHEM INF COMP SCI, V38, P819, DOI 10.1021/ci980039b
   Anjum M.S., 2019, ENG APPL SCI LETT, V2, P19
   BALABAN AT, 1982, CHEM PHYS LETT, V89, P399, DOI 10.1016/0009-2614(82)80009-2
   Basavanagoud Bommanahal, 2019, OPEN J DISCRETE APPL, V2, P59
   Bruckler FM, 2011, CHEM PHYS LETT, V503, P336, DOI 10.1016/j.cplett.2011.01.033
   Changyin Gan, PREPRINT
   Chel Kwun Young, 2018, J CHEM, V2018, P1
   Chowdhury P, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198226
   DE N, 2018, OPEN J MATH SCI, V2, P338, DOI DOI 10.30538/oms2018.0039
   Deutsch E, 2015, IRAN J MATH CHEM, V6, P93
   Dhanalakshmi K., 2017, INT J MATH ITS APPL, V5, P285
   Doslic T, 2013, J MATH CHEM, V51, P1599, DOI 10.1007/s10910-013-0167-2
   Fajtlowicz S., 1987, C NUMER, V60, P189
   Furtula B, 2015, J MATH CHEM, V53, P1184, DOI 10.1007/s10910-015-0480-z
   Furtula B, 2010, J MATH CHEM, V48, P370, DOI 10.1007/s10910-010-9677-3
   Gao W., 2018, OPEN J MATH ANAL, V2, P10, DOI DOI 10.30538/PSRP-0MA2018.0014
   Gao W, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8030071
   Ghorbani M, 2013, DISCRET MATH ALGORIT, V5, DOI 10.1142/S1793830913500390
   GUTMAN I, 1972, CHEM PHYS LETT, V17, P535, DOI 10.1016/0009-2614(72)85099-1
   GUTMAN I, 1975, J CHEM PHYS, V62, P3399, DOI 10.1063/1.430994
   Gutman I., 1986, MATH CONCEPTS ORGANI
   Gutman I., 1993, GRAPH THEORY NOTES N, V125, P13
   Gutman I, 2013, CROAT CHEM ACTA, V86, P351, DOI 10.5562/cca2294
   Hassani F, 2013, MATCH-COMMUN MATH CO, V69, P87
   Hosamani SM, 2017, J APPL MATH COMPUT, V54, P425, DOI 10.1007/s12190-016-1016-9
   HOSOYA H, 1988, DISCRETE APPL MATH, V19, P239, DOI 10.1016/0166-218X(88)90017-0
   Iberoamerica C, 2020, LANCET, V395, P497
   Javaid M, 2019, TWMS J APPL ENG MATH, V9, P864
   Kwun YC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08309-y
   LIU G, 2018, OPEN J MATH SCI, V2, P221, DOI DOI 10.30538/oms2018.0030
   Lokesha V., 2016, INT J SCI ENG RES, V7, P53
   Lung JH, 2020, J MED VIROL, V92, P693, DOI 10.1002/jmv.25761
   Mohamed Rania Ali El Hadi, 2013, Journal of Entomology and Zoology Studies, V1, P1
   Mondal S., 2019, ARXIV190606660
   Mondal S., 2018, ARXIV180505273
   Mondal S, 2019, INT J MATH IND, V11, DOI 10.1142/S2661335219500060
   Mondal S, 2019, COMMUN FAC SCI UNIV, V68, P2104, DOI 10.31801/cfsuasmas.587655
   Mondal S, 2019, ACTA CHEM IASI, V27, P31, DOI 10.2478/achi-2019-0003
   Mondal Sourav, 2019, INT J APPL MATH, V32, P1037, DOI DOI 10.12732/IJAM.V32I6.10
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Munir M, 2016, SYMMETRY-BASEL, V8, DOI 10.3390/sym8120149
   Munir M, 2016, SYMMETRY-BASEL, V8, DOI 10.3390/sym8110134
   Munir M, 2016, SYMMETRY-BASEL, V8, DOI 10.3390/sym8110117
   Munir M, 2016, SYMMETRY-BASEL, V8, DOI 10.3390/sym8090097
   Ranjini P.S., 2013, INT J GRAPH THEORY, V1, P116
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Shao Z., 2019, ENG APPL SCI LETT, V2, P1
   Trinajsti N., 1983, CHEM GRAPH THEORY
   Verma Ashish, 2019, INT J MATH TRENDS TE, V67, P83
   Vukicevic D, 2010, CROAT CHEM ACTA, V83, P261
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   WIENER H, 1947, J AM CHEM SOC, V69, P17, DOI 10.1021/ja01193a005
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
   Yang H, 2019, J CHEM-NY, V2019, DOI 10.1155/2019/7297253
   Yang ZF, 2014, FITOTERAPIA, V93, P47, DOI 10.1016/j.fitote.2013.12.011
   Zhang HP, 1996, DISCRETE APPL MATH, V69, P147, DOI 10.1016/0166-218X(95)00081-2
   Zheng LN, 2019, OPEN CHEM, V17, P81, DOI 10.1515/chem-2019-0009
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 62
TC 5
Z9 5
U1 5
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1040-6638
EI 1563-5333
J9 POLYCYCL AROMAT COMP
JI Polycycl. Aromat. Compd.
DI 10.1080/10406638.2020.1770306
EA MAY 2020
PG 15
WC Chemistry, Organic
SC Chemistry
GA LZ1ZG
UT WOS:000541027400001
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Despres, C
   Brunin, Y
   Berthier, F
   Pili-Floury, S
   Besch, G
AF Despres, Cyrielle
   Brunin, Yannick
   Berthier, Francis
   Pili-Floury, Sebastien
   Besch, Guillaume
TI Prone positioning combined with high-flow nasal or conventional oxygen
   therapy in severe Covid-19 patients
SO CRITICAL CARE
LA English
DT Letter
C1 [Despres, Cyrielle; Brunin, Yannick; Berthier, Francis; Pili-Floury, Sebastien; Besch, Guillaume] Univ Franche Comte, Univ Hosp Besancon, Dept Anesthesiol & Intens Care Med, Besancon, France.
   [Pili-Floury, Sebastien; Besch, Guillaume] Univ Franche Comte, EA 3920, 3 Bvd Alexander Fleming, F-25000 Besancon, France.
RP Besch, G (corresponding author), Univ Franche Comte, Univ Hosp Besancon, Dept Anesthesiol & Intens Care Med, Besancon, France.; Besch, G (corresponding author), Univ Franche Comte, EA 3920, 3 Bvd Alexander Fleming, F-25000 Besancon, France.
EM gbesch@chu-besancon.fr
RI Besch, Guillaume/J-1070-2019
OI Besch, Guillaume/0000-0001-8975-4754
CR Ding L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2738-5
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Pan C, 2020, AM J RESP CRIT CARE, V201, P1294, DOI 10.1164/rccm.202003-0527LE
   Perez-Nieto Orlando R, 2020, Crit Care, V24, P114, DOI 10.1186/s13054-020-2821-y
   Roca O, 2019, AM J RESP CRIT CARE, V199, P1368, DOI 10.1164/rccm.201803-0589OC
   Scaramuzzo G, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00179
NR 6
TC 3
Z9 3
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD MAY 26
PY 2020
VL 24
IS 1
AR 256
DI 10.1186/s13054-020-03001-6
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA LY0ZF
UT WOS:000540251500002
PM 32456663
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Siow, WT
   Tang, SH
   Agrawal, RV
   Tan, AYH
   See, KC
AF Siow, Wen Ting
   Tang, Simeon H.
   Agrawal, Rohit Vijay
   Tan, Addy Y. H.
   See, Kay Choong
TI Essential ICU drug shortages for COVID-19: what can frontline clinicians
   do?
SO CRITICAL CARE
LA English
DT Letter
C1 [Siow, Wen Ting; See, Kay Choong] Natl Univ Hlth Syst, Natl Univ Hosp, Div Resp & Crit Care Med, Dept Med, 1E Kent Ridge Rd, Singapore 119228, Singapore.
   [Tang, Simeon H.] Natl Univ Singapore Hosp, Dept Pharm, Singapore, Singapore.
   [Agrawal, Rohit Vijay; Tan, Addy Y. H.] Natl Univ Singapore Hosp, Dept Anaesthesia, Singapore, Singapore.
RP Siow, WT (corresponding author), Natl Univ Hlth Syst, Natl Univ Hosp, Div Resp & Crit Care Med, Dept Med, 1E Kent Ridge Rd, Singapore 119228, Singapore.
EM siow_wen_ting@nuhs.edu.sg
CR Chlan LL, 2013, JAMA-J AM MED ASSOC, V309, P2335, DOI 10.1001/jama.2013.5670
   Fox Erin R, 2018, Am J Health Syst Pharm, V75, P1742, DOI 10.2146/ajhp180441
   Lamontagne F, 2020, JAMA-J AM MED ASSOC, V323, P938, DOI 10.1001/jama.2020.0930
   Li L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02848-z
   Whitson MR, 2016, CHEST, V149, P1380, DOI 10.1016/j.chest.2016.02.657
NR 5
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD MAY 26
PY 2020
VL 24
IS 1
AR 260
DI 10.1186/s13054-020-02971-x
PG 3
WC Critical Care Medicine
SC General & Internal Medicine
GA LY0ZF
UT WOS:000540251500006
PM 32456691
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nuccetelli, M
   Pieri, M
   Grelli, S
   Ciotti, M
   Miano, R
   Andreoni, M
   Bernardini, S
AF Nuccetelli, Marzia
   Pieri, Massimo
   Grelli, Sandro
   Ciotti, Marco
   Miano, Roberto
   Andreoni, Massimo
   Bernardini, Sergio
TI SARS-CoV-2 infection serology: a useful tool to overcome lockdown?
SO CELL DEATH DISCOVERY
LA English
DT Article
ID CORONAVIRUS
AB The outbreak of 2019 novel coronavirus disease (Covid-19) caused by SARS-CoV-2 has spread rapidly, inducing a progressive growth in infected patients number. Social isolation (lockdown) has been assessed to prevent and control virus diffusion, leading to a worldwide financial and political crisis. Currently, SARS-CoV-2 RNA detection in nasopharyngeal swab takes place by real-time PCR (RT-qPCR). However, molecular tests can give some false-negative results. In this context, serological assays can be useful to detect IgG/IgM antibodies, to assess the degree of immunization, to trace the contacts, and to support the decision to re-admit people at work. A lot of serological diagnostic kits have been proposed on the market but validation studies have not been published for many of them. The aim of our work was to compare and to evaluate different assays analytical performances (two different immunochromatographic cards, an immunofluorescence chromatographic card, and a chemiluminescence-automated immunoassay) on 43 positive samples with RT-qPCR-confirmed SARS-CoV-2 infection and 40 negative control subjects. Our data display excellent IgG/IgM specificities for all the immunocromatographic card tests (100% IgG and 100% IgM) and for the chemiluminescence-automated assay (100% IgG and 94% IgM); IgG/IgM sensitivities are moderately lower for all methods, probably due to the assay viral antigen's nature and/or to the detection time of nasopharyngeal swab RT-qPCR, with respect to symptoms onset. Given that sensitivities (around 94% and 84% for IgG and IgM, respectively) implicate false-negative cases and given the lack of effective vaccines or treatments, the only currently available procedure to reduce SARS-CoV-2 transmission is to identify and isolate persons who are contagious. For this reason, we would like to submit a flowchart in which serological tests, integrated with nasopharyngeal swab RT-qPCR, are included to help social and work activities implementation after the pandemic acute phase and to overcome lockdown.
C1 [Nuccetelli, Marzia; Grelli, Sandro; Ciotti, Marco; Andreoni, Massimo] Tor Vergata Univ Hosp, Rome, Italy.
   [Pieri, Massimo; Grelli, Sandro; Bernardini, Sergio] Univ Tor Vergata, Dept Expt Med, Rome, Italy.
   [Andreoni, Massimo] Univ Tor Vergata, Dept Syst Med, Rome, Italy.
   [Bernardini, Sergio] IFCC Emerging Technol Div, Milan, Italy.
   [Miano, Roberto] Univ Tor Vergata, Dept Surg Sci, Rome, Italy.
RP Pieri, M (corresponding author), Univ Tor Vergata, Dept Expt Med, Rome, Italy.
EM massimo.pieri@unirom2.it
RI Pieri, Massimo/ABE-7686-2020
OI Pieri, Massimo/0000-0002-3463-0268
CR Abbasi J, 2020, JAMA-J AM MED ASSOC, V323, P1881, DOI 10.1001/jama.2020.6170
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Armitage R, 2020, LANCET PUBLIC HEALTH, V5, pE256, DOI 10.1016/S2468-2667(20)30061-X
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Broughton JP, 2020, NAT BIOTECHNOL, V38, P870, DOI 10.1038/s41587-020-0513-4
   Chen WH, 2020, HUM VACC IMMUNOTHER, V16, P1239, DOI 10.1080/21645515.2020.1740560
   Ciotti M, 2020, CHEMOTHERAPY, V64, P215, DOI [10.1159/000507423, 10.1080/10408363.2020.1783198]
   Cui P, 2020, JPN J APPL PHYS, V59
   Cullen W, 2020, QJM-INT J MED, V113, P311, DOI 10.1093/qjmed/hcaa110
   FDA F. a. D. A, 2020, POLICY DIAGNOSTIC TE
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Lee J, 2020, LANCET CHILD ADOLESC, VS2352-4642, P30109
   Lee VJ, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa039
   Lei Shaoqing, 2020, EClinicalMedicine, V21, P100331, DOI 10.1016/j.eclinm.2020.100331
   Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727
   Liu Y., 2020, DIAGNOSTIC INDEXES R, V2020, DOI [10.1101/2020.03.26.20044883, DOI 10.1101/2020.03.26.20044883]
   Lou B., 2020, SEROLOGY CHARACTERIS, DOI [10.1101/2020.03.23.20041707, DOI 10.1101/2020.03.23.20041707]
   Lv DF, 2020, CLIN CHIM ACTA, V506, P172, DOI 10.1016/j.cca.2020.03.032
   Madore DV, 2010, VACCINE, V28, P4539, DOI 10.1016/j.vaccine.2010.04.094
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Padoan A, 2020, CLIN CHEM LAB MED, V58, P1081, DOI 10.1515/cclm-2020-0443
   Pan YY, 2020, EUR RADIOL, V30, P3306, DOI 10.1007/s00330-020-06731-x
   Pan YB, 2020, J INFECTION, V81, pE28, DOI 10.1016/j.jinf.2020.03.051
   Sebastiani G, 2020, EUR J EPIDEMIOL, V35, P341, DOI 10.1007/s10654-020-00631-6
   Seyfzadeh A, 2019, IRAN J PUBLIC HEALTH, V48, P365
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Tuite AR, 2020, ANN INTERN MED, V172, P699, DOI 10.7326/M20-0696
   Wang YS, 2020, J MED VIROL, V92, P538, DOI 10.1002/jmv.25721
   Wells CR, 2020, P NATL ACAD SCI USA, V117, P7504, DOI 10.1073/pnas.2002616117
   West CP, 2020, MAYO CLIN PROC, V95, P1127, DOI 10.1016/j.mayocp.2020.04.004
   Woo PCY, 2004, CLIN DIAGN LAB IMMUN, V11, P665, DOI 10.1128/CDLI.11.4.665-668.2004
   World Health Organization, 2020, POP BAS AG STRAT SER
   World Health Organization, COR DIS 2019 COVID 1
   World Health Organization, NOV COR COVID 19 SIT
   World Health Organization, 2020, LAB TEST 2019 NOV CO
   Xiang F, 2020, CLIN INFECT DIS, V71, P1930, DOI 10.1093/cid/ciaa461
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 41
TC 9
Z9 10
U1 4
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2058-7716
J9 CELL DEATH DISCOV
JI Cell Death Discov.
PD MAY 26
PY 2020
VL 6
IS 1
AR 38
DI 10.1038/s41420-020-0275-2
PG 9
WC Cell Biology
SC Cell Biology
GA LU4WS
UT WOS:000537758200003
PM 32501411
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kanji, S
   Burry, L
   Williamson, D
   Pittman, M
   Dubinsky, S
   Patel, D
   Natarajan, S
   MacLean, R
   Huh, JH
   Scales, DC
   Neilipovitz, D
AF Kanji, Salmaan
   Burry, Lisa
   Williamson, David
   Pittman, Michelle
   Dubinsky, Samuel
   Patel, Deep
   Natarajan, Sabrina
   MacLean, Robert
   Huh, Jin-Hyeun
   Scales, Damon C.
   Neilipovitz, David
CA Ontario COVID-19 ICU Drug Task For
TI Therapeutic alternatives and strategies for drug conservation in the
   intensive care unit during times of drug shortage: a report of the
   Ontario COVID-19 ICU Drug Task Force
SO CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article
DE drug shortage; COVID-19; pandemic; therapeutic alternatives;
   conservation strategies
ID CRITICALLY-ILL PATIENTS; STRESS-ULCER PROPHYLAXIS; NEUROMUSCULAR
   BLOCKADE; CONTINUOUS-INFUSION; SEDATION; SAFETY; MANAGEMENT; PAIN
AB During the coronavirus disease (COVID-19) global pandemic, urgent strategies to alleviate shortages are required. Evaluation of the feasibility, practicality, and value of drug conservation strategies and therapeutic alternatives requires a collaborative approach at the provincial level. The Ontario COVID-19 ICU Drug Task Force was directed to create recommendations suggesting drug conservation strategies and therapeutic alternatives for essential drugs at risk of shortage in the intensive care unit during the COVID-19 pandemic. Recommendations were rapidly developed using a modified Delphi method and evaluated on their ease of implementation, feasibility, and supportive evidence. This article describes the recommendations for drug conservation strategies and therapeutic alternatives for drugs at risk of shortage that are commonly used in the care of critically ill patients. Recommendations are identified as preferred and secondary ones that might be less desirable. Although the impetus for generating this document was the COVID-19 pandemic, recommendations should also be applicable for mitigating drug shortages outside of a pandemic. Proposed provincial strategies for drug conservation and therapeutic alternatives may not all be appropriate for every institution. Local implementation will require consultation from end-users and hospital administrators. Competing equipment shortages and available resources should be considered when evaluating the appropriateness of each strategy.
C1 [Kanji, Salmaan] Ottawa Hosp Res Inst, Ottawa Hosp, Dept Pharm, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
   [Burry, Lisa] Mt Sinai Hosp, Toronto, ON, Canada.
   [Williamson, David; Scales, Damon C.] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada.
   [Burry, Lisa] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada.
   [Williamson, David] Univ Montreal, Sacre Coeur Hosp, Montreal, PQ, Canada.
   [Pittman, Michelle; Dubinsky, Samuel; Patel, Deep; Natarajan, Sabrina; MacLean, Robert; Neilipovitz, David] Ottawa Hosp, Ottawa, ON, Canada.
   [Huh, Jin-Hyeun] Univ Hlth Network, Toronto, ON, Canada.
   [Scales, Damon C.] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
RP Kanji, S (corresponding author), Ottawa Hosp Res Inst, Ottawa Hosp, Dept Pharm, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
EM skanji@toh.ca
CR Alhazzani W, 2018, INTENS CARE MED, V44, P1, DOI 10.1007/s00134-017-5005-8
   Barletta JF, 2014, J CRIT CARE, V29, P955, DOI 10.1016/j.jcrc.2014.06.025
   Bowles SK, 2019, CAN J HOSP PHARM, V72, P3
   Canadian Agency for Drugs and Technologies in Health, 2015, CONT VERS INT INTR P
   Canadian Society of Hospital Pharmacists, DRUG SHORT
   Chanques G, 2010, PAIN, V151, P711, DOI 10.1016/j.pain.2010.08.039
   Chlan LL, 2017, AM J CRIT CARE, V26, P288, DOI 10.4037/ajcc2017408
   deBacker J, 2017, CHEST, V151, P697, DOI 10.1016/j.chest.2016.10.040
   Devlin JW, 2018, CRIT CARE MED, V46, pE825, DOI 10.1097/CCM.0000000000003299
   Ebert TJ, 2005, ANESTHESIOLOGY, V103, P20, DOI 10.1097/00000542-200507000-00007
   Epstein HM, 2017, CRIT CARE NURSE, V37, P55, DOI 10.4037/ccn2017724
   Fan E, 2018, JAMA-J AM MED ASSOC, V319, P698, DOI 10.1001/jama.2017.21907
   Fox ER, 2014, MAYO CLIN PROC, V89, P361, DOI 10.1016/j.mayocp.2013.11.014
   Geier MR, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109760
   Gelinas C, 2006, AM J CRIT CARE, V15, P420
   Gesin G, 2011, J CRIT CARE, V26, P122, DOI 10.1016/j.jcrc.2010.09.008
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Hanidziar D, 2020, ANESTH ANALG, V131, pE40, DOI 10.1213/ANE.0000000000004887
   Hashimoto S, 2017, J INTENSIVE CARE, V5, DOI 10.1186/s40560-017-0222-3
   Health Canada, 2020, IMP US LAB PANC BROM
   Huang HB, 2018, CRIT CARE, V22, DOI 10.1186/s13054-017-1937-1
   Jurado LV, 2011, PHARMACOTHERAPY, V31, P1250, DOI 10.1592/phco.31.12.1250
   Kaki R, 2011, J ANTIMICROB CHEMOTH, V66, P1223, DOI 10.1093/jac/dkr137
   Kanji S, 2013, ANN PHARMACOTHER, V47, P637, DOI 10.1345/aph.1R414
   Kanji S, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.10.011
   Karthik S, 2006, SEMIN DIALYSIS, V19, P465, DOI 10.1111/j.1525-139X.2006.00208.x
   Kim HY, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008976
   Lamontagne F, 2018, INTENS CARE MED, V44, P12, DOI 10.1007/s00134-017-5016-5
   Liu M, 2020, JAMA INTERN MED, V180, P1116, DOI 10.1001/jamainternmed.2020.1764
   Mehta S, 2012, JAMA-J AM MED ASSOC, V308, P1985, DOI 10.1001/jama.2012.13872
   Mistraletti G, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-92
   Ng KT, 2018, J CARDIOTHOR VASC AN, V32, P2303, DOI 10.1053/j.jvca.2018.01.004
   Perbet S, 2018, ANAESTH CRIT CARE PA, V37, P589, DOI 10.1016/j.accpm.2018.09.006
   Pinard AM, 2003, CAN J ANAESTH, V50, P172, DOI 10.1007/BF03017852
   Rapier G, 2020, PEOPLE ARE NOW HOARD
   Reddel HK, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01046-2019
   Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138
   Shaiova L, 2007, J PALLIAT MED, V10, P1063, DOI 10.1089/jpm.2006.0262
   Sibley S, 2015, CAN RESPIR J, V22, P179, DOI 10.1155/2015/394961
   The Multi-Stakeholder Steering Committee On Drug Shortages In Canada, 2017, MULT TOOLK TOOLK IMP
   Videau M, 2019, CAN J HOSP PHARM, V72, P7
   Wampole CR, 2019, J PHARM PRACT, V32, P256, DOI 10.1177/0897190019834479
   Wang CT, 2019, INTENS CRIT CARE NUR, V54, P7, DOI 10.1016/j.iccn.2019.06.004
   Wanzuita R, 2012, CRIT CARE, V16, DOI 10.1186/cc11250
   Weingart S, 2015, CLIN EXP EMERG MED, V2, P131, DOI 10.15441/ceem.15.010
   Whitson MR, 2016, CHEST, V149, P1380, DOI 10.1016/j.chest.2016.02.657
NR 46
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0832-610X
EI 1496-8975
J9 CAN J ANESTH
JI Can. J. Anesth.
PD OCT
PY 2020
VL 67
IS 10
BP 1405
EP 1416
DI 10.1007/s12630-020-01713-5
EA MAY 2020
PG 12
WC Anesthesiology
SC Anesthesiology
GA NJ1JB
UT WOS:000535670000002
PM 32458267
OA Bronze
DA 2021-01-01
ER

PT J
AU Sun, J
   Deng, XY
   Chen, XP
   Huang, JJ
   Huang, SQ
   Li, YF
   Feng, JH
   Liu, JY
   He, GF
AF Sun, Ji
   Deng, Xuanyu
   Chen, Xiaoping
   Huang, Juanjuan
   Huang, Siqiong
   Li, Yanfei
   Feng, Jinhui
   Liu, Jiyang
   He, Gefei
TI Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An
   Active Monitoring Study by Hospital Pharmacovigilance System
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID EFFICACY
AB To evaluate the incidence, type, and risk factors associated with adverse drug reactions (ADRs) among patients with coronavirus disease 2019 (COVID-19) by Hospital Pharmacovigilance System (CHPS). A retrospective analysis was performed on 217 patients with COVID-19 admitted to the First Hospital of Changsha in China, from January 17, 2020, to February 29, 2020. The active monitoring model in CHPS was used to detect ADR signals of the hospital information system. The risk factors for the ADRs were classified using the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) system. Univariate and multivariate logistic regressions were carried out to analyze the risk factors of ADRs. Our results showed that the prevalence of ADRs was 37.8% in the patients, which was predominated by drug-induced gastrointestinal disorders and liver system disorders (23.0% vs. 13.8%). The ADR could be explained by the use of lopinavir/ ritonavir and umifenovir by 63.8% and 18.1%, respectively. There were 96.8% of ADRs that occurred within 14 days of hospitalization. Multivariable analysis showed that length of stay (odds ratio (OR): 2.02; 95% confidence interval (CI) 1.03-3.96; P = 0.04), number of drugs used in the hospital (OR: 3.17; 95% CI 1.60-6.27; P = 0.001) and underlying basic diseases (OR: 2.07; 95% CI 1.02-4.23; P = 0.04) were independent risk factor for ADRs in the patients. Together, the incidence of ADRs was significantly high during the treatment period. Moreover, the active monitoring of the CHPS system reflected ADRs during COVID-19 treatment in the real world, which provided reference for safe medication in the clinic.
C1 [Sun, Ji; Deng, Xuanyu; Huang, Juanjuan; Huang, Siqiong; Li, Yanfei; Feng, Jinhui; Liu, Jiyang; He, Gefei] First Hosp Changsha, Changsha, Peoples R China.
   [Chen, Xiaoping] Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Hunan, Peoples R China.
   [Chen, Xiaoping] Cent South Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha, Hunan, Peoples R China.
   [Chen, Xiaoping] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Hunan, Peoples R China.
RP Liu, JY; He, GF (corresponding author), First Hosp Changsha, Changsha, Peoples R China.
EM 306138986@qq.com; tinysun2016@outlook.com
FU Hunan Provincial Science and Technology Major Project [2020SK3014];
   scientific research project of Hunan Health Commission [20200202];
   Natural Science Foundation of Hunan ProvinceNatural Science Foundation
   of Hunan Province [2017JJ2285]
FX The research is supported by Hunan Provincial Science and Technology
   Major Project (No. 2020SK3014), the scientific research project of Hunan
   Health Commission (No. 20200202), and Natural Science Foundation of
   Hunan Province (No. 2017JJ2285).
CR Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Behera SK, 2018, INT J CLIN PHARM-NET, V40, P903, DOI 10.1007/s11096-018-0694-9
   Blignaut M, 2019, CARDIOVASC DRUG THER, V33, P1, DOI 10.1007/s10557-018-06847-9
   Bongiovanni M, 2005, INT J ANTIMICROB AG, V26, P88, DOI 10.1016/j.ijantimicag.2005.03.003
   Chandwani Ashish, 2008, Ther Clin Risk Manag, V4, P1023
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   General Office of National Health Commission of the People's Republic of China, 2020, DIAGN TREATM NOV COR
   Giocanti-Auregan A, 2018, J FR OPHTALMOL, V41, P363, DOI 10.1016/j.jfo.2017.08.014
   Gonzalez-Garcia J, 2010, AIDS RES HUM RETROV, V26, P841, DOI 10.1089/aid.2009.0307
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Kojima T, 2020, GERIATR GERONTOL INT, V20, P144, DOI 10.1111/ggi.13844
   Li XL, 2018, EUR J CLIN PHARMACOL, V74, P863, DOI 10.1007/s00228-018-2455-z
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Naidu R Purushotham, 2013, Perspect Clin Res, V4, P233, DOI 10.4103/2229-3485.120173
   Osorio L, 2019, REV CHIL INFECTOL, V36, P475, DOI 10.4067/S0716-10182019000400475
   Ostroumova T M, 2019, Zh Nevrol Psikhiatr Im S S Korsakova, V119, P86, DOI 10.17116/jnevro201911911186
   Pedros C, 2014, EUR J CLIN PHARMACOL, V70, P361, DOI 10.1007/s00228-013-1630-5
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Therapeutic Goods Administration of Department of Health of Australian Government, 2000, NOT GUID CLIN SAF DA
   Wang R., 2020, CHIN J HOSP PHARM, V40, P5
   Wire MB, 2012, ANTIMICROB AGENTS CH, V56, P2846, DOI 10.1128/AAC.05214-11
   World Health Organization, 2020, COR DIS COVID 2019 S
   Xu Kaijin, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P147, DOI 10.3785/j.issn.1008-9292.2020.02.02
   Yang S., 2020, MED J W CHINA, V4, P469
NR 26
TC 11
Z9 11
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD OCT
PY 2020
VL 108
IS 4
BP 791
EP 797
DI 10.1002/cpt.1866
EA MAY 2020
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NQ3JW
UT WOS:000535319200001
PM 32324898
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Yu, EW
   Tsourdi, E
   Clarke, BL
   Bauer, DC
   Drake, MT
AF Yu, Elaine W.
   Tsourdi, Elena
   Clarke, Bart L.
   Bauer, Douglas C.
   Drake, Matthew T.
TI Osteoporosis Management in the Era of COVID-19
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ABALOPARATIDE; BISPHOSPHONAT; COVID-19; DENOSUMAB; FRACTURES;
   OSTEOPOROSIS; ROMOSOZUMAB; TERIPARATIDE
ID BONE-MINERAL DENSITY; LONG-TERM TREATMENT; POSTMENOPAUSAL WOMEN;
   TERIPARATIDE TREATMENT; FRACTURE PREVENTION; VERTEBRAL FRACTURES;
   ZOLEDRONIC ACID; BREAST-CANCER; DENOSUMAB; DISCONTINUATION
AB Osteoporosis is a chronic condition that reflects reduced bone strength and an associated increased risk for fracture. As a chronic condition, osteoporosis generally requires sustained medical intervention(s) to limit the risks for additional bone loss, compromise of skeletal integrity, and fracture occurrence. Further complicating this issue is the fact that the abrupt cessation of some therapies can be associated with an increased risk for harm. It is in this context that the COVID-19 pandemic has brought unprecedented disruption to the provision of health care globally, including near universal requirements for social distancing. In this Perspective, we provide evidence, where available, regarding the general care of patients with osteoporosis in the COVID-19 era and provide clinical recommendations based primarily on expert opinion when data are absent. Particular emphasis is placed on the transition from parenteral osteoporosis therapies. It is hoped that these recommendations can be used to safely guide care for patients with osteoporosis until a return to routine clinical care standards is available. (c) 2020 American Society for Bone and Mineral Research.
C1 [Yu, Elaine W.] Harvard Med Sch, Endocrine Unit, Massachusetts Gen Hosp, Boston, MA 02115 USA.
   [Tsourdi, Elena] Univ Klinikum Dresden, Dept Med 3, Dresden, Germany.
   [Tsourdi, Elena] Univ Klinikum Dresden, Ctr Hlth Aging, Dresden, Germany.
   [Clarke, Bart L.; Drake, Matthew T.] Mayo Clin, Div Endocrinol Diabet Metab & Nutr, Rochester, MN 55905 USA.
   [Bauer, Douglas C.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Bauer, Douglas C.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA.
   [Drake, Matthew T.] Mayo Clin, Robert & Arlene Kogod Ctr Aging, Rochester, MN 55905 USA.
RP Drake, MT (corresponding author), Mayo Clin, Div Endocrinol, Coll Med, Rochester, MN 55905 USA.; Drake, MT (corresponding author), Mayo Clin, Kogod Ctr Aging, Coll Med, Rochester, MN 55905 USA.
EM drake.matthew@mayo.edu
OI Clarke, Bart/0000-0002-3801-9546; Bauer, Douglas/0000-0001-5261-7721;
   Drake, Matthew/0000-0002-3662-7345
CR Anastasilakis AD, 2019, J BONE MINER RES, V34, P2220, DOI 10.1002/jbmr.3853
   Artero A, 2012, SEMIN THROMB HEMOST, V38, P797, DOI 10.1055/s-0032-1328883
   ASBMR, 2020, ASBMR WEB PAN TREAT
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2012, J BONE MINER RES, V27, P243, DOI 10.1002/jbmr.1494
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213-8587(17)30138-9
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010-1502
   Boonen S, 2008, J CLIN ENDOCR METAB, V93, P852, DOI 10.1210/jc.2007-0711
   Chen IJ, 2015, OSTEOPOROSIS INT, V26, P681, DOI 10.1007/s00198-014-2930-z
   Cobin RH, 2017, ENDOCR PRACT, V23, P869, DOI 10.4158/EP171828.PS
   Coleman R, 2020, LANCET ONCOL, V21, P60, DOI 10.1016/S1470-2045(19)30687-4
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2019, BONE, V120, P246, DOI 10.1016/j.bone.2018.10.020
   Cosman F, 2015, J CLIN ENDOCR METAB, V100, P2769, DOI 10.1210/jc.2015-1715
   Cosman F, 2009, J CLIN ENDOCR METAB, V94, P3772, DOI 10.1210/jc.2008-2719
   Cummings SR, 2018, J BONE MINER RES, V33, P190, DOI 10.1002/jbmr.3337
   Curry SJ, 2018, JAMA-J AM MED ASSOC, V319, P2521, DOI 10.1001/jama.2018.7498
   Curtis JR, 2015, ARTHRITIS RHEUMATOL, V67, P1456, DOI 10.1002/art.39075
   Eastell R, 2011, J CLIN ENDOCR METAB, V96, P3367, DOI 10.1210/jc.2011-0412
   Ebina K, 2019, J BONE MINER RES S, VS1, pS259
   Epstein S, 2006, MATURITAS, V54, P1, DOI 10.1016/j.maturitas.2006.01.011
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Everts-Graber J, 2020, J BONE MINER RES, V35, P1207, DOI 10.1002/jbmr.3962
   Ferguson NM, BEHALF IMPERIAL COLL
   Freemantle N, 2012, OSTEOPOROSIS INT, V23, P317, DOI 10.1007/s00198-011-1780-1
   Gonzalez-Rodriguez E, 2018, CASE REP RHEUMATOL, V17
   Gonzalez-Rodriguez E, 2020, BREAST CANCER RES TR, V179, P153, DOI 10.1007/s10549-019-05458-8
   Grey A, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgaa062
   Grey A, 2012, BONE, V50, P1389, DOI 10.1016/j.bone.2012.03.016
   Henneman ZJ, 2008, J BIOMED MATER RES A, V85A, P993, DOI 10.1002/jbm.a.31599
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kanis JA, 2009, BONE, V44, P734, DOI 10.1016/j.bone.2009.01.373
   Kendler DL, 2019, OSTEOPOROSIS INT, V30, P2437, DOI 10.1007/s00198-019-05146-9
   Kendler D, 2020, J CLIN ENDOCR METAB, V105, pE255, DOI 10.1210/clinem/dgz095
   Kurland ES, 2004, OSTEOPOROSIS INT, V15, P992, DOI 10.1007/s00198-004-1636-z
   Lamy O, 2019, OSTEOPOROSIS INT, V30, P1111, DOI 10.1007/s00198-018-04820-8
   Langdahl BL, 2017, LANCET, V390, P1585, DOI 10.1016/S0140-6736(17)31613-6
   Lau AN, 2018, J RHEUMATOL, V45, P170, DOI 10.3899/jrheum.161270
   Leder BZ, 2019, J BONE MINER RES, V34, P2213, DOI 10.1002/jbmr.3848
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140-6736(15)61120-5
   Leder BZ, 2009, J CLIN ENDOCR METAB, V94, P2915, DOI 10.1210/jc.2008-2630
   Lindsay R, 2004, ARCH INTERN MED, V164, P2024, DOI 10.1001/archinte.164.18.2024
   Marshall John K, 2002, Expert Opin Drug Saf, V1, P71, DOI 10.1517/14740338.1.1.71
   McClung MR, 2018, J BONE MINER RES, V33, P1397, DOI 10.1002/jbmr.3452
   Miller PD, 2011, J CLIN ENDOCR METAB, V96, P394, DOI 10.1210/jc.2010-1805
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ravn P, 2000, J CLIN ENDOCR METAB, V85, P1492, DOI 10.1210/jc.85.4.1492
   Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24
   Reid IR, 2018, NEW ENGL J MED, V379, P2407, DOI 10.1056/NEJMoa1808082
   Reid IR, 2017, CALCIFIED TISSUE INT, V101, P371, DOI 10.1007/s00223-017-0288-x
   Rittmaster RS, 2000, J CLIN ENDOCR METAB, V85, P2129, DOI 10.1210/jc.85.6.2129
   Rosenbaum L, 2020, NEW ENGL J MED, V382, P2368, DOI 10.1056/NEJMms2009984
   Saag KG, 2019, ARTHRITIS RHEUMATOL, V71, P1174, DOI 10.1002/art.40874
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Schwartz AV, 2010, J BONE MINER RES, V25, P976, DOI 10.1002/jbmr.11
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Stopeck AT, 2016, SUPPORT CARE CANCER, V24, P447, DOI 10.1007/s00520-015-2904-5
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Watts NB, 2008, OSTEOPOROSIS INT, V19, P365, DOI 10.1007/s00198-007-0460-7
   World Health Organization, 2020, COR DIS 2019 COVID 1
NR 62
TC 12
Z9 12
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
EI 1523-4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2020
VL 35
IS 6
BP 1009
EP 1013
DI 10.1002/jbmr.4049
EA MAY 2020
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA LX6GO
UT WOS:000535308000001
PM 32406536
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Viale, G
   Licata, L
   Sica, L
   Zambelli, S
   Zucchinelli, P
   Rognone, A
   Aldrighetti, D
   Di Micco, R
   Zuber, V
   Pasetti, M
   Di Muzio, NG
   Rodighiero, MG
   Panizza, P
   Sassi, I
   Petrella, G
   Cascinu, S
   Gentilini, OD
   Bianchini, G
AF Viale, Giulia
   Licata, Luca
   Sica, Lorenzo
   Zambelli, Stefania
   Zucchinelli, Patrizia
   Rognone, Alessia
   Aldrighetti, Daniela
   Di Micco, Rosa
   Zuber, Veronica
   Pasetti, Marcella
   Di Muzio, Nadia Gisella
   Rodighiero, Maria Grazia
   Panizza, Pietro
   Sassi, Isabella
   Petrella, Giovanna
   Cascinu, Stefano
   Gentilini, Oreste Davide
   Bianchini, Giampaolo
TI Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the
   Epicenter of COVID-19 Outbreak
SO ONCOLOGIST
LA English
DT Article
DE COVID-19; SARS-CoV-2; Breast cancer; Treatment
ID ENDOCRINE THERAPY; ADJUVANT THERAPY
AB Northern Italy has been one of the European regions reporting the highest number of COVID-19 cases and deaths. The pandemic spread has challenged the National Health System, requiring reallocation of most of the available health care resources to treat COVID-19-positive patients, generating a competition with other health care needs, including cancer. Patients with cancer are at higher risk of developing critical illness after COVID-19 infection. Thus, mitigation strategies should be adopted to reduce the likelihood of infection in all patients with cancer. At the same time, suboptimal care and treatments may result in worse cancer-related outcome. In this article, we attempt to estimate the individual risk-benefit balance to define personalized strategies for optimal breast cancer management, avoiding as much as possible a general untailored approach. We discuss and report the strategies our Breast Unit adopted from the beginning of the COVID-19 outbreak to ensure the continuum of the best possible cancer care for our patients while mitigating the risk of infection, despite limited health care resources.
   Implications for Practice Managing patients with breast cancer during the COVID-19 outbreak is challenging. The present work highlights the need to estimate the individual patient risk of infection, which depends on both epidemiological considerations and individual clinical characteristics. The management of patients with breast cancer should be adapted and personalized according to the balance between COVID-19-related risk and the expected benefit of treatments. This work also provides useful suggestions on the modality of patient triage, the conduct of clinical trials, the management of an oncologic team, and the approach to patients' and health workers' psychological distress.
C1 [Viale, Giulia; Licata, Luca; Sica, Lorenzo; Zambelli, Stefania; Zucchinelli, Patrizia; Rognone, Alessia; Aldrighetti, Daniela; Bianchini, Giampaolo] IRCCS San Raffaele Hosp, Breast Canc Grp, Dept Med Oncol, Milan, Italy.
   [Di Micco, Rosa; Zuber, Veronica; Gentilini, Oreste Davide] IRCCS San Raffaele Hosp, Breast Surg Unit, Milan, Italy.
   [Pasetti, Marcella; Di Muzio, Nadia Gisella] IRCCS San Raffaele Hosp, Radiotherapy Unit, Milan, Italy.
   [Rodighiero, Maria Grazia; Panizza, Pietro] IRCCS San Raffaele Hosp, Breast Imaging Unit, Milan, Italy.
   [Sassi, Isabella] IRCCS San Raffaele Hosp, Pathol Unit, Milan, Italy.
   [Petrella, Giovanna; Cascinu, Stefano] IRCCS San Raffaele Hosp, Med Oncol, Milan, Italy.
   [Di Micco, Rosa] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy.
   [Di Muzio, Nadia Gisella] Univ Vita Salute San Raffaele, Milan, Italy.
RP Bianchini, G (corresponding author), Osped San Raffaele, Dept Med Oncol, Breast Canc Grp, Via Olgettina 60, I-20132 Milan, Italy.
EM bianchini.giampaolo@hsr.it
RI panizza, pietro/ABD-1242-2020; Di Micco, Rosa/AAC-3067-2019
OI panizza, pietro/0000-0003-4314-2044; Di Micco, Rosa/0000-0002-2575-8729
FU Associazione Italiana per la Ricerca sul CancroAssociazione Italiana per
   la Ricerca sul Cancro (AIRC) [IG 2018 ID 21787]
FX We thank Dr. Carmen Criscitiello (European Institute of Oncology, Milan)
   for the useful comments and suggestions. This work was partially
   supported by the Associazione Italiana per la Ricerca sul Cancro (IG
   2018 ID 21787). The funders had no role in the decision to publish or
   preparation of the manuscript.
CR Agenzia Italiana del Farmaco (AIFA), CLIN TRIALS MAN IT C
   American Society of Clinical Oncology (ASCO), COVID 19 PAT CAR INF
   Barton MK, 2016, CA-CANCER J CLIN, V66, P3, DOI 10.3322/caac.21296
   Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Breast Oncology Center Dana-Farber/Brigham and Women's Cancer Center, SUGG TREATM MOD MULT
   ESMO, CANC PAT MAN COVID 1
   European Medicines Agency (EMA), Q A GOOD CLIN PRACT
   Gourd E, 2020, LANCET ONCOL, V21, pE184, DOI 10.1016/S1470-2045(20)30167-4
   Grasselli G, 2020, JAMA
   Hwang ES, 2020, J CLIN ONCOL, V38, P1284, DOI 10.1200/JCO.19.00510
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mateo AM, 2020, ANN SURG ONCOL, V27, P1679, DOI 10.1245/s10434-019-08050-y
   NCCN, COR DIS 2019 COVID 1
   Spring LM, 2016, JAMA ONCOL, V2, P1477, DOI 10.1001/jamaoncol.2016.1897
   Yung R, 2020, BREAST CANCER RES TR, V180, P747, DOI 10.1007/s10549-020-05572-y
NR 18
TC 4
Z9 5
U1 2
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD JUL
PY 2020
VL 25
IS 7
BP E1013
EP E1020
DI 10.1634/theoncologist.2020-0316
EA MAY 2020
PG 8
WC Oncology
SC Oncology
GA MI6PW
UT WOS:000535279300001
PM 32412693
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Biernacka, EK
   Kosior, DA
   Zienciuk-Krajka, A
   Miszczak-Knecht, M
   Kempa, M
   Przybylski, A
   Baranowski, R
   Kulakowski, P
AF Biernacka, Elzbieta K.
   Kosior, Dariusz A.
   Zienciuk-Krajka, Agnieszka
   Miszczak-Knecht, Maria
   Kempa, Maciej
   Przybylski, Andrzej
   Baranowski, Rafal
   Kulakowski, Piotr
CA Polish Cardiac Soc
TI Safety of antiviral and anti-inflammatory drugs prolonging QT interval
   in patients with coronavirus disease 2019: an opinion of the Heart
   Rhythm Section of the Polish Cardiac Society
SO KARDIOLOGIA POLSKA
LA English
DT Article
C1 [Biernacka, Elzbieta K.] Cardinal Stefan Wyszynski Natl Inst Cardiol, Dept Congenital Heart Dis, Ul Alpejska 42, PL-04628 Warsaw, Poland.
   [Kosior, Dariusz A.] Minist Interior & Adm, Electrophysiol Lab, Cent Res Hosp, Dept Cardiol & Hypertens, Warsaw, Poland.
   [Kosior, Dariusz A.] Polish Acad Sci, Mossakowski Med Res Ctr, Warsaw, Poland.
   [Zienciuk-Krajka, Agnieszka; Kempa, Maciej] Med Univ Gdansk, Dept Cardiol & Electrotherapy, Gdansk, Poland.
   [Miszczak-Knecht, Maria] Childrens Mem Hlth Inst, Dept Cardiol, Warsaw, Poland.
   [Przybylski, Andrzej] Univ Rzeszow, Med Coll, Rzeszow, Poland.
   [Przybylski, Andrzej] Clin Prov Hosp 2, Cardiol Dept, Coronary Syndromes Subdiv, Rzeszow, Poland.
   [Baranowski, Rafal] Cardinal Stefan Wyszynski Natl Inst Cardiol, Dept Heart Arrhythmia 1, Warsaw, Poland.
   [Kulakowski, Piotr] Ctr Postgrad Med Educ, Dept Cardiol, Warsaw, Poland.
RP Biernacka, EK (corresponding author), Cardinal Stefan Wyszynski Natl Inst Cardiol, Dept Congenital Heart Dis, Ul Alpejska 42, PL-04628 Warsaw, Poland.
EM k.biernacka@ikard.pl
OI Przybylski, Andrzej/0000-0002-8136-7589
CR Behr ER, 2013, EUR HEART J, V34, P1958, DOI 10.1093/eurheartj/ehs172
   Drew BJ, 2010, J AM COLL CARDIOL, V55, P934, DOI 10.1016/j.jacc.2010.01.001
   Giudicessi JR, 2020, MAYO CLIN P
   Mitra RL, 2020, HEART RHYTHM CASE RE
   Prutkin JM, 2019, CORONAVIRUS DIS 2019
   Simpson TF, VENTRICULAR ARRHYTHM
NR 6
TC 1
Z9 1
U1 1
U2 2
PU POLSKIE TOWARZYSTOWO KARDIOLOGICZNE
PI WARSZAWA
PA UL STAWKI 3 A LOK 1-2, WARSZAWA, POLAND
SN 0022-9032
EI 1897-4279
J9 KARDIOL POL
JI Kardiol. Pol.
PD MAY 25
PY 2020
VL 78
IS 5
BP 493
EP 497
DI 10.33963/KP.15354
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA LS3MN
UT WOS:000536292200032
PM 32394693
OA Bronze
DA 2021-01-01
ER

PT J
AU Plonska-Gosciniak, E
   Suwalski, P
   Bartus, S
   Kukulski, T
   Komar, M
   Wojakowski, W
   Grygier, M
   Pruszczyk, P
   Gasior, Z
   Huczek, Z
   Berger-Kucza, A
   Bak, J
   Sorysz, D
   Kasprzak, JD
   Lesiak, M
   Deja, M
   Jasinski, M
   Hryniewiecki, T
   Hirnle, T
   Oko-Sarnowska, Z
   Trojnarska, O
   Tomkiewicz-Pajak, L
   Olszowska, M
   Mizia-Stec, K
AF Plonska-Gosciniak, Edyta
   Suwalski, Piotr
   Bartus, Stanislaw
   Kukulski, Tomasz
   Komar, Monika
   Wojakowski, Wojciech
   Grygier, Marek
   Pruszczyk, Piotr
   Gasior, Zbigniew
   Huczek, Zenon
   Berger-Kucza, Adrianna
   Bak, Janusz
   Sorysz, Danuta
   Kasprzak, Jaroslaw D.
   Lesiak, Maciej
   Deja, Marek
   Jasinski, Marek
   Hryniewiecki, Tomasz
   Hirnle, Tomasz
   Oko-Sarnowska, Zofia
   Trojnarska, Olga
   Tomkiewicz-Pajak, Lidia
   Olszowska, Maria
   Mizia-Stec, Katarzyna
CA Polish Cardiac Soc
TI Management of valvular and structural heart diseases during the
   coronavirus disease 2019 pandemic
SO KARDIOLOGIA POLSKA
LA English
DT Article
DE coronavirus disease 2019; pandemic; structural heart disease; valvular
   heart disease
ID ASSOCIATION; CARDIOLOGY; SOCIETY
AB The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents a major challenge for healthcare. The involvement of cardiovascular system in COVID-19 has been proven and increased healthcare system resources are redirected towards handling infected patients, which induces major changes in access to services and prioritization in the management of patients with chronic cardiovascular disease unrelated to COVID-19. In this expert opinion, conceived by the task force involving the Working Groups on Valvular Heart Diseases and Cardiac Surgery as well as the Association of Cardiovascular Intervention of the Polish Cardiac Society, modification of diagnostic pathways, principles of healthcare personnel protection, and treatment guidelines regarding triage and prioritization are suggested. Heart Teams responsible for the treatment of valvular heart disease should continue their work using telemedicine and digital technology. Diagnostic tests must be simplified or deferred to minimize the number of potentially dangerous aerosol-generating procedures, such as transesophageal echocardiography or exercise imaging. The treatment of aortic stenosis and mitral regurgitation has to be offered particularly due to urgent indications and in patients with advanced disease and poor prognosis. Expert risk stratification is essential for triage and setting the priority lists. In each case, an appropriate level of personal protection must be ensured for the healthcare personnel to prevent spreading infection and preserve specialized manpower, who will supply the continuing need for handling serious chronic cardiovascular disease. Importantly, as soon as the local epidemic situation improves, efforts must be made to restore standard opportunities for elective treatment of valvular heart disease and occluder-based therapies according to existing guidelines, thus rebuilding the state-of-the-art cardiovascular services.
C1 [Plonska-Gosciniak, Edyta] Pomeranian Med Univ, Dept Cardiol, Szczecin, Poland.
   [Suwalski, Piotr] Minist Interior & Adm, Ctr Postgrad Med Educ, Clin Dept Cardiac Surg, Cent Clin Hosp, Warsaw, Poland.
   [Bartus, Stanislaw; Sorysz, Danuta] Jagiellonian Univ, Inst Cardiol, Dept Cardiol & Cardiovasc Intervent, Med Coll, Ul Jakubowskiego 2, PL-30688 Krakow, Poland.
   [Kukulski, Tomasz] Med Univ Silesia, Fac Med Sci Zabrze, Dept Cardiol Congenital Heart Dis & Electrotherap, Katowice, Poland.
   [Komar, Monika; Tomkiewicz-Pajak, Lidia; Olszowska, Maria] Jagiellonian Univ, Inst Cardiol, Dept Cardiac & Vasc Dis, Med Coll, Krakow, Poland.
   [Wojakowski, Wojciech] Med Univ Silesia, Div Cardiol 3, Katowice, Poland.
   [Grygier, Marek] Poznan Univ Med Sci, Poznan, Poland.
   [Pruszczyk, Piotr] Med Univ Warsaw, Dept Internal Med & Cardiol, Warsaw, Poland.
   [Gasior, Zbigniew] Med Univ Silesia, Sch Hlth Sci, Dept Cardiol, Katowice, Poland.
   [Huczek, Zenon] Med Univ Warsaw, Dept Cardiol 1, Warsaw, Poland.
   [Berger-Kucza, Adrianna; Mizia-Stec, Katarzyna] Med Univ Silesia, Upper Silesian Med Ctr, Sch Med Katowice, Dept Cardiol 1, Katowice, Poland.
   [Bak, Janusz] Clin Prov Hosp 2, Dept Cardiac Surg, Rzeszow, Poland.
   [Kasprzak, Jaroslaw D.] Med Univ Lodz, Bieganski Hosp, Dept Cardiol 1, Lodz, Poland.
   [Lesiak, Maciej; Oko-Sarnowska, Zofia; Trojnarska, Olga] Poznan Univ Med Sci, Dept Cardiol 1, Poznan, Poland.
   [Deja, Marek] Med Univ Silesia, Sch Med Katowice, Dept Cardiac Surg, Katowice, Poland.
   [Jasinski, Marek] Wroclaw Med Univ, Dept & Clin Cardiac Surg, Wroclaw, Poland.
   [Hryniewiecki, Tomasz] Cardinal Stefan Wyszynski Natl Inst Cardiol, Dept Acquired Cardiac Defects, Warsaw, Poland.
   [Hirnle, Tomasz] Med Univ Bialystok, Dept Cardiosurg, Bialystok, Poland.
RP Sorysz, D (corresponding author), Jagiellonian Univ, Inst Cardiol, Dept Cardiol & Cardiovasc Intervent, Med Coll, Ul Jakubowskiego 2, PL-30688 Krakow, Poland.
EM dsorysz@gmail.com
CR [Anonymous], CARD SURG COVID 19 O
   Basman C, 2020, EUR J CARDIOTHORAC S
   Baumgartner H, 2017, EUR HEART J, V38, P2739, DOI 10.1093/eurheartj/ehx391
   Choi AD, 2020, J CARDIOVASC CO 0321
   Chung CJ, 2020, J AM COLL CARDIOL
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Elbaz-Greener G, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.010407
   Faroux L, 2019, J AM COLL CARDIOL, V74, P362, DOI 10.1016/j.jacc.2019.06.012
   Gackowski A, 2020, KARDIOL POL, V78, P357, DOI 10.33963/KP.15265
   Holmes DR, 2020, J AM HEART ASSOC, V9
   Kowalewski M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02925-3
   National Health Service, 2020, CLIN GUID MAN ANT SE
   Nicoara A, 2020, J AM SOC ECHOCARDIOG
   Parma R, 2017, KARDIOL POL, V75, P937, DOI 10.5603/KP.2017.0175
   Shah PB, 2020, JACC CARDIOVASC INTE
   Skali H, 2020, J NUCL CARDIOL, V27, P1022, DOI 10.1007/s12350-020-02123-2
   Society for Cardiovascular Magnetic Resonance, SCMRS COVID 19 PREP
   Stone GW, 2018, NEW ENGL J MED, V379, P2307, DOI 10.1056/NEJMoa1806640
   Tang L, 2018, CIRC-CARDIOVASC INTE, V11, DOI 10.1161/CIRCINTERVENTIONS.118.007220
   The European Society for Cardiology, ESC GUID DIAGN MAN C
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 22
TC 2
Z9 2
U1 4
U2 5
PU POLSKIE TOWARZYSTOWO KARDIOLOGICZNE
PI WARSZAWA
PA UL STAWKI 3 A LOK 1-2, WARSZAWA, POLAND
SN 0022-9032
EI 1897-4279
J9 KARDIOL POL
JI Kardiol. Pol.
PD MAY 25
PY 2020
VL 78
IS 5
BP 498
EP 507
DI 10.33963/KP.15358
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA LS3MN
UT WOS:000536292200033
PM 32415767
OA Bronze
DA 2021-01-01
ER

PT J
AU Panera, N
   Tozzi, AE
   Alisi, A
AF Panera, Nadia
   Tozzi, Alberto Eugenio
   Alisi, Anna
TI The G-Quadruplex/Helicase World as a Potential Antiviral Approach
   Against COVID-19
SO DRUGS
LA English
DT Article
ID G-QUADRUPLEXES; SARS; REPLICATION; APTAMERS; BINDING; EBSELEN
AB G-Quadruplexes (G4s) are non-canonical secondary structures formed within guanine-rich regions of DNA or RNA. G4 sequences/structures have been detected in human and in viral genomes, including Coronaviruses Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and SARS-CoV-2. Here, we outline the existing evidence indicating that G4 ligands and inhibitors of SARS-CoV-2 helicase may exert some antiviral activity reducing viral replication and can represent a potential therapeutic approach to tackle the COVID-19 pandemic due to SARS-CoV-2 infection. We also discuss how repositioning of FDA-approved drugs against helicase activity of other viruses, could represent a rapid strategy to limit deaths associated with COVID-19 pandemic.
C1 [Panera, Nadia; Alisi, Anna] Bambino Gesu Pediat Hosp, Res Unit Mol Genet Complex Phenotypes, IRCCS, 4 Piazza St Onofrio, I-00165 Rome, Italy.
   [Tozzi, Alberto Eugenio] Bambino Gesu Pediat Hosp, Multifactorial Dis & Complex Phenotype Res Area, IRCCS, Rome, Italy.
RP Alisi, A (corresponding author), Bambino Gesu Pediat Hosp, Res Unit Mol Genet Complex Phenotypes, IRCCS, 4 Piazza St Onofrio, I-00165 Rome, Italy.
EM anna.alisi@opbg.net
FU Bambino Gesu Children's Hospital and Italy Ministry of Health
FX This study was supported by Bambino Gesu Children's Hospital and Italy
   Ministry of Health.
CR Briguglio I, 2011, INT J MED CHEM, V2011, DOI 10.1155/2011/213135
   Cho JB, 2015, J MICROBIOL BIOTECHN, V25, P2007, DOI 10.4014/jmb.1507.07078
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Fay MM, 2017, J MOL BIOL, V429, P2127, DOI 10.1016/j.jmb.2017.05.017
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kikin O, 2006, NUCLEIC ACIDS RES, V34, pW676, DOI 10.1093/nar/gkl253
   Kil J, 2017, LANCET, V390, P969, DOI 10.1016/S0140-6736(17)31791-9
   Kusov Y, 2015, VIROLOGY, V484, P313, DOI 10.1016/j.virol.2015.06.016
   Lane AN, 2008, NUCLEIC ACIDS RES, V36, P5482, DOI 10.1093/nar/gkn517
   Lavezzo E, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006675
   Li TF, 2018, J VIROL, V92, DOI 10.1128/JVI.01606-17
   Lombardi EP, 2020, NUCLEIC ACIDS RES, V48, P1, DOI 10.1093/nar/gkz1097
   Lombardi EP, 2019, MOLECULES, V24, DOI 10.3390/molecules24101942
   Mendoza O, 2016, NUCLEIC ACIDS RES, V44, P1989, DOI 10.1093/nar/gkw079
   Metifiot M, 2014, NUCLEIC ACIDS RES, V42, P12352, DOI 10.1093/nar/gku999
   Mukherjee S, 2014, ACS CHEM BIOL, V9, P2393, DOI 10.1021/cb500512z
   Prentice E, 2004, J VIROL, V78, P9977, DOI 10.1128/JVI.78.18.9977-9986.2004
   Ramadan N, 2019, GERMS, V9, P35, DOI 10.18683/germs.2019.1155
   Rhodes D, 2015, NUCLEIC ACIDS RES, V43, P8627, DOI 10.1093/nar/gkv862
   Ruggiero E, 2018, NUCLEIC ACIDS RES, V46, P3270, DOI 10.1093/nar/gky187
   Shu T, 2019, NUCLEIC ACIDS RES, V47, P5837, DOI 10.1093/nar/gkz340
   Shum KT, 2008, CHEMBIOCHEM, V9, P3037, DOI 10.1002/cbic.200800491
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   Tan JZ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000428
   Tanner JA, 2005, CHEM BIOL, V12, P303, DOI 10.1016/j.chembiol.2005.01.006
   Thorlund K, 2020, LANCET DIGIT HEALTH, V2, pE286, DOI 10.1016/S2589-7500(20)30086-8
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zou XR, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01462
NR 31
TC 2
Z9 2
U1 5
U2 9
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PD JUL
PY 2020
VL 80
IS 10
BP 941
EP 946
DI 10.1007/s40265-020-01321-z
EA MAY 2020
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA MC7GV
UT WOS:000535638600003
PM 32451923
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Baker, N
   Williams, AJ
   Tropsha, A
   Ekins, S
AF Baker, Nancy
   Williams, Antony J.
   Tropsha, Alexander
   Ekins, Sean
TI Repurposing Quaternary Ammonium Compounds as Potential Treatments for
   COVID-19
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE ammonium chloride; antiseptic; cetylpyridinium chloride; SARS-CoV-2
ID CORONAVIRUS; INHIBITORS
AB The COVID-19 pandemic has highlighted an important role for drug repurposing. Quaternary ammonium compounds such as ammonium chloride, cetylpyridinium and miramistin represent widely accessible antiseptic molecules with well-known broad-spectrum antiviral activities and represent a repurposing opportunity as therapeutics against SARS-CoV-2.
C1 [Baker, Nancy] Leidos, Durham, NC USA.
   [Williams, Antony J.] US EPA, Ctr Computat Toxicol & Exposure, Off Res & Dev, Durham, NC USA.
   [Tropsha, Alexander] Univ N Carolina, UNC Eshelman Sch Pharm, Lab Mol Modeling, Chapel Hill, NC 27599 USA.
   [Ekins, Sean] Collaborat Pharmaceut Inc, 840 Main Campus Dr,Lab 3510, Raleigh, NC 27606 USA.
   [Ekins, Sean] Univ N Carolina, Eshelman Sch Pharm, UNC Catalyst Rare Dis, Chapel Hill, NC 27599 USA.
RP Ekins, S (corresponding author), Collaborat Pharmaceut Inc, 840 Main Campus Dr,Lab 3510, Raleigh, NC 27606 USA.; Ekins, S (corresponding author), Univ N Carolina, Eshelman Sch Pharm, UNC Catalyst Rare Dis, Chapel Hill, NC 27599 USA.
EM sean@collaborationspharma.com
FU NIH: NIGMSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R44GM122196-02A1]; NIH: NCATSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [R21TR001718]; NIH: NCCAMUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Complementary & Alternative Medicine [R43AT010585-01S1]; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [1OT2TR002514-01]
FX We kindly acknowledge NIH funding: R44GM122196-02A1 from NIGMS,
   R21TR001718 from NCATS and R43AT010585-01S1 from NCCAM (PI - Sean Ekins)
   and 1OT2TR002514-01 (Pi - Alexander Tropsha).
CR Agafonov A. P., 2005, Antibiotiki i Khimioterapiya, V50, P9
   Anon, 2020, DISINFECTANT CONCENT
   Ashfaq UA, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-163
   Baker NC, 2018, DRUG DISCOV TODAY, V23, P661, DOI 10.1016/j.drudis.2018.01.018
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Dellanno C, 2009, AM J INFECT CONTROL, V37, P649, DOI 10.1016/j.ajic.2009.03.012
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Ekins S, 2020, DRUG DISCOV TODAY, V25, P928, DOI 10.1016/j.drudis.2020.03.019
   Fromm-Dornieden C, 2015, J MED MICROBIOL, V64, P407, DOI 10.1099/jmm.0.000034
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Hoffmann MM, NOVEL CORONAVIRUS 20, DOI DOI 10.1101/2020.01.31.929042V1.FULL.PDF
   Jeon S, IDENTIFICATION ANTIV, DOI DOI 10.1101/2020.03.20.999730V1
   Jin Z, STRUCTURE MPRO 1 COV, DOI DOI 10.1101/2020.02.26.964882V2
   Krivorutchenko Iu L, 1994, Vopr Virusol, V39, P267
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   MIZZEN L, 1985, VIROLOGY, V142, P378, DOI 10.1016/0042-6822(85)90345-9
   Mukherjee PK, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2177-8
   Rabenau HF, 2005, J HOSP INFECT, V61, P107, DOI 10.1016/j.jhin.2004.12.023
   Riva L, 2020, LARGE SCALE DRUG REP, V2020, P044016
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Zhu DM, 2006, LANGMUIR, V22, P3735, DOI 10.1021/la052161s
NR 24
TC 4
Z9 4
U1 8
U2 10
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD MAY 25
PY 2020
VL 37
IS 6
AR 104
DI 10.1007/s11095-020-02842-8
PG 4
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA LR0BD
UT WOS:000535361000001
PM 32451736
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Karamloo, F
   Konig, R
AF Karamloo, Fariba
   Koenig, Renate
TI SARS-CoV-2 immunogenicity at the crossroads
SO ALLERGY
LA English
DT Letter
DE infections; inflammation; lung diseases other than asthma and COPD;
   vaccines; virus
C1 [Karamloo, Fariba] Paul Ehrlich Inst, Div Haematol Transfus Med, Langen, Germany.
   [Koenig, Renate] Paul Ehrlich Inst, Host Pathogen Interact, Langen, Germany.
   [Koenig, Renate] Sanford Burnham Prebys Med Discovery Inst, Immun & Pathogenesis Program, La Jolla, CA USA.
RP Karamloo, F (corresponding author), Paul Ehrlich Inst, Div Haematol Transfus Med, Langen, Germany.; Konig, R (corresponding author), Paul Ehrlich Inst, Host Pathogen Interact, Langen, Germany.
EM Fariba.Karamloo@pei.de; Renate.Koenig@pei.de
OI Konig, Renate/0000-0003-4882-9179
FU Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG)
   [SPP1923, KO4573/1-2]; German One Health Initiative (GOHI)
FX We thank Dr Egbert Flory for critical review of the manuscript. RK is
   supported by the Deutsche Forschungsgemeinschaft (DFG) SPP1923 Project
   KO4573/1-2 and the German One Health Initiative (GOHI).
CR Braun J., 2020, PRESENCE SARS COV 2, DOI [10.1101/2020.04.17.20061440, 10.1101/2020.04.17.20061440., DOI 10.1101/2020.04.17.20061440]
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Ju B, 2020, POTENT HUMAN NEUTRAL, DOI [10.1101/2020.03.21.990770, DOI 10.1101/2020.03.21.990770, 10.1101/2020.03.21.990770.]
   Poh CM, 2020, POTENT NEUTRALIZING, DOI [10.1101/2020.03.30.015461, DOI 10.1101/2020.03.30.015461]
   Riva Laura, 2020, bioRxiv, DOI 10.1101/2020.04.16.044016
   Su Y. C. F., 2020, BIORXIV, DOI [10.1101/2020.03.11.987222, DOI 10.1101/2020.03.11.987222]
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Wang Q, 2020, CELL, Vd181, P894
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
NR 12
TC 9
Z9 8
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD JUL
PY 2020
VL 75
IS 7
BP 1822
EP 1824
DI 10.1111/all.14360
EA MAY 2020
PG 3
WC Allergy; Immunology
SC Allergy; Immunology
GA NE8EB
UT WOS:000535185900001
PM 32401346
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Hijikata, A
   Shionyu-Mitsuyama, C
   Nakae, S
   Shionyu, M
   Ota, M
   Kanaya, S
   Shirai, T
AF Hijikata, Atsushi
   Shionyu-Mitsuyama, Clara
   Nakae, Setsu
   Shionyu, Masafumi
   Ota, Motonori
   Kanaya, Shigehiko
   Shirai, Tsuyoshi
TI Knowledge-based structural models of SARS-CoV-2 proteins and their
   complexes with potential drugs
SO FEBS LETTERS
LA English
DT Article
DE coronavirus; COVID-19; crude drug; drug repurposing; homology modeling;
   SARS-CoV
ID STRUCTURES REVEAL; SARS; MECHANISMS; INHIBITOR; BINDING; SYSTEM;
   CLASSIFICATION; DISCOVERY; CAPTOPRIL; RECEPTOR
AB The World Health Organization (WHO) has declared the coronavirus disease 2019 (COVID-19) caused by the novel coronavirus SARS-CoV-2 a pandemic. There is, however, no confirmed anti-COVID-19 therapeutic currently. In order to assist structure-based discovery efforts for repurposing drugs against this disease, we constructed knowledge-based models of SARS-CoV-2 proteins and compared the ligand molecules in the template structures with approved/experimental drugs and components of natural medicines. Our theoretical models suggest several drugs, such as carfilzomib, sinefungin, tecadenoson, and trabodenoson, that could be further investigated for their potential for treating COVID-19.
C1 [Hijikata, Atsushi; Shionyu-Mitsuyama, Clara; Nakae, Setsu; Shionyu, Masafumi; Shirai, Tsuyoshi] Nagahama Inst Biosci & Technol, Fac Biosci, 1266 Tamura Cho, Nagahama, Shiga 5260829, Japan.
   [Ota, Motonori] Nagoya Univ, Grad Sch Informat, Dept Complex Syst Sci, Nagoya, Aichi, Japan.
   [Kanaya, Shigehiko] Nara Inst Sci & Technol NAIST, Computat Biol Lab, Div Informat Sci, Grad Sch Sci & Technol, Ikoma, Japan.
RP Shirai, T (corresponding author), Nagahama Inst Biosci & Technol, Fac Biosci, 1266 Tamura Cho, Nagahama, Shiga 5260829, Japan.
EM t_shirai@nagahama-i-bio.ac.jp
OI Shionyu, Masafumi/0000-0002-0431-3456; Hijikata,
   Atsushi/0000-0003-4297-8368; Ota, Motonori/0000-0001-9090-668X
FU Platform Project for Supporting Drug Discovery and Life Science Research
   (Basis of Supporting Innovative Drug Discovery and Life Science Research
   (BINDS)) from AMED [JP20am0101111, JP20am0101069]
FX This work was partly supported by the Platform Project for Supporting
   Drug Discovery and Life Science Research (Basis of Supporting Innovative
   Drug Discovery and Life Science Research (BINDS)) from AMED
   (JP20am0101111 and JP20am0101069).
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Afendi FM, 2012, PLANT CELL PHYSIOL, V53, DOI 10.1093/pcp/pcr165
   Akaji K, 2011, J MED CHEM, V54, P7962, DOI 10.1021/jm200870n
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Bekker Gert-Jan, 2020, Biophys Rev, V12, P371, DOI 10.1007/s12551-020-00632-5
   Berman H, 2003, NAT STRUCT BIOL, V10, P980, DOI 10.1038/nsb1203-980
   Bouvet M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000863
   BRUNNER DB, 1981, BRIT J CLIN PHARMACO, V11, P461, DOI 10.1111/j.1365-2125.1981.tb01151.x
   BRUNNER HR, 1978, LANCET, V2, P704
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen Y, 2016, VIROL SIN, V31, P3, DOI 10.1007/s12250-016-3726-4
   Chen Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002294
   Chen Y, 2009, P NATL ACAD SCI USA, V106, P3484, DOI 10.1073/pnas.0808790106
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Dias DA, 2012, METABOLITES, V2, DOI 10.3390/metabo2020303
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   GROSS DM, 1981, J PHARMACOL EXP THER, V216, P552
   HAMILL RL, 1973, J ANTIBIOT, V26, P463, DOI 10.7164/antibiotics.26.463
   Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892
   Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988
   Kortuem KM, 2013, BLOOD, V121, P893, DOI 10.1182/blood-2012-10-459883
   Kuhn DJ, 2007, BLOOD, V110, P3281, DOI 10.1182/blood-2007-01-065888
   Kuroda Y, 2019, J ANTIBIOT, V72, P981, DOI 10.1038/s41429-019-0234-4
   Lee TW, 2007, J MOL BIOL, V366, P916, DOI 10.1016/j.jmb.2006.11.078
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li GR, 2018, INVEST OPHTH VIS SCI, V59, P383, DOI 10.1167/iovs.17-23212
   Li J, 2016, BRIEF BIOINFORM, V17, P2, DOI 10.1093/bib/bbv020
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Ling CQ, 2020, J INTEGR MED-JIM, V18, P87, DOI 10.1016/j.joim.2020.02.004
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Malik S, 2013, EUR J MED CHEM, V67, P1, DOI [10.1016/j.ejmech.2013.06.026, 10.1016/j.ejmech.2012.10.053]
   Masoudi-Sobhanzadeh Y, 2020, GENOMICS, V112, P1087, DOI 10.1016/j.ygeno.2019.06.021
   McCarthy MW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030909
   Menche J, 2015, SCIENCE, V347, DOI 10.1126/science.1257601
   Mills JEJ, 1996, J COMPUT AID MOL DES, V10, P607, DOI 10.1007/BF00134183
   Mushtaq S, 2018, EXCLI J, V17, P420, DOI 10.17179/excli2018-1174
   Natesh R, 2004, BIOCHEMISTRY-US, V43, P8718, DOI 10.1021/bi049480n
   Natesh R, 2003, NATURE, V421, P551, DOI 10.1038/nature01370
   Neudert G, 2011, J CHEM INF MODEL, V51, P2731, DOI 10.1021/ci200274q
   Nguyen D., 2020, POTENTIALLY HIGHLY P
   O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189
   ONDETTI MA, 1994, ANNU REV PHARMACOL, V34, P1
   Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623
   Peterman Carla, 2005, Cardiol Rev, V13, P315, DOI 10.1097/01.crd.0000181621.84565.9d
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Robert-Gero M, 1989, LEISHMANIASIS NATO A
   Saito M, 2012, J MOL BIOL, V424, P379, DOI 10.1016/j.jmb.2012.10.001
   Savelieva I, 2008, EUROPACE, V10, P647, DOI 10.1093/europace/eun130
   Sharma A, 2017, J CLIN PSYCHIAT, V78, pE656, DOI 10.4088/JCP.16r11113
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Wang JY, 2020, DRUG DISCOV TODAY, V25, P561, DOI 10.1016/j.drudis.2020.02.006
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Webb B., 2014, CURR PROTOC BIOINF, V47, DOI [10.1002/0471250953.bi0506s47, DOI 10.1088/1751-8113/47/31/315202]
   WEISS SR, 1994, ARCH VIROL, P349
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Z, 2020, NELFINAVIR WAR PREDI
   Yates CJ, 2014, J BIOL CHEM, V289, P1798, DOI 10.1074/jbc.M113.512335
   Yildirim MA, 2007, NAT BIOTECHNOL, V25, P1119, DOI 10.1038/nbt1338
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhu LL, 2011, ANTIVIR RES, V92, P204, DOI 10.1016/j.antiviral.2011.08.001
NR 78
TC 3
Z9 3
U1 6
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-5793
EI 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD JUN
PY 2020
VL 594
IS 12
BP 1960
EP 1973
DI 10.1002/1873-3468.13806
EA MAY 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA MA2KU
UT WOS:000535062400001
PM 32379896
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bauer, DC
   Tay, AP
   Wilson, LOW
   Reti, D
   Hosking, C
   McAuley, AJ
   Pharo, E
   Todd, S
   Stevens, V
   Neave, MJ
   Tachedjian, M
   Drew, TW
   Vasan, SS
AF Bauer, Denis C.
   Tay, Aidan P.
   Wilson, Laurence O. W.
   Reti, Daniel
   Hosking, Cameron
   McAuley, Alexander J.
   Pharo, Elizabeth
   Todd, Shawn
   Stevens, Vicky
   Neave, Matthew J.
   Tachedjian, Mary
   Drew, Trevor W.
   Vasan, Seshadri S.
TI Supporting pandemic response using genomics and bioinformatics: A case
   study on the emergent SARS-CoV-2 outbreak
SO TRANSBOUNDARY AND EMERGING DISEASES
LA English
DT Article
DE alignment-free phylogeny; bioinformatics; COVID-19; genomics; PHEIC;
   viral evolution
ID SARS-CORONAVIRUS; EVOLUTION
AB Pre-clinical responses to fast-moving infectious disease outbreaks heavily depend on choosing the best isolates for animal models that inform diagnostics, vaccines and treatments. Current approaches are driven by practical considerations (e.g. first available virus isolate) rather than a detailed analysis of the characteristics of the virus strain chosen, which can lead to animal models that are not representative of the circulating or emerging clusters. Here, we suggest a combination of epidemiological, experimental and bioinformatic considerations when choosing virus strains for animal model generation. We discuss the currently chosen SARS-CoV-2 strains for international coronavirus disease (COVID-19) models in the context of their phylogeny as well as in a novel alignment-free bioinformatic approach. Unlike phylogenetic trees, which focus on individual shared mutations, this new approach assesses genome-wide co-developing functionalities and hence offers a more fluid view of the 'cloud of variances' that RNA viruses are prone to accumulate. This joint approach concludes that while the current animal models cover the existing viral strains adequately, there is substantial evolutionary activity that is likely not considered by the current models. Based on insights from the non-discrete alignment-free approach and experimental observations, we suggest isolates for future animal models.
C1 [Bauer, Denis C.; Tay, Aidan P.; Wilson, Laurence O. W.; Reti, Daniel; Hosking, Cameron] CSIRO, Transformat Bioinformat Grp, Sydney, NSW, Australia.
   [Bauer, Denis C.] Macquarie Univ, Dept Biomed Sci, Sydney, NSW, Australia.
   [McAuley, Alexander J.; Pharo, Elizabeth; Todd, Shawn; Tachedjian, Mary; Vasan, Seshadri S.] CSIRO, Hlth & Biosecur, Geelong, Vic, Australia.
   [Stevens, Vicky; Neave, Matthew J.; Drew, Trevor W.] CSIRO, Australian Ctr Dis Preparedness, Geelong, Vic, Australia.
   [Vasan, Seshadri S.] Univ York, Dept Hlth Sci, York, N Yorkshire, England.
RP Vasan, SS (corresponding author), CSIRO, Australian Ctr Dis Preparedness, Dangerous Pathogens Team, 5 Portarlington Rd, Geelong, Vic 3220, Australia.
EM vasan.vasan@csiro.au
RI Drew, Trevor/ABB-5205-2020; Pharo, Elizabeth A/M-4706-2017; Bauer,
   Denis/C-3903-2009; Tachedjian, Mary/H-4572-2013
OI Pharo, Elizabeth A/0000-0002-5573-1746; Bauer,
   Denis/0000-0001-8033-9810; Tachedjian, Mary/0000-0002-8936-6564; Drew,
   Trevor/0000-0002-0448-1062
FU Commonwealth Scientific and Industrial Research OrganisationCommonwealth
   Scientific & Industrial Research Organisation (CSIRO); Coalition for
   Epidemic Preparedness Innovations
FX Commonwealth Scientific and Industrial Research Organisation; Coalition
   for Epidemic Preparedness Innovations
CR Abadi S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08822-w
   [Anonymous], 2020, WHO DIR GEN OP REM M
   [Anonymous], 2020, NARRATIVE GENOMIC AN
   Callaway Ewen, 2020, Nature, V579, P183, DOI 10.1038/d41586-020-00698-x
   Drew TW, 2011, REV SCI TECH OIE, V30, P95
   EIGEN M, 1988, J PHYS CHEM-US, V92, P6881, DOI 10.1021/j100335a010
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Eurosurveillance Editorial Team, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.5.200131e
   Eurosurveillance Editorial Team, 2019, Euro Surveill, V24, DOI 10.2807/1560-7917.ES.2019.24.29.190718e
   Goebel SJ, 2004, J VIROL, V78, P7846, DOI 10.1128/JVI.78.14.7846-7851.2004
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Grubaugh ND, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0690-4
   Jolliffe IT, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0202
   Kozlov AM, 2019, BIOINFORMATICS, V35, P4453, DOI 10.1093/bioinformatics/btz305
   Letunic I, 2019, NUCLEIC ACIDS RES, V47, pW256, DOI 10.1093/nar/gkz239
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Sims GE, 2009, P NATL ACAD SCI USA, V106, P2677, DOI 10.1073/pnas.0813249106
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Thi T, 2020, BIORXIV PREPRINT, DOI [10.1101/2020.02.21.959817, DOI 10.1101/2020.02.21.959817]
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wilke CO, 2001, NATURE, V412, P331, DOI 10.1038/35085569
   Zhao ZM, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-21
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 25
TC 4
Z9 3
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1865-1674
EI 1865-1682
J9 TRANSBOUND EMERG DIS
JI Transbound. Emerg. Dis.
PD JUL
PY 2020
VL 67
IS 4
BP 1453
EP 1462
DI 10.1111/tbed.13588
EA MAY 2020
PG 10
WC Infectious Diseases; Veterinary Sciences
SC Infectious Diseases; Veterinary Sciences
GA MI7PE
UT WOS:000535069500001
PM 32306500
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Xu, QH
   Wang, T
   Qin, XM
   Jie, YL
   Zha, L
   Lu, WH
AF Xu, Qiancheng
   Wang, Tao
   Qin, Xuemei
   Jie, Yanli
   Zha, Lei
   Lu, Weihua
TI Early awake prone position combined with high-flow nasal oxygen therapy
   in severe COVID-19: a case series
SO CRITICAL CARE
LA English
DT Letter
DE COVID-19; High-flow nasal cannula; Prone positioning; SARS-CoV-2
C1 [Xu, Qiancheng; Wang, Tao; Qin, Xuemei; Lu, Weihua] Wannan Med Coll, Yijishan Hosp, Dept Crit Care Med, 2 West Rd Zheshan, Wuhu 241000, Anhui, Peoples R China.
   [Xu, Qiancheng; Wang, Tao; Qin, Xuemei; Lu, Weihua] Wannan Med Coll, Yijishan Hosp, Affiliated Hosp 1, 2 West Rd Zheshan, Wuhu 241000, Anhui, Peoples R China.
   [Jie, Yanli] Second Peoples Hosp, Dept Crit Care Med, Wuhu 241000, Anhui, Peoples R China.
   [Zha, Lei] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 7BE, Merseyside, England.
RP Lu, WH (corresponding author), Wannan Med Coll, Yijishan Hosp, Dept Crit Care Med, 2 West Rd Zheshan, Wuhu 241000, Anhui, Peoples R China.; Lu, WH (corresponding author), Wannan Med Coll, Yijishan Hosp, Affiliated Hosp 1, 2 West Rd Zheshan, Wuhu 241000, Anhui, Peoples R China.
EM lwh683@126.com
FU Anhui Provincial Special Project of Central Government Guiding Local
   Science and Technology Development of China [201907d07050001, 2020dx2-1,
   2020dx2-2]
FX This work was supported, in part, by the Anhui Provincial Special
   Project of Central Government Guiding Local Science and Technology
   Development of China (201907d07050001) and the special fund for
   coronavirus disease 2019 of Wuhu (no. 2020dx2-1 and 2020dx2-2).
CR Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Ding L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2738-5
   DiSilvio B, 2019, CRIT CARE NURS Q, V42, P349, DOI 10.1097/CNQ.0000000000000275
   Thille AW, 2019, JAMA-J AM MED ASSOC, V322, P1465, DOI 10.1001/jama.2019.14901
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   刘茜, 2020, [法医学杂志, Journal of Forensic Medicine], V36, P21
NR 6
TC 15
Z9 15
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD MAY 24
PY 2020
VL 24
IS 1
AR 250
DI 10.1186/s13054-020-02991-7
PG 3
WC Critical Care Medicine
SC General & Internal Medicine
GA LU4BY
UT WOS:000537703700008
PM 32448330
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tong, T
   Wu, YQ
   Ni, WJ
   Shen, AZ
   Liu, S
AF Tong, Tong
   Wu, Ying-Qi
   Ni, Wei-Jian
   Shen, Ai-Zong
   Liu, Sheng
TI The potential insights of Traditional Chinese Medicine on treatment of
   COVID-19
SO CHINESE MEDICINE
LA English
DT Article
DE Traditional Chinese medicine; SARS-CoV-2; COVID-19; Treatment; Mechanism
AB Corona Virus Disease 2019 (COVID-19) broke out in 2019 and spread rapidly around the world. There is still no specific antiviral therapy to the current pandemic. In China, historical records show that Traditional Chinese Medicine (TCM) is effective in prevention and enhancing the resistance to pandemic with unique insights. To fight with COVID-19, National Health and Commission of PRC has recommended some TCM in the guideline, such as HuoxiangZhengqi, LianhuaQingwen ShufengJiedu and XueBijing, and actually displayed a remarkable effect in clinical treatment strategic for COVID-19. We review studies to provide an in-depth understanding into the effect of TCM, and also introduce the possible mechanism involved in COVID-19 treatment.
C1 [Tong, Tong; Wu, Ying-Qi; Ni, Wei-Jian; Shen, Ai-Zong; Liu, Sheng] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp 1, Dept Pharm,Anhui Prov Hosp, Hefei 230001, Anhui, Peoples R China.
RP Shen, AZ; Liu, S (corresponding author), Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp 1, Dept Pharm,Anhui Prov Hosp, Hefei 230001, Anhui, Peoples R China.
EM 1649441800@qq.com; lslcclhl@163.com
FU 13th Five-Year National Science and Technology Major Project from
   Ministry of Science and Technology of the People's Republic of China
   [2017ZX09304027]; Department of Pharmaceutical Administration of the
   National Health Commission of the People's Republic of China in 2018 [2]
FX This research were funded by the 13th Five-Year National Science and
   Technology Major Project from Ministry of Science and Technology of the
   People's Republic of China (Grant No.: 2017ZX09304027) and research
   project commissioned by the Department of Pharmaceutical Administration
   of the National Health Commission of the People's Republic of China in
   2018 (Grant No.: Pharmaceutical Administration [2018] No.2: A study on
   the commonality of drug use list of medical institutions at all levels).
CR Cheng D., 2020, WORLD CHIN MED, V15, P150, DOI DOI 10.3969/j.issn.1673-7202.2020.02.006
   Dai Xin-gui, 2009, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V21, P135
   Dai XinGui, 2009, Chinese Journal of Emergency Medicine, V18, P932
   [邓燕君 Deng Yanjun], 2020, [中草药, Chinese Traditional and Herbal Drugs], V51, P1113
   Duan L, 2015, CHINA CONTIN MED ED, V7, P219
   [何天目 He Tianmu], 2020, [中国现代应用药学, Chinese Journal of Modern Applied Pharmacy], V37, P398
   He YH, 2006, WORLD J GASTROENTERO, V12, P7346, DOI 10.3748/wjg.v12.i45.7346
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ji S, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109652
   Li Hai, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P321
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   Lin L, 2020, AM J OTOLARYNG, V41, DOI 10.1016/j.amjoto.2019.102311
   Lin Q, 2019, MOD J INTEGRATED TRA, V28, P153
   [凌晓颖 Ling Xiaoying], 2020, [中草药, Chinese Traditional and Herbal Drugs], V51, P1723
   Peng Y, 2008, CHIN J TCM WM CRIT C, V03, P178
   [瞿香坤 Qu Xiangkun], 2020, [中草药, Chinese Traditional and Herbal Drugs], V51, P1167
   Shen F, 2020, GUIDING J TRADIT CHI, V26, P8
   Sun MJ, 2018, J TIANJIN U TRADI CH, V37, P13
   Tao ZG, 2014, BIOSCI TRENDS, V8, P45, DOI 10.5582/bst.8.45
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yao Xin, 2017, China Journal of Traditional Chinese Medicine and Pharmacy, V32, P347
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang Shu-wen, 2006, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V18, P673
   Zhang Z, 2020, VIROL SIN, V35, P330, DOI 10.1007/s12250-020-00203-8
NR 25
TC 9
Z9 9
U1 10
U2 17
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749-8546
J9 CHIN MED-UK
JI Chin. Med.
PD MAY 24
PY 2020
VL 15
IS 1
AR 51
DI 10.1186/s13020-020-00326-w
PG 6
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA LT3AM
UT WOS:000536942800001
PM 32483409
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, YM
   Zhou, F
   Zhang, DY
   Zhao, JP
   Du, RH
   Hu, Y
   Cheng, ZS
   Gao, L
   Jin, Y
   Luo, GW
   Fu, SZ
   Lu, QF
   Du, GH
   Wang, K
   Lu, Y
   Fan, GH
   Zhang, Y
   Liu, Y
   Ruan, SN
   Liu, W
   Jaki, T
   Hayden, FG
   Horby, PW
   Cao, B
   Wang, C
AF Wang, Yeming
   Zhou, Fei
   Zhang, Dingyu
   Zhao, Jianping
   Du, Ronghui
   Hu, Yi
   Cheng, Zhenshun
   Gao, Ling
   Jin, Yang
   Luo, Guangwei
   Fu, Shouzhi
   Lu, Qiaofa
   Du, Guanhua
   Wang, Ke
   Lu, Yang
   Fan, Guohui
   Zhang, Yi
   Liu, Ying
   Ruan, Shunan
   Liu, Wen
   Jaki, Thomas
   Hayden, Frederick G.
   Horby, Peter W.
   Cao, Bin
   Wang, Chen
TI Evaluation of the efficacy and safety of intravenous remdesivir in adult
   patients with severe COVID-19: study protocol for a phase 3 randomized,
   double-blind, placebo-controlled, multicentre trial
SO TRIALS
LA English
DT Article
DE COVID-19; Clinical trial; Remdesivir; Antiviral; China; Administrative
   information
ID THERAPEUTIC-EFFICACY; GS-5734
AB Background Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China towards the end of 2019. Large-scale spread within China and internationally led the World Health Organization to declare a Public Health Emergency of International Concern on 30(th) January 2020. The clinical manifestations of COVID-19 virus infection include asymptomatic infection, mild upper respiratory symptoms, severe viral pneumonia with respiratory failure, and even death. There are no antivirals of proven clinical efficacy in coronavirus infections. Remdesivir (GS-5734), a nucleoside analogue, has inhibitory effects on animal and human highly pathogenic coronaviruses, including MERS-CoV and SARS-CoV, in in vitro and in vivo experiments. It is also inhibitory against the COVID-19 virus in vitro. The aim of this study is to assess the efficacy and safety of remdesivir in adult patients with severe COVID-19. Methods The protocol is prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. This is a phase 3, randomized, double-blind, placebo-controlled, multicentre trial. Adults (>= 18 years) with laboratory-confirmed COVID-19 virus infection, severe pneumonia signs or symptoms, and radiologically confirmed severe pneumonia are randomly assigned in a 2:1 ratio to intravenously administered remdesivir or placebo for 10 days. The primary endpoint is time to clinical improvement (censored at day 28), defined as the time (in days) from randomization of study treatment (remdesivir or placebo) until a decline of two categories on a six-category ordinal scale of clinical status (1 = discharged; 6 = death) or live discharge from hospital. One interim analysis for efficacy and futility will be conducted once half of the total number of events required has been observed. Discussion This is the first randomized, placebo-controlled trial in COVID-19. Enrolment began in sites in Wuhan, Hubei Province, China on 6(th) February 2020.
C1 [Wang, Yeming; Zhou, Fei; Fan, Guohui; Zhang, Yi; Cao, Bin; Wang, Chen] China Japan Friendship Hosp, Ctr Resp Med, Natl Clin Res Ctr Resp Dis, Dept Pulm & Crit Care Med, Beijing, Peoples R China.
   [Zhang, Dingyu; Liu, Ying; Ruan, Shunan; Liu, Wen] Jin Yin Tan Hosp, Wuhan, Hubei, Peoples R China.
   [Zhao, Jianping] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China.
   [Du, Ronghui] Wuhan Lung Hosp, Wuhan, Peoples R China.
   [Hu, Yi] Cent Hosp Wuhan, Wuhan, Peoples R China.
   [Cheng, Zhenshun] Wuhan Univ, Zhongnan Hosp, Wuhan, Peoples R China.
   [Gao, Ling] Wuhan Univ, Renmin Hosp, Wuhan, Peoples R China.
   [Jin, Yang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China.
   [Luo, Guangwei] Wuhan First Hosp, Wuhan, Peoples R China.
   [Fu, Shouzhi] Wuhan Third Hosp, Wuhan, Peoples R China.
   [Lu, Qiaofa] Wuhan Fourth Hosp, Wuhan, Peoples R China.
   [Du, Guanhua; Wang, Ke; Lu, Yang] Chinese Acad Med Sci, Inst Med, Beijing, Peoples R China.
   [Fan, Guohui] China Japan Friendship Hosp, Inst Clin Med Sci, Beijing, Peoples R China.
   [Jaki, Thomas] Univ Lancaster, Lancaster, England.
   [Hayden, Frederick G.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.
   [Horby, Peter W.] Univ Oxford, ISARIC, Oxford, England.
   [Cao, Bin; Wang, Chen] Chinese Acad Med Sci, Inst Resp Med, Beijing, Peoples R China.
   [Wang, Chen] Peking Union Med Coll, Beijing, Peoples R China.
RP Cao, B; Wang, C (corresponding author), China Japan Friendship Hosp, Ctr Resp Med, Natl Clin Res Ctr Resp Dis, Dept Pulm & Crit Care Med, Beijing, Peoples R China.; Cao, B; Wang, C (corresponding author), Chinese Acad Med Sci, Inst Resp Med, Beijing, Peoples R China.; Wang, C (corresponding author), Peking Union Med Coll, Beijing, Peoples R China.
EM caobin_ben@163.com; cyh-birm@263.net
FU Emergency project for novel coronavirus pneumonia of the Ministry of
   Science and Technology [2020YFC0841300]; Chinese Academy of Medical
   Sciences (CAMS) Innovation Fund for Medical Sciences [CIFMS
   2018-I2M-1-003]; National Science Grant for Distinguished Young Scholars
   [81425001/H0104]; National Key Research and Development Program of China
   [2018YFC1200102]; Beijing Science and Technology Project
   [Z19110700660000]; National Mega-projects for Infectious Diseases in
   China [2017ZX10103004, 2018ZX10305409]; National Institute for Health
   Research (NIHR) Senior Research FellowshipNational Institute for Health
   Research (NIHR) [2015-08-001]; Bill & Melinda Gates FoundationBill &
   Melinda Gates Foundation; Wellcome TrustWellcome Trust; UK Department of
   Health and Social Care; China Evergrande Group; Jack Ma Foundation; Sino
   Biopharmaceutical Limited; Ping An Insurance (Group); New Sunshine
   Charity Foundation
FX Funding was provided by the following:; Emergency project for novel
   coronavirus pneumonia of the Ministry of Science and Technology
   (2020YFC0841300); Chinese Academy of Medical Sciences (CAMS) Innovation
   Fund for Medical Sciences (CIFMS 2018-I2M-1-003); National Science Grant
   for Distinguished Young Scholars (81425001/H0104); The National Key
   Research and Development Program of China (2018YFC1200102); The Beijing
   Science and Technology Project (Z19110700660000); National Mega-projects
   for Infectious Diseases in China (2017ZX10103004 and 2018ZX10305409); TJ
   is funded by a National Institute for Health Research (NIHR) Senior
   Research Fellowship (2015-08-001); PWH is funded by the Bill & Melinda
   Gates Foundation, the Wellcome Trust, and the UK Department of Health
   and Social Care. This work was also supported by China Evergrande Group,
   Jack Ma Foundation, Sino Biopharmaceutical Limited, Ping An Insurance
   (Group) and New Sunshine Charity Foundation.
CR [Anonymous], 2011, GUID IND INFL DEV DR
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dimairo M, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1196-2
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jordan PC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006889
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Nuffield Council on Bioethics, 2020, RES GLOB HLTH EM ETH
   Saxena A, 2019, BMC MED ETHICS, V20, DOI 10.1186/s12910-019-0366-x
   Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI 10.4103/0976-500X.72352
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   WHITEHEAD J, 1983, BIOMETRICS, V39, P227, DOI 10.2307/2530822
   Whitehead J, 1997, DESIGN ANAL SEQUENTI
   World Health Organization, 2020, WHO R D BLUEPR INF C
   World Health Organization, 2015, ETH EP EM DIS RES SU
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 23
TC 5
Z9 5
U1 7
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD MAY 24
PY 2020
VL 21
IS 1
AR 422
DI 10.1186/s13063-020-04352-9
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LT3GW
UT WOS:000536960100003
PM 32448345
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU King, AJ
   Burke, LM
   Halson, SL
   Hawley, JA
AF King, Andy J.
   Burke, Louise M.
   Halson, Shona L.
   Hawley, John A.
TI The Challenge of Maintaining Metabolic Health During a Global Pandemic
SO SPORTS MEDICINE
LA English
DT Article
ID INTRAINDIVIDUAL VARIABILITY; PHYSIOLOGICAL ADAPTATIONS;
   PHYSICAL-ACTIVITY; HIGH-FAT; SLEEP; APPETITE; ADULTS; MEALS; TIME; FOOD
AB The ongoing global pandemic brought on by the spread of the novel coronavirus SARS-CoV-2 is having profound effects on human health and well-being. With no viable vaccine presently available and the virus being rapidly transmitted, governments and national health authorities have acted swiftly, recommending 'lockdown' policies and/or various levels of social restriction/isolation to attenuate the rate of infection. An immediate consequence of these strategies is reduced exposure to daylight, which can result in marked changes in patterns of daily living such as the timing of meals, and sleep. These disruptions to circadian biology have severe cardiometabolic health consequences for susceptible individuals. We discuss the consequences of reductions in patterns of daily physical activity and the resulting energy imbalance induced by periods of isolation, along with several home-based strategies to maintain cardiometabolic health in the forthcoming months.
C1 [King, Andy J.; Burke, Louise M.; Hawley, John A.] Australian Catholic Univ, Mary Mackillop Inst Hlth Res, Exercise & Nutr Res Program, Level 5,215 Spring St, Melbourne, Vic 3000, Australia.
   [Burke, Louise M.] Australian Inst Sport, Leverrier St, Canberra, ACT 2617, Australia.
   [Halson, Shona L.] Australian Catholic Univ, Sch Behav & Hlth Sci, Brisbane, Qld 4010, Australia.
RP Hawley, JA (corresponding author), Australian Catholic Univ, Mary Mackillop Inst Hlth Res, Exercise & Nutr Res Program, Level 5,215 Spring St, Melbourne, Vic 3000, Australia.
EM john.hawley@acu.edu.au
RI King, Andy/AAA-7296-2019; Burke, Louise/ABC-5691-2020; Hawley, John
   A/U-3814-2018
OI King, Andy/0000-0002-3647-7025; Hawley, John A/0000-0002-0886-9881
FU Novo Nordisk Foundation Challenge Grant [NNF14OC0011493]
FX The work in the laboratory of the senior author (JAH) on
   exercise-nutrient interactions and circadian biology is funded, in part,
   by a Novo Nordisk Foundation Challenge Grant (NNF14OC0011493). No
   specific sources of funding were used to assist in the preparation of
   this article.
CR Altena E, 2020, J SLEEP RES, V29, DOI 10.1111/jsr.13052
   Areta JL, 2013, J PHYSIOL-LONDON, V591, P2319, DOI 10.1113/jphysiol.2012.244897
   Asher G, 2015, CELL, V161, P84, DOI 10.1016/j.cell.2015.03.015
   Bankoski A, 2011, DIABETES CARE, V34, P497, DOI 10.2337/dc10-0987
   Bei B, 2017, SLEEP, V40, DOI 10.1093/sleep/zsw067
   Bei B, 2016, SLEEP MED REV, V28, P108, DOI 10.1016/j.smrv.2015.06.003
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Burd NA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012033
   Caia J, 2017, CHRONOBIOL INT, V34, P1239, DOI 10.1080/07420528.2017.1358736
   Coccurello R, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00271
   Deighton K, 2019, BRIT J NUTR, V121, P945, DOI 10.1017/S0007114519000205
   Delezie J, 2011, ANN NY ACAD SCI, V1243, P30, DOI 10.1111/j.1749-6632.2011.06246.x
   Department of Health and Social Care, 2019, UK CHIEF MED OFF PHY
   Eckel-Mahan K, 2013, PHYSIOL REV, V93, P107, DOI 10.1152/physrev.00016.2012
   Ezzati M, 2017, LANCET, V390, P2627, DOI 10.1016/S0140-6736(17)32129-3
   Fitbit, 2020, IMP COR GLOB ACT
   Francois ME, 2014, DIABETOLOGIA, V57, P1437, DOI 10.1007/s00125-014-3244-6
   Gallagher S, 2020, INDEPENDENT, V19, P20
   Galvan E, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070404
   Gibala MJ, 2020, J PHYSIOL-LONDON, V598, P61, DOI 10.1113/JP276849
   Gibala MJ, 2012, J PHYSIOL-LONDON, V590, P1077, DOI 10.1113/jphysiol.2011.224725
   Gill S, 2015, CELL METAB, V22, P789, DOI 10.1016/j.cmet.2015.09.005
   Halson SL, 2014, SPORTS MED, V44, P13, DOI 10.1007/s40279-014-0147-0
   Hamburg NM, 2007, ARTERIOSCL THROM VAS, V27, P2650, DOI 10.1161/ATVBAHA.107.153288
   Hamilton MT, 2007, DIABETES, V56, P2655, DOI 10.2337/db07-0882
   Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI 10.1249/mss.0b013e3180616b27
   Hatori M, 2012, CELL METAB, V15, P848, DOI 10.1016/j.cmet.2012.04.019
   Hawkins LK, 2020, APPETITE, V149, DOI 10.1016/j.appet.2020.104611
   Homer A.R., 2018, CURR OPIN ENDOCR MET, V4, P42, DOI DOI 10.1016/j.coemr.2018.09.003
   Hopkins M, 2016, BRIT J NUTR, V115, P1875, DOI 10.1017/S0007114516000775
   Islam H, 2017, J APPL PHYSIOL, V123, P614, DOI 10.1152/japplphysiol.00218.2017
   Jenkins EM, 2019, APPL PHYSIOL NUTR ME, V44, P681, DOI 10.1139/apnm-2018-0675
   Kant AK, 2014, AM J CLIN NUTR, V100, P938, DOI 10.3945/ajcn.114.085191
   Krogh-Madsen R, 2010, J APPL PHYSIOL, V108, P1034, DOI 10.1152/japplphysiol.00977.2009
   Lee SWH, 2017, SLEEP MED REV, V31, P91, DOI 10.1016/j.smrv.2016.02.001
   Lowe H, 2019, CLIN PSYCHOL REV, V68, P1, DOI 10.1016/j.cpr.2018.11.002
   MacInnis MJ, 2017, J PHYSIOL-LONDON, V595, P2915, DOI 10.1113/JP273196
   Marr B, 2020, CORONAVIRUS FAKE NEW
   McGlory C, 2019, J PHYSIOL-LONDON, V597, P1251, DOI 10.1113/JP275443
   Monsivais P, 2014, AM J PREV MED, V47, P796, DOI 10.1016/j.amepre.2014.07.033
   Morton RW, 2018, BRIT J SPORT MED, V52, P376, DOI 10.1136/bjsports-2017-097608
   Moynihan AB, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00369
   Muhlheim L, 2020, VERYWELLMIND
   Murphy MH, 2019, SPORTS MED, V49, P1585, DOI 10.1007/s40279-019-01145-2
   Parr EB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020505
   Parr EB, 2020, EXERC SPORT SCI REV, V48, P4, DOI 10.1249/JES.0000000000000207
   Piercy KL, 2018, JAMA-J AM MED ASSOC, V320, P2020, DOI 10.1001/jama.2018.14854
   Renner B, 2012, APPETITE, V59, P117, DOI 10.1016/j.appet.2012.04.004
   Reutrakul S, 2018, METABOLISM, V84, P56, DOI 10.1016/j.metabol.2018.02.010
   Shad BJ, 2019, MED SCI SPORT EXER, V51, P2125, DOI 10.1249/MSS.0000000000002034
   St-Onge MP, 2019, EUR J CLIN NUTR, V72, P76, DOI 10.1038/s41430-018-0312-x
   Stamatakis E, 2019, BRIT J SPORT MED, V53, P1137, DOI 10.1136/bjsports-2018-100397
   Stensel DJ, 2016, NUTR BULL, V41, P314, DOI 10.1111/nbu.12234
   Sutton EF, 2018, CELL METAB, V27, P1212, DOI 10.1016/j.cmet.2018.04.010
   World Health Organization, 2010, GLOB REC PHYS ACT HL
   Yang Y, 2017, INT J BEHAV MED, V24, P481, DOI 10.1007/s12529-016-9609-0
   Yau YHC, 2013, MINERVA ENDOCRINOL, V38, P255
NR 57
TC 5
Z9 5
U1 3
U2 5
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0112-1642
EI 1179-2035
J9 SPORTS MED
JI Sports Med.
PD JUL
PY 2020
VL 50
IS 7
BP 1233
EP 1241
DI 10.1007/s40279-020-01295-8
EA MAY 2020
PG 9
WC Sport Sciences
SC Sport Sciences
GA LZ5CD
UT WOS:000535155100001
PM 32449141
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Pianta, L
   Vinciguerra, A
   Bertazzoni, G
   Morello, R
   Mangiatordi, F
   Lund, VJ
   Trimarchi, M
AF Pianta, L.
   Vinciguerra, A.
   Bertazzoni, G.
   Morello, R.
   Mangiatordi, F.
   Lund, V. J.
   Trimarchi, M.
TI Acetic acid disinfection as a potential adjunctive therapy for
   non-severe COVID-19
SO EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
LA English
DT Article
DE COVID-19; Acid acetic; Disinfection; Coronavirus
ID INACTIVATION; STABILITY
AB Purpose SARS-CoV-2 is a new pandemic influenza caused by a coronavirus which main route of transmission is through exhaled droplets that primarily infect the nose and the nasopharynx. The aim of this paper is to evaluate the effect of acetic acid, the active component of vinegar, as a potential disinfectant agent for upper airways. Methods Twenty-nine patients were enrolled and divided into two groups: group 1 (14 patients) was composed of patients treated with off-label hydroxychloroquine and lopinavir/ritonavir, whereas group 2 (15 patients) was composed of patients treated with hydroxychloroquine only, combined with the inhalation of acetic acid disinfectant at a 0.34% concentration. A questionnaire-based evaluation of symptoms was performed after 15 days in both groups. Results It appears that the number of patients treated with acetic acid (group 2) that experienced improvement in individual symptoms was double that of the other group of patients (group 1), although numbers are too small for robust statistical analysis. Conclusions Considering its potential benefits and high availability, acetic acid disinfection appears to be a promising adjunctive therapy in cases of non-severe COVID-19 and deserves further investigation.
C1 [Pianta, L.; Bertazzoni, G.; Morello, R.] ASST Cremona, Dept Otorhinolaryngol, Cremona, Italy.
   [Vinciguerra, A.; Trimarchi, M.] IRCCS San Raffaele Sci Inst, San Raffaele Hosp, Div Head & Neck Dept, Otorhinolaryngol Unit, Via Olgettina 68, I-20100 Milan, Italy.
   [Vinciguerra, A.; Trimarchi, M.] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.
   [Mangiatordi, F.] ASST Cremona, Dept Emergency, Cremona, Italy.
   [Lund, V. J.] UCLH, Royal Natl Throat Nose & Ear Hosp, London, England.
RP Trimarchi, M (corresponding author), IRCCS San Raffaele Sci Inst, San Raffaele Hosp, Div Head & Neck Dept, Otorhinolaryngol Unit, Via Olgettina 68, I-20100 Milan, Italy.; Trimarchi, M (corresponding author), Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.
EM trimarchi.matteo@hsr.it
RI Trimarchi, Matteo/I-7401-2012
OI Trimarchi, Matteo/0000-0001-6472-3484
CR Alphin RL, 2009, POULTRY SCI, V88, P1181, DOI 10.3382/ps.2008-00527
   Eliezer M, 2020, JAMA OTOLARYNGOL, V146, P674, DOI 10.1001/jamaoto.2020.0832
   Fraise AP, 2013, J HOSP INFECT, V84, P329, DOI 10.1016/j.jhin.2013.05.001
   Greatorex JS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008987
   Halstead FD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136190
   Han Y, 2020, J MED VIROL, V92, P639, DOI 10.1002/jmv.25749
   Hopkins C, 2020, RHINOLOGY, V58, P295, DOI 10.4193/Rhin20.116
   Rabenau HF, 2005, MED MICROBIOL IMMUN, V194, P1, DOI 10.1007/s00430-004-0219-0
   Societa Italiana di Malattie Infettive e Tropicali (SIMIT), 2020, VAD CUR PERS CONM CO
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 10
TC 0
Z9 0
U1 2
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0937-4477
EI 1434-4726
J9 EUR ARCH OTO-RHINO-L
JI Eur. Arch. Oto-Rhino-Laryn.
PD OCT
PY 2020
VL 277
IS 10
BP 2921
EP 2924
DI 10.1007/s00405-020-06067-8
EA MAY 2020
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA NM3DP
UT WOS:000535168800007
PM 32449022
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Gazendam, A
   Nucci, N
   Ekhtiari, S
   Gohal, C
   Zhu, M
   Payne, A
   Bhandari, M
AF Gazendam, Aaron
   Nucci, Nicholas
   Ekhtiari, Seper
   Gohal, Chetan
   Zhu, Meng
   Payne, Abbey
   Bhandari, Mohit
TI Trials and tribulations: so many potential treatments, so few answers
SO INTERNATIONAL ORTHOPAEDICS
LA English
DT Article
DE COVID-19; Clinical trials; Resource allocation; Google Trends
ID METAANALYSIS
AB Purpose The purpose of this review is to quantify the landscape of current clinical trials ongoing for therapies in the treatment of COVID-19. A secondary purpose is to examine the relationship between public and scientific interests in potential therapies for COVID-19. Methods A systematic search of clinicaltrials.gov was undertaken on April 22, 2020, to identify all currently registered clinical trials investigating potential therapies for patients with COVID-19. Public interest in the various therapies was quantified utilizing Google Trends. Public interest in hydroxychloroquine and chloroquine was plotted against the cumulative number of active clinical trials evaluating antimalarials as potential COVID-19 therapies over time. Results There were 341 interventional studies and 208 different therapies actively registered on clinicaltrials.gov whose primary aim is the treatment of COVID-19. The median sample size was 120 patients (range 4-6000) with 154 (45%) trials reporting a planned sample size of 100 patients or less. There was a strong positive correlation (r = 0.76, p = 0.01) between the number of registered clinical trials and the public interest in the top ten proposed therapies. Following the spike in public interest, the average number of new trials increased tenfold with respect to antimalarial therapies. Conclusions The relatively small sample sizes and the number of independent trials investigating similar therapies are concerning. Resources may not be being allocated based on scientific merit and may be driven by public consciousness and speculation. Moving forward, a concerted effort focused on implementing large, well-coordinated and carefully designed multi-armed clinical trials will help to ensure that the most promising therapeutic options are rigorously studied and clinically meaningful results produced.
C1 [Gazendam, Aaron; Ekhtiari, Seper; Gohal, Chetan; Bhandari, Mohit] McMaster Univ, Ctr Evidence Based Orthopaed, Div Orthopaed Surg, Hamilton, ON, Canada.
   [Nucci, Nicholas] Lakehead Univ, Northern Ontario Sch Med, Thunder Bay, ON, Canada.
   [Zhu, Meng; Payne, Abbey; Bhandari, Mohit] OrthoEvidence, Burlington, ON, Canada.
RP Gazendam, A (corresponding author), McMaster Univ, Ctr Evidence Based Orthopaed, Div Orthopaed Surg, Hamilton, ON, Canada.
EM Aaron.gazendam@gmail.com
CR [Anonymous], 2020, COVID 19 INFODEMICS
   Apuzzo M, 2020, NY TIMES
   Bhandari M, 2013, J ORTHOP TRAUMA, V27, P183, DOI 10.1097/BOT.0b013e3182647e0e
   Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475
   de Winter JCF, 2013, PRACT ASSESSMENT RES
   Dean NE, 2020, NEW ENGL J MED, V382, P1366, DOI 10.1056/NEJMsb1905390
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   IntHout J, 2015, J CLIN EPIDEMIOL, V68, P860, DOI 10.1016/j.jclinepi.2015.03.017
   Ioannidis JPA, 2005, JAMA-J AM MED ASSOC, V294, P218, DOI 10.1001/jama.294.2.218
   Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124
   Ioannidis JPA, 2005, J CLIN EPIDEMIOL, V58, P543, DOI 10.1016/j.jclinepi.2004.10.019
   Ioannidis JPA, 2007, BR MED J
   Ioannidis JPA, 2018, GETTING GOOD RES INT
   John Alex, 2020, SCIENCE
   London AJ, 2019, HASTINGS CENT REP, V49, P31, DOI 10.1002/hast.1034
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Mullard A, 2020, LANCET, V395, P1245, DOI 10.1016/S0140-6736(20)30894-1
   Paul HLee, 2020, CMAJ
   Rerkasem K, 2010, BRIT J SURG, V97, P466, DOI 10.1002/bjs.6988
   Shm YShoham, 2020, INFECT DIS SOC AM
   THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351
   YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421
NR 22
TC 1
Z9 1
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0341-2695
EI 1432-5195
J9 INT ORTHOP
JI Int. Orthop.
PD AUG
PY 2020
VL 44
IS 8
SI SI
BP 1467
EP 1471
DI 10.1007/s00264-020-04625-7
EA MAY 2020
PG 5
WC Orthopedics
SC Orthopedics
GA MP1AX
UT WOS:000534974400002
PM 32447429
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Whitehead, CL
   Walker, SP
AF Whitehead, Clare L.
   Walker, Susan P.
TI Consider pregnancy in COVID-19 therapeutic drug and vaccine trials
SO LANCET
LA English
DT Letter
C1 [Whitehead, Clare L.; Walker, Susan P.] Univ Melbourne, Dept Obstet & Gynaecol, Parkville, Vic 3052, Australia.
   [Whitehead, Clare L.] Royal Womens Hosp, Pregnancy Res Ctr, Parkville, Vic, Australia.
   [Walker, Susan P.] Mercy Hosp Women, Mercy Perinatal, Heidelberg, Vic, Australia.
RP Whitehead, CL (corresponding author), Univ Melbourne, Dept Obstet & Gynaecol, Parkville, Vic 3052, Australia.; Whitehead, CL (corresponding author), Royal Womens Hosp, Pregnancy Res Ctr, Parkville, Vic, Australia.
EM clarew@unimelb.edu.au
CR [Anonymous], 2020, COALITION ADV MATERN
   Cohen J, 2017, SCIENCE, V357, P241, DOI 10.1126/science.357.6348.241
   Di Mascio D, 2020, AM J OBSTET GYNECOL
   Hinton DM, 2020, REQUEST EMERGENCY US
   Mullard A, 2020, LANCET, V395, P1245, DOI 10.1016/S0140-6736(20)30894-1
NR 5
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD MAY 23
PY 2020
VL 395
IS 10237
BP E92
EP E92
DI 10.1016/S0140-6736(20)31029-1
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA LZ1JO
UT WOS:000540986100002
PM 32410758
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhang, SP
   Lv, ZZ
   Zhu, QG
   Sun, WQ
   Yao, F
   Fang, L
   Cheng, YB
   Wu, ZW
   Fang, M
AF Zhang, Shuaipan
   Lv, Zhizhen
   Zhu, Qingguang
   Sun, Wuquan
   Yao, Fei
   Fang, Lei
   Cheng, Yanbin
   Wu, Zhiwei
   Fang, Min
TI Efficacy of Liu-zi-jue in Patients with 2019 Novel Coronavirus Pneumonia
   (COVID-19): structured summary of a study protocol for a randomized
   controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; Randomized controlled trial; protocol; Liu-zi-jue;
   Conventional therapy
AB Objectives Efficacy of conventional treatment plus the complementary therapy Liu-zi-jue (a mind-body exercise) to treat patients with mild COVID-19. Trial design The study is a single-center 2 arm, randomized controlled trial with parallel-group design.
C1 [Zhang, Shuaipan; Lv, Zhizhen; Sun, Wuquan; Wu, Zhiwei; Fang, Min] Shanghai Univ Tradit Chinese Med, Yue Yang Hosp Integrated Tradit Chinese & Western, Tuina Dept, Shanghai 200437, Peoples R China.
   [Zhang, Shuaipan; Lv, Zhizhen; Zhu, Qingguang; Cheng, Yanbin; Wu, Zhiwei; Fang, Min] Shanghai Inst Tradit Chinese Med, Inst Tuina, Shanghai 200437, Peoples R China.
   [Yao, Fei; Fang, Lei; Fang, Min] Shanghai Univ Tradit Chinese Med, Shanghai 201203, Peoples R China.
RP Fang, M (corresponding author), Shanghai Univ Tradit Chinese Med, Yue Yang Hosp Integrated Tradit Chinese & Western, Tuina Dept, Shanghai 200437, Peoples R China.; Fang, M (corresponding author), Shanghai Inst Tradit Chinese Med, Inst Tuina, Shanghai 200437, Peoples R China.; Fang, M (corresponding author), Shanghai Univ Tradit Chinese Med, Shanghai 201203, Peoples R China.
EM fangmin19650510@163.com
FU project of Emergency scientific research project for prevention and
   control of new coronavirus (COVID-19) by Shanghai University of
   Traditional Chinese Medicine (first batch); Shanghai's three-year action
   project on further accelerating the development of Traditional Chinese
   Medicine [ZY (2018-2020)-CCCX-2004-02]
FX This study is supported financially by the project of Emergency
   scientific research project for prevention and control of new
   coronavirus (COVID-19) by Shanghai University of Traditional Chinese
   Medicine (first batch) (No fund number) and Shanghai's three-year action
   project on further accelerating the development of Traditional Chinese
   Medicine (ZY (2018-2020)-CCCX-2004-02). The funding is widely used and
   applicable to this study. The funder had no role in the design of the
   study, analysis, collection, and interpretation of the data, or the
   writing and decision for publication of the manuscript.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD MAY 23
PY 2020
VL 21
IS 1
AR 416
DI 10.1186/s13063-020-04383-2
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LT1HS
UT WOS:000536826300002
PM 32446311
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lango, MN
AF Lango, Miriam N.
TI How did we get here? A short history of COVID-19 and other
   coronavirus-related epidemics
SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND
   NECK
LA English
DT Article
DE coronavirus; COVID-19; otolaryngology; head and neck surgery; review
ID SARS; PNEUMONIA; ESCAPE; INFECTION; INSIGHTS
AB The COVID-19 epidemic was not the first coronavirus epidemic of this century and represents one of the increasing number of zoonoses from wildlife to impact global health. SARS CoV-2, the virus causing the COVID-19 epidemic is distinct from, but closely resembles SARS CoV-1, which was responsible for the severe acute respiratory syndrome (SARS) outbreak in 2002. SARS CoV-1 and 2 share almost 80% of genetic sequences and use the same host cell receptor to initiate viral infection. However, SARS predominantly affected individuals in close contact with infected animals and health care workers. In contrast, CoV-2 exhibits robust person to person spread, most likely by means of asymptomatic carriers, which has resulted in greater spread of disease, overall morbidity and mortality, despite its lesser virulence. We review recent coronavirus-related epidemics and distinguish clinical and molecular features of CoV-2, the causative agent for COVID-19, and review the current status of vaccine trials.
C1 [Lango, Miriam N.] MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA.
RP Lango, MN (corresponding author), MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM MNLango@mdanderson.org
RI Lango, Miriam/ABI-2650-2020
CR Alexander AJ, 2003, J OTOLARYNGOL, V32, P281, DOI 10.2310/7070.2003.11398
   Allen T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00923-8
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Chan JFW, 2012, J INFECTION, V65, P477, DOI 10.1016/j.jinf.2012.10.002
   Cheng MP, 2020, ANN INTERN MED, V172, P726, DOI 10.7326/M20-1301
   Coughlin MM, 2012, REV MED VIROL, V22, P2, DOI 10.1002/rmv.706
   Coughlin MM, 2009, VIROLOGY, V394, P39, DOI 10.1016/j.virol.2009.07.028
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Hao P, 2020, EMERG MICROBES INFEC, V9, P545, DOI 10.1080/22221751.2020.1738279
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536
   Li JY, 2020, MICROBES INFECT, V22, P80, DOI 10.1016/j.micinf.2020.02.002
   Lin JT, 2007, ANTIVIR THER, V12, P1107
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Mitsuki YY, 2008, MICROBES INFECT, V10, P908, DOI 10.1016/j.micinf.2008.05.009
   Parrish CR, 2008, MICROBIOL MOL BIOL R, V72, P457, DOI 10.1128/MMBR.00004-08
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Petherick A, 2020, LANCET, V395, P1101, DOI 10.1016/S0140-6736(20)30788-1
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rockx B, 2010, J INFECT DIS, V201, P946, DOI 10.1086/651022
   Stefanelli P, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.13.2000305
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tirado SMC, 2003, VIRAL IMMUNOL, V16, P69, DOI 10.1089/088282403763635465
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Yang S, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.66
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zimmer C., 2020, NY TIMES
NR 31
TC 2
Z9 2
U1 1
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1043-3074
EI 1097-0347
J9 HEAD NECK-J SCI SPEC
JI Head Neck-J. Sci. Spec. Head Neck
PD JUL
PY 2020
VL 42
IS 7
SI SI
BP 1535
EP 1538
DI 10.1002/hed.26275
EA MAY 2020
PG 4
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA MF8CB
UT WOS:000534746900001
PM 32445249
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Lu, X
   Xu, SX
AF Lu, Xiao
   Xu, Shanxiang
TI Therapeutic effect of high-flow nasal cannula on severe COVID-19
   patients in a makeshift intensive-care unit A case report
SO MEDICINE
LA English
DT Article
DE COVID-19; HFNC; makeshift intensive-care unit
ID ACUTE RESPIRATORY-FAILURE; OXYGEN-THERAPY
AB Introduction: Several intensive-care units (ICUs) in Wuhan are nonstandard wards that were repurposed from general wards. Considering the shortage of medical resources and the need to prevent nosocomic infection, the respiratory-treatment strategy in these nonstandard ICUs is different from those in general wards and standard ICUs. High-flow nasal cannula (HFNC) plays an important role in nonstandard ICUs and is beneficial to the patients therein. Patient concerns: In this study, we analyzed four cases of HFNC-treated patients with severe coronavirus disease 2019 (COVID-19) in a makeshift ICU and summarized our experience. Diagnoses: Four patients diagnosed with COVID-19 according to World Health Organization (WHO) interim guidance were admitted to the makeshift ICU. Interventions: All patients had oxygen treatment with HFNC, as well as regular treatment of antivirals and traditional Chinese medicine. Outcomes: Two patients survived after treatment, while the other two died from acute respiratory distress syndrome (ARDS) and heart failure, respectively. Conclusion: Patients with severe and critical COVID-19 often have poor prognoses after mechanical ventilation, exhibiting corresponding complications such as ventilator-associated pneumonia and deep-vein thrombosis, which significantly prolongs length of stay in the ICU. HFNC could prevent intubation in some patients, thereby avoiding the above complications; however, this needs confirmation in further clinical studies. This treatment reduced difficulty and workloads for healthcare professionals, had good tolerability for patients, might not significantly increase the risk of infection for healthcare professionals, and do not require additional preventive measures against nosocomic infection. HFNC treatment has its advantages in providing oxygen therapy in COVID-19, but healthcare professionals should still pay close attention to changes in patients' oxygenation rates and respiratory frequency.
C1 [Lu, Xiao; Xu, Shanxiang] Zhejiang Univ, Sch Med, Dept Emergency Med, Affiliated Hosp 2, 88 Jiefang Rd, Hangzhou 31009, Peoples R China.
RP Lu, X (corresponding author), Zhejiang Univ, Sch Med, Dept Emergency Med, Affiliated Hosp 2, 88 Jiefang Rd, Hangzhou 31009, Peoples R China.
EM jill44840@zju.edu.cn
CR Carteaux G, 2016, CRIT CARE MED, V44, P282, DOI 10.1097/CCM.0000000000001379
   Delorme M, 2017, CRIT CARE MED, V45, P1981, DOI 10.1097/CCM.0000000000002693
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Gaunt KA, 2015, RESP CARE, V60, P1383, DOI 10.4187/respcare.04016
   Huang HW, 2018, J INTENSIVE CARE MED, V33, P609, DOI 10.1177/0885066617705118
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Kernick J, 2010, AUST CRIT CARE, V23, P53, DOI 10.1016/j.aucc.2010.01.001
   Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007
   Lin L, 2020, ZHONGHUA YI XUE ZA Z, V7, P100
   Monro-Somerville T, 2017, CRIT CARE MED, V45, pE449, DOI 10.1097/CCM.0000000000002091
   Roca O, 2010, RESP CARE, V55, P408
   Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016
   Sztrymf B, 2011, INTENS CARE MED, V37, P1780, DOI 10.1007/s00134-011-2354-6
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 14
TC 2
Z9 2
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAY 22
PY 2020
VL 99
IS 21
AR e20393
DI 10.1097/MD.0000000000020393
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA MO4OT
UT WOS:000551508200095
PM 32481340
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Manto, M
   Dupre, N
   Hadjivassiliou, M
   Louis, ED
   Mitoma, H
   Molinari, M
   Shaikh, AG
   Soong, BW
   Strupp, M
   Van Overwalle, F
   Schmahmann, JD
AF Manto, Mario
   Dupre, Nicolas
   Hadjivassiliou, Marios
   Louis, Elan D.
   Mitoma, Hiroshi
   Molinari, Marco
   Shaikh, Aasef G.
   Soong, Bing-Wen
   Strupp, Michael
   Van Overwalle, Frank
   Schmahmann, Jeremy D.
TI Medical and Paramedical Care of Patients With Cerebellar Ataxia During
   the COVID-19 Outbreak: Seven Practical Recommendations of the COVID 19
   Cerebellum Task Force
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; cerebellum; therapies; ataxia
ID RESPIRATORY SYNDROME CORONAVIRUS
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), the cause of the current pandemic coronavirus disease 2019 (COVID-19), primarily targets the respiratory system. Some patients also experience neurological signs and symptoms ranging from anosmia, ageusia, headache, nausea, and vomiting to confusion, encephalitis, and stroke. Approximately 36% of those with severe COVID-19 experience neurological complications. The virus may enter the central nervous system through the olfactory nerve in the nasal cavity and damage neurons in the brainstem nuclei involved in the regulation of respiration. Patients with cerebellar ataxia (CA) are particularly vulnerable to severe outcome if they contract COVID-19 because of the complexity of their disease, the presence of comorbidities, and their use of immunosuppressive therapies. Most CA patients burdened by progressive neurologic deficits have substantially impaired mobility and other essential functions, for which they rely heavily on ambulatory services, including rehabilitation and psychosocial care. Cessation of these interventions because of isolation restrictions places the CA patient population at risk of further deterioration. This international panel of ataxia experts provides recommendations for neurologists caring for patients with CA, emphasizing a pro-active approach designed to maintain their autonomy and well-being: continue long-term medications, promote rehabilitation efforts, utilize the technology of virtual visits for regular contact with healthcare providers, and pay attention to emotional and psychosocial health. Neurologists should play an active role in decision-making in those CA cases requiring escalation to intensive care and resuscitation. Multi-disciplinary collaboration between care teams is always important, and never more so than in the context of the current pandemic.
C1 [Manto, Mario] Univ Mons, CHU Charleroi, Mons, Belgium.
   [Manto, Mario] Univ Mons, Serv Neurosci, Mons, Belgium.
   [Dupre, Nicolas] Univ Laval, Fac Med, Dept Med, Quebec City, PQ, Canada.
   [Dupre, Nicolas] CHU Quebec Univ Laval, Neurosci Axis, Quebec City, PQ, Canada.
   [Hadjivassiliou, Marios] Sheffield Teaching Hosp NHS Trust, Acad Dept Neurosci, Sheffield, S Yorkshire, England.
   [Louis, Elan D.] Univ Texas Southwestern, Dept Neurol & Neurotherapeut, Dallas, TX USA.
   [Mitoma, Hiroshi] Tokyo Med Univ, Dept Med Educ, Tokyo, Japan.
   [Molinari, Marco] IRCCS Fdn S Lucia, Rome, Italy.
   [Shaikh, Aasef G.] Case Western Reserve Univ, Univ Hosp Cleveland Med Ctr, Cleveland VA Med Ctr, Dept Neurol, Cleveland, OH 44106 USA.
   [Soong, Bing-Wen] Taipei Med Univ, Taipei Neurosci Inst, Taipei, Taiwan.
   [Soong, Bing-Wen] Taipei Med Univ, Dept Neurol, Shuang Ho Hosp, New Taipei, Taiwan.
   [Soong, Bing-Wen] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Dept Neurol, Taipei, Taiwan.
   [Soong, Bing-Wen] Natl Yang Ming Univ, Brain Res Ctr, Taipei, Taiwan.
   [Strupp, Michael] Ludwig Maximilians Univ Munchen, Dept Neurol, Munich, Germany.
   [Van Overwalle, Frank] Vrije Univ Brussel, Fac Psychol, Brain Body & Cognit Lab, Brussels, Belgium.
   [Schmahmann, Jeremy D.] Massachusetts Gen Hosp, Dept Neurol, Lab Neuroanat & Cerebellar Neurobiol, Ataxia Ctr,Cognit Behav Neurol Unit, Boston, MA 02114 USA.
   [Schmahmann, Jeremy D.] Harvard Med Sch, Boston, MA 02115 USA.
RP Manto, M (corresponding author), Univ Mons, CHU Charleroi, Mons, Belgium.; Manto, M (corresponding author), Univ Mons, Serv Neurosci, Mons, Belgium.
EM mmanto@ulb.ac.be
CR Ahmadian N, 2019, CEREBELLUM, V18, P941, DOI 10.1007/s12311-019-01060-2
   Bolton Corey, 2019, Cerebellum Ataxias, V6, P13, DOI 10.1186/s40673-019-0107-4
   Bouadma L, 2020, INTENS CARE MED, V46, P579, DOI 10.1007/s00134-020-05967-x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Qiu HB, 2020, INTENS CARE MED, V46, P576, DOI 10.1007/s00134-020-05966-y
   Ronnefarth M, 2020, CEREBELLUM, V19, P437, DOI 10.1007/s12311-020-01122-w
   Schmahmann JD, 2007, CEREBELLUM, V6, P254, DOI 10.1080/14734220701490995
   Van Overwalle F, 2019, MED HYPOTHESES, V128, P33, DOI 10.1016/j.mehy.2019.05.014
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Xu J, 2005, CLIN INFECT DIS, V41, P1089, DOI 10.1086/444461
   Zhang WR, 2020, PSYCHOTHER PSYCHOSOM, V89, P242, DOI 10.1159/000507639
NR 13
TC 0
Z9 0
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD MAY 22
PY 2020
VL 11
AR 516
DI 10.3389/fneur.2020.00516
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA MA8YL
UT WOS:000542196800001
PM 32574247
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mahanta, S
   Chowdhury, P
   Gogoi, N
   Goswami, N
   Borah, D
   Kumar, R
   Chetia, D
   Borah, P
   Buragohain, AK
   Gogoi, B
AF Mahanta, Saurov
   Chowdhury, Purvita
   Gogoi, Neelutpal
   Goswami, Nabajyoti
   Borah, Debajit
   Kumar, Rupesh
   Chetia, Dipak
   Borah, Probodh
   Buragohain, Alak K.
   Gogoi, Bhaskarjyoti
TI Potential anti-viral activity of approved repurposed drug against main
   protease of SARS-CoV-2: anin silicobased approach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Letter; Early Access
DE SARS-CoV-2; COVID-19; M-pro; viomycin; docking; molecular dynamics; FDA
   approved drugs
ID SARS
AB The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which was first reported in Wuhan province of China, has become a deadly pandemic causing alarmingly high morbidity and mortality. In the absence of new targeted drugs and vaccines against SARS-CoV-2 at present, the choices for effective treatments are limited. Therefore, considering the exigency of the situation, we focused on identifying the available approved drugs as potential inhibitor against the promising Coronavirus drug target, the Main Protease, using computer-aided methods. We created a library of U. S. Food and Drug Administration approved anti-microbial drugs and virtually screened it against the available crystal structures of Main Protease of the virus. The study revealed that Viomycin showed the highest -CDocker energy after docking at the active site of SARS-CoV-2 Main Protease. It is noteworthy that Viomycin showed higher -CDocker energy as compared to the drugs currently under clinical trial for SARS-CoV-2 treatmentviz.Ritonavir and Lopinavir. Additionally, Viomycin formed higher number of H-bonds with SARS-CoV-2 Main Protease than its co-crystallised inhibitor compound N3. Molecular dynamics simulation further showed that Viomycin embedded deeply inside the binding pocket and formed robust binding with SARS-CoV-2 Main Protease. Therefore, we propose that Viomycin may act as a potential inhibitor of the Main Protease of SARS-CoV-2. Further optimisations with the drug may support the much-needed rapid response to mitigate the pandemic. Communicated by Ramaswamy H. Sarma
C1 [Mahanta, Saurov] Natl Inst Elect & Informat Technol NIELIT, Gauhati, Assam, India.
   [Chowdhury, Purvita] Model Rural Hlth Res Unit MRHRU, Agartala, India.
   [Gogoi, Neelutpal] Dibrugarh Univ, Dept Pharmaceut Sci, Dibrugarh, Assam, India.
   [Goswami, Nabajyoti; Borah, Probodh] Assam Agr Univ, Coll Vet Sci, Bioinformat Infrastruct Facil, Gauhati, India.
   [Borah, Debajit; Kumar, Rupesh; Buragohain, Alak K.; Gogoi, Bhaskarjyoti] Royal Global Univ, Dept Biotechnol, Gauhati, India.
RP Gogoi, B (corresponding author), Royal Global Univ, Dept Biotechnol, Gauhati, India.
EM gogoi.bhaskar2608@gmail.com
RI Gogoi, Neelutpal/AAA-2624-2020
OI Gogoi, Neelutpal/0000-0001-5419-3942; Mahanta,
   Saurov/0000-0002-5118-9945; Goswami, Nabajyoti/0000-0002-6300-5410;
   CHOWDHURY, PURVITA/0000-0002-8484-853X
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abdel-Hamid MK, 2014, MOLECULES, V19, P6609, DOI 10.3390/molecules19056609
   ABDELLI I, 2020, J BIOMOL STRUCT 0513, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1763199
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   ANDERSEN KG, 2020, NAT MED 0317, DOI DOI HTTPS://DOI.ORG/10.1038/S41591-020-0820-9
   [Anonymous], 2020, WHO REPORT
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   Durrant JD, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-71
   ELFIKY AA, 2020, J BIOMOL STRUCT 0424, DOI DOI https://doi.org/10.1080/07391102.2020.1758789
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gogoi Neelutpal, 2019, Curr Comput Aided Drug Des, DOI 10.2174/1573409916666191226103000
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Holm M, 2016, P NATL ACAD SCI USA, V113, P978, DOI 10.1073/pnas.1517541113
   Hsu MF, 2005, J BIOL CHEM, V280, P31257, DOI 10.1074/jbc.M502577200
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kupferschmidt K., 2020, SCIENCE
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   NAIR PC, 2014, IN SILICO PHARMACOL, V2, DOI DOI https://doi.org/10.1186/s40203-014-0004-8
   NASUTION MAF, 2018, BMC BIOINFORMATI S14, V19, DOI DOI https://doi.org/10.1186/s12859-018-2387-8
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   WAHEDI HM, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762743
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wang Q., 2020, QUANT SCI STUD, V1, P239, DOI 10.1162/qss_a_00011
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 47
TC 13
Z9 14
U1 9
U2 13
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1768902
EA MAY 2020
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LX8WU
UT WOS:000540107200001
PM 32406317
DA 2021-01-01
ER

PT J
AU Li, QH
   Zhu, F
   Xiao, Y
   Liu, T
   Liu, XX
   Wu, G
   Zhang, LL
AF Li, Qiuhui
   Zhu, Fang
   Xiao, Yin
   Liu, Tao
   Liu, Xinxiu
   Wu, Gang
   Zhang, Liling
TI A Primary Mediastinal Large B-Cell Lymphoma Patient With COVID-19
   Infection After Intensive Immunochemotherapy: A Case Report
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE COVID-19; lymphoma; myelosuppression; chemotherapy; immunotherapy
ID RITUXIMAB; VACCINATION; INFLUENZA; THERAPY; CANCER; RISK
AB Background: The outbreak of coronavirus disease 2019 (COVID-19) had become a global public health event. Lymphoma patients need to be distinguished from the general population because of their deficient immune status and intensive anti-tumor treatment. The impacts of cancer subtypes and treatment on COVID-19 infection are unclear.
   Case Presentation: We here report the case of a primary mediastinal large B-cell lymphoma patient who was infected with COVID-19 after intensive immunochemotherapy (DA-EPOCH-R). The patient developed a neutropenic fever during chemotherapy, and fever was persistent, although antibiotics were used. Initial chest CT was negative, and the patient received a throat swab test since the second CT showed evidence of pneumonia. With treatment with Arbidol Hydrochloride and LianHuaQingWen capsule, his COVID-19 was cured.
   Conclusions: To the best of our knowledge, this is the first report focusing on COVID-19 infection in a lymphoma patient undergoing intensive immunochemotherapy. For those patients being treated with immunochemotherapy in epidemic areas, a reduced dose intensity of intensive chemotherapy should be considered, and the effect of immunotherapies such as rituximab on COVID-19 infection should be considered. The impacts of anti-cancer treatment on COVID-19 infection need to be explored further.
C1 [Li, Qiuhui; Zhu, Fang; Xiao, Yin; Liu, Tao; Liu, Xinxiu; Wu, Gang; Zhang, Liling] Huazhong Univ Sci & Technol, Ctr Canc, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China.
RP Zhang, LL (corresponding author), Huazhong Univ Sci & Technol, Ctr Canc, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China.
EM lily-1228@hotmail.com
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Berglund A, 2014, ACTA ONCOL, V53, P1212, DOI 10.3109/0284186X.2014.914243
   Dunleavy K, 2013, NEW ENGL J MED, V368, P1408, DOI 10.1056/NEJMoa1214561
   Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534
   Giulino-Roth L, 2018, BLOOD, V132, P782, DOI 10.1182/blood-2018-04-791566
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lyman GH, 2010, CANCER-AM CANCER SOC, V116, P5555, DOI 10.1002/cncr.25332
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Yri OE, 2011, BLOOD, V118, P6769, DOI 10.1182/blood-2011-08-372649
NR 14
TC 1
Z9 1
U1 1
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD MAY 22
PY 2020
VL 10
AR 924
DI 10.3389/fonc.2020.00924
PG 5
WC Oncology
SC Oncology
GA LX3CN
UT WOS:000539713200001
PM 32574278
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Khan, S
   Siddique, R
   Li, Z
   Xue, MZ
   Liu, JB
   Nabi, G
AF Khan, Suliman
   Siddique, Rabeea
   Li, Zhe
   Xue, Mengzhou
   Liu, Jianbo
   Nabi, Ghulam
TI COVID-19 pandemic; prevention, treatment, and mental health
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE Novel Coronavirus; vaccine; quarantine; treatment; mental health
C1 [Khan, Suliman; Siddique, Rabeea; Li, Zhe; Xue, Mengzhou] Zhengzhou Univ, Affiliated Hosp 2, Dept Cerebrovasc Dis, Zhengzhou, Peoples R China.
   [Khan, Suliman; Siddique, Rabeea; Liu, Jianbo] Zhengzhou Univ, Affiliated Hosp 2, Dept Resp Dis, Zhengzhou, Peoples R China.
   [Nabi, Ghulam] Hebei Normal Univ, Coll Life Sci, Key Lab Anim Physiol Biochem & Mol Biol Hebei Pro, Shijiazhuang, Hebei, Peoples R China.
RP Xue, MZ (corresponding author), Zhengzhou Univ, Affiliated Hosp 2, Dept Cerebrovasc Dis, Zhengzhou, Peoples R China.; Liu, JB (corresponding author), Zhengzhou Univ, Affiliated Hosp 2, Dept Resp Dis, Zhengzhou, Peoples R China.; Nabi, G (corresponding author), Hebei Normal Univ, Coll Life Sci, Key Lab Anim Physiol Biochem & Mol Biol Hebei Pro, Shijiazhuang, Hebei, Peoples R China.
EM xuemengzhou@zzu.edu.cn; jbliuzz@zzu.edu.cn; ghulamnabiqau@gmail.com
OI Khan, Suliman/0000-0003-4954-0748
FU Second Affiliated Hospital of Zhengzhou University; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81870942, 81471174, 81520108011]; National Key Research and
   Development Program of China [2018YFC1312200]; Innovation Scientists and
   Technicians Troop Constructions Projects of Henan Province of China
FX The authors acknowledge the Postdoctoral grant from The Second
   Affiliated Hospital of Zhengzhou University (for SK), and operating
   grant support from the National Natural Science Foundation of China
   (grants no: 81870942, 81471174 and 81520108011), National Key Research
   and Development Program of China (grant no: 2018YFC1312200), and
   Innovation Scientists and Technicians Troop Constructions Projects of
   Henan Province of China (for MX).
CR Chen H, 2020, LANCET, V6736, P1, DOI DOI 10.1016/S0140-67362030360-3
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Khan S, 2020, J CLIN MICROBIOL, V58, DOI [10.1128/JCM.01297-20, 10.1128/JCM.00187-20]
   Khan S, 2018, INT J BIOL SCI, V14, P791, DOI 10.7150/ijbs.23744
   Liem A, 2020, LANCET PSYCHIAT, V0366, P30076
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   W.H.O, 2020, COR SIT REP
   Walker WH, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-0694-0
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wiley JA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007142
   Wohlford-Lenane CL, 2009, J VIROL, V83, P11385, DOI 10.1128/JVI.01363-09
   Yang Y, 2020, LANCET PSYCHIAT, V0366, P30079
   Zitting KM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29358-x
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 16
TC 2
Z9 2
U1 3
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD SEP 1
PY 2020
VL 16
IS 9
BP 2215
EP 2216
DI 10.1080/21645515.2020.1759976
EA MAY 2020
PG 2
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA NU9MN
UT WOS:000538396900001
PM 32437231
OA Bronze
DA 2021-01-01
ER

PT J
AU Kleinwechter, H
AF Kleinwechter, Helmut
TI Diabetes and pregnancy-update 2020
SO DIABETOLOGE
LA German
DT Article
DE Glucose; Diagnostic techniques; endocrine; Body weight; Bariatric
   surgery; Stillbirth
AB In this short review, the current findings on coronoavirus disease 2019 (COVID-19) in pregnant women are presented. Self-monitoring of capillary blood glucose levels is currently the gold standard in pregnant women. When using subcutaneous glucose sensors, the time in range (TIR) of 63-140 & x202f;mg/dl (3.5-7.8 & x202f;mmol/l) >70% should be reached as early as possible. In pregnant women with pre-existing diabetes, there is a high risk for stillbirth in a fetus with growth restriction. In the absence of evidence for improvement of relevant endpoints, pharmacological therapies in pregnant women with early gestational diabetes at <24 & x202f;+ 0 weeks of gestation should be considered critically. Women who are obese prior to conception should not gain more than 6 & x202f;kg during pregnancy. In women who have undergone bariatric-metabolic surgery, there are advantages for the mothers and increased risks for newborns, e.g., an increased rate of newborns small for gestational age after Roux-en-Y gastric bypass.
C1 [Kleinwechter, Helmut] Diabet Schwerpunktpraxis & Schulungszentrum, Diabetol Kiel, Alter Markt 11, D-24103 Kiel, Germany.
RP Kleinwechter, H (corresponding author), Diabet Schwerpunktpraxis & Schulungszentrum, Diabetol Kiel, Alter Markt 11, D-24103 Kiel, Germany.
EM hkleinwechter@gmail.com
CR Akhter Z, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002866
   Battelino T, 2019, DIABETES CARE, V42, P1593, DOI 10.2337/dci19-0028
   Cosson E, 2019, DIABETES METAB, V45, P465, DOI 10.1016/j.diabet.2018.11.006
   Harper LM, 2020, AM J OBSTET GYNECOL, V222, DOI 10.1016/j.ajog.2019.12.021
   Jones LV, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009613.pub4
   Kleinwechter H, 2020, DIABETOLOGE, V16, P242, DOI 10.1007/s11428-020-00611-0
   Kristensen K, 2019, DIABETOLOGIA, V62, P1143, DOI 10.1007/s00125-019-4850-0
   Lane AS, 2019, AM J PERINAT, V36, P891, DOI 10.1055/s-0039-1678733
   Law G, 2019, DIABETES CARE, DOI [10.2337/dc182212, DOI 10.2337/DC182212]
   Mackin ST, 2019, DIABETOLOGIA, V62, P1938, DOI 10.1007/s00125-019-4943-9
   Moser O, 2019, DIABETES OBES METAB, V21, P2505, DOI 10.1111/dom.13835
   Murphy HR, 2019, DIABETOLOGIA, V62, P1123, DOI 10.1007/s00125-019-4904-3
   Neoh S, 2019, DIABETES CARE, DOI [10.2337/dc19-1908/-/DC1, DOI 10.2337/DC19-1908/-/DC1]
   Neoh SL, 2020, DIABETIC MED, V37, P1841, DOI 10.1111/dme.13937
   Neovius M, 2019, JAMA-J AM MED ASSOC, V322, P1515, DOI 10.1001/jama.2019.12925
   Osmundson SS, 2016, AM J PERINAT, V33, P172, DOI 10.1055/s-0035-1563715
   Roeder Hilary A, 2019, Am J Obstet Gynecol MFM, V1, P33, DOI 10.1016/j.ajogmf.2019.03.003
   Rogozinska E, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2472-7
   Timmermans YEG, 2020, OBES REV, V21, DOI 10.1111/obr.12974
   Vinter CA, 2018, DIABETES CARE, V41, P2079, DOI 10.2337/dc18-0808
   Voerman E, 2019, JAMA-J AM MED ASSOC, V321, P1702, DOI 10.1001/jama.2019.3820
   Yamamoto JM, 2019, DIABETIC MED, V36, P1046, DOI 10.1111/dme.13988
NR 22
TC 0
Z9 0
U1 1
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1860-9716
EI 1860-9724
J9 DIABETOLOGE
JI Diabetologe
PD JUL
PY 2020
VL 16
IS 5
SI SI
BP 470
EP 477
DI 10.1007/s11428-020-00629-4
EA MAY 2020
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA ML6TO
UT WOS:000534841400001
OA Bronze
DA 2021-01-01
ER

PT J
AU Goodman-Casanov, JM
   Dura-Perez, E
   Guzman-Parra, J
   Cuesta-Vargas, A
   Mayoral-Cleries, F
AF Marian Goodman-Casanov, Jessica
   Dura-Perez, Elena
   Guzman-Parra, Jose
   Cuesta-Vargas, Antonio
   Mayoral-Cleries, Fermin
TI Telehealth Home Support During COVID-19 Confinement for
   Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild
   Dementia: Survey Study
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE telehealth; confinement; coronavirus; COVID-19; well-being; emergency
   response; public health; mental health; physical health; elderly; older
   adults; cognitive impairment; dementia
ID PEOPLE
AB Background: The public health emergency of coronavirus disease (COVID-19) is rapidly evolving worldwide; some countries, including Spain, have implemented restrictive measures. Populations that are vulnerable to this outbreak and its physical and mental health effects include community-dwelling older adults with mild cognitive impairment or mild dementia. Telehealth is a potential tool to deliver health care and decrease exposure risk.
   Objective: The aims of this study were to explore the impact of confinement on the health and well-being of community-dwelling older adults with mild cognitive impairment or mild dementia, to provide television-based and telephone-based health and social support, and to study the effects of a television-based assistive integrated technology, TV-AssistDem (TeleVision-based AS Sistive Integrated Service to supporT European adults living with mild DEMentia or mild cognitive impairment).
   Methods: A telephone-based survey was administered in Spain to 93 participants in the TV-AssistDem clinical trial from March 25 to April 6, 2020.
   Results: Of the respondents, 60/93 (65%) were women. The mean age was 73.34 (SD 6.07), and 69/93 (74%) lived accompanied. Lockdown measures forced 17/93 respondents (18%) to change their living arrangements. Health status was found to be optimal in 89/93 respondents (96%), with no COVID-19 symptoms. Grocery and pharmacy outings were performed by family members of 68/93 participants (73%); 57 (61%) reported overall well-being, and 65 (70%) maintained their sleep quality. However, participants living alone reported greater negative feelings and more sleeping problems. Regarding leisure activities, 53/93 respondents (57%) took walks, 32 (35%) played memory games, 55 (60%) watched television, and 91(98%) telephoned relatives. 58/93 (64%) respondents reported accessing moderate or too much COVID-19 information, 89 (97%) received it from television, and 56 (62%) stated that their understanding of the information was extreme. 39/93 (39%) respondents had contacted health and social services, while 29 (31%) requested information regarding these services during the telephone call. There were no significant differences in health and well-being between the intervention and control groups. Respondents with TV-AssistDem performed more memory exercises (24/93, 52% vs 8/93, 17.4%; P<.001) than control respondents.
   Conclusions: Our findings suggest that during COVID-19 confinement, the physical and mental health and well-being was optimal for the majority of our vulnerable population. However, those living alone reported greater negative psychological effects and sleeping problems. Measures adopted to address the negative experiences of confinement included keeping informed about the situation, accessing health and social services, having a support network that prevents risk of exposure to COVID-19 and guarantees food and medical supplies, a daily routine with maintained sleeping habits and leisure activities, staying physically and mentally active with cognitive stimulation exercises, and ensuring social connectedness using technology. Television sets were preferred technological devices to access COVID-19 information, watch television as a recreational activity, and perform memory exercises as an intellectual activity. Television-based telehealth support using TV-AssistDem demonstrated potential for cognitive stimulation.
C1 [Marian Goodman-Casanov, Jessica; Dura-Perez, Elena; Guzman-Parra, Jose; Mayoral-Cleries, Fermin] Reg Univ Hosp Malaga, Biomed Res Inst Malaga IBIMA, Dept Mental Hlth, Plaza Hosp Civil S-N, Malaga 29009, Spain.
   [Cuesta-Vargas, Antonio] Univ Malaga, Biomed Res Inst Malaga IBIMA, Dept Physiotherapy, Malaga, Spain.
RP Goodman-Casanov, JM (corresponding author), Reg Univ Hosp Malaga, Biomed Res Inst Malaga IBIMA, Dept Mental Hlth, Plaza Hosp Civil S-N, Malaga 29009, Spain.
EM jmariangoodman@gmail.com
RI Guzman-Parra, Jose/X-4172-2019
OI Guzman-Parra, Jose/0000-0002-1463-6435; Goodman-Casanova, Jessica
   Marian/0000-0002-8598-594X; Mayoral-Cleries, Fermin/0000-0002-9710-9672;
   Cuesta-Vargas, Antonio I/0000-0002-8880-4315; Dura-Perez,
   Elena/0000-0003-4155-5929
FU European Active and Assisted Living Programme: TV-AssistDem
   [AAL-2016-024]; Instituto Carlos IIIInstituto de Salud Carlos III
   [AC16/00080]
FX The authors acknowledge the TV-AssistDem consortium, SmartHealth TV
   Solution, for the project technology and COVID-19 adaptation and
   Stimulus for providing the cognitive stimulation software. This project
   is nested in the TV-AssistDem project, which was selected for funding
   under the 2016 Call for Proposals focused on "Living well with dementia:
   The contribution of information and communications technology to
   integrated solutions for enabling the well-being of people living with
   dementia and their communities" by the European Active and Assisted
   Living Programme: TV-AssistDem (AAL-2016-024). This study was
   additionally funded by Instituto Carlos III through project AC16/00080.
CR Braak H, 2012, ALZHEIMERS DEMENT, V8, P227, DOI 10.1016/j.jalz.2012.01.011
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Calton B, 2020, J PAIN SYMPTOM MANAG, P1
   Chan SSC, 2007, INT J NURS STUD, V44, P1120, DOI 10.1016/j.ijnurstu.2006.04.019
   Comas-Herrera A, 2020, LTC RESPONSES COVID
   Cotterell N, 2018, MATURITAS, V113, P80, DOI 10.1016/j.maturitas.2018.04.014
   Etnier JL, 2019, PSYCHOL SPORT EXERC, V42, P156, DOI 10.1016/j.psychsport.2018.12.006
   European Commission, 2016, CALL PROP AAL 2016 A
   Fancourt D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39354-4
   Gordon M., 2008, ASSESS NOTES NURSING
   Hawton A, 2011, QUAL LIFE RES, V20, P57, DOI 10.1007/s11136-010-9717-2
   Kelly ME, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0632-2
   Khosravi P, 2016, INT J MED INFORM, V85, P17, DOI 10.1016/j.ijmedinf.2015.05.014
   Kuiper JS, 2015, AGEING RES REV, V22, P39, DOI 10.1016/j.arr.2015.04.006
   Legido-Quigley H, 2020, LANCET PUBLIC HEALTH, V5, pE251, DOI 10.1016/S2468-2667(20)30060-8
   Goodman-Casanova JM, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1267-z
   Nyman SR, 2016, PERSPECT PUBLIC HEAL, V136, P99, DOI 10.1177/1757913915626193
   O'Luanaigh C, 2012, AGING MENT HEALTH, V16, P347, DOI 10.1080/13607863.2011.628977
   Schrempft S, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6424-y
   Singh-Manoux A, 2003, J EPIDEMIOL COMMUN H, V57, P907, DOI 10.1136/jech.57.11.907
   Smith AC, 2020, J TELEMED TELECARE, V26, P309, DOI 10.1177/1357633X20916567
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Wang HL, 2020, LANCET, V395, P1190, DOI 10.1016/S0140-6736(20)30755-8
   World Health Organization, 2020, MENT HLTH PSYCH CONS
NR 24
TC 25
Z9 25
U1 6
U2 25
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD MAY 22
PY 2020
VL 22
IS 5
AR e19434
DI 10.2196/19434
PG 13
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA LQ6VO
UT WOS:000535139600001
PM 32401215
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Esteves, SC
   Lombardo, F
   Garrido, N
   Alvarez, J
   Zini, A
   Colpi, GM
   Kirkman-Brown, J
   Lewis, SEM
   Bjorndahl, L
   Majzoub, A
   Cho, CL
   Vendeira, P
   Hallak, J
   Amar, E
   Cocuzza, M
   Bento, FC
   Figueira, RC
   Sciorio, R
   Laursen, RJ
   Metwalley, AM
   Jindal, SK
   Parekattil, S
   Ramasamy, R
   Alviggi, C
   Humaidan, P
   Yovich, JL
   Agarwal, A
AF Esteves, Sandro C.
   Lombardo, Francesco
   Garrido, Nicolas
   Alvarez, Juan
   Zini, Armand
   Colpi, Giovanni M.
   Kirkman-Brown, Jackson
   Lewis, Sheena E. M.
   Bjorndahl, Lars
   Majzoub, Ahmad
   Cho, Chak-Lam
   Vendeira, Pedro
   Hallak, Jorge
   Amar, Edouard
   Cocuzza, Marcello
   Bento, Fabiola C.
   Figueira, Rita C.
   Sciorio, Romualdo
   Laursen, Rita J.
   Metwalley, Ahmad M.
   Jindal, Sunil K.
   Parekattil, Sijo
   Ramasamy, Ranjith
   Alviggi, Carlo
   Humaidan, Peter
   Yovich, John L.
   Agarwal, Ashok
TI SARS-CoV-2 pandemic and repercussions for male infertility patients: A
   proposal for the individualized provision of andrological services
SO ANDROLOGY
LA English
DT Article; Early Access
DE azoospermia; male infertility; opinion; SARS-CoV-2; semen analysis;
   sperm banking; systemic auto-immune diseases
ID INFLAMMATORY-BOWEL-DISEASE; FERTILITY PRESERVATION; SPERM BANKING;
   HYPOGONADOTROPIC HYPOGONADISM; NONOBSTRUCTIVE AZOOSPERMIA; OXIDATIVE
   STRESS; MEN; MANAGEMENT; CANCER; SPERMATOGENESIS
AB The prolonged lockdown of health facilities providing non-urgent gamete cryopreservation-as currently recommended by many reproductive medicine entities and regulatory authorities due to the SARS-CoV-2 pandemic will be detrimental for subgroups of male infertility patients. We believe the existing recommendations should be promptly modified and propose that the same permissive approach for sperm banking granted for men with cancer is expanded to other groups of vulnerable patients. These groups include infertility patients (eg, azoospermic and cryptozoospermic) undergoing medical or surgical treatment to improve sperm quantity and quality, as well as males of reproductive age affected by inflammatory and systemic auto-immune diseases who are about to start treatment with gonadotoxic drugs or who are under remission. In both scenarios, the "fertility window" may be transitory; postponing diagnostic semen analysis and sperm banking in these men could compromise the prospects of biological parenthood. Moreover, we provide recommendations on how to continue the provision of andrological services in a considered manner and a safe environment. Our opinion is timely and relevant given the fact that fertility services are currently rated as of low priority in most countries.
C1 [Esteves, Sandro C.; Bento, Fabiola C.; Figueira, Rita C.] ANDROFERT, Androl & Human Reprod Clin, Av Dr Heitor Penteado 1463, BR-13075460 Campinas, SP, Brazil.
   [Esteves, Sandro C.] Univ Estadual Campinas, UNICAMP, Dept Surg, Div Urol, Campinas, Brazil.
   [Esteves, Sandro C.; Humaidan, Peter] Aarhus Univ, Fac Hlth, Aarhus, Denmark.
   [Lombardo, Francesco] Univ Roma La Sapienza, Dept Med Physiopathol, Rome, Italy.
   [Garrido, Nicolas] IVI Fdn, Hlth Res Inst La Fe, Valencia, Spain.
   [Alvarez, Juan] Ctr ANDROGEN, La Coruna, Spain.
   [Zini, Armand] McGill Univ, St Marys Hosp, Dept Surg, Div Urol, Montreal, PQ, Canada.
   [Colpi, Giovanni M.] Procrea Swiss Fertil Ctr, Androl Serv, Lugano, Switzerland.
   [Colpi, Giovanni M.] San Carlo Cin, Androl & IVF Dept, Paderno Dugnano Milano, Italy.
   [Kirkman-Brown, Jackson] Univ Birmingham, Coll Med & Dent Sci, Ctr Human Reprod Sci, IMSR, Birmingham, W Midlands, England.
   [Kirkman-Brown, Jackson] Birmingham Womens & Childrens NHS Fdn Trust, Birmingham Womens Fertil Ctr, Birmingham, W Midlands, England.
   [Lewis, Sheena E. M.] Queens Univ Belfast, Belfast, Antrim, North Ireland.
   [Lewis, Sheena E. M.] Examenlab Ltd, Belfast, Antrim, North Ireland.
   [Bjorndahl, Lars] Karolinska Univ Hosp, ANOVA, Stockholm, Sweden.
   [Bjorndahl, Lars] Karolinska Inst, Stockholm, Sweden.
   [Majzoub, Ahmad] Hamad Med Corp, Dept Urol, Doha, Qatar.
   [Majzoub, Ahmad] Weill Cornell Med Qatar, Doha, Qatar.
   [Cho, Chak-Lam] Union Hosp, Dept Surg, Hong Kong, Peoples R China.
   [Cho, Chak-Lam] Chinese Univ Hong Kong, SH Ho Urol Ctr, Dept Surg, Hong Kong, Peoples R China.
   [Vendeira, Pedro] Clin Dragao, Urol Androl Unit, Saude Atlantica, Porto, Portugal.
   [Hallak, Jorge] Androsci Sci & Innovat Ctr Androl, Sao Paulo, Brazil.
   [Hallak, Jorge] High Complex Clin & Androl Lab, Sao Paulo, Brazil.
   [Hallak, Jorge] Univ Sao Paulo, Div Urol, Sao Paulo, Brazil.
   [Hallak, Jorge] Univ Sao Paulo, Inst Adv Studies, Mens Hlth Study Grp, Sao Paulo, Brazil.
   [Hallak, Jorge] Univ Sao Paulo, Dept Pathol, Reprod Toxicol Unit, Sao Paulo, Brazil.
   [Amar, Edouard] Amer Hosp Paris, Cabinet Androl Victor Hugo, Reprod Ctr, Paris, France.
   [Cocuzza, Marcello] Univ Sao Paulo, Human Reprod Ctr, Div Urol, Sao Paulo, Brazil.
   [Sciorio, Romualdo] Royal Infirm Edinburgh NHS Trust, EFREC, Edinburgh Assisted Concept Programme, Edinburgh, Midlothian, Scotland.
   [Laursen, Rita J.; Humaidan, Peter] Skive Reg Hosp, Fertil Clin Skive, Skive, Denmark.
   [Metwalley, Ahmad M.] AI Saad Specialist Hosp, IVF Lab, Jeddah, Saudi Arabia.
   [Metwalley, Ahmad M.] GEBRI, Reprod Med & Genet Unit, Sadat City, Egypt.
   [Jindal, Sunil K.] Jindal Hosp, Div Reprod Med & Androl, Meerut, Uttar Pradesh, India.
   [Parekattil, Sijo] PUR Clin, Clermont, FL USA.
   [Parekattil, Sijo] Univ Cent Florida, Clermont, FL USA.
   [Ramasamy, Ranjith] Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA.
   [Alviggi, Carlo] Univ Naples Federico II, Dept Neurosci Reprod Sci & Odontostomatol, Naples, Italy.
   [Yovich, John L.] PIVET Med Ctr, Perth, WA, Australia.
   [Yovich, John L.] Curtin Univ, Perth, WA, Australia.
   [Yovich, John L.] Cairns Fertil Ctr, Cairns, Qld, Australia.
   [Agarwal, Ashok] Cleveland Clin, Dept Urol, Androl Ctr, Cleveland, OH 44106 USA.
RP Esteves, SC (corresponding author), ANDROFERT, Androl & Human Reprod Clin, Av Dr Heitor Penteado 1463, BR-13075460 Campinas, SP, Brazil.
EM s.esteves@androfert.com.br
RI Ramasamy, Ranjith/ABD-7373-2020; Garrido, Nicolas/ABG-3235-2020;
   Metwalley, AHMAD/ABG-3314-2020; Kirkman-Brown, Jackson C/C-6600-2013;
   Esteves, Sandro/G-4416-2012
OI Ramasamy, Ranjith/0000-0003-1387-7904; Metwalley,
   AHMAD/0000-0001-5751-9506; Lombardo, Francesco/0000-0002-6943-2966;
   Kirkman-Brown, Jackson C/0000-0003-2833-8970; Colpi, Giovanni
   M./0000-0003-1431-1777; Zini, Armand/0000-0002-2194-5578; Bjorndahl,
   Lars/0000-0002-4709-5807; Esteves, Sandro/0000-0002-1313-9680; Majzoub,
   Ahmad/0000-0001-7423-6241
CR Agarwal A, 2014, TRANSL ANDROL UROL, V3, P27, DOI 10.3978/j.issn.2223-4683.2014.02.06
   Agarwal A, 2012, NAT REV UROL, V9, P678, DOI 10.1038/nrurol.2012.197
   Alonso V, 2009, REPROD TOXICOL, V27, P35, DOI 10.1016/j.reprotox.2008.10.007
   ASRM, 2020, AM SOC REPR MED PAT
   Behre HM, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00322
   Bertoncelli Tanaka M, 2019, PANMINERVA MED, V61, P138, DOI 10.23736/S0031-0808.18.03512-7
   Boivin J, 2005, FERTIL STERIL, V83, P1745, DOI 10.1016/j.fertnstert.2004.12.039
   Brubaker WD, 2018, ANDROLOGY-US, V6, P94, DOI 10.1111/andr.12436
   Carbone DJ, 1998, J UROLOGY, V159, P827, DOI 10.1016/S0022-5347(01)63744-3
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Choux C, 2018, REV MED INTERNE, V39, P557, DOI 10.1016/j.revmed.2018.02.010
   Drobnis EZ, 2017, ADV EXP MED BIOL, V1034, P163, DOI 10.1007/978-3-319-69535-8_11
   Esteves SC, 2016, ASIAN J ANDROL, V18, P246, DOI 10.4103/1008-682X.169562
   Esteves SC, 2015, ASIAN J ANDROL, V17, P459, DOI 10.4103/1008-682X.148719
   Esteves SC, 2013, REPROD BIOMED ONLINE, V26, P9, DOI 10.1016/j.rbmo.2012.10.010
   Esteves SC, 2011, CLINICS, V66, P1463, DOI 10.1590/S1807-59322011000800026
   Esteves SC, 2013, QUALITY MANAGEMENT A, P79
   European Society for Human Reproduction and Embryology (ESHRE), 2020, COR COV 19 ESHRE ASS
   Farber NJ, 2019, J UROLOGY, V201, P241, DOI 10.1016/j.juro.2018.07.092
   Fraietta R, 2013, CLINICS, V68, P81, DOI 10.6061/clinics/2013(Sup01)09
   Freour T, 2012, INT J CLIN ONCOL, V17, P598, DOI 10.1007/s10147-011-0330-3
   Hussein A, 2013, BJU INT, V111, pE110, DOI 10.1111/j.1464-410X.2012.11485.x
   Jennings MO, 2017, FERTIL STERIL, V107, P324, DOI 10.1016/j.fertnstert.2016.11.018
   Johnson MD, 2013, EUR J OBSTET GYN R B, V170, P177, DOI 10.1016/j.ejogrb.2013.06.021
   Koscinski I, 2007, HUM REPROD, V22, P2679, DOI 10.1093/humrep/dem190
   Laursen RJ, 2019, INT UROL NEPHROL, V51, P453, DOI 10.1007/s11255-019-02091-8
   Miyaoka R, 2019, PANMINERVA MED, V61, P164, DOI 10.23736/S0031-0808.18.03508-5
   Moein MR, 2012, ANDROLOGIA, V44, P194, DOI 10.1111/j.1439-0272.2011.01163.x
   Norgard B, 2004, ALIMENT PHARM THER, V19, P679, DOI 10.1111/j.1365-2036.2004.01889.x
   Palomba S, 2014, WORLD J GASTROENTERO, V20, P7123, DOI 10.3748/wjg.v20.i23.7123
   Pan F, 2020, FERTIL STERIL, V113, P1135, DOI 10.1016/j.fertnstert.2020.04.024
   Pan PP, 2013, INT J MOL SCI, V14, P21071, DOI 10.3390/ijms141021071
   Paoli D, 2020, J ENDOCRINOL INVEST, V43, P1819, DOI 10.1007/s40618-020-01261-1
   Pasqualotto FF, 2006, FERTIL STERIL, V85, P635, DOI 10.1016/j.fertnstert.2005.08.043
   Peterson BD, 2007, FERTIL STERIL, V88, P911, DOI 10.1016/j.fertnstert.2006.12.023
   Petherick A, 2020, LANCET, V395, P1101, DOI 10.1016/S0140-6736(20)30788-1
   Rajapakse RO, 2000, AM J GASTROENTEROL, V95, P684
   Ramstorp M, 2017, CLEAN ROOM TECHNOLOG, P3
   Sands K, 2015, ALIMENT PHARM THER, V41, P821, DOI 10.1111/apt.13142
   Shin T, 2014, SYST BIOL REPROD MED, V60, P373, DOI 10.3109/19396368.2014.952391
   Shinjo E, 2013, ANDROLOGY-US, V1, P929, DOI 10.1111/j.2047-2927.2013.00141.x
   Song C, DETECTION 2019 NOVEL
   Tiseo BC, 2016, INT BRAZ J UROL, V42, P11, DOI 10.1590/S1677-5538.IBJU.2014.0595
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wang ZP, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040920
   West CP, 2020, MAYO CLIN PROC, V95, P1127, DOI 10.1016/j.mayocp.2020.04.004
   Williams DH, 2010, THER ADV UROL, V2, P19, DOI 10.1177/1756287210368279
   Xu J, 2006, BIOL REPROD, V74, P410, DOI 10.1095/biolreprod.105.044776
   Xu R, 2019, ANDROLOGY-US, V7, P449, DOI 10.1111/andr.12602
   Yang L, 2012, INT UROL NEPHROL, V44, P393, DOI 10.1007/s11255-011-0065-0
   Yu N, 2020, LANCET INFECT DIS, V20, P559, DOI 10.1016/S1473-3099(20)30176-6
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
NR 52
TC 10
Z9 10
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-2919
EI 2047-2927
J9 ANDROLOGY-US
JI Andrology
DI 10.1111/andr.12809
EA MAY 2020
PG 9
WC Andrology
SC Endocrinology & Metabolism
GA LQ0FJ
UT WOS:000534688700001
PM 32357288
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tursen, U
   Tursen, B
   Lotti, T
AF Tursen, Umit
   Tursen, Belma
   Lotti, Torello
TI Cutaneous side-effects of the potential COVID-19 drugs
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE COVID-19; dermatology; side-effects; skin
ID ANTIRETROVIRAL THERAPY; ADVERSE EVENTS; 2019-NCOV; SAFETY
AB COVID-19 disease is a highly contagious and particularly popular problem in all countries. A variety of repurposed drugs and investigational drugs such as remdesivir, chloroquine, hydroxychloroquine, ritonavir, lopinavir, interferon-beta, and other potential drugs have been studied for COVID19 treatment. We reviewed the potential dermatological side-effects of these drugs.
C1 [Tursen, Umit] Mersin Univ, Sch Med, Dept Dermatol, Mersin, Turkey.
   [Tursen, Belma] Toros Univ, Dept Hlth Sci, Mersin, Turkey.
   [Lotti, Torello] Marconi Univ, Sch Med, Dept Dermatol, Rome, Italy.
RP Tursen, U (corresponding author), Mersin Univ, Sch Med, Dept Dermatol, Mersin, Turkey.
EM utursen@gmail.com
CR An I, 2017, CUTAN OCUL TOXICOL, V36, P199, DOI 10.1080/15569527.2016.1206556
   Belum VR, 2016, EUR J CANCER, V60, P12, DOI 10.1016/j.ejca.2016.02.010
   Brannagan TH, 1996, NEUROLOGY, V47, P674, DOI 10.1212/WNL.47.3.674
   Bush AE, 2017, J DRUGS DERMATOL, V16, P714
   Cao W, 2020, OPEN FORUM INFECT DI, V21, P7, DOI DOI 10.1093/0FID/0FAA102.0FAA102.EC0LLECTI0N
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Das A, 2016, INDIAN J PHARMACOL, V48, P83, DOI 10.4103/0253-7613.174565
   Estebanez A, 2020, J EUR ACAD DERMATOL, V34, pE250, DOI 10.1111/jdv.16474
   Esther J, 2015, COCHRANE DB SYST REV, V4
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gupta M, 2018, DERMATOL THER, V31, DOI 10.1111/dth.12679
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holdiness MR, 2001, INT J DERMATOL, V40, P427, DOI 10.1046/j.1365-4362.2001.01218.x
   Introcaso CE, 2010, J AM ACAD DERMATOL, V63, P549, DOI 10.1016/j.jaad.2010.01.061
   Jawhara S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072272
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Joshua B, 2020, NEW ENGL J MED, V20, P882
   Kalsi T, 2011, BMJ CASE REP, V4, P2011
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Koumaki D, 2019, EUR J CASE REP INTER, V7
   Kullenberg T, 2016, RHEUMATOLOGY, V55, P1499, DOI 10.1093/rheumatology/kew208
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Lorcy S, 2016, ANN DERMATOL VENER, V143, P336, DOI 10.1016/j.annder.2016.02.028
   Markatseli Theodora E, 2019, Mediterr J Rheumatol, V30, P177, DOI 10.31138/mjr.30.3.177
   Mason SE, 2006, J CUTAN PATHOL, V33, P309, DOI 10.1111/j.0303-6987.2006.00393.x
   Matsushima Y, 2019, CASE REP DERMATOL, V11, P317, DOI 10.1159/000504429
   Perez CE, 2020, PEDIATR ANN, V49, pE132, DOI 10.3928/19382359-20200224-01
   Peterson D, 2020, J AM ACAD DERMATOL, V9
   Pistone G, 2014, CASE REP DERMATOL, V6, P145, DOI 10.1159/000354030
   Praveen D, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105967
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Reihill JA, 2016, AM J RESP CRIT CARE, V194, P701, DOI 10.1164/rccm.201511-2216OC
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Salido M, 2002, ARTHRITIS RHEUM, V46, P3392, DOI 10.1002/art.10565
   Sehgal R, 2018, CLIN MED RES, V16, P41, DOI 10.3121/cmr.2017.1364
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Sharma A, 2008, INDIAN J DERMATOL VE, V74, P234
   Sonthalia Sidharth, 2019, Indian Dermatol Online J, V10, P503, DOI 10.4103/idoj.IDOJ_474_18
   Spada F, 2018, AUSTRALAS J DERMATOL, V59, pE168, DOI 10.1111/ajd.12762
   Speich B, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001685
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Vaine CA, 2014, ADV IMMUNOL, V121, P191, DOI 10.1016/B978-0-12-800100-4.00005-2
   Vastert SJ, 2019, RHEUMATOLOGY, V58, P9, DOI 10.1093/rheumatology/kez350
   Verma P, 2017, J CHEMOTHERAPY, V29, P380, DOI 10.1080/1120009X.2016.1245235
   Yang CN, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001127.pub4
   Zuo W, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015553
NR 49
TC 10
Z9 10
U1 2
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13476
DI 10.1111/dth.13476
EA MAY 2020
PG 6
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000534685800001
PM 32358890
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Krejner-Bienias, A
   Grzela, K
   Grzela, T
AF Krejner-Bienias, Alicja
   Grzela, Katarzyna
   Grzela, Tomasz
TI Do novel drugs for diabetes help in COVID-19? Another brick in the wall?
SO JOURNAL OF DIABETES
LA English
DT Letter
C1 [Krejner-Bienias, Alicja; Grzela, Tomasz] Med Univ Warsaw, Dept Histol & Embryol, Warsaw, Poland.
   [Grzela, Katarzyna] Med Univ Warsaw, Dept Pediat Pulmonol & Allergol, Warsaw, Poland.
RP Grzela, T (corresponding author), Med Univ Warsaw, Biostruct Res Ctr, Chalubinskiego 5, PL-02004 Warsaw, Poland.
EM tomekgrzela@gmail.com
CR Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Dudkowski C, 2017, EUR J CLIN PHARMACOL, V73, P279, DOI 10.1007/s00228-016-2175-1
   Lamers D, 2011, DIABETES, V60, P1917, DOI 10.2337/db10-1707
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
NR 5
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1753-0393
EI 1753-0407
J9 J DIABETES
JI J. Diabetes
PD SEP
PY 2020
VL 12
IS 9
BP 703
EP 704
DI 10.1111/1753-0407.13050
EA MAY 2020
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA MV4ZA
UT WOS:000534636400001
PM 32388906
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gupta, N
AF Gupta, Nisha
TI Singing Away the Social Distancing Blues: Art Therapy in a Time of
   Coronavirus
SO JOURNAL OF HUMANISTIC PSYCHOLOGY
LA English
DT Article
DE coronavirus; art therapy; music therapy; cinematherapy; expressive art
   therapies; solidarity; community crisis
AB This essay explores the abundance of art flourishing as a therapeutic antidote to the COVID-19 pandemic and panic arising across the world. Specifically, I discuss how the act of viewing, making, and sharing music, street art, paintings, graphic art, cinema, and digital videos can serve as a therapeutic vehicle for empowerment, solidarity, and collective action as most human beings strive to adopt practices of extreme social distancing as the recommended community mitigation strategy to help save lives before a vaccine is developed. This essay explores how therapeutic art-making can promote physical, mental, and social health at a time in history when all of these are under threat by COVID-19. I root these claims in theoretical literature from art therapy, as well as in inspiring and heart-warming examples of the beautiful coronavirus art that has already begun to fill our digital landscape with motivation, resiliency, and hope, though the crisis is still in its early stages.
C1 [Gupta, Nisha] Univ West Georgia, Psychol, Carrollton, GA USA.
RP Gupta, N (corresponding author), Univ West Georgia, Melson Hall,1601 Maple St, Carrollton, GA 30118 USA.
EM ngupta@westga.edu
OI Gupta, Nisha/0000-0002-6155-5734
CR Jennings P., 1990, PSYCHOTHERAPY PRIVAT, V8, P135, DOI DOI 10.1300/J294V08N01_15
   Johnson JL, 2008, ART PSYCHOTHER, V35, P11, DOI 10.1016/j.aip.2007.08.004
   Laurence F., 2011, MUSIC SOLIDARITY QUE
   May R., 1975, COURAGE CREATE
   MCNIFF S, 1998, TRUST PROCESS ARTIST
   McNiff S, 1981, ARTS PSYCHOTHERAPY
   Nicholls T., 2014, INTERNET ENCY PHILOS
   Sharp C., 2002, COUNSELING PSYCHOL Q, V15, P269, DOI DOI 10.1080/09515070210140221
   Shulman H., 2008, PSYCHOLOGIES LIBERAT
   Thoma MV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070156
NR 10
TC 1
Z9 1
U1 9
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-1678
EI 1552-650X
J9 J HUMANIST PSYCHOL
JI J. Humanist. Psychol.
PD SEP
PY 2020
VL 60
IS 5
SI SI
BP 593
EP 603
AR 0022167820927807
DI 10.1177/0022167820927807
EA MAY 2020
PG 11
WC Psychology, Multidisciplinary
SC Psychology
GA MS6KN
UT WOS:000535034800001
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jakhar, R
   Kaushik, S
   Gakhar, SK
AF Jakhar, Renu
   Kaushik, Samander
   Gakhar, Surendra K.
TI 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2
   using immunoinformatics
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE 3CL hydrolase; COVID-19; immunoinformatics; multiepitope; peptide
   vaccine; SARS-CoV-2
ID EPITOPE-BASED DIAGNOSTICS; SECONDARY-STRUCTURE; PREDICTION; DESIGN;
   PROTEINS; TOOL; EXPRESSION
AB The present study provides the first multiepitope vaccine construct using the 3CL hydrolase protein of SARS-CoV-2. The coronavirus 3CL hydrolase (Mpro) enzyme is essential for proteolytic maturation of the virus. This study was based on immunoinformatics and structural vaccinology strategies. The design of the multiepitope vaccine was built using helper T-cell and cytotoxic T-cell epitopes from the 3CL hydrolase protein along with an adjuvant to enhance immune response; these are joined to each other by short peptide linkers. The vaccine also carries potential B-cell linear epitope regions, B-cell discontinuous epitopes, and interferon-gamma-inducing epitopes. Epitopes of the constructed multiepitope vaccine were found to be antigenic, nonallergic, nontoxic, and covering large human populations worldwide. The vaccine construct was modeled, validated, and refined by different programs to achieve a high-quality three-dimensional structure. The resulting high-quality model was applied for conformational B-cell epitope selection and docking analyses with toll-like receptor-3 for understanding the capability of the vaccine to elicit an immune response. In silico cloning and codon adaptation were also performed with the pET-19b plasmid vector. The designed multiepitope peptide vaccine may prompt the development of a vaccine to control SARS-CoV-2 infection.
C1 [Jakhar, Renu; Gakhar, Surendra K.] Maharshi Dayanand Univ, Ctr Med Biotechnol, Rohtak 124001, Haryana, India.
   [Kaushik, Samander] Maharshi Dayanand Univ, Ctr Biotechnol, Rohtak, Haryana, India.
RP Jakhar, R (corresponding author), Maharshi Dayanand Univ, Ctr Med Biotechnol, Rohtak 124001, Haryana, India.
EM renujakhar22@gmail.com
OI JAKHAR, RENU/0000-0002-3556-6536; Kaushik, Samander/0000-0003-4835-6383
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Azim KF, 2019, INFECT GENET EVOL, V74, DOI 10.1016/j.meegid.2019.103936
   Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Calis JJ, 2019, PLOS COMPUT BIOL, V9, P10
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chauhan V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39299-8
   Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619
   Dimitrov I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S4
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Duits LA, 2003, FEMS IMMUNOL MED MIC, V38, P59, DOI 10.1016/S0928-8244(03)00106-8
   EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985
   Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681
   Ghosh AK, 2005, J MED CHEM, V48, P6767, DOI 10.1021/JM050548m
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458
   Hu WG, 2004, J BIOTECHNOL, V107, P83, DOI 10.1016/j.jbiotec.2003.09.009
   Jakhar R, 2019, BIOINFORMATION, V15, P600, DOI 10.6026/97320630015600
   Johansson MU, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-173
   Karosiene E, 2013, IMMUNOGENETICS, V65, P711, DOI 10.1007/s00251-013-0720-y
   KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768
   Khatoon N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08842-w
   KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q
   Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Macindoe G, 2010, NUCLEIC ACIDS RES, V38, pW445, DOI 10.1093/nar/gkq311
   Needle D, 2015, ACTA CRYSTALLOGR D, V71, P1102, DOI 10.1107/S1399004715003521
   Nezafat N, 2016, COMPUT BIOL CHEM, V62, P82, DOI 10.1016/j.compbiolchem.2016.04.006
   Ojha R, 2019, ACS OMEGA, V4, P13069, DOI 10.1021/acsomega.9b00944
   Pandey RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19456-1
   PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343
   Sanchez-Trincado JL, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/2680160
   Shi JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144475
   Solanki V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41496-4
   Srivastava S, 2018, INFECT DRUG RESIST, V11, P2377, DOI 10.2147/IDR.S175114
   Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wilkins MR, 1999, METH MOL B, V112, P531
   Wilson JA, 2001, J VIROL, V75, P2660, DOI 10.1128/JVI.75.6.2660-2664.2001
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yadav R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060785
   Zhang LM, 2012, BRIEF BIOINFORM, V13, P350, DOI 10.1093/bib/bbr060
NR 50
TC 2
Z9 2
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2020
VL 92
IS 10
BP 2114
EP 2123
DI 10.1002/jmv.25993
EA MAY 2020
PG 10
WC Virology
SC Virology
GA NK4OX
UT WOS:000534690000001
PM 32379348
DA 2021-01-01
ER

PT J
AU Chong, VH
   Chong, PL
   Metussin, D
   Asli, R
   Momin, RN
   Mani, BI
   Abdullah, MS
AF Chong, Vui Heng
   Chong, Pui Lin
   Metussin, Dhiya
   Asli, Rosmonaliza
   Momin, Riamiza Natalie
   Mani, Babu Ivan
   Abdullah, Muhammad Syafiq
TI Conduction abnormalities in hydroxychloroquine add on therapy to
   lopinavir/ritonavir in COVID-19
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Letter
ID RISK
C1 [Chong, Vui Heng; Mani, Babu Ivan] PMMPMHAMB Hosp, Dept Med, Tutong, Brunei.
   [Chong, Vui Heng; Chong, Pui Lin; Abdullah, Muhammad Syafiq] RIPAS Hosp, Dept Med, Bandar Seri Begawan, Brunei.
   [Metussin, Dhiya; Asli, Rosmonaliza; Momin, Riamiza Natalie] RIPAS Hosp, Dept Med, Infect Dis Unit, Bandar Seri Begawan, Brunei.
RP Chong, VH (corresponding author), PMMPMHAMB Hosp, Dept Med, Tutong, Brunei.
EM chongvuih@yahoo.co.uk
CR Abena PM, 2020, AM J TROP MED HYG, V102, P1184, DOI 10.4269/ajtmh.20-0290
   Brufsky A, 2020, J MED VIROL, V92, P770, DOI 10.1002/jmv.25887
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chorin E, 2020, QT INTERVAL PATIENTS, V2020, DOI [10.1101/2020.04.02.20047050, DOI 10.1101/2020.04.02.20047050]
   Jaffe S, 2020, LANCET, V395, P1179, DOI 10.1016/S0140-6736(20)30817-5
   Liu D, 2018, DRUG DES DEV THER, V12, P1685, DOI 10.2147/DDDT.S166893
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Sarma P, 2020, J MED VIROL, V92, P776, DOI 10.1002/jmv.25898
   Taccone FS, 2020, LANCET RESP MED, V8, P539, DOI 10.1016/S2213-2600(20)30172-7
   Tisdale JE, 2013, CIRC-CARDIOVASC QUAL, V6, P479, DOI 10.1161/CIRCOUTCOMES.113.000152
   Tripathy JP, 2020, J MED VIROL, V92, P1391, DOI 10.1002/jmv.25933
NR 11
TC 5
Z9 5
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2322
EP 2324
DI 10.1002/jmv.26004
EA MAY 2020
PG 3
WC Virology
SC Virology
GA NU0EN
UT WOS:000534689000001
PM 32401368
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Andina, D
   Noguera-Morel, L
   Bascuas-Arribas, M
   Gaitero-Tristan, J
   Alonso-Cadenas, JA
   Escalada-Pellitero, S
   Hernandez-Martin, A
   de la Torre-Espi, M
   Colmenero, I
   Torrelo, A
AF Andina, David
   Noguera-Morel, Lucero
   Bascuas-Arribas, Marta
   Gaitero-Tristan, Jara
   Antonio Alonso-Cadenas, Jose
   Escalada-Pellitero, Silvia
   Hernandez-Martin, Angela
   de la Torre-Espi, Mercedes
   Colmenero, Isabel
   Torrelo, Antonio
TI Chilblains in children in the setting of COVID-19 pandemic
SO PEDIATRIC DERMATOLOGY
LA English
DT Article
DE acral ischemia; chilblain; COVID-19; dermoscopy; pernio; SARS-CoV-2;
   skin
ID PERNIO CHILBLAINS
AB Background Different skin manifestations of COVID-19 are being reported. Acral lesions on the hands and feet, closely resembling chilblains, have been recognized during the peak incidence of the COVID-19 pandemic.
   Material and methods A retrospective review of 22 children and adolescents with chilblain-like lesions seen over a short period of time in the Emergency Department of a children's hospital during the peak incidence of COVID-19 in Madrid, Spain.
   Results All patients had lesions clinically consistent with chilblains of the toes or feet, with three also having lesions of the fingers. Pruritus and mild pain were the only skin symptoms elicited, and only 10 had mild respiratory and/or GI symptoms. None had fever. Coagulation tests, hemogram, serum chemistry, and lupus anticoagulant were normal in all patients tested. One out of 16 tested cases had elevated D-dimer results, but without systemic symptoms or other laboratory anomalies. SARS-CoV-2 PCR tested in 19 cases was positive in just one case. Skin biopsies obtained in six patients were consistent with chilblains. On follow-up, all cases showed spontaneous marked improvement or complete healing.
   Conclusion Acute chilblains were observed during COVID-19 pandemic in children and teenagers. It is a mildly symptomatic condition with an excellent prognosis, usually requiring no therapy. Etiopathogenesis remains unknown.
C1 [Andina, David; Bascuas-Arribas, Marta; Gaitero-Tristan, Jara; Antonio Alonso-Cadenas, Jose; Escalada-Pellitero, Silvia; de la Torre-Espi, Mercedes] Hosp Infantil Univ Nino Jesus, Emergency Dept, Madrid, Spain.
   [Noguera-Morel, Lucero; Hernandez-Martin, Angela; Torrelo, Antonio] Hosp Infantil Univ Nino Jesus, Dept Dermatol, Menendez Pelayo 65, Madrid 28009, Spain.
   [Colmenero, Isabel] Hosp Infantil Univ Nino Jesus, Dept Pathol, Madrid, Spain.
RP Torrelo, A (corresponding author), Hosp Infantil Univ Nino Jesus, Dept Dermatol, Menendez Pelayo 65, Madrid 28009, Spain.
EM atorrelo@aedv.es
OI Noguera-Morel, Lucero/0000-0001-5694-8536
CR Al Aboud A, 2011, J AM ACAD DERMATOL, V64, P1218, DOI 10.1016/j.jaad.2009.11.010
   Cappel JA, 2014, MAYO CLIN PROC, V89, P207, DOI 10.1016/j.mayocp.2013.09.020
   Cribier B, 2001, J AM ACAD DERMATOL, V45, P924, DOI 10.1067/mjd.2001.117861
   George R, 2007, ARCH DERMATOL, V143, P274, DOI 10.1001/archderm.143.2.274
   Gurung P, 2018, CLIN EXP DERMATOL, V43, P596, DOI 10.1111/ced.13621
   Gutierrez-Ortiz C, 2020, NEUROLOGY, V95, pE601, DOI 10.1212/WNL.0000000000009619
   Henry D, 2020, J EUR ACAD DERMATOL, V34, pE244, DOI 10.1111/jdv.16472
   Kearby R, 2010, CLIN PEDIATR, V49, P495, DOI 10.1177/0009922809355314
   Kim H, 2016, J MOL MED, V94, P1111, DOI 10.1007/s00109-016-1465-5
   Kolivras A, 2008, J CUTAN PATHOL, V35, P774, DOI 10.1111/j.1600-0560.2007.00900.x
   Kolivras Athanassios, 2020, JAAD Case Rep, V6, P489, DOI 10.1016/j.jdcr.2020.04.011
   Lutz V, 2010, BRIT J DERMATOL, V163, P645, DOI 10.1111/j.1365-2133.2010.09829.x
   Mahe A, 2020, J EUR ACAD DERMATOL, V34, pE246, DOI 10.1111/jdv.16471
   Manalo IF, 2020, J AM ACAD DERMATOL, V83, pE157, DOI [10.1016/j.jaad.2020.04.018, 10.1016/j.jaad.2020.05.001]
   Marzano AV, 2020, J AM ACAD DERMATOL, V83, P280, DOI 10.1016/j.jaad.2020.04.044
   Mazzotta F, 2020, EUR J PEDIAT DERMATO
   Nyssen A, 2020, VASA, V49, P133, DOI 10.1024/0301-1526/a000838
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Shahi V, 2015, DERMATOLOGY, V231, P274, DOI 10.1159/000437224
   Simon TD, 2005, PEDIATRICS, V116, pE472, DOI 10.1542/peds.2004-2681
   Syed RH, 2008, JCR-J CLIN RHEUMATOL, V14, P30, DOI 10.1097/RHU.0b013e3181639aaa
   Tagarro Alfredo, 2020, JAMA Pediatr, DOI 10.1001/jamapediatrics.2020.1346
   Viguier M, 2001, MEDICINE, V80, P180, DOI 10.1097/00005792-200105000-00004
   Wang ML, 2018, AM J DERMATOPATH, V40, P265, DOI 10.1097/DAD.0000000000000945
   Weston WL, 2000, PEDIATR DERMATOL, V17, P97, DOI 10.1046/j.1525-1470.2000.01722.x
   Zhang Y, 2020, ZHONGHUA XUE YE XUE, V41, pE006
   Zhou Z., 2020, SSRN ELECT J, DOI [10.2139/ssrn.3551623, DOI 10.2139/SSRN.3551623]
NR 27
TC 43
Z9 45
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-8046
EI 1525-1470
J9 PEDIATR DERMATOL
JI Pediatr. Dermatol.
PD MAY
PY 2020
VL 37
IS 3
BP 406
EP 411
DI 10.1111/pde.14215
EA MAY 2020
PG 6
WC Dermatology; Pediatrics
SC Dermatology; Pediatrics
GA MD3ZR
UT WOS:000534724600001
PM 32386460
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zeng, FF
   Dai, C
   Cai, PC
   Wang, JB
   Xu, L
   Li, JY
   Hu, GY
   Wang, Z
   Zheng, F
   Wang, L
AF Zeng, Fanfan
   Dai, Chan
   Cai, Pengcheng
   Wang, Jinbiao
   Xu, Lei
   Li, Jianyu
   Hu, Guoyun
   Wang, Zheng
   Zheng, Fang
   Wang, Lin
TI A comparison study of SARS-CoV-2 IgG antibody between male and female
   COVID-19 patients: A possible reason underlying different outcome
   between sex
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE COVID-19 patients; SARS-CoV-2 IgG antibody; sexual discrepancy
AB The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China at the end of 2019 has spread throughout the world and caused many thousands of deaths. The previous study reported a higher severe status rate and mortality rate in male patients in China. However, the reason underlying this difference has not been reported. The convalescent plasma containing a high level of SARS-CoV-2 immunoglobulin G (IgG) antibody has been used in clinical therapy and achieved good effects in China. In this study, to compare the differences of the SARS-CoV-2 IgG antibody between male and female patients, a total number of 331 patients confirmed SARS-CoV-2 infection were enrolled. The serum of these patients was collected during hospitalization and detected for the SARS-CoV-2 IgG antibody. Our data showed that the concentration of IgG antibody in mild, general, and recovering patients showed no difference between male and female patients. In severe status, compared with male patients, there were more female patients having a relatively high concentration of serum SARS-CoV-2 IgG antibody. In addition, the generation of IgG antibody in female patients was stronger than male patients in disease early phase. Our study identified a discrepancy in the SARS-CoV-2 IgG antibody level in male and female patients, which may be a potential cause leading to a different outcome of Coronavirus Disease 2019 between sex.
C1 [Zeng, Fanfan; Cai, Pengcheng; Wang, Jinbiao; Xu, Lei; Li, Jianyu; Hu, Guoyun; Wang, Lin] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Clin Lab, Jiefang Ave 1277, Wuhan 430022, Hubei, Peoples R China.
   [Dai, Chan; Zheng, Fang] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Immunol, Hangkong Rd 13, Wuhan 430030, Hubei, Peoples R China.
   [Wang, Zheng] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Jiefang Ave 1277, Wuhan 430022, Hubei, Peoples R China.
RP Wang, L (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Clin Lab, Jiefang Ave 1277, Wuhan 430022, Hubei, Peoples R China.; Zheng, F (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Immunol, Hangkong Rd 13, Wuhan 430030, Hubei, Peoples R China.; Wang, Z (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Jiefang Ave 1277, Wuhan 430022, Hubei, Peoples R China.
EM zhengwang@hust.edu.cn; zhengfangtj@hust.edu.cn; lin_wang@hust.edu.cn
OI Zeng, Fanfan/0000-0002-4731-7641
FU Department of Clinical Laboratory, Union Hospital, Tongji Medical
   College, Huazhong University of Science and Technology
FX We thank all of the doctors, nurses, and public health workers for their
   efforts in fighting against SARS-CoV-2 and saving the lives of COVID-19
   patients. The project was supported by the Department of Clinical
   Laboratory, Union Hospital, Tongji Medical College, Huazhong University
   of Science and Technology.
CR Cassaniti I, 2020, J MED VIROL, V92, P1724, DOI 10.1002/jmv.25800
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li H, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE002, DOI 10.3760/cma.j.issn.1001-0939.2020.0002
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiang F, 2020, CLIN INFECT DIS, DOI 10.1093/cid/ciaa461
   Ye Q, 2020, J MED VIROL, V92, P755, DOI 10.1002/jmv.25813
   Zeng H, 2020, JAMA-J AM MED ASSOC, V323, P1848, DOI 10.1001/jama.2020.4861
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 14
TC 32
Z9 32
U1 2
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2020
VL 92
IS 10
BP 2050
EP 2054
DI 10.1002/jmv.25989
EA MAY 2020
PG 5
WC Virology
SC Virology
GA NK4OX
UT WOS:000534689100001
PM 32383183
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Grandolfo, M
   Romita, P
   Bonamonte, D
   Cazzato, G
   Hansel, K
   Stingeni, L
   Conforti, C
   Giuffrida, R
   Foti, C
AF Grandolfo, Mauro
   Romita, Paolo
   Bonamonte, Domenico
   Cazzato, Gerardo
   Hansel, Katharina
   Stingeni, Luca
   Conforti, Claudio
   Giuffrida, Roberta
   Foti, Caterina
TI Drug reaction with eosinophilia and systemic symptoms syndrome to
   hydroxychloroquine, an old drug in the spotlight in the COVID-19 era
SO DERMATOLOGIC THERAPY
LA English
DT Letter
ID DRESS
C1 [Grandolfo, Mauro; Romita, Paolo; Bonamonte, Domenico; Foti, Caterina] Univ Bari, Dermatol Sect, Dept Biomed Sci & Human Oncol, Bari, Italy.
   [Cazzato, Gerardo] Univ Bari, Dept Emergency & Organ Transplantat, Pathol Unit, Bari, Italy.
   [Hansel, Katharina; Stingeni, Luca] Univ Perugia, Dermatol Sect, Dept Med, Perugia, Italy.
   [Conforti, Claudio] Univ Trieste, Maggiore Hosp, Dermatol Clin, Trieste, Italy.
   [Giuffrida, Roberta] Univ Messina, Dept Clin & Expt Med, Dermatol, Via Consolare Valeria 1, I-98125 Messina, Italy.
RP Giuffrida, R (corresponding author), Univ Messina, Dept Clin & Expt Med, Dermatol, Via Consolare Valeria 1, I-98125 Messina, Italy.
EM roberta_giuffrida@hotmail.it
RI Conforti, Claudio/AAJ-9186-2020
OI Romita, Paolo/0000-0002-5559-9722; GIUFFRIDA,
   ROBERTA/0000-0002-5492-3033
CR Cho YT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061243
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13437
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13298
   Foti C, 2012, EUR J DERMATOL, V22, P799, DOI 10.1684/ejd.2012.1853
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Girijala RL, 2019, J DRUGS DERMATOL, V18, P207
   Hansel K, 2017, J ALLER CL IMM-PRACT, V5, P808, DOI 10.1016/j.jaip.2016.10.009
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Schwartz RA, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13380
NR 9
TC 5
Z9 5
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13499
DI 10.1111/dth.13499
EA MAY 2020
PG 2
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000534687400001
PM 32362051
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hao, XT
   Zhou, D
   Li, Z
   Zeng, GJ
   Hao, NY
   Li, EZ
   Li, WJ
   Deng, AP
   Lin, MT
   Yan, B
AF Hao, Xiaoting
   Zhou, Dong
   Li, Zhe
   Zeng, Guojun
   Hao, Nanya
   Li, Enzhi
   Li, Wenjing
   Deng, Aiping
   Lin, Mintao
   Yan, Bo
TI Severe psychological distress among patients with epilepsy during the
   COVID-19 outbreak in southwest China
SO EPILEPSIA
LA English
DT Article
DE COVID-19; drug-resistant epilepsy; epilepsy; outbreak; psychological
   distress; stress status
ID SERIOUS MENTAL-ILLNESS; PSYCHIATRIC COMORBIDITY; ILAE COMMISSION;
   RISK-FACTORS; TASK-FORCE; POPULATION; SUICIDE; ANXIETY; STRESS; PEOPLE
AB Objective To compare the severity of psychological distress between patients with epilepsy and healthy controls during the COVID-19 outbreak in southwest China, as well as identify potential risk factors of severe psychological distress among patients with epilepsy.
   Methods This cross-sectional case-control study examined a consecutive sample of patients older than 15 years treated at the epilepsy center of West China Hospital between February 1 and February 29, 2020. As controls, sex- and age-matched healthy visitors of inpatients (unrelated to the patients) were also enrolled during the same period. Data on demographics and attention paid to COVID-19 were collected by online questionnaire, data on epilepsy features were collected from electronic medical records, and psychological distress was evaluated using the 6-item Kessler Psychological Distress Scale (K-6). Potential risk factors of severe psychological distress were identified using multivariate logistic regression.
   Results The 252 patients and 252 controls in this study were similar along all demographic variables except family income. Patients with epilepsy showed significantly higher K-6 scores than healthy controls and spent significantly more time following the COVID-19 outbreak (both P < .001). Univariate analyses associated both diagnosis of drug-resistant epilepsy and time spent paying attention to COVID-19 with severe psychological distress (defined as K-6 score >12; both P <= .001). Multivariate logistic regression identified two independent predictors of severe psychological distress: time spent paying attention to COVID-19 (odds ratio [OR] = 1.172, 95% confidence interval [CI] = 1.073-1.280) and diagnosis of drug-resistant epilepsy (OR = 0.283, 95% CI = 0.128-0.623).
   Significance During public health outbreaks, clinicians and caregivers should focus not only on seizure control but also on mental health of patients with epilepsy, especially those with drug-resistant epilepsy. K-6 scores > 12 indicate severe psychological distress. This may mean, for example, encouraging patients to engage in other activities instead of excessively following media coverage of the outbreak.
C1 [Hao, Xiaoting; Zhou, Dong; Hao, Nanya; Li, Enzhi; Yan, Bo] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu 610000, Sichuan, Peoples R China.
   [Li, Zhe] Sichuan Univ, West China Hosp, Mental Hlth Ctr, Chengdu, Sichuan, Peoples R China.
   [Zeng, Guojun] Sichuan Univ, Dept Vasc Surg, West China Hosp, Chengdu, Sichuan, Peoples R China.
   [Li, Enzhi; Li, Wenjing; Deng, Aiping] Sichuan Univ, West China Sch Nursing, Chengdu, Sichuan, Peoples R China.
   [Li, Wenjing; Deng, Aiping] Sichuan Univ, West China Hosp, Outpatient Dept, Chengdu, Sichuan, Peoples R China.
   [Lin, Mintao] Sichuan Univ, West China Sch Med, Chengdu, Sichuan, Peoples R China.
RP Yan, B (corresponding author), Sichuan Univ, West China Hosp, Dept Neurol, Chengdu 610000, Sichuan, Peoples R China.
EM yanbo_huaxi@126.com
FU National Key R&D Program of China [2017YFC0907702, 2017YFC0907705]
FX This work was funded by the National Key R&D Program of China
   (2017YFC0907702 and 2017YFC0907705).
CR Altintas E, 2015, J NEUROPSYCH CLIN N, V27, P339, DOI 10.1176/appi.neuropsych.15030061
   Bell G S, 2002, Seizure, V11 Suppl A, P306
   Bell GS, 2009, EPILEPSIA, V50, P1933, DOI 10.1111/j.1528-1167.2009.02106.x
   Blumcke I, 2019, EPILEPTIC DISORD, V21, P129, DOI 10.1684/epd.2019.1039
   Bragatti JA, 2011, ARQ NEURO-PSIQUIAT, V69, P159, DOI 10.1590/S0004-282X2011000200003
   Bromet EJ, 2012, J RADIOL PROT, V32, pN71, DOI 10.1088/0952-4746/32/1/N71
   Chan KW, 2019, AM J CHINESE MED, V2020, P1
   Christensen J, 2007, LANCET NEUROL, V6, P693, DOI 10.1016/S1474-4422(07)70175-8
   Feng XQ, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1926-1
   Ferro MA, 2019, CAN J PSYCHIAT, V64, P647, DOI 10.1177/0706743718818414
   Fiest KM, 2013, NEUROLOGY, V80, P590, DOI 10.1212/WNL.0b013e31827b1ae0
   Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550
   Fountain NB, 2015, NEUROLOGY, V84, P1483, DOI 10.1212/WNL.0000000000001448
   Furukawa TA, 2008, INT J METH PSYCH RES, V17, P152, DOI 10.1002/mpr.257
   Gaitatzis A, 2004, ACTA NEUROL SCAND, V110, P207, DOI 10.1111/j.1600-0404.2004.00324.x
   Gilboa T, 2012, EPILEPSIA, V53, pe29, DOI 10.1111/j.1528-1167.2011.03342.x
   Han SH, 2019, EPILEPSY BEHAV, V101, DOI 10.1016/j.yebeh.2019.106569
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Jones JE, 2007, EPILEPSIA, V48, P2357
   Jones JE, 2003, EPILEPSY BEHAV, V4, pS31, DOI 10.1016/j.yebeh.2003.08.019
   Kang YK, 2015, COMPR PSYCHIAT, V63, P105, DOI 10.1016/j.comppsych.2015.08.011
   Kanner AM, 2010, EPILEPSIA, V51, P1152, DOI 10.1111/j.1528-1167.2010.02582.x
   Kessler RC, 2003, ARCH GEN PSYCHIAT, V60, P184, DOI 10.1001/archpsyc.60.2.184
   Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074
   Kessler RC, 2010, INT J METH PSYCH RES, V19, P4, DOI 10.1002/mpr.310
   Kunii Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158821
   Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x
   Lacey CJ, 2014, EPILEPSY BEHAV, V35, P1, DOI 10.1016/j.yebeh.2014.03.025
   Larsen SE, 2019, PSYCHIAT RES, V275, P261, DOI 10.1016/j.psychres.2019.02.015
   Li H, 2020, GLOB HEALTH RES POL, V5, DOI 10.1186/s41256-020-00140-9
   Mckee HR, 2017, SEIZURE-EUR J EPILEP, V44, P21, DOI 10.1016/j.seizure.2016.12.009
   Petrovski S, 2010, NEUROLOGY, V75, P1015, DOI 10.1212/WNL.0b013e3181f25b16
   Privitera M, 2014, EPILEPSY BEHAV, V41, P74, DOI 10.1016/j.yebeh.2014.09.028
   Scheffer IE, 2017, EPILEPSIA, V58, P512, DOI 10.1111/epi.13709
   Scott AJ, 2017, EPILEPSIA, V58, P973, DOI 10.1111/epi.13769
   Siarava E, 2020, EPILEPSY BEHAV, V102, DOI 10.1016/j.yebeh.2019.106647
   Srugo SA, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16224364
   Tomitaka S, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01387
   Wang FS, 2020, LANCET, V395, P391, DOI 10.1016/S0140-6736(20)30300-7
   Zhang GH, 2020, J AFFECT DISORDERS, V260, P498, DOI 10.1016/j.jad.2019.09.047
NR 40
TC 19
Z9 19
U1 3
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD JUN
PY 2020
VL 61
IS 6
BP 1166
EP 1173
DI 10.1111/epi.16544
EA MAY 2020
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA LY9QU
UT WOS:000534622400001
PM 32353184
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hillen, HS
   Kokic, G
   Farnung, L
   Dienemann, C
   Tegunov, D
   Cramer, P
AF Hillen, Hauke S.
   Kokic, Goran
   Farnung, Lucas
   Dienemann, Christian
   Tegunov, Dimitry
   Cramer, Patrick
TI Structure of replicating SARS-CoV-2 polymerase
SO NATURE
LA English
DT Article
ID RNA-POLYMERASE; CRYO-EM; CORONAVIRUS; SARS; ENZYMES
AB The new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses an RNA-dependent RNA polymerase (RdRp) for the replication of its genome and the transcription of its genes(1-3). Here we present a cryo-electron microscopy structure of the SARS-CoV-2 RdRp in an active form that mimics the replicating enzyme. The structure comprises the viral proteins non-structural protein 12 (nsp12), nsp8 and nsp7, and more than two turns of RNA template-product duplex. The active-site cleft of nsp12 binds to the first turn of RNA and mediates RdRp activity with conserved residues. Two copies of nsp8 bind to opposite sides of the cleft and position the second turn of RNA. Long helical extensions in nsp8 protrude along exiting RNA, forming positively charged 'sliding poles'. These sliding poles can account for the known processivity of RdRp that is required for replicating the long genome of coronaviruses(3). Our results enable a detailed analysis of the inhibitory mechanisms that underlie the antiviral activity of substances such as remdesivir, a drug for the treatment of coronavirus disease 2019 (COVID-19)(4).
   A cryo-electron microscopy structure of the RNA-dependent RNA polymerase of SARS-CoV-2 sheds light on coronavirus replication and enables the analysis of the inhibitory mechanisms of candidate antiviral drugs.
C1 [Hillen, Hauke S.; Kokic, Goran; Farnung, Lucas; Dienemann, Christian; Tegunov, Dimitry; Cramer, Patrick] Max Planck Inst Biophys Chem, Dept Mol Biol, Gottingen, Germany.
RP Cramer, P (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Biol, Gottingen, Germany.
EM patrick.cramer@mpibpc.mpg.de
RI Tegunov, Dimitry/D-7834-2015
OI Tegunov, Dimitry/0000-0001-7019-3221; Hillen, Hauke/0000-0002-1206-0129
FU Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG)
   [FOR2848]; ERC Advanced Investigator Grant TRANSREGULON [693023];
   Volkswagen FoundationVolkswagen; Deutsche Forschungsgemeinschaft,
   Germany's Excellence StrategyGerman Research Foundation (DFG) [SFB860,
   SPP2191, EXC 2067/1-390729940]
FX We thank all members of the Department of Molecular Biology at the
   Max-Planck-Institute for Biophysical Chemistry for support; J.
   Schmitzova for helpful discussions and advice; and H. Urlaub for mass
   spectrometry. H.S.H. was supported by the Deutsche
   Forschungsgemeinschaft (FOR2848). P.C. was supported by the Deutsche
   Forschungsgemeinschaft (SFB860, SPP2191), Germany's Excellence Strategy
   (EXC 2067/1-390729940), the ERC Advanced Investigator Grant TRANSREGULON
   (grant agreement no. 693023) and the Volkswagen Foundation.
CR Afonine PV, 2018, ACTA CRYSTALLOGR D, V74, P531, DOI 10.1107/S2059798318006551
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Ahn DG, 2012, ARCH VIROL, V157, P2095, DOI 10.1007/s00705-012-1404-x
   Appleby TC, 2015, SCIENCE, V347, P771, DOI 10.1126/science.1259210
   Bouvet M, 2012, P NATL ACAD SCI USA, V109, P9372, DOI 10.1073/pnas.1201130109
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gong P, 2010, P NATL ACAD SCI USA, V107, P22505, DOI 10.1073/pnas.1007626107
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Hilgenfeld R, 2013, ANTIVIR RES, V100, P286, DOI 10.1016/j.antiviral.2013.08.015
   Huang CC, 2014, NUCLEIC ACIDS RES, V42, pW478, DOI 10.1093/nar/gku377
   Jordan Paul C., 2018, Antiviral Chemistry & Chemotherapy, V26, p2040206618764483, DOI 10.1177/2040206618764483
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Ledford Heidi, 2020, Nature, DOI 10.1038/d41586-020-01295-8
   Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007
   Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003
   Posthuma CC, 2017, VIRUS RES, V234, P58, DOI 10.1016/j.virusres.2017.01.023
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Subissi L, 2014, ANTIVIR RES, V101, P122, DOI 10.1016/j.antiviral.2013.11.006
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Tegunov D, 2019, NAT METHODS, V16, P1146, DOI 10.1038/s41592-019-0580-y
   Vos SM, 2016, ELIFE, V5, DOI 10.7554/eLife.14981
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao YB, 2012, J VIROL, V86, P4444, DOI 10.1128/JVI.06635-11
   Yin W., 2020, STRUCTURAL BASIS INH, DOI [DOI 10.1101/2020.04.08.032763, 10.1101/2020.04.08.032763]
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zamyatkin DF, 2009, J MOL BIOL, V390, P10, DOI 10.1016/j.jmb.2009.04.069
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zivanov J, 2019, IUCRJ, V6, P5, DOI 10.1107/S205225251801463X
NR 34
TC 33
Z9 35
U1 16
U2 24
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD AUG 6
PY 2020
VL 584
IS 7819
BP 154
EP +
DI 10.1038/s41586-020-2368-8
EA MAY 2020
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NB1QU
UT WOS:000554511100001
PM 32438371
OA Bronze
DA 2021-01-01
ER

PT J
AU Yahalom, J
   Dabaja, BS
   Ricardi, U
   Ng, A
   Mikhaeel, NG
   Vogelius, IR
   Illidge, T
   Qi, SN
   Wirth, A
   Specht, L
AF Yahalom, Joachim
   Dabaja, Bouthaina Shbib
   Ricardi, Umberto
   Ng, Andrea
   Mikhaeel, N. George
   Vogelius, Ivan R.
   Illidge, Tim
   Qi, Shunan
   Wirth, Andrew
   Specht, Lena
CA Int Lymphoma Radiation Oncol
TI ILROG emergency guidelines for radiation therapy of hematological
   malignancies during the COVID-19 pandemic
SO BLOOD
LA English
DT Article
ID LYMPHOMA GUIDELINES; HODGKIN LYMPHOMA; DOSE GUIDELINES; ONCOLOGY; FIELD
AB The International Lymphoma Radiation Oncology Group (ILROG) guidelines for using radiation therapy (RT) in hematological malignancies are widely used in many countries. The emergency situation created by the COVID-19 pandemic may result in limitations of treatment resources. Furthermore, in recognition of the need to also reduce the exposure of patients and staff to potential infection with COVID-19, the ILROG task force has made recommendations for alternative radiation treatment schemes. The emphasis is on maintaining clinical efficacy and safety by increasing the dose per fraction while reducing the number of daily treatments. The guidance is informed by adhering to acceptable radiobiological parameters and clinical tolerability. The options for delaying or omitting RT in some hematological categories are also discussed.
C1 [Yahalom, Joachim] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   [Dabaja, Bouthaina Shbib] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Ricardi, Umberto] Univ Turin, Dept Oncol, Turin, Italy.
   [Ng, Andrea] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Mikhaeel, N. George] Guys & St Thomas Hosp, London, England.
   [Vogelius, Ivan R.; Specht, Lena] Univ Copenhagen, Rigshosp, Copenhagen, Denmark.
   [Illidge, Tim] Univ Manchester, Natl Inst Hlth Res NIHR Manchester Biomed Res Ctr, Christie Natl Hlth Serv NHS Fdn Trust, Manchester, Lancs, England.
   [Qi, Shunan] Chinese Acad Med Sci CAMS & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China.
   [Wirth, Andrew] Peter MacCallum Canc Inst, Melbourne, Vic, Australia.
RP Yahalom, J (corresponding author), Mem Sloan Kettering Canc Ctr, ILROG Cent Off, Koch Bldg,Room 20-193D,530 East 74th St, New York, NY 10021 USA.
EM yahalomj@mskcc.org
RI Illidge, Tim/M-3659-2015
OI Illidge, Tim/0000-0003-3191-7324; Specht, Lena/0000-0002-6902-2190;
   Mikhaeel, Nabegh George/0000-0003-0359-0328; Vogelius, Ivan
   Richter/0000-0002-8877-1218
CR Aldridge DR, 1998, CANCER RES, V58, P2817
   Appel BE, 2016, J CLIN ONCOL, V34, P2372, DOI 10.1200/JCO.2015.65.3469
   Bakst RL, 2018, INT J RADIAT ONCOL, V102, P314, DOI 10.1016/j.ijrobp.2018.05.045
   Bentzen SM, 2012, RADIOTHER ONCOL, V105, P266, DOI 10.1016/j.radonc.2012.10.006
   Constine LS, 2018, INT J RADIAT ONCOL, V100, P1100, DOI 10.1016/j.ijrobp.2018.01.011
   Dabaja BS, 2018, INT J RADIAT ONCOL, V102, P508, DOI 10.1016/j.ijrobp.2018.05.078
   Dabaja BS, 2018, BLOOD, V132, P1635, DOI 10.1182/blood-2018-03-837633
   Illidge T, 2014, INT J RADIAT ONCOL, V89, P49, DOI 10.1016/j.ijrobp.2014.01.006
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   National Comprehensive Cancer Network (NCCN), 2020, PRIM CUT LYMPH
   National Comprehensive Cancer Network (NCCN), 2020, B CELL LYMPH
   Ng AK, 2018, INT J RADIAT ONCOL, V100, P652, DOI 10.1016/j.ijrobp.2017.12.005
   Pinnix CC, 2018, INT J RADIAT ONCOL, V102, P53, DOI 10.1016/j.ijrobp.2018.05.067
   Specht L, 2015, INT J RADIAT ONCOL, V92, P32, DOI 10.1016/j.ijrobp.2015.01.008
   Specht L, 2014, INT J RADIAT ONCOL, V89, P854, DOI 10.1016/j.ijrobp.2013.05.005
   Tsang RW, 2018, INT J RADIAT ONCOL, V102, P1602, DOI 10.1016/j.ijrobp.2018.08.004
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yahalom J, 2015, INT J RADIAT ONCOL, V92, P11, DOI 10.1016/j.ijrobp.2015.01.009
NR 18
TC 18
Z9 19
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAY 21
PY 2020
VL 135
IS 21
BP 1829
EP 1832
DI 10.1182/blood.2020006028
PG 4
WC Hematology
SC Hematology
GA LR8SY
UT WOS:000535968000007
PM 32275740
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Verscheijden, LFM
   van der Zanden, TM
   van Bussel, LPM
   de Hoop-Sommen, M
   Russel, FGM
   Johnson, TN
   de Wildt, SN
AF Verscheijden, Laurens F. M.
   van der Zanden, Tjitske M.
   van Bussel, Lianne P. M.
   de Hoop-Sommen, Marika
   Russel, Frans G. M.
   Johnson, Trevor N.
   de Wildt, Saskia N.
TI Chloroquine Dosing Recommendations for Pediatric COVID-19 Supported by
   Modeling and Simulation
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID PHARMACOKINETICS; CHILDREN; DRUG; EFFICACY; PBPK
AB As chloroquine (CHQ) is part of the Dutch Centre for Infectious Disease Control coronavirus disease 2019 (COVID-19) experimental treatment guideline, pediatric dosing guidelines are needed. Recent pediatric data suggest that existing World Health Organization (WHO) dosing guidelines for children with malaria are suboptimal. The aim of our study was to establish best-evidence to inform pediatric CHQ doses for children infected with COVID-19. A previously developed physiologically-based pharmacokinetic (PBPK) model for CHQ was used to simulate exposure in adults and children and verified against published pharmacokinetic data. The COVID-19 recommended adult dosage regimen of 44 mg/kg total was tested in adults and children to evaluate the extent of variation in exposure. Based on differences in area under the concentration-time curve from zero to 70 hours (AUC(0-70h)) the optimal CHQ dose was determined in children of different ages compared with adults. Revised doses were re-introduced into the model to verify that overall CHQ exposure in each age band was within 5% of the predicted adult value. Simulations showed differences in drug exposure in children of different ages and adults when the same body-weight based dose is given. As such, we propose the following total cumulative doses: 35 mg/kg (CHQ base) for children 0-1 month, 47 mg/kg for 1-6 months, 55 mg/kg for 6 months-12 years, and 44 mg/kg for adolescents and adults, not to exceed 3,300 mg in any patient. Our study supports age-adjusted CHQ dosing in children with COVID-19 in order to avoid suboptimal or toxic doses. The knowledge-driven, model-informed dose selection paradigm can serve as a science-based alternative to recommend pediatric dosing when pediatric clinical trial data is absent.
C1 [Verscheijden, Laurens F. M.; van der Zanden, Tjitske M.; van Bussel, Lianne P. M.; Russel, Frans G. M.; de Wildt, Saskia N.] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Pharmacol & Toxicol, Med Ctr, Nijmegen, Netherlands.
   [van der Zanden, Tjitske M.; de Hoop-Sommen, Marika; de Wildt, Saskia N.] Dutch Knowledge Ctr Pharmacotherapy Children, The Hague, Netherlands.
   [van der Zanden, Tjitske M.] Sophia Childrens Univ Hosp, Dept Paediat, Erasmus MC, Rotterdam, Netherlands.
   [de Hoop-Sommen, Marika] Royal Dutch Pharmacist Assoc, The Hague, Netherlands.
   [Johnson, Trevor N.] Certara UK Ltd, Sheffield, S Yorkshire, England.
   [de Wildt, Saskia N.] Erasmus MC Sophia Childrens Hosp, Intens Care, Rotterdam, Netherlands.
   [de Wildt, Saskia N.] Erasmus MC Sophia Childrens Hosp, Dept Paediat, Rotterdam, Netherlands.
RP de Wildt, SN (corresponding author), Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Pharmacol & Toxicol, Med Ctr, Nijmegen, Netherlands.; de Wildt, SN (corresponding author), Dutch Knowledge Ctr Pharmacotherapy Children, The Hague, Netherlands.; de Wildt, SN (corresponding author), Erasmus MC Sophia Childrens Hosp, Intens Care, Rotterdam, Netherlands.; de Wildt, SN (corresponding author), Erasmus MC Sophia Childrens Hosp, Dept Paediat, Rotterdam, Netherlands.
EM Saskia.deWildt@radboudumc.nl
RI Verscheijden, Laurens FM/Q-7188-2017; Russel, Frans G.M./B-3184-2014; de
   Hoop-Sommen, Marika/ABD-3445-2020
OI Verscheijden, Laurens FM/0000-0003-0303-898X; Russel, Frans
   G.M./0000-0002-7959-2314; 
FU Bill & Melinda Gates FoundationBill & Melinda Gates Foundation [INV
   001822]
FX This work was supported by the Bill & Melinda Gates Foundation (INV
   001822).
CR Abduljalil K, 2014, AAPS J, V16, P568, DOI 10.1208/s12248-014-9592-9
   Anderson HN, 2015, PEDIATR CARDIOL, V36, P1350, DOI 10.1007/s00246-015-1164-y
   CANN HM, 1961, PEDIATRICS, V27, P95
   Grimstein M, 2019, J PHARM SCI-US, V108, P21, DOI 10.1016/j.xphs.2018.10.033
   Hinton DM, 2020, REQUEST EMERGENCY US
   Karunajeewa HA, 2008, ANTIMICROB AGENTS CH, V52, P237, DOI 10.1128/AAC.00555-07
   Kelly J.C., 1990, CHLOROQUINE POISONIN
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Luzon E, 2017, CLIN PHARMACOL THER, V102, P98, DOI 10.1002/cpt.539
   MEB, 2018, SUMM PROD CHAR CHLOR
   Obua C, 2008, BRIT J CLIN PHARMACO, V65, P493, DOI 10.1111/j.1365-2125.2007.03050.x
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Ursing J, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01846-19
   Ursing J, 2011, J INFECT DIS, V203, P109, DOI 10.1093/infdis/jiq001
   van den Anker J, 2018, J CLIN PHARMACOL, V58, pS10, DOI 10.1002/jcph.1284
   van der Zanden TM, 2017, ARCH DIS CHILD, V102, P357, DOI 10.1136/archdischild-2016-311674
   Vollaard A., 2020, LCI RICHTLIJN COVID
   Wagner C, 2015, CPT-PHARMACOMET SYST, V4, P226, DOI 10.1002/psp4.33
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Health organization, 2016, GUID TREATM MAL
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhao QY, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-36
   Zhou W, 2016, CPT-PHARMACOMET SYST, V5, P475, DOI 10.1002/psp4.12101
   Zhou WD, 2018, CLIN PHARMACOL THER, V104, P188, DOI 10.1002/cpt.905
NR 24
TC 3
Z9 3
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD AUG
PY 2020
VL 108
IS 2
BP 248
EP 252
DI 10.1002/cpt.1864
EA MAY 2020
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MJ4KB
UT WOS:000535217700001
PM 32320477
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Scaldaferri, F
   Pugliese, D
   Privitera, G
   Onali, S
   Lopetuso, LR
   Rizzatti, G
   Settanni, CR
   Pizzoferrato, M
   Schiavoni, E
   Turchini, L
   Amatucci, V
   Napolitano, D
   Bernabei, T
   Mora, V
   Laterza, L
   Papa, A
   Guidi, L
   Rapaccini, GL
   Gasbarrini, A
   Armuzzi, A
AF Scaldaferri, Franco
   Pugliese, Daniela
   Privitera, Giuseppe
   Onali, Sara
   Lopetuso, Loris Riccardo
   Rizzatti, Gianenrico
   Settanni, Carlo Romano
   Pizzoferrato, Marco
   Schiavoni, Elisa
   Turchini, Laura
   Amatucci, Valeria
   Napolitano, Daniele
   Bernabei, Tiziana
   Mora, Vincenzina
   Laterza, Lucrezia
   Papa, Alfredo
   Guidi, Luisa
   Rapaccini, Gian Lodovico
   Gasbarrini, Antonio
   Armuzzi, Alessandro
TI Impact of COVID-19 pandemic on the daily management of biotechnological
   therapy in inflammatory bowel disease patients: Reorganisational
   response in a high-volume Italian inflammatory bowel disease centre
SO UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
LA English
DT Article
DE COVID-19; inflammatory bowel disease centre; organisational impact;
   clinical impact; biological therapy
AB The coronavirus disease 2019 (COVID-19) pandemic is having a major clinical as well as organisational impact on the national health-care system in Italy, particularly in high-volume hospitals which are usually active for many essential clinical needs, including inflammatory bowel disease (IBD). Here, we report major clinical and organisational challenges at a high-volume Italian IBD centre one month after the start of the Italian government's restrictions due to the COVID-19 pandemic. All routine follow-up IBD visits of patients in remission were cancelled or rescheduled for 8-12 weeks' time. However, access to the hospital for therapy or for unstable/relapsing patients was not considered postponable. Everyone attending the centre (e.g. physicians, nurses, administrative personnel and patients) were advised to respect the general recommended rules for hand hygiene and social distancing, to disclose if they had a fever or cough or flu-like symptoms and to wear a surgical mask and gloves. At the entrance of the therapy area, a control station was set up in order to double-check all patients with a clinical interview and conduct thermal scanning. A total of 1451 IBD patients under biotechnological or experimental therapy actively followed in the CEMAD IBD centre were included in the study. About 65% of patients maintained their appointment schedules without major problems, while in 20% of cases planned infusions were delayed because of the patient's decision or practical issues. About 10% of patients receiving subcutaneous therapy were allowed to collect their medicine without a follow-up visit. Finally, 10% of patients living outside the Lazio region requested access to their therapy at a local centre closer to their home. At present, five patients have been found to be positive for SARS-CoV-2 infection but with minimal symptoms, 22 are in 'quarantine' for contact considered to be 'at risk' for the infection. Up to now, none of them has experienced significant symptoms. This study represents the first observational detailed report about short-term impact of the COVID-19 pandemic on patient organisation and management in a high-volume IBD centre.
C1 [Scaldaferri, Franco; Pugliese, Daniela; Onali, Sara; Lopetuso, Loris Riccardo; Rizzatti, Gianenrico; Settanni, Carlo Romano; Pizzoferrato, Marco; Schiavoni, Elisa; Turchini, Laura; Amatucci, Valeria; Napolitano, Daniele; Bernabei, Tiziana; Mora, Vincenzina; Laterza, Lucrezia; Papa, Alfredo; Guidi, Luisa; Rapaccini, Gian Lodovico; Gasbarrini, Antonio; Armuzzi, Alessandro] C Fdn Policlin Univ A Gemelli IRCCS, CEMAD IBD UNIT Unita Operat Complessa Med Interna, Rome, Italy.
   [Scaldaferri, Franco; Privitera, Giuseppe; Papa, Alfredo; Guidi, Luisa; Rapaccini, Gian Lodovico; Gasbarrini, Antonio; Armuzzi, Alessandro] Univ Cattolica Sacro Cuore, Dipartimento Univ Med & Chirurg Traslaz, I-20123 Milan, Italy.
RP Armuzzi, A (corresponding author), Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg, Largo A Gemelli 8, I-00168 Rome, Italy.
EM alessandro.armuzzi@policlinicogemelli.it
RI Taha, Samy/N-4620-2019; Pugliese, Daniela/G-4903-2018
OI Taha, Samy/0000-0003-0284-7806; PAPA, Alfredo/0000-0002-4186-7298;
   scaldaferri, franco/0000-0001-8334-7541; Privitera,
   Giuseppe/0000-0002-7020-5808; Pugliese, Daniela/0000-0001-7930-5402
CR [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   Bai XY, 2020, J CROHNS COLITIS, V14, P1494, DOI 10.1093/ecco-jcc/jjaa064
   Danese S, 2020, NAT REV GASTRO HEPAT, V17, P253, DOI 10.1038/s41575-020-0294-8
   Dulai PS, 2018, GASTROENTEROLOGY, V154, P37, DOI 10.1053/j.gastro.2017.09.052
   Fiorino G, 2020, J CROHNS COLITIS, V14, P1330, DOI 10.1093/ecco-jcc/jjaa058
   Fiorino G, 2020, J CROHNS COLITIS, V14, P1037, DOI 10.1093/ecco-jcc/jjaa023
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   John Hopkins University, 2020, COR RES CTR COR COVI
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   Rubin DT, 2020, GASTROENTEROLOGY, V159, P350, DOI 10.1053/j.gastro.2020.04.012
   Rubin DT, 2020, GASTROENTEROLOGY, V159, P6, DOI 10.1053/j.gastro.2020.04.002
   WHO, 2020, Q A COR COVID 19
   Wisniewski A, 2020, UNITED EUR GASTROENT, V8, P303, DOI 10.1177/2050640619889763
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 14
TC 6
Z9 6
U1 2
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2050-6406
EI 2050-6414
J9 UNITED EUR GASTROENT
JI United European Gastroenterol. J.
PD AUG
PY 2020
VL 8
IS 7
BP 775
EP 781
AR 2050640620929133
DI 10.1177/2050640620929133
EA MAY 2020
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA MV8GX
UT WOS:000534918000001
PM 32438878
OA Green Published
DA 2021-01-01
ER

PT J
AU Tumlinson, A
   Altman, W
   Glaudemans, J
   Gleckman, H
   Grabowski, DC
AF Tumlinson, Anne
   Altman, William
   Glaudemans, Jon
   Gleckman, Howard
   Grabowski, David C.
TI Post-Acute Care Preparedness in a COVID-19 World
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE post-acute care; COVID-19; skilled nursing facilities
AB Coronavirus disease 2019 (COVID-19) has led to a surge of patients requiring post-acute care. In order to support federal, state and corporate planning, we offer a four-stage regionally oriented approach to achieving optimal systemwide resource allocation across a region's post-acute service settings and providers over time. In the first stage, the post-acute care system must, to the extent possible, help relieve acute hospitals of non-COVID-19 patients to create as much inpatient capacity as possible over the surge period. In the second stage after the initial surge as subsided, post-acute providers must protect vulnerable populations from COVID-19, prepare treat-in-place protocols for non-COVID-19 admissions, and create and formalize COVID-19 specific settings. In the third stage after a vaccine has been developed or an effective prophylactic option is available, post-acute care providers must assist with distribution and administration of vaccinations and prophylaxis, develop strategies to deliver non-COVID-19 related medical care, and begin to transition to the post-COVID-19 landscape. In the final stage, we must create health advisory bodies to review post-acute sector's response, identify opportunities to improve performance going forward, and develop a pandemic response plan for post-acute care providers.
C1 [Tumlinson, Anne; Glaudemans, Jon] ATI Advisory, Washington, DC USA.
   [Altman, William] Kindred Healthcare, Louisville, KY USA.
   [Gleckman, Howard] Urban Inst, Washington, DC 20037 USA.
   [Grabowski, David C.] Harvard Med Sch, Boston, MA 02115 USA.
RP Grabowski, DC (corresponding author), 180 Longwood Ave, Boston, MA 02115 USA.
EM grabowski@med.harvard.edu
OI Grabowski, David/0000-0003-2915-5770
FU National Institute on AgingUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA); Agency for Healthcare Research QualityUnited States
   Department of Health & Human ServicesAgency for Healthcare Research &
   Quality; Arnold Foundation; Warren Alpert Foundation
FX There were no direct funding sources for the writing or production of
   the article. Howard Gleckman is a senior fellow at the Urban Institute.
   The views expressed in this article are the author's own and do not
   reflect the view of the Urban Institute. David Grabowski reported that
   he receives research support from grants from the National Institute on
   Aging; the Agency for Healthcare Research & Quality; the Arnold
   Foundation; and the Warren Alpert Foundation; serving as a paid
   consultant to Vivacitas; serving on the Scientific Advisory Committee
   for NaviHealth; and receiving fees from the Medicare Payment Advisory
   Commission, Compass Lexecon, Analysis Group, the Research Triangle
   Institute, and Abt Associates.
CR Gleckman H., 2020, FORBES
   Gottlieb S, 2020, NATL CORONAVIRUS RES
   Grabowski DC, 2020, JAMA-J AM MED ASSOC, V323, P2007, DOI 10.1001/jama.2020.4686
   Levine DM, 2020, ANN INTERN MED, V172, P77, DOI 10.7326/M19-0600
   Lynn J., PRAGMATISTS ADVICE N
NR 5
TC 5
Z9 5
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUN
PY 2020
VL 68
IS 6
BP 1150
EP 1154
DI 10.1111/jgs.16519
EA MAY 2020
PG 5
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA LX7IY
UT WOS:000534419500001
PM 32343366
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Barnes, GD
   Burnett, A
   Allen, A
   Blumenstein, M
   Clark, NP
   Cuker, A
   Dager, WE
   Deitelzweig, SB
   Ellsworth, S
   Garcia, D
   Kaatz, S
   Minichiello, T
AF Barnes, Geoffrey D.
   Burnett, Allison
   Allen, Arthur
   Blumenstein, Marilyn
   Clark, Nathan P.
   Cuker, Adam
   Dager, William E.
   Deitelzweig, Steven B.
   Ellsworth, Stacy
   Garcia, David
   Kaatz, Scott
   Minichiello, Tracy
TI Thromboembolism and anticoagulant therapy during the COVID-19 pandemic:
   interim clinical guidance from the anticoagulation forum
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Article
DE Anticoagulation; COVID-19; Direct oral anticoagulant; Prophylaxis;
   Stewardship; Venous thromboembolism
ID HOSPITALIZED MEDICAL PATIENTS; HEMATOLOGY 2018 GUIDELINES; ED
   AMERICAN-COLLEGE; VENOUS THROMBOEMBOLISM; ANTITHROMBOTIC THERAPY;
   RISK-ASSESSMENT; PREVENTION; PROPHYLAXIS; MANAGEMENT; THROMBOSIS
AB Coronavirus disease 2019 (COVID-19) is a viral infection that can, in severe cases, result in cytokine storm, systemic inflammatory response and coagulopathy that is prognostic of poor outcomes. While some, but not all, laboratory findings appear similar to sepsis-associated disseminated intravascular coagulopathy (DIC), COVID-19- induced coagulopathy (CIC) appears to be more prothrombotic than hemorrhagic. It has been postulated that CIC may be an uncontrolled immunothrombotic response to COVID-19, and there is growing evidence of venous and arterial thromboembolic events in these critically ill patients. Clinicians around the globe are challenged with rapidly identifying reasonable diagnostic, monitoring and anticoagulant strategies to safely and effectively manage these patients. Thoughtful use of proven, evidence-based approaches must be carefully balanced with integration of rapidly emerging evidence and growing experience. The goal of this document is to provide guidance from the Anticoagulation Forum, a North American organization of anticoagulation providers, regarding use of anticoagulant therapies in patients with COVID-19. We discuss in-hospital and post-discharge venous thromboembolism (VTE) prevention, treatment of suspected but unconfirmed VTE, laboratory monitoring of COVID-19, associated anticoagulant therapies, and essential elements for optimized transitions of care specific to patients with COVID-19.
C1 [Barnes, Geoffrey D.] Univ Michigan, 2800 Plymouth Rd,B14 G214, Ann Arbor, MI 48109 USA.
   [Burnett, Allison] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA.
   [Allen, Arthur] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA.
   [Blumenstein, Marilyn] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   [Clark, Nathan P.] Colorado Univ, Skaggs Sch Pharm, Kaiser Permanente Colorado, Aurora, CO USA.
   [Cuker, Adam] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Dager, William E.] UC Davis Med Ctr, Sacramento, CA USA.
   [Deitelzweig, Steven B.] Ochsner Hlth Syst, New Orleans, LA USA.
   [Ellsworth, Stacy; Kaatz, Scott] Henry Ford Hosp, Detroit, MI 48202 USA.
   [Garcia, David] Univ Washington, Seattle, WA 98195 USA.
   [Minichiello, Tracy] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
RP Barnes, GD (corresponding author), Univ Michigan, 2800 Plymouth Rd,B14 G214, Ann Arbor, MI 48109 USA.
EM gbarnes@med.umich.edu
RI Barnes, Geoffrey/AAK-1780-2020
OI Barnes, Geoffrey/0000-0002-6532-8440
CR Anderson DR, 2019, BLOOD ADV, V3, P3898, DOI 10.1182/bloodadvances.2019000975
   [Anonymous], 2019, NICE GUIDELINE VENOU
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Barbar S, 2010, J THROMB HAEMOST, V8, P2450, DOI 10.1111/j.1538-7836.2010.04044.x
   Barnes GD, 2018, J THROMB HAEMOST, V16, P1307, DOI 10.1111/jth.14150
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Caprini JA, 2005, DM-DIS MON, V51, P70, DOI 10.1016/j.disamonth.2005.02.003
   Chatterjee S, 2014, JAMA-J AM MED ASSOC, V311, P2414, DOI 10.1001/jama.2014.5990
   Chiasakul T, 2020, THROMB RES
   Cohen AT, 2016, NEW ENGL J MED, V375, P534, DOI 10.1056/NEJMoa1601747
   Cohen AT, 2013, NEW ENGL J MED, V368, P513, DOI 10.1056/NEJMoa1111096
   Cohen AT, 2006, BMJ-BRIT MED J, V332, P325, DOI 10.1136/bmj.38733.466748.7C
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Decousus H, 2011, CHEST, V139, P69, DOI 10.1378/chest.09-3081
   Helms J, HIGH RISK THROMBOSIS
   Hunt B, 2020, PRACTICAL GUIDANCE P
   Ikesaka R, 2014, THROMB RES, V133, P682, DOI 10.1016/j.thromres.2014.01.021
   James A, 2018, OBSTET GYNECOL, V132, pE1, DOI 10.1097/AOG.0000000000002706
   Kahn SR, 2012, CHEST, V141, pE195S, DOI 10.1378/chest.11-2296
   Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026
   Kearon C, 2012, CHEST, V141, pE419S, DOI 10.1378/chest.11-2301
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Konstantinides SV, 2020, EUR HEART J, V41, P543, DOI 10.1093/eurheartj/ehz405
   Leizorovicz A, 2004, CIRCULATION, V110, P874, DOI 10.1161/01.CIR.0000138928.83266.24
   Lodigiania C, 2020, ITALY THROMB RES, DOI [10.1016/j.thromres.2020.04.024, DOI 10.1016/J.THROMRES.2020.04.024]
   Obi AT, 2019, J VASC SURG-VENOUS L, V7, P317, DOI 10.1016/j.jvsv.2018.08.010
   Obi AT, 2020, J VASC SURG VENOUS L
   RCOG, 2015, RED RISK VEN THROMB, V37
   Royal College of Obstetricians and Gynaecologists, COR COVID 19 INF PRE
   Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103
   Schulman S, 2011, ANN INTERN MED, V155, P653, DOI 10.7326/0003-4819-155-10-201111150-00003
   Schunemann HJ, 2018, BLOOD ADV, V2, P3198, DOI 10.1182/bloodadvances.2018022954
   Simone EP, 2008, SURG ENDOSC, V22, P2392, DOI 10.1007/s00464-008-9997-6
   Spyropoulos AC, 2011, CHEST, V140, P706, DOI 10.1378/chest.10-1944
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Walker CK, 2017, ANN PHARMACOTHER, V51, P323, DOI 10.1177/1060028016683970
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
   Wang TF, 2014, THROMB HAEMOSTASIS, V111, P88, DOI 10.1160/TH13-01-0042
   Witt DM, 2010, J THROMB HAEMOST, V8, P744, DOI 10.1111/j.1538-7836.2010.03756.x
   Witt DM, 2018, BLOOD ADV, V2, P3257, DOI 10.1182/bloodadvances.2018024893
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 43
TC 55
Z9 55
U1 1
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
PD JUL
PY 2020
VL 50
IS 1
BP 72
EP 81
DI 10.1007/s11239-020-02138-z
EA MAY 2020
PG 10
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA LY0ER
UT WOS:000534735100001
PM 32440883
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kobayashi, J
   Murata, I
AF Kobayashi, Jun
   Murata, Isamu
TI Nitric oxide inhalation as an interventional rescue therapy for
   COVID-19-induced acute respiratory distress syndrome
SO ANNALS OF INTENSIVE CARE
LA English
DT Letter
AB COVID-19 is an emerging disease of public health concern. While there is no specific recommended treatment for COVID-19, nitric oxide has the potential to be of therapeutic value for managing acute respiratory distress syndrome in patients with COVID-19. However, inhaled nitric oxide has not yet been formally evaluated. Given the extent of the COVID-19 pandemic, and the large numbers of hospitalized patients requiring respiratory support, clinical use of inhaled nitric oxide may become an alternate rescue therapy before extracorporeal membrane oxygenation for the management of acute respiratory distress syndrome in patients with COVID-19.
C1 [Kobayashi, Jun; Murata, Isamu] Josai Univ, Fac Pharm & Pharmaceut Sci, 1-1 Keyakidai, Sakado, Saitama 3500295, Japan.
RP Kobayashi, J (corresponding author), Josai Univ, Fac Pharm & Pharmaceut Sci, 1-1 Keyakidai, Sakado, Saitama 3500295, Japan.
EM junkoba@josai.ac.jp
CR Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008
   Lei C, 2020, PROTOCOL RANDOMIZED, DOI [10.1101/2020.03.09.20033530, DOI 10.1101/2020.03.09.20033530]
   Li L, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00661-z
   McMahon Timothy J, 2006, Proc Am Thorac Soc, V3, P153, DOI 10.1513/pats.200507-066BG
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
NR 5
TC 6
Z9 6
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2110-5820
J9 ANN INTENSIVE CARE
JI Ann. Intensive Care
PD MAY 20
PY 2020
VL 10
IS 1
AR 61
DI 10.1186/s13613-020-00681-9
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA LT4PD
UT WOS:000537053300002
PM 32436029
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bhardwaj, VK
   Singh, R
   Sharma, J
   Rajendran, V
   Purohit, R
   Kumar, S
AF Bhardwaj, Vijay Kumar
   Singh, Rahul
   Sharma, Jatin
   Rajendran, Vidya
   Purohit, Rituraj
   Kumar, Sanjay
TI Identification of bioactive molecules from tea plant as SARS-CoV-2 main
   protease inhibitors
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; main protease; bioactive molecules
ID CORONAVIRUS; SARS; DYNAMICS; MINIMIZATION; POLYPHENOLS; EFFICIENT;
   CATECHINS; GROMACS; DESIGN; ENERGY
AB The SARS-CoV-2 is the causative agent of COVID-19 pandemic that is causing a global health emergency. The lack of targeted therapeutics and limited treatment options have triggered the scientific community to develop new vaccines or small molecule therapeutics against various targets of SARS-CoV-2. The main protease (Mpro) is a well characterized and attractive drug target because of its crucial role in processing of the polyproteins which are required for viral replication. In order to provide potential lead molecules against the Mpro for clinical use, we docked a set of 65 bioactive molecules of Tea plant followed by exploration of the vast conformational space of protein-ligand complexes by long term molecular dynamics (MD) simulations (1.50 mu s). Top three bioactive molecules (Oolonghomobisflavan-A, Theasinensin-D, and Theaflavin-3-O-gallate) were selected by comparing their docking scores with repurposed drugs (Atazanavir, Darunavir, and Lopinavir) against SARS-CoV-2. Oolonghomobisflavan-A molecule showed a good number of hydrogen bonds with Mpro and higher MM-PBSA binding energy when compared to all three repurposed drug molecules. during the time of simulation. This study showed Oolonghomobisflavan-A as a potential bioactive molecule to act as an inhibitor for the Mpro of SARS-CoV-2.
   [GRAPHICS]
   .
C1 [Bhardwaj, Vijay Kumar; Singh, Rahul; Sharma, Jatin; Purohit, Rituraj] CSIR IHBT, Struct Bioinformat Lab, Palampur, Himachal Prades, India.
   [Bhardwaj, Vijay Kumar; Singh, Rahul; Sharma, Jatin; Rajendran, Vidya; Purohit, Rituraj; Kumar, Sanjay] AcSIR, CSIR IHBT Campus, Palampur, Himachal Prades, India.
RP Purohit, R (corresponding author), CSIR IHBT, Struct Bioinformat Lab, Palampur, Himachal Prades, India.
EM rituraj@ihbt.res.in
RI Singh, Rahul/U-1327-2018
OI Singh, Rahul/0000-0003-1213-2708
FU Board of Research in Nuclear Sciences, Department of Atomic Energy,
   Mumbai, India [37(1)/14/26/2015/BRNS]; CSIRCouncil of Scientific &
   Industrial Research (CSIR) - India [MLP0201, HCP0007]; Department of
   Science and Technology, New Delhi, IndiaDepartment of Science &
   Technology (India) [ECR/2016/000031]
FX We gratefully acknowledge to the Director, CSIR-Institute of Himalayan
   Bioresource Technology, Palampur for providing the facilities to carry
   out this work. RP gratefully acknowledges the Board of Research in
   Nuclear Sciences, Department of Atomic Energy, Mumbai, India for
   financial support vide letter No: 37(1)/14/26/2015/BRNS. The CSIR
   support in the form of projects MLP0201 for bioinformatics studies and
   HCP0007 for providing project fellowship is highly acknowledged. VB
   acknowledges the Department of Science and Technology, New Delhi, India
   for providing junior research fellowship SERB File No: ECR/2016/000031.
   This manuscript represents CSIR-IHBT communication no. 4608 and Academy
   of Scientific and Innovative Research.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Bhardwaj VK, 2020, INT J BIOL MACROMOL, V148, P999, DOI 10.1016/j.ijbiomac.2020.01.212
   Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   Borgio JF, 2020, ARCH MED SCI, V16, P508, DOI 10.5114/aoms.2020.94567
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   Cameron CE, 2001, CURR OPIN INFECT DIS, V14, P757, DOI 10.1097/00001432-200112000-00015
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fujiki H, 1998, MUTAT RES-FUND MOL M, V402, P307, DOI 10.1016/S0027-5107(97)00310-2
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Green Tee J., 2000, CHEM COMPOSITION VAR
   Han DP, 2006, VIROLOGY, V350, P15, DOI 10.1016/j.virol.2006.01.029
   Hashimoto F, 1996, BIOORG MED CHEM LETT, V6, P695, DOI 10.1016/0960-894X(96)00095-9
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   IKEDA I, 1992, BIOCHIM BIOPHYS ACTA, V1127, P141, DOI 10.1016/0005-2760(92)90269-2
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   John A, 2020, ACS OMEGA, V5, P4270, DOI 10.1021/acsomega.9b04203
   John A, 2020, J BIOMOL STRUCT DYN, V38, P1995, DOI 10.1080/07391102.2019.1623075
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lee TW, 2005, J MOL BIOL, V353, P1137, DOI 10.1016/j.jmb.2005.09.004
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Nagarajan H, 2020, MUTAT RES-FUND MOL M, V819, DOI 10.1016/j.mrfmmm.2020.111687
   Nakai M, 2005, J AGR FOOD CHEM, V53, P4593, DOI 10.1021/jf047814+
   Ortega JT, 2020, EXCLI J, V19, P400, DOI 10.17179/excli2020-1189
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Purohit R, 2014, J BIOMOL STRUCT DYN, V32, P1033, DOI 10.1080/07391102.2013.803264
   Rajendran V, 2018, J CELL BIOCHEM, V119, P918, DOI 10.1002/jcb.26257
   Rajendran V, 2014, J BIOMOL STRUCT DYN, V32, P209, DOI 10.1080/07391102.2012.759885
   Sadhasivam A, 2020, J BIOMOL STRUCT DYN, V38, P3131, DOI 10.1080/07391102.2019.1652691
   Sadhasivam A, 2019, J CELL BIOCHEM, V120, P2271, DOI 10.1002/jcb.27553
   Sai V., 2011, J MED PLANTS RES, V5, P2110
   Sharma J, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1720818
   Singh R, 2020, J BIOMOL STRUCT DYN, V38, P5126, DOI 10.1080/07391102.2019.1696709
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Studio  D, 2015, DASS SYST BIOVIA DIS
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu CD, 2002, NUTRITION, V18, P443, DOI 10.1016/S0899-9007(02)00763-3
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   YEN GC, 1995, J AGR FOOD CHEM, V43, P27, DOI 10.1021/jf00049a007
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zheng JJ, 2017, J CHEM THEORY COMPUT, V13, P6424, DOI 10.1021/acs.jctc.7b00719
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 50
TC 29
Z9 30
U1 4
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1766572
EA MAY 2020
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LT3NB
UT WOS:000536976800001
PM 32397940
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Smith, TRF
   Patel, A
   Ramos, S
   Elwood, D
   Zhu, XZ
   Yan, J
   Gary, EN
   Walker, SN
   Schultheis, K
   Purwar, M
   Xu, ZY
   Walters, J
   Bhojnagarwala, P
   Yang, M
   Chokkalingam, N
   Pezzoli, P
   Parzych, E
   Reuschel, EL
   Doan, A
   Tursi, N
   Vasquez, M
   Choi, J
   Tello-Ruiz, E
   Maricic, I
   Bah, MA
   Wu, YH
   Amante, D
   Park, DH
   Dia, Y
   Ali, AR
   Zaidi, FI
   Generotti, A
   Kim, KY
   Herring, TA
   Reeder, S
   Andrade, VM
   Buttigieg, K
   Zhao, G
   Wu, JM
   Li, D
   Bao, LL
   Liu, JN
   Deng, W
   Qin, C
   Brown, AS
   Khoshnejad, M
   Wang, NS
   Chu, AQLN
   Wrapp, D
   McLellan, JS
   Muthumani, K
   Wang, B
   Carroll, MW
   Kim, JJ
   Boyer, J
   Kulp, DW
   Humeau, LMPF
   Weiner, DB
   Broderick, KE
AF Smith, Trevor R. F.
   Patel, Ami
   Ramos, Stephanie
   Elwood, Dustin
   Zhu, Xizhou
   Yan, Jian
   Gary, Ebony N.
   Walker, Susanne N.
   Schultheis, Katherine
   Purwar, Mansi
   Xu, Ziyang
   Walters, Jewell
   Bhojnagarwala, Pratik
   Yang, Maria
   Chokkalingam, Neethu
   Pezzoli, Patrick
   Parzych, Elizabeth
   Reuschel, Emma L.
   Doan, Arthur
   Tursi, Nicholas
   Vasquez, Miguel
   Choi, Jihae
   Tello-Ruiz, Edgar
   Maricic, Igor
   Bah, Mamadou A.
   Wu, Yuanhan
   Amante, Dinah
   Park, Daniel H.
   Dia, Yaya
   Ali, Ali Raza
   Zaidi, Faraz, I
   Generotti, Alison
   Kim, Kevin Y.
   Herring, Timothy A.
   Reeder, Sophia
   Andrade, Viviane M.
   Buttigieg, Karen
   Zhao, Gan
   Wu, Jiun-Ming
   Li, Dan
   Bao, Linlin
   Liu, Jiangning
   Deng, Wei
   Qin, Chuan
   Brown, Ami Shah
   Khoshnejad, Makan
   Wang, Nianshuang
   Chu, Jacqueline
   Wrapp, Daniel
   McLellan, Jason S.
   Muthumani, Kar
   Wang, Bin
   Carroll, Miles W.
   Kim, J. Joseph
   Boyer, Jean
   Kulp, Daniel W.
   Humeau, Laurent M. P. F.
   Weiner, David B.
   Broderick, Kate E.
TI Immunogenicity of a DNA vaccine candidate for COVID-19
SO NATURE COMMUNICATIONS
LA English
DT Article
ID SYNDROME (SARS)-ASSOCIATED CORONAVIRUS; PROTECTIVE EFFICACY; SARS-COV;
   MICE; NEUTRALIZATION; DELIVERY; IMMUNIZATION; PNEUMONIA; INFECTION;
   IMMUNITY
AB The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for the pandemic viral pneumonia disease, COVID-19. At this time, no vaccine is available to control further dissemination of the disease. We have previously engineered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein, the major surface antigen of coronaviruses, which is currently in clinical study. Here we build on this prior experience to generate a synthetic DNA-based vaccine candidate targeting SARS-CoV-2 S protein. The engineered construct, INO-4800, results in robust expression of the S protein in vitro. Following immunization of mice and guinea pigs with INO-4800 we measure antigen-specific T cell responses, functional antibodies which neutralize the SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and biodistribution of SARS-CoV-2 targeting antibodies to the lungs. This preliminary dataset identifies INO-4800 as a potential COVID-19 vaccine candidate, supporting further translational study. There is currently no licensed SARS-CoV-2 vaccine. Here, the authors generate an optimized DNA vaccine candidate encoding the SARS-CoV-2 spike antigen, demonstrating induction of specific T cells and neutralizing antibody responses in mice and guinea pigs. These initial results support further development of this vaccine candidate.
C1 [Smith, Trevor R. F.; Ramos, Stephanie; Elwood, Dustin; Yan, Jian; Schultheis, Katherine; Walters, Jewell; Yang, Maria; Pezzoli, Patrick; Doan, Arthur; Vasquez, Miguel; Maricic, Igor; Amante, Dinah; Generotti, Alison; Herring, Timothy A.; Andrade, Viviane M.; Brown, Ami Shah; Kim, J. Joseph; Boyer, Jean; Humeau, Laurent M. P. F.; Broderick, Kate E.] Inovio Pharmaceut, Plymouth Meeting, Philadelphia, PA 19462 USA.
   [Patel, Ami; Zhu, Xizhou; Gary, Ebony N.; Walker, Susanne N.; Purwar, Mansi; Xu, Ziyang; Bhojnagarwala, Pratik; Chokkalingam, Neethu; Parzych, Elizabeth; Reuschel, Emma L.; Tursi, Nicholas; Choi, Jihae; Tello-Ruiz, Edgar; Bah, Mamadou A.; Wu, Yuanhan; Park, Daniel H.; Dia, Yaya; Ali, Ali Raza; Zaidi, Faraz, I; Kim, Kevin Y.; Reeder, Sophia; Khoshnejad, Makan; Chu, Jacqueline; Muthumani, Kar; Kulp, Daniel W.; Weiner, David B.] Wistar Inst Anat & Biol, Vaccine & Immunotherapy Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA.
   [Buttigieg, Karen; Carroll, Miles W.] Publ Hlth England, Natl Infect Serv, Porton Down, Wilts, England.
   [Zhao, Gan; Wu, Jiun-Ming] Advaccine Suzhou Biopharmaceut Co Ltd, Suzhou, Peoples R China.
   [Li, Dan; Bao, Linlin; Liu, Jiangning; Deng, Wei; Qin, Chuan; Wang, Bin] Fudan Univ, Sch Basic Med Sci, Key Lab Med Mol Virol MOH & MOE, Shanghai, Peoples R China.
   [Li, Dan; Bao, Linlin; Liu, Jiangning; Deng, Wei; Qin, Chuan; Wang, Bin] Fudan Univ, Sch Basic Med Sci, Dept Med Microbiol & Parasitol, Shanghai, Peoples R China.
   [Wang, Nianshuang; Wrapp, Daniel; McLellan, Jason S.] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA.
RP Broderick, KE (corresponding author), Inovio Pharmaceut, Plymouth Meeting, Philadelphia, PA 19462 USA.
EM kate.broderick@inovio.com
RI qin, chuan/ABG-4508-2020
OI Machado de Mello Andrade, Viviane/0000-0002-5056-298X; Xu,
   Ziyang/0000-0001-7690-7029; Gary, Ebony/0000-0002-2928-1120; Ramos,
   Stephanie/0000-0002-5326-4937; Zhu, Xizhou/0000-0002-3646-6668; Bah,
   Mamadou/0000-0002-3238-1085
FU Coalition for Epidemic Preparedness Innovations (CEPI)
FX The studies described in this manuscript were funded by a grant from the
   Coalition for Epidemic Preparedness Innovations (CEPI). The authors
   would like to additional thank Stacy Guzman at The Wistar Institute, and
   Olivia Bedoya, Gloria Mendez, Francisco Vega Vega and Jon Schantz at
   Inovio Pharmaceuticals for their assistance.
CR Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Bagarazzi ML, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004414
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Caly L, 2020, MED J AUSTRALIA, V212, P459, DOI 10.5694/mja2.50569
   Carter D, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aas9930
   Darnell MER, 2007, J INFECT DIS, V196, P1329, DOI 10.1086/522431
   Deng Y, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0056-7
   GISAID, 2020, COR COVID 19 GLOB CA
   He YX, 2005, VIROLOGY, V334, P74, DOI 10.1016/j.virol.2005.01.034
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang PS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024109
   Hulkower RL, 2011, AM J INFECT CONTROL, V39, P401, DOI 10.1016/j.ajic.2010.08.011
   Iwata-Yoshikawa N, 2014, J VIROL, V88, P8597, DOI 10.1128/JVI.00983-14
   Jiang JJ, 2019, HUM VACC IMMUNOTHER, V15, P2066, DOI 10.1080/21645515.2019.1616499
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Luke T, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1061
   Luo F, 2018, VIROL SIN, V33, P201, DOI 10.1007/s12250-018-0009-2
   Modjarrad K, 2019, LANCET INFECT DIS, V19, P1013, DOI 10.1016/S1473-3099(19)30266-X
   Muthumani K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7462
   Oh HLJ, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.26
   Patel A, 2019, J INFECT DIS, V219, P544, DOI 10.1093/infdis/jiy537
   Qin E, 2006, VACCINE, V24, P1028, DOI 10.1016/j.vaccine.2005.06.038
   Roberts A, 2010, VIRAL IMMUNOL, V23, P509, DOI 10.1089/vim.2010.0028
   Rosen O, 2019, J VIROL METHODS, V265, P77, DOI 10.1016/j.jviromet.2018.11.009
   Sardesai NY, 2011, CURR OPIN IMMUNOL, V23, P421, DOI 10.1016/j.coi.2011.03.008
   Schultheis K, 2017, VACCINE, V35, P61, DOI 10.1016/j.vaccine.2016.11.052
   Smith TRF, 2017, VACCINE, V35, P2840, DOI 10.1016/j.vaccine.2017.04.008
   Tebas P, 2019, J INFECT DIS, V220, P400, DOI 10.1093/infdis/jiz132
   Tebas Pablo, 2017, N Engl J Med, DOI 10.1056/NEJMoa1708120
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Voytko L, 2020, CHINESE HEALTHCARE W
   Wang L, 2018, J VIROL, V92, DOI 10.1128/JVI.01060-18
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yan J, 2007, MOL THER, V15, P411, DOI 10.1038/sj.mt.6300036
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
   Zhang NR, 2016, CELL MOL IMMUNOL, V13, P180, DOI 10.1038/cmi.2015.03
   Zhao JX, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan5393
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 45
TC 65
Z9 66
U1 28
U2 38
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAY 20
PY 2020
VL 11
IS 1
AR 2601
DI 10.1038/s41467-020-16505-0
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LT4RV
UT WOS:000537060500001
PM 32433465
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Abdelmaksoud, A
   Vestita, M
   El-Amawy, HS
   Ayhan, E
   An, I
   Ozturk, M
   Goldust, M
AF Abdelmaksoud, Ayman
   Vestita, Michelangelo
   El-Amawy, Heba Saed
   Ayhan, Erhan
   An, Isa
   Ozturk, Murat
   Goldust, Mohamad
TI Systemic isotretinoin therapy in the era of COVID-19
SO DERMATOLOGIC THERAPY
LA English
DT Letter
C1 [Abdelmaksoud, Ayman] Mansoura Dermatol Venerol & Leprol Hosp, 5 Amien Alsamanoudy St, Mansoura, Egypt.
   [Vestita, Michelangelo] Univ Bari, Dept Emergency & Organ Transplantat, Unit Plast & Reconstruct Surg, Bari, Italy.
   [Vestita, Michelangelo] Harvard Med Sch, Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA.
   [El-Amawy, Heba Saed] Tanta Univ, Dermatol & Venereol Dept, Tanta, Egypt.
   [Ayhan, Erhan] Univ Hlth Sci, Gazi Yasargil Training & Res Hosp, Dept Dermatol, Diyarbakir, Turkey.
   [An, Isa] Sanliurfa Training & Res Hosp, Sanliurfa, Turkey.
   [Ozturk, Murat] Van Training & Res Hosp, Van, Turkey.
   [Goldust, Mohamad] Univ Rome G Marconi, Dept Dermatol, Rome, Italy.
   [Goldust, Mohamad] Univ Med Ctr Mainz, Dept Dermatol, Mainz, Germany.
   [Goldust, Mohamad] Univ Hosp Basel, Dept Dermatol, Basel, Switzerland.
RP Abdelmaksoud, A (corresponding author), Mansoura Dermatol Venerol & Leprol Hosp, 5 Amien Alsamanoudy St, Mansoura, Egypt.
EM behcet.behcet@yahoo.com
RI Ozturk, Murat/AAN-2646-2020; Saed, Heba/AAW-3980-2020
OI Ozturk, Murat/0000-0002-4499-3724; Ayhan, Erhan/0000-0003-1416-2636;
   Vestita, Michelangelo/0000-0002-2203-0353
CR Abdelmaksoud A, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13251
   Ayanoglu BT, 2019, DERMATOL THER, V32, DOI 10.1111/dth.12873
   Butowt R, 2020, ACS CHEM NEUROSCI, V11, P1200, DOI 10.1021/acschemneuro.0c00172
   Cengiz AB, 2018, EUR ARCH OTO-RHINO-L, V275, P3025, DOI 10.1007/s00405-018-5190-2
   Del Rosso James Q, 2019, J Clin Aesthet Dermatol, V12, P11
   Dessinioti C, 2020, J EUR ACAD DERMATOL, V34, P2229, DOI 10.1111/jdv.16430
   Feily Amir, 2020, Int J Womens Dermatol, V6, P102, DOI 10.1016/j.ijwd.2019.10.007
   Gorpelioglu C, 2010, INT J DERMATOL, V49, P87, DOI 10.1111/j.1365-4632.2009.04232.x
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Huang L, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.006
   Islek Akif, 2020, Ear Nose Throat J, p145561320920425, DOI 10.1177/0145561320920425
   Kartal D, 2017, AN BRAS DERMATOL, V92, P190, DOI 10.1590/abd1806-4841.20175483
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Singh J, 2016, AUST NZ J PSYCHIAT, V50, P99, DOI 10.1177/0004867415589385
   Skroza Nevena, 2018, J Clin Aesthet Dermatol, V11, P21
   Takci Z, 2013, J DRUGS DERMATOL, V12, P124
   Wambier CG, 2020, J AM ACAD DERMATOL, V83, P308, DOI 10.1016/j.jaad.2020.04.032
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yan YC, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13310
NR 19
TC 5
Z9 5
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13482
DI 10.1111/dth.13482
EA MAY 2020
PG 2
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000535212600001
PM 32358858
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Peric, S
   Stulnig, TM
AF Peric, Slobodan
   Stulnig, Thomas M.
TI Diabetes and COVID-19 Disease-Management-People
SO WIENER KLINISCHE WOCHENSCHRIFT
LA English
DT Article
DE Viral pneumonia; SARS-CoV2; Diabetes complications; Diabetes therapy;
   Telemedicine
ID CLINICAL CHARACTERISTICS; CORONAVIRUS; SARS; METAANALYSIS; PREVALENCE;
   INFECTION; RECEPTOR; COV
AB The current pandemic of SARS-CoV-2 coronavirus disease 2019 (COVID-19) is a particular challenge for diabetes patients. Diabetes mellitus predisposes to a particularly severe course of the disease and doubles the COVID-19 mortality risk due to pulmonary and cardiac involvement. In addition, diabetes patients often suffer from comorbidities which further worsen clinical outcomes. Glycemic control during infectious diseases is often suboptimal, and antidiabetic drugs and insulin therapy have to be adapted accordingly. On the other hand, access of diabetes patients to outpatient clinics are limited during the ongoing season urging alternative treatment options, particularly the implementation of novel telemedicine strategies. Hence, the opportunity of the COVID 19 crisis should be taken to make a significant step forward in the care for diabetes patients.
C1 [Peric, Slobodan; Stulnig, Thomas M.] Hietzing Hosp, Dept Med Metab Dis & Nephrol 3, Neurol Ctr Rosenhuegel, Wolkersbergenstr 1, A-1130 Vienna, Austria.
   [Peric, Slobodan; Stulnig, Thomas M.] Hietzing Hosp, Karl Landsteiner Inst Metab Dis & Nephrol, Neurol Ctr Rosenhuegel, Vienna, Austria.
RP Stulnig, TM (corresponding author), Hietzing Hosp, Dept Med Metab Dis & Nephrol 3, Neurol Ctr Rosenhuegel, Wolkersbergenstr 1, A-1130 Vienna, Austria.; Stulnig, TM (corresponding author), Hietzing Hosp, Karl Landsteiner Inst Metab Dis & Nephrol, Neurol Ctr Rosenhuegel, Vienna, Austria.
EM thomas.stulnig@meduniwien.ac.at
OI Stulnig, Thomas/0000-0003-3300-6161
FU Karl Landsteiner Society
FX This work was supported by the Karl Landsteiner Society.
CR [Anonymous], 2020, INFORM COVID 19 MENS
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015
   Bundesministerium fur Soziales G Pflege und Konsumentenschutz, 2020, COVID 19 ERKR PERS B
   Carey IM, 2018, DIABETES CARE, V41, P513, DOI 10.2337/dc17-2131
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Du Y, 2020, AM J RESP CRIT CARE, P2020
   Dungan KM, 2009, LANCET, V373, P1798, DOI 10.1016/S0140-6736(09)60553-5
   Fadini GP, 2020, J ENDOCRINOL INVEST, V43, P867, DOI 10.1007/s40618-020-01236-2
   Faruque LI, 2017, CAN MED ASSOC J, V189, pE341, DOI 10.1503/cmaj.150885
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guan WJ, 2020, N ENGL J MED
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Gupta R, 2020, DIABETES METAB SYND, V14, P211, DOI 10.1016/j.dsx.2020.03.002
   Hoffmann M, 2020, CELL
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jaeckel E, 2002, ANN NY ACAD SCI, V958, P7
   James MT, 2015, AM J KIDNEY DIS, V66, P602, DOI 10.1053/j.ajkd.2015.02.338
   Kohio HP, 2013, VIROLOGY, V444, P301, DOI 10.1016/j.virol.2013.06.026
   Kulcsar KA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131774
   Lee SWH, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00330
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Liu K, 2020, CHIN MED J
   Mader JK, 2019, WIEN KLIN WOCHENSCHR, V131, P200, DOI 10.1007/s00508-019-1447-z
   Mansfield KE, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012690
   McKillop AM, 2018, PEPTIDES, V100, P165, DOI 10.1016/j.peptides.2017.12.020
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P2012, DOI 10.26355/eurrev_202002_20379
   Muniyappa R, 2020, AM J PHYSL ENDOCRINO
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Reading PC, 1998, J VIROL, V72, P6884, DOI 10.1128/JVI.72.8.6884-6887.1998
   Rogers LC, 2020, J AM PODIATR MED ASS
   Shi S, 2020, JAMA CARDIOL
   Tam CCF, 2020, CATHETER CARDIO INTE, DOI 10.1002/ccd.28943
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Umpierrez Guillermo E, 2003, Treat Endocrinol, V2, P95, DOI 10.2165/00024677-200302020-00003
   University JH, COR COVID 19 GLOB CA
   Vaduganathan M, 2020, NEW ENGL J MED, V382
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Wysocki J, 2006, DIABETES, V55, P2132, DOI 10.2337/db06-0033
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Yang JK, 2010, ACTA DIABETOL, V47, P193, DOI 10.1007/s00592-009-0109-4
   Zhai YK, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000312
   Zhou J, 2020, METABOLISM
NR 47
TC 2
Z9 2
U1 0
U2 3
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0043-5325
EI 1613-7671
J9 WIEN KLIN WOCHENSCHR
JI Wien. Klin. Wochen.
PD JUL
PY 2020
VL 132
IS 13-14
SI SI
BP 356
EP 361
DI 10.1007/s00508-020-01672-3
EA MAY 2020
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA MM6IL
UT WOS:000534677800004
PM 32435867
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Bearden, DM
   Aiken, PB
   Cheng, YH
   Mai, E
   Peters, TM
AF Bearden, Donna M.
   Aiken, Patricia B.
   Cheng, Yu Hsin
   Mai, Emily
   Peters, Timothy M.
TI COVID-19: a primer for healthcare providers
SO WIENER KLINISCHE WOCHENSCHRIFT
LA English
DT Article
DE Pandemic; SARS-CoV-2; Hospitalist; Coronavirus; Nosocomial
ID OUTBREAK; CHINA
AB According to the World Health Organization (WHO) the China office was first notified of cases of atypical pneumonia in Wuhan City on 31 December 2019. A viral genome sequence of a novel coronavirus, currently termed SARS-CoV-2, with a disease process called COVID-19 was released 1 week later via online resources to obtain public health support in control of spread. Since then, the virus rapidly evolved into a global pandemic. Therefore, healthcare providers need to be familiar with the clinical presentation of infected patients and measures to quickly isolate them. The prevention of nosocomial spread is paramount to proper control of COVID-19 and is reviewed. Currently, treatment is supportive. Researchers are working to develop vaccines and identify effective antiviral interventions. Those recently discussed in the literature are briefly reviewed.
C1 [Bearden, Donna M.; Aiken, Patricia B.; Cheng, Yu Hsin; Mai, Emily; Peters, Timothy M.] Univ Alabama Birmingham, Hospitalists Serv, Birmingham Hosp, Birmingham, AL 35294 USA.
RP Bearden, DM (corresponding author), Univ Alabama Birmingham, Hospitalists Serv, Birmingham Hosp, Birmingham, AL 35294 USA.
EM dbearden@uabmc.edu
CR [Anonymous], 2020, XINHUANET
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen ZM, 2020, WORLD J PEDIATR, V16, P240, DOI 10.1007/s12519-020-00345-5
   Cho SY, 2016, LANCET, V388, P994, DOI 10.1016/S0140-6736(16)30623-7
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Government of Canada, 2020, INT NAT CAS DEF NOV
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   McDonald LC, 2004, EMERG INFECT DIS, V10, P777, DOI 10.3201/eid1005.030791
   Nowak Jan K, 2020, F1000Res, V9, P93, DOI 10.12688/f1000research.22299.1
   Pan YY, 2020, EUR RADIOL, V30, P3612, DOI 10.1007/s00330-020-06713-z
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Sanders J, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama2020.6019, DOI 10.1001/JAMA2020.6019]
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wax RS, 2020, CAN J ANESTH, V67, P568, DOI 10.1007/s12630-020-01591-x
   World Health Organization, 2018, MIDDL E RESP SYNDR C
   Wu C, 2020, JAMA INTERN MED, DOI [10.1001/jaminternalmed.2020.0994, DOI 10.1001/JAMINTERNALMED.2020.0994]
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhao S, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2020.101568
NR 26
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0043-5325
EI 1613-7671
J9 WIEN KLIN WOCHENSCHR
JI Wien. Klin. Wochen.
PD JUL
PY 2020
VL 132
IS 13-14
SI SI
BP 390
EP 395
DI 10.1007/s00508-020-01678-x
EA MAY 2020
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA MM6IL
UT WOS:000534677800005
PM 32435870
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gomeni, R
   Xu, TH
   Gao, XJ
   Bressolle-Gomeni, F
AF Gomeni, Roberto
   Xu, Tianhong
   Gao, Xuejuan
   Bressolle-Gomeni, Francoise
TI Model based approach for estimating the dosage regimen of indomethacin a
   potential antiviral treatment of patients infected with SARS CoV-2
SO JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
LA English
DT Article
DE SARS-CoV-2; Indomethacin; Model-based; Clinical dose; Translational
   model
ID TUMOR-CELLS; IN-VITRO; PROTEIN; PLASMA; INTERLEUKIN-6; INHIBITION;
   EFFICACY; IMMUNITY; BLOOD; DOGS
AB To face SARS-CoV-2 pandemic various attempts are made to identify potential effective treatments by repurposing available drugs. Among them, indomethacin, an anti-inflammatory drug, was shown to have potent in-vitro antiviral properties on human SARS-CoV-1, canine CCoV, and more recently on human SARS-CoV-2 at low micromolar range. Our objective was to show that indomethacin could be considered as a promising candidate for the treatment of SARS-CoV-2 and to provide criteria for comparing benefits of alternative dosage regimens using a model-based approach. A multi-stage model-based approach was developed to characterize % of recovery and viral load in CCoV-infected dogs, to estimate the PK of indomethacin in dog and human using published data after administration of immediate (IR) and sustained-release (SR) formulations, and to estimate the expected antiviral activity as a function of different assumptions on the effective exposure in human. Different dosage regimens were evaluated for IR formulation (25 mg and 50 mg three-times-a-day, and 25 mg four-times-a-day), and SR formulation (75 mg once and twice-a-day). The best performing dosing regimens were: 50 mg three-times-a-day for the IR formulation, and 75 mg twice-a-day for the SR formulation. The treatment with the SR formulation at the dose of 75 mg twice-a-day is expected to achieve a complete response in three days for the treatment in patients infected by the SARS-CoV-2 coronavirus. These results suggest that indomethacin could be considered as a promising candidate for the treatment of SARS-CoV-2 whose potential therapeutic effect need to be further assessed in a prospective clinical trial.
C1 [Gomeni, Roberto; Bressolle-Gomeni, Francoise] Pharmacometr, F-12270 Lieu Dit Longcol, La Fouillade, France.
   [Xu, Tianhong; Gao, Xuejuan] BaylorOracle Inc, Hangzhou, Peoples R China.
RP Gomeni, R (corresponding author), Pharmacometr, F-12270 Lieu Dit Longcol, La Fouillade, France.
EM roberto.gomeni@pharmacometrica.com
OI gomeni, roberto/0000-0003-3916-9578
CR Amici C, 2006, ANTIVIR THER, V11, P1021
   Amici C, 2015, CELL MICROBIOL, V17, P1391, DOI 10.1111/cmi.12446
   Arai I, 2004, EUR SPINE J, V13, P691, DOI 10.1007/s005860100268
   Aziz M, 2020, J MED VIROL, V92, P2283, DOI 10.1002/jmv.25948
   Bour AMJJ, 2000, EXP GERONTOL, V35, P1017, DOI 10.1016/S0531-5565(00)00128-5
   Bridges K, 2016, CAN VET J, V57, P513
   Brunelli C, 2012, BIOCHEM J, V443, P379, DOI 10.1042/BJ20111236
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Eli Y, 2001, BIOCHEM PHARMACOL, V61, P565, DOI 10.1016/S0006-2952(00)00578-5
   EMORI HW, 1976, ANN RHEUM DIS, V35, P333, DOI 10.1136/ard.35.4.333
   Gentile LB, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/924028
   HANLY PJ, 1987, LANCET, V1, P351
   HART FD, 1963, BMJ-BRIT MED J, P965
   Hojka-Osinska A, 2012, BIOCHEM BIOPH RES CO, V419, P590, DOI 10.1016/j.bbrc.2012.02.092
   HUSKISSON EC, 1970, ANN RHEUM DIS, V29, P393, DOI 10.1136/ard.29.4.393
   Ji CM, 2007, J DRUG TARGET, V15, P123, DOI 10.1080/10611860601143727
   Jukic MK, 2010, COLLEGIUM ANTROPOL, V34, P899
   Levin G, 2000, CHEMOTHERAPY, V46, P429, DOI 10.1159/000007323
   Magagnoli L, 2020, OUTCOMES HYDROXYCHLO, DOI [10.1101/2020.04.16.20065920, DOI 10.1101/2020.04.16.20065920]
   Mahevas M, 2020, NO EVIDENCE CLIN EFF, P369, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]
   Mihara M, 2011, OPEN ACCESS RHEUMATO, V3, P19, DOI 10.2147/OARRR.S17118
   Morecki S, 2000, CANCER IMMUNOL IMMUN, V48, P613
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Onufrak NJ, 2016, CLIN THER, V38, P1930, DOI 10.1016/j.clinthera.2016.06.015
   Paine SW, 2011, DRUG METAB DISPOS, V39, P1008, DOI 10.1124/dmd.110.037267
   Preston SL, 2003, ANTIMICROB AGENTS CH, V47, P3393, DOI 10.1128/AAC.47.11.3393-3399.2003
   RANE A, 1978, CLIN PHARMACOL THER, V23, P658
   SACERDOTE P, 1995, INFLAMM RES, V44, P486, DOI 10.1007/BF01837915
   Sato K, 2017, BIOSCI BIOTECH BIOCH, V81, P2307, DOI 10.1080/09168451.2017.1394812
   SHACTER E, 1992, BLOOD, V80, P194
   Shen KL, 2020, WORLD J PEDIATR, V16, P219, DOI 10.1007/s12519-020-00344-6
   Smith DA, 2010, NAT REV DRUG DISCOV, V9, P929, DOI 10.1038/nrd3287
   Smith PF, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14314
   Somasundaram R, 2014, J INVEST DERMATOL, V134, P1198, DOI 10.1038/jid.2014.1
   STEINBERG SM, 1990, CIRC SHOCK, V30, P375
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WILAIRATANA P, 1994, ANN TROP MED PARASIT, V88, P359, DOI 10.1080/00034983.1994.11812877
   Xu T., 2020, BIORXIV, DOI DOI 10.1101/2020.04.01.017624
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   YEH KC, 1985, AM J MED, V79, P3, DOI 10.1016/0002-9343(85)90510-8
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 43
TC 3
Z9 3
U1 1
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1567-567X
EI 1573-8744
J9 J PHARMACOKINET PHAR
JI J. Pharmacokinet. Pharmacodyn.
PD JUN
PY 2020
VL 47
IS 3
BP 189
EP 198
DI 10.1007/s10928-020-09690-4
EA MAY 2020
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LY0GN
UT WOS:000534466700001
PM 32435882
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Pandey, P
   Litoriya, R
AF Pandey, Prateek
   Litoriya, Ratnesh
TI Promoting Trustless Computation Through Blockchain Technology
SO NATIONAL ACADEMY SCIENCE LETTERS-INDIA
LA English
DT Article; Early Access
DE Blockchain; COVID-19; Proof of work; Trustless computing
AB Records, irrespective of their nature (whether electronic or paper-based), are vulnerable to fraud. People's hard-earned money, their personal information, identity, and health are at a higher risk than ever due to the misuse of technology in doing forgery. However, the technology can also be used as an answer to counteracting against fraudulence prevalent in affairs from every walk of life. This short paper attempts to present the blockchain technology as a solution to overcome the menace of forgery by promoting trustless computing in business transactions. The paper explains the blockchain technology and a variety of its implementation through five different use cases in the field of drug supply chain, health insurance, land record management, courier services, and immigration records. The immigration blockchain is also proposed as a solution to check pandemic like the coronavirus (COVID-19) effectively. The implementation of the Blockchain is performed using a locally built IBM's hyper-ledger fabric-based platform, and Ethereum public platform. The results are encouraging enough to substitute existing business operations using Blockchain-based solutions.
C1 [Pandey, Prateek; Litoriya, Ratnesh] JAYPEE Univ Engn & Technol, Raghogarh, Guna, India.
RP Litoriya, R (corresponding author), JAYPEE Univ Engn & Technol, Raghogarh, Guna, India.
EM pandeyprat@yahoo.com; litoriya.ratnesh@gmail.com
CR [Anonymous], HYP FABR FLEX BLOCKC
   Ghunawat V, 2017, INDIA TODAY
   Hao X., 2018, 2018 IEEE C COMM NET, P1
   Hooda P, 2018, PROOF WORK POW CONSE
   Jaeger LG, 2018, PUBLIC VERSUS PRIVAT
   Mahajan Vijay, 2010, Indian J Med Ethics, V7, P18
   Matisek JW, 2018, BLOCKCHAIN ARMS RACE
   Naveen P, 2017, TIMES INDIA
   Pandey P, 2020, HEALTH POLICY TECHN, V9, P69, DOI 10.1016/j.hlpt.2020.01.004
   The Ministry of Home Affairs, 2020, ADV TRAV VIS RESTR R
NR 10
TC 0
Z9 0
U1 7
U2 12
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0250-541X
EI 2250-1754
J9 NATL ACAD SCI LETT
JI Natl. Acad. Sci. Lett.-India
DI 10.1007/s40009-020-00978-0
EA MAY 2020
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LP6YX
UT WOS:000534465300003
PM 32836612
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Melgosa, M
   Madrid, A
   Alvarez, O
   Lumbreras, J
   Nieto, F
   Parada, E
   Perez-Beltran, V
AF Melgosa, M.
   Madrid, A.
   Alvarez, O.
   Lumbreras, J.
   Nieto, F.
   Parada, E.
   Perez-Beltran, V
CA Spanish Pediat Nephrology Assoc
TI SARS-CoV-2 infection in Spanish children with chronic kidney pathologies
SO PEDIATRIC NEPHROLOGY
LA English
DT Article
DE COVID-19; CKD; Children; Nephrotic syndrome; Immunosuppression
AB Background There is little information about Coronavirus Disease 2019 (COVID-19) in children with underlying chronic renal pathologies. Cases report From March until April 15, 2020, 16 children with chronic renal pathologies were diagnosed with COVID-19 in Spain. Of these, 6 had end-stage kidney disease (ESKD) (3 transplant recipients and 3 on chronic hemodialysis). The severity of symptoms was mild in all the patients, with little radiological involvement. Three patients were asymptomatic. Fever and upper respiratory symptoms were the most frequent findings. Basal glomerular filtration worsened in 3 patients; however, recovery was rapidly achieved with rehydration and drug dose adjustment. In 2 patients diagnosed with steroid-dependent nephrotic syndrome, COVID-19 provoked a disease relapse. None required oxygen therapy, and 7 could be managed as outpatients. Conclusions COVID-19 disease appears to have a similar clinical course in children with underlying chronic renal pathologies, even in immunosuppressed cases, as in healthy children of the same age; however, special attention must be paid to fluid management and drug dose adjustment.
C1 [Melgosa, M.] La Paz Univ Hosp, Pediat Nephrol Dept, Madrid, Spain.
   [Madrid, A.] St Joan Deu Univ Hosp, Pediat Nephrol Dept, Barcelona, Spain.
   [Alvarez, O.] Gregorio Maranon Univ Hosp, Pediat Nephrol Dept, Madrid, Spain.
   [Lumbreras, J.] Son Espases Univ Hosp, Pediat Nephrol Dept, Palma De Mallorca, Spain.
   [Nieto, F.] Malaga Univ Hosp, Pediat Nephol Dept, Malaga, Spain.
   [Parada, E.] Joan XXIII Univ Hosp, Pediat Nephrol Dept, Tarragona, Spain.
   [Perez-Beltran, V] Vall dHebron Univ Hosp, Pediat Nephrol Dept, Barcelona, Spain.
RP Melgosa, M (corresponding author), La Paz Univ Hosp, Pediat Nephrol Dept, Madrid, Spain.
EM marta.melgosa@salud.madrid.org; amadrid@sjdhospitalbarcelona.org;
   olallaalvarezblanco@gmail.com; jlumfer@gmail.com;
   franciscoantonionieto@gmail.com; esterparada@yahoo.es;
   victorpbeltran@gmail.com
OI MELGOSA HIJOSA, MARTA/0000-0001-6236-414X; Lumbreras Fernandez,
   Javier/0000-0003-1855-0724; Nieto-Vega, Francisco
   Antonio/0000-0002-4265-8172
CR Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Calvo C, 2020, AN PEDIATR, V92, P239, DOI 10.1016/j.anpedi.2020.03.001
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Henry BM, 2020, INT UROL NEPHROL, V52, P1193, DOI 10.1007/s11255-020-02451-9
   Hrusak O, 2020, EUR J CANCER, V132, P11, DOI 10.1016/j.ejca.2020.03.021
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Red Nacional de Vigilancia Epidemiologica, 2020, 22 RED NAC VIG EP
   Turner Dan, 2020, J Pediatr Gastroenterol Nutr, DOI 10.1097/MPG.0000000000002729
   Wang L, 2020, CHINA AM J NEPHROL, V31, P1, DOI [10.1681/ASN.2019111179, DOI 10.1681/ASN.2019111179]
   WHO, 2020, REP WHO CHIN JOINT M
NR 14
TC 8
Z9 8
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0931-041X
EI 1432-198X
J9 PEDIATR NEPHROL
JI Pediatr. Nephrol.
PD AUG
PY 2020
VL 35
IS 8
BP 1521
EP 1524
DI 10.1007/s00467-020-04597-1
EA MAY 2020
PG 4
WC Pediatrics; Urology & Nephrology
SC Pediatrics; Urology & Nephrology
GA MC3WU
UT WOS:000534460200001
PM 32435879
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Patruno, C
   Stingeni, L
   Fabbrocini, G
   Hansel, K
   Napolitano, M
AF Patruno, Cataldo
   Stingeni, Luca
   Fabbrocini, Gabriella
   Hansel, Katharina
   Napolitano, Maddalena
TI Dupilumab and COVID-19: What should we expect?
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE adult atopic dermatitis; COVID-19; dupilumab
AB Coronavirus disease 2019 (COVID-19) is a pandemic disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high morbidity and mortality. There are very limited data on the interference of immunomodulating drugs on the risk of infection and on the course of the disease. In particular, there are no current clinical data about the interference exerted by dupilumab, a biologic drugs blocking IL-4 and IL-13, used for adult atopic dermatitis. The pathogenesis of COVID-19 is complex, characterized by an immune response mainly Th1/Th17. The hyper-activation of these cells may cause the release of pro-inflammatory cytokines that may result in lung impairment. IL-4 and IL-13 are Th2 cytokines, thus being part of a pathway not considered implicated in host defense mechanism against viral infections. Indeed, viral infections, including respiratory infections, have not been reported as a significant adverse event in clinical trials. Furthermore, dupilumab has been proved to be efficacious also in exacerbations of asthma, and it is known that viral infections can worsen asthma. Therefore, the current data seem to suggest that treatment with dupilumab should not be stopped during COVID-19 pandemic. Obviously, a careful assessment is mandatory for each individual patient and further studies are necessary to characterize the immunologic responses in COVID-19.
C1 [Patruno, Cataldo] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Stingeni, Luca; Hansel, Katharina] Univ Perugia, Dept Med, Dermatol Sect, Perugia, Italy.
   [Fabbrocini, Gabriella] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Naples, Italy.
   [Napolitano, Maddalena] Univ Molise, Dept Hlth Sci Vincenzo Tiberio, Campobasso, Italy.
RP Napolitano, M (corresponding author), Univ Molise, Dept Med & Hlth Sci Vincenzo Tiberio, Campobasso, Italy.
EM maddy.napolitano@gmail.com
OI Patruno, Cataldo/0000-0001-8661-2822
CR AGACHE I, 2020, ALLERGY 0401, DOI DOI 10.1111/ALL.14268
   [Anonymous], 2017, DUPILUMAB SUMMARY PR
   Cascella M, 2020, FEATURES EVALUATION
   Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9
   Eichenfield LF, 2019, AM J CLIN DERMATOL, V20, P443, DOI 10.1007/s40257-019-00445-7
   Fabbrocini G, 2018, DERMATOLOGY THER, V8, P527, DOI 10.1007/s13555-018-0258-x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   International League of Dermatological Societoes (ILDS), 2020, GUID US SYST THER PA
   Jartti T, 2020, SEMIN IMMUNOPATHOL, V42, P61, DOI 10.1007/s00281-020-00781-5
   Kok WL, 2019, ACTA DERM-VENEREOL, V99, P652, DOI 10.2340/00015555-3175
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1036
   Mizumoto K, 2020, EMERG INFECT DIS, V26
   Napolitano M, 2019, DERMATOL THER, V32, DOI 10.1111/dth.13142
   Rademaker M, 2020, AUSTRALAS J DERMATOL, V61, P158, DOI 10.1111/ajd.13295
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Takabayashi T, 2013, AM J RESP CRIT CARE, V187, P49, DOI 10.1164/rccm.201207-1292OC
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   Wollenberg A, 2020, J EUR ACAD DERMATOL
   Worm M, 2020, JAMA DERMATOL, V156, P131, DOI 10.1001/jamadermatol.2019.3617
   Wynn TA, 2015, NAT REV IMMUNOL, V15, P271, DOI 10.1038/nri3831
NR 23
TC 6
Z9 6
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13502
DI 10.1111/dth.13502
EA MAY 2020
PG 3
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000534136100001
PM 32362061
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Standing, JF
AF Standing, Joseph F.
TI Response to: Optimizing Hydroxychloroquine Dosing for Patients With
   COVID-19: An Integrative Modeling Approach for Effective Drug
   Repurposing Quantitative Clinical Pharmacology Input to SARS-CoV-2
   Therapeutics Should Be Based on Robust Data
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Letter
C1 [Standing, Joseph F.] UCL, Great Ormond St Inst Child Hlth, London, England.
RP Standing, JF (corresponding author), UCL, Great Ormond St Inst Child Hlth, London, England.
EM j.standing@ucl.ac.uk
CR Garcia-Cremades M, 2020, CLIN PHARMACOL THER, V108, P253, DOI 10.1002/cpt.1856
   Paton NI, 2011, LANCET INFECT DIS, V11, P677, DOI 10.1016/S1473-3099(11)70065-2
   Vogels C.B.F., 2020, ANAL SENSITIVITY EFF, DOI [10.1101/2020.03.30.20048108, DOI 10.1101/2020.03.30.20048108]
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 4
TC 2
Z9 2
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD AUG
PY 2020
VL 108
IS 2
BP 187
EP 187
DI 10.1002/cpt.1872
EA MAY 2020
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MJ4KB
UT WOS:000534022300001
PM 32348551
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Conforti, C
   Giuffrida, R
   Dianzani, C
   Di Meo, N
   Zalaudek, I
AF Conforti, Claudio
   Giuffrida, Roberta
   Dianzani, Caterina
   Di Meo, Nicola
   Zalaudek, Iris
TI Biologic therapy for psoriasis during the COVID-19 outbreak: The choice
   is to weigh risks and benefits
SO DERMATOLOGIC THERAPY
LA English
DT Letter
C1 [Conforti, Claudio; Di Meo, Nicola; Zalaudek, Iris] Univ Trieste, Dept Dermatol & Venereol, Dermatol Clin, Maggiore Hosp, Trieste, Italy.
   [Giuffrida, Roberta] Univ Messina, Dept Clin & Expt Med, Dermatol Sect, Via Consolare Valeria 1, I-98125 Messina, Italy.
   [Dianzani, Caterina] Campus Biomed Univ Hosp, Dept Plast Reconstruct & Cosmet Surg, Dermatol Sect, Rome, Italy.
RP Giuffrida, R (corresponding author), Univ Messina, Dept Clin & Expt Med, Dermatol Sect, Via Consolare Valeria 1, I-98125 Messina, Italy.
EM roberta_giuffrida@hotmail.it
RI Conforti, Claudio/AAJ-9186-2020
OI GIUFFRIDA, ROBERTA/0000-0002-5492-3033; di Meo,
   Nicola/0000-0002-5987-1375
CR Abdelmaksoud A, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13360
   American Academy of Dermatology (AAD), 2020, GUID US BIOL AG COVI
   Bardazzi F, 2020, J DERMATOL TREAT, DOI 10.1080/09546634.2020.1749545
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13298
   Di Lernia V, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13345
   International League of Dermatological Societies, 2020, GUIS US SYST THER PA
   International Psoriasis Council, STAT COR COVID 19 OU
   SIDeMaST, 2020, INF COR VAD PAZ AFF
NR 8
TC 4
Z9 4
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13490
DI 10.1111/dth.13490
EA MAY 2020
PG 2
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000534174100001
PM 32358864
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hillaker, E
   Belfer, JJ
   Bondici, A
   Murad, H
   Dumkow, LE
AF Hillaker, Emily
   Belfer, Julie J.
   Bondici, Anamaria
   Murad, Hani
   Dumkow, Lisa E.
TI Delayed Initiation of Remdesivir in a COVID-19-Positive Patient
SO PHARMACOTHERAPY
LA English
DT Article
DE COVID-19; remdesivir; SARS-CoV-2; coronavirus; pneumonia; viral
   pneumonia
ID THERAPEUTIC-EFFICACY; VIRUS
AB We present a case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a mixed medical intensive care unit of a community teaching hospital. A previously healthy 40-year-old man was admitted to the hospital 3 days after the onset of coronavirus disease 2019 (COVID-19) symptoms including dry cough, fever, and shortness of breath progressing to intubation and increased mechanical ventilator support. A request for compassionate use remdesivir was submitted on the same hospital day as the positive COVID-19 polymerase chain reaction result. Supportive measures, in addition to a 5-day course of hydroxychloroquine, were maintained until remdesivir could be supplied on day 9 of hospitalization, 13 days after symptom onset. Sixty hours after initiating remdesivir, the patient was successfully extubated and able to transition to room air within 24 hours of extubation. Late initiation of remdesivir may be effective in treating SARS-CoV-2, unlike antivirals utilized for different disease states, such as oseltamivir, that are most effective when started as soon as possible following symptom onset. Urgent action is needed by regulatory agencies to work with drug manufacturers to expedite the study and approval of investigational agents targeting SARS-CoV-2 as well as to meet manufacturing demands.
C1 [Hillaker, Emily] Mercy Hlth St Marys, Dept Family Practice Educ, Grand Rapids, MI 49503 USA.
   [Belfer, Julie J.; Dumkow, Lisa E.] Mercy Hlth St Marys, Dept Pharm Serv, 200 Jefferson SE, Grand Rapids, MI 49503 USA.
   [Bondici, Anamaria] Mercy Hlth St Marys, Div Infect Dis, Grand Rapids, MI 49503 USA.
   [Murad, Hani] Mercy Hlth St Marys, Div Crit Care, Grand Rapids, MI 49503 USA.
RP Belfer, JJ (corresponding author), Mercy Hlth St Marys, Dept Pharm Serv, 200 Jefferson SE, Grand Rapids, MI 49503 USA.
EM julie.j.belfer@mercyhealth.com
RI Belfer, Julie/AAY-7497-2020
OI , Julie/0000-0002-9189-0752
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Centers for Disease Control and Prevention (CDC), 2020, 1 TRAV REL CAS 2019
   Centers for DiseaseControl and Prevention, INT INF PREV CONTR R
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gilead Sciences, 2020, GIL SCI STAT ACC REM
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Intensive Care National Audit and Research Centre, 2010, ICNARC REP COVID 19
   Ko WC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105933
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Sanville Bradley, 2020, Clin Infect Dis, V71, P2222, DOI 10.1093/cid/ciaa347
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Strand A, 2002, SEX TRANSM INFECT, V78, P435, DOI 10.1136/sti.78.6.435
   Uyeki TM, 2019, CLIN INFECT DIS, V68, pE1, DOI 10.1093/cid/ciy866
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
NR 19
TC 15
Z9 15
U1 2
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-0008
EI 1875-9114
J9 PHARMACOTHERAPY
JI Pharmacotherapy
PD JUN
PY 2020
VL 40
IS 6
BP 592
EP 598
DI 10.1002/phar.2403
EA MAY 2020
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LV9KT
UT WOS:000534250700001
PM 32281114
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Moll, G
   Drzeniek, N
   Kamhieh-Milz, J
   Geissler, S
   Volk, HD
   Reinke, P
AF Moll, Guido
   Drzeniek, Norman
   Kamhieh-Milz, Julian
   Geissler, Sven
   Volk, Hans-Dieter
   Reinke, Petra
TI MSC Therapies for COVID-19: Importance of Patient Coagulopathy,
   Thromboprophylaxis, Cell Product Quality and Mode of Delivery for
   Treatment Safety and Efficacy
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE mesenchymal stromal cells (MSC); severe acute respiratory distress
   syndrome coronavirus-2 (SARS-CoV-2); coronavirus-induced disease 2019
   (COVID19); intensive care unit (ICU); intravascular and intravenous
   infusion; hemocompatibility testing; tissue factor (TF; CD142);
   coagulation; clotting; thrombosis
ID MESENCHYMAL STROMAL CELLS; ACUTE RESPIRATORY-DISTRESS; STEM-CELLS;
   INTERNATIONAL-SOCIETY; VENOUS THROMBOEMBOLISM; TISSUE FACTOR;
   COAGULATION; CHALLENGES; CRITERIA; ARDS
AB Numerous clinical trials of mesenchymal stromal/stem cells (MSCs) as a new treatment for coronavirus-induced disease (COVID-19) have been registered recently, most of them based on intravenous (IV) infusion. There is no approved effective therapy for COVID-19, but MSC therapies have shown first promise in the treatment of acute respiratory distress syndrome (ARDS) pneumonia, inflammation, and sepsis, which are among the leading causes of mortality in COVID-19 patients. Many of the critically ill COVID-19 patients are in a hypercoagulable procoagulant state and at high risk for disseminated intravascular coagulation, thromboembolism, and thrombotic multi-organ failure, another cause of high fatality. It is not yet clear whether IV infusion is a safe and effective route of MSC delivery in COVID-19, since MSC-based products express variable levels of highly procoagulant tissue factor (TF/CD142), compromising the cells' hemocompatibility and safety profile. Of concern, IV infusions of poorly characterized MSC products with unchecked (high) TF/CD142 expression could trigger blood clotting in COVID-19 and other vulnerable patient populations and further promote the risk for thromboembolism. In contrast, well-characterized products with robust manufacturing procedures and optimized modes of clinical delivery hold great promise for ameliorating COVID-19 by exerting their beneficial immunomodulatory effects, inducing tissue repair and organ protection. While the need for MSC therapy in COVID-19 is apparent, integrating both innate and adaptive immune compatibility testing into the current guidelines for cell, tissue, and organ transplantation is critical for safe and effective therapies. It is paramount to only use well-characterized, safe MSCs even in the most urgent and experimental treatments. We here propose three steps to mitigate the risk for these vulnerable patients: (1) updated clinical guidelines for cell and tissue transplantation, (2) updated minimal criteria for characterization of cellular therapeutics, and (3) updated cell therapy routines reflecting specific patient needs.
C1 [Moll, Guido; Drzeniek, Norman; Geissler, Sven; Volk, Hans-Dieter; Reinke, Petra] Charite Univ Med Berlin, BIH Ctr Regenerat Therapies BCRT, Berlin, Germany.
   [Moll, Guido; Drzeniek, Norman] Charite Univ Med Berlin, Berlin Brandenburg Sch Regenerat Therapies BSRT, Berlin, Germany.
   [Drzeniek, Norman; Volk, Hans-Dieter] Charite Univ Med Berlin, Inst Med Immunol, Berlin, Germany.
   [Kamhieh-Milz, Julian] Charite Univ Med Berlin, Dept Transfus Med, Berlin, Germany.
   [Geissler, Sven] Charite Univ Med Berlin, Julius Wolff Inst JWI, Berlin, Germany.
   [Reinke, Petra] Charite Univ Med Berlin, Dept Nephrol & Internal Intens Care Med, Berlin, Germany.
   [Reinke, Petra] All Charite Univ Med Berlin, Berlin Ctr Adv Therapies BECAT, Berlin, Germany.
   [Reinke, Petra] Free Univ Berlin, Berlin, Germany.
   [Reinke, Petra] Humboldt Univ, Berlin, Germany.
   [Reinke, Petra] Berlin Inst Hlth BIH, Berlin, Germany.
RP Moll, G (corresponding author), Charite Univ Med Berlin, BIH Ctr Regenerat Therapies BCRT, Berlin, Germany.; Moll, G (corresponding author), Charite Univ Med Berlin, Berlin Brandenburg Sch Regenerat Therapies BSRT, Berlin, Germany.
EM guido.moll@charite.de
RI Moll, Guido/Q-1044-2018; Geissler, Sven/J-7275-2013; Drzeniek,
   Norman/AAU-8372-2020
OI Moll, Guido/0000-0001-6173-5957; Geissler, Sven/0000-0002-8750-6324;
   Drzeniek, Norman/0000-0001-6562-2351
FU German Research Foundation (DFG)German Research Foundation (DFG); German
   Federal Ministry of Education and Research (BMBF) through the
   BSRTFederal Ministry of Education & Research (BMBF) [GSC203]; German
   Federal Ministry of Education and Research (BMBF) through BCRTFederal
   Ministry of Education & Research (BMBF); European UnionEuropean Union
   (EU) [733006, 779293]; Open Access Publication Fund of Charite
   Universitatsmedizin Berlin
FX The authors' contributions were supported among others by the German
   Research Foundation (DFG) and German Federal Ministry of Education and
   Research (BMBF) funding through the BSRT (GSC203) and BCRT. This study
   has received support under the European Union's Horizon 2020 research
   and innovation program (Horizon 2020 Framework Program) under the grant
   agreements no. 733006 (PACE) and no. 779293 (HIPGEN). We acknowledge
   support from the Open Access Publication Fund of Charite
   Universitatsmedizin Berlin.
CR Abou-El-Enein M, 2016, CELL STEM CELL, V19, P293, DOI 10.1016/j.stem.2016.08.012
   Abou-El-Enein M, 2014, NAT BIOTECHNOL, V32, P1192, DOI 10.1038/nbt.3084
   Ankrum J, 2020, SCI TRANSL MED, V12, peabb0792, DOI 10.1126/scitranslmed.abb0792
   Ankrum JA, 2014, NAT BIOTECHNOL, V32, P252, DOI 10.1038/nbt.2816
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Barbar S, 2010, J THROMB HAEMOST, V8, P2450, DOI 10.1111/j.1538-7836.2010.04044.x
   Bioinformant, 2020, COR COVID 19 GLOB MA
   Braid LR, 2018, CYTOTHERAPY, V20, P232, DOI 10.1016/j.jcyt.2017.09.013
   Caplan H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01645
   Cell-Trials-Data, 2020, ALL COV 19 CLIN TRIA
   CellTrials.Org, 2020, ROL MSC TREAT COR 1
   CONNORS JM, 2020, J THROMB HAEMOS 0526, DOI DOI 10.1182/blood.2020006000
   Cooney E, 2020, BLOOD CLOTS SEVERE C
   Cruz FF, 2019, J THORAC DIS, V11, pS1329, DOI 10.21037/jtd.2019.04.22
   Cyranoski D, 2010, NATURE, V468, P485, DOI 10.1038/468485a
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004
   Galipeau J, 2016, CYTOTHERAPY, V18, P151, DOI 10.1016/j.jcyt.2015.11.008
   George MJ, 2020, STEM CELL TRANSL MED, V9, P491, DOI 10.1002/sctm.19-0206
   George MJ, 2018, STEM CELL TRANSL MED, V7, P731, DOI 10.1002/sctm.18-0015
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Giri J, 2020, BLOOD ADV, V4, P1987, DOI 10.1182/bloodadvances.2020001711
   Giri J, 2020, CELL REP, V30, P1923, DOI 10.1016/j.celrep.2020.01.047
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Gratwohl A, 2019, EBMT HANDBOOK: HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELLULAR THERAPIES, P11, DOI 10.1007/978-3-030-02278-5_2
   ISCT, 2020, ISCT REL STAT UNPR S
   ISSCR, 2020, ISSCR STAT REG MARK
   Ji FP, 2020, STEM CELL TRANSL MED, V9, P813, DOI 10.1002/sctm.20-0083
   Johnson CL, 2017, STEM CELL TRANSL MED, V6, P1141, DOI 10.1002/sctm.16-0415
   Jung JW, 2013, YONSEI MED J, V54, P1293, DOI 10.3349/ymj.2013.54.5.1293
   Khan RS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01952
   Khoury M, 2020, CYTOTHERAPY, V22, P602, DOI 10.1016/j.jcyt.2020.04.089
   Khoury M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00858-2020
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Knoepfler P, 2020, ATHERSYS MESOBLAST S
   Laffey JG, 2017, AM J RESP CRIT CARE, V196, P266, DOI 10.1164/rccm.201701-0107CP
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Liang B., 2020, CLIN REMISSION CRITI
   Liu KD, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/s13613-014-0022-z
   London AJ, 2020, SCIENCE, V368, P476, DOI 10.1126/science.abc1731
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Markiewski MM, 2007, TRENDS IMMUNOL, V28, P184, DOI 10.1016/j.it.2007.02.006
   Marks PW, 2017, NEW ENGL J MED, V376, P1007, DOI 10.1056/NEJMp1613723
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   Mezher M, 2020, EUROPEAN MED AGENCY
   Moberg L, 2002, LANCET, V360, P2039, DOI 10.1016/S0140-6736(02)12020-4
   Moll G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00243
   Moll G, 2019, TRENDS MOL MED, V25, P149, DOI 10.1016/j.molmed.2018.12.006
   Moll G, 2016, ADV EXP MED BIOL, V951, P77, DOI 10.1007/978-3-319-45457-3_7
   Moll G, 2015, STEM CELLS DEV, V24, P2269, DOI 10.1089/scd.2015.0120
   Moll G, 2014, STEM CELLS, V32, P2430, DOI 10.1002/stem.1729
   Moll G, 2012, STEM CELLS, V30, P1565, DOI 10.1002/stem.1111
   Morrissey JH, 2004, INT J HEMATOL, V79, P103, DOI 10.1532/IJH97.03167
   Nacoti M, 2020, CATALYST NON ISSUE C, P1, DOI [10.1186/s12939-020-01162-y, DOI 10.1186/S12939-020-01162-Y]
   Nilsson B, 2010, TRENDS IMMUNOL, V31, P32, DOI 10.1016/j.it.2009.09.005
   O'Shea O, 2019, WHOBS20192376 EXP CO
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Perlee D, 2019, STEM CELL TRANSL MED, V8, P785, DOI 10.1002/sctm.18-0260
   Perlee D, 2018, STEM CELLS, V36, P1778, DOI 10.1002/stem.2891
   Pluristem-Therapeutics-Inc, 2020, PLUR FORMS COV 19 DR
   Qazi TH, 2019, J CACHEXIA SARCOPENI, V10, P501, DOI 10.1002/jcsm.12416
   RINGDEN O, 2014, J STEM CELL RES THER, V4, P244, DOI DOI 10.4172/2157-7633.1000244
   Ringden Olle, 2015, Lancet Respir Med, V3, pe12, DOI 10.1016/S2213-2600(15)00047-8
   Risitano AM, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0320-7
   Selby R, 2009, THROMB RES, V124, P281, DOI 10.1016/j.thromres.2008.10.002
   Sheridan C, 2018, NAT BIOTECHNOL, V36, P212, DOI 10.1038/nbt0318-212a
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Simonson OE, 2015, STEM CELL TRANSL MED, V4, P1199, DOI 10.5966/sctm.2015-0021
   Spyropoulos AC, 2020, LANCET, V395, pE75, DOI 10.1016/S0140-6736(20)30926-0
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327
   Wallin RF, 1998, PRACTICAL GUIDE ISO
   Walter J, 2014, LANCET RESP MED, V2, P1016, DOI 10.1016/S2213-2600(14)70217-6
   Wang T, 2020, LANCET HAEMATOL, V7, pE362, DOI 10.1016/S2352-3026(20)30109-5
   WHO, 2020, REP WHO CHIN JOINT M
   WHO, 2005, 1 GLOB CONS REG REQ
   Whyte CS, 2020, J THROMB HAEMOST, V18, P1548, DOI 10.1111/jth.14872
   Winkler T, 2018, J CACHEXIA SARCOPENI, V9, P880, DOI 10.1002/jcsm.12316
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu Z, 2017, TRANSPL P, V49, P1656, DOI 10.1016/j.transproceed.2017.03.078
   Zagury-Orly I, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2009405
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 87
TC 7
Z9 7
U1 6
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAY 19
PY 2020
VL 11
AR 1091
DI 10.3389/fimmu.2020.01091
PG 10
WC Immunology
SC Immunology
GA LW5YV
UT WOS:000539222800001
PM 32574263
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lu, XF
   Chen, TG
   Wang, Y
   Wang, J
   Yan, FR
AF Lu, Xiaofan
   Chen, Taige
   Wang, Yang
   Wang, Jun
   Yan, Fangrong
TI Adjuvant corticosteroid therapy for critically ill patients with
   COVID-19
SO CRITICAL CARE
LA English
DT Letter
C1 [Lu, Xiaofan; Yan, Fangrong] China Pharmaceut Univ, Res Ctr Biostat & Computat Pharm, State Key Lab Nat Med, Nanjing 210009, Peoples R China.
   [Chen, Taige] Nanjing Univ, Med Sch, Nanjing, Peoples R China.
   [Wang, Yang] Nanjing Univ, Med Sch, Dept Radiol, Affiliated Nanjing Drum Tower Hosp, Nanjing, Peoples R China.
   [Wang, Jun] Soochow Univ, Dept Intens Care Med, Affiliated Hosp 1, Suzhou, Peoples R China.
RP Yan, FR (corresponding author), China Pharmaceut Univ, Res Ctr Biostat & Computat Pharm, State Key Lab Nat Med, Nanjing 210009, Peoples R China.
EM f.r.yan@163.com
OI Wang, Jun/0000-0001-8708-3096
FU National Key R&D Program of China [2019YFC1711000]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81973145]; "Double First-Class" University Project
   [CPU2018GY09]; China Postdoctoral Science FoundationChina Postdoctoral
   Science Foundation [2019 M651805]; Science Foundation of Jiangsu
   Commission of Health [H2018117]; Emergency Project for the Prevention
   and Control of the Novel Coronavirus Outbreak in Suzhou [SYS2020012]
FX This work was supported by the National Key R&D Program of China
   (2019YFC1711000), the National Natural Science Foundation of China
   (81973145), the "Double First-Class" University Project (CPU2018GY09),
   the China Postdoctoral Science Foundation (2019 M651805), the Science
   Foundation of Jiangsu Commission of Health (H2018117), and the Emergency
   Project for the Prevention and Control of the Novel Coronavirus Outbreak
   in Suzhou (SYS2020012).
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Kim SH, 2011, AM J RESP CRIT CARE, V183, P1207, DOI 10.1164/rccm.201101-0110OC
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   WHO, 2020, CLIN MAN SEV AC RESP
   Zhou F, 2020, LANCET, V6736, P30566
NR 5
TC 17
Z9 18
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD MAY 19
PY 2020
VL 24
IS 1
AR 241
DI 10.1186/s13054-020-02964-w
PG 4
WC Critical Care Medicine
SC General & Internal Medicine
GA LT0JM
UT WOS:000536763300004
PM 32430057
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Clerkin, KJ
   Fried, JA
   Raikhelkar, J
   Sayer, G
   Griffin, JM
   Masoumi, A
   Jain, SS
   Burkhoff, D
   Kumaraiah, D
   Rabbani, L
   Schwartz, A
   Uriel, N
AF Clerkin, Kevin J.
   Fried, Justin A.
   Raikhelkar, Jayant
   Sayer, Gabriel
   Griffin, Jan M.
   Masoumi, Amirali
   Jain, Sneha S.
   Burkhoff, Daniel
   Kumaraiah, Deepa
   Rabbani, LeRoy
   Schwartz, Allan
   Uriel, Nir
TI COVID-19 and Cardiovascular Disease
SO CIRCULATION
LA English
DT Article
DE cardiovascular diseases; COVID-19; pandemics; severe acute respiratory
   syndrome coronavirus 2
ID CONVERTING ENZYME 2; MYOCARDIAL-INFARCTION; ACE2 EXPRESSION; MERS-COV;
   SARS; REMDESIVIR; BLOCKADE; RECEPTOR; OUTCOMES; CHINA
AB Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and >3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor. Among patients with COVID-19, there is a high prevalence of cardiovascular disease, and >7% of patients experience myocardial injury from the infection (22% of critically ill patients). Although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, affecting donor selection, immunosuppression, and posttransplant management. There are a number of promising therapies under active investigation to treat and prevent COVID-19.
C1 [Clerkin, Kevin J.; Fried, Justin A.; Raikhelkar, Jayant; Sayer, Gabriel; Griffin, Jan M.; Masoumi, Amirali; Jain, Sneha S.; Burkhoff, Daniel; Kumaraiah, Deepa; Rabbani, LeRoy; Schwartz, Allan; Uriel, Nir] Columbia Univ, Vagelos Coll Phys & Surg, Dept Med, Div Cardiol, New York, NY 10032 USA.
RP Uriel, N (corresponding author), Columbia Univ, New York Presbyterian Heart Failure, Weill Cornell Med,Irving Med Ctr, Heart Transplant & Mech Circulatory Support Progr, 622 West 168th St,PH4-129, New York, NY 10032 USA.
EM nu2126@cumc.columbia.edu
OI Masoumi, Amirali/0000-0002-1079-7258
CR AlGhamdi M, 2015, AM J TRANSPLANT, V15, P1101, DOI 10.1111/ajt.13085
   American Society of Transplantation, 2019 NCOV COR FAQS O
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2020, RAND CONTR TRIAL LOS
   [Anonymous], 2020, GUIDANCE CARDIOTHORA
   [Anonymous], 2020, RAND CONTR TRIAL LOS
   Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Burchill LJ, 2012, CLIN SCI, V123, P649, DOI 10.1042/CS20120162
   Burrell LM, 2005, EUR HEART J, V26, P369, DOI 10.1093/eurheartj/ehi114
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Centers for Disease Control and Prevention, INT CLIN GUID MAN PA
   Chan JWM, 2003, THORAX, V58, P686, DOI 10.1136/thorax.58.8.686
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu H, 2020, EUR HEART J, DOI [10.1093/eurheartj/ehaa190/5807656, DOI 10.1093/EURHEARTJ/EHAA190/5807656]
   Hu Hongde, 2020, Eur Heart J, DOI 10.1093/eurheartj/ehaa190
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Ishiyama Y, 2004, HYPERTENSION, V43, P970, DOI 10.1161/01.HYP.0000124667.34652.1a
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Klimas J, 2015, J CELL MOL MED, V19, P1965, DOI 10.1111/jcmm.12573
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kumar D, 2003, AM J TRANSPLANT, V3, P977, DOI 10.1034/j.1600-6143.2003.00197.x
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li F, 2020, J HEART LUNG TRANSPL, V39, P496, DOI 10.1016/j.healun.2020.03.006
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Ocaranza MP, 2006, LIFE SCI, V78, P1535, DOI 10.1016/j.lfs.2005.07.026
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Ren ZL, 2020, J HEART LUNG TRANSPL, V39, P412, DOI 10.1016/j.healun.2020.03.008
   Tikellis Chris, 2012, Int J Pept, V2012, P256294, DOI 10.1155/2012/256294
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Walters TE, 2017, EUROPACE, V19, P1280, DOI 10.1093/europace/euw246
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, 2020, REP WHO CHIN JOINT M
   World Health Organization, 2020, CLIN MAN SEV AC RSP
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zeng J, 2020, 1 CASE COVID 19 INFE, DOI [10.20944/preprints202003.0180.v1, DOI 10.20944/PREPRINTS202003.0180.V1]
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhao Y, 2020, SINGLE CELL RNA EXPR, DOI [DOI 10.1101/2020.01.26.919985V1, 10.1101/2020.01.26.919985v1]
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 56
TC 268
Z9 277
U1 20
U2 32
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD MAY 19
PY 2020
VL 141
IS 20
BP 1648
EP 1655
DI 10.1161/CIRCULATIONAHA.120.046941
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA LT0UG
UT WOS:000536791300012
PM 32200663
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Shah, A
AF Shah, Adnan
TI Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential
   Drug Target in the Treatment of COVID-19
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE NLRP3 inflammasome; viroporins; cytokines; SARS-CoV; COVID-19
ID SARS; INHIBITOR; PATHOGENESIS; PNEUMONIA; ACID
C1 [Shah, Adnan] Univ Ulm, Ulm, Germany.
RP Shah, A (corresponding author), Univ Ulm, Ulm, Germany.
EM adnan.shah@alumni.uni-ulm.de
CR Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Castano-Rodriguez C, 2018, MBIO, V9, DOI 10.1128/mBio.02325-17
   Chen IY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00050
   Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806
   D'Elia RV, 2013, CLIN VACCINE IMMUNOL, V20, P319, DOI 10.1128/CVI.00636-12
   da Costa LS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1579-0
   Daniels MJD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12504
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   Elliott EI, 2015, IMMUNOL REV, V265, P35, DOI 10.1111/imr.12286
   Fernando S, 2017, HEART LUNG CIRCUL, V26, pS69, DOI [10.1016/j.hlc.2017.06.060, DOI 10.1016/J.HLC.2017.06.060]
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grailer JJ, 2014, J IMMUNOL, V192, P5974, DOI 10.4049/jimmunol.1400368
   Han SH, 2015, J IMMUNOL, V194, P855, DOI 10.4049/jimmunol.1402513
   He HB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04947-6
   He L, 2006, J PATHOL, V210, P288, DOI 10.1002/path.2067
   Her M, 2016, J ALLERGY CLIN IMMUN, V137, P19, DOI 10.1016/j.jaci.2015.10.023
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang Y, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708689
   Huppert LA, 2019, SEMIN RESP CRIT CARE, V40, P31, DOI 10.1055/s-0039-1683996
   Jiang H, 2017, J EXP MED, V214, P3219, DOI 10.1084/jem.20171419
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Jones HD, 2014, AM J RESP CELL MOL, V50, P270, DOI 10.1165/rcmb.2013-0087OC
   Juliana C, 2010, J BIOL CHEM, V285, P9792, DOI 10.1074/jbc.M109.082305
   Lamkanfi M, 2009, J CELL BIOL, V187, P61, DOI 10.1083/jcb.200903124
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Leung YY, 2015, SEMIN ARTHRITIS RHEU, V45, P341, DOI 10.1016/j.semarthrit.2015.06.013
   Li DD, 2018, MOL MED REP, V18, P4399, DOI 10.3892/mmr.2018.9427
   Nieva JL, 2012, NAT REV MICROBIOL, V10, P563, DOI 10.1038/nrmicro2820
   Mangan MSJ, 2018, NAT REV DRUG DISCOV, V17, P588, DOI [10.1038/nrd.2018.97, 10.1038/nrd.2018.149]
   Marchetti C, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1664-2
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Misawa T, 2013, NAT IMMUNOL, V14, P454, DOI 10.1038/ni.2550
   Nieto-Torres JL, 2015, VIROLOGY, V485, P330, DOI 10.1016/j.virol.2015.08.010
   Nieto-Torres JL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004077
   Otani K, 2016, SCI REP-UK, V6, DOI 10.1038/srep32587
   Park YH, 2016, NAT IMMUNOL, V17, P914, DOI 10.1038/ni.3457
   Parsons PE, 2005, CRIT CARE MED, V33, P1, DOI 10.1097/01.CCM.0000149854.61192.DC
   Robertson S, 2016, CLIN SCI, V130, P1237, DOI 10.1042/CS20160090
   Rothan HA, 2016, ANTIVIR RES, V127, P50, DOI 10.1016/j.antiviral.2016.01.006
   Shim DW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15314-8
   Siu KL, 2019, FASEB J, V33, P8865, DOI 10.1096/fj.201802418R
   Tan YJ, 2005, ANTIVIR RES, V65, P69, DOI 10.1016/j.antiviral.2004.10.001
   Torres J, 2007, PROTEIN SCI, V16, P2065, DOI 10.1110/ps.062730007
   Van Gorp H, 2016, P NATL ACAD SCI USA, V113, P14384, DOI 10.1073/pnas.1613156113
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wilson L, 2006, VIROLOGY, V353, P294, DOI 10.1016/j.virol.2006.05.028
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yue Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0917-y
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 52
TC 12
Z9 12
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAY 19
PY 2020
VL 11
AR 1021
DI 10.3389/fimmu.2020.01021
PG 5
WC Immunology
SC Immunology
GA LW1DJ
UT WOS:000538885900001
PM 32574259
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Babadaei, MMN
   Hasan, A
   Vahdani, Y
   Bloukh, SH
   Sharifi, M
   Kachooei, E
   Haghighat, S
   Falahati, M
AF Babadaei, Mohammad Mahdi Nejadi
   Hasan, Anwarul
   Vahdani, Yasaman
   Bloukh, Samir Haj
   Sharifi, Majid
   Kachooei, Ehsan
   Haghighat, Setareh
   Falahati, Mojtaba
TI Development of remdesivir repositioning as a nucleotide analog against
   COVID-19 RNA dependent RNA polymerase
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Corona virus; COVID-19; SARS; MERS; SARS-CoV-2; anti-viral; remdesivir
ID RESPIRATORY SYNDROME; MERS-COV; CORONAVIRUS; INFECTION; VIRUS; SARS;
   INHIBITORS; DISCOVERY; GS-5734; LESSONS
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative representative of a severe respiratory illness resulted in widespread human infections and deaths in nearly all of the countries since late 2019. There is no therapeutic FDA-approved drug against SARS-CoV-2 infection, although a combination of anti-viral drugs is directly being practiced in some countries. A broad-spectrum of antiviral agents are being currently evaluated in clinical trials, and in this review, we specifically focus on the application of Remdesivir (RVD) as a potential anti-viral compound against Middle East respiratory syndrome (MERS) -CoV, SARS-CoV and SARS-CoV-2. First, we overview the general information about SARS-CoV-2, followed by application of RDV as a nucleotide analogue which can potentially inhibits RNA-dependent RNA polymerase of COVs. Afterwards, we discussed the kinetics of SARS- or MERS-CoV proliferation in animal models which is significantly different compared to that in humans. Finally, some ongoing challenges and future perspective on the application of RDV either alone or in combination with other anti-viral agents against CoVs infection were surveyed to determine the efficiency of RDV in preclinical trials. As a result, this paper provides crucial evidence of the potency of RDV to prevent SARS-CoV-2 infections. Communicated by Ramaswamy H. Sarma
C1 [Babadaei, Mohammad Mahdi Nejadi] Islamic Azad Univ, Fac Biol Sci, Dept Mol Genet, North Tehran Branch, Tehran, Iran.
   [Hasan, Anwarul] Qatar Univ, Coll Engn, Dept Mech & Ind Engn, Doha, Qatar.
   [Hasan, Anwarul] Qatar Univ, Biomed Res Ctr, Doha, Qatar.
   [Vahdani, Yasaman] Islamic Azad Univ, Fac Pharmaceut Sci, Dept Microbiol, Tehran Med Sci, Tehran, Iran.
   [Bloukh, Samir Haj] Ajman Univ, Coll Pharm & Hlth Sci, Dept Clin Sci, Ajman, U Arab Emirates.
   [Sharifi, Majid; Falahati, Mojtaba] Islamic Azad Univ, Fac Adv Sci & Technol, Dept Nanotechnol, Tehran Med Sci, Tehran, Iran.
   [Kachooei, Ehsan] Macquarie Univ, Dept Mol Sci, Sydney, NSW, Australia.
   [Haghighat, Setareh] Islamic Azad Univ, Fac Adv Sci & Technol, Dept Microbiol, Tehran Med Sci, Tehran, Iran.
RP Hasan, A (corresponding author), Qatar Univ, Coll Engn, Dept Mech & Ind Engn, Doha, Qatar.; Hasan, A (corresponding author), Qatar Univ, Biomed Res Ctr, Doha, Qatar.; Falahati, M (corresponding author), Islamic Azad Univ, Fac Adv Sci & Technol, Dept Nanotechnol, Tehran Med Sci, Tehran, Iran.; Haghighat, S (corresponding author), Islamic Azad Univ, Fac Adv Sci & Technol, Dept Microbiol, Tehran Med Sci, Tehran, Iran.
EM ahasan@qu.edu.qa; haghighat.s@iaups.ac.ir;
   mojtaba.alahati@alumni.ut.ac.ir
RI Sharifi, Majid/AAD-8050-2020; Hasan, Anwarul/AAX-7440-2020
OI Sharifi, Majid/0000-0002-1546-7864; Hasan, Anwarul/0000-0001-8380-2233
FU Qatar National Research Fund (QNRF) under Qatar Foundation
   [NPRP10-120-170-211]; GCC Collaborative Research Program from Qatar
   University [GCC-2017-005]
FX This research was supported by the grants NPRP10-120-170-211 from Qatar
   National Research Fund (QNRF) under Qatar Foundation and GCC-2017-005
   under the GCC Collaborative Research Program from Qatar University. The
   statements made herein are the sole responsibility of the authors.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Aggarwal M, 2020, J VIROL, V94, DOI 10.1128/JVI.01888-19
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   AHMED SF, 2020, VIRUSES BASEL, V12, DOI DOI HTTPS://DOI.ORG/10.3390/V12030254
   Andersen PI, 2020, INT J INFECT DIS, V93, P268, DOI 10.1016/j.ijid.2020.02.018
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Cascella M, 2020, STATPEARLS
   Chen L., 2020, CARDIOVASC RES, DOI [10.2139/ssrn.3537961, DOI 10.2139/SSRN.3537961]
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Chhikara B. S., 2020, CHEM BIOL LETT, V7, P63, DOI DOI 10.1007/s00058-020-1496-8
   Choi WS, 2016, INFECT CHEMOTHER, V48, P118, DOI 10.3947/ic.2016.48.2.118
   CUI H, 2020, VIROL J, V17, DOI DOI https://doi.org/10.1186/s12985-020-1283-9
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Douglas MG, 2018, VIROLOGY, V517, P98, DOI 10.1016/j.virol.2017.12.006
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fung SY, 2020, EMERG MICROBES INFEC, V9, P558, DOI 10.1080/22221751.2020.1736644
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Gretebeck LM, 2015, CURR OPIN VIROL, V13, P123, DOI 10.1016/j.coviro.2015.06.009
   Guo DY, 2020, VIROL SIN, V35, P253, DOI 10.1007/s12250-020-00204-7
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Heymann DL, 2020, LANCET, V395, P542, DOI 10.1016/S0140-6736(20)30374-3
   Ianevski A, 2018, ANTIVIR RES, V154, P174, DOI 10.1016/j.antiviral.2018.04.016
   Ji XY, 2020, MED RES REV, V40, P1519, DOI 10.1002/med.21664
   Jordan PC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006889
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Ju J., 2020, NUCLEOTIDE ANALOGUES, DOI [10.1101/2020.03.12.989186, DOI 10.1101/2020.03.12.989186]
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kouznetsova J, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.88
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Li G, 2020, THERAPEUTIC OPTIONS
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Lo MK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9242
   Mackie P L, 2003, Paediatr Respir Rev, V4, P84, DOI 10.1016/S1526-0542(03)00031-9
   Mahase E., 2020, BRIT MED J PUBLISHIN
   Menendez-Arias L, 2014, CURR OPIN VIROL, V8, P1, DOI 10.1016/j.coviro.2014.04.005
   Mercorelli B, 2018, TRENDS MICROBIOL, V26, P865, DOI 10.1016/j.tim.2018.04.004
   MORRA ME, 2018, REV MED VIROL, V28, DOI DOI https://doi.org/10.1002/rmv.1977
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Oh MD, 2016, NEW ENGL J MED, V375, P1303, DOI 10.1056/NEJMc1511695
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Plotkin S, 2017, VACCINE, V35, P4064, DOI 10.1016/j.vaccine.2017.06.003
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Senanayake S. L., 2020, FUTURE SCI, V2, P1
   Senathilake K., 2020, PREPRINTS, DOI [10.20944/preprints202003.0042.v1., DOI 10.20944/PREPRINTS202003.0042.V1, 10.20944/preprints202003.0042.v1]
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Siegel D, 2017, DISCOVERY SYNTHESIS
   SONG ZQ, 2019, VIRUSES BASEL, V11, DOI DOI https://doi.org/10.3390/v11010059
   TCHESNOKOV EP, 2019, VIRUSES BASEL, V11, DOI DOI https://doi.org/10.3390/v11040326
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Xiong R., 2020, NOVEL POTENT INHIBIT, DOI [10.1101/2020.03.11.983056, DOI 10.1101/2020.03.11.983056]
   Xu JM, 2020, ACS INFECT DIS, V6, P909, DOI 10.1021/acsinfecdis.0c00052
   Xu M, 2016, NAT MED, V22, P1101, DOI 10.1038/nm.4184
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yao YF, 2014, J INFECT DIS, V209, P236, DOI 10.1093/infdis/jit590
   Zhu ZB, 2020, ZHONGHUA YU FANG YI, V54, pE022, DOI [10.3760/cma.j.cn112150-20200222-00163, DOI 10.3760/CMA.J.CN112150-20200222-00163]
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
   2020, UNDERSTANDING NATURE, P1
NR 80
TC 13
Z9 13
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1767210
EA MAY 2020
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LT3MD
UT WOS:000536974400001
PM 32397906
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Basit, A
   Ali, T
   Rehman, SU
AF Basit, Abdul
   Ali, Tanveer
   Rehman, Shafiq Ur
TI Truncated human angiotensin converting enzyme 2; a potential inhibitor
   of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE ACE2; SARS-CoV-2; spike glycoprotein; inhibitor; protein-protein
   docking; MD simulation
ID WEB SERVER; MOLECULAR-DYNAMICS; PROTEIN; PEPTIDE; DOCKING; BINDING;
   ASPARAGINASE; ZDOCK
AB The current pandemic of Covid-19 caused by SARS-CoV-2 is continued to spread globally and no potential drug or vaccine against it is available. Spike (S) glycoprotein is the structural protein of SARS-CoV-2 located on the envelope surface, involve in interaction with angiotensin converting enzyme 2 (ACE2), a cell surface receptor, followed by entry into the host cell. Thereby, blocking the S glycoprotein through potential inhibitor may interfere its interaction with ACE2 and impede its entry into the host cell. Here, we present a truncated version of human ACE2 (tACE2), comprising the N terminus region of the intact ACE2 from amino acid position 21-119, involved in binding with receptor binding domain (RBD) of SARS-CoV-2. We analyzed the in-silico potential of tACE2 to compete with intact ACE2 for binding with RBD. The protein-protein docking and molecular dynamic simulation showed that tACE2 has higher binding affinity for RBD and form more stabilized complex with RBD than the intact ACE2. Furthermore, prediction of tACE2 soluble expression in E. coli makes it a suitable candidate to be targeted for Covid-19 therapeutics. This is the first MD simulation based findings to provide a high affinity protein inhibitor for SARS-CoV-2 S glycoprotein, an important target for drug designing against this unprecedented challenge. Communicated by Ramaswamy H. Sarma
C1 [Basit, Abdul; Ali, Tanveer; Rehman, Shafiq Ur] Univ Punjab, Dept Microbiol & Mol Genet, Lahore 54590, Pakistan.
RP Rehman, SU (corresponding author), Univ Punjab, Dept Microbiol & Mol Genet, Lahore 54590, Pakistan.
EM shafiq.mmg@pu.edu.pk
RI Rehman, shafiq ur/AAE-9102-2019; basit, abdul/AAT-3398-2020
OI Rehman, shafiq ur/0000-0002-1265-3442; 
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Ardalan N, 2018, MED HYPOTHESES, V112, P7, DOI 10.1016/j.mehy.2018.01.004
   Basit A, 2019, J BIOTECHNOL, V306, P118, DOI 10.1016/j.jbiotec.2019.09.011
   Basit Abdul, 2018, Biotechnology Reports, V20, pe00288, DOI 10.1016/j.btre.2018.e00288
   Basit A, 2018, BIOTECHNOL BIOENG, V115, P1675, DOI 10.1002/bit.26602
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Bruno BJ, 2013, THER DELIV, V4, P1443, DOI [10.4155/TDE.13.104, 10.4155/tde.13.104]
   Chakraborti S, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-73
   Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   ERVA RR, 2015, 3 BIOTECH, V6, DOI DOI https://doi.org/10.1007/s13205-015-0339-9
   Fosgerau K, 2015, DRUG DISCOV TODAY, V20, P122, DOI 10.1016/j.drudis.2014.10.003
   Geng CL, 2017, METHODS MOL BIOL, V1561, P109, DOI 10.1007/978-1-4939-6798-8_8
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Gupta R, 2004, NETNGLYC 1 0 SERVER
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Haschke M, 2013, CLIN PHARMACOKINET, V52, P783, DOI 10.1007/s40262-013-0072-7
   Huang LL, 2003, J BIOL CHEM, V278, P15532, DOI 10.1074/jbc.M212934200
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Jenny-Avital ER, 2003, NEW ENGL J MED, V349, P1770
   Johnson RJ, 2007, J MOL BIOL, V368, P434, DOI 10.1016/j.jmb.2007.02.005
   Kastritis PL, 2010, J PROTEOME RES, V9, P2216, DOI 10.1021/pr9009854
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Koehler JW, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002430
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kumar KM, 2014, MOL BIOSYST, V10, P891, DOI 10.1039/c3mb70537d
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083
   Liu Y, 2018, INT J BIOL SCI, V14, P946, DOI 10.7150/ijbs.24121
   Maqsood B, 2020, INT J BIOL MACROMOL, V152, P584, DOI 10.1016/j.ijbiomac.2020.02.246
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pierce BG, 2014, BIOINFORMATICS, V30, P1771, DOI 10.1093/bioinformatics/btu097
   Procko E., 2020, SEQUENCE HUMAN ACE2, P1
   Ramirez D, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040525
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Schrodinger L., 2010, PYMOL MOL GRAPHIC SY
   Schymkowitz J, 2005, NUCLEIC ACIDS RES, V33, pW382, DOI 10.1093/nar/gki387
   Shu C., 2020, STEMEDICINE, V1, pe41, DOI [https://doi.org/10.37175/stemedicine.v1i2.41, DOI 10.37175/STEMEDICINE.V1I2.41]
   Sormanni P, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a033845
   Steentoft C, 2013, EMBO J, V32, P1478, DOI 10.1038/emboj.2013.79
   Su MG, 2017, BMC SYST BIOL, V11, DOI 10.1186/s12918-017-0506-1
   Turner AJ, 2004, HDB PROTEOLYTIC ENZY, P349, DOI DOI 10.1016/B978-0-12-079611-3.50092-6
   Van Durme J, 2011, BIOINFORMATICS, V27, P1711, DOI 10.1093/bioinformatics/btr254
   van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014
   Vangone A, 2017, PROTEINS, V85, P417, DOI 10.1002/prot.25198
   Vangone A, 2015, ELIFE, V4, DOI 10.7554/eLife.07454
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wojcik P, 2016, BIOORG MED CHEM LETT, V26, P707, DOI 10.1016/j.bmcl.2015.12.084
   Xue LC, 2016, BIOINFORMATICS, V32, P3676, DOI 10.1093/bioinformatics/btw514
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhang C, 1997, J MOL BIOL, V267, P707, DOI 10.1006/jmbi.1996.0859
   Zhang G., 2020, BIORXIV, DOI [10.1101/2020.03.19.999318, DOI 10.1101/2020.03.19.999318]
   Zhao J., 2018, ACTA SCI MALAYS, V2, P1, DOI [10.26480/asm.01.2018.01.04, DOI 10.26480/ASM.01.2018.01.04]
NR 60
TC 9
Z9 9
U1 5
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1768150
EA MAY 2020
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LT3OH
UT WOS:000536980000001
PM 32396773
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Mittal, L
   Kumari, A
   Srivastava, M
   Singh, M
   Asthana, S
AF Mittal, Lovika
   Kumari, Anita
   Srivastava, Mitul
   Singh, Mrityunjay
   Asthana, Shailendra
TI Identification of potential molecules against COVID-19 main protease
   through structure-guided virtual screening approach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Virtual screening; COVID-19; SARS-CoV-2; M-pro protease; molecular
   docking analysis; binding free energy
AB The pandemic caused by novel coronavirus disease 2019 (COVID-19) infecting millions of populations worldwide and counting, has demanded quick and potential therapeutic strategies. Current approved drugs or molecules under clinical trials can be a good pool for repurposing through in-silico techniques to quickly identify promising drug candidates. The structural information of recently released crystal structures of main protease (M-pro) in APO and complex with inhibitors, N3, and 13b molecules was utilized to explore the binding site architecture through Molecular dynamics (MD) simulations. The stable state of M-pro was used to conduct extensive virtual screening of the aforementioned drug pool. Considering the recent success of HIV protease molecules, we also used anti-protease molecules for drug repurposing purposes. The identified top hits were further evaluated through MD simulations followed by the binding free energy calculations using MM-GBSA. Interestingly, in our screening, several promising drugs stand out as potential inhibitors of M-pro. However, based on control (N3 and 13b), we have identified six potential molecules, Leupeptin Hemisulphate, Pepstatin A, Nelfinavir, Birinapant, Lypression and Octreotide which have shown the reasonably significant MM-GBSA score. Further insight shows that the molecules form stable interactions with hot-spot residues, that are mainly conserved and can be targeted for structure- and pharmacophore-based designing. The pharmacokinetic annotations and therapeutic importance have suggested that these molecules possess drug-like properties and pave their way for in-vitro studies. Communicated by Ramaswamy H. Sarma
C1 [Mittal, Lovika; Kumari, Anita; Srivastava, Mitul; Singh, Mrityunjay; Asthana, Shailendra] THSTI, NCR Biotech Sci Cluster 3rd Milestone, Faridabad 121001, Haryana, India.
RP Asthana, S (corresponding author), THSTI, NCR Biotech Sci Cluster 3rd Milestone, Faridabad 121001, Haryana, India.
EM sasthana@thsti.res.in
OI Singh, Mrityunjay/0000-0001-7931-9601
FU THSTI
FX The work has been supported by the facilities provided by THSTI.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Al-Khafaji K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764392
   Anang S, 2018, J VIROL, V92, DOI 10.1128/JVI.00684-18
   Asthana S, 2015, J AGR FOOD CHEM, V63, P7236, DOI 10.1021/acs.jafc.5b02636
   Asthana S, 2014, BIOCHEMISTRY-US, V53, P6941, DOI 10.1021/bi500490z
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   ClinicalTrials.gov, CHLOR HYDR PREV COR
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Ghosh AK, 2016, J MED CHEM, V59, P5172, DOI 10.1021/acs.jmedchem.5b01697
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kellici TF, 2019, ARAB J CHEM, V12, P5062, DOI 10.1016/j.arabjc.2016.11.014
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kumar D, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752310
   LigPrep, 2017, LIGPREP VERS 4 2
   Lobo-Galo N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764393
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Maestro, 2017, MAESTR VERS
   Mattapally Saidulu, 2018, Oncotarget, V9, P13713, DOI 10.18632/oncotarget.24459
   Mittal L, 2019, J PHYS CHEM B, V123, P6150, DOI 10.1021/acs.jpcb.9b01859
   Mittal L, 2020, J BIOMOL STRUCT DYN, V38, P1612, DOI 10.1080/07391102.2019.1614480
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Nutho B, 2020, BIOCHEMISTRY-US, V59, P1769, DOI 10.1021/acs.biochem.0c00160
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   SiteMap, 2017, SITEMAP VERS 4 2
   Srivastava Mitul, 2018, Oncotarget, V9, P34289, DOI 10.18632/oncotarget.26136
   Thakur SK, 2020, ACS OMEGA, V5, P9585, DOI 10.1021/acsomega.0c00961
   Tirumalaraju D., 2020, CHINA BEGINS PHASE C
   Tirumalaraju D., 2020, CLIN TRIALS ARE 0326
   Tirumalaraju D., 2020, 1 US CLIN TRIAL COVI
   Turner P., 2005, XMGRACE VERSION 5 1
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Yang S, 2006, J MED CHEM, V49, P4971, DOI 10.1021/jm0603926
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 49
TC 19
Z9 20
U1 6
U2 13
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1768151
EA MAY 2020
PG 19
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LT3NR
UT WOS:000536978400001
PM 32396769
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Xu, XL
   Han, MF
   Li, TT
   Sun, W
   Wang, DS
   Fu, BQ
   Zhou, YG
   Zheng, XH
   Yang, Y
   Li, XY
   Zhang, XH
   Pan, AJ
   Wei, HM
AF Xu, Xiaoling
   Han, Mingfeng
   Li, Tiantian
   Sun, Wei
   Wang, Dongsheng
   Fu, Binqing
   Zhou, Yonggang
   Zheng, Xiaohu
   Yang, Yun
   Li, Xiuyong
   Zhang, Xiaohua
   Pan, Aijun
   Wei, Haiming
TI Effective treatment of severe COVID-19 patients with tocilizumab
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE tocilizumab; interleukin-6; COVID-19; SARS-CoV-2; cytokine storm
ID RESPIRATORY SYNDROME CORONAVIRUS; DOUBLE-BLIND; ARTHRITIS; BLOCKADE
AB After analyzing the immune characteristics of patients with severe coronavirus disease 2019 (COVID-19), we have identified that pathogenic T cells and inflammatory monocytes with large amount of interleukin 6 secreting may incite the inflammatory storm, which may potentially be curbed through monoclonal antibody that targets the IL-6 pathways. Here, we aimed to assess the efficacy of tocilizumab in severe patients with COVID-19 and seek a therapeutic strategy. The patients diagnosed as severe or critical COVID-19 in The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) and Anhui Fuyang Second People's Hospital were given tocilizumab in addition to routine therapy between 5 and 14 February 2020. The changes of clinical manifestations, computerized tomography (CT) scan image, and laboratory examinations were retrospectively analyzed. Fever returned to normal on the first day, and other symptoms improved remarkably within a few days. Within 5 d after tocilizumab, 15 of the 20 patients (75.0%) had lowered their oxygen intake, and 1 patient needed no oxygen therapy. CT scans manifested that the lung lesion opacity absorbed in 19 patients (90.5%). The percentage of lymphocytes in peripheral blood, which decreased in 85.0% of patients (17/20) before treatment (mean, 15.52 +/- 8.89%), returned to normal in 52.6% of patients (10/19) on the fifth day after treatment. Abnormally elevated C-reactive protein decreased significantly in 84.2% of patients (16/19). No obvious adverse reactions were observed. All patients have been discharged on average 15.1 d after giving tocilizumab. Preliminary data show that tocilizumab, which improved the clinical outcome immediately in severe and critical COVID-19 patients, isan effective treatment to reduce mortality.
C1 [Xu, Xiaoling; Li, Tiantian; Wang, Dongsheng] Univ Sci & Technol China, Affiliated Hosp 1, Anhui Prov Hosp, Resp & Crit Care Med, Hefei 230000, Anhui, Peoples R China.
   [Han, Mingfeng; Sun, Wei; Zhang, Xiaohua] Anhui Fuyang Second Peoples Hosp, Resp & Crit Care Med, Fuyang 230000, Anhui, Peoples R China.
   [Fu, Binqing; Zhou, Yonggang; Zheng, Xiaohu; Wei, Haiming] Univ Sci & Technol China, Inst Immunol, Sch Life Sci & Med Ctr, Hefei 230000, Anhui, Peoples R China.
   [Fu, Binqing; Zhou, Yonggang; Zheng, Xiaohu; Wei, Haiming] Univ Sci & Technol China, Chinese Acad Sci CAS, Key Lab Innate Immun & Chron Dis, Sch Life Sci & Med Ctr, Hefei 230000, Anhui, Peoples R China.
   [Fu, Binqing; Zhou, Yonggang; Zheng, Xiaohu; Wei, Haiming] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230000, Anhui, Peoples R China.
   [Yang, Yun; Pan, Aijun] Univ Sci & Technol China, Anhui Prov Hosp, Intens Care Unit, Affiliated Hosp 1, Hefei 230000, Anhui, Peoples R China.
   [Li, Xiuyong] Anhui Fuyang Second Peoples Hosp, Hemodialysis Ctr, Fuyang 236000, Anhui, Peoples R China.
RP Xu, XL (corresponding author), Univ Sci & Technol China, Affiliated Hosp 1, Anhui Prov Hosp, Resp & Crit Care Med, Hefei 230000, Anhui, Peoples R China.; Wei, HM (corresponding author), Univ Sci & Technol China, Inst Immunol, Sch Life Sci & Med Ctr, Hefei 230000, Anhui, Peoples R China.; Wei, HM (corresponding author), Univ Sci & Technol China, Chinese Acad Sci CAS, Key Lab Innate Immun & Chron Dis, Sch Life Sci & Med Ctr, Hefei 230000, Anhui, Peoples R China.; Wei, HM (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230000, Anhui, Peoples R China.
EM xxlahh08@163.com; ustcwhm@ustc.edu.cn
OI han, ming feng/0000-0001-6646-8085
FU Department of Science and Technology of Anhui Province; Health
   Commission of Anhui Province [202004a07020001]; China National Center
   for Biotechnology Development 175 Grant [2020YFC0843800]
FX This work was supported by Department of Science and Technology of Anhui
   Province and Health Commission of Anhui Province Grant 202004a07020001
   and China National Center for Biotechnology Development 175 Grant
   2020YFC0843800.
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   China NHCOTPSRO, DIAGN TREATM PROT NO
   Davies R, 2014, SEMIN IMMUNOL, V26, P97, DOI 10.1016/j.smim.2013.12.002
   Gabay C, 2013, LANCET, V381, P1541, DOI 10.1016/S0140-6736(13)60250-0
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Hu B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006698
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jones SA, 2011, J CLIN INVEST, V121, P3375, DOI 10.1172/JCI57158
   Kaly L, 2012, BEST PRACT RES CL RH, V26, P157, DOI 10.1016/j.berh.2012.01.001
   Lau SKP, 2013, J GEN VIROL, V94, P2679, DOI 10.1099/vir.0.055533-0
   Li Y, 2013, MICROBES INFECT, V15, P88, DOI 10.1016/j.micinf.2012.10.008
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Tanyi JL, 2017, J IMMUNOTHER, V40, P104, DOI 10.1097/CJI.0000000000000160
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Watanabe K, 2020, SOC SCI COMPUT REV, DOI 10.1177/0894439320907027
   WHO, 2020, WHO DIR GEN REM MED
   Wolf J, 2014, CYTOKINE, V70, P11, DOI 10.1016/j.cyto.2014.05.024
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yokota S, 2008, LANCET, V371, P998, DOI 10.1016/S0140-6736(08)60454-7
NR 22
TC 537
Z9 550
U1 26
U2 32
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 19
PY 2020
VL 117
IS 20
BP 10970
EP 10975
DI 10.1073/pnas.2005615117
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LR3HS
UT WOS:000535585100051
PM 32350134
OA Green Published, Other Gold
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Albini, A
   Di Guardo, G
   Noonan, DM
   Lombardo, M
AF Albini, Adriana
   Di Guardo, Giovanni
   Noonan, Douglas McClain
   Lombardo, Michele
TI The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell
   types: implications for ACE-inhibitor- and angiotensin II receptor
   blocker-based cardiovascular therapies
SO INTERNAL AND EMERGENCY MEDICINE
LA English
DT Article
DE COVID-19; Cardiovascular disease; Thrombosis; Endothelium; Angiotensin
   II receptor blockers; ACE-inhibitors
ID CONVERTING ENZYME 2; SARS CORONAVIRUS; SYSTEM; HEART
AB SARS-CoV-2 is characterized by a spike protein allowing viral binding to the angiotensin-converting enzyme (ACE)-2, which acts as a viral receptor and is expressed on the surface of several pulmonary and extra-pulmonary cell types, including cardiac, renal, intestinal and endothelial cells. There is evidence that also endothelial cells are infected by SARS-COV-2, with subsequent occurrence of systemic vasculitis, thromboembolism and disseminated intravascular coagulation. Those effects, together with the "cytokine storm" are involved in a worse prognosis. In clinical practice, angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) are extensively used for the treatment of hypertension and other cardiovascular diseases. In in vivo studies, ACE-Is and ARBs seem to paradoxically increase ACE-2 expression, which could favour SARS-CoV-2 infection of host's cells and tissues. By contrast, in patients treated with ACE-Is and ARBs, ACE-2 shows a downregulation at the mRNA and protein levels in kidney and cardiac tissues. Yet, it has been claimed that both ARBs and ACE-Is could result potentially useful in the clinical course of SARS-CoV-2-infected patients. As detected in China and as the Italian epidemiological situation confirms, the most prevalent comorbidities in deceased patients with COVID-19 are hypertension, diabetes and cardiovascular diseases. Older COVID-19-affected patients with cardiovascular comorbidities exhibit a more severe clinical course and a worse prognosis, with many of them being also treated with ARBs or ACE-Is. Another confounding factor is cigarette smoking, which has been reported to increase ACE-2 expression in both experimental models and humans. Sex also plays a role, with chromosome X harbouring the gene coding for ACE-2, which is one of the possible explanations of why mortality in female patients is lower. Viral entry also depends on TMPRSS2 protease activity, an androgen dependent enzyme. Despite the relevance of experimental animal studies, to comprehensively address the question of the potential hazards or benefits of ACE-Is and ARBs on the clinical course of COVID-19-affected patients treated by these anti-hypertensive drugs, we will need randomized human studies. We claim the need of adequately powered, prospective studies aimed at answering the following questions of paramount importance for cardiovascular, internal and emergency medicine: Do ACE-Is and ARBs exert similar or different effects on infection or disease course? Are such effects dangerous, neutral or even useful in older, COVID-19-affected patients? Do they act on multiple cell types? Since ACE-Is and ARBs have different molecular targets, the clinical course of SARS-CoV-2 infection could be also different in patients treated by one or the other of these two drug classes. At present, insufficient detailed data from trials have been made available.
C1 [Albini, Adriana; Noonan, Douglas McClain] IRCCS MultiMed, Sci & Technol Pole, Milan, Italy.
   [Di Guardo, Giovanni] Univ Teramo, Fac Vet Med, I-64100 Teramo, Italy.
   [Noonan, Douglas McClain] Univ Insubria, Dept Biotechnol & Life Sci, Varese, Italy.
   [Lombardo, Michele] San Giuseppe Hosp MultiMed, Cardiol Unit, Milan, Italy.
RP Albini, A (corresponding author), IRCCS MultiMed, Sci & Technol Pole, Milan, Italy.
EM adriana.albini@multimedica.it
OI Albini, Adriana/0000-0002-9624-5103
FU Italian Ministry of Health Ricerca Corrente-IRCCS MultiMedica
FX We thank Andrea Sonaglioni (Cardiology Unit, San Giuseppe
   Hospital-MultiMedica, Milan, Italy) and Mario Milco D'Elios (Department
   of Experimental and Clinical Medicine, University of Florence, Florence,
   Italy) for helpful discussion and revision of the manuscript. This work
   has been supported by Italian Ministry of Health Ricerca Corrente-IRCCS
   MultiMedica.
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bangalore S, 2020, NEW ENGL J MED, V382, P2478, DOI 10.1056/NEJMc2009020
   Batlle D, 2010, CIRC RES, V107, P822, DOI 10.1161/CIRCRESAHA.110.229831
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Bozkurt B, 2020, HFSA ACC AHA STATEME
   Brake SJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030841
   Chamsi-Pasha Mohammed A R, 2014, Curr Heart Fail Rep, V11, P58, DOI 10.1007/s11897-013-0178-0
   Chen Li, 2020, Cardiovasc Res, V116, P1932, DOI 10.1093/cvr/cvaa093
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   de Simone G., 2020, EUR SOC CARDIOL
   Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Escher R, 2020, THROMB RES, V190, P62, DOI 10.1016/j.thromres.2020.04.014
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Forrester SJ, 2018, PHYSIOL REV, V98, P1627, DOI 10.1152/physrev.00038.2017
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Gibson WT, 2020, BIORXIV, DOI [10.1101/2020.04.05.026633, DOI 10.1101/2020.04.05.026633]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Klimas J, 2015, J CELL MOL MED, V19, P1965, DOI 10.1111/jcmm.12573
   Koka V, 2008, AM J PATHOL, V172, P1174, DOI 10.2353/ajpath.2008.070762
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Li JY, 2020, DIABETES OBES METAB, V22, P1935, DOI 10.1111/dom.14057
   Li Q, 2020, BIORXIV, DOI [10.1101/2020.04.14.041434, DOI 10.1101/2020.04.14.041434]
   Lippi G, 2020, EUR J INTERN MED, V75, P107, DOI 10.1016/j.ejim.2020.03.014
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mehta N, 2020, JAMA CARDIOL, V5, P1020, DOI 10.1001/jamacardio.2020.1855
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Sarkissian SD, 2008, HYPERTENSION, V51, P712, DOI 10.1161/HYPERTENSIONAHA.107.100693
   Shi S, 2020, JAMA CARDIOL
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Stawiski EW, 2020, BIORXIV, DOI [10.1101/2020.04.07.024752, DOI 10.1101/2020.04.07.024752]
   Tikellis C, 2011, CURR OPIN NEPHROL HY, V20, P62, DOI 10.1097/MNH.0b013e328341164a
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Venuti A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01358
   Wang Q., 2020, QUANT SCI STUD, V1, P239, DOI [10.1162/qss_a_00011, DOI 10.1016/j.cell.2020.03.045]
   Wang XL, 2020, CELL MOL IMMUNOL, DOI 10.1038/s41423-020-0424-9
   Williams B, 2018, J HYPERTENS, V36, P1953, DOI 10.1097/HJH.0000000000001940
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiong TY, 2020, EUR HEART J, V41, P1798, DOI 10.1093/eurheartj/ehaa231
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhao YL, 2015, BURNS, V41, P1468, DOI 10.1016/j.burns.2015.04.010
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 59
TC 22
Z9 22
U1 3
U2 9
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1828-0447
EI 1970-9366
J9 INTERN EMERG MED
JI Intern. Emerg. Med.
PD AUG
PY 2020
VL 15
IS 5
SI SI
BP 759
EP 766
DI 10.1007/s11739-020-02364-6
EA MAY 2020
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA MZ0DG
UT WOS:000535254100002
PM 32430651
OA Other Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Khunti, S
   Khunti, N
   Seidu, S
   Khunti, K
AF Khunti, Sachin
   Khunti, Nitisha
   Seidu, Samuel
   Khunti, Kamlesh
TI Therapeutic uncertainties in people with cardiometabolic diseases and
   severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19)
SO DIABETES OBESITY & METABOLISM
LA English
DT Article
DE type 2 diabetes
ID ASSOCIATION; ADHERENCE
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) has been declared a pandemic by the World Health Organization and sent all countries scrambling to review emergency healthcare provisions. There is global evidence of each nation struggling to effectively manage the number of people being diagnosed with the virus. These are testing times which have not been experienced in recent generations and there are a number of insecurities regarding the management of people with COVID-19 and cardiometabolic diseases. This review highlights the current concerns related to COVID-19 and provides advice in terms of the therapeutic uncertainty and potential adverse harms associated with therapy when managing people, particularly those with cardiometabolic diseases, who have contracted or are at increased risk of contracting COVID-19.
C1 [Khunti, Sachin] Barts & London Queen Marys Sch Med & Dent, Sch Med & Dent, London, England.
   [Khunti, Nitisha] Univ Hosp Coventry & Warwickshire, Coventry, W Midlands, England.
   [Seidu, Samuel] Leicester Gen Hosp, Leicester Diabet Ctr, NIHR Clin Lecturer Primary Care, Leicester LE5 4PW, Leics, England.
   [Khunti, Kamlesh] Univ Leicester, Diabet Res Ctr, Primary Care Diabet & Vasc Med, Leicester, Leics, England.
RP Khunti, K (corresponding author), Univ Leicester, Leicester Gen Hosp, Coll Life Sci, Primary Care Diabet & Vasc Med,Leicester Diabet C, Gwendolen Rd, Leicester LE5 4PW, Leics, England.; Khunti, K (corresponding author), Univ Leicester, Leicester Gen Hosp, Coll Life Sci, Leicester Diabet Ctr Air Wing,Diabet Res Ctr, Gwendolen Rd, Leicester LE5 4PW, Leics, England.
EM kk22@leicester.ac.uk
OI Seidu, Samuel/0000-0002-8335-7018; Khunti, Kamlesh/0000-0003-2343-7099
FU National Institute for Health Research (NIHR) Applied Research
   Collaboration East Midlands (ARC EM); NIHR Leicester Biomedical Research
   Centre (BRC)
FX K.K. and S.S. are supported by the National Institute for Health
   Research (NIHR) Applied Research Collaboration East Midlands (ARC EM)
   and the NIHR Leicester Biomedical Research Centre (BRC).
CR American College of Cardiology, 2020, HFSA ACC AHA STAT AD
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   DeFronzo R, 2016, METABOLISM, V65, P20, DOI 10.1016/j.metabol.2015.10.014
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Down S, 2020, DIABETES PRIMARY CAR
   European Society of Cardiology, 2020, POS STAT ESC COUNC H
   European Society of Hypertension, 2020, ESH UPDATE COVID 19
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grenard JL, 2011, J GEN INTERN MED, V26, P1175, DOI 10.1007/s11606-011-1704-y
   Khunti K, 2017, DIABETES CARE, V40, P1588, DOI 10.2337/dc16-1925
   NHS Leeds, 2020, DIAB COVID 19
   Pearson-Stuttard J, 2016, LANCET DIABETES ENDO, V4, P148, DOI 10.1016/S2213-8587(15)00379-4
   Perico Luca, 2020, Nephron, V144, P213, DOI 10.1159/000507305
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Society for Endocrinology, 2020, ADR CRIS INF
   Tam CCF, 2020, CATHETER CARDIO INTE, DOI 10.1002/ccd.28943
   Teljeur C, 2013, EUR J GEN PRACT, V19, P17, DOI 10.3109/13814788.2012.714768
   The Renal Association, 2020, REN ASS UK POS STAT
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1
   WHO, 2020, CLIN MAN SEV AC RESP
   Wondafrash DZ, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/5214751
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiong TY, 2020, EUR HEART J, V41, P1798, DOI 10.1093/eurheartj/ehaa231
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
NR 27
TC 3
Z9 3
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8902
EI 1463-1326
J9 DIABETES OBES METAB
JI Diabetes Obes. Metab.
PD OCT
PY 2020
VL 22
IS 10
BP 1942
EP 1945
DI 10.1111/dom.14062
EA MAY 2020
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NK1QY
UT WOS:000534020000001
PM 32319200
OA Green Published
DA 2021-01-01
ER

PT J
AU Aviv, A
AF Aviv, Abraham
TI Telomeres and COVID-19
SO FASEB JOURNAL
LA English
DT Article
DE COVID-19; lymphopenia; Telomeres; T cells
ID T-CELL; LENGTH; EXPRESSION; PNEUMONIA; IMMUNITY; CANCER; SPAN; SARS
AB The medical, public health, and scientific communities are grappling with monumental imperatives to contain COVID-19, develop effective vaccines, identify efficacious treatments for the infection and its complications, and find biomarkers that detect patients at risk of severe disease. The focus of this communication is on a potential biomarker, short telomere length (TL), that might serve to identify patients more likely to die from the SARS-CoV-2 infection, regardless of age. The common thread linking these patients is lymphopenia, which largely reflects a decline in the numbers of CD4/CD8 T cells but not B cells. These findings are consistent with data that lymphocyte TL dynamics impose a limit on T-cell proliferation. They suggest that T-cell lymphopoiesis might stall in individuals with short TL who are infected with SARS-CoV-2.
C1 [Aviv, Abraham] Rutgers State Univ, New Jersey Med Sch, Ctr Human Dev & Aging, Newark, NJ USA.
RP Aviv, A (corresponding author), Rutgers State Univ, New Jersey Med Sch, Ctr Human Dev & Aging, Room F-464 MSB, Newark, NJ 07103 USA.
EM avivab@njms.rutgers.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 HL134840, U01AG066529]; Norwegian
   Research Council (NFR)Research Council of Norway [ES562296]
FX A. Aviv current telomere research is funded by the NIH (R01 HL134840 and
   U01AG066529) and the Norwegian Research Council (NFR) ES562296
CR AlGhatrif M, 2020, JAMA CARDIOL, DOI [10.1001/jamacardio.2020.1329, DOI 10.1001/JAMACARDI0.2020.1329]
   ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114
   Aubert G, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002696
   Aviv A, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2016.0436
   Aviv A, 2017, TRENDS CANCER, V3, P253, DOI 10.1016/j.trecan.2017.02.005
   Benetos A, 2018, CIRC RES, V122, P616, DOI 10.1161/CIRCRESAHA.117.311751
   de Jesus BB, 2011, AGING CELL, V10, P604, DOI 10.1111/j.1474-9726.2011.00700.x
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Blackburn EH, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003558
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Brouilette S, 2003, ARTERIOSCL THROM VAS, V23, P842, DOI 10.1161/01.ATV.0000067426.96344.32
   Carter R, 2002, CLIN MICROBIOL REV, V15, P564, DOI 10.1128/CMR.15.4.564-594.2002
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cohen J., 2020, SCIENCE, DOI [10.1126/science.abc5422, DOI 10.1126/SCIENCE.ABC5422]
   Danser AHJ, 2020, HYPERTENSION, DOI [10.1016/j.ando.2020.04.005, DOI 10.1016/J.AND0.2020.04.005]
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Dingli D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000345
   DOBZHANSKY T, 1973, AM BIOL TEACH, V35, P125, DOI 10.2307/4444260
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Doolan DL, 2009, CLIN MICROBIOL REV, V22, P13, DOI 10.1128/CMR.00025-08
   Factor-Litvak P, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3927
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Hansen MEB, 2016, HUM MOL GENET, V25, P2324, DOI 10.1093/hmg/ddw070
   Harley CB, 2011, REJUV RES, V14, P45, DOI 10.1089/rej.2010.1085
   He FJ, 1998, HYPERTENSION, V32, P820, DOI 10.1161/01.HYP.32.5.820
   Hjelmborg JB, 2015, J MED GENET, V52, P297, DOI 10.1136/jmedgenet-2014-102736
   Hodes RJ, 2002, NAT REV IMMUNOL, V2, P699, DOI 10.1038/nri890
   Horvath K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36923-x
   Hunt SC, 2008, AGING CELL, V7, P451, DOI 10.1111/j.1474-9726.2008.00397.x
   Joy DA, 2003, SCIENCE, V300, P318, DOI 10.1126/science.1081449
   Kimura M, 2010, EXP HEMATOL, V38, P854, DOI 10.1016/j.exphem.2010.06.010
   Ko JH, 2016, J INFECTION, V73, P468, DOI 10.1016/j.jinf.2016.08.005
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Lu Q, 2020, J MED VIROL, V92, P564, DOI 10.1002/jmv.25740
   Martens UM, 2002, BRIT J HAEMATOL, V119, P810, DOI 10.1046/j.1365-2141.2002.03910.x
   Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359
   Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000
   Molgora Brenda, 2013, Cells, V2, P57, DOI 10.3390/cells2010057
   Mollica L, 2009, J GERONTOL A-BIOL, V64, P965, DOI 10.1093/gerona/glp065
   Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152]
   Nanni S, 2002, J CLIN INVEST, V110, P219, DOI 10.1172/JCI200215552
   Napoli P.E., 2020, J CLIN MED, V9
   Parri N, 2020, NEW ENGL J MED, V383, P187, DOI 10.1056/NEJMc2007617
   Parrish CR, 2008, MICROBIOL MOL BIOL R, V72, P457, DOI 10.1128/MMBR.00004-08
   Patrick M, 2019, CELL IMMUNOL, V345, DOI 10.1016/j.cellimm.2019.103989
   Patrick MS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01993
   Shepherd BE, 2004, EXP HEMATOL, V32, P1040, DOI 10.1016/j.exphem.2004.07.023
   Sidorov I, 2009, EXP HEMATOL, V37, P514, DOI 10.1016/j.exphem.2008.11.009
   SLAGBOOM PE, 1994, AM J HUM GENET, V55, P876
   Steenstrup T, 2017, AGING-US, V9, P1130, DOI 10.18632/aging.101216
   Stone RC, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006144
   Van Blerkom LM, 2003, YEARB PHYS ANTHROPOL, V46, P14, DOI 10.1002/ajpa.10384
   VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Weng NP, 1997, IMMUNOL REV, V160, P43, DOI 10.1111/j.1600-065X.1997.tb01026.x
   White NJ, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2509-9
   WHO, 2020, REP WHO CHIN JOINT M
   World Health Organization, 2018, THIS YEARS WORLD MAL
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
NR 64
TC 5
Z9 5
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JUN
PY 2020
VL 34
IS 6
BP 7247
EP 7252
DI 10.1096/fj.202001025
EA MAY 2020
PG 6
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA MR4QG
UT WOS:000533887200001
PM 32427393
OA Other Gold, Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Yekeduz, E
   Dursun, B
   Aydin, GC
   Yazgan, SC
   Ozturks, HH
   Azap, A
   Utkan, G
   Urun, Y
AF Yekeduz, Emre
   Dursun, Bengu
   Aydin, Gule C.
   Yazgan, Sati C.
   Ozturks, Halis H.
   Azap, Alpay
   Utkan, Gungor
   Urun, Yuksel
TI Clinical course of COVID-19 infection in elderly patient with melanoma
   on nivolumab
SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE
LA English
DT Article
DE COVID-19; SARS-CoV2; immunotherapy
ID T-CELLS
AB Outbreak of the new type coronavirus infection, known as coronavirus infection 2019 (COVID-19), has begun in December 2019, in Wuhan, China. As of today, 3 April 2020, 972,640 people affected and 50,325 people died from Severe Acute Respiratory Syndrome-Coronavirus 2. There is not any standard treatment for coronavirus infection 2019; however, there are promising data for hydroxychloroquine and some anti-retroviral drugs. Programmed death-1 (PD-1)/programmed death ligand-1 (PDL-1) pathway is an important target for the cancer immunotherapy. However, there is a robust pre-clinical and clinical data regarding inhibitor effect of this pathway on the acute or chronic viral infections. Thus, blockade of this pathway may lead to an anti-viral effect and decrease viral load. Here, we report the clinical course of coronavirus infection 2019 infection of a patient in whom older aged, having multiple co-morbidities, and taking nivolumab for metastatic malignant melanoma. In contrast to her older age, comorbidities, and cancer diagnosis, she was in a good condition, and there was also no pneumonia finding. We think that this good clinical course of coronavirus infection 2019 infection may be related to blockade of PD-1/PDL-1 pathway with nivolumab. It is impossible to say that blockade of PD-1/PDL-1pathway is a treatment option for COVID-19; however, we want to share our experience.
C1 [Yekeduz, Emre; Dursun, Bengu; Utkan, Gungor; Urun, Yuksel] Ankara Univ, Dept Med Oncol, Ankara, Turkey.
   [Yekeduz, Emre; Dursun, Bengu; Utkan, Gungor; Urun, Yuksel] Ankara Univ, Canc Res Inst, Ankara, Turkey.
   [Aydin, Gule C.; Azap, Alpay] Ankara Univ, Dept Infect Dis & Clin Microbiol, Ankara, Turkey.
   [Yazgan, Sati C.] Ankara Univ, Dept Internal Med, Ankara, Turkey.
   [Ozturks, Halis H.] Ankara Univ, Dept Radiol, Ankara, Turkey.
RP Yekeduz, E (corresponding author), Ankara Univ, Tip Fak, Tibbi Onkol Bilim Dali, Cebeci Hastanesi, TR-06590 Cebeci Ankara, Turkey.
EM dremre1988@gmail.com
RI Urun, Yuksel/AAQ-3612-2020; Cinar, Gule/ABA-2413-2020; Yekeduz,
   Emre/ABA-5814-2020
OI Urun, Yuksel/0000-0002-9152-9887; Cinar, Gule/0000-0002-7635-8848;
   Yekeduz, Emre/0000-0001-6819-5930
CR Ahn E, 2018, P NATL ACAD SCI USA, V115, P4749, DOI 10.1073/pnas.1718217115
   Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444
   Erickson JJ, 2012, J CLIN INVEST, V122, P2967, DOI 10.1172/JCI62860
   Gao PP, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0743-4
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hage MP, 2014, THER ADV ENDOCRINOL, V5, P10, DOI 10.1177/2042018813517522
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   NCI, 2020, AG CANC RISK 2020
   Sahni S, 2018, CUREUS, V10, DOI 10.7759/cureus.3700
   Sangro B, 2013, J HEPATOL, V59, P81, DOI 10.1016/j.jhep.2013.02.022
   Schonrich G, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00207
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 14
TC 3
Z9 4
U1 1
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1078-1552
EI 1477-092X
J9 J ONCOL PHARM PRACT
JI J. Oncol. Pharm. Pract.
PD JUL
PY 2020
VL 26
IS 5
BP 1289
EP 1294
AR 1078155220924084
DI 10.1177/1078155220924084
EA MAY 2020
PG 6
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA MG6CL
UT WOS:000534322200001
PM 32423324
OA Bronze
DA 2021-01-01
ER

PT J
AU Pinto, D
   Park, YJ
   Beltramello, M
   Walls, AC
   Tortorici, MA
   Bianchi, S
   Jaconi, S
   Culap, K
   Zatta, F
   De Marco, A
   Peter, A
   Guarino, B
   Spreafico, R
   Cameroni, E
   Case, JB
   Chen, RE
   Havenar-Daughton, C
   Snell, G
   Telenti, A
   Virgin, HW
   Lanzavecchia, A
   Diamond, MS
   Fink, K
   Veesler, D
   Corti, D
AF Pinto, Dora
   Park, Young-Jun
   Beltramello, Martina
   Walls, Alexandra C.
   Tortorici, M. Alejandra
   Bianchi, Siro
   Jaconi, Stefano
   Culap, Katja
   Zatta, Fabrizia
   De Marco, Anna
   Peter, Alessia
   Guarino, Barbara
   Spreafico, Roberto
   Cameroni, Elisabetta
   Case, James Brett
   Chen, Rita E.
   Havenar-Daughton, Colin
   Snell, Gyorgy
   Telenti, Amalio
   Virgin, Herbert W.
   Lanzavecchia, Antonio
   Diamond, Michael S.
   Fink, Katja
   Veesler, David
   Corti, Davide
TI Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV
   antibody
SO NATURE
LA English
DT Article
ID CRYO-EM STRUCTURE; SPIKE GLYCOPROTEIN; FC-RECEPTOR; CORONAVIRUS;
   VALIDATION; VOLUNTEERS; REFINEMENT; MICROSCOPY; PROTECTION; INFECTION
AB The monoclonal antibody S309, identified from memory B cells of an individual infected with SARS-CoV in 2003, or antibody cocktails that contain this antibody potently neutralize SARS-CoV-2.
   Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020(1,2). Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within theSarbecovirussubgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease.
C1 [Pinto, Dora; Beltramello, Martina; Bianchi, Siro; Jaconi, Stefano; Culap, Katja; Zatta, Fabrizia; De Marco, Anna; Peter, Alessia; Guarino, Barbara; Cameroni, Elisabetta; Lanzavecchia, Antonio; Fink, Katja; Corti, Davide] Humabs BioMed SA, Vir Biotechnol, Bellinzona, Switzerland.
   [Park, Young-Jun; Walls, Alexandra C.; Tortorici, M. Alejandra; Veesler, David] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
   [Tortorici, M. Alejandra] Inst Pasteur, Paris, France.
   [Tortorici, M. Alejandra] CNRS, UMR 3569, Unite Virol Struct, Paris, France.
   [Spreafico, Roberto; Havenar-Daughton, Colin; Snell, Gyorgy; Telenti, Amalio; Virgin, Herbert W.] Vir Biotechnol, San Francisco, CA USA.
   [Case, James Brett; Chen, Rita E.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Chen, Rita E.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
   [Lanzavecchia, Antonio] Univ Svizzera Italiana, Inst Res Biomed, Bellinzona, Switzerland.
   [Diamond, Michael S.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
RP Corti, D (corresponding author), Humabs BioMed SA, Vir Biotechnol, Bellinzona, Switzerland.; Veesler, D (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
EM dveesler@uw.edu; dcorti@vir.bio
OI Tortorici, M. Alejandra/0000-0002-2260-2577; Culap,
   Katja/0000-0002-0956-0018; Virgin, Herbert/0000-0001-8580-7628; Zatta,
   Fabrizia/0000-0003-4945-8058
FU National Institute of General Medical SciencesUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R01GM120553];
   National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [HHSN272201700059C, 75N93019C00062]; Pew Biomedical Scholars Award;
   Burroughs Wellcome FundBurroughs Wellcome Fund; University of Washington
   Arnold and Mabel Beckman cryo-EM centre; Pasteur Institute; Department
   of Energy Office of Science User FacilityUnited States Department of
   Energy (DOE) [DE-AC02-05CH11231]
FX This study was supported by the National Institute of General Medical
   Sciences (R01GM120553, D.V.), the National Institute of Allergy and
   Infectious Diseases (HHSN272201700059C to D.V. and 75N93019C00062 to
   M.S.D.)), a Pew Biomedical Scholars Award (D.V.), an Investigators in
   the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome
   Fund (D.V.), the University of Washington Arnold and Mabel Beckman
   cryo-EM centre, the Pasteur Institute (M.A.T.) and beamline 5.0.2 at the
   Advanced Light Source at Lawrence Berkley National Laboratory. Beamline
   5.0.2 is supported by The Berkeley Center for Structural Biology. The
   Advanced Light Source is a Department of Energy Office of Science User
   Facility under Contract No. DE-AC02-05CH11231. We thank N. Zheng for use
   of his crystallization robot. We gratefully acknowledge the authors,
   originating and submitting laboratories of the sequences from GISAID's
   EpiFlu Database upon which this research is based.
CR Agirre J, 2015, NAT STRUCT MOL BIOL, V22, P833, DOI 10.1038/nsmb.3115
   Barad BA, 2015, NAT METHODS, V12, P943, DOI [10.1038/nmeth.3541, 10.1038/NMETH.3541]
   Battye TGG, 2011, ACTA CRYSTALLOGR D, V67, P271, DOI 10.1107/S0907444910048675
   Brown A, 2015, ACTA CRYSTALLOGR D, V71, P136, DOI 10.1107/S1399004714021683
   CALLOW KA, 1985, J HYG-CAMBRIDGE, V95, P173, DOI 10.1017/S0022172400062410
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Corti D, 2016, SCIENCE, V351, P1339, DOI 10.1126/science.aad5224
   Corti D, 2015, P NATL ACAD SCI USA, V112, P10473, DOI 10.1073/pnas.1510199112
   Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669
   DiLillo DJ, 2015, CELL, V161, P1035, DOI 10.1016/j.cell.2015.04.016
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061
   Frenz B, 2019, STRUCTURE, V27, P134, DOI 10.1016/j.str.2018.09.006
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Goddard TD, 2007, J STRUCT BIOL, V157, P281, DOI 10.1016/j.jsb.2006.06.010
   Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235
   He WQ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00928-3
   Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Joyce M Gordon, 2020, bioRxiv, DOI 10.1101/2020.03.15.992883
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kelley B, 2020, NAT BIOTECHNOL, V38, P540, DOI 10.1038/s41587-020-0512-5
   Klasse PJ, 2002, J GEN VIROL, V83, P2091, DOI 10.1099/0022-1317-83-9-2091
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Levine MM, 2019, NEW ENGL J MED, V381, P2365, DOI 10.1056/NEJMe1915350
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Li XG, 2020, J MED VIROL, V92, P501, DOI 10.1002/jmv.25701
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   Liu C, 2020, VIRAL ARCHITECTURE S, DOI [10.1101/2020.03.02.972927, DOI 10.1101/2020.03.02.972927]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Millet Jean Kaoru, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.2035
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Park YJ, 2019, NAT STRUCT MOL BIOL, V26, P1151, DOI 10.1038/s41594-019-0334-7
   Pond S., 2020, SARS COV 2 NATURAL S
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   REED SE, 1984, J MED VIROL, V13, P179, DOI 10.1002/jmv.1890130208
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rockx B, 2010, J INFECT DIS, V201, P946, DOI 10.1086/651022
   Rossen JWA, 1998, J VIROL, V72, P497, DOI 10.1128/JVI.72.1.497-503.1998
   Scheres SHW, 2012, NAT METHODS, V9, P853, DOI 10.1038/nmeth.2115
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Smith EC, 2014, ANNU REV VIROL, V1, P111, DOI 10.1146/annurev-virology-031413-085507
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Suloway C, 2005, J STRUCT BIOL, V151, P41, DOI 10.1016/j.jsb.2005.03.010
   Tan YZ, 2017, NAT METHODS, V14, P793, DOI [10.1038/NMETH.4347, 10.1038/nmeth.4347]
   Tegunov D, 2019, NAT METHODS, V16, P1146, DOI 10.1038/s41592-019-0580-y
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang RYR, 2016, ELIFE, V5, DOI 10.7554/eLife.17219
   Wang XH, 2018, PROTEIN CELL, V9, P63, DOI 10.1007/s13238-017-0473-8
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiong XL, 2018, J VIROL, V92
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang Y, 2015, J VIROL, V89, P9119, DOI 10.1128/JVI.01279-15
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zalevsky J, 2010, NAT BIOTECHNOL, V28, P157, DOI 10.1038/nbt.1601
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zivanov J, 2019, IUCRJ, V6, P5, DOI 10.1107/S205225251801463X
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
NR 78
TC 130
Z9 126
U1 47
U2 56
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUL 9
PY 2020
VL 583
IS 7815
BP 290
EP +
DI 10.1038/s41586-020-2349-y
EA MAY 2020
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MH5KF
UT WOS:000543229800001
PM 32422645
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Murphy, HR
AF Murphy, Helen R.
TI Managing Diabetes in Pregnancy Before, During, and After COVID-19
SO DIABETES TECHNOLOGY & THERAPEUTICS
LA English
DT Article
DE Diabetes pregnancy; Type 1diabetes; Type 2 diabetes; Gestational
   diabetes; Continuous glucose monitoring; Insulin pump therapy;
   Closed-loop; COVID-19
AB Background: Pregnant women with diabetes are identified as being more vulnerable to the severe effects of COVID-19 and advised to stringently follow social distancing measures. Here, we review the management of diabetes in pregnancy before and during the lockdown.
   Methods: Majority of antenatal diabetes and obstetric visits are provided remotely, with pregnant women attending hospital clinics only for essential ultrasound scans and labor and delivery. Online resources for supporting women planning pregnancy and for self-management of pregnant women with type 1 diabetes (T1D) using intermittent or continuous glucose monitoring are provided. Retinal screening procedures, intrapartum care, and the varying impact of lockdown on maternal glycemic control are considered. Alternative screening procedures for diagnosing hyperglycemia during pregnancy and gestational diabetes mellitus (GDM) are discussed. Case histories describe the remote initiation of insulin pump therapy and automated insulin delivery in T1D pregnancy.
   Results: Initial feedback suggests that video consultations are well received and that the patient experiences for women requiring face-to-face visits are greatly improved. As the pandemic eases, formal evaluation of remote models of diabetes education and technology implementation, including women's views, will be important.
   Conclusions: Research and audit activities will resume and we will find new ways for supporting pregnant women with diabetes to choose their preferred glucose monitoring and insulin delivery.
C1 [Murphy, Helen R.] Cambridge Univ Hosp, Addenbrookes Hosp, Diabet Pregnancy Team, Cambridge, England.
   [Murphy, Helen R.] Kings Coll London, Div Womens Hlth, St Thomas Campus, London, England.
   [Murphy, Helen R.] Norwich Med Sch, Bob Champ Res & Educ Bldg, Norwich, Norfolk, England.
RP Murphy, HR (corresponding author), Univ East Anglia, Norwich Med Sch, Bob Champ Res & Educ Bldg, Norwich NR4 7UQ, Norfolk, England.
EM helen.murphy@uea.ac.uk
FU Tommy's charity
FX H.R.M. is supported by Tommy's charity.
CR Battelino T, 2019, DIABETES CARE, V42, P1593, DOI 10.2337/dci19-0028
   Draper ES, 2015, MBRRACE UK 2015 PERI
   Garg SK, 2020, DIABETES TECHNOL THE, V22, P431, DOI 10.1089/dia.2020.0161
   Jones MS, 2020, DIABETES TECHNOL THE, V22, P444, DOI 10.1089/dia.2020.0206
   Panzirer D, 2020, DIABETES TECHNOL THE, V22, P440, DOI 10.1089/dia.2020.0219
   Peters AL, 2020, DIABETES TECHNOL THE, V22, P449, DOI 10.1089/dia.2020.0187
   Stacey T, 2019, BJOG-INT J OBSTET GY, V126, P973, DOI 10.1111/1471-0528.15659
   Thangaratinam S, 2020, GUIDANCE MATERNAL ME
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
NR 9
TC 5
Z9 5
U1 7
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1520-9156
EI 1557-8593
J9 DIABETES TECHNOL THE
JI Diabetes Technol. Ther.
PD JUN 1
PY 2020
VL 22
IS 6
BP 454
EP 461
DI 10.1089/dia.2020.0223
EA MAY 2020
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA LT9PA
UT WOS:000535522700001
PM 32396397
OA Bronze
DA 2021-01-01
ER

PT J
AU Cross, R
AF Cross, Ryan
TI Can adenoviral vectors overcome a checkered past to win the COVID-19
   vaccine race?
SO CHEMICAL & ENGINEERING NEWS
LA English
DT Article
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0009-2347
EI 1520-605X
J9 CHEM ENG NEWS
JI Chem. Eng. News
PD MAY 18
PY 2020
VL 98
IS 20
BP 20
EP 23
PG 4
WC Chemistry, Multidisciplinary; Engineering, Chemical
SC Chemistry; Engineering
GA LP5XM
UT WOS:000534390600037
DA 2021-01-01
ER

PT J
AU Noh, JY
   Seong, H
   Yoon, JG
   Song, JY
   Cheong, HJ
   Kim, WJ
AF Noh, Ji Yun
   Seong, Hye
   Yoon, Jin Gu
   Song, Joon Young
   Cheong, Hee Jin
   Kim, Woo Joo
TI Social Distancing against COVID-19: Implication for the Control of
   Influenza
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE Social Distancing; Coronavirus Disease 2019; Influenza
AB Social distancing has been adopted as one of basic protective measures against coronavirus disease 2019 (COVID-19). During 2019-2020 season, influenza epidemic period was exceptionally short and epidemic peak was low in comparison with previous seasons in Korea. Influenza epidemic pattern was bimodal in 2016-2017 and 2018-2019 seasons, however, influenza viruses have rarely been circulating in spring, 2020 in Korea. Although multiple factors could affect the size of influenza epidemic, extensive application of nonpharmaceutical interventions including mask wearing and social distancing in response to COVID-19 seems to be a major factor of reduced influenza epidemic. Social distancing measures with high feasibility and high acceptability should be implemented even if severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are developed in the future. Establishment of guideline for workplace social distancing is needed and it would contribute to reduce disease burden of influenza, especially in vaccine mismatch year.
C1 [Noh, Ji Yun; Seong, Hye; Yoon, Jin Gu; Song, Joon Young; Cheong, Hee Jin; Kim, Woo Joo] Korea Univ, Dept Internal Med, Div Infect Dis, Coll Med, Seoul, South Korea.
   [Noh, Ji Yun; Song, Joon Young; Cheong, Hee Jin; Kim, Woo Joo] Korea Univ, Asia Pacific Influenza Inst, Coll Med, Seoul, South Korea.
RP Cheong, HJ (corresponding author), Korea Univ, Guro Hosp, Coll Med, Div Infect Dis,Dept Internal Med, 148 Gurodong Ro, Seoul 08308, South Korea.
EM heejinmd@korea.ac.kr
RI ; Kim, Woo Joo/D-2733-2015
OI Seong, Hye/0000-0002-5633-7214; Song, Joon Young/0000-0002-0148-7194;
   Kim, Woo Joo/0000-0002-4546-3880; Yoon, Jin Gu/0000-0003-3283-1880
CR Ahmed F, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5446-1
   [Anonymous], 2019, COR DIS
   Cowling BJ, 2020, LANCET PUBLIC HEALTH, V5, pE279, DOI 10.1016/S2468-2667(20)30090-6
   Korea Centers for Disease Control and Prevention, INF DIS PORT
   Korea Centers for Disease Control and Prevention, 2017, WEEKL SENT SURV REP
   Korea Centers for Disease Control and Prevention, KOR INFL LAB SURV RE
   Korea Centers for Disease Control and Prevention, 2018, PATH VECT SURV WEEKL
   Korea Centers for Disease Control and Prevention, 2020, PATH VECT SURV WEEKL
   Qualls N, 2017, MMWR RECOMM REP, V66, P1, DOI 10.15585/mmwr.rr6601a1
   Song JY, 2020, NEW ENGL J MED, V382, P1858, DOI 10.1056/NEJMc2001801
   Wolfel R, 2020, NATURE
   World Health Organization, 2005, 2 M INT HLTH REG EM
   World Health Organization, 2019, NOV COR 2019 NCOV SI
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 14
TC 5
Z9 5
U1 1
U2 4
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD MAY 18
PY 2020
VL 35
IS 19
AR e182
DI 10.3346/jkms.2020.35.e182
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA LP8TS
UT WOS:000534590700007
PM 32419400
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sciarra, A
   Salciccia, S
   Maggi, M
   Del Giudice, F
   Busetto, GM
   Musio, D
   Ciardi, A
   Catalano, C
   Cortesi, E
   Panebianco, V
AF Sciarra, Alessandro
   Salciccia, Stefano
   Maggi, Martina
   Del Giudice, Francesco
   Busetto, Gian Maria
   Musio, Daniela
   Ciardi, Antonio
   Catalano, Carlo
   Cortesi, Enrico
   Panebianco, Valeria
TI Elective procedures for prostate cancer in the time of Covid-19: a
   multidisciplinary team experience
SO PROSTATE CANCER AND PROSTATIC DISEASES
LA English
DT Article
AB On March 29th 2020, 97,689 cases of COVID-19 have been diagnosed only in Italy, with 73,880 actually positive cases, a daily increase of 3815 cases, 27,386 hospitalized and 3906 patients in intensive care units, causing a total of 10,779 known deaths. In all urological departments, quickly inpatient and outpatient services have been significantly reduced. Even in this COVID-19 situation, urological neoplasm care must go on, but significant changes need to be made in the way some care is delivered. We compared diagnostic and therapeutic elective procedures requested and performed for PC management from our multidisciplinary team (MDT) during 1 month activity in the highest national level of COVID-19 infection (March 2020) and under restrictions for all the population, with the management performed in a no-COVID-19 month (March 2019) 1 year ago. The only management that did not received a significant reduction are medical therapies for advanced hormone sensitive (HS) or castration resistant (CR) PC. We describe our MDT identifications of elective undeferrable PC management in this COVID-19 time. These suggestions have been considered for a country (ITALY) under a rapid increase of COVID-19 cases and complications, but in a region with an actual lower impact (2914 actual positive and 1079 hospitalized cases) from the infection and in an hospital not completely converted to COVID-19 management. Indications should be different and restricted only to emergencies on the basis of COVID-19 pandemic situation and hospital involvement.
C1 [Sciarra, Alessandro; Salciccia, Stefano; Maggi, Martina; Del Giudice, Francesco; Busetto, Gian Maria] Univ Sapienza, Dept Urol, Rome, Italy.
   [Musio, Daniela] Univ Sapienza, Dept Radiol Sci Oncol & Pathol, Rome, Italy.
   [Ciardi, Antonio; Catalano, Carlo; Cortesi, Enrico; Panebianco, Valeria] Sapienza Univ Rome, Dept Radiol Oncol & Pathol, Rome, Italy.
RP Salciccia, S (corresponding author), Univ Sapienza, Dept Urol, Rome, Italy.
EM stefano.salciccia@uniroma1.it
OI DEL GIUDICE, FRANCESCO/0000-0003-3865-5988; Panebianco,
   Valeria/0000-0001-8466-918X
CR Chan MC, 2020, EUR UROL, DOI [10.1016/j.eururo.2020.03.004, DOI 10.1016/J.EURUR0.2020.03.004]
   Ficarra V, 2020, MINERVA UROL NEFROL, V72, P369, DOI 10.23736/S0393-2249.20.03846-1
   Kashi AH, 2020, UROL J, V17, P327, DOI 10.22037/uj.v0i0.6064
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Maggi M, 2020, EUR UROL FOCUS, V6, P463, DOI 10.1016/j.euf.2019.06.014
   Nowroozi A, 2020, UROL J, V17, P326, DOI 10.22037/uj.v0i0.6065
   Sciarra A, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2018.03.022
   Stensland KD, 2020, EUR UROL
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
NR 9
TC 0
Z9 1
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1365-7852
EI 1476-5608
J9 PROSTATE CANCER P D
JI Prostate Cancer Prostatic Dis.
PD SEP
PY 2020
VL 23
IS 3
BP 407
EP 409
DI 10.1038/s41391-020-0240-4
EA MAY 2020
PG 3
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA NB9HB
UT WOS:000534278900002
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Li, WM
   Wang, DY
   Guo, JM
   Yuan, GL
   Yang, ZZ
   Gale, RP
   You, Y
   Chen, ZC
   Chen, SM
   Wan, CC
   Zhu, XJ
   Chang, W
   Sheng, LS
   Cheng, H
   Zhang, YS
   Meng, L
   Jiang, Q
   Li, Q
   Qin, J
AF Li, Weiming
   Wang, Danyu
   Guo, Jingming
   Yuan, Guolin
   Yang, Zhuangzhi
   Gale, Robert Peter
   You, Yong
   Chen, Zhichao
   Chen, Shiming
   Wan, Chucheng
   Zhu, Xiaojian
   Chang, Wei
   Sheng, Lingshuang
   Cheng, Hui
   Zhang, Youshan
   Meng, Li
   Jiang, Qian
   Li, Qing
   Qin, Jun
CA Hubei Anti-Canc Assoc
TI COVID-19 in persons with chronic myeloid leukaemia
SO LEUKEMIA
LA English
DT Article
AB We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N = 4) or probable COVID-19 (N = 1). Prevalence of COVID-19 in our subjects, 0.9% (95% Confidence Interval, 0.1, 1.8%) was ninefold higher than 0.1% (0, 0.12%) reported in normals but lower than 10% (6, 17%) reported in hospitalised persons with other haematological cancers or normal health-care providers, 7% (4, 12%). Co-variates associated with an increased risk of developing COVID-19 amongst persons with CML were exposure to someone infected with SARS-CoV-2 (P = 0.037), no complete haematologic response (P = 0.003) and co-morbidity(ies) (P = 0.024). There was also an increased risk of developing COVID-19 in subjects in advanced phase CML (P = 0.004) even when they achieved a complete cytogenetic response or major molecular response at the time of exposure to SARS-CoV-2. 1 of 21 subjects receiving 3rd generation tyrosine kinase-inhibitor (TKI) developed COVID-19 versus 3 of 346 subjects receiving imatinib versus 0 of 162 subjects receiving 2nd generation TKIs (P = 0.096). Other co-variates such as age and TKI-therapy duration were not significantly associated with an increased risk of developing COVID-19. Persons with these risk factors may benefit from increased surveillance of SARS-CoV-2 infection and possible protective isolation.
C1 [Li, Weiming; You, Yong; Chen, Zhichao] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Wang, Danyu] Huazhong Univ Sci & Technol, Union Shenzhen Hosp, Guangdong Med Univ, Shenzhen, Guangdong, Peoples R China.
   [Guo, Jingming] China Three Gorges Univ, Yi Chang Cent Peoples Hosp, Coll Clin Med Sci 1, Yichang, Hubei, Peoples R China.
   [Yuan, Guolin] Hubei Univ Arts & Sci, Affiliated Hosp, Xiangyang Cent Hosp, Xiangyang, Hubei, Peoples R China.
   [Yang, Zhuangzhi] Hubei Univ Med, Suizhou Hosp, Suizhou, Hubei, Peoples R China.
   [Gale, Robert Peter] Imperial Coll London, Ctr Haematol Res, Dept Immunol & Inflammat, London, England.
   [Chen, Shiming] Huangshi Cent Hosp, Huangshi, Hubei, Peoples R China.
   [Wan, Chucheng] Hubei Univ Med, Affiliated Taihe Hosp, Shiyan, Hubei, Peoples R China.
   [Zhu, Xiaojian; Sheng, Lingshuang; Meng, Li] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Chang, Wei] China Resources, Wuhan, Hubei, Peoples R China.
   [Chang, Wei] Wisco Gen Hosp, Wuhan, Hubei, Peoples R China.
   [Cheng, Hui; Li, Qing] Wuhan 1 Hosp, Wuhan, Hubei, Peoples R China.
   [Zhang, Youshan] Yangtze Univ, Affiliated Hosp 1, Jingzhou Peoples Hosp 1, Jingzhou, Hubei, Peoples R China.
   [Qin, Jun] Hubei Univ Med, Renmin Hosp, Shiyan, Hubei, Peoples R China.
   [Jiang, Qian] Peking Univ, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Natl Clin Res Ctr Hematol Dis, Inst Hematol,Peoples Hosp, Beijing, Peoples R China.
RP Li, WM (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China.; Meng, L (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China.; Jiang, Q (corresponding author), Peking Univ, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Natl Clin Res Ctr Hematol Dis, Inst Hematol,Peoples Hosp, Beijing, Peoples R China.
EM lee937@126.com; mengli@jth.tjmu.edu.cn; jiangqian@medmail.com.cn
RI li, weiming/AAP-1516-2020
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81873440, 81770161, 81700142]; National Institute of
   Health Research (NIHR) Biomedical Research Centre funding schemeNational
   Institute for Health Research (NIHR)
FX We thank patients, families and physicians from Hubei Anti-Cancer
   Association (XLZ, DZJ, HXW, JH, YFZ, BC, QW, ZPH, QHL, YB, DLZ, XHZ, ZZ,
   RYG, JD, YPW, HBR, HH, YHW, and HX) who participated in the study. This
   study is funded by the Natural Science Foundation of China (Nos.
   81873440, 81770161, and 81700142). RPG acknowledges support from the
   National Institute of Health Research (NIHR) Biomedical Research Centre
   funding scheme.
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dorfel D, 2018, CANCER IMMUNOL IMMUN, V67, P775, DOI 10.1007/s00262-018-2129-9
   Gale RP, 2017, LEUKEMIA RES, V57, P109, DOI 10.1016/j.leukres.2017.03.003
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   Hochhaus A, 2020, LEUKEMIA, V34, P966, DOI 10.1038/s41375-020-0776-2
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kutikov A, 2020, ANN INTERN MED, V172, P756, DOI 10.7326/M20-1133
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lilienfeld-Toal M, 2020, LEUKEMIA
   Spychalski P, 2020, LANCET INFECT DIS
   The Lancet Oncology, 2020, Lancet Oncol, V21, P467, DOI 10.1016/S1470-2045(20)30175-3
   Thiant S, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.29
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Weichsel R, 2008, CLIN CANCER RES, V14, P2484, DOI 10.1158/1078-0432.CCR-07-4393
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 19
TC 13
Z9 13
U1 2
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD JUL
PY 2020
VL 34
IS 7
BP 1799
EP 1804
DI 10.1038/s41375-020-0853-6
EA MAY 2020
PG 6
WC Oncology; Hematology
SC Oncology; Hematology
GA NI4DK
UT WOS:000534113900001
PM 32424293
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Collier, EK
   Hsiao, JL
   Shi, VY
AF Collier, Erin K.
   Hsiao, Jennifer L.
   Shi, Vivian Y.
TI Conducting clinical trials during the COVID-19 pandemic
SO JOURNAL OF DERMATOLOGICAL TREATMENT
LA English
DT Article
DE Clinical trials; compliance; COVID-19; safety
AB The COVID-19 pandemic has greatly impacted dermatology clinical trial operations due to mandated governmental and institutional shut-downs and newly implemented restrictions. During this unprecedented time, measures should be taken to maintain research conduct compliance while also ensuring the safety of trial staff and participants. Herein, we underscore the challenges facing dermatology trials during the COVID-19 pandemic, and offer strategies to maintain compliant and safe conduct.
C1 [Collier, Erin K.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Hsiao, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA.
   [Shi, Vivian Y.] Univ Arizona, Dept Med, Div Dermatol, Tucson, AZ USA.
RP Shi, VY (corresponding author), Univ Arizona, Dept Med, 7165 N Pima Canyon Dr, Tucson, AZ 85718 USA.
EM vshi@email.arizona.edu
RI Hsiao, Jennifer/ABB-4999-2020
OI Hsiao, Jennifer/0000-0002-8843-3630
CR Adlhoch C, 2020, CONSIDERATIONS RELAT, P1
   [Anonymous], 2020, CTR DIS CONTROL PREV, V69, P1
   [Anonymous], 2020, GUIDANCE MANAGEMENT, P3
   European Data Protection Supervisor, 2020, PREL OP DAT PROT SCI, P1
   Price KN, 2020, J AM ACAD DERMATOL, V82, pE173, DOI 10.1016/j.jaad.2020.03.046
   U.S. Food and Drug Administration, 2020, FDA GUID COND CLIN T
NR 6
TC 1
Z9 1
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0954-6634
EI 1471-1753
J9 J DERMATOL TREAT
JI J. Dermatol. Treat.
PD MAY 18
PY 2020
VL 31
IS 4
BP 330
EP 332
DI 10.1080/09546634.2020.1759770
PG 3
WC Dermatology
SC Dermatology
GA LN0TK
UT WOS:000532657800009
PM 32343162
OA Bronze
DA 2021-01-01
ER

PT J
AU De Maio, A
   Hightower, LE
AF De Maio, Antonio
   Hightower, Lawrence E.
TI COVID-19, acute respiratory distress syndrome (ARDS), and hyperbaric
   oxygen therapy (HBOT): what is the link?
SO CELL STRESS & CHAPERONES
LA English
DT Letter
ID REPERFUSION INJURY; SEPSIS; PROTECTS; DEFINITIONS; MECHANISMS; ISCHEMIA
C1 [De Maio, Antonio] Univ Calif San Diego, Dept Surg, Div Trauma Crit Care Burns & Acute Care Surg, San Diego, CA 92093 USA.
   [De Maio, Antonio] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92093 USA.
   [De Maio, Antonio] Univ Calif San Diego, Sch Med, Ctr Invest Hlth & Educ Dispar, San Diego, CA 92093 USA.
   [Hightower, Lawrence E.] Univ Connecticut, Dept Mol & Cell Biol, Mansfield, CT 06269 USA.
RP Hightower, LE (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, Mansfield, CT 06269 USA.
EM lawrence.hightower@uconn.edu
CR Bessereau J, 2017, INT MARIT HEALTH, V68, P46, DOI 10.5603/IMH.2017.0008
   Buras JA, 2007, NEUROL RES, V29, P127, DOI 10.1179/016164107X174147
   Buras JA, 2006, CRIT CARE MED, V34, P2624, DOI 10.1097/01.CCM.0000239438.22758.E0
   Cauvi DM, 2019, FASEB J, V33, P2995, DOI 10.1096/fj.201801579R
   Cauvi DM, 2012, J BIOL CHEM, V287, P19804, DOI 10.1074/jbc.M112.359562
   Chan CP, 2006, J VIROL, V80, P9279, DOI 10.1128/JVI.00659-06
   Comar CE, 2019, MBIO, V10, DOI 10.1128/mBio.00319-19
   Coopersmith CM, 2017, SHOCK, V47, P264, DOI 10.1097/SHK.0000000000000763
   De Maio A, 2005, SHOCK, V23, P11, DOI 10.1097/01.shk.0000144134.03598.c5
   Deutschman CS, 2014, IMMUNITY, V40, P464, DOI 10.1016/j.immuni.2014.04.001
   Edremitlioglu M, 2005, SURG TODAY, V35, P653, DOI 10.1007/s00595-004-3000-5
   FRY DE, 1980, ARCH SURG-CHICAGO, V115, P136
   Fuller AM, 2013, CELL STRESS CHAPERON, V18, P97, DOI 10.1007/s12192-012-0362-2
   Gill AL, 2004, QJM-INT J MED, V97, P385, DOI 10.1093/qjmed/hch074
   Godman CA, 2010, CELL STRESS CHAPERON, V15, P431, DOI 10.1007/s12192-009-0159-0
   GOODMAN MW, 1964, AEROSPACE MED, V35, P1204
   Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386
   Halbach JL, 2019, AM J PHYSIOL-REG I, V317, pR160, DOI 10.1152/ajpregu.00083.2019
   Harrison LE, 2018, CELL STRESS CHAPERON, V23, P1143, DOI 10.1007/s12192-018-0944-8
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Ioakeimidis F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104237
   Kirby John, 2019, Mo Med, V116, P192
   Kirby John P, 2019, Mo Med, V116, P198
   MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007
   Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732
   Puskarich MA, 2009, CRIT CARE, V13, DOI 10.1186/cc8138
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Richter-Dennerlein R, 2014, CELL METAB, V20, P158, DOI 10.1016/j.cmet.2014.04.016
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Stoekenbroek RM, 2014, EUR J VASC ENDOVASC, V47, P647, DOI 10.1016/j.ejvs.2014.03.005
   Tezgin D, 2020, CELL STRESS CHAPERON, V25, P667, DOI 10.1007/s12192-020-01100-5
   Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506
   Vincent JL, 2017, AM J RESP CRIT CARE, V196, P670, DOI 10.1164/rccm.201703-0475ED
   Yu SY, 2005, J SURG RES, V128, P28, DOI 10.1016/j.jss.2005.04.025
NR 34
TC 5
Z9 5
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1355-8145
EI 1466-1268
J9 CELL STRESS CHAPERON
JI Cell Stress Chaperones
PD SEP
PY 2020
VL 25
IS 5
SI SI
BP 717
EP 720
DI 10.1007/s12192-020-01121-0
EA MAY 2020
PG 4
WC Cell Biology
SC Cell Biology
GA NL5ZG
UT WOS:000533814400001
PM 32424591
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sichitiu, J
   Fakhouri, F
   Desseauve, D
AF Sichitiu, Joanna
   Fakhouri, Fadi
   Desseauve, David
TI Antenatal corticosteroid therapy and COVID-19: Pathophysiological
   considerations
SO ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
LA English
DT Letter
C1 [Sichitiu, Joanna; Desseauve, David] Lausanne Univ Hosp, Women Mother Child Dept, Lausanne, Switzerland.
   [Fakhouri, Fadi] Lausanne Univ Hosp, Dept Hypertens & Nephrol, Lausanne, Switzerland.
RP Sichitiu, J (corresponding author), Lausanne Univ Hosp, Women Mother Child Dept, Lausanne, Switzerland.
EM joanna.sichitiu@chuv.ch
RI Sichitiu, Joanna/Q-8980-2019
OI Sichitiu, Joanna/0000-0002-4453-1167; Desseauve,
   David/0000-0003-1308-7750
CR Liang H, 2020, ACTA OBSTET GYN SCAN, V99, P439, DOI 10.1111/aogs.13836
   MENDELSOHN FAO, 1982, J CLIN INVEST, V70, P684, DOI 10.1172/JCI110663
   Ullian ME, 1999, CARDIOVASC RES, V41, P55, DOI 10.1016/S0008-6363(98)00230-2
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   World Health Organization (WHO), NOV COR TECHN GUID P
NR 5
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6349
EI 1600-0412
J9 ACTA OBSTET GYN SCAN
JI Acta Obstet. Gynecol. Scand.
PD JUL
PY 2020
VL 99
IS 7
BP 952
EP 952
DI 10.1111/aogs.13887
EA MAY 2020
PG 1
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA LY7PU
UT WOS:000533144400001
PM 32356302
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Huang, JF
   Cheng, AG
   Lin, S
   Zhu, YY
   Chen, GP
AF Huang, Jiaofeng
   Cheng, Aiguo
   Lin, Su
   Zhu, Yueyong
   Chen, Gongping
TI Individualized prediction nomograms for disease progression in mild
   COVID-19
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE COVID-19; mild; nomogram; progression; risk factor
AB The coronavirus disease 2019 (COVID-19) has evolved into a pandemic rapidly. The majority of COVID-19 patients are with mild syndromes. This study aimed to develop models for predicting disease progression in mild cases. The risk factors for the requirement of oxygen support in mild COVID-19 were explored using multivariate logistic regression. Nomogram as visualization of the models was developed using R software. A total of 344 patients with mild COVID-19 were included in the final analysis, 45 of whom progressed and needed high-flow oxygen therapy or mechanical ventilation after admission. There were 188 (54.7%) males, and the average age of the cohort was 52.9 +/- 16.8 years. When the laboratory data were not included in multivariate analysis, diabetes, coronary heart disease, T >= 38.5celcius and sputum were independent risk factors of progressive COVID-19 (Model 1). When the blood routine test was included the CHD, T >= 38.5celcius and neutrophil-to-lymphocyte ratio were found to be independent predictors (Model 2). The area under the receiver operator characteristic curve of model 2 was larger than model 1 (0.872 vs 0.849, P = .023). The negative predictive value of both models was greater than 96%, indicating they could serve as simple tools for ruling out the possibility of disease progression. In conclusion, two models comprised common symptoms (fever and sputum), underlying diseases (diabetes and coronary heart disease) and blood routine test are developed for predicting the future requirement of oxygen support in mild COVID-19 cases.
C1 [Huang, Jiaofeng; Lin, Su; Zhu, Yueyong] Fujian Med Univ, Dept Liver Res Ctr, Affiliated Hosp 1, 20 Chazhong Rd, Fuzhou, Peoples R China.
   [Cheng, Aiguo] Third Peoples Hosp Yichang, Dept Crit Care, Yichang, Peoples R China.
   [Chen, Gongping] Fujian Med Univ, Dept Resp, Affiliated Hosp 1, 20 Chazhong Rd, Fuzhou, Fujian, Peoples R China.
RP Zhu, YY (corresponding author), Fujian Med Univ, Dept Liver Res Ctr, Affiliated Hosp 1, 20 Chazhong Rd, Fuzhou, Peoples R China.; Chen, GP (corresponding author), Fujian Med Univ, Dept Resp, Affiliated Hosp 1, 20 Chazhong Rd, Fuzhou, Fujian, Peoples R China.
EM zhuyueyong@fjmu.edu.cn; cgp3542@163.com
FU Chinese National 13th Five-Year Plan's Science and Technology Projects
   [2017ZX10202201]; Fujian Province Health Youth Research Project
   [2019-1-37]; Fujian Medical University Sailing Fund Project [2018QH1047]
FX Chinese National 13th Five-Year Plan's Science and Technology Projects,
   Grant/Award Number: 2017ZX10202201; Fujian Province Health Youth
   Research Project, Grant/Award Number: 2019-1-37; Fujian Medical
   University Sailing Fund Project, Grant/Award Number: 2018QH1047
CR Arulkumaran N, 2020, LANCET RESP MED
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   El Zowalaty ME, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100124
   Feng G, 2020, J CLIN TRANSL HEPATO, V8, P18, DOI 10.14218/JCTH.2020.00018
   Graziano O, 2020, JAMA
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Haddad C, 2020, ENVIRON SCI POLLUT R, V27, P19352, DOI 10.1007/s11356-020-08162-z
   Huang JF, 2020, AM J TRANSPLANT, V20, P1907, DOI 10.1111/ajt.15909
   Ji D, 2020, CLIN INFECT DIS
   La Maestra S, 2020, J MED VIROL, V92, P1956, DOI 10.1002/jmv.25908
   Lagunas-Rangel FA, 2020, J MED VIROL
   Li C, 2020, EUR REV MED PHARMACO, V24, P4576, DOI 10.26355/eurrev_202004_21044
   Li YM, 2011, J DIGEST DIS, V12, P45, DOI 10.1111/j.1751-2980.2010.00477.x
   Liu Y, 2020, J INFECT
   Razai MS, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m800
   Tan TP, 2015, ANZ J SURG, V85, P414, DOI 10.1111/ans.13036
   Wells C.R., 2020, LANCET INFECT DIS
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   World Health Organization, CLIN MANAGEMENT SEVE
   Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328
   Xie HS, 2020, LIVER INT, V40, P1321, DOI 10.1111/liv.14449
   Yang AP, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106504
   Yang C, 2020, JAMA CARDIOL
   Zhang YF, 2020, LIVER INT, V40, P2095, DOI 10.1111/liv.14455
   Zhao QW, 2020, J MED VIROL, V92, P1915, DOI 10.1002/jmv.25889
NR 27
TC 4
Z9 4
U1 5
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2020
VL 92
IS 10
BP 2074
EP 2080
DI 10.1002/jmv.25969
EA MAY 2020
PG 7
WC Virology
SC Virology
GA NK4OX
UT WOS:000533446800001
PM 32369205
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Musarrat, F
   Chouljenko, V
   Dahal, A
   Nabi, R
   Chouljenko, T
   Jois, SD
   Kousoulas, KG
AF Musarrat, Farhana
   Chouljenko, Vladimir
   Dahal, Achyut
   Nabi, Rafiq
   Chouljenko, Tamara
   Jois, Seetharama D.
   Kousoulas, Konstantin G.
TI The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor
   of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting
   further evaluation as an antiviral against COVID-19 infections
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE antiviral agents; cell fusion; cellular effect; coronavirus; entry
   inhibitors; fusion protein; glycoproteins; infection; SARS coronavirus;
   virus classification
ID RESPIRATORY SYNDROME CORONAVIRUS; PROTEASE INHIBITOR; IN-VITRO;
   MERS-COV; SARS; VIRUS; APOPTOSIS; EXPRESSION; RECEPTOR
AB Severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) is the causative agent of the coronavirus disease-2019 (COVID-19) pandemic. Coronaviruses enter cells via fusion of the viral envelope with the plasma membrane and/or via fusion of the viral envelope with endosomal membranes after virion endocytosis. The spike (S) glycoprotein is a major determinant of virus infectivity. Herein, we show that the transient expression of the SARS CoV-2 S glycoprotein in Vero cells caused extensive cell fusion (formation of syncytia) in comparison to limited cell fusion caused by the SARS S glycoprotein. Both S glycoproteins were detected intracellularly and on transfected Vero cell surfaces. These results are in agreement with published pathology observations of extensive syncytia formation in lung tissues of patients with COVID-19. These results suggest that SARS CoV-2 is able to spread from cell-to-cell much more efficiently than SARS effectively avoiding extracellular neutralizing antibodies. A systematic screening of several drugs including cardiac glycosides and kinase inhibitors and inhibitors of human immunodeficiency virus (HIV) entry revealed that only the FDA-approved HIV protease inhibitor, nelfinavir mesylate (Viracept) drastically inhibited S-n- and S-o-mediated cell fusion with complete inhibition at a 10-mu M concentration. In-silico docking experiments suggested the possibility that nelfinavir may bind inside the S trimer structure, proximal to the S2 amino terminus directly inhibiting S-n- and S-o-mediated membrane fusion. Also, it is possible that nelfinavir may act to inhibit S proteolytic processing within cells. These results warrant further investigations of the potential of nelfinavir mesylate to inhibit virus spread at early times after SARS CoV-2 symptoms appear.
C1 [Musarrat, Farhana; Chouljenko, Vladimir; Nabi, Rafiq; Kousoulas, Konstantin G.] Louisiana State Univ, Div Biotechnol & Mol Med, Baton Rouge, LA 70803 USA.
   [Musarrat, Farhana; Chouljenko, Vladimir; Nabi, Rafiq; Kousoulas, Konstantin G.] Louisiana State Univ, Sch Vet Med, Dept Pathobiol Sci, Baton Rouge, LA 70803 USA.
   [Dahal, Achyut; Jois, Seetharama D.] Univ Louisiana Monroe, Coll Pharm, Sch Basic Pharmaceut & Toxicol Sci, Monroe, LA USA.
   [Chouljenko, Tamara] Louisiana State Univ, Agr Ctr, Agr Biotechnol Lab, Baton Rouge, LA 70803 USA.
RP Kousoulas, KG (corresponding author), Louisiana State Univ, Div Biotechnol & Mol Med, Baton Rouge, LA 70803 USA.
EM vtgusk@lsu.edu
OI KOUSOULAS, KONSTANTIN/0000-0001-7077-9003
FU Louisiana Board of Regents Governor's Biotechnology Initiative; School
   of Veterinary Medicine, Division of Biotechnology & Molecular Medicine
   (BioMMED) [NIGMS P20 GM103424, NIGMS P20GM130555]
FX Louisiana Board of Regents Governor's Biotechnology Initiative,
   Grant/Award Number: KGK; The School of Veterinary Medicine, Division of
   Biotechnology & Molecular Medicine (BioMMED) and Core Facilities,
   Grant/Award Numbers: NIGMS P20 GM103424 (Louisiana Biomedical Research
   Network), NIGMS P20GM130555 (Center for Lung Biology).
CR Al Mutair A, 2020, J INT MED RES, V48, DOI 10.1177/0300060519858030
   Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015
   Bardsley-Elliot A, 2000, DRUGS, V59, P581, DOI 10.2165/00003495-200059030-00014
   Bosch BJ, 2004, P NATL ACAD SCI USA, V101, P8455, DOI 10.1073/pnas.0400576101
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Bruning A, 2009, CANCER BIOL THER, V8, P222
   Demmler Gail J, 2003, Semin Pediatr Infect Dis, V14, P240
   Dimitrov DS, 2003, CELL, V115, P652, DOI 10.1016/S0092-8674(03)00976-0
   Du LY, 2009, VIROLOGY, V393, P144, DOI 10.1016/j.virol.2009.07.018
   Gills JJ, 2008, AUTOPHAGY, V4, P107, DOI 10.4161/auto.5224
   Gills J, 2007, CLIN CANCER RES, V13, P5183, DOI 10.1158/1078-0432.CCR-07-0161
   Guan M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09698
   Gupta AK, 2007, NEOPLASIA, V9, P271, DOI 10.1593/neo.07124
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hofmann H, 2004, BIOCHEM BIOPH RES CO, V319, P1216, DOI 10.1016/j.bbrc.2004.05.114
   Kozisek M, 2007, J MOL BIOL, V374, P1005, DOI 10.1016/j.jmb.2007.09.083
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Mothes W, 2010, J VIROL, V84, P8360, DOI 10.1128/JVI.00443-10
   Pai VB, 1999, ANN PHARMACOTHER, V33, P325, DOI 10.1345/aph.18089
   Pajonk F, 2002, CANCER RES, V62, P5230
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Petit CM, 2007, VIROLOGY, V360, P264, DOI 10.1016/j.virol.2006.10.034
   Petit CM, 2005, VIROLOGY, V341, P215, DOI 10.1016/j.virol.2005.06.046
   Podbilewicz B, 2014, ANNU REV CELL DEV BI, V30, P111, DOI 10.1146/annurev-cellbio-101512-122422
   Pyrko P, 2007, CANCER RES, V67, P10920, DOI 10.1158/0008-5472.CAN-07-0796
   Ramadan N, 2019, GERMS, V9, P35, DOI 10.18683/germs.2019.1155
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Tebas P, 2000, Expert Opin Pharmacother, V1, P1429, DOI 10.1517/14656566.1.7.1429
   Tripet B, 2004, J BIOL CHEM, V279, P20836, DOI 10.1074/jbc.M400759200
   Vijayanand P, 2004, CLIN MED, V4, P152, DOI 10.7861/clinmedicine.4-2-152
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yang Y, 2005, CANCER SCI, V96, P425, DOI 10.1111/j.1349-7006.2005.00063.x
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 43
TC 17
Z9 17
U1 7
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2020
VL 92
IS 10
BP 2087
EP 2095
DI 10.1002/jmv.25985
EA MAY 2020
PG 9
WC Virology
SC Virology
GA NK4OX
UT WOS:000533161000001
PM 32374457
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Manenti, A
   Maggetti, M
   Casa, E
   Martinuzzi, D
   Torelli, A
   Trombetta, CM
   Marchi, S
   Montomoli, E
AF Manenti, Alessandro
   Maggetti, Marta
   Casa, Elisa
   Martinuzzi, Donata
   Torelli, Alessandro
   Trombetta, Claudia M.
   Marchi, Serena
   Montomoli, Emanuele
TI Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based
   colorimetric live virus micro-neutralization assay in human serum
   samples
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE epidemiology; humoral immunity; neutralization; pandemic; SARS
   coronavirus
ID RESPIRATORY SYNDROME CORONAVIRUS; SARS
AB The micro-neutralization assay is a fundamental test in virology, immunology, vaccine assessment, and epidemiology studies. Since the SARS-CoV-2 outbreak at the end of December 2019 in China, it has become extremely important to have well-established and validated diagnostic and serological assays for this new emerging virus. Here, we present a micro-neutralization assay with the use of SARS-CoV-2 wild type virus with two different methods of read-out. We evaluated the performance of this assay using human serum samples taken from an Italian seroepidemiological study being performed at the University of Siena, along with the human monoclonal antibody CR3022 and some iper-immune animal serum samples against Influenza and Adenovirus strains. The same panel of human samples have been previously tested in enzyme-linked immunosorbent assay (ELISA) as a pre-screening. Positive, borderline, and negative ELISA samples were evaluated in neutralization assay using two different methods of read-out: subjective (by means of an inverted optical microscope) and objective (by means of a spectrophotometer). Our findings suggest that at least 50% of positive ELISA samples are positive in neutralization as well, and that method is able to quantify different antibody concentrations in a specific manner. Taken together, our results confirm that the colorimetric cytopathic effect-based microneutralization assay could be used as a valid clinical test method for epidemiological and vaccine studies.
C1 [Manenti, Alessandro; Casa, Elisa; Martinuzzi, Donata; Torelli, Alessandro; Montomoli, Emanuele] VisMederi Res Srl, Siena, Italy.
   [Manenti, Alessandro; Maggetti, Marta; Casa, Elisa; Montomoli, Emanuele] VisMederi Srl, Siena, Italy.
   [Trombetta, Claudia M.; Marchi, Serena; Montomoli, Emanuele] Univ Siena, Dept Mol & Dev Med, Siena, Italy.
RP Manenti, A (corresponding author), VisMederi Srl, Siena, Italy.; Manenti, A (corresponding author), Str Petriccio & Belriguardo, I-53100 Siena, Italy.
EM alessandro.manenti@vismederiresearch.com
RI MONTOMOLI, EMANUELE/Q-2122-2015
OI MONTOMOLI, EMANUELE/0000-0001-7595-4974; Manenti,
   Alessandro/0000-0002-4027-7296; Marchi, Serena/0000-0002-6817-2461
FU European Virus Archive goes Global (EVAg) project - European Union's
   Horizon 2020 research and innovation programme [653316]
FX This publication was supported by the European Virus Archive goes Global
   (EVAg) project, which has received funding from the European Union's
   Horizon 2020 research and innovation programme under grant agreement No
   653316. We thank the University of Siena for providing the human serum
   samples from the Epidemiological study on SARS-CoV-2. The authors would
   like to thank Inesa Hyseni, Virginia Cianchi, Ilaria Razzano and Linda
   Benincasa for the lab support in VisMederi Research.
CR Abreu-Mota T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06741-w
   Algaissi Abdullah, 2020, Methods Mol Biol, V2099, P107, DOI 10.1007/978-1-0716-0211-9_9
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   EMA, 1995, CPMPICH38195 EMA
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Heald-Sargent T, 2012, VIRUSES-BASEL, V4, P557, DOI 10.3390/v4040557
   Jin Y, 2020, VIRUSES, V12
   Kaye M, 2006, EMERG INFECT DIS, V12, P128, DOI 10.3201/eid1201.050496
   Lassauniere Ria, EVALUATION NINE COMM, DOI DOI 10.1101/2020.04.09.20056325V1.FULL.PDF
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Lu YN, 2008, BIOCHEM BIOPH RES CO, V369, P344, DOI 10.1016/j.bbrc.2008.02.023
   Manenti A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010043
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1024, DOI 10.3201/eid2605.190921
   Park WB, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e84
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Trombetta CM, 2018, INFLUENZA OTHER RESP, V12, P675, DOI 10.1111/irv.12591
   Wang JJ, 2016, VIROL SIN, V31, P49, DOI 10.1007/s12250-015-3690-4
   Winckler J, 1974, Prog Histochem Cytochem, V6, P1
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 26
TC 6
Z9 6
U1 2
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2020
VL 92
IS 10
BP 2096
EP 2104
DI 10.1002/jmv.25986
EA MAY 2020
PG 9
WC Virology
SC Virology
GA NK4OX
UT WOS:000533160100001
PM 32383254
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Choudhury, A
   Mukherjee, S
AF Choudhury, Abhigyan
   Mukherjee, Suprabhat
TI In silico studies on the comparative characterization of the
   interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor
   homologs and human TLRs
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE ACE-2 receptor; human TLRs; phylogeny; SARS-CoV-2; spike glycoprotein;
   therapeutic intervention
ID CORONAVIRUS OUTBREAK; GLOBAL HEALTH
AB Coronavirus disease-2019 (COVID-19) outbreak due to novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has come out as a major threat for mankind in recent times. It is continually taking an enormous toll on mankind by means of increasing number of deaths, associated comorbidities, and socioeconomic loss around the globe. Unavailability of chemotherapeutics/vaccine has posed tremendous challenges to scientists and doctors for developing an urgent therapeutic strategy. In this connection, the present in silico study aims to understand the sequence divergence of spike protein (the major infective protein of SARS-CoV-2), its mode of interaction with the angiotensin-converting enzyme-2 receptor (ACE2) receptor of human and related animal hosts/reservoir. Moreover, the involvement of the human Toll-like receptors (TLRs) against the spike protein has also been demonstrated. Our data indicated that the spike glycoprotein of SARS-CoV-2 is phylogenetically close to bat coronavirus and strongly binds with ACE2 receptor protein from both human and bat origin. We have also found that cell surface TLRs, especially TLR4 is most likely to be involved in recognizing molecular patterns from SARS-CoV-2 to induce inflammatory responses. The present study supported the zoonotic origin of SARS-CoV-2 from a bat and also revealed that TLR4 may have a crucial role in the virus-induced inflammatory consequences associated with COVID-19. Therefore, selective targeting of TLR4-spike protein interaction by designing competitive TLR4-antagonists could pave a new way to treat COVID-19. Finally, this study is expected to improve our understanding on the immunobiology of SARS-CoV-2 and could be useful in adopting spike protein, ACE2, or TLR-guided intervention strategy against COVID-19 shortly.
C1 [Choudhury, Abhigyan; Mukherjee, Suprabhat] Kazi Nazrul Univ, Dept Anim Sci, Integrat Biochem & Immunol Lab, Asansol, W Bengal, India.
RP Mukherjee, S (corresponding author), Kazi Nazrul Univ, Dept Anim Sci, Asansol 713340, W Bengal, India.
EM babaimbc@gmail.com
OI Mukherjee, Suprabhat/0000-0002-5709-9190
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Angeletti S, 2020, J MED VIROL, V92, P584, DOI 10.1002/jmv.25719
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P4016, DOI 10.26355/eurrev_202004_20871
   Chakraborty C, 2020, ASIAN PAC J TROP MED, V13, P242, DOI 10.4103/1995-7645.281613
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Goswami R, 2016, CLEAN TECHNOL ENVIR, V18, P1565, DOI 10.1007/s10098-016-1141-z
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   Mukherjee S, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12771
   Mukherjee S, 2016, BRAZ J INFECT DIS, V20, P193, DOI 10.1016/j.bjid.2015.10.011
   Mukherjee S, 2014, INFECT DIS POVERTY, V3, DOI 10.1186/2049-9957-3-13
   Raoult D, 2020, CELL STRESS, V4, P66, DOI 10.15698/cst2020.04.216
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   World Health Organization, COVID 19 PAND UPD SI
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 23
TC 13
Z9 14
U1 7
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2020
VL 92
IS 10
BP 2105
EP 2113
DI 10.1002/jmv.25987
EA MAY 2020
PG 9
WC Virology
SC Virology
GA NK4OX
UT WOS:000533159700001
PM 32383269
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wang, YM
   Zhang, DY
   Du, GH
   Du, RH
   Zhao, JP
   Jin, Y
   Fu, SZ
   Gao, L
   Cheng, ZS
   Lu, QF
   Hu, Y
   Luo, GW
   Wang, K
   Lu, Y
   Li, HD
   Wang, SZ
   Ruan, SN
   Yang, CQ
   Mei, CL
   Wang, Y
   Ding, D
   Wu, F
   Tang, X
   Ye, XZ
   Ye, YC
   Liu, B
   Yang, J
   Yin, W
   Wang, AL
   Fan, GH
   Zhou, F
   Liu, ZB
   Gu, XY
   Xu, JY
   Shang, LH
   Zhang, Y
   Cao, LJ
   Guo, TT
   Wan, Y
   Qin, H
   Jiang, YS
   Jaki, T
   Hayden, FG
   Horby, PW
   Cao, B
   Wang, C
AF Wang, Yeming
   Zhang, Dingyu
   Du, Guanhua
   Du, Ronghui
   Zhao, Jianping
   Jin, Yang
   Fu, Shouzhi
   Gao, Ling
   Cheng, Zhenshun
   Lu, Qiaofa
   Hu, Yi
   Luo, Guangwei
   Wang, Ke
   Lu, Yang
   Li, Huadong
   Wang, Shuzhen
   Ruan, Shunan
   Yang, Chengqing
   Mei, Chunlin
   Wang, Yi
   Ding, Dan
   Wu, Feng
   Tang, Xin
   Ye, Xianzhi
   Ye, Yingchun
   Liu, Bing
   Yang, Jie
   Yin, Wen
   Wang, Aili
   Fan, Guohui
   Zhou, Fei
   Liu, Zhibo
   Gu, Xiaoying
   Xu, Jiuyang
   Shang, Lianhan
   Zhang, Yi
   Cao, Lianjun
   Guo, Tingting
   Wan, Yan
   Qin, Hong
   Jiang, Yushen
   Jaki, Thomas
   Hayden, Frederick G.
   Horby, Peter W.
   Cao, Bin
   Wang, Chen
TI Remdesivir in adults with severe COVID-19: a randomised, double-blind,
   placebo-controlled, multicentre trial
SO LANCET
LA English
DT Article
ID THERAPEUTIC-EFFICACY; EBOLA-VIRUS; GS-5734
AB Background No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models.
   Methods We did a randomised, double- blind, placebo-controlled, multicentre trial at ten hospitals in Hubei, China. Eligible patients were adults (aged >= 18 years) admitted to hospital with laboratory-confirmed SARS- CoV-2 infection, with an interval from symptom onset to enrolment of 12 days or less, oxygen saturation of 94% or less on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or less, and radiologically confirmed pneumonia. Patients were randomly assigned in a 2:1 ratio to intravenous remdesivir (200 mg on day 1 followed by 100 mg on days 2-10 in single daily infusions) or the same volume of placebo infusions for 10 days. Patients were permitted concomitant use of lopinavir-ritonavir, interferons, and corticosteroids. The primary endpoint was time to clinical improvement up to day 28, defined as the time (in days) from randomisation to the point of a decline of two levels on a six-point ordinal scale of clinical status ( from 1=discharged to 6=death) or discharged alive from hospital, whichever came first. Primary analysis was done in the intention-to-treat (ITT) population and safety analysis was done in all patients who started their assigned treatment. This trial is registered with ClinicalTrials.gov, NCT04257656.
   Findings Between Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo); one patient in the placebo group who withdrew after randomisation was not included in the ITT population. Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1.23 [95% CI 0.87-1.75]). Although not statistically significant, patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio 1.52 [0.95-2.43]). Adverse events were reported in 102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients. Remdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients who stopped placebo early.
   Interpretation In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits. However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies. Copyright (c) 2020 Elsevier Ltd. All rights reserved.
C1 [Wang, Yeming; Zhou, Fei; Liu, Zhibo; Shang, Lianhan; Zhang, Yi; Cao, Bin; Wang, Chen] China Japan Friendship Hosp, Dept Pulm & Crit Care Med, Ctr Resp Med, Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China.
   [Fan, Guohui; Gu, Xiaoying] China Japan Friendship Hosp, Inst Clin Med Sci, Beijing, Peoples R China.
   [Wang, Yeming; Cao, Bin] Capital Med Univ, Dept Resp Med, Beijing, Peoples R China.
   [Zhang, Dingyu; Li, Huadong; Wang, Shuzhen; Ruan, Shunan] JinYin Tan Hosp, Wuhan, Hubei, Peoples R China.
   [Du, Guanhua; Wang, Ke; Lu, Yang] Chinese Acad Med Sci, Inst Mat Med, Beijing, Peoples R China.
   [Du, Guanhua; Wang, Ke; Lu, Yang; Wang, Chen] Peking Union Med Coll, Beijing 100730, Peoples R China.
   [Du, Ronghui; Yang, Chengqing; Mei, Chunlin] Wuhan Lung Hosp, Wuhan, Peoples R China.
   [Zhao, Jianping; Wang, Yi; Ding, Dan] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China.
   [Jin, Yang; Wu, Feng; Tang, Xin] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China.
   [Fu, Shouzhi; Ye, Xianzhi] Wuhan Third Hosp, Wuhan, Peoples R China.
   [Gao, Ling; Ye, Yingchun] Wuhan Univ, Renmin Hosp, Wuhan, Peoples R China.
   [Cheng, Zhenshun; Liu, Bing] Wuhan Univ, Zhongnan Hosp, Wuhan, Peoples R China.
   [Lu, Qiaofa; Yang, Jie] Wuhan Fourth Hosp, Wuhan, Peoples R China.
   [Hu, Yi; Yin, Wen] Cent Hosp Wuhan, Wuhan, Peoples R China.
   [Luo, Guangwei; Wang, Aili] Wuhan First Hosp, Wuhan, Peoples R China.
   [Xu, Jiuyang] Tsinghua Univ, Sch Med, Beijing, Peoples R China.
   [Shang, Lianhan] Beijing Univ Chinese Med, Beijing, Peoples R China.
   [Cao, Lianjun; Guo, Tingting; Wan, Yan] Tigermed Consulting, Hangzhou, Peoples R China.
   [Qin, Hong] Teddy Clin Res Lab, Shanghai, Peoples R China.
   [Jiang, Yushen] Hangzhou DIAN Med Lab, Hangzhou, Peoples R China.
   [Jaki, Thomas] Univ Lancaster, Lancaster, England.
   [Jaki, Thomas] Univ Cambridge, Cambridge, England.
   [Hayden, Frederick G.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.
   [Horby, Peter W.] Univ Oxford, Int Severe Acute Resp & Emerging Infect Consortiu, Oxford, England.
   [Cao, Bin; Wang, Chen] Chinese Acad Med Sci, Inst Resp Med, Beijing, Peoples R China.
   [Cao, Bin; Wang, Chen] Tsinghua Univ Peking Univ Joint Ctr Life Sci, Beijiing, Peoples R China.
RP Wang, C (corresponding author), Peking Union Med Coll, Beijing 100730, Peoples R China.; Cao, B (corresponding author), China Japan Friendship Hosp, Dept Pulm & Crit Care Med, Beijing 100029, Peoples R China.
EM caobin_ben@163.com; wangchen@pumc.edu.cn
OI Tang, Xin/0000-0002-6860-6530
FU Chinese Academy of Medical Sciences Emergency Project of COVID-19
   [2020HY320001]; Major Projects of National Science and Technology on New
   Drug Creation and Development [2020ZX09201012]; National Key Research
   and Development Program of China [2018YFC1200102]; Beijing Science and
   Technology Project [Z19110700660000]; National Institutes of Health
   Research (NIHR) Senior Research Fellowship [2015-08-001]; Wellcome
   TrustWellcome Trust; UK Department for International Development
   [215091/Z/18/Z]; Bill & Melinda Gates FoundationBill & Melinda Gates
   Foundation [OPP1209135]; NIHRNational Institute for Health Research
   (NIHR) [200907]
FX We thank Gilead Sciences for providing the study drugs and Huyen Cao and
   Anu Osinusi for advice regarding safe use of remdesivir. We thank Joe
   Yao and Ella Lin for statistical consultation. We also thank members of
   the international data safety monitoring board (Jieming Qu [chair],
   Weichung Joe Shih, Robert Fowler, Rory Collins, and Chen Yao),
   independent statisticians (Xiaoyan Yan and Bin Shan), academic
   secretaries (Lingling Gao and Junkai Lai), and eDMC system providers
   (Tai Xie, Rong Ran, Peng Zhang, and Emily Wang) for their services.
   Roche Diagnostics (Shanghai) provided instruments and SARS-CoV-2 assay
   detection; SMO assistance was provided by Shanghai MedKey Med-Tech
   Development, Clinplus, Hangzhou SIMO, and MEDPISON. This work was
   supported by the Chinese Academy of Medical Sciences Emergency Project
   of COVID-19 (2020HY320001); Major Projects of National Science and
   Technology on New Drug Creation and Development (2020ZX09201012); the
   National Key Research and Development Program of China (2018YFC1200102);
   and the Beijing Science and Technology Project (Z19110700660000). TJ is
   funded by a National Institutes of Health Research (NIHR) Senior
   Research Fellowship (2015-08-001). PH is funded by the Wellcome Trust
   and the UK Department for International Development [215091/Z/18/Z], the
   Bill & Melinda Gates Foundation [OPP1209135], and NIHR [200907].
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Gilead Sciences, 2020, INV BROCH REMD
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Jacobs M, 2016, LANCET, V388, P498, DOI 10.1016/S0140-6736(16)30386-5
   Johns Hopkins University and Medicine, COVID 19 MAP
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Pizzorno A, 2020, BIORXIV, DOI [10.1101/2020.03.31.017889, DOI 10.1101/2020.03.31.017889]
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Wang M, 2020, CELL RES, V30, P2
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   WHITEHEAD J, 1983, BIOMETRICS, V39, P227, DOI 10.2307/2530822
   Williamson Brandi N, 2020, bioRxiv, DOI 10.1101/2020.04.15.043166
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 28
TC 557
Z9 574
U1 63
U2 72
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD MAY 16
PY 2020
VL 395
IS 10236
BP 1569
EP 1578
DI 10.1016/S0140-6736(20)31022-9
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA LS7EF
UT WOS:000536542900023
PM 32423584
OA Bronze, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Sarma, P
   Shekhar, N
   Prajapat, M
   Avti, P
   Kaur, H
   Kumar, S
   Singh, S
   Kumar, H
   Prakash, A
   Dhibar, DP
   Medhi, B
AF Sarma, Phulen
   Shekhar, Nishant
   Prajapat, Manisha
   Avti, Pramod
   Kaur, Hardeep
   Kumar, Subodh
   Singh, Sanjay
   Kumar, Harish
   Prakash, Ajay
   Dhibar, Deba Prasad
   Medhi, Bikash
TI In-silico homology assisted identification of inhibitor of RNA binding
   against 2019-nCoV N-protein (N terminal domain)
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Nucleocapsid protein; N terminal domain; drug design; RNA binding; 2019
   novel corona virus; 2019-nCoV; SARS-CoV-2
ID CORONAVIRUS; DOCKING; VIRUS
AB The N terminal domain (NTD) of Nucleocapsid protein (N protein) of coronavirus (CoV) binds to the viral (+) sense RNA and results in CoV ribonucleoprotien (CoV RNP) complex, essential for the virus replication. In this study, the RNA-binding N terminal domain (NTD) of the N protein was targeted for the identification of possible inhibitors of RNA binding. Two NTD structures of N proteins were selected (2OFZ and 1SSK, 92% homology) for virtual screening of 56,079 compounds from Asinex and Maybridge library to identify top 15 hits for each of the targets based on 'docking score'. These top-hits were further screened for MM-GBSA binding free energy, pharmacokinetic properties (QikProp) and drug-likeness (SwissADME) and subjected to molecular dynamics (MD) studies. Two suitable binders (ZINC00003118440 and ZINC0000146942) against the target 2OFZ were identified. ZINC00003118440 is a theophylline derivative under the drug class 'bronchodilators' and further screening with approved bronchodilators was also studied to identify their ability to bind to the RNA binding region on the N protein. The other identified top hit is ZINC0000146942, which is a 3,4dihydropyrimidone class molecule. Hence this study suggests two important class of compounds, theophylline and pyrimidone derivaties as possible inhibitors of RNA binding to the N terminal domain of N protein of coronavirus, thus opening new avenues for in vitro validations. Communicated by Ramaswamy H. Sarma
C1 [Sarma, Phulen; Shekhar, Nishant; Prajapat, Manisha; Kaur, Hardeep; Kumar, Subodh; Kumar, Harish; Prakash, Ajay; Medhi, Bikash] Postgrad Inst Med Educ & Res, Dept Pharmacol, Res Block B,4th Floor,Room 4043, Chandigarh 160012, India.
   [Avti, Pramod] Postgrad Inst Med Educ & Res, Dept Biophys, Chandigarh, India.
   [Singh, Sanjay] Postgrad Inst Med Educ & Res, Biomed Informat Ctr, Chandigarh, India.
   [Dhibar, Deba Prasad] Postgrad Inst Med Educ & Res, Internal Med, Chandigarh, India.
RP Medhi, B (corresponding author), Postgrad Inst Med Educ & Res, Dept Pharmacol, Res Block B,4th Floor,Room 4043, Chandigarh 160012, India.
EM drbikashus@yahoo.com
RI ; Avti, Pramod/I-2939-2017
OI Singh, Sanjay Kumar/0000-0001-5935-3829; Shekhar,
   Nishant/0000-0002-8187-3246; Kumar, Dr Subodh/0000-0003-0553-387X; Avti,
   Pramod/0000-0001-5603-4523
CR Adasme-Carreno F, 2014, PHYS CHEM CHEM PHYS, V16, P14047, DOI 10.1039/c4cp01378f
   [Anonymous], WHAT DO ALL PRIME MM
   [Anonymous], GLIDESCORE DOCK SCOR
   Chang CK, 2016, DRUG DISCOV TODAY, V21, P562, DOI 10.1016/j.drudis.2015.11.015
   Chang CK, 2006, J BIOMED SCI, V13, P59, DOI 10.1007/s11373-005-9035-9
   Chenavas S, 2013, FUTURE MICROBIOL, V8, P1537, DOI 10.2217/fmb.13.128
   Franco R, 2013, NUTRIENTS, V5, P4159, DOI 10.3390/nu5104159
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang QL, 2004, BIOCHEMISTRY-US, V43, P6059, DOI 10.1021/bi036155b
   Jin YH, 2020, MILITARY MED RES, V7
   LigPrep S., LIGPREP
   Lin SY, 2014, J MED CHEM, V57, P2247, DOI 10.1021/jm500089r
   Meng XY, 2011, CURR COMPUT-AID DRUG, V7, P146
   Nain Z., 2019, ENERGY OPTIMIZED PHA
   PDB Database, PDB DAT
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Saikatendu KS, 2007, J VIROL, V81, P3913, DOI 10.1128/JVI.02236-06
   Sarma P, 2020, INDIAN J PHARMACOL, V52, P1, DOI 10.4103/ijp.IJP_119_20
   Seley-Radtke KL, 2018, ANTIVIR RES, V154, P66, DOI 10.1016/j.antiviral.2018.04.004
   Sharma V, 2014, INT J MED CHEM, V2014, DOI 10.1155/2014/202784
   Singh KD, 2013, ACTA PHARMACOL SIN, V34, P1592, DOI 10.1038/aps.2013.129
   SKULNICK HI, 1985, J MED CHEM, V28, P1864, DOI 10.1021/jm00150a018
   Tripathi K. D., 2013, ESSENTIALS MED PHARM
   Tumtin S., 2009, RASAYAN J CHEM, V2, P662, DOI DOI 10.1002/CHIN.201447283
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   WIERENGA W, 1985, PHARMACOL THERAPEUT, V30, P67, DOI 10.1016/0163-7258(85)90048-8
   YAMAZAKI Z, 1980, J GEN VIROL, V50, P429, DOI 10.1099/0022-1317-50-2-429
   Zhavoronkov A., 2020, POTENTIAL 2019 NCOV, DOI [10.26434/chemrxiv.11829102.v1, DOI 10.26434/CHEMRXIV.11829102.V1]
   Zheng ZR, 2011, ANTIVIR RES, V89, P149, DOI 10.1016/j.antiviral.2010.12.004
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 30
TC 58
Z9 59
U1 15
U2 24
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1753580
EA MAY 2020
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LQ6NV
UT WOS:000535116800001
PM 32266867
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Manderson, L
   Wahlberg, A
AF Manderson, Lenore
   Wahlberg, Ayo
TI Chronic Living in a Communicable World
SO MEDICAL ANTHROPOLOGY
LA English
DT Article
DE Chronic disease; chronicity; COVID-19; illness work; prioritization
ID SOUTH-AFRICA; VACCINE HESITANCY; CARE; DISABILITY; SYNDEMICS; UNIT
AB By April 2020, COVID-19 lockdowns had restricted the movements of over half the world's population. As health authorities advise people living with chronic conditions to self-isolate because they are at particular risk of serious complications and death, the epidemiological split between communicable and noncommunicable disease is tenuous. We argue that much more is at stake for people living with (multiple) medical conditions than being "at risk" of infection of coronavirus. We emphasize the need to attend to the long-term effects of COVID-19, but also the importance of the continued care of people living with other lifelong medical conditions.
C1 [Manderson, Lenore] Univ Witwatersrand, Sch Publ Hlth, Publ Hlth & Med Anthropol, Johannesburg, South Africa.
   [Wahlberg, Ayo] Univ Copenhagen, Dept Anthropol, Copenhagen, Denmark.
RP Manderson, L (corresponding author), Univ Witwatersrand, Sch Publ Hlth, 27 St Andrews Rd, ZA-2193 Johannesburg, South Africa.
EM lenore.manderson@wits.ac.za
OI Wahlberg, Ayo/0000-0001-6862-5208; Manderson, Lenore/0000-0002-7883-1790
FU National Research Foundation, South AfricaNational Research Foundation -
   South Africa; DSI-NRF Centre of Excellence in Human Development at the
   University of the Witwatersrand, Johannesburg; European Research Council
   grantEuropean Research Council (ERC) [ERC-2014-STG-639275]
FX We received no specific funding for this article. However, Lenore
   Manderson acknowledges the National Research Foundation, South Africa,
   and the DSI-NRF Centre of Excellence in Human Development at the
   University of the Witwatersrand, Johannesburg, which supported work that
   has informed this article. Ayo Wahlberg would like to acknowledge the
   European Research Council grant (ERC-2014-STG-639275, The Vitality of
   Disease-Quality of Life in the Making).
CR Bury M, 1982, Sociol Health Illn, V4, P167, DOI 10.1111/1467-9566.ep11339939
   Caduff C, 2015, PANDEMIC PERHAPS: DRAMATIC EVENTS IN A PUBLIC CULTURE OF DANGER, P1
   Calabresi G., 1978, FELS LECT PUBLIC POL
   Charmaz K, 1993, GOOD DAYS BAD DAYS S
   Constantinou CS, 2012, MED ANTHROPOL, V31, P29, DOI 10.1080/01459740.2011.603400
   Corbin J., 1985, QUALITATIVE SOCIOLOG, V8, P224, DOI DOI 10.1007/BF00989485
   Dokumaci A, 2020, CURR ANTHROPOL, V61, pS97, DOI 10.1086/705783
   Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212
   Farmer P., 2006, AIDS ACCUSATION HAIT
   Greco C, 2019, MED ANTHROPOL, V38, P384, DOI 10.1080/01459740.2019.1592171
   Guo A, 2017, AM J TROP MED HYG, V97, P1033, DOI 10.4269/ajtmh.17-0208
   Han KSL, 2019, J INFECT DEV COUNTR, V13, P748, DOI 10.3855/jidc.10685
   Hansen HP, 2008, MED ANTHROPOL Q, V22, P360, DOI 10.1111/j.1548-1387.2008.00035.x
   Hardin J., 2018, FAITH PURSUIT HLTH C
   Hardin J, 2016, MED ANTHROPOL, V35, P105, DOI 10.1080/01459740.2015.1092143
   Harling G, 2020, J GERONTOL B-PSYCHOL, V75, P148, DOI 10.1093/geronb/gby013
   Hart L, 2017, LANCET, V389, P888, DOI 10.1016/S0140-6736(17)30599-8
   Hiam L, 2020, BRIT MED BULL, V133, P4, DOI 10.1093/bmb/ldz041
   Illangasekare S, 2013, J URBAN HEALTH, V90, P934, DOI 10.1007/s11524-013-9797-8
   Kierans C., 2020, CHRONIC FAILURES KID
   Kingod N, 2020, HEALTH-LONDON, V24, P152, DOI 10.1177/1363459318800140
   Krishnan V., 2020, LOS ANGELES TIMES
   Kumar D, 2016, ISR J HEALTH POLICY, V5, DOI 10.1186/s13584-016-0062-y
   Lakoff A., 2017, UNPREPARED GLOBAL HL
   Langstrup H, 2013, SOCIOL HEALTH ILL, V35, P1008, DOI 10.1111/1467-9566.12013
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lee J, 2019, MED ANTHROPOL Q, V33, P501, DOI 10.1111/maq.12532
   Livingston J., 2012, IMPROVISING MED AFRI
   Madhavan S, 2015, J COMP FAM STUD, V46, P483
   Mahomed S, 2017, SAMJ S AFR MED J, V107, P1086, DOI [10.7196/samj.2017.v107i12.12631, 10.7196/SAMJ.2017.v107i12.12631]
   Manderson L, 2016, MED ANTHROPOL Q, V30, P479, DOI 10.1111/maq.12277
   Manderson L, 2016, SOC DYNAMICS, V42, P335, DOI 10.1080/02533952.2016.1218140
   Manderson L, 2016, AIDS CARE, V28, P1, DOI 10.1080/09540121.2016.1195487
   Manderson Lenore, 2010, CHRONIC CONDITIONS F
   Mattingly C, 2011, CULT MED PSYCHIAT, V35, P347, DOI 10.1007/s11013-011-9225-z
   Matuka DO, 2018, SAMJ S AFR MED J, V108, P474, DOI [10.7196/SAMJ.2018.v108i6.12485, 10.7196/samj.2018.v108i6.12485]
   Mee P, 2016, GLOB HEALTH EPIDEM G, V1, DOI 10.1017/gheg.2016.3
   Mendenhall E., 2012, SYNDEMIC SUFFERING S
   Mkhwanazi N, 2020, CONNECTED LIVES FAMI
   Moran-Thomas A., 2019, TRAVELING SUGAR CHRO
   Naemiratch B, 2006, SOC SCI MED, V63, P1147, DOI 10.1016/j.socscimed.2006.03.006
   Nguyen Vinh-Kim, 2010, REPUBLIC THERAPY TRI
   Nichter M, 2016, MED ANTHROPOL Q, V30, P536, DOI 10.1111/maq.12319
   Nxumalo N, 2016, AIDS CARE, V28, P61, DOI 10.1080/09540121.2016.1195484
   Oecd, 2017, HLTH GLANC 2017 OECD
   OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375
   Quesada J, 2011, MED ANTHROPOL, V30, P339, DOI 10.1080/01459740.2011.576725
   Saleem Z, 2019, PATHOG GLOB HEALTH, V113, P191, DOI 10.1080/20477724.2019.1632070
   Sambala EZ, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1341225
   Sampathkumar P, 2016, CURR GERIATR REP, V5, P9, DOI 10.1007/s13670-016-0159-8
   Schatz E, 2018, J GERONTOL B-PSYCHOL, V73, P1112, DOI 10.1093/geronb/gbx081
   Shing SLH, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00773
   Singer M, 2017, LANCET, V389, P941, DOI 10.1016/S0140-6736(17)30003-X
   Singh-Moodley A, 2018, AFR J LAB MED, V7, DOI 10.4102/ajlm.v7i2.741
   Smith TC, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx146
   Song P, 2017, PRINCE STUD CULT TEC, P1
   Street A, 2014, BIOMEDICINE UNSTABLE
   Wahlberg A, 2015, ECON SOC, V44, P60, DOI 10.1080/03085147.2014.983830
   Wahlberg A, 2009, THEOR TECH SOC, P89
   Weaver LJ, 2016, MED ANTHROPOL Q, V30, P498, DOI 10.1111/maq.12283
   Wendland C.L., 2010, HEART WORK JOURNEYS
   WHO, 2018, MON HLTH SDGS
   Whyte S.R., 2015, 2 CHANCES SURVIVING
   Whyte SR, 2012, ANTHROPOL MED, V19, P63, DOI 10.1080/13648470.2012.660465
   Will CM, 2020, SOCIOL REV, V68, P55, DOI 10.1177/0038026119887330
   World Health Organization , 2005, WHOCDSCSRGIP20054
   World Health Organization, 2005, PREV CHRON DIS VIT I
NR 67
TC 1
Z9 1
U1 2
U2 3
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0145-9740
EI 1545-5882
J9 MED ANTHROPOL
JI Med. Anthropol.
PD JUL 3
PY 2020
VL 39
IS 5
SI SI
BP 428
EP 439
DI 10.1080/01459740.2020.1761352
EA MAY 2020
PG 12
WC Anthropology; Reproductive Biology; Social Sciences, Biomedical
SC Anthropology; Reproductive Biology; Biomedical Social Sciences
GA ME1US
UT WOS:000534996400001
PM 32412308
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Durante-Mangoni, E
   Andini, R
   Bertolino, L
   Mele, F
   Florio, LL
   Murino, P
   Corcione, A
   Zampino, R
AF Durante-Mangoni, Emanuele
   Andini, Roberto
   Bertolino, Lorenzo
   Mele, Ferruccio
   Florio, Letizia Lucia
   Murino, Patrizia
   Corcione, Antonio
   Zampino, Rosa
TI Early experience with remdesivir in SARS-CoV-2 pneumonia
SO INFECTION
LA English
DT Article
DE Remdesivir; SARS-CoV-2; COVID 19; Pneumonia; Antiviral therapy
AB At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients had been previously treated with other antivirals before remdesivir initiation. One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure. Three patients showed biochemical signs of liver injury. Lymphocyte count increased in all patients soon after remdesivir initiation. Nasal swab SARS-CoV-2 RNA became negative in three of four patients after 3 days of therapy. We observed an in vivo virological effect of remdesivir in four critically ill, COVID-19 patients, coupled with a significant burden of adverse events. Although limited by the low number of subjects studied, our preliminary experience may be relevant for clinicians treating COVID-19.
C1 [Durante-Mangoni, Emanuele; Bertolino, Lorenzo; Mele, Ferruccio; Florio, Letizia Lucia; Zampino, Rosa] Univ Campania L Vanvitelli, Monaldi Hosp, Div Internal Med, Piazzale Ettore Ruggieri, I-80131 Naples, Italy.
   [Durante-Mangoni, Emanuele; Andini, Roberto; Zampino, Rosa] AORN Osped Colli Monaldi Hosp, Unit Infect & Transplant Med, Naples, Italy.
   [Murino, Patrizia; Corcione, Antonio] AORN Osped Colli Monaldi Hosp, Intens Care Unit, Naples, Italy.
RP Durante-Mangoni, E (corresponding author), Univ Campania L Vanvitelli, Monaldi Hosp, Div Internal Med, Piazzale Ettore Ruggieri, I-80131 Naples, Italy.; Durante-Mangoni, E (corresponding author), AORN Osped Colli Monaldi Hosp, Unit Infect & Transplant Med, Naples, Italy.
EM emanuele.durante@unicampania.it
OI Durante-Mangoni, Emanuele/0000-0002-5381-3537; Bertolino,
   Lorenzo/0000-0003-3205-4292
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 6
TC 5
Z9 5
U1 3
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8126
EI 1439-0973
J9 INFECTION
JI Infection
PD OCT
PY 2020
VL 48
IS 5
BP 779
EP 782
DI 10.1007/s15010-020-01448-x
EA MAY 2020
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA NT0QS
UT WOS:000533191200002
PM 32418190
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Desouky, E
AF Desouky, Elsayed
TI BCG versus COVID-19: impact on urology
SO WORLD JOURNAL OF UROLOGY
LA English
DT Article; Early Access
DE COVID-19; Pandemic; Urology; BCG; Bladder cancer
AB Purpose To search for evidence base for using BCG in the fight against COVID-19 and the possible impact of these clinical trials on urology practice. Methods A literature review about the basis of the ongoing clinical trials using BCG against COVID-19, as well as the use of BCG in urology and if there are any implications of these trials on our practice. Results Based on data from some epidemiological studies, there are some current clinical trials on the use BCG as a possible prophylactic vaccine against SARS CoV-2 which can affect urology practice. Urologists are already struggling with the global shortage of BCG which can be even more aggravated by such trials. In addition, if the ongoing trials proved the efficacy of BCG as a prophylaxis against COVID-19, this may open the door to more urological research opportunities to question the possibility that intra-vesical BCG, given its systemic immunologic effect, may have been protective to this subgroup of urological patients. Conclusion The ongoing clinical trials using BCG against COVID-19 can affect our urology practice. We need to stay vigilant to such impacts: BCG shortage and possible new chances for urology research work.
C1 [Desouky, Elsayed] Wexham Pk NHS Hosp, Urol Dept, Slough, Berks, England.
   [Desouky, Elsayed] Alexandria Main Univ Hosp, Urol Dept, Alexandria, Egypt.
RP Desouky, E (corresponding author), Wexham Pk NHS Hosp, Urol Dept, Slough, Berks, England.; Desouky, E (corresponding author), Alexandria Main Univ Hosp, Urol Dept, Alexandria, Egypt.
EM sayedurology@hotmail.com
OI Desouky, Elsayed/0000-0001-6224-9854
CR Buffen K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004485
   Crispen PL, 2020, CANCER IMMUNOL IMMUN, V69, P3, DOI 10.1007/s00262-019-02443-4
   Fuge O, 2015, RES REP UROL, V7, P65, DOI 10.2147/RRU.S63447
   Puja M., 2020, LANCET
   Schellhammer P F, 1975, Urology, V6, P562, DOI 10.1016/0090-4295(75)90503-8
   Zlotta AR, 1997, CLIN EXP IMMUNOL, V109, P157, DOI 10.1046/j.1365-2249.1997.4141313.x
NR 6
TC 3
Z9 3
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0724-4983
EI 1433-8726
J9 WORLD J UROL
JI World J. Urol.
DI 10.1007/s00345-020-03251-7
EA MAY 2020
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA LN8MR
UT WOS:000533187700003
PM 32417996
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kim, Y
   Kwon, O
   Paek, JH
   Park, WY
   Jin, K
   Hyun, M
   Lee, JY
   Kim, HA
   Han, S
AF Kim, Yaerim
   Kwon, Ohyun
   Paek, Jin H.
   Park, Woo Y.
   Jin, Kyubok
   Hyun, Miri
   Lee, Ji Y.
   Kim, Hyun A.
   Han, Seungyeup
TI Two distinct cases with COVID-19 in kidney transplant recipients
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE clinical research; practice; immunosuppressant; infection and infectious
   agents - viral; infectious disease; kidney (allograft) function;
   dysfunction; kidney transplantation; nephrology
ID TACROLIMUS
AB The fatality of novel coronavirus disease 2019 (COVID-19) is precipitously increased in patients with underlying comorbidities or elderly people. Kidney transplant (KT) recipients are one of the vulnerable populations for infection. COVID-19 infection in KT recipients might be a complicated and awkward situation, but there has been a lack of reports concerning this group. Herein, we demonstrated two distinct cases with different clinical progress. The first case was a 36-year-old man who underwent KT 3 years ago. He was diagnosed with COVID-19 expressing relevant symptoms. Following administration of lopinavir/ritonavir and hydroxychloroquine with reduced immunosuppressant, he recovered from COVID-19. However, the unexpected fluctuations in tacrolimus trough levels needed to be managed because of drug-to-drug interaction. The second case was developed in a 56-year-old man without any symptoms. He received a second KT from an ABO-incompatible donor 8 years ago. He was diagnosed with COVID-19 by screening due to exposure history. During the hospitalization period, the chest infiltrative lesion showed a wax and wane, but he successfully recovered by administration of hydroxychloroquine with azithromycin. These apparently different cases suggest that assertive screening and management could improve the clinical course. In addition, antiviral agents should be used cautiously, especially in patients on calcineurin inhibitors.
C1 [Kim, Yaerim; Kwon, Ohyun; Paek, Jin H.; Park, Woo Y.; Jin, Kyubok; Han, Seungyeup] Keimyung Univ, Dept Internal Med, Div Nephrol, Sch Med, Daegu, South Korea.
   [Kim, Yaerim; Paek, Jin H.; Park, Woo Y.; Jin, Kyubok; Han, Seungyeup] Keimyung Univ, Kidney Inst, Daegu, South Korea.
   [Hyun, Miri; Lee, Ji Y.; Kim, Hyun A.] Keimyung Univ, Dept Internal Med, Div Infect Dis, Sch Med, Daegu, South Korea.
RP Han, S (corresponding author), Keimyung Univ, Dept Internal Med, Div Nephrol, Sch Med, Daegu, South Korea.; Han, S (corresponding author), Keimyung Univ, Kidney Inst, Daegu, South Korea.
EM hansy@dsmc.or.kr
OI Han, Seungyeup/0000-0002-7561-6534; Kim, Yaerim/0000-0003-1596-1528
CR Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI DOI 10.15585/MMWR.MM6912E2
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   Eckerle I, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-359
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kumar GN, 1999, DRUG METAB DISPOS, V27, P902
   Li H, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE002, DOI 10.3760/cma.j.issn.1001-0939.2020.0002
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Saran R, 2018, AM J KIDNEY DIS, V71, pS1, DOI 10.1053/j.ajkd.2018.01.002
   Schonder KS, 2003, ANN PHARMACOTHER, V37, P1793, DOI 10.1345/aph.1D076
   Shrestha BM, 2017, J NEPAL MED ASSOC, V56, P482, DOI 10.31729/jnma.3375
   Vanichanan J, 2018, KIDNEY RES CLIN PRAC, V37, P323, DOI 10.23876/j.krcp.18.0063
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zuo XC, 2013, PHARMACOGENET GENOM, V23, P251, DOI 10.1097/FPC.0b013e32835fcbb6
NR 19
TC 16
Z9 16
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD AUG
PY 2020
VL 20
IS 8
BP 2269
EP 2275
DI 10.1111/ajt.15947
EA MAY 2020
PG 7
WC Surgery; Transplantation
SC Surgery; Transplantation
GA MS1DI
UT WOS:000532980100001
PM 32337859
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Asensio, E
   Acunzo, R
   Uribe, W
   Saad, EB
   Saenz, LC
AF Asensio, Enrique
   Acunzo, Rafael
   Uribe, William
   Saad, Eduardo B.
   Saenz, Luis C.
TI Recommendations for the measurement of the QT interval during the use of
   drugs for COVID-19 infection treatment. Updatable in accordance with the
   availability of new evidence
SO JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY
LA English
DT Article
DE Hydroxychloroquine; Chloroquine; Azithromycin; QT interval; Torsade de
   pointes; COVID 19
AB COVID-19 infection has shown rapid growth worldwide, and different therapies have been proposed for treatment, in particular, the combination of immune response modulating drugs such as chloroquine and hydroxychloroquine (antimalarials) alone or in combination with azithromycin. Although the clinical evidence supporting their use is scarce, the off label use of these drugs has spread very quickly in face of the progression of the epidemic and the high mortality rate in susceptible populations. However, these medications can pathologically prolong the QT interval and lead to malignant ventricular arrhythmias such that organized guidance on QT evaluation and management strategies are important to reduce morbidity associated with the potential large-scale use.
C1 [Asensio, Enrique] Hosp H, Div Internal Med, Queretaro, Mexico.
   [Acunzo, Rafael] Hosp Ramos Mejia, Div Cardiol, Buenos Aires, DF, Argentina.
   [Uribe, William] CES Cardiol, Medellin, Colombia.
   [Saad, Eduardo B.] Hosp Procardiaco, Arrhythmias Serv, Rio De Janeiro, Brazil.
   [Saenz, Luis C.] Fdn CardioInfantill, Int Ctr Arrhythmias, Inst Cardiol, Bogota, Colombia.
RP Saenz, LC (corresponding author), Fdn CardioInfantill, Int Ctr Arrhythmias, Inst Cardiol, Bogota, Colombia.
EM lcsaenz@cardioinfantil.org
CR Choi Y, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1574806
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   EHLERT FA, 1992, AM J CARDIOL, V70, P332, DOI 10.1016/0002-9149(92)90614-5
   Garabelli P, 2016, J CARDIOVASC ELECTR, V27, P827, DOI 10.1111/jce.12976
   Giudicessi JR, 2020, MAYO CLIN P, V95
   Goldenberg I, 2006, J CARDIOVASC ELECTR, V17, P333, DOI 10.1111/j.1540-8167.2006.00408.x
   Hocht C, 2004, REV ARGENT CARDIOL, V72, P474
   Johnson JN, 2009, BRIT J SPORT MED, V43, P657, DOI 10.1136/bjsm.2008.054734
   Tisdale JE, 2013, CIRC-CARDIOVASC QUAL, V6, P479, DOI 10.1161/CIRCOUTCOMES.113.000152
   Woosley RL, 2020, CARDIOLOGY
NR 10
TC 3
Z9 3
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1383-875X
EI 1572-8595
J9 J INTERV CARD ELECTR
JI J. Interv. Card. Electrophysiol.
PD NOV
PY 2020
VL 59
IS 2
BP 315
EP 320
DI 10.1007/s10840-020-00765-3
EA MAY 2020
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OK5YF
UT WOS:000533170800001
PM 32418181
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Mazer-Amirshahi, M
   Fox, ER
   Farmer, BM
   Stolbach, AI
AF Mazer-Amirshahi, Maryann
   Fox, Erin R.
   Farmer, Brenna Michelle
   Stolbach, Andrew, I
TI ACMT Position Statement: Medication Shortages During Coronavirus Disease
   Pandemic
SO JOURNAL OF MEDICAL TOXICOLOGY
LA English
DT Article
DE Drug shortages; Medication shortages; COVID-19; Coronavirus; Toxicology
ID DRUG SHORTAGES
C1 [Mazer-Amirshahi, Maryann] MedStar Washington Hosp, Dept Emergency Med, Washington, DC USA.
   [Mazer-Amirshahi, Maryann] Georgetown Univ, Sch Med, Washington, DC USA.
   [Fox, Erin R.] Univ Utah Hlth, Drug Informat & Support Serv, Salt Lake City, UT USA.
   [Fox, Erin R.] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA.
   [Farmer, Brenna Michelle] Weill Cornell Med, Dept Emergency Med, New York, NY USA.
   [Stolbach, Andrew, I] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.
RP Stolbach, AI (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.
EM positionstatements@acmt.net
CR [Anonymous], 2010, OFF J EUR COMMUN L, VL15, P1
   [Anonymous], ABC NEWS
   Gudeman J, 2013, DRUGS R&D, V13, P1, DOI 10.1007/s40268-013-0005-9
   Hick JL, 2014, NEW ENGL J MED, V370, P1573, DOI 10.1056/NEJMp1401833
   Hicks RW, 2006, J INFUS MURS, V29, P20, DOI 10.1097/00129804-200601000-00005
   Kaiser J, 2011, SCIENCE, V332, P523, DOI 10.1126/science.332.6029.523
   Labus B., 2008, Morbidity and Mortality Weekly Report, V57, P513
   Mazer-Amirshahi M, 2017, J CRIT CARE, V41, P283, DOI 10.1016/j.jcrc.2017.06.005
   Mazer-Amirshahi M, 2014, ACAD EMERG MED, V21, P704, DOI 10.1111/acem.12389
   Quadri F, 2015, CLIN INFECT DIS, V60, P1737, DOI 10.1093/cid/civ201
   Woodcock J, 2013, CLIN PHARMACOL THER, V93, P170, DOI 10.1038/clpt.2012.220
NR 14
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1556-9039
EI 1937-6995
J9 J MED TOXICOL
JI J. Med. Toxicol.
PD JUL
PY 2020
VL 16
IS 3
SI SI
BP 346
EP 348
DI 10.1007/s13181-020-00782-8
EA MAY 2020
PG 3
WC Toxicology
SC Toxicology
GA MC7JB
UT WOS:000533175200001
PM 32418120
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Frieden, IJ
   Puttgen, KB
   Drolet, BA
   Garzon, MC
   Chamlin, SL
   Pope, E
   Mancini, AJ
   Lauren, CT
   Mathes, EF
   Siegel, DH
   Gupta, D
   Haggstrom, AN
   Tollefson, MM
   Baselga, E
   Morel, KD
   Shah, SD
   Holland, KE
   Adams, DM
   Horii, KA
   Newell, BD
   Powell, J
   McCuaig, CC
   Nopper, AJ
   Metry, DW
   Maguiness, S
AF Frieden, Ilona J.
   Puttgen, Katherine B.
   Drolet, Beth A.
   Garzon, Maria C.
   Chamlin, Sarah L.
   Pope, Elena
   Mancini, Anthony J.
   Lauren, Christine T.
   Mathes, Erin F.
   Siegel, Dawn H.
   Gupta, Deepti
   Haggstrom, Anita N.
   Tollefson, Megha M.
   Baselga, Eulalia
   Morel, Kimberly D.
   Shah, Sonal D.
   Holland, Kristen E.
   Adams, Denise M.
   Horii, Kimberly A.
   Newell, Brandon D.
   Powell, Julie
   McCuaig, Catherine C.
   Nopper, Amy J.
   Metry, Denise W.
   Maguiness, Sheilagh
CA Hemangioma Investigator Grp
TI Management of infantile hemangiomas during the COVID pandemic
SO PEDIATRIC DERMATOLOGY
LA English
DT Article
DE health care delivery; hemangiomas; vascular tumors; therapy-systemic
ID TOPICAL TIMOLOL; PROPRANOLOL; EFFICACY; PARENTS
AB The COVID-19 pandemic has caused significant shifts in patient care including a steep decline in ambulatory visits and a marked increase in the use of telemedicine. Infantile hemangiomas (IH) can require urgent evaluation and risk stratification to determine which infants need treatment and which can be managed with continued observation. For those requiring treatment, prompt initiation decreases morbidity and improves long-term outcomes. The Hemangioma Investigator Group has created consensus recommendations for management of IH via telemedicine. FDA/EMA-approved monitoring guidelines, clinical practice guidelines, and relevant, up-to-date publications regarding initiation and monitoring of beta-blocker therapy were used to inform the recommendations. Clinical decision-making guidelines about when telehealth is an appropriate alternative to in-office visits, including medication initiation, dosage changes, and ongoing evaluation, are included. The importance of communication with caregivers in the context of telemedicine is discussed, and online resources for both hemangioma education and propranolol therapy are provided.
C1 [Frieden, Ilona J.; Mathes, Erin F.; Shah, Sonal D.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Puttgen, Katherine B.] Intermt Healthcare, Salt Lake City, UT USA.
   [Drolet, Beth A.; Garzon, Maria C.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
   [Lauren, Christine T.; Morel, Kimberly D.] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY USA.
   [Chamlin, Sarah L.; Mancini, Anthony J.] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Pope, Elena] Univ Toronto, Hosp Sick Children, Toronto, ON, Canada.
   [Siegel, Dawn H.; Holland, Kristen E.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
   [Gupta, Deepti] Univ Washington, Sch Med, Seattle Childrens Hosp, Seattle, WA USA.
   [Haggstrom, Anita N.] Indiana Univ, Indianapolis, IN 46204 USA.
   [Tollefson, Megha M.] Mayo Clin, Rochester, MN USA.
   [Baselga, Eulalia] Hosp St Joan de Deu, Barcelona, Spain.
   [Adams, Denise M.] Harvard Med Sch, Boston, MA 02115 USA.
   [Horii, Kimberly A.; Newell, Brandon D.; Nopper, Amy J.] Univ Missouri, Kansas City, MO 64110 USA.
   [Powell, Julie; McCuaig, Catherine C.] Univ Montreal, St Justine Univ Hosp Ctr, Dept Pediat, Div Pediat Dermatol, Montreal, PQ, Canada.
   [Metry, Denise W.] Baylor Coll Med, Houston, TX 77030 USA.
   [Maguiness, Sheilagh] Univ Minnesota, Minneapolis, MN USA.
RP Frieden, IJ (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.
EM Ilona.frieden@ucsf.edu
OI Mancini, Anthony J/0000-0003-0903-7734; Frieden,
   Ilona/0000-0001-7305-5940
CR Agency for Healthcare Research and Quality, EFF HLTH CAR PROGR D
   [Anonymous], 2014, HEM PROP HYDR OR SOL
   Borok J, 2018, BRIT J DERMATOL, V178, pE51, DOI 10.1111/bjd.15865
   de Graaf M, 2014, J AM ACAD DERMATOL, V70, P893, DOI 10.1016/j.jaad.2013.10.040
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Drolet BA, 2020, J AM ACAD DERMATOL, V82, P733, DOI 10.1016/j.jaad.2019.02.029
   Drolet BA, 2013, PEDIATRICS, V131, P128, DOI 10.1542/peds.2012-1691
   Garzon MC, 2016, J PEDIATR-US, V178, P24, DOI 10.1016/j.jpeds.2016.07.054
   Hoeger PH, 2015, EUR J PEDIATR, V174, P855, DOI 10.1007/s00431-015-2570-0
   Khan M, 2017, ACTA DERM-VENEREOL, V97, P1167, DOI 10.2340/00015555-2681
   Krowchuk DP, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-3475
   Leaute-Labreze C, 2015, NEW ENGL J MED, V372, P735, DOI 10.1056/NEJMoa1404710
   Leaute-Labreze C, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-1628
   Martin K, 2013, PEDIATR DERMATOL, V30, P155, DOI 10.1111/pde.12022
   Putterman E, 2019, PEDIATR DERMATOL, V36, P471, DOI 10.1111/pde.13843
   Puttgen K, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0355
   Puttgen Katherine B, 2020, J Am Acad Dermatol, DOI 10.1016/j.jaad.2020.04.013
   Robert J, 2020, BRIT J DERMATOL, V183, P573, DOI 10.1111/bjd.19047
   Smithson SL, 2017, AUSTRALAS J DERMATOL, V58, P155, DOI 10.1111/ajd.12600
   Solman L, 2018, BRIT J DERMATOL, V179, P582, DOI 10.1111/bjd.16779
   Wedgeworth E, 2016, BRIT J DERMATOL, V174, P594, DOI 10.1111/bjd.14233
   Weibel L, 2016, PEDIATR DERMATOL, V33, P184, DOI 10.1111/pde.12767
NR 22
TC 4
Z9 4
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-8046
EI 1525-1470
J9 PEDIATR DERMATOL
JI Pediatr. Dermatol.
PD MAY
PY 2020
VL 37
IS 3
BP 412
EP 418
DI 10.1111/pde.14196
EA MAY 2020
PG 7
WC Dermatology; Pediatrics
SC Dermatology; Pediatrics
GA MD3ZR
UT WOS:000532992100001
PM 32298480
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhou, X
   Zhu, JK
   Xu, T
AF Zhou, Xian
   Zhu, Jingkang
   Xu, Tao
TI Clinical characteristics of coronavirus disease 2019 (COVID-19) patients
   with hypertension on renin-angiotensin system inhibitors
SO CLINICAL AND EXPERIMENTAL HYPERTENSION
LA English
DT Article; Early Access
DE Clinical characteristics; coronavirus disease 2019; hypertension; ACEI
   or ARB
ID CONVERTING ENZYME 2; ACE2; EXPRESSION; ACID; WUHAN; AXIS
AB In December 2019, COVID-19 outbroke in Wuhan, China. The current study aimed to explore the clinical characteristics of COVID-19 complicated by hypertension. In this retrospective, single-center study, we recruited 110 discharged patients with COVID-19 at Wuhan Fourth Hospital in Wuhan, China, from January 25 to February 20, 2020. All study cases were grouped according to whether they had a history of hypertension. Then, a subgroup analysis for all hypertensive patients was carried out based on whether to take ACEI or ARB drugs. The mean age of 110 patients was 57.7 years (range, 25-86 years), of which 60 (54.5%) were male patients. The main underlying diseases included hypertension [36 (32.7%)] and diabetes [11 (10.0%)]. Compared with the non-hypertensive group, the lymphocyte count was significantly lower in the hypertensive group (average value, 0.96 x 10(9)/L vs 1.26 x 10(9)/L), and analysis of clinical outcomes showed that the crude mortality rate was higher in the hypertensive group [7/36 (19.4%) vs 2/74 (2.7%)]. Patients treated with ACEI or ARB, compared with the control group, were younger (average age, 58.5 years vs 69.2 years), but there was no statistical difference in the crude cure rate [10/15 (66.7%) vs 15/21 (71.4%)] and the crude mortality rate [2/15 (13.3%) vs 5/21 (23.8%)]. In conclusions, the COVID-19 patients with a history of hypertension had a significantly lower lymphocyte count on admission. The elderly and comorbidities such as hypertension may together constitute risk factors for poor prognosis in patients with COVID-19. Taking ACEI or ARB drugs may not change the prognosis of COVID-19 patients with hypertension.
C1 [Zhou, Xian; Xu, Tao] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Crit Care Med, Puai Hosp,Wuhan Hosp 4, Wuhan 430034, Hubei, Peoples R China.
   [Zhu, Jingkang] Fujian Med Univ, Prov Clin Med Coll, Fujian Prov Cardiovasc Dis Inst, Hypertens Lab, Fuzhou, Fujian, Peoples R China.
RP Xu, T (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Crit Care Med, Puai Hosp,Wuhan Hosp 4, Wuhan 430034, Hubei, Peoples R China.
EM dcxutao@163.com
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dijkman R, 2012, J GEN VIROL, V93, P1924, DOI 10.1099/vir.0.043919-0
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Fan ZM, 2019, LIFE SCI, V225, P39, DOI 10.1016/j.lfs.2019.03.059
   Ferrario CM, 2010, AM J PHYSIOL-RENAL, V298, pF1297, DOI 10.1152/ajprenal.00110.2010
   Glowacka I, 2010, J VIROL, V84, P1198, DOI 10.1128/JVI.01248-09
   Gorbalenya A. E., 2020, SEVERE ACUTE RESP SY
   Gupta RM, 2017, CELL, V170, P522, DOI 10.1016/j.cell.2017.06.049
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Kuba K, 2010, PHARMACOL THERAPEUT, V128, P119, DOI 10.1016/j.pharmthera.2010.06.003
   Liu J., 2020, NEUTROPHIL TO LYMPHO
   Mitchell KD, 2007, ACTA PHYSIOL HUNG, V94, P31, DOI 10.1556/APhysiol.94.2007.1-2.5
   Nicholls J, 2005, NAT MED, V11, P821, DOI 10.1038/nm0805-821
   Shoemaker R, 2019, BIOL SEX DIFFER, V10, DOI 10.1186/s13293-019-0260-8
   Sodhi CP, 2018, AM J PHYSIOL-LUNG C, V314, pL17, DOI 10.1152/ajplung.00498.2016
   Stec DE, 2016, J AM SOC HYPERTENS, V10, P346, DOI 10.1016/j.jash.2016.01.023
   Tikellis C, 2006, KIDNEY INT, V70, P34, DOI 10.1038/sj.ki.5000428
   Vuille-Dit-Bille RN, 2015, AMINO ACIDS, V47, P693, DOI 10.1007/s00726-014-1889-6
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yan R, 2020, STRUCTURE DIMERIC FU
   Zhong JC, 2004, HYPERTENSION, V44, P907, DOI 10.1161/01.HYP.0000146400.57221.74
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 23
TC 8
Z9 8
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1064-1963
EI 1525-6006
J9 CLIN EXP HYPERTENS
JI Clin. Exp. Hypertens.
DI 10.1080/10641963.2020.1764018
EA MAY 2020
PG 5
WC Pharmacology & Pharmacy; Peripheral Vascular Disease
SC Pharmacology & Pharmacy; Cardiovascular System & Cardiology
GA LP2UO
UT WOS:000534175400001
PM 32404011
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Naz, F
   Arish, M
AF Naz, Farha
   Arish, Mohd
TI Battling COVID-19 Pandemic: Sphingosine-1-Phosphate Analogs as an
   Adjunctive Therapy?
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; S1P analogs; cytokine storm; immuno-modulators
ID RESPIRATORY SYNDROME CORONAVIRUS; CYTOKINE STORM; SPHINGOSINE
   1-PHOSPHATE; T-CELLS; INTERFERON; PNEUMONIA; INDUCTION; RESPONSES;
   TARGET
AB With the sudden outbreak of COVID-19 patient worldwide and associated mortality, it is critical to come up with an effective treatment against SARS-CoV-2. Studies suggest that mortality due to COVID 19 is mainly attributed to the hyper inflammatory response leading to cytokine storm and ARDS in infected patients. Sphingosine-1-phosphate receptor 1 (S1PR1) analogs, AAL-R and RP-002, have earlier providedin-vivoprotection from the pathophysiological response during H1N1 influenza infection and improved mortality. Recently, it was shown that the treatment with sphingosine-1-phosphate receptor 1 analog, CYM5442, resulted in the significant dampening of the immune response upon H1N1 challenge in mice and improved survival of H1N1 infected mice in combination with an antiviral drug, oseltamivir. Hence, here we suggest to investigate the possible utility of using S1P analogs to treat COVID-19.
C1 [Naz, Farha] Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, New Delhi, India.
   [Arish, Mohd] Jamia Hamdard, Inst Mol Med, New Delhi, India.
RP Arish, M (corresponding author), Jamia Hamdard, Inst Mol Med, New Delhi, India.
EM dr.mohdarish@gmail.com
FU Department of Health Research (DHR), Ministry of Health and Family
   Welfare (MoHFW), Government of India [12014/15/2018-HR]
FX This work was supported by Department of Health Research (DHR), Ministry
   of Health and Family Welfare (MoHFW), Government of India (Young
   Scientist Grant No. 12014/15/2018-HR).
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arish M, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006647
   Arish M, 2016, DRUG DISCOV TODAY, V21, P133, DOI 10.1016/j.drudis.2015.09.013
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   D'Elia RV, 2013, CLIN VACCINE IMMUNOL, V20, P319, DOI 10.1128/CVI.00636-12
   De Lang A, 2007, PLOS PATHOG, V3, P1129, DOI 10.1371/journal.ppat.0030112
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mohammed S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00296
   Park SJ, 2017, BIOMOL THER, V25, P80, DOI 10.4062/biomolther.2016.160
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Sali M, 2009, INT J IMMUNOPATH PH, V22, P175, DOI 10.1177/039463200902200120
   Teijaro JR, 2016, P NATL ACAD SCI USA, V113, P1351, DOI 10.1073/pnas.1525356113
   Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015
   Walsh KB, 2014, J VIROL, V88, P6281, DOI 10.1128/JVI.00464-14
   Walsh KB, 2011, P NATL ACAD SCI USA, V108, P12018, DOI 10.1073/pnas.1107024108
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhao JN, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02322-y
   Zhao JN, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41760-7
   Zhou J, 2014, J INFECT DIS, V209, P1331, DOI 10.1093/infdis/jit504
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 27
TC 2
Z9 2
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAY 15
PY 2020
VL 11
AR 1102
DI 10.3389/fimmu.2020.01102
PG 4
WC Immunology
SC Immunology
GA MW0KF
UT WOS:000556735600001
PM 32670273
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhou, Q
   Chen, V
   Shannon, CP
   Wei, XS
   Xiang, X
   Wang, X
   Wang, ZH
   Tebbutt, SJ
   Kollmann, TR
   Fish, EN
AF Zhou, Qiong
   Chen, Virginia
   Shannon, Casey P.
   Wei, Xiao-Shan
   Xiang, Xuan
   Wang, Xu
   Wang, Zi-Hao
   Tebbutt, Scott J.
   Kollmann, Tobias R.
   Fish, Eleanor N.
TI Interferon-alpha 2b Treatment for COVID-19
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE interferon; COVID-19; viral shedding; IL-6; inflammation; ARDS
ID PNEUMONIA
AB The global pandemic of COVID-19 cases caused by infection with SARS-CoV-2 is ongoing, with no approved antiviral intervention. We describe here the effects of treatment with interferon (IFN)-alpha 2b in a cohort of confirmed COVID-19 cases in Wuhan, China. In this uncontrolled, exploratory study, 77 adults hospitalized with confirmed COVID-19 were treated with either nebulized IFN-alpha 2b (5 mU b.i.d.), arbidol (200 mg t.i.d.) or a combination of IFN-alpha 2b plus arbidol. Serial SARS-CoV-2 testing along with hematological measurements, including cell counts, blood biochemistry and serum cytokine levels, and temperature and blood oxygen saturation levels, were recorded for each patient during their hospital stay. Treatment with IFN-alpha 2b with or without arbidol significantly reduced the duration of detectable virus in the upper respiratory tract and in parallel reduced duration of elevated blood levels for the inflammatory markers IL-6 and CRP. These findings suggest that IFN-alpha 2b should be further investigated as a therapy in COVID-19 cases.
C1 [Zhou, Qiong; Wei, Xiao-Shan; Xiang, Xuan; Wang, Xu; Wang, Zi-Hao] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Resp & Crit Care Med, Wuhan, Peoples R China.
   [Chen, Virginia; Shannon, Casey P.; Tebbutt, Scott J.] Univ British Columbia, St Pauls Hosp, Prevent Organ Failure PROOF Ctr Excellence, Vancouver, BC, Canada.
   [Chen, Virginia; Shannon, Casey P.; Tebbutt, Scott J.] Univ British Columbia, St Pauls Hosp, Ctr Heart Lung Innovat, Vancouver, BC, Canada.
   [Tebbutt, Scott J.] Univ British Columbia, Dept Med, Div Resp Med, Vancouver, BC, Canada.
   [Kollmann, Tobias R.] Telethon Kids Inst, Ctr Precis Hlth, Syst Vaccinol, Nedlands, WA, Australia.
   [Fish, Eleanor N.] Univ Toronto, Univ Hlth Network, Toronto Gen Hosp, Res Inst, Toronto, ON, Canada.
   [Fish, Eleanor N.] Univ Toronto, Dept Immunol, Toronto, ON, Canada.
RP Fish, EN (corresponding author), Univ Toronto, Univ Hlth Network, Toronto Gen Hosp, Res Inst, Toronto, ON, Canada.; Fish, EN (corresponding author), Univ Toronto, Dept Immunol, Toronto, ON, Canada.
EM en.fish@utoronto.ca
OI Kollmann, Tobias/0000-0003-2403-9762
CR Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Butt Y, 2016, ARCH PATHOL LAB MED, V140, P345, DOI 10.5858/arpa.2015-0519-RA
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Huang XJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep08528
   Lian N, 2020, CLIN MICROBIOL INFEC, V26, P917, DOI 10.1016/j.cmi.2020.04.026
   Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Wang B, 2019, SEMIN IMMUNOL, V43, DOI 10.1016/j.smim.2019.101300
NR 12
TC 45
Z9 45
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAY 15
PY 2020
VL 11
AR 1061
DI 10.3389/fimmu.2020.01061
PG 6
WC Immunology
SC Immunology
GA MW0JO
UT WOS:000556733900001
PM 32574262
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Xiang, CL
   Wu, G
AF Xiang, Chunlin
   Wu, Gang
TI SARS-CoV-2 pneumonia with subcutaneous emphysema, mediastinal emphysema,
   and pneumothorax A case report
SO MEDICINE
LA English
DT Article
DE heart failure; pneumothorax; SARS-CoV-2; subcutaneous emphysema
AB Introduction: Since the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has affected more than 1,000,000 population in the world. Subcutaneous emphysema and pneumothorax are uncommon complications of SARS-CoV-2 pneumonia. Herein, we describe a fatal case of SARS-CoV-2 pneumonia with subcutaneous emphysema and pneumothorax. Patient concerns: Subcutaneous emphysema was found in neck, bilateral chest walls, abdomen wall, groin area, and scrotum of a 67-year-old man. Extensive air-space opacities, subcutaneous emphysema and a small amount of pneumothorax were found in his chest X-ray scan. Echocardiography showed left ventricular enlargement with ejection fraction 20%. Diagnosis: This resident of Wuhan with laboratory-confirmed SARS-CoV-2 infection had chronic pulmonary and cardiac diseases. Liver dysfunction, myocardial injury, and coagulation disorder were suggested by laboratory findings. Pneumonia, subcutaneous emphysema, and pneumothorax were confirmed with chest X-ray. Heart failure was revealed by echocardiography. Interventions: He was transferred to intensive care unit, where invasive ventilation was used for him during the whole hospitalization. Prone position ventilation, vasoconstrictor, antibacteria, and antiviral therapy were given. Outcomes: He died on the twelfth day after admission. Conclusions: Subcutaneous emphysema and pneumothorax may occur in patients with SARS-CoV-2 pneumonia and chronic pulmonary disease. Chronic cardiac disease might be aggravated by SARS-CoV-2 infection, and develop heart failure.
C1 [Xiang, Chunlin; Wu, Gang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Radiol, Wuhan, Peoples R China.
RP Wu, G (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China.
EM tongjiwugang1984@qq.com
FU National Natural Science of Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81801663]
FX National Natural Science of Foundation of China, No. 81801663.
CR Badaoui R, 2013, ANN FR ANESTH, V32, P718, DOI 10.1016/j.annfar.2013.07.815
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Gadre SK, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010487
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Shokouhi Shervin, 2018, Infectious Disorders - Drug Targets, V18, P23, DOI 10.2174/1871526517666170505122057
   Sonobe S, 2019, JA CLIN REP, V5, DOI 10.1186/s40981-019-0305-3
   Sun RH, 2020, KOREAN J RADIOL, V21, P541, DOI 10.3348/kjr.2020.0180
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 8
TC 4
Z9 5
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAY 15
PY 2020
VL 99
IS 20
AR e20208
DI 10.1097/MD.0000000000020208
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA MO4OD
UT WOS:000551506600061
PM 32443345
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Saha, P
   Banerjee, AK
   Tripathi, PP
   Srivastava, AK
   Ray, U
AF Saha, Priyanka
   Banerjee, Arup Kumar
   Tripathi, Prem Prakash
   Srivastava, Amit Kumar
   Ray, Upasana
TI A virus that has gone viral: amino acid mutation in S protein of Indian
   isolate of Coronavirus COVID-19 might impact receptor binding, and thus,
   infectivity
SO BIOSCIENCE REPORTS
LA English
DT Article
AB Since 2002, beta coronaviruses (CoVs) have caused three zoonotic outbreaks, SARS-CoV in 2002, MERS-CoV in 2012, and the recent outbreak of SARS-CoV-2 late in 2019 (also named as COVID-19 or novel coronavirus 2019 or nCoV2019). Spike (S) protein, one of the structural proteins of this virus plays key role in receptor (ACE2) binding and thus virus entry. Thus, this protein has attracted scientists for detailed study and therapeutic targeting. As the nCoV2019 takes its course throughout the world, more and more sequence analyses are being done and genome sequences are being deposited in various databases. From India, two clinical isolates have been sequenced and the full genome has been deposited in GenBank. We have performed sequence analyses of the Spike protein of the Indian isolates and compared with that of the Wuhan, China (where the outbreak was first reported). While all the sequences of Wuhan isolates are identical, we found point mutations in the Indian isolates. Out of the two isolates, one was found to harbor a mutation in its receptor-binding domain (RBD) at position 407. At this site, arginine (a positively charged amino acid) was replaced by isoleucine (a hydrophobic amino acid that is also a C-beta branched amino acid). This mutation has been seen to change the secondary structure of the protein at that region and this can potentially alter receptor binding of the virus. Although this finding needs further validation and more sequencing, the information might be useful in rational drug designing and vaccine engineering.
C1 [Saha, Priyanka; Srivastava, Amit Kumar] CSIR, Canc Biol & Inflammatory Disorder Div, Indian Inst Chem Biol, 4 Raja SC,Mullick Rd, Kolkata 700032, W Bengal, India.
   [Banerjee, Arup Kumar] North Bengal Med Coll & Hosp, Dept Biochem, Siliguri 734012, W Bengal, India.
   [Tripathi, Prem Prakash] CSIR, Cell Biol & Physiol Div, Indian Inst Chem Biol, 4 Raja SC,Mullick Rd, Kolkata 700032, W Bengal, India.
   [Ray, Upasana] CSIR, Infect Biol & Immunol Div, Indian Inst Chem Biol, 4 Raja SC,Mullick Rd, Kolkata 700032, W Bengal, India.
RP Srivastava, AK (corresponding author), CSIR, Canc Biol & Inflammatory Disorder Div, Indian Inst Chem Biol, 4 Raja SC,Mullick Rd, Kolkata 700032, W Bengal, India.; Banerjee, AK (corresponding author), North Bengal Med Coll & Hosp, Dept Biochem, Siliguri 734012, W Bengal, India.; Tripathi, PP (corresponding author), CSIR, Cell Biol & Physiol Div, Indian Inst Chem Biol, 4 Raja SC,Mullick Rd, Kolkata 700032, W Bengal, India.; Ray, U (corresponding author), CSIR, Infect Biol & Immunol Div, Indian Inst Chem Biol, 4 Raja SC,Mullick Rd, Kolkata 700032, W Bengal, India.
EM dr.arup.banerjee@gmail.com; prem.tripathi@gmail.com;
   amitsrivastava8503@gmail.com; ray.upasana@gmail.com
FU Department of Biotechnology, DBTDepartment of Biotechnology (DBT) India
FX We would like to thank Dr. Anupam Das Talukdar, Department of Life
   Sciences and Bioinformatics, Assam University for sharing server. We
   also thank Department of Biotechnology, DBT for supporting P.S. CSIR is
   acknowledged for institutional support. We also thank North Bengal
   Medical College and Hospital, Siliguri.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   CORNISH VW, 1994, BIOCHEMISTRY-US, V33, P12022, DOI 10.1021/bi00206a003
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Liu ZX, 2020, J MED VIROL, V92, P595, DOI 10.1002/jmv.25726
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v4, DOI 10.26434/CHEMRXIV.11871402.V4]
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Wu Y., 2020, BIORXIV, DOI [10.1101/2020.03.04.975995, DOI 10.1101/2020.03.04.975995]
   Ziff AL, 2020, FRACTAL KINETICS COV, DOI [DOI 10.1101/2020.02.16.20023820, 10.1101/2020.02.16.20023820]
NR 9
TC 10
Z9 10
U1 7
U2 7
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD MAY 15
PY 2020
VL 40
AR BSR20201312
DI 10.1042/BSR20201312
PN 5
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA LY5VV
UT WOS:000540598000001
PM 32378705
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gordon, CJ
   Tchesnokov, EP
   Woolner, E
   Perry, JK
   Feng, JY
   Porter, DP
   Gotte, M
AF Gordon, Calvin J.
   Tchesnokov, Egor P.
   Woolner, Emma
   Perry, Jason K.
   Feng, Joy Y.
   Porter, Danielle P.
   Gotte, Matthias
TI Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA
   polymerase from severe acute respiratory syndrome coronavirus 2 with
   high potency
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE RNA polymerase; plus-stranded RNA virus; drug action; drug development;
   drug discovery; COVID-19; coronavirus (CoV); MERS; SARS; SARS-CoV-2;
   Ebola virus; Lassa virus; RNA-dependent RNA polymerase (RdRp);
   replication; remdesivir; sofosbuvir; favipiravir; ribavirin
ID THERAPEUTIC-EFFICACY; STRUCTURAL BASIS; EBOLA-VIRUS; INTERFERON;
   RIBAVIRIN; EXCISION; GS-5734; EXORIBONUCLEASE; REPLICATION; DISCOVERY
AB Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analogue remdesivir (RDV). RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain termination is RDV's plausible mechanism of action. Here, we expressed and purified active SARS-CoV-2 RdRp composed of the nonstructural proteins nsp8 and nsp12. Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA. Incorporation of RDV-TP at position i caused termination of RNA synthesis at position i+3. We obtained almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps. A unique property of RDV-TP is its high selectivity over incorporation of its natural nucleotide counterpart ATP. In this regard, the triphosphate forms of 2?-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits. Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by the distantly related Lassa virus RdRp, and termination of RNA synthesis was not observed. These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral.
C1 [Gordon, Calvin J.; Tchesnokov, Egor P.; Woolner, Emma; Gotte, Matthias] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2R3, Canada.
   [Gotte, Matthias] Univ Alberta, Li Ka Shing Inst Virol, Edmonton, AB T6G 2R3, Canada.
   [Perry, Jason K.; Feng, Joy Y.; Porter, Danielle P.] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA.
RP Gotte, M (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2E1, Canada.
EM gotte@ualberta.ca
OI Tchesnokov, Egor/0000-0003-1698-2961; Perry, Jason/0000-0001-5492-0652;
   Woolner, Emma/0000-0002-8697-7802
FU Canadian Institutes of Health Research (CIHR)Canadian Institutes of
   Health Research (CIHR) [170343]; Gilead SciencesGilead Sciences; Alberta
   Ministry of Economic Development, Trade, and Tourism Major Innovation
   Fund Program for the AMR-One Health Consortium
FX This study was supported by Canadian Institutes of Health Research
   (CIHR) Grant 170343, Gilead Sciences, and the Alberta Ministry of
   Economic Development, Trade, and Tourism Major Innovation Fund Program
   for the AMR-One Health Consortium (to M. G.). M. G. has previously
   received funding from Gilead Sciences in support of the study of EBOV
   RdRp inhibition by RDV. This study is also sponsored in part by a grant
   from Gilead Sciences to M. G., J. K. P., J. Y. F., and D. P. P. are
   Gilead employees.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Appleby TC, 2015, SCIENCE, V347, P771, DOI 10.1126/science.1259210
   Berger I, 2004, NAT BIOTECHNOL, V22, P1583, DOI 10.1038/nbt1036
   Bieniossek Christoph, 2008, Curr Protoc Protein Sci, VChapter 5, DOI 10.1002/0471140864.ps0520s51
   Bouvet M, 2012, P NATL ACAD SCI USA, V109, P9372, DOI 10.1073/pnas.1201130109
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Crotty S, 2000, NAT MED, V6, P1375
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Delang L, 2018, ANTIVIR RES, V153, P85, DOI 10.1016/j.antiviral.2018.03.003
   Feld JJ, 2005, NATURE, V436, P967, DOI 10.1038/nature04082
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gong P, 2010, P NATL ACAD SCI USA, V107, P22505, DOI 10.1073/pnas.1007626107
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Hawman DW, 2018, ANTIVIR RES, V157, P18, DOI 10.1016/j.antiviral.2018.06.013
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jacobson MP, 2002, J MOL BIOL, V320, P597, DOI 10.1016/S0022-2836(02)00470-9
   Jin ZN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068347
   Jordan PC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006889
   Kennedy EM, 2010, J BIOL CHEM, V285, P39380, DOI 10.1074/jbc.M110.178582
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kumaki Y, 2011, ANTIVIR RES, V92, P329, DOI 10.1016/j.antiviral.2011.09.001
   Li HO, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00483-20
   Lo MK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9242
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maag D, 2001, J BIOL CHEM, V276, P46094, DOI 10.1074/jbc.C100349200
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Oestereich L, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002804
   Posthuma CC, 2017, VIRUS RES, V234, P58, DOI 10.1016/j.virusres.2017.01.023
   Pruijssers AJ, 2019, CURR OPIN VIROL, V35, P57, DOI 10.1016/j.coviro.2019.04.002
   Schinazi R, 2014, LIVER INT, V34, P69, DOI 10.1111/liv.12423
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Stuyver LJ, 2004, ANTIMICROB AGENTS CH, V48, P651, DOI 10.1128/AAC.48.2.651-654.2004
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Tchesnokov EP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22328-3
   Tchesnokov EP, 2008, J BIOL CHEM, V283, P34218, DOI 10.1074/jbc.M806797200
   TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361
   Uebelhoer LS, 2014, ANTIVIR RES, V106, P86, DOI 10.1016/j.antiviral.2014.03.018
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Welch SR, 2017, ANTIVIR RES, V147, P91, DOI 10.1016/j.antiviral.2017.10.008
   Welch SR, 2016, ANTIVIR RES, V136, P9, DOI 10.1016/j.antiviral.2016.10.007
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Zamyatkin DF, 2008, J BIOL CHEM, V283, P7705, DOI 10.1074/jbc.M709563200
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 50
TC 106
Z9 106
U1 27
U2 49
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 15
PY 2020
VL 295
IS 20
BP 6785
EP 6797
DI 10.1074/jbc.RA120.013679
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA LS2IH
UT WOS:000536212600001
PM 32284326
OA Bronze, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Honore, PM
   Mugisha, A
   Kugener, L
   Redant, S
   Attou, R
   Gallerani, A
   De Bels, D
AF Honore, Patrick M.
   Mugisha, Aude
   Kugener, Luc
   Redant, Sebastien
   Attou, Rachid
   Gallerani, Andrea
   De Bels, David
TI Therapeutic plasma exchange as a routine therapy in septic shock and as
   an experimental treatment for COVID-19: we are not sure
SO CRITICAL CARE
LA English
DT Letter
C1 [Honore, Patrick M.; Mugisha, Aude; Kugener, Luc; Redant, Sebastien; Attou, Rachid; Gallerani, Andrea; De Bels, David] Brugmann Univ Hosp, ICU Dept, Ctr Hosp Univ Brugmann, Pl Van Gehuchtenpl 4, B-1020 Brussels, Belgium.
RP Honore, PM (corresponding author), Brugmann Univ Hosp, ICU Dept, Ctr Hosp Univ Brugmann, Pl Van Gehuchtenpl 4, B-1020 Brussels, Belgium.
EM Patrick.Honore@CHU-Brugmann.be
CR Keith P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2836-4
   Knaup H, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2220-9
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rimmer E, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0699-2
   Szczeklik W, 2013, ANAESTH INTENSIVE TH, V45, P7, DOI 10.5603/AIT.2013.0002
NR 5
TC 3
Z9 3
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1364-8535
EI 1466-609X
J9 CRIT CARE
JI Crit. Care
PD MAY 15
PY 2020
VL 24
IS 1
AR 226
DI 10.1186/s13054-020-02943-1
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA LS2BP
UT WOS:000536195200004
PM 32414417
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Santoli, JM
   Lindley, MC
   DeSilva, MB
   Kharbanda, EO
   Daley, MF
   Galloway, L
   Gee, J
   Glover, M
   Herring, B
   Kang, Y
   Lucas, P
   Noblit, C
   Tropper, J
   Vogt, T
   Weintraub, E
AF Santoli, Jeanne M.
   Lindley, Megan C.
   DeSilva, Malini B.
   Kharbanda, Elyse O.
   Daley, Matthew F.
   Galloway, Lisa
   Gee, Julianne
   Glover, Mick
   Herring, Ben
   Kang, Yoonjae
   Lucas, Paul
   Noblit, Cameron
   Tropper, Jeanne
   Vogt, Tara
   Weintraub, Eric
TI Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering
   and Administration - United States, 2020
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Santoli, Jeanne M.; Lindley, Megan C.; Galloway, Lisa; Kang, Yoonjae; Lucas, Paul; Noblit, Cameron; Tropper, Jeanne; Vogt, Tara] CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA.
   [DeSilva, Malini B.; Kharbanda, Elyse O.] HealthPartners Inst, Minneapolis, MN USA.
   [Daley, Matthew F.] Kaiser Permanente Colorado, Inst Hlth Res, Aurora, CO USA.
   [Gee, Julianne; Weintraub, Eric] CDC, Natl Ctr Emerging Zoonot & Infect Dis, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
   [Glover, Mick] Total Solut Inc, Madison, AL USA.
   [Herring, Ben] Carter Consulting Inc, Atlanta, GA USA.
RP Santoli, JM (corresponding author), CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA.
EM jsantoli@cdc.gov
CR Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P465, DOI [10.15585/mmwr.mm6915e4, DOI 10.15585/MMWR.MM6915E4]
   Dunn J, 2020, YOUR KIDS STILL NEED
   Federal Emergency Management Agency, 2020, BRING RES STAT LOC T
   Financial Industry Regulatory Authority, 2020, STAT SHELT IN PLAC S
   Hoffman J., 2020, NY TIMES
NR 5
TC 57
Z9 59
U1 3
U2 3
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD MAY 15
PY 2020
VL 69
IS 19
BP 591
EP 593
DI 10.15585/mmwr.mm6919e2
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA LR9IB
UT WOS:000536007700005
PM 32407298
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Gao, Y
   Yan, LM
   Huang, YC
   Liu, FJ
   Zhao, Y
   Cao, L
   Wang, T
   Sun, QQ
   Ming, ZH
   Zhang, LQ
   Ge, J
   Zheng, LT
   Zhang, Y
   Wang, HF
   Zhu, Y
   Zhu, C
   Hu, TY
   Hua, T
   Zhang, B
   Yang, XN
   Li, J
   Yang, HT
   Liu, ZJ
   Xu, WQ
   Guddat, LW
   Wang, Q
   Lou, ZY
   Rao, ZH
AF Gao, Yan
   Yan, Liming
   Huang, Yucen
   Liu, Fengjiang
   Zhao, Yao
   Cao, Lin
   Wang, Tao
   Sun, Qianqian
   Ming, Zhenhua
   Zhang, Lianqi
   Ge, Ji
   Zheng, Litao
   Zhang, Ying
   Wang, Haofeng
   Zhu, Yan
   Zhu, Chen
   Hu, Tianyu
   Hua, Tian
   Zhang, Bing
   Yang, Xiuna
   Li, Jun
   Yang, Haitao
   Liu, Zhijie
   Xu, Wenqing
   Guddat, Luke W.
   Wang, Quan
   Lou, Zhiyong
   Rao, Zihe
TI Structure of the RNA-dependent RNA polymerase from COVID-19 virus
SO SCIENCE
LA English
DT Article
ID CORONAVIRUS; REPLICATION; PNEUMONIA; PROTEIN
AB A novel coronavirus [severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)] outbreak has caused a global coronavirus disease 2019 (COVID-19) pandemic, resulting in tens of thousands of infections and thousands of deaths worldwide. The RNA-dependent RNA polymerase [(RdRp), also named nsp12] is the central component of coronaviral replication and transcription machinery, and it appears to be a primary target for the antiviral drug remdesivir. We report the cryo-electron microscopy structure of COVID-19 virus full-length nsp12 in complex with cofactors nsp7 and nsp8 at 2.9-angstrom resolution. In addition to the conserved architecture of the polymerase core of the viral polymerase family, nsp12 possesses a newly identified b-hairpin domain at its N terminus. A comparative analysis model shows how remdesivir binds to this polymerase. The structure provides a basis for the design of new antiviral therapeutics that target viral RdRp.
C1 [Gao, Yan; Yan, Liming; Huang, Yucen; Wang, Tao; Zhang, Lianqi; Ge, Ji; Zheng, Litao; Zhang, Ying; Lou, Zhiyong; Rao, Zihe] Tsinghua Univ, Sch Life Sci, Lab Struct Biol, Beijing, Peoples R China.
   [Gao, Yan; Yan, Liming; Huang, Yucen; Wang, Tao; Zhang, Lianqi; Ge, Ji; Zheng, Litao; Zhang, Ying; Lou, Zhiyong; Rao, Zihe] Tsinghua Univ, Sch Med, Beijing, Peoples R China.
   [Gao, Yan; Liu, Fengjiang; Zhao, Yao; Sun, Qianqian; Wang, Haofeng; Zhu, Yan; Zhu, Chen; Hu, Tianyu; Hua, Tian; Zhang, Bing; Yang, Xiuna; Li, Jun; Yang, Haitao; Liu, Zhijie; Xu, Wenqing; Wang, Quan; Rao, Zihe] ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai, Peoples R China.
   [Gao, Yan; Liu, Fengjiang; Zhao, Yao; Sun, Qianqian; Wang, Haofeng; Zhu, Yan; Zhu, Chen; Hu, Tianyu; Hua, Tian; Zhang, Bing; Yang, Xiuna; Li, Jun; Yang, Haitao; Liu, Zhijie; Xu, Wenqing; Wang, Quan; Rao, Zihe] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China.
   [Cao, Lin; Rao, Zihe] Nankai Univ, Coll Life Sci, Frontiers Sci Ctr Cell Response, State Key Lab Med Chem Biol, Tianjin, Peoples R China.
   [Cao, Lin; Rao, Zihe] Nankai Univ, Coll Pharm, Tianjin, Peoples R China.
   [Ming, Zhenhua] Guangxi Univ, Coll Life Sci & Technol, State Key Lab Conservat & Utilizat Subtrop Agrobi, Nanning, Peoples R China.
   [Wang, Haofeng] Tianjin Univ, Sch Life Sci, Tianjin, Peoples R China.
   [Guddat, Luke W.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia.
   [Rao, Zihe] Chinese Acad Sci, Inst Biophys, CAS Ctr Excellence Biomacromol, Natl Lab Biomacromol, Beijing, Peoples R China.
RP Lou, ZY; Rao, ZH (corresponding author), Tsinghua Univ, Sch Life Sci, Lab Struct Biol, Beijing, Peoples R China.; Lou, ZY; Rao, ZH (corresponding author), Tsinghua Univ, Sch Med, Beijing, Peoples R China.; Wang, Q; Rao, ZH (corresponding author), ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai, Peoples R China.; Wang, Q; Rao, ZH (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China.; Rao, ZH (corresponding author), Nankai Univ, Coll Life Sci, Frontiers Sci Ctr Cell Response, State Key Lab Med Chem Biol, Tianjin, Peoples R China.; Rao, ZH (corresponding author), Nankai Univ, Coll Pharm, Tianjin, Peoples R China.; Rao, ZH (corresponding author), Chinese Acad Sci, Inst Biophys, CAS Ctr Excellence Biomacromol, Natl Lab Biomacromol, Beijing, Peoples R China.
EM wangq@shanghaitech.edu.cn; louzy@mail.tsinghua.edu.cn;
   raozh@mail.tsinghua.edu.cn
OI Gao, Yan/0000-0002-0364-6427; Yang, Xiuna/0000-0003-3443-9815; yan, li
   ming/0000-0003-0648-9604; Liu, Fengjiang/0000-0002-9400-308X; Zhao,
   Yao/0000-0002-2932-2164
FU National Program on Key Research Project of China [2017YFC0840300,
   2020YFA0707500]; Strategic Priority Research Program of the Chinese
   Academy of SciencesChinese Academy of Sciences [XDB08020200]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81520108019, 813300237]; Science and Technology
   Commission of Shanghai MunicipalityScience & Technology Commission of
   Shanghai Municipality (STCSM) [20431900200]
FX This work was supported by the National Program on Key Research Project
   of China (grant nos. 2017YFC0840300 and 2020YFA0707500), the Strategic
   Priority Research Program of the Chinese Academy of Sciences (grant
   XDB08020200), the National Natural Science Foundation of China (grant
   nos. 81520108019 and 813300237), and the Science and Technology
   Commission of Shanghai Municipality (20431900200).
CR Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308
   Appleby TC, 2015, SCIENCE, V347, P771, DOI 10.1126/science.1259210
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen C, 2020, FAVIPIRAVIR VERSUS A
   Chen C, 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17, DOI 10.1101/2020.03.17]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Gane EJ, 2013, NEW ENGL J MED, V368, P34, DOI 10.1056/NEJMoa1208953
   Gong P, 2010, P NATL ACAD SCI USA, V107, P22505, DOI 10.1073/pnas.1007626107
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Lehmann KC, 2015, NUCLEIC ACIDS RES, V43, P8416, DOI 10.1093/nar/gkv838
   Li S, 2010, PROTEIN CELL, V1, P198, DOI 10.1007/s13238-010-0028-8
   Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007
   McDonald SM, 2013, WIRES RNA, V4, P351, DOI 10.1002/wrna.1164
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 25
TC 152
Z9 155
U1 45
U2 72
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAY 15
PY 2020
VL 368
IS 6492
BP 779
EP +
DI 10.1126/science.abb7498
PG 24
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LR3QQ
UT WOS:000535608300049
PM 32277040
OA Green Published, Other Gold
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Yu, B
   Li, CZ
   Chen, P
   Zhou, N
   Wang, LY
   Li, J
   Jiang, HL
   Wang, DW
AF Yu Bo
   Li Chenze
   Chen Peng
   Zhou Ning
   Wang Luyun
   Li Jia
   Jiang Hualiang
   Wang Dao-Wen
TI Low dose of hydroxychloroquine reduces fatality of critically ill
   patients with COVID-19
SO SCIENCE CHINA-LIFE SCIENCES
LA English
DT Article
ID CHLOROQUINE
AB Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs and high fatality. The most urgent need is to find effective treatments. We sought to determine whether hydroxychloroquine (HCQ) application may reduce the death risk of critically ill COVID-19 patients. In this retrospective study, we included 550 critically ill COVID-19 patients who need mechanical ventilation in Tongji Hospital, Wuhan, from February 1, 2020 to April 4, 2020. All 550 patients received comparable basic treatments including antiviral drugs and antibiotics, and 48 of them were treated with oral HCQ treatment (200 mg twice a day for 7-10 days) in addition to the basic treatments. Primary endpoint is fatality of patients, and inflammatory cytokine levels were compared between HCQ and non-hydroxychloroquine (NHCQ) treatments. We found that fatalities are 18.8% (9/48) in HCQ group, which is significantly lower than 47.4% (238/502) in the NHCQ group (P<0.001). The time of hospital stay before patient death is 15 (10-21) days and 8 (4-14) days for the HCQ and NHCQ groups, respectively (P<0.05). The levels of inflammatory cytokine IL-6 were significantly reduced from 22.2 (8.3-118.9) pg mL(-1) at the beginning of the treatment to 5.2 (3.0-23.4) pg mL(-1) (P<0.05) at the end of the treatment in the HCQ group but there is no change in the NHCQ group. These data demonstrate that addition of HCQ on top of the basic treatments is highly effective in reducing the fatality of critically ill patients of COVID-19 through attenuation of inflammatory cytokine storm. Therefore, HCQ should be prescribed as a part of treatment for critically ill COVID-19 patients, with possible outcome of saving lives. hydroxychloroquine, IL-6, mortalities, COVID-19
C1 [Yu Bo; Li Chenze; Chen Peng; Zhou Ning; Wang Luyun; Wang Dao-Wen] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Div Cardiol,Dept Internal Med, Wuhan 430030, Peoples R China.
   [Yu Bo; Li Chenze; Chen Peng; Zhou Ning; Wang Luyun; Wang Dao-Wen] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Wuhan 430030, Peoples R China.
   [Li Jia; Jiang Hualiang] Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
   [Jiang Hualiang] Shanghai Tech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China.
   [Jiang Hualiang] Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China.
RP Wang, DW (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Div Cardiol,Dept Internal Med, Wuhan 430030, Peoples R China.; Wang, DW (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Wuhan 430030, Peoples R China.
EM dwwang@tjh.tjmu.edu.cn
RI Li, Jia/F-9116-2011
OI Wang, Dao Wen/0000-0002-9774-3980
FU Ministry of Science and Technology of ChinaMinistry of Science and
   Technology, China [2020YFC0844500]; National Natural Science Foundation
   of ChinaNational Natural Science Foundation of China (NSFC) [31130031];
   Chinese Academy of SciencesChinese Academy of Sciences [2020YJFK0105];
   Chinese Academy of Engineering and Ma Yun Foundation [2020-CMKYGG-05]
FX This work was supported in part by projects from Ministry of Science and
   Technology of China (2020YFC0844500), the National Natural Science
   Foundation of China (31130031), Emergency Project Fund of Chinese
   Academy of Sciences (2020YJFK0105) and Chinese Academy of Engineering
   and Ma Yun Foundation (2020-CMKYGG-05). We thank all our colleagues from
   the Department of Internal Medicine, Tongji Hospital, as well as all the
   medical staff fighting against COVID-19, for their tremendous efforts.
   We also thank Professor H. Eric Xu in Shanghai Institute of Materia
   Medica, Chinese Academy of Sciences for his great help in writing this
   paper.
CR Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Bian X, 2020, IMMUNOL PATHOL
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, N ENGL J MED
   Grein J, 2020, N ENGL J MED
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He YZ, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001450
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Magagnoli J, 2020, OUTCOMES HYDROXYCHLO
   Mahevas M, 2020, NO EVIDENCE CLIN EFF
   MCCHESNEY EW, 1967, TOXICOL APPL PHARM, V10, P501, DOI 10.1016/0041-008X(67)90089-0
   National Health Commission of China, 2020, CHIN MAN GUID COVID
   Plantone D, 2018, CLIN DRUG INVEST, V38, P653, DOI 10.1007/s40261-018-0656-y
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Shiratori H, 2018, EUR J PHARMACOL, V833, P328, DOI 10.1016/j.ejphar.2018.06.017
   Snijder EJ, 2006, J VIROL, V80, P5927, DOI 10.1128/JVI.02501-05
   Yao X, 2020, CLIN INFECT DIS
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 19
TC 25
Z9 25
U1 0
U2 2
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1674-7305
EI 1869-1889
J9 SCI CHINA LIFE SCI
JI Sci. China-Life Sci.
PD OCT
PY 2020
VL 63
IS 10
BP 1515
EP 1521
DI 10.1007/s11427-020-1732-2
EA MAY 2020
PG 7
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA NW1CU
UT WOS:000533450200001
PM 32418114
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Yi, CY
   Sun, XY
   Ye, J
   Ding, LF
   Liu, MQ
   Yang, Z
   Lu, X
   Zhang, YG
   Ma, LY
   Gu, WP
   Qu, AD
   Xu, JQ
   Shi, ZL
   Ling, ZY
   Sun, B
AF Yi, Chunyan
   Sun, Xiaoyu
   Ye, Jing
   Ding, Longfei
   Liu, Meiqin
   Yang, Zhuo
   Lu, Xiao
   Zhang, Yaguang
   Ma, Liyang
   Gu, Wangpeng
   Qu, Aidong
   Xu, Jianqing
   Shi, Zhengli
   Ling, Zhiyang
   Sun, Bing
TI Key residues of the receptor binding motif in the spike protein of
   SARS-CoV-2 that interact with ACE2 and neutralizing antibodies
SO CELLULAR & MOLECULAR IMMUNOLOGY
LA English
DT Article
DE SARS-CoV-2; spike protein; receptor binding motif; cross-neutralizing
   antibody; substitution mutation
ID SARS CORONAVIRUS; DOMAIN
AB Coronavirus disease 2019 (COVID-19), caused by the novel human coronavirus SARS-CoV-2, is currently a major threat to public health worldwide. The viral spike protein binds the host receptor angiotensin-converting enzyme 2 (ACE2) via the receptor-binding domain (RBD), and thus is believed to be a major target to block viral entry. Both SARS-CoV-2 and SARS-CoV share this mechanism. Here we functionally analyzed the key amino acid residues located within receptor binding motif of RBD that may interact with human ACE2 and available neutralizing antibodies. The in vivo experiments showed that immunization with either the SARS-CoV RBD or SARS-CoV-2 RBD was able to induce strong clade-specific neutralizing antibodies in mice; however, the cross-neutralizing activity was much weaker, indicating that there are distinct antigenic features in the RBDs of the two viruses. This finding was confirmed with the available neutralizing monoclonal antibodies against SARS-CoV or SARS-CoV-2. It is worth noting that a newly developed SARS-CoV-2 human antibody, HA001, was able to neutralize SARS-CoV-2, but failed to recognize SARS-CoV. Moreover, the potential epitope residues of HA001 were identified as A475 and F486 in the SARS-CoV-2 RBD, representing new binding sites for neutralizing antibodies. Overall, our study has revealed the presence of different key epitopes between SARS-CoV and SARS-CoV-2, which indicates the necessity to develop new prophylactic vaccine and antibody drugs for specific control of the COVID-19 pandemic although the available agents obtained from the SARS-CoV study are unneglectable.
C1 [Yi, Chunyan; Sun, Xiaoyu; Ye, Jing; Yang, Zhuo; Zhang, Yaguang; Ma, Liyang; Gu, Wangpeng; Ling, Zhiyang; Sun, Bing] Chinese Acad Sci, Ctr Excellence Mol Cell Sci, Shanghai Inst Biochem & Cell Biol, State Key Lab Cell Biol, Shanghai 200031, Peoples R China.
   [Ye, Jing; Lu, Xiao; Sun, Bing] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China.
   [Ding, Longfei; Xu, Jianqing] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai 201508, Peoples R China.
   [Liu, Meiqin; Shi, Zhengli] Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, Key Lab Special Pathogens, Wuhan 430071, Peoples R China.
   [Qu, Aidong] Shanghai Inst Biol Prod, Shanghai 200052, Peoples R China.
RP Ling, ZY; Sun, B (corresponding author), Chinese Acad Sci, Ctr Excellence Mol Cell Sci, Shanghai Inst Biochem & Cell Biol, State Key Lab Cell Biol, Shanghai 200031, Peoples R China.; Sun, B (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China.; Shi, ZL (corresponding author), Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, Key Lab Special Pathogens, Wuhan 430071, Peoples R China.
EM zlshi@wh.iov.cn; lingzhiyang@sibs.ac.cn; bsun@sibs.ac.cn
OI Zhang, Yaguang/0000-0002-2417-6516
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [82041015]; Strategic Priority Research
   Program of the Chinese Academy of SciencesChinese Academy of Sciences
   [XDB19000000]; Key International Partnership Program of the Chinese
   Academy of Sciences [153D31KYSB20180055]; National Major Science and
   Technology Projects of China [2018ZX10301403]
FX This work was supported by the National Natural Science Foundation of
   China (82041015), the Strategic Priority Research Program of the Chinese
   Academy of Sciences (XDB19000000), the Key International Partnership
   Program of the Chinese Academy of Sciences (153D31KYSB20180055) and the
   National Major Science and Technology Projects of China
   (2018ZX10301403). We are grateful to Prof. Linqi Zhang (Tsinghua
   University) for providing pNL4-3.luc.RE plasmid.
CR Bian C, 2009, VIROLOGY, V383, P39, DOI 10.1016/j.virol.2008.09.029
   Cagliani R, 2020, J VIROL, V94, DOI 10.1128/JVI.00411-20
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lu W, 2005, FEBS LETT, V579, P2130, DOI 10.1016/j.febslet.2005.02.070
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Navas-Martin S, 2005, J VIROL, V79, P7629, DOI 10.1128/JVI.79.12.7629-7640.2005
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Patel MR, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001282
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang PH, 2020, CELL MOL IMMUNOL, V17, P555, DOI 10.1038/s41423-020-0407-x
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 26
TC 12
Z9 12
U1 5
U2 22
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1672-7681
EI 2042-0226
J9 CELL MOL IMMUNOL
JI Cell. Mol. Immunol.
PD JUN
PY 2020
VL 17
IS 6
BP 621
EP 630
DI 10.1038/s41423-020-0458-z
EA MAY 2020
PG 10
WC Immunology
SC Immunology
GA LZ6WY
UT WOS:000533048500003
PM 32415260
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Wambier, CG
   Goren, A
   Vano-Galvan, S
   Ramos, PM
   Ossimetha, A
   Nau, G
   Herrera, S
   McCoy, J
AF Wambier, Carlos Gustavo
   Goren, Andy
   Vano-Galvan, Sergio
   Ramos, Paulo Muller
   Ossimetha, Angelina
   Nau, Gerard
   Herrera, Sabina
   McCoy, John
TI Androgen sensitivity gateway to COVID-19 disease severity
SO DRUG DEVELOPMENT RESEARCH
LA English
DT Article
DE alopecia; androgens; anti-androgen; clinical trial; COVID-19; pandemic;
   SARS-CoV-2; TMPRSS2
ID SERINE-PROTEASE; RECEPTOR GENE; TMPRSS2; PROSTATE; ACE2; SARS-COV-2;
   EXPRESSION; CLONING
AB In this communication, we present arguments for androgen sensitivity as a likely determinant of COVID-19 disease severity. The androgen sensitivity model explains why males are more likely to develop severe symptoms while children are ostensibly resistant to infection. Further, the model explains the difference in COVID-19 mortality rates among different ethnicities. Androgen sensitivity is determined by genetic variants of the androgen receptor. The androgen receptor regulates transcription of the transmembrane protease, serine 2 (TMPRSS2), which is required for SARS-CoV-2 infectivity. TMPRSS2 primes the Spike protein of the virus, which has two consequences: diminishing viral recognition by neutralizing antibodies and activating SARS-CoV-2 for virus-cell fusion. Genetic variants that have been associated with androgenetic alopecia, prostate cancer, benign prostatic hyperplasia and polycystic ovary syndrome could be associated with host susceptibility. In addition to theoretical epidemiological and molecular mechanisms, there are reports of high rates of androgenetic alopecia of from hospitalized COVID-19 patients due to severe symptoms. Androgen sensitivity is a likely determinant of COVID-19 disease severity. We believe that the evidence presented in this communication warrants the initiation of trials using anti-androgen agents.
C1 [Wambier, Carlos Gustavo] Brown Univ, Warren Alpert Med Sch, Dept Dermatol, Providence, RI 02912 USA.
   [Goren, Andy; McCoy, John] Appl Biol Inc, Irvine, CA USA.
   [Vano-Galvan, Sergio; Herrera, Sabina] Hosp Univ Ramon Y Cajal, Trichol Unit, Madrid, Spain.
   [Ramos, Paulo Muller] Sao Paulo State Univ UNESP, Dept Dermatol & Radiotherapy, Sao Paulo, SP, Brazil.
   [Ossimetha, Angelina] Brown Univ, Providence, RI 02912 USA.
   [Nau, Gerard] Brown Univ, Warren Alpert Med Sch, Dept Med, Div Infect Dis, Providence, RI 02912 USA.
RP Wambier, CG (corresponding author), Rhode Isl Hosp, Dept Dermatol, APC, 593 Eddy St,10th Floor, Providence, RI 02903 USA.
EM carlos_wambier@brown.edu
OI Vano-Galvan, Sergio/0000-0003-2773-7494
CR Afar DEH, 2001, CANCER RES, V61, P1686
   Bani Mohammad Majid, 2017, Asian Pac J Cancer Prev, V18, P17
   Bennett CL, 2002, J CLIN ONCOL, V20, P3599, DOI 10.1200/JCO.2002.11.085
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI DOI 10.15585/MMWR.MM6912E2
   Canarutto D, 2020, PEDIATR PULM, V55, pE4, DOI 10.1002/ppul.24754
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Dalpiaz PLM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127515
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Goren A, 2020, J COSMET DERMATOL-US, V19, P1545, DOI 10.1111/jocd.13443
   Goren A, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13365
   Gu JY, 2020, GASTROENTEROLOGY, V158, P1518, DOI 10.1053/j.gastro.2020.02.054
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jacquinet E, 2001, EUR J BIOCHEM, V268, P2687, DOI 10.1046/j.1432-1327.2001.02165.x
   Koptyug E, 2020, CORONAVIRUS COVID 19
   Lin BY, 1999, CANCER RES, V59, P4180
   Lizneva D, 2016, FERTIL STERIL, V106, P6, DOI 10.1016/j.fertnstert.2016.05.003
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Lucas JM, 2014, CANCER DISCOV, V4, P1310, DOI 10.1158/2159-8290.CD-13-1010
   McCoy J, 2020, J COSMET DERMATOL-US, V19, P1542, DOI 10.1111/jocd.13455
   National Institutes of Health, 2020, TMPRSS2 TRANSM SER P
   New MI, 2006, J CLIN ENDOCR METAB, V91, P4205, DOI 10.1210/jc.2006-1645
   Ober C, 2008, NAT REV GENET, V9, P911, DOI 10.1038/nrg2415
   Paoloni-Giacobino A, 2001, GENOMICS, V77, P114
   PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845
   Petersen E, 2020, INT J INFECT DIS, V93, P205, DOI 10.1016/j.ijid.2020.02.052
   Propper RE, 2020, NICOTINE TOB RES, V22, P1666, DOI 10.1093/ntr/ntaa073
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rossato M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01290-2020
   Ruth KS, 2020, NAT MED, V26, P252, DOI 10.1038/s41591-020-0751-5
   Schuring AN, 2012, EXP CLIN ENDOCR DIAB, V120, P73, DOI 10.1055/s-0031-1291343
   Shi Y, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2833-7
   Stopsack KH, 2020, CANCER DISCOV, V10, P779, DOI 10.1158/2159-8290.CD-20-0451
   Thebault R, 2020, WASHINGTON POST
   Wambier CG, 2020, J AM ACAD DERMATOL, V83, P308, DOI 10.1016/j.jaad.2020.04.032
   White PC, 2000, ENDOCR REV, V21, P245, DOI 10.1210/er.21.3.245
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
NR 41
TC 24
Z9 24
U1 61
U2 69
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4391
EI 1098-2299
J9 DRUG DEVELOP RES
JI Drug Dev. Res.
PD NOV
PY 2020
VL 81
IS 7
BP 771
EP 776
DI 10.1002/ddr.21688
EA MAY 2020
PG 6
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OP0AZ
UT WOS:000532825400001
PM 32412125
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Di Ciaccio, P
   McCaughan, G
   Trotman, J
   Ho, PJ
   Cheah, CY
   Gangatharan, S
   Wight, J
   Ku, MH
   Quach, H
   Gasiorowski, R
   Polizzotto, MN
   Prince, HM
   Mulligan, S
   Tam, CS
   Gregory, G
   Hapgood, G
   Spencer, A
   Dickinson, M
   Latimer, M
   Johnston, A
   Armytage, T
   Lee, C
   Cochrane, T
   Berkhahn, L
   Weinkove, R
   Doocey, R
   Harrison, SJ
   Webber, N
   Lee, HP
   Chapman, S
   Campbell, BA
   Gibbs, SDJ
   Hamad, N
AF Di Ciaccio, Pietro
   McCaughan, Georgia
   Trotman, Judith
   Ho, Phoebe Joy
   Cheah, Chan Y.
   Gangatharan, Shane
   Wight, Joel
   Ku, Matthew
   Quach, Hang
   Gasiorowski, Robin
   Polizzotto, Mark N.
   Prince, Henry Miles
   Mulligan, Stephen
   Tam, Constantine S.
   Gregory, Gareth
   Hapgood, Greg
   Spencer, Andrew
   Dickinson, Michael
   Latimer, Maya
   Johnston, Anna
   Armytage, Tasman
   Lee, Cindy
   Cochrane, Tara
   Berkhahn, Leanne
   Weinkove, Robert
   Doocey, Richard
   Harrison, Simon J.
   Webber, Nicholas
   Lee, Hui-Peng
   Chapman, Scott
   Campbell, Belinda A.
   Gibbs, Simon D. J.
   Hamad, Nada
TI Australian and New Zealand consensus statement on the management of
   lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19
   pandemic
SO INTERNAL MEDICINE JOURNAL
LA English
DT Article
DE COVID-19; lymphoma; myeloma; chronic lymphocytic leukaemia
ID B-CELL LYMPHOMA; NON-HODGKIN-LYMPHOMA; MULTIPLE-MYELOMA; OPEN-LABEL;
   T-CELL; SUBCUTANEOUS RITUXIMAB; DOSE-INTENSIFICATION; BRENTUXIMAB
   VEDOTIN; 1ST-LINE TREATMENT; ADAPTED TREATMENT
AB The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID-19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID-19, including the use of telehealth, avoidance of non-essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy-associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID-19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID-19 and available local healthcare resources.
C1 [Di Ciaccio, Pietro; McCaughan, Georgia; Polizzotto, Mark N.; Hamad, Nada] St Vincents Hosp, Dept Haematol, Darlinghurst, NSW, Australia.
   [Chapman, Scott] St Vincents Hosp, Dept Infect Dis, Darlinghurst, NSW, Australia.
   [Di Ciaccio, Pietro; McCaughan, Georgia; Polizzotto, Mark N.; Hamad, Nada] Univ New South Wales, Sydney, NSW, Australia.
   [McCaughan, Georgia; Trotman, Judith; Ho, Phoebe Joy; Gasiorowski, Robin; Mulligan, Stephen; Hamad, Nada] Univ Sydney, Sydney, NSW, Australia.
   [Trotman, Judith; Gasiorowski, Robin] Concord Repatriat Gen Hosp, Dept Haematol, Concord, NSW, Australia.
   [Ho, Phoebe Joy] Royal Prince Alfred Hosp, Dept Haematol, Camperdown, NSW, Australia.
   [Polizzotto, Mark N.] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
   [Mulligan, Stephen] Royal North Shore Hosp, Dept Haematol, Sydney, NSW, Australia.
   [Armytage, Tasman] Gosford Hosp, Dept Haematol, Gosford, NSW, Australia.
   [Cheah, Chan Y.] Sir Charles Gairdner Hosp, Dept Haematol, Nedlands, WA, Australia.
   [Cheah, Chan Y.] Pathwest Lab Med, Dept Haematol, Nedlands, WA, Australia.
   [Cheah, Chan Y.; Gangatharan, Shane] Univ Western Australia, Perth, WA, Australia.
   [Gangatharan, Shane] Fiona Stanley Hosp, Dept Haematol, Perth, WA, Australia.
   [Wight, Joel] Townsville Univ Hosp, Townsville, Qld, Australia.
   [Hapgood, Greg] Princess Alexandra Hosp, Dept Haematol, Woolloongabba, Qld, Australia.
   [Cochrane, Tara] Griffith Univ, Brisbane, Qld, Australia.
   [Webber, Nicholas] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia.
   [Cochrane, Tara] Gold Coast Univ Hosp, Dept Haematol, Southport, Qld, Australia.
   [Wight, Joel; Ku, Matthew; Quach, Hang; Prince, Henry Miles; Tam, Constantine S.; Spencer, Andrew; Dickinson, Michael; Harrison, Simon J.; Campbell, Belinda A.] Univ Melbourne, Melbourne, Vic, Australia.
   [Ku, Matthew; Quach, Hang; Tam, Constantine S.] St Vincents Hosp, Dept Haematol, Darlinghurst, NSW, Australia.
   [Prince, Henry Miles; Tam, Constantine S.; Dickinson, Michael; Harrison, Simon J.] Peter MacCallum Canc Ctr, Dept Clin Haematol, Melbourne, Vic, Australia.
   [Prince, Henry Miles; Tam, Constantine S.; Dickinson, Michael; Harrison, Simon J.] Royal Melbourne Hosp, Melbourne, Vic, Australia.
   [Prince, Henry Miles] Epworth Healthcare, Dept Haematol, Richmond, Vic, Australia.
   [Gregory, Gareth] Monash Hlth, Dept Haematol, Clayton, Vic, Australia.
   [Spencer, Andrew] Alfred Hosp, Dept Haematol, Melbourne, Vic, Australia.
   [Campbell, Belinda A.] Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia.
   [Gibbs, Simon D. J.] Eastern Hlth, Dept Haematol, Box Hill, Vic, Australia.
   [Gibbs, Simon D. J.] Monash Univ, Melbourne, Vic, Australia.
   [Latimer, Maya] Canberra Hosp, Dept Haematol, Canberra, ACT, Australia.
   [Johnston, Anna] Royal Hobart Hosp, Dept Haematol, Hobart, Tas, Australia.
   [Johnston, Anna] Univ Tasmania, Hobart, Tas, Australia.
   [Lee, Cindy] Queen Elizabeth Hosp, Dept Haematol, Adelaide, SA, Australia.
   [Lee, Hui-Peng] Southern Adelaide Local Hlth Network, Flinders Med Ctr, Dept Haematol, Adelaide, SA, Australia.
   [Berkhahn, Leanne; Doocey, Richard] Auckland City Hosp, Dept Haematol, Auckland, New Zealand.
   [Berkhahn, Leanne] Univ Auckland, Auckland, New Zealand.
   [Weinkove, Robert] Capital & Coast Dist Hlth Board, Wellington Blood & Canc Ctr, Dept Haematol, Wellington, New Zealand.
   [Weinkove, Robert] Malaghan Inst Med Res, Canc Immunotherapy Programme, Wellington, New Zealand.
RP Hamad, N (corresponding author), St Vincents Hosp, Kinghorn Canc Ctr, Haematol, Level 5,370 Victoria St, Darlinghurst, NSW 2010, Australia.
EM nada.hamad@svha.org.au
RI Weinkove, Robert/S-4457-2019; Gasiorowski, Robin/AAO-6267-2020; Hamad,
   Nada/AAR-9461-2020
OI Weinkove, Robert/0000-0003-3645-7988; Gasiorowski,
   Robin/0000-0003-1225-8757; Hamad, Nada/0000-0001-7929-1450; Di Ciaccio,
   Pietro/0000-0002-9282-8619; Cheah, Chan Yoon/0000-0001-7988-1565;
   Gangatharan, Shane/0000-0003-1022-9899
FU Haematology Society of Australia and New Zealand (HSANZ)
FX The Haematology Society of Australia and New Zealand (HSANZ) supports
   this document with recognition of the need for individual patient
   decision-making based on data available at that time.
CR Ando Y, 2020, INT SOC AMYLOIDOSIS
   Andre MPE, 2017, J CLIN ONCOL, V35, P1786, DOI 10.1200/JCO.2016.68.6394
   Ardeshna KM, 2003, LANCET, V362, P516, DOI 10.1016/S0140-6736(03)14110-4
   Bachy E, 2019, J CLIN ONCOL, V37, P2815, DOI 10.1200/JCO.19.01073
   Backhaus E, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1648-2
   Baden LR, 2016, J NATL COMPR CANC NE, V14, P882, DOI 10.6004/jnccn.2016.0093
   Barr H, 2018, LEUKEMIA, V32, P2495, DOI 10.1038/s41375-018-0120-2
   Barraclough A, 2019, BLOOD ADV, V3, P2013, DOI 10.1182/bloodadvances.2019000251
   Bartlett NL, 2019, J CLIN ONCOL, V37, P1790, DOI 10.1200/JCO.18.01994
   Blimark C, 2015, HAEMATOLOGICA, V100, P107, DOI 10.3324/haematol.2014.107714
   Borchmann P, 2017, LANCET, V390, P2790, DOI 10.1016/S0140-6736(17)32134-7
   Brice P, 1997, J CLIN ONCOL, V15, P1110, DOI 10.1200/JCO.1997.15.3.1110
   Bringhen S, 2018, LEUKEMIA, V32, P979, DOI 10.1038/leu.2017.327
   Casasnovas RO, 2019, LANCET ONCOL, V20, P202, DOI 10.1016/S1470-2045(18)30784-8
   Chan EK, 2011, INT J RADIAT ONCOL, V81, pE781, DOI 10.1016/j.ijrobp.2010.10.013
   CHAPEL HM, 1994, LANCET, V343, P1059, DOI 10.1016/S0140-6736(94)90180-5
   Chemaly RF, 2012, CANCER-AM CANCER SOC, V118, P4627, DOI 10.1002/cncr.27447
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen R, 2019, BLOOD, V134, P1144, DOI 10.1182/blood.2019000324
   Cheson BD, 2010, CL LYMPH MYELOM LEUK, V10, P452, DOI 10.3816/CLML.2010.n.079
   Chua CC, 2018, BONE MARROW TRANSPL, V53, P1116, DOI 10.1038/s41409-018-0152-2
   Cooley L, 2014, INTERN MED J, V44, P1350, DOI 10.1111/imj.12599
   Crump M, 2017, BLOOD, V130, P1800, DOI 10.1182/blood-2017-03-769620
   Crump M, 2014, J CLIN ONCOL, V32, P3490, DOI 10.1200/JCO.2013.53.9593
   Cunningham D, 2013, LANCET, V381, P1817, DOI 10.1016/S0140-6736(13)60313-X
   Davies A, 2017, ADV THER, V34, P2210, DOI 10.1007/s12325-017-0610-z
   Davies A, 2017, LANCET HAEMATOL, V4, pE272, DOI 10.1016/S2352-3026(17)30078-9
   Dimopoulos MA, 2016, LANCET ONCOL, V17, P27, DOI 10.1016/S1470-2045(15)00464-7
   Dunleavy K, 2013, NEW ENGL J MED, V369, P1915, DOI 10.1056/NEJMoa1308392
   Ellin F, 2014, BLOOD, V124, P1570, DOI 10.1182/blood-2014-04-573089
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Gafter-Gvili A, 2016, LEUKEMIA LYMPHOMA, V57, P512, DOI 10.3109/10428194.2015.1110748
   Gafter-Gvili A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004386.pub3
   Gibbs SDJ, 2019, CLIN PRACTICE GUIDEL
   Gisselbrecht C, 2010, J CLIN ONCOL, V28, P4184, DOI 10.1200/JCO.2010.28.1618
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Green H, 2007, MAYO CLIN PROC, V82, P1052, DOI 10.4065/82.9.1052
   Hiddemann W, 2018, J CLIN ONCOL, V36, P2395, DOI 10.1200/JCO.2017.76.8960
   Hoelzer D, 2014, BLOOD, V124, P3870, DOI 10.1182/blood-2014-03-563627
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Johnson P, 2016, NEW ENGL J MED, V374, P2419, DOI 10.1056/NEJMoa1510093
   Kim YJ, 2019, INFECT DIS-NOR, V51, P502, DOI 10.1080/23744235.2019.1592217
   LAMY T, 2014, BLOOD, V124, P393
   Larocca A, 2019, HEMASPHERE, V3, P244, DOI [10.1097/01.HS9.0000560632.24271.d7, DOI 10.1097/01.HS9.0000560632.24271.D7]
   Li Chan EH, 2019, CANCER MED-US, V8, P4626, DOI 10.1002/cam4.2347
   Martin P, 2008, ANN ONCOL, V19, P1327, DOI 10.1093/annonc/mdn045
   Martinez-Calle N, 2019, BRIT J HAEMATOL, V184, P957, DOI 10.1111/bjh.15722
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Merlin T, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-34
   Mhaskar R., 2014, COCHRANE DB SYST REV, V10, DOI DOI 10.1002/14651858.CD003039.PUB2
   Mikulska M, 2018, J INFECTION, V76, P20, DOI 10.1016/j.jinf.2017.10.009
   Moreau P, 2018, LANCET ONCOL, V19, P953, DOI 10.1016/S1470-2045(18)30354-1
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140-6736(10)62051-X
   Moskowitz AJ, 2015, LANCET ONCOL, V16, P284, DOI 10.1016/S1470-2045(15)70013-6
   Moskowitz CH, 2012, BLOOD, V119, P1665, DOI 10.1182/blood-2011-10-388058
   Mounier N, 2014, ANN ONCOL, V25, P1622, DOI 10.1093/annonc/mdu189
   Neumann S, 2013, ANN HEMATOL, V92, P433, DOI 10.1007/s00277-013-1698-0
   Oki Y, 2014, BRIT J HAEMATOL, V166, P891, DOI 10.1111/bjh.12982
   Park SI, 2019, CANCER-AM CANCER SOC, V125, P1507, DOI 10.1002/cncr.31861
   Persky DO, 2019, BLOOD, V134, DOI 10.1182/blood-2019-123871
   PHILIP T, 1995, NEW ENGL J MED, V333, P1540, DOI 10.1056/NEJM199512073332305
   Poeschel V, 2019, LANCET, V394, P2271, DOI 10.1016/S0140-6736(19)33008-9
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Quach H, 2019, CLIN PRACTICE GUIDEL
   Raanani P, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006501.pub2
   Radford J, 2015, NEW ENGL J MED, V372, P1598, DOI 10.1056/NEJMoa1408648
   Raje N, 2016, CLIN CANCER RES, V22, P1378, DOI 10.1158/1078-0432.CCR-15-1864
   Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5
   Reeder CB, 2010, BLOOD, V115, P3416, DOI 10.1182/blood-2010-02-271676
   Renaud L, 2019, CANCER MED-US, V8, P3822, DOI 10.1002/cam4.2253
   SANDHU S, 2015, BLOOD, V126, P5294
   SAVAGE KJ, 2012, BLOOD, V120
   Schmitz N, 2010, BLOOD, V116, P3418, DOI 10.1182/blood-2010-02-270785
   Sehn LH, 2020, J CLIN ONCOL, V38, P155, DOI 10.1200/JCO.19.00172
   Skoetz N, 2013, LANCET ONCOL, V14, P943, DOI 10.1016/S1470-2045(13)70341-3
   Stadtmauer EA, 2019, J CLIN ONCOL, V37, P589, DOI 10.1200/JCO.18.00685
   Taplitz RA, 2018, J CLIN ONCOL, V36, P1443, DOI 10.1200/JCO.2017.77.6211
   Ueda M, 2018, BLOOD REV, V32, P106, DOI 10.1016/j.blre.2017.09.003
   Vilar-Compte D, 2018, J MED VIROL, V90, P50, DOI 10.1002/jmv.24930
   Viviani S, 2011, NEW ENGL J MED, V365, P203, DOI 10.1056/NEJMoa1100340
   von Tresckow B, 2012, J CLIN ONCOL, V30, P907, DOI 10.1200/JCO.2011.38.5807
   Weinkove R, 2020, MED J AUSTRALIA, V212, P481, DOI 10.5694/mja2.50607
   Willan J, 2020, BRIT J HAEMATOL, V189, P241, DOI 10.1111/bjh.16620
   Wingard John R, 2008, J Natl Compr Canc Netw, V6, P215
   Yahalom J, 2020, BLOOD, V135, P1829, DOI 10.1182/blood.2020006028
   Younes A, 2012, J CLIN ONCOL, V30, P2183, DOI 10.1200/JCO.2011.38.0410
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 87
TC 7
Z9 8
U1 2
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1444-0903
EI 1445-5994
J9 INTERN MED J
JI Intern. Med. J.
PD JUN
PY 2020
VL 50
IS 6
BP 667
EP 679
DI 10.1111/imj.14859
EA MAY 2020
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA LX6ZT
UT WOS:000532863700001
PM 32415723
OA Bronze
DA 2021-01-01
ER

PT J
AU Barra, S
   Guarnieri, A
   Bastia, MBDE
   Marcenaro, M
   Tornari, E
   Belgioia, L
   Magrini, SM
   Ricardi, U
   Corvo, R
AF Barra, Salvina
   Guarnieri, Alessia
   di Monale e Bastia, Michela Buglione
   Marcenaro, Michela
   Tornari, Elena
   Belgioia, Liliana
   Magrini, Stefano Maria
   Ricardi, Umberto
   Corvo, Renzo
TI Short fractionation radiotherapy for early prostate cancer in the time
   of COVID-19: long-term excellent outcomes from a multicenter Italian
   trial suggest a larger adoption in clinical practice
SO RADIOLOGIA MEDICA
LA English
DT Article; Early Access
DE COVID-19; SBRT; Prostate cancer; Hi-tech; Hypofractionated radiotherapy
ID STEREOTACTIC RADIOTHERAPY; RADIATION-THERAPY; TOXICITY
AB Introduction To evaluate stereotactic body radiotherapy (SBRT) in low-risk Prostate Cancer patients as preferred treatment option in emergency health conditions. Materials and methods From April 2013 to September 2015, 28 patients with low-risk prostate cancer were prospectively enrolled. The SBRT prescribed dose was 36.25 Gy in 5 fractions, twice a week. Primary endpoints were acute and late toxicity. Secondary endpoints were biochemical recurrence free survival (bRFS) and overall survival. Results Median follow-up was 65.5 months (range 52-81). No acute G3 or G4 toxicity was recorded. Acute G1 or G2 genitourinary (GU) toxicity occurred in 43% and acute G1-G2 gastrointestinal (GI) toxicity in 14%. Late G1 and G3 GU toxicity in 18% and 3.5%, respectively. The G3 toxicity was not directly attributable to radiotherapy. Late G1 GI toxicity occurred in 18%. 5yy bRFS was 96.5% (95% CI 82.3-99.4%). Conclusions Stereotactic body radiotherapy for early prostate cancer reported safe toxicity profile and a good clinical outcome at the median follow-up of 5 years. It may be an useful option if radiotherapy is required in emergency medical conditions.
C1 [Barra, Salvina; Marcenaro, Michela; Belgioia, Liliana; Corvo, Renzo] IRCCS Osped Policlin San Martino, Radiat Oncol Dept, Genoa, Italy.
   [Guarnieri, Alessia; Ricardi, Umberto] Univ Turin, Radiat Oncol Dept, AO Citta Salute & Sci Molinette, Turin, Italy.
   [di Monale e Bastia, Michela Buglione; Magrini, Stefano Maria] Univ & Spedali Civili Brescia, Radiat Oncol Dept, Brescia, Italy.
   [Tornari, Elena; Belgioia, Liliana; Corvo, Renzo] Univ Genoa, Hlth Sci Dept DISSAL, Genoa, Italy.
RP Belgioia, L (corresponding author), IRCCS Osped Policlin San Martino, Radiat Oncol Dept, Genoa, Italy.; Belgioia, L (corresponding author), Univ Genoa, Hlth Sci Dept DISSAL, Genoa, Italy.
EM liliana.belgioia@unige.it
RI Magrini, Stefano Maria/ABE-8820-2020
OI Magrini, Stefano Maria/0000-0002-4126-733X
CR Achard V, 2020, INT J RADIAT ONCOL, V107, P600, DOI 10.1016/j.ijrobp.2020.03.008
   Barra S, 2018, CANCER MANAG RES, V10, P473, DOI 10.2147/CMAR.S146131
   Bellavita R, 2016, TUMORI J, V102, P209, DOI 10.5301/tj.5000433
   Brand DH, 2019, LANCET ONCOL, V20, P1531, DOI 10.1016/S1470-2045(19)30569-8
   Buglione M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224151
   Coles CE, 2020, CLIN ONCOL-UK, V32, P279, DOI 10.1016/j.clon.2020.03.006
   Corvo R, 2013, TUMORI J, V99, P159, DOI 10.1700/1283.14186
   De Felice F, 2014, ANTICANCER RES, V34, P3747
   Detti B, 2015, WORLD J UROL, V33, P1197, DOI 10.1007/s00345-014-1427-x
   Ferlay J, 2018, EUR J CANCER, V103, P356, DOI 10.1016/j.ejca.2018.07.005
   Filippi AR, 2020, INT J RAD BIOL BIOL, DOI [10.1016/j.ijrobp.2020.03.007, DOI 10.1016/J.IJR0BP.2020.03.007]
   Grossman DC, 2018, JAMA-J AM MED ASSOC, V319, P1901, DOI 10.1001/jama.2018.3710
   Jackson WC, 2019, INT J RADIAT ONCOL, V104, P778, DOI 10.1016/j.ijrobp.2019.03.051
   Marvaso G, 2019, INT J RADIAT ONCOL, V105, P735, DOI 10.1016/j.ijrobp.2019.07.027
   Michalski JM, 2013, INT J RADIAT ONCOL, V87, P932, DOI 10.1016/j.ijrobp.2013.07.041
   Mohler JL, 2020, PROSTATE CANC, V167, P479
   Nicosia L, 2019, J CANCER RES CLIN, V145, P2547, DOI 10.1007/s00432-019-02983-3
   Pontoriero A, 2016, TECHNOL CANCER RES T, V15, P179, DOI 10.1177/1533034614566994
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Simcock R, 2020, CLIN TRANSL RAD ONCO, V22, P55, DOI 10.1016/j.ctro.2020.03.009
   Widmark A, 2019, LANCET, V394, P385, DOI 10.1016/S0140-6736(19)31131-6
   Yu T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154499
NR 22
TC 3
Z9 3
U1 1
U2 1
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 0033-8362
EI 1826-6983
J9 RADIOL MED
JI Radiol. Med.
DI 10.1007/s11547-020-01216-9
EA MAY 2020
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA LN6TU
UT WOS:000533068000006
PM 32415472
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Cure, E
   Kucuk, A
   Cure, MC
AF Cure, Erkan
   Kucuk, Adem
   Cumhur Cure, Medine
TI Cyclosporine therapy in cytokine storm due to coronavirus disease 2019
   (COVID-19)
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Letter
ID REPLICATION
C1 [Cure, Erkan] Ota&Jinemed Hosp, Dept Internal Med, Muradiye Mahallesi Nuzhetiye Cad, TR-34357 Istanbul, Turkey.
   [Kucuk, Adem] Necmettin Erbakan Univ, Dept Rheumatol, Meram Tip Fac, Konya, Turkey.
   [Cumhur Cure, Medine] Dept Biochem, Istanbul, Turkey.
RP Cure, E (corresponding author), Ota&Jinemed Hosp, Dept Internal Med, Muradiye Mahallesi Nuzhetiye Cad, TR-34357 Istanbul, Turkey.
EM erkancure@yahoo.com; drademk@gmail.com; medinecure@yahoo.com
RI cure, erkan/W-4922-2017
OI cure, erkan/0000-0001-7807-135X; Kucuk, Adem/0000-0001-8028-1671
CR Akool ES, 2012, BIOCHEM PHARMACOL, V83, P286, DOI 10.1016/j.bcp.2011.11.001
   Behrens EM, 2017, ARTHRITIS RHEUMATOL, V69, P1135, DOI 10.1002/art.40071
   Campana C, 1996, CLIN PHARMACOKINET, V30, P141, DOI 10.2165/00003088-199630020-00004
   Carbajo-Lozoya J, 2014, VIRUS RES, V184, P44, DOI 10.1016/j.virusres.2014.02.010
   Chighizola CB, 2017, CLIN REV ALLERG IMMU, V52, P401, DOI 10.1007/s12016-016-8582-3
   Cure E, 2020, DIABETES METAB SYND, V14, P405, DOI 10.1016/j.dsx.2020.04.024
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   Dixon DB, 1996, VISION RES, V36, P3925, DOI 10.1016/S0042-6989(96)00129-0
   Elgebaly Salwa A., 2017, JOURNAL OF THE EGYPTIAN SOCIETY OF PARASITOLOGY, V47, P25
   Epting T, 2006, PEDIATR NEPHROL, V21, P939, DOI 10.1007/s00467-006-0097-3
   Forsse A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40245-x
   Georgiev T, 2020, RHEUMATOL INT, V40, P825, DOI 10.1007/s00296-020-04570-z
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Palau V, 2020, NEPHROL DIAL TRANSPL, V35, P1071, DOI 10.1093/ndt/gfaa093
   Perico Luca, 2020, Nephron, V144, P213, DOI 10.1159/000507305
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Song J, 2020, RHEUMATOL INT, V40, P991, DOI 10.1007/s00296-020-04584-7
NR 17
TC 5
Z9 5
U1 0
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0172-8172
EI 1437-160X
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD JUL
PY 2020
VL 40
IS 7
BP 1177
EP 1179
DI 10.1007/s00296-020-04603-7
EA MAY 2020
PG 3
WC Rheumatology
SC Rheumatology
GA LS8OA
UT WOS:000533073200001
PM 32415310
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sia, SF
   Yan, LM
   Chin, AWH
   Fung, K
   Choy, KT
   Wong, AYL
   Kaewpreedee, P
   Perera, RAPM
   Poon, LLM
   Nicholls, JM
   Peiris, M
   Yen, HL
AF Sia, Sin Fun
   Yan, Li-Meng
   Chin, Alex W. H.
   Fung, Kevin
   Choy, Ka-Tim
   Wong, Alvina Y. L.
   Kaewpreedee, Prathanporn
   Perera, Ranawaka A. P. M.
   Poon, Leo L. M.
   Nicholls, John M.
   Peiris, Malik
   Yen, Hui-Ling
TI Pathogenesis and transmission of SARS-CoV-2 in golden hamsters
SO NATURE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; SYNDROME CORONAVIRUS INFECTION;
   SARS-CORONAVIRUS; MICE; RECEPTOR; MODELS
AB The pathogenicity and transmissibility of SARS-CoV-2 in golden (Syrian) hamsters resemble features of COVID-19 in human patients, suggesting that these hamsters could be used to model this disease.
   Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus with high nucleotide identity to SARS-CoV and to SARS-related coronaviruses that have been detected in horseshoe bats, has spread across the world and had a global effect on healthcare systems and economies(1,2). A suitable small animal model is needed to support the development of vaccines and therapies. Here we report the pathogenesis and transmissibility of SARS-CoV-2 in golden (Syrian) hamsters (Mesocricetus auratus). Immunohistochemistry assay demonstrated the presence of viral antigens in nasal mucosa, bronchial epithelial cells and areas of lung consolidation on days 2 and 5 after inoculation with SARS-CoV-2, followed by rapid viral clearance and pneumocyte hyperplasia at 7 days after inoculation. We also found viral antigens in epithelial cells of the duodenum, and detected viral RNA in faeces. Notably, SARS-CoV-2 was transmitted efficiently from inoculated hamsters to naive hamsters by direct contact and via aerosols. Transmission via fomites in soiled cages was not as efficient. Although viral RNA was continuously detected in the nasal washes of inoculated hamsters for 14 days, the communicable period was short and correlated with the detection of infectious virus but not viral RNA. Inoculated and naturally infected hamsters showed apparent weight loss on days 6-7 post-inoculation or post-contact; all hamsters returned to their original weight within 14 days and developed neutralizing antibodies. Our results suggest that features associated with SARS-CoV-2 infection in golden hamsters resemble those found in humans with mild SARS-CoV-2 infections.
C1 [Sia, Sin Fun; Yan, Li-Meng; Chin, Alex W. H.; Choy, Ka-Tim; Wong, Alvina Y. L.; Kaewpreedee, Prathanporn; Perera, Ranawaka A. P. M.; Poon, Leo L. M.; Peiris, Malik; Yen, Hui-Ling] Univ Hong Kong, Sch Publ Hlth, Li Ka Shing Fac Med, Hong Kong, Peoples R China.
   [Fung, Kevin; Nicholls, John M.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Peoples R China.
RP Yen, HL (corresponding author), Univ Hong Kong, Sch Publ Hlth, Li Ka Shing Fac Med, Hong Kong, Peoples R China.
EM hyen@hku.hk
RI Yen, Hui-Ling/C-4501-2009; Poon, Leo/AAP-6887-2020; Dr, Ranawaka A.P.M
   Perera -/N-8263-2015
OI Yen, Hui-Ling/0000-0003-2493-3609; Dr, Ranawaka A.P.M Perera
   -/0000-0003-3936-1535; Kaewpreedee, Prathanporn/0000-0002-0464-2401
FU Croucher Foundation; National Institute of Allergy and Infectious
   Diseases of the National Institutes of Health (USA)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [HHSN272201400006C]; Research Grants Council (Hong Kong SAR, China)Hong
   Kong Research Grants Council [T11-705/14N]
FX We thank N. Ip for comments on the interpretation of nasal mucosal data;
   D. Rowlands, C. Y. H. Leung and J. Rudds for comments on hamster
   handling; and the Laboratory Animal Unit (University of Hong Kong) and
   Laboratory Animal Services Centre (Chinese University of Hong Kong) for
   animal husbandry support. L.L.M.P. was supported by Croucher Foundation.
   This study was supported by contract HHSN272201400006C from the National
   Institute of Allergy and Infectious Diseases of the National Institutes
   of Health (USA) and the theme-based research scheme (T11-705/14N) from
   the Research Grants Council (Hong Kong SAR, China).
CR ALI MJ, 1982, ARCH VIROL, V72, P187, DOI 10.1007/BF01348964
   Baas T, 2008, J VIROL, V82, P9465, DOI 10.1128/JVI.00489-08
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Belser JA, 2013, FUTURE MICROBIOL, V8, P961, DOI [10.2217/FMB.13.64, 10.2217/fmb.13.64]
   BUTHALA DA, 1964, J INFECT DIS, V114, P226, DOI 10.1093/infdis/114.3.226
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   de Wit E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069127
   Glass WG, 2004, J IMMUNOL, V173, P4030, DOI 10.4049/jimmunol.173.6.4030
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Hogan RJ, 2004, J VIROL, V78, P11416, DOI 10.1128/JVI.78.20.11416-11421.2004
   Iwatsuki-Horimoto K, 2018, J VIROL, V92, DOI 10.1128/JVI.01693-17
   Jones RM, 2015, J OCCUP ENVIRON MED, V57, P501, DOI 10.1097/JOM.0000000000000448
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI 10.1053/S0016-5085(03)01215-0
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   MacPhail M, 2004, J GEN VIROL, V85, P1655, DOI 10.1099/vir.0.79805-0
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Miao JX, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02329
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Nicholls JM, 2006, PLOS MED, V3, P222, DOI 10.1371/journal.pmed.0030027
   Nishiura H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055358
   Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005
   Roberts A, 2005, J VIROL, V79, P5833, DOI 10.1128/JVI.79.9.5833-5838.2005
   Roberts A, 2008, VIRUS RES, V133, P20, DOI 10.1016/j.virusres.2007.03.025
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Tseng CTK, 2007, J VIROL, V81, P1162, DOI 10.1128/JVI.01702-06
   Warner BM, 2017, ADV EXP MED BIOL, V972, P87, DOI 10.1007/5584_2016_135
   World Health Organization, 2020, COR DIS COVID 2019 S
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zivcec M, 2011, J IMMUNOL METHODS, V368, P24, DOI 10.1016/j.jim.2011.02.004
NR 37
TC 82
Z9 80
U1 15
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUL 30
PY 2020
VL 583
IS 7818
BP 834
EP +
DI 10.1038/s41586-020-2342-5
EA MAY 2020
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MT2XH
UT WOS:000551400700001
PM 32408338
OA Green Accepted, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Bojkova, D
   Klann, K
   Koch, B
   Widera, M
   Krause, D
   Ciesek, S
   Cinatl, J
   Munch, C
AF Bojkova, Denisa
   Klann, Kevin
   Koch, Benjamin
   Widera, Marek
   Krause, David
   Ciesek, Sandra
   Cinatl, Jindrich
   Muench, Christian
TI Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
SO NATURE
LA English
DT Article
ID NUCLEOCAPSID PROTEIN; CORONAVIRUS; RIBAVIRIN; INTERACTOME; SARS;
   REPLICATION; CYTOSCAPE
AB A new coronavirus was recently discovered and named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infection with SARS-CoV-2 in humans causes coronavirus disease 2019 (COVID-19) and has been rapidly spreading around the globe(1,2). SARS-CoV-2 shows some similarities to other coronaviruses; however, treatment options and an understanding of how SARS-CoV-2 infects cells are lacking. Here we identify the host cell pathways that are modulated by SARS-CoV-2 and show that inhibition of these pathways prevents viral replication in human cells. We established a human cell-culture model for infection with a clinical isolate of SARS-CoV-2. Using this cell-culture system, we determined the infection profile of SARS-CoV-2 by translatome(3)and proteome proteomics at different times after infection. These analyses revealed that SARS-CoV-2 reshapes central cellular pathways such as translation, splicing, carbon metabolism, protein homeostasis (proteostasis) and nucleic acid metabolism. Small-molecule inhibitors that target these pathways prevented viral replication in cells. Our results reveal the cellular infection profile of SARS-CoV-2 and have enabled the identification of drugs that inhibit viral replication. We anticipate that our results will guide efforts to understand the molecular mechanisms that underlie the modulation of host cells after infection with SARS-CoV-2. Furthermore, our findings provide insights for the development of therapies for the treatment of COVID-19.
   SARS-CoV-2 modulates central cellular pathways, such as translation, splicing, carbon metabolism, proteostasis and nucleic acid metabolism, in human cells; these pathways can be inhibited by small-molecule inhibitors to prevent viral replication in the cells.
C1 [Bojkova, Denisa; Widera, Marek; Ciesek, Sandra; Cinatl, Jindrich] Goethe Univ, Univ Hosp Frankfurt, Inst Med Virol, Frankfurt, Germany.
   [Klann, Kevin; Krause, David; Muench, Christian] Goethe Univ, Fac Med, Inst Biochem 2, Frankfurt, Germany.
   [Koch, Benjamin] Univ Hosp Frankfurt, Med Clin 3, Nephrol, Frankfurt, Germany.
   [Ciesek, Sandra] German Ctr Infect Res DZIF, External Partner Site Frankfurt, Frankfurt, Germany.
   [Muench, Christian] Frankfurt Canc Inst, Frankfurt, Germany.
   [Muench, Christian] Cardiopulm Inst, Frankfurt, Germany.
RP Cinatl, J (corresponding author), Goethe Univ, Univ Hosp Frankfurt, Inst Med Virol, Frankfurt, Germany.; Munch, C (corresponding author), Goethe Univ, Fac Med, Inst Biochem 2, Frankfurt, Germany.; Munch, C (corresponding author), Frankfurt Canc Inst, Frankfurt, Germany.; Munch, C (corresponding author), Cardiopulm Inst, Frankfurt, Germany.
EM cinatl@em.uni-frankfurt.de; ch.muench@em.uni-frankfurt.de
RI Munch, Christian/AAW-7256-2020
OI Widera, Marek/0000-0001-5417-9307; Munch, Christian/0000-0003-3832-090X;
   Klann, Kevin/0000-0003-2276-8128; Koch, Benjamin/0000-0002-3253-8396
FU Hilfe fur krebskranke Kinder Frankfurt; Frankfurter Stiftung fur
   krebskranke Kinder; European Research Council under the European
   UnionEuropean Research Council (ERC) [ERC StG 803565, CRC 1177]; Emmy
   Noether Programme of the Deutsche Forschungsgemeinschaft (DFG)German
   Research Foundation (DFG) [MU 4216/1-1]; Johanna Quandt Young Academy at
   Goethe; Aventis Foundation Bridge Award
FX We thank C. Pallas and L. Stegmann for experimental support and G.
   Tascher and M. Adrian-Allgood for proteomics support. J.C. acknowledges
   funding by the Hilfe fur krebskranke Kinder Frankfurt and the
   Frankfurter Stiftung fur krebskranke Kinder. C.M. was supported by the
   European Research Council under the European Union's Seventh Framework
   Programme (ERC StG 803565), CRC 1177 and the Emmy Noether Programme of
   the Deutsche Forschungsgemeinschaft (DFG, MU 4216/1-1), the Johanna
   Quandt Young Academy at Goethe and an Aventis Foundation Bridge Award.
CR Chen JY, 2009, ARCH VIROL, V154, P507, DOI 10.1007/s00705-009-0323-y
   Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cretu C, 2018, MOL CELL, V70, P265, DOI 10.1016/j.molcel.2018.03.011
   Emmott E, 2013, J VIROL, V87, P9486, DOI 10.1128/JVI.00321-13
   Gualdoni GA, 2018, P NATL ACAD SCI USA, V115, pE7158, DOI 10.1073/pnas.1800525115
   Hoehl S, 2020, NEW ENGL J MED, V382, P1278, DOI 10.1056/NEJMc2001899
   Jia HP, 2009, AM J PHYSIOL-LUNG C, V297, pL84, DOI 10.1152/ajplung.00071.2009
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Jourdan SS, 2012, PROTEOMICS, V12, P1015, DOI 10.1002/pmic.201100469
   Kamitani W, 2009, NAT STRUCT MOL BIOL, V16, P1134, DOI 10.1038/nsmb.1680
   Klann K, 2020, MOL CELL, V77, P913, DOI 10.1016/j.molcel.2019.11.010
   Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551
   Marcelin JR, 2014, TRANSPL INFECT DIS, V16, P242, DOI 10.1111/tid.12194
   Martin P, 2008, J GASTROEN HEPATOL, V23, P844, DOI 10.1111/j.1440-1746.2008.05398.x
   McKinney W, 2010, P 9 PYTH SCI C, V9, P51, DOI DOI 10.1016/S0168-0102(02)00204-3
   Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984
   Narayananj K, 2008, J VIROL, V82, P4471, DOI 10.1128/JVI.02472-07
   Neuman BW, 2008, J VIROL, V82, P5279, DOI 10.1128/JVI.02631-07
   Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Plubell DL, 2017, MOL CELL PROTEOMICS, V16, P873, DOI 10.1074/mcp.M116.065524
   Pruijssers AJ, 2019, CURR OPIN VIROL, V35, P57, DOI 10.1016/j.coviro.2019.04.002
   Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25
   Saijo M, 2005, ANTIVIR RES, V66, P159, DOI 10.1016/j.antiviral.2005.01.003
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   She J, 2020, CLIN TRANSL MED, V9, DOI 10.1186/s40169-020-00271-z
   Shen L, 2019, J VIROL, V93, DOI 10.1128/JVI.00023-19
   Song T, 2016, J PROTEOMICS, V142, P70, DOI 10.1016/j.jprot.2016.05.009
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/nmeth.3901, 10.1038/NMETH.3901]
   van der Walt S, 2011, COMPUT SCI ENG, V13, P22, DOI 10.1109/MCSE.2011.37
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wong HH, 2015, J VIROL, V89, P11116, DOI 10.1128/JVI.01360-15
   Wu GM, 2017, METHODS MOL BIOL, V1558, P235, DOI 10.1007/978-1-4939-6783-4_11
   Wu LS, 2015, ANTIMICROB AGENTS CH, V59, P2179, DOI 10.1128/AAC.04618-14
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Yan BP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010073
   Ye YH, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00039
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhang JT, 2019, EUR J PHARM SCI, V133, P86, DOI 10.1016/j.ejps.2019.03.020
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 43
TC 69
Z9 69
U1 13
U2 30
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUL 16
PY 2020
VL 583
IS 7816
BP 469
EP +
DI 10.1038/s41586-020-2332-7
EA MAY 2020
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MK4AA
UT WOS:000546554300001
PM 32408336
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Yu, Y
   Xu, D
   Fu, SZ
   Zhang, J
   Yang, XB
   Xu, L
   Xu, JQ
   Wu, YR
   Huang, CL
   Ouyang, YQ
   Yang, LY
   Fang, MH
   Xiao, HW
   Ma, J
   Zhu, W
   Hu, S
   Hu, Q
   Ding, DY
   Hu, M
   Zhu, GC
   Xu, WJ
   Guo, J
   Xu, JL
   Yuan, HT
   Zhang, B
   Yu, Z
   Chen, DC
   Yuan, SY
   Shang, Y
AF Yu, Yuan
   Xu, Dan
   Fu, Shouzhi
   Zhang, Jun
   Yang, Xiaobo
   Xu, Liang
   Xu, Jiqian
   Wu, Yongran
   Huang, Chaolin
   Ouyang, Yaqi
   Yang, Luyu
   Fang, Minghao
   Xiao, Hongwen
   Ma, Jing
   Zhu, Wei
   Hu, Song
   Hu, Quan
   Ding, Daoyin
   Hu, Ming
   Zhu, Guochao
   Xu, Weijiang
   Guo, Jun
   Xu, Jinglong
   Yuan, Haitao
   Zhang, Bin
   Yu, Zhui
   Chen, Dechang
   Yuan, Shiying
   Shang, You
TI Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional
   study
SO CRITICAL CARE
LA English
DT Article
DE COVID-19; Critically ill patients; Complications; Epidemic
ID RESPIRATORY-DISTRESS-SYNDROME
AB Background A COVID-19 outbreak started in Wuhan, China, last December and now has become a global pandemic. The clinical information in caring of critically ill patients with COVID-19 needs to be shared timely, especially under the situations that there is still a largely ongoing spread of COVID-19 in many countries. Methods A multicenter prospective observational study investigated all the COVID-19 patients received in 19 ICUs of 16 hospitals in Wuhan, China, over 24 h between 8 AM February 2h and 8 AM February 27, 2020. The demographic information, clinical characteristics, vital signs, complications, laboratory values, and clinical managements of the patients were studied. Results A total of 226 patients were included. Their median (interquartile range, IQR) age was 64 (57-70) years, and 139 (61.5%) patients were male. The duration from the date of ICU admission to the study date was 11 (5-17) days, and the duration from onset of symptoms to the study date was 31 (24-36) days. Among all the patients, 155 (68.6%) had at least one coexisting disease, and their sequential organ failure assessment score was 4 (2-8). Organ function damages were found in most of the patients: ARDS in 161 (71.2%) patients, septic shock in 34 (15.0%) patients, acute kidney injury occurred in 57 (25.2%) patients, cardiac injury in 61 (27.0%) patients, and lymphocytopenia in 160 (70.8%) patients. Of all the studied patients, 85 (37.6%) received invasive mechanical ventilation, including 14 (6.2%) treated with extracorporeal membrane oxygenation (ECMO) at the same time, 20 (8.8%) received noninvasive mechanical ventilation, and 24 (10.6%) received continuous renal replacement therapy. By April 9, 2020, 87 (38.5%) patients were deceased and 15 (6.7%) were still in the hospital. Conclusions Critically ill patients with COVID-19 are associated with a higher risk of severe complications and need to receive an intensive level of treatments. COVID-19 poses a great strain on critical care resources in hospitals.
C1 [Yu, Yuan; Xu, Dan; Yang, Xiaobo; Xu, Jiqian; Wu, Yongran; Ouyang, Yaqi; Yuan, Shiying; Shang, You] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Crit Care Med, Wuhan, Peoples R China.
   [Fu, Shouzhi; Yang, Luyu] Wuhan Third Hosp, Dept Intens Care Unit, Wuhan, Peoples R China.
   [Zhang, Jun] Wuhan Hosp Tradit Chinese Med, Dept Crit Care Med, Wuhan, Peoples R China.
   [Xu, Liang] Wuhan Wuchang Hosp, Dept Crit Care Med, Wuhan, Peoples R China.
   [Huang, Chaolin] Jinyintan Hosp, Wuhan, Peoples R China.
   [Fang, Minghao] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Emergency Internal Med, Wuhan, Peoples R China.
   [Xiao, Hongwen] Xiehe Wuhan Red Cross Hosp, Intens Care Unit, Wuhan, Peoples R China.
   [Ma, Jing] Huazhong Univ Sci & Technol, Dept Intens Care Unit, Liyuan Hosp, Tongji Med Coll, Wuhan, Peoples R China.
   [Zhu, Wei] Wuhan Univ Sci & Technol, Intens Care Unit, Tianyou Hosp, Wuhan, Peoples R China.
   [Hu, Song] Fifth Hosp Wuhan, Intens Care Unit, Wuhan, Peoples R China.
   [Hu, Quan; Ding, Daoyin] First Peoples Hosp Jiangxia Dist, Intens Care Unit, Wuhan, Peoples R China.
   [Hu, Ming] Wuhan Pulm Hosp, Dept Crit Care Med, Wuhan, Peoples R China.
   [Zhu, Guochao] Jianghan Univ, Dept Crit Care Med, Affiliated Hosp, Wuhan, Peoples R China.
   [Xu, Weijiang] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Dept Crit Care Med, Wuhan, Peoples R China.
   [Guo, Jun; Xu, Jinglong] Huazhong Univ Sci & Technol, Union Jiangbei Hosp, Intens Care Unit, Wuhan, Peoples R China.
   [Yuan, Haitao] Dongxi Lake Dist Peoples Hosp, Intens Care Unit, Wuhan, Peoples R China.
   [Zhang, Bin] Three Gorges Univ, Dept Intens Care Unit, Second Peoples Hosp, Yichang, Peoples R China.
   [Yu, Zhui] Wuhan Univ, Dept Crit Care Med, Renmin Hosp, Wuhan, Peoples R China.
   [Chen, Dechang] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Crit Care Med, Sch Med, Shanghai, Peoples R China.
RP Yuan, SY; Shang, Y (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Crit Care Med, Wuhan, Peoples R China.; Yu, Z (corresponding author), Wuhan Univ, Dept Crit Care Med, Renmin Hosp, Wuhan, Peoples R China.; Chen, DC (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Crit Care Med, Sch Med, Shanghai, Peoples R China.
EM yuzhui@whu.edu.cn; icudechangchen@163.com; yuan_shiying@163.com;
   you_shanghust@163.com
CR Adrie C, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0242-0
   [Anonymous], 2020, MARCH 16 DAILY BRIEF
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Fowler RA, 2003, JAMA-J AM MED ASSOC, V290, P367, DOI 10.1001/jama.290.3.367
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Ji YP, 2020, LANCET GLOB HEALTH, V8, pE480, DOI 10.1016/S2214-109X(20)30068-1
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   Laffey JG, 2017, LANCET RESP MED, V5, P627, DOI [10.1016/S2213-2600(17)30213-8, 10.1016/s2213-2600(17)30213-8]
   Li Z, 2020, MEDRXIV, DOI [10.1101/2020.02.08.20021212, DOI 10.1101/2020.02.08.20021212]
   Liu L, 2018, J THORAC DIS, V10, P5394, DOI 10.21037/jtd.2018.08.137
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   McNicholas BA, 2018, CURR OPIN CRIT CARE, V24, P41, DOI 10.1097/MCC.0000000000000473
   National Health Commission of the People's Republic of China, FEB 27 DAIL BRIEF NO
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   See KC, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2105-y
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Vahedi HSM, 2019, ARCH ACAD EMERG MED, V7
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 55 WHO
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 27
TC 12
Z9 12
U1 5
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD MAY 14
PY 2020
VL 24
IS 1
AR 219
DI 10.1186/s13054-020-02939-x
PG 10
WC Critical Care Medicine
SC General & Internal Medicine
GA LS2SK
UT WOS:000536239000001
PM 32410714
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zeng, Y
   Zhang, B
   Zhang, XF
   Yi, CJ
AF Zeng, Yong
   Zhang, Bo
   Zhang, Xufeng
   Yi, Cunjian
TI Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection
SO CHINESE MEDICINE
LA English
DT Article
DE Cancer; SARS-CoV-2; Clinical characteristics; Outcomes
AB In December 2019, a cluster of pneumonia cases was caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China. Cancer patients are a special group, the immunity of them will be suppressed because of various anti-tumor treatments, and the risk of infection will be greatly increased, so we will report clinical features of 9 cancer patients with SARS-CoV-2 infection. 5 (56%) patients were ordinary type, 3 (33%) were severe type, and 1 (11%) was critical type. A total of 8 patients received combined therapy of traditional Chinese medicines and western medicines. From the clinical outcomes of these 8 patients, western combined therapy of traditional Chinese medicine was indeed an effective treatment method. D-dimmer rise, infection index rise, and chest CT(computed tomography) progression may be clinical warning indicators for severe patients, in our study, more 50% of patients had elevated levels of these indicators, but only 44% (including the dead) of patients had received treatment in the intensive care unit. 5 (56%) ordinary type patients had been discharged, while the 1 (11%) critical type patient died 3 days after admission. Cancer comorbidity seems to have no direct relationship with severe events, and the combination of traditional Chinese medicine and western medicine may be effective in the prevention and treatment of novel coronavirus-infected pneumonia (NICP).
C1 [Zeng, Yong; Zhang, Xufeng; Yi, Cunjian] Yangtze Univ Jingzhou, Peoples Hosp 1, 8 Hangkong Rd, Jingzhou, Hubei, Peoples R China.
   [Zhang, Bo] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China.
RP Yi, CJ (corresponding author), Yangtze Univ Jingzhou, Peoples Hosp 1, 8 Hangkong Rd, Jingzhou, Hubei, Peoples R China.
EM cunjiany@163.com
FU Key project of hubei provincial health commission [WJ2017Z024]; Hubei
   provincial health commission medical college special [WJ2018H175]
FX 1. Key project of hubei provincial health commission (WJ2017Z024), 2.
   Hubei provincial health commission medical college special (WJ2018H175)
CR Kamboj M, 2009, LANCET ONCOL, V10, P589, DOI 10.1016/S1470-2045(09)70069-5
   Li JY, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/286170
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Longbottom ER, 2016, ANN SURG, V264, P370, DOI 10.1097/SLA.0000000000001484
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Sica A, 2017, J AUTOIMMUN, V85, P117, DOI 10.1016/j.jaut.2017.07.010
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   World Health Organization, 2019, NOV COR 2019 NCOV
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
NR 12
TC 3
Z9 3
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749-8546
J9 CHIN MED-UK
JI Chin. Med.
PD MAY 14
PY 2020
VL 15
IS 1
AR 47
DI 10.1186/s13020-020-00328-8
PG 3
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA LS0RC
UT WOS:000536100200001
PM 32435272
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gyebi, GA
   Ogunro, OB
   Adegunloye, AP
   Ogunyemi, OM
   Afolabi, SO
AF Gyebi, Gideon A.
   Ogunro, Olalekan B.
   Adegunloye, Adegbenro P.
   Ogunyemi, Oludare M.
   Afolabi, Saheed O.
TI Potential inhibitors of coronavirus 3-chymotrypsin-like protease
   (3CL(pro)): an in silico screening of alkaloids and terpenoids from
   African medicinal plants
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; coronavirus 3CLpro; natural product; molecular
   docking
ID COV 3CL PROTEASE; MAIN PROTEASE; PROTEINASE; PNEUMONIA; DISCOVERY;
   DESIGN; UPDATE; DRUGS
AB The novel coronavirus disease 2019 (COVID-19) caused by SARS-COV-2 has raised myriad of global concerns. There is currently no FDA approved antiviral strategy to alleviate the disease burden. The conserved 3-chymotrypsin-like protease (3CL(pro)), which controls coronavirus replication is a promising drug target for combating the coronavirus infection. This study screens some African plants derived alkaloids and terpenoids as potential inhibitors of coronavirus 3CL(pro) using in silico approach. Bioactive alkaloids (62) and terpenoids (100) of plants native to Africa were docked to the 3CL(pro) of the novel SARS-CoV-2. The top twenty alkaloids and terpenoids with high binding affinities to the SARS-CoV-2 3CL(pro) were further docked to the 3CL(pro) of SARS-CoV and MERS-CoV. The docking scores were compared with 3CL(pro)-referenced inhibitors (Lopinavir and Ritonavir). The top docked compounds were further subjected to ADEM/Tox and Lipinski filtering analyses for drug-likeness prediction analysis. This ligand-protein interaction study revealed that more than half of the top twenty alkaloids and terpenoids interacted favourably with the coronaviruses 3CL(pro), and had binding affinities that surpassed that of lopinavir and ritonavir. Also, a highly defined hit-list of seven compounds (10-Hydroxyusambarensine, Cryptoquindoline, 6-Oxoisoiguesterin, 22-Hydroxyhopan-3-one, Cryptospirolepine, Isoiguesterin and 20-Epibryonolic acid) were identified. Furthermore, four non-toxic, druggable plant derived alkaloids (10-Hydroxyusambarensine, and Cryptoquindoline) and terpenoids (6-Oxoisoiguesterin and 22-Hydroxyhopan-3-one), that bind to the receptor-binding site and catalytic dyad of SARS-CoV-2 3CL(pro) were identified from the predictive ADME/tox and Lipinski filter analysis. However, further experimental analyses are required for developing these possible leads into natural anti-COVID-19 therapeutic agents for combating the pandemic. Communicated by Ramaswamy H. Sarma
C1 [Gyebi, Gideon A.; Ogunyemi, Oludare M.] Salem Univ, Dept Biol Sci, Lokoja, Nigeria.
   [Ogunro, Olalekan B.] KolaDaisi Univ, Dept Biol Sci, Ibadan, Nigeria.
   [Adegunloye, Adegbenro P.] Univ Ilorin, Fac Life Sci, Dept Biochem, Ilorin, Nigeria.
   [Afolabi, Saheed O.] Univ Ilorin, Fac Basic Med Sci, Dept Pharmacol & Therapeut, Ilorin, Nigeria.
RP Gyebi, GA (corresponding author), Salem Univ, Dept Biol Sci, Lokoja, Nigeria.
EM gideonagyebi@gmail.com
RI Ogunro, Olalekan Bukunmi/AAR-2453-2020
OI Ogunro, Olalekan Bukunmi/0000-0003-0524-5958; Gyebi,
   Gideon/0000-0002-1945-1739; Ogunyemi, Oludare/0000-0002-9956-3860
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Berry M, 2015, VIRUSES-BASEL, V7, P6642, DOI 10.3390/v7122963
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Cascella M, 2020, FEATURES EVALUATION
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Lessene G, 2013, NAT CHEM BIOL, V9, P390, DOI [10.1038/NCHEMBIO.1246, 10.1038/nchembio.1246]
   Li JY, 2020, MICROBES INFECT, V22, P80, DOI 10.1016/j.micinf.2020.02.002
   Lipinski CA, 2000, J PHARMACOL TOX MET, V44, P235, DOI 10.1016/S1056-8719(00)00107-6
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Ndhlala AR, 2013, ELSEV INSIGHT, P621, DOI 10.1016/B978-0-12-405927-6.00016-3
   Nickel J, 2014, NUCLEIC ACIDS RES, V42, pW26, DOI 10.1093/nar/gku477
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   Onguene PA, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-449
   Osafo N, 2017, ADV PHARMACOL SCI, V2017, DOI 10.1155/2017/3026370
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pelz NF, 2016, J MED CHEM, V59, P2054, DOI 10.1021/acs.jmedchem.5b01660
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Sanchez-Linares I, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S14-S13
   Sang P., 2020, PREPRINT
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Setzer WN, 2001, PLANTA MED, V67, P65, DOI 10.1055/s-2001-10879
   Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Who W.-C J., 2020, REPORT WHO CHINA JOI
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu Z., 2020, NELFINAVIR WAS PREDI, V1, P2
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhao Q, 2008, J VIROL, V82, P8647, DOI 10.1128/JVI.00298-08
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 46
TC 22
Z9 23
U1 4
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1764868
EA MAY 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LQ6AZ
UT WOS:000535083400001
PM 32367767
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Abbott, TR
   Dhamdhere, G
   Liu, YX
   Lin, XQ
   Goudy, L
   Zeng, LP
   Chemparathy, A
   Chmura, S
   Heaton, NS
   Debs, R
   Pande, T
   Endy, D
   La Russa, MF
   Lewis, DB
   Qi, LS
AF Abbott, Timothy R.
   Dhamdhere, Girija
   Liu, Yanxia
   Lin, Xueqiu
   Goudy, Laine
   Zeng, Leiping
   Chemparathy, Augustine
   Chmura, Stephen
   Heaton, Nicholas S.
   Debs, Robert
   Pande, Tara
   Endy, Drew
   La Russa, Marie F.
   Lewis, David B.
   Qi, Lei S.
TI Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and
   Influenza
SO CELL
LA English
DT Article
ID VIRUS-RNA SEGMENTS; VACCINE; PROTEIN; RESERVOIRS; SEQUENCES; DELIVERY;
   ORIGIN; COV
AB The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has highlighted the need for antiviral approaches that can target emerging viruses with no effective vaccines or pharmaceuticals. Here, we demonstrate a CRISPR-Cas13-based strategy, PAC -MAN (prophylactic antiviral CRISPR in human cells), for viral inhibition that can effectively degrade RNA from SARS-CoV-2 sequences and live influenza A virus (IAV) in human lung epithelial cells. We designed and screened CRISPR RNAs (crRNAs) targeting conserved viral regions and identified functional crRNAs targeting SARS-CoV-2. This approach effectively reduced H1 N1 IAV load in respiratory epithelial cells. Our bioinformatic analysis showed that a group of only six crRNAs can target more than 90% of all coronaviruses. With the development of a safe and effective system for respiratory tract delivery, PAC -MAN has the potential to become an important pan-coronavirus inhibition strategy.
C1 [Abbott, Timothy R.; Liu, Yanxia; Lin, Xueqiu; Goudy, Laine; Zeng, Leiping; Endy, Drew; La Russa, Marie F.; Qi, Lei S.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.
   [Dhamdhere, Girija; Lewis, David B.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA.
   [Chemparathy, Augustine] Stanford Univ, Dept Management Sci & Engn, Stanford, CA 94305 USA.
   [Chmura, Stephen; Debs, Robert] DNARx, San Francisco, CA 94107 USA.
   [Heaton, Nicholas S.] Duke Univ, Dept Mol Genet & Microbiol, Sch Med, Durham, NC 27710 USA.
   [Pande, Tara] Los Altos High Sch, Los Altos, CA 94022 USA.
   [Qi, Lei S.] Stanford Univ, Dept Chem & Syst Biol, Stanford, CA 94305 USA.
   [Qi, Lei S.] Stanford Univ, ChEM H, Stanford, CA 94305 USA.
RP La Russa, MF; Qi, LS (corresponding author), Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.; Lewis, DB (corresponding author), Stanford Univ, Dept Pediat, Stanford, CA 94305 USA.; Qi, LS (corresponding author), Stanford Univ, Dept Chem & Syst Biol, Stanford, CA 94305 USA.; Qi, LS (corresponding author), Stanford Univ, ChEM H, Stanford, CA 94305 USA.
EM mlarussa@stanford.edu; dblewis@stanford.edu; stanley.qi@stanford.edu
FU Defense Advanced Research Projects Agency (DARPA)United States
   Department of DefenseDefense Advanced Research Projects Agency (DARPA)
   [HR001119C0060]; Li Ka Shing Foundation
FX The authors thank all members from the Stanley Qi lab and David Lewis
   lab for facilitating experiments and useful discussions. The authors
   thank the researchers who generated and contributed the SARS-CoV-2
   sequence data to GISAID (https://www.gisaid.org/).The authors would also
   like to thank Dr. Elodie Ghedin (NYU) for her advice on targeting
   influenza with Cas13 and insights about influenza replication. The
   project is supported by a contract grant from Defense Advanced Research
   Projects Agency (DARPA) (HR001119C0060). L.S.Q. is also supported by the
   Li Ka Shing Foundation.
CR Amirkhanov RN, 2019, RUSS J BIOORG CHEM+, V45, P431, DOI 10.1134/S1068162019060025
   Bawage SS, 2018, BIORXIV, DOI [10.1101/370460, DOI 10.1101/370460]
   Breen M., 2016, VIRUSES, V8, P1
   Carrat F, 2007, VACCINE, V25, P6852, DOI 10.1016/j.vaccine.2007.07.027
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   DESSELBERGER U, 1980, GENE, V8, P315, DOI 10.1016/0378-1119(80)90007-4
   DIJK J, 1979, NUCLEIC ACIDS RES, V6, P2717, DOI 10.1093/nar/6.8.2717
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Freije CA, 2019, MOL CELL, V76, P826, DOI 10.1016/j.molcel.2019.09.013
   Fujii Y, 2003, P NATL ACAD SCI USA, V100, P2002, DOI 10.1073/pnas.0437772100
   Gerber M, 2014, TRENDS MICROBIOL, V22, P446, DOI 10.1016/j.tim.2014.04.001
   Gootenberg JS, 2018, SCIENCE, V360, P439, DOI 10.1126/science.aaq0179
   Guan S, 2019, NAT NANOTECHNOL, V14, P287, DOI 10.1038/s41565-018-0358-x
   Handumrongkul C, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax0217
   Harding AT, 2017, MBIO, V8, DOI 10.1128/mBio.00669-17
   Heaton BE, 2017, CELL REP, V20, P1503, DOI 10.1016/j.celrep.2017.07.060
   Hendel A, 2015, NAT BIOTECHNOL, V33, P985, DOI 10.1038/nbt.3290
   Huang CY, 1998, CHEM BIOL, V5, P345, DOI 10.1016/S1074-5521(98)90173-9
   Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Konermann S, 2018, CELL, V173, P665, DOI 10.1016/j.cell.2018.02.033
   Krammer F, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0002-y
   Krishnamurthy S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12922-y
   Lakdawala SS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003971
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Letunic I, 2019, NUCLEIC ACIDS RES, V47, pW256, DOI 10.1093/nar/gkz239
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Liu L., 2014, CLIN INFECT DIS, V59, P613, DOI DOI 10.1093/CID/CIU346
   McAuley JL, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00039
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   McKinlay CJ, 2017, P NATL ACAD SCI USA, V114, pE448, DOI 10.1073/pnas.1614193114
   Mehta A, 2020, J PHARM SCI-US, V109, P62, DOI 10.1016/j.xphs.2019.10.003
   Mohd HA, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0544-0
   Muramoto Y, 2006, J VIROL, V80, P2318, DOI 10.1128/JVI.80.5.2318-2325.2006
   Rappuoli R, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4615
   Sago CD, 2018, P NATL ACAD SCI USA, V115, pE9944, DOI 10.1073/pnas.1811276115
   Shaner NC, 2013, NAT METHODS, V10, P407, DOI [10.1038/NMETH.2413, 10.1038/nmeth.2413]
   Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0
   Shi ZL, 2008, VIRUS RES, V133, P74, DOI 10.1016/j.virusres.2007.03.012
   SKEHEL JJ, 1978, NUCLEIC ACIDS RES, V5, P1207, DOI 10.1093/nar/5.4.1207
   Smargon AA, 2017, MOL CELL, V65, P618, DOI 10.1016/j.molcel.2016.12.023
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Wang H, 2019, SCIENCE, V365, P1301, DOI 10.1126/science.aax7852
   Wessels HH, 2020, NAT BIOTECHNOL, V38, P722, DOI 10.1038/s41587-020-0456-9
   Williams GD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02886-w
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Cong-Fei, 2019, Adv Drug Deliv Rev, DOI 10.1016/j.addr.2019.11.005
   Yan WX, 2018, MOL CELL, V70, P327, DOI 10.1016/j.molcel.2018.02.028
   Yang LZ, 2019, MOL CELL, V76, P981, DOI 10.1016/j.molcel.2019.10.024
   Zhou B, 2009, J VIROL, V83, P10309, DOI 10.1128/JVI.01109-09
NR 51
TC 48
Z9 48
U1 20
U2 34
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD MAY 14
PY 2020
VL 181
IS 4
BP 865
EP +
DI 10.1016/j.cell.2020.04.020
PG 24
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA LO4UD
UT WOS:000533623900012
PM 32353252
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Al-Khafaji, K
   AL-DuhaidahawiL, D
   Tok, TT
AF Al-Khafaji, Khattab
   AL-DuhaidahawiL, Dunya
   Taskin Tok, Tugba
TI Using integrated computational approaches to identify safe and rapid
   treatment for SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; covalent docking; drug repurposing; MD simulation; PCA; Mpro
ID DRUG DISCOVERY; FORCE-FIELD; IDENTIFICATION; INHIBITORS; DOCKING
AB SARS-CoV-2 is a new generation of coronavirus, which was first determined in Wuhan, China, in December 2019. So far, however, there no effective treatment has been found to stop this new generation of coronavirus but discovering of the crystal structure of SARS-CoV-2 main protease (SARS-CoV-2 Mpro) may facilitate searching for new therapies for SARS-COV-2. The aim was to assess the effectiveness of available FDA approved drugs which can construct a covalent bond with Cys145 inside binding site SARS-CoV-2 main protease by using covalent docking screening. We conducted the covdock module MMGBSA module in the Schrodinger suite 2020-1, to examine the covalent bonding utilizing. Besides, we submitted the top three drugs to molecular dynamics simulations via Gromacs 2018.1. The covalent docking showed that saquinavir, ritonavir, remdesivir, delavirdine, cefuroxime axetil, oseltamivir and prevacid have the highest binding energies MMGBSA of -72.17, -72.02, -65.19, -57.65, -54.25, -51.8, and -51.14 kcal/mol, respectively. The 50 ns molecular dynamics simulation was conducted for saquinavir, ritonavir and remdesivir to evaluate the stability of these drugs inside the binding pocket of SARS-CoV-2 main protease. The current study provides a powerful in silico results, means for rapid screening of drugs as anti-protease medications and recommend that the above-mentioned drugs can be used in the treatment of SARS-CoV-2 in combined or sole therapy. Communicated by Ramaswamy H. Sarma
C1 [Al-Khafaji, Khattab; Taskin Tok, Tugba] Gaziantep Univ, Fac Arts & Sci, Dept Chem, Gaziantep, Turkey.
   [AL-DuhaidahawiL, Dunya] Univ Kufi, Coll Pharm, Pharmaceut Chem, Al Najaf, Iraq.
   [Taskin Tok, Tugba] Gaziantep Univ, Inst Hlth Sci, Dept Bioinformat & Computat Biol, Gaziantep, Turkey.
RP AL-DuhaidahawiL, D (corresponding author), Univ Kufi, Coll Pharm, Pharmaceut Chem, Al Najaf, Iraq.
EM dunialafta1982@yahoo.com
RI Al-Khafaji, Khattab/AAU-4146-2020; AL-Duhaidahawi, Dunya/N-5107-2017
OI Al-Khafaji, Khattab/0000-0002-2165-9256; AL-Duhaidahawi,
   Dunya/0000-0002-1290-6921
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   ALKHAFAJI K, 2020, J BIOMOL STRUCT 0323, DOI DOI https://doi.org/10.1080/07391102.2020.1742792
   ALKHAFAJI K, 2020, J BIOMOL STRUCT 0306, DOI DOI https://doi.org/10.1080/07391102.2020.1736159
   AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408
   Bjelkmar P, 2010, J CHEM THEORY COMPUT, V6, P459, DOI 10.1021/ct900549r
   Cameron D, 2013, J BIOMED INFORM, V46, P238, DOI 10.1016/j.jbi.2012.09.004
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Ekins S, 2007, BRIT J PHARMACOL, V152, P9, DOI 10.1038/sj.bjp.0707305
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   FISHER D, 2020, BMC MED, V18, DOI DOI https://doi.org/10.1186/s12916-020-01533-w
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952
   Jin Z., 2020, NATURE, P1
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan S, 2020, MITOCHONDRIAL DNA A, DOI [10.1080/24701394.2020.1845323, 10.1016/B978-0-12-816960-5.00001-X]
   Kumalo HM, 2015, MOLECULES, V20, P1984, DOI 10.3390/molecules20021984
   Kumar N, 2019, J BIOMOL STRUCT DYN, V37, P2355, DOI 10.1080/07391102.2018.1481457
   Lim J, 2020, J KOREAN MED SCI, V35
   McMahon CG, 2012, THER ADV UROL, V4, P233, DOI 10.1177/1756287212453866
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Shukla R, 2019, J MOL GRAPH MODEL, V91, P91, DOI 10.1016/j.jmgm.2019.06.008
   Sweeney Danielle D, 2005, Rev Urol, V7, P81
   Vijayakumar B, 2014, PHARMACOGN MAG, V10, P639, DOI 10.4103/0973-1296.139809
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
NR 38
TC 17
Z9 18
U1 6
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1764392
EA MAY 2020
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LQ3XN
UT WOS:000534939200001
PM 32364041
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Hu, YG
   Chen, TY
   Liu, MM
   Zhang, L
   Wang, F
   Zhao, S
   Liu, H
   Xia, H
   Wang, YW
   Li, L
AF Hu, Yaguang
   Chen, Tianyan
   Liu, Miaomiao
   Zhang, Li
   Wang, Fang
   Zhao, Shuo
   Liu, Hui
   Xia, Han
   Wang, Yawen
   Li, Li
TI Positive detection of SARS-CoV-2 combined HSV1 and HHV6B virus nucleic
   acid in tear and conjunctival secretions of a non-conjunctivitis
   COVID-19 patient with obstruction of common lacrimal duct
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
AB Background The current outbreak of COVID-19 has spread rapidly all over the world. Respiratory droplets and contaction with infected patients are the two major transmission routes. However, the value of tear virus nucleic acid is still not clear. We dynamic detected the SARS-CoV-2 in eye sample of one COVID-19 patient with obstruction of common lacrimal ducts.
   Methods Besides the routine examination, nasopharyngeal and eye swab were continuously measured by polymerase chain reaction assay and next-generation sequencing (NGS). Gene detection was performed for drug use guidance, and flow cytometry was performed to analyse the lymphocyte subsets.
   Results Nasopharyngeal swabs were positive for 22 days, but eye swabs were still continuously positive for 2 weeks after nasopharyngeal swabs turned negative. The low level of lymphocyte and the high level IL-6 lasted for almost 4 weeks, then became near normal. Next-generation sequencing (NGS) confirmed the existing of SARS-CoV-2, HSV1 and HHV6B virus nucleic acid. The gene detection for drug use guidance showed the genetic locus ABCB1 (3435T>C) rs1045642 belonged to type CC and it mean the efficiency of lopinavir-ritonavir would be significantly decreased. The flow cytometry of lymphocyte subsets showed PD-1(+) CD95(+) cells was accounting for 94.8% in CD3(+) CD8(+) T subset and for 94.8% in CD3(+) TCR gamma delta(+) T subset.
   Conclusions As obstruction of common lacrimal duct, positively detection in one eye for 2 weeks more after nasopharyngeal swab became negative. More eye swabs should be collected from COVID-19 patients, especially from those immunocompromised, those with eye symptoms and those had a history of ocular diseases.
C1 [Hu, Yaguang; Zhang, Li; Li, Li] Xi An Jiao Tong Univ, Dept Ophthalmol, Affiliated Hosp 1, Xian, Peoples R China.
   [Chen, Tianyan] Xi An Jiao Tong Univ, Dept Infect Dis, Affiliated Hosp 1, Xian, Peoples R China.
   [Liu, Miaomiao] Xi An Jiao Tong Univ, Dept Cardiac Surg, Affiliated Hosp 1, Xian, Peoples R China.
   [Wang, Fang; Wang, Yawen] Xi An Jiao Tong Univ, Dept Lab Med, Affiliated Hosp 1, Xian, Peoples R China.
   [Zhao, Shuo] Xi An Jiao Tong Univ, Dept Surg, Affiliated Hosp 1, Intens Care Unit, Xian, Peoples R China.
   [Liu, Hui] Xi An Jiao Tong Univ, Biobank, Affiliated Hosp 1, Xian, Peoples R China.
   [Xia, Han] Xi An Jiao Tong Univ, Fac Elect & Informat Engn, Sch Automat Sci & Engn, Xian, Peoples R China.
RP Wang, YW; Li, L (corresponding author), 277 West YanTa Rd, Xian, Shaanxi, Peoples R China.
EM wangyw1269@xjtu.edu.cn; eyelili2010@mail.xjtu.edu.cn
CR Agut H, 2017, MED MALADIES INFECT, V47, P83, DOI 10.1016/j.medmal.2016.09.004
   Bausch DG, 2007, J INFECT DIS, V196, pS142, DOI 10.1086/520545
   Brezar V, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006489
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Loon SC, 2004, BRIT J OPHTHALMOL, V88, P861, DOI 10.1136/bjo.2003.035931
   Lu CW, 2020, LANCET, V395, pE39, DOI 10.1016/S0140-6736(20)30313-5
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   STEELE RJ, 1993, AM J OPHTHALMOL, V115, P265, DOI 10.1016/S0002-9394(14)73942-X
   Vegh Mihaly, 2015, Orv Hetil, V156, P431, DOI 10.1556/OH.2015.30110
   Wang YM, 2018, J INFECT DIS, V217, P1708, DOI 10.1093/infdis/jiy115
   Xia JH, 2020, J MED VIROL, V92, P589, DOI 10.1002/jmv.25725
   Xu D, 2005, EUR J CLIN MICROBIOL, V24, P165, DOI 10.1007/s10096-005-1299-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 14
TC 8
Z9 9
U1 5
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2020
VL 98
IS 8
BP 859
EP 863
DI 10.1111/aos.14456
EA MAY 2020
PG 5
WC Ophthalmology
SC Ophthalmology
GA PE4TH
UT WOS:000532530000001
PM 32406606
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Evgen'ev, MB
   Frenkel, A
AF Evgen'ev, Mikhail B.
   Frenkel, Anton
TI Possible application of H2S-producing compounds in therapy of
   coronavirus (COVID-19) infection and pneumonia
SO CELL STRESS & CHAPERONES
LA English
DT Letter
ID SODIUM THIOSULFATE; HYDROGEN-SULFIDE
C1 [Evgen'ev, Mikhail B.] Russian Acad Sci, Engelhardt Inst Mol Biol, Lab Mol Mech Biol Adaptat, Moscow 119991, Russia.
   [Frenkel, Anton] Clexio Biosci Ltd, Petah Tiqwa, Israel.
RP Evgen'ev, MB (corresponding author), Russian Acad Sci, Engelhardt Inst Mol Biol, Lab Mol Mech Biol Adaptat, Moscow 119991, Russia.
EM misha672011@yahoo.com
FU Russian Science FoundationRussian Science Foundation (RSF) [17-74-30030]
FX The work was supported by Grant of Russian Science Foundation
   #17-74-30030 (to M.E.).
CR Barkov V.A, 2006, THESIS
   Bazhanov N, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050249
   Bazhanov N, 2017, SCI REP-UK, V7, DOI 10.1038/srep41029
   Bebarta VS, 2017, ANN EMERG MED, V69, P718, DOI 10.1016/j.annemergmed.2016.09.034
   Bhattacharyya S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079167
   Egorychev V E, 1987, Pediatriia, P100
   Faller S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33101-x
   Faller S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176649
   Farese S, 2011, CLIN J AM SOC NEPHRO, V6, P1447, DOI 10.2215/CJN.10241110
   Gorbacheva, 2009, VESTNIK STPETESBOURG, P109
   Gorbacheva, 2009, PHARM J, P71
   Kakinohana M, 2019, FREE RADICAL BIO MED, V131, P243, DOI 10.1016/j.freeradbiomed.2018.12.003
   Kaya-Yasar Y, 2017, PULM PHARMACOL THER, V45, P170, DOI 10.1016/j.pupt.2017.06.006
   Kimura H, 2014, MOLECULES, V19, P16146, DOI 10.3390/molecules191016146
   Leskova A, 2017, AM J PHYSIOL-HEART C, V313, pH256, DOI 10.1152/ajpheart.00723.2016
   Sakaguchi M, 2014, ANESTHESIOLOGY, V121, P1248, DOI 10.1097/ALN.0000000000000456
   Shilova V, 2020, CELL STRESS CHAPERON, V25, P305, DOI 10.1007/s12192-020-01074-4
   Singh RP, 2011, CLIN J AM SOC NEPHRO, V6, P1155, DOI 10.2215/CJN.09671010
   Snijder PM, 2015, BRIT J PHARMACOL, V172, P1494, DOI 10.1111/bph.12825
   Wallace JL, 2015, NAT REV DRUG DISCOV, V14, P329, DOI 10.1038/nrd4433
   Xiao Q, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013065
   Yurinskaya MM, 2020, INFLAMM RES, V69, P481, DOI 10.1007/s00011-020-01329-x
   Zatsepina, REDOX BIOL
   Zhang ZL, 2019, LIFE SCI, V232, DOI 10.1016/j.lfs.2019.116650
NR 24
TC 4
Z9 5
U1 2
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1355-8145
EI 1466-1268
J9 CELL STRESS CHAPERON
JI Cell Stress Chaperones
PD SEP
PY 2020
VL 25
IS 5
SI SI
BP 713
EP 715
DI 10.1007/s12192-020-01120-1
EA MAY 2020
PG 3
WC Cell Biology
SC Cell Biology
GA NL5ZG
UT WOS:000532864500001
PM 32409956
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ozkan, H
   Adem, S
AF Ozkan, Hamdi
   Adem, Sevki
TI Synthesis, Spectroscopic Characterizations of Novel Norcantharimides,
   Their ADME Properties and Docking Studies Against COVID-19 M-pr degrees
SO CHEMISTRYSELECT
LA English
DT Article
DE ADME; Cantharidin; COVID-19 M-pr degrees; Drug design; Medicinal
   chemistry; Molecular docking studies; Norcantharidin; Norcantharimide
ID DRUG DISCOVERY; CANTHARIDIN; ANALOGS; PHTHALIMIDE
AB A series of novel Norcantharimide derivatives were synthesized and their structures were characterized by FTIR, H-1 and C-13 NMR spectroscopy as well as elemental analyses. The absorption, distribution, metabolism and excretion (ADME) properties of the synthesized molecules were investigated. The results obtained in silico demonstrated that these molecules can be considered as orally active drug candidates due to their physicochemical properties. Also, docking studies demonstrated that all derivatives exhibit a good theoretical affinity with MolDock Score in between 124-138 against the main protease of Coronavirus Disease 2019 (COVID-19 M-pr degrees) that caused worldwide epidemics. We believe that newly synthesized norcantharimide derivatives can guide many future studies in organic synthesis, medicine and pharmaceutical applications.
C1 [Ozkan, Hamdi] Gazi Univ, Fac Sci, Dept Chem, TR-06500 Ankara, Turkey.
   [Adem, Sevki] Cankiri Karatekin Univ, Fac Sci, Dept Chem, TR-18100 Cankiri, Turkey.
RP Ozkan, H (corresponding author), Gazi Univ, Fac Sci, Dept Chem, TR-06500 Ankara, Turkey.
EM hozkan@edu.tr
CR Baba Y, 2005, BIOORGAN MED CHEM, V13, P5164, DOI 10.1016/j.bmc.2005.05.013
   Binev IG, 1999, J MOL STRUCT, V513, P231, DOI 10.1016/S0022-2860(99)00123-4
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Egan WJ, 2000, J MED CHEM, V43, P3867, DOI 10.1021/jm000292e
   Ferreira LLG, 2019, DRUG DISCOV TODAY, V24, P1157, DOI 10.1016/j.drudis.2019.03.015
   Ghose AK, 1999, J COMB CHEM, V1, P55, DOI 10.1021/cc9800071
   Hill TA, 2007, BIOORGAN MED CHEM, V15, P6126, DOI 10.1016/j.bmc.2007.06.034
   Hollenberg PF, 2002, DRUG METAB REV, V34, P17, DOI 10.1081/DMR-120001387
   HONKANEN RE, 1993, FEBS LETT, V330, P283, DOI 10.1016/0014-5793(93)80889-3
   Jin J., NATURE, DOI [10.1038/s415860202223, DOI 10.1038/S415860202223]
   Kirchmair J, 2015, NAT REV DRUG DISCOV, V14, P387, DOI 10.1038/nrd4581
   Kose A, 2020, BIOORG CHEM, V94, DOI 10.1016/j.bioorg.2019.103421
   Lin PY, 1998, J CHIN CHEM SOC-TAIP, V45, P323, DOI 10.1002/jccs.199800052
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Liu DW, 2009, ANTI-CANCER AGENT ME, V9, P392, DOI 10.2174/1871520610909040392
   Massicot F, 2005, BASIC CLIN PHARMACOL, V96, P26, DOI 10.1111/j.1742-7843.2005.pto960104.x
   McCluskey A, 2001, BIOORG MED CHEM LETT, V11, P2941, DOI 10.1016/S0960-894X(01)00594-7
   Molegro A., 2019, MVD 7 0 MOLEGRO VIRT
   Muegge I, 2001, J MED CHEM, V44, P1841, DOI 10.1021/jm015507e
   NICKOLLS LC, 1954, BRIT MED J, V2, P1384, DOI 10.1136/bmj.2.4901.1384
   Peng Zong-gen, 2010, Yaoxue Xuebao, V45, P224
   Robinson G, 2020, CURR DERMATOL REP, V9, P83, DOI 10.1007/s13671-020-00289-z
   Torrico-Vallejos S, 2010, J MOL STRUCT, V975, P227, DOI 10.1016/j.molstruc.2010.04.028
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   WANG GS, 1989, J ETHNOPHARMACOL, V26, P147, DOI 10.1016/0378-8741(89)90062-7
NR 25
TC 2
Z9 2
U1 3
U2 7
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 2365-6549
J9 CHEMISTRYSELECT
JI ChemistrySelect
PD MAY 14
PY 2020
VL 5
IS 18
BP 5422
EP 5428
DI 10.1002/slct.202001123
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA LN2TP
UT WOS:000532796500008
PM 32518817
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Zhou, YQ
   Han, T
   Chen, JX
   Hou, C
   Hua, L
   He, S
   Guo, Y
   Zhang, S
   Wang, YJ
   Yuan, JX
   Zhao, CH
   Zhang, J
   Jia, QW
   Zuo, XR
   Li, JH
   Wang, LS
   Cao, Q
   Jia, EZ
AF Zhou, Yaqing
   Han, Tao
   Chen, Jiaxin
   Hou, Can
   Hua, Lei
   He, Shu
   Guo, Yi
   Zhang, Sheng
   Wang, Yanjun
   Yuan, Jinxia
   Zhao, Chenhui
   Zhang, Jing
   Jia, Qiaowei
   Zuo, Xiangrong
   Li, Jinhai
   Wang, Liansheng
   Cao, Quan
   Jia, Enzhi
TI Clinical and Autoimmune Characteristics of Severe and Critical Cases of
   COVID-19
SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
AB In this study we report on the clinical and autoimmune characteristics of severe and critical novel coronavirus pneumonia caused by severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2). The clinical, autoimmune, and laboratory characteristics of 21 patients who had laboratory-confirmed severe and critical cases of coronavirus disease 2019 (COVID-19) from the intensive care unit of the Huangshi Central Hospital, Hubei Province, China, were investigated. A total of 21 patients (13 men and 8 women), including 8 (38.1%) severe cases and 13 (61.9%) critical cases, were enrolled. Cough (90.5%) and fever (81.0%) were the dominant symptoms, and most patients (76.2%) had at least one coexisting disorder on admission. The most common characteristics on chest computed tomography were ground-glass opacity (100%) and bilateral patchy shadowing (76.2%). The most common findings on laboratory measurement were lymphocytopenia (85.7%) and elevated levels of C-reactive protein (94.7%) and interleukin-6 (89.5%). The prevalence of anti-52 kDa SSA/Ro antibody, anti-60 kDa SSA/Ro antibody, and antinuclear antibody was 20%, 25%, and 50%, respectively. We also retrospectively analyzed the clinical and laboratory data from 21 severe and critical cases of COVID-19. Autoimmune phenomena exist in COVID-19 subjects, and the present results provide the rationale for a strategy of preventing immune dysfunction and optimal immunosuppressive therapy.
C1 [Zhou, Yaqing; Chen, Jiaxin; Hou, Can; Hua, Lei; He, Shu; Guo, Yi; Zhang, Sheng; Wang, Yanjun; Yuan, Jinxia; Zhao, Chenhui; Zhang, Jing; Jia, Qiaowei; Wang, Liansheng; Jia, Enzhi] Nanjing Med Univ, Dept Cardiovasc Med, Affiliated Hosp 1, Nanjing, Peoples R China.
   [Han, Tao; Zuo, Xiangrong; Li, Jinhai; Cao, Quan] Nanjing Med Univ, Dept Intens Care Med, Affiliated Hosp 1, Nanjing, Peoples R China.
RP Jia, EZ (corresponding author), Nanjing Med Univ, Dept Cardiovasc Med, Affiliated Hosp 1, Nanjing, Peoples R China.; Han, T; Cao, Q (corresponding author), Nanjing Med Univ, Dept Intens Care Med, Affiliated Hosp 1, Nanjing, Peoples R China.
EM 1051761386@qq.com; 2004caoquan@163.com; enzhijia@njmu.edu.cn
FU National Natural Science Foundations of ChinaNational Natural Science
   Foundation of China (NSFC) [81970302, 81170180, 30400173, 30971257];
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions
FX This study was supported by the National Natural Science Foundations of
   China (No. 81970302, 81170180, 30400173, and 30971257) and the Priority
   Academic Program Development of Jiangsu Higher Education Institutions.
CR Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Lin YS, 2005, CLIN EXP IMMUNOL, V141, P500, DOI 10.1111/j.1365-2249.2005.02864.x
   National Health Commission (NHC) of the PRC National Administration of Traditional Medicine of the PRC, 2020, GUID COR VIR DIS 201
   Wang YS, 2004, CELL MOL IMMUNOL, V1, P304
   Wu J, 2020, CLIN INFECT DIS, V71, P706, DOI 10.1093/cid/ciaa199
   Xu YH, 2020, J INFECTION, V80, P394, DOI 10.1016/j.jinf.2020.02.017
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 9
TC 26
Z9 27
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1752-8054
EI 1752-8062
J9 CTS-CLIN TRANSL SCI
JI CTS-Clin. Transl. Sci.
PD NOV
PY 2020
VL 13
IS 6
BP 1077
EP 1086
DI 10.1111/cts.12805
EA MAY 2020
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PA7WR
UT WOS:000532518400001
PM 32315487
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Huang, Q
   Deng, XY
   Li, YZ
   Sun, XX
   Chen, Q
   Xie, MX
   Liu, S
   Qu, H
   Liu, SX
   Wang, L
   He, GF
   Gong, ZC
AF Huang, Qiong
   Deng, Xuanyu
   Li, Yongzhong
   Sun, Xuexiong
   Chen, Qiong
   Xie, Mingxuan
   Liu, Shao
   Qu, Hui
   Liu, Shouxian
   Wang, Ling
   He, Gefei
   Gong, Zhicheng
TI Clinical characteristics and drug therapies in patients with the
   common-type coronavirus disease 2019 in Hunan, China
SO INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
LA English
DT Article
DE Clinical characteristics; COVID-19; Infection; Pharmacotherapy
ID INTERFERON-ALPHA-2B
AB Background Clinical characteristics of patients with the coronavirus disease 2019 (COVID-19) may present differently within and outside the epicenter of Wuhan, China. More clinical investigations are needed. Objective The study was aimed to describe the clinical characteristics, laboratory parameters, and therapeutic methods of COVID-19 patients in Hunan, China. Setting The First Hospital of Changsha, First People's Hospital of Huaihua, and the Central Hospital of Loudi, Hunan province, China. Methods This was a retrospective multi-center case-series analysis. Patients with confirmed COVID-19 diagnosis hospitalized at the study centers from January 17 to February 10, 2020, were included. The following data were obtained from electronic medical records: demographics, medical history, exposure history, underlying comorbidities, symptoms, signs, laboratory findings, computer tomography scans, and treatment measures. Main outcome measure Epidemiological, clinical, laboratory, and radiological characteristics and treatments. Results A total of 54 patients were included (51 had the common-type COVID-19, three had the severe-type), the median age was 41, and 52% of them were men. The median time from the first symptoms to hospital admission was seven days. Among patients with the common-type COVID-19, the median length of stay was nine days, and 21 days among patients with severe COVID-19. The most common symptoms at the onset of illness were fever (74.5%), cough (56.9%), and fatigue (43.1%) among patients in the common-type group. Fourteen patients (37.8%) had a reduced WBC count, 23 (62.2%) had reduced eosinophil ratio, and 21 (56.76%) had decreased eosinophil count. The most common patterns on chest-computed tomography were ground-glass opacity (52.2%) and patchy bilateral shadowing (73.9%). Pharmacotherapy included recombinant human interferon alpha 2b, lopinavir/ritonavir, novaferon, antibiotics, systematic corticosteroids and traditional Chinese medicine prescription. The outcome of treatment indicated that in patients with the common-type COVID-19, interferon-alpha 2b, but not novaferon, had some benefits, antibiotics treatment was not needed, and corticosteroids should be used cautiously. Conclusion As of February 10, 2020, the symptoms of COVID-19 patients in Hunan province were relatively mild comparing to patients in Wuhan, the epicenter. We observed some treatment benefits with interferon-alpha 2b and corticosteroid therapies but not with novaferon and antibiotic treatment in our study population.
C1 [Huang, Qiong; Liu, Shao; Gong, Zhicheng] Cent South Univ, Xiangya Hosp, Dept Pharm, Changsha, Hunan, Peoples R China.
   [Deng, Xuanyu; He, Gefei] First Hosp Changsha, Changsha, Hunan, Peoples R China.
   [Li, Yongzhong; Qu, Hui] First Peoples Hosp Huaihua, Huaihua, Hunan, Peoples R China.
   [Sun, Xuexiong; Liu, Shouxian] Cent Hosp Loudi, Dept Pharm, Loudi, Hunan, Peoples R China.
   [Huang, Qiong; Liu, Shao; Gong, Zhicheng] Hunan Inst Pharm Practice & Clin Res, Changsha, Hunan, Peoples R China.
   [Huang, Qiong; Liu, Shao; Gong, Zhicheng] Cent South Univ, Inst Hosp Pharm, Changsha, Hunan, Peoples R China.
   [Chen, Qiong; Xie, Mingxuan] Cent South Univ Changsha, Xiangya Hosp, Dept Geriatr, Resp Med, Changsha, Hunan, Peoples R China.
   [Wang, Ling] Nationwide Childrens Hosp, Columbus, OH USA.
RP Gong, ZC (corresponding author), Cent South Univ, Xiangya Hosp, Dept Pharm, Changsha, Hunan, Peoples R China.; He, GF (corresponding author), First Hosp Changsha, Changsha, Hunan, Peoples R China.; Gong, ZC (corresponding author), Cent South Univ, Inst Hosp Pharm, Changsha, Hunan, Peoples R China.
EM 326366726@qq.com; gongzhicheng@csu.edu.cn
FU Changsha Science and Technology Project [202003]
FX Changsha Science and Technology Project (No. 202003).
CR Cao B, 2020, N ENGL J MED
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang D, 2020, JAMA-J AM MED ASSOC, V323, P1092, DOI 10.1001/jama.2020.1623
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Khan S, 2020, J CLIN MICROBIOL, V58, DOI [10.1128/JCM.01297-20, 10.1128/JCM.00187-20]
   Li M, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-8
   Lin HL, 2016, ARCH VIROL, V161, P3073, DOI 10.1007/s00705-016-3012-7
   Liu S, 2020, INT J CLIN PHARM-NET, V42, P299, DOI 10.1007/s11096-020-01017-0
   Lu H., 2020, J MED VIROL
   Meng L, 2020, INT J CLIN PHARM-NET, V42, P305, DOI 10.1007/s11096-020-01020-5
   Qazi Nadeem A, 2002, Expert Opin Pharmacother, V3, P315, DOI 10.1517/14656566.3.3.315
   Song YL, 2019, CRIT CARE MED, V47, pE735, DOI 10.1097/CCM.0000000000003842
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yan YB, 2016, AMINO ACIDS, V48, P1775, DOI 10.1007/s00726-016-2217-0
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 3
Z9 3
U1 2
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2210-7703
EI 2210-7711
J9 INT J CLIN PHARM-NET
JI Int. J. Clin. Phar,.
PD JUN
PY 2020
VL 42
IS 3
BP 837
EP 845
DI 10.1007/s11096-020-01031-2
EA MAY 2020
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LV2DL
UT WOS:000532907400001
PM 32410206
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Chiappetta, S
   Sharma, AM
   Bottino, V
   Stier, C
AF Chiappetta, Sonja
   Sharma, Arya M.
   Bottino, Vincenzo
   Stier, Christine
TI COVID-19 and the role of chronic inflammation in patients with obesity
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
ID STAGING SYSTEM; DYSFUNCTION; MORTALITY
AB Coronavirus disease 2019 (COVID-19) and the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a particular risk to people living with preexisting conditions that impair immune response or amplify pro-inflammatory response. Low-grade chronic systemic inflammation, common in people with obesity, is associated with the development of atherosclerosis, type 2 diabetes, and hypertension, well known comorbidities that adversely affect the outcomes of patients with COVID-19. Risk stratification based on the Edmonton Obesity Staging System (EOSS), which classifies obesity based on the presence of medical, mental, and/or functional complications rather than on body mass index (BMI), has been shown to be a better predictor of all-cause mortality and it may well be that EOSS stages may better describe the risk of hyperinflammation in patients with COVID-19 infection. Analyzing a group of metabolic ill patients with obesity (EOSS 2 and 3), we found an increased interleukin-6 and linear regression analysis showed a positive correlation with C-reactive protein (CRP) (p = 0.014) and waist-to-hip-ratio (WHR) (p = 0.031). Physicians should be aware of these findings in patients with COVID-19 infection. Early identification of possible hyperinflammation could be fundamental and should guide decision making regarding hospitalization, early respiratory support, and therapy with immunosuppression to improve mortality.
C1 [Chiappetta, Sonja; Bottino, Vincenzo] Osped Evangelico Betania, Dept Obes & Metab Surg, Naples, Italy.
   [Sharma, Arya M.] Univ Alberta, Div Endocrinol, Dept Med, Edmonton, AB, Canada.
   [Stier, Christine] Sana Kliniken Germany, Obes Ctr NRW, Huerth, Germany.
   [Stier, Christine] Univ Hosp Aachen, Clin Gen Visceral & Transplant Surg, Aachen, Germany.
RP Chiappetta, S (corresponding author), Osped Evangelico Betania, Dept Obes & Metab Surg, Naples, Italy.
EM drschiappetta@gmail.com
RI Chiappetta, Sonja/ABE-3340-2020
OI Chiappetta, Sonja/0000-0002-1964-416X; Sharma, Arya
   Mitra/0000-0001-9360-6519
CR Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Chiappetta S, 2020, SURG OBES RELAT DIS, V16, P99, DOI 10.1016/j.soard.2019.10.007
   Chiappetta S, 2018, OBES SURG, V28, P3028, DOI 10.1007/s11695-018-3320-y
   Chiappetta S, 2016, SURG OBES RELAT DIS, V12, P1847, DOI 10.1016/j.soard.2016.02.042
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Frydrych L, 2018, J LEUKOCYTE BIOL, V104, P525, DOI 10.1002/JLB.5VMR0118-021RR
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gudowska-Sawczuk M, 2018, SCAND J CLIN LAB INV, V78, P125, DOI 10.1080/00365513.2017.1420217
   Hales Craig M, 2017, NCHS Data Brief, P1
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Kuk JL, 2011, APPL PHYSIOL NUTR ME, V36, P570, DOI [10.1139/h11-058, 10.1139/H11-058]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Peters MC, 2016, LANCET RESP MED, V4, P574, DOI 10.1016/S2213-2600(16)30048-0
   Poulakou G, 2012, CURR OPIN CRIT CARE, V18, P441, DOI 10.1097/MCC.0b013e32835605f2
   Selim Bernardo J, 2016, Hosp Pract (1995), V44, P146, DOI 10.1080/21548331.2016.1179558
   Sharma AM, 2009, INT J OBESITY, V33, P289, DOI 10.1038/ijo.2009.2
   Voiriot G, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0553-6
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 21
TC 23
Z9 23
U1 2
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
EI 1476-5497
J9 INT J OBESITY
JI Int. J. Obes.
PD AUG
PY 2020
VL 44
IS 8
BP 1790
EP 1792
DI 10.1038/s41366-020-0597-4
EA MAY 2020
PG 3
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA MP1CW
UT WOS:000532882800001
PM 32409680
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Horvath, D
   Orlov, A
   Osolodkin, DI
   Ishmukhametov, AA
   Marcou, G
   Varnek, A
AF Horvath, Dragos
   Orlov, Alexey
   Osolodkin, Dmitry I.
   Ishmukhametov, Aydar A.
   Marcou, Gilles
   Varnek, Alexandre
TI A Chemographic Audit of anti-Coronavirus Structure-Activity Information
   from Public Databases (ChEMBL)
SO MOLECULAR INFORMATICS
LA English
DT Article
DE Antivirals; coronavirus; SARS; chemography; Generative Topographic
   Mapping; Structure-Activity Relationships
ID SPACE; CORONAVIRUSES; VISUALIZATION; ANTIMALARIAL; INHIBITION; DRUGS
AB Discovery of drugs against newly emerged pathogenic agents like the SARS-CoV-2 coronavirus (CoV) must be based on previous research against related species. Scientists need to get acquainted with and develop a global oversight over so-far tested molecules. Chemography (herein used Generative Topographic Mapping, in particular) places structures on a human-readable 2D map (obtained by dimensionality reduction of the chemical space of molecular descriptors) and is thus well suited for such an audit. The goal is to map medicinal chemistry efforts so far targeted against CoVs. This includes comparing libraries tested against various virus species/genera, predicting their polypharmacological profiles and highlighting often encountered chemotypes. Maps are challenged to provide predictive activity landscapes against viral proteins. Definition of "anti-CoV" map zones led to selection of therein residing 380 potential anti-CoV agents, out of a vast pool of 800 M organic compounds.
C1 [Horvath, Dragos; Orlov, Alexey; Marcou, Gilles; Varnek, Alexandre] Univ Strasbourg, Chemoinformat Lab, CNRS, UMR 7140, 4 Rue Blaise Pascal, F-67000 Strasbourg, France.
   [Orlov, Alexey; Osolodkin, Dmitry I.; Ishmukhametov, Aydar A.] FSBSI Chumakov FSC R&D IBP RAS, Poselok Inst Poliomielita, 8 Bd 1, Moscow 108819, Russia.
   [Osolodkin, Dmitry I.; Ishmukhametov, Aydar A.] Sechenov First Moscow State Med Univ, Inst Translat Med & Biotechnol, Trubetskaya Ul 8, Moscow 119991, Russia.
RP Horvath, D; Varnek, A (corresponding author), Univ Strasbourg, Chemoinformat Lab, CNRS, UMR 7140, 4 Rue Blaise Pascal, F-67000 Strasbourg, France.
EM dhorvath@unistra.fr; varnek@unistra.fr
RI Osolodkin, Dmitry/D-6732-2011; Horvath, Dragos/W-9789-2018; Orlov,
   Alexey/AAT-4363-2020; Varnek, Alexandre/E-7076-2017
OI Osolodkin, Dmitry/0000-0002-0462-2945; Horvath,
   Dragos/0000-0003-0173-5714; Orlov, Alexey/0000-0002-0597-7705; Varnek,
   Alexandre/0000-0003-1886-925X
FU State Research Funding for FSBSI "Chumakov FSC RD IBP RAS"
   [0837-2019-0002]
FX The High Performance Computing (HPC) Center of the Strasbourg University
   is acknowledged for technical support. Yuliana Zabolotna, Ph.D. student
   of the Chemoinformatics Laboratory in Strasbourg, is acknowledged for
   the curation and mapping of 1.5 billion ZINC compounds. D.I.O thanks the
   State Research Funding for FSBSI "Chumakov FSC R&D IBP RAS" (research
   topic no. 0837-2019-0002) for support.
CR Agrafiotis DK, 2003, J COMPUT CHEM, V24, P1215, DOI 10.1002/jcc.10234
   Agrafiotis DK, 2001, J COMPUT CHEM, V22, P488, DOI 10.1002/1096-987X(20010415)22:5<488::AID-JCC1020>3.0.CO;2-4
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Bishop CM, 1998, NEUROCOMPUTING, V21, P203, DOI 10.1016/S0925-2312(98)00043-5
   Bishop CM, 1998, NEURAL COMPUT, V10, P215, DOI 10.1162/089976698300017953
   Casciuc I, 2019, J CHEM INF MODEL, V59, P564, DOI 10.1021/acs.jcim.8b00650
   Di Pisa F, 2017, MOLECULES, V22, DOI 10.3390/molecules22030426
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Gaspar HA, 2015, MOL INFORM, V34, P348, DOI 10.1002/minf.201400153
   Gaspar HA, 2016, ACS SYM SER, V1222, P211
   Gaspar HA, 2015, J CHEM INF MODEL, V55, P84, DOI 10.1021/ci500575y
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Haviernik J, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040184
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Jolliffe I., 2002, PRINCIPAL COMPONENT
   Kadam RU, 2017, P NATL ACAD SCI USA, V114, P206, DOI 10.1073/pnas.1617020114
   Kilianski A, 2014, ANTIVIR RES, V101, P105, DOI 10.1016/j.antiviral.2013.11.004
   Klimenko K, 2016, J CHEM INF MODEL, V56, P1438, DOI 10.1021/acs.jcim.6b00192
   Kohonen T., 1984, SELF ORG ASS MEMORY
   Kohonen T, 2001, SELF ORGANIZING MAPS
   Lin A., 2019, J COMPUT AIDED MOL D
   Lin A, 2019, J COMPUT AID MOL DES, V33, P331, DOI 10.1007/s10822-019-00188-x
   Liu L., 2014, CLIN INFECT DIS, V59, P613, DOI DOI 10.1093/CID/CIU346
   Liu WB, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00461-20
   Medvedev A, 2018, BIOFACTORS, V44, P95, DOI 10.1002/biof.1408
   Nikitina A. A., 2019, DATABASE, V2019
   Ogando NS, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01813
   Oprea TI, 2001, J COMB CHEM, V3, P157, DOI 10.1021/cc0000388
   Orlov AA, 2019, MOL INFORM, V38, DOI 10.1002/minf.201800166
   Pecheur EI, 2007, BIOCHEMISTRY-US, V46, P6050, DOI 10.1021/bi700181j
   Raj R, 2014, CHEM BIOL DRUG DES, V83, P622, DOI 10.1111/cbdd.12273
   Sidorov P, 2017, J COMPUT AID MOL DES, V31, P441, DOI 10.1007/s10822-017-0019-4
   Sidorov P, 2015, J COMPUT AID MOL DES, V29, P1087, DOI 10.1007/s10822-015-9882-z
   Stolbov LA, 2020, MOLECULES, V25, DOI 10.3390/molecules25010087
   Suarez AAR, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006839
   Tarasova OA, 2015, J CHEM INF MODEL, V55, P1388, DOI 10.1021/acs.jcim.5b00019
   Wang YL, 2017, NUCLEIC ACIDS RES, V45, pD955, DOI 10.1093/nar/gkw1118
   Weston S, 2019, J VIROL, V93, DOI 10.1128/JVI.00197-19
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 42
TC 0
Z9 0
U1 1
U2 1
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1868-1743
EI 1868-1751
J9 MOL INFORM
JI Mol. Inf.
PD DEC
PY 2020
VL 39
IS 12
SI SI
DI 10.1002/minf.202000080
EA MAY 2020
PG 18
WC Chemistry, Medicinal; Computer Science, Interdisciplinary Applications;
   Mathematical & Computational Biology
SC Pharmacology & Pharmacy; Computer Science; Mathematical & Computational
   Biology
GA PB7CG
UT WOS:000532521400001
PM 32363750
OA Green Published
DA 2021-01-01
ER

PT J
AU Alexander, M
   Jupp, J
   Chazan, G
   O'Connor, S
   Chan, AL
AF Alexander, Marliese
   Jupp, Jennifer
   Chazan, Grace
   O'Connor, Shaun
   Chan, Alexandre
TI Global oncology pharmacy response to COVID-19 pandemic: Medication
   access and safety
SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE
LA English
DT Article
DE COVID-19; ISOPP; pandemic; oncology pharmacy; pharmacist
AB Response, action, and adaptation of the way health services are delivered will impact our ability to provide optimized and continuity of care while acting within resource constraints imposed by COVID-19. Care for patients with cancer is particularly important given increased infection rates and worse outcomes from COVID-19 in this patient population, as well as potential adverse outcomes if treatment pathways need to be compromised. In this commentary, we provide a global oncology pharmacy perspective (including both developed and developing nations) on how COVID-19 has impacted access to and delivery of cancer therapies. This perspective was prepared by the International Society of Oncology Pharmacy Practitioners, with input from national and regional oncology pharmacy practice groups (42 practice leaders from 28 countries and regions) who contributed to a snapshot survey between 10 and 22 April 2020. Specifically, we highlight challenges related to safe handling of hazardous drugs and maintaining high-quality medication safety standards that have impacted various stakeholders.
C1 [Alexander, Marliese] Peter MacCallum Canc Ctr, Dept Pharm, Melbourne, Vic, Australia.
   [Alexander, Marliese; Chazan, Grace] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia.
   [Alexander, Marliese; Jupp, Jennifer; O'Connor, Shaun; Chan, Alexandre] Int Soc Oncol Pharm Practitioners, N Vancouver, BC, Canada.
   [Jupp, Jennifer] Alberta Hlth Serv, Serv Pharm, Calgary, AB, Canada.
   [Chazan, Grace] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia.
   [O'Connor, Shaun] St Vincents Hosp, Dept Pharm, Melbourne, Vic, Australia.
   [O'Connor, Shaun] Dept Hlth & Human Serv, Hlth & Wellbeing Div, Melbourne, Vic, Australia.
   [Chan, Alexandre] Univ Calif Irvine, Dept Clin Pharm Practice, 101 Theory,Suite 100, Irvine, CA 92697 USA.
RP Chan, AL (corresponding author), Univ Calif Irvine, Dept Clin Pharm Practice, 101 Theory,Suite 100, Irvine, CA 92697 USA.
EM a.chan@uci.edu
RI Chan, Alexandre/D-5035-2016
OI Chan, Alexandre/0000-0003-4391-4219; Alexander,
   Marliese/0000-0001-5782-7912; O'Connor, Shaun/0000-0002-4971-1693
CR [Anonymous], 2007, J ONCOL PHARM PRACT, V13, P1
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   States Pharmacopeia, 2020, USP GEN HAZ DRUGS HA
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
NR 4
TC 0
Z9 0
U1 3
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1078-1552
EI 1477-092X
J9 J ONCOL PHARM PRACT
JI J. Oncol. Pharm. Pract.
PD JUL
PY 2020
VL 26
IS 5
BP 1225
EP 1229
AR 1078155220927450
DI 10.1177/1078155220927450
EA MAY 2020
PG 5
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA MG6CL
UT WOS:000533109700001
PM 32408842
OA Bronze
DA 2021-01-01
ER

PT J
AU Chen, ST
AF Chen, Shitao
TI An online solution focused brief therapy for adolescent anxiety during
   the novel coronavirus disease (COVID-19) pandemic: a structured summary
   of a study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomized controlled trial; Protocol; Solution focused brief
   therapy; Adolescents; Anxiety
AB Objectives This study aims to assess the effectiveness of delivering Solution Focused Brief Therapy (SFBT) through telecommunication with a group of adolescents who present anxiety symptoms during the COVID-19 outbreak. We hypothesize that participants who are randomly assigned to receive 2-4 sessions of Solution Focused Brief Therapy would have better clinical outcomes than participants who are in the waitlist group. We additionally hypothesized that using SFBT can also change participants' depression levels and their coping strategies in dealing with distress during the COVID-19 pandemic. Trial design This study employs a randomized delayed crossover open label controlled trial in adolescents who are presenting anxiety symptoms during the COVID-19 outbreak. Participants who meet the enrollment criteria stated below will be invited to participate in this study through telecommunication. Those accepting will be randomly allocated to the intervention group or waitlist group.
C1 [Chen, Shitao] Beijing Normal Univ, Fac Psychol, Beijing, Peoples R China.
RP Chen, ST (corresponding author), Beijing Normal Univ, Fac Psychol, Beijing, Peoples R China.
EM chenshitao@bnu.edu.cn
FU Beijing Normal University Education Foundation
FX Beijing Normal University Education Foundation will provide funding for
   this study.
NR 0
TC 0
Z9 0
U1 9
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD MAY 13
PY 2020
VL 21
IS 1
AR 402
DI 10.1186/s13063-020-04355-6
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LS3HN
UT WOS:000536278900001
PM 32404126
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kim, YI
   Kim, SG
   Kim, SM
   Kim, EH
   Park, SJ
   Yu, KM
   Chang, JH
   Kim, EJ
   Lee, S
   Casel, MAB
   Um, J
   Song, MS
   Jeong, HW
   Lai, VD
   Kim, Y
   Chin, BS
   Park, JS
   Chung, KH
   Foo, SS
   Poo, H
   Mo, IP
   Lee, OJ
   Webby, RJ
   Jung, JU
   Choi, YK
AF Kim, Young-Il
   Kim, Seong-Gyu
   Kim, Se-Mi
   Kim, Eun-Ha
   Park, Su-Jin
   Yu, Kwang-Min
   Chang, Jae-Hyung
   Kim, Eun Ji
   Lee, Seunghun
   Casel, Mark Anthony B.
   Um, Jihye
   Song, Min-Suk
   Jeong, Hye Won
   Lai, Van Dam
   Kim, Yeonjae
   Chin, Bum Sik
   Park, Jun-Sun
   Chung, Ki-Hyun
   Foo, Suan-Sin
   Poo, Haryoung
   Mo, In-Pil
   Lee, Ok-Jun
   Webby, Richard J.
   Jung, Jae U.
   Choi, Young Ki
TI Infection and Rapid Transmission of SARS-CoV-2 in Ferrets
SO CELL HOST & MICROBE
LA English
DT Article
ID RESPIRATORY SYNDROME SARS; CORONAVIRUS; VIRUS; MODELS
AB The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China and rapidly spread worldwide. To prevent SARS-CoV-2 dissemination, understanding the in vivo characteristics of SARS-CoV-2 is a high priority. We report a ferret model of SARS-CoV-2 infection and transmission that recapitulates aspects of human disease. SARS-CoV-2-infected ferrets exhibit elevated body temperatures and virus replication. Although fatalities were not observed, SARS-CoV-2-infected ferrets shed virus in nasal washes, saliva, urine, and feces up to 8 days post-infection. At 2 days post-contact, SARS-CoV-2 was detected in all naive direct contact ferrets. Furthermore, a few naive indirect contact ferrets were positive for viral RNA, suggesting airborne transmission. Viral antigens were detected in nasal turbinate, trachea, lungs, and intestine with acute bronchiolitis present in infected lungs. Thus, ferrets represent an infection and transmission animal model of COVID-19 that may facilitate development of SARS-CoV-2 therapeutics and vaccines.
C1 [Kim, Young-Il; Kim, Seong-Gyu; Kim, Se-Mi; Kim, Eun-Ha; Park, Su-Jin; Yu, Kwang-Min; Chang, Jae-Hyung; Kim, Eun Ji; Lee, Seunghun; Casel, Mark Anthony B.; Song, Min-Suk; Jeong, Hye Won; Lee, Ok-Jun; Choi, Young Ki] Chungbuk Natl Univ, Coll Med, Cheongju, South Korea.
   [Kim, Young-Il; Kim, Seong-Gyu; Kim, Se-Mi; Kim, Eun-Ha; Park, Su-Jin; Yu, Kwang-Min; Chang, Jae-Hyung; Kim, Eun Ji; Lee, Seunghun; Casel, Mark Anthony B.; Song, Min-Suk; Jeong, Hye Won; Lee, Ok-Jun; Choi, Young Ki] Chungbuk Natl Univ, Med Res Inst, Cheongju, South Korea.
   [Kim, Young-Il; Kim, Eun-Ha; Park, Su-Jin; Yu, Kwang-Min; Casel, Mark Anthony B.; Song, Min-Suk; Choi, Young Ki] Chungbuk Natl Univ, Zoonot Infect Dis Res Ctr, Cheongju, South Korea.
   [Lai, Van Dam; Mo, In-Pil] Chungbuk Natl Univ, Coll Vet Med, Cheongju, South Korea.
   [Um, Jihye; Kim, Yeonjae; Chin, Bum Sik; Park, Jun-Sun; Chung, Ki-Hyun] Natl Med Ctr, Res Inst Publ Hlth, Seoul, South Korea.
   [Foo, Suan-Sin; Jung, Jae U.] Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.
   [Poo, Haryoung] Univ Sci & Technol, Infect Dis Res Ctr, Korea Res Inst Biosci & Biotechnol, Daejeon, South Korea.
   [Webby, Richard J.] St Jude Childrens Res Hosp, Dept Infect Dis, Div Virol, Memphis, TN 38105 USA.
RP Choi, YK (corresponding author), Chungbuk Natl Univ, Coll Med, Cheongju, South Korea.; Choi, YK (corresponding author), Chungbuk Natl Univ, Med Res Inst, Cheongju, South Korea.; Choi, YK (corresponding author), Chungbuk Natl Univ, Zoonot Infect Dis Res Ctr, Cheongju, South Korea.; Jung, JU (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.
EM jaeujung@med.usc.edu; choiki55@chungbuk.ac.kr
FU National Research Foundation of KoreaNational Research Foundation of
   Korea [NRF2018M3A9H4056536, 2020R1A2C 3008339]; Korea Research Institute
   of Bioscience and Biotechnology (KRIBB) Research Initiative Program
   [KGM9942011]; National Institute of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [AI140705, AI140718, AI152190, AI116585]; National Institute of Allergy
   and Infectious Diseases (Centers of Excellence for Influenza Research
   and Surveillance [CEIRS]) [HHSN272201400006C]
FX This work was supported by National Research Foundation of Korea
   (NRF2018M3A9H4056536, 2020R1A2C 3008339), the Korea Research Institute
   of Bioscience and Biotechnology (KRIBB) Research Initiative Program
   (KGM9942011), the National Institute of Health (AI140705, AI140718,
   AI152190, and AI116585), and the National Institute of Allergy and
   Infectious Diseases (Centers of Excellence for Influenza Research and
   Surveillance [CEIRS] contract number HHSN272201400006C).
CR [Anonymous], 2012, RNEASY MIN HDB
   Bao L, 2020, BIORXIV
   Bouvier NM, 2015, CURR OPIN VIROL, V13, P101, DOI 10.1016/j.coviro.2015.06.002
   Capraro GA, 2008, VIROLOGY, V376, P416, DOI 10.1016/j.virol.2008.03.034
   Chan KF, 2018, J INFECT DIS, V218, P406, DOI 10.1093/infdis/jiy184
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   El-Duah P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010043
   Enkirch T, 2015, VIROLOGY, V479, P259, DOI 10.1016/j.virol.2015.03.017
   Glass WG, 2004, J IMMUNOL, V173, P4030, DOI 10.4049/jimmunol.173.6.4030
   ICTV, 2020, NAM 2019 COR
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e86
   Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI 10.1053/S0016-5085(03)01215-0
   Li K, 2017, P NATL ACAD SCI USA, V114, pE3119, DOI 10.1073/pnas.1619109114
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Masters PS, 2013, FIELDS VIROLOGY, V6, P825
   Park SJ, 2018, VIRULENCE, V9, P133, DOI 10.1080/21505594.2017.1366408
   Park SJ, 2014, J GEN VIROL, V95, P793, DOI 10.1099/vir.0.058636-0
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   WHO, 2020, WHO DIR GEN OP REN M
   Woo PCY, 2005, J CLIN MICROBIOL, V43, P3054, DOI 10.1128/JCM.43.7.3054-3058.2005
   World Health Organization, 2020, 2019 NCOV OUTBR IS E
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 26
TC 134
Z9 132
U1 10
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD MAY 13
PY 2020
VL 27
IS 5
BP 704
EP +
DI 10.1016/j.chom.2020.03.023
PG 8
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA LO3OH
UT WOS:000533537800009
PM 32259477
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Lobo-Galo, N
   Terrazas-Lopez, M
   Martinez-Martinez, A
   Diaz-Sanchez, AG
AF Lobo-Galo, Naun
   Terrazas-Lopez, Manuel
   Martinez-Martinez, Alejandro
   Diaz-Sanchez, Angel Gabriel
TI FDA-approved thiol-reacting drugs that potentially bind into the
   SARS-CoV-2 main protease, essential for viral replication
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; 3CL main protease; thiol-reacting drugs;
   disulfiram
ID BETAINE ALDEHYDE DEHYDROGENASE; DISULFIRAM; CORONAVIRUS; INACTIVATION;
   INHIBITION; TARGET; SITE
AB Emergent novel SARS-CoV-2 is responsible for the current pandemic outbreak of severe acute respiratory syndrome with high mortality among the symptomatic population worldwide. Given the absence of a current vaccine or specific antiviral treatment, it is urgent to search for FDA-approved drugs that can potentially inhibit essential viral enzymes. The inhibition of 3CL(pro) has potential medical application, due to the fact that it is required for processing of the first translated replicase polyproteins into a series of native proteins, which are essential for viral replication in the host cell. We employed an in silico approach to test if disulfiram, as well as its metabolites, and captopril could be used as potential antiviral drugs against COVID-19. We provide data on the potential covalent interaction of disulfiram and its metabolites with the substrate binding subsite of 3CL(pro) and propose a possible mechanism for the irreversible protease inactivation thought the reaction of the aforementioned compounds with the Cys145. Although, captopril is shown to be a potential ligand of 3CL(pro), it is not recommended anti-COVID-19 therapy, due to the fact that it can induce the expression of the viral cellular receptor such as, angiotensin-converting enzyme ACE-2, and thus, making the patient potentially more susceptible to infection. On the other hand, disulfiram, an alcoholism-averting drug, has been previously proposed as an antimicrobial and anti-SARS and MERS agent, safe to use even at higher doses with low side effects, it is recommended to be tested for control of SARS-CoV-2 infection. Communicated by Ramaswamy H. Sarma
C1 [Lobo-Galo, Naun; Terrazas-Lopez, Manuel; Martinez-Martinez, Alejandro; Diaz-Sanchez, Angel Gabriel] Univ Autonoma Ciudad Juarez, Dept Ciencias Quim Biol, Inst Ciencias Biomed, Ciudad Juarez 32310, Chihuahua, Mexico.
RP Lobo-Galo, N; Diaz-Sanchez, AG (corresponding author), Univ Autonoma Ciudad Juarez, Dept Ciencias Quim Biol, Inst Ciencias Biomed, Ciudad Juarez 32310, Chihuahua, Mexico.
EM naun.lobo@uacj.mx; angel.diaz@uacj.mx
RI ; Martinez-Martinez, Alejandro/N-1161-2018; Lobo Galo, Naun/A-4626-2019;
   Diaz-Sanchez, Angel/Y-5213-2018
OI Terrazas-Lopez, Manuel/0000-0002-5414-5796; Martinez-Martinez,
   Alejandro/0000-0003-3448-910X; Lobo Galo, Naun/0000-0002-2328-4953;
   Diaz-Sanchez, Angel/0000-0002-6398-7274
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Chen Y, 2019, CELL SYST, V9, P129, DOI 10.1016/j.cels.2019.06.007
   CLAYTON GD, 1981, PATTYS IND HYGIENE T
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Dalecki AG, 2015, ANTIMICROB AGENTS CH, V59, P4835, DOI 10.1128/AAC.00692-15
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Ellenhorn M. J., 1987, MEDICAL TOXICOLOGY D
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Diaz-Sanchez AG, 2016, MOLECULES, V21, DOI 10.3390/molecules21121628
   Galkin A, 2014, J BIOL CHEM, V289, P10502, DOI 10.1074/jbc.M114.553123
   Gillner D, 2009, BIOORG MED CHEM LETT, V19, P6350, DOI 10.1016/j.bmcl.2009.09.077
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lee YM, 2016, J AM CHEM SOC, V138, P3856, DOI 10.1021/jacs.6b00299
   Lin MH, 2018, ANTIVIR RES, V150, P155, DOI 10.1016/j.antiviral.2017.12.015
   Lipsky JJ, 2001, CHEM-BIOL INTERACT, V130, P93, DOI 10.1016/S0009-2797(00)00225-8
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Macomber L, 2015, J CHEM INF MODEL, V55, P354, DOI 10.1021/ci500562t
   MAHASE E, 2020, BMJ-BRIT MED J, V368, P48071, DOI DOI 10.1136/BMJ.M641
   McCance-Katz EF, 2014, AM J ADDICTION, V23, P137, DOI 10.1111/j.1521-0391.2013.12081.x
   Messerli FH, 2020, CIRCULATION, V141, P2042, DOI 10.1161/CIRCULATIONAHA.120.047022
   Mousavi M, 2018, IRAN RED CRESCENT ME, V20, DOI 10.5812/ircmj.61606
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Starus A, 2015, BIOCHEMISTRY-US, V54, P4834, DOI 10.1021/acs.biochem.5b00475
   Velasco-Garcia R, 2006, BIOCHEM BIOPH RES CO, V341, P408, DOI 10.1016/j.bbrc.2006.01.003
   Velasco-Garcia R, 2003, CHEM-BIOL INTERACT, V143, P149, DOI 10.1016/S0009-2797(02)00199-0
   Wadman M., 2020, SCI AAAS, DOI [10.1126/ science.abc3208, DOI 10.1126/SCIENCE.ABC3208, 10.1126/science.abc3208]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Woo PCY, 2005, MICROBIOL IMMUNOL, V49, P899, DOI 10.1111/j.1348-0421.2005.tb03681.x
   Yoshimura A, 2014, ALCOHOL CLIN EXP RES, V38, P572, DOI 10.1111/acer.12278
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
   Zaldivar-Machorro VJ, 2011, BIOCHIMIE, V93, P286, DOI 10.1016/j.biochi.2010.09.022
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 45
TC 16
Z9 16
U1 5
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1764393
EA MAY 2020
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LP2PV
UT WOS:000534163000001
PM 32364011
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Ljungman, P
   Mikulska, M
   de la Camara, R
   Basak, GW
   Chabannon, C
   Corbacioglu, S
   Duarte, R
   Dolstra, H
   Lankester, AC
   Mohty, M
   Montoto, S
   Murray, J
   de Latour, RP
   Snowden, JA
   Yakoub-Agha, I
   Verhouven, B
   Kroger, N
   Styczynski, J
AF Ljungman, Per
   Mikulska, Malgorzata
   de la Camara, Rafael
   Basak, Grzegorz W.
   Chabannon, Christian
   Corbacioglu, Selim
   Duarte, Rafael
   Dolstra, Harry
   Lankester, Arjan C.
   Mohty, Mohamad
   Montoto, Silvia
   Murray, John
   de Latour, Regis Peffault
   Snowden, John A.
   Yakoub-Agha, Ibrahim
   Verhouven, Bregje
   Kroeger, Nicolaus
   Styczynski, Jan
CA European Soc Blood Marrow Transpla
TI The challenge of COVID-19 and hematopoietic cell transplantation; EBMT
   recommendations for management of hematopoietic cell transplant
   recipients, their donors, and patients undergoing CAR T-cell therapy
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
AB The new coronavirus SARS-CoV-2 has rapidly spread over the world causing the disease by WHO called COVID-19. This pandemic poses unprecedented stress on the health care system including programs performing allogeneic and autologous hematopoietic cell transplantation (HCT) and cellular therapy such as with CAR T cells. Risk factors for severe disease include age and predisposing conditions such as cancer. The true impact on stem cell transplant and CAR T-cell recipients in unknown. The European Society for Blood and Marrow Transplantation (EBMT) has therefore developed recommendations for transplant programs and physicians caring for these patients. These guidelines were developed by experts from the Infectious Diseases Working Party and have been endorsed by EBMT's scientific council and board. This work intends to provide guidelines for transplant centers, management of transplant candidates and recipients, and donor issues until the COVID-19 pandemic has passed.
C1 [Ljungman, Per] Karolinska Univ Hosp Huddinge, Dept Cellular Therapy & Allogene Stem Cell Transp, Stockholm, Sweden.
   [Ljungman, Per] Karolinska Inst, Dept Med Huddinge, Div Hematol, Stockholm, Sweden.
   [Mikulska, Malgorzata] Univ Genoa, Div Infect Dis, Genoa, Italy.
   [Mikulska, Malgorzata] Osped Policlin San Martino, Genoa, Italy.
   [de la Camara, Rafael] Hosp Princesa, Dept Hematol, Madrid, Spain.
   [Basak, Grzegorz W.] Med Univ Warsaw, Dept Hematol Oncol & Internal Med, Warsaw, Poland.
   [Chabannon, Christian] Ctr Invest Clin Biotherapies, Inst Paoli Calmettes, Marseille, France.
   [Chabannon, Christian] Ctr Invest Clin Biotherapies, Inserm CBT 1409, Marseille, France.
   [Corbacioglu, Selim] Univ Regensburg, Pediat Hematol Oncol & Stem Cell Transplantat Dep, Regensburg, Germany.
   [Duarte, Rafael] Hosp Univ Puerta Hierro, Serv Hematol & Hemoterapia, Madrid, Spain.
   [Dolstra, Harry] Radboud Univ Nijmegen, Dept Lab Med, Lab Hematol, Med Ctr, Nijmegen, Netherlands.
   [Lankester, Arjan C.] Leiden Univ, Willem Alexander Childrens Hosp, Dept Pediat, Med Ctr Leiden, Leiden, Netherlands.
   [Mohty, Mohamad] Hosp St Antoine, Dept Hematol, Paris, France.
   [Montoto, Silvia] Barts Hlth NHS Trust, St Bartholomews Hosp, London, England.
   [Murray, John] Christie NHS Fdn Trust, Manchester, Lancs, England.
   [de Latour, Regis Peffault] Hosp St Louis, Dept Hematol, BMT Unit, Paris, France.
   [Snowden, John A.] Sheffield Teaching Hosp NHS Fdn Trust, Dept Haematol, Sheffield, S Yorkshire, England.
   [Yakoub-Agha, Ibrahim] Univ Lille, U1285, INSERM, CHU Lille, Lille, France.
   [Verhouven, Bregje] Leiden Univ, Willem Alexander Childrens Hosp, Dept Pediat, Med Ctr, Leiden, Netherlands.
   [Kroeger, Nicolaus] Univ Hosp Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany.
   [Styczynski, Jan] Nicolaus Copernicus Univ Torun, Univ Hosp, Coll Med, Pediat Hematol & Oncol, Bydgoszcz, Poland.
RP Ljungman, P (corresponding author), Karolinska Univ Hosp Huddinge, Dept Cellular Therapy & Allogene Stem Cell Transp, Stockholm, Sweden.; Ljungman, P (corresponding author), Karolinska Inst, Dept Med Huddinge, Div Hematol, Stockholm, Sweden.
EM Per.Ljungman@ki.se
RI de la Camara, Rafael/B-2106-2009
OI de la Camara, Rafael/0000-0002-8189-5779; Ljungman,
   Per/0000-0002-8281-3245
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chang L, 2020, TRANSFUS MED REV, V34, P75, DOI 10.1016/j.tmrv.2020.02.003
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Ran Li, 2020, Clin Infect Dis, V71, P2218, DOI 10.1093/cid/ciaa287
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wingard JR, 2006, BIOL BLOOD MARROW TR, V12, P1229, DOI 10.1016/j.bbmt.2006.08.001
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang L, 2020, ANN ONCOL, DOI [10.1016/j.annonc.2020.03.296, DOI 10.1016/J.ANN0NC.2020.03.296]
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 20
TC 24
Z9 24
U1 1
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD NOV
PY 2020
VL 55
IS 11
BP 2071
EP 2076
DI 10.1038/s41409-020-0919-0
EA MAY 2020
PG 6
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA OK1DI
UT WOS:000532637500004
PM 32404975
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Back, D
   Marzolini, C
   Hodge, C
   Marra, F
   Boyle, A
   Gibbons, S
   Burger, D
   Khoo, S
AF Back, David
   Marzolini, Catia
   Hodge, Catherine
   Marra, Fiona
   Boyle, Alison
   Gibbons, Sara
   Burger, David
   Khoo, Saye
TI COVID-19 treatment in patients with comorbidities: Awareness of
   drug-drug interactions
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Letter; Early Access
C1 [Back, David; Marzolini, Catia; Hodge, Catherine; Gibbons, Sara; Khoo, Saye] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England.
   [Marzolini, Catia] Univ Hosp Basel, Dept Med, Div Infect Dis, Basel, Switzerland.
   [Marzolini, Catia] Univ Hosp Basel, Dept Med, Hosp Epidemiol, Basel, Switzerland.
   [Marzolini, Catia] Univ Hosp Basel, Dept Clin Res, Basel, Switzerland.
   [Marzolini, Catia] Univ Basel, Basel, Switzerland.
   [Marra, Fiona; Boyle, Alison] NHS Greater Glasgow & Clyde, Dept Pharm, Glasgow, Lanark, Scotland.
   [Burger, David] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands.
   [Khoo, Saye] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England.
RP Back, D (corresponding author), Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England.
EM daveback@liverpool.ac.uk
RI Marzolini, Catia/C-8253-2019
OI Back, David/0000-0002-7381-4799; Hodge, Catherine/0000-0003-2288-7020
FU NovartisNovartis Funding Source: Medline; Abbvie Funding Source: Medline
CR Back D, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25449
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Smith PF, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14314
NR 4
TC 7
Z9 7
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
DI 10.1111/bcp.14358
EA MAY 2020
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LM9DM
UT WOS:000532547800001
PM 32384171
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Jozaghi, E
   Maynard, R
   Hemm, D
   Marsh, S
AF Jozaghi, Ehsan
   Maynard, Russ
   Hemm, Dave
   Marsh, Samona
TI COVID-19 and people who use drugs: a call for action
SO CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE
LA English
DT Letter; Early Access
C1 [Jozaghi, Ehsan] British Columbia Ctr Dis Control, 655 W 12th Ave, Vancouver, BC V5Z 4R4, Canada.
   [Jozaghi, Ehsan] Univ British Columbia, Sch Populat & Publ Hlth, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.
   [Maynard, Russ] PHS Community Serv Soc, 9 E Hastings St, Vancouver, BC V6A 1M9, Canada.
   [Hemm, Dave] Vancouver Area Network Drug Users, 380 E Hastings St, Vancouver, BC V6A 1P4, Canada.
   [Marsh, Samona] Western Aboriginal Harm Reduct Soc, 380 E Hastings St, Vancouver, BC V6A 1P4, Canada.
   [Marsh, Samona] BC Yukon Assoc Drug War Survivors, 380 E Hastings St, Vancouver, BC V6A 1P4, Canada.
   [Marsh, Samona] Sex Workers United Violence, 334 Alexander St, Vancouver, BC V6A 1C3, Canada.
   [Marsh, Samona] Canadian Assoc People Who Use Drugs, Vancouver, BC, Canada.
RP Jozaghi, E (corresponding author), British Columbia Ctr Dis Control, 655 W 12th Ave, Vancouver, BC V5Z 4R4, Canada.; Jozaghi, E (corresponding author), Univ British Columbia, Sch Populat & Publ Hlth, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.
EM ejozaghi@yahoo.com
OI /0000-0002-3555-085X
CR [Anonymous], 2019, NOVEL CORONAVIRUS 20
   Ling J, 2020, VICE NEWS
   The Canadian Press, 2020, VANCOUVER SUN
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   Woo A, 2020, THE GLOBE MAIL
NR 5
TC 5
Z9 3
U1 1
U2 1
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 0008-4263
EI 1920-7476
J9 CAN J PUBLIC HEALTH
JI Can. J. Public Health-Rev. Can. Sante Publ.
DI 10.17269/s41997-020-00326-1
EA MAY 2020
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA LN0FL
UT WOS:000532621500001
PM 32406015
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Manto, M
   Dupre, N
   Hadjivassiliou, M
   Louis, ED
   Mitoma, H
   Molinari, M
   Shaikh, AG
   Soong, BW
   Strupp, M
   Van Overwalle, F
   Schmahmann, JD
AF Manto, Mario
   Dupre, Nicolas
   Hadjivassiliou, Marios
   Louis, Elan D.
   Mitoma, Hiroshi
   Molinari, Marco
   Shaikh, Aasef G.
   Soong, Bing-Wen
   Strupp, Michael
   Van Overwalle, Frank
   Schmahmann, Jeremy D.
TI Management of Patients with Cerebellar Ataxia During the COVID-19
   Pandemic: Current Concerns and Future Implications
SO CEREBELLUM
LA English
DT Article
DE SARS-CoV-2; COVID-19; Cerebellar ataxia; Cerebellum
AB The current worldwide severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic that causes coronavirus disease 2019 (COVID-19) has brought some medical systems to the brink of collapse. This crisis is also negatively impacting the care of patients with non-COVID-19 conditions, including those with cerebellar ataxia (CA). Older patients with CA and those with immune-mediated ataxias on immunosuppressive medication are potentially at high risk of developing serious complications of the infection, although it is also possible that immunosuppressive agents may provide a defense against cytokine storm. This has implications for even greater attention to preventing contracting the disease through physical distancing and/or isolation. The CA patient population is also at higher risk because of the neurological complexities of their underlying disorder and the comorbid medical illnesses that often accompany the genetic ataxias. As the disruption of social patterns and healthcare delivery in response to the crisis continues, interruption of rehabilitation, speech and language therapy, and face-to-face consultations threatens to have a negative impact on the course and well-being of CA patients. Mental and physical health is also potentially at greater risk because the prevailing uncertainty and anxiety may be superimposed upon cerebellum-specific neuropsychological challenges. We identify and review some of the short- and long-term consequences of this global pandemic for the community of ataxia patients and their families and for the clinical and academic neurologists/ataxiologists caring for these patients. This includes the recognition that telemedicine has emerged as a principle means of caregiver-patient contact and that neurological manifestations of COVID-19 including those specific to cerebellar neurobiology are increasingly recognized and will require close surveillance and monitoring. This COVID-19 Cerebellum Task Force consensus provides some guidance on how we may approach this uncertain time and consider preparing for the new realities we face in CA patient care once this acute crisis has passed.
C1 [Manto, Mario] CHU Charleroi, Unite Ataxies Cerebelleuses, Serv Neurol, B-6000 Charleroi, Belgium.
   [Manto, Mario] Univ Mons, CHU Charleroi, B-7000 Mons, Belgium.
   [Manto, Mario] Univ Mons, Serv Neurosci, B-7000 Mons, Belgium.
   [Dupre, Nicolas] Univ Laval, Fac Med, Dept Med, Quebec City, PQ, Canada.
   [Dupre, Nicolas] CHU Quebec Univ Laval, Neurosci Axis, Quebec City, PQ, Canada.
   [Hadjivassiliou, Marios] Sheffield Teaching Hosp NHS Trust, Acad Dept Neurosci, Sheffield, S Yorkshire, England.
   [Louis, Elan D.] Univ Texas Southwestern, Dept Neurol & Neurotherapeut, Dallas, TX USA.
   [Mitoma, Hiroshi] Tokyo Med Univ, Dept Med Educ, Tokyo, Japan.
   [Molinari, Marco] IRCCS Fdn S Lucia, Rome, Italy.
   [Shaikh, Aasef G.] Case Western Reserve Univ, Dept Neurol, Univ Hosp Cleveland Med Ctr, Cleveland VA Med Ctr, Cleveland, OH 44106 USA.
   [Soong, Bing-Wen] Taipei Med Univ, Taipei Neurosci Inst, Taipei, Taiwan.
   [Soong, Bing-Wen] Taipei Med Univ, Dept Neurol, Shuang Ho Hosp, New Taipei, Taiwan.
   [Soong, Bing-Wen] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Dept Neurol, Taipei, Taiwan.
   [Soong, Bing-Wen] Natl Yang Ming Univ, Brain Res Ctr, Taipei, Taiwan.
   [Strupp, Michael] Ludwig Maximilians Univ Munchen, Dept Neurol, Munich, Germany.
   [Van Overwalle, Frank] Vrije Univ Brussel, Fac Psychol, Brain Body & Cognit Lab, Brussels, Belgium.
   [Schmahmann, Jeremy D.] Massachusetts Gen Hosp, Dept Neurol, Ataxia Ctr, Cognit Behav Neurol Unit,Lab Neuroanat & Cerebell, Boston, MA 02114 USA.
   [Schmahmann, Jeremy D.] Harvard Med Sch, Boston, MA 02115 USA.
RP Manto, M (corresponding author), CHU Charleroi, Unite Ataxies Cerebelleuses, Serv Neurol, B-6000 Charleroi, Belgium.; Manto, M (corresponding author), Univ Mons, CHU Charleroi, B-7000 Mons, Belgium.; Manto, M (corresponding author), Univ Mons, Serv Neurosci, B-7000 Mons, Belgium.
EM mmanto@ulb.ac.be
CR Albuquerque UP, 2020, ETHNOBIOL CONSERV, V9, DOI 10.15451/ec2020-03-9.08-1-53
   Avitzur O., 2020, NEUROL TODAY
   Conti P, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13191
   ESO Stroke Research, 2020, STROK CAR COVID 19 P
   Fancellu R, 2013, J NEUROL, V260, P3134, DOI 10.1007/s00415-013-7138-1
   Ilg W, 2010, MOVEMENT DISORD, V25, P2239, DOI 10.1002/mds.23222
   Jacob S, 2020, J NEUROL SCI, V412, DOI 10.1016/j.jns.2020.116803
   Jiang XX, 2020, PSYCHIAT RES, V286, DOI 10.1016/j.psychres.2020.112903
   Liu K, 2020, J INFECT
   Manto Mario, 2015, Cerebellum Ataxias, V2, P2, DOI 10.1186/s40673-015-0023-1
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Natoli S, 2020, EUR J NEUROL, V27, P1764, DOI 10.1111/ene.14277
   Osler W., 1904, AEQUANIMITAS OTHER A
   Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
NR 18
TC 0
Z9 0
U1 2
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1473-4222
EI 1473-4230
J9 CEREBELLUM
JI Cerebellum
PD AUG
PY 2020
VL 19
IS 4
BP 562
EP 568
DI 10.1007/s12311-020-01139-1
EA MAY 2020
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA MH8FC
UT WOS:000532664600002
PM 32405955
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Du, SQ
   Yuan, WM
AF Du Sean Quan
   Yuan Weiming
TI Mathematical modeling of interaction between innate and adaptive immune
   responses in COVID-19 and implications for viral pathogenesis
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE adaptive immunity; antiviral drugs; COVID-19; innate immunity;
   SARS-CoV-2; target cell-limited model
ID INFLUENZA; DYNAMICS; CORONAVIRUS; WUHAN; CHINA; SARS; DRUG; H5N1
AB We have applied mathematical modeling to investigate the infections of the ongoing coronavirus disease-2019 (COVID-19) pandemic caused by SARS-CoV-2 virus. We first validated our model using the well-studied influenza viruses and then compared the pathogenesis processes between the two viruses. The interaction between host innate and adaptive immune responses was found to be a potential cause for the higher severity and mortality in COVID-19 patients. Specifically, the timing mismatch between the two immune responses has a major impact on disease progression. The adaptive immune response of the COVID-19 patients is more likely to come before the peak of viral load, while the opposite is true for influenza patients. This difference in timing causes delayed depletion of vulnerable epithelial cells in the lungs in COVID-19 patients while enhancing viral clearance in influenza patients. Stronger adaptive immunity in COVID-19 patients can potentially lead to longer recovery time and more severe secondary complications. Based on our analysis, delaying the onset of adaptive immune responses during the early phase of infections may be a potential treatment option for high-risk COVID-19 patients. Suppressing the adaptive immune response temporarily and avoiding its interference with the innate immune response may allow the innate immunity to more efficiently clear the virus.
C1 [Du Sean Quan; Yuan Weiming] Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, 1450 Biggy St,NRT5516, Los Angeles, CA 90033 USA.
RP Du, SQ; Yuan, WM (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, 1450 Biggy St,NRT5516, Los Angeles, CA 90033 USA.
EM seand168@gmail.com; weiming.yuan@usc.edu
OI Yuan, Weiming/0000-0002-4780-7157
FU NIH from the National Cancer CenterUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [P30CA014089];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R21 AI 149365]
FX The authors would like to express their appreciation for Professor
   Yong-Zhong Qian for some productive discussions. Weiming Yuan is
   supported by the NIH grant (R21 AI 149365) and partially supported by
   NIH grant P30CA014089 to the University of Southern California Norris
   Comprehensive Cancer Center from the National Cancer Center.
CR Backer JA, 2020, EURO SURVEILL, V25
   Beauchemin CAA, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S1-S7
   Bonhoeffer S, 1997, P NATL ACAD SCI USA, V94, P6971, DOI 10.1073/pnas.94.13.6971
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Doherty PC, 2006, NAT IMMUNOL, V7, P449, DOI 10.1038/ni1343
   Gizurarson S, 2012, CURR DRUG DELIV, V9, P566, DOI 10.2174/156720112803529828
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Janeway C. A., 2001, IMMUNOBIOLOGY IMMUNE
   Levy M, 2008, BERNE LEVY PHYSL
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Maines TR, 2008, IMMUNOL REV, V225, P68, DOI 10.1111/j.1600-065X.2008.00690.x
   Miao HY, 2010, J VIROL, V84, P6687, DOI 10.1128/JVI.00266-10
   Navarro S, 2017, GERONTOLOGY, V63, P270, DOI 10.1159/000451081
   Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103
   Nicholls JM, 2007, NAT MED, V13, P147, DOI 10.1038/nm1529
   Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74
   Nowak MA, 1996, P NATL ACAD SCI USA, V93, P4398, DOI 10.1073/pnas.93.9.4398
   Nowak MAMR, 2001, VIRUS DYNAMICS MATH
   Pawlina W, 2015, HISTOLOGY TEXT ATLAS
   Potter CW, 2004, PRINCIPLES PRACTICE, P271, DOI DOI 10.1002/0470020970
   Rawlins EL, 2008, AM J PHYSIOL-LUNG C, V295, pL231, DOI 10.1152/ajplung.90209.2008
   Tamura SI, 2004, JPN J INFECT DIS, V57, P236
   Thomas PG, 2006, EMERG INFECT DIS, V12, P48, DOI 10.3201/eid1201.051237
   van Riel D, 2006, SCIENCE, V312, P399, DOI 10.1126/science.1125548
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YJW, 2020, EARLY LOW DOSE SHORT
   Wodarz D, 2002, BIOESSAYS, V24, P1178, DOI 10.1002/bies.10196
   Wu C, 2020, SINGLE CELL RNA EXPR
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Zaza G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02978
   Zhao Y., 2020, BIORXIV
   Zhao Z, 2003, J MED MICROBIOL, V52, P715, DOI 10.1099/jmm.0.05320-0
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zitzmann C, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01546
NR 35
TC 9
Z9 9
U1 2
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD SEP
PY 2020
VL 92
IS 9
BP 1615
EP 1628
DI 10.1002/jmv.25866
EA MAY 2020
PG 14
WC Virology
SC Virology
GA NA8CG
UT WOS:000532535200001
PM 32356908
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Weinkove, R
   McQuilten, ZK
   Adler, J
   Agar, MR
   Blyth, E
   Cheng, AC
   Conyers, R
   Haeusler, GM
   Hardie, C
   Jackson, C
   Lane, SW
   Middlemiss, T
   Mollee, P
   Mulligan, SP
   Ritchie, D
   Ruka, M
   Solomon, B
   Szer, J
   Thursky, KA
   Wood, EM
   Worth, LJ
   Yong, MK
   Slavin, MA
   Teh, BW
AF Weinkove, Robert
   McQuilten, Zoe K.
   Adler, Jonathan
   Agar, Meera R.
   Blyth, Emily
   Cheng, Allen C.
   Conyers, Rachel
   Haeusler, Gabrielle M.
   Hardie, Claire
   Jackson, Christopher
   Lane, Steven W.
   Middlemiss, Tom
   Mollee, Peter
   Mulligan, Stephen P.
   Ritchie, David
   Ruka, Myra
   Solomon, Benjamin
   Szer, Jeffrey
   Thursky, Karin A.
   Wood, Erica M.
   Worth, Leon J.
   Yong, Michelle K.
   Slavin, Monica A.
   Teh, Benjamin W.
TI Managing haematology and oncology patients during the COVID-19 pandemic:
   interim consensus guidance
SO MEDICAL JOURNAL OF AUSTRALIA
LA English
DT Article
DE Immunosuppression; Hematologic neoplasms; Virus diseases; COVID-19
ID CELL TRANSPLANT RECIPIENTS; OUTCOMES; INFECTIONS; GUIDELINES; DIAGNOSIS;
   CHILDREN; VIRUS
AB Introduction A pandemic coronavirus, SARS-CoV-2, causes COVID-19, a potentially life-threatening respiratory disease. Patients with cancer may have compromised immunity due to their malignancy and/or treatment, and may be at elevated risk of severe COVID-19. Community transmission of COVID-19 could overwhelm health care services, compromising delivery of cancer care. This interim consensus guidance provides advice for clinicians managing patients with cancer during the pandemic.
   Main recommendations During the COVID-19 pandemic:
   In patients with cancer with fever and/or respiratory symptoms, consider causes in addition to COVID-19, including other infections and therapy-related pneumonitis.
   For suspected or confirmed COVID-19, discuss temporary cessation of cancer therapy with a relevant specialist.
   Provide information on COVID-19 for patients and carers.
   Adopt measures within cancer centres to reduce risk of nosocomial SARS-CoV-2 acquisition; support population-wide social distancing; reduce demand on acute services; ensure adequate staffing; and provide culturally safe care. Measures should be equitable, transparent and proportionate to the COVID-19 threat.
   Consider the risks and benefits of modifying cancer therapies due to COVID-19. Communicate treatment modifications, and review once health service capacity allows.
   Consider potential impacts of COVID-19 on the blood supply and availability of stem cell donors.
   Discuss and document goals of care, and involve palliative care services in contingency planning.
   Changes in management as a result of this statement This interim consensus guidance provides a framework for clinicians managing patients with cancer during the COVID-19 pandemic. In view of the rapidly changing situation, clinicians must also monitor national, state, local and institutional policies, which will take precedence.
   Endorsed by Australasian Leukaemia and Lymphoma Group; Australasian Lung Cancer Trials Group; Australian and New Zealand Children's Haematology/Oncology Group; Australia and New Zealand Society of Palliative Medicine; Australasian Society for Infectious Diseases; Bone Marrow Transplantation Society of Australia and New Zealand; Cancer Council Australia; Cancer Nurses Society of Australia; Cancer Society of New Zealand; Clinical Oncology Society of Australia; Haematology Society of Australia and New Zealand; National Centre for Infections in Cancer; New Zealand Cancer Control Agency; New Zealand Society for Oncology; and Palliative Care Australia.
C1 [Weinkove, Robert] Wellington Blood & Canc Ctr, Capital & Coast Dist Hlth Board, Wellington, New Zealand.
   [Weinkove, Robert] Malaghan Inst Med Res, Wellington, New Zealand.
   [McQuilten, Zoe K.; Cheng, Allen C.; Wood, Erica M.] Monash Univ, Melbourne, Vic, Australia.
   [McQuilten, Zoe K.; Wood, Erica M.] Monash Hlth, Melbourne, Vic, Australia.
   [Adler, Jonathan] Wellington Reg Hosp, Capital & Coast Dist Hlth Board, Wellington, New Zealand.
   [Agar, Meera R.] Univ Technol, Improving Palliat Aged & Chron Care Clin Res & Tr, Sydney, NSW, Australia.
   [Blyth, Emily] Westmead Hosp, Sydney, NSW, Australia.
   [Blyth, Emily] Westmead Inst Med Res, Sydney, NSW, Australia.
   [Conyers, Rachel] Royal Childrens Hosp, Childrens Canc Ctr, Melbourne, Vic, Australia.
   [Conyers, Rachel] Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   [Haeusler, Gabrielle M.; Szer, Jeffrey; Thursky, Karin A.; Worth, Leon J.; Yong, Michelle K.; Slavin, Monica A.; Teh, Benjamin W.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
   [Haeusler, Gabrielle M.; Worth, Leon J.; Yong, Michelle K.; Slavin, Monica A.; Teh, Benjamin W.] Royal Childrens Hosp, Melbourne, Vic, Australia.
   [Hardie, Claire] MidCent Dist Hlth Board, Palmerston North, New Zealand.
   [Jackson, Christopher] Canc Soc New Zealand, Wellington, New Zealand.
   [Jackson, Christopher] Univ Otago, Dunedin, New Zealand.
   [Lane, Steven W.] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia.
   [Middlemiss, Tom] Le Omanga Hosp, Lower Hutt, New Zealand.
   [Mollee, Peter] Princess Alexandra Hosp, Brisbane, Qld, Australia.
   [Mollee, Peter] Univ Queensland, Brisbane, Qld, Australia.
   [Mulligan, Stephen P.] Royal North Shore Hosp, Sydney, NSW, Australia.
   [Ritchie, David; Szer, Jeffrey; Thursky, Karin A.] Royal Melbourne Hosp, Melbourne, Vic, Australia.
   [Ruka, Myra] Waikato Dist Hlth Board, Hamilton, New Zealand.
   [Ruka, Myra] Univ Auckland, Auckland, New Zealand.
   [Solomon, Benjamin] Univ Melbourne, Melbourne, Vic, Australia.
RP McQuilten, ZK (corresponding author), Monash Univ, Melbourne, Vic, Australia.; McQuilten, ZK (corresponding author), Monash Hlth, Melbourne, Vic, Australia.
EM zoe.mcquilten@monash.edu
RI Weinkove, Robert/S-4457-2019
OI Weinkove, Robert/0000-0003-3645-7988; Yong,
   Michelle/0000-0002-8692-4145; Agar, Meera/0000-0002-6756-6119
CR AABB, 2020, UPD IMP 2019 NOV COR
   Australasian Bone Marrow Transplant Recipient Registry, 2018, ANN DAT SUMM 2018
   Australian Government Department of Health, 2020, AUSTR HLTH SECT EM R
   Bodey GP, 2000, INT J ANTIMICROB AG, V16, P93, DOI 10.1016/S0924-8579(00)00241-7
   Brouwers MC, 2010, PREV MED, V51, P421, DOI 10.1016/j.ypmed.2010.08.005
   Campbell AP, 2015, CLIN INFECT DIS, V61, P192, DOI 10.1093/cid/civ272
   Cancer Australia, OPT CAR PATHW AB TOR
   Carson JL, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub4
   Carville KS, 2007, PEDIATR INFECT DIS J, V26, P210, DOI 10.1097/01.inf.0000254148.09831.7f
   Centers for Disease Control and Prevention, INT CLIN GUID MAN PA
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang L, 2020, TRANSFUS MED REV, V34, P75, DOI 10.1016/j.tmrv.2020.02.003
   Chen Z, 2020, Zhonghua Xue Ye Xue Za Zhi, V41, P341, DOI 10.3760/cma.j.issn.0253-2727.2020.0004
   Couch Robert B., 1997, American Journal of Medicine, V102, P2, DOI 10.1016/S0002-9343(97)00003-X
   Cunningham J, 2008, LANCET ONCOL, V9, P585, DOI 10.1016/S1470-2045(08)70150-5
   Docherty AB, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1351
   Downar J, 2010, J PAIN SYMPTOM MANAG, V39, P291, DOI 10.1016/j.jpainsymman.2009.11.241
   Eichenberger EM, 2019, BONE MARROW TRANSPL, V54, P1058, DOI 10.1038/s41409-018-0386-z
   Engelmann I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170774
   Estcourt LJ, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3663-2
   Estcourt LJ, 2017, BRIT J HAEMATOL, V176, P365, DOI 10.1111/bjh.14423
   European Society for Blood and Marrow Transplantation, COR DIS COVID 19 EBM
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hakki M, 2015, J CLIN VIROL, V68, P1, DOI 10.1016/j.jcv.2015.04.012
   Hirsch HH, 2013, CLIN INFECT DIS, V56, P258, DOI 10.1093/cid/cis844
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Karafin MS, 2017, TRANSFUSION, V57, P2903, DOI 10.1111/trf.14370
   Kmeid J, 2016, BIOL BLOOD MARROW TR, V22, P542, DOI 10.1016/j.bbmt.2015.11.015
   Leong IYO, 2004, PALLIATIVE MED, V18, P12, DOI 10.1191/0269216304pm859oa
   Li W, 2020, PEDIATR RADIOL, V50, P796, DOI 10.1007/s00247-020-04656-7
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Medical Council of New Zealand, 2018, SAF PRACT ENV RES LI
   Medical Council of New Zealand, 2019, STAT CULT COMP PROV
   Mo A, 2017, INTERN MED J, V47, P695, DOI 10.1111/imj.13434
   Mueller MM, 2019, JAMA-J AM MED ASSOC, V321, P983, DOI 10.1001/jama.2019.0554
   Mukherjee R K, 2003, Australas Radiol, V47, P143, DOI 10.1046/j.0004-8461.2003.01165.x
   National Blood Authority, NAT BLOOD SUPPL CONT
   National Bone Marrow Donor Program, RESP COVID 19
   Ogimi C, 2019, J PEDIAT INF DIS SOC, V8, P21, DOI 10.1093/jpids/pix093
   Shah DP, 2014, BLOOD, V123, P3263, DOI 10.1182/blood-2013-12-541359
   Simcock R, 2020, CLIN TRANSL RAD ONCO, V22, P55, DOI 10.1016/j.ctro.2020.03.009
   Stanworth SJ, 2020, BRIT J HAEMATOL, V189, P279, DOI 10.1111/bjh.16347
   Stanworth SJ, 2013, NEW ENGL J MED, V368, P1771, DOI 10.1056/NEJMoa1212772
   Szer J, 2020, BONE MARROW TRANSPL, V55, P2043, DOI 10.1038/s41409-020-0873-x
   Teng AM, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2781-4
   Therapeutic Goods Administration, 2018, ICH GUID GOOD CLIN P
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   World Health Organization, 2019, PROT BLOOD SUPPL INF
   World Marrow Donor Association, COVID 19 IMP REG OP
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xia W, 2020, PEDIATR PULM, V55, P1169, DOI 10.1002/ppul.24718
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660
NR 57
TC 25
Z9 24
U1 4
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0025-729X
EI 1326-5377
J9 MED J AUSTRALIA
JI Med. J. Aust.
PD JUN
PY 2020
VL 212
IS 10
BP 481
EP 489
DI 10.5694/mja2.50607
EA MAY 2020
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA LU9RG
UT WOS:000532246700001
PM 32401360
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Johnson, NF
   Velasquez, N
   Restrepo, NJ
   Leahy, R
   Gabriel, N
   El Oud, S
   Zheng, MZ
   Manrique, P
   Wuchty, S
   Lupu, Y
AF Johnson, Neil F.
   Velasquez, Nicolas
   Restrepo, Nicholas Johnson
   Leahy, Rhys
   Gabriel, Nicholas
   El Oud, Sara
   Zheng Minzhang
   Manrique, Pedro
   Wuchty, Stefan
   Lupu, Yonatan
TI The online competition between pro- and anti-vaccination views
SO NATURE
LA English
DT Article
AB Insights into the interactions between pro- and anti-vaccination clusters on Facebook can enable policies and approaches that attempt to interrupt the shift to anti-vaccination views and persuade undecided individuals to adopt a pro-vaccination stance.
   Distrust in scientific expertise(1-14) is dangerous. Opposition to vaccination with a future vaccine against SARS-CoV-2, the causal agent of COVID-19, for example, could amplify outbreaks(2-4), as happened for measles in 2019(5,6). Homemade remedies(7,8) and falsehoods are being shared widely on the Internet, as well as dismissals of expert advice(9-11). There is a lack of understanding about how this distrust evolves at the system level(13,14). Here we provide a map of the contention surrounding vaccines that has emerged from the global pool of around three billion Facebook users. Its core reveals a multi-sided landscape of unprecedented intricacy that involves nearly 100 million individuals partitioned into highly dynamic, interconnected clusters across cities, countries, continents and languages. Although smaller in overall size, anti-vaccination clusters manage to become highly entangled with undecided clusters in the main online network, whereas pro-vaccination clusters are more peripheral. Our theoretical framework reproduces the recent explosive growth in anti-vaccination views, and predicts that these views will dominate in a decade. Insights provided by this framework can inform new policies and approaches to interrupt this shift to negative views. Our results challenge the conventional thinking about undecided individuals in issues of contention surrounding health, shed light on other issues of contention such as climate change(11), and highlight the key role of network cluster dynamics in multi-species ecologies(15).
C1 [Johnson, Neil F.; Gabriel, Nicholas; El Oud, Sara] George Washington Univ, Dept Phys, Washington, DC 20052 USA.
   [Johnson, Neil F.; Velasquez, Nicolas; Restrepo, Nicholas Johnson; Leahy, Rhys] George Washington Univ, Inst Data Democracy & Polit, Washington, DC 20052 USA.
   [Zheng Minzhang] Michigan State Univ, Inst Quantitat Hlth Sci & Engn, E Lansing, MI 48824 USA.
   [Manrique, Pedro] Los Alamos Natl Lab, Theoret Biol & Biophys Grp, Los Alamos, NM USA.
   [Wuchty, Stefan] Univ Miami, Dept Comp Sci, Coral Gables, FL 33124 USA.
   [Lupu, Yonatan] George Washington Univ, Dept Polit Sci, Washington, DC USA.
RP Johnson, NF (corresponding author), George Washington Univ, Dept Phys, Washington, DC 20052 USA.; Johnson, NF (corresponding author), George Washington Univ, Inst Data Democracy & Polit, Washington, DC 20052 USA.
EM neiljohnson@gwu.edu
RI Zheng, Minzhang/AAD-2861-2019
OI Zheng, Minzhang/0000-0003-2689-9539; Manrique, Pedro
   D./0000-0001-6715-8660; Lupu, Yonatan/0000-0002-1735-7511; Johnson, Neil
   F./0000-0002-3224-3213
CR Ammari T, 2016, ACM CONFERENCE ON COMPUTER-SUPPORTED COOPERATIVE WORK AND SOCIAL COMPUTING (CSCW 2016), P1363, DOI 10.1145/2818048.2819927
   [Anonymous], 2018, AUSTR CLIM SCI TARG
   Bail CA, 2018, P NATL ACAD SCI USA, V115, P9216, DOI 10.1073/pnas.1804840115
   Broniatowski DA, 2018, AM J PUBLIC HEALTH, V108, P1378, DOI 10.2105/AJPH.2018.304567
   Centola D, 2018, SCIENCE, V360, P1116, DOI 10.1126/science.aas8827
   CTCA, 2017, DANG FAK MED NEWS
   DiResta R, 2018, NAPSNET SPECIAL REPO
   Dredze M, 2016, VACCINE, V34, P3441, DOI 10.1016/j.vaccine.2016.05.008
   Frenkel S., 2020, NY TIMES
   Frimer JA, 2017, J EXP SOC PSYCHOL, V72, P1, DOI 10.1016/j.jesp.2017.04.003
   Fryxell JM, 2007, NATURE, V449, P1041, DOI 10.1038/nature06177
   Gavrilets S, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2014.1067
   Givetash L., 2019, NBC NEWS
   Haerlin B, 1999, NATURE, V400, P499, DOI 10.1038/22867
   Havlin S, 2014, EUR PHYS J-SPEC TOP, V223, P2087, DOI 10.1140/epjst/e2014-02251-6
   Huang YH, 2017, 2017 6TH IIAI INTERNATIONAL CONGRESS ON ADVANCED APPLIED INFORMATICS (IIAI-AAI), P542, DOI 10.1109/IIAI-AAI.2017.30
   Johnson NF, 2019, NATURE, V573, P261, DOI 10.1038/s41586-019-1494-7
   Johnson NF, 2016, SCIENCE, V352, P1459, DOI 10.1126/science.aaf0675
   Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022
   Kennedy W, 2019, TLS-TIMES LIT SUPPL, P6
   Lama Y, 2018, J MED INTERNET RES, V20, DOI 10.2196/10244
   Larson HJ, 2020, NATURE, V580, P306, DOI 10.1038/d41586-020-00920-w
   Manrique PD, 2018, PHYS REV LETT, V121, DOI 10.1103/PhysRevLett.121.048301
   Martin S, 2020, ROUTL INTERD PERSP, P18
   May R, 2007, THEORETICAL ECOLOGY
   Murray J D, 2003, MATH BIOL
   Newman MEJ, 2006, P NATL ACAD SCI USA, V103, P8577, DOI 10.1073/pnas.0601602103
   Palla G, 2007, NATURE, V446, P664, DOI 10.1038/nature05670
   Shapiro N, 2019, FORBES
   Starbird K, 2019, NATURE, V571, P449, DOI 10.1038/d41586-019-02235-x
   Zadrozny Brandon, 2019, NBC NEWS
   Zhao ZY, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.056107
   Zhao ZY, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.148701
NR 33
TC 18
Z9 18
U1 14
U2 22
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUN
PY 2020
VL 582
IS 7811
BP 230
EP +
DI 10.1038/s41586-020-2281-1
EA MAY 2020
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MB8KL
UT WOS:000532688300006
PM 32499650
OA Bronze
DA 2021-01-01
ER

PT J
AU Sepay, N
   Sepay, N
   Al Hoque, A
   Mondal, R
   Halder, UC
   Muddassir, M
AF Sepay, Nayim
   Sepay, Nadir
   Al Hoque, Ashique
   Mondal, Rina
   Halder, Umesh Chandra
   Muddassir, Mohd
TI In silico fight against novel coronavirus by finding chromone
   derivatives as inhibitor of coronavirus main proteases enzyme
SO STRUCTURAL CHEMISTRY
LA English
DT Article
DE Novel coronavirus; SARC-CoV-2 M-pro; Benzylidenechromanones; ADME; DFT;
   Docking
ID NATURALLY-OCCURRING HOMOISOFLAVONOIDS; POTENT; LIPOPHILICITY;
   PREDICTION; DESIGN; QSAR
AB Novel coronavirus, 2019-nCoV is a danger to the world and is spreading rapidly. Very little structural information about 2019-nCoV make this situation more difficult for drug designing. Benzylidenechromanones, naturally occurring oxygen heterocyclic compounds, having capability to inhibit various protein and receptors, have been designed here to block mutant variety of coronavirus main protease enzyme (SARC-CoV-2 M-pro) isolated from 2019-nCoV with the assistance of molecular docking, bioinformatics and molecular electrostatic potential. (Z)-3-(4 '-chlorobenzylidene)-thiochroman-4-one showed highest binding affinity to the protein. Binding of a compound to this protein actually inhibits the replication and transcription of the virus and, ultimately, stop the virus multiplication. Incorporation of any functional groups to the basic benzylidenechromanones enhances their binding ability. Chloro and bromo substitutions amplify the binding affinity. ADME studies of all these compounds indicate they are lipophilic, high gastro intestine absorbable and blood-brain barrier permeable. The outcome reveals that the investigated benzylidenechromanones can be examined in the case of 2019-nCoV as potent inhibitory drug of SARC-CoV-2 M-pro, for their strong inhibition ability, high reactivity and effective pharmacological properties.
C1 [Sepay, Nayim; Halder, Umesh Chandra] Jadavpur Univ, Dept Chem, Kolkata 700032, India.
   [Sepay, Nadir] Ramakrishna Mission Vivekananda Centenary Coll, Post Grad Dept Bot, Plant Biotechnol Lab, Kolkata 700118, India.
   [Al Hoque, Ashique] Jadavpur Univ, Dept Pharmaceut Technol, Kolkata 700032, India.
   [Mondal, Rina] Uluberia Coll, Dept Chem, Howrah 711315, W Bengal, India.
   [Muddassir, Mohd] King Saud Univ, Coll Sci, Dept Chem, Riyadh 11451, Saudi Arabia.
RP Sepay, N; Halder, UC (corresponding author), Jadavpur Univ, Dept Chem, Kolkata 700032, India.
EM nayimsepay@yahoo.com; uhalder2002@yahoo.com
RI Muddassir, Mohd/ABB-4258-2020
OI Muddassir, Mohd/0000-0001-7069-2557
FU University Grant Commission (UGC)-CAS-IIUniversity Grants Commission,
   India; King Saud University, Riyadh, Saudi ArabiaKing Saud University
   [RSP-2019/141]; DST-PURSE-II Program of Jadavpur University, Kolkata
FX This study is financially supported by University Grant Commission
   (UGC)-CAS-II and DST-PURSE-II Program of Jadavpur University, Kolkata
   and King Saud University (RSP-2019/141), Riyadh, Saudi Arabia.
CR Ali J, 2012, J CHEM INF MODEL, V52, P420, DOI 10.1021/ci200387c
   Arnott JA, 2012, EXPERT OPIN DRUG DIS, V7, P863, DOI 10.1517/17460441.2012.714363
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Cheng TJ, 2007, J CHEM INF MODEL, V47, P2140, DOI 10.1021/ci700257y
   Cohen J, 2016, INFECT DIS, V1
   Cohen J, 2016, INFECT DIS, V2
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Delaney JS, 2004, J CHEM INF COMP SCI, V44, P1000, DOI 10.1021/ci034243x
   Desideri N, 2011, J MED CHEM, V54, P2155, DOI 10.1021/jm1013709
   Emami S, 2015, EUR J MED CHEM, V93, P539, DOI 10.1016/j.ejmech.2015.02.048
   Famuyiwa SO, 2013, S AFR J BOT, V88, P17, DOI 10.1016/j.sajb.2013.04.009
   Foroumadi A, 2007, BIOORG MED CHEM LETT, V17, P6764, DOI 10.1016/j.bmcl.2007.10.034
   Frisch M. J., 2013, GAUSSIAN 09 REVISION
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Lin LG, 2008, J MED CHEM, V51, P4419, DOI 10.1021/jm701501x
   Lin LG, 2014, PLANTA MED, V80, P1053, DOI 10.1055/s-0034-1383026
   Ma LY, 2015, J MED CHEM, V58, P1705, DOI 10.1021/acs.jmedchem.5b00037
   Mannhold R, 2009, J PHARM SCI-US, V98, P861, DOI 10.1002/jps.21494
   MORIGUCHI I, 1994, CHEM PHARM BULL, V42, P976
   MORIGUCHI I, 1992, CHEM PHARM BULL, V40, P127
   Ottaviani G, 2010, EUR J PHARM SCI, V41, P452, DOI 10.1016/j.ejps.2010.07.012
   Panche AN, 2016, J NUTR SCI, V5, DOI 10.1017/jns.2016.41
   Perjesi P, 2008, EUR J MED CHEM, V43, P839, DOI 10.1016/j.ejmech.2007.06.017
   Pliska V., 2008, LIPOPHILICITY DRUG A, V4, DOI 10.1002/9783527614998.
   Ravasco JMJM, 2019, CHEM-EUR J, V25, P43, DOI 10.1002/chem.201803174
   Roy K, 2005, QSAR COMB SCI, V24, P579, DOI 10.1002/qsar.200430901
   Roy K, 2001, QUANT STRUCT-ACT REL, V20, P319, DOI 10.1002/1521-3838(200111)20:4&lt;319::AID-QSAR319&gt;3.0.CO;2-M
   Roy SK, 2013, EUR J MED CHEM, V66, P499, DOI 10.1016/j.ejmech.2013.06.024
   Savjani KT, 2010, ISRN PHARM, V2012, P195727
   Sepay N, 2016, RSC ADV, V6, P96016, DOI 10.1039/c6ra13584f
   Siddalah V, 2006, BIOORGAN MED CHEM, V14, P2545, DOI 10.1016/j.bmc.2005.11.031
   Sousa SF, 2006, PROTEINS, V65, P15, DOI 10.1002/prot.21082
   Wildman SA, 1999, J CHEM INF COMP SCI, V39, P868, DOI 10.1021/ci990307l
   World Health Organization, COR DIS COVID 2019 S
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yan J, 2012, PHYTOCHEMISTRY, V80, P37, DOI 10.1016/j.phytochem.2012.05.014
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 40
TC 3
Z9 3
U1 1
U2 3
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1040-0400
EI 1572-9001
J9 STRUCT CHEM
JI Struct. Chem.
PD OCT
PY 2020
VL 31
IS 5
BP 1831
EP 1840
DI 10.1007/s11224-020-01537-5
EA MAY 2020
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Crystallography
SC Chemistry; Crystallography
GA NK5NY
UT WOS:000532617800002
PM 32412544
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Meziyerh, S
   Zwart, TC
   van Etten, RW
   Janson, JA
   van Gelder, T
   Alwayn, IPJ
   de Fijter, JW
   Reinders, MEJ
   Moes, DJAR
   de Vries, APJ
AF Meziyerh, Soufian
   Zwart, Tom C.
   van Etten, Ronald W.
   Janson, Jeroen A.
   van Gelder, Teun
   Alwayn, Ian P. J.
   de Fijter, Johan W.
   Reinders, Marlies E. J.
   Moes, Dirk J. A. R.
   de Vries, Aiko P. J.
TI Severe COVID-19 in a renal transplant recipient: A focus on
   pharmacokinetics
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE clinical decision-making; clinical research; practice; drug interaction;
   immunosuppressive regimens; infection and infectious agents - viral;
   infectious disease; kidney transplantation; nephrology;
   pharmacokinetics; pharmacodynamics; pharmacology
ID CLINICAL PHARMACOKINETICS; PHARMACODYNAMICS; CYCLOSPORINE; REPLICATION;
   CELL
AB The current coronavirus disease 2019 (COVID-19) pandemic requires extra attention for immunocompromised patients, including solid organ transplant recipients. We report on a case of a 35-year-old renal transplant recipient who suffered from a severe COVID-19 pneumonia. The clinical course was complicated by extreme overexposure to the mammalian target of rapamycin inhibitor everolimus, following coadministration of chloroquine and lopinavir/ritonavir therapy. The case is illustrative for dilemmas that transplant professionals may face in the absence of evidence-based COVID-19 therapy and concurrent pressure for exploration of experimental pharmacological treatment options. However, the risk-benefit balance of experimental or off-label therapy may be weighed differently in organ transplant recipients than in otherwise healthy COVID-19 patients, owing to their immunocompromised status and potential drug interactions with immunosuppressive therapy. With this case report, we aimed to achieve increased awareness and improved management of drug-drug interactions associated with the various treatment options for COVID-19 in renal transplant patients.
C1 [Meziyerh, Soufian; de Fijter, Johan W.; Reinders, Marlies E. J.; de Vries, Aiko P. J.] Leiden Univ, Med Ctr, Div Nephrol, Dept Internal Med, Leiden, Netherlands.
   [Meziyerh, Soufian; Alwayn, Ian P. J.; de Fijter, Johan W.; Reinders, Marlies E. J.; de Vries, Aiko P. J.] Leiden Univ, Med Ctr, LUMC Transplant Ctr, Leiden, Netherlands.
   [Zwart, Tom C.; van Gelder, Teun; Moes, Dirk J. A. R.] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands.
   [van Etten, Ronald W.] Amphia Hosp, Div Nephrol, Dept Internal Med, Breda, Netherlands.
   [Janson, Jeroen A.] Leiden Univ, Med Ctr, Dept Intens Care, Leiden, Netherlands.
   [Alwayn, Ian P. J.] Leiden Univ, Med Ctr, Dept Surg, Div Transplantat Surg, Leiden, Netherlands.
RP Meziyerh, S (corresponding author), Leiden Univ, Med Ctr, Div Nephrol, Dept Internal Med, Leiden, Netherlands.; Meziyerh, S (corresponding author), Leiden Univ, Med Ctr, LUMC Transplant Ctr, Leiden, Netherlands.
EM s.meziyerh@lumc.nl
RI de Vries, Aiko/J-5397-2015
OI de Vries, Aiko/0000-0002-9284-3595; Meziyerh,
   Soufian/0000-0001-7694-8381; Reinders, Marlies/0000-0001-9543-567X
CR Al Ghamdi M, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1492-4
   Bergmann TK, 2012, CLIN PHARMACOKINET, V51, P711, DOI 10.1007/s40262-012-0007-8
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   FINIELZ P, 1993, NEPHRON, V65, P333, DOI 10.1159/000187506
   Guan WJ, 2020, NEW ENGL J MED, V382, P727
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Kim YJ, 2007, SEMIN RESP CRIT CARE, V28, P222, DOI 10.1055/s-2007-976494
   Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001
   NAMPOORY MRN, 1992, NEPHRON, V62, P108
   Staatz CE, 2007, CLIN PHARMACOKINET, V46, P13, DOI 10.2165/00003088-200746010-00002
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   van Maarseveen EM, 2012, AIDS PATIENT CARE ST, V26, P568, DOI 10.1089/apc.2012.0169
   Vollaard E, 2020, DRUG TREATMENT OPTIO
   White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1
   Xu TM, 2020, INT J INFECT DIS, V94, P68, DOI 10.1016/j.ijid.2020.03.022
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 20
TC 15
Z9 15
U1 2
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUL
PY 2020
VL 20
IS 7
BP 1896
EP 1901
DI 10.1111/ajt.15943
EA MAY 2020
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA MD1JV
UT WOS:000531893300001
PM 32337790
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Abdelli, I
   Hassani, F
   Brikci, SB
   Ghalem, S
AF Abdelli, Imane
   Hassani, Faical
   Brikci, Sohayb Bekkel
   Ghalem, Said
TI In silico study the inhibition of angiotensin converting enzyme 2
   receptor of COVID-19 by Ammoides verticillata components harvested from
   Western Algeria
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Ammoides verticillata; Angiotensin converting enzyme 2; COVID-19;
   isothymol; molcular docking
ID NORMAL-MODE ANALYSIS; DRUG DISCOVERY; PREDICTION; OIL
AB The objective of this present study is to focus on the in silico study to screen for an alternative drug that can block the activity of the angiotensin converting enzyme 2 (ACE2) as a receptor for SARS-CoV-2, potential therapeutic target of the COVID-19 virus using natural compounds (Isothymol, Thymol, Limonene, P-cymene and gamma-terpinene) derived from the essential oil of the antiviral and antimicrobial plant Ammoides verticillata (Desf.) Briq. which is located in the occidental Algeria areas. This study reveals that Isothymol, a major component of this plant, gives the best docking scores, compared to, the co-crystallized inhibitor beta-D-mannose of the enzyme ACE2, to Captropil drug as good ACE2 inhibitor and to Chloroquine antiviral drug also involved in other mechanisms as inhibition of ACE2 cellular receptor. In silico (ADME), drug-likeness, PASS & P450 site of metabolism prediction, pharmacophore Mapper showed that the compound Isothymol has given a good tests results compared to the beta-D-mannose co-crystallized inhibitor, to Captopril and Chloroquine drugs. Also the other natural compounds gave good results. The Molecular Dynamics Simulation study showed good result for the Isotymol- ACE2 docked complex. This study revealed for the first time that Isothymol is a functional inhibitor of angiotensin converting enzyme 2 activity and the components of essential oils Ammoides verticillata can be used as potential inhibitors to the ACE2 receptor of SARS-CoV-2. Communicated by Ramaswamy H. Sarma
C1 [Abdelli, Imane] Higher Sch Appl Sci, Tilimsen, Algeria.
   [Abdelli, Imane; Ghalem, Said] Fac Sci Univ, Lab Nat & Bioact Subst, Tilimsen, Algeria.
   [Hassani, Faical; Brikci, Sohayb Bekkel] Fac SNV STU Univ, Dept Ecol & Environm, Ecol & Management Naturals Ecosyst Lab, Tilimsen, Algeria.
RP Hassani, F (corresponding author), Fac SNV STU Univ, Dept Ecol & Environm, Ecol & Management Naturals Ecosyst Lab, Tilimsen, Algeria.
EM faicalhassani@yahoo.fr
RI GHALEM, Said/ABE-3599-2020
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abdelouahid D. E., 2002, BIOL SANTE, V4, P91
   Aronov MM, 2005, DRUG DISCOV TODAY, V10, P149, DOI 10.1016/S1359-6446(04)03278-7
   Avesina A., 1985, LAW MED, P187
   Awan FM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010139
   Bekhechi C., 2002, ANAL HUILE ESSENTIEL
   Bekhechi C, 2010, NAT PROD COMMUN, V5, P1107
   Bhargava H., 1961, J AM OIL CHEM SOC, V72, P1215, DOI [10.1007/BF02540992, DOI 10.1007/BF02540992]
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Boskabady MH, 2000, J ETHNOPHARMACOL, V69, P217, DOI 10.1016/S0378-8741(99)00116-6
   Clement G., 2006, FUNDAMENTALS SPACE B, P18
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Didierjean C., 2016, INTRO PROTEIN SCI AR, P466
   Dixon SL, 2006, J COMPUT AID MOL DES, V20, P647, DOI 10.1007/s10822-006-9087-6
   Dubey N. K., 1990, T INDIAN DRUGS, V27, P529
   Egan WJ, 2000, J MED CHEM, V43, P3867, DOI 10.1021/jm000292e
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Ghose AK, 1999, J COMB CHEM, V1, P55, DOI 10.1021/cc9800071
   Grosjean N., 2004, HUILES ESSENTIELLES, P98
   Guastalegname M, 2020, CLIN INFECT DIS, V71, P888, DOI 10.1093/cid/ciaa321
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Higley C., 2005, QUICK REFERENCE GUID, P6
   Hopkins C, 2020, LOSS SENSE SMELL MAR
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   HyperChem v8, 2009, MOL MODELLING SYSTEM
   JOSHI B. S., 1963, Bull. Jammu Res. Lab., V1, P94
   Kambouche N, 2003, J ESSENT OIL RES, V15, P39, DOI 10.1080/10412905.2003.9712259
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Lagunin A, 2000, BIOINFORMATICS, V16, P747, DOI 10.1093/bioinformatics/16.8.747
   Lawrence B. M., 2006, PERFUMER FLAVORIST, V31, P63
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Muegge I, 2001, J MED CHEM, V44, P1841, DOI 10.1021/jm015507e
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   NARAYANA C, 1967, INDIAN J TECHNOL, V5, P268
   Pant S., 2020, J BIOMOLECULAR STRUC, DOI [10.1080/07391102.1757510, DOI 10.1080/07391102.1757510]
   Pole S., 2013, AYURVEDIC MED PRINCI, P122
   Prabhakar PK, 2016, J BIOMOL STRUCT DYN, V34, P778, DOI 10.1080/07391102.2015.1054430
   Quezel P., 1963, NOUVELLE FLORE ALGER, VII, P671
   Lopez-Blanco JR, 2014, NUCLEIC ACIDS RES, V42, pW271, DOI 10.1093/nar/gku339
   Lopez-Blanco JR, 2011, BIOINFORMATICS, V27, P2843, DOI 10.1093/bioinformatics/btr497
   Sahin S, 2008, PHARM RES-DORDR, V25, P2869, DOI 10.1007/s11095-008-9787-9
   Sandberg F., 2001, NATURAL REMEDIES THE
   SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Schirner M., 2004, GUY TREDANIEL, P23
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Simon L, 2017, INTERDISCIP SCI, V9, P445, DOI 10.1007/s12539-016-0169-4
   Smalling RW, 1996, AM J CARDIOL, V78, P2, DOI 10.1016/S0002-9149(96)00736-9
   Stewart JJP, 2007, J MOL MODEL, V13, P1173, DOI 10.1007/s00894-007-0233-4
   Swierczewska M, 2015, EXPERT OPIN EMERG DR, V20, P531, DOI 10.1517/14728214.2015.1113254
   Trabut L, 1935, COLLECTION CENTENAIR
   Trabut L. C., 1935, COLLECTION CENTENAIR, P355
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Zaretzki J, 2013, BIOINFORMATICS, V29, P497, DOI 10.1093/bioinformatics/bts705
NR 60
TC 14
Z9 15
U1 5
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1763199
EA MAY 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LP2LO
UT WOS:000534151600001
PM 32362217
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Friedlaender, A
   Kim, C
   Addeo, A
AF Friedlaender, Alex
   Kim, Chul
   Addeo, Alfredo
TI Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in
   Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE NSCLC; COVID19; immune checkpoint inhibitors; duration; first line
ID ADVERSE EVENTS; ASSOCIATION; PEMBROLIZUMAB; IMMUNOTHERAPY; NIVOLUMAB;
   OUTCOMES
AB Immune checkpoint inhibitors (ICPIs) have revolutionized the management and prognosis of fit patients with advanced non-small cell lung cancer (NSCLC). Recently, the publication of 5-year survival rates has cemented the role of ICPIs in NSCLC. An ongoing challenge is to determine the optimal treatment duration to find the balance between efficacy, toxicity and cost. From the onset of ICPI trials, different durations were used, ranging from treatment until progression or toxicity, to fixed durations of 2 years. Subsequently, exploratory analyses from a 1-year fixed duration trial failed to change practice. There are, to date, no adequately powered prospective trials addressing this important question. With today's severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) pandemic, more than ever, the question resurfaces with added factors tilting the already shaky therapeutic balance. Here, we will discuss current data regarding ICPI treatment duration and incorporate this into the context of the ongoing pandemic. We conclude with a discussion of pragmatic approaches, should physicians be unable to continue standard therapy.
C1 [Friedlaender, Alex; Addeo, Alfredo] Univ Hosp Geneva HUG, Dept Oncol, Geneva, Switzerland.
   [Kim, Chul] Georgetown Univ, Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA.
RP Addeo, A (corresponding author), Univ Hosp Geneva HUG, Dept Oncol, Geneva, Switzerland.
EM alfdoc2@libero.it
CR Addeo A, 2019, JAMA ONCOL, V5, P934, DOI 10.1001/jamaoncol.2019.0626
   Addeo A, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00264
   Banna G, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2020-000765
   Berner F, 2019, JAMA ONCOL, V5, P1043, DOI 10.1001/jamaoncol.2019.0402
   Borrero-Abarca A, 2020, LUNG CANCER, V139, pS56
   Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609
   Facchinetti F, 2020, EUR J CANCER, V130, P155, DOI 10.1016/j.ejca.2020.02.023
   Friedlaender A, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00142
   Friedlaender A, 2020, CANCER TREAT REV, V85, DOI 10.1016/j.ctrv.2020.101978
   Friedlaender A, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0852-9
   Garassino M, 2020, 1 RESULTS GLOBAL COL
   Gettinger S, 2018, J CLIN ONCOL, V36, P1675, DOI 10.1200/JCO.2017.77.0412
   Goldberg SB, 2018, CLIN CANCER RES, V24, P1872, DOI 10.1158/1078-0432.CCR-17-1341
   Gray JE, 2020, J THORAC ONCOL, V15, P288, DOI 10.1016/j.jtho.2019.10.002
   Haratani K, 2018, JAMA ONCOL, V4, P374, DOI 10.1001/jamaoncol.2017.2925
   Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231
   Hellmann MD, 2020, CLIN CANCER RES, V26, P2849, DOI 10.1158/1078-0432.CCR-19-3418
   Jansen YJL, 2019, ANN ONCOL, V30, P1154, DOI 10.1093/annonc/mdz110
   Kleiman MA, 2004, NEW TREATMENTS ADDIC, P213
   Leigh NB, 2019, LANCET RESP MED, V7, P347, DOI 10.1016/S2213-2600(18)30500-9
   Levra MG, 2020, LUNG CANCER, V140, P99, DOI 10.1016/j.lungcan.2019.12.017
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mezquita L, 2018, JAMA ONCOL, V4, P351, DOI 10.1001/jamaoncol.2017.4771
   Middleton G, 2020, LANCET RESP MED, V8, P895, DOI 10.1016/S2213-2600(20)30033-3
   multicenter collaboration group of Department of S Technology of Guangdong P Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus p, 2020, ZHONGHUA JIE HE HE H, V43, pE019, DOI DOI 10.3760/cma.j.cn112147-20200221-00138
   Passaro A, 2019, J CLIN ONCOL, V37, P1863, DOI 10.1200/JCO.18.02118
   PLANCHARD D, 2019, J CLIN ONCOL S, V37, DOI DOI 10.1200/JCO.2019.37.15_suppl.9054
   Reck M, 2019, J CLIN ONCOL, V37, P537, DOI 10.1200/JCO.18.00149
   Robert C, 2019, LANCET ONCOL, V20, P1239, DOI 10.1016/S1470-2045(19)30388-2
   Simonaggio A, 2019, JAMA ONCOL, V5, P1310, DOI 10.1001/jamaoncol.2019.1022
   Tan AC, 2020, LUNG CANCER, V139, P207, DOI 10.1016/j.lungcan.2019.11.022
   Teraoka S, 2017, J THORAC ONCOL, V12, P1798, DOI 10.1016/j.jtho.2017.08.022
   Teulings HE, 2015, J CLIN ONCOL, V33, P773, DOI 10.1200/JCO.2014.57.4756
   Thomas S, 2017, ANN ONCOL, V28
   Topalian SL, 2019, JAMA ONCOL, V5, P1411, DOI 10.1001/jamaoncol.2019.2187
   Torralvo J, 2019, CANCER GENOM PROTEOM, V16, P577, DOI 10.21873/cgp.20160
   von Pawel J, 2019, EUR J CANCER, V107, P124, DOI 10.1016/j.ejca.2018.11.020
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
NR 39
TC 4
Z9 3
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD MAY 12
PY 2020
VL 10
AR 862
DI 10.3389/fonc.2020.00862
PG 6
WC Oncology
SC Oncology
GA LV5JP
UT WOS:000538471500001
PM 32574277
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Verma, V
   Vishwakarma, RK
   Verma, A
   Nath, DC
   Khan, HTA
AF Verma, Vivek
   Vishwakarma, Ramesh K.
   Verma, Anita
   Nath, Dilip C.
   Khan, Hafiz T. A.
TI Time-to-Death approach in revealing Chronicity and Severity of COVID-19
   across the World
SO PLOS ONE
LA English
DT Article
AB Background
   The outbreak of coronavirus disease, 2019 (COVID-19), which started from Wuhan, China, in late 2019, have spread worldwide. A total of 5,91,971 cases and 2,70,90 deaths were registered till 28th March, 2020. We aimed to predict the impact of duration of exposure to COVID-19 on the mortality rates increment.
   Methods
   In the present study, data on COVID-19 infected top seven countries viz., Germany, China, France, United Kingdom, Iran, Italy and Spain, and World as a whole, were used for modeling. The analytical procedure of generalized linear model followed by Gompertz link function was used to predict the impact lethal duration of exposure on the mortality rates.
   Findings
   Of the selected countries and World as whole, the projection based on 21st March, 2020 cases, suggest that a total (95% Cl) of 76 (65-151) days of exposure in Germany, mortality rate will increase by 5 times to 1%. In countries like France and United Kingdom, our projection suggests that additional exposure of 48 days and 7 days, respectively, will raise the mortality rates to10%. Regarding Iran, Italy and Spain, mortality rate will rise to 10% with an additional 3-10 days of exposure. World's mortality rates will continue increase by 1% in every three weeks. The predicted interval of lethal duration corresponding to each country has found to be consistent with the mortality rates observed on 28th March, 2020.
   Conclusion
   The prediction of lethal duration was found to have apparently effective in predicting mortality, and shows concordance with prevailing rates. In absence of any vaccine against COVID-19 infection, the present study adds information about the quantum of the severity and time elapsed to death will help the Government to take necessary and appropriate steps to control this pandemic.
C1 [Verma, Vivek; Verma, Anita] All India Inst Med Sci AIIMS, Dept Neurol, New Delhi, India.
   [Vishwakarma, Ramesh K.] King Saud bin Abdulaziz Univ Hlth Sci MNGHA, King Abdullah Int Med Res Ctr, Dept Biostat & Bioinformat, Riyadh, Saudi Arabia.
   [Nath, Dilip C.] Assam Univ, Silchar, Assam, India.
   [Khan, Hafiz T. A.] Univ West London, Grad Sch, London, England.
RP Verma, V (corresponding author), All India Inst Med Sci AIIMS, Dept Neurol, New Delhi, India.
EM viv_verma456@yahoo.com
OI VERMA, VIVEK/0000-0003-2537-4431
CR Annelies Wilder-Smith, 2020, J TRAVEL MED, V27
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Notomi T, 1999, CHEMOTHERAPY, V45, P242, DOI 10.1159/000007192
   Padmanaban V, 2020, CUREUS, V12, DOI 10.7759/cureus.7398
   Peeri Noah C., 2020, INT J EPIDEMIOLOGY
   Petropoulos F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231236
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang C, 2020, LANCET GASTROENTEROL
NR 13
TC 7
Z9 7
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 12
PY 2020
VL 15
IS 5
AR e0233074
DI 10.1371/journal.pone.0233074
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LU0SY
UT WOS:000537475000041
PM 32396542
OA DOAJ Gold, Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Mohn, N
   Pul, R
   Kleinschnitz, C
   Pruss, H
   Witte, T
   Stangel, M
   Skripuletz, T
AF Moehn, Nora
   Pul, Refik
   Kleinschnitz, Christoph
   Pruess, Harald
   Witte, Torsten
   Stangel, Martin
   Skripuletz, Thomas
TI Implications of COVID-19 Outbreak on Immune Therapies in Multiple
   Sclerosis Patients-Lessons Learned From SARS and MERS
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE SARS; MERS; COVID-19; multiple sclerosis; immunosuppressive therapy;
   DMTs
ID RESPIRATORY SYNDROME CORONAVIRUS; INTERFERON-BETA; RESPONSES; INNATE;
   REPLICATION; INDUCTION; DISEASE; CELLS
AB Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic keeps the world in suspense. In addition to the fundamental challenges for the health care system, the individual departments must decide how to deal with patients at risk. Neurologists are confronted with the question, how they should advise their patients regarding immunosuppressive treatment. In particular, the large number of different disease-modifying therapies (DMTs) in the treatment of neuroimmunological diseases such as multiple sclerosis poses a challenge. To a limited extent, it might be useful to transfer knowledge from previous SARS- and Middle East respiratory syndrome (MERS) coronavirus outbreaks in 2002/2003 and 2012 to the current situation. Overall, immunosuppressive therapy does neither seem to have a major impact on infection with SARS- and MERS-CoV nor does it seem to lead to a severe disease course in many cases. Considering the immunological responses against infections with novel coronaviruses in humans, interferons, glatiramer acetate, and teriflunomide appear to be safe. As lymphopenia seems to be associated with a more severe disease course, all DMTs causing lymphopenia, such as cladribine, alemtuzumab, and dimethyl fumarate, need to be reviewed more thoroughly. As they are, in general, associated with a higher risk of infection, depleting anti-CD20 antibodies may be problematic drugs. However, it has to be differentiated between the depletion phase and the phase of immune reconstitution. In summary, previous coronavirus outbreaks have not shown an increased risk for immunocompromised patients. Patients with severe neuroimmunological diseases should be kept from hasty discontinuation of immunotherapy.
C1 [Moehn, Nora; Stangel, Martin; Skripuletz, Thomas] Hannover Med Sch, Dept Neurol, Hannover, Germany.
   [Pul, Refik; Kleinschnitz, Christoph] Univ Hosp Essen, Dept Neurol, Essen, Germany.
   [Pruess, Harald] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany.
   [Pruess, Harald] German Ctr Neurodegenerat Dis DZNE, Berlin, Germany.
   [Witte, Torsten] Hannover Med Sch, Dept Rheumatol & Immunol, Hannover, Germany.
RP Skripuletz, T (corresponding author), Hannover Med Sch, Dept Neurol, Hannover, Germany.
EM skripuletz.thomas@MH-Hannover.de
FU Deutsche Forschungsgemeinschaft through the Cluster of Excellence
   RESISTGerman Research Foundation (DFG) [EXC 2155, 390874280]
FX MS and TW are supported by the Deutsche Forschungsgemeinschaft through
   the Cluster of Excellence RESIST (EXC 2155)-Project ID 390874280.
CR Al-Abdallat MM, 2014, CLIN INFECT DIS, V59, P1225, DOI 10.1093/cid/ciu359
   Al-Qahtani AA, 2017, ONCOTARGET, V8, P9053, DOI 10.18632/oncotarget.14754
   Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Bar-Or A, 2014, DRUGS, V74, P659, DOI 10.1007/s40265-014-0212-x
   Butler D, 2012, NATURE, V492, P166, DOI 10.1038/492166a
   Cameron MJ, 2007, J VIROL, V81, P8692, DOI 10.1128/JVI.00527-07
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chu H, 2014, VIROLOGY, V454, P197, DOI 10.1016/j.virol.2014.02.018
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   de Wilde AH, 2013, J GEN VIROL, V94, P1749, DOI 10.1099/vir.0.052910-0
   Gilli F, 2017, J NEUROVIROL, V23, P825, DOI 10.1007/s13365-017-0570-8
   Gingele S, 2020, NEURAL REGEN RES, V15, P663, DOI 10.4103/1673-5374.266913
   Gingele S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010012
   Hart BJ, 2014, J GEN VIROL, V95, P571, DOI 10.1099/vir.0.061911-0
   Hemmer B, 2017, NAT REV NEUROL, V13, P72, DOI 10.1038/nrneurol.2017.2
   Hensley LE, 2004, EMERG INFECT DIS, V10, P317, DOI 10.3201/eid1002.030482
   Hoey J, 2003, CAN MED ASSOC J, V168, P1566
   Horga A, 2010, EXPERT OPIN PHARMACO, V11, P1183, DOI 10.1517/14656561003769866
   Kohlmeier JE, 2009, ANNU REV IMMUNOL, V27, P61, DOI 10.1146/annurev.immunol.021908.132625
   Lau SKP, 2013, J GEN VIROL, V94, P2679, DOI 10.1099/vir.0.055533-0
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lucchinetti CF, 1998, SEMIN NEUROL, V18, P337, DOI 10.1055/s-2008-1040885
   Luna G, 2020, JAMA NEUROL, V77, P184, DOI 10.1001/jamaneurol.2019.3365
   Modica CM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182729
   Mubarak A, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6491738
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Pol S, 2019, J NEUROIMAGING, V29, P52, DOI 10.1111/jon.12561
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ruggieri M, 2007, CNS DRUG REV, V13, P178, DOI 10.1111/j.1527-3458.2007.00010.x
   Spiegel M, 2004, J CLIN VIROL, V30, P211, DOI 10.1016/j.jcv.2003.11.013
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
   Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576
   Xu XJ, 2004, CELL MOL IMMUNOL, V1, P119
   Yang LT, 2006, CLIN IMMUNOL, V120, P171, DOI 10.1016/j.clim.2006.05.002
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zumla A, 2015, LANCET, V386, P995, DOI 10.1016/S0140-6736(15)60454-8
NR 38
TC 3
Z9 3
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAY 12
PY 2020
VL 11
AR 1059
DI 10.3389/fimmu.2020.01059
PG 5
WC Immunology
SC Immunology
GA LT4VO
UT WOS:000537070700001
PM 32477373
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nutho, B
   Mahalapbutr, P
   Hengphasatporn, K
   Pattaranggoon, NC
   Simanon, N
   Shigeta, Y
   Hannongbua, S
   Rungrotmongkol, T
AF Nutho, Bodee
   Mahalapbutr, Panupong
   Hengphasatporn, Kowit
   Pattaranggoon, Nawanwat Chainuwong
   Simanon, Nattapon
   Shigeta, Yasuteru
   Hannongbua, Supot
   Rungrotmongkol, Thanyada
TI Why Are Lopinavir and Ritonavir Effective against the Newly Emerged
   Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms
SO BIOCHEMISTRY
LA English
DT Article
ID MOLECULAR-DYNAMICS; MAIN PROTEINASE; SARS; PROTEASE; BINDING;
   LOPINAVIR/RITONAVIR; SUSCEPTIBILITY; SIMULATIONS; DISCOVERY; DESIGN
AB Since the emergence of a novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported from Wuhan, China, neither a specific vaccine nor an antiviral drug against SARS-CoV-2 has become available. However, a combination of two HIV-1 protease inhibitors, lopinavir and ritonavir, has been found to be effective against SARS-CoV, and both drugs could bind well to the SARS-CoV 3C-like protease (SARS-CoV 3CL(pro)). In this work, molecular complexation between each inhibitor and SARS-CoV-2 3CL(pro) was studied using all-atom molecular dynamics simulations, free energy calculations, and pair interaction energy analyses based on MM/PB(GB)SA and FMO-MP2/PCM/6-31G* methods. Both anti-HIV drugs interacted well with the residues at the active site of SARS-CoV-2 3CL(pro). Ritonavir showed a somewhat higher number atomic contacts, a some what higher binding efficiency, and a somewhat higher number of key binding residues compared to lopinavir, which correspond with the slightly lower water accessibility at the 3CL(pro) active site. In addition, only ritonavir could interact with the oxyanion hole residues N142 and G143 via the formation of two hydrogen bonds. The interactions in terms of electrostatics, dispersion, and charge transfer played an important role in the drug binding. The obtained results demonstrated how repurposed anti-HIV drugs could be used to combat COVID-19.
C1 [Rungrotmongkol, Thanyada] Chulalongkorn Univ, Grad Sch, Dept Biochem, Struct & Computat Biol Res Unit,Fac Sci, Bangkok 10330, Thailand.
   [Pattaranggoon, Nawanwat Chainuwong; Simanon, Nattapon; Rungrotmongkol, Thanyada] Chulalongkorn Univ, Grad Sch, Program Bioinformat & Computat Biol, Bangkok 10330, Thailand.
   [Nutho, Bodee; Hannongbua, Supot] Chulalongkorn Univ, Fac Sci, Dept Chem, Ctr Excellence Computat Chem CECC, Bangkok 10330, Thailand.
   [Mahalapbutr, Panupong] Chulalongkorn Univ, Fac Sci, Dept Biochem, Struct & Computat Biol Res Unit, Bangkok 10330, Thailand.
   [Hengphasatporn, Kowit; Shigeta, Yasuteru] Univ Tsukuba, Ctr Computat Sci, Tsukuba, Ibaraki 3058577, Japan.
RP Rungrotmongkol, T (corresponding author), Chulalongkorn Univ, Grad Sch, Dept Biochem, Struct & Computat Biol Res Unit,Fac Sci, Bangkok 10330, Thailand.; Rungrotmongkol, T (corresponding author), Chulalongkorn Univ, Grad Sch, Program Bioinformat & Computat Biol, Bangkok 10330, Thailand.; Hannongbua, S (corresponding author), Chulalongkorn Univ, Fac Sci, Dept Chem, Ctr Excellence Computat Chem CECC, Bangkok 10330, Thailand.
EM supot.h@chula.ac.th; thanyada.r@chula.ac.th
RI Shigeta, Yasuteru/D-4714-2015
OI Shigeta, Yasuteru/0000-0002-3219-6007; Rungrotmongkol,
   Thanyada/0000-0002-7402-3235; Nutho, Bodee/0000-0003-1979-2418;
   Mahalapbutr, Panupong/0000-0003-4389-334X
FU Second Century Fund (C2F), Chulalongkorn University (CU)
FX The Second Century Fund (C2F), Chulalongkorn University (CU) is
   acknowledged for B.N. and P.M. (postdoctoral fellowship) and N.C.P.
   (Ph.D. scholarship). NSTDA Supercomputer Center (ThaiSC) is acknowledged
   for facilities and computing resources.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anandakrishnan R, 2012, NUCLEIC ACIDS RES, V40, pW537, DOI 10.1093/nar/gks375
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Cao K, 2018, J BIOL CHEM, V293, P6075, DOI 10.1074/jbc.M117.818997
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen JZ, 2014, SCI REP-UK, V4, DOI 10.1038/srep06872
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Choi J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31080-7
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   De Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI 10.1128/CMR.00102-15
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Duan LL, 2017, PHYS CHEM CHEM PHYS, V19, P10140, DOI 10.1039/c7cp00841d
   Fedorov DG, 2007, J COMPUT CHEM, V28, P222, DOI 10.1002/jcc.20496
   FEYEREISEN M, 1993, CHEM PHYS LETT, V208, P359, DOI 10.1016/0009-2614(93)87156-W
   Frisch M.J, 2009, GAUSSIAN 09 REV B 01
   Hengphasatporn K, 2020, SCI PHARM, V88, DOI 10.3390/scipharm88010002
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kammarabutr J, 2019, J MOL GRAPH MODEL, V89, P122, DOI 10.1016/j.jmgm.2019.03.006
   Kaplan SS, 2005, EXPERT OPIN PHARMACO, V6, P1573, DOI 10.1517/14656566.6.9.1573
   Kitaura K, 2001, CHEM PHYS LETT, V336, P163, DOI 10.1016/S0009-2614(01)00099-9
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mahalapbutr P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46668-w
   Mahalapbutr P, 2019, CANCERS, V11, DOI 10.3390/cancers11040437
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Maruyama K, 2018, COMPUT THEOR CHEM, V1132, P23, DOI 10.1016/j.comptc.2018.04.001
   Meeprasert A, 2014, J CHEM INF MODEL, V54, P1208, DOI 10.1021/ci400605a
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Mukherjee P, 2011, J CHEM INF MODEL, V51, P1376, DOI 10.1021/ci1004916
   Nukoolkarn V, 2008, J THEOR BIOL, V254, P861, DOI 10.1016/j.jtbi.2008.07.030
   Nutho B, 2019, J MOL GRAPH MODEL, V92, P227, DOI 10.1016/j.jmgm.2019.08.001
   Otto HH, 1997, CHEM REV, V97, P133, DOI 10.1021/cr950025u
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Shahbaaz M, 2018, MOL SIMULAT, V44, P179, DOI 10.1080/08927022.2017.1357813
   Shi JH, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001084
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Uberuaga BP, 2004, J CHEM PHYS, V120, P6363, DOI 10.1063/1.1667473
   Verschueren KHG, 2008, CHEM BIOL, V15, P597, DOI 10.1016/j.chembiol.2008.04.011
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Xu RH, 2004, EMERG INFECT DIS, V10, P1030, DOI 10.3201/eid1006.030852
   Yang HT, 2006, CURR PHARM DESIGN, V12, P4573, DOI 10.2174/138161206779010369
   Zeldin RK, 2004, J ANTIMICROB CHEMOTH, V53, P4, DOI 10.1093/jac/dkh029
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   ZHANG XM, 1994, J MED VIROL, V44, P152, DOI 10.1002/jmv.1890440207
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 53
TC 29
Z9 30
U1 8
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD MAY 12
PY 2020
VL 59
IS 18
BP 1769
EP 1779
DI 10.1021/acs.biochem.0c00160
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA LQ8FD
UT WOS:000535232800009
PM 32293875
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Buonaguro, L
   Buonaguro, FM
AF Buonaguro, Luigi
   Buonaguro, Franco M.
TI Knowledge-based repositioning of the anti-HCV direct antiviral agent
   Sofosbuvir as SARS-CoV-2 treatment
SO INFECTIOUS AGENTS AND CANCER
LA English
DT Article
AB The new human coronavirus named SARS-CoV-2 is a positive-sense RNA virus for which no specific drugs are currently available. A knowledge-based analysis strongly suggests a possible repositioning of the anti-HCV direct antiviral agent (DAA) Sofosbuvir as treatment for SARS-CoV-2. Indeed, the RNA-dependent RNA-polymerases (RdRp) of the two viruses show high sequence and structural homology, supporting the likelihood of binding the Sofosbuvir molecule with similar efficiency. Such a repositioning would allow the containment of the SARS-CoV-2 pandemic and limit the progression of disease to potentially deadly COVID19.
C1 [Buonaguro, Luigi] Fdn Pascale IRCCS, Ist Nazl Studio & Cura Tumori, Lab Innovat Immunol Models, Via Mariano Semmola 1, I-80131 Naples, Italy.
   [Buonaguro, Franco M.] Fdn Pascale IRCCS, Ist Nazl Studio & Cura Tumori, Lab Mol Biol & Viral Oncol, Via Mariano Semmola 52, I-80131 Naples, Italy.
RP Buonaguro, L (corresponding author), Fdn Pascale IRCCS, Ist Nazl Studio & Cura Tumori, Lab Innovat Immunol Models, Via Mariano Semmola 1, I-80131 Naples, Italy.
EM l.buonaguro@istitutotumori.na.it
RI Buonaguro, Luigi/AAV-5655-2020
FU H2020 Transcan2-HEPAMUT project [643638]; Italian Ministry of Health
   through Institutional "Ricerca Corrente"Ministry of Health,
   ItalyMinistry of Health Italy - Ricerca Corrente (MOH-RC); POR FESR
   2014/2020 "Campania OncoTerapie"
FX H2020 Transcan2-HEPAMUT project (Grant Nr. 643638) (LB); Italian
   Ministry of Health through Institutional "Ricerca Corrente" (LB); POR
   FESR 2014/2020 "Campania OncoTerapie" (LB).
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Boettler Tobias, 2020, JHEP Rep, V2, P100113, DOI 10.1016/j.jhepr.2020.100113
   Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa011
   Bourliere M, 2019, INT J ANTIMICROB AG, V53, P755, DOI 10.1016/j.ijantimicag.2018.12.010
   Buonaguro L, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02355-3
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jacome R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139001
   Jia HX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01945
   Jiang W, 2018, ANTIVIR RES, V154, P51, DOI 10.1016/j.antiviral.2018.04.007
   Lu CW, 2020, LANCET, V395, pE39, DOI 10.1016/S0140-6736(20)30313-5
   Mendes EA, 2019, ANN HEPATOL, V18, P816, DOI 10.1016/j.aohep.2019.09.001
   POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Talevi A, 2020, EXPERT OPIN DRUG DIS, V15, P397, DOI 10.1080/17460441.2020.1704729
   To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149
NR 18
TC 4
Z9 4
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1750-9378
J9 INFECT AGENTS CANCER
JI Infect. Agents Cancer
PD MAY 12
PY 2020
VL 15
IS 1
AR 32
DI 10.1186/s13027-020-00302-x
PG 3
WC Oncology; Immunology
SC Oncology; Immunology
GA LR3IR
UT WOS:000535587600001
PM 32419838
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Umesh
   Kundu, D
   Selvaraj, C
   Singh, SK
   Dubey, VK
AF Umesh
   Kundu, Debanjan
   Selvaraj, Chandrabose
   Singh, Sanjeev Kumar
   Dubey, Vikash Kumar
TI Identification of new anti-nCoV drug chemical compounds from Indian
   spices exploiting SARS-CoV-2 main protease as target
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Novel coronavirus (nCoV); corona virus disease-2019 (COVID-19); novel
   coronavirus main protease (SARS-CoV-2 Mpro); molecular docking;
   bioinformatics; ADME
AB The 2019-novel coronavirus (nCoV) has caused a global health crisis by causing coronavirus disease-19 (COVID-19) pandemic in the human population. The unavailability of specific vaccines and anti-viral drug for nCoV, science demands sincere efforts in the field of drug design and discovery for COVID-19. The novel coronavirus main protease (SARS-CoV-2 Mpro) play a crucial role during the disease propagation, and hence SARS-CoV-2 Mpro represents as a drug target for the drug discovery. Herein, we have applied bioinformatics approach for screening of chemical compounds from Indian spices as potent inhibitors of SARS-CoV-2 main protease (PDBID: 6Y84). The structure files of Indian spices chemical compounds were taken from PubChem database or Zinc database and screened by molecular docking, by using AutoDock-4.2, MGLTools-1.5.6, Raccoon virtual screening tools. Top 04 hits based on their highest binding affinity were analyzed. Carnosol exhibited highest binding affinity -8.2 Kcal/mol and strong and stable interactions with the amino acid residues present on the active site of SARS-CoV-2 Mpro. Arjunglucoside-I (-7.88 Kcal/mol) and Rosmanol (-7.99 Kcal/mol) also showed a strong and stable binding affinity with favourable ADME properties. These compounds on MD simulations for 50 ns shows strong hydrogen-bonding interactions with the protein active site and remains stable inside the active site. Our virtual screening results suggest that these small chemical molecules can be used as potential inhibitors against SARS-CoV-2 Mpro and may have an anti-viral effect on nCoV. However, further validation and investigation of these inhibitors against SARS-CoV-2 main protease are needed to claim their candidacy for clinical trials. Communicated by Ramaswamy H. Sarma
C1 [Umesh; Kundu, Debanjan; Dubey, Vikash Kumar] Indian Inst Technol BHU, Sch Biochem Engn, Varanasi 221005, Uttar Pradesh, India.
   [Selvaraj, Chandrabose; Singh, Sanjeev Kumar] Alagappa Univ, Dept Bioinformat, Comp Aided Drug Design & Mol Modeling Lab, Karaikkudi, Tamil Nadu, India.
RP Dubey, VK (corresponding author), Indian Inst Technol BHU, Sch Biochem Engn, Varanasi 221005, Uttar Pradesh, India.
EM vkdubey.bce@iitbhu.ac.in
RI Singh, Kumar/AAP-1954-2020; Kundu, Debanjan/AAU-8119-2020; Selvaraj,
   Chandrabose/F-4168-2012
OI Singh, Kumar/0000-0003-4153-6437; Kundu, Debanjan/0000-0002-8408-2175;
   Selvaraj, Chandrabose/0000-0002-8115-0486; , Umesh/0000-0001-6692-1556
FU CSIRCouncil of Scientific & Industrial Research (CSIR) - India
   [27(344)/19-EMR-II]; IIT (BHU) Varanasi; SERBDepartment of Science &
   Technology (India)Science Engineering Research Board (SERB), India
   [CVD/2020/000031]; Dept. of Edn, Govt. of India [F.24-51/2014-U]
FX The infrastructure facilities by IIT (BHU) Varanasi is acknowledged.
   Umesh is supported by CSIR project [27(344)/19-EMR-II] to VKD. DK
   acknowledges research fellowship from IIT (BHU) Varanasi. VKD also
   acknowledges SERB funding [CVD/2020/000031]. The Authors CS and SKS
   thankfully acknowledge RUSA-Phase 2.0 Policy (TNmulti-Gen), Dept. of
   Edn, Govt. of India (Grant No: F.24-51/2014-U).
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   BANERJEE A, 2019, VIRUSES BASEL, V11, DOI DOI https://doi.org/10.3390/v11010041
   Bhagya H.P., 2017, ACTA SCI NUTR HLTH, V1, P3
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Chhikara B. S., 2020, CHEM BIOL LETT, V7, P63, DOI DOI 10.1007/s00058-020-1496-8
   Chow E., 2008, DESMOND PERFORMANCE
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Kumar S, 2020, CURR TOP MED CHEM, V20, P599, DOI 10.2174/1568026620999200305144319
   Lau SKP, 2018, J VIROL, V92, DOI [10.1128/JVI.00265-18, 10.1128/jvi.00265-18]
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Owen C. D., 2019, SARS COV 2 MAIN PROT
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Sachan K. R. A., 2018, J MED PLANT STUDIES, V6, P116
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Selvaraj C, 2015, RSC ADV, V5, P100498, DOI 10.1039/c5ra12869b
   Selvaraj C, 2014, J BIOMOL STRUCT DYN, V32, P1333, DOI 10.1080/07391102.2013.818577
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wang H J, 2020, Fa Yi Xue Za Zhi, V36, P16, DOI 10.12116/j.issn.1004-5619.2020.01.004
   Zhang L., 2020, SCIENCE, V20, peabb3405
NR 24
TC 39
Z9 39
U1 11
U2 19
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1763202
EA MAY 2020
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LO6RP
UT WOS:000533752700001
PM 32362243
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Singh, S
   Chakravarty, T
   Chen, P
   Akhmerov, A
   Falk, J
   Friedman, O
   Zaman, T
   Ebinger, JE
   Gheorghiu, M
   Marban, L
   Marban, E
   Makkar, RR
AF Singh, Siddharth
   Chakravarty, Tarun
   Chen, Peter
   Akhmerov, Akbarshakh
   Falk, Jeremy
   Friedman, Oren
   Zaman, Tanzira
   Ebinger, Joseph E.
   Gheorghiu, Mitch
   Marban, Linda
   Marban, Eduardo
   Makkar, Raj R.
TI Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill
   COVID-19 patients: compassionate-use case series
SO BASIC RESEARCH IN CARDIOLOGY
LA English
DT Article
DE Coronavirus; Hyperinflammation; Cytokine storm; Cell therapy
ID STEM-CELLS; TRANSPLANTATION; REGENERATION; BENEFITS; EFFICACY; EXOSOMES;
   MOUSE; MODEL
AB There are no definitive therapies for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Therefore, new therapeutic strategies are needed to improve clinical outcomes, particularly in patients with severe disease. This case series explores the safety and effectiveness of intravenous allogeneic cardiosphere-derived cells (CDCs), formulated as CAP-1002, in critically ill patients with confirmed coronavirus disease 2019 (COVID-19). Adverse reactions to CAP-1002, clinical status on the World Health Organization (WHO) ordinal scale, and changes in pro-inflammatory biomarkers and leukocyte counts were analyzed. All patients (n = 6; age range 19-75 years, 1 female) required ventilatory support (invasive mechanical ventilation, n = 5) with PaO2/FiO(2) ranging from 69 to 198. No adverse events related to CAP-1002 administration were observed. Four patients (67%) were weaned from respiratory support and discharged from the hospital. One patient remains mechanically ventilated as of April 28th, 2020; all survive. A contemporaneous control group of critically ill COVID-19 patients (n = 34) at our institution showed 18% overall mortality at a similar stage of hospitalization. Ferritin was elevated in all patients at baseline (range of all patients 605.43-2991.52 ng/ml) and decreased in 5/6 patients (range of all patients 252.89-1029.90 ng/ml). Absolute lymphocyte counts were low in 5/6 patients at baseline (range 0.26-0.82 x 10(3)/mu l) but had increased in three of these five patients at last follow-up (range 0.23-1.02 x 10(3)/mu l). In this series of six critically ill COVID-19 patients, intravenous infusion of CAP-1002 was well tolerated and associated with resolution of critical illness in 4 patients. This series demonstrates the apparent safety of CAP-1002 in COVID-19. While this initial experience is promising, efficacy will need to be further assessed in a randomized controlled trial.
C1 [Singh, Siddharth; Chakravarty, Tarun; Akhmerov, Akbarshakh; Friedman, Oren; Ebinger, Joseph E.; Gheorghiu, Mitch; Marban, Eduardo; Makkar, Raj R.] Cedars Sinai Med Ctr, Smidt Heart Inst, 127 S San Vicente Blvd,Adv Hlth Sci Pavil, Los Angeles, CA 90048 USA.
   [Chen, Peter; Falk, Jeremy; Friedman, Oren; Zaman, Tanzira] Cedars Sinai Med Ctr, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90048 USA.
   [Marban, Linda] Capricor Inc, Beverly Hills, CA 90211 USA.
RP Makkar, RR (corresponding author), Cedars Sinai Med Ctr, Smidt Heart Inst, 127 S San Vicente Blvd,Adv Hlth Sci Pavil, Los Angeles, CA 90048 USA.
EM Raj.Makkar@cshs.org
OI Chen, Peter/0000-0002-5330-1718; Akhmerov,
   Akbarshakh/0000-0002-4054-4550
FU Smidt Family Foundation; Mark S. Siegel Family Foundation Distinguished
   Chair; Stephen R. Corday, MD Chair in Interventional Cardiology
FX Expenses specific to the clinical study, and analyses of the clinical
   data, were funded by a gift from the Smidt Family Foundation. Capricor
   provided regulatory support for the study and the cell product,
   CAP-1002, free of charge for this study. EM holds the Mark S. Siegel
   Family Foundation Distinguished Chair, and RRM holds the Stephen R.
   Corday, MD Chair in Interventional Cardiology.
CR Akhmerov A, 2020, CIRC RES, V126, P1443, DOI 10.1161/CIRCRESAHA.120.317055
   Aminzadeh MA, 2018, STEM CELL REP, V10, P942, DOI 10.1016/j.stemcr.2018.01.023
   Aminzadeh MA, 2015, EUR HEART J, V36, P751, DOI 10.1093/eurheartj/ehu196
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bonios M, 2011, J NUCL CARDIOL, V18, P443, DOI 10.1007/s12350-011-9369-9
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Centers for Disease Control and Prevention, EV TEST PERS COR DIS
   Chakravarty T, 2017, CELL TRANSPLANT, V26, P205, DOI 10.3727/096368916X692933
   Chen Jiajia, 2020, Engineering (Beijing), V6, P1153, DOI 10.1016/j.eng.2020.02.006
   Cheng K, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001260
   de Couto G, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0269-4
   de Couto G, 2017, CIRCULATION, V136, P200, DOI 10.1161/CIRCULATIONAHA.116.024590
   de Couto G, 2015, J CLIN INVEST, V125, P3147, DOI 10.1172/JCI81321
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754
   Gallet R, 2017, EUR HEART J, V38, P201, DOI 10.1093/eurheartj/ehw240
   Gallet Romain, 2016, JACC Basic Transl Sci, V1, P14
   Gori T, 2020, BASIC RES CARDIOL, V115, DOI 10.1007/s00395-020-0792-4
   Grens K, 2019, THESCIENTIST
   Grigorian-Shamagian L, 2017, EUR HEART J, V38, P2957, DOI 10.1093/eurheartj/ehx454
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li TS, 2012, J AM COLL CARDIOL, V59, P942, DOI 10.1016/j.jacc.2011.11.029
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Makkar RR, 2012, LANCET, V379, P895, DOI 10.1016/S0140-6736(12)60195-0
   Marban E, 2018, NAT BIOMED ENG, V2, P353, DOI 10.1038/s41551-018-0216-z
   Marban E, 2018, J AM COLL CARDIOL, V71, P193, DOI 10.1016/j.jacc.2017.11.013
   Maxeiner H, 2014, J CELL PHYSIOL, V229, P1681, DOI 10.1002/jcp.24613
   Middleton RC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183557
   Nana-Leventaki E, 2019, J CARDIOVASC PHARM T, V24, P70, DOI 10.1177/1074248418784287
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Reich H, 2016, J HEART LUNG TRANSPL, V35, P1348, DOI 10.1016/j.healun.2016.05.008
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rizzo P, 2020, BASIC RES CARDIOL, V115, DOI 10.1007/s00395-020-0791-5
   Rogers RG, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130202
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Smith RR, 2007, CIRCULATION, V115, P896, DOI 10.1161/CIRCULATIONAHA.106.655209
   Taylor M, 2019, NEUROLOGY, V92, pE866, DOI 10.1212/WNL.0000000000006950
   Vaninov Natalie, 2020, Nat Rev Immunol, V20, P277, DOI 10.1038/s41577-020-0305-6
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, COR DIS COVID 10 PAN
   World Health Organisation, 2020, WHO R D BLUEPR COVID
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
NR 48
TC 6
Z9 6
U1 1
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8428
EI 1435-1803
J9 BASIC RES CARDIOL
JI Basic Res. Cardiol.
PD MAY 12
PY 2020
VL 115
IS 4
AR 36
DI 10.1007/s00395-020-0795-1
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA LM3QF
UT WOS:000532165000001
PM 32399655
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Takami, A
AF Takami, Akiyoshi
TI Possible role of low-dose etoposide therapy for hemophagocytic
   lymphohistiocytosis by COVID-19
SO INTERNATIONAL JOURNAL OF HEMATOLOGY
LA English
DT Letter
C1 [Takami, Akiyoshi] Aichi Med Univ, Sch Med, Dept Internal Med, Div Hematol, 1-1 Yazakokarimata, Nagakute, Aichi 4801195, Japan.
RP Takami, A (corresponding author), Aichi Med Univ, Sch Med, Dept Internal Med, Div Hematol, 1-1 Yazakokarimata, Nagakute, Aichi 4801195, Japan.
EM takami-knz@umin.ac.jp
OI Takami, Akiyoshi/0000-0002-1822-9976
CR Aoyagi T, 2019, SHOCK, V52, P83, DOI 10.1097/SHK.0000000000001231
   Arca M, 2015, BRIT J HAEMATOL, V168, P63, DOI 10.1111/bjh.13102
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bergsten E, 2017, BLOOD, V130, P2728, DOI 10.1182/blood-2017-06-788349
   Bode SFN, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3843
   Ferraro C, 2000, CELL DEATH DIFFER, V7, P197, DOI 10.1038/sj.cdd.4400595
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imashuku S, 2001, J CLIN ONCOL, V19, P2665, DOI 10.1200/JCO.2001.19.10.2665
   Johnson TS, 2014, J IMMUNOL, V192, P84, DOI 10.4049/jimmunol.1302282
   Koyama M, 2007, INT J HEMATOL, V86, P466, DOI [10.1007/BF02984009, 10.1532/IJH97.07130]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Morimoto A, 2016, PEDIATR INT, V58, P817, DOI 10.1111/ped.13064
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 16
TC 3
Z9 3
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0925-5710
EI 1865-3774
J9 INT J HEMATOL
JI Int. J. Hematol.
PD JUL
PY 2020
VL 112
IS 1
BP 122
EP 124
DI 10.1007/s12185-020-02888-9
EA MAY 2020
PG 3
WC Hematology
SC Hematology
GA LY4SW
UT WOS:000532093400001
PM 32399895
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Amanat, F
   Stadlbauer, D
   Strohmeier, S
   Nguyen, THO
   Chromikova, V
   McMahon, M
   Jiang, KJ
   Arunkumar, GA
   Jurczyszak, D
   Polanco, J
   Bermudez-Gonzalez, M
   Kleiner, G
   Aydillo, T
   Miorin, L
   Fierer, DS
   Lugo, LA
   Kojic, EM
   Stoever, J
   Liu, STH
   Cunningham-Rundles, C
   Felgner, PL
   Moran, T
   Garcia-Sastre, A
   Caplivski, D
   Cheng, ALC
   Kedzierska, K
   Vapalahti, O
   Hepojoki, JM
   Simon, V
   Krammer, F
AF Amanat, Fatima
   Stadlbauer, Daniel
   Strohmeier, Shirin
   Nguyen, Thi H. O.
   Chromikova, Veronika
   McMahon, Meagan
   Jiang, Kaijun
   Arunkumar, Guha Asthagiri
   Jurczyszak, Denise
   Polanco, Jose
   Bermudez-Gonzalez, Maria
   Kleiner, Giulio
   Aydillo, Teresa
   Miorin, Lisa
   Fierer, Daniel S.
   Lugo, Luz Amarilis
   Kojic, Erna Milunka
   Stoever, Jonathan
   Liu, Sean T. H.
   Cunningham-Rundles, Charlotte
   Felgner, Philip L.
   Moran, Thomas
   Garcia-Sastre, Adolfo
   Caplivski, Daniel
   Cheng, Allen C.
   Kedzierska, Katherine
   Vapalahti, Olli
   Hepojoki, Jussi M.
   Simon, Viviana
   Krammer, Florian
TI A serological assay to detect SARS-CoV-2 seroconversion in humans
SO NATURE MEDICINE
LA English
DT Article
ID SARS CORONAVIRUS; SPIKE; ANTIBODIES; BINDING
AB Development of an enzyme-linked immunosorbent assay to detect antibodies to the SARS-CoV-2 spike protein in human sera and plasma.
   Here, we describe a serological enzyme-linked immunosorbent assay for the screening and identification of human SARS-CoV-2 seroconverters. This assay does not require the handling of infectious virus, can be adjusted to detect different antibody types in serum and plasma and is amenable to scaling. Serological assays are of critical importance to help define previous exposure to SARS-CoV-2 in populations, identify highly reactive human donors for convalescent plasma therapy and investigate correlates of protection.
C1 [Amanat, Fatima; Stadlbauer, Daniel; Strohmeier, Shirin; Chromikova, Veronika; McMahon, Meagan; Jiang, Kaijun; Arunkumar, Guha Asthagiri; Jurczyszak, Denise; Polanco, Jose; Bermudez-Gonzalez, Maria; Kleiner, Giulio; Aydillo, Teresa; Miorin, Lisa; Liu, Sean T. H.; Moran, Thomas; Garcia-Sastre, Adolfo; Simon, Viviana; Krammer, Florian] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.
   [Amanat, Fatima; Arunkumar, Guha Asthagiri; Jurczyszak, Denise] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA.
   [Strohmeier, Shirin] Univ Nat Resources & Life Sci, Dept Biotechnol, Vienna, Austria.
   [Nguyen, Thi H. O.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia.
   [Polanco, Jose] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA.
   [Aydillo, Teresa; Miorin, Lisa; Simon, Viviana] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA.
   [Fierer, Daniel S.; Lugo, Luz Amarilis; Kojic, Erna Milunka; Simon, Viviana] Icahn Sch Med Mt Sinai, Div Infect Dis, Dept Med, New York, NY 10029 USA.
   [Stoever, Jonathan] Icahn Sch Med Mt Sinai, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA.
   [Liu, Sean T. H.] Mt Sinai Queens, Dept Med, Astoria, NY USA.
   [Liu, Sean T. H.] Mt Sinai Hlth Syst, Hosp Med, New York, NY USA.
   [Cunningham-Rundles, Charlotte] Icahn Sch Med Mt Sinai, Div Clin Immunol, Dept Med, New York, NY 10029 USA.
   [Cunningham-Rundles, Charlotte] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA.
   [Felgner, Philip L.] Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA USA.
   [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
   [Fierer, Daniel S.] Icahn Sch Med Mt Sinai, Travel Med Program, Div Infect Dis, New York, NY 10029 USA.
   [Cheng, Allen C.] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia.
   [Cheng, Allen C.] Alfred Hlth, Infect Prevent & Healthcare Epidemiol Unit, Melbourne, Vic, Australia.
   [Vapalahti, Olli; Hepojoki, Jussi M.] Univ Helsinki, Dept Virol, Medicum, Helsinki, Finland.
   [Vapalahti, Olli] Univ Helsinki, Fac Vet, Vet Biosci, Helsinki, Finland.
   [Vapalahti, Olli] Helsinki Univ Hosp HUSLAB, Dept Virol & Immunol, Helsinki, Finland.
   [Hepojoki, Jussi M.] Univ Zurich, Vetsuisse Fac, Inst Vet Pathol, Zurich, Switzerland.
RP Krammer, F (corresponding author), Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.
EM florian.krammer@mssm.edu
RI Arunkumar, Guha Asthagiri/J-6238-2019; Stadlbauer, Daniel/AAV-7433-2020;
   Hepojoki, Jussi/W-4667-2017; Krammer, Florian/H-3237-2019
OI Arunkumar, Guha Asthagiri/0000-0003-3665-2708; Stadlbauer,
   Daniel/0000-0001-6792-7650; Hepojoki, Jussi/0000-0001-5699-214X;
   Krammer, Florian/0000-0003-4121-776X; Fierer,
   Daniel/0000-0002-3427-8022; Kleiner, Giulio/0000-0002-1830-3961; Liu,
   Sean/0000-0002-3842-6838; Aydillo Gomez, Teresa
   Allende/0000-0003-3086-1058; Vapalahti, Olli/0000-0003-2270-6824
FU Mount Sinai Health System Translational Science Hub 'ConduITS' (NIH)
   [U54TR001433]; NIAID Centers of Excellence for Influenza Research and
   Surveillance (CEIRS) [HHSN272201400008C]; Collaborative Influenza
   Vaccine Innovation Centers (CIVIC) [75N93019C00051]; Open Philanthropy;
   Australian National Health and Medical Research Council (NHMRC)National
   Health and Medical Research Council of Australia [1071916, 1102792];
   Academy of FinlandAcademy of Finland; Jane and Aatos Erkko Foundation;
   Helsinki University Hospital Funds
FX We thank Y.-Z. Zhang (Fudan University) and E. Holmes (University of
   Sydney) for sharing the sequence of the first SARS-CoV-2 isolate in a
   very timely manner. We thank J. Garlick and J. Roney (Alfred Hospital,
   Melbourne) for data and specimen collection, N. Aboelregal for making
   many different NHIG products (Mount Sinai) available and L.
   Martinez-Sobrido (Texas Biomedical Research Institute) for initially
   characterizing mAb 1C7. We are also thankful to Genewiz for speeding up
   gene synthesis for this project, and for being very accommodating to our
   needs. Furthermore, we thank D. Tidmore for help with ordering primers
   quickly, and finally S. Dong for commuting to New Jersey on several
   occasions to pick up reagents from Genewiz. We also thank the Mount
   Sinai Health System Translational Science Hub 'ConduITS' (NIH grant
   U54TR001433) for supporting sample collection. The work of the
   Personalized Virology Initiative is supported by institutional funds and
   philanthropic donations. This work was partially supported by the NIAID
   Centers of Excellence for Influenza Research and Surveillance (CEIRS;
   contract HHSN272201400008C to F.K. and A.G.-S.), the Collaborative
   Influenza Vaccine Innovation Centers (CIVIC; contract 75N93019C00051 to
   F.K. and A.G.-S.), Open Philanthropy, the Australian National Health and
   Medical Research Council (NHMRC Program Grant 1071916 and NHMRC Research
   Fellowship Level B (1102792) to K.K.), the Academy of Finland to O.V.
   and J.M.H., as well as Jane and Aatos Erkko Foundation and Helsinki
   University Hospital Funds to O.V. Furthermore, we thank our generous
   community for providing essential funds and support for our SARS-CoV-2
   and COVID-19 research efforts. The following reagent was deposited by
   the Centers for Disease Control and Prevention and obtained through BEI
   Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020,
   NR-52281. Finally, we thank all of the study participants for their
   contribution to the research. We wish the patients with COVID-19 a
   speedy recovery.
CR Amanat F, 2019, EMERG MICROBES INFEC, V8, P155, DOI 10.1080/22221751.2018.1564369
   Amanat F, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00189-18
   Berry JD, 2010, MABS-AUSTIN, V2, P53, DOI 10.4161/mabs.2.1.10788
   Gonzalez-Reiche A, 2020, INTRO EARLY SPREAD S, DOI [10.1101/2020.04.08.20056929, DOI 10.1101/2020.04.08.20056929]
   Haveri A, 2020, SEROLOGICAL MOL FIND
   Huang Angkana T, 2020, medRxiv, DOI 10.1101/2020.04.14.20065771
   Khan Saahir, 2020, bioRxiv, DOI 10.1101/2020.03.24.006544
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Krammer F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043603
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Margine I, 2013, JOVE-J VIS EXP, DOI 10.3791/51112
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Rajendran M, 2017, MBIO, V8, DOI [10.1128/mBio.02281-16, 10.1128/mbio.02281-16]
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wohlbold TJ, 2017, NAT MICROBIOL, V2, P1415, DOI 10.1038/s41564-017-0011-8
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yuan J, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.4467
NR 25
TC 165
Z9 162
U1 7
U2 13
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD JUL
PY 2020
VL 26
IS 7
BP 1033
EP +
DI 10.1038/s41591-020-0913-5
EA MAY 2020
PG 12
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA MK3XO
UT WOS:000532113900001
PM 32398876
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Debuc, B
   Smadja, DM
AF Debuc, Benjamin
   Smadja, David M.
TI Is COVID-19 a New Hematologic Disease?
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article; Early Access
DE SARS-CoV-2; Covid-19; Coagulopathy; D-dimers; Lymphopenia; Mesenchymal
   stem cells; Cytokine; Inflammation; Thrombosis; Stem cells
ID MESENCHYMAL STEM-CELLS; BONE-MARROW; IN-VIVO; BLOOD; TRANSPLANTATION;
   CORONAVIRUS; ISCHEMIA; RECEPTOR; ADULT
AB SARS-CoV-2 viruses are positive single-stranded RNA viruses, whose infection can be asymptomatic or lead to the coronavirus disease 2019 (Covid-19). Covid-19 is a respiratory infection with a significant impact on the hematopoietic system and hemostasis leading to several cardiovascular complications. Hematologic consequences of this new infection allowed medical community to start new treatment approaches concerning infection going from targeted anti-inflammatory drugs to anticoagulation or stem cell therapies. A better understanding of Covid-19 pathophysiology, in particular hematological disorders, will help to choose appropriate treatment strategies.
C1 [Debuc, Benjamin] Univ Paris, Georges Pompidou European Hosp, AP HP, Plast Surg Dept, F-75015 Paris, France.
   [Smadja, David M.] Univ Paris, Innovat Therapies Haemostasis, INSERM UMR S 1140, F-75006 Paris, France.
   [Smadja, David M.] Georges Pompidou European Hosp, AP HP, Hematol Dept, Carpentier Fdn, 20 Rue Leblanc, F-75015 Paris, France.
   [Smadja, David M.] Georges Pompidou European Hosp, AP HP, Biosurg Res Lab, Carpentier Fdn, 20 Rue Leblanc, F-75015 Paris, France.
RP Smadja, DM (corresponding author), Univ Paris, Innovat Therapies Haemostasis, INSERM UMR S 1140, F-75006 Paris, France.; Smadja, DM (corresponding author), Georges Pompidou European Hosp, AP HP, Hematol Dept, Carpentier Fdn, 20 Rue Leblanc, F-75015 Paris, France.; Smadja, DM (corresponding author), Georges Pompidou European Hosp, AP HP, Biosurg Res Lab, Carpentier Fdn, 20 Rue Leblanc, F-75015 Paris, France.
EM david.smadja@aphp.fr
RI Smadja, David/M-3872-2017
OI Smadja, David/0000-0001-7731-9202
FU French research national agency (Agence Nationale pour la Recherche) ANR
   SARCODOFrench National Research Agency (ANR)
FX David M. Smadja' research on Covid-19 is supported by a grant from the
   French research national agency (Agence Nationale pour la Recherche) ANR
   SARCODO.
CR Amati E, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-017-0755-3
   Au P, 2008, BLOOD, V111, P4551, DOI 10.1182/blood-2007-10-118273
   Bari E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040924
   Bernard SC, 2014, NAT MED, V20, P725, DOI 10.1038/nm.3563
   Crosnier C, 2011, NATURE, V480, P534, DOI 10.1038/nature10606
   d'Alessandro E, 2020, THROMB HAEMOSTASIS, V120, P538, DOI [10.1055/s-0040-1708035., 10.1055/s-0040-1708035]
   D'Amico F., 2020, CLIN GASTROENTEROLOG
   Dawn B, 2008, STEM CELLS, V26, P1646, DOI 10.1634/stemcells.2007-0715
   Golchin A, 2020, STEM CELL REV REP, V16, P427, DOI 10.1007/s12015-020-09973-w
   Grimsholm O, 2020, CELL REP, V30, P2963, DOI 10.1016/j.celrep.2020.02.022
   Guan WJ, 2020, NEW ENGLAND J MED
   Guerin CL, 2017, STEM CELL REV REP, V13, P561, DOI 10.1007/s12015-017-9732-6
   Guerin CL, 2017, STEM CELL REV REP, V13, P552, DOI 10.1007/s12015-017-9731-7
   Guerin CL, 2015, THROMB HAEMOSTASIS, V113, P1084, DOI 10.1160/TH14-09-0748
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Han H, 2020, CLIN CHEM LAB MED
   Harzallah I, 2020, J THROMB HAEMOST, V18, P2064, DOI 10.1111/jth.14867
   Heringer-Walther S, 2009, HAEMATOL-HEMATOL J, V94, P857, DOI 10.3324/haematol.2008.000034
   Higashi Kiyoshi, 2015, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, V34, P7, DOI 10.1089/mab.2014.0075
   Hoffmann M, 2020, CELL
   Jarajapu Y. P, 2020, MOL PHARM
   Joshi S., 2020, J APPL PHYSL
   Kassmer SH, 2013, STEM CELLS, V31, P2759, DOI 10.1002/stem.1413
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Melero-Martin JM, 2008, CIRC RES, V103, P194, DOI 10.1161/CIRCRESAHA.108.178590
   Melero-Martin JM, 2007, BLOOD, V109, P4761, DOI 10.1182/blood-2006-12-062471
   Michot JM, 2020, ANN ONCOLOGY
   Monteil V, 2020, CELL
   Poissy J, 2020, CIRCULATION
   Qanadli SD, 2020, AM J ROENTGENOL, V215, pW15, DOI 10.2214/AJR.20.23185
   Quinti I, 2020, J ALLERGY CLIN IMMUN
   Ratajczak MZ, 2012, LEUKEMIA, V26, P1166, DOI 10.1038/leu.2011.389
   Ratajczak MZ, 2020, STEM CELL REV REP, V16, P425, DOI 10.1007/s12015-020-09978-5
   Ratajczak MZ, 2017, CIRC RES, V120, P166, DOI 10.1161/CIRCRESAHA.116.309362
   Rossi E, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00010
   Rossi E, 2017, THROMB HAEMOSTASIS, V117, P1908, DOI 10.1160/TH17-01-0007
   Shammaa R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00072
   Smadja DM, 2012, BONE MARROW TRANSPL, V47, P997, DOI 10.1038/bmt.2011.196
   Smadja D. M., 2015, THROMBOSIS HAEMOSTAS, V114
   Smadja DM, 2017, STEM CELL REV REP, V13, P198, DOI 10.1007/s12015-017-9718-4
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tang N, 2020, J THROMBOSIS HAEMOST
   Tang N., 2020, J THROMBOSIS HAEMOST
   Thachil J., 2020, J THROMBOSIS HAEMOST
   Ulrich H, 2020, STEM CELL REV REP, V16, P434, DOI 10.1007/s12015-020-09976-7
   Varga Z, 2020, LANCET
   Wojakowski W, 2010, INT J ONCOL, V37, P237, DOI 10.3892/ijo_00000671
   Xu B., 2020, J INFECT
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhou F., 2020, LANCET
NR 51
TC 13
Z9 12
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629-3269
EI 2629-3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
DI 10.1007/s12015-020-09987-4
EA MAY 2020
PG 5
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA LM4JS
UT WOS:000532216700001
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Garcia-Cremades, M
   Solans, BP
   Hughes, E
   Ernest, JP
   Wallender, E
   Aweeka, F
   Luetkemeyer, AF
   Savic, RM
AF Garcia-Cremades, Maria
   Solans, Belen P.
   Hughes, Emma
   Ernest, Jacqueline P.
   Wallender, Erika
   Aweeka, Francesca
   Luetkemeyer, Anne F.
   Savic, Radojka M.
TI Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An
   Integrative Modeling Approach for Effective Drug Repurposing
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID CHLOROQUINE; ANTIMALARIAL; PROLONGATION; TRIAL; RISK
AB Hydroxychloroquine (HCQ) is a promising candidate for Coronavirus disease of 2019 (COVID-19) treatment. The optimal dosing of HCQ is unknown. Our goal was to integrate historic and emerging pharmacological and toxicity data to understand safe and efficacious HCQ dosing strategies for COVID-19 treatment. The data sources included were (i) longitudinal clinical, pharmacokinetic (PK), and virologic data from patients with severe acute respiratory syndrome-2 (SARS-CoV-2) infection who received HCQ with or without azithromycin (n = 116), (ii) in vitro viral replication data and SARS-CoV-2 viral load inhibition by HCQ, (iii) a population PK model of HCQ, and (iv) a model relating chloroquine PKs to corrected QT (QTc) prolongation. A mechanistic PK/virologic/QTc model for HCQ was developed and externally validated to predict SARS-CoV-2 rate of viral decline and QTc prolongation. SARS-CoV-2 viral decline was associated with HCQ PKs (P < 0.001). The extrapolated patient half-maximal effective concentration (EC50) was 4.7 mu M, comparable to the reported in vitro EC50s. HCQ doses > 400 mg b.i.d. for >= 5 days were predicted to rapidly decrease viral loads, reduce the proportion of patients with detectable SARS-CoV-2 infection, and shorten treatment courses, compared with lower dose (<= 400 mg daily) regimens. However, HCQ doses > 600 mg b.i.d. were also predicted to prolong QTc intervals. This prolongation may have clinical implications warranting further safety assessment. Due to COVID-19's variable natural history, lower dose HCQ regimens may be indistinguishable from controls. Evaluation of higher HCQ doses is needed to ensure adequate safety and efficacy.
C1 [Garcia-Cremades, Maria; Solans, Belen P.; Hughes, Emma; Ernest, Jacqueline P.; Savic, Radojka M.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.
   [Wallender, Erika; Aweeka, Francesca] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA.
   [Luetkemeyer, Anne F.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
RP Savic, RM (corresponding author), Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.
EM rada.savic@ucsf.edu
RI Garcia-Cremades, Maria/AAE-1468-2020
OI Garcia-Cremades, Maria/0000-0002-3369-1210
FU Savic laboratory
FX The investigators thank the Savic laboratory for all their help and
   support during this project. We would also like to thank Tia Tummino for
   her help addressing reviewer comments.
CR Ahn JE, 2008, J PHARMACOKINET PHAR, V35, P401, DOI 10.1007/s10928-008-9094-4
   [Anonymous], 2017, HYDR PACKINS
   Balevic SJ, 2019, CLIN PHARMACOKINET, V58, P525, DOI 10.1007/s40262-018-0712-z
   Beal SL, 2001, J PHARMACOKINET PHAR, V28, P481, DOI 10.1023/A:1012299115260
   Biot C, 2006, J MED CHEM, V49, P2845, DOI 10.1021/jm0601856
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Centers for Disease Control and Prevention, 2020, INF CLIN THER OPT CO
   Chansky Peter B, 2017, BMJ Case Rep, V2017, DOI 10.1136/bcr-2016-218786
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chinappi M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014064
   Collins KP, 2018, J PHARMACOL EXP THER, V365, P447, DOI 10.1124/jpet.117.245639
   DANIEL WA, 1995, PHARMACOL TOXICOL, V77, P402, DOI 10.1111/j.1600-0773.1995.tb01050.x
   de Olano J, 2019, AM J EMERG MED, V37, DOI 10.1016/j.ajem.2019.158387
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Kaye M, 2006, EMERG INFECT DIS, V12, P128, DOI 10.3201/eid1201.050496
   Kazama I, 2012, J PHYSIOL SCI, V62, P267, DOI 10.1007/s12576-012-0195-x
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Melles RB, 2014, JAMA OPHTHALMOL, V132, P1453, DOI 10.1001/jamaophthalmol.2014.3459
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Munster T, 2002, ARTHRITIS RHEUM-US, V46, P1460, DOI 10.1002/art.10307
   Mzayek Fawaz, 2007, PLoS Clin Trials, V2, pe6, DOI 10.1371/journal.pctr.0020006
   Negoescu A., 2013, ACR ARHP ANN M OCT 2
   NEWTON DW, 1978, DRUG INTEL CLIN PHAR, V12, P546, DOI 10.1177/106002807801200906
   O'Laughlin JP, 2016, CASE REP CARDIOL, V2016, DOI 10.1155/2016/4626279
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Rodriguez-Menchaca AA, 2008, P NATL ACAD SCI USA, V105, P1364, DOI 10.1073/pnas.0708153105
   ROHATGI A., 2019, WEBPLOTDIGITIZER
   Sarathy JP, 2016, ACS INFECT DIS, V2, P552, DOI 10.1021/acsinfecdis.6b00051
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Strydom N, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002773
   Tisdale JE, 2013, CIRC-CARDIOVASC QUAL, V6, P479, DOI 10.1161/CIRCOUTCOMES.113.000152
   Touret F., VITRO SCREENING FDA, DOI [10.1101/2020.04.03.023846, DOI 10.1101/2020.04.03.023846]
   UGES DRA, 1988, PHARM WEEKBLAD, V10, P185, DOI 10.1007/BF01956868
   Ursing J, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01846-19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Warhurst DC, 2003, J ANTIMICROB CHEMOTH, V52, P188, DOI 10.1093/jac/dkg319
   White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 50
TC 42
Z9 41
U1 6
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD AUG
PY 2020
VL 108
IS 2
BP 253
EP 263
DI 10.1002/cpt.1856
EA MAY 2020
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MJ4KB
UT WOS:000531701600001
PM 32285930
OA Other Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Deacon, RM
   Mammen, K
   Holmes, J
   Dunlop, A
   Bruno, R
   Mills, L
   Graham, R
   Lintzeris, N
AF Deacon, Rachel M.
   Mammen, Kristie
   Holmes, Jennifer
   Dunlop, Adrian
   Bruno, Raimondo
   Mills, Llewellyn
   Graham, Robert
   Lintzeris, Nicholas
TI Assessing the validity of the Australian Treatment Outcomes Profile for
   telephone administration in drug health treatment populations
SO DRUG AND ALCOHOL REVIEW
LA English
DT Article
DE telemedicine; outcome assessment; health care; psychometric;
   substance-related disorder
ID FACE-TO-FACE; TIMELINE FOLLOWBACK; VALIDATION; INTERVIEW; ALCOHOL;
   AGREEMENT; QUALITY; MODES; NORMS
AB Introduction and Aims The Australian Treatment Outcomes Profile (ATOP) is a brief clinical tool measuring recent substance use, health and wellbeing among clients attending alcohol and other drug (AOD) treatment services. It has previously been assessed for concurrent validity and inter-rater reliability. In this study we examine whether it is suitable for administration over the telephone.
   Design and Methods We recruited a sample of 107 AOD clients across public sector specialist AOD treatment services in New South Wales, Australia between 2016 and 2018. Participants had a mean age of 47 years and 46% were female. Participants completed a face-to-face ATOP and a phone ATOP with a researcher within 5 days. Comparisons between the two administration modes were undertaken using Spearman's rank correlation coefficient for continuous or ordinal variables, and Cohen's Kappa for nominal variables.
   Results Among 107 participants, 59% were attending for alcohol treatment and 41% for opioid treatment. Most ATOP items (76%) reached above 0.7 (good) or 0.9 (excellent) agreement between face-to-face and telephone use.
   Discussion and Conclusions Our findings suggest that the ATOP is a suitable instrument for telephone monitoring of recent substance use, health and social functioning among AOD clients. Its validation for remote use over the telephone will support staff to monitor clients' risks and outcomes-of particular relevance in response to the COVID-19 pandemic in which services are increasingly relying on telework approaches to client monitoring.
C1 [Deacon, Rachel M.; Mills, Llewellyn; Lintzeris, Nicholas] Univ Sydney, Fac Med & Hlth, Sydney Sch Med, Cent Clin Sch, Sydney, NSW, Australia.
   [Deacon, Rachel M.; Mammen, Kristie; Mills, Llewellyn; Lintzeris, Nicholas] South Eastern Sydney Local Hlth Dist, Drug & Alcohol Serv, Sydney, NSW, Australia.
   [Deacon, Rachel M.; Mammen, Kristie; Holmes, Jennifer; Dunlop, Adrian; Mills, Llewellyn; Graham, Robert; Lintzeris, Nicholas] NSW Drug & Alcohol Clin Res & Improvement Network, Sydney, NSW, Australia.
   [Holmes, Jennifer] Minist Hlth, Ctr Populat Hlth, Alcohol & Other Drugs, Sydney, NSW, Australia.
   [Bruno, Raimondo] UNSW Sydney, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia.
   [Dunlop, Adrian] Hunter New England Local Hlth Dist, Drug & Alcohol Serv, Newcastle, NSW, Australia.
   [Dunlop, Adrian] Univ Newcastle, Hunter Med Res Inst, Newcastle, NSW, Australia.
   [Bruno, Raimondo] Univ Tasmania, Sch Psychol Sci, Hobart, Tas, Australia.
   [Graham, Robert] Western Sydney Local Hlth Dist, Drug Hlth, Sydney, NSW, Australia.
   [Graham, Robert] Western Sydney Univ, Sch Med, Sydney, NSW, Australia.
RP Deacon, RM (corresponding author), Langton Ctr, 591 South Dowling St, Surry Hills, NSW 2010, Australia.
EM rachel.deacon@sydney.edu.au
RI Deacon, Rachel M/ABF-1676-2020
OI Deacon, Rachel M/0000-0002-0877-3089
FU Clinical Outcomes and Quality Improvement Framework study - Centre for
   Population Health at the NSW Ministry of Health
FX We thank clients and study participants at the recruitment sites: AOD
   services in the Hunter New England, Western Sydney and South Eastern
   Sydney Local Health Districts. We also thank other research staff:
   Elaine Murray, Susan Hazelwood, Janet Dunbabin, Woroud Alzaher, Consuelo
   Rivas, Dr Nghi Phung, Jennifer (Mary) Luksza and Dr Thao Lam. This work
   was funded as part of the Clinical Outcomes and Quality Improvement
   Framework study funded by the Centre for Population Health at the NSW
   Ministry of Health.
CR Australian Institute of Health and Welfare, 2019, ALC OTH DRUG TREATM
   Conwell Y, 2018, INT PSYCHOGERIATR, V30, P95, DOI 10.1017/S1041610217001752
   Deacon RM, ASSESSING CONCURRENT
   Evans M, 2004, PSYCHOL MED, V34, P157, DOI 10.1017/S0033291703008055
   García María, 2005, Gac Sanit, V19, P433, DOI 10.1016/S0213-9111(05)71393-5
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   IBM Corporation, 2016, IBM SPSS STAT WIND V
   Lin SY, 2010, J PRIM HEALTH CARE, V2, P35
   Lintzeris N, 2016, DRUG ALCOHOL REV, V35, P673, DOI 10.1111/dar.12393
   Maisto SA, 2008, J STUD ALCOHOL DRUGS, V69, P468, DOI 10.15288/jsad.2008.69.468
   Marsden J, 2008, ADDICTION, V103, P1450, DOI 10.1111/j.1360-0443.2008.02284.x
   MCHORNEY CA, 1994, MED CARE, V32, P551, DOI 10.1097/00005650-199406000-00002
   Mills L, 2020, DRUG ALCOHOL REV, V39, P356, DOI 10.1111/dar.13050
   NSW Health, 2016, NSW HLTH TEL FRAM IM
   NSW Health, 2016, EHEALTH STRAT NSW HL
   Nunnally J.C., 1978, PSYCHOMETRIC THEORY
   Perkins JJ, 1998, J CLIN EPIDEMIOL, V51, P969, DOI 10.1016/S0895-4356(98)00088-2
   Roberts DM, 2018, AUST PRESCR, V41, P2, DOI 10.18773/austprescr.2018.006
   ROBINS LN, 1985, ARCH GEN PSYCHIAT, V42, P918
   Ryan A, 2014, DRUG ALCOHOL REV, V33, P33, DOI 10.1111/dar.12083
   Sobell LC, 1996, DRUG ALCOHOL DEPEN, V42, P49, DOI 10.1016/0376-8716(96)01263-X
   SOBIN C, 1993, PSYCHIATR GENET, V3, P227, DOI 10.1097/00041444-199324000-00005
   Wang M, 2017, QUAL LIFE RES, V26, P2973, DOI 10.1007/s11136-017-1640-3
   Ware J, 1994, SF 36 PHYS MENTAL HL
   Watson E, 1995, P HLTH OUTC QUAL LIF
   Watson EK, 1996, AUST NZ J PUBL HEAL, V20, P359, DOI 10.1111/j.1467-842X.1996.tb01046.x
   WELLS KB, 1988, J PSYCHIAT RES, V22, P207, DOI 10.1016/0022-3956(88)90006-4
NR 28
TC 1
Z9 1
U1 6
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0959-5236
EI 1465-3362
J9 DRUG ALCOHOL REV
JI Drug Alcohol Rev.
PD JUL
PY 2020
VL 39
IS 5
BP 441
EP 446
DI 10.1111/dar.13088
EA MAY 2020
PG 6
WC Substance Abuse
SC Substance Abuse
GA MI7AZ
UT WOS:000531588800001
PM 32395850
DA 2021-01-01
ER

PT J
AU Sugrue, M
   O'Keeffe, D
   Sugrue, R
   MacLean, L
   Varzgalis, M
AF Sugrue, Michael
   O'Keeffe, Derek
   Sugrue, Ryan
   MacLean, Lorraine
   Varzgalis, Manvydas
TI A cloth mask for under-resourced healthcare settings in the COVID19
   pandemic
SO IRISH JOURNAL OF MEDICAL SCIENCE
LA English
DT Article
DE COVID19; Face mask; Infectious disease; Pandemic; Personal protection
   equipment; SARS-CoV-2
AB Introduction COVID19 pandemic poses a global threat, with many unknowns. The potential for resource limited countries to suffer huge mortality is of major concern. Prevention and risk reduction strategies are paramount in the current absence of effective treatment or a vaccine. There is a global shortage of personal protective equipment. Aims This short paper describes the rationale for and development of a cloth homemade mask and has a step by step video. Results The template is reproducible around the world and is both washable and cheap. Conclusion This article describes a simple way to make a cloth mask, suitable if medical masks are not available.
C1 [Sugrue, Michael; Varzgalis, Manvydas] Letterkenny Univ Hosp, Dept Surg, Letterkenny, Ireland.
   [Sugrue, Michael; Varzgalis, Manvydas] Donegal Clin Res Acad, Letterkenny, Ireland.
   [Sugrue, Michael; Varzgalis, Manvydas] Ctr Personalised Med, Emergency Surg Outcome Adv Project, Letterkenny, Ireland.
   [O'Keeffe, Derek] Natl Univ Ireland, Coll Med Nursing & Hlth Sci, Dept Med, Galway, Ireland.
   [Sugrue, Ryan] Univ Hosp Galway Ireland, Dept Plast Surg, Galway, Ireland.
   [MacLean, Lorraine] Zip Yard Dress Maker, Letterkenny, Donegal, Ireland.
RP Sugrue, M (corresponding author), Letterkenny Univ Hosp, Dept Surg, Letterkenny, Ireland.; Sugrue, M (corresponding author), Donegal Clin Res Acad, Letterkenny, Ireland.; Sugrue, M (corresponding author), Ctr Personalised Med, Emergency Surg Outcome Adv Project, Letterkenny, Ireland.
EM michaelesugrue@gmail.com
FU EUEuropean Union (EU)
FX Seamus Hughes Letterkenny for providing some test material. Marite
   Vilcane dressmaker with Zip Yard Letterkenny Donegal Ireland. We thank
   SEUBP and Inter Regional EU Support.
CR [Anonymous], 2020, TRAV COUNTR WID SUST
   Bourouiba L, 2020, JAMA-J AM MED ASSOC, V323, P1837, DOI 10.1001/jama.2020.4756
   Cherry JD, 2004, PEDIATR RES, V56, P1, DOI 10.1203/01.PDR.0000129184.87042.FC
   Greenhalgh T, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1435
   Jefferson T, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006207.pub4
   Livingston E, 2020, JAMA-J AM MED ASSOC, V323, P1912, DOI 10.1001/jama.2020.5317
   Loeb M, 2009, JAMA-J AM MED ASSOC, V302, P1865, DOI 10.1001/jama.2009.1466
   Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
   van der Sande M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002618
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Winski T, 2017, OCCUP ENV MED S1, V74, pA118, DOI [10.1136/oemed-2017-104636.310, DOI 10.1136/OEMED-2017-104636.310]
NR 11
TC 3
Z9 3
U1 1
U2 10
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0021-1265
EI 1863-4362
J9 IRISH J MED SCI
JI Irish J. Med. Sci.
PD NOV
PY 2020
VL 189
IS 4
BP 1155
EP 1157
DI 10.1007/s11845-020-02241-3
EA MAY 2020
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC8MC
UT WOS:000531776000001
PM 32394153
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Staats, P
   Giannakopoulos, G
   Blake, J
   Liebler, E
   Levy, RM
AF Staats, Peter
   Giannakopoulos, Georgios
   Blake, Justyna
   Liebler, Eric
   Levy, Robert M.
TI The Use of Non-invasive Vagus Nerve Stimulation to Treat Respiratory
   Symptoms Associated With COVID-19: A Theoretical Hypothesis and Early
   Clinical Experience
SO NEUROMODULATION
LA English
DT Article
DE Cholinergic anti-inflammatory pathway; COVID-19; cytokine storm;
   neuromodulation; non-invasive vagus nerve stimulation; respiratory
   symptoms
AB Objectives Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a pandemic with no specific therapeutic agents and substantial mortality, and finding new treatments is critical. Most cases are mild, but a significant minority of patients develop moderate to severe respiratory symptoms, with the most severe cases requiring intensive care and/or ventilator support. This respiratory compromise appears to be due to a hyperimmune reaction, often called a cytokine storm. Vagus nerve stimulation has been demonstrated to block production of cytokines in sepsis and other medical conditions. We hypothesize that non-invasive vagus nerve stimulation (nVNS) might provide clinical benefits in patients with respiratory symptoms similar to those associated with COVID-19.
   Materials and Methods Information on two case reports was obtained via email correspondence and phone interviews with the patients.
   Results Both patients reported clinically meaningful benefits from nVNS therapy. In case 1, the patient used nVNS to expedite symptomatic recovery at home after hospital discharge and was able to discontinue use of opioid and cough suppressant medications. In case 2, the patient experienced immediate and consistent relief from symptoms of chest tightness and shortness of breath, as well as an improved ability to clear his lungs.
   Conclusions Preliminary observations and a strong scientific foundation suggest that nVNS might provide clinical benefits in patients with COVID-19 via multiple mechanisms.
C1 [Staats, Peter; Blake, Justyna; Liebler, Eric] ElectroCore Inc, 150 Allen Rd,Suite 201, Basking Ridge, NJ 07920 USA.
   [Giannakopoulos, Georgios] Hackensack Meridian Hlth, Bayshore Med Ctr, Holmdel, NJ USA.
   [Levy, Robert M.] Anesthesia Pain Care Consultants, Tamarac, FL USA.
RP Liebler, E (corresponding author), ElectroCore Inc, 150 Allen Rd,Suite 201, Basking Ridge, NJ 07920 USA.
EM eric.liebler@electrocore.com
OI Liebler, Eric/0000-0002-8083-9660
FU electroCore, Inc.
FX Writing assistance and editorial support were provided by Elizabeth S.
   O. Barton, MS, of MedLogix Communications, LLC, in cooperation with the
   authors and were funded by electroCore, Inc.
CR Ahmadpoor P, 2020, TRANSPL INT, V33, P824, DOI 10.1111/tri.13611
   Andersson U, 2012, ANNU REV IMMUNOL, V30, P313, DOI 10.1146/annurev-immunol-020711-075015
   Borovikova LV, 2000, NATURE, V405, P458
   Cao B, 2016, CRIT CARE MED, V44, pE318, DOI 10.1097/CCM.0000000000001616
   Goh KJ, 2020, ANN ACAD MED SINGAP, V49, P108
   Hoffmann TJ, 2009, NEUROMODULATION, V12, P261, DOI 10.1111/j.1525-1403.2009.00234.x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jacoby DB, 2004, J AEROSOL MED, V17, P169, DOI 10.1089/0894268041457156
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Johnson RL, 2016, RESP PHYSIOL NEUROBI, V229, P1, DOI 10.1016/j.resp.2016.03.014
   Kaczmarczyk R, 2018, J NEUROCHEM, V146, P76, DOI 10.1111/jnc.14284
   Kessler W, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/467620
   Koopman FA, 2016, P NATL ACAD SCI USA, V113, P8284, DOI 10.1073/pnas.1605635113
   Lerman I, 2016, NEUROMODULATION, V19, P283, DOI 10.1111/ner.12398
   Miner JR, 2012, ACAD EMERG MED, V19, P421, DOI 10.1111/j.1553-2712.2012.01329.x
   Pavlov VA, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a034140
   Pavlov VA, 2012, NAT REV ENDOCRINOL, V8, P743, DOI 10.1038/nrendo.2012.189
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Staats P, 2018, NEUROMODULATION COMP, V1, P1339
   Steyn E, 2013, INT J EMERG MED, V6, DOI 10.1186/1865-1380-6-7
   Tarn J, 2019, NEUROMODULATION, V22, P580, DOI 10.1111/ner.12879
   Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555
   Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321
   Ulhaq ZS, 2020, GRAEF ARCH CLIN EXP, V258, P1351, DOI 10.1007/s00417-020-04695-8
   WHITE SR, 1987, J APPL PHYSIOL, V62, P972
   World Health Organization, CLIN MAN SEV AC RESP
   World Health Organization, MOD TRANSM VIR CAUS
   World Health Organization (WHO), WHO DIR GEN OP REM M
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhao M, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-013-0345-1
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 32
TC 6
Z9 6
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1094-7159
EI 1525-1403
J9 NEUROMODULATION
JI Neuromodulation
PD AUG
PY 2020
VL 23
IS 6
BP 784
EP 788
DI 10.1111/ner.13172
EA MAY 2020
PG 5
WC Medicine, Research & Experimental; Clinical Neurology
SC Research & Experimental Medicine; Neurosciences & Neurology
GA ND7PA
UT WOS:000531734900001
PM 32342609
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Jin, YH
   Huang, Q
   Wang, YY
   Zeng, XT
   Luo, LS
   Pan, ZY
   Yuan, YF
   Chen, ZM
   Cheng, ZS
   Huang, X
   Wang, N
   Li, BH
   Zi, H
   Zhao, MJ
   Ma, LL
   Deng, T
   Wang, Y
   Wang, XH
AF Jin, Ying-Hui
   Huang, Qiao
   Wang, Yun-Yun
   Zeng, Xian-Tao
   Luo, Li-Sha
   Pan, Zhen-Yu
   Yuan, Yu-Feng
   Chen, Zhi-Min
   Cheng, Zhen-Shun
   Huang, Xing
   Wang, Na
   Li, Bing-Hui
   Zi, Hao
   Zhao, Ming-Juan
   Ma, Lin-Lu
   Deng, Tong
   Wang, Ying
   Wang, Xing-Huan
TI Perceived infection transmission routes, infection control practices,
   psychosocial changes, and management of COVID-19 infected healthcare
   workers in a tertiary acute care hospital in Wuhan: a cross-sectional
   survey
SO MILITARY MEDICAL RESEARCH
LA English
DT Article
DE COVID-19; SARS-CoV-2; 2019-nCoV; Healthcare worker; Healthcare
   professional; Infection transmission route; Psychosocial status
AB Background Many healthcare workers were infected by coronavirus disease 2019 (COVID-19) early in the epidemic posing a big challenge for epidemic control. Hence, this study aims to explore perceived infection routes, influencing factors, psychosocial changes, and management procedures for COVID-19 infected healthcare workers. Methods This is a cross-sectional, single hospital-based study. We recruited all 105 confirmed COVID-19 healthcare workers in the Zhongnan Hospital of Wuhan University from February 15 to 29, 2020. All participants completed a validated questionnaire. Electronic consent was obtained from all participants. Perceived causes of infection, infection prevention, control knowledge and behaviour, psychological changes, symptoms and treatment were measured. Results Finally, 103 professional staff with COVID-19 finished the questionnaire and was included (response rate: 98.1%). Of them, 87 cases (84.5%) thought they were infected in working environment in hospital, one (1.0%) thought their infection was due to the laboratory environment, and 5 (4.9%) thought they were infected in daily life or community environment. Swab of throat collection and physical examination were the procedures perceived as most likely causing their infection by nurses and doctors respectively. Forty-three (41.8%) thought their infection was related to protective equipment, utilization of common equipment (masks and gloves). The top three first symptoms displayed before diagnosis were fever (41.8%), lethargy (33.0%) and muscle aches (30.1%). After diagnosis, 88.3% staff experienced psychological stress or emotional changes during their isolation period, only 11.7% had almost no emotional changes. Arbidol (Umifenovir; an anti-influza drug; 69.2%) was the drug most commonly used to target infection in mild and moderate symptoms. Conclusion The main perceived mode of transmission was not maintaining protection when working at a close distance and having intimate contact with infected cases. Positive psychological intervention is necessary.
C1 [Jin, Ying-Hui; Huang, Qiao; Wang, Yun-Yun; Zeng, Xian-Tao; Luo, Li-Sha; Huang, Xing; Li, Bing-Hui; Zi, Hao; Zhao, Ming-Juan; Ma, Lin-Lu; Deng, Tong; Wang, Xing-Huan] Wuhan Univ, Zhongnan Hosp, Ctr Evidence Based & Translat Med, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.
   [Jin, Ying-Hui; Huang, Qiao; Wang, Yun-Yun; Zeng, Xian-Tao; Luo, Li-Sha; Huang, Xing; Li, Bing-Hui; Zi, Hao; Zhao, Ming-Juan; Ma, Lin-Lu; Deng, Tong; Wang, Xing-Huan] Wuhan Univ, Clin Coll 2, Dept Evidence Based Med & Clin Epidemiol, Wuhan 430071, Hubei, Peoples R China.
   [Pan, Zhen-Yu] Wuhan Univ, Div Med Affairs, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
   [Yuan, Yu-Feng] Wuhan Univ, Dept Hepatopancreatobiliary Surg, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
   [Chen, Zhi-Min] Wuhan Univ, Div Social & Med Dev, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
   [Cheng, Zhen-Shun] Wuhan Univ, Dept Resp Med, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
   [Wang, Na] Henan Univ, Sch Nursing & Hlth, Kaifeng 475000, Henan, Peoples R China.
   [Wang, Na; Li, Bing-Hui; Zi, Hao; Deng, Tong] Henan Univ, Inst Evidence Based Med & Knowledge Translat, Kaifeng 475000, Henan, Peoples R China.
   [Wang, Ying] Wuhan Univ, Dept Infect Dis, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
   [Wang, Xing-Huan] Leishenshan Hosp Wuhan, Wuhan 430200, Hubei, Peoples R China.
RP Wang, XH (corresponding author), Wuhan Univ, Zhongnan Hosp, Ctr Evidence Based & Translat Med, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.; Wang, XH (corresponding author), Wuhan Univ, Clin Coll 2, Dept Evidence Based Med & Clin Epidemiol, Wuhan 430071, Hubei, Peoples R China.; Wang, XH (corresponding author), Leishenshan Hosp Wuhan, Wuhan 430200, Hubei, Peoples R China.
EM wangxinghuan1965@163.com
RI Taha, Samy/N-4620-2019
OI Taha, Samy/0000-0003-0284-7806
FU Emergency Science and Technology Project in Hubei Province [2020FCA008]
FX This work was supported by the Emergency Science and Technology Project
   in Hubei Province (2020FCA008). The authors had complete control over
   the design, conduct, and analysis of the study and the decision to
   submit the manuscript for publication.
CR [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   [Anonymous], 2020, INTERIM INFECT PREVE
   [Anonymous], 2020, CCTV SEGMENT NEWS 11
   [Anonymous], 2018, ACCREDITATION REGULA
   [Anonymous], 2020, CORONAVIRUS DIS COVI
   Ayanian JZ, 2020, MENTAL HLTH NEEDS HL
   Chen QN, 2020, LANCET PSYCHIAT, V7, pE15, DOI 10.1016/S2215-0366(20)30078-X
   Cherrie J, 2020, PROTECTING WORKERS C
   Daily C, 2020, 20 000 HEATHCARE WOR
   Daily C, 2020, XI PROTECTION CARE H
   Greenberg N, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1211
   Huang J, 2020, NEW MED, V30, P10
   Huh S, 2020, J EDUC EVAL HEALTH P, V17, DOI 10.3352/jeehp.2020.17.10
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Mason D., 2020, PROTECTING HLTH CARE
   Ng K, 2020, ANN INTERN MED, V172, P766, DOI 10.7326/L20-0175
   Petersen E, 2020, INT J INFECT DIS, V93, P205, DOI 10.1016/j.ijid.2020.02.052
   Schwartz J, 2020, CLIN INFECT DIS, V71, P858, DOI [10.1093/cid/ciaa255, 10.1080/10409238.2020.1841726]
   Wang RC, 2020, J INFECTION, V80, P354, DOI 10.1016/j.jinf.2020.01.017
   [王云云 Wang Yunyun], 2020, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V20, P723
NR 21
TC 13
Z9 13
U1 8
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-7467
EI 2054-9369
J9 MILITARY MED RES
JI MILITARY MED. RES.
PD MAY 11
PY 2020
VL 7
IS 1
AR 24
DI 10.1186/s40779-020-00254-8
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA LP4UJ
UT WOS:000534313900001
PM 32393381
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Das, S
   Sarmah, S
   Lyndem, S
   Roy, AS
AF Das, Sourav
   Sarmah, Sharat
   Lyndem, Sona
   Singha Roy, Atanu
TI An investigation into the identification of potential inhibitors of
   SARS-CoV-2 main protease using molecular docking study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2 M-pro; molecular docking; natural products; anti-virals;
   anti-fungals
ID ANTIVIRAL DRUGS
AB A new strain of a novel infectious disease affecting millions of people, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has recently been declared as a pandemic by the World Health Organization (WHO). Currently, several clinical trials are underway to identify specific drugs for the treatment of this novel virus. The inhibition of the SARS-CoV-2 main protease is necessary for the blockage of the viral replication. Here, in this study, we have utilized a blind molecular docking approach to identify the possible inhibitors of the SARS-CoV-2 main protease, by screening a total of 33 molecules which includes natural products, anti-virals, anti-fungals, anti-nematodes and anti-protozoals. All the studied molecules could bind to the active site of the SARS-CoV-2 protease (PDB: 6Y84), out of which rutin (a natural compound) has the highest inhibitor efficiency among the 33 molecules studied, followed by ritonavir (control drug), emetine (anti-protozoal), hesperidin (a natural compound), lopinavir (control drug) and indinavir (anti-viral drug). All the molecules, studied out here could bind near the crucial catalytic residues, HIS41 and CYS145 of the main protease, and the molecules were surrounded by other active site residues like MET49, GLY143, HIS163, HIS164, GLU166, PRO168, and GLN189. As this study is based on molecular docking, hence being particular about the results obtained, requires extensive wet-lab experimentation and clinical trials under in vitro as well as in vivo conditions. Communicated by Ramaswamy H. Sarma
C1 [Das, Sourav; Sarmah, Sharat; Lyndem, Sona; Singha Roy, Atanu] Natl Inst Technol Meghalaya, Dept Chem, Shillong 793003, Meghalaya, India.
RP Roy, AS (corresponding author), Natl Inst Technol Meghalaya, Dept Chem, Shillong 793003, Meghalaya, India.
EM singharoyatanu@gmail.com
FU TEQIP III, National Institute of Technology Meghalaya
FX The authors are grateful to National Institute of Technology Meghalaya
   for providing research platform. SD and SS thank TEQIP III, National
   Institute of Technology Meghalaya for their fellowship. The study was
   not supported by any funding authority. The authors thank the reviewers
   for their valuable suggestions to increase the scientific quality of the
   manuscript.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Akinboye E. S., 2011, Open Natural Products Journal, V4, P8, DOI 10.2174/1874848101104010008
   [Anonymous], 2017, PYMOL MOL GRAPHICS S
   [Anonymous], 2020, CORONAVIRUS COVID 19
   Arthur DE, 2019, J KING SAUD UNIV SCI, V31, P1151, DOI 10.1016/j.jksus.2019.01.011
   Biovia D.S., 2019, DISCOVERY STUDIO VIS
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Thuy BTP, 2020, ACS OMEGA, V5, P8312, DOI 10.1021/acsomega.0c00772
   CORY H, 2018, FRONT NUTR, V5, DOI DOI https://doi.org/10.3389/fnut.2018.00087
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   De Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI 10.1128/CMR.00102-15
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Fitchett JR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105722
   Ganeshpurkar A, 2017, SAUDI PHARM J, V25, P149, DOI 10.1016/j.jsps.2016.04.025
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Law GL, 2013, CURR OPIN IMMUNOL, V25, P588, DOI 10.1016/j.coi.2013.08.004
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Owen C. D., 2020, RCSB PROTEIN DATA BA, V6Y84, P3, DOI [https://doi.org/10.2210/pdb6Y84, DOI 10.2210/PDB6Y84]
   Panic G, 2014, INT J PARASITOL-DRUG, V4, P185, DOI 10.1016/j.ijpddr.2014.07.002
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Park Kyungsoo, 2019, Transl Clin Pharmacol, V27, P59, DOI 10.12793/tcp.2019.27.2.59
   Parvez MK, 2019, SAUDI PHARM J, V27, P389, DOI 10.1016/j.jsps.2018.12.008
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Thayil S. M., 2016, INT J PHARMACOGN, V8, P1020
   Thompson MA, 2004, ACS M
   Vardakas KZ, 2005, BRIT J HAEMATOL, V131, P22, DOI 10.1111/j.1365-2141.2005.05727.x
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, J INFECT DIS, V221, P1688, DOI 10.1093/infdis/jiz656
   Wu YS, 2006, CURR MED CHEM, V13, P2003, DOI 10.2174/092986706777584988
   Xu Z., 2020, MELFINAVIR WAS PREDI, DOI [2020.01.27.921627, 10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Zakaryan H, 2017, ARCH VIROL, V162, P2539, DOI 10.1007/s00705-017-3417-y
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 46
TC 33
Z9 33
U1 5
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1763201
EA MAY 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LP2DL
UT WOS:000534128000001
PM 32362245
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Harter, G
   Spinner, CD
   Roider, J
   Bickel, M
   Krznaric, I
   Grunwald, S
   Schabaz, F
   Gillor, D
   Postel, N
   Mueller, MC
   Muller, M
   Romer, K
   Schewe, K
   Hoffmann, C
AF Haerter, Georg
   Spinner, Christoph D.
   Roider, Julia
   Bickel, Markus
   Krznaric, Ivanka
   Grunwald, Stephan
   Schabaz, Farhad
   Gillor, Daniel
   Postel, Nils
   Mueller, Matthias C.
   Mueller, Markus
   Roemer, Katja
   Schewe, Knud
   Hoffmann, Christian
TI COVID-19 in people living with human immunodeficiency virus: a case
   series of 33 patients
SO INFECTION
LA English
DT Article
DE SARS-CoV-2; COVID-19; HIV infection; AIDS; Antiretroviral therapy
ID CORONAVIRUS INFECTION
AB Introduction Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population. Methods Retrospective analysis of anonymized data including age, gender, HIV-associated parameters, symptoms, and outcome. Results Three out of 32 patients with documented outcomes died (9%). 91% of the patients recovered and 76% have been classified as mild cases. All patients were on antiretroviral treatment, of them 22 on tenofovir-containing regimen and 4 on the protease inhibitor darunavir. Conclusions This preliminary case series does not support excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART.
C1 [Haerter, Georg] Medicover Ulm MVZ, Munsterpl 6, D-89073 Ulm, Germany.
   [Spinner, Christoph D.] Tech Univ Munich, Univ Hosp Klinikum Rechts Isar, Sch Med, Dept Med 2, Ismaninger Str 22, D-81675 Munich, Germany.
   [Roider, Julia] Ludwig Maximilians Univ Munchen, Klinikum Univ, Med Klin & Poliklin 4, Sekt Klin Infektiol, Pettenkoferstr 8a, D-80336 Munich, Germany.
   [Roider, Julia] Partner Site Munich, German Ctr Infect Res DZIF, Munich, Germany.
   [Bickel, Markus] Infektiologikum Frankfurt, Stresemannallee 3, D-60596 Frankfurt, Germany.
   [Krznaric, Ivanka; Grunwald, Stephan] Zentrum Infektiol Berlin Prenzelberg, Driesener Str 11, D-10439 Berlin, Germany.
   [Schabaz, Farhad] MVZ Karlspl Munchen, Karlspl 8, D-80335 Munich, Germany.
   [Gillor, Daniel] MVZ Innere Med Koln, Hohenstaufenring 59, D-50674 Cologne, Germany.
   [Postel, Nils] Prinzmed, Sendlinger Tor Pl 8, D-80336 Munich, Germany.
   [Mueller, Matthias C.] MVZ Clotten, Dept Infect Med, Med Care Ctr, Berliner Allee 29, D-79110 Freiburg, Germany.
   [Mueller, Matthias C.] Univ Freiburg, Fac Med, Med Ctr, Dept Med 2,Div Infect Dis, Hugstetter Str 55, D-79106 Freiburg, Germany.
   [Schewe, Knud; Hoffmann, Christian] ICH Study Ctr Hamburg, Glockengiesserwall 1, D-20095 Hamburg, Germany.
   [Hoffmann, Christian] Univ Hosp Schleswig Holstein, Campus Kiel,Arnold Heller Str 3, D-24105 Kiel, Germany.
RP Harter, G (corresponding author), Medicover Ulm MVZ, Munsterpl 6, D-89073 Ulm, Germany.
EM ghaerter@gmx.de
RI Spinner, Christoph/H-7039-2019; Harter, Georg/AAV-4703-2020
OI Spinner, Christoph/0000-0002-3875-5367; Harter,
   Georg/0000-0001-9946-6246
CR Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen G, 2020, J CLIN INVEST, V2020, P137244
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   He ZP, 2005, INT J INFECT DIS, V9, P323, DOI 10.1016/j.ijid.2004.07.014
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lynfield R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101785
   Machnowska P, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209605
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Park SY, 2019, J HOSP INFECT, V101, P42, DOI 10.1016/j.jhin.2018.09.005
   Peters PJ, 2011, CLIN INFECT DIS, V52, pS183, DOI 10.1093/cid/ciq036
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Robert-Koch Institute Berlin Germany, COR VIR DIS 2019 DAI
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shi Y, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2833-7
   Stecher M, 2019, INFECTION, V47, P247, DOI 10.1007/s15010-018-1248-8
   US Department of Health and Human Services, INT GUID COVID 19 PE
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   WHO, 2019, COR DIS COVID 19 OUT
   Wong ATY, 2004, AIDS, V18, P829, DOI 10.1097/00002030-200403260-00021
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu F, 2020, J MED VIROL, V92, P529, DOI 10.1002/jmv.25732
NR 28
TC 46
Z9 46
U1 1
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8126
EI 1439-0973
J9 INFECTION
JI Infection
PD OCT
PY 2020
VL 48
IS 5
BP 681
EP 686
DI 10.1007/s15010-020-01438-z
EA MAY 2020
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA NT0QS
UT WOS:000531785200002
PM 32394344
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Roncon, L
   Zuin, M
   Zonzin, P
AF Roncon, Loris
   Zuin, Marco
   Zonzin, Pietro
TI Fibrinolysis in COVID-19 patients with hemodynamic unstable acute
   pulmonary embolism: yes or no?
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Letter
ID THROMBOCYTOPENIA; THERAPY
C1 [Roncon, Loris; Zonzin, Pietro] Santa Maria Misericordia Hosp, Dept Cardiol, Rovigo, Italy.
   [Zuin, Marco] Univ Ferrara, Sch Med, Ferrara, Italy.
   [Roncon, Loris] Rovigo Gen Hosp, Viale Tre Martiri, I-45100 Rovigo, Italy.
RP Roncon, L (corresponding author), Santa Maria Misericordia Hosp, Dept Cardiol, Rovigo, Italy.; Roncon, L (corresponding author), Rovigo Gen Hosp, Viale Tre Martiri, I-45100 Rovigo, Italy.
EM lorisroncon@gmail.com
CR Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Dolhnikoff M, 2020, J THROMB HAEMOST, V18, P1517, DOI 10.1111/jth.14844
   HARRINGTON RA, 1994, J AM COLL CARDIOL, V23, P891, DOI 10.1016/0735-1097(94)90634-3
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Marone EM, 2020, J VASC SURG-VENOUS L, V8, P694, DOI 10.1016/j.jvsv.2020.04.004
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Yang XB, 2020, J THROMB HAEMOST, V18, P1469, DOI 10.1111/jth.14848
   Zuin M, 2016, INT J CARDIOL, V225, P14, DOI 10.1016/j.ijcard.2016.09.104
NR 8
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
PD JUL
PY 2020
VL 50
IS 1
BP 221
EP 222
DI 10.1007/s11239-020-02131-6
EA MAY 2020
PG 2
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA LY0ER
UT WOS:000531769500001
PM 32394238
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Abdelmageed, MI
   Abdelmoneim, AH
   Mustafa, MI
   Elfadol, NM
   Murshed, NS
   Shantier, SW
   Makhawi, AM
AF Abdelmageed, Miyssa I.
   Abdelmoneim, Abdelrahman H.
   Mustafa, Mujahed I.
   Elfadol, Nafisa M.
   Murshed, Naseem S.
   Shantier, Shaza W.
   Makhawi, Abdelrafie M.
TI Design of a Multiepitope-Based Peptide Vaccine against the E Protein of
   Human COVID-19: An Immunoinformatics Approach
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID NEURAL-NETWORKS; CORONAVIRUS; PREDICTION; BINDING; IMMUNIZATION;
   GENERATION; AFFINITIES; EXPRESSION; EPITOPES; SERVER
AB Background. A new endemic disease has spread across Wuhan City, China, in December 2019. Within few weeks, the World Health Organization (WHO) announced a novel coronavirus designated as coronavirus disease 2019 (COVID-19). In late January 2020, WHO declared the outbreak of a "public-health emergency of international concern" due to the rapid and increasing spread of the disease worldwide. Currently, there is no vaccine or approved treatment for this emerging infection; thus, the objective of this study is to design a multiepitope peptide vaccine against COVID-19 using an immunoinformatics approach. Method. Several techniques facilitating the combination of the immunoinformatics approach and comparative genomic approach were used in order to determine the potential peptides for designing the T-cell epitope-based peptide vaccine using the envelope protein of 2019-nCoV as a target. Results. Extensive mutations, insertion, and deletion were discovered with comparative sequencing in the COVID-19 strain. Additionally, ten peptides binding to MHC class I and MHC class II were found to be promising candidates for vaccine design with adequate world population coverage of 88.5% and 99.99%, respectively. Conclusion. The T-cell epitope-based peptide vaccine was designed for COVID-19 using the envelope protein as an immunogenic target. Nevertheless, the proposed vaccine rapidly needs to be validated clinically in order to ensure its safety and immunogenic profile to help stop this epidemic before it leads to devastating global outbreaks.
C1 [Abdelmageed, Miyssa I.] Univ Khartoum, Fac Pharm, Khartoum, Sudan.
   [Abdelmoneim, Abdelrahman H.] Alneelain Univ, Fac Med, Khartoum, Sudan.
   [Mustafa, Mujahed I.; Makhawi, Abdelrafie M.] Univ Bahri, Dept Biotechnol, Khartoum, Sudan.
   [Elfadol, Nafisa M.] Natl Univ Biomed Res Inst, Natl Univ, Dept Mol Biol, Khartoum, Sudan.
   [Murshed, Naseem S.] Int Univ Africa, Dept Microbiol, Khartoum, Sudan.
   [Shantier, Shaza W.] Univ Khartoum, Dept Pharmaceut Chem, Fac Pharm, Khartoum, Sudan.
RP Mustafa, MI (corresponding author), Univ Bahri, Dept Biotechnol, Khartoum, Sudan.
EM miyssaimam@outlook.com; abduhamza009@gmail.com;
   mujahedibrahim44@gmail.com; nosa_911_5@hotmail.com;
   naseemziadi@gmail.com; shaza.shantier@uofk.edu; amakhawi2000@gmail.com
RI Abdelmoneim, Abdelrahman H./AAX-8505-2020
OI Abdelmoneim, Abdelrahman H./0000-0002-5037-8488; Mustafa,
   Mujahed/0000-0001-6893-0536
FU Deanship of Scientific Research at University of Bahri
FX The authors acknowledge the Deanship of Scientific Research at
   University of Bahri for the supportive cooperation.
CR Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639
   Arya R., 2020, POTENTIAL INHIBITORS
   Bahrami AA, 2019, INT REV IMMUNOL, V38, P307, DOI 10.1080/08830185.2019.1657426
   Bedford T., 2020, GENOMIC EPIDEMIOLOGY
   Benson DA, 2018, NUCLEIC ACIDS RES, V46, pD41, DOI [10.1093/nar/gkx1094, 10.1093/nar/gkw1070]
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Black M, 2010, EXPERT REV VACCINES, V9, P157, DOI [10.1586/erv.09.160, 10.1586/ERV.09.160]
   Brusic Vladimir, 2005, Expert Rev Clin Immunol, V1, P145, DOI 10.1586/1744666X.1.1.145
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Buus S, 2003, TISSUE ANTIGENS, V62, P378, DOI 10.1034/j.1399-0039.2003.00112.x
   Carver TJ, 2005, BIOINFORMATICS, V21, P3422, DOI 10.1093/bioinformatics/bti553
   Chakraborty Sajib, 2010, In Silico Biology, V10, P235, DOI 10.3233/ISB-2010-0435
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chaudhury S, 2020, HUM VACC IMMUNOTHER, V16, P400, DOI 10.1080/21645515.2019.1654807
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Choo JAL, 2014, ANGEW CHEM INT EDIT, V53, P13390, DOI 10.1002/anie.201406295
   Christie JML, 1999, HEPATOLOGY, V30, P1037, DOI 10.1002/hep.510300403
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   CoV2020, 2020, GISAID EPIFLUDB ARCH
   Curtis KM, 2002, J VIROL, V76, P1422, DOI 10.1128/JVI.76.3.1422-1434.2002
   De Groot A. S., 2014, EXPERT REV VACCINES, V3, P59
   DeDiego ML, 2008, VIROLOGY, V376, P379, DOI 10.1016/j.virol.2008.03.005
   Dermine S, 2004, BBA-REV CANCER, V1704, P11, DOI 10.1016/j.bbcan.2004.03.002
   Dhanda SK, 2017, BRIEF BIOINFORM, V18, P467, DOI 10.1093/bib/bbw025
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Dudek NL, 2010, CURR PHARM DESIGN, V16, P3149
   El Sahly H. M., 2020, NEW ENGLAND J MED
   Fauci AS, 2006, CELL, V124, P665, DOI 10.1016/j.cell.2006.02.010
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gilbert C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4348
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Guo XJ, 2015, IMMUNOLOGY, V145, P476, DOI 10.1111/imm.12462
   Hardison RC, 2003, PLOS BIOL, V1, P156, DOI 10.1371/journal.pbio.0000058
   Hasan MA, 2013, BIOINFORM BIOL INSIG, V7, P347, DOI 10.4137/BBI.S13402
   Hegde NR, 2018, EXPERT OPIN DRUG DIS, V13, P117, DOI 10.1080/17460441.2018.1413088
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Khalili S, 2014, ACTA MICROBIOL IMM H, V61, P285, DOI 10.1556/AMicr.61.2014.3.4
   Khazaei-Poul Yalda, 2020, Curr Pharm Biotechnol, DOI 10.2174/1573412916666200120155104
   Korber B, 2006, PLOS COMPUT BIOL, V2, P484, DOI 10.1371/journal.pcbi.0020071
   Letko M, 2020, FUNCTIONAL ASSESSMEN
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515
   Lo YT, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S4-S3
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lundegaard C, 2008, BIOINFORMATICS, V24, P1397, DOI 10.1093/bioinformatics/btn128
   Lundegaard C, 2008, NUCLEIC ACIDS RES, V36, pW509, DOI 10.1093/nar/gkn202
   Lundegaard C, 2006, TRENDS BIOTECHNOL, V24, P537, DOI 10.1016/j.tibtech.2006.10.001
   Mahony JB, 2011, CRIT REV CL LAB SCI, V48, P217, DOI 10.3109/10408363.2011.640976
   Marshall SJ, 2004, B WORLD HEALTH ORGAN, V82, P556
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Meloen RH, 2001, BIOLOGICALS, V29, P233, DOI 10.1006/biol.2001.0298
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Mortola E, 2004, FEBS LETT, V576, P174, DOI 10.1016/j.febslet.2004.09.009
   Netland J, 2010, VIROLOGY, V399, P120, DOI 10.1016/j.virol.2010.01.004
   Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403
   Nieto-Torres JL, 2011, VIROLOGY, V415, P69, DOI 10.1016/j.virol.2011.03.029
   Oni OO, 2018, TROP ANIM HEALTH PRO, V50, P267, DOI 10.1007/s11250-017-1425-2
   Ortego J, 2002, J VIROL, V76, P11518, DOI 10.1128/JVI.76.22.11518-11529.2002
   Patronov A, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120139
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Purcell AW, 2007, NAT REV DRUG DISCOV, V6, P404, DOI 10.1038/nrd2224
   Regla-Nava JA, 2015, J VIROL, V89, P3870, DOI 10.1128/JVI.03566-14
   Ruch TR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002674
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   SESARDIC D, 1993, J MED MICROBIOL, V39, P241, DOI 10.1099/00222615-39-4-241
   Sharmin R, 2016, SOURCE CODE BIOL MED, V11, DOI 10.1186/s13029-016-0049-7
   Southwood S, 1998, J IMMUNOL, V160, P3363
   Stecher G, 2020, MOL BIOL EVOL, V37, P1237, DOI 10.1093/molbev/msz312
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Tomar Namrata, 2014, Methods Mol Biol, V1184, P23, DOI 10.1007/978-1-4939-1115-8_3
   Tomar N, 2010, IMMUNOLOGY, V131, P153, DOI 10.1111/j.1365-2567.2010.03330.x
   Twiddy SS, 2003, MOL BIOL EVOL, V20, P122, DOI 10.1093/molbev/msg010
   ul Qamar MT, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1672-7
   Usmani SS, 2018, ADV PROTEIN CHEM STR, V112, P221, DOI 10.1016/bs.apcsb.2018.01.006
   Venkatagopalan P, 2015, VIROLOGY, V478, P75, DOI 10.1016/j.virol.2015.02.005
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang S, 2016, NUCLEIC ACIDS RES, V44, pW430, DOI 10.1093/nar/gkw306
   Westerbeck JW, 2015, J VIROL, V89, P9313, DOI 10.1128/JVI.01237-15
   Xu Jing, 2003, Genomics Proteomics & Bioinformatics, V1, P226
   Zhang NR, 2020, J MED VIROL, V92, P408, DOI 10.1002/jmv.25674
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
NR 85
TC 18
Z9 18
U1 3
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD MAY 11
PY 2020
VL 2020
AR 2683286
DI 10.1155/2020/2683286
PG 12
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA LO1GP
UT WOS:000533376900001
PM 32461973
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU O'Neill, LAJ
   Netea, MG
AF O'Neill, Luke A. J.
   Netea, Mihai G.
TI BCG-induced trained immunity: can it offer protection against COVID-19?
SO NATURE REVIEWS IMMUNOLOGY
LA English
DT Article; Early Access
ID NONSPECIFIC PROTECTION; VIRAL-INFECTION; VACCINATION; RESISTANCE; VIRUS;
   MICE
AB Bacillus Calmette-Guerin (BCG) vaccination has been reported to decrease susceptibility to respiratory tract infections, an effect proposed to be mediated by the general long-term boosting of innate immune mechanisms, also termed trained immunity. Here, we discuss the non-specific beneficial effects of BCG against viral infections and whether this vaccine may afford protection to COVID-19.
   Could the BCG vaccine be used to bridge the gap until a specific COVID-19 vaccine is developed? Luke O'Neill and Mihai Netea discuss the science behind this approach.
C1 [O'Neill, Luke A. J.; Netea, Mihai G.] Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Dublin, Ireland.
   [Netea, Mihai G.] Radboud Univ Nijmegen, Dept Internal Med, Nijmegen, Netherlands.
   [Netea, Mihai G.] Radboud Univ Nijmegen, Ctr Infect Dis, Nijmegen, Netherlands.
   [Netea, Mihai G.] Univ Bonn, Immunol & Metab Life & Med Sci Inst, Bonn, Germany.
RP O'Neill, LAJ (corresponding author), Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Dublin, Ireland.
EM laoneill@tcd.ie
FU European Research Council (ERC)European Research Council (ERC) [834370];
   Wellcome Trust Investigator AwardWellcome Trust; ERC advanced
   grantEuropean Research Council (ERC) [833247]; Spinoza grant of the
   Netherlands Association for Scientific Research
FX L.A.J.O.N. was supported by a European Research Council (ERC) advanced
   grant (no. 834370) and a Wellcome Trust Investigator Award. M.G.N. was
   supported by an ERC advanced grant (no. 833247) and a Spinoza grant of
   the Netherlands Association for Scientific Research.
CR Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Gursel M, 2020, ALLERGY, V75, P1815, DOI 10.1111/all.14345
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   IKEDA S, 1985, ANTIVIR RES, V5, P207, DOI 10.1016/0166-3542(85)90025-7
   Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/NEJMoa1714021, 10.1056/nejmoa1714021]
   Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098
   Ohrui Takashi, 2005, Nihon Ronen Igakkai Zasshi, V42, P34
   Shann F, 2010, ARCH DIS CHILD, V95, P662, DOI 10.1136/adc.2009.157537
   SPENCER JC, 1977, J INFECT DIS, V136, P171, DOI 10.1093/infdis/136.2.171
   STARR SE, 1976, P SOC EXP BIOL MED, V152, P57
   Stensballe LG, 2005, VACCINE, V23, P1251, DOI 10.1016/j.vaccine.2004.09.006
   Wardhana, 2011, Acta Med Indones, V43, P185
NR 16
TC 68
Z9 68
U1 9
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-1733
EI 1474-1741
J9 NAT REV IMMUNOL
JI Nat. Rev. Immunol.
DI 10.1038/s41577-020-0337-y
EA MAY 2020
PG 3
WC Immunology
SC Immunology
GA LL7VH
UT WOS:000531763800001
PM 32393823
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wang, J
   Hajizadeh, N
   Moore, EE
   McIntyre, RC
   Moore, PK
   Veress, LA
   Yaffe, MB
   Moore, HB
   Barrett, CD
AF Wang, Janice
   Hajizadeh, Negin
   Moore, Ernest E.
   McIntyre, Robert C.
   Moore, Peter K.
   Veress, Livia A.
   Yaffe, Michael B.
   Moore, Hunter B.
   Barrett, Christopher D.
TI Tissue plasminogen activator (tPA) treatment for COVID-19 associated
   acute respiratory distress syndrome (ARDS): A case series
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE acute respiratory distress syndrome (ARDS); case report; COVID-19;
   fibrinolysis; tissue plasminogen activator (tPA)
AB A prothrombotic coagulopathy is commonly found in critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS). A unique feature of COVID-19 respiratory failure is a relatively preserved lung compliance and high Alveolar-arterial oxygen gradient, with pathology reports consistently demonstrating diffuse pulmonary microthrombi on autopsy, all consistent with a vascular occlusive etiology of respiratory failure rather than the more classic findings of low-compliance in ARDS. The COVID-19 pandemic is overwhelming the world's medical care capacity with unprecedented needs for mechanical ventilators and high rates of mortality once patients progress to needing mechanical ventilation, and in many environments including in parts of the United States the medical capacity is being exhausted. Fibrinolytic therapy has previously been used in a Phase 1 clinical trial that led to reduced mortality and marked improvements in oxygenation. Here we report a series of three patients with severe COVID-19 respiratory failure who were treated with tissue plasminogen activator. All three patients had a temporally related improvement in their respiratory status, with one of them being a durable response.
C1 [Wang, Janice; Hajizadeh, Negin] Northwell Hlth, Feinstein Inst Med Res, Manhasset, NY USA.
   [Moore, Ernest E.] Denver Hlth, Dept Surg, Ernest E Moore Shock Trauma Ctr, Denver, CO USA.
   [Moore, Ernest E.; McIntyre, Robert C.; Moore, Hunter B.] Univ Colorado Denver, Dept Surg, 12631 E 17th Ave 6117, Aurora, CO 80045 USA.
   [Moore, Peter K.] Univ Colorado Denver, Dept Med, Aurora, CO USA.
   [Veress, Livia A.] Univ Colorado Denver, Dept Pediat, Pulm Med, Aurora, CO USA.
   [Yaffe, Michael B.; Barrett, Christopher D.] MIT, Koch Inst Integrat Canc Res, Ctr Precis Canc Med, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Yaffe, Michael B.; Barrett, Christopher D.] MIT, Dept Biol, Koch Inst Integrat Canc Res, Ctr Precis Canc Med, Cambridge, MA USA.
   [Yaffe, Michael B.; Barrett, Christopher D.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Surg, Div Acute Care Surg Trauma & Surg Crit Care, Boston, MA 02115 USA.
RP Moore, HB (corresponding author), Univ Colorado Denver, Dept Surg, 12631 E 17th Ave 6117, Aurora, CO 80045 USA.; Barrett, CD (corresponding author), Beth Israel Deaconess Med Ctr, Dept Surg, Div Acute Care Surg Trauma & Surg Crit Care, 110 Francis St,Suite 9B, Boston, MA 02215 USA.
EM hunter.moore@ucdenver.edu; cdbarret@mit.edu
OI Moore, Peter/0000-0001-6446-067X
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   HARDAWAY RM, 1990, CRIT CARE MED, V18, P1413, DOI 10.1097/00003246-199012000-00021
   Konstantinides S, 2002, NEW ENGL J MED, V347, P1143, DOI 10.1056/NEJMoa021274
   Li TH, 2020, EMERG MICROBES INFEC, V9, P687, DOI 10.1080/22221751.2020.1741327
   Liu C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01898
   Luo W, 2020, CLIN PATHOLOGY CRITI, DOI [10.1101/2020.03.07.20032573, DOI 10.1101/2020.03.07.20032573]
   Stringer KA, 1998, FREE RADICAL BIO MED, V25, P184, DOI 10.1016/S0891-5849(98)00047-1
   TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu J, 2020, RESP RES, DOI [10.21203/rs.3.rs-18340/v1, DOI 10.21203/RS.3.RS-18340/V1]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 12
TC 139
Z9 144
U1 6
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD JUL
PY 2020
VL 18
IS 7
BP 1752
EP 1755
DI 10.1111/jth.14828
EA MAY 2020
PG 4
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA MG6WK
UT WOS:000531502700001
PM 32267998
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Roy, NBA
   Telfer, P
   Eleftheriou, P
   de la Fuente, J
   Drasar, E
   Shah, F
   Roberts, D
   Atoyebi, W
   Trompeter, S
   Layton, DM
   Lugthart, S
   Stuart-Smith, S
   Chakravorty, S
   Wright, J
   Porter, J
   Inusa, B
   Howard, J
AF Roy, Noemi B. A.
   Telfer, Paul
   Eleftheriou, Perla
   de la Fuente, Josu
   Drasar, Emma
   Shah, Farrukh
   Roberts, David
   Atoyebi, Wale
   Trompeter, Sara
   Layton, D. Mark
   Lugthart, Sanne
   Stuart-Smith, Sara
   Chakravorty, Subarna
   Wright, Josh
   Porter, John
   Inusa, Baba
   Howard, Jo
CA Natl Haemoglobinopathy Panel
TI Protecting vulnerable patients with inherited anaemias from unnecessary
   death during the COVID-19 pandemic
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
AB With the developing COVID-19 pandemic, patients with inherited anaemias require specific advice regarding isolation and changes to usual treatment schedules. The National Haemoglobinopathy Panel (NHP) has issued guidance on the care of patients with sickle cell disease, thalassaemia, Diamond Blackfan anaemia (DBA), congenital dyserythropoietic anaemia (CDA), sideroblastic anaemia, pyruvate kinase deficiency and other red cell enzyme and membrane disorders. Cascading of accurate information for clinicians and patients is paramount to preventing adverse outcomes, such as patients who are at increased risk of fulminant bacterial infection due to their condition or its treatment erroneously self-isolating if their fever is mistakenly attributed to a viral cause, delaying potentially life-saving antibiotic therapy. Outpatient visits should be minimised for most patients, however some, such as first transcranial dopplers for children with sickle cell anaemia should not be delayed as known risk of stroke will outweigh the unknown risk from COVID-19 infection. Blood transfusion programmes should be continued, but specific changes to usual clinical pathways can be instituted to reduce risk of patient exposure to COVID-19, as well as contingency planning for possible reductions in blood available for transfusions. Bone marrow transplants for these disorders should be postponed until further notice. With the current lack of evidence on the risk and complications of COVID-19 infection in these patients, national data collection is ongoing to record outcomes and eventually to identify predictors of disease severity, particularly important if further waves of infection travel through the population.
C1 [Roy, Noemi B. A.; Atoyebi, Wale] John Radcliffe Hosp, Oxford, England.
   [Roy, Noemi B. A.] NIHR Biomed Res Ctr, Oxford, England.
   [Telfer, Paul] Barts Hlth NHS Trust, London, England.
   [Eleftheriou, Perla; de la Fuente, Josu; Layton, D. Mark] Imperial Coll London, London, England.
   [de la Fuente, Josu] Imperial Coll Healthcare NHS Trust, London, England.
   [Drasar, Emma; Shah, Farrukh; Porter, John] Univ Coll London Hosp, London, England.
   [Drasar, Emma; Shah, Farrukh] Whittigton Hlth NHS Trust, London, England.
   [Roberts, David; Trompeter, Sara] NHS Blood & Transplant, London, England.
   [Trompeter, Sara] Univ Coll London Hosp NHS Fdn Trust, London, England.
   [Lugthart, Sanne] Univ Hosp Bristol, Bristol, Avon, England.
   [Stuart-Smith, Sara; Chakravorty, Subarna] Kings Coll Hosp NHS Trust, London, England.
   [Wright, Josh] Sheffield Teaching Hosp, Sheffield, S Yorkshire, England.
   [Inusa, Baba; Howard, Jo] Guys & St Thomass NHS Trust, London, England.
RP Roy, NBA (corresponding author), John Radcliffe Hosp, Oxford, England.
EM noemi@romahi.com
OI Lugthart, Sanne/0000-0003-3007-8303; de la Fuente,
   Josu/0000-0002-0974-1249; Trompeter, Sara/0000-0002-7099-8449
CR Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Brousse V, 2014, BRIT J HAEMATOL, V166, P165, DOI 10.1111/bjh.12950
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Iskander D, 2019, BRIT J HAEMATOL, V186, P321, DOI 10.1111/bjh.15915
   Martinez N, 2019, IEEE IMAGE PROC, P2020, DOI 10.1109/ICIP.2019.8803109
NR 5
TC 15
Z9 16
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD MAY
PY 2020
VL 189
IS 4
BP 635
EP 639
DI 10.1111/bjh.16687
EA MAY 2020
PG 5
WC Hematology
SC Hematology
GA LN6FE
UT WOS:000531167200001
PM 32330288
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Henderson, LA
   Canna, SW
   Schulert, GS
   Volpi, S
   Lee, PY
   Kernan, KF
   Caricchio, R
   Mahmud, S
   Hazen, MM
   Halyabar, O
   Hoyt, KJ
   Han, J
   Grom, AA
   Gattorno, M
   Ravelli, A
   De Benedetti, F
   Behrens, EM
   Cron, RQ
   Nigrovic, PA
AF Henderson, Lauren A.
   Canna, Scott W.
   Schulert, Grant S.
   Volpi, Stefano
   Lee, Pui Y.
   Kernan, Kate F.
   Caricchio, Roberto
   Mahmud, Shawn
   Hazen, Melissa M.
   Halyabar, Olha
   Hoyt, Kacie J.
   Han, Joseph
   Grom, Alexei A.
   Gattorno, Marco
   Ravelli, Angelo
   De Benedetti, Fabrizio
   Behrens, Edward M.
   Cron, Randy Q.
   Nigrovic, Peter A.
TI On the Alert for Cytokine Storm: Immunopathology in COVID-19
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID MACROPHAGE ACTIVATION SYNDROME; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
AB Poor outcomes in COVID-19 correlate with clinical and laboratory features of cytokine storm syndrome. Broad screening for cytokine storm and early, targeted antiinflammatory therapy may prevent immunopathology and could help conserve limited health care resources. While studies are ongoing, extrapolating from clinical experience in cytokine storm syndromes may benefit the multidisciplinary teams caring for patients with severe COVID-19.
C1 [Henderson, Lauren A.; Lee, Pui Y.; Hazen, Melissa M.; Halyabar, Olha; Hoyt, Kacie J.] Boston Childrens Hosp, Boston, MA USA.
   [Henderson, Lauren A.; Lee, Pui Y.; Hazen, Melissa M.; Halyabar, Olha; Hoyt, Kacie J.; Nigrovic, Peter A.] Harvard Med Sch, Boston, MA 02115 USA.
   [Canna, Scott W.; Kernan, Kate F.] UPMC Childrens Hosp Pittsburgh, Pittsburgh, PA USA.
   [Canna, Scott W.; Kernan, Kate F.] Univ Pittsburgh, Pittsburgh, PA USA.
   [Schulert, Grant S.; Grom, Alexei A.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
   [Schulert, Grant S.; Grom, Alexei A.] Univ Cincinnati, Coll Med, Cincinnati, OH USA.
   [Volpi, Stefano; Gattorno, Marco] IRCCS Ist Giannina Gaslini, Ctr Autoinflammatory Dis & Immunodeficiency, Genoa, Italy.
   [Volpi, Stefano; Gattorno, Marco; Ravelli, Angelo] Univ Genoa, Genoa, Italy.
   [Caricchio, Roberto] Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA.
   [Caricchio, Roberto] Lewis Katz Sch Med, Philadelphia, PA USA.
   [Mahmud, Shawn] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA.
   [Mahmud, Shawn] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.
   [Han, Joseph] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
   [Ravelli, Angelo] IRCCS Ist Giannina Gaslini, Clin Pediat & Reumatol, Genoa, Italy.
   [De Benedetti, Fabrizio] Osped Pediat Bambino Gesu, Rome, Italy.
   [Behrens, Edward M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   [Behrens, Edward M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Cron, Randy Q.] Univ Alabama Birmingham, Childrens Alabama, Birmingham, AL USA.
   [Nigrovic, Peter A.] Brigham & Womens Hosp, Boston Childrens Hosp, 75 Francis St, Boston, MA 02115 USA.
RP Henderson, LA (corresponding author), 1 Blackfan Circle,Karp Family Res Bldg, Boston, MA 02115 USA.
EM Lauren.Henderson@childrens.harvard.edu
RI de benedetti, fabrizio/J-9577-2018
OI de benedetti, fabrizio/0000-0001-8749-8232; Gattorno,
   Marco/0000-0003-0704-1916; Canna, Scott/0000-0003-3837-5337; Caricchio,
   Roberto/0000-0002-1379-1118; Mahmud, Shawn/0000-0001-5169-651X
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases,
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS) [K08-AR-073339, P30-AR-070253,
   2R01-AR-065538, R01-AR-075906, R01-AR-073201, R21-AR-076630];
   Investigator Award of the Rheumatology Research Foundation; National
   Institute of Child Health and Human Development, NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD) [R01-HD-098428]; National Institute of General
   Medical Sciences, NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [2R01-GM-108618]; RK Mellon
   Institute for Pediatric Research; Lupus Research Alliance; University of
   Minnesota Medical School Academic Investment Education Program grant;
   National Heart, Lung, and Blood Institute, NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R21-HL-150575]; Fundacion
   Bechara; Arbuckle Family Fund for Arthritis Research
FX Dr. Henderson's work was supported by the National Institute of
   Arthritis and Musculoskeletal and Skin Diseases, NIH (grants
   K08-AR-073339 and P30-AR-070253) and the Investigator Award of the
   Rheumatology Research Foundation. Dr. Canna's work was supported by the
   National Institute of Child Health and Human Development, NIH (grant
   R01-HD-098428), the National Institute of General Medical Sciences, NIH
   (grant 2R01-GM-108618), and the RK Mellon Institute for Pediatric
   Research. Dr. Caricchio's work was supported in part by a grant from the
   Lupus Research Alliance. Dr. Mahmud's work was supported in part by a
   University of Minnesota Medical School Academic Investment Education
   Program grant. Dr. Nigrovic's work was supported by the National
   Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH
   (awards 2R01-AR-065538, R01-AR-075906, R01-AR-073201, P30-AR-070253, and
   R21-AR-076630), the National Heart, Lung, and Blood Institute, NIH
   (award R21-HL-150575), the Fundacion Bechara, and the Arbuckle Family
   Fund for Arthritis Research.
CR Carcillo JA, 2015, PEDIATR CRIT CARE ME, V16, P598, DOI 10.1097/PCC.0000000000000460
   Centers for Disease Control and Prevention, 2020, INT CLIN GUID MAN PA
   Chen G, 2020, J CLIN INVEST
   Eloseily EM, 2020, ARTHRITIS RHEUMATOL, V72, P326, DOI 10.1002/art.41103
   Halyabar O, 2019, PEDIATR RHEUMATOL, V17, DOI 10.1186/s12969-019-0309-6
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Kumar B, 2017, J CLIN IMMUNOL, V37, P638, DOI 10.1007/s10875-017-0439-x
   Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Schulert GS, 2016, J INFECT DIS, V213, P1180, DOI 10.1093/infdis/jiv550
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Weiss ES, 2018, BLOOD, V131, P1442, DOI 10.1182/blood-2017-12-820852
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 17
TC 119
Z9 124
U1 4
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD JUL
PY 2020
VL 72
IS 7
BP 1059
EP 1063
DI 10.1002/art.41285
EA MAY 2020
PG 5
WC Rheumatology
SC Rheumatology
GA MD8BH
UT WOS:000531164200001
PM 32293098
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Sun, TZ
   Weng, D
AF Sun Tingzhe
   Weng Dan
TI Estimating the effects of asymptomatic and imported patients on COVID-19
   epidemic using mathematical modeling
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE computer modeling; coronavirus; epidemiology
AB The epidemic of Coronavirus Disease 2019 has been a serious threat to public health worldwide. Data from 23 January to 31 March at Jiangsu and Anhui provinces in China were collected. We developed an adjusted model with two novel features: the asymptomatic population and threshold behavior in recovery. Unbiased parameter estimation identified faithful model fitting. Our model predicted that the epidemic for asymptomatic patients (ASP) was similar in both provinces. The latent periods and outbreak sizes are extremely sensitive to strongly controlled interventions such as isolation and quarantine for both asymptomatic and imported cases. We predicted that ASP serve as a more severe factor with faster outbreaks and larger outbreak sizes compared with imported patients. Therefore, we argued that the currently strict interventions should be continuously implemented, and unraveling the asymptomatic pool is critically important before preventive strategy such as vaccines.
C1 [Sun Tingzhe; Weng Dan] Anqing Normal Univ, Sch Life Sci, 1318 North Jixian Rd, Anqing 246011, Anhui, Peoples R China.
   [Sun Tingzhe; Weng Dan] Nanjing Univ Sci & Technol, Sch Environm & Biol Engn, 200 Xiaolingwei St, Nanjing 210094, Jiangsu, Peoples R China.
RP Sun, TZ (corresponding author), Anqing Normal Univ, Sch Life Sci, 1318 North Jixian Rd, Anqing 246011, Anhui, Peoples R China.; Weng, D (corresponding author), Nanjing Univ Sci & Technol, Sch Environm & Biol Engn, 200 Xiaolingwei St, Nanjing 210094, Jiangsu, Peoples R China.
EM suntz@aqnu.edu.cn; danweng@njust.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31971185, 31970897]
FX National Natural Science Foundation of China, Grant/Award Number:
   31971185, 31970897
CR Benvenuto D, 2020, DATA BRIEF, V29, DOI 10.1016/j.dib.2020.105340
   CDC, 2020, 2019 NOV COR 2019 NC
   Dai CX, 2020, MATH BIOSCI ENG, V17, P2781, DOI 10.3934/mbe.2020152
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Karako K, 2020, BIOSCI TRENDS, V14, P134, DOI 10.5582/bst.2020.01482
   Koo JR, 2020, LANCET INFECT DIS, V20, P678, DOI 10.1016/S1473-3099(20)30162-6
   Kuniya T, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030789
   Li G., 2020, CLIN INFECT DIS
   Liu ZH, 2020, MATH BIOSCI ENG, V17, P3040, DOI 10.3934/mbe.2020172
   Maiwald T, 2008, BIOINFORMATICS, V24, P2037, DOI 10.1093/bioinformatics/btn350
   Mandal Sandip, 2020, Indian J Med Res, V151, P190, DOI 10.4103/ijmr.IJMR_504_20
   Mizumoto K, 2020, INFECT DIS MODEL, V5, P264, DOI 10.1016/j.idm.2020.02.003
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Qiu J.J.N., 2020, COVERT CORONAVIRUS I
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Stehle J, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-87
   Wang HW, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0148-0
   WHO, 20 WHO
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Zhao SL, 2020, QUANT BIOL, V8, P11, DOI 10.1007/s40484-020-0199-0
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 23
TC 3
Z9 3
U1 2
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2020
VL 92
IS 10
BP 1995
EP 2003
DI 10.1002/jmv.25939
EA MAY 2020
PG 9
WC Virology
SC Virology
GA NK4OX
UT WOS:000531167000001
PM 32330299
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Alattar, R
   Ibrahim, TBH
   Shaar, SH
   Abdalla, S
   Shukri, K
   Daghfal, JN
   Khatib, MY
   Aboukamar, M
   Abukhattab, M
   Alsoub, HA
   Almaslamani, MA
   Omrani, AS
AF Alattar, Rand
   Ibrahim, Tawheeda B. H.
   Shaar, Shahd H.
   Abdalla, Shiema
   Shukri, Kinda
   Daghfal, Joanne N.
   Khatib, Mohamed Y.
   Aboukamar, Mohamed
   Abukhattab, Mohamed
   Alsoub, Hussam A.
   Almaslamani, Muna A.
   Omrani, Ali S.
TI Tocilizumab for the treatment of severe coronavirus disease 2019
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE coronavirus; COVID-19; IL-6; SARS-CoV-2; tocilizumab
ID COVID-19
AB Tocilizumab, an interleukin-6 inhibitor, may ameliorate the inflammatory manifestations associated with severe coronavirus disease 2019 (COVID-19) and thus improve clinical outcomes. This was a retrospective review of patients with laboratory-confirmed severe COVID-19 who received tocilizumab and completed 14 days of follow up. Twenty-five patients were included, median age was 58 years (interquartile range, 50-63) and the majority were males (92%). Co-morbidities included diabetes mellitus (48%), chronic kidney disease (16%), and cardiovascular disease (12%). Fever (92%), cough (84%), and dyspnea (72%) were the commonest presenting symptoms. All patients received at least two concomitant investigational antiviral agents. Median oral temperature was on day 1, 3, and 7 was 38.0 degrees C, 37.3 degrees C (P = .043), and 37.0 degrees C (P = .064), respectively. Corresponding median C-reactive protein was 193 and 7.9 mg/L (P < .0001) and <6 mg/L (P = .0001). Radiological improvement was noted in 44% of patients by day 7% and 68% by day 14. Nine patients (36%) were discharged alive from intensive care unit and three (12%) died. The proportion of patients on invasive ventilation declined from (84%) at the time of tocilizumab initiation to 60% on day 7 (P = .031) and 28% on day 14 (P = .001). The majority (92%) of patients experienced at least one adverse event. However, it is not possible to ascertain which adverse events were directly related to tocilizumab therapy. In patients with severe COVID-19, tocilizumab was associated with dramatic decline in inflammatory markers, radiological improvement and reduced ventilatory support requirements. Given the study's limitations, the results require assessment in adequately powered randomized controlled trials.
C1 [Alattar, Rand; Ibrahim, Tawheeda B. H.; Shaar, Shahd H.; Abdalla, Shiema; Shukri, Kinda; Daghfal, Joanne N.; Aboukamar, Mohamed; Abukhattab, Mohamed; Alsoub, Hussam A.; Almaslamani, Muna A.; Omrani, Ali S.] Hamad Med Corp, Communicable Dis Ctr, POB 3050, Doha, Qatar.
   [Khatib, Mohamed Y.] Hamad Med Corp, Dept Med, Div Crit Care & Pulm Med, Doha, Qatar.
   [Abukhattab, Mohamed; Alsoub, Hussam A.; Almaslamani, Muna A.; Omrani, Ali S.] Hamad Med Corp, Dept Med, Div Infect Dis, Doha, Qatar.
RP Omrani, AS (corresponding author), Hamad Med Corp, Communicable Dis Ctr, POB 3050, Doha, Qatar.
EM aomrani@hamad.qa
OI Omrani, Ali/0000-0001-5309-6358; Abukhattab,
   Mohammed/0000-0002-3335-0563; Shaar, Shahd H./0000-0002-7414-1215;
   Alattar, Rand/0000-0002-5161-4155
CR Angus DC, 2020, JAMA
   [Anonymous], 2020, 51 WHO
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Centers for Communicable Disease Control and Prevention, 2020, INF CLIN THER OPT CO
   Ferrey AJ, 2020, AM J NEPHROL, V51, P337, DOI 10.1159/000507417
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   McCreary EK, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa105
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Qatar Ministry of Public Health, 2020, COR DIS 2019 COVID 1
   Republic of Ireland's Health Service Executive, 2020, INT REC US TOC MAN P
   Scott LJ, 2017, DRUGS, V77, P1029, DOI 10.1007/s40265-017-0752-y
   Shim E, 2020, INT J INFECT DIS, V93, P339, DOI 10.1016/j.ijid.2020.03.031
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   U.S. Department of Health and Human Services, 2017, COMM TERM CRIT ADV E
   US Food and Drug Administration, 2017, ACTEMRA TOC INJ INTR
   WHO, 2020, 88 WHO
   WHO, 2020, REP WHO CHIN JOINT M
   World Health Organisation, 2020, 41 WHO
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 30
TC 68
Z9 71
U1 4
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2020
VL 92
IS 10
BP 2042
EP 2049
DI 10.1002/jmv.25964
EA MAY 2020
PG 8
WC Virology
SC Virology
GA NK4OX
UT WOS:000531166800001
PM 32369191
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Piszczatoski, CR
   Powell, J
AF Piszczatoski, Christopher R.
   Powell, Jason
TI Emergency Approval of Chloroquine and Hydroxychloroquine for Treatment
   of COVID-19
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Article
DE COVID-19; coronavirus; hydroxychloroquine; chloroquine; SARS-CoV-2;
   nCoV-2019
AB The world is suffering a respiratory pandemic disease caused by a novel coronavirus (2019-nCoV), commonly known as COVID-19 (coronavirus disease 2019). The Food and Drug Administration issued an emergency authorization for chloroquine and hydroxychloroquine as experimental treatments for COVID-19 leading to a shortage of both medications. A literature review conducted in April 2020 shows a lack of high-quality data available, resulting in ambiguous guideline recommendations. Decisions to use either drug should be made with careful consideration of risks versus benefits along with proper monitoring. Because of its higher potency and better safety profile, hydroxychloroquine may be the more reasonable treatment option if treatment is initiated.
C1 [Piszczatoski, Christopher R.; Powell, Jason] Univ Florida, Gainesville, FL USA.
RP Piszczatoski, CR (corresponding author), Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, 1225 Ctr Dr, Gainesville, FL 32610 USA.
EM CPiszczatoski@cop.ufl.edu
OI Piszczatoski, Christopher/0000-0002-7094-2322
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   [Anonymous], 2020, REC INV COVID 19 CON
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Clinical Pharmacology [database online], 2020, CLIN PHARM
   ClinicalTrials.gov, REG TRIALS COVID 19
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hinton DM, 2020, COMMUNICATION   0328
   Infectious Diseases Society of America, 2020, INF DIS SOC AM GUID
   International Society of Antimicrobial Chemotherapy, STAT IJAA PAP
   Johns Hopkins University and Medicine, 2020, COVID 19 MAP
   Lee J, 2020, THESE 19 CO ARE WORK
   Lover A.A., 2020, QUANTIFYING TREATMEN, DOI [10.1101/2020.03.22.20040949, DOI 10.1101/2020.03.22.20040949]
   Lupkin S, 2020, FDA OKS ADDITION ADD
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Poison Control, CHLORE HYDR CAN HAV
   Roden DM, 2020, CIRCULATION, V141, pE906, DOI 10.1161/CIRCULATIONAHA.120.047521
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   US Food and Drug Administration, FDA DRUG SHORT
   US Food Drug and Administration, FACT SHEET HLTH CAR
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wilson KC, COVID 19 INTERIM GUI
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 26
TC 1
Z9 2
U1 2
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1060-0280
EI 1542-6270
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD AUG
PY 2020
VL 54
IS 8
BP 827
EP 831
AR 1060028020925558
DI 10.1177/1060028020925558
EA MAY 2020
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MG5UN
UT WOS:000533956600001
PM 32389025
OA Bronze
DA 2021-01-01
ER

PT J
AU Covian, C
   Retamal-Diaz, A
   Bueno, SM
   Kalergis, AM
AF Covian, Camila
   Retamal-Diaz, Angello
   Bueno, Susan M.
   Kalergis, Alexis M.
TI Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; BCG; innate immunity; trained immunity; vaccine
ID RESPIRATORY SYNCYTIAL VIRUS; MYCOBACTERIUM-BOVIS BCG; T-CELL IMMUNITY;
   NONSPECIFIC PROTECTION; INFECTION; IMMUNIZATION; TUBERCULOSIS;
   REINFECTION; GENOMICS; EFFICACY
AB Trained immunity is a type of non-specific memory-like immune response induced by some pathogens and vaccines, such as BCG, which can confer antigen-independent protection against a wide variety of pathogens. The BCG vaccine has been extensively used to protect against tuberculosis for almost a 100 years. Interestingly, this vaccine reduces children's mortality caused by infections unrelated to Mycobacterium tuberculosis infection, a phenomenon thought to be due to the induction of trained immunity. The SARS-CoV-2 pandemic has infected, as of April 22, 2020, 2,623,231 people globally, causing a major public health problem worldwide. Currently, no vaccine or treatment is available to control this pandemic. We analyzed the number of positive cases and deaths in different countries and correlated them with the inclusion of BCG vaccination at birth in their national vaccination programs. Interestingly, those countries where BCG vaccination is given at birth have shown a lower contagion rate and fewer COVID-19-related deaths, suggesting that this vaccine may induce trained immunity that could confer some protection for SARS-CoV-2.
C1 [Covian, Camila; Retamal-Diaz, Angello; Bueno, Susan M.; Kalergis, Alexis M.] Pontificia Univ Catolica Chile, Fac Ciencias Biol, Millenium Inst Immunol & Immunotherapy, Dept Genet Mol & Microbiol, Santiago, Chile.
   [Kalergis, Alexis M.] Pontificia Univ Catolica Chile, Fac Med, Millennium Inst Immunol & Imminotherapy, Dept Endocrinol, Santiago, Chile.
RP Kalergis, AM (corresponding author), Pontificia Univ Catolica Chile, Fac Ciencias Biol, Millenium Inst Immunol & Immunotherapy, Dept Genet Mol & Microbiol, Santiago, Chile.; Kalergis, AM (corresponding author), Pontificia Univ Catolica Chile, Fac Med, Millennium Inst Immunol & Imminotherapy, Dept Endocrinol, Santiago, Chile.
EM akelergis@bio.puc.cl
FU CONICYT PAI project Chile [I781902009]; Millennium Institute on
   Immunology and Immunotherapy [P09/016-F]; Regional Government of
   Antofagasta through the Innovation Fund for Competitiveness FICR 2017
   [30488811-0]; FONDECYTComision Nacional de Investigacion Cientifica y
   Tecnologica (CONICYT)CONICYT FONDECYT [1190830]
FX This research was funded by CONICYT PAI project I781902009 Chile, as
   well as the Millennium Institute on Immunology and Immunotherapy grant
   number P09/016-F. This work was also supported by the Regional
   Government of Antofagasta through the Innovation Fund for
   Competitiveness FICR 2017 (BIP Code: 30488811-0). FONDECYT Number:
   1190830. AK is a Helen C. Levitt visiting professor at the Department of
   Microbiology and Immunology of the University of Iowa.
CR Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Arts RJW, 2015, J LEUKOCYTE BIOL, V98, P995, DOI 10.1189/jlb.4MA0215-059R
   Benn CS, 2016, EBIOMEDICINE, V10, P312, DOI 10.1016/j.ebiom.2016.07.016
   Brosch R, 2000, INT J MED MICROBIOL, V290, P143
   Bueno SM, 2008, P NATL ACAD SCI USA, V105, P20822, DOI 10.1073/pnas.0806244105
   Cautivo KM, 2010, J IMMUNOL, V185, P7633, DOI 10.4049/jimmunol.0903452
   Cespedes PF, 2017, VACCINE, V35, P757, DOI 10.1016/j.vaccine.2016.12.048
   Ciarlo Eleonora, 2020, J Infect Dis, V222, P1869, DOI 10.1093/infdis/jiz692
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Covian C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02806
   da Cunha SS, 2004, ALLERGY, V59, P857
   de Bree LCJ, 2018, SEMIN IMMUNOL, V39, P35, DOI 10.1016/j.smim.2018.06.002
   de Bree LCJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02471
   dos Santos JC, 2019, CELL REP, V28, P2659, DOI 10.1016/j.celrep.2019.08.004
   Ehreth J, 2003, VACCINE, V21, P596, DOI 10.1016/S0264-410X(02)00623-0
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Huang Y, 2020, CLIN CHARACTERISTICS, DOI [10.1101/2020.02.27.20029009, DOI 10.1101/2020.02.27.20029009]
   de Castro MJ, 2015, CLIN INFECT DIS, V60, P1611, DOI 10.1093/cid/civ144
   Jungblut PR, 1999, MOL MICROBIOL, V33, P1103, DOI 10.1046/j.1365-2958.1999.01549.x
   Kaufmann SHE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00316
   Kleinnijenhuis J, 2015, T ROY SOC TROP MED H, V109, P29, DOI 10.1093/trstmh/tru168
   Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628
   Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109
   Lai Shengjie, 2020, medRxiv, DOI 10.1101/2020.03.03.20029843
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996
   Miller A, 2020, CORRELATION UNIVERSA, DOI [10.3113/JSOA.2020.0036, DOI 10.3113/JSOA.2020.0036]
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Mukherjee S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180143
   Netea MG, 2011, CELL HOST MICROBE, V9, P355, DOI 10.1016/j.chom.2011.04.006
   Palavecino CE, 2014, J IMMUNOL, V192, P214, DOI 10.4049/jimmunol.1300118
   Park Sung Soo, 2015, Int J Med Sci, V12, P668, DOI 10.7150/ijms.12233
   Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039
   Quintin J, 2012, CELL HOST MICROBE, V12, P223, DOI 10.1016/j.chom.2012.06.006
   Rey-Jurado E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00026
   Rey-Jurado E, 2017, HUM VACC IMMUNOTHER, V13, P2092, DOI 10.1080/21645515.2017.1334026
   Rolling KE, 2016, J AM PHARM ASSOC, V56, P687, DOI 10.1016/j.japh.2016.09.009
   Roth AE, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c671
   Sanchez-Ramon S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02936
   Soto JA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02875
   SPENCER JC, 1977, J INFECT DIS, V136, P171, DOI 10.1093/infdis/136.2.171
   Sun JC, 2011, J IMMUNOL, V186, P1891, DOI 10.4049/jimmunol.1003035
   Tagarro Alfredo, 2020, JAMA Pediatr, DOI 10.1001/jamapediatrics.2020.1346
   Wardhana, 2011, Acta Med Indones, V43, P185
   WHO, 2018, GLOB WHO
   WHO, BAC CALM GUER BCG VA
   Worldometer, 2020, COUNTR WORLD POP
   Zhang L, 2016, MOL THER, V24, P398, DOI 10.1038/mt.2015.216
NR 49
TC 13
Z9 13
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAY 8
PY 2020
VL 11
AR 970
DI 10.3389/fimmu.2020.00970
PG 7
WC Immunology
SC Immunology
GA LT2CL
UT WOS:000536880300001
PM 32574258
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Salahuddin, H
   Castonguay, AC
   Zaidi, SF
   Burgess, R
   Jadhav, AP
   Jumaa, MA
AF Salahuddin, Hisham
   Castonguay, Alicia C.
   Zaidi, Syed F.
   Burgess, Richard
   Jadhav, Ashutosh P.
   Jumaa, Mouhammad A.
TI Interventional Stroke Care in the Era of COVID-19
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE COVID-19; stroke; pandemic; thrombectomy; ischemic; coronavirus;
   cerebrovascular; neurointervention
ID ISCHEMIC-STROKE; ENDOVASCULAR THROMBECTOMY; CONSCIOUS SEDATION;
   GENERAL-ANESTHESIA; CLINICAL-OUTCOMES; THERAPY; SCORE; MANAGEMENT;
   SELECTION
AB The current coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 has led to immense strain on healthcare systems and workers. Patients with severe symptoms of COVID-19 may also present with acute neurological emergencies such as ischemic stroke. Ischemic stroke in these patients may result from COVID-19 related complications or decompensation of previously asymptomatic cerebrovascular disorders, or concurrent ischemic stroke from common stroke risk factors in a patient with COVID-19. Acute ischemic stroke patients with large vessel occlusions require emergent triage, intensive care, and mechanical thrombectomy. Management of patients with large vessel occlusions (LVO) requires special considerations in the current pandemic. Physicians must now account for prognosis of severe COVID-19, resource utilization, and risk of infection to healthcare workers when determining eligibility for mechanical thrombectomy (MT). Here, we describe important prognostic factors including age, laboratory, and imaging findings to consider for MT selection and provide suggestions for taking care of patients with LVO and possible or confirmed COVID-19. It is recommended to perform MT in patients within the established guidelines, and consider a conservative approach in cases where there is clinical equipoise to minimize futile reperfusion. Lastly, we describe an illustrative case of a patient with ischemic stroke and COVID-19.
C1 [Salahuddin, Hisham; Castonguay, Alicia C.; Zaidi, Syed F.; Burgess, Richard; Jumaa, Mouhammad A.] Univ Toledo, Dept Neurol, 2801 W Bancroft St, Toledo, OH 43606 USA.
   [Zaidi, Syed F.; Jumaa, Mouhammad A.] Univ Toledo, Promed Neurosci Ctr, 2801 W Bancroft St, Toledo, OH 43606 USA.
   [Jadhav, Ashutosh P.] Univ Pittsburgh, Med Ctr, Dept Neurol, Pittsburgh, PA USA.
RP Jumaa, MA (corresponding author), Univ Toledo, Dept Neurol, 2801 W Bancroft St, Toledo, OH 43606 USA.; Jumaa, MA (corresponding author), Univ Toledo, Promed Neurosci Ctr, 2801 W Bancroft St, Toledo, OH 43606 USA.
EM mouhammad.jumaa@utoledo.edu
OI Jumaa, Mouhammad/0000-0002-7165-797X
CR Adalja AA, 2020, JAMA-J AM MED ASSOC, V323, P1343, DOI 10.1001/jama.2020.3413
   Alawieh A, 2019, J NEUROINTERV SURG, V11, P545, DOI 10.1136/neurintsurg-2018-014289
   Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   [Anonymous], 2020, STROKE, V51, P1910, DOI [DOI 10.1161/STROKEAHA.120.030023, 10.1161/STROKEAHA.120.030023]
   [Anonymous], 2020, REPORT WHO CHINA JOI
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Campbell BCV, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00657
   CDC, 2003, GUIDELINES ENV INFEC
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Day M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1375
   Deng Y, 2020, CHINESE MED J-PEKING, V133, P1261, DOI 10.1097/CM9.0000000000000824
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   FDA, 2020, AUTH ID NOW COVID 19
   Fiorella D, 2020, J NEUROINTERV SURG, V12, P537, DOI 10.1136/neurintsurg-2020-016117
   Flint AC, 2013, STROKE, V44, P3370, DOI 10.1161/STROKEAHA.113.002796
   Fraser JF, 2020, J NEUROINTERV SURG, V12, P539, DOI 10.1136/neurintsurg-2020-016098
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01227-2020
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Gutierrez-Ortiz C, 2020, NEUROLOGY, V95, pE601, DOI 10.1212/WNL.0000000000009619
   Henry BM, 2020, INT UROL NEPHROL, V52, P1193, DOI 10.1007/s11255-020-02451-9
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Kaye R, 2020, OTOLARYNG HEAD NECK, V163, P132, DOI 10.1177/0194599820922992
   Khosravani H, 2020, STROKE, V51, P1891, DOI 10.1161/STROKEAHA.120.029838
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li TH, 2020, EMERG MICROBES INFEC, V9, P687, DOI 10.1080/22221751.2020.1741327
   Li Y, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3550025, DOI 10.2139/SSRN.3550025]
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   Luo W, 2020, PREPRINT
   Mao L, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3544840, DOI 10.2139/SSRN.3544840]
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Mei H, 2020, Zhonghua Xue Ye Xue Za Zhi, V41, P185, DOI 10.3760/cma.j.issn.0253-2727.2020.0002
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Office of Emergency Preparedness HSPP, AIRB INF DIS MAN MET
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Rangaraju S, 2015, J NEUROINTERV SURG, V7, P783, DOI 10.1136/neurintsurg-2014-011351
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Rezai MK, 2019, CEREBROVASC DIS, V47, P65, DOI 10.1159/000497315
   Sarraj A, 2019, JAMA NEUROL, V76, P1147, DOI 10.1001/jamaneurol.2019.2109
   Sarraj A, 2013, STROKE, V44, P3324, DOI 10.1161/STROKEAHA.113.001050
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Schonenberger S, 2016, JAMA-J AM MED ASSOC, V316, P1986, DOI 10.1001/jama.2016.16623
   Simonsen CZ, 2018, JAMA NEUROL, V75, P470, DOI 10.1001/jamaneurol.2017.4474
   Slawski DE, 2018, INTERV NEUROL, V7, P246, DOI 10.1159/000487333
   Talke PO, 2014, J NEUROSURG ANESTH, V26, P95, DOI 10.1097/ANA.0000000000000042
   Tam CCF, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006631
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   Wood S, TCTMD
   World Health Organization (WHO), 2020, NOV COR CHIN
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yoo AJ, 2014, STROKE, V45, P746, DOI 10.1161/STROKEAHA.113.004260
   Zhang Y, 2020, Zhonghua Xue Ye Xue Za Zhi, V41, pE006, DOI [10.3760/cma.j.issn.0253-2727.2020.008, 10.3760/cma.j.issn.0253-2727.2020.0006]
   Zhao H, 2020, LANCET NEUROL, V19, P383, DOI 10.1016/S1474-4422(20)30109-5
   Zhao K, ACUTE MYELITIS SARS
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou LY, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101642
   Zhou SC, 2020, AM J ROENTGENOL, V214, P1287, DOI 10.2214/AJR.20.22975
NR 75
TC 3
Z9 3
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD MAY 8
PY 2020
VL 11
AR 468
DI 10.3389/fneur.2020.00468
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA LS9GS
UT WOS:000536687600001
PM 32574245
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pantos, C
   Tseti, I
   Mourouzis, I
AF Pantos, Constantinos
   Tseti, Ioulia
   Mourouzis, Iordanis
TI Use of triiodothyronine to treat critically ill COVID-19 patients: a new
   clinical trial
SO CRITICAL CARE
LA English
DT Letter
C1 [Pantos, Constantinos; Tseti, Ioulia; Mourouzis, Iordanis] Natl & Kapodistrian Univ Athens, Sch Med, Dept Pharmacol, 75 Mikras Asias Ave, Athens 11527, Greece.
RP Pantos, C (corresponding author), Natl & Kapodistrian Univ Athens, Sch Med, Dept Pharmacol, 75 Mikras Asias Ave, Athens 11527, Greece.
EM cpantos@med.uoa.gr
OI Pantos, Constantinos/0000-0003-2449-0991
CR Marchant D, 2009, CIRC RES, V104, P813, DOI 10.1161/CIRCRESAHA.108.191171
   Padhi Rajesh, 2018, Int J Crit Illn Inj Sci, V8, P165, DOI 10.4103/IJCIIS.IJCIIS_29_17
   Pantos C, 2015, HEART FAIL REV, V20, P273, DOI 10.1007/s10741-014-9465-4
   Sato R, 2019, J INTENSIVE CARE MED, DOI 10.1177/0885066619892218
   Varedi M, 2014, ENDOCR RES, V39, P51, DOI 10.3109/07435800.2013.808208
NR 5
TC 3
Z9 3
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD MAY 8
PY 2020
VL 24
IS 1
AR 209
DI 10.1186/s13054-020-02934-2
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA LO8MU
UT WOS:000533880700006
PM 32384906
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Abouhashem, AS
   Singh, K
   Azzazy, HME
   Sen, CK
AF Abouhashem, Ahmed S.
   Singh, Kanhaiya
   Azzazy, Hassan M. E.
   Sen, Chandan K.
TI Is Low Alveolar Type II Cell SOD3 in the Lungs of Elderly Linked to the
   Observed Severity of COVID-19?
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Article
DE COVID19; single-cell RNA sequencing; lung; ROS; SOD3; ATF4
ID LECITHINIZED SUPEROXIDE-DISMUTASE; GENE-EXPRESSION; STRESS
AB Human lungs single-cell RNA sequencing data from healthy donors (elderly and young; GEO accession no. GSE122960) were analyzed to isolate and specifically study gene expression in alveolar type II cells. Colocalization of angiotensin-converting enzyme 2 (ACE2) and TMPRSS2 enables severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2) to enter the cells. Expression levels of these genes in the alveolar type II cells of elderly and young patients were comparable and, therefore, do not seem to be responsible for worse outcomes observed in coronavirus disease 2019 (COVID-19) affected elderly. In cells from the elderly, 263 genes were downregulated and 95 upregulated. Superoxide dismutase 3 (SOD3) was identified as the top-ranked gene that was most downregulated in the elderly. Other redox-active genes that were also downregulated in cells from the elderly included activating transcription factor 4 (ATF4) and metallothionein 2A (M2TA). ATF4 is an endoplasmic reticulum stress sensor that defends lungs via induction of heme oxygenase 1. The study of downstream factors known to be induced by ATF4, according to Ingenuity Pathway Analysis (TM), identified 24 candidates. Twenty-one of these were significantly downregulated in the cells from the elderly. These downregulated candidates were subjected to enrichment using the Reactome Database identifying that in the elderly, the ability to respond to heme deficiency and the ATF4-dependent ability to respond to endoplasmic reticulum stress is significantly compromised. SOD3-based therapeutic strategies have provided beneficial results in treating lung disorders including fibrosis. The findings of this study propose the hypotheses that lung-specific delivery of SOD3/ATF4-related antioxidants will work in synergy with promising antiviral drugs such as remdesivir to further improve COVID-19 outcomes in the elderly.
C1 [Abouhashem, Ahmed S.; Singh, Kanhaiya; Sen, Chandan K.] Indiana Univ Sch Med, Dept Surg, Indiana Ctr Regenerat Med & Engn, Indianapolis, IN 46202 USA.
   [Azzazy, Hassan M. E.] Amer Univ Cairo, Sch Sci & Engn, Dept Chem, New Cairo, Egypt.
RP Singh, K (corresponding author), Indiana Univ Sch Med, Dept Surg, Indiana Ctr Regenerat Med & Engn, Indianapolis, IN 46202 USA.
EM kanh@iu.edu
RI Abouhashem, Ahmed S/AAM-6335-2020
OI Singh, Kanhaiya/0000-0002-4126-9618
FU NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01 GM108014] Funding Source: Medline; NINDS
   NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [R01 NS042617] Funding Source: Medline; NINR
   NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Nursing
   Research (NINR) [R01 NR015676] Funding Source: Medline
CR Aran D, 2019, NAT IMMUNOL, V20, P163, DOI 10.1038/s41590-018-0276-y
   Assa'ad AH, 1998, ANN ALLERG ASTHMA IM, V80, P215, DOI 10.1016/S1081-1206(10)62960-2
   Castro SM, 2006, AM J RESP CRIT CARE, V174, P1361, DOI 10.1164/rccm.200603-319OC
   Folz RJ, 1997, AM J RESP CELL MOL, V17, P393, DOI 10.1165/ajrcmb.17.4.2826
   Gharebaghi R, 2020, ARCH ACAD EMERG MED, V8
   Gongora MC, 2008, AM J PATHOL, V173, P915, DOI 10.2353/ajpath.2008.080119
   Hernandez-Saavedra Daniel, 2017, Adv Exp Med Biol, V967, P57, DOI 10.1007/978-3-319-63245-2_5
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jassal B, 2020, NUCLEIC ACIDS RES, V48, pD498, DOI 10.1093/nar/gkz1031
   Khomich OA, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080392
   Kropski JA, 2018, J CLIN INVEST, V128, P64, DOI 10.1172/JCI93560
   Lartigue A, 2015, J VIROL, V89, P824, DOI 10.1128/JVI.02588-14
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Olajuyin AM, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0147-9
   Parent R. A., 2015, COMP BIOL NORMAL LUN
   Prevention CfDCa, 2020, PROV DEATH COUNTS CO
   Reyfman PA, 2019, AM J RESP CRIT CARE, V199, P1517, DOI 10.1164/rccm.201712-2410OC
   Richter K, 2016, CELL TISSUE RES, V365, P591, DOI 10.1007/s00441-016-2445-3
   Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192
   Singh K, 2019, DIABETES, V68, P2175, DOI 10.2337/db19-0202
   Singh K, 2017, MOL THER, V25, P2689, DOI 10.1016/j.ymthe.2017.09.009
   Tanaka KI, 2011, J PHARMACOL EXP THER, V338, P810, DOI 10.1124/jpet.111.179051
   Tanaka KI, 2010, AM J PHYSIOL-LUNG C, V298, pL348, DOI 10.1152/ajplung.00289.2009
   Webb CB, 2008, J FELINE MED SURG, V10, P423, DOI 10.1016/j.jfms.2008.01.008
   Wisler JR, 2020, SURG INFECT, V21, P101, DOI 10.1089/sur.2019.051
   Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533
NR 30
TC 13
Z9 12
U1 6
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523-0864
EI 1557-7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD JUL 10
PY 2020
VL 33
IS 2
BP 59
EP 65
DI 10.1089/ars.2020.8111
EA MAY 2020
PG 7
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA LW6HZ
UT WOS:000532190000001
PM 32323565
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ho, JSY
   Tambyah, PA
   Sia, CH
AF Ho, Jamie S. Y.
   Tambyah, Paul A.
   Sia, Ching-Hui
TI A Call for Vaccine Against COVID-19: Implications for Cardiovascular
   Morbidity and Healthcare Utilization
SO CARDIOVASCULAR DRUGS AND THERAPY
LA English
DT Letter
ID INFLUENZA VACCINATION
C1 [Ho, Jamie S. Y.] Univ Cambridge, Sch Clin Med, Cambridge, England.
   [Tambyah, Paul A.] Natl Univ Singapore Hosp, Div Infect Dis, Univ Med Cluster, Singapore, Singapore.
   [Tambyah, Paul A.; Sia, Ching-Hui] Natl Univ Singapore, Dept Med, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Sia, Ching-Hui] Natl Univ Heart Ctr, Dept Cardiol, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.
RP Sia, CH (corresponding author), Natl Univ Singapore, Dept Med, Yong Loo Lin Sch Med, Singapore, Singapore.; Sia, CH (corresponding author), Natl Univ Heart Ctr, Dept Cardiol, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.
EM ching_hui_sia@nuhs.edu.sg
CR Ciszewski A, 2008, EUR HEART J, V29, P1350, DOI 10.1093/eurheartj/ehm581
   Clar C, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005050.pub3
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090
   Udell JA, 2013, JAMA-J AM MED ASSOC, V310, P1711, DOI 10.1001/jama.2013.279206
   WCG, 2020, RES CTR COVID 19 CLI
NR 8
TC 1
Z9 1
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-3206
EI 1573-7241
J9 CARDIOVASC DRUG THER
JI Cardiovasc. Drugs Ther.
PD AUG
PY 2020
VL 34
IS 4
BP 585
EP 587
DI 10.1007/s10557-020-06985-z
EA MAY 2020
PG 3
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA MF1HU
UT WOS:000531127200001
PM 32385785
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Shojaei, A
   Salari, P
AF Shojaei, Amirahmad
   Salari, Pooneh
TI COVID-19 and off label use of drugs: an ethical viewpoint
SO DARU-JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Off-label uses; Off-label prescription; Ethical challenges;
   Investigational off-label uses
AB Background The COVID-19 outbreak is rapidly spread over the world and kills infected patients. There is no proven medication for its treatment, so, all of the medications used for treatment are considered to be off-label. Off-label uses are not under regulation in the outbreak because there is no specific regulation for this condition. Objectives In this short communication we aim at describing two ways of off-label use as clinical practice or investigational use. Further, we will describe the third way of off-label use, we named it pseudo-research and then we will state the most possible ethical challenges of off-label use for better perceptions and responsibility. Results The WHO considers off-label uses as country-specific. All international regulatory bodies consider off-label prescription as the physician's responsibility and legal by necessitating some requirements. There is no international guideline for regulating investigational off-label uses as clinical practice. Conclusion There are different types of approaches, none of them is comprehensive and conclusive. Furthermore, respecting the four ethical principles necessitates codification and strict regulation of off-label uses either as clinical practice or investigational. Besides, compilation of a special guideline based on ethical principles especially non-maleficence and autonomy for investigational off-label uses in disasters is highly recommended.
C1 [Shojaei, Amirahmad] Univ Tehran Med Sci, Med Eth & Hist Med Res Ctr, Dept Med Eth, Tehran, Iran.
   [Salari, Pooneh] Univ Tehran Med Sci, Med Eth & Hist Med Res Ctr, 23 16 Azar Ave,Keshavarz Blvd, Tehran, Iran.
RP Salari, P (corresponding author), Univ Tehran Med Sci, Med Eth & Hist Med Res Ctr, 23 16 Azar Ave,Keshavarz Blvd, Tehran, Iran.
EM poonehsalari@gmail.com
OI Salari, Pooneh/0000-0001-5595-0087
CR [Anonymous], 1992, Am J Hosp Pharm, V49, P2006
   Barlow A, 2020, PHARMACOTHERAPY, V40, P416, DOI 10.1002/phar.2398
   Borysowski J, 2019, BRIT J CLIN PHARMACO, V85, P501, DOI 10.1111/bcp.13833
   Bowbrick P, 1993, EUROPEAN J MARKETING
   Carr AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02851-4
   Council of Australian Therapeutic Advisory Groups (CATAG), RETH MED DEC MAK AUS
   Darrow JJ, 2015, NEW ENGL J MED, V372, P279, DOI 10.1056/NEJMhle1409465
   Eguale T, 2016, JAMA INTERN MED, V176, P55, DOI 10.1001/jamainternmed.2015.6058
   Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701
   Federico CA, 2019, JAMA INTERN MED, V179, P90, DOI 10.1001/jamainternmed.2018.5705
   Massachusetts General Hospital, 2020, MASS GEN HOSP COVID
   Ministry of Health and Medical Education, DAIL SIT REP COR DIS
   Ministry of Health and Medical Education, FLOWCH DIAGN TREATM
   Ministry of Health and Medical Education; Iran Food and Drug Administration, INSTR CLIN TRIALS CO
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Shimazawa R, 2012, CLIN THER, V34, P2104, DOI 10.1016/j.clinthera.2012.09.004
   Stafford RS, 2008, NEW ENGL J MED, V358, P1427, DOI 10.1056/NEJMp0802107
   The UK Government, LAB UNL US MED PRESC
   The World Medical Association, WMA DECL HELS ETH PR
   US Food and Drug Administration, FDA GUID COND CLIN T
   US. Food & Drug Administration, LAB INV US MARK DRUG
   Weda M., 2017, STUDY OFF LABEL USE
   World Health Organisation, CLIN CAR SEV AC RESP
   World Health Organization, Q A COR COVID 19
   World Health Organization (WHO), WHO BEST PRACT STAT
   World Health Organization (WHO), 2019, COR DIS COVID 19 SIT
   World Health Organization (WHO), 2019, 82 WHO
NR 27
TC 6
Z9 6
U1 0
U2 0
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
EI 2008-2231
J9 DARU
JI DARU
PD DEC
PY 2020
VL 28
IS 2
BP 789
EP 793
DI 10.1007/s40199-020-00351-y
EA MAY 2020
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OZ3QF
UT WOS:000531139500001
PM 32385829
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Waller, G
   Pugh, M
   Mulkens, S
   Moore, E
   Mountford, VA
   Carter, J
   Wicksteed, A
   Maharaj, A
   Wade, TD
   Wisniewski, L
   Farrell, NR
   Raykos, B
   Jorgensen, S
   Evans, J
   Thomas, JJ
   Osenk, I
   Paddock, C
   Bohrer, B
   Anderson, K
   Turner, H
   Hildebrandt, T
   Xanidis, N
   Smit, V
AF Waller, Glenn
   Pugh, Matthew
   Mulkens, Sandra
   Moore, Elana
   Mountford, Victoria A.
   Carter, Jacqueline
   Wicksteed, Amy
   Maharaj, Aryel
   Wade, Tracey D.
   Wisniewski, Lucene
   Farrell, Nicholas R.
   Raykos, Bronwyn
   Jorgensen, Susanne
   Evans, Jane
   Thomas, Jennifer J.
   Osenk, Ivana
   Paddock, Carolyn
   Bohrer, Brittany
   Anderson, Kristen
   Turner, Hannah
   Hildebrandt, Tom
   Xanidis, Nikos
   Smit, Vera
TI Cognitive-behavioral therapy in the time of coronavirus: Clinician tips
   for working with eating disorders via telehealth when face-to-face
   meetings are not possible
SO INTERNATIONAL JOURNAL OF EATING DISORDERS
LA English
DT Article
DE cognitive-behavioral therapy; coronavirus; COVID-19; eating disorders;
   psychotherapy; telehealth
ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; PROCESSING
   THERAPY; PROLONGED EXPOSURE; BULIMIA-NERVOSA; TELEMEDICINE; VETERANS;
   HEALTH
AB Objective The coronavirus pandemic has led to a dramatically different way of working for many therapists working with eating disorders, where telehealth has suddenly become the norm. However, many clinicians feel ill equipped to deliver therapy via telehealth, while adhering to evidence-based interventions. This article draws together clinician experiences of the issues that should be attended to, and how to address them within a telehealth framework.
   Method Seventy clinical colleagues of the authors were emailed and invited to share their concerns online about how to deliver cognitive-behavioral therapy for eating disorders (CBT-ED) via telehealth, and how to adapt clinical practice to deal with the problems that they and others had encountered. After 96 hr, all the suggestions that had been shared by 22 clinicians were collated to provide timely advice for other clinicians.
   Results A range of themes emerged from the online discussion. A large proportion were general clinical and practical domains (patient and therapist concerns about telehealth; technical issues in implementing telehealth; changes in the environment), but there were also specific considerations and clinical recommendations about the delivery of CBT-ED methods.
   Discussion Through interaction and sharing of ideas, clinicians across the world produced a substantial number of recommendations about how to use telehealth to work with people with eating disorders while remaining on track with evidence-based practice. These are shared to assist clinicians over the period of changed practice.
C1 [Waller, Glenn] Univ Sheffield, Dept Psychol, Sheffield, S Yorkshire, England.
   [Pugh, Matthew] Cent & North West London NHS Fdn Trust, London, England.
   [Mulkens, Sandra] Univ Maastricht, Maastricht, Netherlands.
   [Moore, Elana] South Yorkshire Eating Disorders Assoc, Sheffield, S Yorkshire, England.
   [Mountford, Victoria A.] Maudsley Hlth, Abu Dhabi, U Arab Emirates.
   [Mountford, Victoria A.] South London & Maudsley NHS Trust, London, England.
   [Carter, Jacqueline] Mem Univ Newfoundland, St John, NF, Canada.
   [Wicksteed, Amy] NHS Specialist Eating Disorders Serv, Sheffield, S Yorkshire, England.
   [Maharaj, Aryel] Univ Toronto, Toronto, ON, Canada.
   [Wade, Tracey D.; Osenk, Ivana] Flinders Univ S Australia, Orama Inst, Blackbird Initiat, Adelaide, SA, Australia.
   [Wisniewski, Lucene] Ctr Evidence Based Treatment, Shaker Hts, OH USA.
   [Farrell, Nicholas R.] Rogers Behav Hlth, Oconomowoc, WI USA.
   [Raykos, Bronwyn] Ctr Clin Intervent, Perth, WA, Australia.
   [Jorgensen, Susanne] Dorset All Age Eating Disorders Serv, Bournemouth, Dorset, England.
   [Evans, Jane] Greater Manchester Mental Hlth NHS Trust, Eating Disorder Serv, Manchester, Lancs, England.
   [Thomas, Jennifer J.] Harvard Med Sch, Dept Psychiat, Boston, MA USA.
   [Paddock, Carolyn] Bedfordshire & Luton Community Eating Disorders S, Luton, Beds, England.
   [Bohrer, Brittany] UCSD Eating Disorders Ctr Treatment & Res, San Diego, CA USA.
   [Anderson, Kristen] Chicago Ctr Evidence Based Treatment, Chicago, IL USA.
   [Turner, Hannah] Southern NHS Fdn Trust, Southampton, Hants, England.
   [Hildebrandt, Tom] Mt Sinai Sch Med, New York, NY USA.
   [Xanidis, Nikos] Lanarkshire NHS CAMHS Eating Disorders Serv, Lothian, Lanark, Scotland.
   [Smit, Vera] GZ Centraal, Dept Eating Disorders, Hilversum, Netherlands.
RP Waller, G (corresponding author), Univ Sheffield, Dept Psychol, Cathedral Court, 1 Vicar Lane, Sheffield, S Yorkshire, England.
EM g.waller@sheffield.ac.uk
RI Mulkens, Sandra/ABH-2102-2020; Thomas, Jennifer J./AAM-4096-2020
OI Waller, Glenn/0000-0001-7794-9546; Wade, Tracey/0000-0003-4402-770X;
   Mulkens, Alexandra/0000-0002-0237-1628
CR Abrahamsson N, 2018, J BEHAV THER EXP PSY, V61, P104, DOI 10.1016/j.jbtep.2018.06.010
   Acierno R, 2017, BEHAV RES THER, V89, P57, DOI 10.1016/j.brat.2016.11.009
   Acierno R, 2016, DEPRESS ANXIETY, V33, P415, DOI 10.1002/da.22476
   Anderson KE, 2017, INT J EAT DISORDER, V50, P1235, DOI 10.1002/eat.22759
   Backhaus A, 2012, PSYCHOL SERV, V9, P111, DOI 10.1037/a0027924
   Becker C. B., 2019, EXPOSURE THERAPY EAT
   Cassin SE, 2016, BEHAV RES THER, V80, P17, DOI 10.1016/j.brat.2016.03.001
   Ertelt TW, 2011, INT J EAT DISORDER, V44, P687, DOI 10.1002/eat.20874
   Fairburn C. G., 2008, COGNITIVE BEHAV THER
   Giel KE, 2015, PSYCHOTHER PSYCHOSOM, V84, P381, DOI 10.1159/000431044
   Hamatani Sayo, 2019, JMIR Form Res, V3, pe15738, DOI 10.2196/15738
   Kazdin AE, 2017, INT J EAT DISORDER, V50, P170, DOI 10.1002/eat.22670
   Mitchell JE, 2008, BEHAV RES THER, V46, P581, DOI 10.1016/j.brat.2008.02.004
   Morland LA, 2015, DEPRESS ANXIETY, V32, P811, DOI 10.1002/da.22397
   Morland LA, 2014, J CLIN PSYCHIAT, V75, P470, DOI 10.4088/JCP.13m08842
   Sockalingam S, 2017, OBES SURG, V27, P670, DOI 10.1007/s11695-016-2322-x
   Sproch LE, 2019, PSYCHIAT CLIN N AM, V42, P243, DOI 10.1016/j.psc.2019.01.008
   Thomas J., 2018, COGNITIVE BEHAV THER
   Turvey C, 2013, TELEMED E-HEALTH, V19, P722, DOI 10.1089/tmj.2013.9989
   Waller G, 2007, COGNITIVE BEHAVIORAL THERAPY FOR EATING DISORDERS: A COMPREHENSIVE TREATMENT GUIDE, P1
   Waller G, 2019, BRIEF COGNITIVE BEHA
   Waller G, 2015, BEHAV RES THER, V70, P1, DOI 10.1016/j.brat.2015.04.004
   Wilson GT, 1996, BEHAV RES THER, V34, P295, DOI 10.1016/0005-7967(95)00084-4
   Yuen EK, 2015, J CLIN PSYCHOL, V71, P500, DOI 10.1002/jclp.22168
NR 24
TC 13
Z9 13
U1 7
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0276-3478
EI 1098-108X
J9 INT J EAT DISORDER
JI Int. J. Eating Disord.
PD JUL
PY 2020
VL 53
IS 7
BP 1132
EP 1141
DI 10.1002/eat.23289
EA MAY 2020
PG 10
WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology
SC Psychology; Nutrition & Dietetics; Psychiatry
GA MF6TT
UT WOS:000530888000001
PM 32383530
OA Other Gold, Green Accepted, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Ning, L
   Liu, L
   Li, WY
   Liu, HT
   Wang, JZ
   Yao, ZQ
   Zhang, SY
   Zhao, DS
   Nashan, B
   Shen, AZ
   Liu, LX
   Li, L
AF Ning, Ling
   Liu, Lei
   Li, Wenyuan
   Liu, Hongtao
   Wang, Jizhou
   Yao, Ziqin
   Zhang, Shengyu
   Zhao, Desheng
   Nashan, Bjorn
   Shen, Aizong
   Liu, Lianxin
   Li, Lei
TI Novel coronavirus (SARS-CoV-2) infection in a renal transplant
   recipient: Case report
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE clinical decision-making; clinical research; practice; immunosuppressive
   regimens-maintenance; infection and infectious agents-viral; infectious
   disease; kidney transplantation; nephrology
ID VIRAL-INFECTIONS; SOLID-ORGAN
AB An ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus 2 (SARS-CoV-2) started in Wuhan, China, with cases now confirmed in multiple countries. The clinical course of patients remains to be fully characterized, clinical presentation ranges from asymptomatic infection to acute respiratory distress syndrome and acute renal failure, and no pharmacological therapies of proven efficacy yet exist. We report a case of SARS-CoV-2 infection in a renal transplant recipient with excellent outcome. This case states the importance of close monitoring of the concentration of cyclosporine in patients treated with lopinavir/ritonavir; the routine treatment of corticosteroid can be continued. This is a rare report of SARS-CoV-2 infection in a renal transplant recipient. Further data are needed to achieve better understanding of the impact of immunosuppressive therapy on the clinical presentation, severity, and outcome of SARS-CoV-2 infections in solid organ transplant recipients.
C1 [Ning, Ling; Liu, Lei; Li, Wenyuan; Liu, Hongtao; Wang, Jizhou; Yao, Ziqin; Zhang, Shengyu; Zhao, Desheng; Nashan, Bjorn; Shen, Aizong; Liu, Lianxin; Li, Lei] Univ Sci & Technol China, Affiliated Hosp 1, Div Life Sci & Med, Hefei, Anhui, Peoples R China.
RP Li, L (corresponding author), Univ Sci & Technol China, Affiliated Hosp 1, Div Life Sci & Med, Hefei, Anhui, Peoples R China.
EM lilei0403@163.com
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P11
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Cvetkovic RS, 2003, DRUGS, V63, P34
   Dayer MR, 2017, ARCH CLIN INFECT DIS, V12, DOI 10.5812/archcid.13823
   Haidar G, 2017, CURR OPIN INFECT DIS, V30, P579, DOI [10.1097/QCO.0000000000000409, 10.1097/qco.0000000000000409]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Monostory K, 2018, CHAPTER 20 METABOLIC, P409, DOI 10.5772/intechopen.74524
   Nashan B, 2005, TRANSPLANT INT, V18, P768, DOI 10.1111/j.1432-2277.2005.00151.x
   office Nh, 2020, NOV COR PNEUM DIAGN
   Paulsen GC, 2017, CLIN CHEST MED, V38, P707, DOI 10.1016/j.ccm.2017.07.012
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 18
TC 24
Z9 24
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUL
PY 2020
VL 20
IS 7
BP 1864
EP 1868
DI 10.1111/ajt.15897
EA MAY 2020
PG 5
WC Surgery; Transplantation
SC Surgery; Transplantation
GA MD1JV
UT WOS:000530883600001
PM 32277555
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Opatz, T
   Senn-Bilfinger, J
   Richert, C
AF Opatz, Till
   Senn-Bilfinger, Joerg
   Richert, Clemens
TI Thoughts on What Chemists Can Contribute to Fighting SARS-CoV-2-A Short
   Note on Hand Sanitizers, Drug Candidates and Outreach
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article
DE alcohols; antivirals; disinfectants; pandemic; SARS-CoV-2
ID CORONAVIRUSES; DISCOVERY
AB The SARS-CoV-2 outbreak causing the respiratory disease COVID-19 has left many chemists in academia without an obvious option to contribute to fighting the pandemic. Some of our recent experiences indicate that there are ways to overcome this dilemma. A three-pronged approach is proposed.
C1 [Opatz, Till] Johannes Gutenberg Univ Mainz, Dept Chem, D-55128 Mainz, Germany.
   [Senn-Bilfinger, Joerg; Richert, Clemens] Univ Stuttgart, Inst Organ Chem, D-70569 Stuttgart, Germany.
RP Richert, C (corresponding author), Univ Stuttgart, Inst Organ Chem, D-70569 Stuttgart, Germany.
EM lehrstuhl-2@oc.uni-stuttgart.de
RI Opatz, Till/Q-1589-2017
OI Opatz, Till/0000-0002-3266-4050
CR Al Kahlout RA, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/1386740
   Best M, 2004, QUAL SAF HEALTH CARE, V13, P233, DOI 10.1136/qshc.2004.010918
   Chan JFW, 2017, J MICROBIOL, V55, P172, DOI 10.1007/s12275-017-7026-y
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan PKS, 2006, CLIN SCI, V110, P193, DOI 10.1042/CS20050188
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Cho A, 2012, BIOORG MED CHEM LETT, V22, P2705, DOI 10.1016/j.bmcl.2012.02.105
   Cinatl J, 2005, ANTIVIR RES, V66, P81, DOI 10.1016/j.antiviral.2005.03.002
   Cini E, 2018, EUR J ORG CHEM, V2018, P2622, DOI 10.1002/ejoc.201800158
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Feng S, 2020, LANCET RESP MED, V8, P434, DOI 10.1016/S2213-2600(20)30134-X
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Haagmans BL, 2006, ANTIVIR RES, V71, P397, DOI 10.1016/j.antiviral.2006.05.019
   Jefferson T, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3675
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Kratzel A., 2020, BIORXIV PREPRINT, DOI [10.1101/2020.03.10.986711, DOI 10.1101/2020.03.10.986711]
   Kyluik DL, 2011, PROGRESS IN MOLECULAR AND ENVIRONMENTAL BIOENGINEERING - FROM ANALYSIS AND MODELING TO TECHNOLOGY APPLICATIONS, P167
   Lachenmeier DW, 2008, J OCCUP MED TOXICOL, V3, DOI 10.1186/1745-6673-3-26
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Mahony JB, 2011, CRIT REV CL LAB SCI, V48, P217, DOI 10.3109/10408363.2011.640976
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096
   Momattin H, 2019, TRAVEL MED INFECT DI, V30, P9, DOI 10.1016/j.tmaid.2019.06.012
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Nacoti M, 2020, NEJM CATALYST, DOI [10.1056/CAT.20.0080, DOI 10.1056/CAT.20.0080, 10.1056/CAT.20.0080#]
   SAKNIMIT M, 1988, EXP ANIM TOKYO, V37, P341, DOI 10.1538/expanim1978.37.3_341
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Slusarczyk Magdalena, 2018, Antiviral Chemistry & Chemotherapy, V26, DOI 10.1177/2040206618775243
   Sofia MJ, 2010, J MED CHEM, V53, P7202, DOI 10.1021/jm100863x
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang J, 2019, HEALTH EDUC BEHAV, V46, P157, DOI 10.1177/1090198118783829
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 35
TC 0
Z9 0
U1 3
U2 6
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PD JUN 8
PY 2020
VL 59
IS 24
BP 9236
EP 9240
DI 10.1002/anie.202004721
EA MAY 2020
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA LX4GY
UT WOS:000530868500001
PM 32329159
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bussalino, E
   De Maria, A
   Russo, R
   Paoletti, E
AF Bussalino, Elisabetta
   De Maria, Andrea
   Russo, Rodolfo
   Paoletti, Ernesto
TI Immunosuppressive therapy maintenance in a kidney transplant recipient
   with SARS-CoV-2 pneumonia: A case report
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE clinical research; practice; immunosuppressive regimens; infection and
   infectious agents-viral; kidney transplantation; nephrology
ID COVID-19
AB The role of systemic inflammation is proving crucial in determining unfavorable outcome in SARS-CoV-2-infected patients. Limited data are available regarding immunosuppression management in kidney transplant recipients (KTRs) with SARS-CoV-2 pneumonia. We report a case of a 32-year-old KTR who developed SARS-CoV-2 infection and fully recovered in 15 days while maintaining standard immunosuppressive therapy.
C1 [Bussalino, Elisabetta; Russo, Rodolfo; Paoletti, Ernesto] Univ Genoa, Nephrol Dialysis & Transplantat, Genoa, Italy.
   [Bussalino, Elisabetta; De Maria, Andrea; Russo, Rodolfo; Paoletti, Ernesto] Policlin San Martino, Genoa, Italy.
   [De Maria, Andrea] Univ Genoa, Infect Dis Unit, Genoa, Italy.
RP Paoletti, E (corresponding author), Univ Genoa, Nephrol Dialysis & Transplantat, Genoa, Italy.; Paoletti, E (corresponding author), Policlin San Martino, Genoa, Italy.
EM ernesto.paoletti@hsanmartino.it
RI Paoletti, Ernesto/L-5099-2017
OI Paoletti, Ernesto/0000-0002-5509-6252
CR D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
NR 8
TC 21
Z9 21
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUL
PY 2020
VL 20
IS 7
BP 1922
EP 1924
DI 10.1111/ajt.15920
EA MAY 2020
PG 3
WC Surgery; Transplantation
SC Surgery; Transplantation
GA MD1JV
UT WOS:000530886000001
PM 32282991
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Bao, LN
   Deng, W
   Huang, BY
   Gao, H
   Liu, JN
   Ren, LL
   Wei, Q
   Yu, P
   Xu, YF
   Qi, FF
   Qu, YJ
   Li, FD
   Lv, Q
   Wang, WL
   Xue, J
   Gong, SR
   Liu, MY
   Wang, GP
   Wang, SY
   Song, ZQ
   Zhao, LN
   Liu, PP
   Zhao, L
   Ye, F
   Wang, HJ
   Zhou, WM
   Zhu, N
   Zhen, W
   Yu, HS
   Zhang, XJ
   Guo, L
   Chen, L
   Wang, CH
   Wang, Y
   Wang, XM
   Xiao, Y
   Sun, QM
   Liu, HQ
   Zhu, FL
   Ma, CX
   Yan, LM
   Yang, ML
   Han, J
   Xu, WB
   Tan, WJ
   Peng, XZ
   Jin, Q
   Wu, GZ
   Qin, C
AF Bao, Linlin
   Deng, Wei
   Huang, Baoying
   Gao, Hong
   Liu, Jiangning
   Ren, Lili
   Wei, Qiang
   Yu, Pin
   Xu, Yanfeng
   Qi, Feifei
   Qu, Yajin
   Li, Fengdi
   Lv, Qi
   Wang, Wenling
   Xue, Jing
   Gong, Shuran
   Liu, Mingya
   Wang, Guanpeng
   Wang, Shunyi
   Song, Zhiqi
   Zhao, Linna
   Liu, Peipei
   Zhao, Li
   Ye, Fei
   Wang, Huijuan
   Zhou, Weimin
   Zhu, Na
   Zhen, Wei
   Yu, Haisheng
   Zhang, Xiaojuan
   Guo, Li
   Chen, Lan
   Wang, Conghui
   Wang, Ying
   Wang, Xinming
   Xiao, Yan
   Sun, Qiangming
   Liu, Hongqi
   Zhu, Fanli
   Ma, Chunxia
   Yan, Lingmei
   Yang, Mengli
   Han, Jun
   Xu, Wenbo
   Tan, Wenjie
   Peng, Xiaozhong
   Jin, Qi
   Wu, Guizhen
   Qin, Chuan
TI The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
SO NATURE
LA English
DT Article
ID SARS
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19), which has become a public health emergency of international concern(1). Angiotensin-converting enzyme 2 (ACE2) is the cell-entry receptor for severe acute respiratory syndrome coronavirus (SARS-CoV)(2). Here we infected transgenic mice that express human ACE2 (hereafter, hACE2 mice) with SARS-CoV-2 and studied the pathogenicity of the virus. We observed weight loss as well as virus replication in the lungs of hACE2 mice infected with SARS-CoV-2. The typical histopathology was interstitial pneumonia with infiltration of considerable numbers of macrophages and lymphocytes into the alveolar interstitium, and the accumulation of macrophages in alveolar cavities. We observed viral antigens in bronchial epithelial cells, macrophages and alveolar epithelia. These phenomena were not found in wild-type mice infected with SARS-CoV-2. Notably, we have confirmed the pathogenicity of SARS-CoV-2 in hACE2 mice. This mouse model of SARS-CoV-2 infection will be valuable for evaluating antiviral therapeutic agents and vaccines, as well as understanding the pathogenesis of COVID-19.
   Infection with SARS-CoV-2 causes interstitial pneumonia and viral replication in the lungs of transgenic mice that express a human version of ACE2, confirming the pathogenicity of the virus in this model.
C1 [Bao, Linlin; Deng, Wei; Gao, Hong; Liu, Jiangning; Wei, Qiang; Yu, Pin; Xu, Yanfeng; Qi, Feifei; Qu, Yajin; Li, Fengdi; Lv, Qi; Xue, Jing; Gong, Shuran; Liu, Mingya; Wang, Guanpeng; Wang, Shunyi; Song, Zhiqi; Zhao, Linna; Yu, Haisheng; Zhang, Xiaojuan; Qin, Chuan] Chinese Acad Med Sci, Beijing Key Lab Anim Models Emerging & Remerging, Inst Lab Anim Sci, Beijing, Peoples R China.
   [Bao, Linlin; Deng, Wei; Gao, Hong; Liu, Jiangning; Wei, Qiang; Yu, Pin; Xu, Yanfeng; Qi, Feifei; Qu, Yajin; Li, Fengdi; Lv, Qi; Xue, Jing; Gong, Shuran; Liu, Mingya; Wang, Guanpeng; Wang, Shunyi; Song, Zhiqi; Zhao, Linna; Yu, Haisheng; Zhang, Xiaojuan; Qin, Chuan] Peking Union Med Coll, Comparat Med Ctr, NHC Key Lab Human Dis Comparat Med, Beijing, Peoples R China.
   [Huang, Baoying; Wang, Wenling; Liu, Peipei; Zhao, Li; Ye, Fei; Wang, Huijuan; Zhou, Weimin; Zhu, Na; Zhen, Wei; Han, Jun; Xu, Wenbo; Tan, Wenjie; Wu, Guizhen] China CDC, Natl Inst Viral Dis Control & Prevent, MHC Key Lab Biosafety, Beijing, Peoples R China.
   [Guo, Li; Chen, Lan; Wang, Conghui; Wang, Ying; Wang, Xinming; Xiao, Yan; Jin, Qi] Chinese Acad Med Sci, Inst Pathogen Biol, Beijing, Peoples R China.
   [Sun, Qiangming; Liu, Hongqi; Zhu, Fanli; Ma, Chunxia; Yan, Lingmei; Yang, Mengli; Peng, Xiaozhong] Chinese Acad Med Sci, Inst Med Biol, Beijing, Peoples R China.
RP Qin, C (corresponding author), Chinese Acad Med Sci, Beijing Key Lab Anim Models Emerging & Remerging, Inst Lab Anim Sci, Beijing, Peoples R China.; Qin, C (corresponding author), Peking Union Med Coll, Comparat Med Ctr, NHC Key Lab Human Dis Comparat Med, Beijing, Peoples R China.; Wu, GZ (corresponding author), China CDC, Natl Inst Viral Dis Control & Prevent, MHC Key Lab Biosafety, Beijing, Peoples R China.
EM wugz@ivdc.chinacdc.cn; qinchuan@pumc.edu.cn
RI qin, chuan/ABG-4508-2020
OI Wang, Conghui/0000-0001-7774-097X
FU National Research and Development Project of China [2020YFC0841100];
   Fundamental Research Funds for CAMS of China [2020HY320001]; National
   Key Research and Development Project of China [2016YFD0500304]; CAMS
   initiative for Innovative Medicine of China [2016-I2M-2-006]; National
   Mega projects of China for Major Infectious Diseases [2017ZX10304402,
   2018ZX10301403]
FX We thank G. F. Gao for his advice and coordination on this work; H.
   Deng, X. Yang and L. Zhang for providing the hACE2 mice as a gift; and
   G. Wong for helping us to proofread the manuscript. This work was
   supported by National Research and Development Project of China
   (2020YFC0841100), Fundamental Research Funds for CAMS of China
   (2020HY320001), National Key Research and Development Project of China
   (2016YFD0500304), CAMS initiative for Innovative Medicine of China
   (2016-I2M-2-006) and National Mega projects of China for Major
   Infectious Diseases (2017ZX10304402, 2018ZX10301403).
CR [Anonymous], 2020, UPD NOV COR PNEUM OU
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Rivers TM, 1937, J BACTERIOL, V33, P1
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 11
TC 152
Z9 153
U1 27
U2 41
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUL 30
PY 2020
VL 583
IS 7818
BP 830
EP +
DI 10.1038/s41586-020-2312-y
EA MAY 2020
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MT2XH
UT WOS:000551400800001
PM 32380511
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Al-Tammemi, AB
AF Al-Tammemi, Ala'a B.
TI The Battle Against COVID-19 in Jordan: An Early Overview of the
   Jordanian Experience
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE COVID-19; Jordan; crises management; pandemic; decision makers
ID ORIGIN
AB Since the initial spark of the COVID-19 outbreak in December 2019, which was later declared by the World Health Organization (WHO) to be a global pandemic, all affected countries are implementing various preventive and control measures to mitigate the spread of the disease. The newly emerging virus brings with it uncertainty-not only regarding its behavior and transmission dynamics but also regarding the current lack of approved antiviral therapy or vaccines-and this represents a major challenge for decision makers at various levels and sectors. This article aims to provide an early overview of the COVID-19 battle within the Jordanian context, including general reflections and conclusions on the value of collaborative efforts in crises management.
C1 [Al-Tammemi, Ala'a B.] Umea Univ, Dept Epidemiol & Global Hlth, S-90187 Umea, Sweden.
RP Al-Tammemi, AB (corresponding author), Umea Univ, Dept Epidemiol & Global Hlth, S-90187 Umea, Sweden.
EM alba0081@student.umu.se
OI Al-Tammemi, Ala'a B./0000-0003-0862-0186
FU Swedish Institute (SI)
FX The author acknowledges with gratitude the generous SISGP scholarship
   provided to him by The Swedish Institute (SI) for his current
   postgraduate study in Public Health.
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
   Boin A., 2000, J CONTING CRISIS MAN, V8, P185
   Centers for Disease Control and Prevention, 2020, SYMPT COVID 19
   Department of Statistics Jordan, 2020, POP COUNT
   Google Health, 2020, COVID 19 COMMUNITY M
   High Health Council, 2016, NAT STRAT HLTH SECT
   International Medical Corps, 2017, UND MENT HLTH PSYCH
   Jordanian Ministry of Health, 2020, COVID 19 JORD
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lawton Graham, 2020, New Sci, V246, P10, DOI 10.1016/S0262-4079(20)30706-5
   Lupia T, 2020, J GLOB ANTIMICROB RE, V21, P22, DOI 10.1016/j.jgar.2020.02.021
   Miller MA, 2009, NEW ENGL J MED, V360, P2595, DOI 10.1056/NEJMp0903906
   National Center for Security and Crises Management, 2020, COVID 19 JORD
   Pennings JME, 2008, DISASTERS, V32, P434, DOI 10.1111/j.1467-7717.2008.01048.x
   Pike BL, 2010, CLIN INFECT DIS, V50, P1636, DOI 10.1086/652860
   Prime Ministry of Jordan, 2020, OFF REP
   Rabi FA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030231
   Safi M, 2020, GUARD
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   The Embassy of The Hashemite Kingdom of Jordan, 2020, QUICK FACTS JORD
   The World Bank, 2019, JORD PROF
   WHO, 2020, COUNTR TECHN GUID CO
   WHO, 2020, WHO EUR COR DIS COVI
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   World Health Organization, 2020, ADV PUBL COVID19
   World Health Organization, 2012, STRENGTH HLTH SYST E
   Xu SQ, 2020, LANCET, V395, P1321, DOI 10.1016/S0140-6736(20)30845-X
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
NR 30
TC 5
Z9 5
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD MAY 7
PY 2020
VL 8
AR 188
DI 10.3389/fpubh.2020.00188
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA LS0WD
UT WOS:000536113300001
PM 32574291
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Islam, R
   Parves, MR
   Paul, AS
   Uddin, N
   Rahman, MS
   Al Mamun, A
   Hossain, MN
   Ali, MA
   Halim, MA
AF Islam, Rajib
   Parves, Md Rimon
   Paul, Archi Sundar
   Uddin, Nizam
   Rahman, Md Sajjadur
   Al Mamun, Abdulla
   Hossain, Md Nayeem
   Ali, Md Ackas
   Halim, Mohammad A.
TI A molecular modeling approach to identify effective antiviral
   phytochemicals against the main protease of SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Antiviral phytochemicals; COVID-19; SARS-CoV-2; molecular docking;
   molecular dynamics
ID SARS CORONAVIRUS; INHIBITORS; OPTIMIZATION; REMDESIVIR; BAICALIN;
   DOCKING; BETA
AB The main protease of SARS-CoV-2 is one of the important targets to design and develop antiviral drugs. In this study, we have selected 40 antiviral phytochemicals to find out the best candidates which can act as potent inhibitors against the main protease. Molecular docking is performed using AutoDock Vina and GOLD suite to determine the binding affinities and interactions between the phytochemicals and the main protease. The selected candidates strongly interact with the key Cys145 and His41 residues. To validate the docking interactions, 100 ns molecular dynamics (MD) simulations on the five top-ranked inhibitors including hypericin, cyanidin 3-glucoside, baicalin, glabridin, and alpha-ketoamide-11r are performed. Principal component analysis (PCA) on the MD simulation discloses that baicalin, cyanidin 3-glucoside, and alpha-ketoamide-11r have structural similarity with the apo-form of the main protease. These findings are also strongly supported by root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), radius of gyration (Rg), and solvent accessible surface area (SASA) investigations. PCA is also used to find out the quantitative structure-activity relationship (QSAR) for pattern recognition of the best ligands. Multiple linear regression (MLR) of QSAR reveals the R-2 value of 0.842 for the training set and 0.753 for the test set. Our proposed MLR model can predict the favorable binding energy compared with the binding energy detected from molecular docking. ADMET analysis demonstrates that these candidates appear to be safer inhibitors. Our comprehensive computational and statistical analysis show that these selected phytochemicals can be used as potential inhibitors against the SARS-CoV-2. Communicated by Ramaswamy H. Sarma
C1 [Islam, Rajib; Parves, Md Rimon; Paul, Archi Sundar; Uddin, Nizam; Rahman, Md Sajjadur; Hossain, Md Nayeem; Ali, Md Ackas; Halim, Mohammad A.] BICCB, Red Green Res Ctr, Div Comp Aided Drug Design, Dhaka, Bangladesh.
   [Uddin, Nizam; Rahman, Md Sajjadur] South Dakota State Univ, Dept Chem & Biochem, Brookings, SD 57007 USA.
   [Al Mamun, Abdulla] Nanjing Univ Sci & Technol, Sch Chem Engn, Key Lab Soft Chem & Funct Mat MOE, Nanjing, Peoples R China.
   [Halim, Mohammad A.] Univ Arkansas Ft Smith, Dept Phys Sci, Ft Smith, AR 72904 USA.
RP Halim, MA (corresponding author), Univ Arkansas Ft Smith, Dept Phys Sci, Ft Smith, AR 72904 USA.
EM mohammad.halim@uafs.edu
RI Halim, Mohammad A./D-1359-2011; Ali, Ackas/AAP-7500-2020; Islam,
   Rajib/AAP-7503-2020; parves/AAF-8816-2020
OI Halim, Mohammad A./0000-0002-1698-7044; Ali, Ackas/0000-0002-8235-3517;
   Islam, Rajib/0000-0001-8499-5516; parves/0000-0003-1379-7410; RAHMAN, MD
   SAJJADUR/0000-0002-2996-4845
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Adinsoft S., 2010, XLSTAT SOFTWARE VERS
   Alam S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06131-0
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Delano WL, 2002, PYMOL MOL GRAPHICS S
   Dickson CJ, 2014, J CHEM THEORY COMPUT, V10, P865, DOI 10.1021/ct4010307
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Fakayode S. O., 2009, ENCY ANAL CHEM, DOI [https://doi.org/10.1002/9780470027318.a9082, 10.1002/9780470027318.a9082, DOI 10.1002/9780470027318.A9082]
   Fakayode SO, 2014, TALANTA, V126, P151, DOI 10.1016/j.talanta.2014.03.037
   Frisch M. J., 2009, GAUSSIAN 09 A 02
   Funar-Timofei S, 2017, MOL DIVERS, V21, P437, DOI 10.1007/s11030-017-9735-x
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Islam MJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52308-0
   Jassim SAA, 2003, J APPL MICROBIOL, V95, P412, DOI 10.1046/j.1365-2672.2003.02026.x
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Krieger E, 2006, J MOL GRAPH MODEL, V25, P481, DOI 10.1016/j.jmgm.2006.02.009
   Krieger E, 2015, J COMPUT CHEM, V36, P996, DOI 10.1002/jcc.23899
   Krieger E, 2012, METHODS MOL BIOL, V819, P405, DOI 10.1007/978-1-61779-465-0_25
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Liu CH, 2017, SCI REP-UK, V7, DOI 10.1038/srep42096
   Liu HY, 2020, BRIT J NUTR, V124, P1013, DOI 10.1017/S0007114520002263
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mark H, 2007, CHEMOMETRICS IN SPECTROSCOPY, P1
   Martens H., 1992, MULTIVARIATE CALIBRA
   Mirza M. U., 2020, STRUCTURAL ELUCIDATI, DOI [10.20944/preprints202003.0085.v1, DOI 10.20944/PREPRINTS202003.0085.V1]
   Morris Garrett M., 2008, V443, P365, DOI 10.1007/978-1-59745-177-2_19
   Motohashi H, 2013, AAPS J, V15, P581, DOI 10.1208/s12248-013-9465-7
   Mukhametov A, 2017, J MOL GRAPH MODEL, V71, P227, DOI 10.1016/j.jmgm.2016.12.008
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Murray C, 2020, FORECASTING COVID 19, V03, DOI [10.1101/2020.03.27.20043752, DOI 10.1101/2020.03.27.20043752]
   Naithani R, 2008, MINI-REV MED CHEM, V8, P1106, DOI 10.2174/138955708785909943
   Nayak MK, 2014, J ANTIMICROB CHEMOTH, V69, P1298, DOI 10.1093/jac/dkt534
   Oo A, 2018, ANTIVIR RES, V150, P101, DOI 10.1016/j.antiviral.2017.12.012
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   R Core Team, 2019, R LANG ENV STAT COMP
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Stewart JJP, 2007, J MOL MODEL, V13, P1173, DOI 10.1007/s00894-007-0233-4
   Talele TT, 2010, CURR TOP MED CHEM, V10, P127, DOI 10.2174/156802610790232251
   Tong TR, 2009, EXPERT OPIN THER PAT, V19, P415, DOI 10.1517/13543770802600698
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang FH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22677
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   WOLD S, 1987, CHEMOMETR INTELL LAB, V2, P37, DOI 10.1016/0169-7439(87)80084-9
   Worldometer, 2020, COVID 19 COR PAND
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 58
TC 50
Z9 50
U1 16
U2 23
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1761883
EA MAY 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LP2AT
UT WOS:000534121000001
PM 32340562
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Sinha, SK
   Shakya, A
   Prasad, SK
   Singh, S
   Gurav, NS
   Prasad, RS
   Gurav, SS
AF Sinha, Saurabh K.
   Shakya, Anshul
   Prasad, Satyendra K.
   Singh, Shashikant
   Gurav, Nilambari S.
   Prasad, Rupali S.
   Gurav, Shailendra S.
TI An in-silico evaluation of different Saikosaponins for their potency
   against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Saikosaponins; 2019-nCoV; 6VSB; In-silico; Corona virus; virtual
   screening; molecular docking; Traditional Chinese Medicine
ID SARS CORONAVIRUS; REPLICATION; PROTEASE
AB The Public Health Emergency of International Concern declared the widespread outbreak of SARS-CoV-2 as a global pandemic emergency, which has resulted in 1,773,086 confirmed cases including 111,652 human deaths, as on 13 April 2020, as reported to World Health Organization. As of now, there are no vaccines or antiviral drugs declared to be officially useful against the infection. Saikosaponin is a group of oleanane derivatives reported in Chinese medicinal plants and are described for their anti-viral, anti-tumor, anti-inflammatory, anticonvulsant, antinephritis and hepatoprotective activities. They have also been known to have anti-coronaviral property by interfering the early stage of viral replication including absorption and penetration of the virus. Thus, the present study was undertaken to screen and evaluate the potency of different Saikosaponins against different sets of SARS-CoV-2 binding protein via computational molecular docking simulations. Docking was carried out on a Glide module of Schrodinger Maestro 2018-1 MM Share Version on NSP15 (PDB ID: 6W01) and Prefusion 2019-nCoV spike glycoprotein (PDB ID: 6VSB) from SARS-CoV-2. From the binding energy and interaction studies, the Saikosaponins U and V showed the best affinity towards both the proteins suggesting them to be future research molecule as they mark the desire interaction with NSP15, which is responsible for replication of RNA and also with 2019-nCoV spike glycoprotein which manage the connection with ACE2. Communicated by Ramaswamy H. Sarma
C1 [Gurav, Shailendra S.] Goa Univ, Goa Coll Pharm, Dept Pharmacognosy, Panaji 403001, Goa, India.
   [Sinha, Saurabh K.] Mohanlal Shukhadia Univ, Dept Pharmaceut Sci, Udaipur, Rajasthan, India.
   [Prasad, Satyendra K.; Prasad, Rupali S.] RTM Univ, Dept Pharmaceut Sci, Nagpur, Maharashtra, India.
   [Shakya, Anshul] Dibrugarh Univ, Fac Sci & Engn, Dept Pharmaceut Sci, Dibrugarh, Assam, India.
   [Singh, Shashikant] Varanasi Coll Pharm, Varanasi, Uttar Pradesh, India.
   [Gurav, Nilambari S.] Goa Univ, PESs Rajaram & Tarabai Bandekar Coll Pharm, Ponda, India.
RP Gurav, SS (corresponding author), Goa Univ, Goa Coll Pharm, Dept Pharmacognosy, Panaji 403001, Goa, India.
EM shailendra.gurav@nic.in
RI Prasad, Satyendra/ABD-2399-2020; Gurav, Shailendra/AAO-4240-2020
OI Gurav, Shailendra/0000-0001-5564-2121; SHAKYA,
   ANSHUL/0000-0002-8232-4476
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Chen H, 2020, POTENTIAL NATURAL CO, V2020010358, DOI [10.20944/preprints202001.0358.v3, DOI 10.20944/PREPRINTS202001.0358.V3]
   Chen JX, 2015, ONCOTARGET, V6, P42541, DOI 10.18632/oncotarget.6448
   Chen LL, 2006, BIOORGAN MED CHEM, V14, P8295, DOI 10.1016/j.bmc.2006.09.014
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Cheng PW, 2006, CLIN EXP PHARMACOL P, V33, P612, DOI 10.1111/j.1440-1681.2006.04415.x
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Deng XF, 2017, P NATL ACAD SCI USA, V114, pE4251, DOI 10.1073/pnas.1618310114
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Goswami T., 2020, MOL DOCKING STUDY RE, DOI [10.26434/chemrxiv.12033774.v1, DOI 10.26434/CHEMRXIV.12033774.V1]
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Huang WQ, 2017, CALCIFIED TISSUE INT, V100, P392, DOI 10.1007/s00223-017-0242-y
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Li CC, 2019, DRUG DISCOV TODAY, V24, P726, DOI 10.1016/j.drudis.2019.01.018
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li XQ, 2018, J ASIAN NAT PROD RES, V20, P399, DOI 10.1080/10286020.2018.1465937
   Li XJY, 2018, PHYTOMEDICINE, V50, P73, DOI 10.1016/j.phymed.2018.09.174
   Lin CW, 2005, ANTIVIR RES, V68, P36, DOI 10.1016/j.antiviral.2005.07.002
   Lin LT, 2015, J HEPATOL, V62, P541, DOI 10.1016/j.jhep.2014.10.040
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Ortega JT, 2020, EXCLI J, V19, P400, DOI 10.17179/excli2020-1189
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   World Health Organization (WHO), 2020, COR DIS COVID 2019
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang HF, 2017, J VET RES, V61, P405, DOI 10.1515/jvetres-2017-0062
NR 38
TC 25
Z9 26
U1 15
U2 21
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1762741
EA MAY 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LO6ZL
UT WOS:000533773100001
PM 32345124
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Wahedi, HM
   Ahmad, S
   Abbasi, SW
AF Wahedi, Hussain Mustatab
   Ahmad, Sajjad
   Abbasi, Sumra Wajid
TI Stilbene-based natural compounds as promising drug candidates against
   COVID-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; Stilbenoids; molecular docking; molecular dynamic simulations;
   MM-PBSA
ID VITIS-VINIFERA; RESVERATROL; PTEROSTILBENE; CORONAVIRUS; PICEATANNOL
AB The pandemic coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents a great threat to public health. Currently, no potent medicine is available to treat COVID-19. Quest for new drugs especially from natural plant sources is an area of immense potential. The current study aimed to repurpose stilbenoid analogs, reported for some other biological activities, against SARS-CoV-2 spike protein and human ACE2 receptor complex for their affinity and stability using molecular dynamics simulation and binding free energy analysis based on molecular docking. Four compounds in total were probed for their binding affinity using molecular docking. All of the compounds showed good affinity (> -7 kcal/mol). However, fifty nanoseconds molecular dynamic simulation in aqueous solution revealed highly stable bound conformation of resveratrol to the viral protein: ACE2 receptor complex. Net free energy of binding using MM-PBSA also affirmed the stability of the resveratrol-protein complex. Based on the results, we report that stilbene based compounds in general and resveratrol, in particular, can be promising anti-COVID-19 drug candidates acting through disruption of the spike protein. Our findings in this study are promising and call for further in vitro and in vivo testing of stiblenoids, especially resveratrol against the COVID-19.
   [GRAPHICS]
   .
   HIGHLIGHTS
   Stilbenoid analogs could be potential disruptors of SARS-CoV-2 spike protein and human ACE2 receptor complex. In particular, resveratrol revealed highly stable conformation to the viral protein: ACE2 receptor complex. The strong interaction of resveratrol is affirmed by molecular dynamic simulation studies and better net free energies.
C1 [Wahedi, Hussain Mustatab; Abbasi, Sumra Wajid] Natl Univ Med Sci, NUMS Dept Biol Sci, Rawalpindi, Pakistan.
   [Ahmad, Sajjad] Quaid I Azam Univ, Natl Ctr Bioinformat, Islamabad, Pakistan.
RP Abbasi, SW (corresponding author), Natl Univ Med Sci, NUMS Dept Biol Sci, Rawalpindi, Pakistan.
EM sumra.abbasi@numspak.edu.pk
RI Ahmad, Sajjad/ABG-7863-2020
OI Ahmad, Sajjad/0000-0003-0754-1742
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Alagaili AN, 2014, MBIO, V5, DOI DOI 10.1128/MBIO.00884-14
   Bhakkiyalakshmi E, 2016, EUR J PHARMACOL, V777, P9, DOI 10.1016/j.ejphar.2016.02.054
   Bonkowski MS, 2016, NAT REV MOL CELL BIO, V17, P679, DOI 10.1038/nrm.2016.93
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Case D., 2018, AMBER 18, V18
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Daniel RR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI DOI 10.1021/ct400341p
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Francioso A, 2014, MED CHEM, V10, P237, DOI 10.2174/15734064113096660053
   Gulcin I, 2010, INNOV FOOD SCI EMERG, V11, P210, DOI 10.1016/j.ifset.2009.07.002
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jeong E, 2013, PHYTOTHER RES, V27, P610, DOI 10.1002/ptr.4770
   Kasiotis KM, 2013, FOOD CHEM TOXICOL, V61, P112, DOI 10.1016/j.fct.2013.03.038
   Khan M, 2019, NUTRIENTS, V11, DOI 10.3390/nu11050983
   Khan OS, 2016, NUTR CANCER, V68, P365, DOI 10.1080/01635581.2016.1152386
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Koskela A, 2014, MOL VIS, V20, P760
   Kwon O, 2018, BMB REP, V51, P302, DOI 10.5483/BMBRep.2018.51.6.024
   LANGCAKE P, 1976, PHYSIOL PLANT PATHOL, V9, P77, DOI 10.1016/0048-4059(76)90077-1
   LANGCAKE P, 1979, PHYTOCHEMISTRY, V18, P1025, DOI 10.1016/S0031-9422(00)91470-5
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Li F, 2008, J VIROL, V82, P6984, DOI 10.1128/JVI.00442-08
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li ZJ, 2004, J CHEM INF COMP SCI, V44, P1886, DOI 10.1021/ci049794h
   Lupala S. C., 2020, COMPUTATIONAL SIMULA, DOI [10.1101/2020.03.24.005561, DOI 10.1101/2020.03.24.005561]
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Murias M, 2005, BIOCHEM PHARMACOL, V69, P903, DOI 10.1016/j.bcp.2004.12.001
   Narayanan K, 2015, VIRUS RES, V202, P89, DOI 10.1016/j.virusres.2014.11.019
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Paul S, 2009, CANCER PREV RES, V2, P650, DOI 10.1158/1940-6207.CAPR-08-0224
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Piotrowska H, 2012, MUTAT RES-REV MUTAT, V750, P60, DOI 10.1016/j.mrrev.2011.11.001
   Qiu Y, 2020, MICROBES INFECT, V22, P221, DOI 10.1016/j.micinf.2020.03.003
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Seyed MA, 2016, J AGR FOOD CHEM, V64, P725, DOI 10.1021/acs.jafc.5b05993
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Tili E, 2010, CARCINOGENESIS, V31, P1561, DOI 10.1093/carcin/bgq143
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Weiskirchen S, 2016, ADV NUTR, V7, P706, DOI 10.3945/an.115.011627
   Yiu CY, 2010, MOLECULES, V15, P7115, DOI 10.3390/molecules15107115
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 52
TC 45
Z9 44
U1 8
U2 15
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1762743
EA MAY 2020
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LO5WW
UT WOS:000533698800001
PM 32345140
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Cao, B
   Wang, Y
   Wen, D
   Liu, W
   Wang, JL
   Fan, G
   Ruan, L
   Song, B
   Cai, Y
   Wei, M
   Li, X
   Xia, J
   Chen, N
   Xiang, J
   Yu, T
   Bai, T
   Xie, X
   Zhang, L
   Li, C
   Yuan, Y
   Chen, H
   Li, HD
   Huang, H
   Tu, S
   Gong, F
   Liu, Y
   Wei, Y
   Dong, C
   Zhou, F
   Gu, X
   Xu, J
   Liu, Z
   Zhang, Y
   Li, H
   Shang, L
   Wang, K
   Li, K
   Zhou, X
   Dong, X
   Qu, Z
   Lu, S
   Hu, X
   Ruan, S
   Luo, S
   Wu, J
   Peng, L
   Cheng, F
   Pan, L
   Zou, J
   Jia, C
   Wang, J
   Liu, X
   Wang, S
   Wu, X
   Ge, Q
   He, J
   Zhan, H
   Qiu, F
   Guo, L
   Huang, C
   Jaki, T
   Hayden, FG
   Horby, PW
   Zhang, D
   Wang, C
AF Cao, B.
   Wang, Y.
   Wen, D.
   Liu, W.
   Wang, Jingli
   Fan, G.
   Ruan, L.
   Song, B.
   Cai, Y.
   Wei, M.
   Li, X.
   Xia, J.
   Chen, N.
   Xiang, J.
   Yu, T.
   Bai, T.
   Xie, X.
   Zhang, L.
   Li, C.
   Yuan, Y.
   Chen, H.
   Li, Huadong
   Huang, H.
   Tu, S.
   Gong, F.
   Liu, Y.
   Wei, Y.
   Dong, C.
   Zhou, F.
   Gu, X.
   Xu, J.
   Liu, Z.
   Zhang, Y.
   Li, Hui
   Shang, L.
   Wang, K.
   Li, K.
   Zhou, X.
   Dong, X.
   Qu, Z.
   Lu, S.
   Hu, X.
   Ruan, S.
   Luo, S.
   Wu, J.
   Peng, L.
   Cheng, F.
   Pan, L.
   Zou, J.
   Jia, C.
   Wang, Juan
   Liu, X.
   Wang, S.
   Wu, X.
   Ge, Q.
   He, J.
   Zhan, H.
   Qiu, F.
   Guo, L.
   Huang, C.
   Jaki, T.
   Hayden, F. G.
   Horby, P. W.
   Zhang, D.
   Wang, C.
TI A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe
   Covid-19
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID EAST RESPIRATORY SYNDROME; SYNDROME CORONAVIRUS; NEURAMINIDASE
   INHIBITORS; LOPINAVIR/RITONAVIR; COMBINATION; INFECTION; SARS;
   REPLICATION
AB BACKGROUND
   No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2.
   METHODS
   We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao(2)) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao(2)) to the fraction of inspired oxygen (Fio(2)) of less than 300 mm Hg. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first.
   RESULTS
   A total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir-ritonavir group, and 100 to the standard-care group. Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.31; 95% confidence interval [CI], 0.95 to 1.80). Mortality at 28 days was similar in the lopinavir-ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, -5.8 percentage points; 95% CI, -17.3 to 5.7). The percentages of patients with detectable viral RNA at various time points were similar. In a modified intention-to-treat analysis, lopinavir-ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91). Gastrointestinal adverse events were more common in the lopinavir-ritonavir group, but serious adverse events were more common in the standard-care group. Lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events.
   CONCLUSIONS
   In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.)
C1 [Cao, B.; Wang, Y.; Fan, G.; Zhou, F.; Gu, X.; Liu, Z.; Zhang, Y.; Li, Hui; Shang, L.; Wang, C.] China Japan Friendship Hosp, Ctr Resp Med, Dept Pulm & Crit Care Med, Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China.
   [Fan, G.; Gu, X.] China Japan Friendship Hosp, Inst Clin Med Sci, Beijing, Peoples R China.
   [Cao, B.; Wang, Y.; Zhou, F.; Liu, Z.; Zhang, Y.; Li, Hui; Wang, C.] Chinese Acad Med Sci, Inst Resp Med, Beijing, Peoples R China.
   [Li, X.] Capital Med Univ, Beijing Ditan Hosp, Clin & Res Ctr Infect Dis, Beijing, Peoples R China.
   [Dong, C.] Peking Univ, Hosp 1, Clin Res Inst, Beijing, Peoples R China.
   [Xu, J.] Tsinghua Univ, Sch Med, Beijing, Peoples R China.
   [Shang, L.] Beijing Univ Chinese Med, Beijing, Peoples R China.
   [Guo, L.] Chinese Acad Med Sci, NHC Key Lab Syst Biol Pathogens, Inst Pathogen Biol, Beijing, Peoples R China.
   [Guo, L.] Chinese Acad Med Sci, Christophe Merieux Lab, Inst Pathogen Biol, Beijing, Peoples R China.
   [Guo, L.; Wang, C.] Peking Union Med Coll, Beijing, Peoples R China.
   [Wen, D.; Liu, W.; Wang, Jingli; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, Huadong; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, Juan; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Huang, C.; Zhang, D.] Jin Yin Tan Hosp, Wuhan, Peoples R China.
   [Jaki, T.] Univ Lancaster, Lancaster, England.
   [Horby, P. W.] Univ Oxford, Oxford, England.
   [Hayden, F. G.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.
RP Cao, B; Wang, C (corresponding author), China Japan Friendship Hosp, Ctr Resp Med, Dept Pulm & Crit Care Med, Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China.; Cao, B; Wang, C (corresponding author), Chinese Acad Med Sci, Inst Resp Med, Beijing, Peoples R China.; Wang, C (corresponding author), Peking Union Med Coll, Beijing, Peoples R China.; Zhang, D (corresponding author), Jin Yin Tan Hosp, Wuhan, Peoples R China.
EM caobin_ben@163.com; 1813886398@qq.com; cyh-birm@263.net
OI Xu, Jiuyang/0000-0002-1906-5918
FU Major Projects of National Science and Technology on New Drug Creation
   and Development [2020ZX09201001, 2020ZX09201012]; Chinese Academy of
   Medical Sciences (CAMS) Emergency Project of Covid-19 [2020HY320001];
   National Science Grant for Distinguished Young Scholars
   [81425001/H0104]; National Institute for Health Research Senior Research
   Fellowship [2015-08-001]; Wellcome TrustWellcome Trust; Bill and Melinda
   Gates FoundationBill & Melinda Gates Foundation; United Kingdom
   Department of Health and Social Care
FX Supported by grants from Major Projects of National Science and
   Technology on New Drug Creation and Development (2020ZX09201001) and
   (2020ZX09201012); the Chinese Academy of Medical Sciences (CAMS)
   Emergency Project of Covid-19 (2020HY320001); and a National Science
   Grant for Distinguished Young Scholars (81425001/H0104). Dr. Jaki is a
   recipient of a National Institute for Health Research Senior Research
   Fellowship (2015-08-001). Dr. Horby reports receiving funding from the
   Wellcome Trust, the Bill and Melinda Gates Foundation, and the United
   Kingdom Department of Health and Social Care.
CR [Anonymous], 2017, NATL EARLY WARNING S
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Hart BJ, 2014, J GEN VIROL, V95, P571, DOI 10.1099/vir.0.061911-0
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Katzen J, 2019, CLIN INFECT DIS, V69, P52, DOI 10.1093/cid/ciy860
   Kim UJ, 2016, ANTIVIR THER, V21, P455, DOI 10.3851/IMP3002
   Liu K, 2020, CHIN MED J
   Louie JK, 2012, CLIN INFECT DIS, V55, P1198, DOI 10.1093/cid/cis636
   Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359
   Muthuri SG, 2014, LANCET RESP MED, V2, P395, DOI 10.1016/S2213-2600(14)70041-4
   Spanakis N, 2014, INT J ANTIMICROB AG, V44, P528, DOI 10.1016/j.ijantimicag.2014.07.026
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang Y, 2019, J INFECT DIS
   WHO, COR DIS COVID 2019 R
   Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Zhou F., 2020, LANCET
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 25
TC 1227
Z9 1264
U1 163
U2 229
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 7
PY 2020
VL 382
IS 19
BP 1787
EP 1799
DI 10.1056/NEJMoa2001282
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA LO1TS
UT WOS:000533411000010
PM 32187464
OA Bronze, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Price, S
   Singh, S
   Ledot, S
   Bianchi, P
   Hind, M
   Tavazzi, G
   Vranckx, P
AF Price, Susanna
   Singh, Suveer
   Ledot, Stephane
   Bianchi, Paolo
   Hind, Matthew
   Tavazzi, Guido
   Vranckx, Pascal
TI Respiratory management in severe acute respiratory syndrome coronavirus
   2 infection
SO EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE
LA English
DT Article
DE Severe acute respiratory syndrome coronavirus 2; coronavirus disease
   2019; respiratory failure; acute respiratory distress syndrome;
   mechanical ventilation; oxygen therapy
ID LUNG INJURY; DISTRESS-SYNDROME; VENTILATION; OXYGEN; INTUBATION;
   SURVIVAL; MODERATE
AB The severe acute respiratory syndrome coronavirus 2 pandemic is to date affecting more than a million of patients and is challenging healthcare professionals around the world. Coronavirus disease 2019 may present with a wide range of clinical spectrum and severity, including severe interstitial pneumonia with high prevalence of hypoxic respiratory failure requiring intensive care admission. There has been increasing sharing experience regarding the patient's clinical features over the last weeks which has underlined the need for general guidance on treatment strategies. We summarise the evidence existing in the literature of oxygen and positive pressure treatments in patients at different stages of respiratory failure and over the course of the disease, including environment and ethical issues related to the ongoing coronavirus disease 2019 infection.
C1 [Price, Susanna; Singh, Suveer; Ledot, Stephane; Bianchi, Paolo] Royal Brompton & Harefield NHS Fdn Trust, Adult Intens Care, London, England.
   [Price, Susanna; Singh, Suveer] Imperial Coll London, London, England.
   [Ledot, Stephane; Bianchi, Paolo] Royal Brompton & Harefield NHS Fdn Trust, Anaesthesia, London, England.
   [Hind, Matthew] Royal Brompton & Harefield NHS Fdn, Dept Resp Med, London, England.
   [Tavazzi, Guido] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy.
   [Tavazzi, Guido] Fdn Policlin San Matteo Hosp IRCCS, Anesthesia & Intens Care, Pavia, Italy.
   [Vranckx, Pascal] Jessaziekenhuis Hasselt, Dept Cardiol & Intens Care, Stadsomvaart 11, B-3500 Hasselt, Belgium.
   [Vranckx, Pascal] Univ Hasselt, Fac Med & Life Sci, Hasselt, Belgium.
RP Vranckx, P (corresponding author), Jessaziekenhuis Hasselt, Dept Cardiol & Intens Care, Stadsomvaart 11, B-3500 Hasselt, Belgium.
EM pascal.vranckx@iccuhasselt.be
OI Hind, Matthew/0000-0002-9966-9446
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639
   [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   Baillard C, 2018, BRIT J ANAESTH, V120, P361, DOI 10.1016/j.bja.2017.11.067
   Barrot L, 2020, NEW ENGL J MED, V382, P999, DOI 10.1056/NEJMoa1916431
   Broccard A, 2000, CRIT CARE MED, V28, P295, DOI 10.1097/00003246-200002000-00001
   Brochard L, 2017, AM J RESP CRIT CARE, V195, P438, DOI 10.1164/rccm.201605-1081CP
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Cabrini L, 2020, LANCET, V395, P685, DOI 10.1016/S0140-6736(20)30359-7
   Canelli R, 2020, NEW ENGL J MED, V382, P1957, DOI 10.1056/NEJMc2007589
   Chang D, 2020, LANCET RESP MED, V8, pE13, DOI 10.1016/S2213-2600(20)30066-7
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Combes A, 2018, NEW ENGL J MED, V378, P1965, DOI 10.1056/NEJMoa1800385
   Cook TM, 2020, ANAESTHESIA, V75, P785, DOI 10.1111/anae.15054
   Cornejo RA, 2013, AM J RESP CRIT CARE, V188, P440, DOI 10.1164/rccm.201207-1279OC
   Fanelli V, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1211-y
   Fowler RA, 2004, AM J RESP CRIT CARE, V169, P1198, DOI 10.1164/rccm.200305-715OC
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Gattinoni L, 2001, NEW ENGL J MED, V345, P568, DOI 10.1056/NEJMoa010043
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Goligher EC, 2018, JAMA-J AM MED ASSOC, V320, P2251, DOI 10.1001/jama.2018.14276
   Guan WJ, 2019, CLIN CHARACTERISTICS, V2020, P2020, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974]
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   MacLaren G, 2020, JAMA-J AM MED ASSOC, V323, P1245, DOI 10.1001/jama.2020.2342
   Mancebo J, 2006, AM J RESP CRIT CARE, V173, P1233, DOI 10.1164/rccm.200503-353OC
   Milton DK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003205
   Moss M, 2019, NEW ENGL J MED, V380, P1997, DOI 10.1056/NEJMoa1901686
   Munshi L, 2019, LANCET RESP MED, V7, P163, DOI 10.1016/S2213-2600(18)30452-1
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372
   Patel BK, 2016, JAMA-J AM MED ASSOC, V315, P2435, DOI 10.1001/jama.2016.6338
   PIEHL MA, 1976, CRIT CARE MED, V4, P13, DOI 10.1097/00003246-197601000-00003
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6
   Rochwerg B, 2019, INTENS CARE MED, V45, P563, DOI 10.1007/s00134-019-05590-5
   Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016
   Sahetya SK, 2017, JAMA-J AM MED ASSOC, V318, P1327, DOI 10.1001/jama.2017.13695
   Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707
   Sud S, 2010, INTENS CARE MED, V36, P585, DOI 10.1007/s00134-009-1748-1
   Taccone P, 2009, JAMA-J AM MED ASSOC, V302, P1977, DOI 10.1001/jama.2009.1614
   Tay JK, 2020, JAMA OTOLARYNGOL, V146, P517, DOI 10.1001/jamaoto.2020.0764
   Tellier R, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3707-y
   Thille AW, 2019, JAMA-J AM MED ASSOC, V322, P1465, DOI 10.1001/jama.2019.14901
   van den Boom W, 2020, CHEST, V157, P566, DOI 10.1016/j.chest.2019.09.015
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zuo Mingzhang, 2020, Chinese Medical Sciences Journal, V35, P105, DOI 10.24920/003724
NR 52
TC 3
Z9 3
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 2048-8726
EI 2048-8734
J9 EUR HEART J-ACUTE CA
JI Eur. Heart J.-Acute Cardiovasc. Care
PD APR
PY 2020
VL 9
IS 3
BP 229
EP 238
AR 2048872620924613
DI 10.1177/2048872620924613
EA MAY 2020
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA LS7FE
UT WOS:000531835300001
PM 32375488
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hungerford, D
   Cunliffe, NA
AF Hungerford, Daniel
   Cunliffe, Nigel A.
TI Coronavirus disease (COVID-19) - impact on vaccine preventable diseases
SO EUROSURVEILLANCE
LA English
DT Letter
C1 [Hungerford, Daniel; Cunliffe, Nigel A.] Univ Liverpool, Liverpool Hlth Partners, Inst Infect & Global Hlth, Ctr Global Vaccine Res, Liverpool, Merseyside, England.
RP Hungerford, D (corresponding author), Univ Liverpool, Liverpool Hlth Partners, Inst Infect & Global Hlth, Ctr Global Vaccine Res, Liverpool, Merseyside, England.
EM d.hungerford@liverpool.ac.uk
FU NIHR Post-Doctoral Fellowship [PDF-2018-11-ST2-006]
FX No associated funding. Daniel Hungerford is funded outside the scope of
   work by an NIHR Post-Doctoral Fellowship (PDF-2018-11-ST2-006).
CR Centers for Disease Control and Prevention (CDC), GLOB MEASL OUTBR
   Eurosurveillance Editorial Team, 2020, Euro Surveill, V25, DOI 10.2807/1560-7917.ES.2020.25.16.2004232
   Hungerford D, 2018, BMC MED, V16, DOI 10.1186/s12916-017-0989-z
   National Health Service ( NHS), STANST SURG COVID 19
   Robert A, 2019, LANCET, V393, P2033, DOI 10.1016/S0140-6736(19)31039-6
   Screening & Immunisations Team (NHS Digital) COVER Team (Public Health England), 2019, CHILDH VACC COV STAT
NR 6
TC 2
Z9 2
U1 3
U2 5
PU EUR CENTRE DIS PREVENTION & CONTROL
PI STOCKHOLM
PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN
SN 1560-7917
J9 EUROSURVEILLANCE
JI Eurosurveillance
PD MAY 7
PY 2020
VL 25
IS 18
BP 34
EP 35
AR 2000756
DI 10.2807/1560-7917.ES.2020.25.18.2000756
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA LK9EC
UT WOS:000531159700006
PM 32400359
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jin, ZM
   Zhao, Y
   Sun, Y
   Zhang, B
   Wang, HF
   Wu, Y
   Zhu, Y
   Zhu, C
   Hu, TY
   Du, XY
   Duan, YK
   Yu, J
   Yang, XB
   Yang, XN
   Yang, KL
   Liu, X
   Guddat, LW
   Xiao, GF
   Zhang, LK
   Yang, HT
   Rao, ZH
AF Jin, Zhenming
   Zhao, Yao
   Sun, Yuan
   Zhang, Bing
   Wang, Haofeng
   Wu, Yan
   Zhu, Yan
   Zhu, Chen
   Hu, Tianyu
   Du, Xiaoyu
   Duan, Yinkai
   Yu, Jing
   Yang, Xiaobao
   Yang, Xiuna
   Yang, Kailin
   Liu, Xiang
   Guddat, Luke W.
   Xiao, Gengfu
   Zhang, Leike
   Yang, Haitao
   Rao, Zihe
TI Structural basis for the inhibition of SARS-CoV-2 main protease by
   antineoplastic drug carmofur
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Article
AB A crystal structure of SARS-CoV-2 with inhibitor carmofur reveals the mechanism of action of this compound and opens the way to develop more potent drugs.
   The antineoplastic drug carmofur is shown to inhibit the SARS-CoV-2 main protease (M-pro). Here, the X-ray crystal structure of M-pro in complex with carmofur reveals that the carbonyl reactive group of carmofur is covalently bound to catalytic Cys145, whereas its fatty acid tail occupies the hydrophobic S2 subsite. Carmofur inhibits viral replication in cells (EC50 = 24.30 mu M) and is a promising lead compound to develop new antiviral treatment for COVID-19.
C1 [Jin, Zhenming; Zhao, Yao; Zhang, Bing; Wang, Haofeng; Zhu, Yan; Zhu, Chen; Hu, Tianyu; Du, Xiaoyu; Duan, Yinkai; Yu, Jing; Yang, Xiaobao; Yang, Xiuna; Yang, Haitao; Rao, Zihe] ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai, Peoples R China.
   [Jin, Zhenming; Zhao, Yao; Zhang, Bing; Wang, Haofeng; Zhu, Yan; Zhu, Chen; Hu, Tianyu; Du, Xiaoyu; Duan, Yinkai; Yu, Jing; Yang, Xiaobao; Yang, Xiuna; Yang, Haitao; Rao, Zihe] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China.
   [Jin, Zhenming; Du, Xiaoyu; Rao, Zihe] Tsinghua Univ, Sch Life Sci, Lab Struct Biol, Beijing, Peoples R China.
   [Jin, Zhenming; Du, Xiaoyu; Rao, Zihe] Tsinghua Univ, Sch Med, Beijing, Peoples R China.
   [Sun, Yuan; Wu, Yan; Xiao, Gengfu; Zhang, Leike] Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Peoples R China.
   [Wang, Haofeng] Tianjin Univ, Sch Life Sci, Tianjin, Peoples R China.
   [Yang, Kailin] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA.
   [Liu, Xiang; Rao, Zihe] Nankai Univ, Coll Life Sci, Coll Pharm, Frontiers Sci Ctr Cell Response,State Key Lab Med, Tianjin, Peoples R China.
   [Guddat, Luke W.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia.
RP Yang, HT (corresponding author), ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai, Peoples R China.; Zhang, LK (corresponding author), Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Peoples R China.
EM zhangleike@wh.iov.cn; yanght@shanghaitech.edu.cn
RI ; Yang, Kailin/L-2205-2013
OI Yang, Xiuna/0000-0003-3443-9815; , Yuan/0000-0001-8244-7436; Du,
   Xiaoyu/0000-0002-8415-8686; Yang, Kailin/0000-0001-5968-6738; Jin,
   Zhenming/0000-0001-6448-820X
FU National Key R&D Program of China [2017YFC0840300, 2020YFA0707500];
   Project of International Cooperation and Exchanges NSFC [81520108019];
   Science and Technology Commission of Shanghai MunicipalityScience &
   Technology Commission of Shanghai Municipality (STCSM) [20431900200];
   Department of Science and Technology of Guangxi Zhuang Autonomous Region
   [2020AB40007]; Natural Science Foundation of ChinaNational Natural
   Science Foundation of China (NSFC) [31970165]
FX We are grateful to the staff at beamlines BL17U1, BL18U1 and BL19U1 at
   Shanghai Synchrotron Radiation Facility (SSRF, China), where data were
   collected. This work was supported by grants from the National Key R&D
   Program of China (grant no. 2017YFC0840300 to Z.R. and 2020YFA0707500.),
   the Project of International Cooperation and Exchanges NSFC (grant no.
   81520108019 to Z.R.), the Science and Technology Commission of Shanghai
   Municipality (grant no. 20431900200), the Department of Science and
   Technology of Guangxi Zhuang Autonomous Region (grant no. 2020AB40007)
   and the Natural Science Foundation of China (grant no. 31970165).
CR Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Dementiev A, 2019, J MED CHEM, V62, P987, DOI 10.1021/acs.jmedchem.8b01723
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   GROHN P, 1990, AM J CLIN ONCOL-CANC, V13, P477
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Morimoto Ken, 2003, Osaka City Medical Journal, V49, P77
   Nguyen HS, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10020045
   Nishio S, 1987, Hinyokika Kiyo, V33, P295
   Ooi K, 2001, BIOL PHARM BULL, V24, P1329, DOI 10.1248/bpb.24.1329
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Ren ZL, 2013, PROTEIN CELL, V4, P248, DOI 10.1007/s13238-013-2841-3
   Sakamoto J, 2005, JPN J CLIN ONCOL, V35, P536, DOI 10.1093/jjco/hyi147
   Sato S, 1999, Gan To Kagaku Ryoho, V26, P1613
   Wang FH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22677
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 25
TC 32
Z9 33
U1 10
U2 20
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1545-9993
EI 1545-9985
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
PD JUN
PY 2020
VL 27
IS 6
BP 529
EP +
DI 10.1038/s41594-020-0440-6
EA MAY 2020
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA LY0QA
UT WOS:000531514100001
PM 32382072
OA Bronze
DA 2021-01-01
ER

PT J
AU Lother, SA
   Abassi, M
   Agostinis, A
   Bangdiwala, AS
   Cheng, MP
   Drobot, G
   Engen, N
   Hullsiek, KH
   Kelly, LE
   Lee, TC
   Lofgren, SM
   MacKenzie, LJ
   Marten, N
   McDonald, EG
   Okafor, EC
   Pastick, KA
   Pullen, MF
   Rajasingham, R
   Schwartz, I
   Skipper, CP
   Turgeon, AF
   Zarychanski, R
   Boulware, DR
AF Lother, Sylvain A.
   Abassi, Mahsa
   Agostinis, Alyssa
   Bangdiwala, Ananta S.
   Cheng, Matthew P.
   Drobot, Glen
   Engen, Nicole
   Hullsiek, Kathy H.
   Kelly, Lauren E.
   Lee, Todd C.
   Lofgren, Sarah M.
   MacKenzie, Lauren J.
   Marten, Nicole
   McDonald, Emily G.
   Okafor, Elizabeth C.
   Pastick, Katelyn A.
   Pullen, Matthew F.
   Rajasingham, Radha
   Schwartz, Ilan
   Skipper, Caleb P.
   Turgeon, Alexis F.
   Zarychanski, Ryan
   Boulware, David R.
TI Post-exposure prophylaxis or pre-emptive therapy for severe acute
   respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a
   pragmatic randomized-controlled trial
SO CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article
DE Hydroxychloroquine; COVID-19; clinical trials; coronavirus; SARS-CoV-2;
   post-exposure prophylaxis; pre-emptive therapy; healthcare worker
AB Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 causing the coronavirus disease (COVID-19) pandemic. Currently, there is a lack of evidence-based therapies to prevent COVID-19 following exposure to the virus, or to prevent worsening of symptoms following confirmed infection. We describe the design of a clinical trial of hydroxychloroquine for post-exposure prophylaxis (PEP) and pre-emptive therapy (PET) for COVID-19. Methods We will conduct two nested multicentre international double-blind randomized placebo-controlled clinical trials of hydroxychloroquine for: 1) PEP of asymptomatic household contacts or healthcare workers exposed to COVID-19 within the past four days, and 2) PET for symptomatic outpatients with COVID-19 showing symptoms for less than four days. We will recruit 1,500 patients each for the PEP and PET trials. Participants will be randomized 1:1 to receive five days of hydroxychloroquine or placebo. The primary PEP trial outcome will be the incidence of symptomatic COVID-19. The primary PET trial outcome will be an ordinal scale of disease severity (not hospitalized, hospitalized without intensive care, hospitalization with intensive care, or death). Participant screening, informed consent, and follow-up will be exclusively internet-based with appropriate regulatory and research ethics board approvals in Canada and the United States. Discussion These complementary randomized-controlled trials are innovatively designed and adequately powered to rapidly answer urgent questions regarding the effectiveness of hydroxychloroquine to reduce virus transmission and disease severity of COVID-19 during a pandemic. In-person participant follow-up will not be conducted to facilitate social distancing strategies and reduce risks of exposure to study personnel. Innovative trial approaches are needed to urgently assess therapeutic options to mitigate the global impact of this pandemic.
C1 [Lother, Sylvain A.; Zarychanski, Ryan] Univ Manitoba, Dept Internal Med, Sect Crit Care, Winnipeg, MB, Canada.
   [Lother, Sylvain A.; MacKenzie, Lauren J.] Univ Manitoba, Dept Internal Med, Sect Infect Dis, Winnipeg, MB, Canada.
   [Abassi, Mahsa; Lofgren, Sarah M.; Okafor, Elizabeth C.; Pastick, Katelyn A.; Pullen, Matthew F.; Rajasingham, Radha; Skipper, Caleb P.; Boulware, David R.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA.
   [Agostinis, Alyssa; Schwartz, Ilan] Univ Alberta, Fac Med & Dent, Dept Med, Div Infect Dis, Edmonton, AB, Canada.
   [Agostinis, Alyssa] Trinity Coll Dublin, Sch Med, Dublin, Ireland.
   [Bangdiwala, Ananta S.; Engen, Nicole; Hullsiek, Kathy H.] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA.
   [Cheng, Matthew P.] McGill Univ Hlth Ctr, Div Infect Dis & Med Microbiol, Montreal, PQ, Canada.
   [Cheng, Matthew P.] McGill Interdisciplinary Initiat Infect & Immun, Montreal, PQ, Canada.
   [Drobot, Glen] Univ Manitoba, Dept Med, Winnipeg, MB, Canada.
   [Kelly, Lauren E.] Univ Manitoba, Dept Pediat & Child Hlth, Dept Pharmacol, Winnipeg, MB, Canada.
   [Lee, Todd C.; McDonald, Emily G.] McGill Univ, Dept Med, Clin Practice Assessment Unit, Montreal, PQ, Canada.
   [MacKenzie, Lauren J.] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada.
   [Marten, Nicole] St Boniface Gen Hosp, Crit Care Res, Winnipeg, MB, Canada.
   [Turgeon, Alexis F.] Univ Laval, CHU Quebec, Univ Laval Res Ctr,Emergency Crit Care Med, Populat Hlth & Optimal Hlth Practices Res Unit Tr, Quebec City, PQ, Canada.
   [Turgeon, Alexis F.] Univ Laval, Fac Med, Dept Anesthesiol & Crit Care Med, Div Crit Care Med, Quebec City, PQ, Canada.
   [Zarychanski, Ryan] Univ Manitoba, Dept Internal Med, Sect Hematol & Oncol, Winnipeg, MB, Canada.
   [Zarychanski, Ryan] CancerCare Manitoba, Dept Med Oncol & Hematol, Winnipeg, MB, Canada.
RP Lother, SA (corresponding author), Univ Manitoba, Dept Internal Med, Sect Crit Care, Winnipeg, MB, Canada.; Lother, SA (corresponding author), Univ Manitoba, Dept Internal Med, Sect Infect Dis, Winnipeg, MB, Canada.
EM slother@manitoba-physicians.ca
RI McDonald, Emily/AAS-8905-2020; Kelly, Lauren E/I-5543-2019; Schwartz,
   Ilan S./J-5666-2019
OI Kelly, Lauren E/0000-0001-7567-0816; Schwartz, Ilan
   S./0000-0002-7522-0281; Lofgren, Sarah M/0000-0001-6717-2614; Pullen,
   Matthew/0000-0002-4644-7487; Lother, Sylvain A./0000-0003-1927-2682;
   Boulware, David/0000-0002-4715-0060
FU Alliance of Minnesota Chinese Organizations; Minnesota Chinese Chamber
   of Commerce; University of MinnesotaUniversity of Minnesota System;
   Manitoba Medical Service Foundation
FX U.S. Funding by Jan and David Baszucki, Alliance of Minnesota Chinese
   Organizations, Minnesota Chinese Chamber of Commerce, and University of
   Minnesota. Canadian funding by the Manitoba Medical Service Foundation.
   The funders will not contribute to the design of the study; collection,
   management, analysis, and interpretation of data; writing of the report;
   and the decision to submit the report for publication. Purolator Canada
   provided in-kind courier support for the participating Canadian sites.
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Bhimraj A, 2020, INFECT DIS SOC AM GU
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI DOI 10.15585/MMWR.MM6912E2
   Borba MGS, 2020, CHLOROQUINE DIPHOSPH, DOI [10.1101/2020.04.07.20056424, DOI 10.1101/2020.04.07.20056424]
   Burke RM, 2020, MMWR-MORBID MORTAL W, V69, P245, DOI 10.15585/mmwr.mm6909e1
   Centers for Disease Control and Prevention, 2020, INF CLIN INV THER PA
   Centers for Disease Control and Prevention, 2020, COR DIV 2019 COVID 1
   Centers for Disease Control and Prevention, 2019, TREATM MAL GUID CLIN
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Cheng MHP, 2020, CAN MED ASSOC J, V192, pE405, DOI 10.1503/cmaj.200438
   Cheng MP, 2020, ANN INTERN MED, V172, P726, DOI 10.7326/M20-1301
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   International Society of Nephrology, 2012, KIDN DIS IMPR GLOB O
   Lexi Drugs, 2016, LEX DRUGS HYDR
   Lexi Drugs, 2020, LEX DRUGS CHLOR
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538
   Liu Y, 2020, LANCET, V395, pE47, DOI 10.1016/S0140-6736(20)30462-1
   Mahevas M, 2020, NO EVIDENCE CLIN EFF, P369, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Organization of Teratology Information Specialists (OTIS), 2018, MOTH BAB FACT SHEET
   Pastick KA, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa130
   Public Health Agency of Canada, 2020, COR DIS COVID 19 PRE
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Tang W., 2020, HYDROXYCHLOROQUINE P
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   WHO, 2020, REP WHO CHIN JOINT M
   World Health Organization, 2020, GLOB SURV HUM INF CO
   World Health Organization, 2020, COVID 19 THER TRIAL
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 41
TC 7
Z9 7
U1 1
U2 10
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0832-610X
EI 1496-8975
J9 CAN J ANESTH
JI Can. J. Anesth.
PD SEP
PY 2020
VL 67
IS 9
BP 1201
EP 1211
DI 10.1007/s12630-020-01684-7
EA MAY 2020
PG 11
WC Anesthesiology
SC Anesthesiology
GA MW4SK
UT WOS:000530978800001
PM 32383125
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Guo, JC
   Xie, H
   Liang, MN
   Wu, H
AF Guo, Jincai
   Xie, Hui
   Liang, Mining
   Wu, Hao
TI COVID-19: a novel coronavirus and a novel challenge for oral healthcare
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Novel coronavirus pneumonia; COVID-19; SARS-CoV-2; Oral healthcare; Oral
   treatment
AB Objectives Explore how to manage oral healthcare during the COVID-19 outbreak. Materials and methods In order to solve oral healthcare during the COVID-19 outbreak, our hospital has taken effective measures: build a team of experts, which provide a 24-h hotline, online video consultation, and online training and push popular science articles on WeChat. For the treatment of emergency patients aside from routine epidemic prevention measures, some special measures for oral treatment need to be added. Results From January 23, 2020, to March 2, 2020, a total of 3035 patients received oral therapy during the COVID-19 epidemic in our hospital. To our knowledge, no oral health worker or patient has been infected with COVID-19 due to oral treatment, and no patients have complained about the suspension of treatment by complaints hotline. Conclusion COVID-19 is a novel challenge for oral healthcare. Attention should be paid to oral healthcare during the outbreak of COVID-19.
C1 [Guo, Jincai; Xie, Hui; Wu, Hao] Changsha Stomatol Hosp, Changsha, Hunan, Peoples R China.
   [Liang, Mining] Cent South Univ, Xiangya Hosp 2, Clin Nursing Teaching & Res Sect, Changsha, Hunan, Peoples R China.
RP Xie, H (corresponding author), Changsha Stomatol Hosp, Changsha, Hunan, Peoples R China.
EM kqyyxh1@126.com
FU Natural Science Foundation of Hunan ProvinceNatural Science Foundation
   of Hunan Province [2019JJ80054, 2019JJ80055]; Scientific Research
   Project of the Hunan Health Commission [B2019133]; Research Project
   Funding of the Changsha Municipal Health and Family Planning Commission
   [201809]
FX Our study was supported by the Natural Science Foundation of Hunan
   Province (No. 2019JJ80054 and No. 2019JJ80055), the Scientific Research
   Project of the Hunan Health Commission (No. B2019133), and Research
   Project Funding of the Changsha Municipal Health and Family Planning
   Commission (No. 201809).
CR Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Lai ChihCheng, 2020, International Journal of Antimicrobial Agents, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Sabino-Silva R, 2020, CLIN ORAL INVEST, V24, P1619, DOI 10.1007/s00784-020-03248-x
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 6
TC 3
Z9 3
U1 1
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1432-6981
EI 1436-3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD JUN
PY 2020
VL 24
IS 6
BP 2137
EP 2138
DI 10.1007/s00784-020-03291-8
EA MAY 2020
PG 2
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA LS8IE
UT WOS:000530982800012
PM 32382932
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Weitz, JS
   Beckett, SJ
   Coenen, AR
   Demory, D
   Dominguez-Mirazo, M
   Dushoff, J
   Leung, CY
   Li, GL
   Magalie, A
   Park, SW
   Rodriguez-Gonzalez, R
   Shivam, S
   Zhao, CNY
AF Weitz, Joshua S.
   Beckett, Stephen J.
   Coenen, Ashley R.
   Demory, David
   Dominguez-Mirazo, Marian
   Dushoff, Jonathan
   Leung, Chung-Yin
   Li, Guanlin
   Magalie, Andreea
   Park, Sang Woo
   Rodriguez-Gonzalez, Rogelio
   Shivam, Shashwat
   Zhao, Conan Y.
TI Modeling shield immunity to reduce COVID-19 epidemic spread
SO NATURE MEDICINE
LA English
DT Article
ID CORONAVIRUS; MULTISCALE; INFECTION; NETWORK
AB A new study models the potential effects of preferentially deploying recovered individuals, who are seropositive for anti-SARS-CoV-2 antibodies, into the community to reduce the number of interactions between susceptible and infected people, thereby limiting transmission of the virus.
   The COVID-19 pandemic has precipitated a global crisis, with more than 1,430,000 confirmed cases and more than 85,000 confirmed deaths globally as of 9 April 2020(1-4). Mitigation and suppression of new infections have emerged as the two predominant public health control strategies(5). Both strategies focus on reducing new infections by limiting human-to-human interactions, which could be both socially and economically unsustainable in the long term. We have developed and analyzed an epidemiological intervention model that leverages serological tests(6,7) to identify and deploy recovered individuals(8) as focal points for sustaining safer interactions via interaction substitution, developing what we term 'shield immunity' at the population scale. The objective of a shield immunity strategy is to help to sustain the interactions necessary for the functioning of essential goods and services(9) while reducing the probability of transmission. Our shield immunity approach could substantively reduce the length and reduce the overall burden of the current outbreak, and can work synergistically with social distancing. The present model highlights the value of serological testing as part of intervention strategies, in addition to its well-recognized roles in estimating prevalence(10,11) and in the potential development of plasma-based therapies(12-15).
C1 [Weitz, Joshua S.; Beckett, Stephen J.; Demory, David; Dominguez-Mirazo, Marian; Leung, Chung-Yin; Magalie, Andreea; Rodriguez-Gonzalez, Rogelio; Zhao, Conan Y.] Georgia Inst Technol, Sch Biol Sci, Atlanta, GA 30332 USA.
   [Weitz, Joshua S.; Coenen, Ashley R.; Leung, Chung-Yin; Li, Guanlin] Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA.
   [Weitz, Joshua S.] Georgia Inst Technol, Ctr Microbial Dynam & Infect, Atlanta, GA 30332 USA.
   [Dominguez-Mirazo, Marian; Li, Guanlin; Magalie, Andreea; Rodriguez-Gonzalez, Rogelio; Zhao, Conan Y.] Georgia Inst Technol, Interdisciplinary Grad Program Quantitat Biosci, Atlanta, GA 30332 USA.
   [Dushoff, Jonathan] McMaster Univ, Dept Biol, Hamilton, ON, Canada.
   [Dushoff, Jonathan] McMaster Univ, DeGroote Inst Infect Dis Res, Hamilton, ON, Canada.
   [Park, Sang Woo] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.
   [Shivam, Shashwat] Georgia Inst Technol, Sch Elect & Comp Engn, Atlanta, GA 30332 USA.
RP Weitz, JS (corresponding author), Georgia Inst Technol, Sch Biol Sci, Atlanta, GA 30332 USA.; Weitz, JS (corresponding author), Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA.; Weitz, JS (corresponding author), Georgia Inst Technol, Ctr Microbial Dynam & Infect, Atlanta, GA 30332 USA.
EM jsweitz@gatech.edu
OI Beckett, Stephen/0000-0002-4410-2960; Dushoff,
   Jonathan/0000-0003-0506-4794
FU Simons Foundation [329108]; Army Research Office [W911NF1910384];
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [1R01AI46592-01];
   National Science FoundationNational Science Foundation (NSF) [1806606,
   1829636]; Canadian Institutes of Health ResearchCanadian Institutes of
   Health Research (CIHR); Natural Sciences and Engineering Research
   Council of CanadaNatural Sciences and Engineering Research Council of
   CanadaCGIAR
FX We thank P.S. Dodds, M. Lipsitch, K. Levy, D. Muratore, A. Sanz and J.
   Shaman for comments and feedback in the initial stages of development,
   and A. Kraay, B. Lopman and K. Nelson for discussions on serological
   testing characteristics as part of ongoing collaborative work. Tweet
   threads by T. Bedford and N. Christakis were influential in refining
   initial ideas into the current form. Research effort by J.S.W. and
   co-authors at the Georgia Institute of Technology was enabled by support
   from grants from the Simons Foundation (SCOPE Award ID 329108), the Army
   Research Office (W911NF1910384), the National Institutes of Health
   (1R01AI46592-01) and the National Science Foundation (1806606 and
   1829636). J.D. was supported in part by grants from the Canadian
   Institutes of Health Research and the Natural Sciences and Engineering
   Research Council of Canada.
CR Amanat F, 2020, SEROLOGICAL ASSAY DE
   [Anonymous], 2020, GLOB OPT TOOLB
   [Anonymous], NAT COVID 19 CONV PL
   [Anonymous], 2018, ANN ESTIMATES RESIDE
   Balcan D, 2009, P NATL ACAD SCI USA, V106, P21484, DOI 10.1073/pnas.0906910106
   Bansal S, 2007, J R SOC INTERFACE, V4, P879, DOI 10.1098/rsif.2007.1100
   Bellan SE, 2014, LANCET, V384, P1499, DOI 10.1016/S0140-6736(14)61839-0
   Bezanson J, 2017, SIAM REV, V59, P65, DOI 10.1137/141000671
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Chan KH, 2013, J INFECTION, V67, P130, DOI 10.1016/j.jinf.2013.03.015
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Colizza V, 2006, P NATL ACAD SCI USA, V103, P2015, DOI 10.1073/pnas.0510525103
   Dormand J., 1980, J COMPUT APPL MATH, V6, P19, DOI [10.1016/0771-050X(80)90013-3, DOI 10.1016/0771-050X(80)90013-3]
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Emanuel EJ, 2020, NY TIMES
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Ferguson NM, 2020, IMPACT NON PHARM INT
   Flaxman S., 2020, 13 IMP COLL
   Gottlieb S, 2020, NATL CORONAVIRUS RES
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Hennekens CH, 2020, AM J MED, V133, P648, DOI 10.1016/j.amjmed.2020.03.001
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Klompas M, 2020, ANN INTERN MED, V172, P619, DOI 10.7326/M20-0751
   Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Lou B, 2020, SEROLOGY CHARACTERIS
   Lourenco J., 2020, FUNDAMENTAL PRINCIPL
   Mckee M, 2020, NAT MED, V26, P640, DOI 10.1038/s41591-020-0863-y
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Park S. W., 2020, TIME SCALE ASYMPTOMA, DOI [10.1101/2020.03.09.20033514v1, DOI 10.1101/2020.03.09.20033514V1]
   Park S. W, 2020, RECONCILING EARLY OU, DOI [10.1101/2020.01.30.20019877v4.full.pdf, DOI 10.1101/2020.01.30.20019877V4.FULL.PDF]
   Rackauckas C., 2017, J OPEN RES STW, V5, P15, DOI [10.5334/jors.151, DOI 10.5334/JORS.151]
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Shampine LF, 1997, SIAM J SCI COMPUT, V18, P1, DOI 10.1137/S1064827594276424
   Soetaert K, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i09
   Tsitouras C, 2011, COMPUT MATH APPL, V62, P770, DOI 10.1016/j.camwa.2011.06.002
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Watts DJ, 2005, P NATL ACAD SCI USA, V102, P11157, DOI 10.1073/pnas.0501226102
   WHITLEY D, 1994, STAT COMPUT, V4, P65
   WHO, 2020, 70 WHO
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 49
TC 17
Z9 15
U1 4
U2 14
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD JUN
PY 2020
VL 26
IS 6
BP 849
EP +
DI 10.1038/s41591-020-0895-3
EA MAY 2020
PG 19
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA LZ3ZG
UT WOS:000530983800004
PM 32382154
OA Bronze
DA 2021-01-01
ER

PT J
AU Kumar, K
   Vogt, JC
   Divanji, PH
   Cigarroa, JE
AF Kumar, Kris
   Vogt, Joshua C.
   Divanji, Punag H.
   Cigarroa, Joaquin E.
TI Spontaneous coronary artery dissection of the left anterior descending
   artery in a patient with COVID-19 infection
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Article; Early Access
DE catheterization diagnostic; coronary angiography; coronary artery
   disease; coronary dissection
AB A 48-year-old woman with a past medical history of migraines and hyperlipidemia presented due to severe retrosternal chest pain with no other associated signs or symptoms. The patient was hemodynamically stable and was found to have an elevated troponin with electrocardiogram showing no ischemic changes. Computed tomography of the coronary arteries showed a left dominant system with dissection extending from the mid-to-distal left anterior descending (LAD) artery. The patient was subsequently discharged on medical therapy but returned 3 days later due to worsening chest pain. Electrocardiogram revealed inferior and anteroseptal ST segment changes with peak troponin of 14.9 ng/ml (reference range <0.80 ng/ml). Coronavirus disease 2019 (COVID-19) nasopharyngeal swab was performed prior to urgent coronary angiogram. Coronary angiogram was performed with full personal protective equipment for respiratory and droplet precautions due to pending COVID-19 testing results. Angiogram revealed spontaneous coronary artery dissection (SCAD) extending from the ostium of the LAD to the distal vessel. COVID-19 testing returned positive while in intensive care unit. The patient was not a percutaneous coronary intervention candidate due to the extent of the dissection and was not a surgical candidate due to a lack of graftable target and medical management was continued. To our knowledge, this case is the first in which SCAD has been reported in the LAD in a patient with COVID-19 with no other symptoms of respiratory illness or symptoms classically associated with the novel coronavirus. SCAD should be considered on the differential as one of the various cardiac manifestations of COVID-19 infection.
C1 [Kumar, Kris; Vogt, Joshua C.; Divanji, Punag H.; Cigarroa, Joaquin E.] Oregon Hlth & Sci Univ, Div Cardiol, Knight Cardiovasc Inst, UHN 62,3181 Southwest Sam Jackson Pk Rd, Portland, OR 97239 USA.
RP Cigarroa, JE (corresponding author), Oregon Hlth & Sci Univ, Div Cardiol, Knight Cardiovasc Inst, UHN 62,3181 Southwest Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM cigarroa@ohsu.edu
CR Akhmerov A, 2020, CIRC RES, V126, P1443, DOI 10.1161/CIRCRESAHA.120.317055
   Bonow RO, 2020, JAMA CARDIOL, DOI [10.1001/jamacardio.2020.1105., DOI 10.1001/JAMACARDI0.2020.1105]
   Courand PY, 2020, JACC-CARDIOVASC INTE, V13, pE107, DOI 10.1016/j.jcin.2020.04.006
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Guo T, 2020, JAMA CARDIOL, DOI [10.1001/jamacardio.2020.1017, DOI 10.1001/JAMACARDI0.2020.1017]
   Madjid M, 2007, EUR HEART J, V28, P1205, DOI 10.1093/eurheartj/ehm035
   Mahmud E, 2020, CATHETER CARDIO INTE, V96, P507, DOI 10.1002/ccd.28894
   Shi S, 2020, JAMA CARDIOL, P802, DOI [10.1001/jamacardio.2020.0950., DOI 10.1001/JAMACARDI0.2020.0950, 10.1001/jamacardio.2020.0950]
   Smeeth L, 2004, NEW ENGL J MED, V351, P2611, DOI 10.1056/NEJMoa041747
   Szerlip M, 2020, CATHETER CARDIO INTE, V96, P586, DOI 10.1002/ccd.28887
   WHO, COR DIS COVID 19 PAN
NR 11
TC 2
Z9 2
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-1946
EI 1522-726X
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
DI 10.1002/ccd.28960
EA MAY 2020
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA LK3FU
UT WOS:000530747500001
PM 32383284
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Beauverd, Y
   Adam, Y
   Assouline, B
   Samii, K
AF Beauverd, Yan
   Adam, Yannick
   Assouline, Benjamin
   Samii, Kaveh
TI COVID-19 infection and treatment with hydroxychloroquine cause severe
   haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase
   deficiency
SO EUROPEAN JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE coronavirus; COVID-19; G6PD deficiency; haemolysis; hydroxychloroquine;
   SARS-CoV-2
AB Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited genetic disorder caused by red cell enzymatic defects and is associated with haemolytic crisis when patients are exposed to oxidative agents (fava beans, drugs, infections). Hydroxychloroquine is suspected to trigger haemolytic crisis in G6PD-deficient patients, and off-label administration of this drug to patients infected with the novel coronavirus (SARS-CoV-2) could cause concern. We report here the first case of severe haemolytic crisis in a patient with G6PD deficiency, initiated by severe COVID-19 infection and hydroxychloroquine use. With worldwide spread of COVID-19, especially in regions with a high prevalence of G6PD deficiency, our case should alert physicians to this possible correlation.
C1 [Beauverd, Yan; Samii, Kaveh] Geneva Univ Hosp, Dept Oncol, Haematol Div, Geneva, Switzerland.
   [Adam, Yannick; Assouline, Benjamin] Geneva Univ Hosp, Dept Acute Med, Intens Care Div, Geneva, Switzerland.
RP Beauverd, Y (corresponding author), Geneva Univ Hosp, Div Haematol, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland.
EM yan.beauverd@hcuge.ch
CR Cappellini MD, 2008, LANCET, V371, P64, DOI 10.1016/S0140-6736(08)60073-2
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1166
   Mohammad S, 2018, ARTHRIT CARE RES, V70, P481, DOI 10.1002/acr.23296
   Yao X, 2020, CLIN INFECT DIS
NR 5
TC 18
Z9 18
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-4441
EI 1600-0609
J9 EUR J HAEMATOL
JI Eur. J. Haematol.
PD SEP
PY 2020
VL 105
IS 3
BP 357
EP 359
DI 10.1111/ejh.13432
EA MAY 2020
PG 3
WC Hematology
SC Hematology
GA NC0RR
UT WOS:000530700600001
PM 32324284
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Kiong, KL
   Guo, TR
   Yao, CMKL
   Gross, ND
   Hanasono, MM
   Ferrarotto, R
   Rosenthal, DI
   Myers, JN
   Hanna, EY
   Lai, SHY
AF Kiong, Kimberley L.
   Guo, Theresa
   Yao, Christopher M. K. L.
   Gross, Neil D.
   Hanasono, Matthew M.
   Ferrarotto, Renata
   Rosenthal, David I.
   Myers, Jeffrey N.
   Hanna, Ehab Y.
   Lai, Stephen Y.
TI Changing practice patterns in head and neck oncologic surgery in the
   early COVID-19 era
SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND
   NECK
LA English
DT Article
DE oncology; otolaryngology; SARS-CoV2
ID CANCER; IMPACT; TIME; RADIOTHERAPY; INITIATION; OUTCOMES; FLAP
AB Background The novel coronavirus 2019 (COVID-19) pandemic has changed health care, challenged by resource constraints and fears of transmission. We report the surgical practice pattern changes in a Head and Neck Surgery department of a tertiary cancer care center and discuss the issues surrounding multidisciplinary care during the pandemic.
   Methods We report data regarding outpatient visits, multidisciplinary treatment planning conference, surgical caseload, and modifications of oncologic therapy during this pandemic and compared this data to the same interval last year.
   Results We found a 46.7% decrease in outpatient visits and a 46.8% decrease in surgical caseload, compared to 2019. We discuss the factors involved in the decision-making process and perioperative considerations.
   Conclusions Surgical practice patterns in head and neck oncologic surgery will continue to change with the evolving pandemic. Despite constraints, we strive to prioritize and balance the oncologic and safety needs of patients with head and neck cancer in the face of COVID-19.
C1 [Kiong, Kimberley L.; Guo, Theresa; Yao, Christopher M. K. L.; Gross, Neil D.; Myers, Jeffrey N.; Hanna, Ehab Y.; Lai, Stephen Y.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA.
   [Hanasono, Matthew M.] Univ Texas MD Anderson Canc Ctr, Dept Plast & Reconstruct Surg, Houston, TX 77030 USA.
   [Ferrarotto, Renata] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.
   [Rosenthal, David I.; Lai, Stephen Y.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA.
RP Lai, SHY (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Div Surg, 1515 Holcombe Blvd,Unit 1445, Houston, TX 77030 USA.
EM sylai@mdanderson.org
CR American Academy of Otolaryngology, POS STAT OT COVID 19
   [Anonymous], ABB EX ORD GA 09
   Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P269, DOI 10.2217/imt-2020-0067
   Canadian Association of Head & Neck Surgical Oncology (CAHNSO), GUID MAN HEAD NECK C
   Chan JYK, 2020, JAMA OTOLARYNGOL, V146, P519, DOI 10.1001/jamaoto.2020.0488
   Chen X, JAMA OTOLARYNGOL
   Coca-Pelaz A, 2018, ADV THER, V35, P153, DOI 10.1007/s12325-018-0663-7
   Corbitt C, 2014, HEAD NECK-J SCI SPEC, V36, P1440, DOI 10.1002/hed.23471
   DeGraaf LH, 2019, ORAL ONCOL, V96, P148, DOI 10.1016/j.oraloncology.2019.07.021
   Gabrysz-Forget F, 2019, J OTOLARYNGOL-HEAD N, V48, DOI 10.1186/s40463-019-0334-y
   Hanasono MM, 2009, HEAD NECK-J SCI SPEC, V31, P1289, DOI 10.1002/hed.21100
   Jensen AR, 2007, RADIOTHER ONCOL, V84, P5, DOI 10.1016/j.radonc.2007.04.001
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Kligerman MP, 2020, HEAD NECK-J SCI SPEC, V42, P1209, DOI 10.1002/hed.26171
   Kovatch KJ, 2019, LARYNGOSCOPE, V129, P138, DOI 10.1002/lary.27257
   Kozin ED, 2016, OTOLARYNG HEAD NECK, V154, P66, DOI 10.1177/0194599815607345
   Lei Shaoqing, 2020, EClinicalMedicine, V21, P100331, DOI 10.1016/j.eclinm.2020.100331
   Leiser Y, 2017, J CRANIOFAC SURG, V28, pE18, DOI 10.1097/SCS.0000000000003168
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Maria SA, JAMA OTOLARYNGOL, DOI [10.1177/0194599820917914, DOI 10.1177/0194599820917914]
   MD Anderson Head and Neck Surgery Treatment Guidelines Consortium, 2020, HEAD NECK SURG ONC T
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Murphy CT, 2016, J CLIN ONCOL, V34, P169, DOI 10.1200/JCO.2015.61.5906
   Parsons JT, 2002, CANCER-AM CANCER SOC, V94, P2967, DOI 10.1002/cncr.10567
   Patel RJ, 2020, HEAD NECK-J SCI SPEC, V42, P1168, DOI 10.1002/hed.26189
   Rosenthal David I, 2007, J Support Oncol, V5, P23
   Schutte HW, 2020, OTOLARYNG HEAD NECK, V162, P446, DOI 10.1177/0194599820906387
   Shellenberger TD, 2018, ORAL MAXIL SURG CLIN, V30, P435, DOI 10.1016/j.coms.2018.06.005
   Sun XY, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5701-6
   Tay JK, 2020, JAMA OTOLARYNGOL, V146, P517, DOI 10.1001/jamaoto.2020.0764
   Thomson DJ, 2020, INT J RADIAT ONCOL, V107, P618, DOI 10.1016/j.ijrobp.2020.04.016
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Workman AD, 2020, INT FORUM ALLERGY RH, V10, P798, DOI 10.1002/alr.22577
   World Health Organization, 2020, LAB TEST COR DIS 201
   Wyatt RM, 2003, PHYS MED BIOL, V48, P139, DOI 10.1088/0031-9155/48/2/301
NR 35
TC 7
Z9 7
U1 2
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1043-3074
EI 1097-0347
J9 HEAD NECK-J SCI SPEC
JI Head Neck-J. Sci. Spec. Head Neck
PD JUN
PY 2020
VL 42
IS 6
BP 1179
EP 1186
DI 10.1002/hed.26202
EA MAY 2020
PG 8
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA LU5GY
UT WOS:000530679300001
PM 32459061
OA Bronze
DA 2021-01-01
ER

PT J
AU Shen, LW
   Qian, MQ
   Yu, K
   Narva, S
   Yu, F
   Wu, YL
   Zhang, W
AF Shen, Li-Wen
   Qian, Man-Qing
   Yu, Kai
   Narva, Suresh
   Yu, Fei
   Wu, Yan-Ling
   Zhang, Wen
TI Inhibition of Influenza A virus propagation by benzoselenoxanthenes
   stabilizing TMPRSS2 Gene G-quadruplex and hence down-regulating TMPRSS2
   expression
SO SCIENTIFIC REPORTS
LA English
DT Article
ID REGION; H7N9; DNA; REPLICATION; APROTININ; PROMOTER; TARGET; ENTRY
AB Proteolytic cleavage of influenza A virus (IAV) hemagglutinin by host proteases is crucial for virus infectivity and spread. The transmembrane serine protease TMPRSS2 was previously identified as the essential protease that can cleave hemagglutinin of many subtypes of influenza virus and spike protein of coronavirus. Herein, we found that a guanine rich tract, capable of forming intramolecular G-quadruplex in the presence of potassium ions, in the promoter region of human TMPRSS2 gene was quite important for gene transcriptional activity, hence affecting its function. Furthermore, 7 new synthesized benzoselenoxanthene analogues were found to enable stabilizing such G-quadruplex. More importantly, compounds can down-regulate TMPRSS2 gene expression, especially endogenous TMPRSS2 protein levels, and consequently suppress influenza A virus propagation in vitro. Our results provide a new strategy for anti-influenza A virus infection by small molecules targeting the TMPRSS2 gene G-quadruplex and thus inhibiting TMPRSS2 expression, which is valuable for developing small molecule drugs against influenza A virus and also may be a potential candidate as anti- SARS-CoV-2 (Severe Acute Respiratory Syndrome CoV 2) lead molecules.
C1 [Shen, Li-Wen; Qian, Man-Qing; Yu, Kai; Narva, Suresh; Zhang, Wen] Zhejiang Univ Technol, Coll Pharmaceut Sci, Lab Chem Biol & Mol Drug Design, Hangzhou 310014, Peoples R China.
   [Qian, Man-Qing; Yu, Kai; Narva, Suresh; Zhang, Wen] Zhejiang Univ Technol, Inst Drug Dev & Chem Biol, Hangzhou 310014, Peoples R China.
   [Yu, Fei] Kunming Univ Sci & Technol, Med Sch, Lab Chem Biol, Kunming 650500, Yunnan, Peoples R China.
   [Wu, Yan-Ling] Zhejiang Prov Ctr Dis Control & Prevent, Virus Inspect Dept, Lab Mol Immunol, Hangzhou 310051, Peoples R China.
RP Zhang, W (corresponding author), Zhejiang Univ Technol, Coll Pharmaceut Sci, Lab Chem Biol & Mol Drug Design, Hangzhou 310014, Peoples R China.; Zhang, W (corresponding author), Zhejiang Univ Technol, Inst Drug Dev & Chem Biol, Hangzhou 310014, Peoples R China.; Wu, YL (corresponding author), Zhejiang Prov Ctr Dis Control & Prevent, Virus Inspect Dept, Lab Mol Immunol, Hangzhou 310051, Peoples R China.
EM ylwu@cdc.zj.cn; wzhang63@zjut.edu.cn
OI Narva, Suresh/0000-0003-0702-784X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [21877101]; Emergency Project of Key Research
   and Development Plan of Zhejiang Province [2020C03124]; Zhejiang Leading
   Innovation and Entrepreneurship Team [2018R01015]
FX We gratefully acknowledge the support by the National Natural Science
   Foundation of China (No. 21877101), the Emergency Project of Key
   Research and Development Plan of Zhejiang Province (2020C03124) and the
   Zhejiang Leading Innovation and Entrepreneurship Team (2018R01015).
CR Baer A, 2014, JOVE-J VIS EXP, DOI 10.3791/52065
   Balasubramanian S, 2009, CURR OPIN CHEM BIOL, V13, P345, DOI 10.1016/j.cbpa.2009.04.637
   Bertram S, 2013, J VIROL, V87, P6150, DOI 10.1128/JVI.03372-12
   Biffi G, 2013, NAT CHEM, V5, P182, DOI [10.1038/nchem.1548, 10.1038/NCHEM.1548]
   Cheng ZS, 2015, J INFECT DIS, V212, P1214, DOI 10.1093/infdis/jiv246
   De Clercq E, 2006, NAT REV DRUG DISCOV, V5, P1015, DOI 10.1038/nrd2175
   Dexheimer TS, 2006, J AM CHEM SOC, V128, P5404, DOI 10.1021/ja0563861
   Esumi M, 2015, HEPATOLOGY, V61, P437, DOI 10.1002/hep.27426
   Feng EG, 2012, CHEMMEDCHEM, V7, P1527, DOI 10.1002/cmdc.201200155
   Gierer S, 2013, J VIROL, V87, P5502, DOI 10.1128/JVI.00128-13
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu YW, 2013, LANCET, V381, P2273, DOI 10.1016/S0140-6736(13)61125-3
   Kim TS, 2006, MOL CELL BIOL, V26, P965, DOI 10.1128/MCB.26.3.965-975.2006
   Li CX, 2017, ONCOL LETT, V13, P177, DOI 10.3892/ol.2016.5453
   Mangano DT, 2006, NEW ENGL J MED, V354, P353, DOI 10.1056/NEJMoa051379
   Mergny JL, 1998, FEBS LETT, V435, P74, DOI 10.1016/S0014-5793(98)01043-6
   Nambiar M, 2011, NUCLEIC ACIDS RES, V39, P936, DOI 10.1093/nar/gkq824
   Nguyen JT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009332
   Onyshchenko MI, 2009, NUCLEIC ACIDS RES, V37, P7570, DOI 10.1093/nar/gkp840
   Risitano A, 2003, BIOCHEMISTRY-US, V42, P6507, DOI 10.1021/bi026997v
   Sakai K, 2014, J VIROL, V88, P5608, DOI 10.1128/JVI.03677-13
   Seenisamy J, 2005, J AM CHEM SOC, V127, P2944, DOI 10.1021/ja0444482
   Seenisamy J, 2004, J AM CHEM SOC, V126, P8702, DOI 10.1021/ja040022b
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   Shirato K, 2013, J VIROL, V87, P12552, DOI 10.1128/JVI.01890-13
   Sun YJ, 2017, EXP THER MED, V13, P952, DOI 10.3892/etm.2017.4090
   Tarnow C, 2014, J VIROL, V88, P4744, DOI 10.1128/JVI.03799-13
   WHO, INFLUENZA
   Yamaya M, 2015, PULM PHARMACOL THER, V33, P66, DOI 10.1016/j.pupt.2015.07.001
   Zhang W, 2015, SCI REP-UK, V5, DOI 10.1038/srep13693
   Zheng KW, 2010, NUCLEIC ACIDS RES, V38, P327, DOI 10.1093/nar/gkp898
   Zhirnov OP, 2011, ANTIVIR RES, V92, P27, DOI 10.1016/j.antiviral.2011.07.014
   Zmora P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176597
NR 34
TC 3
Z9 3
U1 4
U2 6
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 6
PY 2020
VL 10
IS 1
DI 10.1038/s41598-020-64368-8
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LP0PL
UT WOS:000534024000002
PM 32376987
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dunlop, A
   Lokuge, B
   Masters, D
   Sequeira, M
   Saul, P
   Dunlop, G
   Ryan, J
   Hall, M
   Ezard, N
   Haber, P
   Lintzeris, N
   Maher, L
AF Dunlop, Adrian
   Lokuge, Buddhima
   Masters, Debbie
   Sequeira, Marcia
   Saul, Peter
   Dunlop, Grace
   Ryan, John
   Hall, Michelle
   Ezard, Nadine
   Haber, Paul
   Lintzeris, Nicholas
   Maher, Lisa
TI Challenges in maintaining treatment services for people who use drugs
   during the COVID-19 pandemic
SO HARM REDUCTION JOURNAL
LA English
DT Article
ID SUBSTANCE USE DISORDERS; GLOBAL BURDEN; BUPRENORPHINE; METHADONE
AB The impact of COVID-19 across health services, including treatment services for people who use drugs, is emerging but likely to have a high impact. Treatment services for people who use drugs provide essential treatment services including opiate agonist treatment and needle syringe programmes alongside other important treatment programmes across all substance types including withdrawal and counselling services. Drug and alcohol hospital consultation-liaison clinicians support emergency departments and other services provided in hospital settings in efficiently managing patients who use drugs and present with other health problems. COVID-19 will impact on staff availability for work due to illness. Patients may require home isolation and quarantine periods. Ensuring ongoing supply of opiate treatment during these periods will require significant changes to how treatment is provided. The use of monthly depot buprenorphine as well as moving from a framework of supervised dosing will be required for patients on sublingual buprenorphine and methadone. Ensuring ready access to take-home naloxone for patients is crucial to reduce overdose risks. Delivery of methadone and buprenorphine to the homes of people with confirmed COVID-19 infections is likely to need to occur to support home isolation. People who use drugs are likely to be more vulnerable during the COVID-19 epidemic, due to poorer health literacy and stigma and discrimination towards this group. People who use drugs may prioritise drug use above other health concerns. Adequate supply of clean injecting equipment is important to prevent outbreaks of blood-borne viruses. Opiate users may misinterpret SARS-CoV2 symptoms as opiate withdrawal and manage this by using opioids. Ensuring people who use drugs have access to drug treatment as well as access to screening and testing for SARS-CoV2 where this is indicated is important.
C1 [Dunlop, Adrian; Lokuge, Buddhima; Masters, Debbie; Sequeira, Marcia; Hall, Michelle] Drug & Alcohol Clin Serv, Newcastle, NSW, Australia.
   [Dunlop, Adrian; Lokuge, Buddhima] Univ Newcastle, Fac Hlth, Callaghan, NSW, Australia.
   [Dunlop, Adrian; Sequeira, Marcia; Dunlop, Grace; Ezard, Nadine; Haber, Paul; Lintzeris, Nicholas] Drug & Alcohol Clin Res & Improvement Network, Surry Hills, NSW, Australia.
   [Dunlop, Adrian; Saul, Peter] John Hunter Hosp, Hunter New England Local Hlth Dist, New Lambton, NSW, Australia.
   [Ryan, John] Penington Inst, Carlton, Vic, Australia.
   [Ezard, Nadine] St Vincents Hosp, Darlinghurst, NSW, Australia.
   [Haber, Paul] Drug Hlth Serv, Camperdown, NSW, Australia.
   [Haber, Paul; Lintzeris, Nicholas] Univ Sydney, Discipline Addict Med, Camperdown, NSW, Australia.
   [Lintzeris, Nicholas] Sydney South East Local Hlth Dist, Drug & Alcohol Serv, Surry Hills, NSW, Australia.
   [Maher, Lisa] UNSW, Kirby Inst, Kensington, NSW, Australia.
RP Dunlop, A (corresponding author), Drug & Alcohol Clin Serv, Newcastle, NSW, Australia.; Dunlop, A (corresponding author), Univ Newcastle, Fac Hlth, Callaghan, NSW, Australia.; Dunlop, A (corresponding author), Drug & Alcohol Clin Res & Improvement Network, Surry Hills, NSW, Australia.; Dunlop, A (corresponding author), John Hunter Hosp, Hunter New England Local Hlth Dist, New Lambton, NSW, Australia.
EM Adrian.Dunlop@health.nsw.gov.au
OI Maher, Lisa/0000-0001-6020-6519
CR Auriacombe M, 2001, JAMA-J AM MED ASSOC, V285, P45, DOI 10.1001/jama.285.1.45
   Australian Institute of Health and Welfare, 2020, ALC TOB OTH DRUGS AU
   Centre for Population Health, 2018, NSW CLIN GUID TREATM
   Dalton CB, 2020, MED J AUSTRALIA, V212, P1
   Degenhardt L, 2018, LANCET PSYCHIAT, V5, P987, DOI 10.1016/S2215-0366(18)30337-7
   Degenhardt L, 2017, LANCET GLOB HEALTH, V5, pE1192, DOI 10.1016/S2214-109X(17)30375-3
   Degenhardt L, 2012, LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0
   Dematteis M, 2017, EXPERT OPIN PHARMACO, V18, P1987, DOI 10.1080/14656566.2017.1409722
   Dorigatti I, 2020, 4 IMP COLL LOND
   Dunlap E, 2011, DISASTER PREVENTION
   Dunlap E, 2016, CRIT CARE MED, V44
   Fazel S, 2017, ADDICTION, V112, P1725, DOI 10.1111/add.13877
   Imai N., 2020, 3 IMP COLL LOND
   Internatoinal Netowrk of People who Use Drugs, 2020, COVID 19 CRIS HARM R
   Khafaie Morteza Abdullatif, 2020, Osong Public Health Res Perspect, V11, P74, DOI 10.24171/j.phrp.2020.11.2.03
   Larance B, 2011, DRUG ALCOHOL DEPEN, V118, P265, DOI 10.1016/j.drugalcdep.2011.04.002
   Lintzeris N, 2019, CLIN GUIDELINES USE
   Neale J., 2001, INT J DRUG POLICY, V12, P353, DOI DOI 10.1016/S0955-3959(01)00097-4
   Ramirez RL, 2018, CURR OPIN PULM MED, V24, P416, DOI 10.1097/MCP.0000000000000513
   Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]
   Sandman P., 1993, RESPONDING COMMUNITY
   Schulte MT, 2013, PUBLIC HEALTH REV, V35
   Tsai J, 2020, COVID 19 POTENTIAL P
   van Boekel LC, 2013, DRUG ALCOHOL DEPEN, V131, P23, DOI 10.1016/j.drugalcdep.2013.02.018
   Vozoris NT, 2016, EUR RESPIR J, V48, P683, DOI 10.1183/13993003.01967-2015
   WHO, 2019, WHO MOD LIST ESS MED
   Wu LT, 2018, DRUG ALCOHOL DEPEN, V186, P86, DOI 10.1016/j.drugalcdep.2018.01.008
   Wu P, 2008, ALCOHOL ALCOHOLISM, V43, P706, DOI 10.1093/alcalc/agn073
   Zhou F., 2020, LANCET
NR 29
TC 20
Z9 20
U1 5
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-7517
J9 HARM REDUCT J
JI Harm Reduct. J.
PD MAY 6
PY 2020
VL 17
IS 1
AR 26
DI 10.1186/s12954-020-00370-7
PG 7
WC Substance Abuse
SC Substance Abuse
GA LO8GM
UT WOS:000533864200001
PM 32375887
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dehority, W
   Spence, D
   Dinwiddie, DL
AF Dehority, Walter
   Spence, Dominique
   Dinwiddie, Darrell L.
TI Severe Acute Respiratory Syndrome Coronavirus 2: Genomic Observations
   and Emerging Therapies
SO PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; pandemic
ID IN-VITRO; VIRUS-REPLICATION; CHLOROQUINE; HYDROXYCHLOROQUINE; DISEASE;
   INHIBITION; INFECTION; SARS
AB Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the etiologic agent of the disease COVID-19, first emerged in late December 2019 in China, and has subsequently become a pandemic with unprecedented clinical impact. The virus appears to more severely affect older individuals and those with co-morbid medical conditions, specifically those with chronic lung disease, obesity, heart failure and diabetes. Fortunately, children appear to be less severely affected, though mortality and severe disease have been reported. In addition, children's role in spreading the disease (potentially through asymptomatic shedding of the virus) remains an important area requiring further investigation. The emergence of SARS-CoV-2 has highlighted the importance of metagenomic next generation sequencing as a tool for pandemic investigation. Though no proven therapeutic options currently exist, ongoing genomic and clinical trial data may help inform the identification and development of both repurposed and novel therapeutic agents for use in this disease.
C1 [Dehority, Walter] Univ New Mexico, Sch Med, Dept Pediat, Div Infect Dis, MSC10 5590,1 Univ New Mexico, Albuquerque, NM 87131 USA.
   [Spence, Dominique; Dinwiddie, Darrell L.] Univ New Mexico, Sch Med, Clin & Translat Sci Ctr, Albuquerque, NM 87131 USA.
   [Dinwiddie, Darrell L.] Univ New Mexico, Sch Med, Dept Pediat, Albuquerque, NM 87131 USA.
RP Dehority, W (corresponding author), Univ New Mexico, Sch Med, Dept Pediat, Div Infect Dis, MSC10 5590,1 Univ New Mexico, Albuquerque, NM 87131 USA.
EM WDehority@salud.unm.edu
FU National Center for Research ResourcesUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Research Resources (NCRR); National Center for Advancing
   Translational Sciences of the National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR001449]; University of New Mexico Clinical and Translational
   Science Center
FX This project was supported in part by the National Center for Research
   Resources and the National Center for Advancing Translational Sciences
   of the National Institutes of Health through grant number UL1TR001449,
   the University of New Mexico Clinical and Translational Science Center.
CR Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   [Anonymous], 2018, SCIENCE, V362, P1140
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Borges MC, 2013, MEM I OSWALDO CRUZ, V108, P596, DOI 10.1590/S0074-02762013000500010
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Chiara M, 2020, COMP GENOMICS SUGGES, DOI [10.1101/2020.03.30.016790, DOI 10.1101/2020.03.30.016790]
   CHORIN E, 2020, NAT MED 0424, DOI DOI 10.1101/2020.04.02.20047050
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Colson P, 2020, INT J ANTIMICROB AG, DOI [10.1016/j.ijantimicag.2020.105949, DOI 10.1016/J.IJANTIMICAG.2020.105949]
   D'Alessandro S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8010085
   De Lamballerie X, 2008, VECTOR-BORNE ZOONOT, V8, P837, DOI 10.1089/vbz.2008.0049
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dowall SD, 2015, J GEN VIROL, V96, P3484, DOI 10.1099/jgv.0.000309
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   GISAID (Global Initiative on Sharing All Influenza Data), 2020, GISAID COMM DISC DIF
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Han YS, 2018, J MED VIROL, V90, P796, DOI 10.1002/jmv.25031
   INGLOT AD, 1969, J GEN VIROL, V4, P203, DOI 10.1099/0022-1317-4-2-203
   Khan M, 2010, J MED VIROL, V82, P817, DOI 10.1002/jmv.21663
   Lighter J, 2020, CLIN INFECT DIS, V71, P896, DOI 10.1093/cid/ciaa415
   Masters PS, 2013, FIELDS VIROLOGY, V6, P825
   Ooi EE, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-39
   Paton NI, 2012, JAMA-J AM MED ASSOC, V308, P353, DOI 10.1001/jama.2012.6936
   Paton NI, 2011, LANCET INFECT DIS, V11, P677, DOI 10.1016/S1473-3099(11)70065-2
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   SPERBER K, 1993, AIDS RES HUM RETROV, V9, P91, DOI 10.1089/aid.1993.9.91
   Toots M, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax5866
   Wang LF, 2015, J INTERF CYTOK RES, V35, P143, DOI 10.1089/jir.2014.0038
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   World Health Organization, 2020, SOL CLIN TRIALS COVI
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 41
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2151-321X
EI 2151-3228
J9 PEDIAT ALLER IMM PUL
JI Pediatr. Allergy Immunol. Pulmonol.
PD JUN 1
PY 2020
VL 33
IS 2
BP 49
EP 52
DI 10.1089/ped.2020.1179
EA MAY 2020
PG 4
WC Allergy; Immunology; Pediatrics; Respiratory System
SC Allergy; Immunology; Pediatrics; Respiratory System
GA LZ4WP
UT WOS:000533203900001
OA Bronze
DA 2021-01-01
ER

PT J
AU Kiyotani, K
   Toyoshima, Y
   Nemoto, K
   Nakamura, Y
AF Kiyotani, Kazuma
   Toyoshima, Yujiro
   Nemoto, Kensaku
   Nakamura, Yusuke
TI Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID CORONAVIRUS
AB To control and prevent the current COVID-19 pandemic, the development of novel vaccines is an emergent issue. In addition, we need to develop tools that can measure/monitor T-cell and B-cell responses to know how our immune system is responding to this deleterious virus. However, little information is currently available about the immune target epitopes of novel coronavirus (SARS-CoV-2) to induce host immune responses. Through a comprehensive bioinformatic screening of potential epitopes derived from the SARS-CoV-2 sequences for HLAs commonly present in the Japanese population, we identified 2013 and 1399 possible peptide epitopes that are likely to have the high affinity (<0.5%- and 2%-rank, respectively) to HLA class I and II molecules, respectively, that may induce CD8(+) and CD4(+) T-cell responses. These epitopes distributed across the structural (spike, envelope, membrane, and nucleocapsid proteins) and the nonstructural proteins (proteins corresponding to six open reading frames); however, we found several regions where high-affinity epitopes were significantly enriched. By comparing the sequences of these predicted T cell epitopes to the other coronaviruses, we identified 781 HLA-class I and 418 HLA-class II epitopes that have high homologies to SARS-CoV. To further select commonly-available epitopes that would be applicable to larger populations, we calculated population coverages based on the allele frequencies of HLA molecules, and found 2 HLA-class I epitopes covering 83.8% of the Japanese population. The findings in the current study provide us valuable information to design widely-available vaccine epitopes against SARS-CoV-2 and also provide the useful information for monitoring T-cell responses.
C1 [Kiyotani, Kazuma; Toyoshima, Yujiro; Nemoto, Kensaku; Nakamura, Yusuke] Japanese Fdn Canc Res, Canc Precis Med Ctr, Project Immunogen, Tokyo 1358550, Japan.
RP Kiyotani, K (corresponding author), Japanese Fdn Canc Res, Canc Precis Med Ctr, Project Immunogen, Tokyo 1358550, Japan.
EM kazuma.kiyotani@jfcr.or.jp
CR Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639
   Andreatta M, 2015, IMMUNOGENETICS, V67, P641, DOI 10.1007/s00251-015-0873-y
   Begovich AB, 2001, TISSUE ANTIGENS, V57, P424, DOI 10.1034/j.1399-0039.2001.057005424.x
   Cheung YK, 2007, VACCINE, V25, P6070, DOI 10.1016/j.vaccine.2007.05.025
   Hirano T., 2020, IMMUNITY
   Hirata J, 2019, NAT GENET, V51, P470, DOI 10.1038/s41588-018-0336-0
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202. Article published online before March 2002, 10.1101/gr.229202]
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Sanders JM, 2020, JAMA
   Tsao YP, 2006, BIOCHEM BIOPH RES CO, V344, P63, DOI 10.1016/j.bbrc.2006.03.152
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 20
TC 14
Z9 14
U1 1
U2 10
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD JUL
PY 2020
VL 65
IS 7
BP 569
EP 575
DI 10.1038/s10038-020-0771-5
EA MAY 2020
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA LX9MI
UT WOS:000530608000001
PM 32372051
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Topf, MC
   Shenson, JA
   Holsinger, FC
   Wald, SH
   Cianfichi, LJ
   Rosenthal, EL
   Sunwoo, JB
AF Topf, Michael C.
   Shenson, Jared A.
   Holsinger, F. Christopher
   Wald, Samuel H.
   Cianfichi, Lisa J.
   Rosenthal, Eben L.
   Sunwoo, John B.
TI Framework for prioritizing head and neck surgery during the COVID-19
   pandemic
SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND
   NECK
LA English
DT Article
DE clinical practice guidelines; COVID-19; head and neck cancer;
   SARS-CoV-2; surgical oncology
ID ACUTE RESPIRATORY SYNDROME; QUALITY METRICS; ASSOCIATION; CANCER;
   DIAGNOSIS; MORTALITY; SURVIVAL; SERVICES; TIME; RISK
AB The COVID-19 pandemic has placed an extraordinary demand on the United States health care system. Many institutions have canceled elective and non-urgent procedures to conserve resources and limit exposure. While operational definitions of elective and urgent categories exist, there is a degree of surgeon judgment in designation. In the present commentary, we provide a framework for prioritizing head and neck surgery during the pandemic. Unique considerations for the head and neck patient are examined including risk to the oncology patient, outcomes following delay in head and neck cancer therapy, and risk of transmission during otolaryngologic surgery. Our case prioritization criteria consist of four categories: urgent-proceed with surgery, less urgent-consider postpone > 30 days, less urgent-consider postpone 30 to 90 days, and case-by-case basis. Finally, we discuss our preoperative clinical pathway for transmission mitigation including defining low-risk and high-risk surgery for transmission and role of preoperative COVID-19 testing.
C1 [Topf, Michael C.; Shenson, Jared A.; Holsinger, F. Christopher; Rosenthal, Eben L.; Sunwoo, John B.] Stanford Univ, Div Head & Neck Surg, Dept Otolaryngol, 875 Blake Wilbur Dr,CC 2227, Palo Alto, CA 94304 USA.
   [Wald, Samuel H.] Stanford Univ, Dept Anesthesiol Perioperat & Pain Med, Palo Alto, CA 94304 USA.
   [Wald, Samuel H.; Cianfichi, Lisa J.] Stanford Healthcare, Dept Perioperat Serv, Stanford, CA USA.
RP Holsinger, FC (corresponding author), Stanford Univ, Div Head & Neck Surg, Dept Otolaryngol, 875 Blake Wilbur Dr,CC 2227, Palo Alto, CA 94304 USA.
EM holsinger@stanford.edu
OI Topf, Michael/0000-0002-1022-4417; Orosco, Ryan/0000-0002-7885-4327;
   Holsinger, Floyd Christopher/0000-0002-9594-1414
CR Alexander EK, 2017, THYROID, V27, P315, DOI 10.1089/thy.2016.0457
   Amit M, 2014, LARYNGOSCOPE, V124, P2837, DOI 10.1002/lary.24744
   ASTRO, COVID 19 REC INF SUM
   Chen MM, 2018, OTOLARYNG HEAD NECK, V158, P1051, DOI 10.1177/0194599817751679
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Clayman GL, 2005, J CLIN ONCOL, V23, P759, DOI 10.1200/JCO.2005.02.155
   Fujiwara RJT, 2017, HEAD NECK-J SCI SPEC, V39, P639, DOI 10.1002/hed.24608
   Givi BS, 2020, JAMA OTOLARYNGOL, DOI [10.1001/jamaoto.2020.0780, DOI 10.1001/JAMA0T0.2020.0780]
   Goel AN, 2019, HEAD NECK-J SCI SPEC, V41, P1756, DOI 10.1002/hed.25643
   Graboyes EM, 2019, JAMA OTOLARYNGOL, V145, P166, DOI 10.1001/jamaoto.2018.2716
   Graboyes EM, 2016, JAMA OTOLARYNGOL, V142, P1154, DOI 10.1001/jamaoto.2016.0657
   Graboyes EM, 2016, JAMA OTOLARYNGOL, V142, P430, DOI 10.1001/jamaoto.2015.3595
   Gu J, 2004, CANCER-AM CANCER SOC, V100, P1374, DOI 10.1002/cncr.20141
   Health NACoSaP, 2003, LEARNING SARS RENEWA
   Health UDo, 2009, UT PAND INFL HOSP IC
   Institute of Medicine, GUIDANCE ESTABLISHIN
   Ito Y, 2018, EJSO-EUR J SURG ONC, V44, P307, DOI 10.1016/j.ejso.2017.03.004
   Jeon MJ, 2017, EUR J ENDOCRINOL, V177, P25, DOI 10.1530/EJE-17-0160
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lu D, 2020, J HOSP INFECT, V104, P454, DOI 10.1016/j.jhin.2020.02.018
   Morse E, 2018, OTOLARYNG HEAD NECK, V159, P987, DOI 10.1177/0194599818779052
   Morse E, 2018, ORAL ONCOL, V82, P122, DOI 10.1016/j.oraloncology.2018.02.010
   Morse E, 2018, OTOLARYNG HEAD NECK, V159, P283, DOI 10.1177/0194599818758020
   Morse E, 2018, LARYNGOSCOPE, V128, P2751, DOI 10.1002/lary.27247
   Nakada HT, 2011, INT J INFECT CONTROL, V7, DOI [10.3396/ijic.v7i4.8154, DOI 10.3396/IJIC.V7I4.8154]
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   RAPOPORT Y, 1993, ANN ONCOL, V4, P69, DOI 10.1093/oxfordjournals.annonc.a058365
   Schull MJ, 2007, CAN MED ASSOC J, V176, P1827, DOI 10.1503/cmaj.061174
   Shin DW, 2013, ANN SURG ONCOL, V20, P2468, DOI 10.1245/s10434-013-2957-y
   Tuttle RM, 2017, JAMA OTOLARYNGOL, V143, P1015, DOI 10.1001/jamaoto.2017.1442
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Vlantis AC, 2004, LARYNGOSCOPE, V114, P171, DOI 10.1097/00005537-200401000-00032
   Vukkadala N, 2020, LARYNGOSCOPE, V130, P2537, DOI 10.1002/lary.28672
   Wong JPH, 2020, CULT HEALTH SEX, DOI 10.1080/13691058.2020.1725643
   World Health Organization, ROLL UPD COR DIS COV
   World Health Organization, MOD TRANSM VIR CAUS
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiao R, 2018, CANCER-AM CANCER SOC, V124, P1400, DOI 10.1002/cncr.31213
   Yu J, 2020, JAMA ONCOL, DOI [10.1001/jamaoncol.2020.0980, DOI 10.1001/JAMA0NC0L.2020.0980]
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 40
TC 26
Z9 27
U1 3
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1043-3074
EI 1097-0347
J9 HEAD NECK-J SCI SPEC
JI Head Neck-J. Sci. Spec. Head Neck
PD JUN
PY 2020
VL 42
IS 6
BP 1159
EP 1167
DI 10.1002/hed.26184
EA MAY 2020
PG 9
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA LU5GY
UT WOS:000530560300001
PM 32298036
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Blum, L
   Geisslinger, G
   Parnham, MJ
   Grunweller, A
   Schiffmann, S
AF Blum, Leonard
   Geisslinger, Gerd
   Parnham, Michael J.
   Gruenweller, Arnold
   Schiffmann, Susanne
TI Natural antiviral compound silvestrol modulates human monocyte-derived
   macrophages and dendritic cells
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE antiviral; cytokines; eIF4A; energy metabolism; immune modulation; RNA
   viruses; rocaglate
ID INHIBITOR SILVESTROL; PIM KINASES; IN-VITRO; TRANSLATION;
   DIFFERENTIATION; ERYTHROMYCIN; ACTIVATION; REQUIRES; INNATE; IL-6
AB Outbreaks of infections with viruses like Sars-CoV-2, Ebola virus and Zika virus lead to major global health and economic problems because of limited treatment options. Therefore, new antiviral drug candidates are urgently needed. The promising new antiviral drug candidate silvestrol effectively inhibited replication of Corona-, Ebola-, Zika-, Picorna-, Hepatis E and Chikungunya viruses. Besides a direct impact on pathogens, modulation of the host immune system provides an additional facet to antiviral drug development because suitable immune modulation can boost innate defence mechanisms against the pathogens. In the present study, silvestrol down-regulated several pro- and anti-inflammatory cytokines (IL-6, IL-8, IL-10, CCL2, CCL18) and increased TNF-alpha during differentiation and activation of M1-macrophages, suggesting that the effects of silvestrol might cancel each other out. However, silvestrol amplified the anti-inflammatory potential of M2-macrophages by increasing expression of anti-inflammatory surface markers CD206, TREM2 and reducing release of pro-inflammatory IL-8 and CCL2. The differentiation of dendritic cells in the presence of silvestrol is characterized by down-regulation of several surface markers and cytokines indicating that differentiation is impaired by silvestrol. In conclusion, silvestrol influences the inflammatory status of immune cells depending on the cell type and activation status.
C1 [Blum, Leonard; Geisslinger, Gerd] Goethe Univ Hosp Frankfurt, Inst Clin Pharmacol, Pharmazentrum Frankfurt ZAFES, Frankfurt, Germany.
   [Geisslinger, Gerd; Parnham, Michael J.; Schiffmann, Susanne] Fraunhofer Inst Mol Biol & Appl Ecol IME, Branch Translat Med & Pharmacol TMP, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.
   [Gruenweller, Arnold] Philipps Univ Marburg, Inst Pharmaceut Chem, Marburg, Germany.
RP Schiffmann, S (corresponding author), Fraunhofer Inst Mol Biol & Appl Ecol IME, Branch Translat Med & Pharmacol TMP, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.
EM susanne.schiffmann@ime.fraunhofer.de
OI Schiffmann, Susanne/0000-0001-5035-2504
FU LOEWE TMP; LOEWE TBG; LOEWE DRUID
FX LOEWE TBG; LOEWE DRUID; LOEWE TMP
CR Atri C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061801
   Azad A. K., 2014, J CYTOL MOL BIOL, V1, P1, DOI [10.13188/2325-4653.1000003, DOI 10.13188/2325-4653.1000003]
   Beharry Z, 2011, P NATL ACAD SCI USA, V108, P528, DOI 10.1073/pnas.1013214108
   Biedenkopf N, 2017, ANTIVIR RES, V137, P76, DOI 10.1016/j.antiviral.2016.11.011
   Blum L, 2018, FIGHTING ANTIMICROBI
   Bordeleau ME, 2008, J CLIN INVEST, V118, P2651, DOI 10.1172/JCI34753
   Cerezo M, 2018, NAT MED, V24, P1877, DOI 10.1038/s41591-018-0217-1
   Chen WL, 2016, BMC CANCER, V16, DOI 10.1186/s12885-015-1988-0
   Chenivesse C, 2018, CYTOKINE, V109, P52, DOI 10.1016/j.cyto.2018.01.023
   Chomarat P, 2000, NAT IMMUNOL, V1, P510, DOI 10.1038/82763
   Collin M, 2013, IMMUNOLOGY, V140, P22, DOI 10.1111/imm.12117
   Corinti S, 2001, J IMMUNOL, V166, P4312, DOI 10.4049/jimmunol.166.7.4312
   Diskin C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00270
   Elgner F, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040149
   Fabriek BO, 2009, BLOOD, V113, P887, DOI 10.1182/blood-2008-07-167064
   Gazi U, 2009, IMMUNOBIOLOGY, V214, P554, DOI 10.1016/j.imbio.2008.11.004
   Gerold Gisa, 2013, Curr Hepat Rep, V12, P200, DOI 10.1007/s11901-013-0187-1
   Glitscher M, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10060301
   Henss L, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110592
   Hillmer EJ, 2016, CYTOKINE GROWTH F R, V31, P1, DOI 10.1016/j.cytogfr.2016.05.001
   Huang Q, 2017, SCI REP-UK, V7, DOI 10.1038/srep39566
   Jackson SH, 2004, J IMMUNOL, V172, P2307, DOI 10.4049/jimmunol.172.4.2307
   Kawasaki S, 1998, ANTIMICROB AGENTS CH, V42, P1499, DOI 10.1128/AAC.42.6.1499
   KHAIR OA, 1995, EUR RESPIR J, V8, P1451
   Kim S, 2007, ANTICANCER RES, V27, P2175
   Kogure T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076136
   Kok SH, 2009, ARTHRITIS RHEUM-US, V60, P1451, DOI 10.1002/art.24452
   Liang S, 2008, P NATL ACAD SCI USA, V105, P8357, DOI 10.1073/pnas.0803341105
   Lucas DM, 2009, BLOOD, V113, P4656, DOI 10.1182/blood-2008-09-175430
   Mason CP, 2015, MOLECULES, V20, P2229, DOI 10.3390/molecules20022229
   McCormick SM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00549
   Meixlsperger S, 2013, BLOOD, V121, P5034, DOI 10.1182/blood-2012-12-473413
   Muller C, 2018, ANTIVIR RES, V150, P123, DOI 10.1016/j.antiviral.2017.12.010
   Muller KH, 2012, TRENDS PHARMACOL SCI, V33, P89, DOI 10.1016/j.tips.2011.10.004
   Muraille E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00603
   ODA H, 1994, CHEST, V106, P1116, DOI 10.1378/chest.106.4.1116
   Patton JT, 2015, ONCOTARGET, V6, P2693, DOI 10.18632/oncotarget.2098
   Regis G, 2008, SEMIN CELL DEV BIOL, V19, P351, DOI 10.1016/j.semcdb.2008.06.004
   Sadlish H, 2013, ACS CHEM BIOL, V8, P1519, DOI 10.1021/cb400158t
   Savill John, 2000, Kidney and Blood Pressure Research, V23, P173
   Schatz JH, 2011, J EXP MED, V208, P1799, DOI 10.1084/jem.20110846
   Shaimerdenova M, 2017, INFECT AGENTS CANCER, V12, DOI 10.1186/s13027-017-0128-7
   Shiratori H, 2018, EUR J PHARMACOL, V833, P328, DOI 10.1016/j.ejphar.2018.06.017
   Solari R, 2015, EUR J PHARMACOL, V763, P169, DOI 10.1016/j.ejphar.2015.05.018
   Song JH, 2015, ONCOGENE, V34, P3728, DOI 10.1038/onc.2014.306
   Sun Jian, 2015, Biochem Biophys Rep, V4, P397, DOI 10.1016/j.bbrep.2015.11.003
   van der Voort R, 2005, J LEUKOCYTE BIOL, V77, P739, DOI 10.1189/jlb.0804435
   Vrancic M, 2012, BRIT J PHARMACOL, V165, P1348, DOI 10.1111/j.1476-5381.2011.01576.x
   WHO Ebola Response Team, 2015, NEW ENGL J MED, V372, P584, DOI 10.1056/NEJMc1414992
   Wolfe AL, 2014, NATURE, V513, P65, DOI 10.1038/nature13485
   Yu CI, 2014, J IMMUNOL, V193, P4335, DOI 10.4049/jimmunol.1401159
NR 51
TC 1
Z9 1
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUN
PY 2020
VL 24
IS 12
BP 6988
EP 6999
DI 10.1111/jcmm.15360
EA MAY 2020
PG 12
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA LY6PW
UT WOS:000530485900001
PM 32374474
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Testa, S
   Prandoni, P
   Paoletti, O
   Morandini, R
   Tala, M
   Dellanoce, C
   Giorgi-Pierfranceschi, M
   Betti, M
   Danzi, GB
   Pan, A
   Palareti, G
AF Testa, Sophie
   Prandoni, Paolo
   Paoletti, Oriana
   Morandini, Rossella
   Tala, Maurizio
   Dellanoce, Claudia
   Giorgi-Pierfranceschi, Matteo
   Betti, Monia
   Battista Danzi, Gian
   Pan, Angelo
   Palareti, Gualtiero
TI Direct oral anticoagulant plasma levels' striking increase in severe
   COVID-19 respiratory syndrome patients treated with antiviral agents:
   The Cremona experience
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE anticoagulant; antiviral agents; COVID-19; DOAC; plasma level
ID THERAPY ANTITHROMBOTIC THERAPY; ED AMERICAN-COLLEGE; RIVAROXABAN;
   THROMBOSIS; PREVENTION
AB Background Antiviral drugs are administered in patients with severe COVID-19 respiratory syndrome, including those treated with direct oral anticoagulants (DOACs). Concomitant administration of antiviral agents has the potential to increase their plasma concentration. A series of patients managed in the Cremona Thrombosis Center were admitted at Cremona Hospital for SARS-CoV-2 and started antiviral drugs without stopping DOAC therapy. DOAC plasma levels were measured in hospital and results compared with those recorded before hospitalization.
   Methods All consecutive patients on DOACs were candidates for administration of antiviral agents (lopinavir, ritonavir, or darunavir). Plasma samples for DOAC measurement were collected 2to 4 days after starting antiviral treatment, at 12 hours from the last dose intake in patients on dabigatran and apixaban, and at 24 hours in those on rivaroxaban and edoxaban. For each patient, C-trough DOAC level, expressed as ng/mL, was compared with the one measured before hospitalization.
   Results Of the 1039 patients hospitalized between February 22 and March 15, 2020 with COVID-19 pneumonia and candidates for antiviral therapy, 32 were on treatment with a DOAC. DOAC was stopped in 20 and continued in the remaining 12. On average, C-trough levels were 6.14 times higher during hospitalization than in the pre-hospitalization period.
   Conclusion DOAC patients treated with antiviral drugs show an alarming increase in DOAC plasma levels. In order to prevent bleeding complications, we believe that physicians should consider withholding DOACs from patients with SARS-CoV-2 and replacing them with alternative parenteral antithrombotic strategies for as long as antiviral agents are deemed necessary and until discharge.
C1 [Testa, Sophie; Paoletti, Oriana; Morandini, Rossella; Tala, Maurizio; Dellanoce, Claudia] Cremona Hosp, Haemostasis & Thrombosis Ctr, Viale Concordia 1, Cremona 26100, Italy.
   [Prandoni, Paolo; Palareti, Gualtiero] Arianna Anticoagulaz Fdn, Bologna, Italy.
   [Giorgi-Pierfranceschi, Matteo] Cremona Hosp, Div Internal Med, Cremona, Italy.
   [Betti, Monia] Cremona Hosp, Div Pneumol, Cremona, Italy.
   [Battista Danzi, Gian] Cremona Hosp, Div Cardiol, Cremona, Italy.
   [Pan, Angelo] Cremona Hosp, Div Infect Dis, Cremona, Italy.
RP Testa, S (corresponding author), Cremona Hosp, Haemostasis & Thrombosis Ctr, Viale Concordia 1, Cremona 26100, Italy.
EM s.testa@asst-cremona.it
RI Danzi, Gian Battista/P-2244-2016; Danzi, Gian Battista/ABF-6413-2020
OI Danzi, Gian Battista/0000-0003-0897-8006; Danzi, Gian
   Battista/0000-0003-0897-8006
CR Ageno W, 2012, CHEST, V141, pE44S, DOI 10.1378/chest.11-2292
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   (EMA) EMA, PRAD SUMM PROD CHAR
   (EMA) EMA, EL SUMM PROD CHAR
   (EMA) EMA, LIX SUMM PROD CHAR
   (EMA) EMA, XARELTO SUMMARY PROD
   Foerster KI, 2020, CLIN PHARMACOKINET, V59, P967, DOI 10.1007/s40262-020-00879-x
   Gong IY, 2013, CAN J CARDIOL, V29, pS24, DOI 10.1016/j.cjca.2013.04.002
   Gosselin RC, 2018, THROMB HAEMOSTASIS, V118, P437, DOI 10.1055/s-0038-1627480
   Holbrook A, 2012, CHEST, V141, pE152S, DOI 10.1378/chest.11-2295
   Lai ChihCheng, 2020, International Journal of Antimicrobial Agents, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Mueck W, 2013, BRIT J CLIN PHARMACO, V76, P455, DOI 10.1111/bcp.12075
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Reilly PA, 2014, J AM COLL CARDIOL, V63, P321, DOI 10.1016/j.jacc.2013.07.104
   Steffel J, 2018, EUR HEART J, V39, P1330, DOI 10.1093/eurheartj/ehy136
   Testa S, 2018, J THROMB HAEMOST, V16, P842, DOI 10.1111/jth.14001
   Testa S, 2019, J THROMB HAEMOST, V17, P1064, DOI 10.1111/jth.14457
   Testa S, 2016, THROMB RES, V137, P178, DOI 10.1016/j.thromres.2015.12.001
   Tripodi A, 2018, BLOOD TRANSFUS-ITALY, V16, P462, DOI 10.2450/2017.0124-17
   World Health Organization, 2020, COR DIS 2019 COVID 1
NR 22
TC 42
Z9 43
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD JUN
PY 2020
VL 18
IS 6
BP 1320
EP 1323
DI 10.1111/jth.14871
EA MAY 2020
PG 4
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA LU2DH
UT WOS:000530441900001
PM 32329231
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Asakura, H
   Ogawa, H
AF Asakura, Hidesaku
   Ogawa, Haruhiko
TI Potential of heparin and nafamostat combination therapy for COVID-19
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Letter
C1 [Asakura, Hidesaku] Kanazawa Univ Hosp, Dept Hematol, Kanazawa, Ishikawa, Japan.
   [Ogawa, Haruhiko] Kanazawa Univ, Dept Environm & Prevent Med, Kanazawa, Ishikawa, Japan.
RP Asakura, H (corresponding author), Kanazawa Univ Hosp, Dept Hematol, Kanazawa, Ishikawa, Japan.
EM hasakura@staff.kanazawa-u.ac.jp
CR AOYAMA T, 1984, JPN J PHARMACOL, V35, P203, DOI 10.1254/jjp.35.203
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Asakura H, 2014, J INTENSIVE CARE, V2, DOI 10.1186/2052-0492-2-20
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Inoue J, IDENTIFICATION EXIST
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 9
TC 24
Z9 24
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD JUN
PY 2020
VL 18
IS 6
BP 1521
EP 1522
DI 10.1111/jth.14858
EA MAY 2020
PG 2
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA LU2DH
UT WOS:000530392000001
PM 32302456
OA Bronze
DA 2021-01-01
ER

PT J
AU Dziedzic, A
   Wojtyczka, R
AF Dziedzic, Arkadiusz
   Wojtyczka, Robert
TI The impact of coronavirus infectious disease 19 (COVID-19) on oral
   health
SO ORAL DISEASES
LA English
DT Article; Early Access
DE COVID-19; immunopathology; oral health; oral medicine; SARS-CoV-2
   coronavirus; therapy
ID SARS; DRUGS
AB Health services across the world face an unprecedented situation as a result of a global COVID-19 outbreak. Urgent joined research efforts regarding the SARS-COV-2 rapid tests, accurate diagnosis, especially early recognition, and effective treatment of life-threatening complications would be highly desirable for humanity and medical workforce all over the world that try to combat a current global pandemic threat. Due to indirect complex effect, intensified COVID-19 therapies and multi-drug treatment, it is believed that some oral conditions could be aggravated by COVID-19 disease, particularly those with autoimmune aetiology, linked to compromised immune system or long-term pharmacotherapy.
C1 [Dziedzic, Arkadiusz] Med Univ Siles, Dept Conservat Dent Endodont, Pl Akad 17, PL-41902 Katowice, Poland.
   [Wojtyczka, Robert] Med Univ Silesia, Sch Pharm, Dept Microbiol & Virol, Sosnowiec, Poland.
   [Wojtyczka, Robert] Med Univ Silesia, Div Lab Med Sosnowiec, Sosnowiec, Poland.
RP Dziedzic, A (corresponding author), Med Univ Siles, Dept Conservat Dent Endodont, Pl Akad 17, PL-41902 Katowice, Poland.
EM adziedzic@sum.edu.pl
RI Dziedzic, Arkadiusz/I-3850-2019
OI Dziedzic, Arkadiusz/0000-0003-0022-8382; Wojtyczka, Robert
   Dariusz/0000-0002-0334-0938
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Jensen JUS, 2015, CRIT CARE MED, V43, P594, DOI 10.1097/CCM.0000000000000746
   Lovato A, 2020, AM J OTOLARYNG, V41, DOI 10.1016/j.amjoto.2020.102474
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1252
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Pubchem, 2020, ROT
   Sabino-Silva R, 2020, CLIN ORAL INVEST, V24, P1619, DOI 10.1007/s00784-020-03248-x
   SAYBURN A, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1206
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Widegren H, 2011, RESP MED, V105, P997, DOI 10.1016/j.rmed.2010.12.021
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
NR 20
TC 11
Z9 11
U1 4
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1354-523X
EI 1601-0825
J9 ORAL DIS
JI Oral Dis.
DI 10.1111/odi.13359
EA MAY 2020
PG 4
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA LJ9MZ
UT WOS:000530486100001
PM 32304276
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Salomaa, S
   Cardis, E
   Bouffler, SD
   Atkinson, MJ
   Hamada, N
AF Salomaa, Sisko
   Cardis, Elisabeth
   Bouffler, Simon D.
   Atkinson, Michael J.
   Hamada, Nobuyuki
TI Low dose radiation therapy for COVID-19 pneumonia: is there any
   supportive evidence?
SO INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
LA English
DT Article
DE COVID-19; pneumonia; low dose radiation therapy; lung cancer;
   circulatory disease
ID IONIZING-RADIATION; RADIOTHERAPY; INACTIVATION; IRRADIATION; MORTALITY;
   EXPOSURE; DISEASE
C1 [Salomaa, Sisko] Univ Eastern Finland, Dept Environm & Biol Sci, Kuopio, Finland.
   [Salomaa, Sisko] STUK Radiat & Nucl Safety Author, Helsinki, Finland.
   [Cardis, Elisabeth] Barcelona Inst Global Hlth ISGlobal, Barcelona Biomed Res Pk PRBB, Campus Mar, Barcelona, Spain.
   [Cardis, Elisabeth] Univ Pompeu Fabra, Barcelona, Spain.
   [Cardis, Elisabeth] Carlos III Inst Hlth, Consortium Biomed Res Epidemiol & Publ Hlth CIBER, Madrid, Spain.
   [Bouffler, Simon D.] Publ Hlth England, Ctr Radiat Chem & Environm Hazards, Didcot, Oxon, England.
   [Atkinson, Michael J.] Helmholtz Ctr Munich, Natl Res Ctr Hlth & Environm, Inst Radiat Biol, Neuherberg, Germany.
   [Hamada, Nobuyuki] Cent Res Inst Elect Power Ind CRIEPI, Radiat Safety Res Ctr, Nucl Technol Res Lab, 2-11-1 Iwado Kita, Komae, Tokyo 2018511, Japan.
RP Hamada, N (corresponding author), Cent Res Inst Elect Power Ind CRIEPI, Radiat Safety Res Ctr, Nucl Technol Res Lab, 2-11-1 Iwado Kita, Komae, Tokyo 2018511, Japan.
EM hamada-n@criepi.denken.or.jp
RI Atkinson, Michael/AAU-5127-2020; Cardis, Elisabeth/C-3904-2017
OI Atkinson, Michael/0000-0003-3358-2089; Hamada,
   Nobuyuki/0000-0003-2518-6131; Cardis, Elisabeth/0000-0003-0999-6839
FU Spanish Ministry of Science, Innovation and Universities through the
   'Centro de Excelencia Severo Ochoa 2019-2023' Program
   [CEX2018-000806-S]; Generalitat de Catalunya through the CERCA Program
FX The authors thank Drs Mark P. Little (NCI, USA) and Dorthe Schaue (UCLA,
   USA) for helpful discussion. ISGlobal acknowledges support from the
   Spanish Ministry of Science, Innovation and Universities through the
   'Centro de Excelencia Severo Ochoa 2019-2023' Program
   (CEX2018-000806-S), and support from the Generalitat de Catalunya
   through the CERCA Program.
CR A Ghadimi-Moghadam, 2020, J Biomed Phys Eng, V10, P241, DOI 10.31661/jbpe.v0i0.2003-1085
   Averbeck D, 2018, MUTAT RES-REV MUTAT, V776, P46, DOI 10.1016/j.mrrev.2018.04.001
   Calabrese Edward J., 2013, Yale Journal of Biology and Medicine, V86, P555
   Castillo R, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-74
   Chaudhuri AA, 2016, RADIOTHER ONCOL, V119, P454, DOI 10.1016/j.radonc.2016.05.007
   Chua F., 2020, LANCET RESP MED
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Driggin E, 2020, J AM COLL CARDIOL
   DUBIN IN, 1946, AM J ROENTGENOL, V55, P478
   Feldmann F, 2019, AM J TROP MED HYG, V100, P1275, DOI 10.4269/ajtmh.18-0937
   FRIED CARL, 1941, RADIOLOGY, V37, P197
   Hamada Nobuyuki, 2011, Curr Mol Pharmacol, V4, P79
   Hope MD, 2020, LANCET, V395, P1189, DOI 10.1016/S0140-6736(20)30728-5
   Huang Y, 2020, LANCET INFECT DIS
   Jain V, 2018, CANCERS, V10, DOI 10.3390/cancers10070222
   Kirkby C, 2020, RADIOTHER ONCOL
   Kumar M, 2015, J VIROL METHODS, V223, P13, DOI 10.1016/j.jviromet.2015.07.002
   Lieberman LM, 1941, AM J MED SCI, V201, P92
   Little MP, 2008, RADIAT RES, V169, P99, DOI 10.1667/RR1070.1
   Little MP, 2016, MUTAT RES-REV MUTAT, V770, P299, DOI 10.1016/j.mrrev.2016.07.008
   Little MP, 2012, ENVIRON HEALTH PERSP, V120, P1503, DOI 10.1289/ehp.1204982
   Lu C.C., 2020, J CHIN MED ASS
   Manning CM, 2013, INT J RADIAT ONCOL, V86, P128, DOI 10.1016/j.ijrobp.2012.10.019
   Mehta SK, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102961
   Misra RS, 2015, RADIAT RES, V184, P3, DOI 10.1667/RR13917.1
   Onoda J M, 1999, Pathol Oncol Res, V5, P49, DOI 10.1053/paor.1999.0049
   Petit SF, 2011, INT J RADIAT ONCOL, V81, P698, DOI 10.1016/j.ijrobp.2010.06.016
   Poon LLM, 2004, LANCET INFECT DIS, V4, P663, DOI 10.1016/S1473-3099(04)01172-7
   Schroder S, 2018, INT J RADIAT BIOL, V95, P23, DOI 10.1080/09553002.2018.1486515
   Seegenschmiedt MH, 2015, BRIT J RADIOL, V88, DOI 10.1259/bjr.20150080
   UKCDR, 2020, COVID 19 RES PROJ TR
   United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), 2008, UNSCEAR 2006 REP
   World Health Organization, 2020, INT GUID, DOI 10.15585/mmwr.mm6942a5
   World Health Organization, 2020, COR DIS COVID 2019 S
   Zumla A, 2015, LANCET, V386, P995, DOI 10.1016/S0140-6736(15)60454-8
NR 35
TC 11
Z9 11
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0955-3002
EI 1362-3095
J9 INT J RADIAT BIOL
JI Int. J. Radiat. Biol.
PD OCT 2
PY 2020
VL 96
IS 10
BP 1224
EP 1227
DI 10.1080/09553002.2020.1762020
EA MAY 2020
PG 4
WC Biology; Nuclear Science & Technology; Radiology, Nuclear Medicine &
   Medical Imaging
SC Life Sciences & Biomedicine - Other Topics; Nuclear Science &
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA NW7JQ
UT WOS:000532446600001
PM 32338559
OA Bronze
DA 2021-01-01
ER

PT J
AU Aanouz, I
   Belhassan, A
   El-Khatabi, K
   Lakhlifi, T
   El-Idrissi, M
   Bouachrine, M
AF Aanouz, I.
   Belhassan, A.
   El-Khatabi, K.
   Lakhlifi, T.
   El-Idrissi, M.
   Bouachrine, M.
TI Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main
   protease: Computational investigations
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Molecular docking; CoV-2019; natural herbal; crocin; digitoxigenin;
   beta-eudesmol
ID ACUTE RESPIRATORY SYNDROME; DOCKING
AB The new Corona-virus, recently called the severe acute respiratory syndrome Coronavirus (SARS-CoV-2) appears for the first time in China and more precisely in Wuhan (December 2019). This disease can be fatal. Seniors, and people with other medical conditions (diabetes, heart disease horizontal ellipsis ), may be more vulnerable and become seriously ill. This is why research into drugs to treat this infection remains essential in several research laboratories. Natural herbal remedies have long been the main, if not the only, remedy in the oral tradition for treating illnesses. Modern medicine has known its success thanks to traditional medicine, the effectiveness of which derives from medicinal plants. The objective of this study is to determine if the components of natural origin have an anti-viral effect and which can prevent humans from infection by this coronavirus using the most reliable method is molecular docking, which used to find the interaction between studied molecules and the protein, in our case we based on the inhibitor of Coronavirus (nCoV-2019) main protease. The results of molecular docking showed that among 67 molecules of natural origin, three molecules (Crocin, Digitoxigenin, and beta-Eudesmol) are proposed as inhibitors against the coronavirus based on the energy types of interaction between these molecules and studied protein.
   [GRAPHICS]
   .
C1 [Aanouz, I.; Belhassan, A.; El-Khatabi, K.; Lakhlifi, T.; El-Idrissi, M.; Bouachrine, M.] Moulay Ismail Univ Meknes, Mol Chem & Nat Subst Lab, Fac Sci, Meknes, Morocco.
   [Bouachrine, M.] Sultan Moulay Sliman Univ, EST Khenifra, Khenifra, Morocco.
RP Bouachrine, M (corresponding author), Moulay Ismail Univ Meknes, Mol Chem & Nat Subst Lab, Fac Sci, Meknes, Morocco.
EM m.bouachrine@umi.ac.ma
RI BelHassan, Assia/AAQ-1377-2020
OI BelHassan, Assia/0000-0002-4447-7308; Bouachrine,
   Mohammed/0000-0002-8901-047X
CR Adnan A., 2019, UTILISATION METHODES
   Astani A, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep187
   Boff L, 2019, EUR J MED CHEM, V167, P546, DOI 10.1016/j.ejmech.2019.01.076
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen Z, 2004, PHYTOTHER RES, V18, P592, DOI 10.1002/ptr.1485
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   G. O. of N. H. Committee Office of State Administration of Traditional Chinese Medicine, 2020, NOT ISS PROGR DIAGN
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2017, CLIN CHEST MED, V38, P71, DOI 10.1016/j.ccm.2016.11.007
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Pilot P, 2016, DASSAULT SYSTEMES BI
   Richman D.D., 2016, CLIN VIROLOGY
   Schwartz DA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020194
   Soleymani S, 2018, CURR DRUG DELIV, V15, P698, DOI 10.2174/1567201814666171129210654
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 21
TC 85
Z9 85
U1 9
U2 18
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1758790
EA MAY 2020
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LM7FX
UT WOS:000532415200001
PM 32306860
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Elfiky, AA
AF Elfiky, Abdo A.
TI SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico
   perspective
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; RdRp; molecular docking; molecular dynamics
   simulation; drug repurposing
ID MOLECULAR-DYNAMICS; DOCKING; CORONAVIRUS; BINDING; DRUGS; OPTIMIZATION;
   INHIBITORS; IDX-184; MODELS
AB New treatment against SARS-CoV-2 now is a must. Nowadays, the world encounters a huge health crisis by the COVID-19 viral infection. Nucleotide inhibitors gave a lot of promising results in terms of its efficacy against different viral infections. In this work, molecular modeling, docking, and dynamics simulations are used to build a model for the viral protein RNA-dependent RNA polymerase (RdRp) and test its binding affinity to some clinically approved drugs and drug candidates. Molecular dynamics is used to equilibrate the system upon binding calculations to ensure the successful reproduction of previous results, to include the dynamics of the RdRp, and to understand how it affects the binding. The results show the effectiveness of Sofosbuvir, Ribavirin, Galidesivir, Remdesivir, Favipiravir, Cefuroxime, Tenofovir, and Hydroxychloroquine, in binding to SARS-CoV-2 RdRp. Additionally, Setrobuvir, YAK, and IDX-184, show better results, while four novel IDX-184 derivatives show promising results in attaching to the SARS-CoV-2 RdRp. There is an urgent need to specify drugs that can selectively bind and subsequently inhibit SARS-CoV-2 proteins. The availability of a punch of FDA-approved anti-viral drugs can help us in this mission, aiming to reduce the danger of COVID-19. The compounds 2 and 3 may tightly bind to the SARS-CoV-2 RdRp and so may be successful in the treatment of COVID-19.
C1 [Elfiky, Abdo A.] Cairo Univ, Fac Sci, Dept Biophys, Giza, Egypt.
RP Elfiky, AA (corresponding author), Cairo Univ, Fac Sci, Dept Biophys, Giza, Egypt.
EM abdo@sci.cu.edu.eg
RI Mohamed, Abdo/H-3595-2019
OI Mohamed, Abdo/0000-0003-4600-6240
FU Abdus Salam International Center for Theoretical Physics (ICTP),
   Trieste, Italy
FX MDS calculations are conducted on the supercomputing facility of the
   Bibliotheca Alexandrina, Alexandria, Egypt. This work is done during the
   Junior associate award granted to the author for the period 2016-2021
   from the Abdus Salam International Center for Theoretical Physics
   (ICTP), Trieste, Italy.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101615
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa008
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4
   Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8
   Elfiky AA, 2018, SAR QSAR ENVIRON RES, V29, P409, DOI 10.1080/1062936X.2018.1454981
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Elfiky AA, 2019, LIFE SCI, V238, DOI 10.1016/j.lfs.2019.116958
   Elfiky AA, 2019, MED CHEM, V15, P130, DOI 10.2174/1573406414666181015152511
   Elfiky AA, 2017, FUTURE VIROL, V12, P720, DOI 10.2217/fvl-2017-0081
   Elfiky AA, 2018, J MED VIROL, V90, P13, DOI 10.1002/jmv.24934
   Elfiky AA, 2017, FUTURE VIROL, V12, P339, DOI 10.2217/fvl-2017-0027
   Elfiky AA, 2017, J MED VIROL, V89, P1040, DOI 10.1002/jmv.24736
   Elfiky AA, 2016, J MED VIROL, V88, P2044, DOI 10.1002/jmv.24678
   Elfiky AA, 2016, MED CHEM RES, V25, P1005, DOI 10.1007/s00044-016-1533-y
   Elfiky AA, 2013, PROTEIN J, V32, P75, DOI 10.1007/s10930-013-9462-9
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Ganesan A, 2017, EXPERT OPIN DRUG DIS, V12, P407, DOI 10.1080/17460441.2017.1291628
   Gao Y., 2020, STRUCTURE RNA DEPEND, DOI [10.1101/2020.03.16.993386, DOI 10.1101/2020.03.16.993386]
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Ismail AM, 2020, J MOL RECOGNIT, V33, DOI 10.1002/jmr.2821
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   Leach A. R., 2001, MOL MODELLING PRINCI
   LII JH, 1989, J AM CHEM SOC, V111, P8576, DOI 10.1021/ja00205a003
   Lythgoe MP, 2020, TRENDS PHARM SCI
   Mark P, 2001, J PHYS CHEM A, V105, P9954, DOI 10.1021/jp003020w
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   NCBI, 2020, NAT CTR BIOT INF NCB
   Organization WH, 2016, MIDDL E RESP SYNDR C
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Parr J., 2020, PNEUMONIA CHINA LACK
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   SAVES, 2020, STRUCT AN VER SERV W
   Stewart JJP, 2007, J MOL MODEL, V13, P1173, DOI 10.1007/s00894-007-0233-4
   Summers KL, 2012, BIOCHEM BIOPH RES CO, V425, P485, DOI 10.1016/j.bbrc.2012.07.141
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   World Health Organization, 2020, LAB TEST HUM SUSP CA
   World Health Organization, 2020, INF PREV CONTR HLTH
   World Health Organization (WHO), 2020, SURV CAS DEF HUM INF
   Yang L., 2020, CHINA CONFIRMS HUMAN
NR 60
TC 27
Z9 27
U1 6
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1761882
EA MAY 2020
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LM7BF
UT WOS:000532403000001
PM 32338164
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Joshi, RS
   Jagdale, SS
   Bansode, SB
   Shankar, SS
   Tellis, MB
   Pandya, VK
   Chugh, A
   Giri, AP
   Kulkarni, MJ
AF Joshi, Rakesh S.
   Jagdale, Shounak S.
   Bansode, Sneha B.
   Shankar, S. Shiva
   Tellis, Meenakshi B.
   Pandya, Vaibhav Kumar
   Chugh, Anita
   Giri, Ashok P.
   Kulkarni, Mahesh J.
TI Discovery of potential multi-target-directed ligands by targeting
   host-specific SARS-CoV-2 structurally conserved main protease
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Coronavirus; COVID-19; hACE-2; MPro; multi-target-directed ligand;
   protease inhibitor; RdRp; SARS-CoV-2 virus
ID EPSILON-VINIFERIN; CORONAVIRUS; VISUALIZATION; RESVERATROL; FLAVONOIDS;
   INHIBITORS; SERVER
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in the current COVID-19 pandemic. Worldwide this disease has infected over 2.5 million individuals with a mortality rate ranging from 5 to 10%. There are several efforts going on in the drug discovery to control the SARS-CoV-2 viral infection. The main protease (M-Pro) plays a critical role in viral replication and maturation, thus can serve as the primary drug target. To understand the structural evolution of M-Pro, we have performed phylogenetic and Sequence Similarity Network analysis, that depicted divergence of Coronaviridae M-Pro in five clusters specific to viral hosts. This clustering was corroborated with the comparison of M-Pro structures. Furthermore, it has been observed that backbone and binding site conformations are conserved despite variation in some of the residues. These attributes can be exploited to repurpose available viral protease inhibitors against SARS-CoV-2 M-Pro. In agreement with this, we performed screening of similar to 7100 molecules including active ingredients present in the Ayurvedic anti-tussive medicines, anti-viral phytochemicals and synthetic anti-virals against SARS-CoV-2 M-Pro as the primary target. We identified several natural molecules like delta-viniferin, myricitrin, taiwanhomoflavone A, lactucopicrin 15-oxalate, nympholide A, afzelin, biorobin, hesperidin and phyllaemblicin B that strongly binds to SARS-CoV-2 M-Pro. Intrestingly, these molecules also showed strong binding with other potential targets of SARS-CoV-2 infection like viral receptor human angiotensin-converting enzyme 2 (hACE-2) and RNA dependent RNA polymerase (RdRp). We anticipate that our approach for identification of multi-target-directed ligand will provide new avenues for drug discovery against SARS-CoV-2 infection. Communicated by Ramaswamy H. Sarma
C1 [Joshi, Rakesh S.; Jagdale, Shounak S.; Bansode, Sneha B.; Shankar, S. Shiva; Tellis, Meenakshi B.; Pandya, Vaibhav Kumar; Giri, Ashok P.; Kulkarni, Mahesh J.] Natl Chem Lab, Biochem Sci Div, CSIR, Pune 411008, Maharashtra, India.
   [Joshi, Rakesh S.; Shankar, S. Shiva; Giri, Ashok P.; Kulkarni, Mahesh J.] Acad Sci & Innovat Res AcSIR, Ghaziabad, India.
   [Tellis, Meenakshi B.] Savitribai Phule Pune Univ, Dept Bot, Pune, Maharashtra, India.
   [Chugh, Anita] INTOX Private Ltd, Pune, Maharashtra, India.
RP Joshi, RS; Giri, AP; Kulkarni, MJ (corresponding author), Natl Chem Lab, Biochem Sci Div, CSIR, Pune 411008, Maharashtra, India.
EM rs.joshi@ncl.res.in; ap.giri@ncl.res.in; mj.kulkarni@ncl.res.in
OI Jagdale, Shounak/0000-0003-0254-2180; Pandya,
   Vaibhav/0000-0002-8500-9009
FU Council of Scientific and Industrial Research (CSIR), New Delhi,
   IndiaCouncil of Scientific & Industrial Research (CSIR) - India;
   CSIRNational Chemical Laboratory, Pune, India
FX The project work is supported by the research grant from the Council of
   Scientific and Industrial Research (CSIR), New Delhi, India and
   CSIRNational Chemical Laboratory, Pune, India.
CR Amirian ES, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100128
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Aresta A, 2003, J AGR FOOD CHEM, V51, P5232, DOI 10.1021/jf034385r
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Bischoff TA, 2004, J ETHNOPHARMACOL, V95, P455, DOI 10.1016/j.jep.2004.06.031
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Daino GL, 2018, BIOCHEMISTRY-US, V57, P6367, DOI 10.1021/acs.biochem.8b00892
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Elegami AA, 2003, PHYTOCHEMISTRY, V63, P727, DOI 10.1016/S0031-9422(03)00238-3
   Fahmi I., 2020, COVID19 CORONAVIRUS, V2019, P1
   Fry H., 2020, NATURE, V579, P482
   Gao Y., 2020, SCIENCE, V7498, P1
   Georgiev V, 2014, NUTRIENTS, V6, P391, DOI 10.3390/nu6010391
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Halary S, 2010, P NATL ACAD SCI USA, V107, P127, DOI 10.1073/pnas.0908978107
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holm L, 2010, NUCLEIC ACIDS RES, V38, pW545, DOI 10.1093/nar/gkq366
   Imbert I, 2006, EMBO J, V25, P4933, DOI 10.1038/sj.emboj.7601368
   Jamroz M, 2013, NUCLEIC ACIDS RES, V41, pW427, DOI 10.1093/nar/gkt332
   Kayikci M, 2018, NAT STRUCT MOL BIOL, V25, P185, DOI 10.1038/s41594-017-0019-z
   Keum YS, 2012, BIOCHEM PHARMACOL, V84, P1351, DOI 10.1016/j.bcp.2012.08.012
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kuhn JH, 2004, CELL MOL LIFE SCI, V61, P2738, DOI 10.1007/s00018-004-4242-5
   Kuo YH, 2002, CHEM PHARM BULL, V50, P1607, DOI 10.1248/cpb.50.1607
   Lee S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100890
   Li WM, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104714
   Lo HP, 2016, SCI REP-UK, V6, DOI 10.1038/srep22088
   Manual C. U., 2018, CYTOSCAPE USER MANUA
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Ortega JT, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0183-6
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pflieger A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081184
   Salata C, 2019, PATHOG DIS, V77, DOI 10.1093/femspd/ftaa006
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Stefanidou M, 2012, ANTIMICROB AGENTS CH, V56, P4381, DOI 10.1128/AAC.00399-12
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vitrac X, 2005, J AGR FOOD CHEM, V53, P5664, DOI 10.1021/jf050122g
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yu B, 2018, PHARMACOL RES, V129, P453, DOI 10.1016/j.phrs.2017.11.016
   Yu MS, 2012, BIOORG MED CHEM LETT, V22, P4049, DOI 10.1016/j.bmcl.2012.04.081
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 50
TC 81
Z9 81
U1 13
U2 23
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1760137
EA MAY 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LM5MG
UT WOS:000532292100001
PM 32329408
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Pant, S
   Singh, M
   Ravichandiran, V
   Murty, USN
   Srivastava, HK
AF Pant, Suyash
   Singh, Meenakshi
   Ravichandiran, V.
   Murty, U. S. N.
   Srivastava, Hemant Kumar
TI Peptide-like and small-molecule inhibitors against Covid-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Covid-19; MD Simulations; Virtual Screening; Drug Repurposing
ID CORONAVIRUS; DISCOVERY
AB Coronavirus disease strain (SARS-CoV-2) was discovered in 2019, and it is spreading very fast around the world causing the disease Covid-19. Currently, more than 1.6 million individuals are infected, and several thousand are dead across the globe because of Covid-19. Here, we utilized the in-silico approaches to identify possible protease inhibitors against SARS-CoV-2. Potential compounds were screened from the CHEMBL database, ZINC database, FDA approved drugs and molecules under clinical trials. Our study is based on 6Y2F and 6W63 co-crystallized structures available in the protein data bank (PDB). Seven hundred compounds from ZINC/CHEMBL databases and fourteen hundred compounds from drug-bank were selected based on positive interactions with the reported binding site. All the selected compounds were subjected to standard-precision (SP) and extra-precision (XP) mode of docking. Generated docked poses were carefully visualized for known interactions within the binding site. Molecular mechanics-generalized born surface area (MM-GBSA) calculations were performed to screen the best compounds based on docking scores and binding energy values. Molecular dynamics (MD) simulations were carried out on four selected compounds from the CHEMBL database to validate the stability and interactions. MD simulations were also performed on the PDB structure 6YF2F to understand the differences between screened molecules and co-crystallized ligand. We screened 300 potential compounds from various databases, and 66 potential compounds from FDA approved drugs. Cobicistat, ritonavir, lopinavir, and darunavir are in the top screened molecules from FDA approved drugs. The screened drugs and molecules may be helpful in fighting with SARS-CoV-2 after further studies.
C1 [Pant, Suyash] Natl Inst Pharmaceut Educ & Res Kolkata, Dept Pharmacoinformat, Kolkata, W Bengal, India.
   [Singh, Meenakshi; Ravichandiran, V.] Natl Inst Pharmaceut Educ & Res Kolkata, Dept Nat Prod, Kolkata, W Bengal, India.
   [Murty, U. S. N.; Srivastava, Hemant Kumar] Natl Inst Pharmaceut Educ & Res Guwahati, Dept Med Chem, Gauhati, Assam, India.
RP Srivastava, HK (corresponding author), Natl Inst Pharmaceut Educ & Res Guwahati, Gauhati 781030, Assam, India.
EM hemantkrsri@gmail.com
RI Srivastava, Hemant Kumar/A-8234-2008
OI Srivastava, Hemant Kumar/0000-0001-6589-6854
FU Science and Engineering Research Board, Department of Science and
   Technology, New Delhi [SB/S2/RJN/004-2015]; Department of Chemistry, IIT
   Guwahati and Param-ishan
FX H.K.S is grateful to the Science and Engineering Research Board,
   Department of Science and Technology, New Delhi, for financial
   assistance through the Ramanujan (SB/S2/RJN/004-2015) grant. We thank
   NIPER Guwahati and NIPER Kolkata for necessary facilities. We thank
   Department of Chemistry, IIT Guwahati and Param-ishan for the support.
   We also acknowledge the useful discussion with Professor C. V. Sastri
   (IIT Guwahati).
CR Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Cascella M, 2020, FEATURES EVALUATION
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Desmond Molecular Dynamics System D. E. Shaw Research., 2020, MAESTR DESM INT TOOL
   ECT Register, 2020, ECT REGISTER
   Fischer A., 2020, PREPRINT, DOI [https://doi.org/10.26434/chemrxiv.11923239.v1, 10.26434/chemrxiv.11923239.v1, DOI 10.26434/CHEMRXIV.11923239.V1]
   Gahtori J, 2019, MOL DIVERS, DOI 10.1007/s11030-019-10015-y
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   GORDALIZA M, 1994, ARCH PHARM, V327, P175, DOI 10.1002/ardp.19943270309
   Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Kupferschmidt K, 2020, SCIENCE, V367, P610, DOI 10.1126/science.367.6478.610
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lin ZH, 2008, PEPTIDES, V29, P1798, DOI 10.1016/j.peptides.2008.06.004
   Lionta E, 2014, CURR TOP MED CHEM, V14, P1923, DOI 10.2174/1568026614666140929124445
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Mesecar A. D., 2020, TAXONOMICALLY DRIVEN, DOI [10.2210/pdb6W63/pdb, DOI 10.2210/PDB6W63/PDB]
   Murty US, 2008, INFORM HEALTH SOC CA, V33, P170, DOI 10.1080/17538150802457687
   Omrani AS, 2015, PATHOG GLOB HEALTH, V109, P354, DOI 10.1080/20477724.2015.1122852
   Rein D, 2019, FOOD FUNCT, V10, P6030, DOI [10.1039/c9fo01398a, 10.1039/C9FO01398A]
   Romano JD, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00368
   Sahu K., 2020, COMPUTATIONAL SCREEN, DOI [10.20944/preprints202004.0015.v2, DOI 10.20944/PREPRINTS202004.0015.V2]
   Schrodinger, 2020, SCHROD REL 2020 1 BI
   Schrodinger, 2018, MAESTR SMALL MOL DRU
   Srivastava HK, 2013, J BIOMOL STRUCT DYN, V31, P522, DOI 10.1080/07391102.2012.703071
   Srivastava HK, 2012, J CHEM INF MODEL, V52, P3088, DOI 10.1021/ci300385h
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Wang J., 2020, FAST IDENTIFICATION, DOI [https://doi.org/10.26434/chemrxiv.11875446.v1, 10.26434/chemrxiv.11875446.v1, DOI 10.26434/CHEMRXIV.11875446.V1]
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Yan AX, 2013, EUR J MED CHEM, V61, P73, DOI 10.1016/j.ejmech.2012.06.037
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhavoronkov A, 2020, POTENTIAL COVID 2019, V2, DOI [10.26434/chemrxiv.11829102.v2, DOI 10.26434/CHEMRXIV.11829102.V2, 10.26434/chemrxiv.11829102.v2.]
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 36
TC 85
Z9 84
U1 19
U2 34
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1757510
EA MAY 2020
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LM6YY
UT WOS:000532397100001
PM 32306822
OA Bronze, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Liu, K
   Fang, YY
   Deng, Y
   Liu, W
   Wang, MF
   Ma, JP
   Xiao, W
   Wang, YN
   Zhong, MH
   Li, CH
   Li, GC
   Liu, HG
AF Liu, Kui
   Fang, Yuan-Yuan
   Deng, Yan
   Liu, Wei
   Wang, Mei-Fang
   Ma, Jing-Ping
   Xiao, Wei
   Wang, Ying-Nan
   Zhong, Min-Hua
   Li, Cheng-Hong
   Li, Guang-Cai
   Liu, Hui-Guo
TI Clinical characteristics of novel coronavirus cases in tertiary
   hospitals in Hubei Province
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE Coronavirus; 2019 Novel coronavirus (2019-nCoV); Clinical
   characteristics; Treatment; Hubei province
ID SARS; EPIDEMIOLOGY; PNEUMONIA
AB Background The 2019 novel coronavirus (2019-nCoV) causing an outbreak of pneumonia in Wuhan, Hubei province of China was isolated in January 2020. This study aims to investigate its epidemiologic history, and analyze the clinical characteristics, treatment regimens, and prognosis of patients infected with 2019-nCoV during this outbreak. Methods Clinical data from 137 2019-nCoV-infected patients admitted to the respiratory departments of nine tertiary hospitals in Hubei province from December 30, 2019 to January 24, 2020 were retrospectively collected, including general status, clinical manifestations, laboratory test results, imaging characteristics, and treatment regimens. Results None of the 137 patients (61 males, 76 females, aged 20-83 years, median age 57 years) had a definite history of exposure to Huanan Seafood Wholesale Market. Major initial symptoms included fever (112/137, 81.8%), coughing (66/137, 48.2%), and muscle pain or fatigue (44/137, 32.1%), with other, less typical initial symptoms observed at low frequency, including heart palpitations, diarrhea, and headache. Nearly 80% of the patients had normal or decreased white blood cell counts, and 72.3% (99/137) had lymphocytopenia. Lung involvement was present in all cases, with most chest computed tomography scans showing lesions in multiple lung lobes, some of which were dense; ground-glass opacity co-existed with consolidation shadows or cord-like shadows. Given the lack of effective drugs, treatment focused on symptomatic and respiratory support. Immunoglobulin G was delivered to some critically ill patients according to their conditions. Systemic corticosteroid treatment did not show significant benefits. Notably, early respiratory support facilitated disease recovery and improved prognosis. The risk of death was primarily associated with age, underlying chronic diseases, and median interval from the appearance of initial symptoms to dyspnea. Conclusions The majority of patients with 2019-nCoV pneumonia present with fever as the first symptom, and most of them still showed typical manifestations of viral pneumonia on chest imaging. Middle-aged and elderly patients with underlying comorbidities are susceptible to respiratory failure and may have a poorer prognosis.
C1 [Liu, Kui; Fang, Yuan-Yuan; Deng, Yan; Liu, Hui-Guo] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Resp & Crit Care Med, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
   [Liu, Wei] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Dept Resp & Crit Care Med, Wuhan 430030, Hubei, Peoples R China.
   [Wang, Mei-Fang] Hubei Univ Med, Taihe Hosp, Dept Resp & Crit Care Med, Affiliated Hosp, Shiyan 442000, Hubei, Peoples R China.
   [Ma, Jing-Ping] Jingzhou Cent Hosp, Dept Resp & Crit Care Med, Jingzhou 434020, Hubei, Peoples R China.
   [Xiao, Wei] First Peoples Hosp Jingzhou, Dept Resp & Crit Care Med, Jingzhou 434000, Hubei, Peoples R China.
   [Wang, Ying-Nan] China Three Gorges Univ, Peoples Hosp Yichang 1, Dept Resp & Crit Care Med, Peoples Hosp, Yichang 443000, Hubei, Peoples R China.
   [Zhong, Min-Hua] Wuhan Univ Sci & Technol, Cent Hosp Xiaogan, Dept Resp & Crit Care Med, Xiaogan Hosp, Xiaogan 432100, Hubei, Peoples R China.
   [Li, Cheng-Hong] Jianghan Univ, Hosp Wuhan 6, Dept Resp & Crit Care Med, Wuhan 430015, Hubei, Peoples R China.
   [Li, Guang-Cai] Wuhan Univ, Cent Hosp Enshi Tujia & Miao Autonmous Prefecture, Dept Resp & Crit Care Med, Enshi Clin Coll, Enshi Tujia Miao Auton 445000, Hubei, Peoples R China.
RP Liu, HG (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Resp & Crit Care Med, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
EM huiguol@163.com
CR [Anonymous], CUM NUMB 549 NOV COR
   [Anonymous], FEV COUGH AR NOT ONL
   [Anonymous], 2020, DAILY BROADCAST NEW
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Griffith JF, 2005, RADIOLOGY, V235, P168, DOI 10.1148/radiol.2351040100
   Ho W, 2003, LANCET, V361, P1313, DOI 10.1016/S0140-6736(03)13085-1
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DSC, 2003, RESPIROLOGY, V8, pS20, DOI 10.1046/j.1440-1843.2003.00520.x
   Levy MM, 2005, AM J RESP CRIT CARE, V171, P518, DOI 10.1164/rccm.200405-621WS
   National Health Commission of the People's Republic of China, DIAGN TREATM PROT NO
   Normile D, 2003, SCIENCE, V300, P714, DOI 10.1126/science.300.5620.714
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   WHO, SUMM PROB SARS CAS O
   Wong G, 2015, CELL HOST MICROBE, V18, P398, DOI 10.1016/j.chom.2015.09.013
   World Health Organization, 2019, NOV COR 2019 NCOV
   Wuhan Municipal Health Commission, LAT REP NOV COR PNEU
   Xu N, 2005, CHIN J HOSP PHARM, V2, P58, DOI [10.3321/j.issn:1001-5213.2005.02.027 ., DOI 10.3321/J.ISSN:1001-5213.2005.02.027]
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou P, 2018, NATURE, V556, P255, DOI 10.1038/s41586-018-0010-9
NR 22
TC 282
Z9 306
U1 11
U2 36
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0366-6999
EI 2542-5641
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD MAY 5
PY 2020
VL 133
IS 9
BP 1025
EP 1031
DI 10.1097/CM9.0000000000000744
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA LL1YX
UT WOS:000531352000004
PM 32044814
OA DOAJ Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Fan, HH
   Wang, LQ
   Liu, WL
   An, XP
   Liu, ZD
   He, XQ
   Song, LH
   Tong, YG
AF Fan, Hua-Hao
   Wang, Li-Qin
   Liu, Wen-Li
   An, Xiao-Ping
   Liu, Zhen-Dong
   He, Xiao-Qi
   Song, Li-Hua
   Tong, Yi-Gang
TI Repurposing of clinically approved drugs for treatment of coronavirus
   disease 2019 in a 2019-novel coronavirus-related coronavirus model
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE Coronavirus disease 2019; 2019-Novel coronavirus; Cepharanthine;
   Selamectin; Mefloquine hydrochloride
ID CEPHARANTHINE
AB Background: Medicines for the treatment of 2019-novel coronavirus (2019-nCoV) infections are urgently needed. However, drug screening using live 2019-nCoV requires high-level biosafety facilities, which imposes an obstacle for those institutions without such facilities or 2019-nCoV. This study aims to repurpose the clinically approved drugs for the treatment of coronavirus disease 2019 (COVID-19) in a 2019-nCoV-related coronavirus model. Methods: A 2019-nCoV-related pangolin coronavirus GX_P2V/pangolin/2017/Guangxi was described. Whether GX_P2V uses angiotensin-converting enzyme 2 (ACE2) as the cell receptor was investigated by using small interfering RNA (siRNA)-mediated silencing of ACE2. The pangolin coronavirus model was used to identify drug candidates for treating 2019-nCoV infection. Two libraries of 2406 clinically approved drugs were screened for their ability to inhibit cytopathic effects on Vero E6 cells by GX_P2V infection. The anti-viral activities and anti-viral mechanisms of potential drugs were further investigated. Viral yields of RNAs and infectious particles were quantified by quantitative real-time polymerase chain reaction (qRT-PCR) and plaque assay, respectively. Results: The spike protein of coronavirus GX_P2V shares 92.2% amino acid identity with that of 2019-nCoV isolate Wuhan-hu-1, and uses ACE2 as the receptor for infection just like 2019-nCoV. Three drugs, including cepharanthine (CEP), selamectin, and mefloquine hydrochloride, exhibited complete inhibition of cytopathic effects in cell culture at 10 mu mol/L. CEP demonstrated the most potent inhibition of GX_P2V infection, with a concentration for 50% of maximal effect [EC50] of 0.98 mu mol/L. The viral RNA yield in cells treated with 10 mu mol/L CEP was 15,393-fold lower than in cells without CEP treatment ([6.48 +/- 0.02] x 10(-4)vs. 1.00 +/- 0.12, t = 150.38, P < 0.001) at 72 h post-infection (p.i.). Plaque assays found no production of live viruses in media containing 10 mu mol/L CEP at 48 h p.i. Furthermore, we found CEP had potent anti-viral activities against both viral entry (0.46 +/- 0.12, vs.1.00 +/- 0.37, t = 2.42, P < 0.05) and viral replication ([6.18 +/- 0.95] x 10(-4)vs. 1.00 +/- 0.43, t = 3.98, P < 0.05). Conclusions: Our pangolin coronavirus GX_P2V is a workable model for 2019-nCoV research. CEP, selamectin, and mefloquine hydrochloride are potential drugs for treating 2019-nCoV infection. Our results strongly suggest that CEP is a wide-spectrum inhibitor of pan-betacoronavirus, and further study of CEP for treatment of 2019-nCoV infection is warranted.
C1 [Fan, Hua-Hao; Wang, Li-Qin; Liu, Wen-Li; An, Xiao-Ping; Liu, Zhen-Dong; He, Xiao-Qi; Song, Li-Hua; Tong, Yi-Gang] Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing Adv Innovat Ctr Soft Matter Sci & Engn, Beijing 100029, Peoples R China.
RP Tong, YG (corresponding author), Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing Adv Innovat Ctr Soft Matter Sci & Engn, Beijing 100029, Peoples R China.; Song, LH (corresponding author), Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing 100029, Peoples R China.
EM songlihua@gmail.com; tong.yigang@gmail.com
OI Fan, Huahao/0000-0001-5007-2158
FU Ministry of Science and Technology of ChinaMinistry of Science and
   Technology, China [2020YFC0840805]; Key Project of Beijing University of
   Chemical Technology [XK1803-06]; Fundamental Research Funds for Central
   UniversitiesFundamental Research Funds for the Central Universities
   [BUCTRC201917]; Beijing Advanced Innovation Center for Soft Matter
   Science and Engineering
FX This work was supported by a project from Ministry of Science and
   Technology of China (No. 2020YFC0840805), Key Project of Beijing
   University of Chemical Technology (No. XK1803-06), Fundamental Research
   Funds for Central Universities (No. BUCTRC201917), and a start-up
   funding for Dr. Yi-Gang Tong from Beijing Advanced Innovation Center for
   Soft Matter Science and Engineering.
CR Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Fan HH, 2017, J VIROL, V91, DOI 10.1128/JVI.00280-17
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Haginaka J, 2013, ANAL BIOCHEM, V434, P202, DOI 10.1016/j.ab.2012.11.010
   Kathawala RJ, 2014, CHIN J CANCER, V33, P223, DOI 10.5732/cjc.013.10122
   Kim DE, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110696
   Lam TT-Y, 2020, IDENTIFICATION 2019, DOI [10.1101/2020.02.13.945485, 10.1101/2020.02.13.945485., DOI 10.1101/2020.02.13.945485]
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu P, 2020, ARE PANGOLINS INTERM, DOI [10.1101/2020.02.18.954628, DOI 10.1101/2020.02.18.954628]
   Liu P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11110979
   Liu X, 2004, STUDIES IMMUNE EVALU
   Matsuda K, 2014, BIOORG MED CHEM LETT, V24, P2115, DOI 10.1016/j.bmcl.2014.03.041
   Rogosnitzky M, 2011, PHARMACOL REP, V63, P337, DOI 10.1016/S1734-1140(11)70500-X
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao K., 2020, ISOLATION CHARACTERI, DOI [10.1101/2020.02.17.951335, DOI 10.1101/2020.02.17.951335]
   Zhang CH, 2005, CHINESE MED J-PEKING, V118, P493
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 19
TC 52
Z9 54
U1 28
U2 50
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0366-6999
EI 2542-5641
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD MAY 5
PY 2020
VL 133
IS 9
BP 1051
EP 1056
DI 10.1097/CM9.0000000000000797
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA LL1YX
UT WOS:000531352000008
PM 32723205
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Qin, YY
   Zhou, YH
   Lu, YQ
   Sun, F
   Yang, S
   Harypursat, V
   Chen, YK
AF Qin, Yuan-Yuan
   Zhou, Yi-Hong
   Lu, Yan-Qiu
   Sun, Feng
   Yang, Sen
   Harypursat, Vijay
   Chen, Yao-Kai
TI Effectiveness of glucocorticoid therapy in patients with severe
   coronavirus disease 2019: protocol of a randomized controlled trial
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE 2019 Novel coronavirus; Coronavirus disease 2019; Glucocorticoids;
   Severe pneumonia; Acute respiratory distress syndrome
ID ACUTE RESPIRATORY SYNDROME; STEROID-INDUCED OSTEONECROSIS; ACUTE LUNG
   INJURY; DISTRESS-SYNDROME; CORTICOSTEROID TREATMENT; SARS; ARDS;
   INFLAMMATION; RESISTANCE; OUTBREAK
AB Background: At the end of 2019, a novel coronavirus outbreak causative organism has been subsequently designated the 2019 novel coronavirus (2019-nCoV). The effectiveness of adjunctive glucocorticoid therapy in the management of 2019-nCoV-infected patients with severe lower respiratory tract infections is not clear, and warrants further investigation. Methods: The present study will be conducted as an open-labeled, randomized, controlled trial. We will enrol 48 subjects from Chongqing Public Health Medical Center. Each eligible subject will be assigned to an intervention group (methylprednisolone via intravenous injection at a dose of 1-2 mg/kg/day for 3 days) or a control group (no glucocorticoid use) randomly, at a 1:1 ratio. Subjects in both groups will be invited for 28 days of follow-up which will be scheduled at four consecutive visit points. We will use the clinical improvement rate as our primary endpoint. Secondary endpoints include the timing of clinical improvement after intervention, duration of mechanical ventilation, duration of hospitalization, overall incidence of adverse events, as well as rate of adverse events at each visit, and mortality at 2 and 4 weeks. Discussion: The present coronavirus outbreak is the third serious global coronavirus outbreak in the past two decades. Oral and parenteral glucocorticoids have been used in the management of severe respiratory symptoms in coronavirus-infected patients in the past. However, there remains no definitive evidence in the literature for or against the utilization of systemic glucocorticoids in seriously ill patients with coronavirus-related severe respiratory disease, or indeed in other types of severe respiratory disease. In this study, we hope to discover evidence either supporting or opposing the systemic therapeutic administration of glucocorticoids in patients with severe coronavirus disease 2019.
C1 [Qin, Yuan-Yuan; Zhou, Yi-Hong; Lu, Yan-Qiu; Sun, Feng; Yang, Sen; Harypursat, Vijay; Chen, Yao-Kai] Chongqing Publ Hlth Med Ctr, Div Infect Dis, Chongqing 400036, Peoples R China.
RP Chen, YK (corresponding author), Chongqing Publ Hlth Med Ctr, Div Infect Dis, Chongqing 400036, Peoples R China.
EM yaokaichen@hotmail.com
FU Chongqing Special Research Project for Prevention and Control of Novel
   Coronavirus Pneumonia [cstc2020jscx-fyzx0074]
FX This work was supported by the Chongqing Special Research Project for
   Prevention and Control of Novel Coronavirus Pneumonia (No.
   cstc2020jscx-fyzx0074).
CR Alfaraj SH, 2019, TRAVEL MED INFECT DI, V29, P48, DOI 10.1016/j.tmaid.2019.03.004
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Buchman AL, 2001, J CLIN GASTROENTEROL, V33, P289, DOI 10.1097/00004836-200110000-00006
   Chan AW, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e7586
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chan MHM, 2006, PATHOLOGY, V38, P229, DOI 10.1080/00313020600696231
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Ewald H, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006150.pub2
   Griffith JF, 2005, RADIOLOGY, V235, P168, DOI 10.1148/radiol.2351040100
   Heymann DL, 2020, LANCET, V395, P469, DOI 10.1016/S0140-6736(20)30184-7
   Ho JC, 2003, AM J RESP CRIT CARE, V168, P1449, DOI 10.1164/rccm.200306-766OC
   Hong N, 2004, CLIN RADIOL, V59, P602, DOI 10.1016/j.crad.2003.12.008
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kido T, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0597-5
   Lee DTS, 2004, CLIN INFECT DIS, V39, P1247, DOI 10.1086/424016
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0
   Meduri GU, 2007, CHEST, V131, P954, DOI 10.1378/chest.06-2100
   Meduri GU, 2016, INTENS CARE MED, V42, P829, DOI 10.1007/s00134-015-4095-4
   Meduri GU, 2005, NEUROIMMUNOMODULAT, V12, P321, DOI 10.1159/000091126
   Meduri GU, 2002, AM J RESP CRIT CARE, V165, P983, DOI 10.1164/ajrccm.165.7.2106014
   National Health Commission of People's Republic of China, GUID DIAGN TREATM NO
   Seam N, 2016, INTENS CARE MED, V42, P924, DOI 10.1007/s00134-015-4160-z
   Sheng B, 2005, EUR PSYCHIAT, V20, P236, DOI 10.1016/j.eurpsy.2004.06.023
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   So LKY, 2003, LANCET, V361, P1615, DOI 10.1016/S0140-6736(03)13265-5
   Song L, 2019, INT IMMUNOPHARMACOL, V71, P392, DOI 10.1016/j.intimp.2019.03.051
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Sung JJY, 2004, THORAX, V59, P414, DOI 10.1136/thx.2003.014076
   Tai DYH, 2007, ANN ACAD MED SINGAP, V36, P438
   Takaki M, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1723-0
   Tongyoo S, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1511-2
   Tsang K, 2003, RESPIROLOGY, V8, pS25, DOI 10.1046/j.1440-1843.2003.00525.x
   Tsang KW, 2003, AM J RESP CRIT CARE, V168, P417, DOI 10.1164/rccm.2305012
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Tsang OTY, 2003, EMERG INFECT DIS, V9, P1381, DOI 10.3201/eid0911.030400
   Tu GW, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1284-7
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang HJ, 2003, NEW ENGL J MED, V349, P507, DOI 10.1056/NEJM200307313490519
   WHO, 2003, SUMM PROB SARS CAS O
   WHO, 2019, MIDDL E RESP SYNDR C
   Who Mers-Cov Research Group, 2013, PLoS Curr, V5, DOI 10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   Yam LYC, 2007, J INFECTION, V54, P28, DOI 10.1016/j.jinf.2006.01.005
   Zhang NF, 2008, J BONE JOINT SURG BR, V90B, P1239, DOI 10.1302/0301-620X.90B9.20056
   Zhong NS, 2003, AM J RESP CRIT CARE, V168, P7, DOI 10.1164/rccm.200305-707OE
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 52
TC 28
Z9 29
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0366-6999
EI 2542-5641
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD MAY 5
PY 2020
VL 133
IS 9
BP 1080
EP 1086
DI 10.1097/CM9.0000000000000791
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA LL1YX
UT WOS:000531352000012
PM 32149773
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Buonaguro, L
   Tagliamonte, M
   Tornesello, ML
   Buonaguro, FM
AF Buonaguro, Luigi
   Tagliamonte, Maria
   Tornesello, Maria Lina
   Buonaguro, Franco M.
TI SARS-CoV-2 RNA polymerase as target for antiviral therapy
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
ID EBOLA-VIRUS; IDENTIFICATION; CORONAVIRUSES; INHIBITOR; MOTIFS; SARS
AB A new human coronavirus named SARS-CoV-2 was identified in several cases of acute respiratory syndrome in Wuhan, China in December 2019. On March 11 2020, WHO declared the SARS-CoV-2 infection to be a pandemic, based on the involvement of 169 nations. Specific drugs for SARS-CoV-2 are obviously not available. Currently, drugs originally developed for other viruses or parasites are currently in clinical trials based on empiric data. In the quest of an effective antiviral drug, the most specific target for an RNA virus is the RNA-dependent RNA-polymerase (RdRp) which shows significant differences between positive-sense and negative-sense RNA viruses. An accurate evaluation of RdRps from different viruses may guide the development of new drugs or the repositioning of already approved antiviral drugs as treatment of SARS-CoV-2. This can accelerate the containment of the SARS-CoV-2 pandemic and, hopefully, of future pandemics due to other emerging zoonotic RNA viruses.
C1 [Buonaguro, Luigi; Tagliamonte, Maria] Fdn Pascale IRCCS, Ist Nazl Studio & Cura Tumori, Innovat Immunol Models, Via Mariano Semmola 52, I-80131 Naples, Italy.
   [Tornesello, Maria Lina; Buonaguro, Franco M.] Fdn Pascale IRCCS, Ist Nazl Studio & Cura Tumori, Lab Mol Biol & Viral Oncol, I-80131 Naples, Italy.
RP Buonaguro, L (corresponding author), Fdn Pascale IRCCS, Ist Nazl Studio & Cura Tumori, Innovat Immunol Models, Via Mariano Semmola 52, I-80131 Naples, Italy.
EM l.buonaguro@istitutotumori.na.it
RI Buonaguro, Luigi/AAV-5655-2020; Tornesello, Maria Lina/A-1964-2008
OI Tornesello, Maria Lina/0000-0002-3523-3264
CR Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa011
   Bourliere M, 2019, INT J ANTIMICROB AG, V53, P755, DOI 10.1016/j.ijantimicag.2018.12.010
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Harwig A, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100309
   Hu B, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0422-1
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jacome R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139001
   Jia HX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01945
   Jiang W, 2018, ANTIVIR RES, V154, P51, DOI 10.1016/j.antiviral.2018.04.007
   Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Mendes EA, 2019, ANN HEPATOL, V18, P816, DOI 10.1016/j.aohep.2019.09.001
   Ng KKS, 2008, CURR TOP MICROBIOL, V320, P137
   Pan JH, 2007, P NATL ACAD SCI USA, V104, P7385, DOI 10.1073/pnas.0611599104
   POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x
   REICH E, 1961, SCIENCE, V134, P556, DOI 10.1126/science.134.3478.556
   Reynard O, 2015, VIRUSES-BASEL, V7, P6233, DOI 10.3390/v7122934
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149
   Vazquez AL, 2000, J VIROL, V74, P3888, DOI 10.1128/JVI.74.8.3888-3891.2000
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
NR 24
TC 8
Z9 8
U1 4
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD MAY 5
PY 2020
VL 18
IS 1
AR 185
DI 10.1186/s12967-020-02355-3
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LL6XL
UT WOS:000531700100001
PM 32370758
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ballout, RA
   Sviridov, D
   Bukrinsky, MI
   Remaley, AT
AF Ballout, Rami A.
   Sviridov, Dmitri
   Bukrinsky, Michael I.
   Remaley, Alan T.
TI The lysosome: A potential juncture between SARS-CoV-2 infectivity and
   Niemann-Pick disease type C, with therapeutic implications
SO FASEB JOURNAL
LA English
DT Article
DE angiotensin-converting enzyme-2 (ACE2); cathepsins; cholesterol;
   COVID-19; lipid rafts; lysosomal storage diseases; pandemic
ID ACUTE RESPIRATORY SYNDROME; TRANSPORT INHIBITOR U18666A; CATHEPSIN-L;
   SARS-CORONAVIRUS; EBOLA-VIRUS; CHOLESTEROL TRANSPORT; FUNCTIONAL
   RECEPTOR; TISSUE DISTRIBUTION; ANTIVIRAL ACTIVITY; LIPID RAFTS
AB Drug repurposing is potentially the fastest available option in the race to identify safe and efficacious drugs that can be used to prevent and/or treat COVID-19. By describing the life cycle of the newly emergent coronavirus, SARS-CoV-2, in light of emerging data on the therapeutic efficacy of various repurposed antimicrobials undergoing testing against the virus, we highlight in this review a possible mechanistic convergence between some of these tested compounds. Specifically, we propose that the lysosomotropic effects of hydroxychloroquine and several other drugs undergoing testing may be responsible for their demonstrated in vitro antiviral activities against COVID-19. Moreover, we propose that Niemann-Pick disease type C (NPC), a lysosomal storage disorder, may provide new insights into potential future therapeutic targets for SARS-CoV-2, by highlighting key established features of the disorder that together result in an "unfavorable" host cellular environment that may interfere with viral propagation. Our reasoning evolves from previous biochemical and cell biology findings related to NPC, coupled with the rapidly evolving data on COVID-19. Our overall aim is to suggest that pharmacological interventions targeting lysosomal function in general, and those particularly capable of reversibly inducing transient NPC-like cellular and biochemical phenotypes, constitute plausible mechanisms that could be used to therapeutically target COVID-19.
C1 [Ballout, Rami A.; Remaley, Alan T.] NHLBI, Lipoprot Metab Sect, Translat Vasc Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Sviridov, Dmitri] Baker Heart & Diabet Inst, Lipoprot & Atherosclerosis Lab, Melbourne, Vic, Australia.
   [Bukrinsky, Michael I.] George Washington Univ, Sch Med & Hlth Sci, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA.
RP Ballout, RA; Remaley, AT (corresponding author), NHLBI, Lipoprot Metab Sect, Translat Vasc Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM rami-ballout@hotmail.com; alan.remaley@nih.gov
FU Intramural Research Program of the National Heart, Lung, and Blood
   Institute (NHLBI) at the National Institutes of Health [HL006092];
   National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01-HL131473];
   District of Columbia Center for AIDS Research (DC-CFAR), an NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [P30-AI117970]
FX RB and AR are supported by the Intramural Research Program of the
   National Heart, Lung, and Blood Institute (NHLBI) [HL006092] at the
   National Institutes of Health. MB and D.S are supported by a research
   grant from the National Heart, Lung, and Blood Institute (NHLBI) under
   award number [R01-HL131473]. MB is also supported by the District of
   Columbia Center for AIDS Research (DC-CFAR), an NIH-funded program
   [P30-AI117970]
CR Adedeji AO, 2014, ANTIMICROB AGENTS CH, V58, P4894, DOI 10.1128/AAC.02994-14
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Amritraj A, 2009, AM J PATHOL, V175, P2540, DOI 10.2353/ajpath.2009.081096
   Ashoor R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082481
   Bach G, 1999, CLIN CHIM ACTA, V280, P173, DOI 10.1016/S0009-8981(98)00183-1
   Balzarini J, 2006, ANTIVIR RES, V72, P20, DOI 10.1016/j.antiviral.2006.03.005
   Barcia-Macay M, 2008, J ANTIMICROB CHEMOTH, V61, P1288, DOI 10.1093/jac/dkn120
   Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   BEAUCHAMP D, 1992, ANTIMICROB AGENTS CH, V36, P2204, DOI 10.1128/AAC.36.10.2204
   Berg RD, 2016, CELL, V165, P139, DOI 10.1016/j.cell.2016.02.034
   Bertram S, 2013, J VIROL, V87, P6150, DOI 10.1128/JVI.03372-12
   Bosch BJ, 2008, J VIROL, V82, P8887, DOI 10.1128/JVI.00415-08
   Carette JE, 2011, NATURE, V477, P340, DOI 10.1038/nature10348
   Cenedella RJ, 2004, J LIPID RES, V45, P1232, DOI 10.1194/jlr.M300469-JLR200
   Cermak S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167428
   Chen PM, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-10
   Chen YZ, 2014, SCI REP-UK, V4, DOI 10.1038/srep07242
   Chung C, 2016, HUM MOL GENET, V25, P1434, DOI 10.1093/hmg/ddw025
   Civra A, 2014, SCI REP-UK, V4, DOI 10.1038/srep07487
   Cortegiani A, 2020, CRIT CARE, V24
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Devlin C, 2010, TRAFFIC, V11, P601, DOI 10.1111/j.1600-0854.2010.01046.x
   Doki T, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9010067
   Elrick MJ, 2012, HUM MOL GENET, V21, P4876, DOI 10.1093/hmg/dds324
   Fan H-H, 2020, CHIN MED J
   Fineran Paul, 2016, Wellcome Open Res, V1, P18, DOI 10.12688/wellcomeopenres.10036.2
   Folts CJ, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002583
   Fraldi A, 2010, EMBO J, V29, P3607, DOI 10.1038/emboj.2010.237
   Fu R, 2010, MOL GENET METAB, V101, P214, DOI 10.1016/j.ymgme.2010.06.018
   Gabande-Rodriguez E, 2014, CELL DEATH DIFFER, V21, P864, DOI 10.1038/cdd.2014.4
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Garver WS, 2002, J LIPID RES, V43, P579
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Glende J, 2008, VIROLOGY, V381, P215, DOI 10.1016/j.virol.2008.08.026
   GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Hartshorn Kevan L, 2010, Front Biosci (Schol Ed), V2, P527
   Heald-Sargent T, 2012, VIRUSES-BASEL, V4, P557, DOI 10.3390/v4040557
   Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holopainen JM, 2001, EUR J BIOCHEM, V268, P5851, DOI 10.1046/j.0014-2956.2001.02530.x
   HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0
   Huang IC, 2006, J BIOL CHEM, V281, P3198, DOI 10.1074/jbc.M508381200
   Janac B, 2005, ANN NY ACAD SCI, V1048, P396, DOI 10.1196/annals.1342.048
   Jelinek David, 2014, J Mol Biochem, V3, P14
   Jensen K, 2012, N-S ARCH PHARMACOL, V385, P519, DOI 10.1007/s00210-011-0719-6
   Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335
   Karypidou K, 2018, BIOORG MED CHEM LETT, V28, P3472, DOI 10.1016/j.bmcl.2018.09.019
   Koo IC, 2008, P NATL ACAD SCI USA, V105, P710, DOI 10.1073/pnas.0708110105
   Kosicek M, 2018, MOL CELL PROTEOMICS, V17, P631, DOI 10.1074/mcp.RA117.000129
   Lawson PR, 2000, IMMUNOL REV, V173, P66, DOI 10.1034/j.1600-065X.2000.917308.x
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li CF, 2017, IMMUNITY, V46, P446, DOI 10.1016/j.immuni.2017.02.012
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li L, 2016, ARCH VIROL, V161, P1883, DOI 10.1007/s00705-016-2838-3
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   LINDLEY ER, 1993, BIOCHEM J, V290, P457, DOI 10.1042/bj2900457
   Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621
   Liu SY, 2013, IMMUNITY, V38, P92, DOI 10.1016/j.immuni.2012.11.005
   Liu Y, 2014, TOXICOLOGY, V320, P1, DOI 10.1016/j.tox.2014.02.014
   Liu Y, 2014, JAMA OPHTHALMOL, V132, P226, DOI 10.1001/jamaophthalmol.2013.6030
   Lloyd-Evans E, 2008, NAT MED, V14, P1247, DOI 10.1038/nm.1876
   Long T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13917-5
   Lusa S, 2001, J CELL SCI, V114, P1893
   Lyu JF, 2017, CANCER LETT, V409, P91, DOI 10.1016/j.canlet.2017.09.009
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Mingo RM, 2015, J VIROL, V89, P2931, DOI 10.1128/JVI.03398-14
   Moreno-Caceres J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.294
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Nujic K, 2012, CELL IMMUNOL, V279, P78, DOI 10.1016/j.cellimm.2012.09.007
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pagler TA, 2007, J LIPID RES, V48, P2141, DOI 10.1194/jlr.M700056-JLR200
   Patterson M, 2000, GENEREVIEWS, P1993
   Pedersen NC, 2019, J FELINE MED SURG, V21, P271, DOI 10.1177/1098612X19825701
   Porter FD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001417
   Reinke LM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179177
   Renna M, 2011, J CLIN INVEST, V121, P3554, DOI 10.1172/JCI46095
   Rodriguez-Gil JL, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010012
   Roszell BR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067084
   Roszell BR, 2012, AM J PHYSIOL-LUNG C, V302, pL919, DOI 10.1152/ajplung.00383.2011
   SCHRIER DJ, 1986, J IMMUNOL, V137, P3284
   Shah PP, 2010, MOL PHARMACOL, V78, P319, DOI 10.1124/mol.110.064261
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shirato K, 2018, VIROLOGY, V517, P9, DOI 10.1016/j.virol.2017.11.012
   Shivanna V, 2014, VIROLOGY, V464, P287, DOI 10.1016/j.virol.2014.07.025
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Sillence DJ, 2013, MOL GENET METAB, V109, P194, DOI 10.1016/j.ymgme.2013.03.015
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Simons K, 2010, NAT REV MOL CELL BIO, V11, P688, DOI 10.1038/nrm2977
   SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J
   Takano T, 2019, VET RES, V50, DOI 10.1186/s13567-019-0625-3
   Takano T, 2017, ANTIVIR RES, V145, P96, DOI 10.1016/j.antiviral.2017.07.022
   TAYLOR MD, 1986, J MED CHEM, V29, P346, DOI 10.1021/jm00153a008
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Tellier E, 2006, EXP CELL RES, V312, P3969, DOI 10.1016/j.yexcr.2006.08.027
   To KF, 2004, J PATHOL, V203, P740, DOI 10.1002/path.1597
   Trinh MN, 2017, P NATL ACAD SCI USA, V114, P89, DOI 10.1073/pnas.1619571114
   Vainio S, 2005, BIOCHEM J, V391, P465, DOI 10.1042/BJ20050460
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Visentin S, 2013, J NEUROSCI, V33, P15388, DOI 10.1523/JNEUROSCI.0558-13.2013
   Vitner EB, 2010, HUM MOL GENET, V19, P3583, DOI 10.1093/hmg/ddq273
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   Willard KA, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010020
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu JZ, 2003, J ANTIMICROB CHEMOTH, V52, P543, DOI 10.1093/jac/dkg405
   Yang HY, 2017, GLIA, V65, P1728, DOI 10.1002/glia.23191
   Yano T, 2015, FASEB J S, V29, P7771
   Zaher NH, 2020, ACTA PHARMACEUT, V70, P145, DOI 10.2478/acph-2020-0024
   Zarn JA, 2003, ENVIRON HEALTH PERSP, V111, P255, DOI 10.1289/ehp.5785
   Zhang J, 2020, BIORXIV, DOI [10.1101/2020.02.05.935387., 10.1101/2020.02.05.9353872020.02.05.935387, DOI 10.1101/2020.02.05.935387]
   Zhang YH, 2019, VET MICROBIOL, V231, P129, DOI 10.1016/j.vetmic.2019.03.004
   Zheng Y, 2018, J VIROL, V92, DOI 10.1128/JVI.01504-18
   Zhong XZ, 2017, J BIOL CHEM, V292, P3445, DOI 10.1074/jbc.M116.743963
   Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 119
TC 7
Z9 7
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JUN
PY 2020
VL 34
IS 6
BP 7253
EP 7264
DI 10.1096/fj.202000654R
EA MAY 2020
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA MR4QG
UT WOS:000530303200001
PM 32367579
OA Green Published, Other Gold, Green Accepted
DA 2021-01-01
ER

PT J
AU Belen-Apak, FB
   Sarialioglu, F
AF Belen-Apak, F. Burcu
   Sarialioglu, F.
TI Pulmonary intravascular coagulation in COVID-19: possible pathogenesis
   and recommendations on anticoagulant/thrombolytic therapy
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Letter
C1 [Belen-Apak, F. Burcu; Sarialioglu, F.] Baskent Univ, Fac Med, Dept Paediat Haemotol & Oncol, Sehit Temel Kuguluoglu Str 24, Ankara, Turkey.
RP Belen-Apak, FB (corresponding author), Baskent Univ, Fac Med, Dept Paediat Haemotol & Oncol, Sehit Temel Kuguluoglu Str 24, Ankara, Turkey.
EM draidabb@gmail.com
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Fox SE., PULMONARY CARDIAC PA, DOI [10.1101/2020.04.06.20050575, DOI 10.1101/2020.04.06.20050575]
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Moore HB, 2020, J TRAUMA ACUTE CARE, V88, P713, DOI 10.1097/TA.0000000000002694
   Pescador R, 2013, VASC PHARMACOL, V59, P1, DOI 10.1016/j.vph.2013.05.001
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Wu Y, 2020, QJM-INT J MED, V113, P539, DOI 10.1093/qjmed/hcaa121
NR 8
TC 9
Z9 9
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
PD AUG
PY 2020
VL 50
IS 2
BP 278
EP 280
DI 10.1007/s11239-020-02129-0
EA MAY 2020
PG 3
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA ML6VE
UT WOS:000530608400001
PM 32372336
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wang, B
   Wang, L
   Kong, XG
   Geng, J
   Xiao, D
   Ma, CH
   Jiang, XM
   Wang, PH
AF Wang, Bin
   Wang, Li
   Kong, Xianggen
   Geng, Jin
   Xiao, Di
   Ma, Chunhong
   Jiang, Xue-Mei
   Wang, Pei-Hui
TI Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19
   patients
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE antibody; COVID-19; IgG; immunity; SARS-CoV-2
ID VACCINES
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing coronavirus disease 2019 (COVID-19) has spread worldwide. Whether antibodies are important for the adaptive immune responses against SARS-CoV-2 infection needs to be determined. Here, 26 cases of COVID-19 in Jinan, China, were examined and shown to be mild or with common clinical symptoms, and no case of severe symptoms was found among these patients. Strikingly, a subset of these patients had SARS-CoV-2 and virus-specific IgG coexist for an unexpectedly long time, with two cases for up to 50 days. One COVID-19 patient who did not produce any SARS-CoV-2-bound IgG successfully cleared SARS-CoV-2 after 46 days of illness, revealing that without antibody-mediated adaptive immunity, innate immunity alone may still be powerful enough to eliminate SARS-CoV-2. This report may provide a basis for further analysis of both innate and adaptive immunity in SARS-CoV-2 clearance, especially in nonsevere cases.
C1 [Wang, Bin; Wang, Li; Kong, Xianggen; Geng, Jin; Xiao, Di; Jiang, Xue-Mei] Shandong Univ, Cheeloo Coll Med, Jinan Infect Dis Hosp, Jinan 250021, Shandong, Peoples R China.
   [Ma, Chunhong; Wang, Pei-Hui] Shandong Univ, Adv Med Res Inst, Cheeloo Coll Med, Jinan 250012, Shandong, Peoples R China.
RP Jiang, XM (corresponding author), Shandong Univ, Cheeloo Coll Med, Jinan Infect Dis Hosp, Jinan 250021, Shandong, Peoples R China.; Wang, PH (corresponding author), Shandong Univ, Adv Med Res Inst, Cheeloo Coll Med, Jinan 250012, Shandong, Peoples R China.
EM shdjxm@163.com; pei-hui.wang@sdu.edu.cn
RI Wang, Pei-Hui/F-7682-2014
OI Wang, Pei-Hui/0000-0001-6853-2423
FU COVID-19 emergency tackling research project of Shandong University
   [2020XGB03]
FX We thank the physicians and nurses in Jinan infectious diseases hospital
   who cared for these patients and made this study possible. This study
   was supported by grants from COVID-19 emergency tackling research
   project of Shandong University (Grant No. 2020XGB03 to P-HW).
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Fafi-Kremer S, 2012, VIRUSES-BASEL, V4, P2016, DOI 10.3390/v4102016
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9
   Kasumba DM, 2019, TRENDS PHARMACOL SCI, V40, P116, DOI 10.1016/j.tips.2018.12.003
   Lu S, 2020, EMERG MICROBES INFEC, V9, P542, DOI 10.1080/22221751.2020.1737580
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Wang PH, 2020, BIORXIV, DOI [10.1101/2020.02.24.963348, DOI 10.1101/2020.02.24.963348]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 10
TC 15
Z9 15
U1 3
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD SEP
PY 2020
VL 92
IS 9
BP 1684
EP 1689
DI 10.1002/jmv.25946
EA MAY 2020
PG 6
WC Virology
SC Virology
GA NA8CG
UT WOS:000530368300001
PM 32343415
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Thao, TTN
   Labroussaa, F
   Ebert, N
   V'kovski, P
   Stalder, H
   Portmann, J
   Kelly, J
   Steiner, S
   Holwerda, M
   Kratzel, A
   Gultom, M
   Schmied, K
   Laloli, L
   Husser, L
   Wider, M
   Pfaender, S
   Hirt, D
   Cippa, V
   Crespo-Pomar, S
   Schroder, S
   Muth, D
   Niemeyer, D
   Corman, VM
   Muller, MA
   Drosten, C
   Dijkman, R
   Jores, J
   Thiel, V
AF Tran Thi Nhu Thao
   Labroussaa, Fabien
   Ebert, Nadine
   V'kovski, Philip
   Stalder, Hanspeter
   Portmann, Jasmine
   Kelly, Jenna
   Steiner, Silvio
   Holwerda, Melle
   Kratzel, Annika
   Gultom, Mitra
   Schmied, Kimberly
   Laloli, Laura
   Huesser, Linda
   Wider, Manon
   Pfaender, Stephanie
   Hirt, Dagny
   Cippa, Valentina
   Crespo-Pomar, Silvia
   Schroeder, Simon
   Muth, Doreen
   Niemeyer, Daniela
   Corman, Victor M.
   Mueller, Marcel A.
   Drosten, Christian
   Dijkman, Ronald
   Jores, Joerg
   Thiel, Volker
TI Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform
SO NATURE
LA English
DT Article
ID INFECTIOUS CLONE; IN-VITRO; CORONAVIRUS; RNA; PNEUMONIA; SYSTEM
AB Reverse genetics has been an indispensable tool to gain insights into viral pathogenesis and vaccine development. The genomes of large RNA viruses, such as those from coronaviruses, are cumbersome to clone and manipulate inEscherichia coliowing to the size and occasional instability of the genome(1-3). Therefore, an alternative rapid and robust reverse-genetics platform for RNA viruses would benefit the research community. Here we show the full functionality of a yeast-based synthetic genomics platform to genetically reconstruct diverse RNA viruses, including members of theCoronaviridae,FlaviviridaeandPneumoviridaefamilies. Viral subgenomic fragments were generated using viral isolates, cloned viral DNA, clinical samples or synthetic DNA, and these fragments were then reassembled in one step inSaccharomyces cerevisiaeusing transformation-associated recombination cloning to maintain the genome as a yeast artificial chromosome. T7 RNA polymerase was then used to generate infectious RNA to rescue viable virus. Using this platform, we were able to engineer and generate chemically synthesized clones of the virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(4), which has caused the recent pandemic of coronavirus disease (COVID-19), in only a week after receipt of the synthetic DNA fragments. The technical advance that we describe here facilitates rapid responses to emerging viruses as it enables the real-time generation and functional characterization of evolving RNA virus variants during an outbreak.
   A yeast-based synthetic genomics platform is used to reconstruct and characterize large RNA viruses from synthetic DNA fragments; this technique will facilitate the rapid analysis of RNA viruses, such as SARS-CoV-2, during an outbreak.
C1 [Tran Thi Nhu Thao; Ebert, Nadine; V'kovski, Philip; Stalder, Hanspeter; Portmann, Jasmine; Kelly, Jenna; Steiner, Silvio; Holwerda, Melle; Kratzel, Annika; Gultom, Mitra; Schmied, Kimberly; Laloli, Laura; Huesser, Linda; Pfaender, Stephanie; Hirt, Dagny; Dijkman, Ronald; Thiel, Volker] IVI, Bern, Switzerland.
   [Tran Thi Nhu Thao; Labroussaa, Fabien; Ebert, Nadine; V'kovski, Philip; Stalder, Hanspeter; Portmann, Jasmine; Kelly, Jenna; Steiner, Silvio; Holwerda, Melle; Kratzel, Annika; Gultom, Mitra; Schmied, Kimberly; Laloli, Laura; Huesser, Linda; Pfaender, Stephanie; Hirt, Dagny; Cippa, Valentina; Crespo-Pomar, Silvia; Dijkman, Ronald; Jores, Joerg; Thiel, Volker] Univ Bern, Vetsuisse Fac, Dept Infect Dis & Pathobiol, Bern, Switzerland.
   [Tran Thi Nhu Thao; Steiner, Silvio; Holwerda, Melle; Kratzel, Annika; Gultom, Mitra; Laloli, Laura] Univ Bern, Grad Sch Biomed Sci, Bern, Switzerland.
   [Labroussaa, Fabien; Cippa, Valentina; Crespo-Pomar, Silvia; Jores, Joerg] Univ Bern, Vetsuisse Fac, Inst Vet Bacteriol, Bern, Switzerland.
   [Holwerda, Melle; Gultom, Mitra; Laloli, Laura; Wider, Manon; Dijkman, Ronald] Univ Bern, Inst Infect Dis, Bern, Switzerland.
   [Pfaender, Stephanie] Ruhr Univ Bochum, Dept Mol & Med Virol, Bochum, Germany.
   [Schroeder, Simon; Muth, Doreen; Niemeyer, Daniela; Corman, Victor M.; Mueller, Marcel A.; Drosten, Christian] Charite Univ Med Berlin, Inst Virol, Berlin, Germany.
   [Schroeder, Simon; Muth, Doreen; Niemeyer, Daniela; Corman, Victor M.; Mueller, Marcel A.; Drosten, Christian] Free Univ Berlin, Berlin, Germany.
   [Schroeder, Simon; Muth, Doreen; Niemeyer, Daniela; Corman, Victor M.; Mueller, Marcel A.; Drosten, Christian] Humboldt Univ, Berlin, Germany.
   [Schroeder, Simon; Muth, Doreen; Niemeyer, Daniela; Corman, Victor M.; Mueller, Marcel A.; Drosten, Christian] Berlin Inst Hearth, Berlin, Germany.
   [Muth, Doreen; Niemeyer, Daniela; Corman, Victor M.; Mueller, Marcel A.; Drosten, Christian] Associated Partner Charite, German Ctr Infect Res, Berlin, Germany.
   [Mueller, Marcel A.] Sechenov Univ, Martsinovsky Inst Med Parasitol Trop & Vector Bor, Moscow, Russia.
RP Thiel, V (corresponding author), IVI, Bern, Switzerland.; Jores, J; Thiel, V (corresponding author), Univ Bern, Vetsuisse Fac, Dept Infect Dis & Pathobiol, Bern, Switzerland.; Jores, J (corresponding author), Univ Bern, Vetsuisse Fac, Inst Vet Bacteriol, Bern, Switzerland.
EM joerg.jores@vetsuisse.unibe.ch; volker.thiel@vetsuisse.unibe.ch
RI Mueller, Marcel/O-2425-2019; Corman, Victor Max/K-1319-2019
OI Mueller, Marcel/0000-0003-2242-5117; Corman, Victor
   Max/0000-0002-3605-0136; Kelly, Jenna/0000-0001-7265-2233; Pfaender,
   Stephanie/0000-0002-3957-5448; Holwerda, Melle/0000-0002-9814-7793;
   Schroeder, Simon/0000-0003-2085-767X; Steiner,
   Silvio/0000-0003-1999-1425; V'kovski, Philip/0000-0002-8366-1220
FU European CommissionEuropean CommissionEuropean Commission Joint Research
   Centre [721367]; Swiss National Science Foundation (SNF)Swiss National
   Science Foundation (SNSF) [CRSII3_160780, 310030_173085]; German
   Research Council (DFG)German Research Foundation (DFG) [SFB-TR84 (TRR
   84/3), DR 772/7-2]; Federal Ministry of Education and Research
   (BMBF)Federal Ministry of Education & Research (BMBF) [01KI1723A];
   University of Bern
FX This work was supported by the European Commission (Marie
   Skodowska-Curie Innovative Training Network "HONOURS"; grant agreement
   no. 721367), the Swiss National Science Foundation (SNF; grants
   CRSII3_160780 and 310030_173085), the German Research Council (DFG;
   grants SFB-TR84 (TRR 84/3, A07) and DR 772/7-2), the Federal Ministry of
   Education and Research (BMBF; grant RAPID, 01KI1723A) and by core funds
   of the University of Bern. We thank S. Vashee for the provision of the
   TAR vectors and for discussions related to his herpesvirus work; J.
   Peters Zocher for her advice in generating the figures; F. Suter-Riniker
   and P. Bittel for providing clinical samples; staff from the Next
   Generation Sequencing platform (University of Bern); and M. Schweizer,
   P. Plattet, M. Gerber, M. Friesland, M. Alves, N. Vielle, B. Zumkehr, M.
   Brugger and D. Brechbuhl for reagents, technical advice and helpful
   discussions. This study is dedicated to S. Kunz.
CR Almazan F, 2000, P NATL ACAD SCI USA, V97, P5516, DOI 10.1073/pnas.97.10.5516
   Baize S, 2014, NEW ENGL J MED, V371, P1418, DOI 10.1056/NEJMoa1404505
   Benders GA, 2010, NUCLEIC ACIDS RES, V38, P2558, DOI 10.1093/nar/gkq119
   Blount BA, 2016, SCI REP-UK, V6, DOI 10.1038/srep26863
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Coley SE, 2005, J VIROL, V79, P3097, DOI 10.1128/JVI.79.5.3097-3106.2005
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Gibson DG, 2010, SCIENCE, V329, P52, DOI 10.1126/science.1190719
   Gietz RD, 2007, NAT PROTOC, V2, P31, DOI 10.1038/nprot.2007.13
   Green MR, 2012, MOL CLONING LAB MANU
   Hierholzer J. C., 1996, P25, DOI 10.1016/B978-012465330-6/50003-8
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu D, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0155-5
   Jonsdottir HR, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11080747
   Kouprina N, 2008, NAT PROTOC, V3, P371, DOI 10.1038/nprot.2008.5
   Lartigue C, 2009, SCIENCE, V325, P1693, DOI 10.1126/science.1173759
   Li H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/bioinformatics/bty191
   Muth D, 2017, J GEN VIROL, V98, P2461, DOI 10.1099/jgv.0.000919
   Mutterer J, 2013, J MICROSC-OXFORD, V252, P89, DOI 10.1111/jmi.12069
   Nikiforuk AM, 2016, J VIROL METHODS, V236, P178, DOI 10.1016/j.jviromet.2016.07.022
   Noskov V, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e8
   Oldfield LM, 2017, P NATL ACAD SCI USA, V114, pE8885, DOI 10.1073/pnas.1700534114
   Polo S, 1997, J VIROL, V71, P5366, DOI 10.1128/JVI.71.7.5366-5374.1997
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273
   V'kovski P, 2019, ELIFE, V8, DOI 10.7554/eLife.42037
   van den Worm SHE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032857
   Vashee S, 2017, MSPHERE, V2, DOI 10.1128/mSphereDirect.00331-17
   Woelfel R., 2020, CLIN PRESENTATION VI, DOI [DOI 10.1101/2020.03.05.20030502, 10.1101/2020.03.05.20030502]
   Yount B, 2000, J VIROL, V74, P10600, DOI 10.1128/JVI.74.22.10600-10611.2000
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zust R, 2007, PLOS PATHOG, V3, P1062, DOI 10.1371/journal.ppat.0030109
NR 36
TC 30
Z9 30
U1 7
U2 18
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUN 25
PY 2020
VL 582
IS 7813
BP 561
EP +
DI 10.1038/s41586-020-2294-9
EA MAY 2020
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OL0DJ
UT WOS:000541050900001
PM 32365353
OA Bronze
DA 2021-01-01
ER

PT J
AU Wang, CY
   Li, WT
   Drabek, D
   Okba, NMA
   van, R
   Osterhaus, ADME
   van Kuppeveld, FJM
   Haagmans, BL
   Grosveld, F
   Bosch, BJ
AF Wang, Chunyan
   Li, Wentao
   Drabek, Dubravka
   Okba, Nisreen M. A.
   van Haperen, Rien
   Osterhaus, Albert D. M. E.
   van Kuppeveld, Frank J. M.
   Haagmans, Bart L.
   Grosveld, Frank
   Bosch, Berend-Jan
TI A human monoclonal antibody blocking SARS-CoV-2 infection
SO NATURE COMMUNICATIONS
LA English
DT Article
ID FUNCTIONAL RECEPTOR; SARS CORONAVIRUS; STRUCTURAL BASIS; SPIKE
AB The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19. Vaccines and targeted therapeutics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are currently lacking. Here, the authors report a human monoclonal antibody capable of neutralizing both authentic SARS-CoV and SARS-CoV-2 by targeting a common epitope.
C1 [Wang, Chunyan; Li, Wentao; van Kuppeveld, Frank J. M.; Bosch, Berend-Jan] Univ Utrecht, Fac Vet Med, Dept Biomol Hlth Sci, Virol Sect,Infect Dis & Immunol Div, Utrecht, Netherlands.
   [Drabek, Dubravka; van Haperen, Rien; Grosveld, Frank] Erasmus MC, Dept Cell Biol, Rotterdam, Netherlands.
   [Drabek, Dubravka; van Haperen, Rien; Grosveld, Frank] Harbour BioMed, Rotterdam, Netherlands.
   [Okba, Nisreen M. A.; Haagmans, Bart L.] Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
   [Osterhaus, Albert D. M. E.] Univ Vet Med, Hannover, Germany.
RP Bosch, BJ (corresponding author), Univ Utrecht, Fac Vet Med, Dept Biomol Hlth Sci, Virol Sect,Infect Dis & Immunol Div, Utrecht, Netherlands.
EM b.j.bosch@uu.nl
RI Li, Wentao/F-9712-2018; Okba, Nisreen MA/K-9984-2017
OI Li, Wentao/0000-0002-7114-762X; Okba, Nisreen MA/0000-0002-2394-1079;
   Haagmans, Bart/0000-0001-6221-2015; Drabek, Dubravka/0000-0002-9781-1701
FU Innovative Medicines Initiative (IMI) Zoonotic Anticipation and
   Preparedness Initiative [ZAPI project] [115760]; Chinese Scholarship
   CouncilChina Scholarship Council [CSC201708620178]
FX We thank Dr. Yoshiharu Matsuura (Osaka University, Japan) for the
   provision of the luciferase-encoding VSV-G-pseudotyped VSV.G-luc virus,
   and Yongle Yang, Michael van der Reijden and Rick Janssens for technical
   support. We thank Christian Drosten (Charite Universitatsmedizin Berlin,
   Germany) for provision of the SARS-CoV-2 virus. This study was done
   within the framework of National Centre for One Health (NCOH), the
   Utrecht Molecular Immunology Hub-Utrecht University and the Innovative
   Medicines Initiative (IMI) Zoonotic Anticipation and Preparedness
   Initiative [ZAPI project; grant agreement no. 115760]. The mice used in
   this study were generated by Harbour Antibodies BV, a daughter company
   of Harbour Biomed (http://www.harbourbiomed.com).C.Wang was supported by
   a grant from the Chinese Scholarship Council (file number
   CSC201708620178).
CR Bosch BJ, 2008, J VIROL, V82, P8887, DOI 10.1128/JVI.00415-08
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Okba NMA, 2019, EMERG INFECT DIS, V25, P1868, DOI [10.3201/eid2509.190051, 10.3201/eid2510.190051]
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Prabakaran P, 2009, EXPERT OPIN BIOL TH, V9, P355, DOI 10.1517/14712590902763755 
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Reguera J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002859
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Saphire EO, 2018, NAT IMMUNOL, V19, P1169, DOI 10.1038/s41590-018-0233-9
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Widjaja I, 2019, EMERG MICROBES INFEC, V8, P516, DOI 10.1080/22221751.2019.1597644
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yu Xiang, 2015, BRAND MARKETING, V5, pp9, DOI DOI 10.1038/srep13133
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 23
TC 222
Z9 220
U1 23
U2 38
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAY 4
PY 2020
VL 11
IS 1
AR 2251
DI 10.1038/s41467-020-16256-y
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LO9ON
UT WOS:000533953700001
PM 32366817
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Wang, L
   Xu, XP
   Ruan, JS
   Lin, SJ
   Jiang, JH
   Ye, H
AF Wang, Ling
   Xu, Xiaopeng
   Ruan, Junshan
   Lin, Saijin
   Jiang, Jinhua
   Ye, Hong
TI Quadruple therapy for asymptomatic COVID-19 infection patients
SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
LA English
DT Article
DE COVID-19; asymptomatic; adverse drug reaction; lopinavir; ritonavir;
   arbidol; IFN-alpha
ID RESPIRATORY SYNDROME CORONAVIRUS; ANTIVIRAL DRUG ARBIDOL;
   INTERFERON-ALPHA; VIRUS-INFECTION; PHARMACOKINETICS; RIBAVIRIN;
   LOPINAVIR/RITONAVIR; HEMAGGLUTININ; SINGLE
AB Introduction: The novel coronavirus (COVID-19) is currently in epidemic stage. After large-scale interpersonal infection, asymptomatic patients appear. Whether asymptomatic patients are contagious or not and whether they need medication are the arguments among clinical experts. Areas covered: This paper reports a special asymptomatic couple with COVID-19, of which the male patient is an intercity bus driver but has not induced confirmed infection of his 188 passengers. The patients were treated with four combinations of lopinavir/ritonavir tablets, arbidol tablets, Lianhuaqingwen granules, and recombinant human interferon-alpha 2b (IFN-alpha 2b) injection via aerosol. Their clinical characteristics and medication were summarized and analyzed. Expert opinion: The two asymptomatic patients far away from Wuhan did not seem to be highly contagious. They improved obviously, after treatment with the quadruple therapy, but the effective drug is still unknown. It should be noted that lopinavir/ritonavir tablets have many drug interactions and are the most likely drugs to cause hyperlipidemia and hyperglycemia in these two patients. IFN-alpha 2b is more effective in the early stage of virus infection. Arbidol instruction dose may not be sufficient to inhibit the novel coronavirus in vivo. The evidence-based medicine of Lianhuaqingwen granules for treating various viral infections is just based on Chinese patients.
C1 [Wang, Ling; Ruan, Junshan; Ye, Hong] Fujian Med Univ, Shengli Clin Med Coll, Fuzhou, Fujian, Peoples R China.
   [Wang, Ling; Ruan, Junshan; Ye, Hong] Fujian Prov Hosp, Dept Pharm, Fuzhou, Fujian, Peoples R China.
   [Xu, Xiaopeng] Nanping Ctr Dis Control & Prevent, Nanping, Fujian, Peoples R China.
   [Lin, Saijin] First Hosp Nanping, Dept Infect Dis, Nanping, Fujian, Peoples R China.
   [Jiang, Jinhua] Songxi Cty Hosp, Nanping, Fujian, Peoples R China.
RP Ruan, JS (corresponding author), Fujian Med Univ, Fujian Prov Hosp, Shengli Clin Med Coll, Dept Pharm, 134 Dongjie Rd, Fuzhou 350001, Fujian, Peoples R China.
EM ruanjunshan@163.com
CR Al-Tawfiq JA, 2014, INT J INFECT DIS, V20, P42, DOI 10.1016/j.ijid.2013.12.003
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chong YP, 2015, INFECT CHEMOTHER, V47, P212, DOI 10.3947/ic.2015.47.3.212
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Deng P, 2013, ANTIMICROB AGENTS CH, V57, P1743, DOI 10.1128/AAC.02282-12
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Giosue S, 1996, EUR RESPIR J, V9, P42, DOI 10.1183/09031936.96.09010042
   Guaraldi G, 2005, TRANSPLANT P, V37, P2609, DOI 10.1016/j.transproceed.2005.06.001
   Gupta SK, 2008, AIDS, V22, P1919, DOI 10.1097/QAD.0b013e32830e011f
   Hulseberg CE, 2019, J VIROL, V93, DOI [10.1128/jvi.02185-18, 10.1128/JVI.02185-18]
   Jia Weina, 2015, ScientificWorldJournal, V2015, P731765, DOI 10.1155/2015/731765
   Khamitov R. A., 2008, Voprosy Virusologii, V53, P9
   Kim UJ, 2016, ANTIVIR THER, V21, P455, DOI 10.3851/IMP3002
   Kramarev S A, 2013, Lik Sprava, P99
   Krasnowska Maryla, 1992, Archivum Immunologiae et Therapiae Experimentalis, V40, P75
   [蓝巧帅 Lan Qiaoshuai], 2020, [中国临床药理学与治疗学, Chinese Journal of Clinical Pharmacology and Therapeutics], V25, P126
   Liu MY, 2009, CLIN THER, V31, P784, DOI 10.1016/j.clinthera.2009.04.016
   Aspiroz EL, 2019, CLIN DRUG INVEST, V39, P1125, DOI 10.1007/s40261-019-00829-x
   MAASILTA P, 1991, LANCET, V337, P371, DOI 10.1016/0140-6736(91)91009-J
   Mizushima D, 2018, J INFECT CHEMOTHER, V24, P549, DOI 10.1016/j.jiac.2018.03.002
   Moll HP, 2011, CYTOKINE, V53, P52, DOI 10.1016/j.cyto.2010.09.006
   Nasser ZH, 2013, ANTIVIR RES, V100, P399, DOI 10.1016/j.antiviral.2013.08.021
   National Health Commission of China, 2020, GUID COVID 19 PNEUM
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Ryom L, 2013, J INFECT DIS, V207, P1359, DOI 10.1093/infdis/jit043
   SATO Y, 1992, J AEROSOL MED, V5, P59, DOI 10.1089/jam.1992.5.59
   Semenenko T. A., 2005, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P24
   Sun YX, 2013, INT J CLIN PHARM TH, V51, P423, DOI 10.5414/CP201843
   van Waterschoot RAB, 2010, BRIT J PHARMACOL, V160, P1224, DOI 10.1111/j.1476-5381.2010.00759.x
   Wang Shi-Heng, 2019, Zhongguo Zhong Yao Za Zhi, V44, P1503, DOI 10.19540/j.cnki.cjcmm.20190102.001
   Wateba MI, 2006, HIV MED, V7, P197, DOI 10.1111/j.1468-1293.2006.00354.x
   Wright ZVF, 2017, BIOORG MED CHEM LETT, V27, P3744, DOI 10.1016/j.bmcl.2017.06.074
   Zeng LY, 2017, EXPERT OPIN INV DRUG, V26, P63, DOI 10.1080/13543784.2017.1269170
   Zhao P, 2014, ALTERN THER HEALTH M, V20, P25
   Zhu S, 2003, LETT BIOTECH, V14, P390, DOI DOI 10.3969/j.issn.1009-0002.2003.05.012
NR 37
TC 6
Z9 6
U1 2
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-7210
EI 1744-8336
J9 EXPERT REV ANTI-INFE
JI Expert Rev. Anti-Infect. Ther.
PD JUL 2
PY 2020
VL 18
IS 7
BP 617
EP 624
DI 10.1080/14787210.2020.1758066
EA MAY 2020
PG 8
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MQ4FU
UT WOS:000532185900001
PM 32362193
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Enmozhi, SK
   Raja, K
   Sebastine, I
   Joseph, J
AF Enmozhi, Sukanth Kumar
   Raja, Kavitha
   Sebastine, Irudhayasamy
   Joseph, Jerrine
TI Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an
   in silico approach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Andrographolide; in silico studies; SWISS-bioinformatics; SARS-CoV-2;
   plant compound
ID HYDROXYCHLOROQUINE
AB SARS-CoV-2 virus which caused the global pandemic the Coronavirus Disease- 2019 (COVID-2019) has infected about 1,203,959 patients and brought forth death rate about 64,788 among 206 countries as mentioned by WHO in the month of April 2020. The clinical trials are underway for Remdesivir, an investigational anti-viral drug from Gilead Sciences. Antimalarial drugs such as Chloroquine and Hydroxychloroquine derivatives are being used in emergency cases; however, they are not suitable for patients with conditions like diabetes, hypertension and cardiac issues. The lack of availability of approved treatment for this disease calls forth the scientific community to find novel compounds with the ability to treat it. This paper evaluates the compound Andrographolide from Andrographis paniculata as a potential inhibitor of the main protease of SARS-COV-2 (Mpro) through in silico studies such as molecular docking, target analysis, toxicity prediction and ADME prediction. Andrographolide was docked successfully in the binding site of SARS-CoV-2 Mpro. Computational approaches also predicts this molecule to have good solubility, pharmacodynamics property and target accuracy. This molecule also obeys Lipinski's rule, which makes it a promising compound to pursue further biochemical and cell based assays to explore its potential for use against COVID-19. Communicated by Ramaswamy H. Sarma
C1 [Enmozhi, Sukanth Kumar; Raja, Kavitha] Univ Madras, Dept Zool, Chennai, Tamil Nadu, India.
   [Sebastine, Irudhayasamy] Periyar Coll Pharmaceut Sci, Dept Pharm, Tiruchirappalli, India.
   [Joseph, Jerrine] Sathyabama Inst Sci & Technol, Ctr Drug Discovery & Dev, Col Dr Jeppiaar Res Pk, Chennai 600119, Tamil Nadu, India.
RP Joseph, J (corresponding author), Sathyabama Inst Sci & Technol, Ctr Drug Discovery & Dev, Col Dr Jeppiaar Res Pk, Chennai 600119, Tamil Nadu, India.
EM jerrine.jj@gmail.com
RI Joseph, Jerrine/AAR-2302-2020; Enmozhi, Sukanth Kumar/AAL-8835-2020
OI Enmozhi, Sukanth Kumar/0000-0002-5291-5195; Sebastine,
   Irudhayasamy/0000-0002-8773-8707
CR Ali SS, 2018, RHEUMATOLOGY ADV S1, V2, prky033, DOI [10.1093/rap/rky033.014., DOI 10.1093/RAP/RKY033.014, 10.1093/rap/rky033.014]
   Bouchentouf S., 2020, IDENTIFICATION COMPO, DOI [10.26434/chemrxiv.12055716, DOI 10.26434/CHEMRXIV.12055716]
   Dai Y, 2019, CRIT REV FOOD SCI, V59, pS17, DOI 10.1080/10408398.2018.1501657
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gfeller D, 2014, NUCLEIC ACIDS RES, V42, pW32, DOI 10.1093/nar/gku293
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guastalegname M, 2020, CLIN INFECT DIS, V71, P888, DOI 10.1093/cid/ciaa321
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Gupta S, 2017, ARCH VIROL, V162, P611, DOI 10.1007/s00705-016-3166-3
   Heald-Sargent T, 2012, VIRUSES-BASEL, V4, P557, DOI 10.3390/v4040557
   Huang C, 2020, LANCET, V395, P496, DOI 10.1016/S0140-6736(20)30252-X
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Pelle MT, 2002, ARCH DERMATOL, V138, P1231, DOI 10.1001/archderm.138.9.1231
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Ramalingam Senthilraja, 2018, Ayu, V39, P87, DOI 10.4103/ayu.AYU_144_17
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Seubsasana S, 2011, MED CHEM, V7, P237, DOI 1573-4064/11 $58.00+.00
   Tailor R, 2012, CASE REP OPHTHALMOL, DOI 10.1155/2012/182747
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wintachai P, 2015, SCI REP-UK, V5, DOI 10.1038/srep14179
   Wondafrash DZ, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/5214751
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 32
TC 43
Z9 43
U1 10
U2 21
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1760136
EA MAY 2020
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LM5MO
UT WOS:000532292900001
PM 32329419
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Wen, W
   Su, WR
   Tang, H
   Le, WQ
   Zhang, XP
   Zheng, YF
   Liu, XX
   Xie, LH
   Li, JM
   Ye, JG
   Dong, LW
   Cui, XL
   Miao, YS
   Wang, DP
   Dong, JT
   Xiao, CL
   Chen, W
   Wang, HY
AF Wen, Wen
   Su, Wenru
   Tang, Hao
   Le, Wenqing
   Zhang, Xiaopeng
   Zheng, Yingfeng
   Liu, Xiuxing
   Xie, Lihui
   Li, Jianmin
   Ye, Jinguo
   Dong, Liwei
   Cui, Xiuliang
   Miao, Yushan
   Wang, Depeng
   Dong, Jiantao
   Xiao, Chuanle
   Chen, Wei
   Wang, Hongyang
TI Immune cell profiling of COVID-19 patients in the recovery stage by
   single-cell sequencing
SO CELL DISCOVERY
LA English
DT Article
ID CORONAVIRUS INFECTIONS; RESPONSES; SARS; ANTIBODIES; DISEASE
AB COVID-19, caused by SARS-CoV-2, has recently affected over 1,200,000 people and killed more than 60,000. The key immune cell subsets change and their states during the course of COVID-19 remain unclear. We sought to comprehensively characterize the transcriptional changes in peripheral blood mononuclear cells during the recovery stage of COVID-19 by single-cell RNA sequencing technique. It was found that T cells decreased remarkably, whereas monocytes increased in patients in the early recovery stage (ERS) of COVID-19. There was an increased ratio of classical CD14(++) monocytes with high inflammatory gene expression as well as a greater abundance of CD14(++)IL1 beta(+) monocytes in the ERS. CD4(+) T cells and CD8(+) T cells decreased significantly and expressed high levels of inflammatory genes in the ERS. Among the B cells, the plasma cells increased remarkably, whereas the naive B cells decreased. Several novel B cell-receptor (BCR) changes were identified, such as IGHV3-23 and IGHV3-7, and isotypes (IGHV3-15, IGHV3-30, and IGKV3-11) previously used for virus vaccine development were confirmed. The strongest pairing frequencies, IGHV3-23-IGHJ4, indicated a monoclonal state associated with SARS-CoV-2 specificity, which had not been reported yet. Furthermore, integrated analysis predicted that IL-1 beta and M-CSF may be novel candidate target genes for inflammatory storm and that TNFSF13, IL-18, IL-2, and IL-4 may be beneficial for the recovery of COVID-19 patients. Our study provides the first evidence of an inflammatory immune signature in the ERS, suggesting COVID-19 patients are still vulnerable after hospital discharge. Identification of novel BCR signaling may lead to the development of vaccines and antibodies for the treatment of COVID-19.
C1 [Wen, Wen; Dong, Liwei; Cui, Xiuliang; Wang, Hongyang] Second Mil Med Univ, Natl Ctr Liver Canc, Shanghai 200438, Peoples R China.
   [Su, Wenru; Zheng, Yingfeng; Liu, Xiuxing; Xie, Lihui; Ye, Jinguo; Xiao, Chuanle] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Peoples R China.
   [Tang, Hao; Miao, Yushan] Second Mil Med Univ, Changzheng Hosp, Dept Resp & Crit Care Med, Shanghai 200003, Peoples R China.
   [Tang, Hao] Wuhan Huoshenshan Hosp, Dept Crit Care, Wuhan 430113, Hubei, Peoples R China.
   [Le, Wenqing] Wuhan Hankou Hosp, Dept Crit Care, Wuhan 430000, Hubei, Peoples R China.
   [Zhang, Xiaopeng; Li, Jianmin; Chen, Wei] Beijing Inst Biotechnol, Lab Vaccine & Antibody Engn, Beijing 100071, Peoples R China.
   [Wang, Depeng] GrandOm Diag Co Ltd, Wuhan 430014, Hubei, Peoples R China.
   [Dong, Jiantao] Berry Genom Co Ltd, Beijing 102206, Peoples R China.
   [Wang, Hongyang] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Shanghai 200438, Peoples R China.
   [Wang, Hongyang] Second Mil Med Univ, Minist Educ MOE, Key Lab Signaling Regulat & Targeting Therapy Liv, Shanghai 200433, Peoples R China.
RP Wang, HY (corresponding author), Second Mil Med Univ, Natl Ctr Liver Canc, Shanghai 200438, Peoples R China.; Xiao, CL (corresponding author), Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Peoples R China.; Chen, W (corresponding author), Beijing Inst Biotechnol, Lab Vaccine & Antibody Engn, Beijing 100071, Peoples R China.; Wang, HY (corresponding author), Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Shanghai 200438, Peoples R China.; Wang, HY (corresponding author), Second Mil Med Univ, Minist Educ MOE, Key Lab Signaling Regulat & Targeting Therapy Liv, Shanghai 200433, Peoples R China.
EM xiaochuanle@126.com; cw0226@foxmail.com; hywangk@vip.sina.com
RI Zhang, XP/AAY-9089-2020
OI Su, Wenru/0000-0002-0506-6362
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81722034, 81670015, 81830054, 81530028,
   91953122, 31871326, 81721003, 81988101, 91859205]; Ministry of Science
   and Technology Key Program [2018ZX09101002, 2017ZX100203205]; Guangdong
   Natural Science Funds for Distinguished Young Scholar [2016A030306006];
   Guangdong Basic and Applied Basic Research Foundation [2020B1515020057];
   Shanghai Pujiang ProgramShanghai Pujiang Program [2019PJD059]
FX This study was supported by National Natural Science Foundation of China
   (81722034, 81670015, 81830054, 81530028, 91953122, 31871326, 81721003,
   81988101, 91859205), the Ministry of Science and Technology Key Program
   (2018ZX09101002, 2017ZX100203205). Guangdong Natural Science Funds for
   Distinguished Young Scholar (2016A030306006), Guangdong Basic and
   Applied Basic Research Foundation (2020B1515020057), and Shanghai
   Pujiang Program (2019PJD059).
CR Aoshi T, 2011, CURR OPIN VIROL, V1, P226, DOI 10.1016/j.coviro.2011.07.002
   Arabi YM, 2020, INTENS CARE MED, V46, P315, DOI 10.1007/s00134-020-05943-5
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Bonilla FA, 2010, J ALLERGY CLIN IMMUN, V125, pS33, DOI 10.1016/j.jaci.2009.09.017
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen G, 2020, J CLIN INVEST, DOI [10.1172/JCI137244, DOI 10.1172/JCI137244]
   Cyranoski D, 2020, NATURE, V577, P607, DOI 10.1038/d41586-020-00190-6
   Ehrhardt SA, 2019, NAT MED, V25, P1589, DOI 10.1038/s41591-019-0602-4
   Fernandez DM, 2019, NAT MED, V25, P1576, DOI 10.1038/s41591-019-0590-4
   Fox A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031535
   Fu Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12780
   Goodwin E, 2018, IMMUNITY, V48, P339, DOI 10.1016/j.immuni.2018.01.005
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kumar MP, 2018, CELL REP, V25, P1458, DOI 10.1016/j.celrep.2018.10.047
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Rothenburg S, 2020, TRENDS MICROBIOL, V28, P46, DOI 10.1016/j.tim.2019.08.007
   Ryon JJ, 2002, CLIN DIAGN LAB IMMUN, V9, P994, DOI 10.1128/CDLI.9.5.994-1003.2002
   Schmitz N, 2005, J VIROL, V79, P6441, DOI 10.1128/JVI.79.10.6441-6448.2005
   See P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02425
   Statement on the second meeting of the International Health Regulations, 2005, EM COMM REG OUTBR NO
   Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031
   Thevarajan I, 2020, BREADTH CONCOMITANT, DOI [10.1101/2020.02.20.20025841, DOI 10.1101/2020.02.20.20025841]
   Thomas PG, 2009, IMMUNITY, V30, P566, DOI 10.1016/j.immuni.2009.02.006
   Thomson CA, 2008, EMBO J, V27, P2592, DOI 10.1038/emboj.2008.179
   Thomson CA, 2011, J IMMUNOL, V186, P2291, DOI 10.4049/jimmunol.0904092
   Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859
   Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ZF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7833
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhang LQ, 2006, J MED VIROL, V78, P1, DOI 10.1002/jmv.20499
   Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006
   Zhao JX, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan5393
   Zhou Y, 2020, BIORXIV, DOI [10.1101/2020.02.12.945576, DOI 10.1101/2020.02.12.945576]
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 49
TC 95
Z9 95
U1 17
U2 21
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2056-5968
J9 CELL DISCOV
JI Cell Discov.
PD MAY 4
PY 2020
VL 6
IS 1
AR 31
DI 10.1038/s41421-020-0168-9
PG 18
WC Cell Biology
SC Cell Biology
GA LL2VT
UT WOS:000531415600001
PM 32377375
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Huang, JF
   Zheng, KI
   George, J
   Gao, HN
   Wei, RN
   Yan, HD
   Zheng, MH
AF Huang, Jiao-Feng
   Zheng, Kenneth I.
   George, Jacob
   Gao, Hai-Nv
   Wei, Ru-Nan
   Yan, Hua-Dong
   Zheng, Ming-Hua
TI Fatal outcome in a liver transplant recipient with COVID-19
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE clinical research; practice; immunosuppressant; immunosuppression;
   immune modulation; infection and infectious agents; infection and
   infectious agents - viral; liver transplantation; hepatology
AB Liver injury is common in patients with COVID-19, but little is known about its clinical presentation and severity in the context of liver transplant. We describe a case of COVID-19 in a patient who underwent transplant 3 years ago for hepatocellular carcinoma. The patient came to clinic with symptoms of respiratory disease; pharyngeal swabs for severe acute respiratory syndrome coronavirus 2 were positive. His disease progressed rapidly from mild to critical illness and was complicated by several nosocomial infections and multiorgan failure. Despite multiple invasive procedures and rescue therapies, he died from the disease. The management of COVID-19 in the posttransplant setting presents complex challenges, emphasizing the importance of strict prevention strategies.
C1 [Huang, Jiao-Feng] Fujian Med Univ, Affiliated Hosp 1, Dept Liver Res Ctr, Fuzhou, Peoples R China.
   [Zheng, Kenneth I.; Zheng, Ming-Hua] Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatol, NAFLD Res Ctr, Wenzhou, Peoples R China.
   [George, Jacob] Westmead Hosp, Westmead Inst Med Res, Storr Liver Ctr, Sydney, NSW, Australia.
   [George, Jacob] Univ Sydney, Sydney, NSW, Australia.
   [Gao, Hai-Nv] Zhejiang Shuren Univ, Shulan Int Med Coll, Shulan Hosp, Dept Infect Dis, Hangzhou, Peoples R China.
   [Wei, Ru-Nan] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, State Key Lab Diag & Treatment Infect Dis, Natl Clin Res Ctr Infect Dis,Coll Med,Affiliated, Hangzhou, Peoples R China.
   [Yan, Hua-Dong] Univ Chinese Acad Sci, Key Lab Diag & Treatment Digest Syst Tumors Zheji, Dept Hepatol, Hwamei Hosp,Ningbo Hosp 2, Ningbo, Peoples R China.
   [Zheng, Ming-Hua] Wenzhou Med Univ, Inst Hepatol, Wenzhou, Peoples R China.
   [Zheng, Ming-Hua] Key Lab Diag & Treatment Dev Chron Liver Dis Zhej, Wenzhou, Peoples R China.
RP Zheng, MH (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatol, NAFLD Res Ctr, Wenzhou, Peoples R China.; Yan, HD (corresponding author), Univ Chinese Acad Sci, Key Lab Diag & Treatment Digest Syst Tumors Zheji, Dept Hepatol, Hwamei Hosp,Ningbo Hosp 2, Ningbo, Peoples R China.; Zheng, MH (corresponding author), Wenzhou Med Univ, Inst Hepatol, Wenzhou, Peoples R China.; Zheng, MH (corresponding author), Key Lab Diag & Treatment Dev Chron Liver Dis Zhej, Wenzhou, Peoples R China.
EM zhengmh@wmu.edu.cn; zhengmh@wmu.edu.cn
RI Zheng, Kenneth I./AAB-3761-2020; Zheng, Ming-Hua/H-5584-2019
OI Zheng, Kenneth I./0000-0002-1726-9298; Zheng,
   Ming-Hua/0000-0003-4984-2631
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81500665]; Medical Health Science and
   Technology Project of Zhejiang Provincial Health Commission [2018ZD039];
   High Level Creative Talents from Department of Public Health in Zhejiang
   Province; Zhejiang Key Research and Development Plan Emergency Project
   [2020C03123]; Project of New Century 551 Talent Nurturing in Wenzhou
FX This work was supported by grants from the National Natural Science
   Foundation of China (81500665), Medical Health Science and Technology
   Project of Zhejiang Provincial Health Commission (2018ZD039), High Level
   Creative Talents from Department of Public Health in Zhejiang Province,
   Zhejiang Key Research and Development Plan Emergency Project
   (2020C03123), and Project of New Century 551 Talent Nurturing in
   Wenzhou.
CR Bouey J, 2020, AM J PUBLIC HEALTH, V110, P939, DOI 10.2105/AJPH.2020.305654
   Commission China National Health, 2020, DIANG TREATM COVID 1
   Feng G, 2020, J CLIN TRANSL HEPATO, V8, P18, DOI 10.14218/JCTH.2020.00018
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   WHO, WHO CHAR COVID 19 PA
   Yeh RF, 2006, JAIDS-J ACQ IMM DEF, V42, P52
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 7
TC 39
Z9 39
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUL
PY 2020
VL 20
IS 7
BP 1907
EP 1910
DI 10.1111/ajt.15909
EA MAY 2020
PG 4
WC Surgery; Transplantation
SC Surgery; Transplantation
GA MD1JV
UT WOS:000530442500001
PM 32277591
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zhong, ZB
   Zhang, QY
   Xia, HY
   Wang, AP
   Liang, WJ
   Zhou, W
   Zhou, LH
   Liu, X
   Rao, LZ
   Li, ZF
   Peng, ZY
   Mo, PZ
   Xiong, Y
   Ye, SJ
   Wang, YF
   Ye, QF
AF Zhong, Zibiao
   Zhang, Qiuyan
   Xia, Haoyang
   Wang, Aiping
   Liang, Wenjin
   Zhou, Wei
   Zhou, Lihua
   Liu, Xiao
   Rao, Lingzhang
   Li, Zhifeng
   Peng, Zhiyong
   Mo, Pingzheng
   Xiong, Yong
   Ye, Shaojun
   Wang, Yanfeng
   Ye, Qifa
TI Clinical characteristics and immunosuppressant management of coronavirus
   disease 2019 in solid organ transplant recipients
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE clinical characteristics; COVID-19; immunosuppressant; solid organ
   transplant recipient
AB Over 1 000 000 cases of coronavirus disease 2019 (COVID-19) have been confirmed since the worldwide outbreak began. Not enough data on infected solid organ transplant (SOT) recipients are available, especially data about the management of immunosuppressants. We report two cases of COVID-19 in two transplant recipients, with different treatments and prognoses. The first patient received liver transplantation due to hepatitis B virus-related hepatocellular carcinoma and was confirmed to have COVID-19 9 days later. Following a treatment regimen consisting of discontinued immunosuppressant use and low-dose methylprednisolone-based therapy, the patient developed acute rejection but eventually recovered. The other patient had undergone a renal transplant from a living-related donor 17 years ago, and was admitted to the hospital because of persistent fever. This patient was also diagnosed with COVID-19. His treatment regimen consisted of reduced immunosuppressant use. No signs of rejection were observed during the regimen. In the end, the patient successfully recovered from COVID-19. These effectively treated cases can provide a basis for immunosuppressant management of COVID-19-positive SOT recipients.
C1 [Zhong, Zibiao; Zhang, Qiuyan; Xia, Haoyang; Liang, Wenjin; Zhou, Wei; Zhou, Lihua; Ye, Shaojun; Wang, Yanfeng; Ye, Qifa] Wuhan Univ, Hubei Key Lab Med Technol Transplantat, Zhongnan Hosp, Inst Hepatobiliary Dis,Transplant Ctr, Wuhan, Hubei, Peoples R China.
   [Wang, Aiping; Liu, Xiao; Rao, Lingzhang] Wuhan Univ Technol, Dept Cardiovasc Med, Wuchang Hosp, Wuhan, Hubei, Peoples R China.
   [Li, Zhifeng; Peng, Zhiyong] Wuhan Univ, Dept Crit Care Med, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
   [Mo, Pingzheng; Xiong, Yong] Wuhan Univ, Dept Infect Dis, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
RP Ye, QF (corresponding author), Wuhan Univ, Hubei Key Lab Med Technol Transplantat, Zhongnan Hosp, Inst Hepatobiliary Dis,Transplant Ctr, Wuhan, Hubei, Peoples R China.
EM yqf_china@163.com
OI Xia, Haoyang/0000-0002-8630-0738; xiong, yong/0000-0003-0678-4064
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81970548, 81570079, 81700657]; Post-Doctoral
   Innovative Talent Support Program
FX This research was supported by the National Natural Science Foundation
   of China, Grant Nos. 81970548, 81570079, and 81700657 and the
   Post-Doctoral Innovative Talent Support Program. We thank the patients
   and the nurses and clinical staff who provided care for the patients,
   and the members of the COVID-19 response teams at the local and national
   levels.
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kotsch K, 2008, ANN SURG, V248, P1042, DOI 10.1097/SLA.0b013e318190e70c
   Kumar D, 2010, LANCET INFECT DIS, V10, P521, DOI 10.1016/S1473-3099(10)70133-X
   Lansbury L, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010406.pub3
   Manuel O, 2019, CLIN TRANSPLANT, V33, DOI 10.1111/ctr.13511
   Michaels MG, 2020, AM J TRANSPLANT, V20, P1768, DOI 10.1111/ajt.15832
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 13
TC 41
Z9 41
U1 4
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUL
PY 2020
VL 20
IS 7
BP 1916
EP 1921
DI 10.1111/ajt.15928
EA MAY 2020
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA MD1JV
UT WOS:000530447900001
PM 32282986
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Helms, J
   Tacquard, C
   Severac, F
   Leonard-Lorant, I
   Ohana, M
   Delabranche, X
   Merdji, H
   Clere-Jehl, R
   Schenck, M
   Gandet, FF
   Fafi-Kremer, S
   Castelain, V
   Schneider, F
   Grunebaum, L
   Angles-Cano, E
   Sattler, L
   Mertes, PM
   Meziani, F
AF Helms, Julie
   Tacquard, Charles
   Severac, Francois
   Leonard-Lorant, Ian
   Ohana, Mickael
   Delabranche, Xavier
   Merdji, Hamid
   Clere-Jehl, Raphael
   Schenck, Malika
   Fagot Gandet, Florence
   Fafi-Kremer, Samira
   Castelain, Vincent
   Schneider, Francis
   Grunebaum, Lelia
   Angles-Cano, Eduardo
   Sattler, Laurent
   Mertes, Paul-Michel
   Meziani, Ferhat
CA CRICS TRIGGERSEP Grp
TI High risk of thrombosis in patients with severe SARS-CoV-2 infection: a
   multicenter prospective cohort study
SO INTENSIVE CARE MEDICINE
LA English
DT Article
DE COVID-19; ARDS; Thrombosis; Lupus anticoagulant; Coagulopathy
ID DISSEMINATED INTRAVASCULAR COAGULATION; RESPIRATORY-DISTRESS-SYNDROME;
   SEPTIC SHOCK; ANTIPHOSPHOLIPID SYNDROME; PATHOGENESIS; CRITERIA;
   HEMOSTASIS; MANAGEMENT; PATHWAYS; INJURY
AB Purpose Little evidence of increased thrombotic risk is available in COVID-19 patients. Our purpose was to assess thrombotic risk in severe forms of SARS-CoV-2 infection. Methods All patients referred to 4 intensive care units (ICUs) from two centers of a French tertiary hospital for acute respiratory distress syndrome (ARDS) due to COVID-19 between March 3rd and 31st 2020 were included. Medical history, symptoms, biological data and imaging were prospectively collected. Propensity score matching was performed to analyze the occurrence of thromboembolic events between non-COVID-19 ARDS and COVID-19 ARDS patients. Results 150 COVID-19 patients were included (122 men, median age 63 [53; 71] years, SAPSII 49 [37; 64] points). Sixty-four clinically relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms (16.7%). 28/29 patients (96.6%) receiving continuous renal replacement therapy experienced circuit clotting. Three thrombotic occlusions (in 2 patients) of centrifugal pump occurred in 12 patients (8%) supported by ECMO. Most patients (> 95%) had elevated D-dimer and fibrinogen. No patient developed disseminated intravascular coagulation. Von Willebrand (vWF) activity, vWF antigen and FVIII were considerably increased, and 50/57 tested patients (87.7%) had positive lupus anticoagulant. Comparison with non-COVID-19 ARDS patients (n = 145) confirmed that COVID-19 ARDS patients (n = 77) developed significantly more thrombotic complications, mainly pulmonary embolisms (11.7 vs. 2.1%, p < 0.008). Coagulation parameters significantly differed between the two groups. Conclusion Despite anticoagulation, a high number of patients with ARDS secondary to COVID-19 developed life-threatening thrombotic complications. Higher anticoagulation targets than in usual critically ill patients should therefore probably be suggested.
C1 [Helms, Julie; Merdji, Hamid; Clere-Jehl, Raphael; Meziani, Ferhat] Hop Univ Strasbourg, Nouvel Hop Civil, Serv Med Intens Reanimat, 1 Pl Hop, F-67091 Strasbourg, France.
   [Helms, Julie; Clere-Jehl, Raphael; Fafi-Kremer, Samira] Univ Strasbourg UNISTRA, ImmunoRhumatol Mol, INSERM,Fac Med,Federat Hosp Univ FHU OMICARE,Fede, UMRS 1109,LabEx TRANSPLANTEX,Ctr Rech Immunol & H, Strasbourg, France.
   [Tacquard, Charles; Delabranche, Xavier; Mertes, Paul-Michel] Hop Univ Strasbourg, Serv Anesthesie Reanimat, Nouvel Hop Civil, Strasbourg, France.
   [Severac, Francois] Hop Univ Strasbourg, Grp Methodes Rech Clin GMRC, Hop Civil, Strasbourg, France.
   [Leonard-Lorant, Ian; Ohana, Mickael] Strasbourg Univ Hosp, Radiol Dept, Nouvel Hop Civil, Strasbourg, France.
   [Merdji, Hamid; Meziani, Ferhat] French Natl Inst Hlth & Med Res, INSERM, FMTS, UMR 1260,Regenerat Nanomed RNM, Strasbourg, France.
   [Schenck, Malika; Fagot Gandet, Florence; Castelain, Vincent; Schneider, Francis] Hop Univ Strasbourg, Serv Med Intens Reanimat, Hautepierre, Strasbourg, France.
   [Fafi-Kremer, Samira] Hop Univ Strasbourg, Lab Virol Med, Strasbourg, France.
   [Grunebaum, Lelia; Sattler, Laurent] Hop Univ Strasbourg, Lab Hematol, Hautepierre, Strasbourg, France.
   [Angles-Cano, Eduardo] Univ Paris, INSERM, UMR S 1140, Innovat Therapies Haemostasis, F-75006 Paris, France.
RP Meziani, F (corresponding author), Hop Univ Strasbourg, Nouvel Hop Civil, Serv Med Intens Reanimat, 1 Pl Hop, F-67091 Strasbourg, France.
EM Ferhat.Meziani@chru-strasbourg.fr
RI Castelain, Vincent/ABG-9778-2020; ANGLES-CANO, Eduardo/ABA-1739-2020
OI ANGLES-CANO, Eduardo/0000-0001-7891-3975; Castelain,
   Vincent/0000-0002-9354-6525; SATTLER, Laurent/0000-0003-2702-6246;
   LEONARD-LORANT, Ian/0000-0001-9323-3839
CR Antoniak S, 2014, BLOOD, V123, P2605, DOI 10.1182/blood-2013-09-526277
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Basler CF, 2017, SEMIN IMMUNOPATHOL, V39, P551, DOI 10.1007/s00281-017-0637-x
   Bautista E, 2013, EXP MOL PATHOL, V94, P486, DOI 10.1016/j.yexmp.2013.03.007
   BERTOZZI P, 1990, NEW ENGL J MED, V322, P890, DOI 10.1056/NEJM199003293221304
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Delabranche X, 2016, CRIT CARE MED, V44, pE930, DOI 10.1097/CCM.0000000000001836
   Delabranche X, 2013, INTENS CARE MED, V39, P1695, DOI 10.1007/s00134-013-2993-x
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Gershom ES, 2010, J THROMB HAEMOST, V8, P1037, DOI 10.1111/j.1538-7836.2010.03789.x
   Giannakopoulos B, 2013, NEW ENGL J MED, V368, P1033, DOI 10.1056/NEJMra1112830
   Glass WG, 2004, J IMMUNOL, V173, P4030, DOI 10.4049/jimmunol.173.6.4030
   Goldman-Mazur S, 2019, THROMB RES, V176, P67, DOI 10.1016/j.thromres.2019.02.008
   Gralinski LE, 2013, MBIO, V4, DOI 10.1128/mBio.00271-13
   Grimmer B, 2017, J APPL PHYSIOL, V123, P1635, DOI 10.1152/japplphysiol.00120.2017
   Gupta N, 2019, THROMB RES, V181, P77, DOI 10.1016/j.thromres.2019.07.013
   Hattori N, 1999, AM J PHYSIOL-LUNG C, V277, pL573
   Hoste Eric A J, 2005, J Intensive Care Med, V20, P43, DOI 10.1177/0885066604271616
   Iba T, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1468-1
   IDELL S, 1989, J CLIN INVEST, V84, P695, DOI 10.1172/JCI114217
   Lim W, 2015, CRIT CARE MED, V43, P401, DOI 10.1097/CCM.0000000000000713
   Malek M, 2018, CHIN J TRAUMATOL, V21, P4, DOI 10.1016/j.cjtee.2017.07.004
   Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x
   Oudemans-van Straaten HM, 2015, SEMIN THROMB HEMOST, V41, P91, DOI 10.1055/s-0034-1398384
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6
   Seeley EJ, 2013, ADV CHRONIC KIDNEY D, V20, P14, DOI 10.1053/j.ackd.2012.10.001
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327
   Thachil J, 2020, J THROMB HAEMOST, DOI [10.1111/jth.14860, DOI 10.1111/JTH.14860]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu YP, 2006, THROMB HAEMOSTASIS, V96, P100, DOI 10.1160/TH05-12-0827
   Yan SF, 1999, ARTERIOSCL THROM VAS, V19, P2029, DOI 10.1161/01.ATV.19.9.2029
NR 33
TC 382
Z9 386
U1 9
U2 14
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD JUN
PY 2020
VL 46
IS 6
BP 1089
EP 1098
DI 10.1007/s00134-020-06062-x
EA MAY 2020
PG 10
WC Critical Care Medicine
SC General & Internal Medicine
GA LX9PL
UT WOS:000530254200004
PM 32367170
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Dashti-Khavidaki, S
   Khalili, H
AF Dashti-Khavidaki, Simin
   Khalili, Hossein
TI Considerations for Statin Therapy in Patients with COVID-19
SO PHARMACOTHERAPY
LA English
DT Letter
DE coronavirus infection; COVID-19; HMG-CoA reductase inhibitor; SARS-CoV;
   statin
ID VENTILATOR-ASSOCIATED PNEUMONIA; INFLAMMATION; MORTALITY
C1 [Dashti-Khavidaki, Simin; Khalili, Hossein] Univ Tehran Med Sci, Dept Clin Pharm, Fac Pharm, Tehran, Iran.
RP Khalili, H (corresponding author), Univ Tehran Med Sci, Clin Pharm, Fac Pharm, POB 1417614411, Tehran, Iran.
EM khalilih@sina.tums.ac.ir
CR [Anonymous], 2020, LEX MOB APPS
   Chansrichavala P, 2009, ASIAN PAC J ALLERGY, V27, P49
   Chen WG, 2014, AM J RESP CELL MOL, V50, P328, DOI 10.1165/rcmb.2013-0058OC
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   Fedson DS, 2020, MBIO, V11, DOI 10.1128/mBio.00398-20
   Garnacho-Montero J, 2018, EXPERT REV ANTI-INFE, V16, P667, DOI 10.1080/14787210.2018.1512403
   Goldstein MR, 2020, QJM-INT J MED, V113, P509, DOI 10.1093/qjmed/hcaa103
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Makris D, 2011, CRIT CARE MED, V39, P2440, DOI 10.1097/CCM.0b013e318225742c
   Papazian L, 2013, JAMA-J AM MED ASSOC, V310, P1692, DOI 10.1001/jama.2013.280031
   Rogers AJ, 2019, CRIT CARE MED, V47, P1089, DOI 10.1097/CCM.0000000000003816
   Schonbeck U, 2004, CIRCULATION, V109, P18, DOI 10.1161/01.CIR.0000129505.34151.23
   Sheahan T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000240
   Shyamsundar M, 2009, AM J RESP CRIT CARE, V179, P1107, DOI 10.1164/rccm.200810-1584OC
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.01303-15
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Turner RM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010022
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yuan S, 2015, MBIO, V6, DOI 10.1128/mBio.01120-15
   Yuan X, 2014, BIOCHEM BIOPH RES CO, V446, P292, DOI 10.1016/j.bbrc.2014.02.091
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 23
TC 26
Z9 25
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-0008
EI 1875-9114
J9 PHARMACOTHERAPY
JI Pharmacotherapy
PD MAY
PY 2020
VL 40
IS 5
BP 484
EP 486
DI 10.1002/phar.2397
EA MAY 2020
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LN4MQ
UT WOS:000530565100001
PM 32267560
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kumar, D
   Kumari, K
   Jayaraj, A
   Kumar, V
   Kumar, RV
   Dass, SK
   Chandra, R
   Singh, P
AF Kumar, Durgesh
   Kumari, Kamlesh
   Jayaraj, Abhilash
   Kumar, Vinod
   Kumar, Ramappa Venkatesh
   Dass, Sujata K.
   Chandra, Ramesh
   Singh, Prashant
TI Understanding the binding affinity of noscapines with protease of
   SARS-CoV-2 for COVID-19 using MD simulations at different temperatures
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Protease of SARS-CoV-2; COVID-19; molecular docking; MD simulations;
   noscapine; screening
ID DOCKING; AMBER
AB The current outbreak of a novel coronavirus, named as SARS-CoV-2 causing COVID-19 occurred in 2019, is in dire need of finding potential therapeutic agents. Recently, ongoing viral epidemic due to coronavirus (SARS-CoV-2) primarily affected mainland China that now threatened to spread to populations in most countries of the world. In spite of this, there is currently no antiviral drug/ vaccine available against coronavirus infection, COVID-19. In the present study, computer-aided drug design-based screening to find out promising inhibitors against the coronavirus (SARS-CoV-2) leads to infection, COVID-19. The lead therapeutic molecule was investigated through docking and molecular dynamics simulations. In this, binding affinity of noscapines(23B)-protease of SARS-CoV-2 complex was evaluated through MD simulations at different temperatures. Our research group has established that noscapine is a chemotherapeutic agent for the treatment of drug resistant cancers; however, noscapine was also being used as anti-malarial, anti-stroke and cough-suppressant. This study suggests for the first time that noscapine exerts its antiviral effects by inhibiting viral protein synthesis.
C1 [Kumar, Durgesh; Singh, Prashant] Univ Delhi, ARSD Coll, Dept Chem, New Delhi 110021, India.
   [Kumar, Durgesh; Chandra, Ramesh] Univ Delhi, Dept Chem, Drug Discovery & Dev Lab, Delhi, India.
   [Kumari, Kamlesh] Univ Delhi, DDU Coll, Dept Zool, New Delhi, India.
   [Jayaraj, Abhilash] Indian Inst Technol, SCFBio, New Delhi, India.
   [Kumar, Vinod] Jawaharlal Nehru Univ, Special Ctr Nano Sci, Delhi, India.
   [Kumar, Ramappa Venkatesh] Babasaheb Bhimrao Ambedkar Univ, Dept Zool, Lucknow, Uttar Pradesh, India.
   [Dass, Sujata K.] BLK Super Special Hosp, Dept Neurol, New Delhi, India.
RP Singh, P (corresponding author), Univ Delhi, ARSD Coll, Dept Chem, New Delhi 110021, India.; Chandra, R (corresponding author), Univ Delhi, Dept Chem, Drug Discovery & Dev Lab, Delhi, India.
EM acbrdu@hotmail.com; psingh@arsd.du.ac.in
RI KUMAR, VINOD/E-5196-2011
OI KUMAR, VINOD/0000-0002-8362-8009
FU University of Delhi under DST-PURSE grant; Council of Scientific and
   Industrial Research (CSIR)Council of Scientific & Industrial Research
   (CSIR) - India; SERB-DST, New Delhi, Government of India
FX Prof. Ramesh Chandra (RC) thankfully acknowledges the financial
   assistance provided by the University of Delhi under DST-PURSE grant;
   Council of Scientific and Industrial Research (CSIR) and SERB-DST, New
   Delhi, Government of India.
CR Aaboud M, 2018, PHYS REV LETT, V121, DOI 10.1103/PhysRevLett.121.152002
   Aaboud M, 2017, EUR PHYS J C, V77, DOI 10.1140/epjc/s10052-017-5442-0
   Abbad A, 2019, EUROSURVEILLANCE, V24, P43, DOI 10.2807/1560-7917.ES.2019.24.48.1900244
   Adasme-Carreno F, 2014, PHYS CHEM CHEM PHYS, V16, P14047, DOI 10.1039/c4cp01378f
   Agarwal Anup, 2020, Indian J Med Res, V151, P177, DOI 10.4103/ijmr.IJMR_518_20
   Agarwal T, 2015, INDIAN J PHARM SCI, V77, P453
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Al-Anazi M, 2018, MOLECULES, V23, DOI 10.3390/molecules23123203
   AL-Johani MA, 2017, MOLECULES, V22, DOI 10.3390/molecules22122114
   Alamri MA, 2019, BIOINFORMATION, V15, P586, DOI 10.6026/97320630015579
   Alexandrescu AT, 2001, PROTEIN SCI, V10, P1856, DOI 10.1110/ps.14301
   Alfaro S, 2020, MINI-REV MED CHEM, V20, P1436, DOI 10.2174/1389557520666191224113830
   Ali L, 2019, COMPUT MATH METHOD M, V2019, DOI 10.1155/2019/6314328
   Ali SA, 2020, J INFECT PUBLIC HEAL, V13, P644, DOI [10.1016/j.jiph.2020.02.033, 10.1016/j.jiph.2019.02.033]
   Ali W, 2019, BIOINFORMATION, V15, P832, DOI 10.6026/97320630015832
   Athir N, 2019, PHYS CHEM CHEM PHYS, V21, P21615, DOI 10.1039/c9cp03221e
   Boldog P, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020571
   Burley SK, 2018, PROTEIN SCI, V27, P316, DOI 10.1002/pro.3331
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chandra A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1734487
   Chaudhari Hemchandra K., 2019, Infectious Disorders - Drug Targets, V19, P145, DOI 10.2174/1871526518666181015145545
   Chinnasamy S, 2020, J BIOMOL STRUCT DYN, V38, P4325, DOI 10.1080/07391102.2019.1674695
   Chtita S, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01304
   Cinaroglu Suleyman Selim, 2020, Brief Bioinform, V21, P2112, DOI 10.1093/bib/bbz143
   Daoui S, 2019, ACTA CRYSTALLOGR E, V75, P1030, DOI 10.1107/S2056989019008557
   De Salazar PM, 2020, EMERG INFECT DIS, V26, P1465, DOI 10.3201/eid2607.200250
   Du J, 2011, J COMPUT CHEM, V32, P2800, DOI 10.1002/jcc.21859
   Duan L, 2020, LANCET PSYCHIAT, V7, P300, DOI 10.1016/S2215-0366(20)30073-0
   Gao YL, 2020, J BIOMOL STRUCT DYN, V38, P4119, DOI 10.1080/07391102.2019.1673823
   Goodsell DS, 2020, PROTEIN SCI, V29, P52, DOI 10.1002/pro.3730
   Gupta A, 2007, PROTEIN PEPTIDE LETT, V14, P632
   Hayes JM, 2011, PROTEINS, V79, P703, DOI 10.1002/prot.22890
   Hollingsworth SA, 2018, NEURON, V99, P1129, DOI 10.1016/j.neuron.2018.08.011
   Hsu KC, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S1-S33
   Joshi T, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1719200
   Kalirajan Rajagopal, 2019, Curr Drug Res Rev, V11, P118, DOI 10.2174/2589977511666190912154817
   Kumar D, 2020, J BIOMOL STRUCT DYN, V38, P3018, DOI 10.1080/07391102.2019.1650830
   Kumar D, 2019, CHEMISTRYSELECT, V4, P4892, DOI 10.1002/slct.201803360
   Pant P, 2017, BIOPOLYMERS, V107, DOI 10.1002/bip.23002
   Pereira GRC, 2019, J CELL BIOCHEM, V120, P3583, DOI 10.1002/jcb.27636
   Do PC, 2018, J CHEM INF MODEL, V58, P1473, DOI 10.1021/acs.jcim.8b00261
   Roe DR, 2018, J COMPUT CHEM, V39, P2110, DOI 10.1002/jcc.25382
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Singh P, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02795
   Skjevik AA, 2015, CHEM COMMUN, V51, P4402, DOI 10.1039/c4cc09584g
   Vora J, 2020, CURR HIV RES, V18, P132, DOI 10.2174/1570162X18666200129112509
   Wang XY, 2019, PHYS CHEM CHEM PHYS, V21, P9159, DOI 10.1039/c8cp07881e
   Yuan SG, 2017, TRENDS BIOTECHNOL, V35, P559, DOI 10.1016/j.tibtech.2017.03.009
   Zhao JJ, 2019, J PHYS CHEM B, V123, P3024, DOI 10.1021/acs.jpcb.9b01674
NR 50
TC 5
Z9 5
U1 12
U2 17
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1752310
EA MAY 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LN5RI
UT WOS:000532994000001
PM 32362235
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Veerapandiyan, A
   Connolly, AM
   Finkel, RS
   Arya, K
   Mathews, KD
   Smith, EC
   Castro, D
   Butterfield, RJ
   Parsons, JA
   Servais, L
   Kuntz, N
   Rao, VK
   Brandsema, JF
   Mercuri, E
   Ciafaloni, E
AF Veerapandiyan, Aravindhan
   Connolly, Anne M.
   Finkel, Richard S.
   Arya, Kapil
   Mathews, Katherine D.
   Smith, Edward C.
   Castro, Diana
   Butterfield, Russell J.
   Parsons, Julie A.
   Servais, Laurent
   Kuntz, Nancy
   Rao, Vamshi K.
   Brandsema, John F.
   Mercuri, Eugenio
   Ciafaloni, Emma
TI Spinal muscular atrophy care in the COVID-19 pandemic era
SO MUSCLE & NERVE
LA English
DT Article
DE corona; epidemic; guidelines; pandemic; SMA; treatment
ID SHAM CONTROL; NUSINERSEN
AB The coronavirus disease 2019 (COVID-19) pandemic has resulted in reorganization of healthcare settings affecting the delivery of clinical care to patients with spinal muscular atrophy (SMA). There is a concern that patients with SMA may be at increased risk of manifesting severe symptoms of COVID-19. Currently approved therapies for SMA improve survival and motor function; however, their delivery requires an increased exposure to the health system and a dedicated healthcare team. In this study, we discuss consensus recommendations pertaining to care of SMA patients during the pandemic. We highlight that SMA treatments should not be perceived as elective. Decisions regarding the delay of treatments should be made with consideration of the potential risks of COVID-19 exposure and the risk of that delay. We emphasize the importance of collaborative treatment decisions between the patient, family, and healthcare provider, considering any geographic- or institution-specific policies and precautions for COVID-19.
C1 [Veerapandiyan, Aravindhan; Arya, Kapil] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Div Neurol, Dept Pediat, Little Rock, AR 72205 USA.
   [Connolly, Anne M.] Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Dept Pediat,Div Neurol, Columbus, OH 43210 USA.
   [Finkel, Richard S.] St Jude Childrens Res Hosp, Expt Neurotherapeut, 332 N Lauderdale St, Memphis, TN 38105 USA.
   [Mathews, Katherine D.] Univ Iowa, Carver Coll Med, Dept Pediat, Iowa City, IA 52242 USA.
   [Smith, Edward C.] Duke Univ, Med Ctr, Dept Pediat, Div Neurol, Durham, NC 27710 USA.
   [Castro, Diana] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA.
   [Butterfield, Russell J.] Univ Utah, Sch Med, Dept Pediat & Neurol, Salt Lake City, UT USA.
   [Parsons, Julie A.] Univ Colorado, Sch Med, Dept Neurol & Pediat, Aurora, CO USA.
   [Servais, Laurent] Univ Liege, Neuromuscular Reference Ctr Dis, Dept Pediat, Liege, Belgium.
   [Servais, Laurent] Univ Oxford, Dept Pediat, MDUK Neuromuscular Ctr, Oxford, England.
   [Kuntz, Nancy; Rao, Vamshi K.] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat,Div Neurol, Chicago, IL 60611 USA.
   [Brandsema, John F.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Div Neurol, Philadelphia, PA 19104 USA.
   [Mercuri, Eugenio] Catholic Univ, Pediat Neurol, Rome, Italy.
   [Mercuri, Eugenio] Fdn Policlin Univ Agostino Gemelli IRCC, Ctr Clin Nemo, Policlin Gemelli, Rome, Italy.
   [Ciafaloni, Emma] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.
RP Ciafaloni, E (corresponding author), Univ Rochester, Med Ctr, 601 Elmwood Ave,POB 673, Rochester, NY 14642 USA.
EM emma_ciafaloni@urmc.rochester.edu
RI Rao, Vamshi/AAK-3259-2020
OI Rao, Vamshi/0000-0002-0130-2292; Servais, Laurent/0000-0001-9270-4061;
   Kuntz, Nancy L/0000-0003-2253-5156
CR Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Centers for Disease Control and Prevention, COR COVID 19
   Cohen BH, 2020, CONTINUUM MINNEAP MI, V26, P1
   CURE, NEWB SCREEN SMA
   Dangouloff T, 2019, THER CLIN RISK MANAG, V15, P1153, DOI 10.2147/TCRM.S172291
   De Vivo DC, 2019, NEUROMUSCULAR DISORD, V29, P842, DOI 10.1016/j.nmd.2019.09.007
   Du W, 2020, CHINA INFECT, DOI [10.1007/s15010-020-01427-2, DOI 10.1007/S15010-020-01427-2]
   European Centre for Disease Prevention and Control, COVID 19 GUID
   Finkel RS, 2017, NEW ENGL J MED, V377, P1723, DOI 10.1056/NEJMoa1702752
   Hoehl S, 2020, NEW ENGL J MED, V382, P1278, DOI 10.1056/NEJMc2001899
   Jeng Mei-Jy, 2020, J Chin Med Assoc, DOI 10.1097/JCMA.0000000000000323
   Ludwig S, 2020, ANESTH ANALG, V131, P93, DOI 10.1213/ANE.0000000000004845
   Luu KT, 2017, J CLIN PHARMACOL, V57, P1031, DOI 10.1002/jcph.884
   Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198
   Mercuri E, 2018, NEW ENGL J MED, V378, P625, DOI 10.1056/NEJMoa1710504
   Ramdas S, 2020, EXPERT OPIN PHARMACO, V21, P307, DOI 10.1080/14656566.2019.1704732
   U.S. Food and Drug Administration, ZOLG ON AB XIOI
   US Food & Drug Administration, SPINR NUS INJ
   Veerapandiyan A., 2019, MEDLINK NEUROLOGY
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wei WE, 2020, MMWR-MORBID MORTAL W, V69, P411, DOI 10.15585/mmwr.mm6914e1
   Zheng YL, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104366
NR 22
TC 3
Z9 3
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD JUL
PY 2020
VL 62
IS 1
BP 46
EP 49
DI 10.1002/mus.26903
EA MAY 2020
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA LY1IN
UT WOS:000529809000001
PM 32329921
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Richardson, PJ
   Ottaviani, S
   Prelle, A
   Stebbing, J
   Casalini, G
   Corbellino, M
AF Richardson, Peter J.
   Ottaviani, Silvia
   Prelle, Alessandro
   Stebbing, Justin
   Casalini, Giacomo
   Corbellino, Mario
TI CNS penetration of potential anti-COVID-19 drugs
SO JOURNAL OF NEUROLOGY
LA English
DT Letter
C1 [Richardson, Peter J.] BenevolentAI, London, England.
   [Ottaviani, Silvia; Stebbing, Justin] Imperial Coll, Dept Surg & Canc, London W12 0NN, England.
   [Prelle, Alessandro] ASST Ovest Milanese, Dept Neurol, Milan, Italy.
   [Prelle, Alessandro] ASST Ovest Milanese, Stroke Unit, Milan, Italy.
   [Casalini, Giacomo; Corbellino, Mario] ASST Fatebenefratelli Sacco, Div Infect Dis 3, Milan, Italy.
RP Ottaviani, S (corresponding author), Imperial Coll, Dept Surg & Canc, London W12 0NN, England.
EM silvia.ottaviani07@imperial.ac.uk
OI Stebbing, Justin/0000-0002-1117-6947; Ottaviani,
   Silvia/0000-0002-8830-9947
FU Department of Health [NIHR-RP-011-053] Funding Source: Medline
CR Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Bixler SL, 2018, ANTIVIR RES, V151, P50, DOI 10.1016/j.antiviral.2017.12.020
   Ene L, 2011, J Med Life, V4, P432
   Gavegnano C, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1565-6
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Jackson KM, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-2084
   Jaruratanasirikul S, 1996, ANTIMICROB AGENTS CH, V40, P825, DOI 10.1128/AAC.40.3.825
   Justin S, 2020, RES SQUARE, DOI [10.21203/rs.3.rs-23195/v1., DOI 10.21203/RS.3.RS-23195/V1, 10.21203/rs.3.rs-23195/v1]
   Mao L., 2020, NEUROLOGICAL MANIFES, DOI [10.1101/2020.02.22.20026500., 10.1101/2020.02.22.20026500, DOI 10.1101/2020.02.22.20026500]
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Nellan A, 2018, BLOOD, V132, P662, DOI 10.1182/blood-2018-05-846428
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Wang W, 2020, CANCERS, V12, DOI 10.3390/cancers12010211
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Ye MX, 2020, BRAIN BEHAV IMMUN, V88, P945, DOI 10.1016/j.bbi.2020.04.017
   Zhang Q, 2014, DRUG METAB DISPOS, V42, P1656, DOI 10.1124/dmd.114.058883
NR 19
TC 3
Z9 3
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD JUL
PY 2020
VL 267
IS 7
BP 1880
EP 1882
DI 10.1007/s00415-020-09866-5
EA MAY 2020
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA MD5FV
UT WOS:000530204300001
PM 32361836
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Wang, X
   Cao, RY
   Zhang, HY
   Liu, J
   Xu, MY
   Hu, HR
   Li, YF
   Zhao, L
   Li, W
   Sun, XL
   Yang, XL
   Shi, ZL
   Deng, F
   Hu, ZH
   Zhong, W
   Wang, ML
AF Wang, Xi
   Cao, Ruiyuan
   Zhang, Huanyu
   Liu, Jia
   Xu, Mingyue
   Hu, Hengrui
   Li, Yufeng
   Zhao, Lei
   Li, Wei
   Sun, Xiulian
   Yang, Xinglou
   Shi, Zhengli
   Deng, Fei
   Hu, Zhihong
   Zhong, Wu
   Wang, Manli
TI The anti-influenza virus drug, arbidol is an efficient inhibitor of
   SARS-CoV-2 in vitro
SO CELL DISCOVERY
LA English
DT Letter
ID REMDESIVIR
C1 [Wang, Xi; Zhang, Huanyu; Liu, Jia; Xu, Mingyue; Hu, Hengrui; Li, Yufeng; Sun, Xiulian; Yang, Xinglou; Shi, Zhengli; Deng, Fei; Hu, Zhihong; Wang, Manli] Chinese Acad Sci, Ctr Biosafety Mega Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China.
   [Cao, Ruiyuan; Zhao, Lei; Li, Wei; Zhong, Wu] Beijing Inst Pharmacol & Toxicol, Natl Engn Res Ctr Emergency Drug, Beijing 100850, Peoples R China.
   [Zhang, Huanyu; Xu, Mingyue; Hu, Hengrui; Li, Yufeng] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Deng, Fei] Chinese Acad Sci, Wuhan Inst Virol, Natl Virus Resource Ctr, Wuhan 430071, Peoples R China.
RP Hu, ZH; Wang, ML (corresponding author), Chinese Acad Sci, Ctr Biosafety Mega Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China.; Zhong, W (corresponding author), Beijing Inst Pharmacol & Toxicol, Natl Engn Res Ctr Emergency Drug, Beijing 100850, Peoples R China.
EM huzh@wh.iov.cn; zhongwu@bmi.ac.cn; wangml@wh.iov.cn
RI yang, xinglou/AAW-6969-2020
FU National Science and Technology Major Projects for "Major New Drugs
   Innovation and Development" [2018ZX09711003]; National Key R&D program
   of China [2020YFC0841700]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [31621061]
FX We thank Prof. Zhenhua Zheng from Wuhan Institute of Virology for kindly
   providing the anti-LAMP1 rabbit polyclonal antibody; Beijing Savant
   Biotechnology Co., ltd for kindly providing the anti-NP monoclonal
   antibody; Jia Wu, Jun Liu, and Hao Tang from BSL-3 Laboratory, and Dr.
   Ding Gao from the Core Faculty of Wuhan Institute of Virology for their
   critical support; Dr. Basil Arif for scientific editing of the paper.
   This work was supported by grants from the National Science and
   Technology Major Projects for "Major New Drugs Innovation and
   Development" (2018ZX09711003), the National Key R&D program of China
   (2020YFC0841700), and the National Natural Science Foundation of China
   (31621061).
CR Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Blaising J, 2013, ANTIVIR RES, V100, P215, DOI 10.1016/j.antiviral.2013.08.008
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   De Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI 10.1128/CMR.00102-15
   Decroly E, 2012, NAT REV MICROBIOL, V10, P51, DOI 10.1038/nrmicro2675
   Gasparini R, 2014, J Prev Med Hyg, V55, P69
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kadam RU, 2017, P NATL ACAD SCI USA, V114, P206, DOI 10.1073/pnas.1617020114
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu Q, 2013, ACTA PHARMACOL SIN, V34, P1075, DOI 10.1038/aps.2013.54
   Si LL, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aau8408
   Sun YX, 2013, INT J CLIN PHARM TH, V51, P423, DOI 10.5414/CP201843
   Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
NR 16
TC 38
Z9 38
U1 1
U2 6
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2056-5968
J9 CELL DISCOV
JI Cell Discov.
PD MAY 2
PY 2020
VL 6
IS 1
AR 28
DI 10.1038/s41421-020-0169-8
PG 5
WC Cell Biology
SC Cell Biology
GA LI9ZP
UT WOS:000529834700001
PM 32373347
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Singh, AG
   Chaturvedi, P
AF Singh, Arjun Gurmeet
   Chaturvedi, Pankaj
TI Clinical trials during COVID-19
SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND
   NECK
LA English
DT Article
DE clinical research; coronavirus; COVID-19; head neck; trials
AB As this ever-evolving pandemic lays itself, more of its impact is being understood. Until recently, most guidelines were reported to aid in managing and treating suspected or confirmed cases. Research institutions around the world are responding with a sense of confusion. Some are continuing routinely, especially those who are overseeing clinical trials that could offer life-saving therapies, particularly against the novel coronavirus. Since research must continue even in the face of a shutdown, we aim to collate the currently available recommendations from various organizations and provide guidance to head and neck researchers across the world during these trying times.
C1 [Singh, Arjun Gurmeet; Chaturvedi, Pankaj] Tata Mem Hosp, Dept Head & Neck Oncol, Mumbai, Maharashtra, India.
RP Chaturvedi, P (corresponding author), Tata Mem Hosp, Dept Head & Neck Oncol, Mumbai, Maharashtra, India.
EM chaturvedi.pankaj@gmail.com
OI Singh, Arjun/0000-0002-8119-8439
CR [Anonymous], 2020, Q A IMPACT COVID 19
   FDA, 2020, RES C CLIN TRIAL CON
   FDA, FDA GUIDANCE CONDUCT
NR 3
TC 5
Z9 5
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1043-3074
EI 1097-0347
J9 HEAD NECK-J SCI SPEC
JI Head Neck-J. Sci. Spec. Head Neck
PD JUL
PY 2020
VL 42
IS 7
SI SI
BP 1516
EP 1518
DI 10.1002/hed.26223
EA MAY 2020
PG 3
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA MF8CB
UT WOS:000529745900001
PM 32348582
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kim, Y
   Jedrzejczak, R
   Maltseva, NI
   Wilamowski, M
   Endres, M
   Godzik, A
   Michalska, K
   Joachimiak, A
AF Kim, Youngchang
   Jedrzejczak, Robert
   Maltseva, Natalia I.
   Wilamowski, Mateusz
   Endres, Michael
   Godzik, Adam
   Michalska, Karolina
   Joachimiak, Andrzej
TI Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2
SO PROTEIN SCIENCE
LA English
DT Article
DE COVID-19; crystal structure; endoribonuclease; EndoU family; NendoU;
   Nsp15; SARS-CoV-2
ID SMALL NUCLEOLAR RNA; PROTEIN 11; CORONAVIRUS; XENDOU; MODEL;
   DETERMINANTS; PURIFICATION; MARKER
AB Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is rapidly spreading around the world. There is no existing vaccine or proven drug to prevent infections and stop virus proliferation. Although this virus is similar to human and animal SARS-CoVs and Middle East Respiratory Syndrome coronavirus (MERS-CoVs), the detailed information about SARS-CoV-2 proteins structures and functions is urgently needed to rapidly develop effective vaccines, antibodies, and antivirals. We applied high-throughput protein production and structure determination pipeline at the Center for Structural Genomics of Infectious Diseases to produce SARS-CoV-2 proteins and structures. Here we report two high-resolution crystal structures of endoribonuclease Nsp15/NendoU. We compare these structures with previously reported homologs from SARS and MERS coronaviruses.
C1 [Kim, Youngchang; Jedrzejczak, Robert; Maltseva, Natalia I.; Wilamowski, Mateusz; Michalska, Karolina; Joachimiak, Andrzej] Univ Chicago, Ctr Struct Genom Infect Dis, Consortium Adv Sci & Engn, Chicago, IL 60637 USA.
   [Kim, Youngchang; Jedrzejczak, Robert; Maltseva, Natalia I.; Endres, Michael; Michalska, Karolina; Joachimiak, Andrzej] Argonne Natl Lab, Xray Sci Div, Struct Biol Ctr, 9700 S Cass Ave, Argonne, IL 60439 USA.
   [Wilamowski, Mateusz; Joachimiak, Andrzej] Univ Chicago, Dept Biochem & Mol Biol, 920 E 58Th St, Chicago, IL 60637 USA.
   [Godzik, Adam] Univ Calif Riverside, Biomed Sci, Riverside, CA 92521 USA.
RP Joachimiak, A (corresponding author), Argonne Natl Lab, Xray Sci Div, Struct Biol Ctr, 9700 S Cass Ave, Argonne, IL 60439 USA.
EM andrzejj@anl.gov
RI Godzik, Adam/AAW-1467-2020
OI Godzik, Adam/0000-0002-2425-852X; Kim, Youngchang/0000-0002-1610-4889;
   Joachimiak, Andrzej/0000-0003-2535-6209
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, Department of Health and Human ServicesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [HHSN272201700060C]; U.S. Department of Energy (DOE)
   Office of ScienceUnited States Department of Energy (DOE)
   [DE-AC02-06CH11357]
FX National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, Department of Health and Human Services,
   Grant/Award Number: HHSN272201700060C; U.S. Department of Energy (DOE)
   Office of Science, Grant/Award Number: DE-AC02-06CH11357
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Bhardwaj K, 2004, J VIROL, V78, P12218, DOI 10.1128/JVI.78.22.12218-12224.2004
   Bhardwaj K, 2008, J BIOL CHEM, V283, P3655, DOI 10.1074/jbc.M708375200
   Bhardwaj K, 2006, J MOL BIOL, V361, P243, DOI 10.1016/j.jmb.2006.06.021
   CAFFARELLI E, 1994, MOL CELL BIOL, V14, P2966, DOI 10.1128/MCB.14.5.2966
   Caffarelli E, 1997, BIOCHEM BIOPH RES CO, V233, P514, DOI 10.1006/bbrc.1997.6487
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Davis IW, 2004, NUCLEIC ACIDS RES, V32, pW615, DOI 10.1093/nar/gkh398
   DELCARDAYRE SB, 1994, BIOCHEMISTRY-US, V33, P6031, DOI 10.1021/bi00186a001
   Deng XF, 2017, P NATL ACAD SCI USA, V114, pE4251, DOI 10.1073/pnas.1618310114
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114
   Gioia U, 2005, J BIOL CHEM, V280, P18996, DOI 10.1074/jbc.M501160200
   Guarino LA, 2005, J MOL BIOL, V353, P1106, DOI 10.1016/j.jmb.2005.09.007
   Huo T, 2015, ACTA CRYSTALLOGR F, V71, P1156, DOI 10.1107/S2053230X15007359
   Ivanov KA, 2004, P NATL ACAD SCI USA, V101, P12694, DOI 10.1073/pnas.0403127101
   Joseph JS, 2007, J VIROL, V81, P6700, DOI 10.1128/JVI.02817-06
   Karplus PA, 2012, SCIENCE, V336, P1030, DOI [10.1126/science.1218231, 10.1126/science.121823]
   Kim Y, 2011, METHODS, V55, P12, DOI 10.1016/j.ymeth.2011.07.010
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Laneve P, 2003, J BIOL CHEM, V278, P13026, DOI 10.1074/jbc.M211937200
   Laneve P, 2017, SCI REP-UK, V7, DOI 10.1038/srep41559
   Laneve P, 2008, J BIOL CHEM, V283, P34712, DOI 10.1074/jbc.M805759200
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Liu XR, 2019, MOL IMMUNOL, V114, P100, DOI 10.1016/j.molimm.2019.07.003
   Makowska-Grzyska M, 2014, METHODS MOL BIOL, V1140, P89, DOI 10.1007/978-1-4939-0354-2_7
   Michalska K, 2018, MOL MICROBIOL, V109, P509, DOI 10.1111/mmi.14007
   Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255
   Nedialkova DD, 2009, J VIROL, V83, P5671, DOI 10.1128/JVI.00261-09
   Padilla JE, 2003, ACTA CRYSTALLOGR D, V59, P1124, DOI 10.1107/S0907444903007947
   Renzi F, 2006, P NATL ACAD SCI USA, V103, P12365, DOI 10.1073/pnas.0602426103
   Ricagno S, 2006, P NATL ACAD SCI USA, V103, P11892, DOI 10.1073/pnas.0601708103
   Ulferts R, 2011, RNA BIOL, V8, P295, DOI 10.4161/rna.8.2.15196
   Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Xu XL, 2006, J VIROL, V80, P7909, DOI 10.1128/JVI.00525-06
   Zhang LQ, 2018, J VIROL, V92, DOI 10.1128/JVI.00893-18
   Zhang MF, 2017, J VIROL, V91, DOI [10.1128/JVI.01309-16, 10.1128/jvi.01309-16]
NR 40
TC 32
Z9 33
U1 4
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0961-8368
EI 1469-896X
J9 PROTEIN SCI
JI Protein Sci.
PD JUL
PY 2020
VL 29
IS 7
BP 1596
EP 1605
DI 10.1002/pro.3873
EA MAY 2020
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MB2ZB
UT WOS:000529747300001
PM 32304108
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Lazcano-Ponce, E
   Alpuche-Aranda, C
AF Lazcano-Ponce, Eduardo
   Alpuche-Aranda, Celia
TI Public health literacy in the face of the Covid-19 pandemic emergency
SO SALUD PUBLICA DE MEXICO
LA Spanish
DT Article
DE health literacy; SARS-CoV-2; Covid-19; surveillance; Mexico
ID INFLUENZA; ADULTS
AB Health literacy is the process of obtaining knowledge, motivation and individual competencies to understand and access information, express opinions and make decisions with respect to health promotion and maintenance. This applies in different contexts, environments, and throughout life.This conceptual perspective is very necessary in the face of the SARS-CoV-2 virus emergency.This virus produces the Covid- 19 disease, which has become a pandemic of devastating effects not only healthwise, but also, importantly, from an economic, political and social point of view. This essay seeks to establish the scientific evidence-based elements that guide public policies for prevention and control. Some of these elements are: a) epidemiologic intelligence. This includes not only the strategy of public surveillance, but also sentinel and event-based surveillance, as it is impossible to actually identify all positive cases; b) Mitigating measures against the spread of the epidemic, such as social distancing and hygiene, washing hands, quarantine, restricting movement and using masks, among others; c) Measures to suppress transmission when the number of cases is very high, such as strict measures to stay at home; d) strengthening health services 'capacity for medical attention and improving health services' ability to prevent transmission, including the use of diagnostic tests; e) the development of prophylactic vaccines against Covid-19, as well as the development of therapeutic agents. All of these actions must be rapidly implemented, from a multidisciplinary and multisectorial public health perspective, and they absolutely must also be taken with the community's participation as shared responsibility.Therefore, public health literacy is needed.
C1 [Lazcano-Ponce, Eduardo] Inst Nacl Salud Publ, Secretaria Acad, Cuernavaca, Morelos, Mexico.
   [Alpuche-Aranda, Celia] Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Cuernavaca, Morelos, Mexico.
RP Lazcano-Ponce, E (corresponding author), Inst Nacl Salud Publ, Av Univ 655, Cuernavaca 62100, Morelos, Mexico.
EM eduardo.lazcano@insp.mx
CR Abbott, 2020, DET COVID 19 ITT 5 M
   [Anonymous], 2020, MOUNT SINAI DEV END
   Bauchner H, 2020, JAMA-J AM MED ASSOC, V323, P1790, DOI 10.1001/jama.2020.6166
   Campos-Nonato I, 2019, SALUD PUBLICA MEXICO, V61, P888, DOI 10.21149/10574
   Centers for Disease Control and Prevention, 2020, FAQ COVID 19 DAT SUR
   Centers for Disease Control and Prevention, 2020, PUBL HLTH SURV DAT
   Centers for Disease Control and Prevention, 2020, UPD INT GUID OUTBR C
   Centros para el Control y la Prevencion de Enfermedades, 2020, SEP MAS CUAND COM LA
   Cepheid, 2020, XP XPR SARS COV 2 HA
   de Lusignan S, 2020, JMIR PUBLIC HLTH SUR, V6, P126, DOI 10.2196/18606
   Ebrahim SH, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1066
   Edmonds-Wilson SL, 2015, J DERMATOL SCI, V80, P3, DOI 10.1016/j.jdermsci.2015.07.006
   Gatwood J, 2012, DRUGS, V72, P35, DOI 10.2165/11597310-000000000-00000
   Gonzalez-Bautista E, 2019, SALUD PUBLICA MEXICO, V61, P764, DOI 10.21149/10563
   Hou C, 2020, J MED VIROL, V92, P841, DOI 10.1002/jmv.25827
   Jumaa PA, 2005, INT J INFECT DIS, V9, P3, DOI 10.1016/j.ijid.2004.05.005
   Klein SL, 2020, CELL IMMUNOL, V348, DOI 10.1016/j.cellimm.2019.104037
   Lane HJ, 2010, AM J PUBLIC HEALTH, V100, P1008, DOI 10.2105/AJPH.2009.185363
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Leung NHL, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0843-2
   Lipsitch M, 2009, LANCET, V374, P1209, DOI 10.1016/S0140-6736(09)61377-5
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   McKernon E., 1925, HARPERS MAGAZINE
   Mizumoto K, 2020, EMERG INFECT DIS, V26, P1251, DOI 10.3201/eid2606.200233
   National Academies of Sciences Engineering and Medicine, 2020, RAP EXP CONS SARS CO
   Organizacion Mundial de la Salud, 2009, GUIA APL ESTR MULT O
   Organizacion Panamericana de la Salud, 2020, DIR LAB DET DIAGN IN
   Organizacion Panamericana de la Salud Unidad de Informacion y Analisis de Salud (HA), 2015, IN REG DAT BAS SAL G
   Qualls N, 2017, MMWR RECOMM REP, V66, P1, DOI 10.15585/mmwr.rr6601a1
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Russell ES, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw113
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Shamah-Levy T, 2019, SALUD PUBLICA MEXICO, V61, P852, DOI 10.21149/10585
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Sorensen K, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-80
   Stern D, 2020, SALUD PUBLICA MEXICO, V62, P319, DOI 10.21149/11379
   Streeck H, 2020, VORLAUFIGES ERGEBNIS
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Villalobos A, 2019, SALUD PUBLICA MEXICO, V61, P876, DOI 10.21149/10546
   WHO, 2019, MIDDL E RESP SYNDR C
   World Health Organization, 2020, UPD 49 SARS CAS FAT
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu H, 2020, ANAL PREDICTION FALS, DOI [10.1101/2020.03.26.20043042, DOI 10.1101/2020.03.26.20043042]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 45
TC 2
Z9 2
U1 0
U2 4
PU INST NACIONAL SALUD PUBLICA
PI CUERNAVACA
PA AV UNIVERSIDAD 655, COL SANTA MARIA AHUACATITLAN, CUERNAVACA 62508,
   MORELOS, MEXICO
SN 0036-3634
EI 1606-7916
J9 SALUD PUBLICA MEXICO
JI Salud Publica Mexico
PD MAY-JUN
PY 2020
VL 62
IS 3
BP 331
EP 340
DI 10.21149/11408
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA PC9LY
UT WOS:000597320100017
PM 32304371
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Addeo, A
   Obeid, M
   Friedlaender, A
AF Addeo, Alfredo
   Obeid, Michel
   Friedlaender, Alex
TI COVID-19 and lung cancer: risks, mechanisms and treatment interactions
SO JOURNAL FOR IMMUNOTHERAPY OF CANCER
LA English
DT Article
DE lung neoplasms; T-Lymphocytes; immunity
ID MACROPHAGE ACTIVATION SYNDROME; INTERFERON-GAMMA; CHLOROQUINE;
   INFECTIONS; PNEUMONIA; DISEASE
AB Cases of the 2019 novel coronavirus also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to rise worldwide. To date, there is no effective treatment. Clinical management is largely symptomatic, with organ support in intensive care for critically ill patients. The first phase I trial to test the efficacy of a vaccine has recently begun, but in the meantime there is an urgent need to decrease the morbidity and mortality of severe cases. It is known that patients with cancer are more susceptible to infection than individuals without cancer because of their systemic immunosuppressive state caused by the malignancy and anticancer treatments. Therefore, these patients might be at increased risk of pulmonary complications from COVID-19. The SARS-CoV-2 could in some case induce excessive and aberrant non-effective host immune responses that are associated with potentially fatal severe lung injury and patients can develop acute respiratory distress syndrome (ARDS). Cytokine release syndrome and viral ARDS result from uncontrolled severe acute inflammation. Acute lung injury results from inflammatory monocyte and macrophage activation in the pulmonary luminal epithelium which lead to a release of proinflammatory cytokines including interleukin (IL)-6, IL-1 and tumor necrosis factor-alpha. These cytokines play a crucial role in immune-related pneumonitis, and could represent a promising target when the infiltration is T cell predominant or there are indirect signs of high IL-6-related inflammation, such as elevated C-reactive protein. A monoclonal anti-IL-6 receptor antibody, tocilizumab has been administered in a number of cases in China and Italy. Positive clinical and radiological outcomes have been reported. These early findings have led to an ongoing randomized controlled clinical trial in China and Italy. While data from those trials are eagerly awaited, patients' management will continue to rely for the vast majority on local guidelines. Among many other aspects, this crisis has proven that different specialists must join forces to deliver the best possible care to patients.
C1 [Addeo, Alfredo; Friedlaender, Alex] Univ Hosp Geneva, Oncol, Geneva, Switzerland.
   [Obeid, Michel] CHU Vaudois, Dept Med, Serv Immunol & Allergie, Lausanne, Switzerland.
RP Addeo, A (corresponding author), Univ Hosp Geneva, Oncol, Geneva, Switzerland.
EM alfredo.addeo@hcuge.ch
CR Ascierto P, 2020, SITC STATEMENT ANTI
   Ballaz Santiago, 2003, Clin Lung Cancer, V5, P46, DOI 10.3816/CLC.2003.n.021
   Banna G, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2020-000765
   Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Billiau AD, 2005, BLOOD, V105, P1648, DOI 10.1182/blood-2004-08-2997
   BIONDILLO DE, 1994, AM J PHYSIOL-LUNG C, V267, pL564
   Bunte K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143394
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cecere TE, 2012, VIRUSES-BASEL, V4, P833, DOI 10.3390/v4050833
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gardner RA, 2019, BLOOD, V134, P2149, DOI 10.1182/blood.2019001463
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Haanen JBAG, 2017, ANN ONCOL, V28, P119, DOI 10.1093/annonc/mdx225
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Karakike E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00055
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Martins F, 2019, LANCET ONCOL, V20, pE54, DOI 10.1016/S1470-2045(18)30828-3
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   multicenter collaboration group of Department of S Technology of Guangdong P Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus p, 2020, ZHONGHUA JIE HE HE H, V43, pE019
   O'Shea JJ, 2013, NEW ENGL J MED, V368, P161, DOI 10.1056/NEJMra1202117
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Santarlasci V, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00182
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Stroud CRG, 2019, J ONCOL PHARM PRACT, V25, P551, DOI 10.1177/1078155217745144
   Tian SF, 2020, MODERN PATHOL, V33, P1007, DOI 10.1038/s41379-020-0536-x
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm1
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
NR 45
TC 5
Z9 5
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2051-1426
J9 J IMMUNOTHER CANCER
JI J. Immunother. Cancer
PD MAY
PY 2020
VL 8
IS 1
AR e000892
DI 10.1136/jitc-2020-000892
PG 7
WC Oncology; Immunology
SC Oncology; Immunology
GA OT2XW
UT WOS:000590715600001
PM 32434788
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Serzan, MT
   Kumar, PN
   Atkins, MB
AF Serzan, Michael T.
   Kumar, Princy N.
   Atkins, Michael B.
TI Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor
   therapy
SO JOURNAL FOR IMMUNOTHERAPY OF CANCER
LA English
DT Article
DE melanoma; immunotherapy; immunomodulation; case reports
ID IPILIMUMAB; NIVOLUMAB; SARS
AB Background
   Immune checkpoint inhibitors (ICIs) can produce specific immune-related adverse events including pneumonitis. The impact of ICI therapy on the severity of acute coronavirus infection symptomatology warrants further exploration.
   Case presentation
   We report a 65-year-old man diagnosed with stage IV melanoma who developed pulmonary and brain metastases and was treated with bilateral craniotomies followed by combined nivolumab and ipilimumab immunotherapy. He developed early-onset severe dyspnea associated with acute coronavirus HKU1 (non-COVID-19) infection, with diffuse pneumonitis evidenced by ground glass opacification on CT scan. He was treated with steroids leading to resolution of pneumonitis on repeat imaging, suggesting an exacerbated immune-mediated toxicity.
   Conclusion
   We report the first case of a patient with melanoma with severe and reversible diffuse pneumonitis in association with coronavirus HKU1 following combined nivolumab and ipilimumab immunotherapy. Although we do not have data on the impact of ICI therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptomatology, a possible interaction should be considered when deciding on dosing in patients with possible SARS-CoV-2 exposure or when evaluating patients with presumed ICI-related pneumonitis during the COVID-19 pandemic.
C1 [Serzan, Michael T.; Atkins, Michael B.] Georgetown Lombardi Comprehens Canc Ctr, Oncol, Washington, DC 20057 USA.
   [Kumar, Princy N.] Georgetown Univ, Med Ctr, Infect Dis, Washington, DC 20007 USA.
RP Atkins, MB (corresponding author), Georgetown Lombardi Comprehens Canc Ctr, Oncol, Washington, DC 20057 USA.
EM michael.t.serzan@gunet.georgetown.edu
OI Serzan, Michael/0000-0001-6453-8035; Atkins, Michael/0000-0003-3901-9924
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Brahmer JR, 2018, J CLIN ONCOL, V36, P1714, DOI 10.1200/JCO.2017.77.6385
   Haanen JBAG, 2017, ANN ONCOL, V28, P119, DOI 10.1093/annonc/mdx225
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Larkin J, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Maude SL, 2014, CANCER J, V20, P119, DOI 10.1097/PPO.0000000000000035
   Naidoo J, 2017, J CLIN ONCOL, V35, P709, DOI 10.1200/JCO.2016.68.2005
   Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI 10.1056/NEJMra1703481
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Stroud CRG, 2019, J ONCOL PHARM PRACT, V25, P551, DOI 10.1177/1078155217745144
   Thompson JA, 2019, J NATL COMPR CANC NE, V17, P255, DOI 10.6004/jnccn.2019.0013
   Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105
   Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Woo PCY, 2005, J INFECT DIS, V192, P1898, DOI 10.1086/497151
   World Health Organization, COR DIS 2019 COVID 1
   Xu X., 2020, P NATL ACAD SCI US
NR 19
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2051-1426
J9 J IMMUNOTHER CANCER
JI J. Immunother. Cancer
PD MAY
PY 2020
VL 8
IS 1
AR e000898
DI 10.1136/jitc-2020-000898
PG 4
WC Oncology; Immunology
SC Oncology; Immunology
GA OT2XW
UT WOS:000590715600003
PM 32434789
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sullivan, RJ
   Johnson, DB
   Rini, BI
   Neilan, TG
   Lovly, CM
   Moslehi, JJ
   Reynolds, KL
AF Sullivan, Ryan J.
   Johnson, Douglas B.
   Rini, Brian, I
   Neilan, Tomas G.
   Lovly, Christine M.
   Moslehi, Javid J.
   Reynolds, Kerry L.
TI COVID-19 and immune checkpoint inhibitors: initial considerations
SO JOURNAL FOR IMMUNOTHERAPY OF CANCER
LA English
DT Article
DE cytotoxicity; immunological
ID CELL
AB COVID-19 infections are characterized by inflammation of the lungs and other organs that ranges from mild and asymptomatic to fulminant and fatal. Patients who are immunocompromised and those with cardiopulmonary comorbidities appear to be particularly afflicted by this illness. During pandemic conditions, many aspects of cancer care have been impacted. One important clinical question is how to manage patients who need anticancer therapy, including immune checkpoint inhibitors (ICIs) during these conditions. Herein, we consider diagnostic and therapeutic implications of using ICI during this unprecedented period of COVID-19 infections. In particular, we consider the impact of ICI on COVID-19 severity, decisions surrounding continuing or interrupting therapy, diagnostic measures in patients with symptoms or manifestations potentially consistent with either COVID-19 or ICI toxicity, and resumption of therapy in infected patients. While more robust data are needed to guide clinicians on management of patients with cancer who may be affected by COVID-19, we hope this commentary provides useful insights for the clinical community.
C1 [Sullivan, Ryan J.; Neilan, Tomas G.; Reynolds, Kerry L.] Massachusetts Gen Hosp, Dept Med, Canc Ctr, Boston, MA 02114 USA.
   [Johnson, Douglas B.; Rini, Brian, I; Lovly, Christine M.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA.
   [Moslehi, Javid J.] Vanderbilt Univ, Med Ctr, Dept Med, Cardiooncol Program, Nashville, TN USA.
RP Johnson, DB (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA.
EM douglas.b.johnson@vumc.org
OI Lovly, Christine/0000-0002-3641-6361
CR Awadalla M, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0535-y
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cortese I, 2019, NEW ENGL J MED, V380, P1597, DOI 10.1056/NEJMoa1815039
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hui DS, 2018, AM J RESP CRIT CARE, V197, P700, DOI 10.1164/rccm.201712-2371ED
   Johnson DB, 2019, NAT MED, V25, P1243, DOI 10.1038/s41591-019-0523-2
   Johnson DB, 2018, JAMA-J AM MED ASSOC, V320, P1702, DOI 10.1001/jama.2018.13995
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Ornstein MC, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0615-z
   Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI 10.1056/NEJMra1703481
   Rini BI, 2016, LANCET ONCOL, V17, P1317, DOI 10.1016/S1470-2045(16)30196-6
   Robert C, 2018, J CLIN ONCOL, V36, P1668, DOI 10.1200/JCO.2017.75.6270
   Saha B, 1996, J IMMUNOL, V157, P3869
   Schonrich G, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00207
   Shah KP, 2020, CANCER IMMUNOL RES, V8, P851, DOI 10.1158/2326-6066.CIR-19-0986
   Stroud CRG, 2019, J ONCOL PHARM PRACT, V25, P551, DOI 10.1177/1078155217745144
   Wang DY, 2018, JAMA ONCOL, V4, P1721, DOI 10.1001/jamaoncol.2018.3923
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Whitfield SJC, 2017, J IMMUNOL, V198, P3989, DOI 10.4049/jimmunol.1601525
   Xia Y, 2020, LANCET ONCOL
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 24
TC 3
Z9 3
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2051-1426
J9 J IMMUNOTHER CANCER
JI J. Immunother. Cancer
PD MAY
PY 2020
VL 8
IS 1
AR e000933
DI 10.1136/jitc-2020-000933
PG 3
WC Oncology; Immunology
SC Oncology; Immunology
GA OT2XW
UT WOS:000590715600002
PM 32434790
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fidel, PL
   Noverr, MC
AF Fidel, Paul L., Jr.
   Noverr, Mairi C.
TI Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure
   To Dampen Septic Inflammation Associated with COVID-19 Infection?
SO MBIO
LA English
DT Article
DE MMR; clinical trial; inflammation; COVID-19; live attenuated vaccines;
   myeloid-derived suppressor cells; sepsis; trained innate immunity
AB We propose the concept that administration of an unrelated live attenuated vaccine, such as MMR (measles, mumps, rubella), could serve as a preventive measure against the worst sequelae of coronavirus disease 2019 (COVID-19). There is mounting evidence that live attenuated vaccines provide nonspecific protection against lethal infections unrelated to the target pathogen of the vaccine by inducing "trained" nonspecific innate immune cells for improved host responses against subsequent infections. Mortality in COVID-19 cases is strongly associated with progressive lung inflammation and eventual sepsis. Vaccination with MMR in immunocompetent individuals has no contraindications and may be especially effective for health care workers who can easily be exposed to COVID-19. Following the lead of other countries conducting clinical trials with the live attenuated Mycobacterium bovis BCG (BCG) vaccine under a similar concept, a clinical trial with MMR in high-risk populations may provide a "low-risk-high-reward" preventive measure in saving lives during this unprecedented COVID-19 pandemic.
C1 [Fidel, Paul L., Jr.] Louisiana State Univ Hlth, Dept Oral & Craniofacial Biol, Sch Dent, New Orleans, LA 70119 USA.
   [Noverr, Mairi C.] Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA.
RP Fidel, PL (corresponding author), Louisiana State Univ Hlth, Dept Oral & Craniofacial Biol, Sch Dent, New Orleans, LA 70119 USA.
EM pfidel@lsuhsc.edu
OI Fidel, Paul/0000-0001-8066-5763
FU Foundation of the National Institutes of Health (FNIH), National
   Institute of Allergy and Infectious Disease [R01-AI116025]; Louisiana
   Clinical and Translational Science (LA CaTS) Center from FNIH [U54
   GM104940]
FX Funding related to the animal studies was provided by Foundation of the
   National Institutes of Health (FNIH), National Institute of Allergy and
   Infectious Disease, grant R01-AI116025 (Noverr). We also acknowledge
   clinical support provided by the Louisiana Clinical and Translational
   Science (LA CaTS) Center, grant U54 GM104940, from the FNIH.
CR Aaby P, 2019, CLIN MICROBIOL INFEC, V25, P1459, DOI 10.1016/j.cmi.2019.08.011
   Biering-Sorensen S, 2017, CLIN INFECT DIS, V65, P1183, DOI 10.1093/cid/cix525
   Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810
   Esher SK, 2019, J FUNGI, V5, DOI 10.3390/jof5020037
   Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031
   Lilly EA, 2019, INFECT IMMUN, V87, DOI [10.1128/IAI.00348-19, 10.1128/iai.00348-19]
   Lilly EA, 2018, MBIO, V9, DOI 10.1128/mBio.01472-17
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 10
TC 17
Z9 17
U1 2
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD MAY-JUN
PY 2020
VL 11
IS 3
AR e00907-20
DI 10.1128/mBio.00907-20
PG 4
WC Microbiology
SC Microbiology
GA NS1VG
UT WOS:000572050700009
PM 32561657
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hua, XL
   Gu, M
   Zeng, F
   Hu, HP
   Zhou, T
   Zhang, Y
   Shi, C
AF Hua, XiaoLi
   Gu, Ming
   Zeng, Fang
   Hu, Huiping
   Zhou, Tao
   Zhang, Yu
   Shi, Chen
TI Pharmacy administration and pharmaceutical care practice in a module
   hospital during the COVID-19 epidemic
SO JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION
LA English
DT Article
AB Objectives: To describe the pharmacy administration and pharmaceutical care in a module hospital during the coronavirus disease 2019 (COVID-19) epidemic and provide reference for domestic and foreign pharmacists participating in the epidemic prevention and control. Setting: The study was performed in a Jianghan module hospital constructed at the Wuhan Convention and Exhibition Center in Wuhan, China. This is 1 of the first 3 module hospitals.
   Practice description: One thousand eight hundred forty-eight patients were admitted to the Jianghan module hospital, and 1327 cases (71.81% of the total number) were cured and discharged. Pharmacists have successfully completed the tasks of purchase, storage, and free distribution of drugs worth (sic)1.03 million (approximately $146,000), reviewed about 20,000 electronic orders, provided one-on-one online medication consultation for 484 patients, and held 5 lectures on rational drug use knowledge, which could help reduce irrational drug use and minimize the risk involved.
   Practice innovation: The new COVID-19 "module" pharmaceutical care model is equipped with new features such as pharmacy emergency command group, organizational structure for pharmacy administration, electronic control of drug prescription, and "zero contact" pharmaceutical care relying on the new media platform "WeChat." This platform provides relevant pharmaceutical care for patients, such as ensuring drug supply, setting up critical care drug trolleys, designing specific drug packaging bags, creating a module radio station to broadcast rational drug use information to the patients, and other aspects.
   Evaluation: With the continuous improvement of the module hospital and the progress in indepth knowledge about COVID-19, some aspects such as patient admission criteria and variety of drugs need to be adjusted depending on the actual situation. Results: The pharmacists provided pharmaceutical care for 1848 patients with mild COVID-19 disease. They not only ensured the timely supply of the drugs but also reduced the incidence of drug-induced risks through medication review and guidance, thereby improving patient compliance and helping the patients rebuild their confidence in overcoming the disease.
   Conclusion: The new COVID-19 module pharmaceutical care model has played an important role in overcoming the epidemic situation of COVID-19 in China and thus can be implemented on a broader scale. (C) 2020 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
C1 [Hua, XiaoLi; Gu, Ming; Zeng, Fang; Zhang, Yu; Shi, Chen] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430022, Hubei, Peoples R China.
   [Hua, XiaoLi; Zhang, Yu; Shi, Chen] Hubei Prov Clin Res Ctr Precis Med Crit Illness, Wuhan, Peoples R China.
   [Hu, Huiping] Huazhong Univ Sci & Technol, Hubei Key Lab Nat Med Chem & Resource Evaluat, Tongji Med Coll, Wuhan, Peoples R China.
RP Zhang, Y; Shi, C (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430022, Hubei, Peoples R China.
EM whxhzy@163.com; 29136909@qq.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81603037]; National Key Research and
   Development Plan of China [2017YFC0909900]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81603037 to CS) and the National Key Research and Development
   Plan of China (2017YFC0909900).
CR Cheng B, 2015, CHIN J TRAUMATOL, V18, P5, DOI 10.1016/j.cjtee.2014.07.004
   General Office of National Health Commission of the People's Republic of China, 2020, DIAGN TREATM PROT NO, P145
   Gorbalenya A. E., 2020, BIORXIV
   International Committee on Taxonomy of Viruses, NAM 2019 COR
   Sugalski G, 2015, ACAD EMERG MED, V22, P616, DOI 10.1111/acem.12664
   Wang Y-M, 2014, CHINESE MED EQUIP J, V35, P133
   Weibo, WUH HAS LARG NUMB PE
   World Health Organization, WHO DIR GEN REM MED
   Yang B, 2017, CHINESE MED EQUIP J, V38, P29
NR 9
TC 3
Z9 3
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1544-3191
EI 1544-3450
J9 J AM PHARM ASSOC
JI J. Am. Pharm. Assoc.
PD MAY-JUN
PY 2020
VL 60
IS 3
BP 431
EP +
DI 10.1016/j.japh.2020.04.006
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OF3MN
UT WOS:000581116500008
PM 32336673
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Namendys-Silva, SA
   Cherit, GD
AF Namendys-Silva, Silvio A.
   Dominguez Cherit, Guillermo
TI Recommendations for the manage men of critically ill adult patients with
   COVID-19
SO GACETA MEDICA DE MEXICO
LA English
DT Article
DE Coronavirus; COVID-19; Intensive care; Critical care
AB Except for pregnant women, the management of critically ill patients with COVID-19 during the pandemic includes the standard procedures that are used for any patient that requires to be attended to at the intensive care unit, as well as limited administration of crystalloid solutions, orotracheal intubation, invasive mechanical ventilation in the event of patient clinical deterioration, and muscle relaxants continuous infusion only if necessary. Non-invasive mechanical ventilation and high-flow oxygen therapy are not recommended due to the generation of aerosol (associated with risk of viral spread among health personnel), and neither is extracorporeal membrane oxygenation or the use of steroids. So far, there is no specific antiviral treatment for patients with COVID-19, and neither are there results of controlled trials supporting the use of any.
C1 [Namendys-Silva, Silvio A.] Inst Nacl Cancerol, Dept Intens Therapy, Mexico City, DF, Mexico.
   [Namendys-Silva, Silvio A.; Dominguez Cherit, Guillermo] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Subdirectorate Crit Med, Mexico City, DF, Mexico.
RP Namendys-Silva, SA (corresponding author), Inst Nacl Cancerol, Dept Intens Therapy, Mexico City, DF, Mexico.; Namendys-Silva, SA (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Subdirectorate Crit Med, Mexico City, DF, Mexico.
EM snamendys@gmail.com
CR Brandon MH, 2020, LANCET, V8, P24
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   MacLaren G, 2020, JAMA-J AM MED ASSOC, V10, P1001
   Moss M, 2019, NEW ENGL J MED, V380, P1997, DOI 10.1056/NEJMoa1901686
   Murthy S, 2020, JAMA-J AM MED ASSOC, V10, P1001
   Namendys-Silva SA, 2020, LANCET RESP MED
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Secretaria de Salud de Mexico, 2020, COM TECN DIAR NUEV C
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, COR DIS COVID 2019 S
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ACAD NACIONAL MEDICINA MEXICO
PI MEXICO
PA CENTRO MEDICO NACIONAL SIGLO XXI, UNIDAD CONGRESOS, GLOQUE B, PROMER
   PISO, MEXICO, DF 06725, MEXICO
SN 0016-3813
J9 GAC MED MEX
JI Gac. Med. Mex.
PD MAY-JUN
PY 2020
VL 156
IS 3
BP 246
EP 248
DI 10.24875/GMM.M20000375
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA OF2WA
UT WOS:000581073500011
PM 32538995
OA Bronze
DA 2021-01-01
ER

PT J
AU Barbieri, L
   Urquijo, ET
   Parise, P
   Nilsson, M
   Reynolds, JV
   Rosati, R
AF Barbieri, Lavinia
   Urquijo, Eider Talavera
   Parise, Paolo
   Nilsson, Magnus
   Reynolds, John, V
   Rosati, Riccardo
TI Esophageal oncologic surgery in SARS-CoV-2 (COVID-19) emergency
SO DISEASES OF THE ESOPHAGUS
LA English
DT Article
DE COVID-19; chemotherapy; esophageal cancer; mortality; radiation therapy;
   surgery
ID CANCER; COMPLICATIONS
C1 [Barbieri, Lavinia; Urquijo, Eider Talavera; Parise, Paolo; Rosati, Riccardo] Osped San Raffaele, Dept Gastrointestinal Surg, Via Olgettina 60, I-20132 Milan, Italy.
   [Nilsson, Magnus] Trinity Coll Dublin, Trinity Ctr Hlth Sci, Dept Surg, Dublin, Ireland.
   [Nilsson, Magnus] St James Hosp, Dublin, Ireland.
   [Reynolds, John, V] Karolinska Univ Hosp, Dept Digest Surg, Stockholm, Sweden.
RP Barbieri, L (corresponding author), Osped San Raffaele, Dept Gastrointestinal Surg, Via Olgettina 60, I-20132 Milan, Italy.
EM barbieri.lavinia@hsr.it
OI Talavera-Urquijo, Eider/0000-0002-4793-5378
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   American Society of Clinical Oncology (ASCO), COVID 19 PAT CAR INF
   American Society of Radiation Oncology (ASTRO), SHOULD WE BE DEL NEW
   [Anonymous], 2020, COVID 19 RAPID GUIDE
   Association of Upper Gastrointestinal Surgery of Great Britain and Ireland (AUGIS), SURG PRIOR OES GASTR
   Biere SSAY, 2011, DIGEST SURG, V28, P29, DOI 10.1159/000322014
   Desai M, 2017, GASTROINTEST ENDOSC, V85, P482, DOI 10.1016/j.gie.2016.09.022
   Di Fiore F, 2020, DIG LIVER DIS
   Inoue J, 2013, DIS ESOPHAGUS, V26, P68, DOI 10.1111/j.1442-2050.2012.01336.x
   Kitagawa Y, 2019, ESOPHAGUS-TOKYO, V16, P1, DOI 10.1007/s10388-018-0641-9
   Klevebro F, 2016, ANN ONCOL, V27, P660, DOI 10.1093/annonc/mdw010
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mariette C, 2019, ANN SURG
   McLoughlin JM, 2013, CANCER CONTROL, V20, P144, DOI 10.1177/107327481302000208
   Noordman BJ, 2018, LANCET ONCOL, V19, P965, DOI 10.1016/S1470-2045(18)30201-8
   Raymond DP, UPTODATE
   Rutegard M, 2012, EJSO-EUR J SURG ONC, V38, P555, DOI 10.1016/j.ejso.2012.02.177
   Schieman C, 2012, DIS ESOPHAGUS, V25, P645, DOI 10.1111/j.1442-2050.2011.01304.x
   Simcock R, 2020, CLIN TRANSL RAD ONCO, V22, P55, DOI 10.1016/j.ctro.2020.03.009
   Tuech J J, 2020, J VISC SURG
NR 20
TC 3
Z9 3
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1120-8694
EI 1442-2050
J9 DIS ESOPHAGUS
JI Dis. Esophagus
PD MAY
PY 2020
VL 33
IS 5
AR doaa028
DI 10.1093/dote/doaa028
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OE6GH
UT WOS:000580626600001
PM 32322892
OA Green Published
DA 2021-01-01
ER

PT J
AU Park, SJ
   Yu, KM
   Kim, YI
   Kim, SM
   Kim, EH
   Kim, SG
   Kim, EJ
   Casel, MAB
   Rollon, R
   Jang, SG
   Lee, MH
   Chang, JH
   Song, MS
   Jeong, HW
   Choi, Y
   Chen, WQ
   Shin, WJ
   Jung, JU
   Choi, YK
AF Park, Su-Jin
   Yu, Kwang-Min
   Kim, Young-Il
   Kim, Se-Mi
   Kim, Eun-Ha
   Kim, Seong-Gyu
   Kim, Eun Ji
   Casel, Mark Anthony B.
   Rollon, Rare
   Jang, Seung-Gyu
   Lee, Min-Hyeok
   Chang, Jae-Hyung
   Song, Min-Suk
   Jeong, Hye Won
   Choi, Younho
   Chen, Weiqiang
   Shin, Woo-Jin
   Jung, Jae U.
   Choi, Young Ki
TI Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection
   in Ferrets
SO MBIO
LA English
DT Article
DE COVID-19; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);
   antiviral therapeutics; immunosuppression; serum neutralization; ferrets
ID LOPINAVIR/RITONAVIR; HYDROXYCHLOROQUINE
AB Due to the urgent need of a therapeutic treatment for coronavirus (CoV) disease 2019 (COVID-19) patients, a number of FDA-approved/repurposed drugs have been suggested as antiviral candidates at clinics, without sufficient information. Furthermore, there have been extensive debates over antiviral candidates for their effectiveness and safety against severe acute respiratory syndrome CoV 2 (SARS-CoV-2), suggesting that rapid preclinical animal studies are required to identify potential antiviral candidates for human trials. To this end, the antiviral efficacies of lopinavir-ritonavir, hydroxychloroquine sulfate, and emtricitabine-tenofovir for SARS-CoV-2 infection were assessed in the ferret infection model. While the lopinavir-ritonavir-, hydroxychloroquine sulfate-, or emtricitabine-tenofovirtreated group exhibited lower overall clinical scores than the phosphate-buffered saline (PBS)-treated control group, the virus titers in nasal washes, stool specimens, and respiratory tissues were similar between all three antiviral-candidate-treated groups and the PBS-treated control group. Only the emtricitabine-tenofovir-treated group showed lower virus titers in nasal washes at 8 days postinfection (dpi) than the PBS-treated control group. To further explore the effect of immune suppression on viral infection and clinical outcome, ferrets were treated with azathioprine, an immunosuppressive drug. Compared to the PBS-treated control group, azathioprine-immunosuppressed ferrets exhibited a longer period of clinical illness, higher virus titers in nasal turbinate, delayed virus clearance, and significantly lower serum neutralization (SN) antibody titers. Taken together, all antiviral drugs tested marginally reduced the overall clinical scores of infected ferrets but did not significantly affect in vivo virus titers. Despite the potential discrepancy of drug efficacies between animals and humans, these preclinical ferret data should be highly informative to future therapeutic treatment of COVID-19 patients.
   IMPORTANCE The SARS-CoV-2 pandemic continues to spread worldwide, with rapidly increasing numbers of mortalities, placing increasing strain on health care systems. Despite serious public health concerns, no effective vaccines or therapeutics have been approved by regulatory agencies. In this study, we tested the FDA-approved drugs lopinavir-ritonavir, hydroxychloroquine sulfate, and emtricitabine-tenofovir against SARS-CoV-2 infection in a highly susceptible ferret infection model. While most of the drug treatments marginally reduced clinical symptoms, they did not reduce virus titers, with the exception of emtricitabine-tenofovir treatment, which led to diminished virus titers in nasal washes at 8 dpi. Further, the azathioprine-treated immunosuppressed ferrets showed delayed virus clearance and low SN titers, resulting in a prolonged infection. As several FDA-approved or repurposed drugs are being tested as antiviral candidates at clinics without sufficient information, rapid preclinical animal studies should proceed to identify therapeutic drug candidates with strong antiviral potential and high safety prior to a human efficacy trial.
C1 [Park, Su-Jin; Yu, Kwang-Min; Kim, Young-Il; Kim, Se-Mi; Kim, Eun-Ha; Kim, Seong-Gyu; Kim, Eun Ji; Casel, Mark Anthony B.; Rollon, Rare; Jang, Seung-Gyu; Lee, Min-Hyeok; Chang, Jae-Hyung; Song, Min-Suk; Choi, Young Ki] Chungbuk Natl Univ Coll Med & Med Res Inst, Dept Microbiol, Cheongju, South Korea.
   [Park, Su-Jin; Yu, Kwang-Min; Kim, Young-Il; Kim, Se-Mi; Kim, Eun-Ha; Kim, Seong-Gyu; Casel, Mark Anthony B.; Song, Min-Suk; Choi, Young Ki] Chungbuk Natl Univ, Zoonot Infect Dis Res Ctr, Cheongju, South Korea.
   [Jeong, Hye Won] Chungbuk Natl Univ Coll Med & Med Res Inst, Dept Internal Med, Cheongju, South Korea.
   [Choi, Younho; Chen, Weiqiang; Shin, Woo-Jin; Jung, Jae U.] Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90007 USA.
RP Choi, YK (corresponding author), Chungbuk Natl Univ Coll Med & Med Res Inst, Dept Microbiol, Cheongju, South Korea.; Choi, YK (corresponding author), Chungbuk Natl Univ, Zoonot Infect Dis Res Ctr, Cheongju, South Korea.; Jung, JU (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90007 USA.
EM jaeujung@med.usc.edu; choiki55@chungbuk.ac.kr
FU National Research Foundation of KoreaNational Research Foundation of
   Korea [NRF-2020R1A2C 3008339]; Korea Research Institute of Bioscience
   and Biotechnology (KRIBB) Research Initiative Program [KGM9942011];
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [CA200422, CA250052,
   AI073099, AI116585, AI129496, AI140718, AI140705, AI140705S, DE023926,
   DE027888, DE028521]
FX This work was supported by the National Research Foundation of Korea
   (grant NRF-2020R1A2C 3008339), the Korea Research Institute of
   Bioscience and Biotechnology (KRIBB) Research Initiative Program (grant
   KGM9942011), and the National Institutes of Health (grants CA200422,
   CA250052, AI073099, AI116585, AI129496, AI140718, AI140705, AI140705S,
   DE023926, DE027888, and DE028521 [J.U.J.]).
CR Brindley E., 2020, CONNECTICUT HOSPITAL
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Danza A, 2016, REV MED CHILE, V144, P232, DOI 10.4067/S0034-98872016000200012
   De Clercq E, 2016, BIOCHEM PHARMACOL, V119, P1, DOI 10.1016/j.bcp.2016.04.015
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Gostner JM, 2012, FEBS OPEN BIO, V2, P241, DOI 10.1016/j.fob.2012.08.004
   Helfgott DC, 2020, INFECT DIS ADVISOR
   Kim UJ, 2016, ANTIVIR THER, V21, P455, DOI 10.3851/IMP3002
   Kim Y, 2020, ROUTL STUD MOD HIST, P54
   Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI 10.1053/S0016-5085(03)01215-0
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lou L, 2013, J CLIN TRANSL HEPATO, V1, P33, DOI 10.14218/JCTH.2013.004XX
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Prada N, 2008, JAIDS-J ACQ IMM DEF, V49, P117, DOI 10.1097/QAI.0b013e3181869a9b
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Spanakis N, 2014, INT J ANTIMICROB AG, V44, P528, DOI 10.1016/j.ijantimicag.2014.07.026
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   WHO, 2020, 88 WHO
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
NR 24
TC 18
Z9 18
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD MAY-JUN
PY 2020
VL 11
IS 3
AR e01114-20
DI 10.1128/mBio.01114-20
PG 10
WC Microbiology
SC Microbiology
GA NS1TV
UT WOS:000572046700014
PM 32444382
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yamaya, M
   Nishimura, H
   Deng, X
   Kikuchi, A
   Nagatomi, R
AF Yamaya, Mutsuo
   Nishimura, Hidekazu
   Deng, Xue
   Kikuchi, Akiko
   Nagatomi, Ryoichi
TI Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory
   Syndrome Coronavirus 2 Replication
SO TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
DE camostat; coronavirus 229E; nafamostat; SARS-CoV-2; type II
   transmembrane protease
ID SARS-CORONAVIRUS; CATHEPSIN-L; CELLS; ACE2
AB The number of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly increased, although the WHO declared a pandemic. However, drugs that function against SARS-CoV-2 have not been established. SARS-CoV-2 has been suggested to bind angiotensin-converting enzyme 2, the receptor of the SARS coronavirus. SARS coronavirus and coronavirus 229E, the cause of the common cold, replicate through cell-surface and endosomal pathways using a protease, the type II transmembrane protease. To examine the effects of protease inhibitors on the replication of coronavirus 229E, we pretreated primary cultures of human nasal epithelial (HNE) cells with camostat or nafamostat, each of which has been used for the treatment of pancreatitis and/or disseminated intravascular coagulation. HNE cells were then infected with coronavirus 229E, and viral titers in the airway surface liquid of the cells were examined. Pretreatment with camostat (0.1-10 mu g/mL) or nafamostat (0.01-1 mu g/mL) reduced the titers of coronavirus 229E. Furthermore, a significant amount of type II transmembrane protease protein was detected in the airway surface liquid of HNE cells. Additionally, interferons have been reported to have antiviral effects against SARS coronavirus. The additive effects of interferons on the inhibitory effects of other candidate drugs to treat SARS-CoV-2 infection, such as lopinavir, ritonavir and favipiravir, have also been studied. These findings suggest that protease inhibitors of this type may inhibit coronavirus 229E replication in human airway epithelial cells at clinical concentrations. Protease inhibitors, interferons or the combination of these drugs may become candidate drugs to inhibit the replication of SARS-CoV-2.
C1 [Yamaya, Mutsuo; Deng, Xue] Tohoku Univ, Grad Sch Med, Dept Adv Prevent Med Infect Dis, Sendai, Miyagi, Japan.
   [Yamaya, Mutsuo] Tohoku Univ, Grad Sch Med, Dept Resp Med, Sendai, Miyagi, Japan.
   [Yamaya, Mutsuo; Nishimura, Hidekazu] Sendai Med Ctr, Virus Res Ctr, Clin Res Div, Sendai, Miyagi, Japan.
   [Deng, Xue; Kikuchi, Akiko] Tohoku Univ, Grad Sch Med, Dept Kampo & Integrat Med, Sendai, Miyagi, Japan.
   [Nagatomi, Ryoichi] Tohoku Univ, Grad Sch Biomed Engn, Div Biomed Engn Hlth & Welf, Lab Hlth & Sports Sci, Sendai, Miyagi, Japan.
RP Yamaya, M (corresponding author), Tohoku Univ, Grad Sch Med, Dept Resp Med, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
EM myamaya@med.tohoku.ac.jp
RI Nagatomi, Ryoichi/Q-8792-2016
OI Nagatomi, Ryoichi/0000-0003-3038-7202
FU Astellas Pharma Inc.Astellas Pharmaceuticals [RS2018A000301,
   RS2019A000174]; Teijin Pharma Co., Ltd. [TJNS20180 506002,
   TJNS20190417024]
FX This work was supported by research support grants from Astellas Pharma
   Inc. (RS2018A000301 and RS2019A000174) and Teijin Pharma Co., Ltd.
   (TJNS20180 506002 and TJNS20190417024). Camostat was provided by Ono
   Pharmaceutical Co., Ltd.
CR Abe T., 1984, JPN PHARMACOL THER, V12, P4941
   Bertram S, 2013, J VIROL, V87, P6150, DOI 10.1128/JVI.03372-12
   Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876
   Burrell LM, 2004, TRENDS ENDOCRIN MET, V15, P166, DOI 10.1016/j.tem.2004.03.001
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   FUJII S, 1981, BIOCHIM BIOPHYS ACTA, V661, P342, DOI 10.1016/0005-2744(81)90023-1
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Huang IC, 2006, J BIOL CHEM, V281, P3198, DOI 10.1074/jbc.M508381200
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Kawase M, 2009, J VIROL, V83, P712, DOI 10.1128/JVI.01933-08
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Martinez M.A., 2020, ANTIMICROB AGENTS CH, V64
   Minakata D, 2019, INT J HEMATOL, V109, P141, DOI 10.1007/s12185-018-02567-w
   Munoz AE, 2000, GUT, V46, P427, DOI 10.1136/gut.46.3.427
   OHKOSHI M, 1981, GANN, V72, P959
   Pharmaceuticals and Medical Devices Agency, 2018, APPR INF CAM MES
   Sai JK, 2010, J GASTROENTEROL, V45, P335, DOI 10.1007/s00535-009-0148-1
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Spiegel M, 2004, J CLIN VIROL, V30, P211, DOI 10.1016/j.jcv.2003.11.013
   Yamamoto T, 2016, ACUTE MED SURG, V3, P237, DOI 10.1002/ams2.173
   Yamaya M, 2020, RESPIR INVESTIG, V58, P155, DOI 10.1016/j.resinv.2019.12.005
NR 24
TC 5
Z9 5
U1 0
U2 0
PU TOHOKU UNIV MEDICAL PRESS
PI SENDAI
PA 2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN
SN 0040-8727
EI 1349-3329
J9 TOHOKU J EXP MED
JI Tohoku J. Exp. Med.
PD MAY
PY 2020
VL 251
IS 1
BP 27
EP 30
DI 10.1620/tjem.251.27
PG 4
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA NR1IK
UT WOS:000571315300004
PM 32448818
OA Other Gold
DA 2021-01-01
ER

PT J
AU Delgado, CA
   Shimabuku, RL
   Chiroque-Solano, PM
AF Delgado, Carlos A.
   Shimabuku, Roberto L.
   Chiroque-Solano, Pamela M.
TI COVID-19 Waves: Importance of Accumulative Mortality per Million
   Inhabitants
SO TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
DE COVID-19; mortality; pandemics; public health; registries
AB The reported number of new cases underestimates the real spread of COVID-19 pandemic because of non-tested asymptomatic people and limited global access to reliable diagnostic tests. In this context, COVID-19 mortality with confirmed diagnosis becomes an attractive source of information to be included in the analysis of perspectives and proposals. Objective data are required to calculate the capacity of resources provided by health systems. New strategies are needed to stabilize or minimize the mortality surge. However, we will not afford this goal until more alternatives were available. We still need an effective treatment, an affordable vaccine, or a collective achievement of sufficient immunity (reaching up to 70% of the whole population). At any time, the arriving waves of the pandemic are testing the capacity of governments. The health services struggle to keep the plateau in a steady-state below 100 deaths per million inhabitants. Therefore, it is necessary to increase the alternatives and supplies based on the current and near-future expected demands imposed by the number of deaths by COVID-19. Estimating COVID-19 mortality in various scenarios with the gradual release of social constraints will help predict the magnitude of those arriving waves.
C1 [Delgado, Carlos A.; Shimabuku, Roberto L.] Univ Nacl Mayor San Marcos, Fac Med, Av Grau 700, Lima 1, Peru.
   [Delgado, Carlos A.] Inst Nacl Salud Nino, Lima, Peru.
   [Chiroque-Solano, Pamela M.] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
RP Shimabuku, RL (corresponding author), Univ Nacl Mayor San Marcos, Fac Med, Av Grau 700, Lima 1, Peru.
EM rshimabukua@unmsm.edu.pe
RI Delgado, Carlos Alberto/Q-2689-2015
OI Delgado, Carlos Alberto/0000-0002-6073-8109
CR Anastassopoulou C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230405
   ANDERSON RM, 1979, NATURE, V280, P361, DOI 10.1038/280361a0
   Boulos MKN, 2020, INT J HEALTH GEOGR, V19, DOI 10.1186/s12942-020-00202-8
   Ferguson N, 2020, REPORT 9 IMPACT NONP
   Lewnard JA, 2020, LANCET INFECT DIS, V20, P631, DOI 10.1016/S1473-3099(20)30190-0
NR 5
TC 1
Z9 1
U1 0
U2 0
PU TOHOKU UNIV MEDICAL PRESS
PI SENDAI
PA 2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN
SN 0040-8727
EI 1349-3329
J9 TOHOKU J EXP MED
JI Tohoku J. Exp. Med.
PD MAY
PY 2020
VL 251
IS 1
BP 47
EP 49
DI 10.1620/tjem.251.47
PG 3
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA NR1IK
UT WOS:000571315300007
PM 32461502
OA Other Gold
DA 2021-01-01
ER

PT J
AU Mamber, SW
   Krakowka, S
   Osborn, J
   Saberski, L
   Rhodes, RG
   Dahlberg, AE
   Pond-Tor, S
   Fitzgerald, K
   Wright, N
   Beseme, S
   McMichael, J
AF Mamber, Stephen W.
   Krakowka, Steven
   Osborn, Jeffrey
   Saberski, Lloyd
   Rhodes, Ryan G.
   Dahlberg, Albert E.
   Pond-Tor, Sunthorn
   Fitzgerald, Kara
   Wright, Neal
   Beseme, Sarah
   McMichael, John
TI Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19
   Symptoms and Severity?
SO MSPHERE
LA English
DT Article
DE COVID-19; SARS-CoV-2; immunomodulatory agents; interferon alpha;
   phytocannabinoids; thimerosal
ID INTERFERON-ALPHA; COV INFECTION; RESPONSES; INFLAMMATION; CORONAVIRUS;
   SUPPRESSION; EXPRESSION; GENES
AB Severe acute respiratory syndrome coronavirus 2 (SARS coronavirus 2, or SARS-CoV-2) is the cause of the respiratory infection known as COVID-19. From an immunopathological standpoint, coronaviruses such as SARS-CoV-2 induce increased levels of a variety of T-helper 1 (Th1) and inflammatory cytokines and chemokines, including interleukin-1 (IL-1), IL-6, CCL2 protein, and CXCL10 protein. In the absence of proven antiviral agents or an effective vaccine, substances with immunomodulatory activity may be able to inhibit inflammatory and Th1 cytokines and/or yield an anti-inflammatory and/or Th2 immune response to counteract COVID-19 symptoms and severity. This report briefly describes the following four unconventional but commercially accessible immunomodulatory agents that can be employed in clinical trials to evaluate their effectiveness at alleviating disease symptoms and severity: low-dose oral interferon alpha, microdose DNA, low-dose thimerosal, and phytocannabinoids.
C1 [Mamber, Stephen W.; McMichael, John] Inst Therapeut Discovery, Delanson, NY 12053 USA.
   [Krakowka, Steven] Ohio State Univ, Columbus, OH 43210 USA.
   [Osborn, Jeffrey] Univ Kentucky, Lexington, KY USA.
   [Saberski, Lloyd] Yale Univ, New Haven, CT USA.
   [Rhodes, Ryan G.] Univ N Carolina, Wilmington, NC USA.
   [Dahlberg, Albert E.; Pond-Tor, Sunthorn] Brown Univ, Providence, RI 02912 USA.
   [Fitzgerald, Kara] Sandy Hook Clin, Sandy, CT USA.
   [Wright, Neal] CMC Biosci, Beverly, MA USA.
   [Beseme, Sarah; McMichael, John] Beech Tree Labs, Providence, RI 02905 USA.
RP McMichael, J (corresponding author), Inst Therapeut Discovery, Delanson, NY 12053 USA.; McMichael, J (corresponding author), Beech Tree Labs, Providence, RI 02905 USA.
EM jm@beechtreelabs.com
OI Fitzgerald, Kara/0000-0003-4062-3790
CR Agrawal A, 2007, J LEUKOCYTE BIOL, V81, P474, DOI 10.1189/jlb.0706467
   Beilharz MW, 2010, PHARMACEUTICALS, V3, P323, DOI 10.3390/ph3020323
   Bennett AL, 2013, INFLUENZA OTHER RESP, V7, P854, DOI 10.1111/irv.12094
   Cavalli G, 2018, IMMUNOL REV, V281, P179, DOI 10.1111/imr.12605
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Cummins JM, 2005, AM J VET RES, V66, P164, DOI 10.2460/ajvr.2005.66.164
   Cummins JM, 1999, J INTERF CYTOK RES, V19, P907, DOI 10.1089/107999099313442
   Dar A, 2014, VET IMMUNOL IMMUNOP, V160, P209, DOI 10.1016/j.vetimm.2014.05.004
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   LETHEM MI, 1990, EUR RESPIR J, V3, P19
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Loison E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092705
   Lopalco G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00200
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Mamber SW, 2016, VET IMMUNOL IMMUNOP, V172, P64, DOI 10.1016/j.vetimm.2016.03.006
   Mamber SW, 2006, J NUTRACEUTICAL ASS, V9, P13
   Mamber SW, 2020, J CANNABIS RES, V2, P5, DOI [10.1186/s42238-019-0014-9, DOI 10.1186/S42238-019-0014-9]
   McMichael J, 1998, US patent, Patent No. [5,726,160, 5726160]
   McMichael J, 2001, US patent, Patent No. [6,174,916, 6174916]
   MILLER JB, 1979, ANN ALLERGY, V42, P295
   Mubarak A, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6491738
   Ribeiro A, 2012, EUR J PHARMACOL, V678, P78, DOI 10.1016/j.ejphar.2011.12.043
   Sun XY, 2020, CELL MOL IMMUNOL, V17, P631, DOI 10.1038/s41423-019-0300-7
   Touzot M, 2015, AUTOIMMUN REV, V14, P370, DOI 10.1016/j.autrev.2014.12.009
   Witt DM, 1996, PHARMACOTHERAPY, V16, P40
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Yuan M, 2002, J NEUROIMMUNOL, V133, P124, DOI 10.1016/S0165-5728(02)00370-3
NR 29
TC 3
Z9 3
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2379-5042
J9 MSPHERE
JI mSphere
PD MAY-JUN
PY 2020
VL 5
IS 3
AR e00288-20
DI 10.1128/mSphere.00288-20
PG 6
WC Microbiology
SC Microbiology
GA NN3LX
UT WOS:000568693900001
PM 32404512
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, LW
   Li, X
   Chen, H
   Yan, SN
   Li, D
   Li, Y
   Gong, ZJ
AF Wang, Luwen
   Li, Xun
   Chen, Hui
   Yan, Shaonan
   Li, Dong
   Li, Yan
   Gong, Zuojiong
TI Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury:
   An Analysis of 116 Hospitalized Patients from Wuhan, China
SO AMERICAN JOURNAL OF NEPHROLOGY
LA English
DT Article
DE Severe acute respiratory syndrome-CoV-2; Coronavirus disease 19; Acute
   kidney injury; Chronic kidney disease; Continuous renal replacement
   therapy
ID PNEUMONIA; OUTBREAK
AB Background: Whether the patients with coronavirus disease 19 (COVID-19) infected by severe acute respiratory syndrome (SARS)-CoV-2 would commonly develop acute kidney injury (AKI) is an important issue worthy of clinical attention. This study aimed to explore the effects of SARS-CoV-2 infection on renal function through analyzing the clinical data of 116 hospitalized COVID-19-confirmed patients. Methods: One hundred sixteen COVID-19-confirmed patients enrolled in this study were hospitalized in the Department of Infectious Diseases, Renmin Hospital of Wuhan University from January 14 to February 13, 2020. The recorded information includes demographic data, medical history, contact history, potential comorbidities, symptoms, signs, laboratory test results, chest computer tomography scans, and treatment measures. SARS-CoV-2 RNA in 53 urine sediments of enrolled patients was detected by real-time reverse transcription-polymerase chain reaction. Results: Twelve (10.8%) patients showed mild increase of blood urea nitrogen or creatinine (<26 mu mol/L within 48 h), and 8 (7.2%) patients showed trace or 1+ albuminuria in 111 COVID-19-confirmed patients without chronic kidney disease (CKD). All these patients did not meet the diagnostic criteria of AKI. In addition, 5 patients with CKD who were undergone regular continuous renal replacement therapy (CRRT) before admission were confirmed infection of SARS-CoV-2 and diagnosed as COVID-19. In addition to therapy for COVID-19, CRRT was also applied 3 times weekly during hospitalization for these 5 patients with CKD. In the course of treatment, the renal function indicators showed stable state in all 5 patients with CKD, without exacerbation of CKD, and pulmonary inflammation was gradually absorbed. All 5 patients with CKD were survived. Moreover, SARS-CoV-2 RNA in urine sediments was positive only in 3 patients from 48 cases without CKD, and 1 patient had a positive for SARS-CoV-2 open reading frame 1ab from 5 cases with CKD. Conclusion: AKI was uncommon in COVID-19. SARS-CoV-2 infection does not result in AKI, or aggravate CKD in the COVID-19 patients.
C1 [Wang, Luwen; Li, Xun; Yan, Shaonan; Gong, Zuojiong] Wuhan Univ, Renmin Hosp, Dept Infect Dis, 238 Jiefang Rd, Wuhan 430060, Peoples R China.
   [Li, Dong; Li, Yan] Wuhan Univ, Renmin Hosp, Dept Lab Med, 238 Jiefang Rd, Wuhan 430060, Peoples R China.
   [Chen, Hui] Hubei Prov Ctr Dis Control & Prevent, Inst Infect Dis, Wuhan, Peoples R China.
RP Gong, ZJ (corresponding author), Wuhan Univ, Renmin Hosp, Dept Infect Dis, 238 Jiefang Rd, Wuhan 430060, Peoples R China.; Li, Y (corresponding author), Wuhan Univ, Renmin Hosp, Dept Lab Med, 238 Jiefang Rd, Wuhan 430060, Peoples R China.
EM yanlitf1120@163.com; zjgong@163.com
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   Guan W, 2020, CLIN CHARACTERISTICS
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   Levin A, 2013, KIDNEY INT SUPPL, V3, P5, DOI 10.1038/kisup.2012.77
   Li Z, 2020, CAUTION KIDNEY DYSFU, V2020
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   National Health Commission of the People's Republic of China, 2020, UPD NOV COR VIR PNEU
   Thongprayoon C, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0220-z
   Thongprayoon C, 2015, NEPHROLOGY, V20, P881, DOI 10.1111/nep.12525
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, COR DIS 2019 COVID 1
   Wuhan Municipal Health Commission, REP CLUST PNEUM UNK
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 21
TC 92
Z9 96
U1 3
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-8095
EI 1421-9670
J9 AM J NEPHROL
JI Am. J. Nephrol.
PD MAY
PY 2020
VL 51
IS 5
BP 343
EP 348
DI 10.1159/000507471
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA LU6JT
UT WOS:000537860300002
PM 32229732
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Rossi, G
   Ferrari, SA
   Sommaruga, S
   Muzzarelli, L
   Piconi, S
AF Rossi, Giovanni
   Ferrari, Stefano Aldo
   Sommaruga, Simona
   Muzzarelli, Lorenzo
   Piconi, Stefania
TI An infection-oriented approach for thoracic endovascular aortic repair
   in a SARS-CoV-2 positive patient. A case report
SO ANNALI ITALIANI DI CHIRURGIA
LA English
DT Article
DE COVID-19; Dissection; TEVAR
AB CASE REPORT: A 64 -year-old woman presented to our emergency department during the outbreak of the covid-19 emergency in Italy with syncope, anosmia, mild dyspnoea and atypical chest and dorsal pain. A chest CT scan showed an acute type B aortic dissection (ATBAD) and bilateral lung involvement with ground-glass opacity, compatible with interstitial pneumonia. Nasopharyngeal swabs resulted positive for SARS-CoV-2. For the persistence of chest pain, despite the analgesic therapy, we decided to treat her with a TEVAR. Patient's chest and back pain resolved during the first few days after the procedure. No surgical or respiratory complications occurred and the patient was discharged 14 days after surgery.
   DISCUSSION: By performing the operation under local anesthesia, it was possible to limit both the staff inside the operatory room and droplet/aerosol release. Since we had to perform the operation in a hemodynamics room, thanks to the limited extension of the endoprosthesis and the good caliber of the right vertebral artery we were able to reduce the risk of spinal cord ischemia despite the lack of a revascularization of the left subclavian artery.
   CONCLUSIONS: A minimally invasive total endovascular approach allows, through local anesthesia and percutaneous access, to avoid surgical cut down and orotracheal intubation. This, combined with a defined management protocol for infected patients, seems to be a reasonable way to perform endovascular aortic procedures in urgent setting, even in a SARSCoV-2 positive patient.
C1 [Rossi, Giovanni; Ferrari, Stefano Aldo; Sommaruga, Simona; Muzzarelli, Lorenzo] Osped Alessandro Manzoni ASST Lecco, Div Vasc Surg, Lecce, Italy.
   [Piconi, Stefania] Osped Alessandro Manzoni ASST Lecco, Div Infect Dis, Lecce, Italy.
RP Rossi, G (corresponding author), Alessandro Manzoni Hosp, Div Vasc Surg, Via Eremo 9-11, Lecce, Italy.
EM rossi@asst-lecco.it
OI Muzzarelli, Lorenzo/0000-0002-1840-9029
CR Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Nano G, 2019, ANN ITAL CHIR, V90, P191
   Orend K. H., 1995, Annali Italiani di Chirurgia, V66, P821
   Porcheddu R, 2020, J INFECT DEV COUNTR, V14, P125, DOI 10.3855/jidc.12600
   Riambau V, 2017, EUR J VASC ENDOVASC, V53, P4, DOI 10.1016/j.ejvs.2016.06.005
   Welt FGP, 2020, J AM COLL CARDIOL, V75, P2372, DOI 10.1016/j.jacc.2020.03.021
NR 6
TC 0
Z9 0
U1 0
U2 0
PU EDIZIONI LUIGI POZZI
PI ROME
PA VIA PANAMA 68, 00198 ROME, ITALY
SN 0003-469X
EI 2239-253X
J9 ANN ITAL CHIR
JI Ann. Ital. Chir.
PD MAY-JUN
PY 2020
VL 91
IS 3
BP 273
EP 276
AR PII S0003469X20033916
PG 4
WC Surgery
SC Surgery
GA NM0OG
UT WOS:000567803900006
PM 32877380
DA 2021-01-01
ER

PT J
AU Singh, D
   Wasan, H
   Mathur, A
   Gupta, YK
AF Singh, Devendra
   Wasan, Himika
   Mathur, Apoorva
   Gupta, Yogendra Kumar
TI Indian perspective of remdesivir: A promising COVID-19 drug
SO INDIAN JOURNAL OF PHARMACOLOGY
LA English
DT Letter
C1 [Singh, Devendra; Wasan, Himika; Gupta, Yogendra Kumar] AIIMS, Dept Pharmacol, New Delhi, India.
   [Mathur, Apoorva] AIIMS, Ctr Dent Educ & Res, New Delhi, India.
RP Gupta, YK (corresponding author), Translat Hlth Sci & Technol Inst, Faridabad, India.
EM ykykgupta@gmail.com
CR Beigel J. H., 2020, N ENGL J MED
   Tulasi GK, 2008, INDIAN J PHARM SCI, V70, P547, DOI 10.4103/0250-474X.45390
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 3
TC 0
Z9 0
U1 2
U2 2
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0253-7613
EI 1998-3751
J9 INDIAN J PHARMACOL
JI Indian J. Pharmacol.
PD MAY-JUN
PY 2020
VL 52
IS 3
BP 227
EP 228
DI 10.4103/ijp.IJP_486_20
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NK9KW
UT WOS:000567048500011
PM 32874008
OA Green Published
DA 2021-01-01
ER

PT J
AU Encinar, JA
   Menendez, JA
AF Antonio Encinar, Jose
   Menendez, Javier A.
TI Potential Drugs Targeting Early Innate Immune Evasion of
   SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA
SO VIRUSES-BASEL
LA English
DT Article
DE COVID-19; drug repurposing; methylation; methyltransferases;
   computational screening; molecular docking; molecular dynamics
ID RESPIRATORY SYNDROME CORONAVIRUS; GENE-RELATED PEPTIDE; THERAPEUTIC
   STRATEGY; INTEGRATED ANALYSIS; CELL-DEATH; INHIBITOR; AXL; ENTRECTINIB;
   KINASE; SAFETY
AB The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing the COVID-19 respiratory disease pandemic utilizes unique 2 ' -O-methyltransferase (2 ' -O-MTase) capping machinery to camouflage its RNA from innate immune recognition. The nsp16 catalytic subunit of the 2 ' -O-MTase is unusual in its requirement for a stimulatory subunit (nsp10) to catalyze the ribose 2 ' -O-methylation of the viral RNA cap. Here we provide a computational basis for drug repositioning or de novo drug development based on three differential traits of the intermolecular interactions of the SARS-CoV-2-specific nsp16/nsp10 heterodimer, namely: (1) the S-adenosyl-l-methionine-binding pocket of nsp16, (2) the unique "activating surface" between nsp16 and nsp10, and (3) the RNA-binding groove of nsp16. We employed approximate to 9000 U.S. Food and Drug Administration (FDA)-approved investigational and experimental drugs from the DrugBank repository for docking virtual screening. After molecular dynamics calculations of the stability of the binding modes of high-scoring nsp16/nsp10-drug complexes, we considered their pharmacological overlapping with functional modules of the virus-host interactome that is relevant to the viral lifecycle, and to the clinical features of COVID-19. Some of the predicted drugs (e.g., tegobuvir, sonidegib, siramesine, antrafenine, bemcentinib, itacitinib, or phthalocyanine) might be suitable for repurposing to pharmacologically reactivate innate immune restriction and antagonism of SARS-CoV-2 RNAs lacking 2 ' -O-methylation.
C1 [Antonio Encinar, Jose] Miguel Hernandez Univ UMH, Inst Res Dev & Innovat Biotechnol Elche IDiBE, Alicante 03202, Spain.
   [Antonio Encinar, Jose] Miguel Hernandez Univ UMH, Mol & Cell Biol Inst IBMC, Alicante 03202, Spain.
   [Menendez, Javier A.] Catalan Inst Oncol, Metab & Canc Grp, Program Canc Therapeut Resistance ProCURE, Girona 17005, Spain.
   [Menendez, Javier A.] Girona Biomed Res Inst, Girona 17007, Spain.
RP Encinar, JA (corresponding author), Miguel Hernandez Univ UMH, Inst Res Dev & Innovat Biotechnol Elche IDiBE, Alicante 03202, Spain.; Encinar, JA (corresponding author), Miguel Hernandez Univ UMH, Mol & Cell Biol Inst IBMC, Alicante 03202, Spain.; Menendez, JA (corresponding author), Catalan Inst Oncol, Metab & Canc Grp, Program Canc Therapeut Resistance ProCURE, Girona 17005, Spain.; Menendez, JA (corresponding author), Girona Biomed Res Inst, Girona 17007, Spain.
EM jant.encinar@umh.es; jmenendez@idibgi.org
RI MENENDEZ, JAVIER A/C-6148-2016; Encinar, Jose Antonio/AAE-9141-2020
OI MENENDEZ, JAVIER A/0000-0001-8733-4561; Encinar, Jose
   Antonio/0000-0002-7219-3863
FU Spanish Ministry of Science and InnovationSpanish Government
   [SAF2016-80639-P]; Fundacio Oncolliga Girona (Lliga catalana d'ajuda al
   malalt de cancer, Girona); Spanish Ministry of Economy and
   Competitiveness (MINECO) [RTI2018-096724-B-C21]; Generalitat
   ValencianaGeneralitat Valenciana [PROMETEO/2016/006]
FX Work in the Menendez laboratory is supported by the Spanish Ministry of
   Science and Innovation (grant SAF2016-80639-P, Plan Nacional de I+D+I,
   founded by the European Regional Development Fund, Spain) and by an
   unrestricted research grant from the Fundacio Oncolliga Girona (Lliga
   catalana d'ajuda al malalt de cancer, Girona). The Spanish Ministry of
   Economy and Competitiveness (MINECO, Project RTI2018-096724-B-C21) and
   the Generalitat Valenciana (PROMETEO/2016/006) supports work in the
   Encinar laboratory.
CR Abidi A, 2016, J PHARMACOL PHARMACO, V7, P194, DOI 10.4103/0976-500X.195920
   Ahn K, 2011, J PHARMACOL EXP THER, V338, P114, DOI 10.1124/jpet.111.180257
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Bansal M, 2020, DIABETES METAB SYND, V14, P247, DOI 10.1016/j.dsx.2020.03.013
   Bell IM, 2010, ACS MED CHEM LETT, V1, P24, DOI 10.1021/ml900016y
   BERRY H, 1983, BRIT J RHEUMATOL, V22, P89
   Bissonnette R, 2016, J DERMATOL TREAT, V27, P332, DOI 10.3109/09546634.2015.1115819
   Boor PPC, 2017, TRANSL RES, V188, P67, DOI 10.1016/j.trsl.2016.11.006
   Bouvet M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000863
   Burness CB, 2015, DRUGS, V75, P1559, DOI 10.1007/s40265-015-0458-y
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen FF, 2018, AM J CANCER RES, V8, P1466
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen L., 2020, OCULAR MANIFESTATION, DOI [10.1101/2020.03.12.20034678, 10.1101/2020.03.12.20034678., DOI 10.1101/2020.03.12.20034678]
   Chen Y, 2013, J VIROL, V87, P6296, DOI 10.1128/JVI.00061-13
   Chen Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002294
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   Collier NJ, 2016, EXPERT REV ANTICANC, V16, P1011, DOI 10.1080/14737140.2016.1230020
   Crowley BM, 2015, BIOORG MED CHEM LETT, V25, P4777, DOI 10.1016/j.bmcl.2015.07.021
   Cuyas E, 2020, AGING-US, V12, P4794, DOI 10.18632/aging.102887
   Cuyas E, 2019, FOOD CHEM TOXICOL, V128, P35, DOI 10.1016/j.fct.2019.03.049
   D'Souza DC, 2019, LANCET PSYCHIAT, V6, P35, DOI 10.1016/S2215-0366(18)30427-9
   Daffis S, 2010, NATURE, V468, P452, DOI 10.1038/nature09489
   Dakhama A, 2004, CURR OPIN PHARMACOL, V4, P215, DOI 10.1016/j.coph.2004.01.006
   de Vries T, 2020, PHARMACOL THERAPEUT, V211, DOI 10.1016/j.pharmthera.2020.107528
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Desai J, 2020, J CLIN ONCOL, V38, P2140, DOI 10.1200/JCO.19.02654
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Doebele RC, 2020, LANCET ONCOL, V21, P271, DOI 10.1016/S1470-2045(19)30691-6
   Donnelly RF, 2008, MICROBIOL RES, V163, P1, DOI 10.1016/j.micres.2007.08.001
   Drilon A, 2020, LANCET ONCOL, V21, P261, DOI 10.1016/S1470-2045(19)30690-4
   Drilon A, 2017, CANCER DISCOV, V7, P400, DOI 10.1158/2159-8290.CD-16-1237
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Facchinetti F, 2019, LUNG CANCER-TARGETS, V10, P87, DOI 10.2147/LCTT.S190786
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Favoni V, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-019-0979-y
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Fried JA, 2020, CIRCULATION, V141, P1930, DOI 10.1161/CIRCULATIONAHA.120.047164
   Fung TS, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00296
   Fung TS, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8070184
   Gadina M, 2019, RHEUMATOLOGY, V58, P4, DOI 10.1093/rheumatology/key432
   Garcia-Sastre A, 2011, NAT IMMUNOL, V12, P114, DOI 10.1038/ni0211-114
   Gassen NC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13659-4
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Georgiadis MO, 2017, MOLECULES, V22, DOI 10.3390/molecules22091408
   Gong XH, 2020, CLIN PHARM DRUG DEV, V9, P677, DOI 10.1002/cpdd.758
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han H, 2020, J MED VIROL, V92, P819, DOI 10.1002/jmv.25809
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Heading C, 2001, Curr Opin Investig Drugs, V2, P266
   Hebner CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039163
   Hewitt DJ, 2011, CEPHALALGIA, V31, P712, DOI 10.1177/0333102411398399
   Hirata Y, 2011, J NEUROCHEM, V119, P839, DOI 10.1111/j.1471-4159.2011.07464.x
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997
   Hyde JL, 2015, VIROLOGY, V479, P66, DOI 10.1016/j.virol.2015.01.019
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jain S, 2017, ONCOTARGETS THER, V10, DOI 10.2147/OTT.S130910
   Jin X, 2013, VIRUS RES, V176, P45, DOI 10.1016/j.virusres.2013.05.001
   Johnson DS, 2011, ACS MED CHEM LETT, V2, P91, DOI 10.1021/ml100190t
   Kampf G, 2020, J HOSP INFECT, V105, P587, DOI 10.1016/j.jhin.2020.01.022.
   Ke M, 2012, VIRUS RES, V167, P322, DOI 10.1016/j.virusres.2012.05.017
   Kettle JG, 2017, EXPERT OPIN THER PAT, V27, P127, DOI 10.1080/13543776.2017.1252753
   Khalili JS, 2020, J MED VIROL, V92, P740, DOI 10.1002/jmv.25798
   Korneev D, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100955
   Krieger E, 2006, J MOL GRAPH MODEL, V25, P481, DOI 10.1016/j.jmgm.2006.02.009
   Krieger E, 2014, BIOINFORMATICS, V30, P2981, DOI 10.1093/bioinformatics/btu426
   Landolt L, 2019, PHYSIOL REP, V7, DOI 10.14814/phy2.14091
   Le Mevel Jean-Claude, 2012, Front Endocrinol (Lausanne), V3, P124, DOI 10.3389/fendo.2012.00124
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Lionta E, 2014, CURR TOP MED CHEM, V14, P1923, DOI 10.2174/1568026614666140929124445
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu MY, 2018, BIOORGAN MED CHEM, V26, P2621, DOI 10.1016/j.bmc.2018.04.029
   Lotsberg ML, 2020, J THORAC ONCOL, V15, P973, DOI 10.1016/j.jtho.2020.01.015
   Ludwig KF, 2018, CANCER RES, V78, P246, DOI 10.1158/0008-5472.CAN-17-1973
   Lugari A, 2010, J BIOL CHEM, V285, P33230, DOI 10.1074/jbc.M110.120014
   Ma S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.208
   Meertens L, 2017, CELL REP, V18, P324, DOI 10.1016/j.celrep.2016.12.045
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Menachery VD, 2014, J VIROL, V88, P4251, DOI 10.1128/JVI.03571-13
   Nahama Alexis, 2020, Med Drug Discov, V5, P100033, DOI 10.1016/j.medidd.2020.100033
   Negro A, 2019, EXPERT OPIN INV DRUG, V28, P555, DOI 10.1080/13543784.2019.1618830
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Nikolaeva-Glomb L, 2017, ACTA VIROL, V61, P341, DOI 10.4149/av_2017_313
   Nukoolkarn V, 2008, J THEOR BIOL, V254, P861, DOI 10.1016/j.jtbi.2008.07.030
   Ostenfeld MS, 2008, AUTOPHAGY, V4, P487, DOI 10.4161/auto.5774
   Ostenfeld MS, 2005, CANCER RES, V65, P8975, DOI 10.1158/0008-5472.CAN-05-0269
   OTTMAN KE, 2020, J CLIN INVEST, V130, DOI DOI 10.1172/JCI137647
   Palanki MSS, 2008, J MED CHEM, V51, P1546, DOI 10.1021/jm7011276
   Park JH, 2020, BIOL BLOOD MARROW TR, V26, pS269
   Paton DM, 2016, DRUG TODAY, V52, P485, DOI 10.1358/dot.2016.52.9.2542066
   Persaud M, 2018, VIROLOGY, V518, P301, DOI 10.1016/j.virol.2018.03.009
   Prussia A, 2011, INT J MOL SCI, V12, P4027, DOI 10.3390/ijms12064027
   Remichkova M, 2017, Z NATURFORSCH C, V72, P123, DOI 10.1515/znc-2016-0119
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Roskoski R, 2016, PHARMACOL RES, V111, P784, DOI 10.1016/j.phrs.2016.07.038
   Rothlin CV, 2007, CELL, V131, P1124, DOI 10.1016/j.cell.2007.10.034
   Ruan Z., 2020, PREPRINTS, DOI [10.20944/preprints202003.0024.v1, DOI 10.20944/PREPRINTS202003.0024.V1]
   Rubio-Beltran Eloisa, 2019, Handb Exp Pharmacol, V255, P131, DOI 10.1007/164_2019_204
   Ruiz-Torres V, 2018, MAR DRUGS, V16, DOI 10.3390/md16100385
   Sadahiro H, 2018, CANCER RES, V78, P3002, DOI 10.1158/0008-5472.CAN-17-2433
   Sahn JJ, 2017, ACS CHEM NEUROSCI, V8, P1801, DOI 10.1021/acschemneuro.7b00200
   Schmidt HR, 2018, NAT STRUCT MOL BIOL, V25, P981, DOI 10.1038/s41594-018-0137-2
   Schwartz DM, 2017, NAT REV DRUG DISCOV, V16, P843, DOI 10.1038/nrd.2017.201
   Seah I, 2020, OCUL IMMUNOL INFLAMM, V28, P391, DOI 10.1080/09273948.2020.1738501
   Seeliger D, 2010, J COMPUT AID MOL DES, V24, P417, DOI 10.1007/s10822-010-9352-6
   Sharma S, 2011, J VIROL, V85, P5995, DOI 10.1128/JVI.00034-11
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shi CS, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0181-7
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Sisk JM, 2018, J GEN VIROL, V99, P619, DOI 10.1099/jgv.0.001047
   Smelkinson MG, 2017, J DEV BIOL, V5, DOI 10.3390/jdb5040014
   Soby KK, 2002, NEUROPHARMACOLOGY, V43, P95, DOI 10.1016/S0028-3908(02)00071-0
   Srinivasan S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040360
   Stellbrink HJ, 2014, JAIDS-J ACQ IMM DEF, V65, P283, DOI 10.1097/QAI.0000000000000003
   Sun Y, 2014, ANTIVIR RES, V104, P156, DOI 10.1016/j.antiviral.2014.02.002
   Tepper SJ, 2018, HEADACHE, V58, P238, DOI 10.1111/head.13379
   Tesei A, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00711
   Totura AL, 2019, EXPERT OPIN DRUG DIS, V14, P397, DOI 10.1080/17460441.2019.1581171
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tutusaus A, 2020, CELL MOL GASTROENTER, V9, P349, DOI 10.1016/j.jcmgh.2019.10.010
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Verdura S, 2020, AGING-US, V12, P8, DOI 10.18632/aging.102646
   Villalpando-Rodriguez GE, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9561281
   Virtanen AT, 2019, BIODRUGS, V33, P15, DOI 10.1007/s40259-019-00333-w
   Vliegen I, 2015, ANTIVIR RES, V120, P112, DOI 10.1016/j.antiviral.2015.05.011
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CH, 2016, J COMPUT CHEM, V37, P2436, DOI 10.1002/jcc.24467
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Wyles DL, 2014, HEPATOLOGY, V60, P56, DOI 10.1002/hep.27053
   Xia JH, 2020, J MED VIROL, V92, P589, DOI 10.1002/jmv.25725
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yang ND, 2020, INT J BIOL SCI, V16, P1724, DOI 10.7150/ijbs.45498
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhitomirsky B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1227-0
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zust R, 2011, NAT IMMUNOL, V12, P137, DOI 10.1038/ni.1979
NR 161
TC 13
Z9 13
U1 5
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD MAY
PY 2020
VL 12
IS 5
AR 525
DI 10.3390/v12050525
PG 25
WC Virology
SC Virology
GA NJ2FF
UT WOS:000565860200042
PM 32397643
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dilucca, M
   Forcelloni, S
   Georgakilas, AG
   Giansanti, A
   Pavlopoulou, A
AF Dilucca, Maddalena
   Forcelloni, Sergio
   Georgakilas, Alexandros G.
   Giansanti, Andrea
   Pavlopoulou, Athanasia
TI Codon Usage and Phenotypic Divergences of SARS-CoV-2 Genes
SO VIRUSES-BASEL
LA English
DT Article
DE coronaviruses; SARS-CoV-2; codon usage bias; mutational bias; natural
   selection; host adaptation
ID CORONAVIRUS; BIAS; EXPRESSION; PNEUMONIA; PROTEIN; FORCES
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first occurred in Wuhan (China) in December of 2019, causes a severe acute respiratory illness with a high mortality rate, and has spread around the world. To gain an understanding of the evolution of the newly emerging SARS-CoV-2, we herein analyzed the codon usage pattern of SARS-CoV-2. For this purpose, we compared the codon usage of SARS-CoV-2 with that of other viruses belonging to the subfamily of Orthocoronavirinae. We found that SARS-CoV-2 has a high AU content that strongly influences its codon usage, which appears to be better adapted to the human host. We also studied the evolutionary pressures that influence the codon usage of five conserved coronavirus genes encoding the viral replicase, spike, envelope, membrane and nucleocapsid proteins. We found different patterns of both mutational bias and natural selection that affect the codon usage of these genes. Moreover, we show here that the two integral membrane proteins (matrix and envelope) tend to evolve slowly by accumulating nucleotide mutations on their corresponding genes. Conversely, genes encoding nucleocapsid (N), viral replicase and spike proteins (S), although they are regarded as are important targets for the development of vaccines and antiviral drugs, tend to evolve faster in comparison to the two genes mentioned above. Overall, our results suggest that the higher divergence observed for the latter three genes could represent a significant barrier in the development of antiviral therapeutics against SARS-CoV-2.
C1 [Dilucca, Maddalena; Forcelloni, Sergio; Giansanti, Andrea] Sapienza Univ Rome, Phys Dept, I-00185 Rome, Italy.
   [Dilucca, Maddalena] Liceo Sci Statale Augusto Righi, I-00187 Rome, Italy.
   [Georgakilas, Alexandros G.] Natl Tech Univ Athens NTUA, Sch Appl Math & Phys Sci, Phys Dept, DNA Damage Lab, Zografou Campous, Athens 15780, Greece.
   [Giansanti, Andrea] Ist Nazl Fis Nucl, Roma1 Unit, I-00185 Rome, Italy.
   [Pavlopoulou, Athanasia] Izmir Biomed & Genome Ctr IBG, TR-35340 Izmir, Turkey.
   [Pavlopoulou, Athanasia] Dokuz Eylul Univ, Izmir Int Biomed & Genome Inst, TR-35340 Izmir, Turkey.
RP Dilucca, M (corresponding author), Sapienza Univ Rome, Phys Dept, I-00185 Rome, Italy.; Dilucca, M (corresponding author), Liceo Sci Statale Augusto Righi, I-00187 Rome, Italy.
EM maddalena.dilucca@gmail.com; sergio.forcelloni@gmail.com;
   alexg@mail.ntua.gr; andrea.giansanti@oma1.infn.it;
   athanasia.pavlopoulou@ibg.edu.tr
RI Georgakilas, Alexandros/AAG-9517-2020
OI Georgakilas, Alexandros/0000-0002-5971-0010; Dilucca,
   Maddalena/0000-0002-2179-4677; Pavlopoulou,
   Athanasia/0000-0002-0815-3808
FU Sapienza University of Rome [RS_PICCOLI_2018_GIANSANTI]
FX This research was partly funded by Sapienza University of Rome, grant
   RS_PICCOLI_2018_GIANSANTI.
CR A Ghadimi-Moghadam, 2020, J Biomed Phys Eng, V10, P241, DOI 10.31661/jbpe.v0i0.2003-1085
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Belalov IS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056642
   Berkhout B, 2015, VIRUS RES, V202, P41, DOI 10.1016/j.virusres.2014.11.031
   Calabrese Edward J., 2013, Yale Journal of Biology and Medicine, V86, P555
   Callaway E., 2020, NATURE, V577, P1, DOI [10.1038/d41586-020-00180-8, DOI 10.1038/D41586-020-00180-8]
   Cavanagh D., 1995, CORONAVIRIDAE, P73, DOI DOI 10.1007/978-1-4899-1531-3_5
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chen Y, 2017, ONCOTARGET, V8, P110337, DOI 10.18632/oncotarget.22738
   Darriba D, 2020, MOL BIOL EVOL, V37, P291, DOI 10.1093/molbev/msz189
   Dilucca M, 2018, GENE, V663, P178, DOI 10.1016/j.gene.2018.04.017
   Forcelloni S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61466-5
   Forcelloni S, 2020, J MOL EVOL, V88, P164, DOI 10.1007/s00239-019-09921-4
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   GRANTHAM R, 1980, NUCLEIC ACIDS RES, V8, pR49, DOI 10.1093/nar/8.1.197-c
   Han SH, 2015, J IMMUNOL, V194, P855, DOI 10.4049/jimmunol.1402513
   Jenkins GM, 2003, VIRUS RES, V92, P1, DOI 10.1016/S0168-1702(02)00309-X
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Kirby C., 2020, RADIOTHER ONCOL, DOI [10.1016/j.radonc.2020.04.004, DOI 10.1016/J.RADONC.2020.04.004]
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   LAI MMC, 1990, ANNU REV MICROBIOL, V44, P303, DOI 10.1146/annurev.mi.44.100190.001511
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Li GR, 2018, VIRULENCE, V9, P1301, DOI 10.1080/21505594.2018.1492863
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   Ruch TR, 2012, VIRUSES-BASEL, V4, P363, DOI 10.3390/v4030363
   Sharp P.M., 1987, NUCLEIC ACIDS RES, V15, P3, DOI 10.1093/nar/15.3.12813547335
   SHARP PM, 1986, J MOL EVOL, V24, P28, DOI 10.1007/BF02099948
   Sheikh A, 2020, J VIROL METHODS, V277, DOI 10.1016/j.jviromet.2019.113806
   Siddell S.G., 2005, MICROBIOL MICROB INF, DOI [10.1002/9780470688618.taw0245, DOI 10.1002/9780470688618.TAW0245]
   SIEVERS F, 2014, CURR PROTOC BIOINFOR, V48, P3, DOI DOI 10.1002/0471250953.BI0313S48
   Sievers F, 2014, METHODS MOL BIOL, V1079, P105, DOI 10.1007/978-1-62703-646-7_6
   SUEOKA N, 1988, P NATL ACAD SCI USA, V85, P2653, DOI 10.1073/pnas.85.8.2653
   Timani KA, 2004, J CLIN VIROL, V30, P309, DOI 10.1016/j.jcv.2004.01.001
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343
   Woo PCY, 2007, VIROLOGY, V369, P431, DOI 10.1016/j.virol.2007.08.010
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Woo PCY, 2009, EXP BIOL MED, V234, P1117, DOI 10.3181/0903-MR-94
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   WRIGHT F, 1990, GENE, V87, P23, DOI 10.1016/0378-1119(90)90491-9
   Xia XH, 2013, MOL BIOL EVOL, V30, P1720, DOI 10.1093/molbev/mst064
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang CX, 2020, J PROTEOME RES, V19, P1351, DOI 10.1021/acs.jproteome.0c00129
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 47
TC 8
Z9 8
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD MAY
PY 2020
VL 12
IS 5
AR 498
DI 10.3390/v12050498
PG 21
WC Virology
SC Virology
GA NJ2FF
UT WOS:000565860200015
PM 32366025
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Takano, T
   Satoh, K
   Doki, T
   Tanabe, T
   Hohdatsu, T
AF Takano, Tomomi
   Satoh, Kumi
   Doki, Tomoyoshi
   Tanabe, Taishi
   Hohdatsu, Tsutomu
TI Antiviral Effects of Hydroxychloroquine and Type I Interferon on In
   Vitro Fatal Feline Coronavirus Infection
SO VIRUSES-BASEL
LA English
DT Article
DE feline coronavirus; feline infectious peritonitis; hydroxychloroquine;
   interferon
ID PERITONITIS VIRUS-INFECTION; PATHOGENESIS; PEPTIDE; OMEGA; CATS
AB Feline infectious peritonitis (FIP) is a viral disease with a high morbidity and mortality by the FIP virus (FIPV, virulent feline coronavirus). Several antiviral drugs for FIP have been identified, but many of these are expensive and not available in veterinary medicine. Hydroxychloroquine (HCQ) is a drug approved by several countries to treat malaria and immune-mediated diseases in humans, and its antiviral effects on other viral infections (e.g., SARS-CoV-2, dengue virus) have been confirmed. We investigated whether HCQ in association with interferon-omega (IFN-omega) is effective for FIPV in vitro. A total of 100 mu M of HCQ significantly inhibited the replication of types I and II FIPV. Interestingly, the combination of 100 mu M of HCQ and 10(4) U/mL of recombinant feline IFN-omega (rfIFN-omega, veterinary registered drug) increased its antiviral activity against type I FIPV infection. Our study suggested that HCQ and rfIFN-omega are applicable for treatment of FIP. Further clinical studies are needed to verify the combination of HCQ and rIFN-omega will be effective and safe treatment for cats with FIP.
C1 [Takano, Tomomi; Satoh, Kumi; Doki, Tomoyoshi; Hohdatsu, Tsutomu] Kitasato Univ, Sch Vet Med, Lab Vet Infect Dis, Towada, Aomori 0348628, Japan.
   [Tanabe, Taishi] Kitasato Univ, Sch Vet Med, Lab Vet Microbiol, Towada, Aomori 0348628, Japan.
RP Takano, T (corresponding author), Kitasato Univ, Sch Vet Med, Lab Vet Infect Dis, Towada, Aomori 0348628, Japan.
EM takanot@vmas.kitasato-u.ac.jp; kumi@vmas.kitasato-u.ac.jp;
   doki@vmas.kitasato-u.ac.jp; tanabe@vmas.kitasato-u.ac.jp;
   hohdatsu@vmas.kitasato-u.ac.jp
OI Takano, Tomomi/0000-0002-3468-0708
CR [Anonymous], 2011, ICTV 9 REPORT CORONA
   Chang HW, 2012, EMERG INFECT DIS, V18, P1089, DOI 10.3201/eid1807.120143
   Dedeurwaerder A, 2014, J GEN VIROL, V95, P393, DOI 10.1099/vir.0.058743-0
   Doki T, 2020, ARCH VIROL, V165, P1197, DOI 10.1007/s00705-020-04605-7
   Doki T, 2018, RES VET SCI, V120, P57, DOI 10.1016/j.rvsc.2018.09.002
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   HOHDATSU T, 1991, ARCH VIROL, V120, P207, DOI 10.1007/BF01310476
   Ishida Y, 2004, J FELINE MED SURG, V6, P107, DOI 10.1016/j.jfms.2003.08.011
   Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581
   Kipar A, 2006, VET IMMUNOL IMMUNOP, V112, P141, DOI 10.1016/j.vetimm.2006.02.004
   Leal Rodolfo Oliveira, 2016, Vet Sci, V3, DOI 10.3390/vetsci3040032
   Licitra BN, 2013, EMERG INFECT DIS, V19, P1066, DOI 10.3201/eid1907.121094
   Liu K, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-019-0132-8
   MACKENZIE AH, 1983, AM J MED, V75, P5, DOI 10.1016/0002-9343(83)91264-0
   Martin V, 2002, VET MICROBIOL, V89, P115, DOI 10.1016/S0378-1135(02)00173-6
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   MOTOKAWA K, 1995, ARCH VIROL, V140, P469, DOI 10.1007/BF01718424
   Pedersen NC, 2019, J FELINE MED SURG, V21, P271, DOI 10.1177/1098612X19825701
   Pedersen NC, 2018, J FELINE MED SURG, V20, P378, DOI 10.1177/1098612X17729626
   Radford AD, 2009, J FELINE MED SURG, V11, P556, DOI 10.1016/j.jfms.2009.05.004
   Ritz S, 2007, J VET INTERN MED, V21, P1193, DOI 10.1892/06-302.1
   Sacre K, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3895
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Takano T, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040300
   Takano T, 2019, VET RES, V50, DOI 10.1186/s13567-019-0625-3
   Takano T, 2013, ANTIVIR RES, V99, P100, DOI 10.1016/j.antiviral.2013.04.016
   Tekes G, 2016, ADV VIRUS RES, V96, P193, DOI 10.1016/bs.aivir.2016.08.002
   UEDA Y, 1993, J VET MED SCI, V55, P251, DOI 10.1292/jvms.55.251
   van Beusekom CD, 2010, J VET PHARMACOL THER, V33, P519, DOI 10.1111/j.1365-2885.2010.01199.x
   Wang LF, 2015, J INTERF CYTOK RES, V35, P143, DOI 10.1089/jir.2014.0038
NR 31
TC 4
Z9 4
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD MAY
PY 2020
VL 12
IS 5
AR 576
DI 10.3390/v12050576
PG 9
WC Virology
SC Virology
GA NJ2FF
UT WOS:000565860200093
PM 32456286
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Green, MH
AF Green, Monica H.
TI Emerging diseases, re-emerging histories
SO CENTAURUS
LA English
DT Article
DE COVID-19; decolonialization; emerging infectious diseases; global
   health; Great Acceleration; palaeogenetics
ID SALMONELLA-ENTERICA; EPIDEMIC; GENOMES; HEALTH
AB The notion of "emerging infectious diseases" (EID) as a category of global health concerns was created in the 1990s to acknowledge that, although public health interventions, vaccines, and antibiotics since the late 19th century had given wealthier parts of the world control over most infectious diseases, the experience of Ebola and HIV/AIDS showed that new human diseases could still arise. "Emerging diseases" have clear histories, and the task the field of EID set itself has been to make those histories as short as possible-to catch emerging diseases as close to their origin as possible and snuff them out before they can become pandemics. In contrast, many of the known infectious diseases, those that were allegedly "conquered" by the rise of biomedicine in the late 19th and early 20th centuries and which (aside from smallpox) nonetheless still persist today, were assumed to have existed "since time immemorial." Their histories had no specific time-depth, no documentable origins, and few discernible narrative arcs. The advent of a new field of research, palaeogenetics, has made possible an evolutionary perspective on pathogenic microorganisms, bringing hitherto unimaginable specificity to their documentable histories. Many origin stories, and nearly all globalization stories, fall within periods that historians and archaeologists study intensively. I argue that the diseases that have proved best suited to global expansion since the advent of the Holocene-those that became pandemics, like COVID-19-are those that have best exploited humans' global networks and behaviors in a given age. This recognition, in turn, gives the fields of both global health and history of medicine a new agenda.
EM monica.h.green@gmail.com
OI Green, Monica/0000-0001-8978-9631
CR Adalja A. A., 2018, CHARACTERISTICS PAND
   Arrizabalaga J., 2016, FIX HEAL PATIENT CAR, P177
   Barquera R, 2020, CURR BIOL, V30, P2078, DOI 10.1016/j.cub.2020.04.002
   Bennett M., 2020, WAR SMALLPOX E JENNE
   Bibbins-Domingo K., 2020, ANN INTERNAL MED
   Bos KI, 2014, NATURE, V514, P494, DOI 10.1038/nature13591
   Brynildsrud OB, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat5869
   Cagle H., 2015, MED TRADE EMPIRE GAR, P107
   Casper S, 2015, M AM ASS HIST MED NE
   Chen S, 2020, S CHINA MORNING POST
   Conis E., 2020, TIME
   Crosby Alfred W., 1972, COLUMBIAN EXCHANGE B
   Curtis D. R., 2020, NOT LEARNING HIST LE
   Daszak Peter, 2020, Biosaf Health, V2, P6, DOI 10.1016/j.bsheal.2020.01.003
   de Ornellas e Castro I., 2015, MED TRADE EMPIRE GAR, P67
   de Waal Alex, 2020, BOSTON REV, V3
   Deslandes A, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.106006
   Devault AM, 2014, NEW ENGL J MED, V370, P334, DOI 10.1056/NEJMoa1308663
   Espinosa M, 2013, ISIS, V104, P798, DOI 10.1086/674946
   Farmer P, 1996, EMERG INFECT DIS, V2, P259, DOI 10.3201/eid0204.960402
   Farmer P, 1999, INFECT INEQUALITIES
   Ghebreyesus T, 2020, WHO DIRECTOR GEN OPE
   Goldbaum C., 2020, NEW YORK TIMES
   Gonzalez-Reiche A, 2020, INTRO EARLY SPREAD S, DOI [10.1101/2020.04.08.20056929, DOI 10.1101/2020.04.08.20056929]
   Green M., 2020, DIS DISPERSION IMPAC, P25
   Green M. H., 2020, S DOUBLEDAY DIA 0206
   Green M. H., AM HIST REV
   Green M. H., 2017, ORIGINS BLACK UNPUB
   Green M. H., 2020, SHAPE DIS SOCIOHISTO
   Green M. H., 2020, WHAT HAPPENS WE EXPA
   Green M. H., 2011, HIV AIDS 30 TEACHING
   Green M. H., ENCY HIST SCI
   Green M. H., 2018, OXFORD RES ENCY ASIA, DOI [10.1093/acrefore/9780190277727.001.0001/acrefore-9780190277727-e-6, DOI 10.1093/ACREFORE/9780190277727.001.0001/ACREFORE-9780190277727-E-6]
   Green M. H., 2014, TEACHING NOTES EBOLA
   Green Monica, 2014, MEDIEVAL GLOBE, V1
   Green MH, 2018, AFRIQUES, V9, DOI 10.4000/afriques.2125
   Green MH, 2017, HUMAN DISPERSAL AND SPECIES MOVEMENT: FROM PREHISTORY TO THE PRESENT, P494
   Green MH, 2015, MEDIEVAL GLOBE, V1, P27
   Green MH, 2012, ASHGATE RESEARCH COMPANION TO THE GLOBALIZATION OF HEALTH, P17
   Grillo KM, 2020, P NATL ACAD SCI USA, V117, P9793, DOI 10.1073/pnas.1920309117
   Gumbs A., 2020, BLACK ENTERPRIS 0417
   Harden V., 1989, COMMUNICATION   0307
   Harper K., 2020, K HARPERS PLAGUES EA
   Harrison M, 2020, MOD ASIAN STUD, V54, P502, DOI 10.1017/S0026749X17001032
   Harrison Mark, 2013, CONTAGION COMMERCE H
   Holmes E., 2020, PS THIS SEQUENCE WAS
   Jones C., 2005, HIST PHILOS LIFE SCI, V27
   Karlsson EK, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006338
   Karow J., 2020, GENOMEWEB       0409
   Key FM, 2020, NAT ECOL EVOL, V4, P324, DOI 10.1038/s41559-020-1106-9
   Lachenal G., 2020, HIST WORKSHOP J
   Ladurie E L, 1973, Schweiz Z Gesch, V23, P627
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Li Hongying, 2019, Biosaf Health, V1, P84, DOI 10.1016/j.bsheal.2019.10.004
   Liasson M., 2020, NPR
   Longform (Producer), 2020, EP 386 E YONG
   Markel H., 2007, JAMA-J AM MED ASSOC, V298, P6
   Marks Simon, POLITICO
   McNeill W.H, 1976, PLAGUES PEOPLES
   Morens DM, 2009, J INFECT DIS, V200, P1018, DOI 10.1086/644537
   Mulholland CV, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02778
   Nextstrain.org, 2020, GEN EP NOV COR GLOB
   Ngabonziza J. C. S., 2020, SISTER LINEAGE MYCOB, DOI [10.1101/2020.01.20.912998v2, DOI 10.1101/2020.01.20.912998V2]
   Richardson ET, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002571
   ROSENBERG CE, 1989, DAEDALUS-US, V118, P1
   Sabin S., 2019, 17 CENTURY MYCOBACTE, DOI [10.1101/588277v1, DOI 10.1101/588277V1]
   Schoch-Spana M, 2017, HEALTH SECUR, V15, P323, DOI 10.1089/hs.2017.0038
   Shaw LP, 2020, MOL ECOL, V29, P3361, DOI 10.1111/mec.15463
   Smith KF, 2007, ECOLOGY, V88, P1903, DOI 10.1890/06-1052.1
   Snowden FM, 2008, IMMUNOL REV, V225, P9, DOI 10.1111/j.1600-065X.2008.00677.x
   Spyrou MA, 2019, NAT REV GENET, V20, P323, DOI 10.1038/s41576-019-0119-1
   Taylor Keeanga-Yamahtta, 2020, NEW YORKER
   Tobin J., 2020, MICHIGAN TODAY
   Vagene AJ, 2018, NAT ECOL EVOL, V2, P520, DOI 10.1038/s41559-017-0446-6
   WHO, 2019, GLOB TUB REP 2019
   Yong EL, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.19706
   Zimmer C., 2020, NEW YORK TIMES
NR 77
TC 2
Z9 2
U1 6
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-8994
EI 1600-0498
J9 CENTAURUS
JI Centaurus
PD MAY
PY 2020
VL 62
IS 2
SI SI
BP 234
EP 247
DI 10.1111/1600-0498.12306
PG 14
WC History & Philosophy Of Science
SC History & Philosophy of Science
GA NG4OY
UT WOS:000563964500003
OA Bronze
DA 2021-01-01
ER

PT J
AU Dolan, B
AF Dolan, Brian
TI It wasn't supposed to be a coronavirus: The quest for an influenza
   A(H5N1)-derived vaccine and the limits of pandemic preparedness
SO CENTAURUS
LA English
DT Article
ID AVIAN INFLUENZA; A H5N1; VIRUSES; RISK; IMMUNOGENICITY; TRANSMISSION;
   INFECTION; EVOLUTION; POULTRY; SAFETY
AB The COVID-19 pandemic has raised questions about what efforts were made across the world to prepare governments and healthcare systems for such an event. This spotlight article looks at developments made in "pre-pandemic preparedness planning" following a number of outbreaks of influenza type A virus in 1997. At that time, a specific avian influenza subtype, referred to as A(H5N1), wreaked havoc among fowl but also infected humans through direct transmission. The potential for slight genetic mutations that could make A(H5N1) more infectious, allowing human-to-human transmission, presented the threat of a deadly influenza pandemic. As a result, the U.S. government (and others coordinating through the World Health Organization) launched a pandemic preparation plan, including strategies to develop vaccines against A(H5N1) and its genetic lineages each year. This spotlight article discusses the events that led to the specific concern about A(H5N1) among public health officials, as well as early efforts to derive and stockpile an appropriate vaccine to protect against a possible pandemic. This perspective presents the challenges the world has faced, in recent history, in striving to keep one step ahead of pandemic threats.
C1 [Dolan, Brian] UCSF, Humanities & Social Sci, San Francisco, CA 94143 USA.
RP Dolan, B (corresponding author), UCSF, Humanities & Social Sci, San Francisco, CA 94143 USA.
EM brian.dolan@ucsf.edu
OI Dolan, Brian/0000-0002-7935-8915
CR [Anonymous], 2013, NAT MED, V19, P113, DOI 10.1038/nm.3099
   [Anonymous], 2015, GLOBAL BIODEFENSE
   Anthony SJ, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex012
   Caduff C, 2014, CURR ANTHROPOL, V55, P296, DOI 10.1086/676124
   Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7
   Dale Daniel, 2020, CNN
   Drexler JF, 2014, ANTIVIR RES, V101, P45, DOI 10.1016/j.antiviral.2013.10.013
   Enserink M, 2005, SCIENCE, V309, P996
   Fauci AS, 2005, NATURE, V435, P423, DOI 10.1038/435423a
   Goldberg D, 2020, POLITICO
   Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419
   Homeland Security Council, 2005, NAT STRAT PAND INFL
   Honigsbaum M, 2011, GUARDIAN
   Horimoto T, 2001, CLIN MICROBIOL REV, V14, P129, DOI 10.1128/CMR.14.1.129-149.2001
   Jamison DT, 2017, DIS CONTROL PRIORITI, DOI [10.1596/978-1-4648-0527-1, DOI 10.1596/978-1-4648-0527-1]
   Jones JC, 2014, J VIROL, V88, P1175, DOI 10.1128/JVI.02526-13
   Karron RA, 2009, VACCINE, V27, P4953, DOI 10.1016/j.vaccine.2009.05.099
   Keck F., 2020, CENTAURUS
   Keck F., 2020, AVIAN RESERVOIRS VIR
   Keitel WA, 2008, J INFECT DIS, V198, P1309, DOI 10.1086/592172
   KIDA H, 1994, J GEN VIROL, V75, P2183, DOI 10.1099/0022-1317-75-9-2183
   Krammer F, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028845
   Krammer F, 2017, LANCET INFECT DIS, V17, P784, DOI 10.1016/S1473-3099(17)30297-9
   Lasley F. A., 2003, AVIAN DIS, V47, P390
   Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746
   Ma MJ, 2018, EMERG INFECT DIS, V24, P1246, DOI 10.3201/eid2407.172059
   Mason Katherine A., 2016, INFECT CHANGE REINVE
   Matthews James T., 2007, Journal of the Pennsylvania Academy of Science, V80, P54
   Morens DM, 2010, CRIT CARE MED, V38, pE10, DOI 10.1097/CCM.0b013e3181ceb25b
   NICHOLSON KG, 1991, BRIT MED J, V302, P425, DOI 10.1136/bmj.302.6774.425
   O'Sullivan TL, 2019, NAT HAZARDS, V98, P103, DOI 10.1007/s11069-019-03584-6
   Osterholm MT, 2007, FOREIGN AFF, V86, P47
   Osterholm MT, 2005, NEW ENGL J MED, V352, P1839, DOI 10.1056/NEJMp058068
   Parashar Umesh D., 2004, Emerging Infectious Diseases, V10, P384
   Perdue ML, 2005, AVIAN DIS, V49, P317, DOI 10.1637/7390-060305R.1
   PREDICT Consortium, 2014, RED PAND RISK PROM G
   Romano Michael, 2007, Mod Healthc, V37, P8
   Searight A, 2020, STRENGTHS VULNERABIL
   Shortridge K F, 1992, Semin Respir Infect, V7, P11
   SHORTRIDGE KF, 1995, LANCET, V346, P1210, DOI 10.1016/S0140-6736(95)92906-1
   Shortridge KF, 1998, VIROLOGY, V252, P331, DOI 10.1006/viro.1998.9488
   Sims LD, 2003, AVIAN DIS, V47, P832, DOI 10.1637/0005-2086-47.s3.832
   Smith GJD, 2006, VIROLOGY, V350, P258, DOI 10.1016/j.virol.2006.03.048
   Swayne DE, 2006, DEV BIOLOGICALS, V124, P85
   Treanor JJ, 2006, NEW ENGL J MED, V354, P1343, DOI 10.1056/NEJMoa055778
   Trump D, 2020, COMMUNICATION   0314
   Trump D., 2020, COMMUNICATION   0306
   Uyeki TM, 2009, CLIN INFECT DIS, V49, P279, DOI 10.1086/600035
   Vigant F, 2015, NAT REV MICROBIOL, V13, P426, DOI 10.1038/nrmicro3475
   Watson K., 2020, CBS NEWS
   Webster RG, 1997, FEMS IMMUNOL MED MIC, V18, P275, DOI 10.1016/S0928-8244(97)00058-8
   WEBSTER RG, 2018, FLU HUNTER UNLOCKING
   Wei PF, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/5717108
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   Wood JM, 2001, PHILOS T R SOC B, V356, P1953, DOI 10.1098/rstb.2001.0981
   World Health Organization, 2006, ANT GEN CHAR ZOON IN
   Xu XY, 1999, VIROLOGY, V261, P15, DOI 10.1006/viro.1999.9820
   Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9
NR 58
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-8994
EI 1600-0498
J9 CENTAURUS
JI Centaurus
PD MAY
PY 2020
VL 62
IS 2
SI SI
BP 331
EP 343
DI 10.1111/1600-0498.12312
PG 13
WC History & Philosophy Of Science
SC History & Philosophy of Science
GA NG4OY
UT WOS:000563964500013
OA Bronze
DA 2021-01-01
ER

PT J
AU Mauri, D
   Tzachanis, D
   Valachis, A
   Kamposioras, K
   Tolias, M
   Dambrosio, M
   Zarkavelis, G
   Gkoura, S
   Gazouli, I
   De Lorenzo, F
   Apostolidis, K
AF Mauri, Davide
   Tzachanis, Dimitrios
   Valachis, Antonis
   Kamposioras, Konstantinos
   Tolias, Maria
   Dambrosio, Mario
   Zarkavelis, Georgios
   Gkoura, Stefania
   Gazouli, Ioanna
   De Lorenzo, Francesco
   Apostolidis, Kathi
CA Int Oncology Panel
   FAVO
   ECPC
TI Behind the numbers and the panic of a viral pandemic: fixed restrictive
   oncology guidance may jeopardize patients' survival
SO JOURNAL OF BUON
LA English
DT Article
DE COVID-19; cancer patients; survival; Federation of Oncology Volunteer
   Associations (FAVO); European Cancer Patient Coalition (EPCC)
ID CANCER
AB To protect cancer patients from COVID-19 exposure, prioritization strategies are being implemented at global level. Measures include use of tele-health services, deferring elective surgeries, delaying non life-saving therapies, interrupting maintenance and supportive care regimens and suspending screening and regular follow-up visits.
   Nonetheless, the risk of infection may not always outweigh oncology treatment benefit. Lives of most oncology patients depend on their ability to receive medical, surgical and radiotherapy care. Postponing screening,follow-up and radical surgeries increase patients' risk of developing metastatic disease.
   A viral pandemic lasts long time and exhibits seasonal and geographical variations. Though vaccines will be available only in the 2021, a global, aggressive, all-embracing and protracted slowdown of oncologic activities will severely jeopardize patients' outcomes.
   A present international oncologists' panel, ECPC and FAVO, strongly suggest that Hospital measures in a specific geographical area/Nation should be in line with the local epidemic, and restrictions adopted should be adapted and stratified over time.
C1 [Mauri, Davide; Zarkavelis, Georgios; Gkoura, Stefania; Gazouli, Ioanna] Univ Ioannina, Dept Med Oncol, Ioannina, Greece.
   [Tzachanis, Dimitrios] UCSD, Moores Canc Ctr, La Jolla, CA USA.
   [Valachis, Antonis] Orebro Univ, Fac Med & Hlth, Dept Oncol, Orebro, Sweden.
   [Kamposioras, Konstantinos] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England.
   [Tolias, Maria] Univ Thessaly, Dept Radiotherapy Radiat Oncol, Univ Hosp Larisa, Fac Med,Sch Hlth Sci,Biopolis, Larisa 41500, Greece.
   [Dambrosio, Mario] Paderno Dugnano, Dept Med Oncol, Clin San Carlo, Milan, Italy.
   [De Lorenzo, Francesco; Int Oncology Panel] FAVO Federat Oncol Volunteer Assoc, Rome, Italy.
   [Apostolidis, Kathi; FAVO] ECPC European Canc Patients Coalit, Brussels, Belgium.
RP Mauri, D (corresponding author), Univ Hosp Ioannina, Dept Med Oncol, S Niarchos Ave, TK-45500 Ioannina, Greece.
EM dvd.mauri@gmail.com; fdelorenzo2@gmail.com; kathiapostolidis@gmail.com
CR Dinmohamed AG, 2020, LANCET ONCOL, V21, P750, DOI 10.1016/S1470-2045(20)30265-5
   Lagergren J, 2017, INT J CANCER, V141, P1971, DOI 10.1002/ijc.30899
   Lapointe-Shaw L, 2016, J NATL COMPR CANC NE, V14, P867, DOI 10.6004/jnccn.2016.0091
   Mauri D, 2020, LANCET ONCOL, V21, P759, DOI 10.1016/S1470-2045(20)30278-3
NR 4
TC 1
Z9 1
U1 0
U2 0
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD MAY-JUN
PY 2020
VL 25
IS 3
BP 1277
EP 1280
PG 4
WC Oncology
SC Oncology
GA NE1UI
UT WOS:000562382600001
PM 32862566
DA 2021-01-01
ER

PT J
AU Salman, S
   Shah, FH
   Idrees, J
   Idrees, F
   Velagala, S
   Ali, J
   Khan, AA
AF Salman, Saad
   Shah, Fahad H.
   Idrees, Jawaria
   Idrees, Fariha
   Velagala, Shreya
   Ali, Johar
   Khan, Abid A.
TI Virtual screening of immunomodulatory medicinal compounds as promising
   anti-SARS-CoV-2 inhibitors
SO FUTURE VIROLOGY
LA English
DT Article
DE acute toxicity; drug repurposing; molecular docking; pharmacokinetics;
   severe acute respiratory syndrome-2
ID COVID-19; MANAGEMENT
AB Aim: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a pernicious viral disease, causes acute respiratory distress responsible for mortality and morbidity worldwide. To screen different immunomodulatory medicinal compounds to unravel their interaction with SARS-CoV-2 viral proteins. Materials & methods: A library of immunomodulatory medicinal compounds with antiviral capability were analyzed against SARS proteases, spike protein and nonstructural proteins (NSP-9, 15) using Autodock vina. Results: Out of more than 300 medicinal compounds, only six compounds: arzanol, ferulic acid, genistein, resveratrol, rosmanol and thymohydroquinone showed significant interaction with the SARS viral proteins by forming hydrogen bonds with the active site residues with low binding energy. Further ADMET (absorption, distribution, metabolism, excretion and toxicity) analysis showed good pharmacokinetic properties and low acute toxicity of these compounds. Conclusion: The current study provides convincing evidence that these medicinal compounds exert antiviral activity against the SARS-CoV-2 virus and could be further exploited for the treatment of this disease.
C1 [Salman, Saad] Univ Lahore, Islamabad Campus, Islamabad 44790, Punjab, Pakistan.
   [Shah, Fahad H.; Khan, Abid A.] Univ Peshawar, Ctr Biotechnol & Microbiol, Khyber Pakhtunkhwa 25120, Pakistan.
   [Idrees, Jawaria; Idrees, Fariha] Islamia Coll Univ, Peshawar 25120, Pakistan.
   [Velagala, Shreya] Quarry Lane Sch, Dublin, CA 94568 USA.
   [Ali, Johar] Sukkur IBA Univ, Dept Comp Sci, Sukkur 65200, Sindh, Pakistan.
   [Ali, Johar] Rehman Med Inst Hayatabad, Ctr Genom Sci, Khyber Pakhtunkhwa 25100, Pakistan.
   [Khan, Abid A.] Muhammad Coll Med, Peshawar 25000, Pakistan.
RP Shah, FH (corresponding author), Univ Peshawar, Ctr Biotechnol & Microbiol, Khyber Pakhtunkhwa 25120, Pakistan.
EM fahad.researcher@outlook.com
OI KHAN, ABID/0000-0001-7715-1040
CR Akram M, 2018, PHYTOTHER RES, V32, P811, DOI 10.1002/ptr.6024
   Alaribe FN, 2019, TISSUE ENG PT A, V25, P827, DOI [10.1089/ten.tea.2019.0060, 10.1089/ten.TEA.2019.0060]
   Anywar G, 2020, EUR J INTEGR MED, V35, DOI 10.1016/j.eujim.2019.101011
   Ben-Shabat S, 2020, DRUG DELIV TRANSL RE, V10, P354, DOI 10.1007/s13346-019-00691-6
   Caesar LK, 2019, NAT PROD REP, V36, P869, DOI 10.1039/c9np00011a
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Gu JY, 2020, GASTROENTEROLOGY, V158, P1518, DOI 10.1053/j.gastro.2020.02.054
   Jantan I, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00655
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Kim Y, 2020, PROTEIN SCI, V29, P1596, DOI 10.1002/pro.3873
   Kumar D, 2012, J MICROBIOL IMMUNOL, V45, P165, DOI 10.1016/j.jmii.2011.09.030
   Lagunin A, 2011, MOL INFORM, V30, P241, DOI 10.1002/minf.201000151
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Littler D.R., 2020, CRYSTAL STRUCTURE SA, DOI [10.1101/2020.03.28.013920, DOI 10.1101/2020.03.28.013920]
   Maxwell NM, 2015, CLIN CASE REP, V3, P379, DOI 10.1002/ccr3.238
   Mielke H, 2017, REGUL TOXICOL PHARM, V89, P26, DOI 10.1016/j.yrtph.2017.07.007
   Patil R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012029
   Ramirez D, 2018, MOLECULES, V23, DOI 10.3390/molecules23051038
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   Velazquez-Libera JL, 2020, BIOINFORMATICS, V36, P2912, DOI 10.1093/bioinformatics/btaa018
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Xu D, 2011, BIOPHYS J, V101, P2525, DOI 10.1016/j.bpj.2011.10.024
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang ZM, 2011, BIOINFORMATICS, V27, P2083, DOI 10.1093/bioinformatics/btr331
NR 33
TC 4
Z9 4
U1 2
U2 2
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
EI 1746-0808
J9 FUTURE VIROL
JI Future Virol.
PD MAY
PY 2020
VL 15
IS 5
BP 267
EP 275
DI 10.2217/fvl-2020-0079
PG 9
WC Virology
SC Virology
GA NC6PO
UT WOS:000561339600003
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU van de Haar, J
   Hoes, LR
   Coles, CE
   Seamon, K
   Frohling, S
   Jager, D
   Valenza, F
   de Braud, F
   De Petris, L
   Bergh, J
   Ernberg, I
   Besse, B
   Barlesi, F
   Garralda, E
   Piris-Gimenez, A
   Baumann, M
   Apolone, G
   Soria, JC
   Tabernero, J
   Caldas, C
   Voest, EE
AF van de Haar, Joris
   Hoes, Louisa R.
   Coles, Charlotte E.
   Seamon, Kenneth
   Frohling, Stefan
   Jager, Dirk
   Valenza, Franco
   de Braud, Filippo
   De Petris, Luigi
   Bergh, Jonas
   Ernberg, Ingemar
   Besse, Benjamin
   Barlesi, Fabrice
   Garralda, Elena
   Piris-Gimenez, Alejandro
   Baumann, Michael
   Apolone, Giovanni
   Soria, Jean Charles
   Tabernero, Josep
   Caldas, Carlos
   Voest, Emile E.
TI Caring for patients with cancer in the COVID-19 era
SO NATURE MEDICINE
LA English
DT Article
ID CORE EUROPE
AB The current COVID-19 pandemic challenges oncologists to profoundly re-organize oncological care in order to dramatically reduce hospital visits and admissions and therapy-induced immune-related complications without compromising cancer outcomes. Since COVID-19 is a novel disease, guidance by scientific evidence is often unavailable, and impactful decisions are inevitably made on the basis of expert opinions. Here we report how the seven comprehensive cancer centers of Cancer Core Europe have organized their healthcare systems at an unprecedented scale and pace to make their operations 'pandemic proof'. We identify and discuss many commonalities, but also important local differences, and pinpoint critical research priorities to enable evidence-based remodeling of cancer care during the COVID-19 pandemic. Also, we discuss how the current situation offers a unique window of opportunity for assessing the effects of de-escalating anticancer regimens, which may fast-forward the development of more-refined and less-toxic treatments. By sharing our joint experiences, we offer a roadmap for proceeding and aim to mobilize the global research community to generate the data that are critically needed to offer the best possible care to patients.
C1 [van de Haar, Joris; Hoes, Louisa R.; Voest, Emile E.] Netherlands Canc Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands.
   [van de Haar, Joris] Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands.
   [van de Haar, Joris; Voest, Emile E.] Netherlands Canc Inst, Oncode Inst, Amsterdam, Netherlands.
   [Coles, Charlotte E.; Seamon, Kenneth; Caldas, Carlos] Canc Res UK Cambridge Canc Ctr, Cambridge, England.
   [Frohling, Stefan] German Canc Consortium, Heidelberg, Germany.
   [Frohling, Stefan] Natl Ctr Tumor Dis Heidelberg, Div Translat Med Oncol, Heidelberg, Germany.
   [Frohling, Stefan; Baumann, Michael] German Canc Res Ctr, Heidelberg, Germany.
   [Jager, Dirk] Natl Ctr Tumor Dis Heidelberg, Dept Med Oncol, Heidelberg, Germany.
   [Jager, Dirk] Heidelberg Univ Hosp, Heidelberg, Germany.
   [Valenza, Franco; de Braud, Filippo] Univ Statale Milano, Milan, Italy.
   [Valenza, Franco; de Braud, Filippo; Apolone, Giovanni] Fdn IRCCS Ist Nazl Tumori Milano, Milan, Italy.
   [De Petris, Luigi; Bergh, Jonas] Karolinska Inst, Dept Oncol & Pathol, Stockholm, Sweden.
   [De Petris, Luigi; Bergh, Jonas] Karolinska Univ Hosp, Theme Canc, Stockholm, Sweden.
   [Ernberg, Ingemar] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden.
   [Besse, Benjamin; Barlesi, Fabrice; Soria, Jean Charles] Gustave Roussy Canc Campus, Villejuif, France.
   [Barlesi, Fabrice] Aix Marseille Univ, CNRS, INSERM, CRCM, Marseille, France.
   [Garralda, Elena; Piris-Gimenez, Alejandro; Tabernero, Josep] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain.
   [Caldas, Carlos] Univ Cambridge, Dept Oncol, Li Ka Shing Ctr, Cambridge, England.
   [Caldas, Carlos] Univ Cambridge, Canc Res UK Cambridge Inst, Li Ka Shing Ctr, Cambridge, England.
RP Voest, EE (corresponding author), Netherlands Canc Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands.; Voest, EE (corresponding author), Netherlands Canc Inst, Oncode Inst, Amsterdam, Netherlands.; Caldas, C (corresponding author), Canc Res UK Cambridge Canc Ctr, Cambridge, England.; Caldas, C (corresponding author), Univ Cambridge, Dept Oncol, Li Ka Shing Ctr, Cambridge, England.; Caldas, C (corresponding author), Univ Cambridge, Canc Res UK Cambridge Inst, Li Ka Shing Ctr, Cambridge, England.
EM carlos.caldas@cruk.cam.ac.uk; e.voest@nki.nl
RI Caldas, Carlos/U-7250-2019; Garralda, Elena/AAU-3499-2020; Soria,
   Jean-Charles/F-3619-2014; Apolone, Giovanni/R-9799-2016
OI Caldas, Carlos/0000-0003-3547-1489; Apolone,
   Giovanni/0000-0001-5179-104X; Baumann, Michael/0000-0002-9340-974X;
   GARRALDA, Elena/0000-0002-4412-7842
FU Cancer Research UK (Major Center Award) [A25117]; National Institute for
   Health Research Cambridge Biomedical Research CenterNational Institute
   for Health Research (NIHR); Mark Foundation for Cancer Research; Dutch
   Cancer SocietyKWF Kankerbestrijding; Radiumhemmets Research Foundations,
   Stockholm; La Caixa FoundationLa Caixa Foundation; FERO Foundation
FX We thank all members of CCE centers who contributed to the development
   of the guidelines presented in this perspective. A list of members of
   CCE centers is provided in the Supplementary Note. The Cancer Research
   UK Cambridge Center acknowledges funding from Cancer Research UK (Major
   Center Award A25117), the National Institute for Health Research
   Cambridge Biomedical Research Center, and The Mark Foundation for Cancer
   Research. Authors with the Netherlands Cancer Institute acknowledge the
   Dutch Cancer Society for funding. Authors with the Karolinska Institutet
   acknowledge Radiumhemmets Research Foundations, Stockholm, for funding.
   Authors with the Vall d'Hebron Institute of Oncology acknowledge the
   Cellex Foundation for providing research facilities and equipment and La
   Caixa Foundation and FERO Foundation for their funding support.
CR Bitterman R, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008983.pub3
   Calvo F, 2018, EUR J CANCER, V103, P155, DOI 10.1016/j.ejca.2018.08.023
   Coles CE, 2020, CLIN ONCOL-UK, V32, P279, DOI 10.1016/j.clon.2020.03.006
   Eggermont AMM, 2019, MOL ONCOL, V13, P521, DOI 10.1002/1878-0261.12447
   Eggermont AMM, 2014, EUR J CANCER, V50, P2745, DOI 10.1016/j.ejca.2014.07.025
   Kunisaki KM, 2009, LANCET INFECT DIS, V9, P493, DOI 10.1016/S1473-3099(09)70175-6
   Lefevre JH, 2016, J CLIN ONCOL, V34, P3773, DOI 10.1200/JCO.2016.67.6049
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   NHS England, 2020, CLIN GUID MAN NONC P
   Persad G, 2020, NEW ENGL J MED, V382
   Walker P., 2020, IMPERIAL COLL LONDON, DOI [10.25561/77735, DOI 10.25561/77735]
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Watanabe K, 2020, SOC SCI COMPUT REV, DOI 10.1177/0894439320907027
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Yang Yang M, 2020, EVALUATING ACCURACY, DOI [10.1101/2020.02.11.20021493, DOI 10.1101/2020.02.11.20021493]
   ZHANG MD, 2020, ANN ONCOL, DOI DOI 10.1016/J.ANNONC.2020.03.296
NR 16
TC 82
Z9 81
U1 8
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD MAY
PY 2020
VL 26
IS 5
BP 665
EP 671
DI 10.1038/s41591-020-0874-8
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA ML1JP
UT WOS:000549231500019
PM 32494062
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Esler, M
   Esler, D
AF Esler, Murray
   Esler, Danielle
TI Can angiotensin receptor-blocking drugs perhaps be harmful in the
   COVID-19 pandemic?
SO JOURNAL OF HYPERTENSION
LA English
DT Article
ID II ANTAGONIST LOSARTAN; UP-REGULATION; BLOCKADE
C1 [Esler, Murray; Esler, Danielle] Baker Heart & Diabet Inst, POB 6492, Melbourne, Vic 3004, Australia.
   [Esler, Danielle] Northern Terr Dept Hlth, Publ Hlth Directorate, Melbourne, Vic, Australia.
RP Esler, M (corresponding author), Baker Heart & Diabet Inst, POB 6492, Melbourne, Vic 3004, Australia.
EM murray.esler@baker.edu.au
FU Victorian Government's Operational Infrastructure Support Program
FX Supported in part by the Victorian Government's Operational
   Infrastructure Support Program.
CR BAUER JH, 1995, J HUM HYPERTENS, V9, P237
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Gallagher PE, 2008, AM J PHYSIOL-CELL PH, V295, pC1169, DOI 10.1152/ajpcell.00145.2008
   Gavras I, 1999, CURR MED RES OPIN, V15, P15, DOI 10.1185/03007999909115169
   GOTTLIEB SS, 1993, CIRCULATION, V88, P1602, DOI 10.1161/01.CIR.88.4.1602
   GROSSMAN E, 1994, AM J HYPERTENS, V7, P1041, DOI 10.1093/ajh/7.12.1041
   Ishiyama Y, 2004, HYPERTENSION, V43, P970, DOI 10.1161/01.HYP.0000124667.34652.1a
   Jessup JA, 2006, AM J PHYSIOL-HEART C, V291, pH2166, DOI 10.1152/ajpheart.00061.2006
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zisman LS, 2003, CIRCULATION, V108, P1707, DOI 10.1161/01.CIR.0000094734.67990.99
NR 10
TC 93
Z9 93
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0263-6352
EI 1473-5598
J9 J HYPERTENS
JI J. Hypertens.
PD MAY
PY 2020
VL 38
IS 5
BP 781
EP 782
DI 10.1097/HJH.0000000000002450
PG 2
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA MU1JB
UT WOS:000555425200001
PM 32195824
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Aeppli, S
   Eboulet, EI
   Eisen, T
   Escudier, B
   Fischer, S
   Larkin, J
   Gruenwald, V
   McDermott, D
   Oldenburg, J
   Omlin, A
   Porta, C
   Rini, B
   Schmidinger, M
   Sternberg, C
   Rothermundt, C
AF Aeppli, Stefanie
   Eboulet, Eric Innocents
   Eisen, Tim
   Escudier, Bernard
   Fischer, Stefanie
   Larkin, James
   Gruenwald, Viktor
   McDermott, David
   Oldenburg, Jan
   Omlin, Aurelius
   Porta, Camillo
   Rini, Brian
   Schmidinger, Manuela
   Sternberg, Cora
   Rothermundt, Christian
TI Impact of COVID-19 pandemic on treatment patterns in metastatic clear
   cell renal cell carcinoma
SO ESMO OPEN
LA English
DT Article
DE renal cell carcinoma; COVID-19; pandemic; treatment pattern; decision
   criteria
ID INITIAL TARGETED THERAPY; INTERFERON-ALPHA; SUNITINIB; RISK
AB Background The coronavirus pandemic has provoked discussions among healthcare providers how to manage cancer patients when faced with the threat of severe acute respiratory syndrome related coronavirus 2 (SARS-CoV-2) infection. Immune checkpoint inhibitor (ICI) containing regimens are standard of care in the majority of metastatic clear cell renal cell carcinoma (mccRCC) patients. It remains unclear whether therapies should be modified in response to the COVID-19 pandemic. Methods We performed an online survey among physicians involved in the treatment of mccRCC, and 41 experts responded. Questions focused on criteria relevant for treatment decision outside the pandemic and the modifications of systemic therapy during COVID-19. Findings For the majority of experts (73%), the combination of International metastatic renal cell carcinoma Database Consortium (IMDC) risk category and patient fitness are two important factors for decision-making. The main treatment choice in fit, favourable risk patients outside the pandemic is pembrolizumab/axitinib for 53%, avelumab/axitinib, sunitinib or pazopanib for 13% of experts each. During the pandemic, ICI-containing regimens are chosen less often in favour of a tyrosine kinase inhibitors (TKI) monotherapy, mainly sunitinib or pazopanib (35%). In fit, intermediate/poor-risk patients outside the pandemic, over 80% of experts choose ipilimumab/nivolumab, in contrast to only 41% of physicians during COVID-19, instead more TKI monotherapies are given. In patients responding to established therapies with ICI/ICI or ICI/TKI combinations, most participants modify treatment regimen by extending cycle length, holding one ICI or even both. Conclusion mccRCC treatment modifications in light of the coronavirus pandemic are variable, with a shift from ICI/ICI to ICI/TKI or TKI monotherapy.
C1 [Aeppli, Stefanie; Fischer, Stefanie; Omlin, Aurelius; Rothermundt, Christian] Kantonsspital St Gallen, Med Oncol & Haematol, St Gallen, Switzerland.
   [Eboulet, Eric Innocents] Swiss Grp Clin Canc Res SAKK, Coordinating Ctr, Bern, Switzerland.
   [Eisen, Tim] Cambridge Univ Hosp NHS Fdn Trust, Dept Oncol, Cambridge, England.
   [Escudier, Bernard] Gustave Roussy, Dept Med Oncol, Villejuif, Ile De France, France.
   [Larkin, James] Royal Marsden Hosp NHS Trust, Med Oncol, London, England.
   [Gruenwald, Viktor] Univ Hosp Essen, Clin Internal Med Tumor Res & Clin Urol, Essen, Germany.
   [McDermott, David] Beth Israel Deaconess Med Ctr, Dana Farber Harvard Canc Ctr, Kidney Canc Program, Boston, MA 02215 USA.
   [Oldenburg, Jan] Akershus Univ Hosp, Div Med Lab Sci, Lorenskog, Norway.
   [Porta, Camillo] Univ Bari Aldo Moro, Biomed Sci & Human Oncol, Bari, Italy.
   [Rini, Brian] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA.
   [Schmidinger, Manuela] Clin Div Oncol, Med 1, Vienna, Austria.
   [Sternberg, Cora] Weill Cornell Med, Med Oncol, New York, NY USA.
RP Rothermundt, C (corresponding author), Kantonsspital St Gallen, Med Oncol & Haematol, St Gallen, Switzerland.
EM christian.rothermundt@kssg.ch
CR Atkins MB, 2020, J CLIN ONCOL, V38
   Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444
   Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P269, DOI 10.2217/imt-2020-0067
   Cannistra SA, 2020, J CLIN ONCOL, V38, P2206, DOI 10.1200/JCO.20.00858
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Choi J, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e9
   Choueiri TK, 2017, J CLIN ONCOL, V35, P591, DOI 10.1200/JCO.2016.70.7398
   Escudier B, 2019, ANN ONCOL, V30, P706, DOI 10.1093/annonc/mdz056
   Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7
   Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7
   Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126
   Motzer R, 2019, LANCET ONCOL, V20, P1370, DOI 10.1016/S1470-2045(19)30413-9
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Motzer RJ, 2019, J NATL COMPR CANC NE, V17, P1279, DOI 10.6004/jnccn.2019.0054
   Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047
   Motzer RJ, 2013, J CLIN ONCOL, V31, P3791, DOI 10.1200/JCO.2012.47.4940
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130
   Panian J, 2020, CLIN GENITOURIN CANC, V18, pE598, DOI 10.1016/j.clgc.2020.03.010
   Plimack ER, 2020, J CLIN ONCOL, V38
   Rini BI, 2019, LANCET, V393, P2404, DOI 10.1016/S0140-6736(19)30723-8
   Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714
   Schonrich G, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00207
   Singer AJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009409
   Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764
   Truog RD, 2020, NEW ENGL J MED, V382, P1973, DOI 10.1056/NEJMp2005689
   WHISENANT JG, 2020, J CLIN ONCOL S, V38, pNIL9, DOI DOI 10.1200/JCO.2020.38.18_suppl.LBA111
   WISE J, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2294
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 33
TC 5
Z9 5
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2059-7029
J9 ESMO OPEN
JI ESMO Open
PD MAY
PY 2020
VL 5
SU 3
AR e000852
DI 10.1136/esmoopen-2020-000852
PG 8
WC Oncology
SC Oncology
GA MT2ZH
UT WOS:000554837200001
PM 32669298
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Haider, II
   Tiwana, F
   Tahir, SM
AF Haider, Imran Ijaz
   Tiwana, Farah
   Tahir, Sania Mumtaz
TI Impact of the COVID-19 Pandemic on Adult Mental Health
SO PAKISTAN JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE COVID-19; Mental Health; Pandemic Impact
ID HONG-KONG; STRESS; SARS; RESILIENCE; INFLUENZA
AB The outbreak of the Novel Coronavirus (COVID-19) in December 2019 has progressed to the status of a global pandemic, with countries across the seven continents adversely affected and the number of human cases exceeding two million. With no available vaccine, the treatment is primarily symptomatic for those affected and preventative for those at risk. Most countries have taken action to curtail the spread of COVID-19 through measures such as lockdowns, social distancing and voluntary self-isolation. Whilst necessary, such measures and the disease itself, may have an adverse impact on mental health. In view of research from previous pandemic crises, it is known that such situations are likely to increase stress levels and have negative psychiatric effects. The impact is likely to be felt by the general public, sufferers of COVID-19, their families and friends, persons with pre-existing mental health conditions and healthcare workers.
C1 [Haider, Imran Ijaz] Fatima Mem Hosp, Psychiat & Behav Sci, Lahore, Pakistan.
   [Tiwana, Farah] Fatima Mem Hosp, Dept Psychiat & Behav Sci, Lahore, Pakistan.
   [Tahir, Sania Mumtaz] King Edward Med Univ, Dept Psychiat & Behav Sci, Lahore, Pakistan.
RP Haider, II (corresponding author), Fatima Mem Hosp, Psychiat & Behav Sci, Lahore, Pakistan.
EM drimranihaider@gmail.com
OI Tiwana, Farah/0000-0003-0558-7659
CR Aiello A, 2011, J CONTIN EDUC HEALTH, V31, P15, DOI 10.1002/chp.20096
   [Anonymous], 2020, Q A COR COVID 19
   [Anonymous], 2020, PAK COR 7 025 CAS 13
   [Anonymous], 2020, NEW SCI
   Bonanno GA, 2008, HEALTH PSYCHOL, V27, P659, DOI 10.1037/0278-6133.27.5.659
   Centers for Disease Control and Prevention, 2020, MENT HLTH COP COVID
   DELAAT B, 2020, PSYCHIAT RES, DOI DOI 10.1101/2020.02.19.20025395
   Depoux A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa031
   Dong L, 2020, EMERG INFECT DIS, V26, P1616, DOI 10.3201/eid2607.200407
   Felix I, 2020, PSYCHOL INTERVENTION, DOI [10.31234/osf.io/8svfa, DOI 10.31234/OSF.IO/8SVFA]
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Gutierrez P, 2020, GUARDIAN
   Hari J., 2019, LOST CONNECTIONS UNC
   Herbert J, 1997, BRIT MED J, V315, P530, DOI 10.1136/bmj.315.7107.530
   Horan WP, 2007, PSYCHIAT RES, V151, P77, DOI 10.1016/j.psychres.2006.10.009
   Kaufman KR, 2020, BJPSYCH OPEN, V6, DOI 10.1192/bjo.2020.25
   Khamsi R., 2020, NATURE COM
   Kumar A, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102053
   Mak IWC, 2009, GEN HOSP PSYCHIAT, V31, P318, DOI 10.1016/j.genhosppsych.2009.03.001
   Maunder RG, 2008, CAN J PUBLIC HEALTH, V99, P486, DOI 10.1007/BF03403782
   McAlonan GM, 2005, PSYCHOL MED, V35, P459, DOI 10.1017/S0033291704004362
   Mukhtar Fatima, 2020, J Ayub Med Coll Abbottabad, V32, P141
   Organization W, 2011, PSYCH 1 AID
   Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017
   Shah K, 2020, CUREUS, V12, DOI 10.7759/cureus.7405
   Shigemura J, 2020, PSYCHIAT CLIN NEUROS, V74, P281, DOI 10.1111/pcn.12988
   Tam CWC, 2004, PSYCHOL MED, V34, P1197, DOI 10.1017/S0033291704002247
   Teo AR, 2015, J AM GERIATR SOC, V63, P2014, DOI 10.1111/jgs.13667
   Zhou XY, 2020, TELEMED E-HEALTH, V26, P377, DOI 10.1089/tmj.2020.0068
NR 29
TC 9
Z9 9
U1 6
U2 6
PU PROFESSIONAL MEDICAL PUBLICATIONS
PI SADDAR
PA PANORAMA CENTRE, RM 522, 5TH FLOOR, BLDG 2, RAJA GHAZANFAR ALI RD, PO
   BOX 8766, SADDAR, KARACHI 00000, PAKISTAN
SN 1682-024X
J9 PAK J MED SCI
JI Pak. J. Med. Sci.
PD MAY
PY 2020
VL 36
IS 4
SU S
SI SI
BP S90
EP S94
DI 10.12669/pjms.36.COVID19-S4.2756
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA MS7ML
UT WOS:000554459400018
PM 32582321
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kamani, L
AF Kamani, Lubna
TI What gastroenterologists should know during COVID-19 Pandemic!
SO PAKISTAN JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Corona virus; Gastrointestinal; Liver; COVID-19; Endoscopy
ID CORONAVIRUS; SARS
AB The WHO has declared a Pandemic due to Novel Corona virus-19 (COVID-19). Patients usually have respiratory symptoms but gastrointestinal and hepatic dysfunction are not uncommon presentations and can lead to a delay in diagnosis and management. Virus shedding can continue even after the nasopharyngeal swab gets negative and could lead to faecal-oral transmission. The effects of COVID-19 on patients with decompensated liver disease is still not clear. Managing immunosuppressive drugs in liver transplant and inflammatory bowel disease is a major challenge without clear guidelines. Only emergency endoscopy is to be done with personal protection equipment. Chloroquine and Hydroxychloroquine has shown some beneficial effects and is being used off-label. Without effective treatment, it is imperative to take precautionary measures.
C1 [Kamani, Lubna] Liaquat Natl Hosp, Dept Gastroenterol, GI Residency Program, Karachi, Pakistan.
RP Kamani, L (corresponding author), Liaquat Natl Hosp, Dept Gastroenterol, GI Residency Program, Karachi, Pakistan.
EM lkamani@yahoo.com
CR Carvalho A, SARS COV 2 GASTROINT
   Chan KH, 2004, EMERG INFECT DIS, V10, P294, DOI 10.3201/eid1002.030610
   Cunningham AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2818-6
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   OSullivan K., IRISH TIMES
   Sultan S, 2020, GASTROENTEROLOGY, V159, P739, DOI 10.1053/j.gastro.2020.03.072
   Wander P, COVID 19 PRESENTING
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 13
TC 0
Z9 0
U1 0
U2 0
PU PROFESSIONAL MEDICAL PUBLICATIONS
PI SADDAR
PA PANORAMA CENTRE, RM 522, 5TH FLOOR, BLDG 2, RAJA GHAZANFAR ALI RD, PO
   BOX 8766, SADDAR, KARACHI 00000, PAKISTAN
SN 1682-024X
J9 PAK J MED SCI
JI Pak. J. Med. Sci.
PD MAY
PY 2020
VL 36
IS 4
SU S
SI SI
BP S124
EP S125
DI 10.12669/pjms.36.COVID19-S4.2651
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA MS7ML
UT WOS:000554459400027
PM 32582330
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Brown, C
   Noble, J
   Coralic, Z
AF Brown, Cortlyn
   Noble, Jeanne
   Coralic, Zlatan
TI Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs
   in the Emergency Department
SO WESTERN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
AB As of March 30th, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the investigational vaccine.(2) We present a brief overview of the potential prophylactic and treatment agents under investigation, some which could be initiated in the ED if proven effective.
C1 [Brown, Cortlyn; Noble, Jeanne] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA.
   [Coralic, Zlatan] Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA.
RP Brown, C (corresponding author), Univ Calif San Francisco, Sch Med, Dept Emergency Med, 1001 Potrero Ave,Bldg 5,Room IE22A, San Francisco, CA 94110 USA.
EM Cortlyn.brown@ucsf.edu
CR Cao B, 2020, NEW ENGL J MED, V382
   Casadevall A, 2020, J CLIN INVEST
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Gao J, 2020, BIOSCI TRENDS
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hoffmann M, 2020, CELL
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Jun C, 2020, J ZHEJIANG U MED SCI, V49
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yao X, 2020, CLIN INFECT DIS
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 11
TC 0
Z9 0
U1 0
U2 0
PU WESTJEM
PI ORANGE
PA C/O SHAHRAM LOTFIPOUR, MD, MPH, 333 CITY BLVD W STE 640, RT 128-01,
   ORANGE, CA 92868 USA
SN 1936-900X
EI 1936-9018
J9 WEST J EMERG MED
JI West. J. Emerg. Med.
PD MAY
PY 2020
VL 21
IS 3
BP 510
EP 513
DI 10.5811/westjem.2020.3.47328
PG 4
WC Emergency Medicine
SC Emergency Medicine
GA MO8JX
UT WOS:000551766000010
PM 32302280
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chatterjee, P
   Anand, T
   Singh, KJ
   Rasaily, R
   Singh, R
   Das, S
   Singh, H
   Praharaj, I
   Gangakhedkar, RR
   Bhargava, B
   Panda, S
AF Chatterjee, Pranab
   Anand, Tanu
   Singh, Kh. Jitenkumar
   Rasaily, Reeta
   Singh, Ravinder
   Das, Santasabuj
   Singh, Harpreet
   Praharaj, Ira
   Gangakhedkar, Raman R.
   Bhargava, Balram
   Panda, Samiran
TI Healthcare workers & SARS-CoV-2 infection in India: A case-control
   investigation in the time of COVID-19
SO INDIAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article
DE Dose-response relationship; healthcare workers; hydroxychloroquine
   prophylaxis; personal risk management; rapid evidence generation;
   SARS-CoV-2
AB Background & objectives: Healthcare workers (HCWs) are at an elevated risk of contracting COVID-19. While intense occupational exposure associated with aerosol-generating procedures underlines the necessity of using personal protective equipment (PPE) by HCWs, high-transmission efficiency of the causative agent [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] could also lead to infections beyond such settings. Hydroxychloroquine (HCQ), a repurposed antimalarial drug, was empirically recommended as prophylaxis by the National COVID-19 Task Force in India to cover such added risk. Against this background, the current investigation was carried out to identify the factors associated with SARS-CoV-2 infection among HCWs in the country.
   Methods: A case-control design was adopted and participants were randomly drawn from the countrywide COVID-19 testing data portal maintained by the ICMR. The test results and contact details of HCWs, diagnosed as positive (cases) or negative (controls) for SARS-CoV-2 using real-time reverse transcription-polymerase chain reaction (qRT-PCR), were available from this database. A 20-item brief-questionnaire elicited information on place of work, procedures conducted and use of PPE.
   Results: Compared to controls, cases were slightly older (34.7 vs. 33.5 yr) and had more males (58 vs. 50%). In multivariate analyses, HCWs performing endotracheal intubation had higher odds of being SARS-CoV-2 infected [adjusted odds ratio (AOR): 4.33, 95% confidence interval (CI): 1.1616.07]. Consumption of four or more maintenance doses of HCQ was associated with a significant decline in the odds of getting infected (AOR: 0.44; 95% CI: 0.22-0.88); a dose-response relationship existed between frequency of exposure to HCQ and such reductions (chi(2) for trend=48.88; P<0.001). In addition, the use of PPE was independently associated with the reduction in odds of getting infected with SARS-CoV-2.
   Interpretations & conclusions: Until results of clinical trials for HCQ prophylaxis become available, this study provides actionable information for policymakers to protect HCWs at the forefront of COVID-19 response. The public health message of sustained intake of HCQ prophylaxis as well as appropriate PPE use need to be considered in conjunction with risk homoeostasis operating at individual levels.
C1 [Chatterjee, Pranab] Indian Council Med Res, Translat Global Hlth Policy Res Cell, New Delhi, India.
   [Bhargava, Balram] Indian Council Med Res, Minist Hlth & Family Welf, Dept Hlth Res, New Delhi, India.
   [Singh, Kh. Jitenkumar] Indian Council Med Res, ICMR Natl Inst Med Stat, New Delhi, India.
   [Rasaily, Reeta] Indian Council Med Res, Div Reprod Biol Maternal Hlth & Child Hlth, New Delhi, India.
   [Singh, Ravinder] Indian Council Med Res, Div Noncommunicable Dis, New Delhi, India.
   [Singh, Harpreet] Indian Council Med Res, Informat Syst & Res Management Cell, New Delhi, India.
   [Praharaj, Ira; Gangakhedkar, Raman R.] Indian Council Med Res, Div Epidemiol & Communicable Dis, New Delhi, India.
   [Anand, Tanu] Indian Council Med Res, Model Rural Hlth Res Unit, Multidisciplinary Res Unit, New Delhi, India.
   [Das, Santasabuj] ICMR Natl Inst Cholera & Enter Dis, Div Clin Med, Kolkata, W Bengal, India.
   [Panda, Samiran] ICMR Natl AIDS Res Inst, 73-G MIDC,Post Box 1895, Pune 411026, Maharashtra, India.
RP Panda, S (corresponding author), ICMR Natl AIDS Res Inst, 73-G MIDC,Post Box 1895, Pune 411026, Maharashtra, India.
EM director@nariindia.org
RI PRAHARAJ, IRA/AAE-9328-2019; Chatterjee, Pranab/P-6272-2017
OI PRAHARAJ, IRA/0000-0002-0541-1146; Chatterjee,
   Pranab/0000-0001-6443-608X; Singh, Harpreet/0000-0002-5838-1884
CR Adams J., 1995, RISK
   Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   Arunkumar G, 2019, J INFECT DIS, V219, P1867, DOI 10.1093/infdis/jiy612
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Barrett ES, 2020, PREVALENCE SARS COV
   Bellizzi S, 2020, INFECT CONT HOSP EP, V41, P1118, DOI 10.1017/ice.2020.149
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chatterjee Pranab, 2020, Indian J Med Res, V151, P147, DOI 10.4103/ijmr.IJMR_519_20
   DUPONT WD, 1988, BIOMETRICS, V44, P1157, DOI 10.2307/2531743
   Hashem AM, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101735
   Hintze J, 2011, PASS 11
   Huang L, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.006
   Jacobsen KH, 2016, ECOHEALTH, V13, P200, DOI 10.1007/s10393-016-1100-5
   Lee SH, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105988
   Legido-Quigley H, 2020, LANCET PUBLIC HEALTH, V5, pE251, DOI 10.1016/S2468-2667(20)30060-8
   Lewnard JA, 2020, LANCET INFECT DIS, V20, P631, DOI 10.1016/S1473-3099(20)30190-0
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu JY, 2020, EMERG INFECT DIS, V26, P1320, DOI 10.3201/eid2606.200239
   Mehra M, 2020, LANCET
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mitja O, 2020, LANCET GLOB HEALTH, V8, pE639, DOI 10.1016/S2214-109X(20)30114-5
   National Task Force for COVID-19 in India, 2020, REC EMP US HYDR PROP
   Nguyen LH, 2020, RISK COVID 19 FRONTL, DOI [10.1101/2020.04.29.2008411, DOI 10.1101/2020.04.29.2008411]
   Pearce N, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i969
   Prather KA, 2020, SCIENCE, V368, P1422, DOI 10.1126/science.abc6197
   Principi N, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30296-6
   Ramadan N, 2019, GERMS, V9, P35, DOI 10.18683/germs.2019.1155
   Richens J, 2000, LANCET, V355, P400, DOI 10.1016/S0140-6736(99)09109-6
   TETT SE, 1989, BRIT J CLIN PHARMACO, V27, P771, DOI 10.1111/j.1365-2125.1989.tb03439.x
   Verbeek JH, 2016, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD011621.PUB2
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   WHO, 2020, 2 WHO
   Wilde GJ, 1994, TARGET RISK DEALING
   World Health Organization, 2020, COR DIS COVID 19 ADV
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 38
TC 22
Z9 22
U1 6
U2 6
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0971-5916
J9 INDIAN J MED RES
JI Indian J. Med. Res.
PD MAY
PY 2020
VL 151
IS 5
BP 459
EP 467
DI 10.4103/ijmr.IJMR_2234_20
PG 9
WC Immunology; Medicine, General & Internal; Medicine, Research &
   Experimental
SC Immunology; General & Internal Medicine; Research & Experimental
   Medicine
GA MM1DU
UT WOS:000549899900011
PM 32611916
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Koseler, A
   Sabirli, R
   Goren, T
   Turkcuer, I
   Kurt, O
AF Koseler, Aylin
   Sabirli, Ramazan
   Goren, Tarik
   Turkcuer, Ibrahim
   Kurt, Ozgur
TI Endoplasmic Reticulum Stress Markers in SARS-COV-2 Infection and
   Pneumonia: Case-Control Study
SO IN VIVO
LA English
DT Article
DE Endoplasmic reticulum stress; SARS-COV-2; pneumonia; GRP78
ID ER CHAPERONE; CORONAVIRUS; GRP78/BIP; BINDING; ROLES
AB Background/Aim: A novel human coronavirus, named SARS-COV-2, has recently caused thousands of deaths all around the world. Endoplasmic reticulum (ER) stress plays an important role in the development of diseases. Patients and Methods: We aimed to to investigate the relationship between ER stress markers in patients infected with SARS-COV-2 and patients with pneumonia. A total of 9 patients (4 patients diagnosed with pneumonia and 5 patients diagnosed with SARS-COV-2 infection) who admitted to the emergency Department with symptoms of pneumonia and SARS-COV-2 were included in the study. A total of 18 healthy individuals without any known chronic or acute disease and drug use were included as the healthy control group. Serum human glucose regulated protein 78 (GRP78), serum human C/EBP homologous protein (CHOP) and serum human phospho extracellular signal regulated kinase (PERK) levels were measured using enzyme-linked immunosorbent assay (ELISA). Results: GRP78 levels were found to be significantly higher in SARS-COV-2 positive cases compared to individuals in other groups. Serum GRP78 level median value was statistically significantly higher in SARS-COV-2-positive group compared to the other groups (p=0.0003). Serum PERK level was statistically significantly higher in SARS-COV-2-positive pneumonia cases (p=0.046). Conclusion: An association was shown between GRP78 and SARS-COV-2 infection. Although a small number of patients was investigated, these results will be important and guide future treatments of SARS-COV-2.
C1 [Koseler, Aylin] Pamukkale Univ, Fac Med, Dept Biophys, Denizli, Turkey.
   [Sabirli, Ramazan] Kafkas Univ, Dept Emergency Med, Fac Med, Kars, Turkey.
   [Goren, Tarik; Turkcuer, Ibrahim] Pamukkale Univ, Dept Emergency Med, Fac Med, Denizli, Turkey.
   [Kurt, Ozgur] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Microbiol, Istanbul, Turkey.
RP Koseler, A (corresponding author), Pamukkale Univ, Fac Med, Dept Biophys, Denizli, Turkey.
EM akoseler@pau.edu.tr
RI GOREN, TARIK/ABI-3119-2020
OI GOREN, TARIK/0000-0002-8292-6717
CR Cnop M, 2012, TRENDS MOL MED, V18, P59, DOI 10.1016/j.molmed.2011.07.010
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Ibrahim IM, 2019, LIFE SCI, V226, P156, DOI 10.1016/j.lfs.2019.04.022
   Keith M, 1998, J AM COLL CARDIOL, V31, P1352, DOI 10.1016/S0735-1097(98)00101-6
   Kincaid MM, 2007, ANTIOXID REDOX SIGN, V9, P2373, DOI 10.1089/ars.2007.1817
   Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000
   Lai ED, 2007, PHYSIOLOGY, V22, P193, DOI 10.1152/physiol.00050.2006
   Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523
   Li YM, 2014, ACTA BIOCH BIOPH SIN, V46, P629, DOI 10.1093/abbs/gmu048
   Liu XY, 2014, HYPERTENSION, V64, P738, DOI 10.1161/HYPERTENSIONAHA.114.03811
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Miller S, 2008, NAT REV MICROBIOL, V6, P363, DOI 10.1038/nrmicro1890
   Nakka VP, 2016, MOL NEUROBIOL, V53, P532, DOI 10.1007/s12035-014-9029-6
   Nath D, 2009, NATURE, V458, P421, DOI 10.1038/458421a
   Nishikawa S, 2005, J BIOCHEM, V137, P551, DOI 10.1093/jb/mvi068
   Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5
   Riehle C, 2019, HERZ, V44, P96, DOI 10.1007/s00059-019-4785-8
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Sabirli R, 2019, IN VIVO, V33, P1581, DOI 10.21873/invivo.11640
   Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4
   Versteeg GA, 2007, J VIROL, V81, P10981, DOI 10.1128/JVI.01033-07
   Yamada Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006130
   Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200
NR 25
TC 2
Z9 2
U1 0
U2 0
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD MAY-JUN
PY 2020
VL 34
SU 3
BP 1645
EP 1650
DI 10.21873/invivo.11956
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MK6MZ
UT WOS:000548901400009
PM 32503824
OA Bronze
DA 2021-01-01
ER

PT J
AU Wang, WP
   Liu, XL
   Zhang, FQ
   Qiu, J
   Hu, K
AF Wang, Weiping
   Liu, Xiaoliang
   Zhang, Fuquan
   Qiu, Jie
   Hu, Ke
TI Radiation Therapy During the COVID-19 Pandemic: Experience from Beijing,
   China
SO IN VIVO
LA English
DT Article
DE COVID-19; radiotherapy; personal protective equipment
AB Background: Coronavirus disease 2019 (COVID-19) is now a global pandemic. It is unclear to radiotherapy practitioners how to carry out radiotherapy during the epidemic. Patients and Methods: After the outbreak of COVID-19, our Institute established measures for the prevention and control of COVID-19, and continues to treat patients according to these measures. The Radiotherapy Department has been divided into a clean zone and a semi-contaminated zone, and corresponding personal protective equipment is used in these zones. The temperature of patients and their escorts, and history of fever are assessed daily. Special procedures are performed during radiotherapy setup and intracavitary brachytherapy. Results: Over a period of 2 months, 655 patients were treated in the Department. Sixteen patients with fever were identified and no patient undergoing radiotherapy or medical staff have been infected with COVID-19. Conclusion: Our protective measures were found to be effective and can be used as a reference in places where COVID-19 situations are not markedly serious.
C1 [Wang, Weiping; Liu, Xiaoliang; Zhang, Fuquan; Qiu, Jie; Hu, Ke] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Radiat Oncol, 1 Shuaifuyuan Wangfujing, Beijing 100730, Peoples R China.
RP Zhang, FQ; Qiu, J; Hu, K (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Radiat Oncol, 1 Shuaifuyuan Wangfujing, Beijing 100730, Peoples R China.
EM zhangfuquan3@sina.com; qj_ww@139.com; huk@pumch.cn
CR China National Health Commission & State Administration of Traditional Chinese Medicine, DIAGN TREATM PROT NO
   Gemici C, 2020, RADIOTHER ONCOL, V149, P107, DOI 10.1016/j.radonc.2020.03.044
   Wei W, 2020, RADIOTHER ONCOL, V148, P203, DOI 10.1016/j.radonc.2020.03.029
   World Health Organization, COR DIS COVID 19 OUT
   Wu S, 2020, ADV RADIAT ONCOL, V5, P531, DOI 10.1016/j.adro.2020.03.004
NR 5
TC 0
Z9 0
U1 1
U2 1
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD MAY-JUN
PY 2020
VL 34
SU 3
BP 1675
EP 1680
DI 10.21873/invivo.11960
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MK6MZ
UT WOS:000548901400013
PM 32503828
OA Bronze
DA 2021-01-01
ER

PT J
AU Mo, A
   Brodin, NP
   Tome, WA
   Garg, MK
   Kabarriti, R
AF Mo, Allen
   Brodin, N. Patrik
   Tome, Wolfgang A.
   Garg, Madhur K.
   Kabarriti, Rafi
TI COVID-19 Incidentally Detected on PET/CT During Work-up for Locally
   Advanced Head and Neck Cancer
SO IN VIVO
LA English
DT Article
DE COVID-19; PET/CT; cancer; radiation therapy; incidental detection
AB Aim: To describe the incidental detection of COVID-19 disease on positron-emission tomography/ computed tomography (PET/CT) in a patient with cancer despite initial negative swab by polymerase chain reaction (PCR). Case Report: Clinical and radiographic data were obtained from the electronic medical record. Nasopharyngeal swabs were obtained and evaluated for COVID-19 by the Food and Drug Administration-approved reverse transcription-PCR assays. On radiographic examination, PET/CT was consistent with COVID-19-related pneumonia not seen on prior imaging. Initial nasopharyngeal swab 2 days after PET/CT imaging was negative for COVID-19. Subsequent repeat swab 10 days later was positive for COVID-19, while the patient was febrile on screening assessment. The patient remained COVID-19-positive until 1 month after abnormal PET/CT imaging. Conclusion: PET/CT can be sensitive for early COVID-19 detection, even in the setting of a negative confirmatory PCR test. This highlights the importance of continued patient surveillance and use of appropriate personal protective equipment to minimize COVID-19 transmission.
C1 [Mo, Allen; Brodin, N. Patrik; Tome, Wolfgang A.; Garg, Madhur K.; Kabarriti, Rafi] Montefiore Med Ctr, Dept Radiat Oncol, New York, NY USA.
   [Brodin, N. Patrik; Tome, Wolfgang A.; Garg, Madhur K.; Kabarriti, Rafi] Albert Einstein Coll Med, Inst Oncophys, New York, NY USA.
RP Kabarriti, R (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, 111 East 210th St, Bronx, NY 10467 USA.
EM rkabarri@montefiore.org
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Albano D, 2020, J NUCL MED, V61, P632, DOI 10.2967/jnumed.120.246256
   [Anonymous], NIH COVID 19 TREATM
   Baumann M, 2020, RADIOTHER ONCOL, V146, P221, DOI 10.1016/j.radonc.2020.04.043
   Chen YL, 2020, ADV RADIAT ONCOL, V5, P534, DOI 10.1016/j.adro.2020.03.005
   Curigliano G, 2020, BREAST, V52, P8, DOI 10.1016/j.breast.2020.04.006
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Kabarriti R, 2020, ADV RADIAT ONCOL, V5, P707, DOI 10.1016/j.adro.2020.04.028
   Mehta V, 2020, CANCER DISCOV, DOI [10.1158/2159-8290.CD-20-051618, DOI 10.1158/2159-8290.CD-20-051618]
   Qin CX, 2020, EUR J NUCL MED MOL I, V47, P1281, DOI 10.1007/s00259-020-04734-w
   Rivera A, 2020, ADV RADIAT ONCOL, V5, P538, DOI 10.1016/j.adro.2020.03.006
   Sepulcri M, 2020, ADV RADIAT ONCOL, V5, P697, DOI 10.1016/j.adro.2020.04.019
   Simcock R, 2020, CLIN TRANSL RAD ONCO, V22, P55, DOI 10.1016/j.ctro.2020.03.009
   Thomson DJ, 2020, INT J RADIAT ONCOL, V107, P618, DOI 10.1016/j.ijrobp.2020.04.016
   Whisenant JG, 2020, CANCER CELL, DOI [10.1016/j.ccell.2020.05.00817, DOI 10.1016/J.CCELL.2020.05.00817]
   Youssef I, 2020, ADV RADIAT ONCOL, V5, P715, DOI 10.1016/j.adro.2020.04.029
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zou SJ, 2020, RADIOLOGY, V296, pE118, DOI 10.1148/radiol.2020200770
NR 18
TC 1
Z9 1
U1 3
U2 5
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD MAY-JUN
PY 2020
VL 34
SU 3
BP 1681
EP 1684
DI 10.21873/invivo.11961
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MK6MZ
UT WOS:000548901400014
PM 32503829
OA Bronze
DA 2021-01-01
ER

PT J
AU Hormati, A
   Shahhamzeh, A
   Aminnejad, R
   Afifian, M
   Ahmadpour, S
AF Hormati, Ahmad
   Shahhamzeh, Alireza
   Aminnejad, Reza
   Afifian, Mahbobeh
   Ahmadpour, Sajjad
TI Gastrointestinal Presentation in a Patient with COVID-19 Without
   Respiratory Tract Symptoms: A Case Report From Qom, Iran
SO JUNDISHAPUR JOURNAL OF MICROBIOLOGY
LA English
DT Article
DE COVID-19; Gastrointestinal Disorder; CT Scan; Pneumonia; RT-PCR
AB Introduction: Considering the increasing number of patients referred to gastroenterology clinics, we report a suspected case of coronavirus disease 2019 (COVID-19) with only gastrointestinal (GI) presentation in Qom, Iran.
   Case Presentation: A 74-year-old man with epigastric pain, diarrhea and vomiting for one week was treated, based on the routine abdominal treatment protocol. Since all GI symptoms were resistant to therapy, we decided to perform laboratory assays for a more accurate diagnosis of the disease. Considering the persistence of abdominal pain and nausea, abdominal and pelvic computed tomography (CT) scans, as well as endoscopy and colonoscopy, were performed. After performing the chest CT scan, we noticed the involvement of the lungs. The patient did not have any respiratory symptoms, and at the time of his hospitalization, the COVID-19 epidemic had been reported in Iran. With the progression of the disease, he started to experience mild fever (38 degrees C). Using a specific COVID-19 kit, he was diagnosed with COVID-19 after precise evaluations. However, without any medications, all of his symptoms subsided after 2 - 3 weeks.
   Conclusions: It is important for all physicians to know that some pure GI symptoms, which are resistant to therapy, may be the only symptoms in suspected COVID-19 patients. Timely diagnosis and isolation of these patients can guarantee population to avoid the spread of this highly contagious infection.
C1 [Hormati, Ahmad; Ahmadpour, Sajjad] Qom Univ Med Sci, Gastroenterol & Hepatol Dis Res Ctr, Qom, Iran.
   [Hormati, Ahmad] Iran Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Tehran, Iran.
   [Shahhamzeh, Alireza] Qom Univ Med Sci, Fac Med, Dept Med Radiol, Qom, Iran.
   [Aminnejad, Reza] Qom Univ Med Sci, Dept Anisthesiol & Cirit Care, Qom, Iran.
   [Aminnejad, Reza] Shahid Beheshti Univ Med Sci, Dept Anisthesiol & Cirit Care, Tehran, Iran.
   [Afifian, Mahbobeh] Univ Tehran Med Sci, Hlth Informat Technol, Tehran, Iran.
RP Ahmadpour, S (corresponding author), Qom Univ Med Sci, Gastroenterol & Hepatol Dis Res Ctr, Qom, Iran.
EM sajjadahmadpour@yahoo.com
RI Ahmadpour, sajjad/ABB-2229-2020; Hormati, Ahmad/D-5032-2018
OI /0000-0003-4321-874X; Aminnejad, Reza/0000-0003-0439-0440; Hormati,
   Ahmad/0000-0002-1322-1318
CR Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Hormati A, 2020, J MICROBIOL IMMUNOL, V53, P384, DOI 10.1016/j.jmii.2020.03.020
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XD, 2020, CLIN RES HEPATOL GAS, V44, pE109, DOI 10.1016/j.clinre.2020.03.013
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 8
TC 0
Z9 0
U1 0
U2 0
PU KOWSAR PUBL
PI HOENSBROEK
PA PATERSWEG 22,, HOENSBROEK, LIMBURG 6431 GC, NETHERLANDS
SN 2008-3645
EI 2008-4161
J9 JUNDISHAPUR J MICROB
JI Jundishapur J. Microbiol.
PD MAY
PY 2020
VL 13
IS 5
AR e102844
DI 10.5812/jjm.102844
PG 5
WC Microbiology
SC Microbiology
GA MK2MH
UT WOS:000548619200001
OA Other Gold
DA 2021-01-01
ER

PT J
AU Li, J
   Feng, J
   Liu, TH
   Xu, FC
   Song, GQ
AF Li, Juan
   Feng, Jing
   Liu, Tian-hu
   Xu, Feng-cheng
   Song, Guo-qiang
TI An infant with a mild SARS-CoV-2 infection detected only by anal swabs:
   a case report
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Severe acute respiratory syndrome; coronavirus 2; Baby; Anal swab
ID OUTBREAK
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China and has spread rapidly worldwide. We present a mild SARS-CoV-2 infection in a baby with non-productive cough and normal chest computed tomography, in whom only anal swabs tested positive by real-time PCR testing for SARS-CoV-2. She was given atomization inhalation therapy with recombinant human interferon alfa-1b for 10 days. Her anal swabs remained positive for eight days, whereas her throat swabs were persistently negative by real-time PCR testing. Mild and asymptomatic cases, especially in children, might present with PCR negative pharyngeaVnasal swabs and PCR positive anal swabs. Those patients are potential sources of infection via fecal-oral transmission for COVID-19. (C) 2020 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U.
C1 [Li, Juan; Feng, Jing] Pidu Dist Peoples Hosp, Dept Infect Dis, Chengdu, Sichuan, Peoples R China.
   [Liu, Tian-hu; Xu, Feng-cheng] Pidu Dist Peoples Hosp, Dept Cardiol, Deyuan Chengdu, Sichuan, Peoples R China.
   [Song, Guo-qiang] Changxing Cty Hosp Tradit Chinese Med, Dept Resp Med, Huzhou, Zhejiang, Peoples R China.
RP Song, GQ (corresponding author), Changxing Cty Hosp Tradit Chinese Med, Dept Resp Med, Huzhou, Zhejiang, Peoples R China.
EM wzyxysgq@126.com
CR Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Hunter P, 2020, EMBO REP
   Johnson HC, 2020, EUROSURVEILLANCE, V25, P8, DOI 10.2807/1560-7917.ES.2020.25.9.2000202
   Ki M, 2020, EPIDEMIOL HEALTH, V42, DOI 10.4178/epih.e2020007
   Lau H, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa037
   Lin QY, 2020, INT J INFECT DIS, V93, P211, DOI 10.1016/j.ijid.2020.02.058
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, ZHONGHUA LIU XING BI, DOI [10.3760/cma.j.issn.0754-6450.2070.02.003, DOI 10.3760/CMA.J.ISSN.0754-6450.2070.02.003]
   Patel A, 2020, MMWR-MORBID MORTAL W, V69, P140, DOI 10.15585/mmwr.mm6905e1
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiao F, 2020, GASTROENTEROLOGY, DOI DOI 10.1053/J.GASTRO.7020.02.055
NR 14
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD MAY-JUN
PY 2020
VL 24
IS 3
BP 247
EP 249
DI 10.1016/j.bjid.2020.04.009
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA MJ7JU
UT WOS:000548264400009
PM 32389618
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Adir, Y
   Segol, O
   Kompaniets, D
   Ziso, H
   Yaffe, Y
   Bergman, I
   Hassidov, E
   Eden, A
AF Adir, Yochai
   Segol, Ori
   Kompaniets, Dmitry
   Ziso, Hadas
   Yaffe, Yechiam
   Bergman, Irina
   Hassidov, Erez
   Eden, Arieh
TI COVID-19: minimising risk to healthcare workers during aerosol-producing
   respiratory therapy using an innovative constant flow canopy
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Letter
ID MECHANICAL VENTILATION
C1 [Adir, Yochai; Segol, Ori; Kompaniets, Dmitry; Bergman, Irina; Eden, Arieh] Lady Davis Carmel Med Ctr, Div Pulm, 7 Micahl St, IL-3436212 Haifa, Israel.
   [Adir, Yochai; Segol, Ori; Kompaniets, Dmitry; Bergman, Irina; Eden, Arieh] Technion Israel Inst Technol, Fac Med, Haifa, Israel.
   [Ziso, Hadas; Hassidov, Erez] Tamar Robot LTD, Yagur, Israel.
   [Yaffe, Yechiam] Yafit Safety & Environm, Mevasseret Zion, Israel.
RP Adir, Y (corresponding author), Lady Davis Carmel Med Ctr, Div Pulm, 7 Micahl St, IL-3436212 Haifa, Israel.
EM adir-sh@zahav.net.il
CR Critical care committee of Chinese Association of Chest Physician, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P189, DOI 10.3760/cma.j.issn.1001-0939.2020.03.010
   Esquinas AM, 2014, EUR RESPIR REV, V23, P427, DOI 10.1183/09059180.00009413
   Guan LL, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00352-2020
   Ni YN, 2018, AM J EMERG MED, V36, P226, DOI 10.1016/j.ajem.2017.07.083
   Rochwerg B, 2019, INTENS CARE MED, V45, P563, DOI 10.1007/s00134-019-05590-5
   Wax RS, 2020, CAN J ANESTH, V67, P568, DOI 10.1007/s12630-020-01591-x
NR 6
TC 6
Z9 6
U1 0
U2 0
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD MAY 1
PY 2020
VL 55
IS 5
AR 2001017
DI 10.1183/13993003.01017-2020
PG 3
WC Respiratory System
SC Respiratory System
GA MJ5VS
UT WOS:000548158300018
PM 32312865
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rello, J
   Storti, E
   Belliato, M
   Serrano, R
AF Rello, Jordi
   Storti, Enrico
   Belliato, Mirko
   Serrano, Ricardo
TI Clinical phenotypes of SARS-CoV-2: implications for clinicians and
   researchers
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Article
AB Patients with COVID-19 present a broad spectrum of clinical presentation. Whereas hypoxaemia is the marker of severity, different strategies of management should be customised to five specific individual phenotypes. Many intubated patients present with phenotype 4, characterised by pulmonary hypoxic vasoconstriction, being associated with severe hypoxaemia with "normal" (>40 mL.cmH(2)O(-1)) lung compliance and likely representing pulmonary microvascular thrombosis. Phenotype 5 is often associated with high plasma procalcitonin and has low pulmonary compliance, Which is a result of co-infection or acute lung injury after noninvasive ventilation. Identifying these clinical phenotypes and applying a personalised approach would benefit the optimisation of therapies and improve outcomes.
C1 [Rello, Jordi] Inst Salud Carlos III, Ctr Invest Biomed Red CIBERES, Madrid, Spain.
   [Rello, Jordi] Vall dHebron Inst Res, CRIPS, Barcelona, Spain.
   [Rello, Jordi] Univ Montpellier Nimes, Clin Res, CHU Nimes, Nimes, France.
   [Storti, Enrico] Hosp Lodi, Anesthesia & ICU Dept, Lodi, Italy.
   [Belliato, Mirko] Fdn IRCCS Policlin San Matteo, UOC Anestesia & Rianimaz 1, Pavia, Italy.
   [Serrano, Ricardo] Hosp Hellin, Crit Care Dept, Albacete, Spain.
RP Rello, J (corresponding author), Ps Vall d Hebron 129,AMI-14, Barcelona 08035, Spain.
EM jrello@crips.es
OI belliato, mirko/0000-0002-3411-6293
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arnold F, 2020, J RESP INFECT, V4, P1
   Barrasa H, 2020, ANESTH CRIT CARE PAI, DOI [10.1016/j.accpm.2020-04.001, DOI 10.1016/J.ACCPM.2020-04.001]
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Maravi-Poma E, 2011, CRIT CARE MED, V39, P945, DOI 10.1097/CCM.0b013e318208ee12
   Rello J, 2018, CLIN MICROBIOL INFEC, V24, P1264, DOI 10.1016/j.cmi.2018.03.011
   Rello J, 2020, ANAESTH CRIT CARE PA, V39, P167, DOI 10.1016/j.accpm.2020.03.001
   Sanjan A, 2019, J EMERG TRAUMA SHOCK, V12, P248, DOI 10.4103/JETS.JETS_47_19
   Walter JM, 2018, CHEST, V154, P1213, DOI 10.1016/j.chest.2018.06.003
   Xia W, 2020, PEDIATR PULM, V55, P1169, DOI 10.1002/ppul.24718
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 14
TC 34
Z9 35
U1 1
U2 1
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD MAY 1
PY 2020
VL 55
IS 5
AR 2001028
DI 10.1183/13993003.01028-2020
PG 4
WC Respiratory System
SC Respiratory System
GA MJ5VS
UT WOS:000548158300020
PM 32341111
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cao, YC
   Deng, QX
   Dai, SX
AF Cao, Yu-chen
   Deng, Qi-xin
   Dai, Shi-xue
TI Remdesivir for severe acute respiratory syndrome coronavirus 2 causing
   COVID-19: An evaluation of the evidence
SO TRAVEL MEDICINE AND INFECTIOUS DISEASE
LA English
DT Article
DE Severe acute respiratory syndrome coronavirus 2; Corona virus disease
   2019; Remdesivir; Phase III clinical trial
ID COV
AB The novel coronavirus infection that initially found at the end of 2019 has attracted great attention. So far, the number of infectious cases has increased globally to more than 100 thousand and the outbreak has been defined as a pandemic situation, but there are still no "specific drug" available. Relevant reports have pointed out the novel coronavirus has 80% homology with SARS. In the difficulty where new synthesized drug cannot be applied immediately to patients, "conventional drug in new use" becomes a feasible solution. The first medication experience of the recovered patients in the US has led remdesivir to be the "specific drug". China has also taken immediate action to put remdesivir into clinical trials with the purpose of applying it into clinical therapeutics for Corona Virus Disease 2019 (COVID-19). We started from the structure, immunogenicity, and pathogenesis of coronavirus infections of the novel coronavirus. Further, we analyzed the pharmacological actions and previous trials of remdesivir to identify the feasibility of conducting experiments on COVID-19.
C1 [Cao, Yu-chen; Deng, Qi-xin] Southern Med Univ, Clin Sch 2, Guangzhou 510515, Guangdong, Peoples R China.
   [Dai, Shi-xue] South China Univ Technol, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Gastroenterol, Guangzhou 510080, Guangdong, Peoples R China.
RP Dai, SX (corresponding author), South China Univ Technol, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Gastroenterol, Guangzhou 510080, Guangdong, Peoples R China.
EM shixuedai@hotmail.com
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China (NSFC) [81300370]; China Postdoctoral
   Science Foundation (CPSF)China Postdoctoral Science Foundation
   [2017M622650, 2018T110855]; Natural Science Foundation of Guangdong
   (NSFG) [2018A030313161]
FX This review was funded by the National Natural Science Foundation of
   China (NSFC, No. 81300370), a General Program (No. 2017M622650) and a
   Special Support Program (No. 2018T110855) from China Postdoctoral
   Science Foundation (CPSF), as well as by the Natural Science Foundation
   of Guangdong (NSFG, 2018A030313161).
CR [Anonymous], 2018, SUMMARIES EVIDENCE S
   [Anonymous], 2019, SCI TRANSL MED, V11
   [Anonymous], 2018, MBIO, V9
   Baseler L, 2017, ANNU REV PATHOL-MECH, V12, P387, DOI 10.1146/annurev-pathol-052016-100506
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen SM, 2020, LANCET, V395, P764, DOI 10.1016/S0140-6736(20)30421-9
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cho A, 2012, BIOORG MED CHEM LETT, V22, P2705, DOI 10.1016/j.bmcl.2012.02.105
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Fan C, 2020, ACE2 EXPRESSION KIDN, P2020
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Hoffmann M, 2020, BIORXIV, P2020
   Huang C, LANCET
   Ja A, 2020, TRAVEL MED INFECT DI
   Jordan Paul C., 2018, Antiviral Chemistry & Chemotherapy, V26, p2040206618764483, DOI 10.1177/2040206618764483
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e61
   Li H, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE002, DOI 10.3760/cma.j.issn.1001-0939.2020.0002
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Pedersen NC, 2019, J FELINE MED SURG, V21, P271, DOI 10.1177/1098612X19825701
   Qiu T, 2020, J GENET GENOM
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Wang M, 2020, CELL RES 0204, V30, P269, DOI [DOI 10.1038/S41422-020-0282-0, 10.1038/s41422-020-0282-0]
   Warren T, 2015, NUCL PRODRUG GS 5734, V139, P311
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wrapp D, 2020, BIORXIV, P2020
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu Z, 2020, LANCET RESP MED, V18, pS2213
   Zhang H., 2020, BIORXIV
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 35
TC 64
Z9 65
U1 10
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1477-8939
EI 1873-0442
J9 TRAVEL MED INFECT DI
JI Travel Med. Infect. Dis.
PD MAY-JUN
PY 2020
VL 35
AR 101647
DI 10.1016/j.tmaid.2020.101647
PG 6
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA MJ1HN
UT WOS:000547845300019
PM 32247927
OA Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Hall, DC
   Ji, HF
AF Hall, Donald C.
   Ji, Hai-Feng
TI A search for medications to treat COVID-19 via in silico molecular
   docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
SO TRAVEL MEDICINE AND INFECTIOUS DISEASE
LA English
DT Article
DE SARS-CoV-2; Coronavirus; Molecular docking; Approved drugs; Medications
AB Background: The COVID-19 has now been declared a global pandemic by the World Health Organization. There is an emergent need to search for possible medications.
   Method: Utilization of the available sequence information, homology modeling, and in slico docking a number of available medications might prove to be effective in inhibiting the SARS-CoV-2 two main drug targets, the spike glycoprotein, and the 3CL protease.
   Results: Several compounds were determined from the in silico docking models that might prove to be effective inhibitors for SARS-CoV-2. Several antiviral medications: Zanamivir, Indinavir, Saquinavir, and Remdesivir show potential as and 3CL(PRO) main proteinase inhibitors and as a treatment for COVID-19.
   Conclusion: Zanamivir, Indinavir, Saquinavir, and Remdesivir are among the exciting hits on the 3CL(PRO) main proteinase. It is also exciting to uncover that Flavin Adenine Dinucleotide (FAD) Adeflavin, B2 deficiency medicine, and Coenzyme A, a coenzyme, may also be potentially used for the treatment of SARS-CoV-2 infections. The use of these off-label medications may be beneficial in the treatment of the COVID-19.
C1 [Hall, Donald C.; Ji, Hai-Feng] Drexel Univ, Dept Chem, Philadelphia, PA 19104 USA.
RP Ji, HF (corresponding author), Drexel Univ, Dept Chem, Philadelphia, PA 19104 USA.
EM hj56@drexel.edu
OI Hall, Donald/0000-0003-4849-3740
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   [Anonymous], 2020, 2020 NOV COR 2019 NC
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   Chen N., LANCET
   Eiland Lea S, 2007, Ther Clin Risk Manag, V3, P461
   Eswar Narayanan, 2008, V426, P145, DOI 10.1007/978-1-60327-058-8_8
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Li Q, 2020, J VASC ACCESS, DOI 10.1177/1129729820938201
   Liu X, CRYTAL STRUCTURE 201
   Pieper U, 2014, NUCLEIC ACIDS RES, V42, pD336, DOI 10.1093/nar/gkt1144
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
NR 15
TC 26
Z9 26
U1 12
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1477-8939
EI 1873-0442
J9 TRAVEL MED INFECT DI
JI Travel Med. Infect. Dis.
PD MAY-JUN
PY 2020
VL 35
AR 101646
DI 10.1016/j.tmaid.2020.101646
PG 3
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA MJ1HN
UT WOS:000547845300016
PM 32294562
OA Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Monteleone, G
   Sarzi-Puttini, PC
   Ardizzone, S
AF Monteleone, Giovanni
   Sarzi-Puttini, Pier Carlo
   Ardizzone, Sandro
TI Preventing COVID-19-induced pneumonia with anticytokine therapy
SO LANCET RHEUMATOLOGY
LA English
DT Letter
C1 [Monteleone, Giovanni] Univ Roma Tor Vergata, Dept Syst Med, I-00133 Rome, Italy.
   [Sarzi-Puttini, Pier Carlo] Univ Milan, ASST Fatebenefratelli Sacco Dept Biochem & Clin S, Rheumatol Unit, Milan, Italy.
   [Ardizzone, Sandro] Univ Milan, ASST Fatebenefratelli Sacco Dept Biochem & Clin S, Gastrointestinal Unit, Milan, Italy.
RP Monteleone, G (corresponding author), Univ Roma Tor Vergata, Dept Syst Med, I-00133 Rome, Italy.
EM gi.monteleone@med.uniroma2.it
CR Chen C, 2020, Zhonghua Shao Shang Za Zhi, V36, P471, DOI 10.3760/cma.j.cn501120-20200224-00088
   Dulai PS, 2014, CLIN GASTROENTEROL H, V12, P1443, DOI 10.1016/j.cgh.2014.01.021
   El-Gabalawy H, 2010, J RHEUMATOL, V37, P2, DOI 10.3899/jrheum.091461
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 5
TC 21
Z9 22
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2665-9913
J9 LANCET RHEUMATOL
JI Lancet Rheumatol.
PD MAY
PY 2020
VL 2
IS 5
BP E255
EP E256
DI 10.1016/S2665-9913(20)30092-8
PG 3
WC Rheumatology
SC Rheumatology
GA MJ1GY
UT WOS:000547843800008
PM 32368737
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Devaux, CA
   Rolain, JM
   Colson, P
   Raoult, D
AF Devaux, Christian A.
   Rolain, Jean-Marc
   Colson, Philippe
   Raoult, Didier
TI New insights on the antiviral effects of chloroquine against
   coronavirus: what to expect for COVID-19?
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE COVID-19; SARS-CoV-2; Coronavirus; Chloroquine
ID RESPIRATORY SYNDROME CORONAVIRUS; TUMOR-NECROSIS-FACTOR; PH-DEPENDENT
   ENTRY; HEPATITIS-A VIRUS; SIALIC-ACID; IN-VITRO; CHIKUNGUNYA VIRUS;
   AMMONIUM-CHLORIDE; VIRAL-INFECTIONS; AVIAN INFLUENZA
AB Recently, a novel coronavirus (2019-nCoV), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Despite drastic containment measures, the spread of this virus is ongoing. SARS-CoV-2 is the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary infection in humans. The efforts of international health authorities have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease. In the absence of a known efficient therapy and because of the situation of a public-health emergency, it made sense to investigate the possible effect of chloroquine/hydroxychloroquine against SARS-CoV-2 since this molecule was previously described as a potent inhibitor of most coronaviruses, including SARS-CoV-1. Preliminary trials of chloroquine repurposing in the treatment of COVID-19 in China have been encouraging, leading to several new trials. Here we discuss the possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle. (C) 2020 The Author(s). Published by Elsevier B.V.
C1 [Devaux, Christian A.; Rolain, Jean-Marc; Colson, Philippe; Raoult, Didier] Aix Marseille Univ, IHU Mediterranee Infect, MEPHI, AP HM,IRD, Marseille, France.
   [Devaux, Christian A.] CNRS, Marseille, France.
   [Devaux, Christian A.; Rolain, Jean-Marc; Colson, Philippe; Raoult, Didier] IHU Mediterranee Infect, 19-21 Blvd Jean Moulin, F-13005 Marseille, France.
RP Devaux, CA (corresponding author), IHU Mediterranee Infect, 19-21 Blvd Jean Moulin, F-13005 Marseille, France.
EM christian.devaux@mediterranee-infection.com
RI Rolain, Jean-Marc/Y-3788-2019
OI Rolain, Jean-Marc/0000-0002-2402-4467; Devaux,
   Christian/0000-0001-5141-5298
FU IHU-Mediterranee Infection; CNRS (Marseille, France); Programme
   d'investissement d'avenirFrench National Research Agency (ANR)
   [Mediterranee Infection 10-1AHU-03]; University of Marseille
FX This study was supported by IHU-Mediterranee Infection, University of
   Marseille and CNRS (Marseille, France). This work has benefited from
   French state support, managed by the Agence nationale de la recherche
   (ANR), including the `Programme d'investissement d'avenir' under the
   reference Mediterranee Infection 10-1AHU-03.
CR Accapezzato D, 2005, J EXP MED, V202, P817, DOI 10.1084/jem.20051106
   Bakkers MJG, 2017, CELL HOST MICROBE, V21, P356, DOI 10.1016/j.chom.2017.02.008
   BERNSTEIN HN, 1991, ANN OPHTHALMOL, V23, P292
   Bishop NE, 1998, INTERVIROLOGY, V41, P261, DOI 10.1159/000024948
   Blau DM, 2001, ADV EXP MED BIOL, V494, P193
   Boelaert JR, 2001, J CLIN VIROL, V20, P137, DOI 10.1016/S1386-6532(00)00140-2
   Boulos A, 2004, ANTIMICROB AGENTS CH, V48, P747, DOI 10.1128/AAC.48.3.747-752.2004
   Briant L, 1998, J VIROL, V72, P6207, DOI 10.1128/JVI.72.7.6207-6214.1998
   BruceChwatt LJ, 1981, WHO MONOGRAPH SERIES, V27
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   CASSELL S, 1984, J VIROL, V52, P857, DOI 10.1128/JVI.52.3.857-864.1984
   Chan CM, 2009, J VIROL, V83, P1026, DOI 10.1128/JVI.01387-08
   COLLINS AR, 1993, IMMUNOL INVEST, V22, P95, DOI 10.3109/08820139309063393
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   CUBERO GI, 1993, BRIT HEART J, V69, P451
   De Lamballerie X, 2008, VECTOR-BORNE ZOONOT, V8, P837, DOI 10.1089/vbz.2008.0049
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Delogu I, 2011, J MED VIROL, V83, P1058, DOI 10.1002/jmv.22019
   Delvecchio R, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8120322
   Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616
   Dowall SD, 2015, J GEN VIROL, V96, P3484, DOI 10.1099/jgv.0.000309
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Ferraris O, 2015, ANTIVIR RES, V118, P75, DOI 10.1016/j.antiviral.2015.03.005
   Freiberg AN, 2010, J GEN VIROL, V91, P765, DOI 10.1099/vir.0.017269-0
   FULD H, 1958, BMJ-BRIT MED J, V2, P1199, DOI 10.1136/bmj.2.5106.1199
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Garulli B, 2013, VACCINE, V31, P1717, DOI 10.1016/j.vaccine.2013.01.037
   Gay B, 2012, INFECT GENET EVOL, V12, P1275, DOI 10.1016/j.meegid.2012.02.003
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   GLUSHAKOVA SE, 1989, ARCH VIROL, V104, P157, DOI 10.1007/BF01313817
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Harley CA, 2001, J VIROL, V75, P1236, DOI 10.1128/JVI.75.3.1236-1251.2001
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang XC, 2015, J VIROL, V89, P7202, DOI 10.1128/JVI.00854-15
   Jang CH, 2006, RHEUMATOLOGY, V45, P703, DOI 10.1093/rheumatology/kei282
   Jeong JY, 2002, IMMUNOLOGY, V105, P83, DOI 10.1046/j.0019-2805.2001.01339.x
   Jeong JY, 1997, J IMMUNOL, V158, P4901
   Keyaerts E, 2009, ANTIMICROB AGENTS CH, V53, P3416, DOI 10.1128/AAC.01509-08
   Khan M, 2010, J MED VIROL, V82, P817, DOI 10.1002/jmv.21663
   KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994
   Kono M, 2008, ANTIVIR RES, V77, P150, DOI 10.1016/j.antiviral.2007.10.011
   KOUROUMALIS E A, 1986, Annals Academy of Medicine Singapore, V15, P149
   KOYAMA AH, 1984, VIROLOGY, V138, P332, DOI 10.1016/0042-6822(84)90356-8
   KRONENBERGER P, 1991, J VIROL, V65, P7008, DOI 10.1128/JVI.65.12.7008-7011.1991
   Kwiek JJ, 2004, BIOCHEMISTRY-US, V43, P4538, DOI 10.1021/bi035923w
   Lee SJ, 2011, NAT REV NEPHROL, V7, P718, DOI 10.1038/nrneph.2011.150
   Li R, 2020, J INFECTION, V80, P469, DOI 10.1016/j.jinf.2020.02.013
   MACKENZIE AH, 1983, AM J MED, V75, P48, DOI 10.1016/0002-9343(83)90474-6
   Milewska A, 2014, J VIROL, V88, P13221, DOI 10.1128/JVI.02078-14
   MILLER DK, 1981, P NATL ACAD SCI-BIOL, V78, P3605, DOI 10.1073/pnas.78.6.3605
   Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111
   Mizui T, 2010, J GASTROENTEROL, V45, P195, DOI 10.1007/s00535-009-0132-9
   Mo Y, 2016, J ANTIMICROB CHEMOTH, V71, P3340, DOI 10.1093/jac/dkw338
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Olofsson S, 2005, LANCET INFECT DIS, V5, P184, DOI 10.1016/S1473-3099(05)01311-3
   Ooi EE, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-39
   Parhizgar AR, 2017, IRAN J MED SCI, V42, P115
   Paton NI, 2011, LANCET INFECT DIS, V11, P677, DOI 10.1016/S1473-3099(11)70065-2
   Perrier A, 2019, J BIOL CHEM, V294, P14406, DOI 10.1074/jbc.RA119.008964
   PICOT S, 1993, IMMUNOLOGY, V80, P127
   Porotto M, 2009, J VIROL, V83, P5148, DOI 10.1128/JVI.00164-09
   RANDOLPH VB, 1990, VIROLOGY, V174, P450, DOI 10.1016/0042-6822(90)90099-D
   Raoult D, 1999, ARCH INTERN MED, V159, P167, DOI 10.1001/archinte.159.2.167
   RAOULT D, 1990, ANTIMICROB AGENTS CH, V34, P1512, DOI 10.1128/AAC.34.8.1512
   RATLIFF NB, 1987, NEW ENGL J MED, V316, P191, DOI 10.1056/NEJM198701223160405
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Romanelli F, 2004, CURR PHARM DESIGN, V10, P2643, DOI 10.2174/1381612043383791
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Savarino A, 2001, J CLIN VIROL, V20, P131, DOI 10.1016/S1386-6532(00)00139-6
   Savarino A, 1996, J ACQ IMMUN DEF SYND, V35, P223
   Seitz M, 2003, J CLIN IMMUNOL, V23, P477, DOI 10.1023/B:JOCI.0000010424.41475.17
   Sharma OP, 1998, ARCH NEUROL-CHICAGO, V55, P1248, DOI 10.1001/archneur.55.9.1248
   Sharma TS, 2016, CURR TREAT OPTIONS R, V2, P1, DOI DOI 10.1007/S40674-016-0036-9
   Shen L, 2016, ANTIMICROB AGENTS CH, V60, P5492, DOI 10.1128/AAC.00814-16
   SHIBATA M, 1983, J GEN VIROL, V64, P1149, DOI 10.1099/0022-1317-64-5-1149
   Farias KJS, 2014, MICROBIOL IMMUNOL, V58, P318, DOI 10.1111/1348-0421.12154
   Simmons G, 2011, VIROLOGY, V413, P265, DOI 10.1016/j.virol.2011.02.020
   SUPERTI F, 1987, ARCH VIROL, V96, P289, DOI 10.1007/BF01320970
   Tricou Vianney, 2010, PLoS Negl Trop Dis, V4, pe785, DOI 10.1371/journal.pntd.0000785
   TSAI WP, 1990, AIDS RES HUM RETROV, V6, P481, DOI 10.1089/aid.1990.6.481
   TSIANG H, 1984, ARCH VIROL, V81, P377, DOI 10.1007/BF01310010
   Varki A, 1997, FASEB J, V11, P248
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang PH, 2020, BIORXIV, DOI [10.1101/2020.02.24.963348, DOI 10.1101/2020.02.24.963348]
   Weber SM, 2000, J IMMUNOL, V165, P1534, DOI 10.4049/jimmunol.165.3.1534
   Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858
   White NJ, 2014, LANCET, V383, P723, DOI 10.1016/S0140-6736(13)60024-0
   Winzeler EA, 2008, NATURE, V455, P751, DOI 10.1038/nature07361
   Wozniacka A, 2006, LUPUS, V15, P268, DOI 10.1191/0961203306lu2299oa
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Zeng QH, 2008, P NATL ACAD SCI USA, V105, P9065, DOI 10.1073/pnas.0800502105
   Zhao XS, 2014, P NATL ACAD SCI USA, V111, P6756, DOI 10.1073/pnas.1320856111
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   ZHU X, 1993, IMMUNOLOGY, V80, P122
NR 101
TC 269
Z9 271
U1 33
U2 43
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD MAY
PY 2020
VL 55
IS 5
AR 105938
DI 10.1016/j.ijantimicag.2020.105938
PG 6
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MH0XX
UT WOS:000546454600004
PM 32171740
OA Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Fantini, J
   Di Scala, C
   Chahinian, H
   Yahi, N
AF Fantini, Jacques
   Di Scala, Coralie
   Chahinian, Henri
   Yahi, Nouara
TI Structural and molecular modelling studies reveal a new mechanism of
   action of chloroquine and hydroxychloroquine against SARS-CoV-2
   infection
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE Coronavirus; Pandemic; SARS-CoV-2; Ganglioside; Spike; Chloroquine
ID BINDING DOMAINS; IDENTIFICATION; SPIKE; CORONAVIRUS; PNEUMONIA;
   RECEPTOR; COMPLEX
AB The recent emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) is responsible for a worldwide pandemic. Given the global health emergency, drug repositioning is the most reliable option to design an efficient therapy for infected patients without delay. The first step of the viral replication cycle [i.e. attachment to the surface of respiratory cells, mediated by the spike (S) viral protein] offers several potential therapeutic targets. The S protein uses the angiotension-converting enzyme-2 (ACE-2) receptor for entry, but also sialic acids linked to host cell surface gangliosides. Using a combination of structural and molecular modelling approaches, this study showed that chloroquine (CLQ), one of the drugs currently under investigation for SARS-CoV-2 treatment, binds sialic acids and gangliosides with high affinity. A new type of ganglioside-binding domain at the tip of the N-terminal domain of the SARS-CoV-2 S protein was identified. This domain (111-158), which is fully conserved among clinical isolates worldwide, may improve attachment of the virus to lipid rafts and facilitate contact with the ACE-2 receptor. This study showed that, in the presence of CLQ [or its more active derivative, hydroxychloroquine (CLQ-OH)], the viral S protein is no longer able to bind gangliosides. The identification of this new mechanism of action of CLQ and CLQ-OH supports the use of these repositioned drugs to cure patients infected with SARS-CoV-2. The in-silico approaches used in this study might also be used to assess the efficiency of a broad range of repositioned and/or innovative drug candidates before clinical evaluation. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Fantini, Jacques; Chahinian, Henri; Yahi, Nouara] INSERM, UMR S 1072, Blvd Pierre Dramard, F-13015 Marseille, France.
   [Fantini, Jacques; Chahinian, Henri; Yahi, Nouara] Aix Marseille Univ, Dept Biol, Marseille, France.
   [Di Scala, Coralie] INSERM, INMED, U1249, Parc Sci Luminy, Marseille, France.
RP Fantini, J (corresponding author), INSERM, UMR S 1072, Blvd Pierre Dramard, F-13015 Marseille, France.
EM jacques.fantini@univ-amu.fr
RI DI SCALA, Coralie/ABF-4895-2020
OI Di Scala, Coralie/0000-0003-0655-7056
CR Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Di Scala C, 2017, METHODS MOL BIOL, V1583, P7, DOI 10.1007/978-1-4939-6875-6_2
   Fantini J, 2015, BRAIN LIPIDS SYNAPTI
   Fantini J, 2006, BIOCHEMISTRY-US, V45, P10957, DOI 10.1021/bi060762s
   Fantini J, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001602
   Flores A, 2019, P NATL ACAD SCI USA, V116, P18098, DOI 10.1073/pnas.1908051116
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Guvench O, 2008, J COMPUT CHEM, V29, P2543, DOI 10.1002/jcc.21004
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang Y, 2018, ELIFE, V7
   Huta BP, 2016, CHEMMEDCHEM, V11, P277, DOI 10.1002/cmdc.201500494
   Lee J, 2019, J CHEM THEORY COMPUT, V15, P775, DOI 10.1021/acs.jctc.8b01066
   Li WT, 2017, P NATL ACAD SCI USA, V114, pE8508, DOI 10.1073/pnas.1712592114
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lu YN, 2008, BIOCHEM BIOPH RES CO, V369, P344, DOI 10.1016/j.bbrc.2008.02.023
   Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200
   Matrosovich M, 2015, TOP CURR CHEM, V367, P1, DOI 10.1007/128_2013_466
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Mullard A, 2012, NAT REV DRUG DISCOV, V11, P1, DOI 10.1038/nrd3776
   Park YJ, 2019, NAT STRUCT MOL BIOL, V26, P1151, DOI 10.1038/s41594-019-0334-7
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Verma DK, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110650
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yahi N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104751
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 30
TC 97
Z9 98
U1 13
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD MAY
PY 2020
VL 55
IS 5
AR 105960
DI 10.1016/j.ijantimicag.2020.105960
PG 8
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MH0XX
UT WOS:000546454600012
PM 32251731
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Li, H
   Liu, SM
   Yu, XH
   Tang, SL
   Tang, CK
AF Li, Heng
   Liu, Shang-Ming
   Yu, Xiao-Hua
   Tang, Shi-Lin
   Tang, Chao-Ke
TI Coronavirus disease 2019 (COVID-19): current status and future
   perspectives
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE COVID-19; SARS-CoV-2; 2019-nCoV; Coronavirus; Pneumonia
ID ACUTE RESPIRATORY SYNDROME; MESENCHYMAL STEM-CELLS; ACUTE LUNG INJURY;
   SARS CORONAVIRUS; CONVALESCENT PLASMA; CLINICAL CHARACTERISTICS;
   TRANSMISSION DYNAMICS; LOPINAVIR-RITONAVIR; ANTIVIRAL ACTIVITY;
   INTERFERON-ALPHA
AB Coronavirus disease 2019 (COVID-19) originated in the city of Wuhan, Hubei Province, Central China, and has spread quickly to 72 countries to date. COVID-19 is caused by a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [previously provisionally known as 2019 novel coronavirus (2019-nCoV)]. At present, the newly identified SARS-CoV-2 has caused a large number of deaths with tens of thousands of confirmed cases worldwide, posing a serious threat to public health. However, there are no clinically approved vaccines or specific therapeutic drugs available for COVID-19. Intensive research on the newly emerged SARS-CoV-2 is urgently needed to elucidate the pathogenic mechanisms and epidemiological characteristics and to identify potential drug targets, which will contribute to the development of effective prevention and treatment strategies. Hence, this review will focus on recent progress regarding the structure of SARS-CoV-2 and the characteristics of COVID-19, such as the aetiology, pathogenesis and epidemiological characteristics. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Li, Heng; Liu, Shang-Ming; Tang, Shi-Lin; Tang, Chao-Ke] Univ South China, Affiliated Hosp 1, Hengyang Med Coll,Dept Intens Care Unit,Hunan Pro, Med Res Expt Ctr,Inst Cardiovasc Dis,Key Lab Arte, Hengyang 421001, Hunan, Peoples R China.
   [Yu, Xiao-Hua] Hainan Med Univ, Inst Clin Med, Affiliated Hosp 2, Haikou 460106, Hainan, Peoples R China.
   [Tang, Chao-Ke] Univ South China, Inst Cardiovasc Dis, Hengyang 421001, Hunan, Peoples R China.
RP Tang, CK (corresponding author), Univ South China, Affiliated Hosp 1, Hengyang Med Coll,Dept Intens Care Unit,Hunan Pro, Med Res Expt Ctr,Inst Cardiovasc Dis,Key Lab Arte, Hengyang 421001, Hunan, Peoples R China.; Tang, CK (corresponding author), Univ South China, Inst Cardiovasc Dis, Hengyang 421001, Hunan, Peoples R China.; Tang, SL (corresponding author), Univ South China, Dept Intens Care Unit, Affiliated Hosp 1, Hengyang 421001, Hunan, Peoples R China.
EM 286756823@qq.com; tangchaoke@qq.com
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81570408, 81770461]
FX This work was supported by the Natural Science Foundation of China [nos.
   81570408 and 81770461].
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062
   Banerjee A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010041
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   Chai X, 2020, SPECIFIC ACE2 EXPRES, DOI [10.1101/2020.02.03.931766, DOI 10.1101/2020.02.03.931766]
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen LL, 2006, BIOORGAN MED CHEM, V14, P8295, DOI 10.1016/j.bmc.2006.09.014
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Chung MS, 2020, EUR RADIOL, V30, P2182, DOI [10.1148/radiol.2020200230, 10.1007/s00330-019-06574-1]
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Dai HS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00183
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Diao B., 2020, REDUCTION FUNCTIONAL, DOI [10.1101/2020.02.18.20024364, DOI 10.1101/2020.02.18.20024364]
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   El Agha E, 2017, CELL STEM CELL, V21, P166, DOI 10.1016/j.stem.2017.07.011
   Fan C, 2020, ACE2 EXPRESSION KIDN, DOI [10.1101/2020.02.12.20022418, DOI 10.1101/2020.02.12.20022418]
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Hammer Q, 2018, NAT IMMUNOL, V19, P800, DOI 10.1038/s41590-018-0163-6
   Hoever G, 2005, J MED CHEM, V48, P1256, DOI 10.1021/jm0493008
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Jones BM, 2004, CLIN EXP IMMUNOL, V135, P467, DOI 10.1111/j.1365-2249.2003.02391.x
   Khamitov R. A., 2008, Voprosy Virusologii, V53, P9
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kumamoto M, 2009, EUR RESPIR J, V34, P740, DOI 10.1183/09031936.00128508
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lessler J, 2009, LANCET INFECT DIS, V9, P291, DOI 10.1016/S1473-3099(09)70069-6
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li Z, 2020, CAUTION KIDNEY DYSFU, DOI [10.1101/2020.02.08.20021212, DOI 10.1101/2020.02.08.20021212]
   Lin CW, 2005, ANTIVIR RES, V68, P36, DOI 10.1016/j.antiviral.2005.07.002
   Lin S., 2020, BIORXIV, DOI [10.1101/2020.01.31.929695, DOI 10.1101/2020.01.31.929695]
   Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222
   Lu CW, 2020, LANCET, V395, pE39, DOI 10.1016/S0140-6736(20)30313-5
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Lu H, 2003, CHINA PHARM, V10
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Matthay MA, 2010, CRIT CARE MED, V38, pS569, DOI 10.1097/CCM.0b013e3181f1ff1d
   Moodley Y, 2009, AM J PATHOL, V175, P303, DOI 10.2353/ajpath.2009.080629
   Ng DL, 2016, AM J PATHOL, V186, P652, DOI 10.1016/j.ajpath.2015.10.024
   Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Pulido F, 2008, AIDS, V22, pF1, DOI 10.1097/QAD.0b013e3282f4243b
   Quilty BJ, 2020, EUROSURVEILLANCE, V25, P4, DOI 10.2807/1560-7917.ES.2020.25.5.2000080
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Ramaiah A., 2020, INSIGHTS CROSS SPECI, DOI [10.1101/2020.01.29.925867, DOI 10.1101/2020.01.29.925867]
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Rinaldo CR, 2005, AM J PUBLIC HEALTH, V95, P790, DOI 10.2105/AJPH.2004.040790
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shi HS, 2020, RADIOLOGY, V295, P20, DOI 10.1148/radiol.2020200269
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Stroher U, 2004, J INFECT DIS, V189, P1164, DOI 10.1086/382597
   Su S, 2015, LANCET, V385, P2349, DOI 10.1016/S0140-6736(15)60859-5
   ter Meulen J, 2004, LANCET, V363, P2139, DOI 10.1016/S0140-6736(04)16506-9
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Varia M, 2003, CAN MED ASSOC J, V169, P285
   Villar J, 2019, CHEST, V155, P587, DOI 10.1016/j.chest.2018.10.022
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang HL, 2008, AM J EMERG MED, V26, P711, DOI 10.1016/j.ajem.2007.10.031
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang XM, 2020, POTENTIAL ANAL, DOI 10.1007/s11118-019-09821-8
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Wenzel RP, 2003, NEW ENGL J MED, V348, P1947, DOI 10.1056/NEJMp030072
   Wong JEL, 2020, JAMA-J AM MED ASSOC, V323, P1243, DOI 10.1001/jama.2020.2467
   Wong SSY, 2008, J ANTIMICROB CHEMOTH, V62, P437, DOI 10.1093/jac/dkn243
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Working Group for the Prevention and Control of Neonatal, 2020, CHINESE J CONT PEDIA, V22, P87
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu C, 2004, CHINA PHARM, V1
   Xia CQ, 2004, AM J CLIN PATHOL, V121, P507, DOI 10.1309/WPK7Y2XKNF4CBF3R
   Xia JH, 2020, J MED VIROL, V92, P589, DOI 10.1002/jmv.25725
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
   Yang D, 2015, VIRUS RES, V206, P120, DOI 10.1016/j.virusres.2015.02.025
   Yeh KM, 2005, J ANTIMICROB CHEMOTH, V56, P919, DOI 10.1093/jac/dki346
   Yi L, 2004, J VIROL, V78, P11334, DOI 10.1128/JVI.78.20.11334-11339.2004
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhang F, PROTOCOL DETECTION C
   Zhang H, 2020, DIGESTIVE SYSTEM IS, DOI [10.1101/2020.01.30.927806, DOI 10.1101/2020.01.30.927806]
   Zhang JN, 2020, LANCET RESP MED, V8, pE11, DOI 10.1016/S2213-2600(20)30071-0
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zorzitto J, 2006, CELL RES, V16, P220, DOI 10.1038/sj.cr.7310030
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
   Zumla A, 2015, LANCET, V386, P995, DOI 10.1016/S0140-6736(15)60454-8
NR 118
TC 115
Z9 116
U1 34
U2 36
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD MAY
PY 2020
VL 55
IS 5
AR 105951
DI 10.1016/j.ijantimicag.2020.105951
PG 8
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MH0XX
UT WOS:000546454600007
PM 32234466
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Praveen, D
   Puvvada, RC
   Aanandhi, MV
AF Praveen, D.
   Puvvada, Ranadheer Chowdary
   Aanandhi, Vijey M.
TI Janus kinase inhibitor baricitinib is not an ideal option for management
   of COVID-19
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE SARS-CoV-2; COVID 19; Baricitinib; Novel Corona Virus
AB The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Praveen, D.; Puvvada, Ranadheer Chowdary] Vels Inst Sci Technol & Adv Studies, Sch Pharmaceut Sci, Chennai 600117, Tamil Nadu, India.
   [Aanandhi, Vijey M.] Vels Inst Sci Technol & Adv Studies, Sch Pharmaceut Sci, Dept Pharmaceut Chem & Anal, Chennai, Tamil Nadu, India.
RP Aanandhi, MV (corresponding author), Vels Inst Sci Technol & Adv Studies VISTAS, Sch Pharmaceut Sci, Dept Pharmaceut Chem & Anal, Chennai, Tamil Nadu, India.
EM praveennandan.1993@gmail.com; ranadheer.pharmd@gmail.com;
   hodpchemistry@velsuniv.ac.in
RI D, Praveen/F-8201-2018
OI D, Praveen/0000-0002-1139-9075
CR Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chaplin S., 2017, PRESCRIBER, V28, P44
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Gruber C.C., 2020, WUHAN CORONAVIRUS 20
   Harigai M, 2020, RMD OPEN, V6, DOI 10.1136/rmdopen-2019-001095
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mehta SK, 2007, J GRAVIT PHYSL, V14, P21
   Mesa RA, 2010, IDRUGS, V13, P394
   Ng M-Y, 2020, RADIOL CARDIOTHORAC, V2, DOI [10.1148/ryct.2020200034, DOI 10.1148/RYCT.2020200034]
   Pu SY, 2018, ANTIVIR RES, V155, P67, DOI 10.1016/j.antiviral.2018.05.001
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Sorrell FJ, 2016, STRUCTURE, V24, P401, DOI 10.1016/j.str.2015.12.015
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 16
TC 26
Z9 26
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD MAY
PY 2020
VL 55
IS 5
AR 105967
DI 10.1016/j.ijantimicag.2020.105967
PG 2
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MH0XX
UT WOS:000546454600014
PM 32259575
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zhai, P
   Ding, YB
   Wu, X
   Long, JK
   Zhong, YJ
   Li, YM
AF Zhai, Pan
   Ding, Yanbing
   Wu, Xia
   Long, Junke
   Zhong, Yanjun
   Li, Yiming
TI The epidemiology, diagnosis and treatment of COVID-19
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE COVID-19; Pandemic; Diagnosis; Isolation; Remdesivir; Clinical trials
ID CORTICOSTEROID TREATMENT; VIRAL-INFECTIONS; SPIKE PROTEIN; CORONAVIRUS;
   CHINA; CHLOROQUINE; PNEUMONIA; WUHAN; COV; AUTOMATION
AB In December 2019, the outbreak of the novel coronavirus disease (COVID-19) in China spread worldwide, becoming an emergency of major international concern. SARS-CoV-2 infection causes clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus. Human-to-human transmission via droplets, contaminated hands or surfaces has been described, with incubation times of 2-14 days. Early diagnosis, quarantine, and supportive treatments are essential to cure patients. This paper reviews the literature on all available information about the epidemiology, diagnosis, isolation and treatments of COVID-19. Treatments, including antiviral agents, chloroquine and hydroxychloroquine, corticosteroids, antibodies, convalescent plasma transfusion and vaccines, are discussed in this article. In addition, registered trials investigating treatment options for COVID-19 infection are listed. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Zhai, Pan; Ding, Yanbing] Hubei Prov Hosp Tradit Chinese Med, Dept Neurol, Wuhan 430073, Hubei, Peoples R China.
   [Wu, Xia] Hubei Prov Hosp Tradit Chinese Med, Dept Resp Med, Wuhan 430073, Hubei, Peoples R China.
   [Long, Junke] Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Med, Changsha 410011, Hunan, Peoples R China.
   [Zhong, Yanjun] Cent South Univ, Xiangya Hosp 2, ICU Ctr, Changsha 41001, Hunan, Peoples R China.
   [Li, Yiming] Wuhan Univ, Dept Crit Care Med, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
RP Li, YM (corresponding author), Wuhan Univ, Dept Crit Care Med, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
EM lym-fly@whu.edu.cn
FU Professional Development Research Project of the National Chinese
   Medicine Clinical Research Base of the State Administration of
   Traditional Chinese Medicine [JDZX2015295]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81701962]
FX This work was supported by the Professional Development Research Project
   of the National Chinese Medicine Clinical Research Base of the State
   Administration of Traditional Chinese Medicine (No. JDZX2015295) and the
   National Natural Science Foundation of China (No. 81701962).
CR Agnandji ST, 2016, NEW ENGL J MED, V374, P1647, DOI 10.1056/NEJMoa1502924
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Backer JA, 2020, EURO SURVEILL, V25
   Bhadra S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123126
   Biot C, 2006, J MED CHEM, V49, P2845, DOI 10.1021/jm0601856
   Chan JFW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00310-20
   Chan JFW, 2015, J CLIN MICROBIOL, V53, P2722, DOI 10.1128/JCM.01224-15
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chu DKW, 2020, CLIN CHEM
   Chung MS, 2020, EUR RADIOL, V30, P2182, DOI [10.1148/radiol.2020200230, 10.1007/s00330-019-06574-1]
   Cobb B, 2017, EXPERT REV MOL DIAGN, V17, P167, DOI 10.1080/14737159.2017.1275962
   Colson P, 2020, INT J ANTIMICROB AG
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cordes AK, 2020, J CLIN VIROL, V125, DOI 10.1016/j.jcv.2020.104305
   Corman V. M., 2020, EURO SURVEILL, V25
   Das KM, 2015, AM J ROENTGENOL, V205, pW267, DOI 10.2214/AJR.15.14445
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Eigner U, 2019, J VIROL METHODS, V269, P49, DOI 10.1016/j.jviromet.2019.03.015
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Fang Y., 2020, RADIOLOGY, DOI DOI 10.1148/RADI0L.2020200432
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gordon CJ, 2020, J BIOL CHEM
   Greub G, 2016, FUTURE MICROBIOL, V11, P403, DOI 10.2217/fmb.15.152
   Harcourt J, 2020, EMERGING INFECT DIS, V26
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang P, 2020, RADIOLOGY
   Huang P, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01101
   Jallouli M, 2015, ARTHRITIS RHEUMATOL, V67, P2176, DOI 10.1002/art.39194
   Jiang X, 2020, J MED VIROL, V92, P476, DOI 10.1002/jmv.25708
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Konrad R., 2020, EURO SURVEILL, V25
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lee DTS, 2004, CLIN INFECT DIS, V39, P1247, DOI 10.1086/424016
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Lee SH, 2017, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02166
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu R, 2020, CLIN CHIM ACTA, V505, P172, DOI 10.1016/j.cca.2020.03.009
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mackenzie JS, 2013, CURR OPIN VIROL, V3, P170, DOI 10.1016/j.coviro.2013.02.002
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Marlowe EM, 2017, EUR J MICROBIOL IMMU, V7, P176, DOI 10.1556/1886.2017.00018
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Pfefferle S., 2020, EURO SURVEILL, V25
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Schwartz DA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020194
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   To KK, 2020, CLIN INFECT DIS
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang Y, 2020, J MED VIROL
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao C, 2020, EMERG MICROBES INFEC, V9, P378, DOI 10.1080/22221751.2020.1727299
   Xie XZ, 2020, RADIOLOGY, V296, pE41, DOI 10.1148/radiol.2020200343
   Xu X, 2020, EUR J NUCL MED MOL I, V47, P1275, DOI 10.1007/s00259-020-04735-9
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Xu Z, 2020, LANCET RESP MED
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
   Yao Bai Y, 2020, JAMA
   Yao T.T., 2020, J MED VIROL
   Yao X, 2020, CLIN INFECT DIS
   Zhang NR, 2020, J MED VIROL, V92, P408, DOI 10.1002/jmv.25674
   Zhang Q, 2020, J MED VIROL, V92, P713, DOI 10.1002/jmv.25803
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zhong NS, 2008, RESPIROLOGY, V13, pS33, DOI 10.1111/j.1440-1843.2008.01255.x
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 93
TC 136
Z9 141
U1 23
U2 24
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD MAY
PY 2020
VL 55
IS 5
AR 105955
DI 10.1016/j.ijantimicag.2020.105955
PG 13
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MH0XX
UT WOS:000546454600010
PM 32234468
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zhang, C
   Wu, Z
   Li, JW
   Zhao, H
   Wang, GQ
AF Zhang, Chi
   Wu, Zhao
   Li, Jia-Wen
   Zhao, Hong
   Wang, Gui-Qiang
TI Cytokine release syndrome in severe COVID-19: interleukin-6 receptor
   antagonist tocilizumab may be the key to reduce mortality
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE COVID-19; Cytokine release syndrome; Tocilizumab; IL-6; IL-6R
ID RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; SARS-COV; JAK-STAT; IL-6;
   EXPRESSION; PATHWAYS; PROTEIN; CELLS; ACTIVATION
AB Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19), from Wuhan, China, has swept the world. Although the case fatality rate is not high, the number of people infected is large and there is still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is an important cause of death. Therefore, treatment of the cytokine storm has become an important part of rescuing severe COVID-19 patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome. If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients. Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Zhang, Chi; Wu, Zhao; Li, Jia-Wen; Zhao, Hong; Wang, Gui-Qiang] Peking Univ, Ctr Liver Dis, Dept Infect Dis, Hosp 1, 8 Xishiku St, Beijing, Peoples R China.
   [Zhao, Hong; Wang, Gui-Qiang] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China.
   [Wang, Gui-Qiang] Peking Univ, Int Hosp, Beijing, Peoples R China.
   [Zhao, Hong; Wang, Gui-Qiang] Peking Univ, Hosp 1, Dept Infect Dis, 8 Xishiku St, Beijing 100034, Peoples R China.
   [Zhao, Hong; Wang, Gui-Qiang] Peking Univ, Hosp 1, Ctr Liver Dis, 8 Xishiku St, Beijing 100034, Peoples R China.
RP Zhao, H; Wang, GQ (corresponding author), Peking Univ, Ctr Liver Dis, Dept Infect Dis, Hosp 1, 8 Xishiku St, Beijing, Peoples R China.; Zhao, H; Wang, GQ (corresponding author), Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China.; Wang, GQ (corresponding author), Peking Univ, Int Hosp, Beijing, Peoples R China.; Zhao, H; Wang, GQ (corresponding author), Peking Univ, Hosp 1, Dept Infect Dis, 8 Xishiku St, Beijing 100034, Peoples R China.; Zhao, H; Wang, GQ (corresponding author), Peking Univ, Hosp 1, Ctr Liver Dis, 8 Xishiku St, Beijing 100034, Peoples R China.
EM zhaohong_pufh@bjmu.edu.cn; john131212@sina.com
OI Zhao, Hong/0000-0002-8069-9901
FU China MegaProject for Infectious Diseases [2017ZX10203202,
   2013ZX10002005]; China Mega-Project for Innovative Drugs
   [2016ZX09101065]
FX This study was supported by the China MegaProject for Infectious
   Diseases [grant nos. 2017ZX10203202 and 2013ZX10002005] and the China
   Mega-Project for Innovative Drugs [grant no. 2016ZX09101065].
CR Baran P, 2018, J BIOL CHEM, V293, P6762, DOI 10.1074/jbc.RA117.001163
   Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   Briso EM, 2008, J IMMUNOL, V180, P7102, DOI 10.4049/jimmunol.180.11.7102
   Brune K, 2015, AM J PHYSIOL-LUNG C, V308, pL731, DOI 10.1152/ajplung.00309.2014
   Campard D, 2006, STEM CELLS, V24, P1302, DOI 10.1634/stemcells.2005-0173
   Campbell IL, 2014, J NEUROSCI, V34, P2503, DOI 10.1523/JNEUROSCI.2830-13.2014
   Castilletti C, 2005, VIROLOGY, V341, P163, DOI 10.1016/j.virol.2005.07.015
   Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Fraunberger P, 2006, SHOCK, V26, P10, DOI 10.1097/01.shk.0000215319.06866.bd
   Genentech Inc, 2019, PRESCR INF ACTEMRA T
   Giles JT, 2020, ARTHRITIS RHEUMATOL, V72, P31, DOI 10.1002/art.41095
   Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134
   Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hunter CA, 2017, NAT IMMUNOL, V18, P1271, DOI 10.1038/ni1117-1271b
   Ito H, 2004, GASTROENTEROLOGY, V126, P989, DOI 10.1053/j.gastro.2004.01.012
   Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8
   Jones BE, 2018, CURR OPIN IMMUNOL, V55, P9, DOI 10.1016/j.coi.2018.09.002
   Jones SA, 2005, J IMMUNOL, V175, P3463, DOI 10.4049/jimmunol.175.6.3463
   Jones SA, 2018, NAT REV IMMUNOL, V18, P773, DOI 10.1038/s41577-018-0066-7
   Kim SC, 2017, ARTHRITIS RHEUMATOL, V69, P1154, DOI 10.1002/art.40084
   Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391
   Knudsen L, 2018, HISTOCHEM CELL BIOL, V150, P661, DOI 10.1007/s00418-018-1747-9
   Kraakman MJ, 2015, CELL METAB, V21, P403, DOI 10.1016/j.cmet.2015.02.006
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Leiva-Juarez MM, 2018, MUCOSAL IMMUNOL, V11, P21, DOI 10.1038/mi.2017.71
   Liu Qian, 2020, J FORENSIC MED, V36, P19, DOI DOI 10.12116/J.ISSN.1004-5619.2020.01.00
   Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794
   Navarro G, 2014, SEMIN ARTHRITIS RHEU, V43, P458, DOI 10.1016/j.semarthrit.2013.08.001
   Nishimoto N, 2005, BLOOD, V106, P2627, DOI 10.1182/blood-2004-12-4602
   Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4
   Qu D, 2014, BRIT J PHARMACOL, V171, P3595, DOI 10.1111/bph.12713
   Scheller J, 2006, MED MICROBIOL IMMUN, V195, P173, DOI 10.1007/s00430-006-0019-9
   Scheller J, 2014, SEMIN IMMUNOL, V26, P2, DOI 10.1016/j.smim.2013.11.002
   Schmidt-Arras D, 2016, J HEPATOL, V64, P1403, DOI 10.1016/j.jhep.2016.02.004
   Shi SQ, 2006, MOL IMMUNOL, V43, P1791, DOI 10.1016/j.molimm.2005.11.005
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Su H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00405
   Taniguchi K, 2015, NATURE, V519, P57, DOI 10.1038/nature14228
   Teachey DT, 2013, BLOOD, V121, P5154, DOI 10.1182/blood-2013-02-485623
   Teijaro JR, 2017, SEMIN IMMUNOPATHOL, V39, P501, DOI 10.1007/s00281-017-0640-2
   The State Council of the People's Republic of China, DIAGN TREATM PROT NO
   Thiem S, 2013, J CLIN INVEST, V123, P767, DOI 10.1172/JCI65086
   Tseng CTK, 2005, J IMMUNOL, V174, P7977, DOI 10.4049/jimmunol.174.12.7977
   Villarino AV, 2017, NAT IMMUNOL, V18, P374, DOI 10.1038/ni.3691
   WEISSENBACH J, 1980, P NATL ACAD SCI-BIOL, V77, P7152, DOI 10.1073/pnas.77.12.7152
   Winkler U, 1999, BLOOD, V94, P2217, DOI 10.1182/blood.V94.7.2217.419k02_2217_2224
   Xie FL, 2019, ARTHRIT CARE RES, V71, P1004, DOI 10.1002/acr.23737
   Xu Xiaoling, EFFECTIVE TREATMENT
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yamada O, 2012, MOL CANCER THER, V11, P1112, DOI 10.1158/1535-7163.MCT-11-0850
   YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546
   YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x
   Yokota S, 2005, ARTHRITIS RHEUM, V52, P818, DOI 10.1002/art.20944
   Zegeye MM, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0268-4
   Zheng Y, 2016, Zhonghua Liu Xing Bing Xue Za Zhi, V37, P291, DOI 10.3760/cma.j.issn.0254-6450.2016.02.028
NR 57
TC 410
Z9 416
U1 35
U2 51
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD MAY
PY 2020
VL 55
IS 5
AR 105954
DI 10.1016/j.ijantimicag.2020.105954
PG 6
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MH0XX
UT WOS:000546454600009
PM 32234467
OA Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Lima, MLSO
   Almeida, RKS
   da Fonseca, FSA
   Goncalves, CCS
AF Lima, Maria L. S. O.
   Almeida, Ramon K. S.
   da Fonseca, Francine S. A.
   Goncalves, Caroline C. S.
TI THE CHEMISTRY OF SANITIZERS IN COVID-19 TIMES: DO YOU KNOW HOW IT WORKS?
SO QUIMICA NOVA
LA Portuguese
DT Article
DE sanitizers; COVID-19; biocidal action, SARS-CoV-2, coronavirus
ID QUATERNARY AMMONIUM-COMPOUNDS; DISINFECTANTS; EFFICACY; ANTIBACTERIAL;
   MECHANISMS; EPIDEMIC; ALCOHOLS; VIRUSES; ETHANOL; THYMOL
AB In December 2019, the first case of severe acute respiratory syndrome (COVID-19). caused by the new coronavirus (SARS-CoV-2) was reported and the disease was declared as a worldwide pandemic in March 2020. As there is no vaccine currently available, the daily hygiene cleaning habits and social distance are the ways to fight COVID-19 indicated by the WHO. Hand and surface hygiene has become essential and the use of 60-90% ethanol is recommended for its effective biocide action. Phenol-based products are effective sanitizers, but they can cause irritation and are not recommended for surfaces that come into contact with food. There are quaternary ammonium salts that present low toxic and are good sanitizers, as they can cause the denaturation of proteins and disruption of viral lipid bilayer. Sodium hypochlorite is one of the most used sanitizers due to its low cost and effective oxidative capacity. In the same direction, peroxides are also used as a biocide, as they cause oxidation of lipids and denaturation of viral proteins. The goal of this paper is to describe the action modes and chemical concepts of the sanitizers recommended by the AN VISA-Brazil to be used against the new coronavirus.
C1 [Lima, Maria L. S. O.] Inst Fed Educ Ciencia & Tecnol Bahia, Dept Ensino, Campus Juazeiro, BR-48918900 Juazeiro, BA, Brazil.
   [Almeida, Ramon K. S.] Univ Fed Rural Pernambuco, Unidade Acad Serra Talhada, BR-56909535 Serra Talhada, PE, Brazil.
   [da Fonseca, Francine S. A.] Univ Fed Minas Gerais, Inst Ciencias Agr, BR-39404547 Montes Claros, MG, Brazil.
   [Goncalves, Caroline C. S.] Univ Fed Integracao Latinoamer, Inst Latino Amer Ciencias Vida & Nat, BR-85866000 Foz Do Iguacu, PR, Brazil.
RP Lima, MLSO (corresponding author), Inst Fed Educ Ciencia & Tecnol Bahia, Dept Ensino, Campus Juazeiro, BR-48918900 Juazeiro, BA, Brazil.
EM marialair@ifba.edu.br; caroline.goncalves@unila.edu.br
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   [Anonymous], 2020, LANCET, V395, P1461, DOI 10.1016/S0140-6736(20)31095-3
   Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
   Barreiros ALBS, 2006, QUIM NOVA, V29, P113, DOI 10.1590/S0100-40422006000100021
   BARRY JA, 1994, BIOCHEMISTRY-US, V33, P8082, DOI 10.1021/bi00192a013
   Bouarab-Chibane L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00829
   Buiochi F., 2003, Controle & Automacao, V14, P330
   Cavallini G. S., 2012, Semina: Ciencias Exatas e Tecnologicas (Londrina), V33, P27, DOI 10.5433/1679-0375.2012v33n1p27
   Chaturvedi UC, 2005, FEMS IMMUNOL MED MIC, V43, P105, DOI 10.1016/j.femsim.2004.11.004
   Costa SAD, 2015, BRAZ ORAL RES, V29, DOI 10.1590/1807-3107BOR-2015.vol29.0038
   Daltin D., 2011, TENSOATIVOS QUIMICA
   DeBono R, 1997, BURNS, V23, P182, DOI 10.1016/S0305-4179(96)00114-3
   Estrela Carlos, 2002, Braz. Dent. J., V13, P113, DOI 10.1590/S0103-64402002000200007
   Felipe L. O., 2017, QNESC, V39, P228
   Fu E., 2007, HDB CLEANING DECONTA
   Fukuzaki Satoshi, 2006, Biocontrol Science, V11, P147
   Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758
   Gerba CP, 2015, APPL ENVIRON MICROB, V81, P464, DOI 10.1128/AEM.02633-14
   GOLDSTEIN DB, 1986, ANN EMERG MED, V15, P1013, DOI 10.1016/S0196-0644(86)80120-2
   Hays JN, 2005, EPIDEMICS PANDEMICS
   Ho CJ, 1997, BIOCHEMISTRY-US, V36, P10630, DOI 10.1021/bi9703150
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ingolfsson HI, 2011, BIOPHYS J, V101, P847, DOI 10.1016/j.bpj.2011.07.013
   Jennings MC, 2015, ACS INFECT DIS, V1, P288, DOI 10.1021/acsinfecdis.5b00047
   Jiao Y, 2017, PROG POLYM SCI, V71, P53, DOI 10.1016/j.progpolymsci.2017.03.001
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Kampf G, 2018, J HOSP INFECT, V98, P331, DOI 10.1016/j.jhin.2017.08.025
   Kehrer J. P., 2010, COMPREHENSIVE TOXICO, V1
   Khattari Z, 2006, BIOPHYS J, V90, P2038, DOI 10.1529/biophysj.105.072892
   Kotz J.C., 2016, QUIMICA GERAL REACOE, V2
   Lau SKP, 2020, EMERG INFECT DIS, V26, P1542, DOI 10.3201/eid2607.200092
   Le Chevallier M. W., 2004, WATER TREATMENT PATH
   Li JY, 2020, MICROBES INFECT, V22, P80, DOI 10.1016/j.micinf.2020.02.002
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Linley E, 2012, J ANTIMICROB CHEMOTH, V67, P1589, DOI 10.1093/jac/dks129
   Maines TR, 2009, SCIENCE, V325, P484, DOI 10.1126/science.1177238
   Marchese A, 2016, FOOD CHEM, V210, P402, DOI 10.1016/j.foodchem.2016.04.111
   McDonnell G, 1999, CLIN MICROBIOL REV, V12, P147, DOI 10.1128/CMR.12.1.147
   Molinaro E. M., 2009, CONCEITOS METODOS FO
   Nuvolari A., 2011, ESGOTO SANITARIO COL
   Olaniyan LWB, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3287-x
   Pan XC, 2020, MICROBES INFECT, V22, P86, DOI 10.1016/j.micinf.2020.02.004
   Penteado JCP, 2006, QUIM NOVA, V29, P1038, DOI 10.1590/S0100-40422006000500025
   Poli JP, 2018, LETT APPL MICROBIOL, V66, P427, DOI 10.1111/lam.12868
   Rabenau HF, 2005, J HOSP INFECT, V61, P107, DOI 10.1016/j.jhin.2004.12.023
   Richman DD, 2017, CLIN VIROLOGY
   Rifici S, 2016, J PHYS CHEM B, V120, P1285, DOI 10.1021/acs.jpcb.5b11427
   da Silva AAR, 2014, J PEDIAT-BRAZIL, V90, P149, DOI 10.1016/j.jped.2013.08.011
   Rocha W. R., 2001, CAD TEMATICOS QUIM N, V4, P31
   Rutala WA, 2019, AM J INFECT CONTROL, V47, pA3, DOI 10.1016/j.ajic.2019.01.018
   Shek W. R., 2015, LAB ANIMAL MED
   SPRINGTHORPE VS, 1990, CRIT REV ENV CONTR, V20, P169, DOI 10.1080/10643389009388396
   Stewart MJ, 1999, J MOL BIOL, V290, P859, DOI 10.1006/jmbi.1999.2907
   Stouten H, 1998, J APPL TOXICOL, V18, P271, DOI 10.1002/(SICI)1099-1263(199807/08)18:4<271::AID-JAT504>3.0.CO;2-B
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tortora G.J., 2016, MICROBIOLOGIA
   Trilla A, 2008, CLIN INFECT DIS, V47, P668, DOI 10.1086/590567
   Tuladhar E, 2012, APPL ENVIRON MICROB, V78, P2456, DOI 10.1128/AEM.07738-11
   Tungmunnithum Duangjai, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030093
   Ujvari S. C., 2012, HIST HUMANIDADE CONT
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277
   Vermeil T, 2019, J HOSP INFECT, V101, P383, DOI 10.1016/j.jhin.2018.09.003
   Wadman M., 2020, SCI AAAS, DOI [10.1126/ science.abc3208, DOI 10.1126/SCIENCE.ABC3208, 10.1126/science.abc3208]
   Wang HH, 2020, EUR J CLIN MICROBIOL, V39, P1629, DOI 10.1007/s10096-020-03899-4
   Weatherly LM, 2017, J TOXICOL ENV HEAL B, V20, P447, DOI 10.1080/10937404.2017.1399306
   Xu J, 2008, LETT APPL MICROBIOL, V47, P174, DOI 10.1111/j.1472-765X.2008.02407.x
   Zhang C, 2015, SCI TOTAL ENVIRON, V518, P352, DOI 10.1016/j.scitotenv.2015.03.007
NR 69
TC 2
Z9 2
U1 27
U2 27
PU SOC BRASILEIRA QUIMICA
PI SAO PAULO
PA CAIXA POSTAL 26037, 05599-970 SAO PAULO, BRAZIL
SN 0100-4042
EI 1678-7064
J9 QUIM NOVA
JI Quim. Nova
PD MAY
PY 2020
VL 43
IS 5
BP 668
EP 678
DI 10.21577/0100-4042.20170552
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA MH3SX
UT WOS:000546654400021
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Sequinel, R
   Lenz, GF
   da Silva, FJLB
   da Silva, FR
AF Sequinel, Rodrigo
   Lenz, Guilherme Felipe
   Liana Baumgardt da Silva, Francis Josiane
   da Silva, Fabiano Rosa
TI ALCOHOL BASED SOLUTIONS FOR HAND AND SURFACE SANITATION IN THE
   PREVENTION OF COVID-19: INFORMATIVE COMPENDIUM REGARDING THE INVOLVED
   CHEMISTRY
SO QUIMICA NOVA
LA Portuguese
DT Article
DE coronavirus; COVID-1 9; SARS-CoV-2; disinfectant, hand sanitizer
AB The recent coronavirus pandemic has already victimized hundreds of thousands of people around the world, and until this moment does not exist any medicine for healing or vaccine to avoid the contamination. Therefore, the actions of social isolation associated with the use of masks and surface and hand sanitation are the most effective actions to avoid the virus dissemination. The hands are one of the main vectors of contagious, and should be washed constantly and sanitized with some disinfectant agent. Among the recommendations, the formulations based on ethyl alcohol and isopropyl alcohol are the most used. being the efficiency of these formulations based on the alcohol type. the concentration, the applied volume, and the contact time. The gel disinfectants are preferred by the population due to the facile and safer manipulation. However, due to the pandemic, the main gelling agent has become sparse and, in the function of this, some countries authorized the utilization of alternative formulations. The World Health Organization recommends two formulations, being one based on ethyl alcohol (80 Vol%) and the second on isopropyl alcohol (75 Vol%). destined for the local manufacture and with a fast and effective action.
C1 [Sequinel, Rodrigo; Lenz, Guilherme Felipe; da Silva, Fabiano Rosa] Univ Fed Parana, Dept Engn & Exatas, BR-85950000 Palotina, PR, Brazil.
   [Liana Baumgardt da Silva, Francis Josiane] Univ Fed Parana, BR-86900000 Jandaia Do Sul, PR, Brazil.
RP Sequinel, R (corresponding author), Univ Fed Parana, Dept Engn & Exatas, BR-85950000 Palotina, PR, Brazil.
EM rsequinel@gmail.com; frosadasilva@gmail.com
RI Sequinel, Rodrigo/AAW-3429-2020
OI Rosa da Silva, Fabiano/0000-0002-8920-9366
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Ashworth WJ, 2001, TECHNOL CULT, V42, P27, DOI 10.1353/tech.2001.0002
   ATKINS P., 2006, PRINCIPIOS QUIMICA Q
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Fujimoto J, 2002, QUIM NOVA, V25, P757, DOI 10.1590/S0100-40422002000500010
   Greenaway RE, 2018, J HOSP INFECT, V100, P195, DOI 10.1016/j.jhin.2018.07.011
   Huber M. A., 2006, J CONT DENT PRACT, V2, P1
   International Union of Pure and Applied Chemistry, 2014, COMP CHEM TERM GOLD
   International Union of Pure and Applied Chemistry, 1968, STAND METH DET ALC C
   Jensen WB, 2004, J CHEM EDUC, V81, P1258, DOI 10.1021/ed081p1258
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Kirk J, 2016, AM J INFECT CONTROL, V44, P1095, DOI 10.1016/j.ajic.2016.03.005
   Klein H. A., 1988, SCI MEASUREMENT HIST
   Konda A, 2020, ACS NANO, V14, P6339, DOI 10.1021/acsnano.0c03252
   Kotz J. C., 2014, QUIMICA GERAL REACOE
   Kulkarni V S, 2016, ESSENTIAL CHEM FORMU
   Magalhaes W. L. E., 2020, COM TEC, V444, P1
   Ministerio da Saude, 2012, FORM NAC FARM BRAS
   Zingg W, 2016, AM J INFECT CONTROL, V44, P1689, DOI 10.1016/j.ajic.2016.07.006
NR 19
TC 2
Z9 2
U1 13
U2 13
PU SOC BRASILEIRA QUIMICA
PI SAO PAULO
PA CAIXA POSTAL 26037, 05599-970 SAO PAULO, BRAZIL
SN 0100-4042
EI 1678-7064
J9 QUIM NOVA
JI Quim. Nova
PD MAY
PY 2020
VL 43
IS 5
BP 679
EP 684
DI 10.21577/0100-4042.20170553
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA MH3SX
UT WOS:000546654400022
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Fischer, A
   Sellner, M
   Neranjan, S
   Smiesko, M
   Lill, MA
AF Fischer, Andre
   Sellner, Manuel
   Neranjan, Santhosh
   Smiesko, Martin
   Lill, Markus A.
TI Potential Inhibitors for Novel Coronavirus Protease Identified by
   Virtual Screening of 606 Million Compounds
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE coronavirus; SARS-2-CoV; virtual screening; computational chemistry
ID 3C-LIKE PROTEASE; SARS-COV; DEGLYCOSYLATION; BOCEPREVIR; MANAGEMENT;
   PNEUMONIA; DISCOVERY; OUTBREAK; PLATFORM; DOCKING
AB The rapid outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China followed by its spread around the world poses a serious global concern for public health. To this date, no specific drugs or vaccines are available to treat SARS-CoV-2 despite its close relation to the SARS-CoV virus that caused a similar epidemic in 2003. Thus, there remains an urgent need for the identification and development of specific antiviral therapeutics against SARS-CoV-2. To conquer viral infections, the inhibition of proteases essential for proteolytic processing of viral polyproteins is a conventional therapeutic strategy. In order to find novel inhibitors, we computationally screened a compound library of over 606 million compounds for binding at the recently solved crystal structure of the main protease (M-pro) of SARS-CoV-2. A screening of such a vast chemical space for SARS-CoV-2 M-pro inhibitors has not been reported before. After shape screening, two docking protocols were applied followed by the determination of molecular descriptors relevant for pharmacokinetics to narrow down the number of initial hits. Next, molecular dynamics simulations were conducted to validate the stability of docked binding modes and comprehensively quantify ligand binding energies. After evaluation of potential off-target binding, we report a list of 12 purchasable compounds, with binding affinity to the target protease that is predicted to be more favorable than that of the cocrystallized peptidomimetic compound. In order to quickly advise ongoing therapeutic intervention for patients, we evaluated approved antiviral drugs and other protease inhibitors to provide a list of nine compounds for drug repurposing. Furthermore, we identified the natural compounds (-)-taxifolin and rhamnetin as potential inhibitors of M-pro. Rhamnetin is already commercially available in pharmacies.
C1 [Fischer, Andre; Sellner, Manuel; Neranjan, Santhosh; Smiesko, Martin; Lill, Markus A.] Univ Basel, Dept Pharmaceut Sci, Computat Pharm, CH-4056 Basel, Switzerland.
RP Smiesko, M; Lill, MA (corresponding author), Univ Basel, Dept Pharmaceut Sci, Computat Pharm, CH-4056 Basel, Switzerland.
EM and.fischer@unibas.ch; manuel.sellner@unibas.ch;
   santhosh.neranjan@stud.unibas.ch; martin.smiesko@unibas.ch;
   markus.lill@unibas.ch
RI ; Lill, Markus/E-5118-2017
OI Fischer, Andre/0000-0002-6386-2324; Lill, Markus/0000-0003-3023-5188;
   Sellner, Manuel/0000-0003-3961-0175
CR Abd El-Hack ME, 2018, AGRICULTURE-BASEL, V8, DOI 10.3390/agriculture8090145
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Belchor MN, 2017, MOLECULES, V22, DOI 10.3390/molecules22091441
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bhal SK, 2007, MOL PHARMACEUT, V4, P556, DOI 10.1021/mp0700209
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   ChemAxon, 2020, MARV V 20 4 0
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen S, 2005, ACTA PHARMACOL SIN, V26, P99, DOI 10.1111/j.1745-7254.2005.00010.x
   Chen YW, 2020, PREDICTION 2019 NCOV, DOI DOI 10.26434/CHEMRXIV.11831103.V1
   Chen ZM, 2020, WORLD J PEDIATR, V16, P240, DOI 10.1007/s12519-020-00345-5
   Corso G, 2016, MOL INFORM, V35, P358, DOI 10.1002/minf.201600024
   Curtis SA, 2006, AEROSP CONF PROC, P44
   Day AJ, 1998, FEBS LETT, V436, P71, DOI 10.1016/S0014-5793(98)01101-6
   de Leuw P, 2018, EXPERT OPIN PHARMACO, V19, P577, DOI 10.1080/14656566.2018.1454428
   Deshmukh V, 2019, OSTEOARTHR CARTILAGE, V27, P1347, DOI 10.1016/j.joca.2019.05.006
   Diamond, 2020, MAIN PROT STRUCT XCH
   Du J, 2011, J COMPUT CHEM, V32, P2800, DOI 10.1002/jcc.21859
   Forssen P, 2018, ANAL CHEM, V90, P5366, DOI 10.1021/acs.analchem.8b00504
   Gao Kaifu, 2020, bioRxiv, DOI 10.1101/2020.01.30.927889
   Ghosh AK, 2016, J MED CHEM, V59, P5172, DOI 10.1021/acs.jmedchem.5b01697
   Goldinger DM, 2015, REGUL TOXICOL PHARM, V71, P453, DOI 10.1016/j.yrtph.2015.01.002
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Han HX, 2016, J FUNCT FOODS, V27, P178, DOI 10.1016/j.jff.2016.09.005
   He LL, 2015, CURR OPIN VIROL, V11, P103, DOI 10.1016/j.coviro.2015.03.013
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Kenny PW, 2019, J CHEMINFORMATICS, V11, DOI 10.1186/s13321-019-0330-2
   Keogh-Brown MR, 2008, HEALTH POLICY, V88, P110, DOI 10.1016/j.healthpol.2008.03.003
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kiser JJ, 2012, HEPATOLOGY, V55, P1620, DOI 10.1002/hep.25653
   Koes DR, 2013, J CHEM INF MODEL, V53, P1893, DOI 10.1021/ci300604z
   Kotowski K, 2020, ANTICANCER RES, V40, P2613, DOI 10.21873/anticanres.14232
   Kumar V, 2016, BIOORGAN MED CHEM, V24, P3035, DOI 10.1016/j.bmc.2016.05.013
   Lee C, 2009, BIOORG MED CHEM LETT, V19, P4538, DOI 10.1016/j.bmcl.2009.07.009
   Lee C, 2009, BIOORG MED CHEM LETT, V19, P1636, DOI 10.1016/j.bmcl.2009.02.010
   Lee H, 2013, CHEMMEDCHEM, V8, P1361, DOI 10.1002/cmdc.201300134
   Lee S, 2011, BIOORG MED CHEM LETT, V21, P3866, DOI 10.1016/j.bmcl.2011.05.043
   Li Y., 2020, BIORXIV, DOI [10.1101/2020.01.28.922922, DOI 10.1101/2020.01.28.922922]
   Lionta E, 2014, CURR TOP MED CHEM, V14, P1923, DOI 10.2174/1568026614666140929124445
   Liu X., 2020, CRYSTAL STRUCTURE CO
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Liu ZH, 2015, BIOINFORMATICS, V31, P405, DOI 10.1093/bioinformatics/btu626
   Lv ZT, 2015, HIV AIDS-RES PALLIAT, V7, P95, DOI 10.2147/HIV.S79956
   Moon YJ, 2008, BIOPHARM DRUG DISPOS, V29, P205, DOI 10.1002/bdd.605
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Okonechnikov K, 2012, BIOINFORMATICS, V28, P1166, DOI 10.1093/bioinformatics/bts091
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Pozharitskaya ON, 2009, PHYTOMEDICINE, V16, P244, DOI 10.1016/j.phymed.2008.10.002
   Raugi DN, 2016, J VIROL, V90, P1062, DOI 10.1128/JVI.01772-15
   Schrodinger LCC, 2019, MAESTR SMALL MOL DRU
   Shaw DE, 2014, INT CONF HIGH PERFOR, P41, DOI 10.1109/SC.2014.9
   Shekfeh S, 2019, CHEMMEDCHEM, V14, P273, DOI 10.1002/cmdc.201800701
   Siddiqui F, 2019, CLIN APPL THROMB-HEM, V25, DOI 10.1177/1076029619847524
   Slamova K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072126
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Stoermer M.J., 2020, HOMOLOGY MODELS PAPA, DOI [10.26434/chemrxiv.11799705.v1, DOI 10.26434/CHEMRXIV.11799705.V1]
   Thi THN, 2012, BIOTECHNOL LETT, V34, P831, DOI 10.1007/s10529-011-0845-8
   Nguyen TTH, 2011, BIOORG MED CHEM LETT, V21, P3088, DOI 10.1016/j.bmcl.2011.03.034
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Tungol A, 2011, J MANAGE CARE PHARM, V17, P685, DOI 10.18553/jmcp.2011.17.9.685
   Vedani A, 2015, TOXICOL LETT, V232, P519, DOI 10.1016/j.toxlet.2014.09.004
   Vedani A, 2012, TOXICOL APPL PHARM, V261, P142, DOI 10.1016/j.taap.2012.03.018
   Walters WP, 2012, EXPERT OPIN DRUG DIS, V7, P99, DOI 10.1517/17460441.2012.648612
   Wang FH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22677
   Waring MJ, 2015, NAT REV DRUG DISCOV, V14, P475, DOI 10.1038/nrd4609
   Waszkowycz B, 2008, DRUG DISCOV TODAY, V13, P219, DOI 10.1016/j.drudis.2007.12.002
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   World Health Organization, 2020, INT HLTH REG EM COMM
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Z., 2020, BIORXIV, V1201, P1
   Xu Z, 2020, NELFINAVIR IS ACTIVE, DOI [10.26434/chemrxiv.12039888.v1, DOI 10.26434/CHEMRXIV.12039888.V1]
   Yang S, 2006, J MED CHEM, V49, P4971, DOI 10.1021/jm0603926
   Ye WL, 2019, CHEMOMETR INTELL LAB, V185, P32, DOI 10.1016/j.chemolab.2018.12.015
   Zhang H., 2020, DEEP LEARNING BASED, DOI DOI 10.20944/PREPRINTS202002.0061.V1
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 79
TC 16
Z9 18
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2020
VL 21
IS 10
DI 10.3390/ijms21103626
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA LW7GO
UT WOS:000539312100222
PM 32455534
OA DOAJ Gold, Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Gemmati, D
   Bramanti, B
   Serino, ML
   Secchiero, P
   Zauli, G
   Tisato, V
AF Gemmati, Donato
   Bramanti, Barbara
   Serino, Maria Luisa
   Secchiero, Paola
   Zauli, Giorgio
   Tisato, Veronica
TI COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of
   ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the
   Double X-Chromosome in Females Be Protective against SARS-CoV-2 Compared
   to the Single X-Chromosome in Males?
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE SARS-CoV-2; COVID-19; ACE1; ACE2; RAS-pathway; TMPRSS2; sex; gender-gap;
   lung shut-down; prognostic molecular; genetic markers; inflammation;
   thrombosis
ID ANGIOTENSIN-CONVERTING ENZYME; RESPIRATORY SYNDROME CORONAVIRUS;
   SEX-BASED DIFFERENCES; ACTIVATED PROTEIN-C; VENOUS LEG ULCER; SARS
   CORONAVIRUS; CLINICAL CHARACTERISTICS; GENDER-DIFFERENCES;
   INSERTION/DELETION POLYMORPHISM; ESSENTIAL-HYPERTENSION
AB In December 2019, a novel severe acute respiratory syndrome (SARS) from a new coronavirus (SARS-CoV-2) was recognized in the city of Wuhan, China. Rapidly, it became an epidemic in China and has now spread throughout the world reaching pandemic proportions. High mortality rates characterize SARS-CoV-2 disease (COVID-19), which mainly affects the elderly, causing unrestrained cytokines-storm and subsequent pulmonary shutdown, also suspected micro thromboembolism events. At the present time, no specific and dedicated treatments, nor approved vaccines, are available, though very promising data come from the use of anti-inflammatory, anti-malaria, and anti-coagulant drugs. In addition, it seems that males are more susceptible to SARS-CoV-2 than females, with males 65% more likely to die from the infection than females. Data from the World Health Organization (WHO) and Chinese scientists show that of all cases about 1.7% of women who contract the virus will die compared with 2.8% of men, and data from Hong Kong hospitals state that 32% of male and 15% of female COVID-19 patients required intensive care or died. On the other hand, the long-term fallout of coronavirus may be worse for women than for men due to social and psychosocial reasons. Regardless of sex- or gender-biased data obtained from WHO and those gathered from sometimes controversial scientific journals, some central points should be considered. Firstly, SARS-CoV-2 has a strong interaction with the human ACE2 receptor, which plays an essential role in cell entry together with transmembrane serine protease 2 (TMPRSS2); it is interesting to note that the ACE2 gene lays on the X-chromosome, thus allowing females to be potentially heterozygous and differently assorted compared to men who are definitely hemizygous. Secondly, the higher ACE2 expression rate in females, though controversial, might ascribe them the worst prognosis, in contrast with worldwide epidemiological data. Finally, several genes involved in inflammation are located on the X-chromosome, which also contains high number of immune-related genes responsible for innate and adaptive immune responses to infection. Other genes, out from the RAS-pathway, might directly or indirectly impact on the ACE1/ACE2 balance by influencing its main actors (e.g., ABO locus, SRY, SOX3, ADAM17). Unexpectedly, the higher levels of ACE2 or ACE1/ACE2 rebalancing might improve the outcome of COVID-19 in both sexes by reducing inflammation, thrombosis, and death. Moreover, X-heterozygous females might also activate a mosaic advantage and show more pronounced sex-related differences resulting in a sex dimorphism, further favoring them in counteracting the progression of the SARS-CoV-2 infection.
C1 [Gemmati, Donato; Secchiero, Paola; Zauli, Giorgio; Tisato, Veronica] Univ Ferrara, Dept Morphol Surg & Expt Med, I-44121 Ferrara, Italy.
   [Gemmati, Donato; Serino, Maria Luisa] Univ Ferrara, Ctr Haemostasis & Thrombosis, I-44121 Ferrara, Italy.
   [Gemmati, Donato; Bramanti, Barbara] Univ Ferrara, Univ Ctr Studies Gender Med, I-44121 Ferrara, Italy.
   [Bramanti, Barbara] Univ Ferrara, Dept Biomed & Specialty Surg Sci, I-44121 Ferrara, Italy.
   [Serino, Maria Luisa] Univ Ferrara, Dept Med Sci, I-44121 Ferrara, Italy.
   [Secchiero, Paola; Zauli, Giorgio; Tisato, Veronica] Univ Ferrara, LTTA Ctr, I-44121 Ferrara, Italy.
RP Gemmati, D (corresponding author), Univ Ferrara, Dept Morphol Surg & Expt Med, I-44121 Ferrara, Italy.; Gemmati, D (corresponding author), Univ Ferrara, Ctr Haemostasis & Thrombosis, I-44121 Ferrara, Italy.; Gemmati, D (corresponding author), Univ Ferrara, Univ Ctr Studies Gender Med, I-44121 Ferrara, Italy.
EM cet@unife.it; barbara.bramanti@unife.it; maria.luisa.serino@unife.it;
   paola.secchiero@unife.it; giorgio.zauli@unife.it;
   veronica.tisato@unife.it
RI Zauli, Giorgio/ABE-8001-2020; Bramanti, Barbara/AAF-8542-2019
OI Bramanti, Barbara/0000-0002-5433-663X; Tisato,
   Veronica/0000-0001-8448-066X; Gemmati, Donato/0000-0001-6213-6120
FU "Local Research grants" from University of Ferrara, Italy (FIR); "Local
   Research grants" from University of Ferrara, Italy (FAR)
FX Study supported by "Local Research grants" from University of Ferrara,
   Italy (FIR and FAR to D.G. and V.T.).
CR Alagaili AN, 2014, MBIO, V5, DOI DOI 10.1128/MBIO.00884-14
   Alghamdi IG, 2014, INT J GEN MED, V7, P417, DOI 10.2147/IJGM.S67061
   Angele MK, 2014, VIRULENCE, V5, P12, DOI 10.4161/viru.26982
   [Anonymous], CLINVAR GENOMIC VARI
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Araujo FC, 2015, PHYSIOL GENOMICS, V47, P177, DOI 10.1152/physiolgenomics.00138.2014
   Asselta R., 2020, ACE2 TMPRSS2 VARIANT, DOI [10.2139/ssrn.3559608, DOI 10.2139/SSRN.3559608]
   Atto B, 2019, CLIN SCI, V133, P1663, DOI 10.1042/CS20181009
   Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015
   Baena E, 2013, GENE DEV, V27, P683, DOI 10.1101/gad.211011.112
   Barcelo D, 2020, J ENVIRON CHEM ENG, V8, DOI 10.1016/j.jece.2020.104006
   Bayoglu B, 2012, PSYCHIAT CLIN NEUROS, V66, P130, DOI 10.1111/j.1440-1819.2011.02318.x
   Benjafield AV, 2004, AM J HYPERTENS, V17, P624, DOI 10.1016/j.amjhyper.2004.02.022
   Berletch JB, 2011, HUM GENET, V130, P237, DOI 10.1007/s00439-011-1011-z
   Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Brake SJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030841
   Brojakowska A, 2020, J AM COLL CARDIOL, V75, P3085, DOI 10.1016/j.jacc.2020.04.028
   Burrell LM, 2004, TRENDS ENDOCRIN MET, V15, P166, DOI 10.1016/j.tem.2004.03.001
   Cai GS, 2020, AM J RESP CRIT CARE, V201, P1557, DOI 10.1164/rccm.202003-0693LE
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Casimir GJ, 2013, BIOL SEX DIFFER, V4, DOI 10.1186/2042-6410-4-16
   Casimir GJA, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-28
   Casimir GJA, 2010, SHOCK, V34, P23, DOI 10.1097/SHK.0b013e3181ce2c3d
   Casimir GJA, 2010, SHOCK, V33, P258, DOI 10.1097/SHK.0b013e3181b2b36b
   Casimir GJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00475
   Chan KCA, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-26
   Changeux J.-P., 2020, QEIOS, DOI [10.32388/FXGQSB.2, DOI 10.32388/FXGQSB.2, 10. 32388/FXGQSB.2]
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chen J., 2020, INDIVIDUAL VARIATION
   Chen J, 2007, ANNU REV IMMUNOL, V25, P443, DOI 10.1146/annurev.immunol.25.022106.141706
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng ZS, 2015, J INFECT DIS, V212, P1214, DOI 10.1093/infdis/jiv246
   Chiu RWK, 2004, CLIN CHEM, V50, P1683, DOI 10.1373/clinchem.2004.035436
   Coccia M, 2020, SCI TOTAL ENVIRON, V729, DOI 10.1016/j.scitotenv.2020.138474
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Crowley SD, 2005, J CLIN INVEST, V115, P1092, DOI 10.1172/JCI200523378
   Daughton C, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138149
   de Haan CAM, 2005, J VIROL, V79, P14451, DOI 10.1128/JVI.79.22.14451-14456.2005
   Dipartimento della Protezione Civile, DIPARTIMENTO PROTEZI
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Driss A, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-271
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Eurosurveillance Editorial Team, 2020, Euro Surveill, V25, DOI 10.2807/1560-7917.ES.2020.25.12.2003261
   Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394
   Fraga-Silva RA, 2010, MOL MED, V16, P210, DOI 10.2119/molmed.2009.00160
   Garufi G, 2020, EUR J INTERN MED, V77, P121, DOI 10.1016/j.ejim.2020.04.042
   Gausman J, 2020, J WOMENS HEALTH, V29, P465, DOI 10.1089/jwh.2020.8472
   Gemmati D, 1998, BLOOD COAGUL FIBRIN, V9, P173, DOI 10.1097/00001721-199803000-00008
   Gemmati D, 2004, WOUND REPAIR REGEN, V12, P512, DOI 10.1111/j.1067-1927.2004.012503.x
   Gemmati D, 2001, BLOOD COAGUL FIBRIN, V12, P691, DOI 10.1097/00001721-200112000-00011
   Gemmati D, 1997, CLIN APPL THROMB-HEM, V3, P168
   Gemmati D, 2001, HAEMOSTASIS, V31, P99
   Gemmati D, 1997, BLOOD COAGUL FIBRIN, V8, P118, DOI 10.1097/00001721-199703000-00006
   Gemmati D, 2007, MOL MED, V13, P112, DOI 10.2119/2006-00049.Gemmati
   Gemmati D, 2006, J VASC SURG, V44, P554, DOI 10.1016/j.jvs.2006.05.011
   Gemmati D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010296
   Gemmati D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35185-x
   Gemmati D, 2015, THROMB HAEMOSTASIS, V114, P123, DOI 10.1160/TH14-11-0952
   Guillon P, 2008, GLYCOBIOLOGY, V18, P1085, DOI 10.1093/glycob/cwn093
   Halim AA, 2016, EGYPT J CHEST DIS TU, V65, P81, DOI 10.1016/j.ejcdt.2015.11.011
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hannah MF, 2008, BRAIN BEHAV IMMUN, V22, P503, DOI 10.1016/j.bbi.2007.10.005
   Haschke M, 2013, CLIN PHARMACOKINET, V52, P783, DOI 10.1007/s40262-013-0072-7
   Hefler M, 2020, TOB CONTROL, V29, P245, DOI 10.1136/tobaccocontrol-2020-055807
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang W, 2006, J HUM HYPERTENS, V20, P968, DOI 10.1038/sj.jhh.1002090
   HUBERT C, 1991, J BIOL CHEM, V266, P15377
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Imai Yumiko, 2008, Masui, V57, P302
   Itoyama S, 2004, BIOCHEM BIOPH RES CO, V323, P1124, DOI 10.1016/j.bbrc.2004.08.208
   Jaillon S, 2019, CLIN REV ALLERG IMMU, V56, P308, DOI 10.1007/s12016-017-8648-x
   Jarcho JA, 2020, NEW ENGL J MED, V382, P2462, DOI 10.1056/NEJMe2012924
   Jerng JS, 2006, CRIT CARE MED, V34, P1001, DOI 10.1097/01.CCM.0000206107.92476.39
   Jespersen L, 2015, AM J CLIN NUTR, V101, P1188, DOI 10.3945/ajcn.114.103531
   Karlberg J, 2004, AM J EPIDEMIOL, V159, P229, DOI 10.1093/aje/kwh056
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Klein SL, 2015, T ROY SOC TROP MED H, V109, P9, DOI 10.1093/trstmh/tru167
   Klein SL, 2012, BIOESSAYS, V34, P1050, DOI 10.1002/bies.201200099
   Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9
   Kovats S, 2015, CELL IMMUNOL, V294, P63, DOI 10.1016/j.cellimm.2015.01.018
   Kron KJ, 2017, NAT GENET, V49, P1336, DOI 10.1038/ng.3930
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Lang JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023710
   Lefevre N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01052
   Leong HN, 2006, ANN ACAD MED SINGAP, V35, P326
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li YY, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00364
   Liu Jun, 2010, Biol Sex Differ, V1, P6, DOI 10.1186/2042-6410-1-6
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   Lu ZP, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0356
   Luo JQ, 2014, PHARMACOGENET GENOM, V24, P306, DOI 10.1097/FPC.0000000000000050
   LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0
   Madu IG, 2007, AVIAN DIS, V51, P45, DOI 10.1637/0005-2086(2007)051[0045:HSIASA]2.0.CO;2
   Malkin CJ, 2004, J CLIN ENDOCR METAB, V89, P3313, DOI 10.1210/jc.2003-031069
   Marshall RP, 2002, AM J RESP CRIT CARE, V166, P646, DOI 10.1164/rccm.2108086
   Meester I, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-019-0278-y
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Mizuiri S, 2001, KIDNEY INT, V60, P1124, DOI 10.1046/j.1523-1755.2001.0600031124.x
   Murin S, 2005, CLEV CLIN J MED, V72, P916, DOI 10.3949/ccjm.72.10.916
   Nakamura K, 2008, HYPERTENS RES, V31, P1953, DOI 10.1291/hypres.31.1953
   Napoli PE, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041138
   National Center for Biotechnology Information( NCBI), DBSNP SHORT GEN VAR
   Ng PC, 2004, PEDIATRICS, V113, pE7, DOI 10.1542/peds.113.1.e7
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Oghumu S, 2019, J IMMUNOL, V203, P789, DOI 10.4049/jimmunol.1800931
   Olkowicz M, 2015, PHARMACOL REP, V67, P778, DOI 10.1016/j.pharep.2015.03.017
   Oruc N, 2008, TURK J GASTROENTEROL, V19, P250
   Oudit GY, 2006, AM J PATHOL, V168, P1808, DOI 10.2353/ajpath.2006.051091
   Patel SK, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00227
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Peretz J, 2016, AM J PHYSIOL-LUNG C, V310, pL415, DOI 10.1152/ajplung.00398.2015
   Pinheiro DS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221248
   Postma DS, 2007, GENDER MED, V4, pS133, DOI 10.1016/S1550-8579(07)80054-4
   Rettew JA, 2008, BIOL REPROD, V78, P432, DOI 10.1095/biolreprod.107.063545
   Robinson DP, 2014, J VIROL, V88, P4711, DOI 10.1128/JVI.02081-13
   Robinson Dionne P, 2011, Biol Sex Differ, V2, P8, DOI 10.1186/2042-6410-2-8
   Ross MT, 2005, NATURE, V434, P325, DOI 10.1038/nature03440
   Russo P, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01116-2020
   Schurz H, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-018-0185-z
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Simons D., 2020, BMJ OPIN
   Smyth LJ, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026777
   Spolarics Z, 2007, SHOCK, V27, P597, DOI 10.1097/SHK.0b013e31802e40bd
   Spolarics Z, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01455
   Srivastava K, 2010, DNA CELL BIOL, V29, P417, DOI 10.1089/dna.2010.1033
   Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001
   Su L, 2020, EMERG MICROBES INFEC, V9, P707, DOI 10.1080/22221751.2020.1744483
   Syrett CM, 2019, J LEUKOCYTE BIOL, V106, P919, DOI 10.1002/JLB.6RI0319-094R
   Terao C, 2013, ANN HUM GENET, V77, P465, DOI 10.1111/ahg.12034
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   Thomas MR, 2017, CIRC RES, V120, P133, DOI 10.1161/CIRCRESAHA.116.309955
   Tikellis Chris, 2012, Int J Pept, V2012, P256294, DOI 10.1155/2012/256294
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Tisato V, 2019, GENES-BASEL, V10, DOI 10.3390/genes10090634
   Tognazzo S, 2006, J VASC SURG, V44, P815, DOI 10.1016/j.jvs.2006.06.006
   Townsend EA, 2012, ENDOCR REV, V33, P1, DOI 10.1210/er.2010-0031
   Tukiainen T, 2017, NATURE, V550, P244, DOI 10.1038/nature24265
   Tzoran I, 2018, SEMIN THROMB HEMOST, V44, P624, DOI 10.1055/s-0038-1657779
   Ubeda F, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13849
   Vicenzi E, 2004, EMERG INFECT DIS, V10, P413, DOI 10.3201/eid1003.030683
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang JL, 2016, P NATL ACAD SCI USA, V113, pE2029, DOI 10.1073/pnas.1520113113
   Wassmer SC, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00121
   Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987
   Wong CM, 2013, INFLUENZA OTHER RESP, V7, P531, DOI 10.1111/j.1750-2659.2012.00411.x
   World Health Organization, CENS DOC EP SEC AC R
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu WX, 2011, AM J PHYSIOL-LUNG C, V300, pL821, DOI 10.1152/ajplung.00267.2010
   Wu YH, 2017, J CLIN LAB ANAL, V31, DOI 10.1002/jcla.22033
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yamamoto K, 2006, HYPERTENSION, V47, P718, DOI 10.1161/01.HYP.0000205833.89478.5b
   Yan R., 2020, BIORXIV, DOI DOI 10.1101/2020.02.17.951848
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang M, 2015, J RENIN-ANGIO-ALDO S, V16, P1240, DOI 10.1177/1470320314549221
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Yang Y, 2020, INFECT CONT HOSP EP, V41, P872, DOI 10.1017/ice.2020.97
   Yin SY, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02105-8
   Yuan X, 2001, J BIOL CHEM, V276, P46647, DOI 10.1074/jbc.M108404200
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zamboni P, 2007, THROMB HAEMOSTASIS, V98, P131, DOI 10.1160/TH06-11-0625
   Zhang H, 2020, DIGESTIVE SYSTEM IS, DOI [10.1101/2020.01.30.927806, DOI 10.1101/2020.01.30.927806]
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang HB, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1882-z
   Zhang R, 2015, AM J RESP CRIT CARE, V192, P315, DOI 10.1164/rccm.201412-2326OC
   Zhang YF, 2014, J RENIN-ANGIO-ALDO S, V15, P547, DOI 10.1177/1470320313475906
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zheng Y, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104821
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
   Zhong JC, 2011, HYPERTENSION, V57, P314, DOI 10.1161/HYPERTENSIONAHA.110.164244
   Zhong WG, 2012, GENET MOL RES, V11, P2268, DOI 10.4238/2012.May.21.1
   Zhou JB, 2009, J RENIN-ANGIO-ALDO S, V10, P31, DOI 10.1177/1470320309103047
   Zhou M, 2020, BIOCHEM BIOPH RES CO, V523, P753, DOI 10.1016/j.bbrc.2020.01.008
   Zito A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13340-w
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
   2014, REGION ANESTH PAIN M, V9, DOI DOI 10.1371/journal.pone.0055903
NR 181
TC 36
Z9 37
U1 5
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2020
VL 21
IS 10
AR 3474
DI 10.3390/ijms21103474
PG 23
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA LW7GO
UT WOS:000539312100070
PM 32423094
OA DOAJ Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Mirabelli, M
   Chiefari, E
   Puccio, L
   Foti, DP
   Brunetti, A
AF Mirabelli, Maria
   Chiefari, Eusebio
   Puccio, Luigi
   Foti, Daniela Patrizia
   Brunetti, Antonio
TI Potential Benefits and Harms of Novel Antidiabetic Drugs during COVID-19
   Crisis
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE COVID-19; diabetes; DPP4 inhibitors; GLP1 receptor agonists; SGLT2
   inhibitors
ID DIABETIC-KETOACIDOSIS; RECEPTOR; ACTIVATION; EXPRESSION; INFECTION;
   IMPACT; CELLS; ACE2
AB Patients with diabetes have been reported to have enhanced susceptibility to severe or fatal COVID-19 infections, including a high risk of being admitted to intensive care units with respiratory failure and septic complications. Given the global prevalence of diabetes, affecting over 450 million people worldwide and still on the rise, the emerging COVID-19 crisis poses a serious threat to an extremely large vulnerable population. However, the broad heterogeneity and complexity of this dysmetabolic condition, with reference to etiologic mechanisms, degree of glycemic derangement and comorbid associations, along with the extensive sexual dimorphism in immune responses, can hamper any patient generalization. Even more relevant, and irrespective of glucose-lowering activities, DPP4 inhibitors and GLP1 receptor agonists may have a favorable impact on the modulation of viral entry and overproduction of inflammatory cytokines during COVID-19 infection, although current evidence is limited and not univocal. Conversely, SGLT2 inhibitors may increase the likelihood of COVID-19-related ketoacidosis decompensation among patients with severe insulin deficiency. Mindful of their widespread popularity in the management of diabetes, addressing potential benefits and harms of novel antidiabetic drugs to clinical prognosis at the time of a COVID-19 pandemic deserves careful consideration.
C1 [Mirabelli, Maria; Chiefari, Eusebio; Foti, Daniela Patrizia; Brunetti, Antonio] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Viale Europa, I-88100 Catanzaro, Italy.
   [Puccio, Luigi] Hosp Pugliese Ciaccio, Complex Operat Unit Endocrinol & Diabet, I-88100 Catanzaro, Italy.
RP Brunetti, A (corresponding author), Magna Graecia Univ Catanzaro, Dept Hlth Sci, Viale Europa, I-88100 Catanzaro, Italy.
EM maria.mirabelli@unicz.it; echiefari@gmail.com; puccio55@libero.it;
   foti@unicz.it; brunetti@unicz.it
RI Brunetti, Antonio/K-7756-2016; Chiefari, Eusebio/Y-2558-2019
OI Chiefari, Eusebio/0000-0001-5329-3124; Brunetti,
   Antonio/0000-0003-1533-8779; Foti, Daniela/0000-0002-9536-5736;
   Mirabelli, Maria/0000-0002-6427-7186
FU European CommissionEuropean CommissionEuropean Commission Joint Research
   Centre; FESR FSE 2014-2020; Regione CalabriaRegione Calabria
FX This publication is co-financed with the support of the European
   Commission, FESR FSE 2014-2020, and Regione Calabria. The European
   Commission and Regione Calabria's support for the production of this
   publication does not constitute an endorsement of the contents, which
   reflect the views only of the authors, and cannot be held responsible
   for any use which may be made of the information contained therein.
CR Ali A, 2019, MOL CLIN ONCOL, V10, P118, DOI 10.3892/mco.2018.1766
   Ayaori M, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.003277
   Benezit F., 2020, INFECTION, V13, P1
   Bettge K, 2017, DIABETES OBES METAB, V19, P336, DOI 10.1111/dom.12824
   Bornstein SR, 2020, LANCET DIABETES ENDO, V8, P546, DOI 10.1016/S2213-8587(20)30152-2
   Brufsky A, 2020, J MED VIROL, V92, P770, DOI 10.1002/jmv.25887
   Chen ZM, 2015, LANCET, V386, P1447, DOI 10.1016/S0140-6736(15)00340-2
   Cheung KS, 2020, GASTROENTEROLOGY, V159, P81, DOI 10.1053/j.gastro.2020.03.065
   Chiefari E, 2015, DIABETES TECHNOL THE, V17, P468, DOI 10.1089/dia.2014.0412
   Chillo O, 2016, CELL REP, V16, P2197, DOI 10.1016/j.celrep.2016.07.040
   Cook DJ, 2020, JAMA-J AM MED ASSOC, V323, P1559, DOI 10.1001/jama.2020.5775
   Davies MJ, 2018, DIABETES CARE, V41, P2669, DOI 10.2337/dci18-0033
   Deacon CF, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00080
   DeVries JH, 2017, DIABETES CARE, V40, P161, DOI 10.2337/dci16-0035
   Drucker DJ, 2020, ENDOCR REV, V41, P457, DOI 10.1210/endrev/bnaa011
   Evans M, 2020, DIABETES THER, V11, P37, DOI 10.1007/s13300-019-00728-6
   Fadini GP, 2020, J ENDOCRINOL INVEST, V43, P867, DOI 10.1007/s40618-020-01236-2
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Gupta R, 2020, DIABETES METAB SYND, V14, P211, DOI 10.1016/j.dsx.2020.03.002
   Hampp C, 2020, DIABETES CARE, V43, P90, DOI 10.2337/dc19-1481
   Iacobellis G, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108125
   Imai Y, 2007, CELL MOL LIFE SCI, V64, P2006, DOI 10.1007/s00018-007-6228-6
   International Diabetes Federation, 2019, IDF DIABETES ATLAS
   Kalra S, 2020, DIABETES THER, V11, P813, DOI 10.1007/s13300-020-00789-y
   Kawase H, 2016, J MOL CELL CARDIOL, V98, P37, DOI 10.1016/j.yjmcc.2016.06.066
   Kim SC, 2015, ANN RHEUM DIS, V74, P1968, DOI 10.1136/annrheumdis-2014-205216
   Kiselar JG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130533
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Kritas SK, 2020, J BIOL REG HOMEOS AG, V34, P9, DOI 10.23812/20-Editorial-Kritas
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   L'epidemiologia per la Sanita Pubblica, EP SAN PUBBL
   Lee YS, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/3094642
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Lin TJ, 2001, INT ARCH ALLERGY IMM, V124, P142, DOI 10.1159/000053693
   Liu H, 2020, J REPROD IMMUNOL, V139, DOI 10.1016/j.jri.2020.103122
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Lyseng-Williamson KA, 2019, CLIN DRUG INVEST, V39, P805, DOI 10.1007/s40261-019-00826-0
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Makrilakis K, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16152720
   Mirabelli M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17010207
   Mirabelli M, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/3971060
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   multicenter collaboration group of Department of S Technology of Guangdong P Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus p, 2020, ZHONGHUA JIE HE HE H, V43, pE019, DOI DOI 10.2337/DC20-S009
   Nyenwe EA, 2016, METABOLISM, V65, P507, DOI 10.1016/j.metabol.2015.12.007
   Palella E, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17010300
   Pan L, 2020, AM J GASTROENTEROL, V115, P766, DOI 10.14309/ajg.0000000000000620
   Pitocco D, 2020, DIABETES RES CLIN PR, V163, DOI 10.1016/j.diabres.2020.108162
   POLONSKY WH, 1994, DIABETES CARE, V17, P1178, DOI 10.2337/diacare.17.10.1178
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Reinhold D, 2014, LANCET INFECT DIS, V14, P100, DOI 10.1016/S1473-3099(13)70696-0
   Rohrborn D, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00386
   Roman Lay Alejandra Andrea, 2020, Curr Gerontol Geriatr Res, V2020, P7816785, DOI 10.1155/2020/7816785
   Romani-Perez M, 2015, ENDOCRINOLOGY, V156, P3559, DOI 10.1210/en.2014-1685
   Rosenstock J, 2015, DIABETES CARE, V38, P1638, DOI 10.2337/dc15-1380
   Seong JM, 2019, BRIT J CLIN PHARMACO, V85, P1719, DOI 10.1111/bcp.13955
   Soriano A, 2002, J INFECT DIS, V186, P922, DOI 10.1086/343741
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Sriram K, 2020, BRIT J PHARMACOL, V177, P4825, DOI 10.1111/bph.15082
   Steven S, 2015, BASIC RES CARDIOL, V110, DOI 10.1007/s00395-015-0465-x
   Sun YH, 2017, MOL MED REP, V16, P929, DOI 10.3892/mmr.2017.6618
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Vedantham S, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7100181
   Wang Katherine M, 2020, Kidney Med, V2, P218, DOI 10.1016/j.xkme.2019.12.006
   Widlansky ME, 2017, VASC MED, V22, P189, DOI 10.1177/1358863X16681486
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang WJ, 2016, DIABETES-METAB RES, V32, P391, DOI 10.1002/dmrr.2723
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 73
TC 7
Z9 7
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD MAY
PY 2020
VL 17
IS 10
AR 3664
DI 10.3390/ijerph17103664
PG 12
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA LW7CK
UT WOS:000539300900321
PM 32456064
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Brown, RE
   Wolf, DA
   Hunter, RL
   Zhao, BH
   Buja, LM
AF Brown, Robert E.
   Wolf, Dwayne A.
   Hunter, Robert L.
   Zhao, Bihong
   Buja, L. Maximilian
TI Morphoproteomics and Etiopathogenic Features of Pulmonary COVID-19 with
   Therapeutic Implications: A Case Study
SO ANNALS OF CLINICAL AND LABORATORY SCIENCE
LA English
DT Article
DE morphoproteomics; pulmonary COVID-19
ID ACTIVATION
AB Objective. The COVID-19 pandemic has challenged the world economically and medically. Understanding and defining the biology of this specific coronavirus infection may lead to targeted therapies to lessen its virulence and expand the host resistance. This study's objective was to apply morphoproteomics to pulmonary lung sections from a forensic autopsy of an untreated COVID-19 victim, so that we may better define its biology from the perspective of its interaction with the host and provide options for therapeutic targets. Design. Morphoproteomic analysis from a case study of this COVID-19 pulmonary infection included immunohistochemical probes to detect phosphorylated p-STAT3 (Tyr 705), as part of the interleukin (IL)-6 pathway; cyclo-oxygenase (COX)-2, CD8+ cytotoxic lymphocytes, Programmed Death (PD)-1 receptor+ lymphoid cells, CD56+ NK lymphoid cells, CD163+ (M2 polarized monocytes/macrophages), and programmed death-ligand 1 (PD-L1) expression as part of the host response to interaction with the COVID-19 virus. Results. Representative sections of the COVID-19 victim's lung showed: nuclear expression of p-STAT3 (Tyr 705) in many of the alveolar pneumocytes and in occasional endothelial cells; COX-2 expression in the alveolar pneumocytes; a relative paucity of CD8+ cytotoxic lymphocytes; absence of CD56+ NK lymphoid cells; abundance of intra-alveolar and alveolar interstitial CD163+ macrophages/ monocytes; PD-L1 expression on occasional macrophages, focally on collections of alveolar pneumocytes, and on cells in the alveolar interstitium; and rare PD-1+ lymphocytes in similar regions as CD8+ lymphocytes. Conclusion. Morphoproteomics and microanatomical features coincide with the etiopathogenic features of pulmonary coronavirus infection and the host response. This suggests that a targeted therapy could address the biology of COVID-19 pneumonia, enhance the host immune response and prevent its progression to a life-threatening, ventilator-dependent clinical situation.
C1 [Brown, Robert E.; Hunter, Robert L.; Zhao, Bihong; Buja, L. Maximilian] UTHlth McGovern Med Sch, Dept Pathol & Lab Med, 6431 Fannin St,MSB 2-292, Houston, TX 77030 USA.
   [Wolf, Dwayne A.] Harris Co Inst Forens Sci Houston, Houston, TX USA.
RP Brown, RE (corresponding author), UTHlth McGovern Med Sch, Dept Pathol & Lab Med, 6431 Fannin St,MSB 2-292, Houston, TX 77030 USA.
EM robert.brown@uth.tmc.edu
CR Ahmed F, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040374
   Amici C, 2006, ANTIVIR THER, V11, P1021
   Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   Bichsel CA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09928-1
   Brown RE, 2005, EXPERT REV PROTEOMIC, V2, P337, DOI 10.1586/14789450.2.3.337
   Brown RE, 2020, ANN CLIN LAB SCI, V50, P287
   Brown RE, 2009, ARCH PATHOL LAB MED, V133, P568, DOI 10.1043/1543-2165-133.4.568
   Cha JH, 2018, MOL CELL, V71, P606, DOI 10.1016/j.molcel.2018.07.030
   Chen X, 2020, CLIN INFECT DIS
   Chou JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099432
   CRESTANI B, 1994, J CLIN INVEST, V94, P731, DOI 10.1172/JCI117392
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Duluc D, 2007, BLOOD, V110, P4319, DOI 10.1182/blood-2007-02-072587
   GREIN J., 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2007016, DOI 10.1056/NEJMOA200701]
   Haitsma Jack J, 2004, Curr Opin Crit Care, V10, P18, DOI 10.1097/00075198-200402000-00004
   Incio J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141392
   Jaitly V, 2019, ANN CLIN LAB SCI, V49, P666
   Liu XD, 2007, BIOCHEM BIOPH RES CO, V353, P121, DOI 10.1016/j.bbrc.2006.11.147
   Matsui K, 2000, ARCH PATHOL LAB MED, V124, P1642
   Mishra AK, 2019, LEUKEMIA, V33, P2695, DOI 10.1038/s41375-019-0470-4
   Morawska L, 2020, ENVIRON INT, V139, DOI 10.1016/j.envint.2020.105730
   Park A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01859
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429
   Zegeye MM, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0268-4
   Zhang H, 2020, INTENS CARE MED, V3, P1, DOI DOI 10.1016/S0140-6736(20)30627-9
   Zhang Z, 2020, J IMMUNOL, V204, P2575, DOI 10.4049/jimmunol.1901213
NR 27
TC 2
Z9 2
U1 0
U2 0
PU ASSOC CLINICAL SCIENTISTS
PI MIDDLEBURY
PA PO BOX 1287, MIDDLEBURY, VT 05753 USA
SN 0091-7370
EI 1550-8080
J9 ANN CLIN LAB SCI
JI Ann. Clin. Lab. Sci.
PD MAY-JUN
PY 2020
VL 50
IS 3
BP 308
EP 313
PG 6
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA MD1ZS
UT WOS:000543773900003
PM 32581017
DA 2021-01-01
ER

PT J
AU Colaneri, M
   Bogliolo, L
   Valsecchi, P
   Sacchi, P
   Zuccaro, V
   Brandolino, F
   Montecucco, C
   Mojoli, F
   Giusti, EM
   Bruno, R
AF Colaneri, Marta
   Bogliolo, Laura
   Valsecchi, Pietro
   Sacchi, Paolo
   Zuccaro, Valentina
   Brandolino, Fabio
   Montecucco, Carlomaurizio
   Mojoli, Francesco
   Giusti, Emanuele Maria
   Bruno, Raffaele
CA COVID IRCCS San Matteo Pavia Task
TI Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary
   Results from SMAtteo COvid19 REgistry (SMACORE)
SO MICROORGANISMS
LA English
DT Article
DE tocilizumab; off label therapy; propensity score matching; COVID-19
   pneumonia; ICU; mortality rate
ID CYTOKINE RELEASE SYNDROME; RHEUMATOID-ARTHRITIS; INTERLEUKIN-6;
   PNEUMONIA
AB Objective: This study aimed to assess the role of Tocilizumab therapy (TCZ) in terms of ICU admission and mortality rate of critically ill patients with severe COVID-19 pneumonia. Design: Patients with COVID-19 pneumonia were prospectively enrolled in SMAtteo COvid19 REgistry (SMACORE). A retrospective analysis of patients treated with TCZ matched using propensity score to patients treated with Standard Of Care (SOC) was conducted. Setting: The study was conducted at IRCCS Policlinico San Matteo Hospital, Pavia, Italy, from March 14, 2020 to March 27, 2020. Participants: Patients with a confirmed diagnosis of COVID-19 hospitalized in our institution at the time of TCZ availability. Interventions: TCZ was administered to 21 patients. The first administration was 8 mg/kg (up to a maximum 800 mg per dose) of Tocilizumab intravenously, repeated after 12 h if no side effects were reported after the first dose. Main Outcomes and Measures: ICU admission and 7-day mortality rate. Secondary outcomes included clinical and laboratory data. Results: There were 112 patients evaluated (82 were male and 30 were female, with a median age of 63.55 years). Using propensity scores, the 21 patients who received TCZ were matched to 21 patients who received SOC (a combination of hydroxychloroquine, azithromycin and prophylactic dose of low weight heparin). No adverse event was detected following TCZ administration. This study found that treatment with TCZ did not significantly affect ICU admission (OR 0.11; 95% CI between 0.00 and 3.38; p = 0.22) or 7-day mortality rate (OR 0.78; 95% CI between 0.06 and 9.34; p = 0.84) when compared with SOC. Analysis of laboratory measures showed significant interactions between time and treatment regarding C-Reactive Protein (CRP), alanine aminotransferase (ALT), platelets and international normalized ratio (INR) levels. Variation in lymphocytes count was observed over time, irrespective of treatment. Conclusions: TCZ administration did not reduce ICU admission or mortality rate in a cohort of 21 patients. Additional data are needed to understand the effect(s) of TCZ in treating patients diagnosed with COVID-19.
C1 [Colaneri, Marta; Valsecchi, Pietro; Sacchi, Paolo; Zuccaro, Valentina; Bruno, Raffaele] Fdn IRCCS Policlin San Matteo, Div Infect Dis 1, I-27100 Pavia, Italy.
   [Bogliolo, Laura; Montecucco, Carlomaurizio] IRCCS Policlin San Matteo Fdn, Div Rheumatol, I-27100 Pavia, Italy.
   [Brandolino, Fabio; Montecucco, Carlomaurizio] Univ Pavia, IRCCS Policlin San Matteo Fdn, Div Rheumatol, I-27100 Pavia, Italy.
   [Mojoli, Francesco; Bruno, Raffaele] Univ Pavia, Dept Clin Surg Diagnost & Paediat Sci, I-27100 Pavia, Italy.
   [Mojoli, Francesco] Fdn IRCCS Policlin S Matteo, Emergency Dept, Anesthesia & Intens Care, I-27100 Pavia, Italy.
   [Mojoli, Francesco] Fdn IRCCS Policlin San Matteo, Anesthesia Intens Care & Pain Therapy, I-27100 Pavia, Italy.
   [Giusti, Emanuele Maria] Catholic Univ Milan, Dept Psychol, I-20123 Milan, Italy.
   [Giusti, Emanuele Maria] San Giuseppe Hosp, Psychol Res Lab, Ist Auxol Italiano IRCCS, I-28824 Verbania, Italy.
RP Bruno, R (corresponding author), Fdn IRCCS Policlin San Matteo, Div Infect Dis 1, I-27100 Pavia, Italy.; Bruno, R (corresponding author), Univ Pavia, Dept Clin Surg Diagnost & Paediat Sci, I-27100 Pavia, Italy.
EM marta.colaneri01@universitadipavia.it; l.bogliolo@smatteo.pv.it;
   pietro.valsecchi01@universitadipavia.it; p.sacchi@smatteo.pv.it;
   v.zuccaro@smatteo.pv.it; fabio.brandolino01@universitadipavia.it;
   carlomaurizio.montecucco@unipv.it; francesco.mojoli@unipv.it;
   e.giusti@auxologico.it; raffaele.bruno@unipv.it
RI Gaiarsa, Stefano/AAC-4152-2019; Giusti, Emanuele Maria/AAC-1351-2019;
   Piralla, Antonio/K-4756-2018; Bruno, Raffaele/L-3530-2018
OI Gaiarsa, Stefano/0000-0002-5847-6568; Giusti, Emanuele
   Maria/0000-0001-5767-8785; Piralla, Antonio/0000-0002-6062-2579; Bruno,
   Raffaele/0000-0002-0235-9207
CR Annane D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002243.pub3
   Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Coomes E.A.H.H., 2020, INT 6 COVID 19 SYST
   Fujiwara H, 2009, MOD RHEUMATOL, V19, P64, DOI 10.1007/s10165-008-0111-7
   Genovese MC, 2017, ARTHRITIS RHEUMATOL, V69, P1751, DOI 10.1002/art.40176
   Ghebreyesus T.A., 2020, WHO DIRECTOR GEN OP
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Milbrandt EB, 2009, MOL MED, V15, P438, DOI 10.2119/molmed.2009.00091
   Park WY, 2001, AM J RESP CRIT CARE, V164, P1896, DOI 10.1164/ajrccm.164.10.2104013
   Pishgar F., MATCHTHEM MATCHING W
   Qu R, 2020, J MED VIROL, V92, P1533, DOI 10.1002/jmv.25767
   Rodrigues JC, 2017, CURR TREATM OPT RHEU, V3, P244, DOI DOI 10.1007/S40674-017-0081-Z]
   Rosado FGN, 2013, AM J CLIN PATHOL, V139, P713, DOI 10.1309/AJCP4ZDKJ4ICOUAT
   Rubin D. B., 2004, MULTIPLE IMPUTATION, V81
   SAYBURN A, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1206
   Schoels MM, 2013, ANN RHEUM DIS, V72, P583, DOI 10.1136/annrheumdis-2012-202470
   Scott LJ, 2017, DRUGS, V77, P1029, DOI 10.1007/s40265-017-0752-y
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Ulhaq ZS, 2020, MED MALADIES INFECT, V50, P382, DOI 10.1016/j.medmal.2020.04.002
   van Buuren S, 2011, J STAT SOFTW, V45, P1
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang ZG, 2018, BIOMARK RES, V6, DOI 10.1186/s40364-018-0116-0
   Wickham H., 2017, TIDYVERSE EASILY INS
   Wilson K.C., COVID19 INTERIM GUID
   World Health Organization, 2020, COR COVID 19 EV THEY
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yakoub-Agha I, 2019, B CANCER, V106, pS102, DOI 10.1016/j.bulcan.2018.12.001
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 39
TC 49
Z9 51
U1 6
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-2607
J9 MICROORGANISMS
JI Microorganisms
PD MAY
PY 2020
VL 8
IS 5
AR 695
DI 10.3390/microorganisms8050695
PG 12
WC Microbiology
SC Microbiology
GA LY0NZ
UT WOS:000540222300076
PM 32397399
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Glinsky, GV
AF Glinsky, Gennadi, V
TI Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin
   D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for
   Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided
   Tracing of SARS-CoV-2 Targets in Human Cells
SO BIOMEDICINES
LA English
DT Article
DE COVID-19; SARS-CoV-2 coronavirus; genomics; mitigation approaches; drugs
   and medicinal substance repurposing; vitamin D; quercetin; luteolin;
   eriodictyol; estradiol
ID RESPIRATORY SYNDROME CORONAVIRUS; D DEFICIENCY; MORTALITY
AB Genes required for SARS-CoV-2 entry into human cells, ACE2 and FURIN, were employed as baits to build genomic-guided molecular maps of upstream regulatory elements, their expression and functions in the human body, and pathophysiologically relevant cell types. Repressors and activators of the ACE2 and FURIN genes were identified based on the analyses of gene silencing and overexpression experiments as well as relevant transgenic mouse models. Panels of repressors (VDR; GATA5; SFTPC; HIF1a) and activators (HMGA2; INSIG1; RUNX1; HNF4a; JNK1/c-FOS) were then employed to identify existing drugs manifesting in their effects on gene expression signatures of potential coronavirus infection mitigation agents. Using this strategy, vitamin D and quercetin have been identified as putative 2019 coronavirus disease (COVID-19) mitigation agents. Quercetin has been identified as one of top-scoring candidate therapeutics in the supercomputer SUMMIT drug-docking screen and Gene Set Enrichment Analyses (GSEA) of expression profiling experiments (EPEs), indicating that highly structurally similar quercetin, luteolin, and eriodictyol could serve as scaffolds for the development of efficient inhibitors of SARS-CoV-2 infection. In agreement with this notion, quercetin alters the expression of 98 of 332 (30%) of human genes encoding protein targets of SARS-CoV-2, thus potentially interfering with functions of 23 of 27 (85%) of the SARS-CoV-2 viral proteins in human cells. Similarly, Vitamin D may interfere with functions of 19 of 27 (70%) of the SARS-CoV-2 proteins by altering expression of 84 of 332 (25%) of human genes encoding protein targets of SARS-CoV-2. Considering the potential effects of both quercetin and vitamin D, the inference could be made that functions of 25 of 27 (93%) of SARS-CoV-2 proteins in human cells may be altered. GSEA and EPEs identify multiple drugs, smoking, and many disease conditions that appear to act as putative coronavirus infection-promoting agents. Discordant patterns of testosterone versus estradiol impacts on SARS-CoV-2 targets suggest a plausible molecular explanation of the apparently higher male mortality during the coronavirus pandemic. Estradiol, in contrast with testosterone, affects the expression of the majority of human genes (203 of 332; 61%) encoding SARS-CoV-2 targets, thus potentially interfering with functions of 26 of 27 SARS-CoV-2 viral proteins. A hypothetical tripartite combination consisting of quercetin/vitamin D/estradiol may affect expression of 244 of 332 (73%) human genes encoding SARS-CoV-2 targets. Of major concern is the ACE2 and FURIN expression in many human cells and tissues, including immune cells, suggesting that SARS-CoV-2 may infect a broad range of cellular targets in the human body. Infection of immune cells may cause immunosuppression, long-term persistence of the virus, and spread of the virus to secondary targets. Present analyses and numerous observational studies indicate that age-associated vitamin D deficiency may contribute to the high mortality of older adults and the elderly. Immediate availability for targeted experimental and clinical interrogations of potential COVID-19 pandemic mitigation agents, namely vitamin D and quercetin, as well as of the highly selective (Ki, 600 pm) intrinsically specific FURIN inhibitor (a1-antitrypsin Portland (a1-PDX), is considered an encouraging factor.
   Observations reported in this contribution are intended to facilitate follow-up targeted experimental studies and, if warranted, randomized clinical trials to identify and validate therapeutically viable interventions to combat the COVID-19 pandemic. Specifically, gene expression profiles of vitamin D and quercetin activities and their established safety records as over-the-counter medicinal substances strongly argue that they may represent viable candidates for further considerations of their potential utility as COVID-19 pandemic mitigation agents. In line with the results of present analyses, a randomized interventional clinical trial evaluating effects of estradiol on severity of the coronavirus infection in COVID19+ and presumptive COVID19+ patients and two interventional randomized clinical trials evaluating effects of vitamin D on prevention and treatment of COVID-19 were listed on the ClinicalTrials.gov website.
C1 [Glinsky, Gennadi, V] Univ Calif San Diego, Inst Engn Med, 9500 Gilman Dr MC 0435, La Jolla, CA 92093 USA.
RP Glinsky, GV (corresponding author), Univ Calif San Diego, Inst Engn Med, 9500 Gilman Dr MC 0435, La Jolla, CA 92093 USA.
EM gglinskii@ucsd.edu
FU OncoScar, Inc.
FX This work was made possible by the open public access policies of major
   grant funding agencies and international genomic databases and the
   willingness of many investigators worldwide to share their primary
   research data. This work was supported in part by the OncoScar, Inc.
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Autier P, 2007, ARCH INTERN MED, V167, P1730, DOI 10.1001/archinte.167.16.1730
   Brielle ES, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050497
   Calder PC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041181
   Caristia S, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102384
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Daneshkhan A., 2020, POSSIBLE ROLE VITAMI, DOI [10.1101/2020.04.08.20, DOI 10.1101/2020.04.08.20]
   Fabbri A, 2020, EUR REV MED PHARMACO, V24, P4038
   Ginde AA, 2009, J AM GERIATR SOC, V57, P1595, DOI 10.1111/j.1532-5415.2009.02359.x
   Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604
   Glinsky G.V., 2020, BIORXIV, P848762, DOI [10.1101/848762, DOI 10.1101/848762]
   Glinsky G.V., 2017, BIORXIV, DOI [10.1101/022913, DOI 10.1101/022913]
   Glinsky G, 2019, STEM CELL RES, V37, DOI 10.1016/j.scr.2019.101456
   Glinsky G, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00667
   Glinsky GV, 2020, DNA CELL BIOL, V39, P126, DOI 10.1089/dna.2019.4988
   Glinsky GV, 2018, CHROMOSOME RES, V26, P61, DOI 10.1007/s10577-018-9571-6
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Guffanti G, 2018, MOL BIOL EVOL, V35, P2435, DOI 10.1093/molbev/msy143
   Heath AK, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16030383
   Helming L, 2005, BLOOD, V106, P4351, DOI 10.1182/blood-2005-03-1029
   Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293
   Kennel KA, 2010, MAYO CLIN PROC, V85, P752, DOI 10.4065/mcp.2010.0138
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Lachmann A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03751-6
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Neme A, 2017, BBA-GENE REGUL MECH, V1860, P952, DOI 10.1016/j.bbagrm.2017.07.002
   Paniz-Mondolfi A, 2020, J MED VIROL, V92, P699, DOI 10.1002/jmv.25915
   Reghunathan R, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-2
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sardu C, 2020, IS COVID 19 ENDOTHEL, P1, DOI [10.20944/preprints202004.0204.v1, DOI 10.20944/PREPRINTS202004.0204.V1, 10.20944/PREPRINTS202004.0204.V1]
   Seuter S, 2016, NUCLEIC ACIDS RES, V44, P4090, DOI 10.1093/nar/gkv1519
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v3, DOI 10.26434/CHEMRXIV.11871402.V3]
   Tavazoie S, 1999, NAT GENET, V22, P281
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wambier CG, 2020, J AM ACAD DERMATOL, V83, P308, DOI 10.1016/j.jaad.2020.04.032
   Wang X., 2020, TRANSCRIPTIONAL INHI, DOI [10.20944/preprints202003.0360.v1., DOI 10.20944/PREPRINTS202003.0360.V1, 10.20944/preprints202003.0360.v1]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yi L, 2004, J VIROL, V78, P11334, DOI 10.1128/JVI.78.20.11334-11339.2004
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 45
TC 16
Z9 17
U1 9
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD MAY
PY 2020
VL 8
IS 5
AR 129
DI 10.3390/biomedicines8050129
PG 26
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA LY9IU
UT WOS:000540842200006
PM 32455629
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sanchez-Alvarez, JE
   Fontan, MP
   Martin, CJ
   Pelicano, MB
   Reina, CJC
   Prieto, AMS
   Melilli, E
   Barrios, MC
   Heras, MM
   Pino, MDDY
AF Emilio Sanchez-Alvarez, J.
   Perez Fontan, Miguel
   Jimenez Martin, Carlos
   Blasco Pelicano, Miquel
   Cabezas Reina, Carlos Jesus
   Sevillano Prieto, Angel M.
   Melilli, Edoardo
   Crespo Barrios, Marta
   Macia Heras, Manuel
   del Pino y Pino, Maria Dolores
TI SARS-CoV-2 infection in patients on renal replacement therapy. Report of
   the COVID-19 Registry of the Spanish Society of Nephrology (SEN)
SO NEFROLOGIA
LA Spanish
DT Article
DE SARS-CoV-2; Registry; Renal replacement therapies; Spain; Spanish
   Society of Nephrology
AB Introduction: The recent appearance of the SARS-CoV-2 coronavirus pandemic has had a significant impact on the general population. Patients on renal replacement therapy (RRT) have not been unaware of this situation and due to their characteristics they are especially vulnerable. We present the results of the analysis of the COVID-19 Registry of the Spanish Society of Nephrology.
   Material and methods: The Registry began operating on March 18th, 2020. It collects epidemiological variables, contagion and diagnosis data, signs and symptoms, treatments and outcomes. It is an online registry. Patients were diagnosed with SARS-CoV-2 infection based on the results of the PCR of the virus, carried out both in patients who had manifested compatible symptoms or had suspicious signs, as well as in those who had undergone screening after some contact acquainted with another patient.
   Results: As of April 11, the Registry had data on 868 patients, from all the Autonomous Communities. The most represented form of RRT is in-center hemodialysis (ICH) followed by transplant patients. Symptoms are similar to the general population. A very high percentage (85%) required hospital admission, 8% in intensive care units. The most used treatments were hydroxychloroquine, lopinavir-ritonavir, and steroids. Mortality is high and reaches 23%; deceased patients were more frequently on ICH, developed pneumonia more frequently, and received less frequently lopinavir-ritonavir and steroids. Age and pneumonia were independently associated with the risk of death.
   Conclusions: SARS-CoV-2 infection already affects a significant number of Spanish patients on RRT, mainly those on ICH, hospitalization rates are very high and mortality is high; age and the development of pneumonia are factors associated with mortality. (C) 2020 Sociedad Espanola de Nefrologia. Published by Elsevier Espana, S.L.U.
C1 [Emilio Sanchez-Alvarez, J.] Hosp Univ Cabuenes, Gijon, Asturias, Spain.
   [Perez Fontan, Miguel] Complexo Hosp Univ A Coruna, Serv Nefrol, La Coruna, Spain.
   [Jimenez Martin, Carlos] Hosp Univ La Paz, Serv Nefrol, Madrid, Spain.
   [Blasco Pelicano, Miquel] Hosp Clin Barcelona, Serv Nefrol, Barcelona, Spain.
   [Cabezas Reina, Carlos Jesus] Complejo Hosp Toledo, Serv Nefrol, Toledo, Spain.
   [Sevillano Prieto, Angel M.] Hosp Univ 12 Octubre, Serv Nefrol, Madrid, Spain.
   [Melilli, Edoardo] Hosp Univ Bellvitge, Serv Nefrol, Barcelona, Spain.
   [Crespo Barrios, Marta] Consorci Parc Salut Mar Barcelona, Serv Nefrol, Barcelona, Spain.
   [Macia Heras, Manuel] Hosp Univ Nuestra Senora de Candelaria, Serv Nefrol, Santa Cruz De Tenerife, Canarias, Spain.
   [del Pino y Pino, Maria Dolores] Complejo Hosp Torrecardenas, Serv Nefrol, Almeria, Spain.
RP Sanchez-Alvarez, JE (corresponding author), Hosp Univ Cabuenes, Gijon, Asturias, Spain.
EM jesastur@hotmail.com
RI Perez-Fontan, Miguel/ABG-4064-2020
CR [Anonymous], 2019, INFORME ANUAL REGIST
   Ferrey AJ, 2020, AM J NEPHROL, V51, P337, DOI 10.1159/000507417
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Henry BM, 2020, INT UROL NEPHROL, V52, P1193, DOI 10.1007/s11255-020-02451-9
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Liu Y, 2020, ANTIHYPERTENSIVE ANG, DOI [10.1101/2020.03.20.20039586, DOI 10.1101/2020.03.20.20039586]
   MEHTA R, 2020, CRIT CARE MED S11, V48
   Ministerio de Sanidad, SIT COVID 19 ESP
   Organizacion Mundial de la Salud, 2019, 84 ORG MUND SAL
   Paton NI, 2011, LANCET INFECT DIS, V11, P677, DOI 10.1016/S1473-3099(11)70065-2
   Sparks MA, 2020, NEPHJC
   Vaziri ND, 2012, J RENAL NUTR, V22, P149, DOI 10.1053/j.jrn.2011.10.020
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 18
TC 17
Z9 17
U1 1
U2 1
PU SOC ESPANOLA NEFROLOGIA DR RAFAEL MATESANZ
PI SANTANDER
PA C/PASAJE DE PENA 2, 3-C, SANTANDER, SPAIN
SN 0211-6995
EI 1989-2284
J9 NEFROLOGIA
JI Nefrologia
PD MAY-JUN
PY 2020
VL 40
IS 3
BP 272
EP 278
DI 10.1016/j.nefro.2020.04.002
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA MA4JQ
UT WOS:000541881900008
PM 32389518
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Koyama, T
   Weeraratne, D
   Snowdon, JL
   Parida, L
AF Koyama, Takahiko
   Weeraratne, Dilhan
   Snowdon, Jane L.
   Parida, Laxmi
TI Emergence of Drift Variants That May Affect COVID-19 Vaccine Development
   and Antibody Treatment
SO PATHOGENS
LA English
DT Article
DE SARS-CoV-2; COVID-19; genomic drift; variant; immune escape; vaccine;
   antibody; spike protein; convalescent plasma
ID SEQUENCE
AB New coronavirus (SARS-CoV-2) treatments and vaccines are under development to combat COVID-19. Several approaches are being used by scientists for investigation, including (1) various small molecule approaches targeting RNA polymerase, 3C-like protease, and RNA endonuclease; and (2) exploration of antibodies obtained from convalescent plasma from patients who have recovered from COVID-19. The coronavirus genome is highly prone to mutations that lead to genetic drift and escape from immune recognition; thus, it is imperative that sub-strains with different mutations are also accounted for during vaccine development. As the disease has grown to become a pandemic, B-cell and T-cell epitopes predicted from SARS coronavirus have been reported. Using the epitope information along with variants of the virus, we have found several variants which might cause drifts. Among such variants, 23403A>G variant (p.D614G) in spike protein B-cell epitope is observed frequently in European countries, such as the Netherlands, Switzerland, and France, but seldom observed in China.
C1 [Koyama, Takahiko; Parida, Laxmi] IBM Corp, TJ Watson Res Ctr, Yorktown Hts, NY 10598 USA.
   [Weeraratne, Dilhan; Snowdon, Jane L.] IBM Corp, Ctr Artificial Intelligence Res & Evaluat, Cambridge, MA 02142 USA.
RP Koyama, T (corresponding author), IBM Corp, TJ Watson Res Ctr, Yorktown Hts, NY 10598 USA.
EM tkoyama@us.ibm.com
OI Koyama, Takahiko/0000-0003-1694-9061; Weeraratne,
   Dilhan/0000-0003-1399-3956; PARIDA, LAXMI/0000-0002-7872-5074
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Lynch M, 2016, NAT REV GENET, V17, P704, DOI 10.1038/nrg.2016.104
   NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Yao H., 2020, PATIENT DERIVED MUTA, DOI [10.1101/2020.04.14.20060160, DOI 10.1101/2020.04.14.20060160]
NR 11
TC 20
Z9 20
U1 3
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-0817
J9 PATHOGENS
JI Pathogens
PD MAY
PY 2020
VL 9
IS 5
AR 324
DI 10.3390/pathogens9050324
PG 7
WC Microbiology
SC Microbiology
GA LZ8AP
UT WOS:000541443700007
PM 32357545
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Neogi, U
   Hill, KJ
   Ambikan, AT
   Heng, X
   Quinn, TP
   Byrareddy, SN
   Sonnerborg, A
   Sarafianos, SG
   Singh, K
AF Neogi, Ujjwal
   Hill, Kyle J.
   Ambikan, Anoop T.
   Heng, Xiao
   Quinn, Thomas P.
   Byrareddy, Siddappa N.
   Soennerborg, Anders
   Sarafianos, Stefan G.
   Singh, Kamal
TI Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs
SO PATHOGENS
LA English
DT Article
DE coronavirus; SARS-CoV; MERS-CoV; SARS-CoV-2; COVID-19; RNA polymerase;
   nsp12
ID ACUTE RESPIRATORY SYNDROME; HEPATITIS-C VIRUS; MOUTH-DISEASE VIRUS;
   SYNDROME CORONAVIRUS; SARS-CORONAVIRUS; REPLICATION FIDELITY; CONFERS
   RESISTANCE; LETHAL MUTAGENESIS; CLINICAL-FEATURES; FAVIPIRAVIR T-705
AB Coronaviruses (CoVs) are positive-stranded RNA viruses that infect humans and animals. Infection by CoVs such as HCoV-229E, -NL63, -OC43 and -HKU1 leads to the common cold, short lasting rhinitis, cough, sore throat and fever. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and the newest SARS-CoV-2 (the causative agent of COVID-19) lead to severe and deadly diseases with mortality rates ranging between similar to 1 to 35% depending on factors such as age and pre-existing conditions. Despite continuous global health threats to humans, there are no approved vaccines or drugs targeting human CoVs, and the recent outbreak of COVID-19 emphasizes an urgent need for therapeutic interventions. Using computational and bioinformatics tools, here we present the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti- SARS-CoV-2 drugs targeting its main RNA polymerase, suggesting that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs. However, we note that it is also possible for SARS-CoV-2 to evolve and acquire drug resistance mutations against these nucleoside inhibitors.
C1 [Neogi, Ujjwal; Ambikan, Anoop T.; Singh, Kamal] Karolinska Inst, Div Clin Microbiol, Dept Lab Med, S-14186 Stockholm, Sweden.
   [Neogi, Ujjwal; Hill, Kyle J.; Soennerborg, Anders; Singh, Kamal] Univ Missouri, Dept Mol Microbiol & Immunol, Columbia, MO 65211 USA.
   [Hill, Kyle J.; Soennerborg, Anders; Singh, Kamal] Univ Missouri, Bond Life Sci Ctr, Columbia, MO 65211 USA.
   [Heng, Xiao; Quinn, Thomas P.] Univ Missouri, Dept Biochem, Columbia, MO 65211 USA.
   [Byrareddy, Siddappa N.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Soennerborg, Anders] Karolinska Inst, Div Infect Dis, Dept Med Huddinge, S-14186 Stockholm, Sweden.
   [Sarafianos, Stefan G.] Emory Univ, Sch Med, Dept Pediat, Biochem Pharmacol Lab, Atlanta, GA 30322 USA.
   [Singh, Kamal] Shift Pharmaceut, Overland Pk, KS 66211 USA.
RP Singh, K (corresponding author), Karolinska Inst, Div Clin Microbiol, Dept Lab Med, S-14186 Stockholm, Sweden.; Singh, K (corresponding author), Univ Missouri, Dept Mol Microbiol & Immunol, Columbia, MO 65211 USA.; Singh, K (corresponding author), Univ Missouri, Bond Life Sci Ctr, Columbia, MO 65211 USA.; Singh, K (corresponding author), Shift Pharmaceut, Overland Pk, KS 66211 USA.
EM ujjwal.neogi@ki.se; kjhy8c@mail.missouri.edu; anoop.ambikan@ki.se;
   hengx@missouri.edu; QuinnT@missouri.edu; sid.byrareddy@unmc.edu;
   Anders.sonnerborg@ki.se; stefanos.sarafianos@emory.edu;
   singhka@missouri.edu
OI Hill, Kyle/0000-0002-3855-9649; Singh, Kamalendra/0000-0001-6153-8929;
   Neogi, Ujjwal/0000-0002-0844-3338
FU Bond Life Science Center, University of Missouri; Swedish research
   CouncilSwedish Research Council [2017-01330, 2016-01675]; Karolinska
   InstitutetKarolinska Institutet; Stockholm County CouncilStockholm
   County Council [ALF 20160074];  [U54 AI150472]
FX K.S. and K.J.H. acknowledge funding from the Bond Life Science Center,
   University of Missouri, Early Concept Grant. U.N. acknowledge the
   funding from the Swedish research Council, Establishment Grant
   (2017-01330). S.G.S acknowledges U54 AI150472. The study was funded by
   the Swedish Research Council (2016-01675, AS), Karolinska Institutet,
   and the Stockholm County Council (ALF 20160074, AS).
CR Abdelnabi R, 2017, J VIROL, V91, DOI 10.1128/JVI.00487-17
   Adams MJ, 2012, ARCH VIROL, V157, P1411, DOI 10.1007/s00705-012-1299-6
   Adedeji AO, 2014, CURR OPIN VIROL, V8, P45, DOI 10.1016/j.coviro.2014.06.002
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Agudo R, 2008, J MOL BIOL, V382, P652, DOI 10.1016/j.jmb.2008.07.033
   Agudo R, 2009, FUTURE MED CHEM, V1, P529, DOI 10.4155/FMC.09.26
   Airaksinen A, 2003, VIROLOGY, V311, P339, DOI 10.1016/S0042-6822(03)00144-2
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Arias A, 2014, ELIFE, V3, DOI 10.7554/eLife.03679
   Arias A, 2008, J VIROL, V82, P12346, DOI 10.1128/JVI.01297-08
   Asahina Y, 2005, J HEPATOL, V43, P623, DOI 10.1016/j.jhep.2005.05.032
   Baranovich T, 2013, J VIROL, V87, P3741, DOI 10.1128/JVI.02346-12
   Beaucourt S, 2011, JOVE-J VIS EXP, DOI 10.3791/2953
   Bernini A, 2006, BIOCHEM BIOPH RES CO, V343, P1101, DOI 10.1016/j.bbrc.2006.03.069
   Bhardwaj K, 2006, J MOL BIOL, V361, P243, DOI 10.1016/j.jmb.2006.06.021
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Campagnola G, 2015, J VIROL, V89, P275, DOI 10.1128/JVI.01574-14
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chan JFW, 2012, J INFECTION, V65, P477, DOI 10.1016/j.jinf.2012.10.002
   Choi JH, 2018, J VET SCI, V19, P788, DOI 10.4142/jvs.2018.19.6.788
   Contreras AM, 2002, J VIROL, V76, P8505, DOI 10.1128/JVI.76.17.8505-8517.2002
   Crotty S, 2000, NAT MED, V6, P1375
   Crotty S, 2001, P NATL ACAD SCI USA, V98, P6895, DOI 10.1073/pnas.111085598
   Day CW, 2005, ANTIVIR RES, V67, P38, DOI 10.1016/j.antiviral.2005.04.002
   de Castro S, 2019, MOLECULES, V24, DOI 10.3390/molecules24132360
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   de la Higuera I, 2017, GENOME BIOL EVOL, V9, P1212, DOI 10.1093/gbe/evx075
   De Palma AM, 2008, EMERG INFECT DIS, V14, P545, DOI 10.3201/eid1404.070439
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Delang L, 2014, J ANTIMICROB CHEMOTH, V69, P2770, DOI 10.1093/jac/dku209
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Falzarano D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01686
   Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200
   Ferrer-Orta C, 2007, P NATL ACAD SCI USA, V104, P9463, DOI 10.1073/pnas.0700518104
   Ferrer-Orta C, 2010, J VIROL, V84, P6188, DOI 10.1128/JVI.02420-09
   Frieman M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028479
   Furuta Y, 2002, ANTIMICROB AGENTS CH, V46, P977, DOI 10.1128/AAC.46.4.977-981.2002
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gao Y., 2020, STRUCTURE RNA DEPEND, DOI [10.1101/2020.03.16.993386, DOI 10.1101/2020.03.16.993386]
   Gong P, 2010, P NATL ACAD SCI USA, V107, P22505, DOI 10.1073/pnas.1007626107
   Gorbalenya AE, 2004, J VIROL, V78, P7863, DOI 10.1128/JVI.78.15.7863-7866.2004
   Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Herold J, 1996, METHOD ENZYMOL, V275, P68
   Hsu LY, 2003, EMERG INFECT DIS, V9, P713
   Kempf BJ, 2016, J VIROL, V90, P8410, DOI 10.1128/JVI.00078-16
   Khalid M, 2015, ANTIVIR THER, V20, P87, DOI 10.3851/IMP2792
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kumthip K, 2012, J VIROL, V86, P8581, DOI 10.1128/JVI.00533-12
   Larsson A, 2014, BIOINFORMATICS, V30, P3276, DOI 10.1093/bioinformatics/btu531
   Lau SKP, 2012, J VIROL, V86, P5481, DOI 10.1128/JVI.06927-11
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lehmann KC, 2015, NUCLEIC ACIDS RES, V43, P8416, DOI 10.1093/nar/gkv838
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Martin P, 2008, J GASTROEN HEPATOL, V23, P844, DOI 10.1111/j.1440-1746.2008.05398.x
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Mosley RT, 2012, J VIROL, V86, P6503, DOI 10.1128/JVI.00386-12
   Naesens L, 2013, MOL PHARMACOL, V84, P615, DOI 10.1124/mol.113.087247
   Navas-Martin S, 2004, J NEUROVIROL, V10, P75, DOI 10.1080/13550280490280292
   Oestereich L, 2016, J INFECT DIS, V213, P934, DOI 10.1093/infdis/jiv522
   Oestereich L, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002804
   Oestereich L, 2014, ANTIVIR RES, V105, P17, DOI 10.1016/j.antiviral.2014.02.014
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Pariente N, 2005, VIRUS RES, V107, P183, DOI 10.1016/j.virusres.2004.11.008
   Pariente N, 2001, J VIROL, V75, P9723, DOI 10.1128/JVI.75.20.9723-9730.2001
   Peersen OB, 2017, VIRUS RES, V234, P4, DOI 10.1016/j.virusres.2017.01.026
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pfeiffer JK, 2003, P NATL ACAD SCI USA, V100, P7289, DOI 10.1073/pnas.1232294100
   Pfeiffer JK, 2005, J VIROL, V79, P2346, DOI 10.1128/JVI.79.4.2346-2355.2005
   Pfeiffer JK, 2005, PLOS PATHOG, V1, P102, DOI 10.1371/journal.ppat.0010011
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Putics A, 2005, J VIROL, V79, P12721, DOI 10.1128/JVI.79.20.12721-12731.2005
   Ricagno S, 2006, P NATL ACAD SCI USA, V103, P11892, DOI 10.1073/pnas.0601708103
   Rosenberg AJ, 2019, ONCOLOGIST, V24, P1039, DOI 10.1634/theoncologist.2019-0330
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sadeghipour S, 2013, J VIROL, V87, P1759, DOI 10.1128/JVI.02139-12
   Sangawa H, 2013, ANTIMICROB AGENTS CH, V57, P5202, DOI 10.1128/AAC.00649-13
   Sawicki SG, 2007, J VIROL, V81, P20, DOI 10.1128/JVI.01358-06
   Sexton NR, 2016, J VIROL, V90, P7415, DOI 10.1128/JVI.00080-16
   Shao RX, 2010, J VIROL, V84, P6060, DOI 10.1128/JVI.02484-09
   Sierra M, 2007, J VIROL, V81, P2012, DOI 10.1128/JVI.01606-06
   Sierra S, 2000, J VIROL, V74, P8316, DOI 10.1128/JVI.74.18.8316-8323.2000
   Singh K, 1998, TRENDS BIOCHEM SCI, V23, P277, DOI 10.1016/S0968-0004(98)01250-X
   Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003565
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Velthuis AJWT, 2010, NUCLEIC ACIDS RES, V38, P203, DOI 10.1093/nar/gkp904
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WECKBECKER G, 1991, PHARMACOL THERAPEUT, V50, P367, DOI 10.1016/0163-7258(91)90051-M
   World Health Organization, 2019, MERS SIT UPD
   World Health Organization, 2020, COR DIS 2019 COV 19
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Young KC, 2003, HEPATOLOGY, V38, P869, DOI 10.1053/jhep.2003.50445
   Ziebuhr J, 2004, CURR OPIN MICROBIOL, V7, P412, DOI 10.1016/j.mib.2004.06.007
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 108
TC 4
Z9 4
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-0817
J9 PATHOGENS
JI Pathogens
PD MAY
PY 2020
VL 9
IS 5
AR 320
DI 10.3390/pathogens9050320
PG 16
WC Microbiology
SC Microbiology
GA LZ8AP
UT WOS:000541443700003
PM 32357471
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sharma, A
AF Sharma, Anuj
TI Chloroquine paradox may cause more damage than help fight COVID-19
SO MICROBES AND INFECTION
LA English
DT Letter
ID HERPES-ZOSTER; IN-VITRO; REPLICATION; INFECTION; HYDROXYCHLOROQUINE;
   INTERFERON; VIRUS
AB Novel coronavirus disease 2019 (COVID-19) pandemic is the most recent health care crisis without specific prophylactic or therapeutic drugs. Antimalarial drug chloroquine (CHL) and its safer derivative hydroxychloroquine (HCHL) have been proposed to be repurposed to treat SARS coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19. CHL/HCHL have anti-inflammatory activity and are used to treat rheumatoid arthritis, osteoarthritis and lupus. Although, CHL/HCHL have an anti-viral activity against several viruses in cell-cultures, the anti-viral activity in-vivo is questionable. Repurposing of CHL/HCHL to treat SARS-CoV-2 infection is appealing. However, there is empirical evidence from animal studies with other viruses suggesting that CHL/HCHL may have an untoward paradoxical effect. One thus cannot exclude the possibility that CHL may increase the severity of the disease and prove deleterious both for the patients and public health efforts to contain the highly contagious and explosive spread of SARS-CoV-2. (c) 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
C1 [Sharma, Anuj] Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA.
RP Sharma, A (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA.
CR Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Anjum MU, 2020, TRAVEL MED INFECT DI
   Barnard Dale L., 2006, Antiviral Chemistry & Chemotherapy, V17, P275
   Borges MC, 2013, MEM I OSWALDO CRUZ, V108, P596, DOI 10.1590/S0074-02762013000500010
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.200407583., DOI 10.1101/2020.03.22.200407583]
   COOK IF, 1985, J TROP MED HYG, V88, P261
   da Cunha GF, 2013, CLINICS, V68, P621, DOI 10.6061/clinics/2013(05)07
   De Lamballerie X, 2008, VECTOR-BORNE ZOONOT, V8, P837, DOI 10.1089/vbz.2008.0049
   Dowall SD, 2015, J GEN VIROL, V96, P3484, DOI 10.1099/jgv.0.000309
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Guastalegname M, 2020, CLIN INFECT DIS
   Jean MJM, 2020, MED MAL INFECT
   Keyaerts E, 2009, ANTIMICROB AGENTS CH, V53, P3416, DOI 10.1128/AAC.01509-08
   MAHESHWARI RK, 1990, IMMUNOL LETT, V25, P53, DOI 10.1016/0165-2478(90)90091-4
   MAHESHWARI RK, 1991, J VIROL, V65, P992, DOI 10.1128/JVI.65.2.992-995.1991
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   Pallister J, 2009, J VIROL, V83, P11979, DOI 10.1128/JVI.01847-09
   Paton NI, 2011, LANCET INFECT DIS, V11, P677, DOI 10.1016/S1473-3099(11)70065-2
   PURI SK, 1988, J INTERFERON RES, V8, P201, DOI 10.1089/jir.1988.8.201
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Roques P, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050268
   Salo J., 2020, NIGERIA REPORTS POIS
   Seth P, 1999, AM J TROP MED HYG, V61, P180, DOI 10.4269/ajtmh.1999.61.180
   SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J
   Streicher F, 2019, TRENDS IMMUNOL, V40, P1134, DOI 10.1016/j.it.2019.10.009
   THORENS B, 1986, NATURE, V321, P618, DOI 10.1038/321618a0
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Tricou Vianney, 2010, PLoS Negl Trop Dis, V4, pe785, DOI 10.1371/journal.pntd.0000785
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Waldrop T, 2020, FEARING CORONAVIRUS
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
NR 33
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD MAY-JUN
PY 2020
VL 22
IS 4-5
BP 154
EP 156
DI 10.1016/j.micinf.2020.04.004
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA MB4ML
UT WOS:000542577500003
PM 32305500
OA Green Published
DA 2021-01-01
ER

PT J
AU Xu, P
   Huang, JP
   Fan, Z
   Huang, WD
   Qi, MH
   Lin, XW
   Song, WD
   Yi, L
AF Xu, Ping
   Huang, Jianping
   Fan, Zhao
   Huang, Wendi
   Qi, Minghua
   Lin, Xuwen
   Song, Weidong
   Yi, Li
TI Arbidol/IFN-a2b therapy for patients with corona virus disease 2019: a
   retrospective multicenter cohort study
SO MICROBES AND INFECTION
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; ARBIDOL HYDROCHLORIDE; POTENT
   INHIBITORS; IN-VITRO
C1 [Xu, Ping; Huang, Wendi; Qi, Minghua; Lin, Xuwen; Song, Weidong] Peking Univ, Shenzhen Hosp, Dept Resp & Crit Care Med, Shenzhen 518036, Guangdong, Peoples R China.
   [Huang, Jianping] Hubei Jianli People Hosp, Dept Infect Dis, Jingzhou 433300, Hubei, Peoples R China.
   [Fan, Zhao] Peking Univ, Dept Emergency, Shenzhen Hosp, Shenzhen, Guangdong, Peoples R China.
   [Yi, Li] Peking Univ, Dept Neurol, Shenzhen Hosp, 1120 Lianhua Rd Futian Area, Shenzhen 518036, Guangdong, Peoples R China.
RP Yi, L (corresponding author), Peking Univ, Dept Neurol, Shenzhen Hosp, 1120 Lianhua Rd Futian Area, Shenzhen 518036, Guangdong, Peoples R China.; Song, WD (corresponding author), Peking Univ, Dept Resp Med, Shenzhen Hosp, 1120 Lianhua Rd Futian Area, Shenzhen 518036, Guangdong, Peoples R China.
EM songwd123@hotmail.com; pkusz123@sina.com
FU Natural Science Foundation of Guangdong ProvinceNational Natural Science
   Foundation of Guangdong Province [2017030313830]
FX The authors thank the Jianli People Hospital, Jianli Traditional Chinese
   medicine Hospital and Peking University Shenzhen Hospital for its
   support in the database construction. This work was supported by the
   Natural Science Foundation of Guangdong Province (No 2017030313830).
CR Al Ghamdi M, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1492-4
   Barnard DL, 2011, FUTURE VIROL, V6, P615, DOI 10.2217/fvl.11.33
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   de Wilde AH, 2013, J GEN VIROL, V94, P1749, DOI 10.1099/vir.0.052910-0
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Du QLL, 2019, INT IMMUNOPHARMACOL, V68, P58, DOI 10.1016/j.intimp.2018.09.043
   Hart BJ, 2014, J GEN VIROL, V95, P571, DOI 10.1099/vir.0.061911-0
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lin L, 2020, Zhonghua Yi Xue Za Zhi, V100, pE001, DOI 10.3760/cma.j.issn.0376-2491.2020.0001
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Pecheur EI, 2016, J VIROL, V90, P3086, DOI 10.1128/JVI.02077-15
   Shalhoub S, 2015, J ANTIMICROB CHEMOTH, V70, P2129, DOI 10.1093/jac/dkv085
   Wang YT, 2017, BIOMED PHARMACOTHER, V91, P393, DOI 10.1016/j.biopha.2017.04.091
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 18
TC 16
Z9 17
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD MAY-JUN
PY 2020
VL 22
IS 4-5
BP 200
EP 205
DI 10.1016/j.micinf.2020.05.012
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA MB4ML
UT WOS:000542577500014
PM 32445881
OA Green Published
DA 2021-01-01
ER

PT J
AU Brogna, B
   Brogna, C
   Martino, A
   Minichiello, S
   Romeo, DM
   Romano, P
   Bignardi, E
   Mazza, EM
   Musto, L
AF Brogna, Barbara
   Brogna, Claudia
   Martino, Alberigo
   Minichiello, Stefana
   Romeo, Domenico M.
   Romano, Paolo
   Bignardi, Elio
   Mazza, Emerico Maria
   Musto, Lanfranco
TI SARS-CoV-2 Infection with Different Radiological Insights
SO DIAGNOSTICS
LA English
DT Article
DE severe acute respiratory syndrome-Coronavirus-2; lung acute embolism;
   acute respiratory distress syndrome
ID CORONAVIRUS; PNEUMONIA
AB Severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) is a novel viral infection characterized by several symptoms range from mild to severe clinical conditions that could lead to death. We report two different radiological findings on computed tomography (CT) in two patients affected by SARS-CoV-2: a lung acute embolism (APE) in the first case and a radiological picture of acute respiratory distress syndrome (ARDS) in the second case. This is an important issue to be identified in order to provide more specific therapy earlier, including both antiviral and anti-inflammatory drugs associated with anti anticoagulant therapy.
C1 [Brogna, Barbara; Martino, Alberigo; Mazza, Emerico Maria; Musto, Lanfranco] Frangipane Hosp, Radiol Unit, ASL Avellino, Via V Emanuele, I-83031 Avellino, Italy.
   [Brogna, Claudia] Neuropsychiat Unit ASL Avellino, Via Imbimbo 10-12, I-83100 Avellino, Italy.
   [Minichiello, Stefana] Frangipane Hosp, Cardiol Unit, ASL Avellino, Via V Emanuele, I-83031 Avellino, Italy.
   [Romeo, Domenico M.] Univ Cattolica Sacro Cuore, Fdn Policlin Agostino Gemelli IRCCS, Neuropsychiat Unit, I-00168 Rome, Italy.
   [Romano, Paolo; Musto, Lanfranco] Criscuoli Hosp, Radiol Unit, ASL Avellino, Via Quadrivio, I-83054 Avellino, Italy.
   [Bignardi, Elio] Cotugno Hosp, Radiol Unit, Via Quagliariello 54, I-80131 Naples, Italy.
RP Brogna, B (corresponding author), Frangipane Hosp, Radiol Unit, ASL Avellino, Via V Emanuele, I-83031 Avellino, Italy.
EM brognabarbara1@gmail.com; claudiabrogna@yahoo.it; albmart@libero.it;
   stefana.minichiello@libero.it; domenico.romeo@policlinicogemelli.it;
   paolorom67@gmail.com; dr.eliobignardi@alice.it; icomazza@alice.it;
   musto.lanfranco@gmail.com
RI brogna, barbara/ABC-2891-2020; Bignardi, Elio/ABE-4387-2020
OI Bignardi, Elio/0000-0002-9484-6968; brogna, barbara/0000-0002-8037-7689
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Chang JC, 2019, CLIN APPL THROMB-HEM, V25, DOI 10.1177/1076029619887437
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Cunningham AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2818-6
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   Gralinski LE, 2013, MBIO, V4, DOI 10.1128/mBio.00271-13
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lillicrap D, 2020, J THROMB HAEMOST, V18, P786, DOI 10.1111/jth.14781
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Mao L, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3544840, DOI 10.2139/SSRN.3544840]
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Pelosi P, 2003, EUR RESPIR J, V22, p48S, DOI 10.1183/09031936.03.00420803
   Rotzinger DC, 2020, THROMB RES, V190, P58, DOI 10.1016/j.thromres.2020.04.011
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Vanden Eynde JJ, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13040065
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
   Ye Z, 2020, EUR RADIOL, V30, P4381, DOI 10.1007/s00330-020-06801-0
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
   Zuckier LS, 2020, J NUCL MED, V61, P630, DOI 10.2967/jnumed.120.245571
NR 27
TC 1
Z9 1
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD MAY
PY 2020
VL 10
IS 5
AR 283
DI 10.3390/diagnostics10050283
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA LZ1XJ
UT WOS:000541022500045
PM 32392859
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vanden Eynde, JJ
AF Vanden Eynde, Jean Jacques
TI COVID-19: An Update about the Discovery Clinical Trial
SO PHARMACEUTICALS
LA English
DT Article
DE chloroquine; COVID-19; hydroxychloroquine; lopinavir; ritonavir; plasma;
   remdesivir; SARS-CoV-2
AB Finding efficacious and safe treatments for COVID-19 emerges as a crucial need in order to control the spread of the pandemic. Whereas plasma therapy attracts much interest, the European project Discovery focuses on the potentialities of small molecules like remdesivir, the combination of lopinavir/ritonavir, hydroxychloroquine, and chloroquine. Results recently published on the clinical evaluation of those drugs are compiled in this brief report, although complete data are still impatiently awaited.
C1 [Vanden Eynde, Jean Jacques] Univ Mons UMONS, Dept Organ Chem FS, B-7000 Mons, Belgium.
RP Vanden Eynde, JJ (corresponding author), Univ Mons UMONS, Dept Organ Chem FS, B-7000 Mons, Belgium.
EM jean-jacques.vandeneynde@ex.umons.ac.be
OI Vanden Eynde, Jean Jacques/0000-0003-4770-4104
CR [Anonymous], GS5734 RDV
   Borba MGS, 2020, CHLOROQUINE DIPHOSPH, DOI [10.1101/2020.04.07.20056424, DOI 10.1101/2020.04.07.20056424]
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cheng CY, 2020, J MICROBIOL IMMUNOL, V53, P488, DOI 10.1016/j.jmii.2020.03.032
   Chun B.K., 2016, U.S. Patent, Patent No. [2016/0122374. A1, 20160122374]
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Klimke A, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109783
   Lan X, 2020, LOPINAVIR RITONAVIR, DOI [10.1101/2020.04.25.20079079, DOI 10.1101/2020.04.25.20079079]
   Lane J.C., 2020, SAFETY HYDROXYCHLORO, DOI [10.1101/2020.04.08.20054551, DOI 10.1101/2020.04.08.20054551]
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Mahevas M, 2020, NO EVIDENCE CLIN EFF, P369, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Nakamura K, 2020, J INFECT CHEMOTHER, V26, P756, DOI 10.1016/j.jiac.2020.03.018
   Ramireddy A, 2020, EXPERIENCE HYDROXYCH, DOI [10.1101/2020.04.22.20075671, DOI 10.1101/2020.04.22.20075671]
   Savarino A, 2020, PHARMACOKINETIC BASE, DOI [10.1101/2020.04.23.20076471, DOI 10.1101/2020.04.23.20076471]
   Savarino A, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0178-0
   Tang Bin, 2020, Kidney Med, V2, P354, DOI 10.1016/j.xkme.2020.03.001
   US National Library of Medicine, CLIN TRIALS
   Vanden Eynde JJ, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13040065
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Watson JA, 2020, CONCENTRATION DEPEND, DOI [10.1101/2020.04.24.20078303, DOI 10.1101/2020.04.24.20078303]
   WHO, UN FDN PARTN LAUNCH
NR 27
TC 2
Z9 2
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD MAY
PY 2020
VL 13
IS 5
AR 98
DI 10.3390/ph13050098
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LZ1ZS
UT WOS:000541028600010
PM 32423027
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ella, KM
   Mohan, VK
AF Ella, Krishna M.
   Mohan, V. Krishna
TI Coronavirus Vaccine: Light at the End of the Tunnel
SO INDIAN PEDIATRICS
LA English
DT Article
DE COVID-19; Immunization; Pandemic; Prevention; SARS-CoV-2
AB The world is currently facing an unprecedented global pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Predicting the next source of the pandemic can be very challenging. As vaccination is the best way to prevent an infectious disease, the development of an effective vaccine against SARS-CoV-2 can not only reduce the morbidity and mortality associated with it, but can also lessen the economic impact. As the traditional method of vaccine development takes many years for a vaccine to be available to the society, the vaccine development for SARS-CoV-2 should be speeded up using a pandemic approach with fast-track approvals from the regulatory authorities. Various challenges associated with developing a vaccine during the pandemic such as technological hurdles, clinical development pathways, regulatory issues, and support from global funding agencies are expressed here.
C1 [Ella, Krishna M.; Mohan, V. Krishna] Bharat Biotech Int Ltd, Hyderabad, Telangana, India.
RP Mohan, VK (corresponding author), Bharat Biotech Int Ltd, Hyderabad, Telangana, India.
EM kmohan@bharatbiotech.com
CR Cascella M, 2020, FEATURES EVALUATION
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Fedson DS, 2006, HUM VACCINES, V2, P38, DOI 10.4161/hv.2.1.2554
   Gorbalenya A. E., 2020, BIORXIV
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Le TT, 2020, NATURE REV DRUG DISC
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lurie N, 2020, N ENGL J MED
   Shen L, 2020, J MED ECON, V23, P456, DOI 10.1080/13696998.2020.1717500
   Wan Y., 2020, J VIROL
   WHO, 2018, 2018 ANN REV DIS PRI
   Yamey G., 2020, LANCET
   Zhang JY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020153
NR 13
TC 3
Z9 3
U1 0
U2 0
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0019-6061
EI 0974-7559
J9 INDIAN PEDIATR
JI Indian Pediatrics
PD MAY
PY 2020
VL 57
IS 5
BP 407
EP 410
DI 10.1007/s13312-020-1812-z
PG 4
WC Pediatrics
SC Pediatrics
GA LQ1UE
UT WOS:000534795300006
PM 32291382
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Andrew, MK
   Searle, SD
   McElhaney, JE
   McNeil, SA
   Clarke, B
   Rockwood, K
   Kelvin, DJ
AF Andrew, Melissa K.
   Searle, Samuel D.
   McElhaney, Janet E.
   McNeil, Shelly A.
   Clarke, Barry
   Rockwood, Kenneth
   Kelvin, David J.
TI COVID-19, frailty and long-term care: Implications for policy and
   practice
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE COVID-19; frailty; older adult; long-term care; biomarker
ID INFLUENZA VACCINE
AB Older adults have been disproportionately affected by the COVID-19 pandemic, with many outbreaks occurring in Long Term Care Facilities (LTCFs). We discuss this vulnerability among LTCF residents using an ecological framework, on levels spanning from the individual to families and caregivers, institutions, health services and systems, communities, and contextual government policies. Challenges abound for fully understanding the burden of COVID-19 in LTCF, including differences in nomenclature, data collection systems, cultural differences, varied social welfare models, and (often) under-resourcing of the LTC sector. Registration of cases and deaths may be limited by testing capacity and policy, record-keeping and reporting procedures. Hospitalisation and death rates may be inaccurate depending on atypical presentations and whether or not residents' goals of care include escalation of care and transfer to hospital. Given the important contribution of frailty, use of the Clinical Frailty Scale (CFS) is discussed as a readily implementable measure, as are lessons learned from the study of frailty in relation to influenza. Biomarkers hold emerging promise in helping to predict disease severity and address the puzzle of why some frail LTCF residents are resilient to COVID-19, either remaining test-negative despite exposure or having asymptomatic infection, while others experience the full range of illness severity including critical illness and death. Strong and coordinated surveillance and research focused on LTCFs and their frail residents is required. These efforts should include widespread assessment of frailty using feasible and readily implementable tools such as the CFS, and rigorous reporting of morbidity and mortality in LTCFs.
C1 [Andrew, Melissa K.; Searle, Samuel D.; Rockwood, Kenneth] Dalhousie Univ, Dept Med Geriatr, 5955 Vet Mem Lane, Halifax, NS, Canada.
   [Andrew, Melissa K.; McNeil, Shelly A.; Kelvin, David J.] Dalhousie Univ, Canadian Ctr Vaccinol, Halifax, NS, Canada.
   [Searle, Samuel D.] UCL, MRC Unit Lifelong Hlth & Ageing, London, England.
   [McElhaney, Janet E.] Hlth Sci North Res Inst, Sudbury, ON, Canada.
   [McNeil, Shelly A.] Dalhousie Univ, Dept Med Infect Dis, Halifax, NS, Canada.
   [Clarke, Barry] Dalhousie Univ, Dept Family Med, Halifax, NS, Canada.
   [Kelvin, David J.] Dalhousie, Dept Microbiol & Immunol, Halifax, NS, Canada.
   [Kelvin, David J.] Shantou Univ, Lab Immun, Med Coll, Shantou, Peoples R China.
RP Andrew, MK (corresponding author), Dalhousie Univ, Dept Med Geriatr, 5955 Vet Mem Lane, Halifax, NS, Canada.
EM mandrew@dal.ca
RI , Polly/AAX-2742-2020
FU Li-Ka Shing Foundation, Shantou University Medical College; Rapid
   Response award for COVID-19, Canadian Institutes of Health
   ResearchCanadian Institutes of Health Research (CIHR); Dalhousie Medical
   Research Foundation; Rapid Response Award from Research Nova Scotia
FX This work was supported by the Li-Ka Shing Foundation, Shantou
   University Medical College; a Rapid Response award for COVID-19,
   Canadian Institutes of Health Research; Dalhousie Medical Research
   Foundation; and a Rapid Response Award from Research Nova Scotia. DJK
   holds the Canada Research Chair in Translational Vaccinology and
   Inflammation at Dalhousie University.
CR Andrew MK, 2018, J FRALITY AGING, V7, P217, DOI 10.14283/jfa.2018.30
   Andrew MK, 2020, INFECT CONT HOSP EP, V41, P499, DOI 10.1017/ice.2020.22
   Andrew MK, 2017, J INFECT DIS, V216, P405, DOI 10.1093/infdis/jix282
   Andrew MK, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-90
   Cameron MJ, 2008, VIRUS RES, V133, P13, DOI 10.1016/j.virusres.2007.02.014
   Cesari M, 2020, CAN GERIATR J, V23, P152
   Chen L, 2017, J AGING STUD, V41, P44, DOI 10.1016/j.jaging.2017.03.004
   Clegg A, 2013, LANCET, V381, P752, DOI 10.1016/S0140-6736(12)62167-9
   Comas-Herrera A., 2020, MORTALITY ASS COVID
   D'Adamo H, 2020, J AM GERIATR SOC, V68, P912, DOI 10.1111/jgs.16445
   Dalhousie Geriatric Medicine Research, 2008, CLIN FRAILT SCAL
   DiazGranados CA, 2015, VACCINE, V33, P4565, DOI 10.1016/j.vaccine.2015.07.003
   Godin J, 2019, HEALTHCARE-BASEL, V7, DOI 10.3390/healthcare7030091
   Guest Paul C, 2020, Methods Mol Biol, V2138, P3, DOI 10.1007/978-1-0716-0471-7_1
   Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567
   Johnstone J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108481
   Keshtkar-Jahromi M, 2018, VACCINE, V36, P2220, DOI 10.1016/j.vaccine.2017.11.045
   Kimball A, 2020, MMWR-MORBID MORTAL W, V69, P377, DOI 10.15585/mmwr.mm6913e1
   Lees C, 2020, J INFECT DIS
   Loeb N, OPEN FORUM INFECT DI
   Marron MM, 2020, J GERONTOL A-BIOL
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Nemiroff L, 2019, J AM MED DIR ASSOC, V20, P1373, DOI 10.1016/j.jamda.2019.03.034
   Paquette SG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038214
   Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051
   Theou O, 2016, J AM GERIATR SOC, V64, pE207, DOI 10.1111/jgs.14490
   Theou O, 2013, J AM GERIATR SOC, V61, P1537, DOI 10.1111/jgs.12420
   Wallace LMK, 2015, AGING CLIN EXP RES, V27, P365, DOI 10.1007/s40520-014-0271-6
   Walsh M, 2020, LONG TERM CARE CONNE
NR 29
TC 1
Z9 1
U1 6
U2 6
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD MAY
PY 2020
VL 14
IS 5
BP 428
EP 432
DI 10.3855/jidc.13003
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA LY8GK
UT WOS:000540766500002
PM 32525825
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lu, RF
   Qin, JR
   Wu, Y
   Wang, J
   Huang, SY
   Tian, LJ
   Zhang, T
   Wu, XM
   Huang, SP
   Jin, X
   Zhang, CY
AF Lu, Renfei
   Qin, Jianru
   Wu, Yan
   Wang, Jian
   Huang, Shengyong
   Tian, Lijun
   Zhang, Tao
   Wu, Xiuming
   Huang, Songping
   Jin, Xia
   Zhang, Chiyu
TI Epidemiological and clinical characteristics of COVID-19 patients in
   Nantong, China
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE COVID-19; SARS-CoV-2; epidemiology; clinical characteristics; pneumonia;
   Nantong
ID CORONAVIRUS; PNEUMONIA; OUTBREAK; WUHAN
AB Introduction: COVID-19 is a newly emerging life-threatening respiratory disease caused by a newly identified coronavirus SARS-CoV-2.
   Methodology: We included 28 COVID-19 patients admitted to Nantong Third Hospital from January 23 to February 26, 2020. SARS-CoV-2 infection was confirmed using real-time RT-PCR. The demographic, epidemiological, clinical, laboratory parameters were obtained from each patient.
   Results: The vast majority (71.4%) of confirmed COVID-19 patients were brought in from outside of the city, and all others had contact history with these confirmed cases. The median age of patients was 50 years old and half had underlying diseases. The most common symptoms at the onset of illness were fever (96.4%), cough (67.9%), and chilly (28.6%), and 75.0% patients had two or more symptoms. Increased erythrocyte sedimentation rate, serum ferritin and C-reactive protein levels, and reduced absolute counts of total lymphocytes and T lymphocyte subsets were observed among the patients. The vast majority (85.7%) of patients showed bilateral or unilateral pneumonia, and three symptomatic patients and one asymptomatic case did not show abnormalities in their CT image. Among the 28 admitted patients, 24 were discharged as of February 26, 2020, with an average hospital stay of 14.96 (+/- 4.27) days, which was not significantly associated with the interval between the onset of symptoms and admission.
   Conclusions: In the absence of specific antiviral drugs or a vaccine, quarantine or isolation is the most effective intervention strategy for preventing the spread of the virus. Adequate supportive medical care is crucial for good prognosis of COVID-19 patients.
C1 [Lu, Renfei; Wu, Yan; Wang, Jian; Huang, Shengyong; Tian, Lijun; Zhang, Tao; Huang, Songping] Nantong Univ, Nantong Hosp 3, Nantong, Peoples R China.
   [Qin, Jianru] Henan Normal Univ, Coll Life Sci, Xinxiang, Henan, Peoples R China.
   [Qin, Jianru; Wu, Xiuming; Zhang, Chiyu] Chinese Acad Sci, Inst Pasteur Shanghai, Pathogen Discovery & Evolut Unit, 320 Yueyang Rd, Shanghai, Peoples R China.
   [Jin, Xia] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China.
RP Zhang, CY (corresponding author), Chinese Acad Sci, Inst Pasteur Shanghai, Pathogen Discovery & Evolut Unit, 320 Yueyang Rd, Shanghai, Peoples R China.
EM zhangcy1999@ips.ac.cn
FU National Science and Technology Major Project of China
   [2017ZX10103009-002, 2019YFC1200603]; Natural Science Research Project
   of Nantong Science and Technology Bureau [MS12019048]
FX This work was supported by the grants from the National Science and
   Technology Major Project of China (2017ZX10103009-002 and
   2019YFC1200603), and Natural Science Research Project of Nantong Science
   and Technology Bureau (MS12019048).
CR BEDELL SE, 1985, AM J MED, V78, P1001, DOI 10.1016/0002-9343(85)90224-4
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Wang W, 2010, BBA-GEN SUBJECTS, V1800, P760, DOI 10.1016/j.bbagen.2010.03.011
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Zhang KK, 2020, CHARACTERIZING TRANS
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 18
TC 3
Z9 3
U1 1
U2 1
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD MAY
PY 2020
VL 14
IS 5
BP 440
EP 446
DI 10.3855/jidc.12678
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA LY8GK
UT WOS:000540766500005
PM 32525828
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Patel, SK
   Pathak, M
   Tiwari, R
   Yatoo, MI
   Malik, YS
   Sah, R
   Rabaan, AA
   Sharun, K
   Dhama, K
   Bonilla-Aldana, DK
   Rodriguez-Morales, AJ
AF Patel, Shailesh Kumar
   Pathak, Mamta
   Tiwari, Ruchi
   Yatoo, Mohd Iqbal
   Malik, Yashpal Singh
   Sah, Ranjit
   Rabaan, Ali A.
   Sharun, Khan
   Dhama, Kuldeep
   Bonilla-Aldana, D. Katterine
   Rodriguez-Morales, Alfonso J.
TI A vaccine is not too far for COVID-19
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE SARS-CoV-2; COVID-19; vaccines
AB Over the last months and weeks of the pandemic of the Coronavirus Disease 2019 (COVID-19) (January-May 2020) caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there has been a significant hope for the development of vaccines against this emerging coronavirus. Dozens of vaccine candidates are currently under assessment in clinical trials already recruiting patients, then there is a real chance to have effective biologicals in relatively short-time, compared to other vaccines.
C1 [Patel, Shailesh Kumar; Pathak, Mamta; Dhama, Kuldeep] ICAR Indian Vet Res Inst, Div Pathol, Bareilly 243122, Uttar Pradesh, India.
   [Tiwari, Ruchi] UP Pandit Deen Dayal Upadhayay Pashu Chikitsa Vig, Dept Vet Microbiol & Immunol, Coll Vet Sci, Mathura, India.
   [Yatoo, Mohd Iqbal] Sher E Kashmir Univ Agr Sci & Technol Kashmir, Div Vet Clin Complex, Fac Vet Sci & Anim Husb, Srinagar, India.
   [Malik, Yashpal Singh] ICAR Indian Vet Res Inst, Div Biol Standardizat, Bareilly, Uttar Pradesh, India.
   [Sah, Ranjit] Tribhuvan Univ Teaching Hosp, Inst Med, Dept Microbiol, Kathmandu, Nepal.
   [Rabaan, Ali A.] Johns Hopkins Aramco Healthcare, Mol Diagnost Lab, Dhahran, Saudi Arabia.
   [Sharun, Khan] ICAR Indian Vet Res Inst, Div Surg, Bareilly, Uttar Pradesh, India.
   [Bonilla-Aldana, D. Katterine; Rodriguez-Morales, Alfonso J.] Univ Tecnol Pereira, Fac Hlth Sci, Publ Hlth & Infect Res Grp, Builiding 14,Floor 3,Off 3-15, Pereira 660003, Risaralda, Colombia.
   [Bonilla-Aldana, D. Katterine] Fdn Univ Autonoma Amer, Grp Invest BIOECOS, Semillero Invest Zoonosis, Pereira, Colombia.
   [Rodriguez-Morales, Alfonso J.] Fdn Univ Autonoma Amer, Fac Med, Grp Invest Biomed, Pereira, Risaralda, Colombia.
RP Dhama, K (corresponding author), ICAR Indian Vet Res Inst, Div Pathol, Bareilly 243122, Uttar Pradesh, India.; Rodriguez-Morales, AJ (corresponding author), Univ Tecnol Pereira, Fac Hlth Sci, Publ Hlth & Infect Res Grp, Builiding 14,Floor 3,Off 3-15, Pereira 660003, Risaralda, Colombia.
EM kdhama@rediffmail.com; arodriguezm@utp.edu.co
RI ; Dhama, Kuldeep/B-7852-2015; sah, Ranjit/T-5865-2018; Sharun,
   Khan/A-3084-2019
OI Malik, Yashpal/0000-0002-2832-4854; Dhama, Kuldeep/0000-0001-7469-4752;
   Patel, Shailesh Kumar/0000-0001-9536-4760; Yatoo, Dr. Mohd.
   Iqbal/0000-0002-4501-7354; sah, Ranjit/0000-0002-2695-8714; Sharun,
   Khan/0000-0003-1040-3746
CR Beigel JH, 2018, LANCET INFECT DIS, V18, P410, DOI 10.1016/S1473-3099(18)30002-1
   Casadevall A, 2020, J CLIN INVEST
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Dhama K, 2020, ORONAVIRUS DIS 2019
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Pang J, 2020, J CLIN MED, V9, pE623
   Phadke M, 2020, DRUG DEVELOP RES, V81, P541, DOI 10.1002/ddr.21666
   Ramaiah A., 2020, INSIGHTS CROSS SPECI, DOI [10.1101/2020.01.29.925867, DOI 10.1101/2020.01.29.925867]
   Rundle AG, 2020, OBESITY, V28, P1008, DOI 10.1002/oby.22813
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Yin C, 2020, GENOMICS
NR 15
TC 5
Z9 4
U1 1
U2 1
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD MAY
PY 2020
VL 14
IS 5
BP 450
EP 453
DI 10.3855/jidc.12744
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA LY8GK
UT WOS:000540766500007
PM 32525830
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Guckenberger, M
   Belka, C
   Bezjak, A
   Bradley, J
   Daly, ME
   DeRuysscher, D
   Dziadziuszko, R
   Faivre-Finn, C
   Flentje, M
   Gore, E
   Higgins, KA
   Iyengar, P
   Kavanagh, BD
   Kumar, S
   Le Pechoux, C
   Lievens, Y
   Lindberg, K
   McDonald, F
   Ramella, S
   Rengan, R
   Ricardi, U
   Rimner, A
   Rodrigues, GB
   Schild, SE
   Senan, S
   Simone, CB
   Slotman, B
   Stuschke, M
   Videtic, G
   Widder, J
   Yom, SS
   Palma, D
AF Guckenberger, Matthias
   Belka, Claus
   Bezjak, Andrea
   Bradley, Jeffrey
   Daly, Megan E.
   DeRuysscher, Dirk
   Dziadziuszko, Rafal
   Faivre-Finn, Corinne
   Flentje, Michael
   Gore, Elizabeth
   Higgins, Kristin A.
   Iyengar, Puneeth
   Kavanagh, Brian D.
   Kumar, Sameera
   Le Pechoux, Cecile
   Lievens, Yolande
   Lindberg, Karin
   McDonald, Fiona
   Ramella, Sara
   Rengan, Ramesh
   Ricardi, Umberto
   Rimner, Andreas
   Rodrigues, George B.
   Schild, Steven E.
   Senan, Suresh
   Simone, Charles B., II
   Slotman, Ben J.
   Stuschke, Martin
   Videtic, Greg
   Widder, Joachim
   Yom, Sue S.
   Palma, David
TI Practice recommendations for lung cancer radiotherapy during the
   COVID-19 pandemic: An ESTRO-ASTRO consensus statement q
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Article
ID RADIATION-THERAPY; TRIAL
C1 [Guckenberger, Matthias] Univ Zurich, Univ Hosp Zurich, Dept Radiat Oncol, Zurich, Switzerland.
   [Belka, Claus] Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, LMU Klinikum, Munich, Germany.
   [Bezjak, Andrea] Univ Toronto, Princess Margaret Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada.
   [Bradley, Jeffrey; Higgins, Kristin A.] Emory Univ, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA 30322 USA.
   [Daly, Megan E.] Univ Calif Davis, Comprehens Canc Ctr, Dept Radiat Oncol, Sacramento, CA 95817 USA.
   [DeRuysscher, Dirk] Maastricht Univ, GROW Res Inst, Dept Radiat Oncol Maastro Clin, Med Ctr, Maastricht, Netherlands.
   [Dziadziuszko, Rafal] Med Univ Gdansk, Dept Oncol & Radiotherapy, Gdansk, Poland.
   [Faivre-Finn, Corinne] Univ Manchester, Div Canc Sci, Manchester, Lancs, England.
   [Faivre-Finn, Corinne] Christie NHS Fdn Trust, Manchester, Lancs, England.
   [Flentje, Michael] Univ Hosp Wurzburg, Dept Radiat Oncol, JMU Wurzburg, Wurzburg, Germany.
   [Gore, Elizabeth] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA.
   [Gore, Elizabeth] Zablocki VAMC, Milwaukee, WI USA.
   [Iyengar, Puneeth] UT Southwestern Med Ctr, Dept Radiat Oncol, Dallas, TX USA.
   [Kavanagh, Brian D.] Univ Colorado, Dept Radiat Oncol, Aurora, CO USA.
   [Kumar, Sameera] Fox Chase Canc Ctr, Dept Radiat Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
   [Le Pechoux, Cecile] Gustave Roussy Canc Campus, Dept Radiat Oncol, Villejuif, France.
   [Lievens, Yolande] Ghent Univ Hosp, Dept Radiat Oncol, Ghent, Belgium.
   [Lievens, Yolande] Univ Ghent, Ghent, Belgium.
   [Lindberg, Karin] Karolinska Univ Hosp, Dept Head Neck Lung & Skin Canc, Theme Canc, Stockholm, Sweden.
   [McDonald, Fiona] Royal Marsden Hosp, London, England.
   [Ramella, Sara] Campus Biomed Univ Rome, Radiat Oncol, Rome, Italy.
   [Rengan, Ramesh] Univ Washington, Sch Med, Dept Radiat Oncol, Seattle, WA USA.
   [Ricardi, Umberto] Univ Turin, Dept Oncol, Turin, Italy.
   [Rimner, Andreas] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA.
   [Rodrigues, George B.; Palma, David] Western Univ, Div Radiat Oncol, London, ON, Canada.
   [Schild, Steven E.] Mayo Clin, Dept Radiat Oncol, Phoenix, AZ USA.
   [Senan, Suresh; Slotman, Ben J.] Amsterdam UMC, Dept Radiat Oncol, Amsterdam, Netherlands.
   [Simone, Charles B., II] New York Proton Ctr, Dept Radiat Oncol, New York, NY USA.
   [Simone, Charles B., II] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   [Stuschke, Martin] Univ Duisburg Essen, Dept Radiotherapy, Duisburg, Germany.
   [Videtic, Greg] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Radiat Oncol, Cleveland, OH 44106 USA.
   [Widder, Joachim] Med Univ Vienna, Comprehens Canc Ctr, Dept Radiat Oncol, Vienna, Austria.
   [Yom, Sue S.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA.
RP Guckenberger, M (corresponding author), Univ Zurich UZH, Univ Hosp Zurich USZ, Dept Radiat Oncol, Ramistr 100, CH-8091 Zurich, Switzerland.
EM Matthias.Guckenberger@usz.ch
RI Guckenberger, Matthias/AAX-4994-2020
OI Guckenberger, Matthias/0000-0002-7146-9071; Faivre-Finn,
   Corinne/0000-0001-5617-9781; Senan, Suresh/0000-0003-3995-2204
CR [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   [Anonymous], 1992, Br J Cancer, V65, P934
   Belderbos J, 2007, EUR J CANCER, V43, P114, DOI 10.1016/j.ejca.2006.09.005
   Bezjak A, 2002, INT J RADIAT ONCOL, V54, P719, DOI 10.1016/S0360-3016(02)02989-9
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Christian MD, 2019, CRIT CARE CLIN, V35, P575, DOI 10.1016/j.ccc.2019.06.009
   Cortiula F, 2020, ANN ONCOL, V31, P553, DOI 10.1016/j.annonc.2020.03.286
   Filippi AR, 2020, INT J RAD ONCOL BIOL
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hsu C-C, DELPHI TECHNIQUE MAK, V12
   Iyengar P, 2016, INT J RADIAT ONCOL, V96, pE451, DOI 10.1016/j.ijrobp.2016.06.1763
   JING CJ, 2020, ZHONGHUA ZHONG LIU Z, V42, DOI DOI 10.1007/S11738-020-03039-7
   Kotter T, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-21
   Krengli M, 2020, ADV RAD ONCOL
   Maguire J, 2014, EUR J CANCER, V50, P2939, DOI 10.1016/j.ejca.2014.07.009
   Medical Research Council Lung Cancer Working Party, 1996, CLIN ONCOL, V8, P167
   Osti MF, 2013, INT J RADIAT ONCOL, V85, pE157, DOI 10.1016/j.ijrobp.2012.10.012
   Persad G, 2020, NEW ENGL J MED, V382
   Rosenbaum L., 2020, N ENGL J MED
   Shen L, 2020, J MED ECON, V23, P456, DOI 10.1080/13696998.2020.1717500
   Stroud C, 2010, CRISIS STANDARDS CAR
   Videtic GM, 2019, INT J RADIAT ONCOL, V103, P1077, DOI 10.1016/j.ijrobp.2018.11.051
   Westover KD, 2015, INT J RADIAT ONCOL, V93, P72, DOI 10.1016/j.ijrobp.2015.05.004
   Xia Y, 2020, LANCET ONCOL
   Yang Y, 2020, BMC EVOL BIOL, V20, DOI 10.1186/s12862-019-1569-y
   Zhou F., 2020, LANCET
NR 26
TC 41
Z9 41
U1 4
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-8140
EI 1879-0887
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD MAY
PY 2020
VL 146
BP 223
EP 229
DI 10.1016/j.radonc.2020.04.001
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA LX6VX
UT WOS:000539968200030
PM 32342863
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Sarkar, B
   Ullah, MA
   Johora, FT
   Taniya, MA
   Araf, Y
AF Sarkar, Bishajit
   Ullah, Md Asad
   Johora, Fatema Tuz
   Taniya, Masuma Afrin
   Araf, Yusha
TI Immunoinformatics-guided designing of epitope-based subunit vaccines
   against the SARS Coronavirus-2 (SARS-CoV-2)
SO IMMUNOBIOLOGY
LA English
DT Article
DE COVID-19; Coronavirus; SARS-COV-2; Reverse vaccinology; Vaccine;
   Immunoinformatics
ID NORMAL-MODE ANALYSIS; PROTEIN; IDENTIFICATION; GENES; PATHOGENESIS;
   MEMORY; CELLS; INDEX
AB SARS Coronavirus-2 (SARS-CoV-2) pandemic has become a global issue which has raised the concern of scientific community to design and discover a counter-measure against this deadly virus. So far, the pandemic has caused the death of hundreds of thousands of people upon infection and spreading. To date, no effective vaccine is available which can combat the infection caused by this virus. Therefore, this study was conducted to design possible epitope-based subunit vaccines against the SARS-CoV-2 virus using the approaches of reverse vaccinology and immunoinformatics. Upon continual computational experimentation, three possible vaccine constructs were designed and one vaccine construct was selected as the best vaccine based on molecular docking study which is supposed to effectively act against the SARS-CoV-2. Thereafter, the molecular dynamics simulation and in silico codon adaptation experiments were carried out in order to check biological stability and find effective mass production strategy of the selected vaccine. This study should contribute to uphold the present efforts of the researches to secure a definitive preventative measure against this lethal disease.
C1 [Sarkar, Bishajit; Ullah, Md Asad; Johora, Fatema Tuz] Jahangirnagar Univ, Fac Biol Sci, Dept Biotechnol & Genet Engn, Dhaka, Bangladesh.
   [Taniya, Masuma Afrin] Independent Univ, Sch Life Sci, Dept Microbiol, Dhaka, Bangladesh.
   [Araf, Yusha] Shahjalal Univ Sci & Technol, Sch Life Sci, Dept Genet Engn & Biotechnol, Sylhet, Bangladesh.
RP Sarkar, B (corresponding author), Jahangirnagar Univ, Fac Biol Sci, Dept Biotechnol & Genet Engn, Dhaka, Bangladesh.
EM sarkarbishajit@gmail.com
RI Taniya, Masuma/ABI-2041-2020; Sarkar, Bishajit/AAO-6619-2020; Ullah,
   Asad/AAM-1802-2020; Araf, Yusha/AAM-1810-2020
OI Taniya, Masuma/0000-0002-1587-5606; Sarkar,
   Bishajit/0000-0001-8439-6994; Ullah, Asad/0000-0002-6615-6433; Araf,
   Yusha/0000-0002-0144-5875
CR [Anonymous], 2020, WHO DIR GEN OP REM M
   ARPIN C, 1995, SCIENCE, V268, P720, DOI 10.1126/science.7537388
   Cano R.L., 2013, INTRO T B LYMPHOCYTE
   Carbone A, 2003, BIOINFORMATICS, V19, P2005, DOI 10.1093/bioinformatics/btg272
   Cavanagh D., 1995, CORONAVIRIDAE, P73, DOI DOI 10.1007/978-1-4899-1531-3_5
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Chang S, 2013, RES J BIOTECHNOL, V8, P8
   Chauhan V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39299-8
   Chong L.C., 2019, VACCINE TARGET DISCO, DOI [10.1016/b978-0-12-809633-8.20100-3., DOI 10.1016/B978-0-12-809633-8.20100-3]
   Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346
   DEMKOWICZ WE, 1992, J VIROL, V66, P386, DOI 10.1128/JVI.66.1.386-398.1992
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7
   Goerdt S, 1999, IMMUNITY, V10, P137, DOI 10.1016/S1074-7613(00)80014-X
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   Hasson Sidgi Syed Anwer Abdo, 2015, Asian Pacific Journal of Tropical Biomedicine, V5, P344, DOI 10.1016/S2221-1691(15)30366-X
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   IKAI A, 1980, J BIOCHEM-TOKYO, V88, P1895
   Kallberg M, 2012, NAT PROTOC, V7, P1511, DOI 10.1038/nprot.2012.085
   Kaufmann SHE, 2014, CURR OPIN IMMUNOL, V28, P18, DOI 10.1016/j.coi.2014.01.009
   Kovacs JA, 2004, PROTEINS, V56, P661, DOI 10.1002/prot.20151
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Maria R.R., 2017, IMPACT BIOINFORMATIC, DOI [10.5772/intechopen.69273.Sep6, DOI 10.5772/INTECHOPEN.69273]
   Masters PS, 2013, FIELDS VIROLOGY, V6, P825
   Merten OW, 2002, CYTOTECHNOLOGY, V39, P91, DOI 10.1023/A:1022969101804
   PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120
   PAVLI P, 1993, IMMUNOLOGY, V78, P132
   Peeri N.C., 2020, INT J EPIDEMIOL, P22
   Petit CM, 2005, VIROLOGY, V341, P215, DOI 10.1016/j.virol.2005.06.046
   Lopez-Blanco JR, 2014, NUCLEIC ACIDS RES, V42, pW271, DOI 10.1093/nar/gku339
   Lopez-Blanco JR, 2011, BIOINFORMATICS, V27, P2843, DOI 10.1093/bioinformatics/btr497
   Rottier P.J., 1995, CORONAVIRIDAE, P115
   Sateesh P, 2010, INT J ENG SCI TECH, V2, P1125
   Siu KL, 2019, FASEB J, V33, P8865, DOI 10.1096/fj.201802418R
   Solanki V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26689-7
   Stratton K., 2002, IMMUNIZATION SAFETY
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4
   Tanchot C, 2003, NAT IMMUNOL, V4, P431, DOI 10.1038/ni0503-431
   Thomsen M, 2013, IMMUNOGENETICS, V65, P655, DOI 10.1007/s00251-013-0714-9
   Ullah M.A., 2020, EXPOLITING REVERSE V
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Wu CY, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-88
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zobayer M., 2018, THESIS, DOI [10.3923/jbs.2018.178.191., DOI 10.3923/JBS.2018.178.191]
NR 50
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0171-2985
J9 IMMUNOBIOLOGY
JI Immunobiology
PD MAY
PY 2020
VL 225
IS 3
AR 151955
DI 10.1016/j.imbio.2020.151955
PG 17
WC Immunology
SC Immunology
GA LW6UZ
UT WOS:000539280500020
PM 32517882
OA Green Published
DA 2021-01-01
ER

PT J
AU Braithwaite, R
   Warren, R
AF Braithwaite, Ronald
   Warren, Rueben
TI The African American Petri Dish
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Article
DE Pandemic; racial inequities; ethnic inequities; minority populations;
   COVID-19
ID EXCESS DEATHS
AB This commentary amplifies the insidious nature of the novel coronavirus (resulting in COVID19) and its ubiquitous spread, which disproportionately and adversely affect the health and well-being of people of color. The consequence is poor health outcomes and premature death. Ample previous literature documents health inequities in the morbidity and mortality statistics for Black and Brown people in the United States. Their excess deaths are due to disproportionately high rates of serious health conditions (diabetes; hypertension; asthma; and lung, kidney, and heart disease), as well as structural factors having to do with income, employment, and the built environment in which they live. The health conditions are exacerbated with ongoing societal problems and stress emerging from the country's history of dehumanizing racial inequities. Current discrimination comes most virulently in the form of systematic and institutionalized racist policies that keep racial and ethnic minorities marginalized and disempowered. Furthermore, people of color encounter the immediate external pressures of working away from home and using public transportation during the country's extraordinary ongoing lockdown, heightening the risk of exposure to the virus. Moreover, the same population is overrepresented in jails and prisons where social distancing is impossible. Any virulent virus without a vaccine is bound to become a human petri dish in which people of color in the U.S. today are caught.The war against the coronavirus for people of color is part and parcel of the war to eliminate historic inequities and to level the socioeconomic playing field. This article covers the racial/ethnic inequities in morbidity and mortality from COVID19 and the slow and untimely response by the federal government to address mediation of the spread of the virus. For people of color to transcend the coronavirus pandemic crisis there must be comprehensive access to COVID-19 testing and early, sustained, and affordable access to health care, including hospitalization. Such access will require national leadership, which seems to be in short supply.
C1 [Braithwaite, Ronald] Morehouse Sch Med, Community Hlth & Prevent Med, Family Med & Psychiat, Atlanta, GA 30310 USA.
   [Warren, Rueben] Tuskegee Univ, Natl Ctr Bioeth Res & Hlth Care, Tuskegee, AL 36088 USA.
RP Braithwaite, R (corresponding author), Morehouse Sch Med, Community Hlth & Prevent Med, Family Med & Psychiat, Atlanta, GA 30310 USA.
CR American Public Media (APM) ResearchLab Staff, 2020, COL COR COV 19 DEATH
   Armstrong K, 2007, AM J PUBLIC HEALTH, V97, P1283, DOI 10.2105/AJPH.2005.080762
   Ashley Kirzinger, 2020, KFF HLTH TRACKING PO
   BRAITHWAITE R, 1996, PRISON AIDS PUBLIC H
   Braithwaite R, 2009, HLTH ISSUES BLACK CO
   Braithwaite RL, 2006, HLTH ISSUES INCARCER
   Busari S, 2020, CABLE NEWS NETWORK C
   Byrd WM, 2001, AM HLTH DILEMMA MED, V2
   Byrd WM, 2000, AM HLTH DILEMMA MED, V1
   CDC, 2020, CAS COR DIS COVID 19
   Charles J, 2020, MIAMI HERALD
   Crepeau M, 2020, CHICAGO TRIBUNE
   Despres C., 2020, ARE LATINOS MORE EXP
   Duffin E., 2019, US HOUSEHOLD INCOME
   Employment and Training Administration, 2020, UN INS WEEKL CLAIMS
   Eric Lipton, 2020, NY TIMES
   Farmer B, 2020, KAISER HLTH NEWS
   Fuchs VR, 1974, WHO SHALL LIVE HLTH
   Hammond E., 2020, CORONAVIRUS HITS BLA
   Harris S, 2020, WASHINGTON POST
   Healthy People 2020, 2020, SOCIAL DETERMINANTS
   Heckler Margaret M., 1985, REPORT SECRETARYS TA
   Jacobs EA, 2006, J GEN INTERN MED, V21, P642, DOI 10.1111/j.1525-1497.2006.00485.x
   Jones Lovell, 2019, LOVELLS FOOD THOUGHT
   Katz RV, 2011, SEARCH LEGACY USPHS
   Kendi Ibram X., 2020, ATLANTIC
   Langreth R., 2020, BLOOMBERG NEWS
   Margolin J, 2020, INTELLIGENCE REPORT
   Miller H., 2020, HUFFINGTON POST
   Pinn V, 2011, SEARCH LEGACY USPHS, V2011, P141
   Robbins J, 2004, J HEALTH CARE POOR U, V15, P530, DOI 10.1353/hpu.2004.0072
   Satcher D, 2005, HEALTH AFFAIR, V24, P459, DOI 10.1377/hlthaff.24.2.459
   Scharff DP, 2010, J HEALTH CARE POOR U, V21, P879, DOI 10.1353/hpu.0.0323
   Schwartzburg R., 2020, NATION
   Sule E, 2017, J RACIAL ETHN HEALTH, V4, P779, DOI 10.1007/s40615-016-0328-7
   Thebault R, 2020, WASHINGTON POST
   U.S. Bureau of Labor Statistics, 2020, LAB FORC STAT CURR P
   Vergano D., 2020, BUZZFEED NEWS
   Walker Jr B., 2017, P ETH FRAM POP HLTH, P79
   Wise Justin, 2020, HILL
NR 40
TC 4
Z9 4
U1 8
U2 9
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
   21218-4363 USA
SN 1049-2089
EI 1548-6869
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD MAY
PY 2020
VL 31
IS 2
BP 491
EP 502
DI 10.1353/hpu.2020.0037
PG 12
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA LW8NH
UT WOS:000539399800002
DA 2021-01-01
ER

PT J
AU Kalathiya, U
   Padariya, M
   Mayordomo, M
   Lisowska, M
   Nicholson, J
   Singh, A
   Baginski, M
   Fahraeus, R
   Carragher, N
   Ball, K
   Haas, J
   Daniels, A
   Hupp, TR
   Alfaro, JA
AF Kalathiya, Umesh
   Padariya, Monikaben
   Mayordomo, Marcos
   Lisowska, Malgorzata
   Nicholson, Judith
   Singh, Ashita
   Baginski, Maciej
   Fahraeus, Robin
   Carragher, Neil
   Ball, Kathryn
   Haas, Juergen
   Daniels, Alison
   Hupp, Ted R.
   Alfaro, Javier Antonio
TI Highly Conserved Homotrimer Cavity Formed by the SARS-CoV-2 Spike
   Glycoprotein: A Novel Binding Site
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE SARS-CoV-2; coronavirus disease 2019 (COVID-19); spike glycoprotein;
   variability; molecular docking; molecular dynamics; inhibitors; trimer
   cavity; binding site
ID RESPIRATORY SYNDROME CORONAVIRUS; PROTEASE INHIBITOR; SARS;
   PERSPECTIVES; PNEUMONIA; SEQUENCE; THERAPY; DISEASE; HKU1
AB An important stage in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) life cycle is the binding of the spike (S) protein to the angiotensin converting enzyme-2 (ACE2) host cell receptor. Therefore, to explore conserved features in spike protein dynamics and to identify potentially novel regions for drugging, we measured spike protein variability derived from 791 viral genomes and studied its properties by molecular dynamics (MD) simulation. The findings indicated that S2 subunit (heptad-repeat 1 (HR1), central helix (CH), and connector domain (CD) domains) showed low variability, low fluctuations in MD, and displayed a trimer cavity. By contrast, the receptor binding domain (RBD) domain, which is typically targeted in drug discovery programs, exhibits more sequence variability and flexibility. Interpretations from MD simulations suggest that the monomer form of spike protein is in constant motion showing transitions between an "up" and "down" state. In addition, the trimer cavity may function as a "bouncing spring" that may facilitate the homotrimer spike protein interactions with the ACE2 receptor. The feasibility of the trimer cavity as a potential drug target was examined by structure based virtual screening. Several hits were identified that have already been validated or suggested to inhibit the SARS-CoV-2 virus in published cell models. In particular, the data suggest an action mechanism for molecules including Chitosan and macrolides such as the mTOR (mammalian target of Rapamycin) pathway inhibitor Rapamycin. These findings identify a novel small molecule binding-site formed by the spike protein oligomer, that might assist in future drug discovery programs aimed at targeting the coronavirus (CoV) family of viruses.
C1 [Kalathiya, Umesh; Padariya, Monikaben; Mayordomo, Marcos; Lisowska, Malgorzata; Singh, Ashita; Fahraeus, Robin; Hupp, Ted R.; Alfaro, Javier Antonio] Univ Gdansk, Int Ctr Canc Vaccine Sci, Wita Stwosza 63, PL-80308 Gdansk, Poland.
   [Nicholson, Judith] Sharp Life Sci EU Ltd, Oxford Sci Pk,Edmund Halley Rd, Oxford OX4 4GB, England.
   [Baginski, Maciej] Gdansk Univ Technol, Dept Pharmaceut Technol & Biochem, Fac Chem, Narutowicza St 11-12, PL-80233 Gdansk, Poland.
   [Carragher, Neil; Ball, Kathryn; Hupp, Ted R.; Alfaro, Javier Antonio] Univ Edinburgh, Inst Genet & Mol Med, Edinburgh EH4 2XR, Midlothian, Scotland.
   [Haas, Juergen; Daniels, Alison] Dept Infect Dis, Edinburgh EH4 2XR, Midlothian, Scotland.
RP Kalathiya, U; Hupp, TR; Alfaro, JA (corresponding author), Univ Gdansk, Int Ctr Canc Vaccine Sci, Wita Stwosza 63, PL-80308 Gdansk, Poland.; Hupp, TR; Alfaro, JA (corresponding author), Univ Edinburgh, Inst Genet & Mol Med, Edinburgh EH4 2XR, Midlothian, Scotland.
EM umesh.kalathiya@ug.edu.pl; monika.padariya@pg.edu.pl;
   marcos1992@hotmail.com; mlisowska@u.nus.edu;
   judith.nicholson@sharp-ls.eu; ashita.nii@gmail.com;
   maciej.baginski@pg.edu.pl; robin.fahraeus@inserm.fr;
   n.carragher@ed.ac.uk; kathryn.ball@ed.ac.uk; juergen.haas@ed.ac.uk;
   A.Daniels@sms.ed.ac.uk; ted.hupp@ed.ac.uk;
   javier.alfaro@proteogenomics.ca
RI Alfaro, Javier/ABA-5639-2020; Baginski, Maciej/C-9201-2011; Kalathiya,
   Umesh/F-3311-2018
OI Padariya, Monikaben/0000-0002-9132-8620; Baginski,
   Maciej/0000-0002-6795-7515; Ball, Kathryn/0000-0002-0728-7169;
   Kalathiya, Umesh/0000-0001-7757-6962; , robin/0000-0003-0402-8492;
   Lisowska, Malgorzata/0000-0003-4858-9312; Daniels,
   Alison/0000-0002-7308-4140; Yebenes, Marcos/0000-0001-5673-8440
FU International Centre for Cancer Vaccine Science, University of Gdansk
FX The APC was funded by the International Centre for Cancer Vaccine
   Science, University of Gdansk.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Al-Motawa M., 2020, BIORXIV
   Aldonza MBD, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aav7416
   [Anonymous], 2011, MOL OP ENV MOE 2011
   Bjelkmar P, 2010, J CHEM THEORY COMPUT, V6, P459, DOI 10.1021/ct900549r
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2013, TRENDS MICROBIOL, V21, P544, DOI 10.1016/j.tim.2013.05.005
   Chen H., 2020, 1 CLIN STUDY USING H
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990
   Deutsch M, 2010, CURR OPIN INVEST DR, V11, P951
   Dryden MW, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-80
   EDELSBRUNNER H, 1995, DISCRETE COMPUT GEOM, V13, P415, DOI 10.1007/BF02574053
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Faccenda E., CORONAVIRUS INFORM I
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Ferlini C, 2009, CANCER RES, V69, P6906, DOI 10.1158/0008-5472.CAN-09-0540
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Gordon DE, 2020, BIORXIV
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   He J, 2020, BIORXIV
   Heiser K., 2020, BIORXIV
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hoffmann M, 2020, BIORXIV
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344
   Kalathiya U, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45206-y
   Kalathiya U, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225644
   Kean T, 2005, J CONTROL RELEASE, V103, P643, DOI 10.1016/j.jconrel.2005.01.001
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   Kitchen DB, 2004, NAT REV DRUG DISCOV, V3, P935, DOI 10.1038/nrd1549
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lau SKP, 2006, J CLIN MICROBIOL, V44, P2063, DOI 10.1128/JCM.02614-05
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lill Markus, 2013, Methods Mol Biol, V993, P1, DOI 10.1007/978-1-62703-342-8_1
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu ZX, 2020, J MED VIROL, V92, P595, DOI 10.1002/jmv.25726
   Milewska A., 2020, BIORXIV
   Milewska A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156552
   Milewska A, 2013, ANTIVIR RES, V97, P112, DOI 10.1016/j.antiviral.2012.11.006
   Mohindra N, 2015, EXPERT OPIN INV DRUG, V24, P1409, DOI 10.1517/13543784.2015.1076792
   Othman H., 2020, BIORXIV
   Padariya M, 2020, CANCERS, V12, DOI 10.3390/cancers12030737
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Park T., 2020, BIORXIV
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peng C., 2020, EXPLORING BINDING ME
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2
   Rose PW, 2011, NUCLEIC ACIDS RES, V39, pD392, DOI 10.1093/nar/gkq1021
   Senathilake K., 2020, PREPRINTS
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Smith M., 2020, BIORXIV
   Smith RD, 2006, SOC SCI MED, V63, P3113, DOI 10.1016/j.socscimed.2006.08.004
   Squillace RM, 2012, INT J ONCOL, V41, P425, DOI 10.3892/ijo.2012.1487
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Utomo R.Y., 2020, PREPRINTS
   Van Gunsteren WF, 1988, MOL SIMULAT, V1, P173, DOI 10.1080/08927028808080941
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wan Y., 2020, J VIROL
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wojciechowski M, 2004, J PHYS CHEM B, V108, P18368, DOI 10.1021/jp046748b
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu A., 2020, BIORXIV
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Yan R., 2020, BIORXIV
   Yeung ML, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.4, 10.1038/nmicrobiol.2016.4]
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zeldin RK, 2004, J ANTIMICROB CHEMOTH, V53, P4, DOI 10.1093/jac/dkh029
   Zhang G, 2020, BIORXIV
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhavoronkov A, 2020, AGING-US, V12, P6492, DOI 10.18632/aging.102988
   Zhou GY, 2020, INT J BIOL SCI, V16, P1718, DOI 10.7150/ijbs.45123
   Zhou H., 2020, BIORXIV
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 90
TC 4
Z9 4
U1 4
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAY
PY 2020
VL 9
IS 5
AR 1473
DI 10.3390/jcm9051473
PG 18
WC Medicine, General & Internal
SC General & Internal Medicine
GA LY0OO
UT WOS:000540223800230
PM 32422996
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nalesso, F
   Garzotto, F
   Cattarin, L
   Gobbi, L
   Qassim, L
   Sgarabotto, L
   Tiberio, I
   Calo, LA
AF Nalesso, Federico
   Garzotto, Francesco
   Cattarin, Leda
   Gobbi, Laura
   Qassim, Laila
   Sgarabotto, Luca
   Tiberio, Ivo
   Calo, Lorenzo A.
TI A Continuous Renal Replacement Therapy Protocol for Patients with Acute
   Kidney Injury in Intensive Care Unit with COVID-19
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE Covid-19; AKI; ARDS; CRRT; CVVHD; HCO; cytokines; intensive care
AB COVID-19 often leads to acute respiratory distress syndrome complicated by acute kidney injury (AKI). The indications for renal replacement therapy for these patients are those commonly accepted to treat AKI. We describe a continuous veno-venous haemodialysis (CVVHD) protocol for AKI, which aims to provide the best treatment according to the particular patient's and medical personnels' needs in biohazard settings with limited human and technological resources. We designed a CVVHD protocol with a high cut-off (HCO) filter in regional citrate anticoagulation (RCA). The HCO filter in diffusion determines the enhanced cytokines clearance with less filter clotting due to a lower filtration fraction. In our hospital, at the beginning of the pandemic outbreak, we treated seven COVID-19 patients with AKI stage 2 and 3 and recorded the circuit lifespan and the number of interventions on monitors. CVVHD in RCA appears to be safe, effective and easy to be performed in a biohazard scenario using lower blood flows and less bag changes with fluid savings, a biohazard reduction and sparing of resources. Although the data come from a very small cohort, our protocol seems related to a low mortality.
C1 [Nalesso, Federico; Cattarin, Leda; Gobbi, Laura; Qassim, Laila; Sgarabotto, Luca; Calo, Lorenzo A.] Univ Padua, Dept Med, Nephrol Dialysis & Transplantat Unit, I-35128 Padua, Italy.
   [Garzotto, Francesco] IRCCS, Healthcare Directorate Unit, Veneto Inst Oncol IOV, I-35128 Padua, Italy.
   [Tiberio, Ivo] Univ Padua, Emergency Urgency Dept, Anesthesia & Intens Care, Azienda Osped Padova, I-35128 Padua, Italy.
RP Calo, LA (corresponding author), Univ Padua, Dept Med, Nephrol Dialysis & Transplantat Unit, I-35128 Padua, Italy.
EM federico.nalesso@aopd.veneto.it; f.garzotto@gmail.com;
   leda.cattarin@gmail.com; laura.gobbi@hotmail.it; laila.87@virgilio.it;
   sgarabottoluca@gmail.com; ivo.tiberio@aopd.veneto.it; renzcalo@unipd.it
RI NALESSO, FEDERICO/ABD-4986-2020; garzotto, francesco/K-3552-2018;
   Nalesso, Federico/AAC-2452-2019
OI NALESSO, FEDERICO/0000-0002-1167-2764; garzotto,
   francesco/0000-0002-0233-3752; Sgarabotto, Luca/0000-0002-0547-8607;
   Cattarin, Leda/0000-0002-2692-8494
CR Ankawi G, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2181-z
   Bouadma L, 2020, INTENS CARE MED, V46, P579, DOI 10.1007/s00134-020-05967-x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Garzotto F, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1355-9
   Griffin BR, 2020, AM J KIDNEY DIS, V75, P435, DOI 10.1053/j.ajkd.2019.10.010
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Joannidis M, 2007, CRIT CARE, V11, DOI 10.1186/cc5937
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Meier-Kriesche HU, 2001, CRIT CARE MED, V29, P748, DOI 10.1097/00003246-200104000-00010
   Ostermann M, 2016, BLOOD PURIFICAT, V42, P224, DOI 10.1159/000448506
   Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6
   Villa G, 2014, BLOOD PURIFICAT, V38, P167, DOI 10.1159/000369155
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   World Health Organization, CLIN MAN SEV AC RESP
NR 14
TC 2
Z9 2
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAY
PY 2020
VL 9
IS 5
AR 1529
DI 10.3390/jcm9051529
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA LY0OO
UT WOS:000540223800286
PM 32438617
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wu, CR
   Liu, Y
   Yang, YY
   Zhang, P
   Zhong, W
   Wang, YL
   Wang, QQ
   Xu, Y
   Li, MX
   Li, XZ
   Zheng, MZ
   Chen, LX
   Li, H
AF Wu, Canrong
   Liu, Yang
   Yang, Yueying
   Zhang, Peng
   Zhong, Wu
   Wang, Yali
   Wang, Qiqi
   Xu, Yang
   Li, Mingxue
   Li, Xingzhou
   Zheng, Mengzhu
   Chen, Lixia
   Li, Hua
TI Analysis of therapeutic targets for SARS-CoV-2 and discovery of
   potential drugs by computational methods
SO ACTA PHARMACEUTICA SINICA B
LA English
DT Article
DE SARS-CoV-2; Drug repurposing; Molecular docking; Remdesivir; Homology
   modeling
ID RESPIRATORY SYNDROME-CORONAVIRUS; HOST GENE-EXPRESSION; I INTERFERON;
   NONSTRUCTURAL PROTEINS; CRITICAL DETERMINANTS; SPIKE PROTEIN; MOUSE
   MODEL; COV ENTRY; VIRUS; IDENTIFICATION
AB SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products. Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail. In addition, a database of 78 commonly used antiviral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new lead compounds and targets for further in vitro and in vivo studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections. (C) 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
C1 [Wu, Canrong; Zheng, Mengzhu; Li, Hua] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Hubei Key Lab Nat Med Chem & Resource Evaluat, Wuhan 430030, Peoples R China.
   [Liu, Yang; Yang, Yueying; Zhang, Peng; Wang, Yali; Wang, Qiqi; Xu, Yang; Li, Mingxue; Chen, Lixia; Li, Hua] Shenyang Pharmaceut Univ, Wuya Coll Innovat, Minist Educ, Key Lab Struct Based Drug Design & Discovery, Shenyang 110016, Peoples R China.
   [Zhong, Wu; Li, Xingzhou] Beijing Inst Pharmacol & Toxicol, Natl Engn Res Ctr Emergency Drug, Beijing 100850, Peoples R China.
RP Zheng, MZ; Li, H (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Hubei Key Lab Nat Med Chem & Resource Evaluat, Wuhan 430030, Peoples R China.; Chen, LX; Li, H (corresponding author), Shenyang Pharmaceut Univ, Wuya Coll Innovat, Minist Educ, Key Lab Struct Based Drug Design & Discovery, Shenyang 110016, Peoples R China.; Li, XZ (corresponding author), Beijing Inst Pharmacol & Toxicol, Natl Engn Res Ctr Emergency Drug, Beijing 100850, Peoples R China.
EM xingzhouli@aliyun.com; mengzhu_zheng@hust.edu.cn; syzyclx@163.com;
   li_hua@hust.edu.cn
FU National Mega-project for Innovative Drugs (China)
   [2019ZX09721001-004-007]; National Natural Science Foundation of China
   (NSFC)National Natural Science Foundation of China (NSFC) [U1803122,
   81773637, 81773594, U1703111]; Fundamental Research Fund for the Central
   Universities (HUST COVID-19 Rapid Response Call, China) [2020kfyXGYJ037]
FX We acknowledge support from National Mega-project for Innovative Drugs
   (grant number 2019ZX09721001-004-007, China), National Natural Science
   Foundation of China (NSFC, grant numbers U1803122, 81773637, 81773594,
   and U1703111), and the Fundamental Research Fund for the Central
   Universities (HUST COVID-19 Rapid Response Call, No. 2020kfyXGYJ037,
   China). This article is dedicated to the heroic medical workers who are
   fighting in the front line of anti epidemic and the people of Wuhan who
   made great sacrifices.
CR ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503
   Agrawal AS, 2015, J VIROL, V89, P3659, DOI 10.1128/JVI.03427-14
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chen H., 2020, POTENTIAL NATURAL CO, DOI [10.20944/preprints202001.0358.v3, 10.20944/preprints202001., DOI 10.20944/PREPRINTS202001.0358.V3]
   Chen XJ, 2014, PROTEIN CELL, V5, P369, DOI 10.1007/s13238-014-0026-3
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Chu Chung K., 2006, Antiviral Chemistry & Chemotherapy, V17, P285
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Forni D, 2016, J VIROL, V90, P3627, DOI 10.1128/JVI.02988-15
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han DP, 2006, VIROLOGY, V350, P15, DOI 10.1016/j.virol.2006.01.029
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Heald-Sargent T, 2012, VIRUSES-BASEL, V4, P557, DOI 10.3390/v4040557
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imbert I, 2006, EMBO J, V25, P4933, DOI 10.1038/sj.emboj.7601368
   Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277
   Ivanov KA, 2004, J VIROL, V78, P7833, DOI 10.1128/JVI.78.14.7833-7838.2004
   Jang KJ, 2008, BIOCHEM BIOPH RES CO, V366, P738, DOI 10.1016/j.bbrc.2007.12.020
   Jaroszewski L, 2005, NUCLEIC ACIDS RES, V33, pW284, DOI 10.1093/nar/gki418
   Kamitani W, 2006, P NATL ACAD SCI USA, V103, P12885, DOI 10.1073/pnas.0603144103
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li SW, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050678
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Muegge I, 1999, J MED CHEM, V42, P791, DOI 10.1021/jm980536j
   Narayananj K, 2008, J VIROL, V82, P4471, DOI 10.1128/JVI.02472-07
   Neves MAC, 2012, J COMPUT AID MOL DES, V26, P675, DOI 10.1007/s10822-012-9547-0
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Shum KT, 2008, CHEMBIOCHEM, V9, P3037, DOI 10.1002/cbic.200800491
   Subissi L, 2014, ANTIVIR RES, V101, P122, DOI 10.1016/j.antiviral.2013.11.006
   Taylor JK, 2015, J VIROL, V89, P11820, DOI 10.1128/JVI.02274-15
   van der Linden L, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004733
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Xia S, 2014, VIRUS RES, V194, P200, DOI 10.1016/j.virusres.2014.10.007
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Ye RS, 2020, EXP MOL PATHOL, V113, DOI 10.1016/j.yexmp.2019.104350
   Yuan L, 2015, J BIOL CHEM, V290, P3172, DOI 10.1074/jbc.M114.619890
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 55
TC 294
Z9 300
U1 36
U2 46
PU INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
PI BEIJING
PA C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA
SN 2211-3835
EI 2211-3843
J9 ACTA PHARMACOL SIN B
JI Acta Pharm. Sin. B
PD MAY
PY 2020
VL 10
IS 5
BP 766
EP 788
DI 10.1016/j.apsb.2020.02.008
PG 23
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LW2OC
UT WOS:000538982700004
PM 32292689
OA DOAJ Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Nguyen, NP
   Vinh-Hung, V
   Baumert, BG
   Zamagni, A
   Arenas, M
   Motta, M
   Lara, PC
   Myint, AS
   Bonet, M
   Popescu, T
   Vuong, T
   Appalanaido, GK
   Trigo, L
   Karlsson, U
   Thariat, J
AF Nguyen, Nam P.
   Vinh-Hung, Vincent
   Baumert, Brigitta G.
   Zamagni, Alice
   Arenas, Meritxell
   Motta, Micaela
   Carlos Lara, Pedro
   Myint, Arthur Sun
   Bonet, Marta
   Popescu, Tiberiu
   Te Vuong
   Appalanaido, Gokula Kumar
   Trigo, Lurdes
   Karlsson, Ulf
   Thariat, Juliette
TI Older Cancer Patients during the COVID-19 Epidemic: Practice Proposal of
   the International Geriatric Radiotherapy Group
SO CANCERS
LA English
DT Article
DE older; cancer patients; epidemic; corona virus 19; treatment
ID TARGETED THERAPY; ADULTS; NAVIGATION; MOBILITY; BARRIERS; CARE
AB The coronavirus disease 19 (COVID-19) pandemic is unprecedented as it reached all countries in the world within a record short period of time. Even though COVID-19 infection may be just severe in any adults, older adults (65-year-old or older) may experience a higher mortality rate. Among those affected, cancer patients may have a worse outcome compared to the general population because of their depressed immune status. As the health resources of most countries are limited, clinicians may face painful decisions about which patients to save if they require artificial ventilation. Cancer patients, especially the older ones, may be denied supportive care because of their shorter life expectancy. Thus, special considerations should be taken to prevent infection of older cancer patients and to provide them with adequate social support during their cancer treatment. The following proposal was reached: (1) Education of health care providers about the special needs of older cancer patients and their risks of infection. (2) Special consideration such as surgical masks and separate scheduling should be made to protect them from being infected. (3) Social services such as patient navigators should be provided to ensure adequate medical supply, food, and daily transportation to cancer centers. (4) Close monitoring through phone calls, telecommunication to ensure social distancing and psychological support from patient family to prevent anxiety and depression. (5) Shorter course of radiotherapy by use of hypofractionation where possible to decrease the needs for daily transportation and exposure to infection. (6) Enrollment of older cancer patients in clinical trials for potential antiviral medications if infection does occur. (7) Home health care telemedicine may be an effective strategy for older cancer patients with COVID-19 infection to avoid hospital admission when health care resources become restricted. (8) For selected patients, immunotherapy and targeted therapy may become the systemic therapy of choice for older cancer patients and need to be tested in clinical trials.
C1 [Nguyen, Nam P.] Howard Univ, Dept Radiat Oncol, Washington, DC 20060 USA.
   [Vinh-Hung, Vincent] Univ Hosp Martinique, Dept Radiat Oncol, F-97200 Fort De France, France.
   [Baumert, Brigitta G.] Cantonal Hosp Graubuenden, Inst Radiat Oncol, CH-7000 Chur, Switzerland.
   [Zamagni, Alice] Univ Bologna, Radiat Oncol Ctr, Dept Expt Diagnost & Specialty Med, St Orsola Malpighi Hosp, I-40138 Bologna, Italy.
   [Arenas, Meritxell] Univ Rovira & Virgili, St Joan Reus Univ, Dept Radiat Oncol, Tarragona 43201, Spain.
   [Motta, Micaela] Hosp Papa Giovanni XXIII, Dept Radiat Oncol, I-24127 Bergamo, Italy.
   [Carlos Lara, Pedro] Fernando Pessoa Canarias Las Palmas Univ, Dept Radiat Oncol, Las Palmas Gran Canaria 35001, Spain.
   [Myint, Arthur Sun] Clatterbridge Canc Ctr, Dept Radiat Oncol, Liverpool CH63 4JY, Merseyside, England.
   [Bonet, Marta] Arnau Vilanova Univ Hosp, Dept Radiat Oncol, Lleida 25198, Spain.
   [Popescu, Tiberiu] Prof Dr Ion Chricuta Oncol Inst, Dept Radiat Oncol, Cluj Napoca 400015, Romania.
   [Te Vuong] McGill Univ, Jewish Gen Hosp, Dept Radiat Oncol, Montreal, PQ H3T 1E2, Canada.
   [Appalanaido, Gokula Kumar] Univ Sains Malaysia, AMDI, Dept Radiat Oncol, George Town 13200, Malaysia.
   [Trigo, Lurdes] Inst Portugues Oncol Porto Francisco Martins Port, Dept Radiat Oncol, P-4200072 Porto, Portugal.
   [Karlsson, Ulf] Int Geriatr Grp, Dept Radiat Oncol, Washington, DC 20001 USA.
   [Thariat, Juliette] Baclesse Canc Ctr, Dept Radiat Oncol, F-14000 Caen, France.
RP Nguyen, NP (corresponding author), Howard Univ, Dept Radiat Oncol, Washington, DC 20060 USA.
EM namphong.nguyen@yahoo.com; anhxang@gmail.com;
   brigitta.baumert@gmail.com; alice.zamagni4@unibo.it;
   meritxell.arenas@gmail.com; Motta.micaela@libero.it;
   pedrocarlos.lara@ulpgc.es; sun.myint@nhs.net;
   mabonet.lleida.ics@gencat.cat; tiberiu_popescu14@yahoo.com;
   te.vuong@mcgill.ca; gokudroid@gmail.com;
   lurdes.trigo@ipoporto.min-saude.pt; karlssonulf30@gmail.com;
   jthariat@gmail.com
RI Baumert, Brigitta G./AAM-6549-2020; Vinh-Hung, Vincent/A-5762-2008;
   Arenas Prat, Meritxell/F-2631-2014
OI Baumert, Brigitta G./0000-0001-8871-4654; Vinh-Hung,
   Vincent/0000-0002-6403-6120; Nguyen, Nam/0000-0001-5106-6665; Bonet,
   Marta/0000-0002-6417-0514; Arenas Prat, Meritxell/0000-0003-0815-2570;
   Zamagni, Alice/0000-0001-8942-793X
CR Adams JG, 2020, JAMA-J AM MED ASSOC, V323, P1439, DOI 10.1001/jama.2020.3972
   Alsahafi AJ, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13121214
   Antonelli G, 2016, ONCOL LETT, V11, P3, DOI 10.3892/ol.2015.3901
   Aronson J.K., 2020, CEBM RES
   Augestad KM, 2020, BRIT J SURG, V107, P509, DOI 10.1002/bjs.11491
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bastawrous A, 2013, J ROY SOC MED, V106, P130, DOI 10.1177/0141076812472620
   Chavarri-Guerra Y, 2019, ONCOLOGIST, V24, P1195, DOI 10.1634/theoncologist.2018-0133
   Cheville AL, 2019, JAMA ONCOL, V5, P644, DOI 10.1001/jamaoncol.2019.0011
   Choi NG, 2016, GERONTOLOGIST, V56, P432, DOI 10.1093/geront/gnu116
   Deckx L, 2015, PSYCHO-ONCOLOGY, V24, P1521, DOI 10.1002/pon.3818
   Deckx L, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0071-7
   Ethun CG, 2017, CA-CANCER J CLIN, V67, P363, DOI 10.3322/caac.21406
   Flodgren G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002098.pub2
   Frederick JT, 2007, AM J PREV MED, V33, P222, DOI 10.1016/j.amepre.2007.04.035
   Fromentin R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08798-7
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Hoffman KE, 2018, J CLIN ONCOL, V36, P2943, DOI 10.1200/JCO.2018.77.9868
   Kelly CM, 2014, J CLIN ONCOL, V32, P2635, DOI 10.1200/JCO.2014.55.4246
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Kim YJ, 2019, INFECT DIS-NOR, V51, P502, DOI 10.1080/23744235.2019.1592217
   Kliger Y, 2003, BMC MICROBIOL, V3, DOI 10.1186/1471-2180-3-20
   Koester KA, 2014, AIDS PATIENT CARE ST, V28, P82, DOI 10.1089/apc.2013.0279
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Massie Mary Jane, 2004, J Natl Cancer Inst Monogr, P57
   MORALES JO, 1994, AM J MED, V97, P28, DOI 10.1016/0002-9343(94)90285-2
   Myint AS, 2014, J GASTROINTEST ONCOL, V5, P212, DOI 10.3978/j.issn.2078-6891.2014.031
   Nguyen NP, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005212
   Paskett ED, 2011, CA-CANCER J CLIN, V61, P237, DOI 10.3322/caac.20111
   Popescu T, 2019, CANCERS, V11, DOI 10.3390/cancers11030371
   Renner A, 2019, J GLOB ONCOL, V5, DOI 10.1200/JGO.19.00142
   Signorelli GR, 2019, J MED INTERNET RES, V21, DOI 10.2196/14360
   Salloum RG, 2012, LUNG CANCER, V75, P255, DOI 10.1016/j.lungcan.2011.07.005
   Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259
   Shafique M, 2019, EXPERT OPIN BIOL TH, V19, P225, DOI 10.1080/14712598.2019.1571036
   Shen J, 2017, J GERIATR ONCOL, V8, P437, DOI 10.1016/j.jgo.2017.08.008
   Shepperd S, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007491
   Skjaker SA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181312
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Syed ST, 2013, J COMMUN HEALTH, V38, P976, DOI 10.1007/s10900-013-9681-1
   Talreja V.T., 2019, CANCER RES, V2, P266
   Tejeda S, 2013, J WOMENS HEALTH, V22, P507, DOI 10.1089/jwh.2012.3590
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   van Holstein Y, 2019, DRUG AGING, V36, P927, DOI 10.1007/s40266-019-00697-2
   Wang J., 2019, J HOSP INFECT
   Wang SL, 2019, LANCET ONCOL, V20, P352, DOI 10.1016/S1470-2045(18)30813-1
   Webber SC, 2010, GERONTOLOGIST, V50, P443, DOI 10.1093/geront/gnq013
   Yoo SH, 2018, ESMO OPEN, V3, DOI 10.1136/esmoopen-2018-000332
   Yu DP, 2017, ONCOL LETT, V14, P1568, DOI 10.3892/ol.2017.6274
NR 51
TC 2
Z9 2
U1 7
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAY
PY 2020
VL 12
IS 5
AR 1287
DI 10.3390/cancers12051287
PG 10
WC Oncology
SC Oncology
GA LW6HT
UT WOS:000539246000228
PM 32438703
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Huang, XT
   Quan, H
   Zhao, B
   Zhou, W
   Chen, C
   Chen, Y
AF Huang, Xiaotian
   Quan, Hong
   Zhao, Bo
   Zhou, Wing
   Chen, Charles
   Chen, Yan
TI Radiation therapy considerations during the COVID-19 Pandemic:
   Literature review and expert opinions
SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS
LA English
DT Article
DE coronavirus; COVID-19; quality assurance; radiotherapy; World Health
   Organization
ID RADIOTHERAPY; CANCER
C1 [Huang, Xiaotian; Quan, Hong] Wuhan Univ, Sch Phys & Technol, Wuhan, Peoples R China.
   [Huang, Xiaotian; Zhou, Wing; Chen, Charles; Chen, Yan] Elekta Shanghai Instruments Ltd, Shanghai, Peoples R China.
   [Zhao, Bo] Peking Univ First Hosp, Dept Radiat Oncol, Beijing, Peoples R China.
RP Chen, Y (corresponding author), Elekta Shanghai Instruments Ltd, Shanghai, Peoples R China.
EM yan.chen@elekta.com
CR Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   [Anonymous], YAL RAD ONC COVID 19
   [Anonymous], MAN PAT CONF 2019 NC
   [Anonymous], CHAR HLTH CAR PERS C
   [Anonymous], 2020, 70000 SPAN NURS MAY
   [Anonymous], 2020, DANILCHEV COVID 19 D
   Bese NS, 2007, INT J RADIAT ONCOL, V68, P654, DOI 10.1016/j.ijrobp.2007.03.010
   Braunstein LZ, 2020, ADV RAD ONCOL
   Burki TK, 2020, LANCET ONCOL, DOI 10.1016/S1470-2045(70)30096-6
   Calabrese Edward J., 2013, Yale Journal of Biology and Medicine, V86, P555
   Center for disease control and prevention, 2003, GUIDELINES ENV INFEC
   Centers for Disease Control and Prevention CDC, TEST US
   Delaney G, 2005, CANCER-AM CANCER SOC, V104, P1129, DOI 10.1002/cncr.21324
   DUBIN IN, 1946, AM J ROENTGENOL, V55, P478
   Emanuel E, 2020, N ENGL J MED
   Filippi AR, 2020, INT J RAD ONCOL BIOL
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Grein J, 2020, N ENGL J MED
   Guckenberger M., 2020, RADIOTHER ONCOL
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Kirkby C, 2020, RADIOTHER ONCOL
   Krengli M, 2020, ADV RAD ONCOL
   Le Thanh T, 2020, NAT REV DRUG DISCOV
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   McGinnis GJ, 2020, J THOR ONCOL
   Mitchell R, 2020, EMERG MED J
   Mukherjee R K, 2003, Australas Radiol, V47, P143, DOI 10.1046/j.0004-8461.2003.01165.x
   New York City Health, COR DIS 2019 COVID 1
   Nogueira LM, 2019, JAMA-J AM MED ASSOC, V322, P269, DOI 10.1001/jama.2019.7657
   Onder G, 2020, JAMA
   Oppenheimer A, 1943, J PEDIAT, V41, P404
   Papachristofilou A, 2020, ADV RAD ONCOL
   Powell EV, 1936, TEX STATE J MED, V32, P237
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Rivera AON, 2020, ADV RAD ONCOL
   Rosenblatt E, 2015, INT J RADIAT ONCOL, V91, P687, DOI 10.1016/j.ijrobp.2014.12.008
   Shankar Abhishek, 2020, Asian Pac J Cancer Prev, V21, P569, DOI 10.31557/APJCP.2020.21.3.569
   Tang X, 2020, NAT SCI REV
   Thomson DJ, 2020, INT J RAD ONCOL BIOL
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   US Food & Drug Administration, FAQS SHORT SURG MASK
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Wei W, 2020, RADIOTHER ONCOL
   WHO, 87 WHO
   Willan J, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1117
   World Health Organization, CANC KEY FACTS
   World Health Organization, INF PREV CONTR HLTH
   Wright JL, 2020, ADV RAD ONCOL
   Wu S, 2020, ADV RAD ONCOL
   Yerramilli D, 2020, ADV RAD ONCOL
   Zaorsky NG, 2020, ADV RAD ONCOL
   Zhang L., 2020, ANN ONCOL
NR 52
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1526-9914
J9 J APPL CLIN MED PHYS
JI J. Appl. Clin. Med. Phys
PD MAY
PY 2020
VL 21
IS 5
BP 13
EP 25
DI 10.1002/acm2.12848
PG 13
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA LW4GJ
UT WOS:000539102200003
PM 32180351
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dixon, DL
   Van Tassell, BW
   Vecchie, A
   Bonaventura, A
   Talasaz, AH
   Kakavand, H
   D'Ascenzo, F
   Perciaccante, A
   Castagno, D
   Ammirati, E
   Biondi-Zoccai, G
   Stevens, MP
   Abbate, A
AF Dixon, Dave L.
   Van Tassell, Benjamin W.
   Vecchie, Alessandra
   Bonaventura, Aldo
   Talasaz, Azita H.
   Kakavand, Hessam
   D'Ascenzo, Fabrizio
   Perciaccante, Antonio
   Castagno, Davide
   Ammirati, Enrico
   Biondi-Zoccai, Giuseppe
   Stevens, Michael P.
   Abbate, Antonio
TI Cardiovascular Considerations in Treating Patients With Coronavirus
   Disease 2019 (COVID-19)
SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
LA English
DT Article
DE coronavirus; COVID-19; cardiovascular; drug interaction
ID VENTILATOR-ASSOCIATED PNEUMONIA; DRUG-DRUG INTERACTIONS; PROTEASE
   INHIBITORS; MORTALITY; HIV; AZITHROMYCIN; REMDESIVIR; INFLUENZA;
   RITONAVIR; THERAPY
AB A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) has a significantly higher mortality rate than seasonal influenza and has disproportionately affected older adults, especially those with cardiovascular disease and related risk factors. Adverse cardiovascular sequelae, such as myocarditis, acute myocardial infarction, and heart failure, have been reported in patients with COVID-19. No established treatment is currently available; however, several therapies, including remdesivir, hydroxychloroquine and chloroquine, and interleukin (IL)-6 inhibitors, are being used off-label and evaluated in ongoing clinical trials. Considering these therapies are not familiar to cardiovascular clinicians managing these patients, this review describes the pharmacology of these therapies in the context of their use in patients with cardiovascular-related conditions.
C1 [Dixon, Dave L.; Van Tassell, Benjamin W.] Virginia Commonwealth Univ, Dept Pharmacotherapy & Outcomes Sci, Sch Pharm, Richmond, VA 23298 USA.
   [Dixon, Dave L.; Van Tassell, Benjamin W.; Vecchie, Alessandra; Bonaventura, Aldo; Abbate, Antonio] Virginia Commonwealth Univ, Pauley Heart Ctr, Dept Internal Med, Div Cardiol, Richmond, VA 23298 USA.
   [Bonaventura, Aldo] Univ Genoa, Dept Internal Med, Clin Internal Med 1, Genoa, Italy.
   [Talasaz, Azita H.; Kakavand, Hessam] Univ Tehran Med Sci, Tehran Heart Ctr, Tehran, Iran.
   [D'Ascenzo, Fabrizio; Castagno, Davide] Univ Turin, Dept Med Sci, Div Cardiol, Turin, Italy.
   [Perciaccante, Antonio] Univ Hlth Agcy Giuliano Isontina, San Giovanni di Dio Hosp, Dept Med, Gorizia, Italy.
   [Ammirati, Enrico] Osped Niguarda Ca Granda, Dept Cardiol, Milan, Italy.
   [Biondi-Zoccai, Giuseppe] Univ Rome, Dept Med Surg Sci & Biotechnol Sapienza, Rome, Italy.
   [Biondi-Zoccai, Giuseppe] Mediterranea Cardioctr, Naples, Italy.
   [Stevens, Michael P.] Virginia Commonwealth Univ, Dept Internal Med, Div Infect Dis, Richmond, VA 23298 USA.
RP Dixon, DL (corresponding author), Virginia Commonwealth Univ, Sch Pharm, 410 N 12th St,Box 980533, Richmond, VA 23298 USA.
EM dldixon@vcu.edu
RI Bonaventura, Aldo/ABC-4051-2020; Abbate, Antonio/G-8805-2016; Stevens,
   Michael P./ABB-3726-2020
OI Abbate, Antonio/0000-0002-1930-785X; Stevens, Michael
   P./0000-0001-5042-4088; Kakavand, Hessam/0000-0001-6719-4856
CR Alvi RM, 2018, J AM COLL CARDIOL, V72, P518, DOI 10.1016/j.jacc.2018.04.083
   Amsden GW, 2005, J ANTIMICROB CHEMOTH, V55, P10, DOI 10.1093/jac/dkh519
   Antonopoulos AS, 2012, CURR PHARM DESIGN, V18, P1519
   Biondi-Zoccai G, 2020, MINERVA CARDIOANGIOL
   Boehm M, 2002, NEW ENGL J MED, V347, P1795, DOI 10.1056/NEJMcibr022472
   Bozkurt B, HFSA ACC AHA STATEME
   Caldeira D, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4260
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Castagne B, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220178
   Chauvin B, 2013, CLIN PHARMACOKINET, V52, P815, DOI 10.1007/s40262-013-0075-4
   Chen J., 2020, INDIVIDUAL VARIATION
   Chen J., 2020, J ZHEJIANG U MED SCI, V49
   de Simone G., POSITION STATEMENT E
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Douglas I, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1642
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Dube MP, 2008, CLIN INFECT DIS, V47, P567, DOI 10.1086/590154
   Egan G, 2014, ANN PHARMACOTHER, V48, P734, DOI 10.1177/1060028014523115
   European Medicines Agency, EMA GIV ADV US NONST
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   FitzGerald GA, 2020, SCIENCE, V367, P1434, DOI 10.1126/science.abb8034
   Foy M, 2014, CURR HIV-AIDS REP, V11, P212, DOI 10.1007/s11904-014-0212-1
   Frost FJ, 2007, CHEST, V131, P1006, DOI 10.1378/chest.06-1997
   Gautret P, CLIN MICROBIOLOGICAL
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hancox JC, 2013, THER ADV INFECT DIS, V1, P155, DOI 10.1177/2049936113501816
   Hsu A, 1998, CLIN PHARMACOKINET, V35, P275, DOI 10.2165/00003088-199835040-00002
   Hu H, 2020, EUR HEART J
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kuster GM, 2020, EUR HEART J
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Liang J, 2020, ADV ENERGY MATER, V10, DOI 10.1002/aenm.202000022
   Lippi G, 2020, PROG CARDIOVASC DIS
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   MacIntyre CR, 2016, HEART, V102, P1953, DOI 10.1136/heartjnl-2016-309983
   Makris D, 2011, CRIT CARE MED, V39, P2440, DOI 10.1097/CCM.0b013e318225742c
   Mao L., 2020, NEUROLOGICAL MANIFES, DOI [10.1101/2020.02.22.20026500., 10.1101/2020.02.22.20026500, DOI 10.1101/2020.02.22.20026500]
   Maude SL, 2014, CANCER J, V20, P119, DOI 10.1097/PPO.0000000000000035
   Momattin H, 2019, TRAVEL MED INFECT DI, V30, P9, DOI 10.1016/j.tmaid.2019.06.012
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Onder G, 2020, JAMA
   Pao V, 2008, CURR ATHEROSCLER REP, V10, P61, DOI 10.1007/s11883-008-0010-6
   Papazian L, 2013, JAMA-J AM MED ASSOC, V310, P1692, DOI 10.1001/jama.2013.280031
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Science Alert, UPD WHO NOW DOESNT R
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shi S, 2020, JAMA CARDIOL
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Tselios K, 2018, LUPUS, V27, P591, DOI 10.1177/0961203317734922
   US Food and Drug Administration, FDA ADV PAT US NONST
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang ZY, 2015, THER CLIN RISK MANAG, V11, P449, DOI 10.2147/TCRM.S80437
   Wiggins BS, 2020, J AM COLL CARDIOL, V75, P1341, DOI 10.1016/j.jacc.2019.12.068
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu Z, 2020, JAMA-J AM MED ASSOC, V2019, P3
   Xu XB, 2020, EXPERT OPIN DRUG SAF, V19, P641, DOI 10.1080/14740338.2020.1734558
   Yang PH, 2014, SCI REP-UK, V4, DOI 10.1038/srep07027
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yeo C, 2020, LANCET GASTROENTEROL, V5, P335, DOI 10.1016/S2468-1253(20)30048-0
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 68
TC 15
Z9 16
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0160-2446
EI 1533-4023
J9 J CARDIOVASC PHARM
JI J. Cardiovasc. Pharmacol.
PD MAY
PY 2020
VL 75
IS 5
BP 359
EP 367
DI 10.1097/FJC.0000000000000836
PG 9
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA LW5UT
UT WOS:000539212200001
PM 32282502
OA Green Published
DA 2021-01-01
ER

PT J
AU Rahman, N
   Basharat, Z
   Yousuf, M
   Castaldo, G
   Rastrelli, L
   Khan, H
AF Rahman, Noor
   Basharat, Zarrin
   Yousuf, Muhammad
   Castaldo, Giuseppe
   Rastrelli, Luca
   Khan, Haroon
TI Virtual Screening of Natural Products against Type II Transmembrane
   Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2
   (SARS-CoV-2)
SO MOLECULES
LA English
DT Article
DE coronavirus; serine protease; natural product; drug design; docking
ID RESPIRATORY-SYNDROME CORONAVIRUS; SARS CORONAVIRUS; SPIKE PROTEIN;
   INHIBITORS; VIRUS; EXPRESSION; DISCOVERY; RELEASE; CELLS
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused about 2 million infections and is responsible for more than 100,000 deaths worldwide. To date, there is no specific drug registered to combat the disease it causes, named coronavirus disease 2019 (COVID-19). In the current study, we used an in silico approach to screen natural compounds to find potent inhibitors of the host enzyme transmembrane protease serine 2 (TMPRSS2). This enzyme facilitates viral particle entry into host cells, and its inhibition blocks virus fusion with angiotensin-converting enzyme 2 (ACE2). This, in turn, restricts SARS-CoV-2 pathogenesis. A three-dimensional structure of TMPRSS2 was built using SWISS-MODEL and validated by RAMPAGE. The natural compounds library Natural Product Activity and Species Source (NPASS), containing 30,927 compounds, was screened against the target protein. Two techniques were used in the Molecular Operating Environment (MOE) for this purpose, i.e., a ligand-based pharmacophore approach and a molecular docking-based screening. In total, 2140 compounds with pharmacophoric features were retained using the first approach. Using the second approach, 85 compounds with molecular docking comparable to or greater than that of the standard inhibitor (camostat mesylate) were identified. The top 12 compounds with the most favorable structural features were studied for physicochemical and ADMET (absorption, distribution, metabolism, excretion, toxicity) properties. The low-molecular-weight compound NPC306344 showed significant interaction with the active site residues of TMPRSS2, with a binding energy score of -14.69. Further in vitro and in vivo validation is needed to study and develop an anti-COVID-19 drug based on the structures of the most promising compounds identified in this study.
C1 [Rahman, Noor; Yousuf, Muhammad] Univ Karachi, HEJ Res Inst Chem, Int Ctr Chem & Biol Sci, Karachi 75270, Pakistan.
   [Basharat, Zarrin] Univ Karachi, ICCBS, PCMD, Jamil ur Rahman Ctr Genome Res, Karachi 75270, Pakistan.
   [Castaldo, Giuseppe; Rastrelli, Luca] NUTRIKETO LAB Unisa San Giuseppe Moscati Natl Hos, I-83100 Avellino, AV, Italy.
   [Rastrelli, Luca] Univ Salerno, Dipartimento Farm, Via Giovanni Paolo II, I-84084 Fisciano, SA, Italy.
   [Khan, Haroon] Abdul Wali Khan Univ, Dept Pharm, Mardan 23200, Pakistan.
RP Rastrelli, L (corresponding author), NUTRIKETO LAB Unisa San Giuseppe Moscati Natl Hos, I-83100 Avellino, AV, Italy.; Rastrelli, L (corresponding author), Univ Salerno, Dipartimento Farm, Via Giovanni Paolo II, I-84084 Fisciano, SA, Italy.; Khan, H (corresponding author), Abdul Wali Khan Univ, Dept Pharm, Mardan 23200, Pakistan.
EM noorbiochemist@gmail.com; zarrin.iiui@gmail.com; planck56@gmail.com;
   giuseppecastaldo@yahoo.it; rastrelli@unisa.it; haroonkhan@awkum.edu.pk
RI Rastrelli, Luca/A-4159-2011; Khan, Haroon/AAY-1785-2020; /D-5805-2014
OI Rastrelli, Luca/0000-0001-6102-2762; Khan, Haroon/0000-0002-1736-4404;
   Rastrelli, Luca/0000-0003-0718-5450; Yousuf,
   Muhammad/0000-0001-9103-5281; /0000-0003-1785-3803; Rahman,
   Noor/0000-0002-7062-2302
FU "San Giuseppe Moscati" National Hospital (AORN), Avellino, Italy; MIUR
   grant FARB, University of Salerno
FX This work was funded by the "San Giuseppe Moscati" National Hospital
   (AORN), Avellino, Italy, and the MIUR grant FARB, University of Salerno.
CR ARPIN N, 1990, ADV EXP MED BIOL, V276, P73
   Asselta R., 2020, ACE2 TMPRSS2 VARIANT, DOI [10.2139/ssrn.3559608, DOI 10.2139/SSRN.3559608]
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Bugge TH, 2009, J BIOL CHEM, V284, P23177, DOI 10.1074/jbc.R109.021006
   Burns AR, 2010, ANGEW CHEM INT EDIT, V49, P5574, DOI 10.1002/anie.201002416
   Celano R, 2017, FOOD RES INT, V99, P298, DOI 10.1016/j.foodres.2017.05.036
   de Haan CAM, 2005, ADV VIRUS RES, V64, P165, DOI 10.1016/S0065-3527(05)64006-7
   Donaldson SH, 2002, J BIOL CHEM, V277, P8338, DOI 10.1074/jbc.M105044200
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Gupta G. L., 2007, Pharmacognosy Reviews, V1, P129
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang BS, 2017, CELL PHYSIOL BIOCHEM, V43, P705, DOI 10.1159/000480657
   Huang HF, 2017, EXP THER MED, V13, P437, DOI 10.3892/etm.2016.4011
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Lucas JM, 2014, CANCER DISCOV, V4, P1310, DOI 10.1158/2159-8290.CD-13-1010
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Matsuyama S, 2005, P NATL ACAD SCI USA, V102, P12543, DOI 10.1073/pnas.0503203102
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Menachery VD, 2020, J VIROL, V94, DOI 10.1128/JVI.01774-19
   Moore MJ, 2004, J VIROL, V78, P10628, DOI 10.1128/JVI.78.19.10628-10635.2004
   Mortola E, 2004, FEBS LETT, V576, P174, DOI 10.1016/j.febslet.2004.09.009
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   NISHIZAWA M, 1988, CHEM PHARM BULL, V36, P87
   Pal M, 2020, CUREUS, V12, DOI 10.7759/cureus.7423
   Plotnikov MB, 2019, MOLECULES, V24, DOI 10.3390/molecules24091722
   Rest JS, 2003, INFECT GENET EVOL, V3, P219, DOI 10.1016/j.meegid.2003.08.001
   Reusken CBEM, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.6.2000082
   Shan MQ, 2017, MOLECULES, V22, DOI 10.3390/molecules22101689
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   Shirato K, 2013, J VIROL, V87, P12552, DOI 10.1128/JVI.01890-13
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Siu YL, 2008, J VIROL, V82, P11318, DOI 10.1128/JVI.01052-08
   Song HC, 2004, J VIROL, V78, P10328, DOI 10.1128/JVI.78.19.10328-10335.2004
   Stermitz FR, 2000, P NATL ACAD SCI USA, V97, P1433, DOI 10.1073/pnas.030540597
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Venkatagopalan P, 2015, VIROLOGY, V478, P75, DOI 10.1016/j.virol.2015.02.005
   WHO, 2003, SUMM PROB SARS CAS O
   Zeng X, 2018, NUCLEIC ACIDS RES, V46, pD1217, DOI 10.1093/nar/gkx1026
   Zhang C, 2020, BRIT J PHARMACOL, V177, P3240, DOI 10.1111/bph.15046
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 46
TC 12
Z9 12
U1 4
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD MAY
PY 2020
VL 25
IS 10
AR 2271
DI 10.3390/molecules25102271
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA LW6ZT
UT WOS:000539293400004
PM 32408547
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chen, YH
   Zheng, JL
   Wu, DY
   Zhang, YX
   Lin, Y
AF Chen, Yihong
   Zheng, Jili
   Wu, Dingyun
   Zhang, Yuxia
   Lin, Ying
TI Application of the PDCA cycle for standardized nursing management in a
   COVID-19 intensive care unit
SO ANNALS OF PALLIATIVE MEDICINE
LA English
DT Article
DE Plan-Do-Check-Act cycle (PDCA cycle); coronavirus disease 2019
   (COVID-19); nursing management; standardization
AB Background: Nursing quality is an integral part of health care quality and one of key performance indicators (KPIs) for health care management. The Plan-Do-Check-Act (PDCA) cycle is a management tool for continuous improvement of a business's products or processes. It can be applied to standardize nursing management and thus improve the nursing quality and increase the survival rate of patients. This study assessed the value of the PDCA cycle in standardizing nursing management in an intensive care unit (ICU) for patients with severe coronavirus disease 2019 (COVID-19).
   Methods: The status quo of the ICU was analyzed, and the relevant issues and countermeasures were proposed. The PDCA cycle was applied to standardize the nursing management in the ICU.
   Results: Nine measures were proposed and applied to improve the management of the COVID-19 ICU: defining the clean or contaminated areas, use of self-designed shoe storage cabinets, defining staff roles and responsibilities, establishing the staffing structure, staff training, placing items at fixed locations, improving shift handover, use of bulletin boards for listing key points, and use of reserved drugs cabinets. The virus contamination awareness, professional skills, awareness of duties and responsibilities, and quality and performance of nursing were remarkably improved 2 weeks after the implementation of the above countermeasures.
   Conclusions: The PDCA cycle helps to standardize nursing management in COVID-19 ICU by developing and applying effective nursing management approaches.
C1 [Chen, Yihong; Zheng, Jili; Wu, Dingyun; Zhang, Yuxia; Lin, Ying] Fudan Univ, Zhongshan Hosp, Dept Nursing, Shanghai 200032, Peoples R China.
RP Zhang, YX; Lin, Y (corresponding author), Fudan Univ, Zhongshan Hosp, Shanghai 200032, Peoples R China.
EM zhang.yuxia@zs-hospital.sh.cn; lin.ying@zs-hospital.sh.cn
FU Youth Medical Talents-Nursing Program [087]
FX This work was supported by the Youth Medical Talents-Nursing Program
   (grant number [2020] No.087).
CR Dai J., 2018, CHINA HLTH STANDARD, V13, P195
   He C, 2017, J CLIN MED PRAC, V21, P106
   Hua L, 2014, PROTEIN EXPRES PURIF, V97, P17, DOI 10.1016/j.pep.2014.02.004
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang W, 2011, ENG ED MANAGEMENT, P625
   Li X., 2019, CHIN J PRIM MED PHAR, V26, P2293
   Liu X., 2018, WORLD LAT MED INFO, V47, P263
   Pan L, 2014, J KUNMING MED U, V35, P175
   Su Z, 2014, J NUR, V21, P15
   Wu Z, 2016, J CLIN MED LIT, V9, P276
   Xie J, 2016, MED PHYS, V43, P3518, DOI 10.1118/1.4956385
   Yang H, 2009, J NUR ADM, V9, P34
   Yu WG, 2019, KOREAN J PHYSIOL PHA, V23, P161, DOI 10.4196/kjpp.2019.23.3.161
   Zhou P, 2020, DISCOVERY NOVEL CORO, DOI [10.1101/2020.01.22.914952, 10.1101/2020.01.22.914952., DOI 10.1101/2020.01.22.914952]
NR 14
TC 0
Z9 0
U1 4
U2 5
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2224-5820
EI 2224-5839
J9 ANN PALLIAT MED
JI Ann. Pallliat. Med.
PD MAY
PY 2020
VL 9
IS 3
BP 1198
EP 1205
DI 10.21037/apm-20-1084
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA LU9DE
UT WOS:000538046500063
PM 32498535
OA Other Gold
DA 2021-01-01
ER

PT J
AU Hu, WB
   Chen, XF
   He, BJ
   Yuan, SD
   Zhang, X
   Wu, GF
   Liu, JJ
   Xu, L
   Cha, W
   Xu, MM
   Sun, XJ
   Shen, HJ
AF Hu, Wenbin
   Chen, Xuefang
   He, Binjun
   Yuan, Shunda
   Zhang, Xing
   Wu, Guofeng
   Liu, Jingjing
   Xu, Liang
   Cha, Wei
   Xu, Mengmin
   Sun, Xiaojun
   Shen, Huajiang
TI Clinical characteristics of 16 patients with COVID-19 infection outside
   of Wuhan, China: a retrospective, single-center study
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE 2019 novel coronavirus (COVID-19); severe acute respiratory syndrome
   coronavirus-2 (SARS-CoV-2); infection; pneumonia
ID CORONAVIRUS; MERS; PNEUMONIA; SARS
AB Background: Since early December 2019, the 2019 novel coronavirus (COVID-19) has emerged in Wuhan and spread rapidly in China. We aimed to describe the clinical characteristics of hospitalized patients with confirmed COVID-19 infection in Shaoxing, and provide an insight into the treatment of COVID-19 across China and elsewhere.
   Methods: In this retrospective, single-center, study, we enrolled 16 patients with laboratory-confirmed COVID-19 admitted to the Affiliated Hospital of Shaoxing University between February 24 and January 25, 2020. Epidemiological, demographic, clinical, laboratory, radiological feature, and treatment data were all collected. Outcomes were followed up until March 16, 2020.
   Results: Among the 16 patients with COVID-19 infection, 11 patients (68.8%) had traveled or lived in Wuhan or surrounding areas, and 2 (12.5%) patients had exposure to patients with confirmed COVID-19 infection. The average age of the patients was 44.1 (16.5) years, and there were 10 women (62.5%) and 6 men (37.5%). More than half had chronic diseases [9 (56.3%)]. The most common symptoms at onset of COVID-19 infection were fever [12 (75%)] and cough [8 (50%)]; 11 (68.8%) patients had lymphopenia, and 12 (75%) had elevated C-reactive protein. On admission, abnormalities in computed tomography (CT) or chest X-ray images were revealed among all patients, and 11 (68.8%) of 16 patients had bilateral involvement. All patients were given psychological counseling, 15 (93.8%) patients were administered with antiviral therapy, 8 (50%) received empirical antibiotic treatment, and 5 (31.3%) patients were given systematic corticosteroids. Complications included acute respiratory distress syndrome (ARDS) requiring non-invasive mechanical ventilation [1 (6.3%)], acute respiratory injury [4 (25%)], acute renal injury [1 (6.3%)], septic shock [1 (6.3%)], liver dysfunction [5 (31.3%)], electrolyte disturbance [8 (50.0%)], and hospital-acquired pneumonia [3 (18.8%)]. None of the 16 patients died of COVID-19 pneumonia.
   Conclusions: Compared with the symptoms of the initial patients with COVID-19 infection in Wuhan, the symptoms of the patients from Shaoxing city were relatively mild. Currently, there is no effective drug treatment or vaccine for COVID-19, and psychological counseling cannot be ignored. Drugs and vaccines against COVID-19 infection need to be developed as soon as possible.
C1 [Hu, Wenbin; Yuan, Shunda] Shaoxing Univ, Affiliated Hosp, Shaoxing Municipal Hosp, Dept Cardiothorac Surg, Shaoxing 312000, Peoples R China.
   [Chen, Xuefang] Shaoxing Univ, Affiliated Hosp, Shaoxing Municipal Hosp, Dept Sci & Educ, Shaoxing 312000, Peoples R China.
   [He, Binjun] Zhejiang Univ, Shaoxing Peoples Hosp, Dept Thoracosurg, Sch Med, Shaoxing 312000, Peoples R China.
   [Zhang, Xing] Shaoxing Univ, Affiliated Hosp, Shaoxing Municipal Hosp, Dept Gastroenterol, Shaoxing 312000, Peoples R China.
   [Wu, Guofeng] Shaoxing Univ, Affiliated Hosp, Shaoxing Municipal Hosp, Dept Pulm, Shaoxing 312000, Peoples R China.
   [Liu, Jingjing; Cha, Wei] Shaoxing Univ, Affiliated Hosp, Shaoxing Municipal Hosp, Dept Cardiol, Shaoxing 312000, Peoples R China.
   [Xu, Liang; Xu, Mengmin; Sun, Xiaojun] Shaoxing Univ, Affiliated Hosp, Shaoxing Municipal Hosp, Dept Resp, Shaoxing 312000, Peoples R China.
   [Shen, Huajiang] Shaoxing Univ, Affiliated Hosp, Shaoxing Municipal Hosp, Dept Infect, Shaoxing 312000, Peoples R China.
RP Shen, HJ (corresponding author), Shaoxing Univ, Affiliated Hosp, Shaoxing Municipal Hosp, Dept Infect, Shaoxing 312000, Peoples R China.
EM shenhuajiang2@126.com
FU Shaoxing Science and Technology Project
FX This study was supported by Shaoxing Science and Technology Project.
CR [Anonymous], 2020, NOTICE PREVENTION CO
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Z, 2020, LANCET, DOI [10.2139/ssrn. 3546044, DOI 10.2139/SSRN.3546044]
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim KH, 2017, J HOSP INFECT, V95, P207, DOI 10.1016/j.jhin.2016.10.008
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Pan Y, 2020, EUR RADIOL
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shen KL, 2020, WORLD J PEDIAT
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   WHO, MIDDL E RESP SYNDR C
   World Health Organization, COR DIS COVID 19 OUT
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 24
TC 0
Z9 0
U1 3
U2 4
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD MAY
PY 2020
VL 8
IS 10
AR 642
DI 10.21037/atm-20-3422
PG 9
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA LU8TW
UT WOS:000538022300032
PM 32566579
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Zhao, Y
   Wei, YY
   Shen, SP
   Zhang, MZ
   Chen, F
AF Zhao, Yang
   Wei, Yongyue
   Shen, Sipeng
   Zhang, Mingzhi
   Chen, Feng
TI Appealing for efficient, well organized clinical trials on COVID-19
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Clinical trials; COVID-19
AB Background: The rapid emergence of clinical trials on COVID-19 stimulated a wave of discussion in scientific community. It is important to understand the characteristics of the ongoing or pending interventional clinical trials on COVID-19.
   Methods: We reviewed the characteristics of interventional trials from Chinese Clinical Trial Registration (ChiCTR) and ClinicalTrials.gov. A total of 171 COVID-19-related interventional trials were identified on Feb 22, 2020. These trials are classified into 4 categories based on treatment modalities, including chemical drugs (CDs), biological therapies (BTs), traditional Chinese medicine (TCM) treatments and other therapies.
   Results: Our analysis focused on the issues of stage, design, randomization, blinding, primary endpoints (PEs) definition and sample size of these trials. Although most trials use parallel-arm design (88.3%) and randomization (77.2%), blinding is applied in only 25 trials (14.6%). More than half of the trials planned to recruit =100 patients, indicating a possibility of insufficient statistical power. About one third of trials will recruit severe and critically ill patients. More trials on traditional Chinese medical treatment use 2 or more PEs than those on CDs or biological treatments (57.6%, 39.4% and 40.5%, respectively).
   Conclusions: We found some studies with potential defects including unreasonable design, inappropriate PE and small sample size. Clinical trials on COVID-19 should be designed based on scientific rules, ethics and benefits for patients.
C1 [Zhao, Yang; Wei, Yongyue; Shen, Sipeng; Zhang, Mingzhi; Chen, Feng] Nanjing Med Univ, Sch Publ Hlth, Dept Biostat, Nanjing 210029, Peoples R China.
RP Zhao, Y; Chen, F (corresponding author), Nanjing Med Univ, Sch Publ Hlth, Dept Biostat, Nanjing 210029, Peoples R China.
EM yzhao@njmu.edu.cn; fengchen@njmu.edu.cn
FU Special Program of National Natural Science Foundation of China on
   tracing, pathogenesis, prevention and treatment for COVID-19 [82041024];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81872709]; Key Project of the Natural
   Science Foundation of the Jiangsu Higher Education Institutions of China
   [18KJA110004]
FX This study was funded by the Special Program of National Natural Science
   Foundation of China on tracing, pathogenesis, prevention and treatment
   for COVID-19 (No. 82041024 to FC, the National Natural Science
   Foundation of China (No. 81872709 to YZ) and Key Project of the Natural
   Science Foundation of the Jiangsu Higher Education Institutions of China
   (No. 18KJA110004 to YZ).
CR Berger VW, 2009, REV RECENT CLIN TRIA, V4, P79, DOI 10.2174/157488709788186021
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Chen F, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P301, DOI 10.3760/cma.j.issn.0254-6450.2020.03.004
   Kasza J, 2017, INT J EPIDEMIOL, V46, P1303, DOI 10.1093/ije/dyx023
   Maxmen A, 2020, NATURE, V578, P347, DOI 10.1038/d41586-020-00444-3
   WHO, 2020, REP WHO CHIN JOINT M
NR 6
TC 0
Z9 0
U1 1
U2 1
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD MAY
PY 2020
VL 8
IS 10
AR 632
DI 10.21037/atm-20-2429
PG 6
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA LU8TW
UT WOS:000538022300022
PM 32566569
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Accorsi, P
   Berti, P
   de Angelis, V
   De Silvestro, G
   Mascaretti, L
   Ostuni, A
AF Accorsi, Patrizia
   Berti, Pierluigi
   de Angelis, Vincenzo
   De Silvestro, Giustina
   Mascaretti, Luca
   Ostuni, Angelo
CA Italian Soc Transfusion Med Immuno
   Italian Soc Haemapheresis Cell Man
TI Position paper on the preparation of immune plasma to be used in the
   treatment of patients with COVID-19
SO BLOOD TRANSFUSION
LA English
DT Article
DE COVID-19; immune plasma
ID CONVALESCENT PLASMA; THERAPY
AB Passive immunotherapy with plasma derived from convalescent patients recovering from SARS-CoV-2 infection can be a promising approach in the treatment of COVID-19 patients. It is important that blood establishments are ready to satisfy requests for immune plasma by defining the requirements applicable to plasma donors and the standards for preparation, qualification, storage, distribution, and control of product use. This Position paper aims to give recommendations on the biological characteristics of a plasma preparation from convalescent donors and to support the evaluation of this therapeutic approach in more rigorous investigations.
C1 [Accorsi, Patrizia] Osped Civile, Dept Haematol Transfus Med & Biotechnol, Pescara, Italy.
   [Berti, Pierluigi] Umberto Parini Hosp, Immunohaematol & Transfus Med, Aosta, Italy.
   [de Angelis, Vincenzo] Azienda Sanitaria Univ Friuli Cent, Transfus Med Dept, Udine, Italy.
   [De Silvestro, Giustina] Univ Hosp Padua, Blood Transfus Serv, Padua, Italy.
   [Mascaretti, Luca] Azienda Sanitaria Univ Giuliano Isontina, Transfus Med Dept, Trieste, Italy.
   [Ostuni, Angelo] Univ Hosp Policlin, Transfus Med Unit, Bari, Italy.
RP de Angelis, V (corresponding author), Azienda Sanitaria Univ Friuli Cent, Transfus Med Dept, Udine, Italy.
EM vincenzo.deangelis@asufc.sanita.fvg.it
RI Mascaretti, Luca/AAS-2022-2020
CR Arabi Y, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1490-9
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Clinical Trials.gov, HYP PLASM CRIT PAT C
   Crowe JE, 2001, J IMMUNOL, V167, P3910, DOI 10.4049/jimmunol.167.7.3910
   Duan J, 2017, INTENS CARE MED, V43, P192, DOI 10.1007/s00134-016-4601-3
   European Directorate for the Quality of Medicines & HealthCare (EDQM) Council of Europe, GUIDE PREPARATION US
   Huaxia c, CHIN PUTS 245 COVID
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Quotidianosanita.it, COR AOST LACKS DRUGS
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Sanquin, SANQ STARTS COLL PLA
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   U.S. Food and Drug Administration, REC INV COVID 19 CON
   World Health Organization, INT CLIN TRIALS REG
   World Health Organization, US CONV WHOL BLOOD P
NR 18
TC 4
Z9 4
U1 2
U2 2
PU SIMTIPRO SRL
PI MILAN
PA VIA DESIDERIO 21, MILAN, 20131, ITALY
SN 1723-2007
J9 BLOOD TRANSFUS-ITALY
JI Blood Transf.
PD MAY-JUN
PY 2020
VL 18
IS 3
BP 163
EP 166
DI 10.2450/2020.0124-20
PG 4
WC Hematology
SC Hematology
GA LV0QU
UT WOS:000538149600002
PM 32453687
DA 2021-01-01
ER

PT J
AU Cattaneo, M
   Morici, N
AF Cattaneo, Marco
   Morici, Nuccia
TI Is thromboprophylaxis with high-dose enoxaparin really necessary for
   COVID-19 patients? A new "prudent" randomised clinical trial
SO BLOOD TRANSFUSION
LA English
DT Letter
C1 [Cattaneo, Marco] Univ Milan, Dipartimento Sci Salute, Milan, Italy.
   [Cattaneo, Marco] ASST Santi Paolo & Carlo, Unita Med 2, Milan, Italy.
   [Morici, Nuccia] ASST Grande Osped Metropolitano Niguarda, Intens Cardiac Care Unit, Milan, Italy.
   [Morici, Nuccia] ASST Grande Osped Metropolitano Niguarda, De Gasperis Cardio Ctr, Milan, Italy.
   [Morici, Nuccia] Univ Milan, Dept Clincal Sci & Community Hlth, Milan, Italy.
RP Morici, N (corresponding author), ASST Grande Osped Metropolitano Niguarda, Intens Cardiac Care Unit, Milan, Italy.; Morici, N (corresponding author), ASST Grande Osped Metropolitano Niguarda, De Gasperis Cardio Ctr, Milan, Italy.; Morici, N (corresponding author), Univ Milan, Dept Clincal Sci & Community Hlth, Milan, Italy.
EM nuccia.morici@ospedaleniguarda.it
CR Cattaneo M, 2020, THROMB HAEMOSTASIS, V120, P1230, DOI 10.1055/s-0040-1712097
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Marietta M, 2020, BLOOD TRANSFUS-ITALY, V18, P167, DOI 10.2450/2020.0083-20
   Wang T, 2020, LANCET HAEMATOL, V7, pE362, DOI 10.1016/S2352-3026(20)30109-5
NR 5
TC 3
Z9 3
U1 0
U2 0
PU SIMTIPRO SRL
PI MILAN
PA VIA DESIDERIO 21, MILAN, 20131, ITALY
SN 1723-2007
J9 BLOOD TRANSFUS-ITALY
JI Blood Transf.
PD MAY-JUN
PY 2020
VL 18
IS 3
BP 237
EP 238
DI 10.2450/2020.0109-20
PG 2
WC Hematology
SC Hematology
GA LV0QU
UT WOS:000538149600015
PM 32453692
DA 2021-01-01
ER

PT J
AU Marietta, M
   Tripodi, A
AF Marietta, Marco
   Tripodi, Armando
TI Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin
   really necessary for COVID-19 patients? A new "prudent" randomised
   clinical trial"
SO BLOOD TRANSFUSION
LA English
DT Letter
C1 [Marietta, Marco] Univ Hosp, Dept Oncol & Haematol, Modena, Italy.
   [Tripodi, Armando] IRCCS Ca Granda Maggiore Hosp Fdn, Angelo Bianchi Bonomi Haemophilia & Thrombosis Ct, Milan, Italy.
   [Tripodi, Armando] Fdn Luigi Villa, Milan, Italy.
RP Marietta, M (corresponding author), Univ Hosp, Dept Oncol & Haematol, Modena, Italy.
EM marco.marietta@unimore.it
CR Cattaneo M, 2020, BLOOD TRANSFUS-ITALY, V18, P237, DOI 10.2450/2020.0109-20
   Marietta M, 2020, BLOOD TRANSFUS-ITALY, V18, P167, DOI 10.2450/2020.0083-20
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Poissy J, 2020, CIRCULATION, DOI [10.1161/CIRCULATIONAHA.120.047430, DOI 10.1161/CIRCULATI0NAHA.120.047430]
   WHO, 2020, CLIN MAN SEV AC RESP
NR 5
TC 1
Z9 1
U1 0
U2 0
PU SIMTIPRO SRL
PI MILAN
PA VIA DESIDERIO 21, MILAN, 20131, ITALY
SN 1723-2007
J9 BLOOD TRANSFUS-ITALY
JI Blood Transf.
PD MAY-JUN
PY 2020
VL 18
IS 3
BP 239
EP 240
DI 10.2450/2020.0116-20
PG 2
WC Hematology
SC Hematology
GA LV0QU
UT WOS:000538149600016
PM 32453693
DA 2021-01-01
ER

PT J
AU Costantini, A
   Mazzotti, E
AF Costantini, Anna
   Mazzotti, Eva
TI Italian validation of CoViD-19 Peritraumatic Distress Index and
   preliminary data in a sample of general population
SO RIVISTA DI PSICHIATRIA
LA English
DT Article
DE peritraumatic distress; PTSD; online survey; CoViD-19; CoViD-19
   Peritraumatic Distress Index
ID IMPACT
AB Introduction. Peritraumatic distress is an important predictor of post-traumatic stress disorder and although several questionnaires are available for its measurement, none of these are specific to CoViD-19.The new CoViD-19 Peritraumatic Distress Index (CPDI), developed in China, is characterized as a rapid compilation tool (10 minutes), easily understandable and appreciated by people. Aim. The objectives of this study were: (1) the validation of the Italian version of the CPDI, and (2) the measurement of the prevalence of peritraumatic distress in this phase 1 CoViD-19. Method. CPDI has been translated using a standard forward-backward-translation procedure and offered online to 329 people (191 females and 137 males, aged 46.49 +/- 13.58 years). The CPDI showed an internal-consistency of C'ronbach's alpha=0.916. Content validity was judged satisfactory by two psychologists experienced in stress and trauma. The construct validity is given by the high correlation with the dimensions of Intrusion, Avoidance and Hyperarousal as measured by the Impact of Event Scale-Revised (r=0.63, r=0.57, r=0.71, respectively). Results. Our results are comparable to the Chinese ones. A third of people experienced symptoms of mild/moderate and severe peritraumatic distress. Females have higher scores, compared to males. Older people are more resilient, compared to younger, and those who have been in quarantine report less distress than those didn't, as evidenced by the results of the multivariate logistic regression model. High distress was associated with use of psychotropic drugs (AOR=4.28; 95% CI=1.55-11.85), sleeping remedies (AOR=4.05; 95% CI=2.07-7.94), be worried about dying in case of contagion CoViD-19 (AOR=3.33; 95% CI=1.83-6.06), female gender (AOR=2.95; 95% CI=1.58-5.53) and have a religious belief (AOR=1.97; 95% CI=1.05-3.70). To be aged 51-71 years, to have been in quarantine and to have received psychological support were variables associated with lower distress scores. Conclusions. The psychometric properties of the Italian version are satisfactory and confirm that CPDI is a tool fast, non-intrusive, administered online, and therefore 'safe' in a phase with a high risk of contagion. It allows, like a psychic thermoscan, to quickly detect the needs of the population and propose equally rapid interventions.
C1 [Costantini, Anna] Sapienza Univ Rome, St Andrea Hosp, Psychooncol Dept Unit, Rome, Italy.
   [Mazzotti, Eva] Sapienza Univ Rome, St Andrea Hosp, Dept Clin & Mol Med, Rome, Italy.
RP Mazzotti, E (corresponding author), Sapienza Univ Rome, St Andrea Hosp, Dept Clin & Mol Med, Rome, Italy.
EM eva.mazzotti@gmail.com
CR Beck JG, 2008, J ANXIETY DISORD, V22, P187, DOI 10.1016/j.janxdis.2007.02.007
   Borrelli A., 2020, C STAMP 30 APR
   Bovin MJ, 2011, PSYCHOL BULL, V137, P47, DOI 10.1037/a0021353
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Conte G., 2020, PRESIDENZA CONSIGLIO
   de Girolamo G, 2020, JAMA PSYCHIAT, V77, P974, DOI 10.1001/jamapsychiatry.2020.1276
   Elhai JD, 2005, J TRAUMA STRESS, V18, P541, DOI 10.1002/jts.20062
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Gorman KR, 2016, COMPREHENSIVE GUIDE
   Holmes E.A., 2020, LANCET PSYCHIAT
   Huang Y, 2020, GEN ANXIETY DISORDER, DOI [10.1101/2020.02.19.20025395., DOI 10.1101/2020.02.19.20025395, 10.1101/2020.02.19.20025395.20025395]
   ISTAT, 2019, ISTAT RAPPORTO ANNUA
   Jeong H, 2016, EPIDEMIOL HEALTH, V38, DOI 10.4178/epih.e2016048
   Lee Dong-Hun, 2016, [Korean Journal of Psychology: General, 한국심리학회지:일반], V35, P355, DOI 10.22257/kjp.2016.06.35.2.355
   Li W, 2020, INT J BIOL SCI, V16, P1732, DOI 10.7150/ijbs.45120
   Mazzotti E, 2011, SUPPORT CARE CANCER, V19, P1931, DOI 10.1007/s00520-010-1033-4
   Nunnally J. C., 1994, PSYCHOMETRIC THEORY
   Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52
   PARGAMENT KI, 1993, J SCI STUD RELIG, V32, P418
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   Rossi R, 2020, COVID 19 PANDEMIC LO, DOI [10.1101/2020.04.09.20057802., DOI 10.1101/2020.04.09.20057802, 10.1101/2020.04.09.20057802]
   Sareen J, 2013, DEPRESS ANXIETY, V30, P321, DOI 10.1002/da.22077
   Van Hoof E., 2020, WORLD EC FORUM
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   WEISS DS, 1996, ASSESSING PSYCHOL TR
NR 25
TC 6
Z9 6
U1 5
U2 7
PU PENSIERO SCIENTIFICO EDITOR
PI ROME
PA VIA BRADANO 3/C, 00199 ROME, ITALY
SN 0035-6484
EI 2038-2502
J9 RIV PSICHIATR
JI Riv. Psichiatr.
PD MAY-JUN
PY 2020
VL 55
IS 3
BP 145
EP 151
DI 10.1708/3382.33570
PG 7
WC Psychiatry
SC Psychiatry
GA LV0UT
UT WOS:000538159900004
PM 32489191
DA 2021-01-01
ER

PT J
AU Goniewicz, K
   Khorram-Manesh, A
   Hertelendy, AJ
   Goniewicz, M
   Naylor, K
   Burkle, FM
AF Goniewicz, Krzysztof
   Khorram-Manesh, Amir
   Hertelendy, Attila J.
   Goniewicz, Mariusz
   Naylor, Katarzyna
   Burkle, Frederick M., Jr.
TI Current Response and Management Decisions of the European Union to the
   COVID-19 Outbreak: A Review
SO SUSTAINABILITY
LA English
DT Article
DE coronavirus; COVID-19; European Union preparedness; pandemics; disaster;
   crisis; crisis management
ID DISASTER MANAGEMENT; EDUCATION
AB COVID-19 has proven to be a formidable challenge for many countries in the European Union to manage effectively. The European Union has implemented numerous strategies to face emerging issues. Member States have adopted measures such as the closure of borders and significant limitations on the mobility of people to mitigate the spread of the virus. An unprecedented crisis coordination effort between Member States has facilitated the ability to purchase equipment, personal protective equipment, and other medical supplies. Attention has also been focused on providing substantive money for research to find a vaccine and promote effective treatment therapies. Financial support has been made available to protect worker salaries and businesses to help facilitate a return to a functional economy. Lessons learned to date from COVID-19 in the European Union are many; the current crisis highlights the need to think about future pandemics from a population-based management approach and apply outside the box critical thinking. Due to the complexity, intensity, and frequency of complex disasters, global leaders in healthcare, government, and business will need to pivot from siloed approaches to decision-making to embrace multidisciplinary and transdisciplinary levels of cooperation. This cooperation requires courage and leadership to recognize that changes are necessary to avoid making the same mistakes we have planned countless times on avoiding. This study focuses on the European Union's initial response to the COVID-19 pandemic, starting with how the European Union first learned and processed the global information arising out of China, followed by the incremental population-based medicine/management decisions made that currently are defining the European Union's capacity and capability. The capacity to organize, deliver, and monitor care to a specific clinical population under a population-based management target includes strict social distancing strategies, contact testing and tracing, testing for the virus antigen and its antibodies, isolation, and treatment modalities such as new mitigating medications, and finally, a vaccine.
C1 [Goniewicz, Krzysztof] Mil Univ Aviat, Dept Aviat Secur, PL-08521 Deblin, Poland.
   [Khorram-Manesh, Amir] Gothenburg Univ, Sahlgrenska Acad, Inst Clin Sci, Dept Surg, S-41345 Gothenburg, Sweden.
   [Khorram-Manesh, Amir] Armed Forces Ctr Def Med, Dept Dev & Res, S-42676 Gothenburg, Vastra Frolunda, Sweden.
   [Hertelendy, Attila J.] Florida Int Univ, Coll Business, Dept Informat Syst & Business Analyt, Miami, FL 33174 USA.
   [Goniewicz, Mariusz] Med Univ Lublin, Dept Emergency Med, PL-20059 Lublin, Poland.
   [Naylor, Katarzyna] Med Univ Lublin, Dept Didact & Med Simulat, PL-20093 Lublin, Poland.
   [Burkle, Frederick M., Jr.] Harvard Univ, TH Chan Sch Publ Hlth, Harvard Humanitarian Initiat, Boston, MA 02115 USA.
RP Goniewicz, K (corresponding author), Mil Univ Aviat, Dept Aviat Secur, PL-08521 Deblin, Poland.
EM k.goniewicz@law.mil.pl; amir.khorram-manesh@surgery.gu.se;
   ahertele@fiu.edu; mariusz.goniewicz@umlub.pl;
   katarzyna.naylor@hotmail.com; fburkle@hsph.harvard.edu
RI Khorram-Manesh, Amir/C-8826-2015; Goniewicz, Krzysztof/G-1480-2012;
   Naylor, Katarzyna/I-8933-2019
OI Khorram-Manesh, Amir/0000-0002-2734-5733; Goniewicz,
   Krzysztof/0000-0003-4368-6850; Naylor, Katarzyna/0000-0002-1307-5015;
   Goniewicz, Mariusz/0000-0002-3004-6195
CR [Anonymous], 2018, OJ L, V320, P28
   [Anonymous], 2013, POP HLTH MAN STEPS R
   Bozorgmehr K, 2020, LANCET PUBLIC HEALTH, V5, pE247, DOI 10.1016/S2468-2667(20)30078-5
   BREMAN JG, 1984, JAMA-J AM MED ASSOC, V252, P1188, DOI 10.1001/jama.1984.03350090064029
   Burkle FM, 2006, ACAD EMERG MED, V13, P1118, DOI 10.1197/j.aem.2006.06.040
   Burkle FM, 2019, TOHOKU J EXP MED, V249, P33, DOI 10.1620/tjem.249.33
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Clifford Chance, 2020, COR GOV FIN AID BUS
   Coombs W. T., 2011, HDB CRISIS COMMUNICA
   Beriain ID, 2015, DISASTER MED PUBLIC, V9, P234, DOI 10.1017/dmp.2015.10
   Djalante R., 2020, PROGR DISASTER SCI, P100080, DOI [DOI 10.1016/J.PDISAS.2020.100080, 10.1016/J.PDISAS.2020.100080]
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   European Commision, EUR INSTR TEMP SUPP
   European Commision, FIGHT DIS
   European Commision, MIGR HOM AFF
   European Commission, ENS AV SUPPL EQ
   European Commission, GUID BORD MAN MEAS P
   European Commission, COR RESP
   European Commission, EUR CIV PROT HUM AID
   European Council, CONCL PRES EUR COUNC
   European Union, EXT ACT
   Foddai A, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100130
   Goniewicz K, 2020, PREHOSP DISASTER MED, V35, P331, DOI 10.1017/S1049023X20000321
   Goniewicz K, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051779
   Government Office of Sweden, EC MEAS RESP COVID 1
   Graffunder C., 2016, PREPARING HLTH CARE
   Johnson HC, 2020, EUROSURVEILLANCE, V25, P8, DOI 10.2807/1560-7917.ES.2020.25.9.2000202
   Khorram-Manesh A., 2020, HLTH PROMOT PERSPECT
   Khorram-Manesh A, 2016, DISASTER MED PUBLIC, V10, P854, DOI 10.1017/dmp.2016.88
   Khorram-Manesh Amir, 2016, Bull Emerg Trauma, V4, P186
   Khorram-Manesh A, 2015, DISASTER MED PUBLIC, V9, P245, DOI 10.1017/dmp.2015.9
   Khorram-Manesh A, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-26
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Lewnard JA, 2020, LANCET INFECT DIS, V20, P631, DOI 10.1016/S1473-3099(20)30190-0
   Pullano G, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.4.2000057
   Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Stoecklin SB, 2020, EUROSURVEILLANCE, V25, P20, DOI 10.2807/1560-7917.ES.2020.25.6.2000094
   The Flether School, 2020, MULT APPR CRIS FLETC
   La VP, 2020, SUSTAINABILITY-BASEL, V12, DOI 10.3390/su12072931
   Website of the Republic of Poland, COR INF REC
   World Health Organization, 2020, WHO2019NCOVPOE
NR 43
TC 16
Z9 16
U1 13
U2 14
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2071-1050
J9 SUSTAINABILITY-BASEL
JI Sustainability
PD MAY
PY 2020
VL 12
IS 9
AR 3838
DI 10.3390/su12093838
PG 12
WC Green & Sustainable Science & Technology; Environmental Sciences;
   Environmental Studies
SC Science & Technology - Other Topics; Environmental Sciences & Ecology
GA LU0TK
UT WOS:000537476200336
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Vardanjani, AE
   Moayedi, S
   Golitaleb, M
AF Vardanjani, Ali Esmaeili
   Moayedi, Siamak
   Golitaleb, Mohamad
TI COVID-19 Pandemic Hemoperfusion Therapy versus Plasma Exchange Therapy
   in Intensive Care
SO IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY
LA English
DT Letter
C1 [Vardanjani, Ali Esmaeili] Univ Tehran Med Sci, Sch Nursing & Midwifery, Dept Crit Care Nursing & Management, Tehran, Iran.
   [Vardanjani, Ali Esmaeili] Hamadan Univ Med Sci, Dept Nursing, Hamadan, Iran.
   [Moayedi, Siamak] Univ Maryland, Sch Med, Dept Emergency Med, Baltimore, MD 21201 USA.
   [Golitaleb, Mohamad] Arak Univ Med Sci, Sch Nursing, Dept Crit Care Nursing, POB 3848176941, Arak, Iran.
RP Golitaleb, M (corresponding author), Arak Univ Med Sci, Sch Nursing, Dept Crit Care Nursing, POB 3848176941, Arak, Iran.
EM m.golitaleb@arakmu.ac.ir
RI Golitaleb, Mohamad/M-9318-2017
OI Golitaleb, Mohamad/0000-0002-9216-9262; moayedi,
   siamak/0000-0001-8168-2776
CR Beutel G, 2011, CRIT CARE, V15, DOI 10.1186/cc10073
   Ghannoum M, 2014, SEMIN DIAL
   Hadem J, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-24
   Kacar CK, 2020, BLOOD PURIFICAT, P1
   La Manna G, 2018, BLOOD PURIFICAT, V46, P228, DOI 10.1159/000490234
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Poli EC, 2019, INTENS CARE MED, V45, P236, DOI 10.1007/s00134-018-5464-6
   Reiter K, 2002, BLOOD PURIFICAT, V20, P380, DOI 10.1159/000063108
   Ronco C, 2020, BLOOD PURIFICAT, V49, P255, DOI [10.1159/000507039, 10.1159/000508125]
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Shimizu T, 2009, LANGENBECK ARCH SURG, V394, P303, DOI 10.1007/s00423-008-0395-2
   SU JB, 2020, LANCET, V395
   Szczeklik W, 2013, ANAESTH INTENSIVE TH, V45, P7, DOI 10.5603/AIT.2013.0002
   Takeda S, 2010, INTENS CARE MED, V36, P906, DOI 10.1007/s00134-010-1830-8
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 15
TC 2
Z9 2
U1 1
U2 1
PU TEHRAN UNIV MEDICAL SCIENCES
PI TEHRAN
PA CTR ELECTR RES PROVISION & J IMPROVEMENT, #7, POURSINA AVE, QODS AVE, PO
   1417653911, TEHRAN, 11498, IRAN
SN 1735-1502
EI 1735-5249
J9 IRAN J ALLERGY ASTHM
JI Iran. J. Allergy Asthma Immunol.
PD MAY
PY 2020
VL 19
SU 1
SI SI
BP 7
EP 9
DI 10.18502/ijaai.v19i(s1.r1).2848
PG 3
WC Allergy; Immunology
SC Allergy; Immunology
GA LU6VX
UT WOS:000537891900003
PM 32534513
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Kim, E
   Erdos, G
   Huang, SH
   Kenniston, TW
   Balmert, SC
   Carey, CD
   Raj, VS
   Epperly, MW
   Klimstra, WB
   Haagmans, BL
   Korkmaz, E
   Falo, LD
   Gambotto, A
AF Kim, Eun
   Erdos, Geza
   Huang, Shaohua
   Kenniston, Thomas W.
   Balmert, Stephen C.
   Carey, Cara Donahue
   Raj, V. Stalin
   Epperly, Michael W.
   Klimstra, William B.
   Haagmans, Bart L.
   Korkmaz, Emrullah
   Falo, Louis D., Jr.
   Gambotto, Andrea
TI Microneedle array delivered recombinant coronavirus vaccines:
   Immunogenicity and rapid translational development
SO EBIOMEDICINE
LA English
DT Article
DE Subunit vaccines; Trimerization; Microneedle array; MERS-CoV S1;
   SARS-CoV-2; COVID-19
ID RECEPTOR-BINDING DOMAIN; ANTIGEN-PRESENTING CELLS; DIPEPTIDYL PEPTIDASE
   4; NECROSIS-FACTOR-ALPHA; MERS-COV; INFLUENZA VACCINE; SPIKE PROTEIN;
   VIRUS; PATCHES; ANTIBODIES
AB Background: Coronaviruses pose a serious threat to global health as evidenced by Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and COVID-19. SARS Coronavirus (SARS-CoV), MERS Coronavirus (MERS-CoV), and the novel coronavirus, previously dubbed 2019-nCoV, and now officially named SARS-CoV-2, are the causative agents of the SARS, MERS, and COVID-19 disease outbreaks, respectively. Safe vaccines that rapidly induce potent and long-lasting virus-specific immune responses against these infectious agents are urgently needed. The coronavirus spike (S) protein, a characteristic structural component of the viral envelope, is considered a key target for vaccines for the prevention of coronavirus infection.
   Methods: We first generated codon optimized MERS-S1 subunit vaccines fused with a foldon trimerization domain to mimic the native viral structure. In variant constructs, we engineered immune stimulants (RS09 or flagellin, as TLR4 or TLR5 agonists, respectively) into this trimeric design. We comprehensively tested the pre-clinical immunogenicity of MERS-CoV vaccines in mice when delivered subcutaneously by traditional needle injection, or intracutaneously by dissolving microneedle arrays (MNAs) by evaluating virus specific IgG antibodies in the serum of vaccinated mice by ELISA and using virus neutralization assays. Driven by the urgent need for COVID-19 vaccines, we utilized this strategy to rapidly develop MNA SARS-CoV-2 subunit vaccines and tested their pre-clinical immunogenicity in vivo by exploiting our substantial experience with MNA MERS-CoV vaccines.
   Findings: Here we describe the development of MNA delivered MERS-CoV vaccines and their pre-clinical immunogenicity. Specifically, MNA delivered MERS-S1 subunit vaccines elicited strong and long-lasting antigen-specific antibody responses. Building on our ongoing efforts to develop MERS-CoV vaccines, promising immunogenicity of MNA-delivered MERS-CoV vaccines, and our experience with MNA fabrication and delivery, including clinical trials, we rapidly designed and produced clinically-translatable MNA SARS-CoV-2 subunit vaccines within 4 weeks of the identification of the SARS-CoV-2 S1 sequence. Most importantly, these MNA delivered SARS-CoV-2 S1 subunit vaccines elicited potent antigen-specific antibody responses that were evident beginning 2 weeks after immunization.
   Interpretation: MNA delivery of coronaviruses-S1 subunit vaccines is a promising immunization strategy against coronavirus infection. Progressive scientific and technological efforts enable quicker responses to emerging pandemics. Our ongoing efforts to develop MNA-MERS-S1 subunit vaccines enabled us to rapidly design and produce MNA SARS-CoV-2 subunit vaccines capable of inducing potent virus-specific antibody responses. Collectively, our results support the clinical development of MNA delivered recombinant protein subunit vaccines against SARS, MERS, COVID-19, and other emerging infectious diseases. (C) 2020 The Author(s). Published by Elsevier B.V.
C1 [Kim, Eun; Huang, Shaohua; Kenniston, Thomas W.; Gambotto, Andrea] Univ Pittsburgh, Sch Med, Dept Surg, W1148 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.
   [Erdos, Geza; Balmert, Stephen C.; Carey, Cara Donahue; Korkmaz, Emrullah; Falo, Louis D., Jr.] Univ Pittsburgh, Sch Med, Dept Dermatol, W1150 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.
   [Epperly, Michael W.] Univ Pittsburgh, Dept Radiat Oncol, Pittsburgh, PA 15213 USA.
   [Klimstra, William B.] Univ Pittsburgh, Ctr Vaccine Res, Dept Immunol, Pittsburgh, PA 15213 USA.
   [Raj, V. Stalin; Haagmans, Bart L.] Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
   [Korkmaz, Emrullah; Falo, Louis D., Jr.] Univ Pittsburgh, Swanson Sch Engn, Dept Bioengn, Pittsburgh, PA 15231 USA.
   [Falo, Louis D., Jr.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15213 USA.
   [Falo, Louis D., Jr.] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA.
   [Raj, V. Stalin] Indian Inst Sci Educ & Res Thiruvananthapuram IIS, Sch Biol, Thiruvananthapuram, Kerala, India.
RP Falo, LD (corresponding author), Univ Pittsburgh, Sch Med, Dept Dermatol, W1150 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.; Gambotto, A (corresponding author), Univ Pittsburgh, Dept Surg, W1148 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM lof2@pitt.edu; gambottoa@upmc.edu
RI Falo, Louis/ABD-1499-2020; Raj, Victor Stalin/E-9670-2016
OI Haagmans, Bart/0000-0001-6221-2015; Carey, Cara
   Donahue/0000-0002-3602-099X; Raj, Victor Stalin/0000-0003-2250-8481;
   Balmert, Stephen/0000-0002-4938-0329; Reis,
   AlessanRSS/0000-0001-8486-7469
FU NIH NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R21-AI114264]; NIH NIAMSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Arthritis & Musculoskeletal & Skin
   Diseases (NIAMS) [R01-AR074285, R01-AR071277, R01-AR068249]; NIH
   National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [T32-CA175294]
FX AG is funded by NIH NIAID (R21-AI114264) and LDF is funded by NIH NIAMS
   (R01-AR074285, R01-AR071277, and R01-AR068249 to LDF). SCB is supported
   by a fellowship from the NIH National Cancer Institute (T32-CA175294).
   These funding institutions had no role in the study design, data
   collection, data analysis, and interpretation of this publication.
CR Al-Kasasbeh R, 2020, DRUG DELIV TRANSL RE, V10, P690, DOI 10.1007/s13346-020-00727-2
   Al-Omari A, 2018, DIAGNOSTIC MICROBIOL
   Arya J, 2016, J CONTROL RELEASE, V240, P135, DOI 10.1016/j.jconrel.2015.11.019
   Bachy V, 2013, P NATL ACAD SCI USA, V110, P3041, DOI 10.1073/pnas.1214449110
   Balmert SC, 2020, J CONTROL RELEASE, V317, P336, DOI 10.1016/j.jconrel.2019.11.023
   Bediz B, 2014, PHARM RES-DORDR, V31, P117, DOI 10.1007/s11095-013-1137-x
   Bhardwaj A, 2008, PROTEIN SCI, V17, P1475, DOI 10.1110/ps.036111.108
   Boopathy AV, 2019, P NATL ACAD SCI USA, V116, P16473, DOI 10.1073/pnas.1902179116
   Chen YQ, 2013, J VIROL, V87, P10777, DOI 10.1128/JVI.01756-13
   Chu LY, 2016, PHARM RES-DORDR, V33, P868, DOI 10.1007/s11095-015-1833-9
   Cohen JA, 2020, J IMMUNOL, V204, P264, DOI 10.4049/jimmunol.1901109
   Depelsenaire ACI, 2014, J INVEST DERMATOL, V134, P2361, DOI 10.1038/jid.2014.174
   Fernando GJP, 2018, VACCINE, V36, P3779, DOI 10.1016/j.vaccine.2018.05.053
   Gao WT, 2006, J VIROL, V80, P1959, DOI 10.1128/JVI.80.4.1959-1964.2006
   Grundner C, 2005, VIROLOGY, V331, P33, DOI 10.1016/j.virol.2004.09.022
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Haglin ER, 2017, BIOCHEMISTRY-US, V56, P5874, DOI 10.1021/acs.biochem.7b00698
   Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997
   Hegde NR, 2011, DRUG DISCOV TODAY, V16, P1061, DOI 10.1016/j.drudis.2011.07.004
   Indermun S, 2014, J CONTROL RELEASE, V185, P130, DOI 10.1016/j.jconrel.2014.04.052
   Kabashima K, 2019, NAT REV IMMUNOL, V19, P19, DOI 10.1038/s41577-018-0084-5
   Kashem SW, 2017, ANNU REV IMMUNOL, V35, P469, DOI 10.1146/annurev-immunol-051116-052215
   Kim E, 2016, EBIOMEDICINE, V13, P315, DOI 10.1016/j.ebiom.2016.09.028
   Kim E, 2014, VACCINE, V32, P5975, DOI 10.1016/j.vaccine.2014.08.058
   Korkmaz E, 2016, J PHARM SCI-US, V105, P3453, DOI 10.1016/j.xphs.2016.07.008
   Korkmaz E, 2015, ACTA BIOMATER, V24, P96, DOI 10.1016/j.actbio.2015.05.036
   Krammer F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043603
   Lee JW, 2008, BIOMATERIALS, V29, P2113, DOI 10.1016/j.biomaterials.2007.12.048
   Li J, 2013, VIRAL IMMUNOL, V26, P126, DOI 10.1089/vim.2012.0076
   Lopez-Boado YS, 2005, INFECT IMMUN, V73, P7525, DOI 10.1128/IAI.73.11.7525-7534.2005
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963
   Mathers AR, 2006, IMMUNOL RES, V36, P127, DOI 10.1385/IR:36:1:127
   Mistilis MJ, 2017, DRUG DELIV TRANSL RE, V7, P195, DOI 10.1007/s13346-016-0282-2
   Mistilis MJ, 2015, J PHARM SCI-US, V104, P740, DOI 10.1002/jps.24283
   Morelli AE, 2005, J IMMUNOL, V175, P7905, DOI 10.4049/jimmunol.175.12.7905
   Nishiura H, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009936
   Norman JJ, 2014, VACCINE, V32, P1856, DOI 10.1016/j.vaccine.2014.01.076
   Okba NMA, 2019, EMERG INFECT DIS, V25, P1868, DOI [10.3201/eid2509.190051, 10.3201/eid2510.190051]
   Park HY, 2015, EUROSURVEILLANCE, V20, P2, DOI 10.2807/1560-7917.ES2015.20.25.21169
   Pascal KE, 2015, P NATL ACAD SCI USA, V112, P8738, DOI 10.1073/pnas.1510830112
   Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504
   Prausnitz MR, 2017, ANNU REV CHEM BIOMOL, V8, P177, DOI 10.1146/annurev-chembioeng-060816-101514
   Quan FS, 2010, J CONTROL RELEASE, V147, P326, DOI 10.1016/j.jconrel.2010.07.125
   Raj VS, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aas9667
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Rouphael NG, 2017, LANCET, V390, P649, DOI 10.1016/S0140-6736(17)30575-5
   Shanmugam A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030839
   Quaresma JAS, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00034-18
   Skountzou I, 2010, VACCINE, V28, P4103, DOI 10.1016/j.vaccine.2009.07.058
   Song HC, 2004, J VIROL, V78, P10328, DOI 10.1128/JVI.78.19.10328-10335.2004
   Song L, 2015, BMC BIOTECHNOL, V15, DOI 10.1186/s12896-015-0195-z
   Steitz J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010492
   Sullivan SP, 2010, NAT MED, V16, P915, DOI 10.1038/nm.2182
   Sumpter TL, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123947
   Tai WB, 2016, VIROLOGY, V499, P375, DOI 10.1016/j.virol.2016.10.005
   Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   WHO, MIDDL E RESP SYNDR C
   Widjaja I, 2019, EMERG MICROBES INFEC, V8, P516, DOI 10.1080/22221751.2019.1597644
   World Health Organization, 2018, ANN REV BLUEPR LIST
   Wu JW, 1999, ACTA BIOCHIM POL, V46, P591, DOI 10.18388/abp.1999_4131
   Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002
   Yu F, 2015, HUM VACC IMMUNOTHER, V11, P2831, DOI 10.1080/21645515.2015.1074363
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhao JC, 2015, J VIROL, V89, P6117, DOI 10.1128/JVI.00446-15
   Zhao X, 2016, J CONTROLL REL, V223
   Zhao ZM, 2018, ADV DRUG DELIVER REV, V127, P3, DOI 10.1016/j.addr.2018.03.010
NR 68
TC 53
Z9 55
U1 12
U2 25
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD MAY
PY 2020
VL 55
AR 102743
DI 10.1016/j.ebiom.2020.102743
PG 12
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA LU0NY
UT WOS:000537461800002
PM 32249203
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Cirrincione, L
   Plescia, F
   Ledda, C
   Rapisarda, V
   Martorana, D
   Moldovan, RE
   Theodoridou, K
   Cannizzaro, E
AF Cirrincione, Luigi
   Plescia, Fulvio
   Ledda, Caterina
   Rapisarda, Venerando
   Martorana, Daniela
   Moldovan, Raluca Emilia
   Theodoridou, Kelly
   Cannizzaro, Emanuele
TI COVID-19 Pandemic: Prevention and Protection Measures to Be Adopted at
   the Workplace
SO SUSTAINABILITY
LA English
DT Article
DE organizational measures; environmental measures; pandemic; infection;
   work; occupational medicine; coronavirus; SARS-CoV-2; COVID-19;
   protection; prevention; protocol; PPE; DPI; mask; gloves; stress;
   competitive sport; fatigue; droplets; inanimate surface; transmission;
   aerosol
ID CONVERTING ENZYME 2; THERAPEUTIC-EFFICACY; CORONAVIRUS; CHLOROQUINE;
   PNEUMONIA; HEALTH; EBOLA; MERS; SARS; TRANSMISSION
AB SARS-CoV-2, identified in Wuhan, China, for the first time in December 2019, is a new viral strain, which has not been previously identified in humans; it can be transmitted both by air and via direct and indirect contact; however, the most frequent way it spreads is via droplets. Like the other viruses belonging to the same family of coronaviruses, it can cause from mild flu-like symptoms, such as cold, sore throat, cough and fever, to more severe ones such as pneumonia and breathing difficulties, and it can even lead to death. Since no effective specific drug therapy has been found yet, nor any vaccine capable of limiting the spread of this pathogen, it is important for ways of preventing the spread of this infection to be established. The purpose of our research was to provide a protocol to prevent the spread of SARS-CoV-2 infection in light of the limited information related to this coronavirus. In detail, we analysed and searched targeted evidence-based guidelines issued in the various countries affected by this epidemic up till now. In addition, we analyzed the recommendations for the prevention and control of other epidemics caused by other pathogens belonging to the same family of coronaviruses or others that present the same mechanisms of transmission. General organizational measures regarding the containment and management of the epidemiological emergency of COVID-19 have been imposed by the competent authorities for an adequate and proportionate management of the evolution of the epidemiological situation. The prevention and protection organizational measures therefore aim to minimize the probability of being exposed to SARS-CoV-2. For this purpose, measures must also be taken at work to avoid new infections or even the spread of the virus where it has already been present. Furthermore, environmental measures are aimed at reducing the risk of transmission of SARS-CoV-2 to individuals through contact with infected subjects, objects, equipment, or contaminated environmental surfaces. Protective devices must be used whenever there is potentially close contact with a suspect case, especially when the potentially infected person does not wear a surgical mask that could reduce the spread of viruses in the environment. By adopting this specific prevention and protection measures recommended in the workplace, it will be possible to help overcome this COVID-19 pandemic.
C1 [Cirrincione, Luigi; Plescia, Fulvio; Cannizzaro, Emanuele] Univ Palermo, Dept Hlth Promot Mother & Child Care, Internal Med & Med Specialties Giuseppe DAlessand, I-90127 Palermo, Italy.
   [Ledda, Caterina; Rapisarda, Venerando] Univ Catania Italy, Occupat Med, Dept Clin & Expt Med, I-95131 Catania, Italy.
   [Martorana, Daniela] Hosp Co Osped Riuniti Villa Sofia Cervello Palerm, Dept Orthoped, I-90146 Palermo, Italy.
   [Moldovan, Raluca Emilia] Dimitrie Cantemir Univ Targu Mures, Fac Econ, Targu Mures 540680, Romania.
   [Theodoridou, Kelly] A Syggros Univ Hosp Athens Greece, Dept Microbiol, Athens 10552, Greece.
RP Cannizzaro, E (corresponding author), Univ Palermo, Dept Hlth Promot Mother & Child Care, Internal Med & Med Specialties Giuseppe DAlessand, I-90127 Palermo, Italy.
EM luigicirrincione@gmail.com; fulvio.plescia@unipa.it; cledda@unict.it;
   vrapisarda@unict.it; dani.m@hotmail.it; ralucaemiliamoldovan@yahoo.it;
   lmktheo@yahoo.com; emanuele.cannizzaro@unipa.it
RI Plescia, Fulvio/AAZ-2591-2020; Ledda, Caterina/A-1118-2011
OI CANNIZZARO, Emanuele/0000-0001-7070-209X; PLESCIA,
   Fulvio/0000-0002-4786-8435; Ledda, Caterina/0000-0003-0739-8798
CR Accelerated Emergency Use Authorization (EUA), ACC EM US AUTH EUA S
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   [Anonymous], 2020, WHO COR DIS 2019 COV, VWHO
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Booth C. M., 2013, Journal of Hospital Infection, V84, P22, DOI 10.1016/j.jhin.2013.02.007
   Cannizzaro E., 2018, EMBJ, V13, P181
   Cannizzaro E, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17020562
   Cannizzaro E, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16204031
   Casanova LM, 2016, INFECT CONT HOSP EP, V37, P1156, DOI 10.1017/ice.2016.169
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chan K, 2011, ADV OPTOELECTRON, V2011, DOI [10.1155/2011/734690, 10.1155/2011/196707]
   Chellamani K.P, 2013, J ACAD IND RES, V2, P6
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Direzione Generale Della Prevenzione Sanitaria, 2020, FAQ COVID 19 DOM RIS
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   European Centre for Disease Prevention and Control An agency of the European Union, CAS DEF EUR SURV COV
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Harding A, 2020, 12 DEADLIEST VIRUSES
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang S, 2020, COVID 19 WHY WE SHOU
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Imai Y, 2010, CIRC J, V74, P405, DOI 10.1253/circj.CJ-10-0045
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Kilinc FS, 2015, J ENG FIBER FABR, V10, P180
   La Sindrome Acuta Respiratoria Severa-Sars Raccomandazioni Per La Prevenzione E Il Controllo, 2003, SINDROME ACUTA RESPI
   Lee SA, 2008, ANN OCCUP HYG, V52, P177, DOI 10.1093/annhyg/men005
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Occupational Safety and Health Adminsitration (OSHA), 2020, GUID PREP WORKPL COV
   Otter JA, 2016, J HOSP INFECT, V92, P235, DOI 10.1016/j.jhin.2015.08.027
   Peng X, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0075-9
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Ravanelli A, 2020, VALUTAZIONE RISCHIO
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shiu EYC, 2019, CURR OPIN INFECT DIS, V32, P372, DOI 10.1097/QCO.0000000000000563
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Sun Z, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051633
   Tellier R, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3707-y
   van der Sande M, 2008, PLOS ONE, V3
   Van Doremalen N, 2020, N ENG J MED
   Verbeek JH, 2020, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD011621.pub4, 10.1002/14651858.CD011621.pub5]
   Walker CM, 2007, ENVIRON SCI TECHNOL, V41, P5460, DOI 10.1021/es070056u
   Wang C., 2020, HUMAN MONOCLONAL ANT
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107
   WHO, 2020, LAB TEST COR DIS COV
   Won J, 2020, EXP NEUROBIOL
   World Health Organization?, 2020, 12 WHO
   World Health Organization, 2020, 732 WHO
   Wu K, 2017, BRIT J PHARMACOL, V174, P4155, DOI 10.1111/bph.13990
   Wysocki J, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9120886
   Xu X, 2020, EFFECTIVE TREATMENT
   Yao X, 2020, CLIN INFECT DIS
   Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhang JF, 2020, SURG INFECT, V21, P793, DOI 10.1089/sur.2019.213
   Zhang M Q, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE013, DOI [10.3760/cma.j.issn.1001-0939.2020.03.015, 10.3760/cma.j.issn.1001-0939.2020.0013]
   Zhao Y, 2020, SINGLE CELL RNA EXPR, V2, P11
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 69
TC 25
Z9 25
U1 19
U2 27
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2071-1050
J9 SUSTAINABILITY-BASEL
JI Sustainability
PD MAY
PY 2020
VL 12
IS 9
AR 3603
DI 10.3390/su12093603
PG 18
WC Green & Sustainable Science & Technology; Environmental Sciences;
   Environmental Studies
SC Science & Technology - Other Topics; Environmental Sciences & Ecology
GA LU0XV
UT WOS:000537487700001
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Rajagopal, K
   Keller, SP
   Akkanti, B
   Bime, C
   Loyalka, P
   Cheema, FH
   Zwischenberger, JB
   El Banayosy, A
   Pappalardo, F
   Slaughter, MS
   Slepian, MJ
AF Rajagopal, Keshava
   Keller, Steven P.
   Akkanti, Bindu
   Bime, Christian
   Loyalka, Pranav
   Cheema, Faisal H.
   Zwischenberger, Joseph B.
   El Banayosy, Aly
   Pappalardo, Federico
   Slaughter, Mark S.
   Slepian, Marvin J.
TI Advanced Pulmonary and Cardiac Support of COVID-19 Patients Emerging
   Recommendations From ASAIO-a Living Working Document
SO CIRCULATION-HEART FAILURE
LA English
DT Article
DE ARDS; coronavirus; extracorporeal membrane oxygenation; mechanical
   circulatory support; pandemic; shock
ID EXTRACORPOREAL MEMBRANE-OXYGENATION; RESPIRATORY SYNDROME SARS;
   CARDIOGENIC-SHOCK; CORONAVIRUS; DEVICES; CHINA; HEART; EPIDEMIOLOGY;
   PATHOGENESIS; PNEUMONIA
AB The severe acute respiratory syndrome-CoV-2 is an emerging viral pathogen responsible for the global coronavirus disease 2019 pandemic resulting in significant human morbidity and mortality. Based on preliminary clinical reports, hypoxic respiratory failure complicated by acute respiratory distress syndrome is the leading cause of death. Further, septic shock, late-onset cardiac dysfunction, and multiorgan system failure are also described as contributors to overall mortality. Although extracorporeal membrane oxygenation and other modalities of mechanical cardiopulmonary support are increasingly being utilized in the treatment of respiratory and circulatory failure refractory to conventional management, their role and efficacy as support modalities in the present pandemic are unclear. We review the rapidly changing epidemiology, pathophysiology, emerging therapy, and clinical outcomes of coronavirus disease 2019; and based on these data and previous experience with artificial cardiopulmonary support strategies, particularly in the setting of infectious diseases, provide consensus recommendations from American Society for Artificial Internal Organs. Of note, this is a living document, which will be updated periodically, as additional information and understanding emerges.
C1 [Rajagopal, Keshava; Cheema, Faisal H.] Univ Houston, Coll Med, Houston, TX 77004 USA.
   [Rajagopal, Keshava; Loyalka, Pranav; Cheema, Faisal H.] HCA Houston Healthcare, Houston Heart, Houston, TX USA.
   [Keller, Steven P.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
   [Keller, Steven P.] Harvard Med Sch, Boston, MA 02115 USA.
   [Akkanti, Bindu] Univ Texas Houston, Mem Hermann Texas Med Ctr, Houston, TX USA.
   [Bime, Christian; Slepian, Marvin J.] Univ Arizona, Coll Med, Tucson, AZ 85724 USA.
   [Bime, Christian; Slepian, Marvin J.] Univ Arizona, Banner Hlth, Tucson, AZ 85724 USA.
   [Cheema, Faisal H.] HCA Res Inst, Nashville, TN USA.
   [Zwischenberger, Joseph B.] Univ Kentucky, Coll Med, Lexington, KY USA.
   [Zwischenberger, Joseph B.] Univ Kentucky, Med Ctr, Lexington, KY USA.
   [El Banayosy, Aly] Integris Baptist Med Ctr, Oklahoma City, OK USA.
   [Pappalardo, Federico] Univ Vita Salute San Raffaele, Milan, Italy.
   [Slaughter, Mark S.] Univ Louisville, Sch Med, Louisville, KY 40292 USA.
   [Slaughter, Mark S.] Jewish Hosp, Louisville, KY USA.
RP Rajagopal, K (corresponding author), Univ Houston, Houston Heart, HCA Houston Healthcare, Dept Clin Sci,Coll Med, 1200 Binz St,Suite 900, Houston, TX 77004 USA.; Slepian, MJ (corresponding author), Univ Arizona, Sarver Heart Ctr, Dept Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA.; Slepian, MJ (corresponding author), Univ Arizona, Sarver Heart Ctr, Dept Biomed Engn, 1501 N Campbell Ave, Tucson, AZ 85724 USA.
EM krajago2@central.uh.edu; slepian@email.arizona.edu
RI Slepian, Marvin/ABG-8305-2020
OI Slepian, Marvin/0000-0002-7864-6691; Bime, Christian/0000-0003-4787-2685
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [U01 HL131052, K08 HL143342] Funding Source: Medline;
   NIBIB NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Biomedical
   Imaging & Bioengineering (NIBIB) [U01 EB012487] Funding Source: Medline
CR [Anonymous], BRIGHAM WOMENS HOSP
   Bartlett RH, 2020, ASAIO J, V66, P472, DOI 10.1097/MAT.0000000000001173
   Baseler L, 2017, ANNU REV PATHOL-MECH, V12, P387, DOI 10.1146/annurev-pathol-052016-100506
   Basir MB, 2019, CATHETER CARDIO INTE, V93, P1173, DOI 10.1002/ccd.28307
   BAVARIA JE, 1988, ANN THORAC SURG, V45, P526, DOI 10.1016/S0003-4975(10)64525-0
   Beitler JR, 2016, CLIN CHEST MED, V37, P633, DOI 10.1016/j.ccm.2016.07.004
   Bemtgen X, ASAIO J, DOI 10.1097/MAT.0000000000001178
   Bernheim A, 2020, COVID 19 RETROSPECTI
   Bonow RO, 2020, JAMA CARDIOL
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Calisher CH, 2006, CLIN MICROBIOL REV, V19, P531, DOI 10.1128/CMR.00017-06
   Cao B, 2020, NEW ENGL J MED, V382
   Carinci F, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m799
   Carroll D, 2018, SCIENCE, V359, P872, DOI 10.1126/science.aap7463
   Centers for Disease Control and Prevention, 2019, EV TEST PERS COR DIS
   Cherian SV, 2018, RESP MED, V141, P150, DOI 10.1016/j.rmed.2018.06.030
   Clerkin KJ, 2020, CIRCULATION
   Cohen J, 2020, SCIENCE, V368, P14, DOI 10.1126/science.368.6486.14
   Delang L, 2018, ANTIVIR RES, V153, P85, DOI 10.1016/j.antiviral.2018.03.003
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Donker DW, 2020, ASAIO J
   Fineberg HV, 2014, NEW ENGL J MED, V370, P1335, DOI 10.1056/NEJMra1208802
   Garraud O, 2017, TRANSFUS APHER SCI, V56, P31, DOI 10.1016/j.transci.2016.12.014
   GLOWER DD, 1985, CIRCULATION, V71, P994, DOI 10.1161/01.CIR.71.5.994
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Guo T, 2020, JAMA CARDIOL
   Hartman ME, ASAIO J, DOI 10.1097/MAT.0000000000001177
   Jonsson CB, 2010, CLIN MICROBIOL REV, V23, P412, DOI 10.1128/CMR.00062-09
   Kapur NK, 2017, CIRCULATION, V136, P314, DOI 10.1161/CIRCULATIONAHA.116.025290
   Kar S, 2018, CURR CARDIOL REP, V20, DOI 10.1007/s11886-018-0946-2
   Khan S, 2020, J CLIN MICROBIOL, Vpii, pJCM00187, DOI 10.1128/JCM.00187-20
   Kim S, 2019, ACUTE CRIT CARE, V34, P263, DOI 10.4266/acc.2019.00577
   Kujawski SA, 2020, 1 12 PATIENTS CORONA, DOI 10.1101/2020.03.09.20032896
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li X, 2020, ASAIO J, DOI 10.1097/MAT.0000000000001172
   Lin Q, 2020, J MICROBIOL IMMUNOL, Vpii, pS1684, DOI 10.1016/j.jmii.2020.03.015
   Lippi G, 2020, PROG CARDIOVASC DIS, Vpii, pS0033, DOI 10.1016/j.pcad.2020.03.001
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Liu SL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020130
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Lyons DM, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080407
   MacLaren G, 2020, JAMA-J AM MED ASSOC, V323, P1245, DOI 10.1001/jama.2020.2342
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Millar JE, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1570-4
   Miller PE, 2017, CRIT CARE MED, V45, P1922, DOI 10.1097/CCM.0000000000002676
   Morine Kevin J, 2016, Curr Treat Options Cardiovasc Med, V18, P6, DOI 10.1007/s11936-015-0426-6
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372
   Rajagopal K, 2019, ASAIO J, V65, P1, DOI 10.1097/MAT.0000000000000789
   Rajgor DD, 2020, LANCET INFECT DIS, Vpii, pS1473
   Ramanathan K, 2020, LANCET RESP MED, V8, P518, DOI 10.1016/S2213-2600(20)30121-1
   Schmidt M, 2018, AM J RESP CRIT CARE, V197, P1297, DOI 10.1164/rccm.201708-1761OC
   Schmidt M, 2015, EUR HEART J, V36, P2246, DOI 10.1093/eurheartj/ehv194
   Scholten EL, 2017, CHEST, V151, P215, DOI 10.1016/j.chest.2016.06.032
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shen I, 2001, ANN THORAC SURG, V71, P862, DOI 10.1016/S0003-4975(00)02280-3
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Solholm A, 2020, PERFUSION-UK, V35, P763, DOI 10.1177/0267659120907557
   Tehrani BN, 2019, J AM COLL CARDIOL, V73, P1659, DOI 10.1016/j.jacc.2018.12.084
   Towner JS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000764
   Truby LK, 2017, ASAIO J, V63, P257, DOI 10.1097/MAT.0000000000000553
   Uriel N, 2018, J AM COLL CARDIOL, V72, P569, DOI 10.1016/j.jacc.2018.05.038
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang Q., 2020, QUANT SCI STUD, V1, P239, DOI 10.1162/qss_a_00011
   Wei WE, 2020, MMWR-MORBID MORTAL W, V69, P411, DOI 10.15585/mmwr.mm6914e1
   World Health Organization, 2020, LAB TEST COR DIS 201
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Wu P, 2020, EUROSURVEILLANCE, V25, P4, DOI 10.2807/1560-7917.ES.2020.25.3.2000044
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiao SY, 2020, J MED VIROL, V92, P464, DOI 10.1002/jmv.25702
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zampieri FG, 2013, J CRIT CARE, V28, P998, DOI 10.1016/j.jcrc.2013.07.047
   Zhang JN, 2020, LANCET RESP MED, V8, pE11, DOI 10.1016/S2213-2600(20)30071-0
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 84
TC 7
Z9 7
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-3289
EI 1941-3297
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD MAY
PY 2020
VL 13
IS 5
DI 10.1161/CIRCHEARTFAILURE.120.007175
PG 14
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA LT6BA
UT WOS:000537153000015
PM 32357074
DA 2021-01-01
ER

PT J
AU Sciascia, S
   Apra, F
   Baffa, A
   Baldovino, S
   Boaro, D
   Boero, R
   Bonora, S
   Calcagno, A
   Cecchi, I
   Cinnirella, G
   Converso, M
   Cozzi, M
   Crosasso, P
   De Iaco, F
   Di Perri, G
   Eandi, M
   Fenoglio, R
   Giusti, M
   Imperiale, D
   Imperiale, G
   Livigni, S
   Manno, E
   Massara, C
   Milone, V
   Natale, G
   Navarra, M
   Oddone, V
   Osella, S
   Piccioni, P
   Radin, M
   Roccatello, D
   Rossi, D
AF Sciascia, S.
   Apra, F.
   Baffa, A.
   Baldovino, S.
   Boaro, D.
   Boero, R.
   Bonora, S.
   Calcagno, A.
   Cecchi, I.
   Cinnirella, G.
   Converso, M.
   Cozzi, M.
   Crosasso, P.
   De Iaco, F.
   Di Perri, G.
   Eandi, M.
   Fenoglio, R.
   Giusti, M.
   Imperiale, D.
   Imperiale, G.
   Livigni, S.
   Manno, E.
   Massara, C.
   Milone, V.
   Natale, G.
   Navarra, M.
   Oddone, V.
   Osella, S.
   Piccioni, P.
   Radin, M.
   Roccatello, D.
   Rossi, D.
TI Pilot prospective open, single-arm multicentre study on off-label use of
   tocilizumab in patients with severe COVID-19
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
LA English
DT Article
DE COVID-19; coronavirus; tocilizumab; pneumonia
AB Objectives
   No agent has yet been proven to be effective for the treatment of patients with severe COVID-19.
   Methods
   We conducted a pilot prospective open, single-arm multicentre study on off-label use of tocilizumab (TCZ) involving 63 hospitalised adult patients (56 males, age 62.6 +/- 12.5) with severe COVID-19. Clinical and laboratory parameters were prospectively collected at baseline, day 1, 2, 7 and 14. No moderate-to-severe adverse events attributable to TCZ were recorded.
   Results
   We observed a significant improvement in the levels of ferritin, C-reactive protein, D-dimer. The ratio of the partial pressure of oxygen (Pa0(2)) to the fraction of inspired oxygen (Fi0(2)) improved (mean +/- SD Pa0(2)/Fi0(2) at admission: 152 +/- 53; at day 7: 283.73 +/- 115.9, at day 14: 302.2 +/- 126, p<0.05). The overall mortality was 11%; D-dimer level at baseline, but not IL-6 levels were predictors of mortality. TCZ administration within 6 days from admission in the hospital was associated with an increased likelihood of survival (HR 2.2 95%CI 1.3-6.7, p<0.05).
   Conclusions
   In hospitalised adult patients with severe COVID-19, TCZ could be a safe option. An improvement in respiratory and laboratory parameters was observed. Future controlled trials in patients with severe illness are urgently needed to confirm the definite benefit with IL-6 target therapy.
C1 [Sciascia, S.; Baffa, A.; Baldovino, S.; Cecchi, I.; Cozzi, M.; Fenoglio, R.; Massara, C.; Oddone, V.; Radin, M.; Roccatello, D.; Rossi, D.] Univ Torino, Coordinating Ctr Network Rare Dis Piemonte & Vall, Ctr Res Immuno Pathol & Rare Dis, Dept Clin & Biol Sci,ASL Citta Torino, Turin, Italy.
   [Sciascia, S.; Apra, F.; Baffa, A.; Baldovino, S.; Boaro, D.; Boero, R.; Bonora, S.; Calcagno, A.; Cecchi, I.; Cinnirella, G.; Converso, M.; Cozzi, M.; Crosasso, P.; De Iaco, F.; Di Perri, G.; Fenoglio, R.; Giusti, M.; Imperiale, D.; Imperiale, G.; Livigni, S.; Manno, E.; Massara, C.; Milone, V.; Natale, G.; Navarra, M.; Oddone, V.; Osella, S.; Piccioni, P.; Radin, M.; Roccatello, D.; Rossi, D.] ASL Citta Torino, Turin, Italy.
   [Eandi, M.] Univ Torino, Pharmacol Dept, Turin, Italy.
RP Roccatello, D (corresponding author), Osped S Giovanni Bosco, Dipartimento Sci Clin & Biol, Ctr Ric Immunopatol & Malattie Rare, Piazza Donatore Sngue 3, I-10154 Turin, Italy.
EM dario.roccatello@unito.it
OI Radin, Massimo/0000-0003-1941-2606; Sciascia, Savino/0000-0003-1266-9441
CR Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
   Ledford H, 2020, NATURE, V580, P311, DOI 10.1038/d41586-020-01056-7
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Zhang XP, 2014, INT J CLIN PHARM TH, V52, P27, DOI 10.5414/CP201951
NR 6
TC 65
Z9 66
U1 2
U2 5
PU CLINICAL & EXPER RHEUMATOLOGY
PI PISA
PA VIA SANTA MARIA 31, 56126 PISA, ITALY
SN 0392-856X
EI 1593-098X
J9 CLIN EXP RHEUMATOL
JI Clin. Exp. Rheumatol.
PD MAY-JUN
PY 2020
VL 38
IS 3
BP 529
EP 532
PG 4
WC Rheumatology
SC Rheumatology
GA LT0GI
UT WOS:000536755100021
PM 32359035
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Bilia, S
   Giannini, D
   Rizzelli, GML
   Tavoni, A
AF Bilia, S.
   Giannini, D.
   Rizzelli, G. M. L.
   Tavoni, A.
TI Anakinra in COVID-19 therapy: what have we learned from adult-onset
   Still's disease?
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
LA English
DT Letter
ID PHASE-III; SEPSIS
C1 [Bilia, S.; Giannini, D.; Tavoni, A.] Univ Pisa, Dept Clin & Expt Med, Clin Immunol Unit, Pisa, Italy.
   [Rizzelli, G. M. L.] Azienda Osped Univ Pisana, UO Med Urgenza & Pronto Soccorso, Nuovo Santa Chiara Hosp, Emergency Dept, Pisa, Italy.
RP Tavoni, A (corresponding author), Univ Pisa, UO Immunoallergol Clin, Dipartmento Med Clin & Sperimentale, Via Roma 67, I-56126 Pisa, Italy.
EM a.tavoni@int.med.unipi.it
CR Angus DC, 2020, ANN AM THORAC SOC
   FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836
   HASAN KS, 2020, J HEART LUNG TRANSPL, V39, P405
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Opal SM, 1997, CRIT CARE MED, V25, P1115, DOI 10.1097/00003246-199707000-00010
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Vitale A, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00296
   Yang XP, 2019, CLIN EXP RHEUMATOL, V37, P83
NR 9
TC 1
Z9 1
U1 0
U2 0
PU CLINICAL & EXPER RHEUMATOLOGY
PI PISA
PA VIA SANTA MARIA 31, 56126 PISA, ITALY
SN 0392-856X
EI 1593-098X
J9 CLIN EXP RHEUMATOL
JI Clin. Exp. Rheumatol.
PD MAY-JUN
PY 2020
VL 38
IS 3
BP 579
EP 579
PG 1
WC Rheumatology
SC Rheumatology
GA LT0GI
UT WOS:000536755100034
PM 32456767
DA 2021-01-01
ER

PT J
AU Zha, L
   Li, SR
   Pan, LL
   Tefsen, B
   Li, YS
   French, N
   Chen, LY
   Yang, G
   Villanueva, EV
AF Zha, Lei
   Li, Shirong
   Pan, Lingling
   Tefsen, Boris
   Li, Yeshan
   French, Neil
   Chen, Liyun
   Yang, Gang
   Villanueva, Elmer V.
TI Corticosteroid treatment of patients with coronavirus disease 2019
   (COVID-19)
SO MEDICAL JOURNAL OF AUSTRALIA
LA English
DT Article
DE Corticosteroids; Pneumonia; viral; Epidemics
ID RESPIRATORY SYNDROME CORONAVIRUS; PNEUMONIA; OUTBREAK; THERAPY; SARS
AB Objectives To assess the efficacy of corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19).
   Design, setting Observational study in the two COVID-19-designated hospitals in Wuhu, Anhui province, China, 24 January - 24 February 2020.
   Participants Thirty-one patients infected with the severe acute respiratory coronavirus 2 (SARS-CoV-2) treated at the two designated hospitals.
   Main outcome measures Virus clearance time, length of hospital stay, and duration of symptoms, by treatment type (including or not including corticosteroid therapy).
   Results Eleven of 31 patients with COVID-19 received corticosteroid treatment. Cox proportional hazards regression analysis indicated no association between corticosteroid treatment and virus clearance time (hazard ratio [HR], 1.26; 95% CI, 0.58-2.74), hospital length of stay (HR, 0.77; 95% CI, 0.33-1.78), or duration of symptoms (HR, 0.86; 95% CI, 0.40-1.83). Univariate analysis indicated that virus clearance was slower in two patients with chronic hepatitis B infections (mean difference, 10.6 days; 95% CI, 6.2-15.1 days).
   Conclusions Corticosteroids are widely used when treating patients with COVID-19, but we found no association between therapy and outcomes in patients without acute respiratory distress syndrome. An existing HBV infection may delay SARS-CoV-2 clearance, and this association should be further investigated.
C1 [Zha, Lei; Tefsen, Boris; Villanueva, Elmer V.] Xian Jiaotong Liverpool Univ, Suzhou, Jiangsu, Peoples R China.
   [Li, Shirong; Li, Yeshan; Yang, Gang] Second Peoples Hosp Wuhu, Wuhu, Anhui, Peoples R China.
   [Pan, Lingling] Wannan Med Coll, Yijishan Hosp, Wuhu, Anhui, Peoples R China.
   [French, Neil] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.
   [Chen, Liyun] Third Peoples Hosp Wuhu, Wuhu, Anhui, Peoples R China.
RP Villanueva, EV (corresponding author), Xian Jiaotong Liverpool Univ, Suzhou, Jiangsu, Peoples R China.
EM Villanueva@xjtlu.edu.cn
RI Tefsen, Boris/AAR-4854-2020
OI Tefsen, Boris/0000-0001-6668-217X; French, Neil/0000-0003-4814-8293
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen J., 2020, CHINESE J INFECT DIS, V38, pE008, DOI [10.3760/cma.j.cn311365-20200210-00050, DOI 10.3760/CMA.J.CN311365-20200210-00050]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   Haviernik J, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040184
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2018, AM J RESP CRIT CARE, V197, P700, DOI 10.1164/rccm.201712-2371ED
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Quispe-Laime AM, 2010, INTENS CARE MED, V36, P33, DOI 10.1007/s00134-009-1727-6
   Mo Y, 2016, J ANTIMICROB CHEMOTH, V71, P3340, DOI 10.1093/jac/dkw338
   Park JJ, 2016, GASTROENTEROLOGY, V150, P684, DOI 10.1053/j.gastro.2015.11.050
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Sibila O, 2008, EUR RESPIR J, V32, P259, DOI 10.1183/09031936.00154107
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, WHO 2019 NCOV CLIN 2
   World Health Organization, 2020, 63 WHO
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhao J P, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE007, DOI 10.3760/cma.j.issn.1001-0939.2020.0007
   Zhou J, 2014, J INFECT DIS, V209, P1331, DOI 10.1093/infdis/jit504
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 28
TC 63
Z9 64
U1 3
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0025-729X
EI 1326-5377
J9 MED J AUSTRALIA
JI Med. J. Aust.
PD MAY
PY 2020
VL 212
IS 9
BP 416
EP 420
DI 10.5694/mja2.50577
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA LS1KN
UT WOS:000536150700008
PM 32266987
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Laufs, J
   Elsbernd, H
   Holzl, F
   Winter, KD
AF Laufs, Jendrik
   Elsbernd, Harry
   Hoelzl, Friedrich
   Winter, Klaus-Dieter
TI Coronavirus (SARS-CoV-2) - Outbreak in North Rhine-Westphalia (District
   of Heinsberg) First diagnosis of a COVID-19 manifestation in a couple
SO DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
LA German
DT Article
DE SARS-CoV-2; coronavirus; COVID-1; district of Heinsberg; outbreak
AB History and clinical findings Up to February 24th 2020 occasionally occuring SARS-CoV-2 infections in Germany without severe course. Emergency presentation of a couple in the emergency room. For seven days now, the man has fever, dry cough und physical weakness and the wife has similar symptoms of a milder form. The clinical examination shows fine crackles over both lungs and a respiratory failure of the husband.
   Investigations and diagnosis Laboratory increase in inflammation parameters as well as transaminases and lactate dehydrogenase. Radiologically lung infiltrates of different severity. Further on diagnosis of a SARS-CoV-2-infection of both patients with a severe course of the male.
   Treatment and course Intubation and mechanical ventilation of the male patient with prolonged intenive care treatment. Recovery of the female patient under conventional oxygen therapy.
   Discussion These two cases show the starting point of an endemic spread of SARS-CoV-2 in the district of Heinsberg (North Rhine-Westphalia) and up to this point the first case of a life-threatenning course in Germany.
C1 [Laufs, Jendrik; Winter, Klaus-Dieter] Hermann Josef Krankenhaus Erkelenz, Klin Kardiol, Tenholter Str 43, D-41812 Erkelenz, Germany.
   [Elsbernd, Harry] Hermann Josef Krankenhaus Erkelenz, Klin Innere Med Gastroenterol, Erkelenz, Germany.
   [Hoelzl, Friedrich] Hermann Josef Krankenhaus Erkelenz, Zent Notaufnahme, Erkelenz, Germany.
RP Winter, KD (corresponding author), Hermann Josef Krankenhaus Erkelenz, Klin Kardiol, Tenholter Str 43, D-41812 Erkelenz, Germany.
EM kwinter@hjk-erkelenz.de
CR Bayerisches Landesamt fur Gesundheit und Lebensmittelsicherheit Robert Koch-Institut, 2020, EPID B, V7, P3
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Gainnier M, 2004, CRIT CARE MED, V32, P113, DOI 10.1097/01.CCM.0000104114.72614.BC
   Hinkelbein J, 2018, ANASTH INTENSIV NOTF, V53, P631, DOI 10.1055/a-0628-3122
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   RKI, COVID 19 VERD MAB
   Schellein O, 2009, ANAESTHESIST, V58, P163, DOI 10.1007/s00101-008-1477-9
   Thompson BT, 2017, NEW ENGL J MED, V377, P562, DOI 10.1056/NEJMra1608077
   World Health Organization, 1 WHO
   World Health Organization, 35 WHO
   Xie XZ, 2020, EUR RADIOL, V30, P4347, DOI 10.1007/s00330-020-06821-w
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 13
TC 0
Z9 0
U1 1
U2 2
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0012-0472
EI 1439-4413
J9 DEUT MED WOCHENSCHR
JI Dtsch. Med. Wochenschr.
PD MAY
PY 2020
VL 145
IS 10
BP 665
EP 669
DI 10.1055/a-1163-1335
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA LS9NR
UT WOS:000536706200017
PM 32428957
DA 2021-01-01
ER

PT J
AU Orser, BA
   Wang, DS
   Lu, WY
AF Orser, Beverley A.
   Wang, Dian-Shi
   Lu, Wei-Yang
TI Sedating ventilated COVID-19 patients with inhalational anesthetic drugs
SO EBIOMEDICINE
LA English
DT Letter
C1 [Orser, Beverley A.] Univ Toronto, Dept Anesthesiol & Pain Med, Toronto, ON M5G 1E2, Canada.
   [Orser, Beverley A.; Wang, Dian-Shi] Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada.
   [Orser, Beverley A.] Sunnybrook Hlth Sci Ctr, Dept Anesthesia, Toronto, ON M4N 3M5, Canada.
   [Lu, Wei-Yang] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada.
RP Orser, BA (corresponding author), Univ Toronto, Dept Anesthesiol & Pain Med, Toronto, ON M5G 1E2, Canada.
EM beverley.orser@utoronto.ca
RI Lu, Wei-Yang/K-4404-2013
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [FDN-154312]
FX Supported by a Foundation Grant (FDN-154312) from the Canadian
   Institutes of Health Research (to B.A.O.).
CR American Society of Anesthesiologists Anesthesia Patient Safety Foundation, APSF ASA GUID PURP A
   Forkuo GS, 2018, MOL PHARMACEUT, V15, P1766, DOI 10.1021/acs.molpharmaceut.7b01013
   Fortis S, 2012, INTENS CARE MED, V38, P1548, DOI 10.1007/s00134-012-2610-4
   Jabaudon M, 2017, AM J RESP CRIT CARE, V195, P792, DOI 10.1164/rccm.201604-0686OC
   Jerath A, 2016, AM J RESP CRIT CARE, V193, P1202, DOI 10.1164/rccm.201512-2435CP
NR 5
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD MAY
PY 2020
VL 55
AR 102770
DI 10.1016/j.ebiom.2020.102770
PG 2
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA LT7UC
UT WOS:000537270600014
PM 32344199
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Basu, D
   Ghosh, A
   Subodh, BN
   Mattoo, SK
AF Basu, Debasish
   Ghosh, Abhishek
   Subodh, B. N.
   Mattoo, S. K.
TI Opioid substitution therapy with buprenorphine-naloxone during COVID-19
   outbreak in India: Sharing our experience and interim standard operating
   procedure
SO INDIAN JOURNAL OF PSYCHIATRY
LA English
DT Article
DE Buprenorphine-naloxone; coronavirus disease 2019; opioid substitution
   therapy; pandemic; standard operating procedures
AB Coronavirus disease 2019 (COVID-19) has been declared as a pandemic by the World Health Organization on March 11, 2020. It has affected most countries of the world, including India. Both the disease and the unavoidable national response to it have posed unique challenges to our health-care system. A particular vulnerable group of patients is those with opioid dependence maintained on opioid substitution therapy (OST). These patients are pharmacologically dependent on the OST medication (buprenorphine, buprenorphine-naloxone combination [BNX], and methadone) for their healthy functioning and recovery. COVID-19 outbreak, lock-down, and difficult access to medical care, all are likely to induce stress and withdrawal, which is a potential risk for relapse among individuals with opioid dependence, who are anyway more vulnerable due to social, housing, living, and medical conditions. In this context, it is essential to re-strategize the existing OST services to adapt to the challenging circumstances. In this communication, we share our experience and formulate interim standard operating procedures (SOPs) for running a hospital-based OST service utilizing take-home BNX. The challenges, principles to meet the challenges, and interim SOPs are shared as being currently practiced in our center. Individual institutes, agencies, hospitals, and clinics running OST service with BNX can adapt these SOPs according to their characteristics, needs, demand, and resources; so long as, the basic principles are adhered to.
C1 [Basu, Debasish; Ghosh, Abhishek; Subodh, B. N.; Mattoo, S. K.] Postgrad Inst Med Educ & Res, Dept Psychiat, Drug De Addict & Treatment Ctr, Chandigarh 160012, India.
RP Basu, D (corresponding author), Postgrad Inst Med Educ & Res, Dept Psychiat, Drug De Addict & Treatment Ctr, Chandigarh 160012, India.
EM db_sm2002@yahoo.com
CR Alexander GC, 2020, ANN INTERN MED, V173, P57, DOI 10.7326/M20-1141
   American Association for the Treatment of Opioid Dependence, AATOD REL GUID OTPS
   Becker WC, 2020, ANN INTERN MED, V173, P59, DOI 10.7326/M20-1210
   Board of Governors in Supersession of the Medical Council of India, TEL PRACT GUID EN RE
   European Monitoring Centre for Drugs and Drug Addiction, EMCDDA UPD IMPL COVI
   National AIDS Control Organization, GUID NOT PERS ENG HI
   Substance Abuse and Mental Health Services Administration, CONV 19 OP TREATM PR
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
   WHO, COR DIS COVID 19 PAN
NR 9
TC 3
Z9 3
U1 1
U2 1
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0019-5545
EI 1998-3794
J9 INDIAN J PSYCHIAT
JI Indian J. Psychiatry
PD MAY-JUN
PY 2020
VL 62
IS 3
BP 322
EP 326
DI 10.4103/psychiatry.IndianJPsychiatry_295_20
PG 5
WC Psychiatry
SC Psychiatry
GA LT7TA
UT WOS:000537267800016
PM 32773878
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Preskorn, SH
AF Preskorn, Sheldon H.
TI Mental Health Care Providers Dealing With Coronavirus Disease 2019
   (COVID-19): What Is the Definition of a Case, How Is That Changing, and
   What Kinds of Tests Are Available?
SO JOURNAL OF PSYCHIATRIC PRACTICE
LA English
DT Article
DE Coronavirus Disease 2019 (COVID-19); mental health professionals; tests;
   immunity; real time Reverse Transcriptase (RT)-Polymerase Chain Reaction
   (PCR) Diagnostics Panel (RT-PCR Panel); treatments; medications;
   vaccines
AB The goal of this column is to inform mental health care professionals about the evolving way the diagnosis of Coronavirus Disease 2019 (COVID-19) is being made, with emphasis on tests to assist in making the diagnosis and to determine the presence of antibodies to the virus. This column also provides some general information about the disease, its relative risks, and efforts to develop effective treatments. Links to credible websites that are being continuously updated are also provided for readers who want more information and to stay current with ongoing developments.
C1 [Preskorn, Sheldon H.] Univ Kansas, Sch Med Wichita, 1010 N Kansas, Wichita, KS 67217 USA.
RP Preskorn, SH (corresponding author), Univ Kansas, Sch Med Wichita, 1010 N Kansas, Wichita, KS 67217 USA.
CR Center of Disease Control, 2020, CDC 2019 NOV COR 201
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   Ioannidis JP, 2020, FIASCO MAKING CORONA
   National Institutes of Health (NIH), 2020, TEST US
   Terhune C, 2020, REUTERS WORLD NEWS
   US Food and Drug Administration (FDA) Consumer update, 2020, FOOD SAF AV COR PAND
   Wikipedia, SPAN FLU
   Wikipedia, SEV AC RESP SYNDR
   Wikipedia, COR
   Worldometer Website, COVID 19 COR PAND
NR 10
TC 2
Z9 2
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1527-4160
EI 1538-1145
J9 J PSYCHIATR PRACT
JI J. Psychiatr. Pract.
PD MAY
PY 2020
VL 26
IS 3
BP 215
EP 218
DI 10.1097/PRA.0000000000000473
PG 4
WC Psychiatry
SC Psychiatry
GA LS2YA
UT WOS:000536253600006
PM 32294077
OA Green Published
DA 2021-01-01
ER

PT J
AU Preskorn, SH
AF Preskorn, Sheldon H.
TI The 5% of the Population at High Risk for Severe COVID-19 Infection Is
   Identifiable and Needs to Be Taken Into Account When Reopening the
   Economy
SO JOURNAL OF PSYCHIATRIC PRACTICE
LA English
DT Article
DE coronavirus disease 2019 (COVID-19); mental health professionals; tests;
   immunity; treatments; medications; vaccines; antibodies; risk
   stratification
AB The goal of this column is to help mental health care professionals understand coronavirus disease 2019 (COVID-19) so that they can better explain the complexities of the current crisis to their patients. The bottom-line of this column is that, while COVID-19 can infect virtually everyone in the human population, only about 5% are susceptible to severe infection requiring admission to an intensive care unit and/or causing a fatal outcome and this population can be identified on the basis of comorbid medical illness and/or age. These numbers are based on experience in China, the United States, and Europe. Table 1 presents an analysis conducted by the US Centers for Disease Control and Prevention (CDC), which is further supported by several other sources reviewed in the article. The population at risk for severe infection are individuals with comorbid medical illness and those 85 years of age and older. The comorbid medical illnesses identified as risk factors are preexisting respiratory and cardiovascular disease, immunocompromised status, morbid obesity (ie, body mass index >= 40), diabetes mellitus, and possibly significant kidney or liver impairment. Parenthetically, news reports and the literature sometimes cite age 60 years and older as a risk factor but age between 60 and 85 years is likely a surrogate for having 1 or more of these comorbid medical conditions. While 5% may initially seem like a small number, it nevertheless potentially represents 16.5 million people, given the United States population of 330 million. That is a tremendous number of people requiring intensive care unit admission and/or potentially dying, and individuals in this population have overwhelmed the US health care system in some hotspots. For this reason, this column suggests taking this at-risk population into account in mitigation strategies when attempting to open the US economy. The column addresses the following questions: (1) What are the 3 aspects of the race to minimize the damage caused by COVID-19? (2) What data are currently available to help guide decisions to be made? (3) What strategies have been employed to date and how successful have they been? and (4) Might risk stratification of exposure be a viable strategy to minimize the damage caused by the virus? The race to minimize the damage caused by COVID-19 requires that we obtain knowledge about the disease and its treatment or prevention, how to best safeguard public health and avoid overwhelming the health care system, and how to minimize the societal damage caused by substantial disruption of the economy. Data gathered over the past 4 months since the COVID-19 virus emerged as a human pathogen have provided guidance for our decisions going forward. The most widely adopted strategies for dealing with the COVID-19 pandemic to date have involved the epidemiological approach of encouraging good hygiene practices and social distancing, including orders to "shelter in place," quarantine of high-risk individuals, and isolation of infected individuals. The goal of this epidemiological approach has been to "flatten the curve" by reducing the height of the peak of the infection to avoid overwhelming the health care system and society in general, while buying time to learn more about the disease and find more effective ways to deal with it.
   However, now that more is known about COVID-19 and the portion of the population that is most at risk for serious adverse outcomes including death, it may be possible to move from a shelter-in-place approach for the entire population to focus on those at most risk and thus facilitate a gradual and rational phased reduction of social restrictions to reopen the economy. Such a graduated opening would be based on regions of countries meeting specific criteria in terms of being able to contain the virus, coupled with vigorous monitoring to look for outbreaks, followed by case monitoring, isolation of infected individuals and quarantine of exposed individuals, and increased use of testing for active disease as well as for immunity. Taking the data on high-risk individuals into account would allow for a gradual lifting of restrictions on the majority of the population while maintaining more stringent safeguards to protect the vulnerable portion of the population. Nevertheless, the entire population would need to continue to practice good hygiene and social distancing while simultaneously-and perhaps even more vigorously-focusing on sheltering the vulnerable population until adequate community immunity has been achieved to prevent the spread of the virus, whether that is accomplished through natural exposure alone or with the addition of safe and effective vaccine(s) which may not be available for a year. Continued widespread testing for antibodies will help determine how far or close this country is-and other countries are-from developing effective community immunity.
C1 [Preskorn, Sheldon H.] Univ Kansas, Sch Med Wichita, 1010 N Kansas, Wichita, KS 67217 USA.
RP Preskorn, SH (corresponding author), Univ Kansas, Sch Med Wichita, 1010 N Kansas, Wichita, KS 67217 USA.
CR Bruggeman L., 2020, ABC NEWS
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Healthcare Fact Sheet, 2020, TRUMP IS BEG NEXT PH
   Hjelmgaard K., 2020, US TODAY
   National Institute of Allergy and Infectious Diseases (NIAID), 2020, CORONAVIRUSES
   Preskorn SH, 2020, J PSYCHIATR PRACT, V26, P215, DOI 10.1097/PRA.0000000000000473
   Wikipedia, BAS REPR NUMB
   Wikipedia, COR
   Wikipedia, SEV AC RESP SYDR
   World Health Organization Regional Office for Europe, COVID 19 WEEKL SURV
   Worldometer Website, COR COVID 19 MORT RA
NR 13
TC 2
Z9 3
U1 6
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1527-4160
EI 1538-1145
J9 J PSYCHIATR PRACT
JI J. Psychiatr. Pract.
PD MAY
PY 2020
VL 26
IS 3
BP 219
EP 227
DI 10.1097/PRA.0000000000000475
PG 9
WC Psychiatry
SC Psychiatry
GA LS2YA
UT WOS:000536253600007
PM 32421292
OA Green Published
DA 2021-01-01
ER

PT J
AU Bzowka, M
   Mitusinska, K
   Raczynska, A
   Samol, A
   Tuszynski, JA
   Gora, A
AF Bzowka, Maria
   Mitusinska, Karolina
   Raczynska, Agata
   Samol, Aleksandra
   Tuszynski, Jack A.
   Gora, Artur
TI Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro
   Is a Challenging Target for Small-Molecule Inhibitor Design
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE coronavirus; SARS-CoV; SARS-CoV-2; COVID-19; molecular dynamics
   simulations; ligand tracking approach; drug design; small-molecule
   inhibitors; evolutionary analysis
ID RESPIRATORY-SYNDROME-CORONAVIRUS; MAIN PROTEASE; WEB SERVER; PREDICTION;
   ALIGNMENT; DYNAMICS
AB The novel coronavirus whose outbreak took place in December 2019 continues to spread at a rapid rate worldwide. In the absence of an effective vaccine, inhibitor repurposing or de novo drug design may offer a longer-term strategy to combat this and future infections due to similar viruses. Here, we report on detailed classical and mixed-solvent molecular dynamics simulations of the main protease (Mpro) enriched by evolutionary and stability analysis of the protein. The results were compared with those for a highly similar severe acute respiratory syndrome (SARS) Mpro protein. In spite of a high level of sequence similarity, the active sites in both proteins showed major differences in both shape and size, indicating that repurposing SARS drugs for COVID-19 may be futile. Furthermore, analysis of the binding site's conformational changes during the simulation time indicated its flexibility and plasticity, which dashes hopes for rapid and reliable drug design. Conversely, structural stability of the protein with respect to flexible loop mutations indicated that the virus' mutability will pose a further challenge to the rational design of small-molecule inhibitors. However, few residues contribute significantly to the protein stability and thus can be considered as key anchoring residues for Mpro inhibitor design.
C1 [Bzowka, Maria; Mitusinska, Karolina; Raczynska, Agata; Samol, Aleksandra; Gora, Artur] Silesian Tech Univ, Tunneling Grp, Biotechnol Ctr, Ul Krzywoustego 8, PL-44100 Gliwice, Poland.
   [Tuszynski, Jack A.] Univ Alberta, Dept Phys, Edmonton, AB T6G 2E1, Canada.
   [Tuszynski, Jack A.] Politecn Torino, DIMEAS, Corso Duca Abruzzi 24, I-10129 Turin, Italy.
RP Gora, A (corresponding author), Silesian Tech Univ, Tunneling Grp, Biotechnol Ctr, Ul Krzywoustego 8, PL-44100 Gliwice, Poland.
EM m.bzowka@tunnelinggroup.pl; k.mitusinska@tunnelinggroup.pl;
   a.raczynska@tunnelinggroup.pl; a.samol@tunnelinggroup.pl;
   jackt@ualberta.ca; a.gora@tunnelinggroup.pl
RI Bzowka, Maria/ABG-2897-2020; Gora, Artur/D-5041-2012
OI Bzowka, Maria/0000-0001-6802-8753; Gora, Artur/0000-0003-2530-6957;
   Mitusinska, Karolina/0000-0002-0183-0845; Tuszynski,
   Jack/0000-0001-9976-0429
FU National Science Centre, PolandNational Science Centre, Poland
   [DEC-2013/10/E/NZ1/00649, DEC-2015/18/M/NZ1/00427]; IBM CAS; NSERC
   (Canada)Natural Sciences and Engineering Research Council of Canada
FX K.M., M.B., A.R., A.S., and A.G.'s work was supported by the National
   Science Centre, Poland (grant no. DEC-2013/10/E/NZ1/00649 and
   DEC-2015/18/M/NZ1/00427). J.A.T. expresses gratitude for research
   support for this project received from IBM CAS and NSERC (Canada).
CR Adem S., 2020, IDENTIFICATION POTEN, V46, P1, DOI [10.20944/preprints202003.0333.v1., 10.20944/preprints202003.0333.v1, DOI 10.20944/PREPRINTS202003.0333.V1]
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Anandakrishnan R, 2012, NUCLEIC ACIDS RES, V40, pW537, DOI 10.1093/nar/gks375
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   [Anonymous], PYMOL MOL GRAPH SYST
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421
   Case D., 2018, AMBER 2018
   Chang CK, 2016, MOL BIOSYST, V12, P59, DOI 10.1039/c5mb00582e
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dayer MR, 2017, ARCH CLIN INFECT DIS, V12, DOI 10.5812/archcid.13823
   de Beer SBA, 2010, CURR TOP MED CHEM, V10, P55, DOI 10.2174/156802610790232288
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Fischer A, 2020, POTENTIAL INHIBITORS, DOI [10.26434/chemrxiv.11923239., DOI 10.26434/CHEMRXIV.11923239]
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Gertz EM, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-41
   Heo L, 2018, PROTEINS, V86, P177, DOI 10.1002/prot.25393
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Klausen MS, 2019, PROTEINS, V87, P520, DOI 10.1002/prot.25674
   Kuipers RK, 2010, PROTEINS, V78, P2101, DOI 10.1002/prot.22725
   Li CM, 2010, J BIOL CHEM, V285, P28134, DOI 10.1074/jbc.M109.095851
   Li Y., 2020, THERAPEUTIC DRUGS TA, DOI [10.1101/2020.01.28.922922, DOI 10.1101/2020.01.28.922922]
   Lim LZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101941
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Luchko T, 2010, J CHEM THEORY COMPUT, V6, P607, DOI 10.1021/ct900460m
   Magdziarz T, 2020, BIOINFORMATICS, V36, P2599, DOI 10.1093/bioinformatics/btz946
   Martinez L, 2009, J COMPUT CHEM, V30, P2157, DOI 10.1002/jcc.21224
   Mitusinska K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072293
   Mitusinska Karolina, 2020, Comput Struct Biotechnol J, V18, P355, DOI 10.1016/j.csbj.2020.02.001
   Mitusinska K, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8040143
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Needle D, 2015, ACTA CRYSTALLOGR D, V71, P1102, DOI 10.1107/S1399004715003521
   Nguyen D.D., 2020, POTENTIALLY HIGHLY P, DOI [10.1101/2020.02.05.936013, DOI 10.1101/2020.02.05.936013]
   Nikitin AM, 2007, J COMPUT CHEM, V28, P2020, DOI [10.1002/jcc.20721, 10.1002/JCC.20721]
   Panjkovich A, 2014, BIOINFORMATICS, V30, P1314, DOI 10.1093/bioinformatics/btu002
   Pence HE, 2010, J CHEM EDUC, V87, P1123, DOI 10.1021/ed100697w
   Resnick E, 2019, J AM CHEM SOC, V141, P8951, DOI 10.1021/jacs.9b02822
   Schymkowitz J, 2005, NUCLEIC ACIDS RES, V33, pW382, DOI 10.1093/nar/gki387
   Sievers F, 2014, METHODS MOL BIOL, V1079, P105, DOI 10.1007/978-1-62703-646-7_6
   Sindhikara DJ, 2012, J COMPUT CHEM, V33, P1536, DOI 10.1002/jcc.22984
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Spyrakis F, 2017, J MED CHEM, V60, P6781, DOI 10.1021/acs.jmedchem.7b00057
   Subramanian K, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9060212
   Talluri S., 2020, VIRTUAL HIGH THROUGH, DOI [10.20944/preprints202002.0418.v2, DOI 10.20944/PREPRINTS202002.0418.V2]
   Tang Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep17155
   Tsai MY, 2010, J BIOCHEM, V148, P349, DOI 10.1093/jb/mvq071
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Zhang LS, 2020, CLIN INFECT DIS, V71, P882, DOI 10.1093/cid/ciaa112
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhong N, 2008, J VIROL, V82, P4227, DOI 10.1128/JVI.02612-07
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 62
TC 10
Z9 10
U1 3
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2020
VL 21
IS 9
AR 3099
DI 10.3390/ijms21093099
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA LR3GK
UT WOS:000535581700070
PM 32353978
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Messina, G
   Polito, R
   Monda, V
   Cipolloni, L
   Di Nunno, N
   Di Mizio, G
   Murabito, P
   Carotenuto, M
   Messina, A
   Pisanelli, D
   Valenzano, A
   Cibelli, G
   Scarinci, A
   Monda, M
   Sessa, F
AF Messina, Giovanni
   Polito, Rita
   Monda, Vincenzo
   Cipolloni, Luigi
   Di Nunno, Nunzio
   Di Mizio, Giulio
   Murabito, Paolo
   Carotenuto, Marco
   Messina, Antonietta
   Pisanelli, Daniela
   Valenzano, Anna
   Cibelli, Giuseppe
   Scarinci, Alessia
   Monda, Marcellino
   Sessa, Francesco
TI Functional Role of Dietary Intervention to Improve the Outcome of
   COVID-19: A Hypothesis of Work
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE COVID-19; IL-6; adiponectin; omega-3 PUFAs; lung infections; diet
   therapies
ID PLASMA ADIPONECTIN LEVELS; POLYUNSATURATED FATTY-ACIDS;
   METABOLIC-DISORDERS; PULMONARY-DISEASE; NERVOUS-SYSTEM; ADIPOSE-TISSUE;
   INFLAMMATION; ALPHA; EXPRESSION; CYTOKINES
AB Background: On the 31 December 2019, the World Health Organization (WHO) was informed of a cluster of cases of pneumonia of unknown origin detected in Wuhan City, Hubei Province, China. The infection spread first in China and then in the rest of the world, and on the 11th of March, the WHO declared that COVID-19 was a pandemic. Taking into consideration the mortality rate of COVID-19, about 5-7%, and the percentage of positive patients admitted to intensive care units being 9-11%, it should be mandatory to consider and take all necessary measures to contain the COVID-19 infection. Moreover, given the recent evidence in different hospitals suggesting IL-6 and TNF-alpha inhibitor drugs as a possible therapy for COVID-19, we aimed to highlight that a dietary intervention could be useful to prevent the infection and/or to ameliorate the outcomes during therapy. Considering that the COVID-19 infection can generate a mild or highly acute respiratory syndrome with a consequent release of pro-inflammatory cytokines, including IL-6 and TNF-alpha, a dietary regimen modification in order to improve the levels of adiponectin could be very useful both to prevent the infection and to take care of patients, improving their outcomes.
C1 [Messina, Giovanni; Polito, Rita; Cipolloni, Luigi; Pisanelli, Daniela; Valenzano, Anna; Cibelli, Giuseppe; Sessa, Francesco] Univ Foggia, Dept Clin & Expt Med, I-71122 Foggia, Italy.
   [Monda, Vincenzo; Messina, Antonietta; Monda, Marcellino] Univ Campania Luigi Vanvitelli, Sect Human Physiol, Dept Expt Med, I-80138 Naples, Italy.
   [Monda, Vincenzo; Messina, Antonietta; Monda, Marcellino] Univ Campania Luigi Vanvitelli, Unit Dietet & Sports Med, I-80138 Naples, Italy.
   [Di Nunno, Nunzio] Univ Salento, Dept Hist Soc & Studies Humanity, I-73100 Lecce, Italy.
   [Di Mizio, Giulio] Magna Graecia Univ Catanzaro, Dept Law Forens Med, I-88100 Catanzaro, Italy.
   [Murabito, Paolo] Univ Catania, Dept Gen Surg & Med Surg Specialties, I-95121 Catania, Italy.
   [Carotenuto, Marco] Univ Campania Luigi Vanvitelli, Clin Child & Adolescent Neuropsychiat, Dept Mental Hlth Phys & Prevent Med, I-81100 Caserta, Italy.
   [Scarinci, Alessia] Univ Bari, Dept Educ Sci Psychol & Commun, I-70121 Bari, Italy.
RP Messina, G (corresponding author), Univ Foggia, Dept Clin & Expt Med, I-71122 Foggia, Italy.; Monda, M (corresponding author), Univ Campania Luigi Vanvitelli, Sect Human Physiol, Dept Expt Med, I-80138 Naples, Italy.; Monda, M (corresponding author), Univ Campania Luigi Vanvitelli, Unit Dietet & Sports Med, I-80138 Naples, Italy.
EM giovanni.messina@unifg.it; rita.polito@unicampania.it;
   vincenzo.monda@unicampania.it; luigi.cipolloni@unifg.it;
   nunzio.dinunno@unisalento.it; giulio.dimizio@unicz.it;
   paolo.murabito@unict.it; marco.carotenuto@unicampania.it;
   anto.messina83@gmail.com; daniela.pisanelli82@gmail.com;
   anna.valenzano@unifg.it; giuseppe.cibelli@unifg.it;
   alessia.scarinci@uniba.it; marcellino.monda@unicampania.it;
   francesco.sessa@unifg.it
RI Sessa, Francesco/G-1754-2018; Cipolloni, Luigi/AAS-2680-2020
OI Sessa, Francesco/0000-0003-0357-8791; Murabito,
   Paolo/0000-0002-2662-1898; Monda, Vincenzo/0000-0002-6083-5814; DI
   MIZIO, Giulio/0000-0001-7279-3693; Messina,
   Giovanni/0000-0002-0011-867X; cipolloni, luigi/0000-0001-6464-3249
CR Adamczak M, 2005, CLIN ENDOCRINOL, V62, P114, DOI 10.1111/j.1365-2265.2004.02182.x
   Agriesti F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58871-1
   Ajuwon KM, 2005, AM J PHYSIOL-REG I, V288, pR1220, DOI 10.1152/ajpregu.00397.2004
   Alvarado A., 2016, CLIN RES TRIALS, DOI [10.15761/CRT.1000163, DOI 10.15761/CRT.1000163]
   Bafunno V, 2013, J ALLERGY CLIN IMMUN, V132, P748, DOI 10.1016/j.jaci.2013.04.006
   Banerjee A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010041
   Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Ben Addi A, 2008, EUR J IMMUNOL, V38, P1610, DOI 10.1002/eji.200737781
   Bertozzi G, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55070396
   Bianco A, 2017, PULM PHARMACOL THER, V43, P20, DOI 10.1016/j.pupt.2017.01.004
   Bianco A, 2013, NUTRIENTS, V5, P4115, DOI 10.3390/nu5104115
   Calder PC, 2013, BRIT J CLIN PHARMACO, V75, P645, DOI 10.1111/j.1365-2125.2012.04374.x
   Capote KR, 2003, J BIOL CHEM, V278, P20461, DOI 10.1074/jbc.M212697200
   Caron E, 2015, BRIT J NUTR, V113, P191, DOI 10.1017/S0007114514003705
   Carr AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02851-4
   Chan KH, 2010, INT J TUBERC LUNG D, V14, P1193
   Christofidou-Solomidou Melpo, 2006, Treat Respir Med, V5, P47, DOI 10.2165/00151829-200605010-00004
   Daniele A, 2012, INT J BIOCHEM CELL B, V44, P563, DOI 10.1016/j.biocel.2011.12.016
   Desruisseaux MS, 2007, INFECT IMMUN, V75, P1066, DOI 10.1128/IAI.01455-06
   Diao B., 2020, REDUCTION FUNCTIONAL, DOI [10.1101/2020.02.18.20024364, DOI 10.1101/2020.02.18.20024364]
   Dushianthan A, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012041.pub2
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Fessler MB, 2016, AM J RESP CELL MOL, V54, P624, DOI 10.1165/rcmb.2016-0011PS
   Fragopoulou E, 2010, J NUTR BIOCHEM, V21, P285, DOI 10.1016/j.jnutbio.2008.12.013
   Furuhashi M, 2003, HYPERTENSION, V42, P76, DOI 10.1161/01.HYP.0000078490.59735.6E
   Galvão André Martins, 2011, Rev. bras. ter. intensiva, V23, P41, DOI 10.1590/S0103-507X2011000100008
   de Acilu MG, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/653750
   Garcia P, 2012, CURR MED CHEM, V19, P5493, DOI 10.2174/092986712803833263
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hecker M, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0933-6
   Hiuge A, 2007, ARTERIOSCL THROM VAS, V27, P635, DOI 10.1161/01.ATV.0000256469.06782.d5
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Imai Y, 2015, BBA-MOL CELL BIOL L, V1851, P496, DOI 10.1016/j.bbalip.2015.01.006
   Iwai M, 2007, AM J HYPERTENS, V20, P579, DOI 10.1016/j.amjhyper.2006.12.010
   Iwata M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192609
   Jayarathne Shasika, 2017, Prev Nutr Food Sci, V22, P251, DOI 10.3746/pnf.2017.22.4.251
   Jones GJB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16098-7
   Kanda Y, 2008, DIABETES RES CLIN PR, V81, P13, DOI 10.1016/j.diabres.2008.01.031
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Koh KK, 2007, DIABETES CARE, V30, P1605, DOI 10.2337/dc06-2267
   Koh KK, 2011, INT J CARDIOL, V146, P434, DOI 10.1016/j.ijcard.2010.10.103
   Koh KK, 2011, ATHEROSCLEROSIS, V214, P144, DOI 10.1016/j.atherosclerosis.2010.10.023
   Kreda SM, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009589
   Li CC, 2015, NUTRIENTS, V7, P5572, DOI 10.3390/nu7075239
   Li M, 2008, DIABETES, V57, P1526, DOI 10.2337/db07-1764
   Li YY, 2016, INTERVIROLOGY, V59, P163, DOI 10.1159/000453066
   Ling LJ, 2020, PHYTOMEDICINE, V67, DOI 10.1016/j.phymed.2019.153150
   Lundblad LKA, 2005, AM J RESP CRIT CARE, V171, P1363, DOI 10.1164/rccm.200410-1349OC
   Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094
   Masaki T, 2004, HEPATOLOGY, V40, P177, DOI 10.1002/hep.20282
   McLaughlin T, 2017, J CLIN INVEST, V127, P5, DOI 10.1172/JCI88876
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Minihane AM, 2015, BRIT J NUTR, V114, P999, DOI 10.1017/S0007114515002093
   Monda V, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10030129
   Monda V, 2018, MOL NEUROBIOL, V55, P6362, DOI 10.1007/s12035-017-0865-z
   Monda V, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00773
   Nacoti M, 2020, NEJM CATALYST, DOI [10.1056/CAT.20.0080, DOI 10.1056/CAT.20.0080, 10.1056/CAT.20.0080#]
   Neumeier M, 2006, J LEUKOCYTE BIOL, V79, P803, DOI 10.1189/jlb.0905521
   Nigro E, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/658913
   Nowak L, 2005, AM J HYPERTENS, V18, P1470, DOI 10.1016/j.amjhyper.2005.05.026
   Ohashi K, 2014, TRENDS ENDOCRIN MET, V25, P348, DOI 10.1016/j.tem.2014.03.009
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Parolini C, 2019, MAR DRUGS, V17, DOI 10.3390/md17060374
   Perrotta F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040912
   Polito R, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/2153934
   Qiao LY, 1999, J BIOL CHEM, V274, P10625, DOI 10.1074/jbc.274.15.10625
   Radzikowska U, 2019, NUTRIENTS, V11, DOI 10.3390/nu11122990
   Reis CEG, 2010, NUTR HOSP, V25, P881, DOI 10.3305/nh.2010.25.6.4760
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Robb CT, 2016, SEMIN IMMUNOPATHOL, V38, P425, DOI 10.1007/s00281-016-0560-6
   Rotzinger DC, 2020, THROMB RES, V190, P58, DOI 10.1016/j.thromres.2020.04.011
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Salerno M, 2019, FRONT BIOSCI-LANDMRK, V24, P564, DOI 10.2741/4736
   Sansbury BE, 2016, CIRC RES, V119, P113, DOI 10.1161/CIRCRESAHA.116.307308
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Schupp M, 2004, CIRCULATION, V109, P2054, DOI 10.1161/01.CIR.0000127955.36250.65
   Seo SH, 2002, J VIROL, V76, P1071, DOI 10.1128/JVI.76.3.1071-1076.2002
   Sessa F., 2018, ACTA MEDICA MEDITERR, DOI [10.19193/0393-6384-2018-4s-322, DOI 10.19193/0393-6384-2018-4S-322]
   Shaikh SR, 2016, J LEUKOCYTE BIOL, V100, P985, DOI 10.1189/jlb.4VMR0316-103R
   Sharma S, 2013, CAN J MICROBIOL, V59, P503, DOI 10.1139/cjm-2012-0521
   Shirey KA, 2013, NATURE, V497, P498, DOI 10.1038/nature12118
   Shore SA, 2006, J ALLERGY CLIN IMMUN, V118, P389, DOI 10.1016/j.jaci.2006.04.021
   Singer P, 2009, CURR OPIN CLIN NUTR, V12, P123, DOI 10.1097/MCO.0b013e328322e70f
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P349, DOI 10.19193/0393-6384_2018_2_55
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Tiesset H, 2011, J NUTR, V141, P1101, DOI 10.3945/jn.110.134585
   Toussirot E, 2012, CURR MED CHEM, V19, P5474, DOI 10.2174/092986712803833119
   Tse GMK, 2004, J CLIN PATHOL, V57, P260, DOI 10.1136/jcp.2003.013276
   Van Lenten BJ, 2004, CIRCULATION, V110, P3252, DOI 10.1161/01.CIR.0000147232.75456.B3
   Velazquez-Salinas L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01057
   Venkatesh B, 2009, CRIT CARE, V13, DOI 10.1186/cc7941
   Weismann D, 2012, BBA-BIOMEMBRANES, V1818, P2465, DOI 10.1016/j.bbamem.2012.01.018
   Whitsett JA, 2015, NAT IMMUNOL, V16, P27, DOI 10.1038/ni.3045
   Wisse BE, 2004, J AM SOC NEPHROL, V15, P2792, DOI 10.1097/01.ASN.0000141966.69934.21
   Wulster-Radcliffe MC, 2004, BIOCHEM BIOPH RES CO, V316, P924, DOI 10.1016/j.bbrc.2004.02.130
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yamaya M, 2020, RESPIR INVESTIG, V58, P155, DOI 10.1016/j.resinv.2019.12.005
   Yang J, 2002, INFECT IMMUN, V70, P3649, DOI 10.1128/IAI.70.7.3649-3655.2002
   Yang N, 2018, INT J MOL MED, V41, P818, DOI 10.3892/ijmm.2017.3292
   Yilmaz MI, 2007, NEPHROLOGY, V12, P147, DOI 10.1111/j.1440-1797.2007.00764.x
   Yilmaz MI, 2004, ENDOCRINE, V25, P207, DOI 10.1385/ENDO:25:3:207
NR 105
TC 24
Z9 24
U1 3
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2020
VL 21
IS 9
AR 3104
DI 10.3390/ijms21093104
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA LR3GK
UT WOS:000535581700075
PM 32354030
OA DOAJ Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Zatroch, I
   Smudla, A
   Babik, B
   Tanczos, K
   Kobori, L
   Szabo, Z
   Fazakas, J
AF Zatroch Istvan
   Smudla Aniko
   Babik Barna
   Tanczos Krisztian
   Kobori Laszlo
   Szabo Zsuzsanna
   Fazakas Janos
TI Procoagulation, hypercoagulation and fibrinolytic "shut down" detected
   with ClotPro (R) viscoelastic tests in COVID-19 patients
SO ORVOSI HETILAP
LA Hungarian
DT Article
DE COVID-19; thromboembolic complication; hypercoagulation; fibrinolysis
   "shut down"; ClotPro (R)
AB Introduction: International data indicate that arterial, venous and microvascular thrombosis or disseminated intravascular coagulation occur in more than 30% of hospitalized patients with COVID-19. This condition is characterized by high levels of D-dimer and fibrinogen, prolonged prothrombin time and activated partial thromboplastin time.
   Method: Blood samples from three COVID-19 patients treated in a Hungarian intensive care unit were collected and analyzed with ClotPro (R) tests. EX-tests, IN-test, FIB-tests, RVV-tests, and TPA-tests were performed. The results were interpreted with respect to the clinical condition of the patients.
   Results: Procoagulation, hypercoagulation and either fibrinolysis or a "shut down" phenomenon of the fibrinolytic process were found with ClotPro (R). The ClotPro (R) parameters were consistent with the conventional coagulation tests and corresponded with the criteria of non-overt disseminated intravascular coagulation.
   Conclusion: These findings encourage further investigations to elucidate the underlying pathophysiology of thromboembolic events in COVID-19 patients and may support the introduction of full dose anticoagulation with or without antiplatelet therapy. Interventional clinical trials may be helpful in defining the appropriate drug(s), for this purpose, the algorithms of administration, and the optimal duration of therapy. At present, the authorization of a clinical trial that attempts to answer these questions is in progress.
C1 [Zatroch Istvan; Szabo Zsuzsanna] Uzsoki Utcai Korhaz, Budapest, Hungary.
   [Smudla Aniko; Kobori Laszlo; Fazakas Janos] Semmelweis Egyet, Altalanos Orvostud Kar, Transzplantacios & Sebeszeti Klin, Budapest, Hungary.
   [Babik Barna] Szegedi Tud Egyet, Altalanos Orvostud Kar, Aneszteziol & Intenz Terapias Int, Szeged, Hungary.
   [Tanczos Krisztian] Soproni Erzsebet Oktato Korhaz & Rehabil Int, Sopron, Hungary.
RP Fazakas, J (corresponding author), Baross U 23-25, H-1083 Budapest, Hungary.
EM jancsidora@gmail.com
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Anita K, 2020, ORVOSI HETILAP, V161, P667, DOI 10.1556/650.2020.31815
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bela F, 2020, ORVOSI HETILAP, V161, P652, DOI 10.1556/650.2020.31808
   Gralinski LE, 2013, MBIO, V4
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Klok FA, 2020, THROMB RES, DOI [10.1016/j.throm- res.2020.04.013, DOI 10.1016/J.THR0M-RES.2020.04.013]
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Sardu C, 2020, IS COVID 19 ENDOTHEL, P1, DOI [10.20944/preprints202004.0204.v1, DOI 10.20944/PREPRINTS202004.0204.V1, 10.20944/PREPRINTS202004.0204.V1]
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
NR 10
TC 4
Z9 4
U1 4
U2 4
PU AKADEMIAI KIADO ZRT
PI BUDAPEST
PA BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY
SN 0030-6002
EI 1788-6120
J9 ORVOSI HETILAP
JI Orvosi Hetilap
PD MAY
PY 2020
VL 161
IS 22
BP 899
EP 907
DI 10.1556/650.2020.31870
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA LT0FM
UT WOS:000536752900001
PM 32453702
OA Other Gold
DA 2021-01-01
ER

PT J
AU Welling, PA
   Batlle, D
   Byrd, JB
   Burrell, LM
   South, AM
   Sparks, MA
AF Welling, Paul A.
   Batlle, Daniel
   Byrd, James Brian
   Burrell, Louise M.
   South, Andrew M.
   Sparks, Matthew A.
TI Rigor before speculation in COVID-19 therapy
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Letter
C1 [Welling, Paul A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   [Welling, Paul A.] Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA.
   [Batlle, Daniel] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Byrd, James Brian] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
   [Burrell, Louise M.] Univ Melbourne, Dept Med, Austin Hlth, Melbourne, Vic, Australia.
   [South, Andrew M.] Wake Forest Sch Med, Winston Salem, NC 27101 USA.
   [Sparks, Matthew A.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA.
   [Sparks, Matthew A.] Durham Vet Affairs Med Ctr, Durham, NC USA.
RP Welling, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.; Welling, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA.
EM pwellin1@jhmi.edu
RI Burrell, Louise/K-1228-2012; Byrd, James Brian/H-6674-2019; Sparks,
   Matthew A./H-8865-2019
OI Burrell, Louise/0000-0003-1863-7539; Byrd, James
   Brian/0000-0002-0509-3520; Sparks, Matthew A./0000-0003-2075-2691
FU National Institute of Diabetes and Digestive and Kidney DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [DK093501, DK110375, DK054231, R01DK104785];
   National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [HL128909, HL146818];
   Foundation LeDucqLeducq Foundation
FX This work was supported in part by National Institute of Diabetes and
   Digestive and Kidney Diseases Grants DK093501, DK110375, DK054231, and
   R01DK104785; National Heart, Lung, and Blood Institute Grants HL128909
   and HL146818; and Foundation LeDucq.
CR Abassi ZA, 2020, AM J PHYSIOL-LUNG C, V318, pL1020, DOI 10.1152/ajplung.00097.2020
   Guan WJ, 2020, NEW ENGL J MED, V1, DOI [10.1056/NEJMoa2002032, DOI 10.1056/NEJMOA2002032]
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kim AHJ, 2020, ANN INTERN MED, V172, P819, DOI 10.7326/M20-1223
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Ramchand J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198144
   Sommerstein R, 2020, BMJ-BRIT MED J, V368, pm810, DOI [10.1136/bmj.m810, DOI 10.1136/BMJ.M810]
   Sommerstein R, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016509
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Sparks MA, 2020, CLIN J AM SOC NEPHRO, V15, P714, DOI 10.2215/CJN.03530320
   Walters TE, 2017, EUROPACE, V19, P1280, DOI 10.1093/europace/euw246
   Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987
NR 12
TC 2
Z9 2
U1 0
U2 0
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD MAY
PY 2020
VL 318
IS 5
BP L1027
EP L1028
DI 10.1152/ajplung.00152.2020
PG 2
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA LR0TB
UT WOS:000535408300025
PM 32364442
OA Bronze
DA 2021-01-01
ER

PT J
AU Yang, ZW
   Zhao, YZ
   Zang, YJ
   Wang, H
   Zhu, X
   Meng, LJ
   Yuan, XH
   Zhang, L
   Zhang, SL
AF Yang, Zhi-Wei
   Zhao, Yi-Zhen
   Zang, Yong-Jian
   Wang, He
   Zhu, Xun
   Meng, Ling-Jie
   Yuan, Xiao-Hui
   Zhang, Lei
   Zhang, Sheng-Li
TI Rapid Structure-Based Screening Informs Potential Agents for Coronavirus
   Disease (COVID-19) Outbreak
SO CHINESE PHYSICS LETTERS
LA English
DT Article
DE 87; 14; E-; 87; 15; A-; 87; 15; B-; 87; 15; ap
ID THERAPEUTIC-EFFICACY; PNEUMONIA; DYNAMICS; BINDING; DOCKING; CHARMM;
   ENERGY
AB Coronavirus Disease 2019 (COVID-19), caused by the novel coronavirus, has spread rapidly across China. Consequently, there is an urgent need to sort and develop novel agents for the prevention and treatment of viral infections. A rapid structure-based virtual screening is used for the evaluation of current commercial drugs, with structures of human angiotensin converting enzyme II (ACE2), and viral main protease, spike, envelope, membrane and nucleocapsid proteins. Our results reveal that the reported drugs Arbidol, Chloroquine and Remdesivir may hinder the entry and release of virions through the bindings with ACE2, spike and envelope proteins. Due to the similar binding patterns, NHC (beta-d-N4-hydroxycytidine) and Triazavirin are also in prospects for clinical use. Main protease (3CLpro) is likely to be a feasible target of drug design. The screening results to target 3CL-pro reveal that Mitoguazone, Metformin, Biguanide Hydrochloride, Gallic acid, Caffeic acid, Sulfaguanidine and Acetylcysteine seem be possible inhibitors and have potential application in the clinical therapy of COVID-19.
C1 [Yang, Zhi-Wei; Zhao, Yi-Zhen; Zang, Yong-Jian; Wang, He; Zhu, Xun; Meng, Ling-Jie; Zhang, Lei; Zhang, Sheng-Li] Xi An Jiao Tong Univ, Sch Sci, MOE Key Lab Nonequilibrium Synth & Modulat Conde, Xian 710049, Peoples R China.
   [Yang, Zhi-Wei] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Xian 710049, Peoples R China.
   [Yuan, Xiao-Hui] Jinan Univ, Inst Biomed, Guangzhou 510632, Peoples R China.
RP Zhang, L; Zhang, SL (corresponding author), Xi An Jiao Tong Univ, Sch Sci, MOE Key Lab Nonequilibrium Synth & Modulat Conde, Xian 710049, Peoples R China.
EM zhangleio@xjtu.edu.cn; zhangsl@xjtu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [11774279, 11774280]; Fundamental Research
   Funds for the Central Universities of ChinaFundamental Research Funds
   for the Central Universities [xjj2017029, xzy032020038]; Natural Science
   Basic Research Plan in Shaanxi Province of China [2019JQ-603]
FX Supported by the National Natural Science Foundation of China (Grant
   Nos. 11774279 and 11774280), the Fundamental Research Funds for the
   Central Universities of China (Grant Nos. xjj2017029 and xzy032020038),
   and the Natural Science Basic Research Plan in Shaanxi Province of China
   (Grant No. 2019JQ-603).
CR [Anonymous], 2020, LANCET, V395, P311, DOI 10.1016/S0140-6736(20)30186-0
   [Anonymous], 2011, THER ADV MED ONCOL, V3, pS7
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   Chen HY, 2019, ACS CHEM NEUROSCI, V10, P677, DOI 10.1021/acschemneuro.8b00489
   Chen L, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009226
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Gong L, 2012, PHARMACOGENET GENOM, V22, P820, DOI 10.1097/FPC.0b013e3283559b22
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277
   Jones R D C, 2006, ADV COLLOID INTERFAC, V59, P518
   Li Z, 2019, J AM CHEM SOC, V141, P19448, DOI 10.1021/jacs.9b10505
   Ow YY, 2003, CURR DRUG METAB, V4, P241, DOI 10.2174/1389200033489479
   Priebe W, 2014, Orally bioavailable caffeic acid related anticancer drugs, VUS8779151, pB2, Patent No. 8779151
   ROEDERER M, 1993, PHARMACOLOGY, V46, P121, DOI 10.1159/000139037
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Uyeki TM, 2020, NEW ENGL J MED, V382
   Wan Y., 2020, J VIROL
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P270, DOI [10.1038/s41586-020-2012-7, DOI 10.1038/S41586-020-2012-7]
   Wu GS, 2003, J COMPUT CHEM, V24, P1549, DOI 10.1002/jcc.10306
   Xia JW, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00134
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang ZW, 2018, CHINESE PHYS B, V27, DOI 10.1088/1674-1056/27/1/018704
   Yang ZW, 2018, J BIOMOL STRUCT DYN, V36, P2567, DOI 10.1080/07391102.2017.1363661
   Yang ZW, 2016, FUTURE MED CHEM, V8, P2245, DOI 10.4155/fmc-2016-0176
   Yang ZW, 2013, J COMPUT AID MOL DES, V27, P935, DOI 10.1007/s10822-013-9691-1
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 30
TC 0
Z9 0
U1 9
U2 10
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0256-307X
EI 1741-3540
J9 CHINESE PHYS LETT
JI Chin. Phys. Lett.
PD MAY
PY 2020
VL 37
IS 5
AR 058701
DI 10.1088/0256-307X/37/5/058701
PG 10
WC Physics, Multidisciplinary
SC Physics
GA LR3OQ
UT WOS:000535603100001
DA 2021-01-01
ER

PT J
AU Bennett, J
   Munavvar, M
   Walker, P
   Phillips, G
AF Bennett, Jonathan
   Munavvar, Mohammmed
   Walker, Paul
   Phillips, Gerrard
TI Respiratory advice for the non-respiratory physician in the time of
   COVID-19
SO CLINICAL MEDICINE
LA English
DT Article
DE Respiratory; COVID-19; coronavirus
AB COVID-19, the disease caused by the SARS-CoV-2 beta-coronavirus, has changed clinical practice in a matter of weeks. Among the physician specialties, respiratory physicians have been at the forefront of the response to this new challenge. Here we provide advice for non-respiratory physicians on the and-based care of patients with this disease. This includes recommendations on hydration, thromboprophylaxis, nutritional support and on the importance of the early detection of deterioration, setting ceilings of care and use of anticipatory drugs where appropriate. We also discuss oxygen support modalities, proning, safe working practices and a new approach to multi-professional working. We include references to a number of important research studies.
C1 [Bennett, Jonathan; Munavvar, Mohammmed; Walker, Paul] British Thorac Soc, London, England.
   [Phillips, Gerrard] Federat Royal Coll Phys UK, London, England.
RP Phillips, G (corresponding author), Dorset Cty Hosp, Dept Resp Med, Williams Ave, Dorchester DT1 2JY, England.
EM gerrard.phillips@dchft.nhs.uk
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Association for Respiratory Technology and Physiology, 2020, DAT CPAP ENTR OX
   Australian and New Zealand Intensive Care Society, 2020, COVID 19 GUID VERS 2
   British Association for Parenteral and Enteral Nutrition, 2020, ROUT NUTR SUPP PAT R
   British Thoracic Society, 2020, BTS GUID VEN THROMB
   British Thoracic Society, US AC NIV PAT HOSP S
   British Thoracic Society, 2020, RESP SUPP PAT MED WA
   British Thoracic Society, 2020, ADD SPACES YOUR COVI
   Hunt B, 2020, PRACTICAL GUIDANCE P
   Intensive Care Society, 2020, ICS GUID PRON POS CO
   National Institute for Health and Care Excellence, 2020, COVID 19 RAP GUID CR
   NHS England, 2020, CLIN GUID OPT US OX
   NHS England, 2020, GUID ROL US NON RESP
   Public Health England, 2020, COVID 19 PERS PROT E
   RECOVERY, 2020, REC RS RESP SUPP RES
   Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051
   Royal College of Physicians, 2017, NAT EARL WARN SCOR N
   Shao F, 2020, RESUSCITATION, V151, P18, DOI 10.1016/j.resuscitation.2020.04.005
   Wang T, 2020, LANCET HAEMATOL, V7, pE362, DOI 10.1016/S2352-3026(20)30109-5
   Wyllie J, 2020, RCUK STATEMENT PHE P
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ROY COLL PHYS LONDON EDITORIAL OFFICE
PI LONDON
PA 11 ST ANDREWS PLACE REGENTS PARK, LONDON NW1 4LE, ENGLAND
SN 1470-2118
EI 1473-4893
J9 CLIN MED
JI Clin. Med.
PD MAY
PY 2020
VL 20
IS 3
BP 251
EP 255
DI 10.7861/clinmed.2020-0188
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA LP5KA
UT WOS:000534355400021
PM 32366580
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Price, E
   MacPhie, E
   Kay, L
   Lanyon, P
   Griffiths, B
   Holroyd, C
   Abhishek, A
   Youngstein, T
   Bailey, K
   Clinch, J
   Shaikh, M
   Rivett, A
AF Price, Elizabeth
   MacPhie, Elizabeth
   Kay, Lesley
   Lanyon, Peter
   Griffiths, Bridget
   Holroyd, Christopher
   Abhishek, Abhishek
   Youngstein, Taryn
   Bailey, Kathryn
   Clinch, Jacqui
   Shaikh, Muddassir
   Rivett, Ali
TI Identifying rheumatic disease patients at high risk and requiring
   shielding during the COVID-19 pandemic
SO CLINICAL MEDICINE
LA English
DT Article
DE SARS-CoV-2; COVID-19; testing; health economics; innovation
ID JUVENILE IDIOPATHIC ARTHRITIS; BRITISH-SOCIETY; SERIOUS INFECTIONS;
   BIOLOGICS REGISTER; THERAPY
AB Rheumatology teams care for patients with diverse, systemic autoimmune diseases who are often immunosuppressed and at high risk of infections. The current COVID-19 pandemic has presented particular challenges in caring for and managing this patient group. The office of the chief medical officer (CMO) for England contacted the rheumatology community to provide expert advice on the identification of extremely vulnerable patients at very high risk during the COVID-19 pandemic who should be 'shielded'. This involves the patients being asked to strictly self-isolate for at least 12 weeks with additional funded support provided for them to remain at home. A group of rheumatologists (the authors) have devised a pragmatic guide to identifying the very highest risk group using a rapidly developed scoring system which went live simultaneous with the Government announcement on shielding and was cascaded to all rheumatologists working in England.
C1 [Price, Elizabeth] Great Western Hosp, Marlborough Rd, Swindon SN6 6LQ, Wilts, England.
   [Price, Elizabeth; Rivett, Ali] British Soc Rheumatol, London, England.
   [MacPhie, Elizabeth] Lancashire & South Cumbria NHS Fdn Trust, Preston, Lancs, England.
   [MacPhie, Elizabeth] British Soc Rheumatol, Clin Affairs Comm, London, England.
   [Kay, Lesley; Griffiths, Bridget] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle, England.
   [Kay, Lesley] NHS England & Improvement, Rheumatol, London, England.
   [Lanyon, Peter] Nottingham Univ Hosp NHS Trust, Nottingham, England.
   [Lanyon, Peter] NHS Improvement, Rheumatol, London, England.
   [Griffiths, Bridget] NHS England, Specialised Rheumatol Clin Reference Grp, London, England.
   [Holroyd, Christopher] Univ Hosp Southampton, Southampton, Hants, England.
   [Abhishek, Abhishek] Univ Nottingham, Rheumatol, Nottingham, England.
   [Abhishek, Abhishek] Nottingham Biomed Res Ctr, Nottingham, England.
   [Youngstein, Taryn] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, London, England.
   [Bailey, Kathryn] Oxford Univ Hosp NHS Fdn Trust, Oxford, England.
   [Clinch, Jacqui] Bristol Royal Hosp Children, Bristol, Avon, England.
   [Clinch, Jacqui] Bath Ctr Pain Serv, Bath, Avon, England.
   [Shaikh, Muddassir] James Cook Univ Hosp, Middlesbrough, Cleveland, England.
RP Price, E (corresponding author), Great Western Hosp, Marlborough Rd, Swindon SN6 6LQ, Wilts, England.
EM elizabeth.price5@nhs.net
CR Alfaro-Lara R, 2019, REUMATOL CLIN, V15, P133, DOI 10.1016/j.reuma.2017.07.020
   Balduzzi S, 2020, ANN RHEUM DIS, DOI annrheumdis-2020-217424
   Bechman K, 2019, RHEUMATOLOGY, V58, P1755, DOI 10.1093/rheumatology/kez087
   Beukelman T, 2012, ARTHRITIS RHEUM-US, V64, P2773, DOI 10.1002/art.34458
   British Society of Radiology, 2020, RISK STRAT PAT AUT R
   British Society of Radiology, 2020, COVID 19 ID PAT SHIE
   Davies R, 2015, ARTHRITIS RHEUMATOL, V67, P2487, DOI 10.1002/art.39197
   Decarriere Guillaume, 2020, Arthritis Care Res (Hoboken), DOI 10.1002/acr.24195
   Dennison EM, 2016, RHEUMATOLOGY, V55, P2093, DOI 10.1093/rheumatology/kew053
   Galloway JB, 2011, RHEUMATOLOGY, V50, P124, DOI 10.1093/rheumatology/keq242
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Hazlewood GS, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010227.pub2
   Holroyd CR, 2019, RHEUMATOLOGY, V58, P220, DOI 10.1093/rheumatology/key207
   Ibrahim A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010015
   Jani M, 2018, ANN RHEUM DIS, V77, P163, DOI 10.1136/annrheumdis-2018-eular.1946
   Kang YJ, 2020, DISASTER MED PUBLIC, V14, P384, DOI [10.1017/dmp.2020.60, 10.1017/dmp.2020.141]
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu CC, 2020, J CHIN MED ASSOC, V83, P534, DOI 10.1097/JCMA.0000000000000318
   Rutherford AI, 2018, RHEUMATOLOGY, V57, P997, DOI 10.1093/rheumatology/key023
   Rutherford AI, 2018, ANN RHEUM DIS, V77, P905, DOI 10.1136/annrheumdis-2017-212825
   Schneeweiss S, 2007, ARTHRITIS RHEUM-US, V56, P1754, DOI 10.1002/art.22600
   Silman A, 2003, ANN RHEUM DIS, V62, P28
   Silva-Fernandez L, 2018, RHEUMATOLOGY, V57, P1533, DOI 10.1093/rheumatology/kex304
   Singh JA, 2016, BMC MED, V14, DOI [10.1186/s12916-016-0673-8, 10.1186/s12916-016-0557-y]
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Subesinghe S, 2018, RHEUMATOLOGY, V57, P651, DOI 10.1093/rheumatology/kex469
   Swart J, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1780-z
   Thong KM, 2019, LUPUS, V28, P334, DOI 10.1177/0961203319829817
   Wagner M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007746.pub2
   Waki D, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019173
   Wang J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001058
   Wang Z, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019193
   Widdifield J, 2013, ARTHRIT CARE RES, V65, P353, DOI 10.1002/acr.21812
   Wijesinghe H, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1673-3
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yeo KJ, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4826-1
   Youssef J, 2016, RHEUM DIS CLIN N AM, V42, P157, DOI 10.1016/j.rdc.2015.08.004
NR 38
TC 6
Z9 6
U1 0
U2 0
PU ROY COLL PHYS LONDON EDITORIAL OFFICE
PI LONDON
PA 11 ST ANDREWS PLACE REGENTS PARK, LONDON NW1 4LE, ENGLAND
SN 1470-2118
EI 1473-4893
J9 CLIN MED
JI Clin. Med.
PD MAY
PY 2020
VL 20
IS 3
BP 256
EP 261
DI 10.7861/clinmed.2020-0149
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA LP5KA
UT WOS:000534355400022
PM 32371418
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Mehta, S
AF Mehta, Shameer
TI Nutritional status and COVID-19: an opportunity for lasting change?
SO CLINICAL MEDICINE
LA English
DT Article
DE Nutrition; screening; COVID-19; coronavirus
ID MULTICENTER; RISK; OUTCOMES
AB The coronavirus disease of 2019 (COVID-19) pandemic has placed many healthcare systems, including the NHS. under unprecedented pressure. Mortality appears to be highest among older people and those with comorbidities, who are also often the most at risk of undernutrition in society. Despite international efforts to identify a specific treatment, therapy remains supportive and is principally focused on optimising respiratory function. However, the timely identification and correction of undernutrition also has the potential to improve outcomes cost-effectively, and should not be forgotten. This piece outlines why nutritional status may be particularly compromised during this crisis, among both the population and hospital inpatients. Practical steps to improve nutritional status at a time when hospital services are particularly stretched are also considered. Finally, the case is made for behaviour change at all levels including government, the general population and healthcare professionals.
C1 [Mehta, Shameer] Univ Coll London Hosp NHS Fdn Trust, 250 Euston Rd, London NW1 2PG, England.
RP Mehta, S (corresponding author), Univ Coll London Hosp NHS Fdn Trust, 250 Euston Rd, London NW1 2PG, England.
EM shameer.mehta@nhs.net
CR Agarwal E, 2013, MATURITAS, V76, P296, DOI 10.1016/j.maturitas.2013.07.013
   Bamford P, 2020, ICS GUIDANCE PRONE P
   Barazzoni R, 2020, CLIN NUTR
   British Association of Parenteral and Enteral Nutrition, MALN SCREEN TOOLM CA
   British Diatetic Association, COVID 19 COR ADV GEN
   Chapple L-A, 2020, NUTR MANAGEMENT CRIT
   Dunn CG, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2005638
   Felder S, 2015, NUTRITION, V31, P1385, DOI 10.1016/j.nut.2015.06.007
   Gavron N, 2020, ONLONDON        0408
   GOV.UK, 2020, NUMB COR COV 19 CAS
   Jie B, 2010, NUTRITION, V26, P1088, DOI 10.1016/j.nut.2009.08.027
   Linn DD, 2015, INTENS CRIT CARE NUR, V31, P38, DOI 10.1016/j.iccn.2014.07.002
   Maruyama T, 2016, CHEST, V149, P526, DOI 10.1378/chest.14-2768
   Reeves A, 2014, CLIN NUTR, V33, P1068, DOI 10.1016/j.clnu.2013.11.012
   Rolland Y, 2011, CLIN GERIATR MED, V27, P423, DOI 10.1016/j.cger.2011.03.008
   Rypkema G, 2004, J Nutr Health Aging, V8, P122
   Singer P, 2019, CLIN NUTR, V38, P48, DOI 10.1016/j.clnu.2018.08.037
   Singer P, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-1947-7
   Sorensen J, 2008, CLIN NUTR, V27, P340, DOI 10.1016/j.clnu.2008.03.012
   Starke J, 2011, CLIN NUTR, V30, P194, DOI 10.1016/j.clnu.2010.07.021
   WHO, 2020, FOOD NUTR SELF QUAR
   World Health Organization (WHO), WHO DIR GEN OP REM M
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 23
TC 5
Z9 5
U1 0
U2 3
PU ROY COLL PHYS LONDON EDITORIAL OFFICE
PI LONDON
PA 11 ST ANDREWS PLACE REGENTS PARK, LONDON NW1 4LE, ENGLAND
SN 1470-2118
EI 1473-4893
J9 CLIN MED
JI Clin. Med.
PD MAY
PY 2020
VL 20
IS 3
BP 270
EP 273
DI 10.7861/clinmed.2020-0187
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA LP5KA
UT WOS:000534355400025
PM 32341077
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sturrock, BRH
   Chevassut, TJT
AF Sturrock, Beattie R. H.
   Chevassut, Timothy J. T.
TI Chloroquine and COVID-19 a potential game changer?
SO CLINICAL MEDICINE
LA English
DT Article
DE COVID-19; chloroquine; SARS-Cov-2; 2019-nCoV; coronavirus
ID VIRAL-INFECTIONS; CORONAVIRUS; SARS; INHIBITION; PNEUMONIA; DRUGS
AB The novel coronavirus SARS-CoV-2, causing the disease COVID-19, first emerged in Wuhan, China in December 2019 and has now spread to 203 countries or territories, infected over 2 million people and caused over 133,000 deaths. There is an urgent need for specific treatments. One potential treatment is chloroquine and its derivatives, including hydroxychloroquine, which have both antiviral and anti-inflammatory effects. These compounds are effective against SARS-CoV-2 in vitro, but in vivo data are lacking. Although some encouraging outcomes have been reported, and these results have been received enthusiastically, we recommend careful and critical evaluation of current evidence only when all methods and data are available for peer review. Chloroquine is safe and cheap. However, further evidence from coordinated multicentre trials is required before it can be confidently said whether it is effective against the current pandemic.
C1 [Sturrock, Beattie R. H.] Brighton & Sussex Med Sch, Brighton, E Sussex, England.
   [Sturrock, Beattie R. H.; Chevassut, Timothy J. T.] Royal Sussex Cty Hosp, Eastern Rd, Brighton BN2 5BE, Sussex, England.
   [Chevassut, Timothy J. T.] Brighton & Sussex Med Sch, Haematol, Brighton, E Sussex, England.
   [Chevassut, Timothy J. T.] Brighton & Sussex Med Sch, Acad Training, Brighton, E Sussex, England.
RP Chevassut, TJT (corresponding author), Royal Sussex Cty Hosp, Eastern Rd, Brighton BN2 5BE, Sussex, England.
EM t.chevassut@bsms.ac.uk
CR Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Avina-Zubieta JA, 1998, ANN RHEUM DIS, V57, P582, DOI 10.1136/ard.57.10.582
   Barnard Dale L., 2006, Antiviral Chemistry & Chemotherapy, V17, P275
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Keyaerts E, 2009, ANTIMICROB AGENTS CH, V53, P3416, DOI 10.1128/AAC.01509-08
   Lake MA, 2020, CLIN MED, V20, P124, DOI 10.7861/clinmed.2019-coron
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lupus Foundation of America, 2020, STAT LUP FDN AM URG
   Mitja O, 2020, LANCET GLOB HEALTH, V8, pE639, DOI 10.1016/S2214-109X(20)30114-5
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Nqoro X, 2017, MOLECULES, V22, DOI 10.3390/molecules22122268
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, 2020, COR DIS COVID 19 PAN
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization (WHO), 2020, NOV COR CHIN
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 37
TC 6
Z9 6
U1 0
U2 3
PU ROY COLL PHYS LONDON EDITORIAL OFFICE
PI LONDON
PA 11 ST ANDREWS PLACE REGENTS PARK, LONDON NW1 4LE, ENGLAND
SN 1470-2118
EI 1473-4893
J9 CLIN MED
JI Clin. Med.
PD MAY
PY 2020
VL 20
IS 3
BP 278
EP 281
DI 10.7861/clinmed.2020-0129
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA LP5KA
UT WOS:000534355400027
PM 32303497
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ren, ZL
   Hu, R
   Wang, ZW
   Zhang, M
   Ruan, YL
   Wu, ZY
   Wu, HB
   Hu, XP
   Hu, ZP
   Ren, W
   Li, LC
   Dai, FF
   Liu, H
   Cai, X
AF Ren, Zong-Li
   Hu, Rui
   Wang, Zhi-Wei
   Zhang, Min
   Ruan, Yong-Le
   Wu, Zhi-Yong
   Wu, Hong-bing
   Hu, Xiao-Ping
   Hu, Zhi-Peng
   Ren, Wei
   Li, Luo-Cheng
   Dai, Fei-Feng
   Liu, Huan
   Cai, Xin
TI Epidemiologic and clinical characteristics of heart transplant
   recipients during the 2019 coronavirus outbreak in Wuhan, China: A
   descriptive survey report
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Article
DE heart transplantation; COVID-19; SARS-CoV-2; angiotensin-converting
   enzyme 2; immunosuppressive therapy
ID RENIN-ANGIOTENSIN SYSTEM; CYCLOSPORINE-A; CONVERTING ENZYME-2;
   INHIBITION; RECEPTOR; DIFFERENTIATION; CALCINEURIN; PNEUMONIA
AB BACKGROUND: The epidemiologic and clinical characteristics of heart transplant (HTx) recipients during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic remains unclear. We studied the characteristics of HTx recipients from December 20, 2019, to February 25, 2020, in an effort to understand their risk and outcomes.
   METHODS: All accessible HTx recipients were included in this single-center retrospective study. We collected information on the recipients using a web-based questionnaire as well as the hospital database.
   RESULTS: We followed 87 HTx recipients (72.4% were men, and the average age was 51 years). A total of 79 recipients resided in Hubei, and 57 recipients had a Wuhan-related history of travel or contact. Most took precautionary measures while in contact with suspicious crowds, and 96.6% of the families and communities undertook prevention and quarantine procedures. Four upper airway infections were reported, and 3 of them tested negative for SARS-CoV-2 (the fourth recovered and was not tested). All cases were mild and successfully recovered after proper treatment. Laboratory results of 47 HTx cases within the last 2 months were extracted. Of these, 21.3% of recipients had pre-existing lymphopenia, and 87.2% of recipients had a therapeutic concentration of tacrolimus (5-12 ng/ml). Liver and kidney insufficiency was seen in 5 and 6 recipients, respectively.
   CONCLUSION: HTx recipients who practiced appropriate prevention measures had a low rate of infection with SARS-CoV-2 and transition to the associated disease COVID-19. These early data will require confirmation as the pandemic establishes around the world. (C) 2020 International Society for Heart and Lung Transplantation. All rights reserved.
C1 [Ren, Zong-Li; Hu, Rui; Wang, Zhi-Wei; Zhang, Min; Ruan, Yong-Le; Wu, Zhi-Yong; Wu, Hong-bing; Hu, Xiao-Ping; Hu, Zhi-Peng; Ren, Wei; Li, Luo-Cheng; Dai, Fei-Feng; Liu, Huan; Cai, Xin] Wuhan Univ, Dept Cardiovasc Surg, 238 Jiefang Rd, Wuhan 430060, Hubei, Peoples R China.
RP Wang, ZW (corresponding author), Wuhan Univ, Dept Cardiovasc Surg, 238 Jiefang Rd, Wuhan 430060, Hubei, Peoples R China.
EM wangzhiwei@whu.edu.cn
OI Hu, Zhipeng/0000-0002-6384-0037
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81501376]; Postdoctoral Research Foundation
   of ChinaChina Postdoctoral Science Foundation [2017M620339]
FX The authors have no conflict of interest to disclose. The authors
   acknowledge all health workers involved in the diagnosis and treatment
   of patients in China. The authors thank the World Health Organization
   for sharing data collection templates publicly on the website. This
   study was supported by grants from National Natural Science Foundation
   of China (81501376) and Postdoctoral Research Foundation of China
   (2017M620339). This study was approved by the ethical review committee
   of Renmin Hospital of Wuhan University.
CR Abe M, 2006, CLIN IMMUNOL, V118, P300, DOI 10.1016/j.clim.2005.09.019
   [Anonymous], 2020, NEW CORONAVIRUS PNEU
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Blaheta RA, 1999, TRANSPLANT P, V31, P1250, DOI 10.1016/S0041-1345(98)01984-8
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cupic B, 2005, INT J MOL MED, V15, P1023
   Ehrchen J, 2007, BLOOD, V109, P1265, DOI 10.1182/blood-2006-02-001115
   EUGUI EM, 1991, SCAND J IMMUNOL, V33, P161, DOI 10.1111/j.1365-3083.1991.tb03746.x
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Gallagher PE, 2006, AM J PHYSIOL-CELL PH, V290, pC420, DOI 10.1152/ajpcell.00409.2004
   Gonzaalez JM, 2003, ARCH VIROL, V148, P2207, DOI 10.1007/s00705-003-0162-1
   Harr MW, 2009, J BIOL CHEM, V284, P31860, DOI 10.1074/jbc.M109.005579
   Hoskova L, 2014, HYPERTENS RES, V37, P724, DOI 10.1038/hr.2014.79
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang J., 2018, CHIN TRANSPL J, V12, P49
   Hung IFN, 2004, EMERG INFECT DIS, V10, P1550, DOI 10.3201/eid1009.040058
   Ju C, CLIN CHARACTERISTICS
   JULIEN J, 1993, TRANSPLANTATION, V56, P885, DOI 10.1097/00007890-199310000-00022
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   KUPFERMAN JC, 1994, TRANSPLANT P, V26, P2891
   Kurdi M, 2005, INT J BIOCHEM CELL B, V37, P1357, DOI 10.1016/j.biocel.2005.01.012
   Letizia C, 1995, INT J CLIN PHARM RES, V15, P209
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H
   LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Rahman A, 2019, AM J PUBLIC HEALTH, V109, P1288, DOI [10.21, 10.2105/AJPH.2019.305186]
   SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J
   Shi B., 2019, ORGAN TRANSPL, V10, P32
   Suda T, 2003, J ALLERGY CLIN IMMUN, V112, P1237, DOI 10.1016/j.jaci.2003.09.028
   Takahira R, 2001, FREE RADICAL BIO MED, V31, P809, DOI 10.1016/S0891-5849(01)00658-X
   Tu Y, 2020, CHINESE J ORGAN TRAN, V41, pE005
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Wevers BA, 2010, FUTURE VIROL, V5, P145, DOI 10.2217/FVL.10.4
   Xu H, 2019, 2018 INTERNATIONAL CONFERENCE ON ZOOLOGY, BOTANY AND ECOLOGY (ICZBE 2018), P21, DOI 10.25236/iczbe.2018.005
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yeung ML, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.4, 10.1038/nmicrobiol.2016.4]
   Youinou P, 2010, AUTOIMMUN REV, V9, P804, DOI 10.1016/j.autrev.2010.06.011
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 44
TC 28
Z9 29
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1053-2498
EI 1557-3117
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD MAY
PY 2020
VL 39
IS 5
BP 412
EP 417
DI 10.1016/j.healun.2020.03.008
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
   Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
   Transplantation
GA LR1BG
UT WOS:000535430200004
PM 32362392
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Thibodeaux, K
   Speyrer, M
   Raza, A
   Yaakov, R
   Serena, TE
AF Thibodeaux, Kerry
   Speyrer, Marcus
   Raza, Amer
   Yaakov, Raphael
   Serena, Thomas E.
TI Hyperbaric oxygen therapy in preventing mechanical ventilation in
   COVID-19 patients: a retrospective case series
SO JOURNAL OF WOUND CARE
LA English
DT Article
DE COVID-19; HBOT; oxygen saturation; SARS; SARS-CoV-2; ventilation
AB Objective: A pandemic afflicts the entire world. The highly contagious SARS-CoV-2 virus originated in Wuhan, China in late 2019 and rapidly spread across the entire globe. According to the World Health Organization (WHO), the novel Coronavirus (COVID-19)has infected more than two million people worldwide, causing over 160,000 deaths. Patients with COVID-19 disease present with a wide array of symptoms, ranging from mild flu-like complaints to life threatening pulmonary and cardiac complications. Older people and patients with underlying disease have an increased risk of developing severe acute respiratory syndrome (SARS) requiring mechanical ventilation. Once intubated, mortality increases exponentially. A number of pharmacologic regimens, including hydroxychloroquine-azithromycin, antiviral therapy (eg, remdesevir), and anti-IL-6 agents (e.g., toclizumab), have been highlighted by investigators over the course of the pandemic, based on the therapy's potential to interrupt the viral life-cycle of SARS-CoV-2 or preventing cytokine storm. At present, there have been no conclusive series of reproducible randomised clinical trials demonstrating the efficacy of any one drug or therapy for COVID-19.
   Cases: COVID-19 positive patients (n=5) at a single institution received hyperbaric oxygen therapy (HBOT) between 13 and 20 April 2020. All the patients had tachypnoea and low oxygen saturation despite receiving high FiO(2). HBOT was added to prevent the need for mechanical ventilation. A standard dive profile of 2.0ATA for 90 minutes was employed. Patients received between one and six treatments in one of two dedicated monoplace hyperbaric chambers.
   Results: All the patients recovered without the need for mechanical ventilation. Following HBOT, oxygen saturation increased, tachypnoea resolved and inflammatory markers fell. At the time of writing, three of the five patients have been discharged from the hospital and two remain in stable condition.
   Conclusion: This small sample of patients exhibited dramatic improvement with HBOT. Most importantly, HBOT potentially prevented the need for mechanical ventilation. Larger studies are likely to define the role of HBOT in the treatment of this novel disease.
C1 [Thibodeaux, Kerry; Speyrer, Marcus] Opelousas Gen Hlth Syst, Wound Treatment Ctr LLC, Opelousas, LA 70570 USA.
   [Raza, Amer] Opelousas Gen Hlth Syst, Opelousas, LA USA.
   [Yaakov, Raphael; Serena, Thomas E.] SerenaGrp Res Fdn Cambridge, Cambridge, MA USA.
RP Thibodeaux, K (corresponding author), Opelousas Gen Hlth Syst, Wound Treatment Ctr LLC, Opelousas, LA 70570 USA.
CR Baugh MA, 2000, MED HYPOTHESES, V55, P232, DOI 10.1054/mehy.2000.1048
   Centers for Disease Control and Prevention, COR COVID 19
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   FOSTER JH, 1992, J ORAL MAXIL SURG, V50, P1081, DOI 10.1016/0278-2391(92)90495-L
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Plafki C, 2000, AVIAT SPACE ENVIR MD, V71, P119
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Thom SR, 2011, PLAST RECONSTR SURG, V127, p131S, DOI 10.1097/PRS.0b013e3181fbe2bf
   Undersea & Hyperbaric Medical Society, IND HYP OX THER
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, COR DIS COVID 19 PAN
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhong Xiaoling TX, 2020, CHINESE J MARINE MED
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 16
TC 6
Z9 6
U1 3
U2 5
PU MA HEALTHCARE LTD
PI LONDON
PA ST JUDES CHURCH, DULWICH ROAD, LONDON SE24 0PB, ENGLAND
SN 0969-0700
EI 2062-2916
J9 J WOUND CARE
JI J. Wound Care
PD MAY
PY 2020
VL 29
IS 5
SU A
BP S4
EP S8
DI 10.12968/jowc.2020.29.Sup5a.S4
PG 4
WC Dermatology
SC Dermatology
GA LQ8VZ
UT WOS:000535277600002
PM 32412891
OA Bronze
DA 2021-01-01
ER

PT J
AU Holm, A
AF Holm, Anja
TI New paths for sustainable solutions to tackle global and emerging
   infectious threats
SO BIOLOGICALS
LA English
DT Article
AB With the dramatic background of a newly emerged virus (SARS-CoV-2) spreading around the world, Coronavirus and other infectious health threats for the human and animal populations were illustrated and debated in excellent presentations at the IABS meeting 26-28 of February 2020. Historical evidence of pandemics and lessons learned from recent epidemics or epizootics caused by many pathogens (e.g., Ebola, Zika, and African Swine Fever viruses) illustrated the overarching need for close international cooperation. New and old technologies in vaccine development and their use were presented, resulting in a call for greater interaction between the human and the veterinary fields in order to leverage the expertise and knowledge in both human and animal medicine. The One Health concept was also emphasized for eliminating the 59,000 fatal human rabies cases annually attributed to unvaccinated dogs. For preventable, infectious diseases commonly spreading in the poorer regions of the world, a new regulatory approach and governance structure was called for to give access to affordable vaccines. Vaccines were touted as one of the most successful health invention ever introduced; on a similar level to health improvements due to clean water.
C1 [Holm, Anja] Cent VetPharma Consultancy Aps, Hauchsvej 7, DK-4180 Soroe, Denmark.
RP Holm, A (corresponding author), Cent VetPharma Consultancy Aps, Hauchsvej 7, DK-4180 Soroe, Denmark.
EM anjaholm@centralvetpharma.com
CR Amirthaligam, 2014, EFFECTIVENESS MATERN, DOI [10.1016/S0140-6736(14)60686-3, DOI 10.1016/S0140-6736(14)60686-3]
   [Anonymous], 2009, STATE WORLD VACCINES
   Barnighausen, 2014, PNEUMOCOCCAL DIS CAN, DOI [10.1073/pnas.1400475111, DOI 10.1073/PNAS.1400475111]
   Cicchetti, 2018, VACCINATION INFLUENZ
   Dabbagh, 2018, WEEKLY EPIDEMIOL REC, V93, P649
   Ethgen, 2018, VACCINATION BUDGET E, DOI [10.1080/21645515.2018.1504528, DOI 10.1080/21645515.2018.1504528]
   Geall, 2012, NONVIRAL DELIVERY SE, DOI [10.1073/pnas.1209367109, DOI 10.1073/PNAS.1209367109]
   Kieny MP, 2016, LANCET, V387, P1509, DOI 10.1016/S0140-6736(16)00686-3
   Sevilla, 2019, ADULT PD VACCINATION, DOI [10.1016/j.jeoa.2019.100203, DOI 10.1016/J.JEOA.2019.100203]
   Verguet, 2013, ROTAVIRUS VACCINATIO, DOI [10.1016/j.vaccine.2013.07.014., DOI 10.1016/J.VACCINE.2013.07.014]
   World Health Organization Global Health Estimates, 2018, DEATHS CAUS AG SEX C
NR 11
TC 0
Z9 0
U1 1
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1045-1056
EI 1095-8320
J9 BIOLOGICALS
JI Biologicals
PD MAY
PY 2020
VL 65
BP 42
EP 45
DI 10.1016/j.biologicals.2020.04.003
PG 4
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
GA LP3YW
UT WOS:000534255800007
PM 32327306
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Zheng, CC
   Wang, JQ
   Guo, H
   Lu, ZH
   Ma, Y
   Zhu, YY
   Xia, DQ
   Wang, YZ
   He, HL
   Zhou, J
   Wang, Y
   Fei, MM
   Yin, YH
   Zheng, M
   Xu, YH
AF Zheng, Changcheng
   Wang, Jinquan
   Guo, Hui
   Lu, Zhaohui
   Ma, Yan
   Zhu, Yuyou
   Xia, Daqing
   Wang, Yinzhong
   He, Hongliang
   Zhou, Jian
   Wang, Yong
   Fei, Mingming
   Yin, Yihong
   Zheng, Mao
   Xu, Yehong
CA Natl Aid Prevent Treat Novel Coron
TI Risk-adapted Treatment Strategy For COVID-19 Patients
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; novel coronavirus pneumonia; risk-adapted treatment strategy;
   antiviral treatment; low-dose corticosteroid
ID CORTICOSTEROID-THERAPY; PNEUMONIA
AB Background: There are no clear expert consensus or guidelines on how to treat 2019 coronavirus disease (COVID-19). The objective of this study is to investigate the short-term effect of risk-adapted treatment strategy on patients with COVID-19.
   Methods: We collected the medical records of 55 COVID-19 patients for analysis. We divided these patients into mild, moderate and severe groups, and risk-adapted treatment approaches were given according to the illness severity.
   Results: Twelve patients were in mild group and 22 were in moderate group (non-severe group, n = 34), and 21 patients were in severe group. At the end of the first two weeks after admission, clinical manifestations had completely despeared in 31(91.2%)patients in non-severe group, and 18(85.7%) patients in severe group (p = 0.85). Both groups had a satisfied chest CT imaging recovery, which includes 22(64.7%) patients in non-severe group and 12(57.1%) patients in severe group recovered at least 50% of the whole leisions in the first week, and 28(82.4%) and 16(76.2%) recovered at least 75% in the second week, respectively. There were no significant differences in SARS-CoV-2 nucleic acid negativity (p = 0.92). There were also no significant differences in the levels of SARS-CoV-2-IgM and IgG antibody production between the two groups (p = 0.13, 0.62). There were 45 cases were discharged from the hospital, and no patients died at the time of this clinical analysis.
   Conclusions: Risk-adapted treatment strategy was associated with significant clinical manifestations alleviation and clinical imaging recovery. In severe COVID-19 patients, early and short-term use of low-dose methylprednisolone was beneficial and did not delay SARS-CoV-2 nucleic acid clearance and influence IgG antibody production. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Zheng, Changcheng; Wang, Jinquan; Lu, Zhaohui; Ma, Yan; Zhu, Yuyou; Xia, Daqing; Wang, Yinzhong; He, Hongliang; Zhou, Jian; Wang, Yong; Fei, Mingming; Yin, Yihong; Zheng, Mao; Xu, Yehong] Univ Sci & Technol China, Affiliated Hosp USTC 1, Div Life Sci & Med, Lujiang Rd 17, Hefei 230001, Peoples R China.
   [Guo, Hui] Huazhong Univ Sci & Technol, Union Hosp Affiliated, Tongji Med Coll, Wuhan, Peoples R China.
RP Zheng, CC; Wang, JQ (corresponding author), Univ Sci & Technol China, Affiliated Hosp USTC 1, Div Life Sci & Med, Lujiang Rd 17, Hefei 230001, Peoples R China.
EM zhengchch1123@ustc.edu.cn; jqwang604@163.com
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Bordi L, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.8.2000170
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Eccles R, 2007, BRIT J HOSP MED, V68, P71, DOI 10.12968/hmed.2007.68.2.22824
   Guan WJ, 2019, CLIN CHARACTERISTICS, V2020, P2020, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974]
   Ho JC, 2003, AM J RESP CRIT CARE, V168, P1449, DOI 10.1164/rccm.200306-766OC
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2018, AM J RESP CRIT CARE, V197, P700, DOI 10.1164/rccm.201712-2371ED
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   MacLaren G, 2020, JAMA-J AM MED ASSOC, V323, P1245, DOI 10.1001/jama.2020.2342
   MLO, 2015, MLO Med Lab Obs, V47, P14
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zou QD, 2020, INT J INFECT DIS, V92, P208, DOI 10.1016/j.ijid.2020.01.017
NR 14
TC 25
Z9 26
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD MAY
PY 2020
VL 94
BP 74
EP 77
DI 10.1016/j.ijid.2020.03.047
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA LO5BT
UT WOS:000533643700018
PM 32229257
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hong, XY
   Xiong, J
   Feng, ZC
   Shi, Y
AF Hong, Xiaoyang
   Xiong, Jing
   Feng, Zhichun
   Shi, Yuan
TI Extracorporeal membrane oxygenation (ECMO): does it have a role in the
   treatment of severe COVID-19?
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE acute respiratory distress syndrome; respiratory failure; extracorporeal
   membrane oxygenation; coronavirus disease 19
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged since December 2019 in Wuhan city, and has quickly spread throughout China and other countries. To date, no specific treatment has been proven to be effective for SARS-CoV-2 infection. According to World Health Organization (WHO), management of coronavirus disease 19 (COVID-19) has mainly focused on infection prevention, case detection and monitoring, and supportive care. Given to the previous experience, extracorporeal membrane oxygenation (ECMO) has been proven to be an effective therapy in the treatment of respiratory failure or acute respiratory distress syndrome (ARDS). On the basis of similar principle, ECMO may be also an effective therapy in the treatment of severe COVID-19. In this study, we described and discussed the clinical outcomes of ECMO for ARDS patients, ECMO use for severe COVID-19 in China, the indications of ECMO use, and some important issues associated with ECMO. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Hong, Xiaoyang; Feng, Zhichun] Peoples Liberat Army Gen Hosp, Med Ctr 7, Bayi Childrens Hosp, Beijing, Peoples R China.
   [Xiong, Jing; Shi, Yuan] Minist Educ, Key Lab Child Dev & Disorders, Dept Neonatol, Beijing, Peoples R China.
   [Xiong, Jing; Shi, Yuan] Natl Clin Res Ctr Child Hlth & Disorders, Chongqing, Peoples R China.
   [Xiong, Jing; Shi, Yuan] China Int Sci & Technol Cooperat Base Child Dev &, Chongqing, Peoples R China.
   [Xiong, Jing; Shi, Yuan] Chongqing Med Univ, Childrens Hosp, Chongqing, Peoples R China.
   [Xiong, Jing; Shi, Yuan] Chongqing Key Lab Pediat, Chongqing 400014, Peoples R China.
RP Feng, ZC (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Med Ctr 7, Bayi Children Hosp, Beijing 100000, Peoples R China.; Shi, Y (corresponding author), Chongqing Med Univ, Dept Neonatol, Childrens Hosp, Chongqing 400014, Peoples R China.
EM zhichunfeng81@163.com; shiyuan@hospital.cqmu.edu.cn
RI ; Shi, Yuan/H-9025-2018
OI Hong, Xiaoyang/0000-0003-0918-6617; Shi, Yuan/0000-0002-4571-4424
CR Alshahrani MS, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-017-0350-x
   Brodie D, 2019, JAMA-J AM MED ASSOC, V322, P557, DOI 10.1001/jama.2019.9302
   Combes A, 2018, NEW ENGL J MED, V378, P1965, DOI 10.1056/NEJMoa1800385
   Critical Care Medicine Committee of the Chinese Association of Chest Physicians, 2019, CHIN J TUBERE RESP D, V9, P660, DOI [10.3760/cma.j.issn.1001-0939.2019.09.006, DOI 10.3760/CMA.J.ISSN.1001-0939.2019.09.006]
   Goligher EC, 2018, JAMA-J AM MED ASSOC, V320, P2251, DOI 10.1001/jama.2018.14276
   Guan WJ, 2020, NEW ENGL J MED, V1, DOI [10.1056/NEJMoa2002032, DOI 10.1056/NEJMOA2002032]
   Guqin Z, 2020, CLIN FEATURES OUTCOM, DOI DOI 10.1101/2020.03.02.2003045203.02.20030452
   Han SW, 2020, CANCER MED-US, V9, P6667, DOI 10.1002/cam4.3289
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Noah MA, 2011, JAMA-J AM MED ASSOC, V306, P1659, DOI 10.1001/jama.2011.1471
   Peek GJ, 2009, LANCET, V374
   The Australia and New Zealand Extracorporeal Membrane Oxygenation. (ANZ ECMO) Influenza Investigators, 2009, JAMA-J AM MED ASSOC
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
NR 14
TC 18
Z9 18
U1 3
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD MAY
PY 2020
VL 94
BP 78
EP 80
DI 10.1016/j.ijid.2020.03.058
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA LO5BT
UT WOS:000533643700019
PM 32251794
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU See, KC
   Liew, SM
   Ng, DCE
   Chew, EL
   Khoo, EM
   Sam, CH
   Sheena, D
   Filzah, ZZ
   Chin, SY
   Lee, PY
   Tan, LP
   Najwa, ZF
   Sabrina, S
   Them, WW
   Saipriya, T
   Zamakhshari, ZAM
   Cheah, WK
   Peariasamy, K
   Goh, PP
   Ibrahim, H
AF See, K. C.
   Liew, S. M.
   Ng, David C. E.
   Chew, E. L.
   Khoo, E. M.
   Sam, C. H.
   Sheena, D.
   Filzah, Z. Zahilah
   Chin, S. Y.
   Lee, P. Y.
   Tan, L. P.
   Najwa, Z. Farah
   Sabrina, S.
   Them, W. W.
   Saipriya, T.
   Zamakhshari, Z. A. Muhammad
   Cheah, W. K.
   Peariasamy, K.
   Goh, P. P.
   Ibrahim, H.
TI COVID-19: Four Paediatric Cases in Malaysia
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; Coronavirus; epidemic; Epidemiology; nCoV; Outbreak;
   Paediatric
AB Objective: This is a brief report of 4 paediatric cases of COVID-19 infection in Malaysia
   Background: COVID-19, a coronavirus, first detected in Wuhan, China has now spread rapidly to over 60 countries and territories around the world, infecting more than 85000 individuals. As the case count amongst children is low, there is need to report COVID-19 in children to better understand the virus and the disease.
   Cases: In Malaysia, until end of February 2020, there were four COVID-19 paediatric cases with ages ranging from 20 months to 11 years. All four cases were likely to have contracted the virus in China. The children had no symptoms or mild flu-like illness. The cases were managed symptomatically. None required antiviral therapy.
   Discussion: There were 2 major issues regarding the care of infected children. Firstly, the quarantine of an infected child with a parent who tested negative was an ethical dilemma. Secondly, oropharyngeal and nasal swabs in children were at risk of false negative results. These issues have implications for infection control. Consequently, there is a need for clearer guidelines for child quarantine and testing methods in the management of COVID-19 in children. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [See, K. C.; Sheena, D.; Filzah, Z. Zahilah; Chin, S. Y.; Lee, P. Y.; Tan, L. P.; Najwa, Z. Farah; Sabrina, S.; Them, W. W.; Saipriya, T.] Minist Hlth, Hosp Sungai Buloh, Dept Paediat, Seremban, Malaysia.
   [Liew, S. M.; Khoo, E. M.] Univ Malaya, Fac Med, Dept Primary Care Med, Kuala Lumpur, Malaysia.
   [Ng, David C. E.; Zamakhshari, Z. A. Muhammad] Minist Hlth, Hosp Tuanku Jaafar, Dept Paediat, Seremban, Malaysia.
   [Chew, E. L.; Sam, C. H.] Minist Hlth, Hosp Sultanah Maliha, Dept Paediat, Seremban, Malaysia.
   [Cheah, W. K.] Minist Hlth, Hosp Taiping, Dept Med, Seremban, Malaysia.
   [Peariasamy, K.; Goh, P. P.] Minist Hlth, Natl Inst Hlth, Inst Clin Res, Block B, Setia Alam, Malaysia.
   [Ibrahim, H.] Minist Hlth, Div Res & Tech Support, Seremban, Malaysia.
RP Goh, PP (corresponding author), Minist Hlth, Natl Inst Hlth, Inst Clin Res, Block B, Setia Alam, Malaysia.
EM pikpin@gmail.com
RI Khoo, Ee Ming/B-8785-2010; Liew, Su May/B-8852-2010
OI Khoo, Ee Ming/0000-0003-3191-1264; Liew, Su May/0000-0003-2865-7955
CR Centers for Disease Control and Prevention, 2020, GUID PREV CONTR INFL
   Shen KL, 2020, WORLD J PEDIAT
   The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY
   Wishaupt JO, 2017, J CLIN VIROL, V90, P1, DOI 10.1016/j.jcv.2017.02.010
NR 4
TC 13
Z9 13
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD MAY
PY 2020
VL 94
BP 125
EP 127
DI 10.1016/j.ijid.2020.03.049
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA LO5BT
UT WOS:000533643700029
PM 32304822
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Goldman, RD
AF Goldman, Ran D.
TI Coronavirus disease 2019 in children Surprising findings in the midst of
   a global pandemic
SO CANADIAN FAMILY PHYSICIAN
LA English
DT Article
AB Question Coronavirus disease 2019 (COVID-19) is affecting millions of people worldwide. It seems that it affects mostly adults older than 40 years of age, and the death rate is highest for older individuals in the population. What should I tell parents worried about their children contracting the coronavirus (SARS-CoV-2) causing COVID-19, and what symptoms should I took for to determine if there is a need to test for the virus?
   Answer The COVID-19 global pandemic affects all ages. Severe respiratory manifestations have been the mainstay of illness in adults, with what seems to be rapid deterioration necessitating mechanical ventilation. Only 5% of those tested and found to have COVID-19 have been younger than 19 years, possibly owing to limited testing, as the symptoms in children are usually mild. Symptoms in children include fever, dry cough, rhinorrhea, sore throat, and fatigue, and in 10% diarrhea or vomiting. Rarely dyspnea or hypoxemia were also described. Blood tests and imaging have been shown to be of little value in children and should only be ordered for those in whom you would normally order these investigations for viral-like illness. No specific therapy is available and supportive care with rest, fluids, and antipyretics for children is the recommended approach. Ibuprofen or acetaminophen for fever and pain can be given. Antiviral and immunomodulatory treatment is not recommended at this time for otherwise healthy children, and corticosteroids should also not be used. Children with immunocompromised states should be isolated and avoid contact with others.
EM rgoldman@cw.bc.ca
OI Goldman, Ran D./0000-0001-8318-5415
CR [Anonymous], 2020, WHO DIR GEN OP REM M
   [Anonymous], 2020, CAN COVID 19 SIT AW
   BC Centre for Disease Control, 2020, UNPR THER COVID 19
   Bousquet J, 2020, ALLERGY, DOI [10.1111/all.14302, DOI 10.1111/ALL.14302.ACCESSED]
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   COVID-19 National Emergency Response Center Epidemiology and Case Management Team Korea Centers for Disease Control and Prevention, 2020, Osong Public Health Res Perspect, V11, P85, DOI 10.24171/j.phrp.2020.11.2.05
   Davies NG, 2020, CMMID COVID 19 WORKI, DOI [10.1101/2020.03.24.20043018v1, DOI 10.1101/2020.03.24.20043018V1.ACCESSED]
   Dong Y, 2020, PEDIATR RES, DOI 10.1038/s41390-020-0888-4
   Hagmann SHF, 2020, TRAVEL MED INFECT DI
   Kelvin A.A., 2020, LANCET INFECT DIS
   Ogimi C, 2019, J PEDIAT INF DIS SOC, V8, P21, DOI 10.1093/jpids/pix093
   Qiu H, 2020, LANCET INFECT DIS
   Rieder M, 2020, CAN NSAIDS BE USED C
   Shen KL, 2020, WORLD J PEDIATR, DOI DOI 10.1007/S12519-020-00344-6.ACCESSED
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wilder-Smith A, 2020, LANCET INFECT DIS
   Wolfel R, 2020, VIROLOGICAL ASSESSME, DOI DOI 10.1101/2020.03.05.20030502V1.ARTICLE-INFO
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 18
TC 5
Z9 5
U1 2
U2 5
PU COLL FAMILY PHYSICIANS CANADA
PI MISSISSAUGA
PA 2630 SKYMARK AVE, MISSISSAUGA, ONTARIO L4W 5A4, CANADA
SN 0008-350X
EI 1715-5258
J9 CAN FAM PHYSICIAN
JI Can. Fam. Phys.
PD MAY 1
PY 2020
VL 66
IS 5
BP 332
EP 334
PG 3
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA LO3JC
UT WOS:000533523900007
PM 32404451
DA 2021-01-01
ER

PT J
AU Schultz, P
   Morvan, JB
   Fakhry, N
   Moriniere, S
   Vergez, S
   Lacroix, C
   Bartier, S
   Barry, B
   Babin, E
   Couloigner, V
   Atallah, I
AF Schultz, P.
   Morvan, J. -B.
   Fakhry, N.
   Moriniere, S.
   Vergez, S.
   Lacroix, C.
   Bartier, S.
   Barry, B.
   Babin, E.
   Couloigner, V.
   Atallah, I.
CA French Soc Otorhinolaryngology He
   French Soc Head Neck Carcinol
TI French consensus regarding precautions during tracheostomy and
   post-tracheostomy care in the context of COVID-19 pandemic
SO EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES
LA English
DT Article
DE COVID-19; SARS-Cov-2; Pandemic; Tracheostomy; Care; Percutaneous
AB Tracheostomy post-tracheostomy care are regarded as at high risk for contamination of health care professionals with the new coronavirus (SARS-CoV-2). Considering the rapid spread of the infection, all patients in France must be considered as potentially infected by the virus. Nevertheless, patients without clinical or radiological (CT scan) markers of COVID-19, and with negative nasopharyngeal sample within 24 h of surgery, are at low risk of being infected. Instructions for personal protection include specific wound dressings and decontamination of all material used. The operating room should be ventilated after each tracheostomy and the pressure of the room should be neutral or negative. Percutaneous tracheostomy is to be preferred over surgical cervicotomy in order to reduce aerosolization and to avoid moving patients from the intensive care unit to the operating room. Ventilation must be optimized during the procedure, to limit patient oxygen desaturation. Drug assisted neuromuscular blockage is advised to reduce coughing during tracheostomy tube insertion. An experienced team is mandatory to secure and accelerate the procedure as well as to reduce risk of contamination. (C) 2020 Published by Elsevier Masson SAS.
C1 [Schultz, P.] Hop Hautepierre, Serv ORL & Chirurg Cervicofaciale, Ave Moliere, F-67098 Strasbourg, France.
   [Morvan, J. -B.] Hop Instruct Armees St Anne, Serv ORL & Chirurg Cervicofaciale, 2 Blvd St Anne, F-83000 Toulon, France.
   [Fakhry, N.] Hop Conception, Serv ORL & Chirurg Cervicofaciale, 147 Blvd Baille, F-13005 Marseille, France.
   [Moriniere, S.] CHRU Bretonneau Tours, Serv ORL & Chirurg Cervicofaciale, 2 Blvd Tonnelle, F-37044 Tours, France.
   [Vergez, S.] CHU Rangueil Larrey, Serv ORL & Chirurg Cervicofaciale, 24 Chemin Pourvourville, F-31400 Toulouse, France.
   [Vergez, S.] Inst Univ Canc Toulouse, Serv Chirurg, 1 Ave Irene Joliot Curie, F-31100 Toulouse, France.
   [Lacroix, C.] Hop Europeen Georges Pompidou, AP HP, Serv ORL & Chirurg Cervicofaciale, 20 Rue Leblanc, F-75015 Paris, France.
   [Bartier, S.] Ctr Hosp Intercommunal Creteil, Serv ORL & Chirurg Cervicofaciale, 40 Ave Verdun, F-94010 Creteil, France.
   [Barry, B.] Hop Bichat Claude Bernard, Serv ORL & Chirurg Cervicofaciale, 46 Rue Henri Huchard, F-75018 Paris, France.
   [Babin, E.] CHU Caen Normandie, Serv ORL & Chirurg Cervicofaciale, Ave Cote Nacre, F-14000 Caen, France.
   [Couloigner, V.] Hop Necker Enfants Malad, AP HP, Serv ORL & Chirurg Cervicofaciale Pediat, 149 Rue Sevres, F-75743 Paris, France.
   [Atallah, I.] CHU Grenoble Alpes, Serv ORL & Chirurg Cervicofaciale, Blvd Chantourne, F-38700 La Tronche, France.
RP Schultz, P (corresponding author), Hop Hautepierre, Serv ORL & Chirurg Cervicofaciale, Ave Moliere, F-67098 Strasbourg, France.
EM philippe.schultz@chru-strasbourg.fr
CR Abe T, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2126-6
   [Anonymous], 2020, REC SOC SAV FRANC OR
   Morvan JB, 2020, TRACHEOTOMIE
   Phua GC, 2008, CLIN CHEST MED, V29, P323, DOI 10.1016/j.ccm.2008.01.001
   SRLF-SFAR-SFMU-GFRUP-SPILF-SPLF, 2020, REC EXP PORT PRIS CH
   To KK-W, 2020, LANCET INFECT DIS, DOI DOI 10.1016/S1473-3099(20)30196-1[S1473-3099(20)30196-1
   Wei WI, 2003, LARYNGOSCOPE, V113, P1777, DOI 10.1097/00005537-200310000-00022
NR 7
TC 11
Z9 11
U1 0
U2 0
PU ELSEVIER MASSON, CORP OFF
PI PARIS
PA 65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE
SN 1879-7296
EI 1879-730X
J9 EUR ANN OTORHINOLARY
JI Eur. Ann. Otorhinolaryngol.-Head Neck Dis.
PD MAY
PY 2020
VL 137
IS 3
BP 167
EP 169
DI 10.1016/j.anorl.2020.04.006
PG 3
WC Otorhinolaryngology
SC Otorhinolaryngology
GA LP7EA
UT WOS:000534479000005
PM 32307265
OA Green Published
DA 2021-01-01
ER

PT J
AU South, AM
   Diz, DI
   Chappell, MC
AF South, Andrew M.
   Diz, Debra, I
   Chappell, Mark C.
TI COVID-19, ACE2, and the cardiovascular consequences
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE ACE2; ANG II; COVID-19; renin-angiotensin system; SARS-CoV-2; statins
ID CONVERTING ENZYME 2; RENIN-ANGIOTENSIN SYSTEM; MESSENGER-RNA; RECEPTOR
   BLOCKERS; RABBIT MODEL; AXIS; EXPRESSION; LUNG;
   ANGIOTENSIN-CONVERTING-ENZYME-2; BLOCKADE
AB The novel SARS coronavirus SARS-CoV-2 pandemic may be particularly deleterious to patients with underlying cardiovascular disease (CVD). The mechanism for SARS-CoV-2 infection is the requisite binding of the virus to the membrane-bound form of angiotensin-converting enzyme 2 (ACE2) and internalization of the complex by the host cell. Recognition that ACE2 is the coreceptor for the coronavirus has prompted new therapeutic approaches to block the enzyme or reduce its expression to prevent the cellular entry and SARS-CoV-2 infection in tissues that express ACE2 including lung. heart, kidney, brain, and gut. ACE2, however. is a key enzymatic component of the renin-angiotensin-aldosterone system (RAAS): ACE2 degrades ANG II, a peptide with multiple actions that promote CVD, and generates Ang-(1-7). which antagonizes the effects of ANG II. Moreover, experimental evidence suggests that RAAS blockade by ACE inhibitors, ANG II type 1 receptor antagonists, and mineralocorticoid antagonists, as well as statins, enhance ACE2 which, in part, contributes to the benefit of these regimens. In lieu of the fact that many older patients with hypertension or other CVDs are routinely treated with RAAS blockers and statins, new clinical concerns have developed regarding whether these patients are at greater risk for SARS-CoV-2 infection, whether RAAS and statin therapy should be discontinued, and the potential consequences of RAAS blockade to COVID-19-related pathologies such as acute and chronic respiratory disease. The current perspective critically examines the evidence for ACE2 regulation by RAAS blockade and statins, the cardiovascular benefits of ACE2, and whether ACE2 blockade is a viable approach to attenuate COVID-19.
   Listen to this article's corresponding podcast at: https://ajpheart.podbean.com/e/covid-19-ace2-and-the-cardiovascular-consequences/.
C1 [South, Andrew M.; Diz, Debra, I; Chappell, Mark C.] Wake Forest Sch Med, Cardiovasc Sci Ctr, Winston Salem, NC 27101 USA.
RP Chappell, MC (corresponding author), Wake Forest Sch Med, Cardiovasc Sci Ctr, Winston Salem, NC 27101 USA.
EM mchappel@wakehealth.edu
OI Chappell, Mark/0000-0001-5869-6037
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HL146818, HL-05952,
   HD-084227, HL-56973]; American Heart AssociationAmerican Heart
   Association [AHA-151521, AHA-18TPA34170522]; Cardiovascular Sciences
   Center [CVSC-830114]; Hypertension and Vascular Research Center; Farley
   Hudson Foundation
FX This work was supported by National Institutes of Health Grants
   HL146818, HL-05952, HD-084227, and HL-56973; American Heart Association
   Grants AHA-151521 and AHA-18TPA34170522; and Cardiovascular Sciences
   Center Grant CVSC-830114 and by the Hypertension and Vascular Research
   Center and the Farley Hudson Foundation.
CR Alenina N, 2019, NEUROCHEM RES, V44, P1323, DOI 10.1007/s11064-018-2679-4
   Burchill L, 2008, EXP PHYSIOL, V93, P622, DOI 10.1113/expphysiol.2007.040386
   Chappell MC, 2007, HYPERTENSION, V50, P596, DOI 10.1161/HYPERTENSIONAHA.106.076216
   Chappell MC, 2016, AM J PHYSIOL-HEART C, V310, pH137, DOI 10.1152/ajpheart.00618.2015
   Chappell MC, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2013.00201
   Chen D, 2020, HYPOKALEMIA CLIN IMP, DOI [10.1101/2020.02.27.20028530, 10.1101/2020.02.27, DOI 10.1101/2020.02.27.20028530]
   Danilczyk U, 2006, NATURE, V444, P1088, DOI 10.1038/nature05475
   Diz DI, 2008, EXP PHYSIOL, V93, P694, DOI 10.1113/expphysiol.2007.040261
   Dong B, 2008, ARTERIOSCL THROM VAS, V28, P1270, DOI 10.1161/ATVBAHA.108.164715
   Ferrario CM, 2005, KIDNEY INT, V68, P2189, DOI 10.1111/j.1523-1755.2005.00675.x
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Garabelli PJ, 2008, EXP PHYSIOL, V93, P613, DOI 10.1113/expphysiol.2007.040246
   Gembardt F, 2005, PEPTIDES, V26, P1270, DOI 10.1016/j.peptides.2005.01.009
   Gilliam-Davis S, 2011, PHYSIOL GENOMICS, V43, P829, DOI 10.1152/physiolgenomics.00167.2010
   Gleeson PJ, 2019, CRIT CARE MED, V47, P152, DOI 10.1097/CCM.0000000000003544
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang FM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4595
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jessup JA, 2006, AM J PHYSIOL-HEART C, V291, pH2166, DOI 10.1152/ajpheart.00061.2006
   Jia HP, 2009, AM J PHYSIOL-LUNG C, V297, pL84, DOI 10.1152/ajplung.00071.2009
   Jiang F, 2014, NAT REV CARDIOL, V11, P413, DOI 10.1038/nrcardio.2014.59
   Kar S, 2010, J APPL PHYSIOL, V108, P923, DOI 10.1152/japplphysiol.00840.2009
   Karram T, 2005, AM J PHYSIOL-HEART C, V289, pH1351, DOI 10.1152/ajpheart.01186.2004
   Keidar S, 2005, CIRC RES, V97, P946, DOI 10.1161/01.RES.0000187500.24964.7A
   Khanna A, 2017, NEW ENGL J MED, V377, P419, DOI 10.1056/NEJMoa1704154
   Kim J, 2017, ACUTE CRIT CARE, V32, P154, DOI 10.4266/kjccm.2016.00976
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lely AT, 2004, J PATHOL, V204, P587, DOI 10.1002/path.1670
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Lovren F, 2008, AM J PHYSIOL-HEART C, V295, pH1377, DOI 10.1152/ajpheart.00331.2008
   Mao L., 2020, NEUROLOGICAL MANIFES, DOI [10.1101/2020.02.22.20026500., 10.1101/2020.02.22.20026500, DOI 10.1101/2020.02.22.20026500]
   Mizuiri S, 2011, NEPHROLOGY, V16, P567, DOI 10.1111/j.1440-1797.2011.01467.x
   Nunes-Silva A, 2017, PROTEIN PEPTIDE LETT, V24, P809, DOI 10.2174/0929866524666170728151401
   Patel VB, 2016, CIRC RES, V118, P1313, DOI 10.1161/CIRCRESAHA.116.307708
   Sahara M, 2014, CARDIOVASC RES, V101, P236, DOI 10.1093/cvr/cvt245
   Sanchez-Aguilar M, 2019, PPAR RES, V2019, DOI 10.1155/2019/1371758
   Shin YH, 2017, HEART VESSELS, V32, P618, DOI 10.1007/s00380-016-0936-5
   Silva ACSE, 2016, PHARMACOL RES, V107, P154, DOI 10.1016/j.phrs.2016.03.018
   Sodhi CP, 2018, AM J PHYSIOL-LUNG C, V314, pL17, DOI 10.1152/ajplung.00498.2016
   Santos RAS, 2019, AM J PHYSIOL-HEART C, V316, pH958, DOI 10.1152/ajpheart.00723.2018
   Tikoo K, 2015, BIOCHEM PHARMACOL, V93, P343, DOI 10.1016/j.bcp.2014.11.013
   Vuille-Dit-Bille RN, 2015, AMINO ACIDS, V47, P693, DOI 10.1007/s00726-014-1889-6
   Wang G, 2009, AM J NEPHROL, V29, P524, DOI 10.1159/000185629
   Wang W, 2016, HYPERTENSION, V68, P365, DOI 10.1161/HYPERTENSIONAHA.115.06892
   Wang XX, 2016, J MOL CELL CARDIOL, V97, P180, DOI 10.1016/j.yjmcc.2016.05.012
   Williams VR, 2018, CURR OPIN NEPHROL HY, V27, P35, DOI 10.1097/MNH.0000000000000378
   Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Xu P, 2011, AM J PHYSIOL-REG I, V300, pR804, DOI 10.1152/ajpregu.00222.2010
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yousif MHM, 2012, PHARMACOL RES, V66, P269, DOI 10.1016/j.phrs.2012.05.001
   Yuan YM, 2015, J RENIN-ANGIO-ALDO S, V16, P249, DOI 10.1177/1470320315576256
   Zambelli Vanessa, 2015, Intensive Care Med Exp, V3, P44, DOI 10.1186/s40635-015-0044-3
   Zhang C, 2010, P NATL ACAD SCI USA, V107, P15886, DOI 10.1073/pnas.1001253107
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhong JC, 2011, REGUL PEPTIDES, V166, P90, DOI 10.1016/j.regpep.2010.09.005
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 62
TC 140
Z9 144
U1 18
U2 36
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
EI 1522-1539
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD MAY
PY 2020
VL 318
IS 5
BP H1084
EP H1090
DI 10.1152/ajpheart.00217.2020
PG 7
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Physiology
GA LM9PC
UT WOS:000532579000009
PM 32228252
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Shaker, MS
   Oppenheimer, J
   Grayson, M
   Stukus, D
   Hartog, N
   Hsieh, EWY
   Rider, N
   Dutmer, CM
   Vander Leek, TK
   Kim, H
   Chan, ES
   Mack, D
   Ellis, AK
   Lang, D
   Lieberman, J
   Fleischer, D
   Golden, DBK
   Wallace, D
   Portnoy, J
   Mosnaim, G
   Greenhawt, M
AF Shaker, Marcus S.
   Oppenheimer, John
   Grayson, Mitchell
   Stukus, David
   Hartog, Nicholas
   Hsieh, Elena W. Y.
   Rider, Nicholas
   Dutmer, Cullen M.
   Vander Leek, Timothy K.
   Kim, Harold
   Chan, Edmond S.
   Mack, Doug
   Ellis, Anne K.
   Lang, David
   Lieberman, Jay
   Fleischer, David
   Golden, David B. K.
   Wallace, Dana
   Portnoy, Jay
   Mosnaim, Giselle
   Greenhawt, Matthew
TI COVID-19: Pandemic Contingency Planning for the Allergy and Immunology
   Clinic
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Article
ID SHARED DECISION-MAKING; TASK-FORCE; TELEMEDICINE; ASTHMA; MANAGEMENT;
   THERAPY; UPDATE; CARE
C1 [Shaker, Marcus S.] Dartmouth Hitchcock Med Ctr, Sect Allergy & Immunol, Lebanon, NH 03766 USA.
   [Shaker, Marcus S.] Dartmouth Geisel Sch Med, Hanover, NH USA.
   [Oppenheimer, John] UMDMJ Rutgers Univ, Sch Med, Newark, NJ USA.
   [Grayson, Mitchell; Stukus, David] Ohio State Univ, Sch Med, Nationwide Childrens Hosp, Columbus, OH 43210 USA.
   [Hartog, Nicholas] Spectrum Hlth Helen DeVos Childrens Hosp, Grand Rapids, MI USA.
   [Hsieh, Elena W. Y.; Dutmer, Cullen M.; Fleischer, David; Greenhawt, Matthew] Univ Colorado, Sch Med, Childrens Hosp Colorado, Aurora, CO 80045 USA.
   [Rider, Nicholas] Texas Childrens Hosp, Sect Immunol Allergy & Retrovirol, Houston, TX 77030 USA.
   [Rider, Nicholas] Baylor Coll Med, Houston, TX 77030 USA.
   [Vander Leek, Timothy K.] Univ Alberta, Dept Pediat, Pediat Allergy & Asthma, Edmonton, AB, Canada.
   [Kim, Harold] Western Univ, London, ON, Canada.
   [Kim, Harold] McMaster Univ, London, ON, Canada.
   [Chan, Edmond S.] Univ British Columbia, BC Childrens Hosp, Vancouver, BC, Canada.
   [Mack, Doug] McMaster Univ, Hamilton, ON, Canada.
   [Mack, Doug] Halton Pediat Allergy, Burlington, ON, Canada.
   [Ellis, Anne K.] Queens Univ, Dept Med, Div Allergy & Immunol, Kingston, ON, Canada.
   [Lang, David] Cleveland Clin, Sect Allergy & Immunol, Dept Med, Cleveland, OH 44106 USA.
   [Lieberman, Jay] Univ Tennessee, Div Allergy & Immunol, Memphis, TN USA.
   [Golden, David B. K.] Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Baltimore, MD USA.
   [Wallace, Dana] Nova Southeastern Univ, Coll Allopath Med, Ft Lauderdale, FL 33314 USA.
   [Portnoy, Jay] Univ Missouri, Sch Med, Childrens Mercy, Kansas City, MO 64108 USA.
   [Mosnaim, Giselle] NorthShore Univ Hlth Syst, Dept Med, Div Pulm Allergy & Crit Care, Evanston, IL USA.
RP Greenhawt, M (corresponding author), Univ Colorado, Sch Med, Childrens Hosp Colorado, Food Challenge & Res Unit,Sect Allergy & Immunol, 13123 E 16th Ave, Aurora, CO 80045 USA.
EM Matthew.Greenhawt@childrenscolorado.org
RI Grayson, Mitchell/AAX-3674-2020
OI Grayson, Mitchell/0000-0002-4673-2122
FU Agency for Healthcare Research and QualityUnited States Department of
   Health & Human ServicesAgency for Healthcare Research & Quality
   [5K08HS024599-02]
FX M.G. is supported by the Agency for Healthcare Research and Quality
   (grant no. 5K08HS024599-02).
CR American College of Allergy Asthma & Immunology, IMP INF COVID 19 THO
   [Anonymous], 2020, WHO DIR GEN OP REM M
   [Anonymous], 2020, WASHINGTON POST
   [Anonymous], 2020, COR COVID 19 NEW TEL
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Baker J, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0814-6
   Barry MJ, 2012, J AMBUL CARE MANAG, V35, P90, DOI 10.1097/JAC.0b013e318249482f
   Bath-Hextall F, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005203.pub2
   Bernstein JA, 2014, J ALLERGY CLIN IMMUN, V133, P1270, DOI 10.1016/j.jaci.2014.02.036
   Center for Connected Health Policy. The National Telehealth Policy Resource Center, 2020, BILL TEL ENC
   Centers for Disease Control and Prevention, MIDDL E RESP SYNDR M
   Centers for Disease Control and Prevention, SEV AC RESP DISTR SY
   Centers for Medicare & Medicaid Services, 2020, COV PAYM REL COVID 1
   Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3
   Chen YY, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9370
   CMA Health Summit, ACC ACT HLTH CAR
   Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1339, DOI 10.1001/jama.2020.3072
   Denman S, 2016, BRIT J DERMATOL, V175, P1405, DOI 10.1111/bjd.15074
   Desai M, 2019, CLIN CHEST MED, V40, P179, DOI 10.1016/j.ccm.2018.10.011
   Elliott T, 2019, CURR ALLERGY ASTHM R, V19, DOI 10.1007/s11882-019-0837-7
   Elliott T, 2017, ANN ALLERG ASTHMA IM, V119, P512, DOI 10.1016/j.anai.2017.09.052
   Elwyn G, 2012, J GEN INTERN MED, V27, P1361, DOI 10.1007/s11606-012-2077-6
   Fang LW, 2018, LANCET RESP MED, V6, P421, DOI 10.1016/S2213-2600(18)30103-6
   Fernandez JM, 2017, IMMUNOL ALLERGY CLIN, V37, P315, DOI 10.1016/j.iac.2017.01.006
   Flodgren G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002098.pub2
   Global Initiative for Asthma, 2019, GINA REP GLOB STRAT
   Golden DBK, 2017, J ALLER CL IMM-PRACT, V5, P330, DOI 10.1016/j.jaip.2017.02.005
   Golden DBK, 2017, ANN ALLERG ASTHMA IM, V118, P28, DOI 10.1016/j.anai.2016.10.031
   Greenhawt M, 2019, JAMA NETW OPEN, V2
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang KW, 2019, LANCET, V394, P407, DOI 10.1016/S0140-6736(19)31147-X
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e112
   Marshall GD, 2007, J ALLERGY CLIN IMMUN, V119, P802, DOI 10.1016/j.jaci.2007.01.040
   Netting MJ, 2017, J ALLER CL IMM-PRACT, V5, P1617, DOI 10.1016/j.jaip.2017.03.013
   Portnoy JM, 2020, J ALLERGY CLIN IMMUN, V145, P445, DOI 10.1016/j.jaci.2019.12.903
   Portnoy JM, 2016, ANN ALLERG ASTHMA IM, V117, P241, DOI 10.1016/j.anai.2016.07.012
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shaker M, 2018, ALLERGY, V73, P1707, DOI 10.1111/all.13446
   Shaker M, 2020, CURR OPIN PEDIATR, V32, P321, DOI 10.1097/MOP.0000000000000879
   Shaker M, 2020, J ALLER CL IMM-PRACT, V8, P2360, DOI 10.1016/j.jaip.2019.11.004
   Shaker M, 2020, J ALLER CL IMM-PRACT, V8, P565, DOI 10.1016/j.jaip.2019.09.037
   Shaker M, 2019, ALLERGY ASTHMA PROC, V40, P290, DOI 10.2500/aap.2019.40.4240
   Shaker M, 2019, ANN ALLERG ASTHMA IM, V122, P79, DOI 10.1016/j.anai.2018.06.035
   Shih J, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0807-5
   Staicu ML, 2018, J ALLER CL IMM-PRACT, V6, P2033, DOI 10.1016/j.jaip.2018.04.038
   Stukus DR, 2019, IMMUNOL ALLERGY CLIN, V39, P583, DOI 10.1016/j.iac.2019.07.011
   Tarbox JA, 2011, ANN ALLERG ASTHMA IM, V107, P239, DOI 10.1016/j.anai.2011.06.008
   The Centers for Disease Control and Prevention, 2019, COR DIS 2019 COVID 1
   The Plasma Protein Therapeutics Association, NEW COR SARS COV 2 P
   Van Bever HP, 2004, PEDIAT ALLERG IMM-UK, V15, P206, DOI 10.1111/j.1399-3038.2004.00137.x
   van Dormalen N, AEROSOL SURFACE STAB, DOI 10.1101/2020.03.09.20033217v2
   Wallace DV, 2017, ANN INTERN MED, V167, P876, DOI 10.7326/M17-2203
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zheng XY, 2018, ARCH VIROL, V163, P845, DOI 10.1007/s00705-017-3700-y
NR 59
TC 70
Z9 71
U1 13
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD MAY
PY 2020
VL 8
IS 5
BP 1477
EP +
PG 17
WC Allergy; Immunology
SC Allergy; Immunology
GA LN2DC
UT WOS:000532753200002
PM 32224232
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zimmermann, P
   Curtis, N
AF Zimmermann, Petra
   Curtis, Nigel
TI Coronavirus Infections in Children Including COVID-19 An Overview of the
   Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention
   Options in Children
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE severe acute respiratory syndrome coronavirus; Middle East respiratory
   syndrome coronavirus; severe acute respiratory syndrome coronavirus 2;
   epidemiology; symptoms; laboratory; imaging; treatment; vaccines;
   prevention; treatment; vaccines; prevention; SARS-CoV; MERS-CoV;
   SARS-CoV-2
ID RESPIRATORY SYNDROME CORONAVIRUS; RECEPTOR-BINDING DOMAIN; MERS-COV
   INFECTION; DIPEPTIDYL PEPTIDASE 4; HEALTH-CARE SETTINGS; PAPAIN-LIKE
   PROTEASE; SPIKE PROTEIN; SARS-CORONAVIRUS; SAUDI-ARABIA; HONG-KONG
AB Coronaviruses (CoVs) are a large family of enveloped, single-stranded, zoonotic RNA viruses. Four CoVs commonly circulate among humans: HCoV2-229E, -HKU1, -NL63 and -OC43. However, CoVs can rapidly mutate and recombine leading to novel CoVs that can spread from animals to humans. The novel CoVs severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012. The 2019 novel coronavirus (SARS-CoV-2) is currently causing a severe outbreak of disease (termed COVID-19) in China and multiple other countries, threatening to cause a global pandemic. In humans, CoVs mostly cause respiratory and gastrointestinal symptoms. Clinical manifestations range from a common cold to more severe disease such as bronchitis, pneumonia, severe acute respiratory distress syndrome, multi-organ failure and even death. SARS-CoV, MERS-CoV and SARS-CoV-2 seem to less commonly affect children and to cause fewer symptoms and less severe disease in this age group compared with adults, and are associated with much lower case-fatality rates. Preliminary evidence suggests children are just as likely as adults to become infected with SARS-CoV-2 but are less likely to be symptomatic or develop severe symptoms. However, the importance of children in transmitting the virus remains uncertain. Children more often have gastrointestinal symptoms compared with adults. Most children with SARS-CoV present with fever, but this is not the case for the other novel CoVs. Many children affected by MERS-CoV are asymptomatic. The majority of children infected by novel CoVs have a documented household contact, often showing symptoms before them. In contrast, adults more often have a nosocomial exposure. In this review, we summarize epidemiologic, clinical and diagnostic findings, as well as treatment and prevention options for common circulating and novel CoVs infections in humans with a focus on infections in children.
C1 [Zimmermann, Petra] Univ Fribourg, Fribourg Hosp HFR, Dept Paediat, Fribourg, Switzerland.
   [Zimmermann, Petra] Univ Fribourg, Fac Sci & Med, Route Arsenaux 41, CH-1700 Fribourg, Switzerland.
   [Zimmermann, Petra; Curtis, Nigel] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia.
   [Zimmermann, Petra; Curtis, Nigel] Murdoch Childrens Res Inst, Infect Dis Res Grp, Parkville, Vic, Australia.
   [Curtis, Nigel] Royal Childrens Hosp Melbourne, Infect Dis Unit, Parkville, Vic, Australia.
RP Zimmermann, P (corresponding author), Univ Fribourg, Fac Sci & Med, Route Arsenaux 41, CH-1700 Fribourg, Switzerland.
EM petra.zimmermann@unifr.ch
RI Zimmermann, Petra/I-4670-2019
OI Zimmermann, Petra/0000-0002-2388-4318
FU European Society for Paediatric Infectious Diseases
FX PP.Z. is supported by a Fellowship from the European Society for
   Paediatric Infectious Diseases.
CR Addo M., 2018, SAFETY TOLERABILITY
   Adedeji AO, 2014, ANTIMICROB AGENTS CH, V58, P4894, DOI 10.1128/AAC.02994-14
   Adney DR, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030212
   Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688
   Al Johani S, 2016, J INFECT PUBLIC HEAL, V9, P216, DOI 10.1016/j.jiph.2016.04.005
   Al-Tawfiq Jaffar A, 2016, World J Clin Pediatr, V5, P391
   Al-Tawfiq JA, 2014, INT J INFECT DIS, V20, P42, DOI 10.1016/j.ijid.2013.12.003
   Aleanizy FS, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2137-3
   Alfaraj SH, 2019, FRONT MED-PRC, V13, P126, DOI 10.1007/s11684-017-0603-y
   AlGhamdi M, 2015, AM J TRANSPLANT, V15, P1101, DOI 10.1111/ajt.13085
   Alhamlan FS, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-011865
   Almazan F, 2013, MBIO, V4, DOI 10.1128/mBio.00650-13
   Alserehi H, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1437-y
   Amer HM, 2018, ANIM HEALTH RES REV, V19, P113, DOI 10.1017/S1466252318000117
   Anderson RM, 2004, PHILOS T R SOC B, V359, P1091, DOI 10.1098/rstb.2004.1490
   [Anonymous], 2004, SUMM PROB SARS CAS O
   [Anonymous], 2019, MIDDLE E RESP SYNDRO
   Assiri A, 2016, CLIN INFECT DIS, V63, P951, DOI 10.1093/cid/ciw412
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Babyn PS, 2004, PEDIATR RADIOL, V34, P47, DOI 10.1007/s00247-003-1081-8
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Barton C, 2014, ANTIMICROB AGENTS CH, V58, P120, DOI 10.1128/AAC.01407-13
   Bermingham A, 2004, PHILOS T R SOC B, V359, P1083, DOI 10.1098/rstb.2004.1493
   Bi Q, 2020, EPIDEMIOLOGY TRANSMI, DOI 10.1101/2020.03.03.20028423
   Bin Saeed AA, 2017, EMERG INFECT DIS, V23, P682, DOI 10.3201/eid2304.161793
   Bin SY, 2016, CLIN INFECT DIS, V62, P755, DOI 10.1093/cid/civ1020
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Bitnun A, 2003, PEDIATRICS, V112, pE261, DOI 10.1542/peds.112.4.e261
   Breban R, 2013, LANCET, V382, P694, DOI 10.1016/S0140-6736(13)61492-0
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Bukreyev A, 2004, LANCET, V363, P2122, DOI 10.1016/S0140-6736(04)16501-X
   Cabeca TK, 2013, INFLUENZA OTHER RESP, V7, P1040, DOI 10.1111/irv.12101
   Cabeca TK, 2012, J CLIN VIROL, V53, P82, DOI 10.1016/j.jcv.2011.09.006
   Cauchemez S, 2016, P NATL ACAD SCI USA, V113, P9081, DOI 10.1073/pnas.1519235113
   Centers for Disease Control and Prevention CfDCaP, 2020, INT CLIN GUID MAN PA
   Centers for Disease Control and Prevention CfDCaP, 2020, EV REP PERS INV PUI
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Chang LY, 2006, J INFECT DIS, V193, P283, DOI 10.1086/498875
   Channappanavar R, 2015, J INFECT DIS, V212, P1894, DOI 10.1093/infdis/jiv325
   Che XY, 2005, J INFECT DIS, V191, P2033, DOI 10.1086/430355
   Chen SC, 2006, INDOOR AIR, V16, P469, DOI 10.1111/j.1600-0668.2006.00443.x
   Chen WH, 2014, HUM VACC IMMUNOTHER, V10, P648, DOI 10.4161/hv.27464
   Chen WJ, 2006, CLIN INFECT DIS, V42, P1561, DOI 10.1086/503843
   Chen XC, 2004, J INFECT DIS, V189, P1158, DOI 10.1086/380397
   Chen ZM, 2020, WORLD J PEDIATR, V16, P240, DOI 10.1007/s12519-020-00345-5
   Cheng FWT, 2005, ARCH DIS CHILD, V90, P747, DOI 10.1136/adc.2004.063446
   Cheng PKC, 2004, LANCET, V363, P1699, DOI 10.1016/S0140-6736(04)16255-7
   Cheng VCC, 2013, ANTIVIR RES, V100, P407, DOI 10.1016/j.antiviral.2013.08.016
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Chim SSC, 2004, CLIN CHEM, V50, P231, DOI 10.1373/clinchem.2003.025536
   Chim Stephen S. C., 2006, V336, P177
   Chiu SS, 2005, CLIN INFECT DIS, V40, P1721, DOI 10.1086/430301
   Chiu Wa-keung, 2003, Pediatr Crit Care Med, V4, P279, DOI 10.1097/01.PCC.0000077079.42302.81
   Chowell G, 2004, EMERG INFECT DIS, V10, P1258, DOI 10.3201/eid1007.030647
   Chowell G, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0450-0
   Chu CM, 2004, CAN MED ASSOC J, V171, P1349, DOI 10.1503/cmaj.1040398
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Corman VM, 2016, P NATL ACAD SCI USA, V113, P9864, DOI 10.1073/pnas.1604472113
   Cowling BJ, 2015, EUROSURVEILLANCE, V20, P7, DOI 10.2807/1560-7917.ES2015.20.25.21163
   Cristallo A, 1997, MICROBIOLOGICA, V20, P105
   Cyranoski D, 2020, MYSTERY DEEPENS ANIM
   Czub M, 2005, VACCINE, V23, P2273, DOI 10.1016/j.vaccine.2005.01.033
   Davis BM, 2018, INFLUENZA OTHER RESP, V12, P582, DOI 10.1111/irv.12563
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   DeDiego ML, 2008, VIROLOGY, V376, P379, DOI 10.1016/j.virol.2008.03.005
   DeDiego ML, 2007, J VIROL, V81, P1701, DOI 10.1128/JVI.01467-06
   Deng Y, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0056-7
   Dessau RB, 1999, ACTA NEUROL SCAND, V100, P88
   Dijkman R, 2008, J CLIN MICROBIOL, V46, P2368, DOI 10.1128/JCM.00533-08
   Dowell SF, 2004, CLIN INFECT DIS, V39, P652, DOI 10.1086/422652
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Esper F, 2010, J CLIN VIROL, V48, P131, DOI 10.1016/j.jcv.2010.03.007
   Faber M, 2005, J GEN VIROL, V86, P1435, DOI 10.1099/vir.0.80844-0
   Fagbo SF, 2017, J MED VIROL, V89, P195, DOI 10.1002/jmv.24632
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Feng K, 2020, Zhonghua Er Ke Za Zhi, V58, pE007, DOI [10.3760/cma.j.cn112140-20200210-00071, 10.3760/cma.j.issn.0578-1310.2020.0007]
   da Siva LVRF, 2012, J INFECT DIS, V206, P384, DOI 10.1093/infdis/jis274
   Friedman N, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10100515
   Gao WT, 2003, LANCET, V362, P1895, DOI 10.1016/S0140-6736(03)14962-8
   Gaunt ER, 2010, J CLIN MICROBIOL, V48, P2940, DOI 10.1128/JCM.00636-10
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Gorse GJ, 2009, J INFECT DIS, V199, P847, DOI 10.1086/597122
   Greenberg SB, 2016, SEMIN RESP CRIT CARE, V37, P555, DOI 10.1055/s-0036-1584797
   Guan WJ, 2020, N ENGL J MED
   Guan Y, 2004, LANCET, V363, P99, DOI 10.1016/S0140-6736(03)15259-2
   Hai P, 2004, J GEN VIROL, V85, P3109, DOI 10.1099/vir.0.80111-0
   Hashem AM, 2019, J INFECT DIS, V220, P1558, DOI 10.1093/infdis/jiz137
   HASONY HJ, 1982, J MED VIROL, V9, P209, DOI 10.1002/jmv.1890090308
   He YX, 2006, VACCINE, V24, P5498, DOI 10.1016/j.vaccine.2006.04.054
   He YX, 2004, BIOCHEM BIOPH RES CO, V325, P445, DOI 10.1016/j.bbrc.2004.10.052
   Hill A, 2018, SAFETY IMMUNOGENICIT
   Hon KLE, 2003, LANCET, V361, P1701, DOI 10.1016/S0140-6736(03)13364-8
   Huang XC, 2015, J VIROL, V89, P7202, DOI 10.1128/JVI.00854-15
   Hung IFN, 2004, EMERG INFECT DIS, V10, P1550, DOI 10.3201/eid1009.040058
   Hunter JC, 2016, EMERG INFECT DIS, V22, P647, DOI 10.3201/eid2204.151615
   Huynh J, 2012, J VIROL, V86, P12816, DOI 10.1128/JVI.00906-12
   IJAZ MK, 1985, J GEN VIROL, V66, P2743, DOI 10.1099/0022-1317-66-12-2743
   ISAACS D, 1983, ARCH DIS CHILD, V58, P500, DOI 10.1136/adc.58.7.500
   Jaume M, 2012, Hong Kong Med J, V18 Suppl 2, P31
   Jevsnik M, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-46
   Jia N, 2009, TROP MED INT HEALTH, V14, P21, DOI 10.1111/j.1365-3156.2008.02147.x
   Jiang LW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008140
   Jiang X, 2020, J MED VIROL, V92, P476, DOI 10.1002/jmv.25708
   Jin Y, 2012, CLIN MICROBIOL INFEC, V18, P74, DOI 10.1111/j.1469-0691.2011.03541.x
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   KAYE HS, 1971, AM J EPIDEMIOL, V94, P43, DOI 10.1093/oxfordjournals.aje.a121293
   Kim DW, 2016, EMERG INFECT DIS, V22, P100, DOI 10.3201/eid2201.151055
   Kim MN, 2016, ANN LAB MED, V36, P450, DOI 10.3343/alm.2016.36.5.450
   Korea Centers for Disease Control and Prevention, 2015, Osong Public Health Res Perspect, V6, P269, DOI 10.1016/j.phrp.2015.08.006
   Kucharski AJ, 2015, EUROSURVEILLANCE, V20, P14, DOI 10.2807/1560-7917.ES2015.20.25.21167
   Kuypers J, 2007, PEDIATRICS, V119, pE70, DOI 10.1542/peds.2006-1406
   Lamirande EW, 2008, J VIROL, V82, P7721, DOI 10.1128/JVI.00304-08
   Lan JM, 2017, VACCINE, V35, P10, DOI 10.1016/j.vaccine.2016.11.064
   Lan JM, 2015, EBIOMEDICINE, V2, P1438, DOI 10.1016/j.ebiom.2015.08.031
   Lau EHY, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-50
   Lau SKP, 2006, J CLIN MICROBIOL, V44, P2063, DOI 10.1128/JCM.02614-05
   Lau SKP, 2015, J VIROL, V89, P3076, DOI 10.1128/JVI.02420-14
   Lee H, 2015, ACS CHEM BIOL, V10, P1456, DOI 10.1021/cb500917m
   Lee JS, 2017, J CLIN MICROBIOL, V55, P2554, DOI 10.1128/JCM.00667-17
   Lessler J, 2009, LANCET INFECT DIS, V9, P291, DOI 10.1016/S1473-3099(09)70069-6
   Leung CW, 2004, PEDIATRICS, V113, pE535, DOI 10.1542/peds.113.6.e535
   Leung GM, 2004, ANN INTERN MED, V141, P662, DOI 10.7326/0003-4819-141-9-200411020-00006
   Leung TF, 2004, J HOSP INFECT, V56, P215, DOI 10.1016/j.jhin.2003.11.004
   Leung TF, 2009, J CLIN MICROBIOL, V47, P3486, DOI 10.1128/JCM.00832-09
   Li AM, 2004, PEDIATR PULM, V38, P427, DOI 10.1002/ppul.20078
   Li AM, 2005, ARCH DIS CHILD-FETAL, V90, pF461, DOI 10.1136/adc.2005.075309
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lin JT, 2007, ANTIVIR THER, V12, P1107
   Lina B, 1996, J CLIN MICROBIOL, V34, P3007, DOI 10.1128/JCM.34.12.3007-3011.1996
   Liniger M, 2008, VACCINE, V26, P2164, DOI 10.1016/j.vaccine.2008.01.057
   Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616
   Lloyd-Smith JO, 2005, NATURE, V438, P355, DOI 10.1038/nature04153
   Luk HKH, 2019, INFECT GENET EVOL, V71, P21, DOI 10.1016/j.meegid.2019.03.001
   Lundin A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004166
   Luo FL, 2007, CLIN VACCINE IMMUNOL, V14, P990, DOI 10.1128/CVI.00076-07
   Ma CQ, 2014, VACCINE, V32, P2100, DOI 10.1016/j.vaccine.2014.02.004
   Mackay IM, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0439-5
   Majumder MS, 2014, PLOS CURR, V6, P1
   Malik A, 2016, EMERG INFECT DIS, V22, P515, DOI 10.3201/eid2203.151049
   Martin ET, 2013, J INFECT DIS, V207, P982, DOI 10.1093/infdis/jis934
   Maslow J, 2018, EVALUATE SAFETY TOLE
   MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7
   MCINTOSH K, 1970, AM J EPIDEMIOL, V91, P585, DOI 10.1093/oxfordjournals.aje.a121171
   Memish ZA, 2014, CLIN MICROBIOL INFEC, V20, P469, DOI 10.1111/1469-0691.12562
   Memish ZA, 2014, J INFECT DIS, V210, P1590, DOI 10.1093/infdis/jiu292
   Menachery VD, 2017, MSPHERE, V2, DOI 10.1128/mSphere.00346-17
   Modjarrad K, 2016, PHASE 1 OPEN LABEL D
   MONTO AS, 1974, J INFECT DIS, V129, P271, DOI 10.1093/infdis/129.3.271
   Muller MA, 2015, LANCET INFECT DIS, V15, P559, DOI 10.1016/S1473-3099(15)70090-3
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Munster VJ, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0029-1
   Muthumani K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7462
   Nassar MS, 2018, EUR REV MED PHARMACO, V22, P4956, DOI 10.26355/eurrev_201808_15635
   Ng PC, 2004, PEDIATRICS, V113, pE7, DOI 10.1542/peds.113.1.e7
   Ng PC, 2003, ARCH DIS CHILD-FETAL, V88, pF405, DOI 10.1136/fn.88.5.F405
   Oh MD, 2018, KOREAN J INTERN MED, V33, P233, DOI 10.3904/kjim.2018.031
   Ommeh S, 2018, VIROL SIN, V33, P484, DOI 10.1007/s12250-018-0076-4
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Oosterhof L, 2010, BONE MARROW TRANSPL, V45, P1115, DOI 10.1038/bmt.2009.292
   Otter JA, 2016, J HOSP INFECT, V92, P235, DOI 10.1016/j.jhin.2015.08.027
   Park JE, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5484-8
   Payne DC, 2014, J INFECT DIS, V209, P1870, DOI 10.1093/infdis/jiu068
   Peak CM, 2017, P NATL ACAD SCI USA, V114, P4023, DOI 10.1073/pnas.1616438114
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Pfefferle S, 2009, EMERG INFECT DIS, V15, P1377, DOI 10.3201/eid1509.090224
   Pyrc K, 2007, J VIROL, V81, P3051, DOI 10.1128/JVI.01466-06
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Rappe JCF, 2018, VIRUS RES, V246, P28, DOI 10.1016/j.virusres.2018.01.002
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Rider TH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022572
   Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478
   Rocha CD, 2004, INT MICROBIOL, V7, P83
   Saif LJ, 2004, REV SCI TECH OIE, V23, P643, DOI 10.20506/rst.23.2.1513
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   See RH, 2006, J GEN VIROL, V87, P641, DOI 10.1099/vir.0.81579-0
   Shalhoub S, 2015, J ANTIMICROB CHEMOTH, V70, P2129, DOI 10.1093/jac/dkv085
   Shek CC, 2003, PEDIATRICS, V112, pE254, DOI 10.1542/peds.112.4.e254
   Shi ZL, 2008, VIRUS RES, V133, P74, DOI 10.1016/j.virusres.2007.03.012
   Shimizu C, 2005, J INFECT DIS, V192, P1767, DOI 10.1086/497170
   Shirato K, 2013, J VIROL, V87, P12552, DOI 10.1128/JVI.01890-13
   Sohrab SS, 2019, J INFECT PUBLIC HLTH
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Spruth M, 2006, VACCINE, V24, P652, DOI 10.1016/j.vaccine.2005.08.055
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Su Y, 2020, ELECTRON J DIFFER EQ
   Tai WB, 2016, VIROLOGY, V499, P375, DOI 10.1016/j.virol.2016.10.005
   Takasuka N, 2004, INT IMMUNOL, V16, P1423, DOI 10.1093/intimm/dxh143
   Tang XC, 2014, P NATL ACAD SCI USA, V111, pE2018, DOI 10.1073/pnas.1402074111
   Taylor S, 2017, J INFECTION, V74, P29, DOI 10.1016/j.jinf.2016.09.003
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Uddin SML, 2018, CLIN INFECT DIS, V67, P1507, DOI 10.1093/cid/ciy317
   Vabret A, 2003, CLIN INFECT DIS, V36, P985, DOI 10.1086/374222
   Vabret A, 2006, CLIN INFECT DIS, V42, P634, DOI 10.1086/500136
   Vabret A, 2001, J VIROL METHODS, V97, P59, DOI 10.1016/S0166-0934(01)00343-3
   van der Hoek L, 2005, PLOS MED, V2, P764, DOI 10.1371/journal.pmed.0020240
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   van Elden LJR, 2004, J INFECT DIS, V189, P652, DOI 10.1086/381207
   Vijgen L, 2004, INT J INFECT DIS, V8, P217, DOI 10.1016/j.ijid.2004.03.004
   Vijgen L, 2005, J VIROL, V79, P1595, DOI 10.1128/JVI.79.3.1595-1604.2005
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Virlogeux V, 2016, SCI REP-UK, V6, DOI 10.1038/srep35839
   Wallinga J, 2004, AM J EPIDEMIOL, V160, P509, DOI 10.1093/aje/kwh255
   Wang LS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8712
   Wang M, 2005, EMERG INFECT DIS, V11, P1860, DOI 10.3201/eid1112.041293
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang X F, 2020, Zhonghua Er Ke Za Zhi, V58, pE008, DOI 10.3760/cma.j.issn.0578-1310.2020.0008
   Wang YX, 2017, HUM VACC IMMUNOTHER, V13, P153, DOI 10.1080/21645515.2016.1225637
   Warren TK, 2014, NATURE, V508, P402, DOI 10.1038/nature13027
   Wei M, 2020, JAMA
   Wong SF, 2004, AM J OBSTET GYNECOL, V191, P292, DOI 10.1016/j.ajog.2003.11.019
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   World Health Organization, 2020, GLOB SURV HUM INF NO
   World Health Organization, DIS OUTBREAK NE 0208
   World Health Organization, 2020, WHO INT GUID CLIN MA
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Wu PS, 2008, EUR J PEDIATR, V167, P75, DOI 10.1007/s00431-007-0429-8
   Wu Z, 2020, JAMA
   Xiong S, 2004, IMMUNOL LETT, V95, P139, DOI 10.1016/j.imlet.2004.06.014
   Yeh EA, 2004, PEDIATRICS, V113, pE73, DOI 10.1542/peds.113.1.e73
   Ying TL, 2014, J VIROL, V88, P7796, DOI 10.1128/JVI.00912-14
   Yount B, 2005, J VIROL, V79, P14909, DOI 10.1128/JVI.79.23.14909-14922.2005
   Zakhartchouk AN, 2005, J GEN VIROL, V86, P211, DOI 10.1099/vir.0.80530-0
   Zhang NR, 2016, CELL MOL IMMUNOL, V13, P180, DOI 10.1038/cmi.2015.03
   Zhang SF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191789
   Zhao Lin-qing, 2006, Zhonghua Er Ke Za Zhi, V44, P262
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou J, 2005, VACCINE, V23, P3202, DOI 10.1016/j.vaccine.2004.11.075
   Zhou J, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao4966
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
   Zumla A, 2015, LANCET, V386, P995, DOI 10.1016/S0140-6736(15)60454-8
NR 244
TC 174
Z9 178
U1 20
U2 32
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD MAY
PY 2020
VL 39
IS 5
BP 355
EP 368
DI 10.1097/INF.0000000000002660
PG 14
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA LM4RR
UT WOS:000532237900005
PM 32310621
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zhang, ZJ
   Wu, WY
   Hou, JJ
   Zhang, LL
   Li, FF
   Gao, L
   Wu, XD
   Shi, JY
   Zhang, R
   Long, HL
   Lei, M
   Wu, WY
   Guo, DA
   Chen, KX
   Hofmann, LA
   Ci, ZH
AF Zhang, Zi-jia
   Wu, Wen-yong
   Hou, Jin-jun
   Zhang, Lin-lin
   Li, Fei-fei
   Gao, Lei
   Wu, Xing-dong
   Shi, Jing-ying
   Zhang, Rong
   Long, Hua-li
   Lei, Min
   Wu, Wan-ying
   Guo, De-an
   Chen, Kai-xian
   Hofmann, Lewis A.
   Ci, Zhong-hua
TI Active constituents and mechanisms of Respiratory Detox Shot, a
   traditional Chinese medicine prescription, for COVID-19 control and
   prevention: Network -molecular docking-LC-MSE analysis
SO JOURNAL OF INTEGRATIVE MEDICINE-JIM
LA English
DT Article
DE Lung-toxin Dispelling Formula No. 1; COVID-19; 3C-like protease; Network
   pharmacology; Molecular docking; Meridian tropism
ID NF-KAPPA-B; PROTEIN; DATABASE; PHARMACOLOGY; INHIBITION
AB Objective: Lung-toxin Dispelling Formula No. 1, referred to as Respiratory Detox Shot (RDS), was developed based on a classical prescription of traditional Chinese medicine (TCM) and the theoretical understanding of herbal properties within TCM. Therapeutic benefits of using RDS for both disease control and prevention, in the effort to contain the coronavirus disease 2019 (COVID-19), have been shown. However, the biochemically active constituents of RDS and their mechanisms of action are still unclear. The goal of the present study is to clarify the material foundation and action mechanism of RDS.
   Methods: To conduct an analysis of RDS, an integrative analytical platform was constructed, including target prediction, protein-protein interaction (PPI) network, and cluster analysis; further, the hub genes involved in the disease-related pathways were identified, and the their corresponding compounds were used for in vitro validation of molecular docking predictions. The presence of these validated compounds was also measured in samples of the RDS formula to quantify the abundance of the biochemically active constituents. In our network pharmacological study, a total of 26 bioinformatic programs and databases were used, and six networks, covering the entire Zang-fu viscera, were constructed to comprehensively analyze the intricate connections among the compounds-targets-disease pathways-meridians of RDS.
   Results: For all 1071 known chemical constituents of the nine ingredients in RDS, identified from established TCM databases, 157 passed drug-likeness screening and led to 339 predicted targets in the constituent-target network. Forty-two hub genes with core regulatory effects were extracted from the PPI network, and 134 compounds and 29 crucial disease pathways were implicated in the target-constitu ent-disease network. Twelve disease pathways attributed to the Lung-Large Intestine meridians, with six and five attributed to the Kidney-Urinary Bladder and Stomach-Spleen meridians, respectively. One-hundred and eighteen candidate constituents showed a high binding affinity with SARS-coronavirus-2 3-chymotrypsin-like protease (3CL(pro)), as indicated by molecular docking using computational pattern recognition. The in vitro activity of 22 chemical constituents of RDS was validated using the 3CL(pro) inhibition assay. Finally, using liquid chromatography mass spectrometry in data-independent analysis mode, the presence of seven out of these 22 constituents was confirmed and validated in an aqueous decoction of RDS, using reference standards in both non-targeted and targeted approaches.
   Conclusion: RDS acts primarily in the Lung-Large Intestine, Kidney-Urinary Bladder and Stomach-Spleen meridians, with other Zang-fu viscera strategically covered by all nine ingredients. In the context of TCM meridian theory, the multiple components and targets of RDS contribute to RDS's dual effects of health-strengthening and pathogen-eliminating. This results in general therapeutic effects for early COVID-19 control and prevention. (C) 2020 Shanghai Changhai Hospital. Published by Elsevier B.V. All rights reserved.
C1 [Zhang, Zi-jia; Wu, Wen-yong; Hou, Jin-jun; Zhang, Lin-lin; Li, Fei-fei; Gao, Lei; Wu, Xing-dong; Shi, Jing-ying; Zhang, Rong; Long, Hua-li; Lei, Min; Wu, Wan-ying; Guo, De-an; Chen, Kai-xian] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
   [Wu, Wen-yong; Li, Fei-fei; Gao, Lei; Shi, Jing-ying; Zhang, Rong] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Hofmann, Lewis A.; Ci, Zhong-hua] World Hlth Sci Org, Leesburg, VA 20176 USA.
RP Wu, WY; Guo, DA; Chen, KX (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
EM wanyingwu@simm.ac.cn; daguo@simm.ac.cn; kxchen@simm.ac.cn
FU National Key Research and Development Program of China [2018YFC1707900]
FX We are grateful for the financial support from National Key Research and
   Development Program of China (No. 2018YFC1707900).
CR Al-Mandhari A, 2020, E MEDITERR HEALTH J, V26, P136, DOI 10.26719/2020.26.2.136
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Berger SI, 2009, BIOINFORMATICS, V25, P2466, DOI 10.1093/bioinformatics/btp465
   Boezio B, 2017, MOL INFORM, V36, DOI 10.1002/minf.201700048
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Das J, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-92
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Kamburov A, 2013, NUCLEIC ACIDS RES, V41, pD793, DOI 10.1093/nar/gks1055
   Kamburov A, 2009, NUCLEIC ACIDS RES, V37, pD623, DOI 10.1093/nar/gkn698
   Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219
   Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284
   Lagorce D, 2017, BIOINFORMATICS, V33, P3658, DOI 10.1093/bioinformatics/btx491
   Li R, 2014, ASIAN PAC J CANCER P, V15, P9835, DOI 10.7314/APJCP.2014.15.22.9835
   Li S.Y., 2020, ZHONGGUO SHI YAN FAN, DOI [10.13422/j.cnki.syfjx.20200843, DOI 10.13422/J.CNKI.SYFJX.20200843]
   Li S, 2016, CHIN J INTEGR MED, V22, P647, DOI 10.1007/s11655-016-2499-9
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875-5364(13)60037-0]
   Ling CQ, 2020, J INTEGR MED-JIM, V18, P87, DOI 10.1016/j.joim.2020.02.004
   Liu X, 2020, CRYSTAL STRUCTURE CO, DOI [10.2210/pdb6LU7/pdb, DOI 10.2210/PDB6LU7/PDB]
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Luo TT, 2020, CHIN J INTEGR MED, V26, P72, DOI 10.1007/s11655-019-3064-0
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Mukherjee P, 2011, J CHEM INF MODEL, V51, P1376, DOI 10.1021/ci1004916
   OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7
   Peng MH, 2018, ANTIVIR RES, V154, P87, DOI 10.1016/j.antiviral.2018.04.013
   Peng MH, 2017, ANTIVIR RES, V143, P176, DOI 10.1016/j.antiviral.2017.03.026
   Pharmacopoeia NCOC, 2015, PHARM PEOPL REP CHIN, VI
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Reginonal Office for Europe World Health Organization, 2020, 2019 NCOV OUTBR IS E
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Rose AS, 2018, BIOINFORMATICS, V34, P3755, DOI 10.1093/bioinformatics/bty419
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Solt LA, 2008, IMMUNOL RES, V42, P3, DOI 10.1007/s12026-008-8025-1
   Song PP, 2020, BIOSCI TRENDS, V14, P1, DOI 10.5582/bst.2020.01056
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Theerawatanasirikul S, 2020, ANTIVIR RES, V174, DOI 10.1016/j.antiviral.2019.104697
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   WHO World Health Organization, 2020, WHO STAT CAS COVID 1
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu CC, 2016, ANTIVIR RES, V132, P99, DOI 10.1016/j.antiviral.2016.05.007
   Wu WJ, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8010006
   Wu WY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051766
   Wu Y, 2019, NUCLEIC ACIDS RES, V47, pD1110, DOI 10.1093/nar/gky1021
   Xiao YH, 2020, LANCET INFECT DIS, V20, P523, DOI 10.1016/S1473-3099(20)30152-3
   Xiong B, 2003, ACTA PHARMACOL SIN, V24, P497
   Xu HY, 2019, NUCLEIC ACIDS RES, V47, pD976, DOI 10.1093/nar/gky987
   Xu Kaijin, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P147, DOI 10.3785/j.issn.1008-9292.2020.02.02
   Xue RC, 2013, NUCLEIC ACIDS RES, V41, pD1089, DOI 10.1093/nar/gks1100
   Yan HY, 2019, J NAT MED-TOKYO, V73, P487, DOI 10.1007/s11418-019-01287-7
   Yao ZJ, 2016, J COMPUT AID MOL DES, V30, P413, DOI 10.1007/s10822-016-9915-2
   Yates B, 2017, NUCLEIC ACIDS RES, V45, pD619, DOI 10.1093/nar/gkw1033
   Yusuf-Makagiansar H, 2002, MED RES REV, V22, P146, DOI 10.1002/med.10001
   Zeng X, 2018, NUCLEIC ACIDS RES, V46, pD1217, DOI 10.1093/nar/gkx1026
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
   Zhao J, 2020, ZHONG CAO YAO, V51, P829
NR 60
TC 7
Z9 7
U1 10
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2095-4964
J9 J INTEGR MED-JIM
JI J. Integr. Med.-JIM
PD MAY
PY 2020
VL 18
IS 3
BP 229
EP 241
DI 10.1016/j.joim.2020.03.004
PG 13
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA LL8VW
UT WOS:000531833100006
PM 32307268
OA Green Published
DA 2021-01-01
ER

PT J
AU Schmeiser, T
   Broll, M
   Dormann, A
   Fraebel, C
   Hermann, W
   Hudowenz, O
   Keil, F
   Mueller-Ladner, U
   Oezden, F
   Pfeiffer, U
   Saech, J
   Schwarting, A
   Stapfer, G
   Steinchen, N
   Storck-Mueller, K
   Strunk, J
   Thiele, A
   Triantafyllias, K
   Wassenberg, S
   Wilden, E
   Hasseli, R
AF Schmeiser, T.
   Broll, M.
   Dormann, A.
   Fraebel, C.
   Hermann, W.
   Hudowenz, O.
   Keil, F.
   Mueller-Ladner, U.
   Oezden, F.
   Pfeiffer, U.
   Saech, J.
   Schwarting, A.
   Stapfer, G.
   Steinchen, N.
   Storck-Mueller, K.
   Strunk, J.
   Thiele, A.
   Triantafyllias, K.
   Wassenberg, S.
   Wilden, E.
   Hasseli, R.
TI A cross sectional study on patients with inflammatory rheumatic diseases
   in terms of their compliance to their immunsuppressive medication during
   COVID-19 pandemic
SO ZEITSCHRIFT FUR RHEUMATOLOGIE
LA German
DT Article
DE COVID-19; Antirheumatic therapy; Rheumatic diesease; Patient
   questionnaire
ID INFECTION
AB The current COVID-19 pandemic inherits an unprecedented challenge for the treating rheumatologists. On the one hand, antirheumatic drugs can increase the risk of infection and potentially deteriorate the course of an infection. On the other hand, an active inflammatory rheumatic disease can also increase the risk for an infection. In the recommendations of the German Society for Rheumatology (), it is recommended that our patients continue the antirheumatic therapy to maintain remission or low state of activity despite the pandemic. In this study, patients with inflammatory rheumatic disease were asked in the first weeks of the pandemic on their opinion of their immunomodulating therapy. The result shows that over 90% of the patients followed the recommendation of the rheumatologist to continue the antirheumatic therapy, and only a small percentage of the patients terminated the therapy on their own. This result was independent of the individual anti-rheumatic therapy. Taken together, the results of this study illustrate not only the trustful patient-physician partnership in a threatening situation but also the high impact of state-of-the art recommendations by the respective scientific society.
C1 [Schmeiser, T.; Dormann, A.; Pfeiffer, U.; Thiele, A.] Krankenhaus St Josef Wuppertal, Klin Rheumatol Immunol & Osteol, Wuppertal, Germany.
   [Broll, M.] Praxisklin Mittelhessen, Wetzlar, Germany.
   [Fraebel, C.] UKGM Univ Klinikum Giessen & Marburg, Klin Kardiol & Angiol Standort Giessen, Med Klin 1, Giessen, Germany.
   [Hermann, W.; Hudowenz, O.; Mueller-Ladner, U.; Stapfer, G.; Hasseli, R.] Justus Liebig Univ Giessen, Abt Rheumatol & Klin Immunol, Campus Kerckhoff, Bad Nauheim, Germany.
   [Keil, F.] Tech Univ Darmstadt, Fachgebiet Integrierte Elekt Syst, Darmstadt, Germany.
   [Oezden, F.] Facharzt Praxis Rheumatol & Osteol Nienburg, Nienburg, Germany.
   [Saech, J.] Gemeinschaftspraxis Rheumatol Ctr Leverkusen, Leverkusen, Germany.
   [Schwarting, A.] Univ Med Johannes Gutenberg Univ Mainz, Klin Rheumatol, Med Klin 1, Mainz, Germany.
   [Steinchen, N.] Praxis Rheumatol Kassel, Kassel, Germany.
   [Storck-Mueller, K.] Kompetenzzentrum Rheumatol Bad Endbach, Rheumazentrum Mittelhessen, Bad Endbach, Germany.
   [Strunk, J.] Krankenhaus Porz Rhein Koln, Klin Rheumatol, Cologne, Germany.
   [Schwarting, A.; Triantafyllias, K.] ACURA Rheuma Akutzentrum Bad Kreuznach, Bad Kreuznach, Germany.
   [Wassenberg, S.] Rheumazentrum Ratingen, Ratingen, Germany.
   [Wilden, E.] Rheumapraxis Wilden Koln Ehrenfeld, Cologne, Germany.
RP Hasseli, R (corresponding author), Justus Liebig Univ Giessen, Abt Rheumatol & Klin Immunol, Campus Kerckhoff, Bad Nauheim, Germany.
EM r.hasseli@kerckhoff-klinik.de
CR Accortt NA, 2018, ARTHRIT CARE RES, V70, P679, DOI 10.1002/acr.23426
   Doran MF, 2002, ARTHRITIS RHEUM, V46, P2287, DOI 10.1002/art.10524
   Gavazzi G, 2002, LANCET INFECT DIS, V2, P659, DOI 10.1016/S1473-3099(02)00437-1
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Robert Koch-Institut, 2019, BER EP INFL DEUTSCHL
   Strangfeld A, 2011, ANN RHEUM DIS, V70, P1914, DOI 10.1136/ard.2011.151043
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 8
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-1855
EI 1435-1250
J9 Z RHEUMATOL
JI Z. Rheumatol.
PD MAY
PY 2020
VL 79
IS 4
SI SI
BP 379
EP 384
DI 10.1007/s00393-020-00800-8
PG 6
WC Rheumatology
SC Rheumatology
GA LK4DG
UT WOS:000530810400008
PM 32303821
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Liu, K
   Chen, Y
   Wu, DZ
   Lin, RZ
   Wang, ZS
   Pan, LQ
AF Liu, Kai
   Chen, Ying
   Wu, Duozhi
   Lin, Ruzheng
   Wang, Zaisheng
   Pan, Liqing
TI Effects of progressive muscle relaxation on anxiety and sleep quality in
   patients with COVID-19
SO COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE
LA English
DT Article
DE Progressive muscle relaxation; COVID-19; Anxiety; Sleep quality
AB Background: Patients with Coronavirus Disease 2019(COVID-19) will experience high levels of anxiety and low sleep quality due to isolation treatment. Some sleep-improving drugs may inhibit the respiratory system and worsen the condition. Prolonged bedside instruction may increase the risk of medical infections.
   Objective: To investigate the effect of progressive muscle relaxation on anxiety and sleep quality of COVID-19.
   Methods: In this randomized controlled clinical trial, a total of 51 patients who entered the isolation ward were included in the study and randomly divided into experimental and control groups. The experimental group used progressive muscle relaxation (PMR) technology for 30 min per day for 5 consecutive days. During this period, the control group received only routine care and treatment. Before and after the intervention, the Spielberger State-Trait Anxiety Scale (STAI) and Sleep State Self-Rating Scale (SRSS) were used to measure and record patient anxiety and sleep quality. Finally, data analysis was performed using SPSS 25.0 software.
   Results: The average anxiety score (STAI) before intervention was not statistically significant (P = 0.730), and the average anxiety score after intervention was statistically significant (P < 0.001). The average sleep quality score (SRSS) of the two groups before intervention was not statistically significant (P = 0.838), and it was statistically significant after intervention (P < 0.001).
   Conclusion: Progressive muscle relaxation as an auxiliary method can reduce anxiety and improve sleep quality in patients with COVID-19.
C1 [Liu, Kai; Wu, Duozhi] Hainan Med Coll, Dept Hlth Care Ctr, Hainan Gen Hosp, Hainan Hosp, Haikou, Hainan, Peoples R China.
   [Chen, Ying] Hainan Med Coll, Dept Clin Lab, Hainan Gen Hosp, Hainan Hosp, Haikou, Hainan, Peoples R China.
   [Lin, Ruzheng; Wang, Zaisheng; Pan, Liqing] Hainan Med Coll, Dept Gen Practice, Hainan Gen Hosp, Hainan Hosp, Haikou, Hainan, Peoples R China.
RP Liu, K (corresponding author), Hainan Med Coll, Dept Hlth Care Ctr, Hainan Gen Hosp, Hainan Hosp, Haikou, Hainan, Peoples R China.
EM hmliukai@163.com
CR Aksu NT, 2018, SLEEP BREATH, V22, P695, DOI 10.1007/s11325-017-1614-2
   Chegeni PS, 2018, COMPLEMENT THER CLIN, V31, P64, DOI 10.1016/j.ctcp.2018.01.010
   Cougle JR, 2020, BEHAV THER, V51, P99, DOI 10.1016/j.beth.2019.05.009
   Ferendiuk Ewa, 2019, Folia Med Cracov, V59, P113, DOI 10.24425/fmc.2019.131140
   Hasanpour-Dehkordi Ali, 2019, Br J Nurs, V28, P174, DOI 10.12968/bjon.2019.28.3.174
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Masih T, 2019, STRESS HEALTH, V35, P595, DOI 10.1002/smi.2891
   Metin ZG, 2019, EUR J ONCOL NURS, V42, P116, DOI 10.1016/j.ejon.2019.09.003
   Rajeswari S, 2020, IRAN J NURS MIDWIFE, V25, P23, DOI 10.4103/ijnmr.IJNMR_207_18
   Wilczynska D, 2019, INT J OCCUP MED ENV, V32, P817, DOI 10.13075/ijomeh.1896.01457
   Xie LQ, 2016, WESTERN J NURS RES, V38, P155, DOI 10.1177/0193945914551509
NR 11
TC 11
Z9 11
U1 1
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1744-3881
EI 1873-6947
J9 COMPLEMENT THER CLIN
JI Complement. Ther. Clin. Pract.
PD MAY
PY 2020
VL 39
AR 101132
DI 10.1016/j.ctcp.2020.101132
PG 4
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA LK5JF
UT WOS:000530901500069
PM 32379667
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Yamoah, P
   Alalbila, TM
   Bangalee, V
   Oosthuizen, F
AF Yamoah, Peter
   Alalbila, Thelma Mpoku
   Bangalee, Varsha
   Oosthuizen, Frasia
TI Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance
   Implications: Expert Opinion
SO THERAPEUTIC INNOVATION & REGULATORY SCIENCE
LA English
DT Article
DE COVID-19; Coronaviruses; Pharmacovigilance; Chloroquine;
   Hydroxychloroquine
AB The Coronavirus Disease 2019 (COVID-19) is rapidly spreading throughout the world after emerging in China in December 2019. Currently, there are no approved treatments for COVID-19 based on large clinical trial data, and hence, management involves infection prevention and control measures and supportive care. With anecdotal reports and in vitro studies suggesting that certain medicines already in use for treatment of other conditions could be viable treatment options, there has been an increased demand for these therapies which could have adverse consequences on patients and healthcare systems. Toxicity from these medicines resulting from a mad rush for them at community pharmacies and pressure on physicians to prescribe for individuals who do not have the infection are worth noting. Furthermore, the indiscriminate use of these medicines could result in viral resistance as well as acute shortage such that patients who routinely take them for other conditions may not get them.
C1 [Yamoah, Peter; Alalbila, Thelma Mpoku] Univ Hlth & Allied Sci, Sch Pharm, Ho, Ghana.
   [Yamoah, Peter; Bangalee, Varsha; Oosthuizen, Frasia] Univ KwaZulu Natal, Coll Hlth Sci, Durban, South Africa.
RP Yamoah, P (corresponding author), Univ Hlth & Allied Sci, Sch Pharm, Ho, Ghana.; Yamoah, P (corresponding author), Univ KwaZulu Natal, Coll Hlth Sci, Durban, South Africa.
EM pyamoah@uhas.edu.gh; talalbila@uhas.edu.gh; bangalee@ukzn.ac.za;
   oosthuizenf@ukzn.ac.za
OI Alalbila, Thelma/0000-0002-3769-9367; Yamoah, Peter/0000-0001-6518-5454
CR Beck KL, 2015, OPEN ACCESS J SPORTS, V6, P259, DOI 10.2147/OAJSM.S33605
   Bello Shaibu O, 2010, Afr J Infect Dis, V4, P29
   Cascella M., 2020, STATPEARLS INTERNET
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Clem AS, 2011, J GLOB INFECT DIS, V3, P73, DOI 10.4103/0974-777X.77299
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Curtis C, ARIZONA MAN DIES ING
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Institute of Medicine (US) Committee on Military Nutrition Research, 1999, MIL STRAT SUST NUTR, P16
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lee J, TRUMP MAKES CASE CHL
   Liu D, 2018, DRUG DES DEV THER, V12, P1685, DOI 10.2147/DDDT.S166893
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Phuong JM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215837
   Soto A, BLOOMBERG NEWS
   Stokkermans TJ, 2020, STATPEARLS INTERNET
   Wetsman N, 2020, WHO DECLARES OUTBREA
   White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 22
TC 0
Z9 0
U1 2
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2168-4790
EI 2168-4804
J9 THER INNOV REGUL SCI
JI Ther. Innov. Regul. Sci.
PD NOV
PY 2020
VL 54
IS 6
SI SI
BP 1359
EP 1362
DI 10.1007/s43441-020-00158-8
EA MAY 2020
PG 4
WC Medical Informatics; Pharmacology & Pharmacy
SC Medical Informatics; Pharmacology & Pharmacy
GA OZ3JD
UT WOS:000531576800001
PM 33258095
OA Bronze
DA 2021-01-01
ER

PT J
AU Ma, J
   Xia, P
   Zhou, YZ
   Liu, ZY
   Zhou, X
   Wang, JL
   Li, TS
   Yan, XW
   Chen, LM
   Zhang, SY
   Qin, Y
   Li, XM
AF Ma, Jie
   Xia, Peng
   Zhou, Yangzhong
   Liu, Zhengyin
   Zhou, Xiang
   Wang, Jinglan
   Li, Taisheng
   Yan, Xiaowei
   Chen, Limeng
   Zhang, Shuyang
   Qin, Yan
   Li, Xuemei
TI Potential effect of blood purification therapy in reducing cytokine
   storm as a late complication of critically ill COVID-19
SO CLINICAL IMMUNOLOGY
LA English
DT Letter
DE Critically ill COVID-19; Cytokine storm; Blood purification; Plasma
   exchange; IL-6
C1 [Ma, Jie; Xia, Peng; Zhou, Yangzhong; Chen, Limeng; Qin, Yan; Li, Xuemei] Chinese Acad Med Sci, Dept Nephrol, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China.
   [Liu, Zhengyin; Li, Taisheng] Chinese Acad Med Sci, Dept Infect Dis, Peking Union Med Coll Hosp, Beijing, Peoples R China.
   [Zhou, Xiang] Chinese Acad Med Sci, Dept Intens Care Med, Peking Union Med Coll Hosp, Beijing, Peoples R China.
   [Wang, Jinglan] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Pulm & Crit Care Med, Beijing, Peoples R China.
   [Yan, Xiaowei; Zhang, Shuyang] Chinese Acad Med Sci, Dept Cardiol, Peking Union Med Coll Hosp, Beijing, Peoples R China.
RP Qin, Y (corresponding author), Chinese Acad Med Sci, Dept Nephrol, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China.
EM qinyanbeijing@126.com
OI Zhou, Yangzhong/0000-0003-3497-0075
FU National Natural Sciences Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81970621, 81801632]
FX This work was supported by the National Natural Sciences Foundation of
   China (grant no.81970621 to Y.Q., no.81801632 to Yz.Z.)
CR Bucciarelli S, 2006, ARTHRITIS RHEUM, V54, P2568, DOI 10.1002/art.22018
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Guan WJ, 2020, N ENGL J MED, V28
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Monard C, 2019, BLOOD PURIFICAT, V47, P2, DOI 10.1159/000499520
   Schwindenhammer V, 2019, BLOOD PURIFICAT, V47, P29, DOI 10.1159/000499510
   Wu C., 2020, JAMA INTERN MED, DOI [10.1001/jamainternmed.2020.0994he, DOI 10.1001/JAMAINTERNMED.2020.0994HE]
   Xu X, 2020, EFFECTIVE TREATMENT
   Yang X., 2020, LANCET RESP MED, V24
NR 9
TC 48
Z9 50
U1 4
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD MAY
PY 2020
VL 214
AR 108408
DI 10.1016/j.clim.2020.108408
PG 3
WC Immunology
SC Immunology
GA LK2MA
UT WOS:000530692800018
PM 32247038
OA Green Published
DA 2021-01-01
ER

PT J
AU Brown, JD
AF Brown, Joshua D.
TI Antihypertensive drugs and risk of COVID-19?
SO LANCET RESPIRATORY MEDICINE
LA English
DT Letter
ID MEDICATION
C1 [Brown, Joshua D.] Univ Florida, Ctr Drug Evaluat & Safety, Dept Pharmaceut Outcomes & Policy, Coll Pharm, Gainesville, FL 32606 USA.
RP Brown, JD (corresponding author), Univ Florida, Ctr Drug Evaluat & Safety, Dept Pharmaceut Outcomes & Policy, Coll Pharm, Gainesville, FL 32606 USA.
EM joshua.brown@ufl.edu
CR Beeftink MMA, 2017, HYPERTENSION, V69, P927, DOI 10.1161/HYPERTENSIONAHA.116.08793
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   van der Wardt V, 2017, J HYPERTENS, V35, P1742, DOI 10.1097/HJH.0000000000001405
   Vaur L, 1998, AM J HYPERTENS, V11, P165, DOI 10.1016/S0895-7061(97)00420-2
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
NR 5
TC 13
Z9 13
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-2600
J9 LANCET RESP MED
JI Lancet Resp. Med.
PD MAY
PY 2020
VL 8
IS 5
BP E28
EP E28
DI 10.1016/S2213-2600(20)30158-2
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA LK7VL
UT WOS:000531069600002
PM 32222168
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Fang, L
   Karakiulakis, G
   Roth, M
AF Fang, Lei
   Karakiulakis, George
   Roth, Michael
TI Antihypertensive drugs and risk of COVID-19? Reply
SO LANCET RESPIRATORY MEDICINE
LA English
DT Letter
ID ANGIOTENSIN-CONVERTING ENZYME; KIDNEY; ACE2
C1 [Fang, Lei; Roth, Michael] Univ Hosp Basel, Dept Biomed & Internal Med, Pulm Cell Res & Pneumol, CH-4031 Basel, Switzerland.
   [Karakiulakis, George] Aristotle Univ Thessaloniki, Sch Med, Dept Pharmacol, Thessaloniki, Greece.
RP Roth, M (corresponding author), Univ Hosp Basel, Dept Biomed & Internal Med, Pulm Cell Res & Pneumol, CH-4031 Basel, Switzerland.
EM michael.roth@usb.ch
RI Roth, Michael/H-8657-2019
OI Roth, Michael/0000-0002-8139-2821
CR Anguiano L, 2015, NEPHROL DIAL TRANSPL, V30, P1176, DOI 10.1093/ndt/gfv025
   Bernstein KE, 2018, NAT REV NEPHROL, V14, P325, DOI 10.1038/nrneph.2018.15
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fedson DS, 2020, MBIO, V11, DOI 10.1128/mBio.00398-20
   Guan W, 2020, NEW ENGL J MED, DOI [10.1056/NRJMED2002032, DOI 10.1056/NRJMED2002032]
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hristova M, 2019, CLIN EXP HYPERTENS, V41, P662, DOI 10.1080/10641963.2018.1529782
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Silva ACSE, 2016, PHARMACOL RES, V107, P154, DOI 10.1016/j.phrs.2016.03.018
   University of Basel, 2020, IB COVID 19
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Vuille-Dit-Bille RN, 2015, AMINO ACIDS, V47, P693, DOI 10.1007/s00726-014-1889-6
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 22
TC 14
Z9 14
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-2600
J9 LANCET RESP MED
JI Lancet Resp. Med.
PD MAY
PY 2020
VL 8
IS 5
BP E32
EP E33
DI 10.1016/S2213-2600(20)30159-4
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA LK7VL
UT WOS:000531069600005
PM 32222169
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lo, KB
   McCullough, PA
   Rangaswami, J
AF Lo, Kevin Bryan
   McCullough, Peter A.
   Rangaswami, Janani
TI Antihypertensive drugs and risk of COVID-19?
SO LANCET RESPIRATORY MEDICINE
LA English
DT Letter
C1 [Lo, Kevin Bryan; Rangaswami, Janani] Einstein Med Ctr, Dept Med, Philadelphia, PA 19141 USA.
   [McCullough, Peter A.] Baylor Heart & Vasc Inst, Dallas, TX USA.
   Thomas Jefferson Univ, Sidney Kimmel Coll, Philadelphia, PA 19107 USA.
RP Lo, KB (corresponding author), Einstein Med Ctr, Dept Med, Philadelphia, PA 19141 USA.
EM lokevinb@einstein.edu
OI Lo, Kevin Bryan/0000-0001-7088-6677
CR Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Jepsen P, 2004, HEART, V90, P956, DOI 10.1136/hrt.2003.017269
   Kleine-Weber H, NOVEL CORONAVIRUS 20, DOI [10.1101/2020.01.31.929042v1, DOI 10.1101/2020.01.31.929042V1]
   Oliveros E, 2020, CARDIORENAL MED, V10, P69, DOI 10.1159/000504167
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 8
TC 7
Z9 7
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-2600
J9 LANCET RESP MED
JI Lancet Resp. Med.
PD MAY
PY 2020
VL 8
IS 5
BP E29
EP E29
DI 10.1016/S2213-2600(20)30156-9
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA LK7VL
UT WOS:000531069600003
PM 32222167
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tignanelli, CJ
   Ingraham, NE
   Sparks, MA
   Reilkoff, R
   Bezdicek, T
   Benson, B
   Schacker, T
   Chipman, JG
   Puskarich, MA
AF Tignanelli, Christopher J.
   Ingraham, Nicholas E.
   Sparks, Matthew A.
   Reilkoff, Ronald
   Bezdicek, Tamara
   Benson, Bradley
   Schacker, Timothy
   Chipman, Jeffrey G.
   Puskarich, Michael A.
TI Antihypertensive drugs and risk of COVID-19?
SO LANCET RESPIRATORY MEDICINE
LA English
DT Letter
ID ANGIOTENSIN-CONVERTING ENZYME-2; SARS; RECEPTOR
C1 [Tignanelli, Christopher J.; Chipman, Jeffrey G.] Univ Minnesota, Dept Surg, Div Acute Care Surg, Box 242 UMHC, Minneapolis, MN 55455 USA.
   [Tignanelli, Christopher J.] Univ Minnesota, Inst Hlth Informat, Minneapolis, MN 55455 USA.
   [Ingraham, Nicholas E.; Reilkoff, Ronald] Univ Minnesota, Dept Med, Div Pulm & Crit Care, Box 736 UMHC, Minneapolis, MN 55455 USA.
   [Benson, Bradley] Univ Minnesota, Dept Med, Div Gen Internal Med, Box 736 UMHC, Minneapolis, MN 55455 USA.
   [Schacker, Timothy] Univ Minnesota, Dept Med, Div Med & Infect Dis, Box 736 UMHC, Minneapolis, MN 55455 USA.
   [Puskarich, Michael A.] Univ Minnesota, Dept Emergency Med, Minneapolis, MN 55455 USA.
   [Sparks, Matthew A.] Duke Univ, Dept Med, Div Nephrol, Durham, NC USA.
   [Bezdicek, Tamara] Fairview Southdale, Dept Pharm, Edina, MN USA.
   [Puskarich, Michael A.] Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA.
RP Tignanelli, CJ (corresponding author), Univ Minnesota, Dept Surg, Div Acute Care Surg, Box 242 UMHC, Minneapolis, MN 55455 USA.; Tignanelli, CJ (corresponding author), Univ Minnesota, Inst Hlth Informat, Minneapolis, MN 55455 USA.
EM ctignane@umn.edu
RI Ingraham, Nicholas/ABG-6337-2020; Sparks, Matthew A./H-8865-2019;
   Puskarich, Michael/N-7849-2014
OI Ingraham, Nicholas/0000-0002-0292-0594; Sparks, Matthew
   A./0000-0003-2075-2691; Puskarich, Michael/0000-0001-6358-4670;
   Tignanelli, Christopher/0000-0002-8079-5565; Bezdicek,
   Tamara/0000-0003-2917-5237
FU AHRQ HHSUnited States Department of Health & Human ServicesAgency for
   Healthcare Research & Quality [K12 HS026379] Funding Source: Medline;
   NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [T32 HL007741] Funding Source: Medline
CR Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuba K, 2006, J MOL MED, V84, P814, DOI 10.1007/s00109-006-0094-9
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Ramchand J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198144
   Walters TE, 2017, EUROPACE, V19, P1280, DOI 10.1093/europace/euw246
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
NR 10
TC 21
Z9 22
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-2600
J9 LANCET RESP MED
JI Lancet Resp. Med.
PD MAY
PY 2020
VL 8
IS 5
BP E30
EP E31
DI 10.1016/S2213-2600(20)30153-3
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA LK7VL
UT WOS:000531069600004
PM 32222166
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Monti, S
   Balduzzi, S
   Delvino, P
   Bellis, E
   Quadrelli, VS
   Montecucco, C
AF Monti, Sara
   Balduzzi, Silvia
   Delvino, Paolo
   Bellis, Elisa
   Quadrelli, Verdiana Serena
   Montecucco, Carlomaurizio
TI Clinical course of COVID-19 in a series of patients with chronic
   arthritis treated with immunosuppressive targeted therapies
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Letter
C1 [Monti, Sara] IRCCS Fdn Policlin San Matteo, Dept Rheumatol, Pavia, Italy.
   [Balduzzi, Silvia] IRCCS Policlin San Matteo, Dept Rheumatol, Pavia, Italy.
   [Delvino, Paolo; Bellis, Elisa; Quadrelli, Verdiana Serena; Montecucco, Carlomaurizio] Fdn IRCCS Policlin San Matteo, Dept Rheumatol, Pavia, Italy.
RP Monti, S (corresponding author), IRCCS Fdn Policlin S Matteo, Rheumatol, Pavia 27100, Italy.
EM sara.saramonti@gmail.com
RI Monti, Sara/D-4505-2019
OI Monti, Sara/0000-0002-1800-6772
CR D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Memoli MJ, 2014, CLIN INFECT DIS, V58, P214, DOI 10.1093/cid/cit725
   Norena I, 2018, EXPERT REV ANTI-INFE, V16, P781, DOI 10.1080/14787210.2018.1521270
   Yuan Y, 2020, J HAZARD MATER, V382, DOI 10.1016/j.jhazmat.2019.121028
NR 5
TC 129
Z9 128
U1 2
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD MAY
PY 2020
VL 79
IS 5
BP 667
EP +
DI 10.1136/annrheumdis-2020-217424
PG 2
WC Rheumatology
SC Rheumatology
GA LL2MQ
UT WOS:000531391400028
PM 32241793
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Rothlin, RP
   Vetulli, HM
   Duarte, M
   Pelorosso, FG
AF Rothlin, Rodolfo Pedro
   Vetulli, Hector Miguel
   Duarte, Mariano
   Pelorosso, Facundo German
TI Telmisartan as tentative angiotensin receptor blocker therapeutic for
   COVID-19
SO DRUG DEVELOPMENT RESEARCH
LA English
DT Article
DE ACE2; angiotensin II; ARDS; clinical trial; COVID-19; SARS-CoV-2;
   telmisartan
ID II TYPE-1 RECEPTOR
AB In late 2019, a new coronavirus emerged in Wuhan Province, China, causing lung complications similar to those produced by the SARS coronavirus in the 2002-2003 epidemic. This new disease was named COVID-19 and the causative virus SARS-CoV-2. The SARS-CoV-2 virus enters the airway and binds, by means of the S protein on its surface to the membrane protein ACE2 in type 2 alveolar cells. The S protein-ACE2 complex is internalized by endocytosis leading to a partial decrease or total loss of the enzymatic function ACE2 in the alveolar cells and in turn increasing the tissue concentration of pro-inflammatory angiotensin II by decreasing its degradation and reducing the concentration of its physiological antagonist angiotensin 1-7. High levels of angiotensin II on the lung interstitium can promote apoptosis initiating an inflammatory process with release of proinflammatory cytokines, establishing a self-powered cascade, leading eventually to ARDS. Recently, Gurwitz proposed the tentative use of agents such as losartan and telmisartan as alternative options for treating COVID-19 patients prior to development of ARDS. In this commentary article, the authors make the case for the election of telmisartan as such alternative on the basis of its pharmacokinetic and pharmacodynamic properties and present an open-label randomized phase II clinical trial for the evaluation of telmisartan in COVID-19 patients (NCT04355936).
C1 [Rothlin, Rodolfo Pedro] Asociac Med Argentina, Soc Argentina Farmacol Clin, Buenos Aires, DF, Argentina.
   [Vetulli, Hector Miguel] Sanatorio Otamendi & Miroli, Serv Electrofisiol Cardiaca Arritmias & Marcapaso, Buenos Aires, DF, Argentina.
   [Duarte, Mariano] Univ Buenos Aires, Fac Med, Hosp Clin Jose de San Martin, Buenos Aires, DF, Argentina.
   [Duarte, Mariano] Univ Buenos Aires, Fac Med, Segunda Catedra Fisiol, Buenos Aires, DF, Argentina.
   [Pelorosso, Facundo German] Hosp Alta Complej Calafate SAMIC, Dept Pathol, Santa Cruz, Argentina.
RP Rothlin, RP (corresponding author), Asociac Med Argentina, Soc Argentina Farmacol Clin, Buenos Aires, DF, Argentina.
EM safc@ama-med.org.ar
CR Cardoso VG, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882-018-0968-4
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Gurwitz D., 2020, DRUG DEV RES
   Imayama I, 2006, CARDIOVASC RES, V72, P184, DOI 10.1016/j.cardiores.2006.07.014
   Kakuta H, 2005, INT J CLIN PHARM RES, V25, P41
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Lu C.-C., 2020, J CHINESE MED ASS JC, P1, DOI 10.1097/JCMA.0000000000000318
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Michel MC, 2013, PHARMACOL REV, V65, P809, DOI 10.1124/pr.112.007278
   Paz Ocaranza Maria, 2020, Nat Rev Cardiol, V17, P116, DOI 10.1038/s41569-019-0244-8
   Schumacher H, 2008, BLOOD PRESSURE, V17, P32, DOI 10.1080/08038020802144383
   Sharpe M, 2001, DRUGS, V61, P1501, DOI 10.2165/00003495-200161100-00009
   Stangier J, 2000, J INT MED RES, V28, P149, DOI 10.1177/147323000002800401
   Tikellis C, 2011, CURR OPIN NEPHROL HY, V20, P62, DOI 10.1097/MNH.0b013e328341164a
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Zhang P, 2020, CIRCULATION RES
NR 19
TC 14
Z9 14
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4391
EI 1098-2299
J9 DRUG DEVELOP RES
JI Drug Dev. Res.
PD NOV
PY 2020
VL 81
IS 7
BP 768
EP 770
DI 10.1002/ddr.21679
EA MAY 2020
PG 3
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OP0AZ
UT WOS:000529601500001
PM 32356926
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Moeinzadeh, F
   Dezfouli, M
   Naimi, A
   Shahidi, S
   Moradi, H
AF Moeinzadeh, Firouzeh
   Dezfouli, Majid
   Naimi, Azar
   Shahidi, Shahrzad
   Moradi, Hazhir
TI Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing
   Immunosuppression Therapy, a Case Report
SO IRANIAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE COVID-19; glomerulonephritis; immunosuppression
AB During the COVID-19 pandemic, we had a 25 years old male case without any underlying disease or history of autoimmune disease in COVID-19 Clinic, Isfahan, Iran. He presented with arthralgia and weakness so we started COVID-19 therapeutic regimen. In his hospitalization, creatinine increases and abnormalities in random urine sediment was seen. Methylprednisolone and cyclophosphamide were prescribed due to suspected glomerulonephritis. After renal biopsy the diagnose was confirmed as crescentic proliferative glomerulonephritis. The patient also, underwent plasmapheresis and intravenous immunoglobulin injection. He was discharged healthy without development of new pulmonary symptoms despite irnmunosuppressive treatment.
C1 [Moeinzadeh, Firouzeh; Shahidi, Shahrzad; Moradi, Hazhir] Isfahan Univ Med Sci, Isfahan Kidney Dis Res Ctr, Esfahan, Iran.
   [Moeinzadeh, Firouzeh; Dezfouli, Majid; Shahidi, Shahrzad] Isfahan Univ Med Sci, Dept Internal Med, Esfahan, Iran.
   [Naimi, Azar] Isfahan Univ Med Sci, Dept Pathol, Esfahan, Iran.
   [Moradi, Hazhir] Isfahan Univ Med Sci, Med Sch, Esfahan, Iran.
RP Moradi, H (corresponding author), Isfahan Univ Med Sci, 20,8th Alley,Amadegah St, Esfahan, Iran.
EM moradi.hazhir@gmail.com
OI Naimi, Azar/0000-0002-7717-9112; Moradi, Hazhir/0000-0002-3306-7493
CR Administration FaD, NEW YORK SARS COV 2
   Centers for Disease Control and Prevention, 2020, CLIN SPEC NOV COR 20
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   education Imoham, 2020, NEW COR VIR COUNTR G
   Fervenza FC, 2016, EVALUATION TREATMENT
   Holshue M. L., 2020, NEW ENGLAND J MED
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jennette J, 2007, HEPTINSTALLS PATHOLO, P643
   Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715
   Michaels MG, 2020, AM J TRANSPLANTATION
   Organization WH, 2005, 2 INT HLTH REG 2005
   Rothe C., 2020, NEW ENGLAND J MED
   World Health Organization, 2020, COR DIS 2019 COVID 1
NR 13
TC 5
Z9 5
U1 0
U2 2
PU IRANIAN SOC NEPHROLGY
PI TEHRAN
PA APT 12, NO 63, SHAHEED TOUSI ST, DR GHARIB ST, KESHAVARZ BLVD, TEHRAN,
   1419783311, IRAN
SN 1735-8582
EI 1735-8604
J9 IRAN J KIDNEY DIS
JI Iran. J. Kidney Dis.
PD MAY
PY 2020
VL 14
IS 3
BP 239
EP 242
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA LK5EA
UT WOS:000530887600012
PM 32361703
DA 2021-01-01
ER

PT J
AU Mitja, O
   Clotet, B
AF Mitja, Oriol
   Clotet, Bonaventura
TI Use of antiviral drugs to reduce COVID-19 transmission
SO LANCET GLOBAL HEALTH
LA English
DT Letter
C1 [Mitja, Oriol; Clotet, Bonaventura] Hosp Badalona Germans Trias & Pujol, Fight AIDS Fdn, Infect Dis Dept, Badalona, Spain.
   [Clotet, Bonaventura] IrsiCaixa Fdn, Barcelona, Spain.
RP Mitja, O (corresponding author), Hosp Badalona Germans Trias & Pujol, Fight AIDS Fdn, Infect Dis Dept, Badalona, Spain.
EM omitja@flsida.org
CR Bi Q, 2020, EPIDEMIOLOGY TRANSMI, DOI [10.1101/2020.03.03.20028423, DOI 10.1101/2020.03.03.20028423]
   Hellewell J, 2020, LANCET GLOB HEALTH, V8, pE488, DOI 10.1016/S2214-109X(20)30074-7
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   TETT SE, 1989, BRIT J CLIN PHARMACO, V27, P771, DOI 10.1111/j.1365-2125.1989.tb03439.x
   Welliver R, 2001, JAMA-J AM MED ASSOC, V285, P748, DOI 10.1001/jama.285.6.748
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 6
TC 53
Z9 54
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2214-109X
J9 LANCET GLOB HEALTH
JI Lancet Glob. Health
PD MAY
PY 2020
VL 8
IS 5
BP E639
EP E640
DI 10.1016/S2214-109X(20)30114-5
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA LH8VX
UT WOS:000529064000014
PM 32199468
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Von Lilienfeld-Toal, M
   Vehreschild, JJ
   Cornely, O
   Pagano, L
   Compagno, F
   Hirsch, HH
   Pagliuca, A
   Akan, H
   Lagrou, K
   Hoenigl, M
   Klimko, N
   Verweij, P
   Duarte, R
   Zimmerli, S
   Bretagne, S
   Racil, Z
AF Von Lilienfeld-Toal, Marie
   Vehreschild, Joerg Janne
   Cornely, Oliver
   Pagano, Livio
   Compagno, Francesca
   Hirsch, Hans H.
   Pagliuca, Antonio
   Akan, Hamdi
   Lagrou, Katrin
   Hoenigl, Martin
   Klimko, Nikolai
   Verweij, Paul
   Duarte, Rafael
   Zimmerli, Stefan
   Bretagne, Stephane
   Racil, Zdenek
CA EHA Infect Dis Sci Working Grp
TI Frequently asked questions regarding SARS-CoV-2 in cancer
   patients-recommendations for clinicians caring for patients with
   malignant diseases
SO LEUKEMIA
LA English
DT Article
ID RESPIRATORY SYNCYTIAL VIRUS; WORKING PARTY AGIHO; EUROPEAN CONFERENCE;
   ADVERSE EVENTS; GERMAN SOCIETY; GUIDELINES; COVID-19; INFECTIONS; ECIL;
   RUXOLITINIB
AB Since early 2020, the SARS-CoV-2 pandemic has a massive impact on health care systems worldwide. Patients with malignant diseases are assumed to be at increased risk for a worse outcome of SARS-CoV-2 infection, and therefore, guidance regarding prevention and management of the infection as well as safe administration of cancer-therapy is required. Here, we provide recommendations for the management of patients with malignant disease in the times of COVID-19. These recommendations were prepared by an international panel of experts and then consented by the EHA Scientific Working Group on Infection in Hematology. The primary aim is to enable clinicians to provide optimal cancer care as safely as possible, since the most important protection for patients with malignant disease is the best-possible control of the underlying disease.
C1 [Von Lilienfeld-Toal, Marie] Univ Klinikum Jena, Klin Innere Med 2, Abt Hamatol & Internist Onkol, Jena, Germany.
   [Von Lilienfeld-Toal, Marie] Leibniz Inst Infekt Biol & Naturstoff Forschung, Hans Knoll Inst, Jena, Germany.
   [Vehreschild, Joerg Janne] Goethe Univ Frankfurt, Dept Internal Med, Hematol Oncol, Frankfurt, Germany.
   [Vehreschild, Joerg Janne; Cornely, Oliver] Univ Cologne, Dept Internal Med 1, Excellence Ctr Med Mycol ECMM, Fac Med, Cologne, Germany.
   [Vehreschild, Joerg Janne; Cornely, Oliver] Univ Cologne, Univ Hosp Cologne, Cologne, Germany.
   [Vehreschild, Joerg Janne; Cornely, Oliver] German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany.
   [Cornely, Oliver] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany.
   [Cornely, Oliver] Univ Cologne, Clin Trials Ctr Cologne ZKS Koln, Cologne, Germany.
   [Cornely, Oliver] EHA Infect Dis Sci Working Grp, Cologne, Germany.
   [Pagano, Livio] Univ Cattolica Sacro Cuore, Dept Hematol, Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy.
   [Compagno, Francesca] Fdn IRCCS Policlin San Matteo, Pediat Hematol Oncol, Pavia, Italy.
   [Hirsch, Hans H.] Univ Hosp Basel, Lab Med, Clin Virol, Basel, Switzerland.
   [Hirsch, Hans H.] Univ Basel, Dept Biomed, Transplantat & Clin Virol, Basel, Switzerland.
   [Hirsch, Hans H.] Univ Hosp Basel, Infect Dis & Hosp Epidemiol, Basel, Switzerland.
   [Pagliuca, Antonio] Kings Coll Hosp NHS Fdn Trust, Dept Haematol Med, London, England.
   [Akan, Hamdi] Ankara Univ, Hematol Clin Res Unit, Cebeci Campus, Ankara, Turkey.
   [Lagrou, Katrin] Katholieke Univ Leuven, Excellence Ctr Med Mycol ECMM, LabClin Bacteriol & Mycol, Dept Microbiol Immunol & Transplantat, Leuven, Belgium.
   [Hoenigl, Martin] Med Univ Graz, Dept Internal Med, Sect Infect Dis & Trop Med, Graz, Austria.
   [Klimko, Nikolai] North Western State Med Univ, Dept Clin Mycol Allergol & Immunol, St Petersburg, Russia.
   [Verweij, Paul] Ctr Expertise Mycol Radboudumc CWZ, Dept Med Microbiol, Excellence Ctr Med Mycol ECMM, Nijmegen, Netherlands.
   [Duarte, Rafael] Hosp Univ Puerta Hierro, Dept Hematol, Madrid, Spain.
   [Zimmerli, Stefan] Univ Hosp Bern, Dept Infect Dis, Bern, Switzerland.
   [Bretagne, Stephane] Hop St Louis, Lab Parasitol Mycol, Grp Hosp Lariboisiere, Inst Pasteur,Mol Mycol Unit,Dept Mycol,CNRS UMR20, St Louis, France.
   [Bretagne, Stephane] Univ Sorbonne Paris Cite, AP HP, Paris, France.
   [Racil, Zdenek] Inst Hematol & Blood Transfus, Prague, Czech Republic.
RP Von Lilienfeld-Toal, M (corresponding author), Univ Klinikum Jena, Klin Innere Med 2, Abt Hamatol & Internist Onkol, Jena, Germany.; Von Lilienfeld-Toal, M (corresponding author), Leibniz Inst Infekt Biol & Naturstoff Forschung, Hans Knoll Inst, Jena, Germany.
EM Marie.von_Lilienfeld-Toal@med.uni-jena.de
RI Hoenigl, Martin/E-8802-2010; Cornely, Oliver A/J-5095-2013; pagliuca,
   antonio/F-8886-2013
OI Hoenigl, Martin/0000-0002-1653-2824; Cornely, Oliver
   A/0000-0001-9599-3137; Hirsch, Hans H./0000-0003-0883-0423; pagliuca,
   antonio/0000-0003-2519-0333
FU Projekt DEAL
FX The authors thank Prof. Bernhard Wormann and Prof. Il-Kang Na for the
   discussion of subtopics and Dr. Marouan Zarrouk for the preparation of
   figures. The authors are grateful to the executive committee of the EHA
   Infectious Disease Working Group for their input. Open access funding
   provided by Projekt DEAL.
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Battegay M, 2020, SWISS MED WKLY, V150, DOI [10.4414/smw.w20203, 10.4414/smw.2020.20203]
   Birndt S, 2020, J CANCER RES CLIN, V146, P1065, DOI 10.1007/s00432-020-03139-4
   Brioli A, 2019, ANN HEMATOL, V98, P713, DOI 10.1007/s00277-019-03621-1
   Chen J, 2020, LANCET INFECT DIS
   Cordonnier C, 2019, LANCET INFECT DIS, V19, pE200, DOI 10.1016/S1473-3099(18)30600-5
   EMA, 2018, GUID COR SMPC HUM NO
   Engelhard D, 2013, TRANSPL INFECT DIS, V15, P219, DOI 10.1111/tid.12054
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hermann B, 2017, EUR J CLIN MICROBIOL, V36, P565, DOI 10.1007/s10096-016-2833-3
   Hirsch HH, 2013, CLIN INFECT DIS, V56, P258, DOI 10.1093/cid/cis844
   Ison MG, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00042-19
   Jefferson T, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006207.pub4
   La Rosee P, 2019, BLOOD, V133, P2465, DOI 10.1182/blood.2018894618
   La Rosee P, 2016, BLOOD, V127, P1626, DOI 10.1182/blood-2016-02-697151
   Lansbury LE, 2019, CRIT CARE MED, V3
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P371, DOI 10.1016/j.jmii.2020.02.011
   Lehners N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148258
   Li W, 2020, PEDIATR RADIOL, V50, P796, DOI 10.1007/s00247-020-04656-7
   Li Y, 2020, ACROSS LANG CULT, V21, P1, DOI [10.1556/084.2020.00001, 10.2214/AJR.20.22954]
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Maschmeyer G, 2019, LEUKEMIA, V33, P844, DOI 10.1038/s41375-019-0388-x
   Mayer JL, 2014, ROFO-FORTSCHR RONTG, V186, P686, DOI 10.1055/s-0033-1356353
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mikulska M, 2019, LANCET INFECT DIS, V19, pE188, DOI 10.1016/S1473-3099(18)30601-7
   Mikulska M, 2018, J INFECTION, V76, P20, DOI 10.1016/j.jinf.2017.10.009
   Neumann S, 2013, ANN HEMATOL, V92, P433, DOI 10.1007/s00277-013-1698-0
   Ogimi C, 2018, BIOL BLOOD MARROW TR, V24, P2293, DOI 10.1016/j.bbmt.2018.05.016
   Song YG, 2020, INFECT CHEMOTHER, V52, P110, DOI 10.3947/ic.2020.52.1.110
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Steegmann JL, 2016, LEUKEMIA, V30, P1648, DOI 10.1038/leu.2016.104
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Tefferi A, 2011, MAYO CLIN PROC, V86, P1188, DOI 10.4065/mcp.2011.0518
   Vehreschild JJ, 2014, ANN ONCOL, V25, P1709, DOI 10.1093/annonc/mdu035
   von Lilienfeld-Toal M, 2016, EUR J CANCER, V67, P200, DOI 10.1016/j.ejca.2016.08.015
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xia W, 2020, PEDIATR PULM, V55, P1169, DOI 10.1002/ppul.24718
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Xie XZ, 2020, RADIOLOGY, V296, pE41, DOI 10.1148/radiol.2020200343
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Zhai ZG, 2020, THROMB HAEMOSTASIS, V120, P937, DOI 10.1055/s-0040-1710019
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou Y, 2020, CELL CYCLE, V19, P2589, DOI 10.1080/15384101.2020.1804720
   Zhu F, 2020, J MED VIROL, V92, P529, DOI 10.1002/jmv.25732
NR 47
TC 21
Z9 22
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD JUN
PY 2020
VL 34
IS 6
BP 1487
EP 1494
DI 10.1038/s41375-020-0832-y
EA MAY 2020
PG 8
WC Oncology; Hematology
SC Oncology; Hematology
GA LU1TA
UT WOS:000529770500003
PM 32358568
OA Other Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Bonavita, S
   Tedeschi, G
   Atreja, A
   Lavorgna, L
AF Bonavita, Simona
   Tedeschi, Gioacchino
   Atreja, Ashish
   Lavorgna, Luigi
TI Digital triage for people with multiple sclerosis in the age of COVID-19
   pandemic
SO NEUROLOGICAL SCIENCES
LA English
DT Article
DE Digital triage; Digital health; Multiple sclerosis; COVID 19
AB We propose a possible approach for the remote monitoring of infection risk in people with multiple sclerosis, especially those on immunosuppressant drugs, during COVID-19 pandemic. We developed a digital triage tool to be sent to patients to quickly identify people with high risk of COVID-19 infection. This tool will also limit unnecessary accesses to the MS centers reducing the risk of spreading the infection.
C1 [Bonavita, Simona; Tedeschi, Gioacchino; Lavorgna, Luigi] Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci, Piazza Miraglia 2, Naples 80138, Italy.
   [Atreja, Ashish] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
RP Bonavita, S (corresponding author), Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci, Piazza Miraglia 2, Naples 80138, Italy.
EM simona.bonavita@unicampania.it
CR Chang Lin M, 2020, JAMA
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Yang YS, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102434
NR 3
TC 12
Z9 12
U1 2
U2 3
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1590-1874
EI 1590-3478
J9 NEUROL SCI
JI Neurol. Sci.
PD MAY
PY 2020
VL 41
IS 5
BP 1007
EP 1009
DI 10.1007/s10072-020-04391-9
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA LI8WX
UT WOS:000529759800003
PM 32303856
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Abramovitz, I
   Palmon, A
   Levy, D
   Karabucak, B
   Kot-Limon, N
   Shay, B
   Kolokythas, A
   Almoznino, G
AF Abramovitz, Itzhak
   Palmon, Aaron
   Levy, David
   Karabucak, Bekir
   Kot-Limon, Nurit
   Shay, Boaz
   Kolokythas, Antonia
   Almoznino, Galit
TI Dental care during the coronavirus disease 2019 (COVID-19 ) outbreak:
   operatory considerations and clinical aspects
SO QUINTESSENCE INTERNATIONAL
LA English
DT Article
DE coronavirus; COVID-19; dental; endodontics; infection control; pulpitis
ID MANAGEMENT; FRACTURES; EMERGENCY; THERAPY
AB Objectives: This paper is aimed at addressing the urgent need to develop a protocol that will address the operatory and clinical aspects of dental care during the Coronavirus disease 2019 (COVID-19) outbreak. Data sources:The epidemiology, clinical signs and symptoms, and modes of transmission of COVID-19 are presented.This protocol was established as an international collaboration of three dental universities: Hadassah School of Dental Medicine, Israel; University of Rochester Medical Center, USA; and the University of Pennsylvania, USA. This protocol is based on a detailed review of the existing English language literature as well on the logistic and clinical experience of each facility and the opinion of the authors.The protocol is designed for a hospital setting and includes considerations related to dental treatment in both healthy subjects and those suspected or diagnosed with COVID-19. The first part of this review discusses operatory considerations; the second part discusses general dental clinical aspects; the third part discusses endodontic considerations; and the fourth part discusses surgical aspects.This protocol may be applicable to other future similar pandemics. Conclusion: Logistic and clinical steps are required to provide dental care during the COVID-19 outbreak while preventing cross-contamination and protecting the dental team during the provision of care.
C1 [Abramovitz, Itzhak; Palmon, Aaron] Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Fac Dent Med, Jerusalem, Israel.
   [Levy, David] Univ Rochester, Eastman Inst Oral Hlth, Rochester, NY USA.
   [Karabucak, Bekir] Univ Penn, Sch Dent Med, Dept Endodont, Philadelphia, PA 19104 USA.
   [Kot-Limon, Nurit; Shay, Boaz; Almoznino, Galit] Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Fac Dent Med, Dept Endodont, Jerusalem, Israel.
   [Kolokythas, Antonia] Univ Rochester, Eastman Inst Oral Hlth, Oral & Maxillofacial Surg, Rochester, NY USA.
   [Almoznino, Galit] Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Oral Med, POB 12272, Jerusalem 91120, Israel.
   [Almoznino, Galit] Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Biomed Data Res Lab, POB 12272, Jerusalem 91120, Israel.
   [Almoznino, Galit] Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Infect Prevent & Control Comm, POB 12272, Jerusalem 91120, Israel.
   [Almoznino, Galit] Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Dept Oral Med Sedat & Maxillofacial Imaging, Orofacial Sensory Taste & Smell Clin, POB 12272, Jerusalem 91120, Israel.
RP Almoznino, G (corresponding author), Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Oral Med, POB 12272, Jerusalem 91120, Israel.; Almoznino, G (corresponding author), Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Biomed Data Res Lab, POB 12272, Jerusalem 91120, Israel.; Almoznino, G (corresponding author), Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Infect Prevent & Control Comm, POB 12272, Jerusalem 91120, Israel.; Almoznino, G (corresponding author), Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Dept Oral Med Sedat & Maxillofacial Imaging, Orofacial Sensory Taste & Smell Clin, POB 12272, Jerusalem 91120, Israel.
EM galit@almoznino.com
CR AAO-HNS AAo0HaNS, 2020, AN HYP DYSG SYMPT CO
   American Association of Endodontists, 2016, GUID CLIN END
   American Association of Endodontists, 2017, SCOP END EXTR TEETH
   American Dental Association, 2020, ADA REC DEN POST EL
   American Dental Association, ASS OFF RES HANDL ST
   [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   [Anonymous], REC GUID EXT US LTD
   [Anonymous], 2020, GUID PREP WORKPL COV
   [Anonymous], 2020, 51 WHO
   [Anonymous], 2009, J ENDODONT, V35, P1634
   Backer JA, 2020, EUROSURVEILLANCE, V25
   CAMERON CE, 1976, J AM DENT ASSOC, V93, P971, DOI 10.14219/jada.archive.1976.0034
   CAMERON CE, 1964, J AM DENT ASSOC, V68, P405, DOI 10.14219/jada.archive.1964.0108
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Centers for Disease Control and Prevention, 2016, SUMM INF PREV PRACT
   Centers for Disease Control and Prevention, INT INF PREV CONTR R
   Centers for Disease Control and Prevention; Department of Health and Human Services; National Institute for Occupational Safety and Health, DHHS NIOSH PUBL, V2010-133
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chinese National Health Commission, 2020, GUID DIAGN TREATM NO, P2020
   Kohn William G, 2003, MMWR Recomm Rep, V52, P1
   CORAH NL, 1978, J AM DENT ASSOC, V97, P816, DOI 10.14219/jada.archive.1978.0394
   Cvek M, 1978, J Endod, V4, P232, DOI 10.1016/S0099-2399(78)80153-8
   Diangelis Anthony J, 2017, Pediatr Dent, V39, P401, DOI 10.1111/j.1600-9657.2011.01103.x
   Dong E, 2020, LANCET INFECT, DOI [10.1016/S1473-3099 (20)30120-1., DOI 10.1016/S1473-3099]
   Dummer PMH, 2019, INT ENDOD J, V52, P923, DOI 10.1111/iej.13080
   Elad S, 2008, ORAL ONCOL, V44, P37, DOI 10.1016/j.oraloncology.2006.12.006
   Fang L, 2020, LANCET RESP MED, DOI [10.1016/52213- 2600(20)30116-8., DOI 10.1016/52213-2600(20)30116-8]
   GATEWOOD RS, 1990, J ENDODONT, V16, P284, DOI 10.1016/S0099-2399(06)81631-6
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Israel Ministry of Health, MIN HLTH LAUNCH HAMA
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Krell KV, 2018, J ENDODONT, V44, P543, DOI 10.1016/j.joen.2017.12.025
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lee M, 2009, J ENDODONT, V35, P35, DOI 10.1016/j.joen.2008.10.007
   Leung C, 2020, INFECT CONT HOSP EP, V41, P594, DOI 10.1017/ice.2020.81
   Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538
   Little JW, 2017, DENT MANAGEMENT MED
   Lockhart PB, 2019, J AM DENT ASSOC, V150, P906, DOI 10.1016/j.adaj.2019.08.020
   Malamed SF, 2010, J AM DENT ASSOC, V141, p3S, DOI 10.14219/jada.archive.2010.0350
   MCCARTHY FM, 1979, J AM DENT ASSOC, V99, P181, DOI 10.14219/jada.archive.1979.0271
   Meng L, 2020, J DENT RES, V99, P481, DOI 10.1177/0022034520914246
   Mohammadi Z, 2011, INT ENDOD J, V44, P697, DOI 10.1111/j.1365-2591.2011.01886.x
   Parirokh M, 2018, INT ENDOD J, V51, P177, DOI 10.1111/iej.12841
   Peng X, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0075-9
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Shi H, 2020, LANCET INFECT DIS, DOI [10.1016/51473-3099(20)30086-4, DOI 10.1016/51473-3099(20)30086-4]
   Solana K, 2020, ADA DEV GUID DENT EM
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Tang A, 2020, EMERG INFECT DIS, V26, P1337, DOI 10.3201/eid2606.200301
   Tennert C, 2015, INT ENDOD J, V48, P84, DOI 10.1111/iej.12280
   US Food and Drug Administration, 2020, FDA ADV PAT US NONST
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WANG K, 2020, ZHONGHUA KOU QIANG Y, V55
   WIDERMAN FH, 1971, J AM DENT ASSOC, V82, P378, DOI 10.14219/jada.archive.1971.0068
   World Health Organization, MOD TRANSM VIR CAUS
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 60
TC 10
Z9 11
U1 2
U2 8
PU QUINTESSENCE PUBLISHING CO INC
PI HANOVER PARK
PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA
SN 0033-6572
EI 1936-7163
J9 QUINTESSENCE INT
JI Quintessence Int.
PD MAY
PY 2020
VL 51
IS 5
BP 418
EP 429
DI 10.3290/j.qi.a44392
PG 12
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA LI9KC
UT WOS:000529794300009
PM 32328595
DA 2021-01-01
ER

PT J
AU Rasool, N
   Akhtar, A
   Hussain, W
AF Rasool, Nouman
   Akhtar, Ammara
   Hussain, Waqar
TI Insights into the inhibitory potential of selective phytochemicals
   against Mpro of 2019-nCoV: a computer-aided study
SO STRUCTURAL CHEMISTRY
LA English
DT Article
DE 2019-nCoV; Main protease; Phytochemicals; Docking; ADMET; DFT
ID PLANT FLAVONOIDS; DESIGN
AB At the end of December 2019, a novel strain of coronavirus, given the name of 2019-nCoV, emerged for exhibiting symptoms of severe acute respiratory syndrome. The virus is spreading rapidly in China and around the globe, affecting thousands of people leading to a pandemic. To control the mortality rate associated with the 2019-nCoV, prompt steps are needed. Until now there is no effective treatment or drug present to control its life-threatening effects in the humans. The scientist is struggling to find new inhibitors of this deadly virus. In this study, to identify the effective inhibitor candidates against the main protease (Mpro) of 2019-nCoV, computational approaches were adopted. Phytochemicals having immense medicinal properties as ligands were docked against the Mpro of 2019-nCoV to study their binding properties. ADMET and DFT analyses were also further carried out to analyze the potential of these phytochemicals as an effective inhibitor against Mpro of 2019-nCoV.
C1 [Rasool, Nouman] Univ Karachi, Int Ctr Chem & Biol Sci, Dr Panjwani Ctr Mol Med & Drug Res, Karachi 75270, Pakistan.
   [Akhtar, Ammara] Univ Management & Technol, Dept Life Sci, Lahore, Pakistan.
   [Hussain, Waqar] Univ Punjab, Punjab Univ Coll Informat Technol, Natl Ctr Artificial Intelligence, Lahore, Pakistan.
   [Rasool, Nouman; Hussain, Waqar] Ctr Profess Studies, Lahore, Pakistan.
RP Rasool, N (corresponding author), Univ Karachi, Int Ctr Chem & Biol Sci, Dr Panjwani Ctr Mol Med & Drug Res, Karachi 75270, Pakistan.; Rasool, N (corresponding author), Ctr Profess Studies, Lahore, Pakistan.
EM nournanrasool@gmail.com
RI Hussain, Waqar/AAC-9367-2020
OI Hussain, Waqar/0000-0001-8991-9424; Rasool, Nouman/0000-0003-0210-5845
CR Akhtar A, 2019, U SCI, V24, P441, DOI [10.11144/Javeriana.SC24-3.artf, DOI 10.11144/Javeriana.SC24-3.artf]
   Amir H, 1999, LYCOPENE 1 25 DIHYDR
   [Anonymous], 2009, VERSION 2 5
   Arif Nadia, 2020, Current Drug Discovery Technologies, V17, P397, DOI 10.2174/1570163816666190214161825
   Chen N, 2020, LANCET
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dayer MR, 2017, ARCH CLIN INFECT DIS, V12, DOI 10.5812/archcid.13823
   Dhama K, 2014, Pak J Biol Sci, V17, P768, DOI 10.3923/pjbs.2014.768.779
   Donnelly CA, 2019, EMERG INFECT DIS, V25, P1758, DOI 10.3201/eid2509.190143
   Hu B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006698
   Hussain W., 2018, J ANTIVIR ANTIRETROV, V10, P28, DOI [10.4172/1948-5964.1000177, DOI 10.4172/1948-5964.1000177]
   Hussain W, 2020, STRUCT CHEM, V31, P1363, DOI 10.1007/s11224-020-01507-x
   Janostikova E, 2005, ACTA VET BRNO, V74, P557, DOI 10.2754/avb200574040557
   Karahan I, 2005, TOXICOLOGY, V215, P198, DOI 10.1016/j.tox.2005.07.007
   Kavitha E, 2010, MOL STRUCTURE VIBRAT
   Kupeli E, 2006, J ETHNOPHARMACOL, V107, P169, DOI 10.1016/j.jep.2006.02.021
   Lelieveld SH, 2016, HUM GENET, V135, P603, DOI 10.1007/s00439-016-1658-6
   Liang QQ, 2019, MICROBIOL RESOUR ANN, V8, DOI 10.1128/MRA.01517-18
   Liu X, 2020, POTENTIAL INHIBITORS
   Lo Giudice T, 2014, EXP NEUROL, V261, P518, DOI 10.1016/j.expneurol.2014.06.011
   Middleton E, 2000, PHARMACOL REV, V52, P673
   Mishra A. K., 2016, Proceedings of the Indian National Science Academy Part B Biological Sciences, V86, P1023, DOI 10.1007/s40011-015-0557-2
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Poon LLM, 2004, LANCET INFECT DIS, V4, P663, DOI 10.1016/S1473-3099(04)01172-7
   Qaddir I, 2017, J VECTOR DIS, V54, P255
   Qin P, 2008, J AM CHEM SOC, V130, P8570, DOI 10.1021/ja8001474
   Rasool N, 2019, TURK J BIOCH
   Rasool N, 2017, J PROTEOM BIOINFORM, V10, P324, DOI [10.4172/jpb.1000458, DOI 10.4172/JPB.1000458]
   Rasool N, 2020, COMB CHEM HIGH T SCR, V23, P41, DOI 10.2174/1386207323666191213142223
   Rasool N, 2019, TURK J BIOCHEM, V44, P261, DOI 10.1515/tjb-2018-0002
   Rasool N, 2018, BRAZ ARCH BIOL TECHN, V61, DOI 10.1590/1678-4324-2018180004
   Sospeter J, 2018, DATA, V4, DOI 10.3390/data4010001
   Vogel HG, 2006, DRUG DISCOVERY EVALU
   Yang HM, 2005, INT J EMERG ELECTR P, V3, DOI 10.2202/1553-779X.1069
   Zheng YG, 2013, BIOORG MED CHEM LETT, V23, P3523, DOI 10.1016/j.bmcl.2013.04.039
NR 35
TC 3
Z9 3
U1 1
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1040-0400
EI 1572-9001
J9 STRUCT CHEM
JI Struct. Chem.
PD OCT
PY 2020
VL 31
IS 5
BP 1777
EP 1783
DI 10.1007/s11224-020-01536-6
EA MAY 2020
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Crystallography
SC Chemistry; Crystallography
GA NK5NY
UT WOS:000529762400001
PM 32362735
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hong, KS
   Lee, KH
   Chung, JH
   Shin, KC
   Choi, EY
   Jin, HJ
   Jang, JG
   Lee, W
   Ahn, JH
AF Hong, Kyung Soo
   Lee, Kwan Ho
   Chung, Jin Hong
   Shin, Kyeong-Cheol
   Choi, Eun Young
   Jin, Hyun Jung
   Jang, Jong Geol
   Lee, Wonhwa
   Ahn, June Hong
TI Clinical Features and Outcomes of 98 Patients Hospitalized with
   SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study
SO YONSEI MEDICAL JOURNAL
LA English
DT Article
DE Coronavirus; SARS-CoV-2; COVID-19; Korea; clinical characteristics
ID APACHE-II; SEPSIS; SCORE
AB Although some information on the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a few selected cases has been reported, data on the clinical characteristics and outcomes of patients hospitalized therewith in South Korea are lacking. We conducted a retrospective single-center study of 98 consecutive hospitalized patients with confirmed SARS-CoV-2 infection at Yeungnam University Medical Center in Daegu, South Korea. Sixty patients were women (61.2%), and the mean age was 55.4 +/- 17.1 years. Thirteen patients (13.3%) were treated in the intensive care unit (ICU). The mean interval from symptom onset to hospitalization was 7.7 +/- 4.5 days. Patients who received ICU care were significantly older and were more likely to have diabetes mellitus. The National Early Warning Score on the day of admission was significantly higher in patients requiring ICU care. Acute respiratory distress syndrome (13/13 patients; 100%), septic shock (9/13; 69.2%), acute cardiac injury (9/13; 69.2%), and acute kidney injury (8/13; 61.5%) were more common in patients who received ICU care. All patients received antibiotic therapy, and most (97/98 patients; 99.0%) received antiviral therapy (lopinavir/ritonavir). Hydroxychloroquine was used in 79 patients (80.6%), and glucocorticoid therapy was used in 18 patients (18.4%). In complete blood counts, lymphopenia was the most common finding (40/98 patients; 40.8%). Levels of all proinflammatory cytokines were significantly higher in ICU patients. As of March 29, 2020, the mortality rate was 5.1%. Here, we report the clinical characteristics and laboratory findings of SARS-CoV-2 patients in South Korea up to March 29, 2020.
C1 [Hong, Kyung Soo; Lee, Kwan Ho; Chung, Jin Hong; Shin, Kyeong-Cheol; Choi, Eun Young; Jin, Hyun Jung; Jang, Jong Geol; Ahn, June Hong] Yeungnam Univ, Coll Med, Dept Internal Med, Div Pulmonol & Allergy, 170 Hyeonchung Ro, Daegu 42415, South Korea.
   [Hong, Kyung Soo; Lee, Kwan Ho; Chung, Jin Hong; Shin, Kyeong-Cheol; Choi, Eun Young; Jin, Hyun Jung; Jang, Jong Geol; Ahn, June Hong] Yeungnam Univ, Med Ctr, Reg Ctr Resp Dis, 170 Hyeonchung Ro, Daegu 42415, South Korea.
   [Lee, Wonhwa] Korea Res Inst Biosci & Biotechnol, Aging Res Ctr, Daejeon, South Korea.
RP Ahn, JH (corresponding author), Yeungnam Univ, Coll Med, Dept Internal Med, Div Pulmonol & Allergy, 170 Hyeonchung Ro, Daegu 42415, South Korea.; Ahn, JH (corresponding author), Yeungnam Univ, Med Ctr, Reg Ctr Resp Dis, 170 Hyeonchung Ro, Daegu 42415, South Korea.
EM fireajh@gmail.com
OI CHUNG, JIN HONG/0000-0003-1829-3051; Lee, Wonhwa/0000-0003-4336-5221;
   Hong, Kyung Soo/0000-0003-2931-6861; Shin,
   Kyeong-Cheol/0000-0003-1972-1847; Jang, Jong Geol/0000-0001-8040-5363;
   Ahn, June Hong/0000-0001-7104-8325
FU Daegu Medical Association COVID-19 scientific committee
FX We thank all of the staff who have helped to care for COVID-19 patients
   at Yeungnam University Medical Center in Daegu, South Korea. This study
   was supported by a research grant from Daegu Medical Association
   COVID-19 scientific committee.
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   Kim ES, 2016, J KOREAN MED SCI, V31, P1717, DOI 10.3346/jkms.2016.31.11.1717
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e112
   Polderman KH, 2001, ANAESTHESIA, V56, P47, DOI 10.1046/j.1365-2044.2001.01763.x
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Smith GB, 2013, RESUSCITATION, V84, P465, DOI 10.1016/j.resuscitation.2012.12.016
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
NR 15
TC 18
Z9 18
U1 4
U2 17
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD MAY
PY 2020
VL 61
IS 5
BP 431
EP 437
DI 10.3349/ymj.2020.61.5.431
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA LJ3RE
UT WOS:000530084400010
PM 32390367
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Prati, C
   Pelliccioni, GA
   Sambri, V
   Chersoni, S
   Gandolfi, MG
AF Prati, C.
   Pelliccioni, G. A.
   Sambri, V.
   Chersoni, S.
   Gandolfi, M. G.
TI COVID-19: its impact on dental schools in Italy, clinical problems in
   endodontic therapy and general considerations
SO INTERNATIONAL ENDODONTIC JOURNAL
LA English
DT Letter
C1 [Prati, C.; Pelliccioni, G. A.; Chersoni, S.; Gandolfi, M. G.] Univ Bologna, Sch Dent, DIBINEM, Endodont Clin Sect,Clin Endodontol, Bologna, Italy.
   [Sambri, V.] Great Romagna Hub Lab, Microbiol Unit, Pievesestina, Italy.
   [Sambri, V.] Univ Bologna, DIMES, Bologna, Italy.
RP Prati, C (corresponding author), Univ Bologna, Sch Dent, DIBINEM, Endodont Clin Sect,Clin Endodontol, Bologna, Italy.
EM carlo.prati@unibo.it
CR Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Peng X, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0075-9
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sabino-Silva R, 2020, CLIN ORAL INVEST, V24, P1619, DOI 10.1007/s00784-020-03248-x
   Phan T, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104211
NR 6
TC 21
Z9 24
U1 3
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0143-2885
EI 1365-2591
J9 INT ENDOD J
JI Int. Endod. J.
PD MAY
PY 2020
VL 53
IS 5
BP 723
EP 725
DI 10.1111/iej.13291
PG 3
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA LH4PX
UT WOS:000528768300015
PM 32277770
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Chen, J
   Qi, TK
   Liu, L
   Ling, Y
   Qian, ZP
   Li, T
   Li, F
   Xu, QN
   Zhang, YY
   Xu, SB
   Song, ZG
   Zeng, YG
   Shen, YZ
   Shi, YX
   Zhu, TY
   Lu, HZ
AF Chen, Jun
   Qi, Tangkai
   Liu, Li
   Ling, Yun
   Qian, Zhiping
   Li, Tao
   Li, Feng
   Xu, Qingnian
   Zhang, Yuyi
   Xu, Shuibao
   Song, Zhigang
   Zeng, Yigang
   Shen, Yinzhong
   Shi, Yuxin
   Zhu, Tongyu
   Lu, Hongzhou
TI Clinical progression of patients with COVID-19 in Shanghai, China
SO JOURNAL OF INFECTION
LA English
DT Article
DE COVID-19; SARS-CoV-2; Clinical progression; Viral clearance; Clinical
   characteristics
ID SARS
AB Background: Studies on the 2019 novel coronavirus disease (COVID-19) have generally been limited to the description of the epidemiology and initial clinical characteristics. We investigated the temporal progression in patients with COVID-19.
   Methods: In this retrospective, single-center study, we included confirmed cases of COVID-19 from Jan 20 to Feb 6, 2020 in Shanghai. Final date of follow-up was February 25, 2020.
   Results: Of the 249 patients enrolled, the median age was 51 years old, and 126 (50.6%) were male. The duration from onset of symptoms to hospitalization was 4(2-7) days in symptomatic patients. Fever was occurred in 235(94.3%) patients. A total of 215 (86.3%) patients had been discharged after 16(12-20) days hospitalization. The estimated median duration of fever in all the patients with fever was 10 days (95 confidential intervals [CIs]: 8-11 days) after onset of symptoms. Patients who were transferred to intensive care units (ICU) had significantly longer duration of fever as compared to those not in ICU (31 days v.s. 9 days after onset of symptoms, respectively, P <0.0001). Radiological aggravation of initial image was observed in 163 (65.7%) patients on day 7 after onset of symptoms. 154(94.5%) of these patients showed radiological improvement on day 14. The median duration to negative reverse-transcriptase PCR tests of upper respiratory tract samples was 11 days (95 CIs: 10-12 days). Viral clearance was more likely to be delayed in patients in ICU than those not in ICU (P <0.0001). In multivariate logistical analysis, age (Odds ratio [OR] = 1.06) and CD4 T cell count (OR = 0.55 per 100 cells/ul increase) were independently associated with ICU admission.
   Conclusions: The majority of COVID-19 cases are mild. The clinical progression pattern suggests that early control of viral replication and application of host-directed therapy in later stage is essential to improve the prognosis of CVOID-19. (C) 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
C1 [Chen, Jun; Qi, Tangkai; Liu, Li; Xu, Shuibao; Shen, Yinzhong] Shanghai Publ Hlth Clin Ctr, Dept Infect Dis & Immunol, Shanghai 201508, Peoples R China.
   [Ling, Yun; Lu, Hongzhou] Shanghai Publ Hlth Clin Ctr, Dept Infect Dis, 2901 Caolang Rd, Shanghai 201508, Peoples R China.
   [Qian, Zhiping; Zhang, Yuyi] Shanghai Publ Hlth Clin Ctr, Dept Liver Intens Care Unit, Shanghai 201508, Peoples R China.
   [Li, Tao] Shanghai Publ Hlth Clin Ctr, Dept TB, Shanghai 201508, Peoples R China.
   [Li, Feng] Shanghai Publ Hlth Clin Ctr, Dept Resp Dis, Shanghai 201508, Peoples R China.
   [Xu, Qingnian] Shanghai Publ Hlth Clin Ctr, Dept Tradit Chinese Med, Shanghai 201508, Peoples R China.
   [Song, Zhigang] Shanghai Publ Hlth Clin Ctr, Dept Pathogen Diag & Biosafety, Shanghai 201508, Peoples R China.
   [Zeng, Yigang; Zhu, Tongyu] Shanghai Publ Hlth Clin Ctr, Dept Urol, 2901 Caolang Rd, Shanghai 201508, Peoples R China.
   [Shi, Yuxin] Shanghai Publ Hlth Clin Ctr, Dept Radiol, Shanghai 201508, Peoples R China.
RP Lu, HZ (corresponding author), Shanghai Publ Hlth Clin Ctr, Dept Infect Dis, 2901 Caolang Rd, Shanghai 201508, Peoples R China.; Zhu, TY (corresponding author), Shanghai Publ Hlth Clin Ctr, Dept Urol, 2901 Caolang Rd, Shanghai 201508, Peoples R China.
EM zhutongyu@shphc.org.cn; luhongzhou@fudan.edu.cn
FU Fudan University [IDF162005]; Shanghai Public Health Clinical Center
   [2020YJKY01]; Shanghai major projects on infectious diseases
   [shslczdzk01102]; Shanghai "Rising stars of Medical Talent" Youth
   Development Program, Specialist Program [2019-72]
FX This study is funded by Fudan University (IDF162005); Shanghai Public
   Health Clinical Center (2020YJKY01); Shanghai major projects on
   infectious diseases (shslczdzk01102); Shanghai "Rising stars of Medical
   Talent" Youth Development Program, Specialist Program (No. 2019-72). We
   thank all patients involved in the study. We also thank Ling Gu and
   Danping Liu for their coordination.
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Chan JF-W, 2020, LANCET
   Chen N, 2020, LANCET
   Choi WS, 2016, INFECT CHEMOTHER, V48, P118, DOI 10.3947/ic.2016.48.2.118
   D Wang, 2020, JAMA
   Eurosurveillance Editorial T, 2020, EURO SURVEILL, V25, p200131e
   Guan W-J, 2020, NEW ENGL J MED
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang C, 2020, LANCET
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e61
   Lau SKP, 2006, J CLIN MICROBIOL, V44, P2063, DOI 10.1128/JCM.02614-05
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Lu R, 2020, LANCET
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Phan LT, 2020, NEW ENGL J MED 2020
   Rothe C, 2020, NEW ENGL J MED
   Russell CD, 2020, LANCET
   Wan S, 2020, CHARACTERISTICS LYMP, DOI [10.1101/2020.02.10.20021832, DOI 10.1101/2020.02.10.20021832.]
   Wang D, 2020, JAMA
   World Health Organization, CLIN MAN SEV AC RESP
   World Health Organization, 2020, 40 WHO
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Z, 2020, JAMA
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhu N, 2020, NEW ENGL J MED
   Zumla A, 2020, LANCET
NR 27
TC 155
Z9 157
U1 5
U2 35
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD MAY
PY 2020
VL 80
IS 5
BP E1
EP E6
DI 10.1016/j.jinf.2020.03.004
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA LE0HZ
UT WOS:000526407300001
PM 32171869
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

EF